PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Rafferty, JA; Clarke, AR; Sellappan, D; Koref, MS; Frayling, IM; Margison, GP				Rafferty, JA; Clarke, AR; Sellappan, D; Koref, MS; Frayling, IM; Margison, GP			Induction of murine O-6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent	ONCOGENE			English	Article						p53; ATase; DNA repair induction; animal model	DNA-DAMAGING AGENTS; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; IONIZING-RADIATION; MESSENGER-RNA; RAT-LIVER; CELLS; TISSUES; TUMORS; MICE	Expression of both the DNA repair protein O-6-alkylguanine-DNA-alkyltransferase (ATase) and the p53 tumour suppressor protein are inducible by a number of DNA damaging agents. It is probable that DNA strand breaks are the common inducing signals. This similarity, and the function of p53 as a transcription factor lead us to reason that p53 might be involved in ATase inducibility. We now report that the induction of ATase activity in mouse tissues following gamma-radiation is p53 gene dose dependent. While the extent and kinetics of induction in p53 wildtype mice are consistent with previous reports (a 2-3-fold peak increase at 36 h), no induction is observed in p53 null animals. Importantly the heterozygous mice show an intermediate response but the same kinetics, The basal levels of expression in all tissues examined are unaffected by p53 status. These data represent the first report of a discrete DNA repair function being p53 regulated in vivo and their potential clinical implications are discussed.	UNIV EDINBURGH,SCH MED,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Rafferty, JA (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,DEPT CARCINOGENESIS,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND.		Clarke, Alan R/A-6256-2008; Margison, Geoff/E-4146-2019; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Frayling, Ian/0000-0002-3420-0794				BAER JC, 1993, BRIT J CANCER, V67, P1299, DOI 10.1038/bjc.1993.241; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DINCALCI M, 1988, CANC TREAT REV, V15, P5723; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1994, CANCER RES, V54, P5824; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; HARKNESS RD, 1957, BRIT MED BULL, V13, P87, DOI 10.1093/oxfordjournals.bmb.a069601; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; JELINEK J, 1988, CARCINOGENESIS, V9, P81, DOI 10.1093/carcin/9.1.81; KAINA B, 1991, CARCINOGENESIS, V12, P1857; KLEIHUES P, 1976, NATURE, V259, P153, DOI 10.1038/259153a0; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; LI J-H, 1989, Molecular Toxicology, V2, P1; MARGISON GP, 1985, CARCINOGENESIS, V6, P1699, DOI 10.1093/carcin/6.12.1699; MARGISON GP, 1990, HDB EXPT PHARM, V94, P547; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MONTECUCCO A, 1995, NUCLEIC ACIDS RES, V23, P962, DOI 10.1093/nar/23.6.962; MONTESANO R, 1979, CANCER RES, V39, P1789; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PEGG AE, 1990, CANCER RES, V50, P6119; POTTER PM, 1991, CARCINOGENESIS, V12, P727, DOI 10.1093/carcin/12.4.727; SMITH ML, 1995, ONCOGENE, V10, P1053; STAMMBERGER I, 1990, CARCINOGENESIS, V11, P219, DOI 10.1093/carcin/11.2.219; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; VONHOFE E, 1988, CARCINOGENESIS, V9, P679, DOI 10.1093/carcin/9.4.679; VONHOFE E, 1992, P NATL ACAD SCI USA, V89, P11199, DOI 10.1073/pnas.89.23.11199; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILSON RE, 1993, CARCINOGENESIS, V14, P679, DOI 10.1093/carcin/14.4.679; ZHAN QM, 1994, CANCER RES, V54, P2755	36	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					693	697						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637727				2022-12-17	WOS:A1996TV59700027
J	Clark, GJ; Kinch, MS; Gilmer, TM; Burridge, K; Der, CJ				Clark, GJ; Kinch, MS; Gilmer, TM; Burridge, K; Der, CJ			Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers	ONCOGENE			English	Article						transformation; adherens junctions; motility	MAMMARY EPITHELIAL-CELLS; HA-RAS; AMINO-ACIDS; ONCOGENE; TRANSFORMATION; EXPRESSION; ACTIVATION; CARCINOMAS; LINE; INVIVO	Although experimental studies suggest that aberrant Ras function can promote the malignant progression of human breast epithelial cells, the occurrence of mutated pas genes in breast tumors is infrequent. One possible explanation for this apparent paradox is that aberrant function of the Ras-related protein TC21/R-Ras2, which causes malignant transformation of NIH 3T3 cells via upregulation of the Ras signal transduction pathway, may contribute to breast tumor development in the absence of Ras mutations. To address this possibility, we utilized two complementary approaches. First, we determined that aberrant TC21 function caused transformation of the MCF-10A human breast epithelial cell line. TC21-transformed MCF-10A cells exhibited altered cellular morphology associated with a disruption of cell-cell adherens junctions, formed colonies in soft agar, and showed enhanced motility in vitro. These alterations were similar to, but more dramatic than, those observed with oncogenic Ras-transformed MCF-10A cells. Furthermore, overexpression of normal TC21, but not Ras, also caused transformation of these cells. Second, we observed that TC21 protein expression was greatly elevated in 7 of 9 breast tumor lines when compared to untransformed MCF-10A cells. Taken together, these results support the possibility that overexpression of TC21 may contribute to aberrant growth properties of breast carcinoma cells.	UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELLULAR BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; GLAXO INC,RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline				Kinch, Michael/0000-0003-3939-3756; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA52072, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CLAIR T, 1987, CANCER RES, V47, P5290; CLARDIELLO F, 1992, MOL CARCINOGEN, V6, P43; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARK GJ, 1993, GTPASES BIOL, V108, P259; CLARK R, 1988, CANCER RES, V48, P4689; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DEBORTOLI ME, 1985, BIOCHEM BIOPH RES CO, V127, P699, DOI 10.1016/S0006-291X(85)80218-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; HAND PH, 1987, J NATL CANCER I, V79, P59; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; HYNES NE, 1994, CANCER BIOL, V4, P19; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; OCHIENG J, 1991, INVAS METAST, V11, P38; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRESS MF, 1994, CANCER RES, V54, P2771; QUI RG, 1995, NATURE, V374, P457; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; REDMOND SMS, 1988, ONCOGENE, V2, P259; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1990, CANCER RES, V50, P6075; SPANDIDOS DA, 1987, ANTICANCER RES, V7, P991; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; THOR A, 1986, LAB INVEST, V6, P603; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001	47	81	85	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					169	176						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552388				2022-12-17	WOS:A1996TQ01400021
J	CHAOUCHI, N; ARVANITAKIS, L; AUFFREDOU, MT; BLANCHARD, DA; VAZQUEZ, A; SHARMA, S				CHAOUCHI, N; ARVANITAKIS, L; AUFFREDOU, MT; BLANCHARD, DA; VAZQUEZ, A; SHARMA, S			CHARACTERIZATION OF TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCED APOPTOSIS IN NORMAL HUMAN B-CELLS AND LYMPHOMA B-CELL LINES	ONCOGENE			English	Article						TGF-BETA; APOPTOSIS; CELL CYCLE; BURKITT; BCL-2; C-MYC	FACTOR-BETA; C-MYC; BCL-2 EXPRESSION; LYMPHOCYTES-B; DEATH; INDUCTION; PROTEIN; INHIBITION; SURVIVAL; GENE	Transforming growth factor beta 1 (TGF beta 1) has been shown to inhibit growth stimulation in normal human B cells as well as in Epstein Barr virus (EBV)-negative Burbitt's lymphoma (BL) cell lines. The mechanisms for this potent growth inhibition are not completely defined. Here me show that a number of EBV-negative lymphoma B cell lines (BL-41, Ramos and CAPA-2), when exposed in vitro to TGF beta 1, undergo apoptosis. Maximum apoptosis was observed at 48 h following TGF beta 1 treatment, with no apparent effect on the expression of c-myc and bcl-2 proteins. Similar induction of apoptosis was observed when these lymphoma cell lines were treated with aphidicolin, a DNA synthesis inhibitor. In contrast, various preparations (14 out of 17) of normal human tonsilar B cells showed no significant apoptosis, although both TGF beta 1 and aphidicolin inhibited anti-mu/IL-4 induced DNA synthesis in all preparations. Furthermore, another TGF beta 1 sensitive EBV-negative BL cell line, CA46, exhibited no apoptosis in response to TGF beta 1 and aphidicolin, corroborating the findings in normal human B cells. Taken together, these data support the hypothesis that exposure to TGF beta 1, which results in cell cycle arrest and DNA synthesis inhibition, may not be obligatory or sufficient for the induction of apoptosis. Rather, induction of apoptosis or lack of-it may be intrinsically determined by an interplay between extracellular and intracellular regulators of cellular growth.	INSERM,U131,F-92140 CLAMART,FRANCE; BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,EXPTL PATHOL SECT,PROVIDENCE,RI 02908	Institut National de la Sante et de la Recherche Medicale (Inserm); Brown University; Roger Williams Medical Center					NCI NIH HHS [CA 55910, CA 54763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055910, R01CA054763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKBAR AN, 1993, J EXP MED, V178, P427, DOI 10.1084/jem.178.2.427; ARVANITAKIS L, 1995, IN PRESS J IMMUNOL; BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAOUCHI N, 1994, CLIN IMMUNOL IMMUNOP, V73, P197, DOI 10.1006/clin.1994.1188; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FERNANDEZRUIZ E, 1989, J IMMUNOL, V143, P4146; FINKE J, 1992, BLOOD, V80, P459; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; FRIED J, 1978, J HISTOCHEM CYTOCHEM, V26, P921, DOI 10.1177/26.11.82573; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HANNON GJ, 1994, NATURE, V371, P534; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLDER MJ, 1992, EUR J IMMUNOL, V22, P2725, DOI 10.1002/eji.1830221037; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KUMAR A, 1991, J IMMUNOL, V147, P998; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEE G, 1987, J EXP MED, V166, P1290, DOI 10.1084/jem.166.5.1290; LI L, 1990, J BIOL CHEM, V265, P1556; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOMO J, 1995, J IMMUNOL, V154, P1634; LOTZ M, 1994, J EXP MED, V179, P999, DOI 10.1084/jem.179.3.999; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; ROUACH EY, 1991, NATURE, V352, P345; Sambrook J., 1989, MOL CLONING LAB MANU; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; TAIEB J, 1994, EUR J IMMUNOL, V24, P480, DOI 10.1002/eji.1830240233; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VAZQUEZ A, 1991, EUR J IMMUNOL, V21, P2311, DOI 10.1002/eji.1830211004; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIE AH, 1980, NATURE, V284, P555; WILLY AH, 1987, INT REV CYTOL S, V17, P755	57	81	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1615	1622						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478586				2022-12-17	WOS:A1995TC53500020
J	OKAN, I; WANG, YS; CHEN, F; HU, LF; IMREH, S; KLEIN, G; WIMAN, KG				OKAN, I; WANG, YS; CHEN, F; HU, LF; IMREH, S; KLEIN, G; WIMAN, KG			THE EBV-ENCODED LMP1 PROTEIN INHIBITS P53-TRIGGERED APOPTOSIS BUT NOT GROWTH ARREST	ONCOGENE			English	Article						LMP1; P53; APOPTOSIS	WILD-TYPE P53; PROGRAMMED CELL-DEATH; CHROMOSOMAL BREAKPOINT; LYMPHOMA LINE; CYCLE CONTROL; EXPRESSION; BCL-2; SUPPRESSION; P53-PROTEIN; INDUCTION	We have previously shown that exogenous wild type p53 induces apoptosis in the Burkitt lymphoma line BL41 that carries endogenous mutant p53, using a temperature sensitive p53 construct expressed as mutant p53 at 37 degrees C and wild type p53 at 32 degrees C (Ramqvist et al., Oncogene, 8, 1495-1500, 1993). We also found that wild type p53-induced apoptosis is blocked by bcl-2 in a mouse T lymphoma line (Wang et al., Oncogene, 8, 3427-3431, 1993) The Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) can protect Burkitt lymphoma cells from apoptosis induced by low serum, In order to test if LMP1 can block p53-triggered apoptosis, we infected BL41 cells expressing the ts p53 construct with an LMP1-carrying retrovirus, The LMP1-expressing BL41-ts p53 cells were arrested in G1 upon induction of wild type p53 expression at 32 degrees C, but did not enter apoptosis as shown by the absence of positive TUNEL staining, WAF1/p21 mRNA was induced at 32 degrees C in both the ts p53-expressing and ts p53/LMP1-expressing BL41 cells, Thus, LMP1 prevents p53-induced apoptosis but does not interfere induction of WAF1/p21, The LMP1-infected expressed elevated bcl-2 protein levels, Therefore, our data suggest that LMP1 blocks p53-triggered apoptosis but not G1 arrest by upregulating bcl-2 expression.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DELDEIRY WS, 1994, CANCER, V54, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GAVRIELI Y, 1993, J CELL BIOL, V119, P493; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAMQVIST T, 1993, ONCOGENE, V8, P1495; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; TOWBIN H, 1979, P NATL ACAD SCI USA, V88, P4350; TRIVEDI P, 1991, INT J CANCER, V48, P794, DOI 10.1002/ijc.2910480527; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WILLIAMS C A, 1989, Methods in Molecular and Cellular Biology, V1, P35; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	35	81	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1027	1031						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566960				2022-12-17	WOS:A1995RX18000003
J	WHITAKER, NJ; BRYAN, TM; BONNEFIN, P; CHANG, ACM; MUSGROVE, EA; BRAITHWAITE, AW; REDDEL, RR				WHITAKER, NJ; BRYAN, TM; BONNEFIN, P; CHANG, ACM; MUSGROVE, EA; BRAITHWAITE, AW; REDDEL, RR			INVOLVEMENT OF RB-1, P53, P16(INK4) AND TELOMERASE IN IMMORTALIZATION OF HUMAN-CELLS	ONCOGENE			English	Article						SENESCENCE; IMMORTALIZATION; RB-1; P53; P16(INK4); TELOMERASE	RETINOBLASTOMA PROTEIN; MONOCLONAL-ANTIBODY; LIFE-SPAN; WILD-TYPE; LINES; IDENTIFICATION; MUTATIONS; CYCLINS; PHOSPHORYLATION; EXPRESSION	Involvement of the retinoblastoma susceptibility (RB-1), p16(INK4), p53 and telomerase genes in immortalisation was examined by determining their status in 15 human cell lines representing four immortalisation complementation groups, No abnormalities of RB-1, p53 and p16(INK4) were detected in cell lines containing DNA tumour virus proteins known to bind to the protein products of the RB-1 and p53 genes, In contrast, in all other cell lines from each of the four groups either RB-1 was mutant or p16(INK4) protein was undetectable and there were cell lines containing p53 mutations in three of Telomerase activity was detected in 12/15 lines, including some of the virally immortalised lines and in some lines from each group, Since none of these changes correlated with complementation group, other genetic changes must be required for immortalisation.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA; ST VINCENTS HOSP,GARVAN INST MED RES,DIV CANC BIOL,SYDNEY,NSW 2010,AUSTRALIA; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 2601,AUSTRALIA	Children's Medical Research Institute - Australia; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Australian National University; John Curtin School of Medical Research			Bryan, Tracy M/B-8468-2014; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1992, EXP GERONTOL, V256, P271; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HE J, 1994, CANCER RES, V54, P5804; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LEHMAN TA, 1991, CANCER RES, V51, P4090; MILNER J, 1987, ONCOGENE, V1, P453; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUGGLETONHARRIS AL, 1980, SOMAT CELL GENET, V6, P689, DOI 10.1007/BF01538968; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; REDDEL RR, 1995, INT J CANCER, V61, P199; ROMANO JW, 1989, ONCOGENE, V4, P1483; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHARMA S, 1993, CELL GROWTH DIFFER, V4, P861; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WHITAKER NJ, 1992, J VIROL, V66, P1202, DOI 10.1128/JVI.66.2.1202-1206.1992; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; XU HJ, 1989, ONCOGENE, V4, P807	41	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					971	976						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675456				2022-12-17	WOS:A1995RU79800018
J	KASTRINAKIS, WV; RAMCHURREN, N; RIEGER, KM; HESS, DT; LODA, M; STEELE, G; SUMMERHAYES, IC				KASTRINAKIS, WV; RAMCHURREN, N; RIEGER, KM; HESS, DT; LODA, M; STEELE, G; SUMMERHAYES, IC			INCREASED INCIDENCE OF P53 MUTATIONS IS ASSOCIATED WITH HEPATIC METASTASIS IN COLORECTAL NEOPLASTIC PROGRESSION	ONCOGENE			English	Article						P53; COLON; HEPATIC METASTASIS	GENE-MUTATIONS; PROGNOSTIC-SIGNIFICANCE; ALLELIC LOSS; CARCINOMA; CANCER; TUMORS; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION; DELETIONS	Within a panel of 15 colon carcinoma cell lines we have characterized the p53 gene status using immunocytochemistry (ICC), SSCP and direct sequence analysis. Extension of this analysis to the use of ICC on 104 colonic lesions, representative of different stages of colonic neoplastic progression, showed an absence of detectable p53 nuclear staining in preneoplastic polyp lesions (20 cases) with staining of 52% (25/48) of primary colon carcinomas and 81% (29/36) of hepatic metastases, suggestive of an increased incidence of p53 mutations in late stage lesions of colonic cancer. To address this issue more directly, we analysed 18 primary colon carcinomas and hepatic metastases excised coincidentally from the same patients. In ICC, p53 nuclear staining was recorded in matching lesions from eight individuals where direct sequencing revealed identical mutations in each case. In four individuals no ICC staining was detected in either lesion and molecular analysis revealed wild type sequence in exons 4-9. In six individuals p53 nuclear staining was observed in the hepatic metastases of patients but not the primary lesion. Molecular analysis revealed point mutation events in hepatic metastases from these patients which were not detected in the primary tumor. The point mutations identified in colon carcinomas were predominantly transition events (83%) located in previously characterized codon hotspot regions. These results demonstrate an increased incidence of p53 mutations associated with secondary lesions of colorectal tumors suggestive of a role for p53 in the establishment of colorectal hepatic metastases.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG,CANC BIOL LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA044704, R23CA042944, T32CA009580, R01CA042944] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704, CA42944, T32 CA 09580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DIX B, 1994, BRIT J CANCER, V70, P585, DOI 10.1038/bjc.1994.355; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; PIGNATELLI M, 1992, INT J CANCER, V50, P638; PURDIE CA, 1991, AM J PATHOL, V138, P807; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; SHIRASAWA S, 1991, CANCER RES, V51, P2874; STARZYNSKA T, 1992, BRIT J CANCER, V66, P558, DOI 10.1038/bjc.1992.314; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402	24	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					647	652						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651727				2022-12-17	WOS:A1995RQ46900005
J	ZORNIG, M; GRZESCHICZEK, A; KOWALSKI, MB; HARTMANN, KU; MOROY, T				ZORNIG, M; GRZESCHICZEK, A; KOWALSKI, MB; HARTMANN, KU; MOROY, T			LOSS OF FAS/APO-1 RECEPTOR ACCELERATES LYMPHOMAGENESIS IN E-MU L-MYC TRANSGENIC MICE BUT NOT IN ANIMALS INFECTED WITH MOMULV	ONCOGENE			English	Note						HOMEOSTASIS; FAS/APO-1; APOPTOSIS; TRANSGENIC MICE; TUMOR PROGRESSION	TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; C-MYC; N-MYC; LEUKEMIA-VIRUS; FAS ANTIGEN; LPR MICE; SYSTEMIC AUTOIMMUNITY; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING	The Fas/Apo-1 receptor is an integral membrane protein that transduces apoptotic signals upon binding to its natural ligand or to specific antibodies. Loss of Fas/Apo-1 receptor leads in (lpr;lpr) mice to a nonmalignant accumulation of abnormal T-cells very probably due to the lack of induction of apoptosis in peripheral T-cells. It has been reported that soluble forms of Fas/Apo-1 receptor that may interfere with apoptotic signaling occur in patients suffering from various forms of lymphoid neoplasms. Therefore, we wished to investigate whether the loss of proper homeostatic regulation through Fas/Apo-1 receptor mediated apoptosis could influence the process of lymphomagenesis, To this end, we performed two experiments (i) we infected (lpr,lpr) animals with Moloney Murine Leukemia Virus (MoMuLV) that causes T-cell lymphoma in mice and (ii) we crossed (lpr,lpr) animals with E mu L-myc transgenic mice that are prone to develop T- and B-cell lymphoma due to deregulated expression of the L-myc transgene by the immunoglobulin enhancer E mu. We find that infection with MoMuLV did not accelerate the formation of lymphoid neoplasms in (lpr,lpr) mice when compared to infected normal animals. However, E mu L-myc/(lpr,lpr) animals that constitutively express the L-myc transgene in the lymphoid lineage clearly show accelerated formation of T- and B-cell lymphoma when compared to normal E mu L-myc transgenics. These data demonstrate that in cooperation with particular oncogenes impairment of Fas/Apo-1 receptor function can indeed affect and modulate the process of tumor formation.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; UNIV MARBURG,INST EXPTL IMMUNOL,D-35037 MARBURG,GERMANY	Philipps University Marburg; Philipps University Marburg			Moroy, Tarik/D-9923-2011					ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHU JL, 1993, J EXP MED, V178, P723, DOI 10.1084/jem.178.2.723; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; KNIPPING E, 1995, IN PRESS BLOOD; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOLLER P, 1993, BLOOD, V81, P2067; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; MOROY T, 1991, MOL F ONCOLOGY, P455; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Nagata S, 1994, Semin Immunol, V6, P3, DOI 10.1006/smim.1994.1002; OEHM A, 1992, J BIOL CHEM, V267, P10709; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	33	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2397	2401						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784089				2022-12-17	WOS:A1995RE54300016
J	ZALCMAN, G; CLOSSON, V; LINARESCRUZ, G; LEREBOURS, F; HONORE, N; TAVITIAN, A; OLOFSSON, B				ZALCMAN, G; CLOSSON, V; LINARESCRUZ, G; LEREBOURS, F; HONORE, N; TAVITIAN, A; OLOFSSON, B			REGULATION OF RAS-RELATED RHOB PROTEIN EXPRESSION DURING THE CELL-CYCLE	ONCOGENE			English	Article						GTP-BINDING PROTEIN; RHO; RNA EXPRESSION; PROTEIN EXPRESSION; CELL CYCLE	GTP-BINDING-PROTEIN; NERVE GROWTH-FACTOR; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GENE-PRODUCT; HUMAN HOMOLOG; SACCHAROMYCES-CEREVISIAE; CLOSTRIDIUM-BOTULINUM; MOLECULAR-CLONING; FAMILY	The immediate-early gene rhoB codes for a small GTP-binding protein highly homologous to the RhoA protein, While RhoA is known to regulate the assembly of focal adhesions and stress fibers in response to growth factors, the function of RhoB remains unknown. In a first attempt to elucidate its function, we examined the variation of the RhoB protein expression in response to induction of its mRNA. We report here that RhoB is an unstable protein rapidly and transiently induced by growth factors in PC12 and HeLa cells. Moreover, RhoB protein accumulation is periodic through the cell cycle. First detected at the G1/S phase transition, the level of the RhoB protein is maximal during the S phase and declines at the S/G2-M transition. This timing suggests that RhoB plays a role in the G1/S phase transition and/or in the S phase of the cell cycle. We also confirm here a vesicular and perinuclear localization of the endogenous RhoB protein induced by growth factors.	FAC MED LARIBOISIERE, INSERM, U248, F-75010 PARIS, FRANCE; INST GENET MOLEC, PHARMACOL EXPTL LAB, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			ZALCMAN, Gérard/L-7809-2015; ZALCMAN, Gerard/P-4150-2015; ZALCMAN, Gerard/M-8113-2019	ZALCMAN, Gérard/0000-0002-0343-9575; 				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DISBURY J, 1989, J BIOL CHEM, V264, P16378; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JUST I, 1994, J BIOL CHEM, V269, P10706; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; LANG P, 1992, J BIOL CHEM, V267, P11677; LINARESCRUZ G, 1994, J MICROSC-OXFORD, V173, P27, DOI 10.1111/j.1365-2818.1994.tb03425.x; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MORII N, 1992, J BIOL CHEM, V267, P20921; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OLOFSSON B, 1988, ONCOGENE, V3, P231; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SUGAI M, 1992, J BIOL CHEM, V267, P2600; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UEDA T, 1990, J BIOL CHEM, V265, P9373; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	62	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					1935	1945						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7539118				2022-12-17	WOS:A1995QZ92600007
J	FIXMAN, ED; NAUJOKAS, MA; RODRIGUES, GA; MORAN, MF; PARK, M				FIXMAN, ED; NAUJOKAS, MA; RODRIGUES, GA; MORAN, MF; PARK, M			EFFICIENT CELL-TRANSFORMATION BY THE TPR-MET ONCOPROTEIN IS DEPENDENT UPON TYROSINE-489 IN THE CARBOXY-TERMINUS	ONCOGENE			English	Article						MET; ONCOPROTEIN; CELL TRANSFORMATION; SUBSTRATES; TYROSINE PHOSPHORYLATION	HEPATOCYTE GROWTH-FACTOR; PAPILLARY THYROID CARCINOMAS; GUANINE-NUCLEOTIDE EXCHANGE; SCATTER FACTOR-RECEPTOR; PHOSPHOLIPASE-C-GAMMA; GRB2 ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; KINASE-ACTIVITY; SH3 DOMAINS	The receptor for hepatocyte growth factor/scatter factor (HGF/SF) was originally identified as an oncogene, Tpr-Met, which consists of the cytoplasmic tyrosine kinase domain of the HGF/SF receptor (Met) fused downstream of sequences encoded by the tpr gene. As a consequence of this rearrangement the Tpr-Met fusion oncoprotein is localized to the cytoplasm and is a constitutively activated kinase. To identify signalling pathways important for Tpr-Met-mediated cell transformation we have generated tyrosine to phenylalanine mutants of Tpr-Met that are compromised in their ability to transform Fischer rat 3T3 (Fr3T3) cells in culture, We show that a single tyrosine residue in the carboxy terminus of Tpr-Met (residue 489) is essential for efficient transformation of Fr3T3 cells by this oncoprotein, Mutation of tyrosine 489 to phenylalanine does not affect the exogenous kinase activity of the Tpr-Met oncoprotein toward casein, but it impairs the ability of the mutant protein to bind to and activate phosphatidylinositol 3 kinase in vivo and completely abolishes the in vivo association with the Grb2 adaptor protein as well as the association and/or phosphorylation of an unknown protein of 110 kDa, These data are consistent with a single tyrosine residue in the Tpr-Met oncoprotein being essential for the activation of several signalling pathways which lead to the transformation of Fr3T3 fibroblasts.	MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT MED, MOLEC ONCOL GRP, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT ONCOL, MONTREAL, PQ H3A 1A1, CANADA; MCGILL UNIV, ROYAL VICTORIA HOSP, DEPT BIOCHEM, MONTREAL, PQ H3A 1A1, CANADA; UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; University of Toronto			Moran, Michael/GYD-3631-2022					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEAR SE, 1989, P NATL ACAD SCI USA, V63, P2959; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; CROWE AJ, 1994, ONCOGENE, V9, P537; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FALETTO DL, 1993, SIGNAL TRANSDUCTION, P108; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GIORDANO S, 1989, ONCOGENE, V4, P1383; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRECO A, 1992, ONCOGENE, V7, P237; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HALABAN R, 1992, ONCOGENE, V7, P2195; HARLOW E, 1988, ANTIBODIES LABORATOR; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; KAZKAUSKAS A, 1992, MOL CELL BIOL, V12, P2534; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANZI C, 1992, ONCOGENE, V7, P2189; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LONGATI P, 1994, ONCOGENE, V9, P49; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	79	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					237	249						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838524				2022-12-17	WOS:A1995QC62400003
J	LEGROS, Y; MEYER, A; ORY, K; SOUSSI, T				LEGROS, Y; MEYER, A; ORY, K; SOUSSI, T			MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT THAT CAN BE DETECTED WITH A PANEL OF MONOCLONAL-ANTIBODIES DIRECTED TOWARD THE CENTRAL PART OF THE P53 PROTEIN	ONCOGENE			English	Note							LARGE T-ANTIGEN; BREAST-CANCER; SUPPRESSOR; EPITOPES; CELLS; GENE	Human p53 displays two immunodominant regions localized in the amino and carboxy termini of the protein. Using a truncated p53 (residues 66 to 361), we selected eight new monoclonal antibodies directed to the central part of the protein. We identified the epitopes recognized by seven out of eight antibodies with a set of overlapping peptides. One of these antibodies had an epitope similar to PAb240, whereas the others recognized novel and diverse antigenic determinants. Using a series of 19 p53 mutants, we show that the behavior of several of the new monoclonal antibodies is similar to that of PAb240 despite their various epitope localizations. This suggests that different mutations in the p53 protein induce an overall conformational change that can be detected by various monoclonal antibodies directed toward the central part of the protein.	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; ESTBA,F-75020 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1994, ONCOGENE, V9, P299; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEBROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1993, B CANCER, V80, P102; LUBIN R, 1993, CANCER RES, V53, P5872; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1987, ONCOGENE, V1, P453; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SCHLICHTHOLZ B, 1994, BRIT J CANCER, V69, P809, DOI 10.1038/bjc.1994.159; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	22	81	86	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3689	3694						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7526318				2022-12-17	WOS:A1994PT39200033
J	MATSUYAMA, H; PAN, Y; SKOOG, L; TRIBUKAIT, B; NAITO, K; EKMAN, P; LICHTER, P; BERGERHEIM, USR				MATSUYAMA, H; PAN, Y; SKOOG, L; TRIBUKAIT, B; NAITO, K; EKMAN, P; LICHTER, P; BERGERHEIM, USR			DELETION MAPPING OF CHROMOSOME 8P IN PROSTATE-CANCER BY FLUORESCENCE IN-SITU HYBRIDIZATION	ONCOGENE			English	Note							INSITU HYBRIDIZATION; COLORECTAL-CANCER; ALLELIC LOSS; ADENOCARCINOMA; ABERRATIONS; CARCINOMA; CELLS; LOCI; RETINOBLASTOMA; ONCOGENES	Double-target fluorescence in situ hybridization (FISH) was applied to 42 cases of prostate cancer and seven cases of histologically proven benign prostate hyperplasia for the detection of structural aberrations of chromosome 8. Cosmid probes for two chromosome 8p loci (LPL/8p22 and D8S7/8p23) were used in 34 specimens of malignant tumors obtained by the touch biopsy technique. Deletion was defined as when the number of cosmid signals was lower than the number of centromere signals in more than 35% of all nuclei observed. In total; thirty of the 42 (71%) specimens demonstrated any type of 8p deletion. Out of the 34 cases in which deletion mapping could be evaluated, distal deletion (D8S7) was detected in 17 (50%), of which 10 also showed deletion of LPL. Deletion of LPL was detected in 18 cases (53%), of which 8 (24%) retained the D8S7 (interstitial deletion). When the deletion pattern was graded as (1) no deletion (2) partial deletion (either D8S7 or LPL deleted) and (3) both deletions, the degree of deletion was well correlated with the tumor grade (P = 0.0009) and with stage (P = 0.0072, Fisher's Exact test). These data support the hypothesis that tumor suppressor gene(s) may be located in the chromosomal region 8p22, hence 8p deletions may play a crucial role in the pathogenesis of prostate cancer.	KAROLINSKA HOSP,DEPT UROL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT MED RADIOBIOL,STOCKHOLM,SWEDEN; KAROLINSKA HOSP,DEPT PATHOL,S-10401 STOCKHOLM,SWEDEN; DEUTSCH KREBSFORSCHUNGSZENTRUM,HEIDELBERG,GERMANY; YAMAGUCHI UNIV,SCH MED,DEPT UROL,UBE,YAMAGUCHI 755,JAPAN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Yamaguchi University			Matsuyama, Hideyasu/AAC-7487-2020	Matsuyama, Hideyasu/0000-0001-5607-7769				ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1993, CANCER-AM CANCER SOC, V71, P1179, DOI 10.1002/1097-0142(19930201)71:3+<1179::AID-CNCR2820711442>3.0.CO;2-B; BOVA GS, 1993, CANCER RES, V53, P3869; BROTHMAN AR, 1990, CANCER RES, V50, P3795; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; CREMER T, 1988, HUM GENET, V80, P235, DOI 10.1007/BF01790091; EMI M, 1992, CANCER RES, V52, P5368; ESPOSTI P L, 1971, Scandinavian Journal of Urology and Nephrology, V5, P199, DOI 10.3109/00365597109133601; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GIBAS Z, 1985, CANCER GENET CYTOGEN, V16, P301, DOI 10.1016/0165-4608(85)90237-7; HOPMAN AHN, 1988, HISTOCHEMISTRY, V89, P307, DOI 10.1007/BF00500631; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; MATSUMURA K, 1992, CANCER RES, V52, P3474; MATSUYAMA H, 1994, IN PRESS CANCER GENE; MCNEAL JE, 1986, LANCET, V1, P60; Mostofi FK, 1973, INT CLASSIFICATION T; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STILGENBAUER S, 1993, BLOOD, V81, P2118; TRIBUKAIT B, 1989, RAPID FLOW CYTOMETRY; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114	28	81	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3071	3076						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084616				2022-12-17	WOS:A1994PG82200040
J	MULERIS, M; ALMEIDA, A; DUTRILLAUX, AM; PRUCHON, E; VEGA, F; DELATTRE, JY; POISSON, M; MALFOY, B; DUTRILLAUX, B				MULERIS, M; ALMEIDA, A; DUTRILLAUX, AM; PRUCHON, E; VEGA, F; DELATTRE, JY; POISSON, M; MALFOY, B; DUTRILLAUX, B			ONCOGENE AMPLIFICATION IN HUMAN GLIOMAS - A MOLECULAR CYTOGENETIC ANALYSIS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; MALIGNANT HUMAN GLIOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; CENTRAL-NERVOUS-SYSTEM; GENE AMPLIFICATION; CHROMOSOMAL-ABNORMALITIES; HUMAN GLIOBLASTOMA; DNA-AMPLIFICATION; SOLID TUMORS; CELL-LINES	Nine cases of malignant gliomas were selected for the presence of double minutes (dmin) or homogeneously staining regions (hsr) detected by conventional cytogenetics. Analyses were performed on fresh (2 cases) or xenografted (5 cases) tumors or both (2 cases). A modified comparative genomic hybridization technique (mCGH) was applied exhibiting a single amplified locus in 8 tumors and 4 amplified loci in one tumor. Recurrent sites of amplification were detected in 7p11-p12 (5 cases) and 1q32.1 (2 cases). Signals were also observed in 4q11-q12, 5p15.1, 7q31, 8q24.1 and 9p2 in one tumor each. Southern blotting demonstrated that the genes for EGFR (epidermal growth factor receptor), PDGFRA (platelet derived growth factor receptor alpha), MET and MYC oncogenes were involved in 7p11-p12, 4q11-q12, 7q31 and 8q24.1 amplifications, respectively. These amplifications were found by ill situ hybridization on tumor spreads, in dmin or episomes for EGFR, dmin for PDGFRA and MET, and hsr and dmin for MYC genes. Other mCGH signals, for which no target genes could be proposed, were confirmed by chromosome paintings on tumor metaphases. In one of the tumors, the coamplification of DNA from 5p15.1 and 9p2 bands in the same dmin was demonstrated.	CEA,DSV DPTE LCG,F-92265 FONTENAY ROSES,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE	CEA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	MULERIS, M (corresponding author), INST CURIE,CNRS,BIOL SECT,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE.							ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; BIGNER SH, 1990, CANCER RES, V50, P8017; BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BIGNER SH, 1989, CANCER GENET CYTOGEN, V40, P111, DOI 10.1016/0165-4608(89)90152-0; BIGNER SH, 1988, ISI ATLAS-BIOCHEM, V1, P333; BIGNER SH, 1987, CANCER GENET CYTOGEN, V29, P165, DOI 10.1016/0165-4608(87)90045-8; BIGNER SH, 1984, HEREDITAS, V101, P103, DOI 10.1111/j.1601-5223.1984.tb00455.x; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COLLINS VP, 1993, SEMIN CANCER BIOL, V4, P27; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; DIRENZO MF, 1993, ONCOGENE, V8, P219; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; FATH I, 1993, NUCLEIC ACIDS RES, V21, P4398, DOI 10.1093/nar/21.18.4398; FLEMING TP, 1992, CANCER RES, V52, P4550; FULLER GN, 1992, MUTAT RES, V276, P299, DOI 10.1016/0165-1110(92)90016-3; HUMPHREY PA, 1988, CANCER RES, V48, P2231; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; JOOS S, 1993, HUM GENET, V90, P584, DOI 10.1007/BF00202475; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI OP, 1993, SEMIN CANCER BIOL, V4, P41; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KUMABE T, 1992, ONCOGENE, V7, P627; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; MULERIS AM, IN PRESS GENES CHROM; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PRUCHON E, IN PRESS CANCER GENE; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SPEICHER MR, 1993, HUM MOL GENET, V2, P1907; THIEL G, 1992, CANCER GENET CYTOGEN, V58, P109, DOI 10.1016/0165-4608(92)90095-P; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; WAHL GM, 1989, CANCER RES, V49, P1333; WELTER C, 1990, CANCER LETT, V52, P57, DOI 10.1016/0304-3835(90)90077-B; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WULCH KJ, 1979, INT HISTOLOGICAL CLA, V21; WULLICH B, 1993, EUR J CANCER, V29A, P1991, DOI 10.1016/0959-8049(93)90460-W; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0	43	81	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2717	2722						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058336				2022-12-17	WOS:A1994PC05400033
J	LUKAS, J; JADAYEL, D; BARTKOVA, J; NACHEVA, E; DYER, MJS; STRAUSS, M; BARTEK, J				LUKAS, J; JADAYEL, D; BARTKOVA, J; NACHEVA, E; DYER, MJS; STRAUSS, M; BARTEK, J			BCL-1 CYCLIN D1 ONCOPROTEIN OSCILLATES AND SUBVERTS THE G1 PHASE-CONTROL IN B-CELL NEOPLASMS CARRYING THE T(1114) TRANSLOCATION	ONCOGENE			English	Article							T(11-14) CHROMOSOME-TRANSLOCATION; CYCLIN GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; CENTROCYTIC LYMPHOMA; NUCLEAR-PROTEIN; OVEREXPRESSION; REARRANGEMENT; BREAKPOINTS; LEUKEMIAS; ONCOGENE	In an effort to elucidate the biological role played by cyclin D1, a candidate BCL-1 oncogene, in human B-cell rumours carrying the t(11;14) translocation, we have studied the properties of this cyclin protein in a series of human lymphoid lines with rearrangements in the BCL-1 locus. The BCL-1/cyclin D1 protein was easily detectable in both immunocytochemistry and immunoblotting, its abundance grossly correlating with the mRNA levels. The cyclin D1 protein was localised predominantly to nuclei and there was a striking variation of staining intensity among the exponentially growing cells, reflecting the maximum level reached in mid/late G1 and the lowest level in S-phase. This characteristic mode of cell cycle-dependent oscillation was confirmed by three independent approaches, demonstrating that even upon rearrangement, the expression of cyclin D1 is regulated in a cyclical manner. Antibody-mediated and anti-sense oligonucleotide 'knockout' experiments revealed that the aberrantly expressed BCL-1/cyclin D1 protein is required for G1 phase progression of all four B-cell tumours with the BCL-1 rearrangement. Consistent with the proposed oncogenic role of this cyclin, our data demonstrate that the BCL-1 deregulation caused by chromosomal rearrangement leads to expression of a functionally active cyclin D1 protein which subverts the G1 phase control in the human B-cell tumours carrying the t(11;14) translocation.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN O, DENMARK; ROYAL CANC HOSP, INST CANC RES, HADDOW LABS, SUTTON SM2 5NG, SURREY, ENGLAND; ADDENBROOKES HOSP, DEPT HAEMATOL, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND; MAX PLANCK GESELL, D-13122 BERLIN, GERMANY	Danish Cancer Society; University of London; Institute of Cancer Research - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Max Planck Society			Bartek, Jiri/G-5870-2014; Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236; Lukas, Jiri/0000-0001-9087-506X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTEK J, 1993, STEM CELLS, V11, P51, DOI 10.1002/stem.5530110611; BARTEK J, 1992, ONCOGENE, V7, P101; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1991, CANCER RES, V51, P3602; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, IN PRESS J CELL BIOL; LUKAS J, 1994, IN PRESS J IMMUNOL M; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEEKER T, 1991, GENE CHROMOSOME CANC, V8, P80; MELO JV, 1988, CLIN EXP IMMUNOL, V73, P23; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NACHEVA E, 1990, BRIT J HAEMATOL, V74, P70, DOI 10.1111/j.1365-2141.1990.tb02540.x; PALMERO I, 1993, ONCOGENE, V8, P1049; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RABBITTS PH, 1988, ONCOGENE, V3, P99; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SALTMAN DL, 1988, BLOOD, V72, P2026, DOI 10.1182/blood.V72.6.2026.2026; Sambrook J., 1989, MOL CLONING LAB MANU; SETO M, 1992, ONCOGENE, V7, P1401; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	46	81	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2159	2167						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036001				2022-12-17	WOS:A1994NX62900006
J	BOND, JA; WYLLIE, FS; ROWSON, J; RADULESCU, A; WYNFORDTHOMAS, D				BOND, JA; WYLLIE, FS; ROWSON, J; RADULESCU, A; WYNFORDTHOMAS, D			IN-VITRO RECONSTRUCTION OF TUMOR INITIATION IN A HUMAN EPITHELIUM	ONCOGENE			English	Article							RET ONCOGENE ACTIVATION; COLORECTAL TUMORIGENESIS; THYROID-TUMORS; RAS ONCOGENE; MUTATIONS OCCUR; HIGH-FREQUENCY; CELL-LINE; PAPILLARY; CARCINOMAS; MARKERS	Knowledge of tumour initiation in human epithelia is limited by sample availability and difficulty in experimental manipulation of human cells. The thyroid is a useful model since, in addition to multiple tumour stages, it presents two distinct 'pathways' of tumorigenesis: 'follicular' tumours, in which vas oncogene mutations occur at high frequency and 'papillary' tumours, associated with ret (or trk) activation. We have used these observations to reconstruct early thyroid tumorigenesis, using amphotropic retroviral vectors. When introduced into normal thyroid epithelial cells, mutant vas induces self-limiting growth of well-demarcated, differentiated colonies - a phenotype consistent with follicular adenoma. Activated ret on the other hand induces smaller, poorly demarcated colonies with a morphology consistent with early papillary tumours. Mutant p53 - which occurs only in the latest stages of thyroid cancer - was without effect. Our results provide the first direct experimental evidence in a human epithelium for alternative initiating oncogenes and their determination of the subsequent 'direction' of tumour development.	UNIV WALES COLL CARDIFF,COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,CARDIFF,S GLAM CF4 4XN,WALES	Cardiff University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hedinger C, 1988, HISTOLOGICAL TYPING; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1992, CANCER RES, V52, P1369; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCHRODER S, 1985, AM J SURG PATHOL, V9, P619, DOI 10.1097/00000478-198509000-00001; SHEPARD TH, 1968, GEN COMP ENDOCR, V10, P174, DOI 10.1016/0016-6480(68)90024-5; SUAREZ HG, 1990, ONCOGENE, V5, P565; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WILLIAMS DW, 1989, THYROID TUMOURS MOL, P57; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; WRIGHT PA, 1993, J PATH S, V169, P230; WYNFORDTHOMAS D, 1991, J PATHOL, V165, P187, DOI 10.1002/path.1711650302	32	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					281	290						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302590				2022-12-17	WOS:A1994MW24700034
J	YAGI, T; SHIGETANI, Y; OKADO, N; TOKUNAGA, T; IKAWA, Y; AIZAWA, S				YAGI, T; SHIGETANI, Y; OKADO, N; TOKUNAGA, T; IKAWA, Y; AIZAWA, S			REGIONAL LOCALIZATION OF FYN IN ADULT BRAIN - STUDIES WITH MICE IN WHICH FYN GENE WAS REPLACED BY LACZ	ONCOGENE			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN; TYROSINE PHOSPHORYLATION; NMDA RECEPTOR; STEM-CELLS; PROTEIN; RNA; PROTOONCOGENE; RECOMBINATION; EXPRESSION	Mutant mice in which beta-galactosidase gene (lacZ) was inserted into fyn locus were generated by homologous recombination in embryonic stem cells to examine the Fyn expression in the central nervous system. In adult brain, intensive beta-galactosidase activity was observed in olfactory bulb, cerebellum and hippocampus of the limbic system; the subcellular distribution of the activity was apparent not only in cell body but also in neural processes, and homozygous mutant mice live-born displayed an anatomical abnormality in the neural cell layer of the hippocampal formation. In spinal cord it was specifically expressed in dorsal horn, and in brain stem it was more characteristic in the sensory pathway, suggesting roles of Fyn in the sensory nervous network. In the white matter area, it was intense at postnatal day 10 but not detectable in adult, suggesting Fyn's role in myelinization.	UNIV TSUKUBA, INST BASIC MED SCI, DEPT ANAT, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	YAGI, T (corresponding author), INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC ONCOL LAB, 3-1-1 KOYADAI, TSUKUBA, IBARAKI 305, JAPAN.							BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; ISHIGURO H, 1991, BRAIN RES, V563, P288, DOI 10.1016/0006-8993(91)91548-F; JACOBSON S, 1963, J COMP NEUROL, V121, P5, DOI 10.1002/cne.901210103; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOMURA S, 1989, DEVELOPMENT, V105, P575; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGI T, 1993, IN PRESS ANAL BIOCH; ZHAO YH, 1991, ONCOGENE, V6, P1725	32	81	81	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3343	3351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247536				2022-12-17	WOS:A1993MG78200018
J	PAJUSOLA, K; APRELIKOVA, O; ARMSTRONG, E; MORRIS, S; ALITALO, K				PAJUSOLA, K; APRELIKOVA, O; ARMSTRONG, E; MORRIS, S; ALITALO, K			2 HUMAN FLT4 RECEPTOR TYROSINE KINASE ISOFORMS WITH DISTINCT CARBOXY-TERMINAL TAILS ARE PRODUCED BY ALTERNATIVE PROCESSING OF PRIMARY TRANSCRIPTS	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; C-KIT; GENE; SPECIFICITY; ORGANIZATION; EXPRESSION; REGION	FLT4 is a recently cloned gene encoding a transmembrane tyrosine kinase related to the FLT1 and KDR/FLK1 vascular endothelial growth factor receptors. We have previously shown that FLT4 is expressed as transcripts of 4.5 and 5.8 kb in several human fetal and adult tissues. Here we show that these transcripts encode two polypeptides, FLT4s (short) and FLT41 (long), which are proteolytically processed in transfected cells and leukemia cells and which have different carboxy terminal tails. The 3' coding region of the 5.8 kb mRNA was found to be 65 codons longer than that of the the 4.5 kb mRNA. Analysis of the genomic structure of the region encoding the two carboxy termini revealed that the two transcripts are generated by alternative polyadenylation and subsequent alternative splicing during RNA processing. Our findings thus show regulation of FLT4 structure in the carboxy terminal tail considered important for receptor function. The significance of the two forms may relate to the role of additional potential autophosphorylation sites in the FLT4 long form.	ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	PAJUSOLA, K (corresponding author), UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, PL 21, SF-00014 HELSINKI, FINLAND.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				ANDRE C, 1992, ONCOGENE, V7, P685; APRELIKOVA O, 1992, CANCER RES, V52, P746; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1993, ONCOGENE, V8, P1233; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HAMPE A, 1989, ONCOGENE RES, V4, P9; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PAJUSOLA K, 1992, CANCER RES, V52, P5738; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SHIBUYA M, 1990, ONCOGENE, V5, P519; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P1829; TAHIRA T, 1990, ONCOGENE, V5, P97; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	23	81	104	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2931	2937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692369				2022-12-17	WOS:A1993MC09300006
J	MAA, MC; WILSON, LK; MOYERS, JS; VINES, RR; PARSONS, JT; PARSONS, SJ				MAA, MC; WILSON, LK; MOYERS, JS; VINES, RR; PARSONS, JT; PARSONS, SJ			IDENTIFICATION AND CHARACTERIZATION OF A CYTOSKELETON-ASSOCIATED, EPIDERMAL GROWTH-FACTOR SENSITIVE PP60C-SRC SUBSTRATE	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; OVEREXPRESSING C-SRC; MITOGENIC RESPONSIVENESS; CELLULAR PROTEINS; CELLS; PHOSPHORYLATION; GENE; CLONING; CYCLE; DOMAINS	In studies aimed at identifying and characterizing pp60c-src substrates that participate in the enhanced mitogenic response to epidermal growth factor (EGF) observed in murine C3H10T1/2 fibroblasts overexpressing c-src, we have identified a 75-kDa protein (p75) whose properties are consistent with those expected of such a substrate. We present evidence to show that p75 is immunologically related to a recently described, cytoskeleton-associated, pp60v-src substrate [Wu et al. (1991). Mol. Cell. Biol., 11, 5113-5124), and that its phosphotyrosine content is increased cooperatively by c-src overexpression and EGF stimulation. p75 is rapidly (within 2 min) phosphorylated on tyrosine upon EGF treatment and undergoes a second, prolonged phase of tyrosyl phosphorylation from 7 to 21 h after EGF addition, suggesting that tyrosyl phosphorylation of p75 is important for late as well as early events following EGF receptor activation. Enhanced tyrosyl phosphorylation of p75 is also seen when cells overexpressing c-src are treated with platelet-derived growth factor (PDGF), but significantly less phosphorylation is observed with insulin and fibroblast growth factor (FGF). Both basal and EGF-induced tyrosyl phosphorylation of p75 are reduced in cells overexpressing mutated forms of c-src (unmyristylated, or kinase deficient) as compared with wild-type c-src overexpressers, indicating the dependence of the enhanced tyrosyl phosphorylation on membrane-associated, enzymatically active pp60c-src. In cellular fractionation experiments p75 partitions with the cytosol, while immunofluorescence studies reveal a striking colocalization with pp60c-src at the plasma membrane and in the perinuclear region. Partial co-staining of p75 and actin occurs at the cell's periphery. These data provide evidence for p75 being a direct substrate of pp60c-src. The possible role of p75 in the enhanced response to EGF seen in c-src overexpressers is discussed.	UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA 40042, CA 29243, CA 39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA029243, R01CA039438, P01CA040042, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COPPER JA, 1990, PEPTIDES PROTEIN PHO, P85; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GENTRY LE, 1986, MOL CELL BIOL, V6, P735, DOI 10.1128/MCB.6.2.735; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOOPER C, 1990, J NIH RES, V2, P67; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MCMAHON AP, 1987, DIFFERENTIATION, V34, P68, DOI 10.1111/j.1432-0436.1987.tb00052.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1988, ONCOGENE, V3, P491; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAMURA T, 1984, FEBS LETT, V177, P151, DOI 10.1016/0014-5793(84)81001-7; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	43	81	83	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2429	2438						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281304				2022-12-17	WOS:A1992KA85600007
J	SCHNEIKERT, J; LUTZ, Y; WASYLYK, B				SCHNEIKERT, J; LUTZ, Y; WASYLYK, B			2 INDEPENDENT ACTIVATION DOMAINS IN C-ETS-1 AND C-ETS-2 LOCATED IN NONCONSERVED SEQUENCES OF THE ETS GENE FAMILY	ONCOGENE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; TAT PROTEIN; ONCOGENE; IDENTIFICATION; EXPRESSION; CELLS; ERYTHROBLASTOSIS; RETROVIRUS-E26	The c-Ets-1 oncoprotein is a transcription activator that specifically binds to DNA. We show, using fusion proteins with heterologous DNA-binding domains, that chicken c-Ets-1 (p68) contains two independent activation domains. The N-terminal activation domain is absent in c-Ets-1 (p54) that is generated from an alternatively spliced mRNA. A closely related member of the ets gene family, c-Ets-2, also contains two separate activation domains. They lie in the regions of the protein that are least conserved with c-Ets-1, suggesting that the activating function will determine the different physiological roles of these two proteins. The activation domains of c-Ets-1 (p68) and -2 are separated by a moderately conserved region that does not activate on its own. These sequences appear to affect stimulation by the domains, suggesting that they regulate transcription activation. Competition experiments show that c-Ets-1 and -2 interact with a common limiting coactivator. These studies provide important clues about the physiological roles of closely related members of the ets gene family.	CNRS, LGME,INSERM,U184,FAC MED,INST CHIM BIOL, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; POGNONEC P, 1990, ONCOGENE, V5, P603; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUBEN S, 1989, J VIROL, V63, P1; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	38	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					249	256						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549346				2022-12-17	WOS:A1992HG98200007
J	TOURAY, M; RYAN, F; JAGGI, R; MARTIN, F				TOURAY, M; RYAN, F; JAGGI, R; MARTIN, F			CHARACTERIZATION OF FUNCTIONAL INHIBITION OF THE GLUCOCORTICOID RECEPTOR BY FOS/JUN	ONCOGENE			English	Article								We have studied the effects of Fos and Fos/Jun on glucocorticoid induction of hormone-sensitive gene expression. In NIH3T3 cells overexpression of Fos or Fos/Jun by transfection of pSV2-fos and pSV2-jun inhibited glucocorticoid-dependent expression of MMTV LTR-CAT. Expression of p39v-mos had a similar effect on glucocorticoid-dependent reporter gene expression which is most likely mediated by simulation of endogenous Fos. In both cases, this inhibition could be overcome by overexpression of the glucocorticoid receptor (GR) from a transiently transfected expression vector. In receptor deficient CV-1 cells glucocorticoid-dependent reporter gene expression was induced by a range of functional GR truncation mutants. It was established that the C/D domain of the receptor was a sufficient target for inhibition by Fos and Fos/Jun. The C/D domain encompasses the DNA-binding domain, a dimerisation domain and a weak transactivational domain of the GR. When present simultaneously in the cell nucleus Fos and Jun were shown to form a specific and stable protein/protein complex with the glucocorticoid receptor. Finally, it was demonstrated that the GR interacts physically with both Fos and Jun when cotranslated simultaneously in vitro. We propose that this interaction may be the mechanism by which Fos of Fos/Jun bring about inhibition of GR function.	NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND; UNIV BERN, DEPT CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND	University College Dublin; University of Bern	MARTIN, F (corresponding author), NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND.		Ryan, Fergus/B-8407-2012					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMILTON BJ, 1989, P NATL ACAD SCI USA, V86, P597, DOI 10.1073/pnas.86.2.597; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAGGI R, 1989, CANCER RES, V49, pS2266; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PRATT WB, 1988, J BIOL CHEM, V263, P267; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TOURAY M, 1991, ONCOGENE, V6, P211; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	50	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1227	1234						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650443				2022-12-17	WOS:A1991GV26000019
J	ALEXANDRE, C; VERRIER, B				ALEXANDRE, C; VERRIER, B			4 REGULATORY ELEMENTS IN THE HUMAN C-FOS PROMOTER MEDIATE TRANSACTIVATION BY HTLV-1 TAX PROTEIN	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; SERUM RESPONSE ELEMENT; MULTIPLE SEQUENCE ELEMENTS; CYCLIC-AMP; GROWTH-FACTOR; RAPID INDUCTION; AUTO-REGULATION; ONCOGENE FOS; ACTIN GENES; T-CELLS	Expression of the human c-fos proto-oncogene is activated in trans by the Tax protein encoded by human T-cell leukemia virus type-1 (HTLV-1). Indeed, we show here that a HeLa clone stably transfected by Tax expresses Fos at a high level. We also show that multiple elements of the human c-fos promoter, i.e. the v-sis conditioned medium inducible element (SIE), the dyad symmetry element (DSE) necessary for growth factor induction, the octanucleotide direct repeat element (DR), and the cyclic AMP response element (CRE) centred at -60, can all mediate Tax transactivation. In the DSE, the 10 bp central core that binds the serum response factor (SRF) is, by itself, sufficient to mediate Tax transactivation. Moreover, a CRE-binding protein is involved in Tax activation through the CRE-60 element. Since Fos is a transregulator of cellular genes, our results suggest that the oncoprotein plays a crucial role in T-cell transformation by HTLV-1 in conjunction with other Tax-inducible genes.	ECOLE NORMALE SUPER LYON,CNRS,UNITE BIOMERIEUX 103,46 ALLEE ITALIE,F-69364 LYONS 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			verrier, bernard/J-4094-2017	verrier, bernard/0000-0002-8478-7095				ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; BALLARD D W, 1989, New Biologist, V1, P83; BEIMLING P, 1990, ONCOGENE, V5, P361; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOHNLEIN E, 1989, J VIROL, V63, P1578; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Curran T, 1988, ONCOGENE HDB, P307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1212; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JACOBSON S, 1988, NATURE, V331, P540, DOI 10.1038/331540a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RUBEN S M, 1989, New Biologist, V1, P275; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SEIKI M, 1985, GANN, V76, P1127; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	60	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					543	551						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1827666				2022-12-17	WOS:A1991FR93900007
J	SCHONTHAL, A; TSUKITANI, Y; FERAMISCO, JR				SCHONTHAL, A; TSUKITANI, Y; FERAMISCO, JR			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF C-FOS EXPRESSION BY THE TUMOR PROMOTER OKADAIC ACID	ONCOGENE			English	Article							PROTEIN-KINASE-C; RABBIT SKELETAL-MUSCLE; SERUM-RESPONSE ELEMENT; SWISS MOUSE 3T3-CELLS; MESSENGER-RNA; GROWTH-FACTOR; CELL-CYCLE; PHOSPHOPROTEIN PHOSPHATASE; SIGNAL TRANSDUCTION; GENE-EXPRESSION	Phosphorylation events are major regulatory mechanisms of signal transduction pathways that control cell growth and differentiation. We analyzed the potential contribution of serine/threonine specific protein phosphatases to the regulation of the c-fos gene, a proto-oncogene that is involved in the regulation of cell growth and differentiation. By use of okadaic acid, an inhibitor of protein phosphatases 1 and 2A, we present evidence that expression of the c-fos gene is regulated by serine/threonine specific protein phosphatases. This control is exerted on the transcriptional as well as the post-transcriptional level. The results suggest that dephosphorylation of regulatory phosphoproteins is an important mechanism for the down-regulation of c-fos promoter activity and the rapid degradation of c-fos mRNA. Examination of two protein kinase pathways that are known to regulate c-fos expression indicated that okadaic acid acted synergistically with protein kinase C, but not with protein kinase A. Since inhibition of serine/threonine specific phosphatases increases proto-oncogene expression, these experiments further strengthen the view that certain protein phosphatases may act as negative regulators of cell growth.	FUJISAWA PHARMACEUT CO LTD, OSAKA 532, JAPAN	Astellas Pharmaceuticals	SCHONTHAL, A (corresponding author), UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; Curran T, 1988, ONCOGENE HDB, P307; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FUJIKI H, 1987, P JPN ACAD B-PHYS, V63, P51, DOI 10.2183/pjab.63.51; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HARLOW E, 1988, ANTIBODIES; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOLMES CFB, 1986, BIOCH BIOPHYS ACTA, V870; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KLEE CB, 1988, MOL ASPECTS CELLULAR, P225; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHONTHAL A, 1990, CELL SIGNAL, V2, P215, DOI 10.1016/0898-6568(90)90049-G; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEWART AA, 1980, FEBS LETT, V119, P16, DOI 10.1016/0014-5793(80)80988-4; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	70	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					423	430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1901402				2022-12-17	WOS:A1991FT34400011
J	BERENSON, JR; KOGA, H; YANG, J; PEARL, J; HOLMES, EC; FIGLIN, R				BERENSON, JR; KOGA, H; YANG, J; PEARL, J; HOLMES, EC; FIGLIN, R			FREQUENT AMPLIFICATION OF THE BCL-1 LOCUS IN POORLY DIFFERENTIATED SQUAMOUS-CELL CARCINOMA OF THE LUNG	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES,VET ADM MED CTR W LOS ANGELES,SCH MED,CTR HLTH SCI,DEPT SURG,LOS ANGELES,CA 90024; LATTER DAY ST HOSP,DEPT MED,SALT LAKE CITY,UT 84143	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BERENSON, JR (corresponding author), UNIV CALIF LOS ANGELES,VET ADM MED CTR W LOS ANGELES,SCH MED,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024, USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; ADNANE J, 1989, ONCOGENE, V4, P1389; ALI IU, 1989, ONCOGENE, V4, P89; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ANTONARAKIS SE, 1982, P NATL ACAD SCI-BIOL, V79, P137, DOI 10.1073/pnas.79.1.137; BERENSON J, 1989, LEUKEMIA, V3, P133; BERENSON J, 1989, J CELL BIOCH B, V13, P80; BERENSON JR, 1989, ONCOGENE, V4, P1111; BERGER MS, 1987, J PATHOL, V152, P297, DOI 10.1002/path.1711520408; BERGER MS, 1988, CANCER RES, V48, P1238; BIRRER MJ, 1988, SEMIN ONCOL, V15, P226; BOS JL, 1989, CANCER RES, V49, P4682; CALLAHAN R, 1989, J CELL BIOCH B, V13, P6; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CLINE MJ, 1987, CANCER, V60, P2669, DOI 10.1002/1097-0142(19871201)60:11<2669::AID-CNCR2820601116>3.0.CO;2-4; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; HATADA I, 1988, ONCOGENE, V3, P537; HEIGHWAY J, 1986, BRIT J CANCER, V53, P285, DOI 10.1038/bjc.1986.47; INCE C, 1988, LEUKEMIA, V2, P343; KAOSHAN CS, 1987, CANCER RES, V47, P6278; KOOP CE, 1986, DHHS CDC878398 US DE; LESTER EP, 1988, P AM ASSOC CANC RES, V29, P28; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYAKI M, 1985, JPN J CANCER RES, V76, P260; MULERIS M, 1987, INT J CANCER, V39, P595, DOI 10.1002/ijc.2910390509; RABBITTS PH, 1988, ONCOGENE, V3, P99; RECHAVI G, 1989, LEUKEMIA, V3, P57; RODENHUIS S, 1988, CANCER RES, V48, P5738; SAKSELA K, 1986, J CELL BIOCHEM, V31, P297, DOI 10.1002/jcb.240310407; SATYAPRAKASH KL, 1981, CANCER GENET CYTOGEN, V3, P61, DOI 10.1016/0165-4608(81)90057-1; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SELVANAYAGAM P, 1987, P AM ASSOC CANC RES, V28, P19; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1989, J IMMUNOL, V142, P2555; TSUDA T, 1988, JPN J CANCER RES, V79, P584, DOI 10.1111/j.1349-7006.1988.tb00026.x; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VANDENBERGHE H, 1984, CANCER GENET CYTOGEN, V11, P381, DOI 10.1016/0165-4608(84)90017-7; VARLEY JM, 1988, ONCOGENE, V3, P87; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WUU KD, 1986, CANCER GENET CYTOGEN, V20, P2798; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; YOKOTA J, 1988, ONCOGENE, V2, P607; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YOSHIMOTO K, 1986, JPN J CANCER RES, V77, P731; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZHOU DJ, 1987, CANCER RES, V47, P6123; ZHOU DJ, 1988, ONCOGENE, V2, P279	60	81	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1343	1348						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2170896				2022-12-17	WOS:A1990EC24100010
J	KROLEWSKI, JJ; LEE, R; EDDY, R; SHOWS, TB; DALLAFAVERA, R				KROLEWSKI, JJ; LEE, R; EDDY, R; SHOWS, TB; DALLAFAVERA, R			IDENTIFICATION AND CHROMOSOMAL MAPPING OF NEW HUMAN TYROSINE KINASE GENES	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT HUMAN GENET,BUFFALO,NY 14263	Columbia University; Columbia University; Roswell Park Cancer Institute					NCI NIH HHS [CA44029] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1988, ONCOGENE, V3, P629; Maniatis T., 1982, MOL CLONING; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1988, ONCOGENE, V3, P491; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	38	81	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					277	282						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2156206				2022-12-17	WOS:A1990CW41500004
J	HOUCK, KA; MICHALOPOULOS, GK; STROM, SC				HOUCK, KA; MICHALOPOULOS, GK; STROM, SC			INTRODUCTION OF A HA-RAS ONCOGENE INTO RAT-LIVER EPITHELIAL-CELLS AND PARENCHYMAL HEPATOCYTES CONFERS RESISTANCE TO THE GROWTH INHIBITORY EFFECTS OF TGF-BETA	ONCOGENE			English	Article									DUKE UNIV,MED CTR,DEPT PATHOL,POB 3432,DURHAM,NC 27710; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PATHOL,RICHMOND,VA 23298	Duke University; Virginia Commonwealth University			Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249	NATIONAL CANCER INSTITUTE [R01CA030241, R01CA043632, R01CA035373, R37CA030241] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43632, CA-35373, CA-30241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CARR BI, 1986, CANCER RES, V44, P2230; COFFEY RJ, 1986, CANCER RES, V46, P1164; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FISZERSZAFARZ B, 1981, ANAL BIOCHEM, V110, P165, DOI 10.1016/0003-2697(81)90130-5; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GRISHAM JW, 1983, MOL CELL BIOCHEM, V53-4, P23; HOUCK KA, 1988, J CELL PHYSIOL, V135, P551, DOI 10.1002/jcp.1041350327; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; JIRTLE RL, 1981, CANCER RES, V41, P3512; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAIHO M, 1986, EXP CELL RES, V164, P399, DOI 10.1016/0014-4827(86)90038-8; LIN P, 1987, BIOCHEM BIOPH RES CO, V143, P26, DOI 10.1016/0006-291X(87)90624-3; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; MOSES HL, 1981, CANCER RES, V41, P2842; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SAND TE, 1985, ACTA ENDOCRINOL-COP, V109, P369, DOI 10.1530/acta.0.1090369; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SPARKS RL, 1986, EXP CELL RES, V165, P345, DOI 10.1016/0014-4827(86)90588-4; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TSAO MS, 1985, CANCER RES, V45, P4428; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WILLIAMS GM, 1971, EXP CELL RES, V69, P106, DOI 10.1016/0014-4827(71)90316-8; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	48	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					19	25						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2783773				2022-12-17	WOS:A1989U567400003
J	Ding, J; Yeh, CR; Sun, Y; Lin, CY; Chou, JS; Ou, ZY; Chang, CS; Qi, J; Yeh, SY				Ding, Jie; Yeh, Chiuan-Ren; Sun, Yin; Lin, Changyi; Chou, Joshua; Ou, Zhenyu; Chang, Chawnshang; Qi, Jun; Yeh, Shuyuan			Estrogen receptor beta promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network	ONCOGENE			English	Article							LONG NONCODING RNA; RESISTANT PROSTATE-CANCER; ANDROGEN-RECEPTOR; ER-BETA; PROGNOSTIC MARKER; TARGETED THERAPY; SIGNALING AXIS; BREAST-CANCER; HOTAIR; EXPRESSION	Recent studies indicated that the estrogen receptor beta (ER beta) could affect the progression of prostate and bladder tumors, however, its roles in the renal cell carcinoma (RCC), remain to be elucidated. Here, we provide clinical evidence that ER beta expression is correlated in a negative manner with the overall survival/disease-free survival in RCC patients. Mechanism dissection revealed that targeting ER beta with ER beta-shRNA and stimulating the transactivation of ER beta with 17 beta-estradiol or environmental endocrine disrupting chemicals, all resulted in altering the lncRNA HOTAIR expression. The ER beta-modulated HOTAIR is able to function via antagonizing several microRNAs, including miR-138, miR-200c, miR-204, or miR-217 to impact various oncogenes, including ADAM9, CCND2, EZH2, VEGFA, VIM, ZEB1, and ZEB2, to promote RCC proliferation and invasion. Together, the identification of the ER beta-HOTAIR axis may provide us new biomarkers and/or therapeutic targets to better suppress RCC progression in the future.	[Ding, Jie; Qi, Jun] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Shanghai 200092, Peoples R China; [Ding, Jie; Yeh, Chiuan-Ren; Sun, Yin; Lin, Changyi; Chou, Joshua; Ou, Zhenyu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; [Ding, Jie; Yeh, Chiuan-Ren; Sun, Yin; Lin, Changyi; Chou, Joshua; Ou, Zhenyu; Chang, Chawnshang; Yeh, Shuyuan] Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA	Shanghai Jiao Tong University; University of Rochester; University of Rochester	Qi, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Shanghai 200092, Peoples R China.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Yeh, SY (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	qijun@xinhuamed.com.cn; shuyuan_yeh@URMC.rochester.edu	Jie, Ding/ABD-8973-2021	Chang, Chawnshang/0000-0001-8510-3516	URMC Urology Department Research fund; George Whipple Professorship Endowment	URMC Urology Department Research fund; George Whipple Professorship Endowment	This work was partially supported by URMC Urology Department Research fund and George Whipple Professorship Endowment.	Batistatou A, 2006, J NEURO-ONCOL, V77, P17, DOI 10.1007/s11060-005-9005-0; Chiyomaru T, 2014, J BIOL CHEM, V289, P12550, DOI 10.1074/jbc.M113.488593; Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070372; Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46; Finley DS, 2011, ONCOLOGIST, V16, P4, DOI 10.1634/theoncologist.2011-S2-04; Fujimura T, 2001, BIOCHEM BIOPH RES CO, V289, P692, DOI 10.1006/bbrc.2001.6038; Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111; Gibb EA, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-38; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006; Hall JM, 2013, MOL CARCINOGEN, V52, P715, DOI 10.1002/mc.21913; Hibino S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.17; HOBISCH A, 1995, CANCER RES, V55, P3068; Hsu I, 2014, CARCINOGENESIS, V35, P651, DOI 10.1093/carcin/bgt348; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kartha RV, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00008; Klotz LV, 2012, LANGENBECK ARCH SURG, V397, P569, DOI 10.1007/s00423-012-0946-4; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kontovinis LF, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-82; Lee HW, 2012, PATHOL INT, V62, P735, DOI 10.1111/pin.12001; Li J, 2015, TUMOR BIOL, V36, P3611, DOI 10.1007/s13277-014-2998-2; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu L, 2016, BJU INT, V117, P351, DOI 10.1111/bju.12702; Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Perkel JM, 2013, BIOTECHNIQUES, V54, P301, DOI 10.2144/000114037; Powles T, 2016, EUR UROL, V70, P705, DOI 10.1016/j.eururo.2016.06.009; Powles T, 2016, EUR UROL, V69, P4, DOI 10.1016/j.eururo.2015.10.017; Qin J, 2014, J CLIN INVEST, V124, P5013, DOI 10.1172/JCI76412; Rapisarda A, 2012, ADV CANCER RES, V114, P237, DOI 10.1016/B978-0-12-386503-8.00006-5; Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sorensen KP, 2013, BREAST CANCER RES TR, V142, P529, DOI 10.1007/s10549-013-2776-7; Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621; Verkasalo PK, 2001, BRIT J NUTR, V86, P415, DOI 10.1079/BJN2001424; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Wang XG, 2015, MOL CANCER RES, V13, P1567, DOI 10.1158/1541-7786.MCR-15-0128; Xu ZQ, 2015, CLIN TRANSL ONCOL, V17, P41, DOI 10.1007/s12094-014-1195-5; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012; Yoon JH, 2014, SEMIN CELL DEV BIOL, V34, P9, DOI 10.1016/j.semcdb.2014.05.015; Younes M, 2011, ARCH PATHOL LAB MED, V135, P63, DOI 10.1043/2010-0448-RAR.1; Yu CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056667; Zheng JC, 2013, ONCOL LETT, V5, P1583, DOI 10.3892/ol.2013.1236; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	49	80	81	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5037	5053		10.1038/s41388-018-0175-6	http://dx.doi.org/10.1038/s41388-018-0175-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789714				2022-12-17	WOS:000444405300001
J	Liang, HC; Xiao, J; Zhou, ZM; Wu, J; Ge, F; Li, ZC; Zhang, HL; Sun, J; Li, FB; Liu, R; Chen, CS				Liang, Huichun; Xiao, Ji; Zhou, Zhongmei; Wu, Jiao; Ge, Fei; Li, Zongcheng; Zhang, Hailin; Sun, Jian; Li, Fubing; Liu, Rong; Chen, Ceshi			Hypoxia induces miR-153 through the IRE1 alpha-XBP1 pathway to fine tune the HIF1 alpha/VEGFA axis in breast cancer angiogenesis	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM-STRESS; INDUCIBLE FACTOR-1-ALPHA EXPRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; VASCULAR-PERMEABILITY FACTOR; HUMAN ENDOTHELIAL-CELLS; LUNG-CANCER; TUMOR-SUPPRESSOR; TARGETING SNAI1; DOWN-REGULATION; STEM-CELLS	It is well documented that hypoxia activates the hypoxia-inducible factor 1-alpha (HIF1 alpha)/vascular endothelial growth factor A (VEGFA) axis to promote angiogenesis in breast cancer. However, it is unclear how this axis is negatively regulated. In this study, we demonstrated that miR-153 directly inhibits expression of HIF1 alpha by binding to the 3'UTR of HIF1A mRNA, as well as suppresses tube formation of primary human umbilical vein endothelial cells (HUVECs) and breast cancer angiogenesis by decreasing the secretion of VEGFA. Importantly, expression of miR-153 was induced by hypoxiastimulated ER stress, which activates IRE1 alpha and its downstream transcription factor X-box binding protein 1 (XBP1). X-box binding protein 1 directly binds to the promoter of the miR-153 host gene PTPRN and activates transcription. These results indicate that hypoxia induces miR-153 to fine tune the HIF1 alpha/VEGFA axis in breast cancer angiogenesis and miR-153 could be used for breast cancer anti-angiogenesis therapy.	[Liang, Huichun; Zhou, Zhongmei; Zhang, Hailin; Li, Fubing; Liu, Rong; Chen, Ceshi] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming, Yunnan, Peoples R China; [Liang, Huichun; Li, Fubing] Univ Chinese Acad Sci, Beijing, Peoples R China; [Xiao, Ji; Sun, Jian] Kunming Univ Sci & Technol, Med Fac, Kunming, Yunnan, Peoples R China; [Wu, Jiao] Kunming Med Univ, Affiliated Hosp 3, Dept Med Oncol 2, Kunming, Yunnan, Peoples R China; [Ge, Fei] Kunming Med Univ, Affiliated Hosp 1, Dept Breast Surg, Kunming, Yunnan, Peoples R China; [Li, Zongcheng] Acad Mil Med Sci, Affiliated Hosp, Translat Med Ctr Stem Cells,Lab Oncol, State Key Lab Prote,Ivy Translat Med Ctr 307, Beijing, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Kunming University of Science & Technology; Kunming Medical University; Kunming Medical University; Academy of Military Medical Sciences - China	Liu, R; Chen, CS (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Chinese Acad Sci & Yunnan Prov, Kunming, Yunnan, Peoples R China.	liurong@mail.kiz.ac.cn; chenc@mail.kiz.ac.cn	Li, Zongcheng/AFP-2645-2022; Li, Zongcheng/AAN-1952-2021	Li, Zongcheng/0000-0002-5189-5268; Chen, Ceshi/0000-0001-6398-3516	Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010303]; National Natural Science Foundation of China [31771516, U1502222, U1602221, 81772847, 81660438]; Yunnan Applied Basic Research Key Projects [2015FA027]	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Yunnan Applied Basic Research Key Projects	We sincerely thank Professor Lingqiang Zhang from the Academy of Chinese Military Medical Sciences and Professor Wen Liu from Xiamen University for providing reagents. This study was supported by a Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12010303), National Natural Science Foundation of China (31771516, U1502222, U1602221, 81772847, and 81660438), and the Yunnan Applied Basic Research Key Projects (2015FA027).	Albini A, 2010, CLIN EXP METASTAS, V27, P419, DOI 10.1007/s10585-010-9312-5; Bao BL, 2012, J NUTR BIOCHEM, V23, P635, DOI 10.1016/j.jnutbio.2011.03.007; Bartoszewska S, 2015, FASEB J, V29, P1467, DOI 10.1096/fj.14-267054; Boelens J, 2007, IN VIVO, V21, P215; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen WJ, 2015, INT J CLIN EXP PATHO, V8, P8671; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Chitnis N, 2013, TRENDS BIOCHEM SCI, V38, P447, DOI 10.1016/j.tibs.2013.06.012; Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025; Dai L, 2015, INT J CLIN EXP PATHO, V8, P4735; Dioufa N, 2010, ENDOCRINE, V38, P167, DOI 10.1007/s12020-010-9362-0; FOLKMAN J, 1986, CANCER RES, V46, P467; Ghasemi A, 2016, CLIN LAB, V62, P573, DOI 10.7754/Clin.Lab.2015.150738; He X, 2015, ARTERIOSCL THROM VAS, V35, P1623, DOI 10.1161/ATVBAHA.115.305469; Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Janaszak-Jasiecka A, 2016, SCI REP-UK, V6, DOI 10.1038/srep22775; Kang SG, 2012, CARCINOGENESIS, V33, P661, DOI 10.1093/carcin/bgr320; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li Q, 2016, ONCOTARGET, V7, P29749, DOI 10.18632/oncotarget.8831; Li WT, 2015, BREAST CANCER RES TR, V150, P501, DOI 10.1007/s10549-015-3346-y; Liu F, 2017, ACTA BIOCH BIOPH SIN, V49, P520, DOI 10.1093/abbs/gmx039; Liu R, 2016, GROWTH, V17, P18; Liu R, 2016, THERANOSTICS, V6, P533, DOI 10.7150/thno.14315; Mandemakers W, 2013, DIABETOLOGIA, V56, P1547, DOI 10.1007/s00125-013-2901-5; Paridaens A, 2014, LIVER INT, V34, pE10, DOI 10.1111/liv.12457; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shan NX, 2015, BIOCHEM BIOPH RES CO, V456, P385, DOI 10.1016/j.bbrc.2014.11.093; Urra H, 2014, MOL CELL, V54, P542, DOI 10.1016/j.molcel.2014.05.013; Wang Y, 2011, INT J MOL SCI, V12, P7569, DOI 10.3390/ijms12117569; Wang ZL, 2016, TUMOR BIOL, V37, P15509, DOI 10.1007/s13277-015-3846-8; Wu J, 2016, CANCER LETT, V380, P393, DOI 10.1016/j.canlet.2016.06.024; Wu XW, 2016, AM J CANCER RES, V6, P1563; Wu ZH, 2016, ONCOL REP, V35, P1696, DOI 10.3892/or.2015.4529; Wu ZQ, 2013, PROSTATE, V73, P596, DOI 10.1002/pros.22600; Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Yang BY, 2016, BIOMED PHARMACOTHER, V84, P845, DOI 10.1016/j.biopha.2016.10.015; Yang W, 2015, ONCOTARGET, V6, P22006, DOI 10.18632/oncotarget.4292; Yuan Y, 2015, INT J CANCER, V136, P1333, DOI 10.1002/ijc.29103; Zeng HF, 2017, BIOCHEM BIOPH RES CO, V487, P140, DOI 10.1016/j.bbrc.2017.04.032; Zhang L, 2013, CANCER RES, V73, P6435, DOI 10.1158/0008-5472.CAN-12-3308; Zou YH, 2016, MOL MED REP, V14, P1033, DOI 10.3892/mmr.2016.5309; Zuo J, 2016, TUMOR BIOL, V37, P16135, DOI 10.1007/s13277-016-5427-x	50	80	85	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1961	1975		10.1038/s41388-017-0089-8	http://dx.doi.org/10.1038/s41388-017-0089-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367761	Green Published, hybrid			2022-12-17	WOS:000429899400002
J	Zeng, AL; Yan, W; Liu, YW; Wang, Z; Hu, Q; Nie, E; Zhou, X; Li, R; Wang, XF; Jiang, T; You, YP				Zeng, A-L; Yan, W.; Liu, Y-W; Wang, Z.; Hu, Q.; Nie, E.; Zhou, X.; Li, R.; Wang, X-F; Jiang, T.; You, Y-P			Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma	ONCOGENE			English	Article							CANCER STEM-CELLS; EXTRACELLULAR VESICLES; MESENCHYMAL TRANSITION; EFFECTIVE STRATEGY; SIGNALING PATHWAY; EMERGING ROLE; MICROVESICLES; GROWTH; GENE; RNA	Exosomes are carriers of pro-tumorigenic factors that participate in glioblastoma (GBM) progression, and many fusion genes are strong driver mutations in neoplasia and are involved in tumorigenesis. However, the ability of fusion genes to be transduced by exosomes is unknown. We characterized exosomes from GBM cells harbouring and not harbouring PTPRZ1-MET fusion (ZM fusion). We also determined the effect of the exosomes from ZM fusion cells (ZM exosomes) on pro-oncogenic secretions and showed that ZM exosomes are internalized by the recipient cells. In addition, we studied the effect of ZM exosome-mediated intercellular communication in the GBM microenvironment. MET proto-oncogene expression was higher in ZM exosomes. Moreover, phosphorylated MET was detected only in ZM exosomes and not in exosomes released by non-ZM fusion GBM cells. ZM exosomes transferred to non-ZM fusion GBM cells and normal human astrocytes altered gene expression and induced epithelial-mesenchymal transition. The uptake of ZM exosomes also induced an exosome-dependent phenotype defined by GBM cell migration and invasion, neurosphere growth and angiogenesis. In addition, ZM exosomes conferred temozolomide resistance to the GBM cells, and exosomederived ZM fusion network proteins targeted multiple pro-oncogenic effectors in recipient cells within the GBM microenvironment. Our findings show that exosomes mediate the aggressive character of GBM and demonstrate the role of ZM fusion in the exacerbation of this effect. These findings have possible implications for the foundation of gene fusion-based therapy for managing GBM.	[Zeng, A-L; Yan, W.; Hu, Q.; Nie, E.; Zhou, X.; Li, R.; Wang, X-F; You, Y-P] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Y-W; Wang, Z.; Jiang, T.] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China; [Jiang, T.] Beijing Inst Brain Disorders Brain Tumor Ctr, Beijing, Peoples R China; [Jiang, T.] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China	Nanjing Medical University; Beijing Neurosurgical Institute; Capital Medical University; Capital Medical University	Yan, W; You, YP (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	neuro_yw@126.com; yypl9@njmu.edu.cn	zeng, ailiang/AAF-4498-2020	Zeng, Ailiang/0000-0003-2869-9899	National Natural Science Foundation of China [81402056, 81472362]; National High Technology Research, Development Program of China (863) [2012AA02A508]; National Key Research and Development Plan [2016YFC0902500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research, Development Program of China (863); National Key Research and Development Plan	This work was supported by a grant from the National Natural Science Foundation of China (No. 81402056 and 81472362), National High Technology Research, Development Program of China (863) (No. 2012AA02A508) and the National Key Research and Development Plan (No. 2016YFC0902500).	Adachi E, 2016, ONCOTARGET, V7, P70779, DOI 10.18632/oncotarget.12221; Aga M, 2014, ONCOGENE, V33, P4613, DOI 10.1038/onc.2014.66; Anastasiadou E, 2014, SCIENCE, V346, P1459, DOI 10.1126/science.aaa4024; Annala MJ, 2013, CANCER LETT, V340, P192, DOI 10.1016/j.canlet.2013.01.011; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Belting M, 2008, J CELL BIOL, V183, P1187, DOI 10.1083/jcb.200810038; Boccaccio C, 2013, CANCER RES, V73, P3193, DOI 10.1158/0008-5472.CAN-12-4039; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Chen HM, 2015, FEBS LETT, V589, P1437, DOI 10.1016/j.febslet.2015.04.032; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; D'Asti E, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00294; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009; Han DF, 2015, ONCOTARGET, V6, P26119, DOI 10.18632/oncotarget.4444; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Javeed N, 2015, CLIN CANCER RES, V21, P1722, DOI 10.1158/1078-0432.CCR-14-2022; Josson S, 2015, ONCOGENE, V34, P2690, DOI 10.1038/onc.2014.212; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Le MTN, 2014, J CLIN INVEST, V124, P5109, DOI 10.1172/JCI75695; Lee JK, 2014, ONCOTARGETS THER, V7, P1933, DOI 10.2147/OTT.S36582; Li CCY, 2013, RNA BIOL, V10, P1333, DOI 10.4161/rna.25281; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Lopez-Bertoni H, 2015, ONCOGENE, V34, P3994, DOI 10.1038/onc.2014.334; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Martinez MC, 2011, CIRC RES, V109, P110, DOI 10.1161/CIRCRESAHA.110.233049; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P899, DOI 10.1016/j.drudis.2015.02.011; Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P772, DOI 10.1016/j.drudis.2015.02.014; Minciacchi VR, 2015, SEMIN CELL DEV BIOL, V40, P41, DOI 10.1016/j.semcdb.2015.02.010; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Ricklefs F, 2016, CANCER RES, V76, P2876, DOI 10.1158/0008-5472.CAN-15-3432; Roma-Rodrigues C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/179486; Shi ZM, 2014, NEURO-ONCOLOGY, V16, P1341, DOI 10.1093/neuonc/nou084; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang L, 2014, ONCOTARGET, V5, P5416, DOI 10.18632/oncotarget.2116; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wickramasinghe D, 2005, CELL CYCLE, V4, P683, DOI 10.4161/cc.4.5.1688; Zeng AL, 2015, ONCOTARGET, V6, P30232, DOI 10.18632/oncotarget.4920; Zhang YN, 2016, ONCOTARGET, V7, P37370, DOI 10.18632/oncotarget.8276; Zomer A, 2016, CANCER RES, V76, P2071, DOI 10.1158/0008-5472.CAN-15-2804	49	80	84	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5369	5381		10.1038/onc.2017.134	http://dx.doi.org/10.1038/onc.2017.134			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28504721	Green Published, hybrid			2022-12-17	WOS:000411382100004
J	Fu, L; Dong, Q; He, J; Wang, X; Xing, J; Wang, E; Qiu, X; Li, Q				Fu, L.; Dong, Q.; He, J.; Wang, X.; Xing, J.; Wang, E.; Qiu, X.; Li, Q.			SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway	ONCOGENE			English	Article							CELL-PROLIFERATION; INSULIN-SECRETION; FISSION; CANCER; DRP1; PHOSPHORYLATION; MIGRATION; SIRTUINS; DIVISION; FUSION	SIRT4 is well-known for its deacetylase activity in energy metabolism, but little is known about its roles in carcinogenesis. We demonstrated that SIRT4 was decreased in 70 out of 133 non-small cell lung cancer (NSCLC) cases by immunohistochemical staining and localized in the mitochondria using confocal microscopy. Low levels of SIRT4 expression was correlated with tumor node metastasis (TNM) stage, histological type of tumor (adenocarcinoma), lymph nodal status, Ki-67 (proliferation index) and poor overall survival. We also studied the biological role of SIRT4 in lung cancer cell lines transfected with SIRT4 plasmid or SIRT4-siRNA. SIRT4 inhibited lung cancer cell proliferation, blocked the cell cycle and repressed cell invasion and migration. Mitochondrial dynamics has been implicated in malignant properties of cells, particularly metastasis that is the major cause of death in patients diagnosed with cancer including lung cancer. This is the first study to identify an association between SIRT4 expression and decreased mitochondrial fission, which was driven by Drp1. SIRT4 inhibited Drp1 phosphorylation and weakened Drp1 recruitment to the mitochondrial membrane via an interaction with Fis-1. SIRT4 expression was lower in nodal metastatic tumor samples than their corresponding primary tumors, and cases with low expression of SIRT4 tended to have high p-Drp1 labeling. Also, MEK/ERK activity appeared to be hampered by SIRT4 expression, which may have implications for cells' invasive capacities. In conclusion, our findings suggest that SIRT4 functions as an important antitumor protein in NSCLC, and should be investigated further with respect to future anticancer strategies.	[Li, Q.] China Med Univ, Coll Basic Med Sci, Shenyang 11000, Liaoning, Peoples R China; China Med Univ Shenyang, Dept Pathol, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China		Li, Q (corresponding author), China Med Univ, Coll Basic Med Sci, Shenyang 11000, Liaoning, Peoples R China.; Li, Q (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Pathol, Shenyang 11000, Peoples R China.	liqingchangcmu@126.com			National Natural Science Foundation of China [81672964, 81302022]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by the National Natural Science Foundation of China (No. 81672964 to Qingchang Li and No. 81302022 to Qianze Dong).	Ahuja N, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M705488200; Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Argmann C, 2006, CELL, V126, P837, DOI 10.1016/j.cell.2006.08.031; Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292; Carafa V, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00004; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Csibi A, 2013, CELL, V153, P840, DOI 10.1016/j.cell.2013.04.023; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Fu L, 2015, MOL CARCINOGEN, V54, pE35, DOI 10.1002/mc.22148; Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Huang GY, 2015, BIOMED PHARMACOTHER, V72, P135, DOI 10.1016/j.biopha.2015.04.013; Jeong SM, 2014, J BIOL CHEM, V289, P4135, DOI 10.1074/jbc.M113.525949; Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Laurent G, 2013, MOL CELL, V50, P686, DOI 10.1016/j.molcel.2013.05.012; Lennon FE, 2014, EXPERT OPIN INV DRUG, V23, P675, DOI 10.1517/13543784.2014.899350; Miyo M, 2015, BRIT J CANCER, V113, P492, DOI 10.1038/bjc.2015.226; Nasrin N, 2010, J BIOL CHEM, V285, P31995, DOI 10.1074/jbc.M110.124164; Pal AD, 2014, CARCINOGENESIS, V35, P1592, DOI 10.1093/carcin/bgu069; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Roberts ER, 2013, COMPUT STRUCT BIOTEC, V6, DOI 10.5936/csbj.201303019; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Thomas KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045319; van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072; Wan YY, 2014, ONCOL REP, V32, P619, DOI 10.3892/or.2014.3235; Wang Y, 2013, MOL CARCINOGEN, V52, P890, DOI 10.1002/mc.21935; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	38	80	82	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2724	2736		10.1038/onc.2016.425	http://dx.doi.org/10.1038/onc.2016.425			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27941873				2022-12-17	WOS:000401120900010
J	Zhong, T; Men, Y; Lu, L; Geng, T; Zhou, J; Mitsuhashi, A; Shozu, M; Maihle, NJ; Carmichael, GG; Taylor, HS; Huang, Y				Zhong, T.; Men, Y.; Lu, L.; Geng, T.; Zhou, J.; Mitsuhashi, A.; Shozu, M.; Maihle, N. J.; Carmichael, G. G.; Taylor, H. S.; Huang, Y.			Metformin alters DNA methylation genome-wide via the H19/SAHH axis	ONCOGENE			English	Article							LONG NONCODING RNA; GENE-EXPRESSION; PROSTATE-CANCER; CELLS; DRUG; CONTRIBUTES; METASTASIS; METABOLISM; MICRORNAS; PROMOTES	The molecular mechanisms underlying the antineoplastic properties of metformin, a first-line drug for type 2 diabetes, remain elusive. Here we report that metformin induces genome-wide alterations in DNA methylation by modulating the activity of S-adenosylhomocysteine hydrolase (SAHH). Exposing cancer cells to metformin leads to hypermethylation of tumor-promoting pathway genes and concomitant inhibition of cell proliferation. Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH. H19 knockdown activates SAHH, enabling DNA methyltransferase 3B to methylate a subset of genes. This metformin-induced H19 repression and alteration of gene methylation are recapitulated in endometrial cancer tissue samples obtained from patients treated with antidiabetic doses of metformin. Our findings unveil a novel mechanism of action for the drug metformin with implications for the molecular basis of epigenetic dysregulation in cancer. This novel mechanism of action also may be occurring in normal cells.	Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA; Gannan Med Univ, Affiliated Hosp 1, Dept Lab Med, Ganzhou, Jiangxi, Peoples R China; Sichuan Univ, West China Hosp Stomatol, Dept Head & Neck Surg, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; Yale Univ, Sch Med, Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, 310 Cedar St,LSOG 205C, New Haven, CT 06510 USA; Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Dept Endocrinol, Xian, Shaanxi, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Sir Run Run Shaw Hosp, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China; Chiba Univ, Grad Sch Med, Dept Reprod Med, Chiba, Japan; Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA; Univ Connecticut, Farmington, CT USA	Yale University; Gannan Medical University; Sichuan University; Yale University; Xi'an Jiaotong University; Zhejiang University; Chiba University; University System of Georgia; Augusta University; University of Connecticut		Yingqun.huang@yale.edu	Zhou, Jichun/Q-8646-2019; Zhong, Tianyu/HCG-8326-2022	Zhou, Jichun/0000-0002-0727-4034; Zhong, Tianyu/0000-0003-1934-0032	Bennack-Polan Foundation; NIGMS [R01 HD072418]; national Natural Science Foundation of China [81602471]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072418] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	Bennack-Polan Foundation; NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); national Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Alessandro Santin for the gift of ARK2 cells. This work was supported by grants from Bennack-Polan Foundation and Discover to Cure to YH, R01 HD072418 from the NIGMS to GGC and national Natural Science Foundation of China (No. 81602471) to JZ.	Albitar L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-166; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Gao Y, 2014, NUCLEIC ACIDS RES, V42, P13799, DOI 10.1093/nar/gku1160; Graham JR, 2010, MOL CELL BIOL, V30, P5295, DOI 10.1128/MCB.00303-10; Gravina GL, 2011, ENDOCRINOLOGY, V152, P4550, DOI 10.1210/en.2011-1056; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Jin BL, 2012, CELL REP, V2, P1411, DOI 10.1016/j.celrep.2012.10.017; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Matouk IJ, 2016, ONCOTARGET, V7, P3748, DOI 10.18632/oncotarget.6387; Merry CR, 2015, HUM MOL GENET, V24, P6240, DOI 10.1093/hmg/ddv343; Milinkovic V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082108; Mitsuhashi A, 2014, CANCER-AM CANCER SOC, V120, P2986, DOI 10.1002/cncr.28853; Oliveras-Ferraros C, 2011, CELL CYCLE, V10, P1144, DOI 10.4161/cc.10.7.15210; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Poulain M, 2014, MOL HUM REPROD, V20, P960, DOI 10.1093/molehr/gau058; Pryor R, 2015, BIOCHEM J, V471, P307, DOI 10.1042/BJ20150497; Raveh E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0458-2; Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008; Su B, 2015, HEPATOLOGY, V61, P585, DOI 10.1002/hep.27551; Trabucchi M, 2009, NATURE, V459, P1010, DOI 10.1038/nature08025; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Xu WJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0425-6; Yan L, 2015, ONCOGENE, V34, P3076, DOI 10.1038/onc.2014.236; Zhang BB, 2009, CELL METAB, V9, P407, DOI 10.1016/j.cmet.2009.03.012; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221	32	80	85	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2345	2354		10.1038/onc.2016.391	http://dx.doi.org/10.1038/onc.2016.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27775072	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000400268900002
J	Knezevic, J; Pfefferle, AD; Petrovic, I; Greene, SB; Perou, CM; Rosen, JM				Knezevic, J.; Pfefferle, A. D.; Petrovic, I.; Greene, S. B.; Perou, C. M.; Rosen, J. M.			Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; TUMOR-INITIATING CELLS; DOWN-REGULATION; ANGIOGENESIS; FAMILY; ZEB1; GENE; IDENTIFICATION; PLASTICITY; SUBTYPE	Claudin-low tumors are a highly aggressive breast cancer subtype with no targeted treatments and a clinically documented resistance to chemotherapy. They are significantly enriched in cancer stem cells (CSCs), which makes claudin-low tumor models particularly attractive for studying CSC behavior and developing novel approaches to minimize CSC therapy resistance. One proposed mechanism by which CSCs arise is via an epithelial-mesenchymal transition (EMT), and reversal of this process may provide a potential therapeutic approach for increasing tumor chemosensitivity. Therefore, we investigated the role of known EMT regulators, miR-200 family of microRNAs in controlling the epithelial state, stem-like properties and therapeutic response in an in vivo primary, syngeneic p53(null) claudin-low tumor model that is normally deficient in miR-200 expression. Using an inducible lentiviral approach, we expressed the miR-200c cluster in this model and found that it changed the epithelial state, and consequently, impeded CSC behavior in these mesenchymal tumors. Moreover, these state changes were accompanied by a decrease in proliferation and an increase in the differentiation status. miR-200c expression also forced a significant reorganization of tumor architecture, affecting important cellular processes involved in cell-cell contact, cell adhesion and motility. Accordingly, induced miR200c expression significantly enhanced the chemosensitivity and decreased the metastatic potential of this p53null claudin-low tumor model. Collectively, our data suggest that miR-200c expression in claudin-low tumors offers a potential therapeutic application to disrupt the EMT program on multiple fronts in this mesenchymal tumor subtype, by altering tumor growth, chemosensitivity and metastatic potential in vivo.	[Knezevic, J.; Petrovic, I.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Pfefferle, A. D.; Perou, C. M.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Pfefferle, A. D.; Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Greene, S. B.] Epic Sci Inc, San Diego, CA USA; [Perou, C. M.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA	Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza M638a, Houston, TX 77030 USA.	jrosen@bcm.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	National Cancer Institute [CA148761]; CPRIT [RP130485, RP140102]; Baylor College of Medicine [P30 AI036211, P30 CA125123, S10 RR024574, P30-CA125123]; NATIONAL CANCER INSTITUTE [R01CA148761, P30CA016086, P30CA125123] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT; Baylor College of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	These studies were supported by grants CA148761 (JMR and CP) from the National Cancer Institute and RP130485 (JMR) and RP140102 (JK) from CPRIT. This project was supported by the following core facilities and their funding: Biostatistics and Informatics (P30-CA125123) and Cytometry and Cell Sorting Core at Baylor College of Medicine (P30 AI036211, P30 CA125123 and S10 RR024574). RPPA arrays were performed at the MD Anderson Cancer Center RPPA Core Facility-Functional Proteomics. We thank Drs Kevin Roarty Amy Shore and Michael Toneff for helpful discussions and paper editing, Dr Jason Herschkowitz for help and advice, and Ms Shirley Small for animal husbandry.	Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chuthapisith S, 2010, SURG ONCOL, V19, P27, DOI 10.1016/j.suronc.2009.01.004; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cui JG, 2014, J CELL BIOCHEM, V115, P1033, DOI 10.1002/jcb.24754; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Humphries B, 2014, CARCINOGENESIS, P1; Hurteau GJ, 2009, CELL CYCLE, V8, P2064, DOI 10.4161/cc.8.13.8883; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kopp F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050469; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pfefferle AD, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r125; Pinto CA, 2013, CANCER LETT, V341, P56, DOI 10.1016/j.canlet.2013.06.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Roybal JD, 2011, MOL CANCER RES, V9, P25, DOI 10.1158/1541-7786.MCR-10-0497; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Usary J, 2013, CLIN CANCER RES, V19, P4889, DOI 10.1158/1078-0432.CCR-13-0522; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Welm Bryan E, 2008, Cell Stem Cell, V2, P90, DOI 10.1016/j.stem.2007.10.002; Wu SY, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008362; Yin JH, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-71; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013	51	80	84	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5997	6006		10.1038/onc.2015.48	http://dx.doi.org/10.1038/onc.2015.48			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25746005	Green Accepted, Green Submitted			2022-12-17	WOS:000366113500006
J	Zhao, S; Kurenbekova, L; Gao, Y; Roos, A; Creighton, CJ; Rao, P; Hicks, J; Man, TK; Lau, C; Brown, AMC; Jones, SN; Lazar, AJ; Ingram, D; Lev, D; Donehower, LA; Yustein, JT				Zhao, S.; Kurenbekova, L.; Gao, Y.; Roos, A.; Creighton, C. J.; Rao, P.; Hicks, J.; Man, T-K; Lau, C.; Brown, A. M. C.; Jones, S. N.; Lazar, A. J.; Ingram, D.; Lev, D.; Donehower, L. A.; Yustein, J. T.			NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma	ONCOGENE			English	Article							PROMOTER HYPERMETHYLATION; P53; GENE; PROGRESSION; MEMBRANE; INVASION; PATHWAYS; MUTATION; BIOLOGY; ALPHA	Osteosarcoma (OS) is the most frequent pediatric malignant bone tumor that has a high propensity for metastases. Through osteoblast-specific alteration of p53 status, we developed a genetically engineered mouse model of localized and metastatic OS to gain an understanding into the molecular pathogenesis of OS. Microarray analysis of both localized tumors and metastatic tumors identified the downregulation of the naked cuticle homolog 2 (NKD2) gene, a negative regulator of Wnt signaling. Overexpression of NKD2 in metastatic human and mouse OS cells significantly decreases cell proliferation, migration and invasion ability in vitro and drastically diminishes OS tumor growth and metastasis in vivo, whereas downregulation enhances migratory and invasive potential. Evaluation of NKD2-overexpressing tumors revealed upregulation of tumor-suppressor genes and downregulation of molecules involved in blood vessel formation and cell migration. Furthermore, assessment of primary human OS revealed downregulation of NKD2 in metastatic and recurrent OS. Finally, we provide biological evidence that use of small-molecule inhibitors targeting the Wnt pathway can have therapeutic efficacy in decreasing metastatic properties in OS. Our studies provide compelling evidence that downregulation of NKD2 expression and alterations in associated regulated pathways have a significant role in driving OS tumor growth and metastasis.	[Zhao, S.; Kurenbekova, L.; Gao, Y.; Roos, A.; Rao, P.; Man, T-K; Lau, C.; Donehower, L. A.; Yustein, J. T.] Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, Houston, TX 77030 USA; [Zhao, S.; Kurenbekova, L.; Gao, Y.; Roos, A.; Rao, P.; Man, T-K; Lau, C.; Donehower, L. A.; Yustein, J. T.] Baylor Coll Med, Texas Childrens Hematol Ctr, Dept Pediat, Houston, TX 77030 USA; [Roos, A.; Donehower, L. A.; Yustein, J. T.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Div Biostat, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Hicks, J.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Brown, A. M. C.] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY USA; [Jones, S. N.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA; [Lazar, A. J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Lazar, A. J.; Ingram, D.] Univ Texas MD Anderson Canc Ctr, Sarcoma Res Ctr, Houston, TX 77030 USA; [Ingram, D.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Lev, D.] Ohio State Univ, Dept Canc Biol, Columbus, OH 43210 USA; [Donehower, L. A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Cornell University; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; Ohio State University; Baylor College of Medicine	Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Canc Ctr, Dept Pediat, One Baylor Plaza,Room 824D, Houston, TX 77030 USA.	yustein@bcm.edu	Lazar, Alexander J/A-3416-2008	Lazar, Alexander J/0000-0002-6395-4499; Man, Tsz-Kwong/0000-0001-5920-5746	Cancer Prevention and Research Institute of Texas; WWWW Foundation, Inc.; St Baldrick's Foundation; Sarcoma Foundation of America; NIH [R01 CA123238]; NCI/NIH [P30 CA125123]; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA123238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008539] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas; WWWW Foundation, Inc.; St Baldrick's Foundation; Sarcoma Foundation of America; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Yiqun Zhang for technical assistance and Dr Neha Parikh for her assistance with figure layout and design. This work was supported by The Cancer Prevention and Research Institute of Texas (to SZ, T-KM, CL, PR, JH, LK, CJC, LAD, JTY), WWWW Foundation, Inc. (QuadW) (to JTY), The St Baldrick's Foundation (to JTY), the Sarcoma Foundation of America (to LAD), NIH R01 CA123238 (to AMCB) and NCI/NIH grant P30 CA125123 (to CJC).	Bacci G, 2003, ANN ONCOL, V14, P1126, DOI 10.1093/annonc/mdg286; Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Baron Roland, 2007, Curr Osteoporos Rep, V5, P73; Brennecke P, 2014, CLIN EXP METASTAS, V31, P339, DOI 10.1007/s10585-013-9632-3; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Cheng JH, 2008, AM J PHYSIOL-GASTR L, V294, pG39, DOI 10.1152/ajpgi.00263.2007; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A, 2009, Nat Rev Cancer, V9, P831, DOI 10.1038/nrc2731; Dumble Melissa L, 2003, Methods Mol Biol, V234, P29; Edamura K, 2007, CANCER GENE THER, V14, P765, DOI 10.1038/sj.cgt.7701071; Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762; Flores RJ, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-50; Gotze S, 2010, INT J CANCER, V126, P2584, DOI 10.1002/ijc.24981; Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hong SH, 2009, INT J CANCER, V124, P2042, DOI 10.1002/ijc.24169; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Hu TH, 2010, J BIOL CHEM, V285, P13561, DOI 10.1074/jbc.M109.075945; Husmann K, 2013, BBA-MOL BASIS DIS, V1832, P347, DOI 10.1016/j.bbadis.2012.11.006; Johnson AS, 1998, CARCINOGENESIS, V19, P213, DOI 10.1093/carcin/19.1.213; Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132; Kanda M, 2011, MOL CARCINOGEN, V50, P571, DOI 10.1002/mc.20735; Kansara M, 2007, DNA CELL BIOL, V26, P1, DOI 10.1089/dna.2006.0505; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Lauvrak SU, 2013, BRIT J CANCER, V109, P2228, DOI 10.1038/bjc.2013.549; Li CX, 2007, MOL BIOL CELL, V18, P3081, DOI 10.1091/mbc.E07-02-0172; Li CX, 2004, P NATL ACAD SCI USA, V101, P5571, DOI 10.1073/pnas.0401294101; Liu F, 2004, INT J DEV BIOL, V48, P645, DOI 10.1387/ijdb.041816fl; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585-005-0365-9; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Miretti S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001828; Mizobuchi Y, 2008, NEURO-ONCOLOGY, V10, P244, DOI 10.1215/15228517-2008-016; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Muff Roman, 2012, Sarcoma, V2012, P937506, DOI 10.1155/2012/937506; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005; Wlazlinski A, 2007, PROSTATE, V67, P1770, DOI 10.1002/pros.20667; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898	46	80	85	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5069	5079		10.1038/onc.2014.429	http://dx.doi.org/10.1038/onc.2014.429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25579177	Green Accepted			2022-12-17	WOS:000361693300007
J	Seo, KS; Park, JH; Heo, JY; Jing, K; Han, J; Min, KN; Kim, C; Koh, G; Lim, K; Kang, GY; Lee, JU; Yim, YH; Shong, M; Kwak, TH; Kweon, G				Seo, K-S; Park, J-H; Heo, J-Y; Jing, K.; Han, J.; Min, K-N; Kim, C.; Koh, G. Y.; Lim, K.; Kang, G-Y; Lee, J. Uee; Yim, Y-H; Shong, M.; Kwak, T-H; Kweon, G. R.			SIRT2 regulates tumour hypoxia response by promoting HIF-1 alpha hydroxylation	ONCOGENE			English	Article							INDUCIBLE FACTOR-1-ALPHA; OXIDOREDUCTASE 1; METABOLISM; HIF1-ALPHA; DEGRADATION; ACTIVATION; PROTEIN; ACETYLATION; SUPPRESSION; OXIDATION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcription factor that has a central role in the regulation of tumour metabolism under hypoxic conditions. HIF-1 alpha stimulates glycolytic energy production and promotes tumour growth. Sirtuins are NAD(+)-dependent protein deacetylases that regulate cellular metabolism in response to stress; however, their involvement in the hypoxic response remains unclear. In this study, it is shown that SIRT2-mediated deacetylation of HIF-1 alpha regulates its stability in tumour cells. SIRT2 overexpression destabilized HIF-1 alpha under hypoxic conditions, whereas HIF-1 alpha protein levels were high in SIRT2-deficient cells. SIRT2 directly interacted with HIF-1 alpha and deacetylated Lys709 of HIF-1 alpha. Deacetylation of HIF-1 alpha by SIRT2 resulted in increased binding affinity for prolyl hydroxylase 2, a key regulator of HIF-1a stability, and increased HIF-1 alpha hydroxylation and ubiquitination. Moreover, a pharmacological agent that increased the intracellular NAD(+)/NADH ratio led to the degradation of HIF-1 alpha by increasing SIRT2-mediated deacetylation and subsequent hydroxylation. These findings suggest that SIRT2-mediated HIF-1 alpha deacetylation is critical for the destablization of HIF-1 alpha and the hypoxic response of tumour cells.	[Seo, K-S; Park, J-H; Heo, J-Y; Jing, K.; Han, J.; Lim, K.; Kweon, G. R.] Chungnam Natl Univ, Sch Med, Dept Biochem, Taejon 301747, South Korea; [Heo, J-Y; Jing, K.; Han, J.; Lim, K.] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Taejon 301747, South Korea; [Min, K-N; Kwak, T-H] KT&G Life Sci Corp R&D Ctr, Suwon, South Korea; [Kim, C.; Koh, G. Y.] Korea Adv Inst Sci & Technol, Natl Res Lab Vasc Biol, Taejon 305701, South Korea; [Kim, C.; Koh, G. Y.] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Taejon 305701, South Korea; [Lim, K.] Chungnam Natl Univ, Sch Med, Canc Res Inst, Taejon 301747, South Korea; [Kang, G-Y] Diatech Korea Co Ltd, Seoul, South Korea; [Lee, J. Uee] Catholic Univ, St Marys Hosp, Dept Pathol, Taejon, South Korea; [Yim, Y-H] Korea Res Inst Standard & Sci, Taejon, South Korea; [Shong, M.] Chungnam Natl Univ, Sch Med, Dept Internal Med, Taejon 301747, South Korea	Chungnam National University; Chungnam National University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Chungnam National University; Catholic University of Korea; Catholic University Korea Hospital; Korea Research Institute of Standards & Science (KRISS); Chungnam National University	Kweon, G (corresponding author), Chungnam Natl Univ, Sch Med, Dept Biochem, Taejon 301747, South Korea.	bioalpha@ktngls.com; mitochondria@cnu.ac.kror	Koh, Gou Young/C-1615-2011; /H-7803-2012	Kim, Chan/0000-0001-9780-6155; Heo, Jun Young/0000-0002-0859-0063; shong, minho/0000-0002-0247-7115; Han, Jeongsu/0000-0001-6524-9841	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2009-1176023, 2011-0011365]; NRF - Ministry of Science, ICT & Future Planning [2007-0054932]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education; NRF - Ministry of Science, ICT & Future Planning	We thank Dr HS Kim, Dr JH Lim and Dr JW Park for their skillful methodological assistance, Dr JJ Lee for the HRE luciferase plasmid and Dr KY Lee for the SIRT2 expression plasmids. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2009-1176023, 2011-0011365) (GRK) and the NRF funded by the Ministry of Science, ICT & Future Planning (2007-0054932).	Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Chen R, 2011, J BIOL CHEM, V286, P13869, DOI 10.1074/jbc.M110.175414; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Choi HJ, 2008, BRIT J PHARMACOL, V154, P114, DOI 10.1038/bjp.2008.70; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hwang JH, 2009, DIABETES, V58, P965, DOI 10.2337/db08-1183; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Jin Y, 2011, J BIOL CHEM, V286, P22699, DOI 10.1074/jbc.M111.237024; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kim SY, 2009, CIRC RES, V104, P842, DOI 10.1161/CIRCRESAHA.108.189837; Kim YH, 2012, FREE RADICAL BIO MED, V52, P880, DOI 10.1016/j.freeradbiomed.2011.12.007; Krishnan J, 2012, GENE DEV, V26, P259, DOI 10.1101/gad.180406.111; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Luthi-Carter R, 2010, P NATL ACAD SCI USA, V107, P7927, DOI 10.1073/pnas.1002924107; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Massudi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042357; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, J BIOL CHEM, V282, P19546, DOI 10.1074/jbc.M702990200; Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Papadakis AI, 2010, CANCER RES, V70, P7820, DOI 10.1158/0008-5472.CAN-10-0215; Schwer B, 2010, P NATL ACAD SCI USA, V107, P21790, DOI 10.1073/pnas.1016306107; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Tanaka H, 2012, CANCER SCI, V103, P767, DOI 10.1111/j.1349-7006.2011.02192.x; Terzuoli E, 2010, CANCER RES, V70, P6837, DOI 10.1158/0008-5472.CAN-10-1075; van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103	45	80	84	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	2015	34	11					1354	1362		10.1038/onc.2014.76	http://dx.doi.org/10.1038/onc.2014.76			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD1AR	24681946				2022-12-17	WOS:000350806500002
J	Hitosugi, T; Chen, J				Hitosugi, T.; Chen, J.			Post-translational modifications and the Warburg effect	ONCOGENE			English	Review						the Warburg effect; post-translational modifications; cancer metabolism	PYRUVATE-KINASE M2; PHOSPHOGLYCERATE MUTASE; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; LACTATE-DEHYDROGENASE; GLYCOLYTIC-ENZYMES; METABOLIC TRANSFORMATION; GENE-TRANSCRIPTION; 3T3-L1 ADIPOCYTES; CELL METABOLISM	Post-translational modification (PTM) is an important step of signal transduction that transfers chemical groups such as phosphate, acetyl and glycosyl groups from one protein to another protein. As most of the PTMs are reversible, normal cells use PTMs as a 'switch' to determine the resting and proliferating state of cells that enables rapid and tight regulation of cell proliferation. In cancer cells, activation of oncogenes and/or inactivation of tumor suppressor genes provide continuous proliferative signals in part by adjusting the state of diverse PTMs of effector proteins that are involved in regulation of cell survival, cell cycle and proliferation, leading to abnormally fast proliferation of cancer cells. In addition to dysregulated proliferation, 'altered tumor metabolism' has recently been recognized as an emerging cancer hallmark. The most common metabolic phenotype of cancer is known as the Warburg effect or aerobic glycolysis that consists of increased glycolysis and enhanced lactate production even in the presence of oxygen. Although Otto Warburg observed aerobic glycolysis nearly 90 years ago, the detailed molecular mechanisms how increased glycolysis is regulated by oncogenic and/or tumor suppressive signaling pathways remain unclear. In this review, we summarize recent advances revealing how these signaling pathways reprogram metabolism through diverse PTMs to provide a metabolic advantage to cancer cells, thereby promoting tumor cell proliferation, tumorigenesis and tumor growth.	[Hitosugi, T.] Mayo Clin, Dept Oncol, Div Oncol Res, Rochester, MN USA; [Chen, J.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst Emory, Atlanta, GA 30322 USA	Mayo Clinic; Emory University	Hitosugi, T (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst Emory, 1365-C Clifton Rd NE,Room C-3002, Atlanta, GA 30322 USA.	Hitosugi.Taro@mayo.edu; jchen@emory.edu			NIH [CA140515]; DoD [W81XWH-12-1-0217]; NATIONAL CANCER INSTITUTE [R01CA140515] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to authors whose contributions were not directly cited owing to space limitations. This study is supported in part by NIH grants CA140515 (JC) and DoD grant W81XWH-12-1-0217 (JC). JC is a Georgia Cancer Coalition Distinguished Cancer Scholar and a Scholar of the Leukemia and Lymphoma Society.	Anastasiou D, 2012, NAT CHEM BIOL, V8, P839, DOI 10.1038/NCHEMBIO.1060; Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; BRITTON HG, 1972, BIOCHEM J, V130, P397, DOI 10.1042/bj1300397; Cheung EC, 2010, CURR OPIN CELL BIOL, V22, P186, DOI 10.1016/j.ceb.2009.12.006; Chouchani ET, 2011, CURR OPIN CHEM BIOL, V15, P120, DOI 10.1016/j.cbpa.2010.11.003; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Corcoran CA, 2006, CANCER BIOL THER, V5, P1610, DOI 10.4161/cbt.5.12.3617; Dang CV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.297pe75; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Doskeland AP, 1996, BIOCHEM J, V319, P941, DOI 10.1042/bj3190941; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Evans MJ, 2007, MOL BIOSYST, V3, P495, DOI 10.1039/b705113a; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fan J, 2011, MOL CELL BIOL, V31, P4938, DOI 10.1128/MCB.06120-11; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Fothergill-Gilmore L. A., 1989, ADV ENZYMOLOGY RELAT, V62, P227; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRISOLIA S, 1968, BIOCHEMISTRY-US, V7, P1115, DOI 10.1021/bi00843a032; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hoshino A, 2007, J BIOL CHEM, V282, P17706, DOI 10.1074/jbc.M700094200; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kondoh H, 2005, CANCER RES, V65, P177; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Medina RA, 2002, BIOL RES, V35, P9, DOI 10.4067/S0716-97602002000100004; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Morelle W, 2006, PROTEOMICS, V6, P3993, DOI 10.1002/pmic.200600129; Parnell KM, 2013, MOL CANCER THER, V12, P1453, DOI 10.1158/1535-7163.MCT-13-0026; Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010; Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z; ROSE ZB, 1976, J BIOL CHEM, V251, P4817; ROSE ZB, 1975, J BIOL CHEM, V250, P7939; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Stetak A, 2007, CANCER RES, V67, P1602, DOI 10.1158/0008-5472.CAN-06-2870; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005	71	80	80	3	52	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4279	4285		10.1038/onc.2013.406	http://dx.doi.org/10.1038/onc.2013.406			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24096483				2022-12-17	WOS:000341156900001
J	Cai, Y; Geutjes, EJ; de Lint, K; Roepman, P; Bruurs, L; Yu, LR; Wang, W; van Blijswijk, J; Mohammad, H; de Rink, I; Bernards, R; Baylin, SB				Cai, Y.; Geutjes, E-J; de Lint, K.; Roepman, P.; Bruurs, L.; Yu, L-R; Wang, W.; van Blijswijk, J.; Mohammad, H.; de Rink, I.; Bernards, R.; Baylin, S. B.			The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes	ONCOGENE			English	Article						NuRD; DNMTs; tumor suppressor genes; silencing; colon cancer; WNT signaling	HISTONE DEACETYLASE INHIBITION; CHROMATIN-REMODELING COMPLEX; DNA METHYLATION; FACTOR CHD4; CANCER; METHYLTRANSFERASE; HYPERMETHYLATION; DEMETHYLATION; EXPRESSION; DAMAGE	Many tumor suppressor genes (TSGs) are silenced through synergistic layers of epigenetic regulation including abnormal DNA hypermethylation of promoter CpG islands, repressive chromatin modifications and enhanced nucleosome deposition over transcription start sites. The protein complexes responsible for silencing of many of such TSGs remain to be identified. Our previous work demonstrated that multiple silenced TSGs in colorectal cancer cells can be partially reactivated by DNA demethylation in cells disrupted for the DNA methyltransferases 1 and 3B (DNMT1 and 3B) or by DNMTi inhibitors (DNMTi). Herein, we used proteomic and functional genetic approaches to identify additional proteins that cooperate with DNMTs in silencing these key silenced TSGs in colon cancer cells. We discovered that DNMTs and the core components of the NuRD (Mi-2/nucleosome remodeling and deacetylase) nucleosome remodeling complex, chromo domain helicase DNA-binding protein 4 (CHD4) and histone deacetylase 1 (HDAC1) occupy the promoters of several of these hypermethylated TSGs and physically and functionally interact to maintain their silencing. Consistent with this, we find an inverse relationship between expression of HDAC1 and 2 and these TSGs in a large panel of primary colorectal tumors. We demonstrate that DNMTs and NuRD cooperate to maintain the silencing of several negative regulators of the WNT and other signaling pathways. We find that depletion of CHD4 is synergistic with DNMT inhibition in reducing the viability of colon cancer cells in correlation with reactivation of TSGs, suggesting that their combined inhibition may be beneficial for the treatment of colon cancer. Since CHD4 has ATPase activity, our data identify CHD4 as a potentially novel drug target in cancer.	[Cai, Y.; Wang, W.; Mohammad, H.; Baylin, S. B.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA; [Cai, Y.; Wang, W.; Mohammad, H.; Baylin, S. B.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Geutjes, E-J; de Lint, K.; Bruurs, L.; van Blijswijk, J.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, North Holland, Netherlands; [Geutjes, E-J; de Lint, K.; Bruurs, L.; van Blijswijk, J.; Bernards, R.] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, North Holland, Netherlands; [Roepman, P.] Agendia NV, Dept Res & Dev, Amsterdam, Netherlands; [Yu, L-R] US FDA, Div Syst Biol, Ctr Excellence Prote, Natl Ctr Toxicol Res, Jefferson, AR USA; [de Rink, I.] Netherlands Canc Inst, Cent Microarray & Deep Sequencing Core Facil, NL-1066 CX Amsterdam, North Holland, Netherlands	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Netherlands Cancer Institute; Netherlands Cancer Institute; Agendia; US Food & Drug Administration (FDA); Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, 121 Plesmanlaan, NL-1066 CX Amsterdam, North Holland, Netherlands.	r.bernards@nki.nl; sbaylin@jhmi.edu		Yu, Li-Rong/0000-0001-6084-991X; Bernards, Rene/0000-0001-8677-3423; Wang, Wei/0000-0003-1339-4080; de Lint, Klaas/0000-0001-7134-444X	Netherlands Organization for Scientific Research (NWO); National Institute of Environmental Health Sciences (NIEHS) [ES011858]; National Cancer Institute (NCI) [CA043318]; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011858] Funding Source: NIH RePORTER	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank JH Dannenberg for the gift of Hdac1 plasmids. We thank JH Dannenberg, P Kumar and members of the Bernards, Baylin laboratory for discussions and Kathy Bender and H. Liu for manuscript preparation. This work was supported by a grant from the Netherlands Organization for Scientific Research (NWO) to RB, and by grants ES011858 National Institute of Environmental Health Sciences (NIEHS) CA043318 National Cancer Institute (NCI) to SB. The views presented in this article do not necessarily reflect those of the US Food and Drug Administration.	Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Choy JS, 2010, J AM CHEM SOC, V132, P1782, DOI 10.1021/ja910264z; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clements EG, 2012, NUCLEIC ACIDS RES, V40, P4334, DOI 10.1093/nar/gks031; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Huss M, 2009, J EXP BIOL, V212, P341, DOI 10.1242/jeb.024067; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jurkin J, 2011, CELL CYCLE, V10, P406, DOI 10.4161/cc.10.3.14712; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Larsen DH, 2010, J CELL BIOL, V190, P731, DOI 10.1083/jcb.200912135; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; Morey L, 2008, MOL CELL BIOL, V28, P5912, DOI 10.1128/MCB.00467-08; Myant K, 2008, MOL CELL BIOL, V28, P215, DOI 10.1128/MCB.01073-07; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Phesse TJ, 2008, MOL CELL BIOL, V28, P6094, DOI 10.1128/MCB.00539-08; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Reale A, 2005, ONCOGENE, V24, P13, DOI 10.1038/sj.onc.1208005; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Smeenk G, 2010, J CELL BIOL, V190, P741, DOI 10.1083/jcb.201001048; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047; Wilting RH, 2010, EMBO J, V29, P2586, DOI 10.1038/emboj.2010.136; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371; Yu LR, 2007, J PROTEOME RES, V6, P4150, DOI 10.1021/pr070152u; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	51	80	82	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2157	2168		10.1038/onc.2013.178	http://dx.doi.org/10.1038/onc.2013.178			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708667	Green Accepted			2022-12-17	WOS:000334996000002
J	Wu, X; Liu, T; Fang, O; Leach, LJ; Hu, X; Luo, Z				Wu, X.; Liu, T.; Fang, O.; Leach, L. J.; Hu, X.; Luo, Z.			miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27(kip1)	ONCOGENE			English	Article						non-small cell lung cancer; metastasis; miR-194; regulatory and signaling pathway; TGF beta; RhoA	TGF-BETA; MICRORNA; ACTIVATION; TARGET; GROWTH; IDENTIFICATION; INVASION; MIR-31; LIVER; RNAS	MicroRNAs (miRNAs) are increasingly implicated in regulating tumor malignance through their capacity to coordinately repress expression of tumor-related genes. Here, we show that overexpression of miR-194 in lung cancer cell lines, results in suppressing metastasis of lung cancer cells, while inhibiting its expression through miRNA sponge promotes the cancer cells to metastasize. miR-194 expression is also found to be in strongly negative association with metastasis in clinical specimens of non-small cell lung cancer. We demonstrate that miR-194 directly targets both BMP1 and p27(kip1). The resulting downregulation of BMP1 leads to suppression of TGF beta activity and, thus, to downregulation of the expression of key oncogenic genes (matrix metalloproteinases MMP2 and MMP9). This leads, in turn, to decreased tumor invasion. In addition, the miRNA-194-induced suppression of p27(kip1) activates the RhoA pathway, producing enhanced development of actin stress fibers and impaired migration of cancer cells. These findings reveal two structurally independent but functionally linked branches of the regulatory and signaling pathway that together provide a bridge between the metastasis-depressing miRNA and the key genes that govern the malignancy of lung cancers.	[Wu, X.; Liu, T.; Fang, O.; Hu, X.; Luo, Z.] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Leach, L. J.; Luo, Z.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England	Fudan University; University of Birmingham	Luo, Z (corresponding author), Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China.	xhhu@fudan.edu.cn; z.luo@bham.ac.uk		Compton, Lindsey/0000-0002-8441-2381	National Basic Research Program of China [2012CB316505]; National Natural Science Foundation of China [81172006]; Leverhulme Trust (UK)	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Leverhulme Trust (UK)(Leverhulme Trust)	We owe gratefully to two anonymous reviewers whose constructively critical comments have been very helpful to improve the quality and presentation of an earlier version of the paper. We thank the unnamed patients for their consent to allow us to use the lung tissue samples in this research. This work was supported by the National Basic Research Program of China (2012CB316505) and National Natural Science Foundation of China (81172006). ZWL is also supported by the Leverhulme Trust (UK).	Aigner A, 2011, J MOL MED, V89, P445, DOI 10.1007/s00109-010-0716-0; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Chadrick ED, 2010, J THORAC CARDIOV SUR, V140, P505; D'Amico TA, 2008, ANN THORAC SURG, V85, pS737, DOI 10.1016/j.athoracsur.2007.11.047; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Ge GX, 2006, J CELL BIOL, V175, P111, DOI 10.1083/jcb.200606058; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Harpole DH, 2007, THORAC SURG CLIN, V17, P67; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jenkins RH, 2012, BIOCHEM J, V443, P407, DOI 10.1042/BJ20111861; Kawauchi T, 2006, NAT CELL BIOL, V8, P17, DOI 10.1038/ncb1338; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Krutzfeldt J, 2012, HEPATOLOGY, V55, P98, DOI 10.1002/hep.24658; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Pan TL, 2012, J PROTEOMICS, V75, P4676, DOI 10.1016/j.jprot.2012.02.017; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Sicinski P, 2007, GENE DEV, V21, P1703, DOI 10.1101/gad.1583207; Song YX, 2012, ANN SURG ONCOL, V19, pS509, DOI 10.1245/s10434-011-1999-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Valastyan S, 2011, GENE DEV, V25, P646, DOI 10.1101/gad.2004211; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Wang JW, 2009, CANCER LETT, V281, P71, DOI 10.1016/j.canlet.2009.02.020; Wang JC, 2007, GENE CHROMOSOME CANC, V46, P192, DOI 10.1002/gcc.20400; Xiong SD, 2011, INT J BIOL SCI, V7, P805, DOI 10.7150/ijbs.7.805; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; 张斯良, 2006, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V15, P430	42	80	86	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1506	1514		10.1038/onc.2013.108	http://dx.doi.org/10.1038/onc.2013.108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584484				2022-12-17	WOS:000333244200004
J	Casar, B; Rimann, I; Kato, H; Shattil, SJ; Quigley, JP; Deryugina, EI				Casar, B.; Rimann, I.; Kato, H.; Shattil, S. J.; Quigley, J. P.; Deryugina, E. I.			In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta 1 integrin and induction of FAK/PI3K/Akt motility signaling	ONCOGENE			English	Article						metastasis; intravasation; invasion; transendothelial migration; Src kinase; prostate cancer	DOMAIN-CONTAINING PROTEIN-1; FOCAL ADHESION KINASE; CUB-DOMAIN; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; PKC-DELTA; SRC; SUBSTRATE; IDENTIFICATION; METASTASIS	Specific cleavage of the transmembrane molecule, CUB domain-containing protein-1 (CDCP1), by plasmin-like serine proteases induces outside-in signal transduction that facilitates early stages of spontaneous metastasis leading to tumor cell intravasation, namely cell escape from the primary tumor, stromal invasion and transendothelial migration. We identified active beta 1 integrin as a biochemical and functional partner of the membrane-retained 70-kDa CDCP1 fragment, newly generated from its full-length 135-kDa precursor though proteolytic cleavage by serine proteases. Both in cell cultures and in live animals, active beta 1 integrin complexed preferentially with functionally activated, phosphorylated 70-kDa CDCP1. Complexing of beta 1 integrin the 70-kDa with CDCP1 fragment induced intracellular phosphorylation signaling, involving focal adhesion kinase-1 (FAK) and PI3 kinase (PI3K)-dependent Akt activation. Thus, inhibition of FAK/PI3K activities by specific inhibitors as well as short-hairpin RNA downregulation of beta 1 integrin significantly reduced FAK/Akt phosphorylation under conditions where CDCP1 was processed by serine proteases, indicating that FAK/PI3K/Akt pathway operates downstream of cleaved CDCP1 complexed with beta 1 integrin. Furthermore, this complex-dependent signaling correlated positively with high levels of tumor cell intravasation and dissemination. Correspondingly, abrogation in vivo of CDCP1 cleavage either by unique cleavage-blocking monoclonal antibody 10-D7 or by inhibition of proteolytic activity of plasmin-like serine proteases with aprotinin prevented beta 1 integrin/CDCP1 complexing and downstream FAK/Akt signaling concomitant with significant reduction of stromal invasion and spontaneous metastasis. Therefore, beta 1 integrin appears to serve as a motility-regulating partner mediating cross-talk between proteolytically cleaved, membrane-retained CDCP1 and members of FAK/PI3K/Akt pathway. This CDCP1 cleavage-induced signaling cascade constitutes a unique mechanism, independent of extracellular matrix remodeling, whereby a proteolytically cleaved CDCP1 regulates in vivo locomotion and metastasis of tumor cells through beta 1 integrin partnering. Our findings indicate that CDCP1 cleavage, occurring at the apex of a beta 1 integrin/FAK/PI3K/Akt signaling cascade, may represent a therapeutic target for CDCP1-positive cancers.	[Casar, B.; Rimann, I.; Quigley, J. P.; Deryugina, E. I.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Kato, H.; Shattil, S. J.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Shattil, S. J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 North Torrey Pines Rd,SP3030 3120, La Jolla, CA 92037 USA.	jquigley@scripps.edu; deryugin@scripps.edu	CASAR, BERTA/M-2291-2014	CASAR, BERTA/0000-0002-3058-5631	NIH [R01 CA 129484, R01 CA 105412, HL56595, HL57900]; NIH/NCRR/STSI [RR 025774]; Science and Innovation Ministry of Spain; Nachwuchsforderungskredit/Stiefel-Zangger Foundation, University of Zurich; NATIONAL CANCER INSTITUTE [R01CA129484, R01CA157792, R01CA105412] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595, P01HL057900] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCRR/STSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Science and Innovation Ministry of Spain(Spanish Government); Nachwuchsforderungskredit/Stiefel-Zangger Foundation, University of Zurich; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by NIH grants R01 CA 129484 and R01 CA 105412 (to JPQ), NIH/NCRR/STSI Grant RR 025774 (Pilot Award to EID), Postdoctoral Fellowship from the Science and Innovation Ministry of Spain (to BC), Research Fellowships from Nachwuchsforderungskredit/Stiefel-Zangger Foundation, University of Zurich (to IR), and NIH grants HL56595 and HL57900 (to SJS).	Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Bekes EM, 2011, NEOPLASIA, V13, P806, DOI 10.1593/neo.11704; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Deryugina EI, 2005, CANCER RES, V65, P10959, DOI 10.1158/0008-5472.CAN-05-2228; Deryugina EI, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/564259; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Perry SE, 2007, FEBS LETT, V581, P1137, DOI 10.1016/j.febslet.2007.02.025; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Yang LF, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.007294; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	35	80	80	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					255	268		10.1038/onc.2012.547	http://dx.doi.org/10.1038/onc.2012.547			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23208492	Green Accepted			2022-12-17	WOS:000329440700013
J	Duran, RV; MacKenzie, ED; Boulahbel, H; Frezza, C; Heiserich, L; Tardito, S; Bussolati, O; Rocha, S; Hall, MN; Gottlieb, E				Duran, R. V.; MacKenzie, E. D.; Boulahbel, H.; Frezza, C.; Heiserich, L.; Tardito, S.; Bussolati, O.; Rocha, S.; Hall, M. N.; Gottlieb, E.			HIF-independent role of prolyl hydroxylases in the cellular response to amino acids	ONCOGENE			English	Article						prolyl hydroxylases; PHD; alpha-ketoglutarate; amino acids; HIF; mTOR	FISSION YEAST; HYPOXIA; GROWTH; MTOR; 4-HYDROXYLASES; DEFICIENCY; EXPRESSION; AUTOPHAGY; PATHWAY; FAMILY	Hypoxia-inducible factor (HIF) prolyl hydroxylases (PHDs) are alpha-ketoglutarate (alpha KG)-dependent dioxygenases that function as cellular oxygen sensors. However, PHD activity also depends on factors other than oxygen, especially aKG, a key metabolic compound closely linked to amino-acid metabolism. We examined the connection between amino-acid availability and PHD activity. We found that amino-acid starvation leads to alpha KG depletion and to PHD inactivation but not to HIF stabilization. Furthermore, pharmacologic or genetic inhibition of PHDs induced autophagy and prevented mammalian target of rapamycin complex 1 (mTORC1) activation by amino acids in a HIF-independent manner. Therefore, PHDs sense not only oxygen but also respond to amino acids, constituting a broad intracellular nutrient-sensing network.	[Duran, R. V.; MacKenzie, E. D.; Boulahbel, H.; Frezza, C.; Heiserich, L.; Tardito, S.; Gottlieb, E.] Beatson Inst Canc Res, Canc Res UK, Apoptosis & Tumour Metab Lab, Glasgow G61 1BD, Lanark, Scotland; [Duran, R. V.; Hall, M. N.] Univ Basel, Biozentrum, Basel, Switzerland; [Tardito, S.; Bussolati, O.] Univ Parma, Dept Expt Med, Unit Gen & Clin Pathol, I-43100 Parma, Italy; [Rocha, S.] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee, Scotland	Beatson Institute; Cancer Research UK; University of Basel; University of Parma; University of Dundee	Gottlieb, E (corresponding author), Beatson Inst Canc Res, Canc Res UK, Apoptosis & Tumour Metab Lab, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	e.gottlieb@beatson.gla.ac.uk	Frezza, Christian/G-2174-2010; Gottlieb, Eyal/G-6450-2010; Bussolati, Ovidio/B-7589-2013; Tardito, Saverio/AAJ-7727-2020; Duran, Raul V./E-4764-2011	Frezza, Christian/0000-0002-3293-7397; Gottlieb, Eyal/0000-0002-9770-0956; Bussolati, Ovidio/0000-0002-4301-2939; Tardito, Saverio/0000-0002-5294-8683; Duran, Raul V./0000-0002-2249-9215; Hall, Michael N/0000-0002-2998-0757	Cancer Research UK; Swiss National Science Foundation; Cancer Research UK [12918] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Cancer Research UK(Cancer Research UK)	PHD2 and PHD3 antibodies were provided by Kevin Gatter. We thank David Sabatini and Fuyuhiko Tamanoi for kindly providing Rag and Rheb plasmids. We thank David Kwiatkowski for TSC2<SUP>+/+</SUP> and TSC2<SUP>-/-</SUP> mouse embryonic fibroblasts. This work was supported by the Cancer Research UK and by the Swiss National Science Foundation.	Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; DalL'Asta V, 1999, AM J PHYSIOL-CELL PH, V276, pC865, DOI 10.1152/ajpcell.1999.276.4.C865; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hughes BT, 2008, EMBO J, V27, P1491, DOI 10.1038/emboj.2008.83; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Keskiaho K, 2007, PLANT CELL, V19, P256, DOI 10.1105/tpc.106.042739; Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; West CM, 2007, DEVELOPMENT, V134, P3349, DOI 10.1242/dev.000893; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhong H, 2000, CANCER RES, V60, P1541	36	80	84	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4549	4556		10.1038/onc.2012.465	http://dx.doi.org/10.1038/onc.2012.465			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23085753	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000324831300010
J	Quintavalle, C; Donnarumma, E; Iaboni, M; Roscigno, G; Garofalo, M; Romano, G; Fiore, D; De Marinis, P; Croce, CM; Condorelli, G				Quintavalle, C.; Donnarumma, E.; Iaboni, M.; Roscigno, G.; Garofalo, M.; Romano, G.; Fiore, D.; De Marinis, P.; Croce, C. M.; Condorelli, G.			Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells	ONCOGENE			English	Article						glioblastoma; TRAIL; therapy; microRNA; treatment; apoptosis	GROWTH IN-VIVO; MICRORNA SIGNATURES; MONOCLONAL-ANTIBODY; DEATH RECEPTORS; DOWN-REGULATION; STEM-CELLS; GLIOBLASTOMA; EXPRESSION; RESISTANCE; TARGETS	Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, survival of patients remains poor. To define novel pathways that regulate susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the 30 untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets for TRAIL resistance in glioma.	[Quintavalle, C.; Iaboni, M.; Roscigno, G.; Fiore, D.; Condorelli, G.] Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, I-80131 Naples, Italy; [Quintavalle, C.; Iaboni, M.; Roscigno, G.; Condorelli, G.] CNR, IEOS, I-80125 Naples, Italy; [Donnarumma, E.; Romano, G.] Fdn IRCCS SDN, Naples, Italy; [Garofalo, M.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [De Marinis, P.] Osped Antonio Cardarelli, Neurosurg Unit, Naples, Italy; [Condorelli, G.] Univ Naples Federico II, Fac Sci Biotechnol, Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Antonio Cardarelli Hospital; University of Naples Federico II	Condorelli, G (corresponding author), Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, Via Pansini,5,Ed 19 A,2 Floor, I-80131 Naples, Italy.	gecondor@unina.it	Quintavalle, Cristina/AHH-9379-2022; Fiore, Danilo/A-6002-2019; Young, Richard A/F-6495-2012; Condorelli, Gerolama/AAC-3472-2022	Fiore, Danilo/0000-0003-3004-6862; Young, Richard A/0000-0001-8855-8647; Condorelli, Gerolama/0000-0003-0177-8829; Roscigno, Giuseppina/0000-0002-5359-6376	Associazione Italiana Ricerca sul Cancro, AIRC [10620]; MERIT [RBNE08E8CZ_002]; 'Federazione Italiana Ricerca sul Cancro' (FIRC); MERIT project Fellowship	Associazione Italiana Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro); MERIT; 'Federazione Italiana Ricerca sul Cancro' (FIRC)(Fondazione AIRC per la ricerca sul cancro); MERIT project Fellowship	This work was partially supported by funds from Associazione Italiana Ricerca sul Cancro, AIRC to GC (grant n.ro 10620), and MERIT (RBNE08E8CZ_002) to GC. CQ and MI are supported by the 'Federazione Italiana Ricerca sul Cancro' (FIRC) Post-Doctoral Research Fellowship. GR is supported by a MERIT project Fellowship.	Balyasnikova IV, 2011, CANCER LETT, V310, P148, DOI 10.1016/j.canlet.2011.06.029; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Garofalo M, 2010, CELL DEATH DIFFER, V17, P200, DOI 10.1038/cdd.2009.105; Garofalo M, 2007, INT J CANCER, V120, P1215, DOI 10.1002/ijc.22495; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Garofalo M, 2008, CURR OPIN PHARMACOL, V8, P661, DOI 10.1016/j.coph.2008.06.005; Gaur AB, 2011, NEURO-ONCOLOGY, V13, P580, DOI 10.1093/neuonc/nor033; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Joglekar MV, 2009, ISLETS, V1, P137, DOI 10.4161/isl.1.2.9578; Kwak HJ, 2011, ONCOGENE, V30, P2433, DOI 10.1038/onc.2010.620; Lakomy R, 2011, CANCER SCI, V102, P2186, DOI 10.1111/j.1349-7006.2011.02092.x; Li Jun-cai, 2010, Xibei Zhiwu Xuebao, V30, P30; Li N, 2012, CANCER RES, V72, P154, DOI 10.1158/0008-5472.CAN-11-2484; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750-3639.2009.00328.x; Moore LM, 2010, EXPERT OPIN THER TAR, V14, P1247, DOI 10.1517/14728222.2010.527334; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Quintavalle C, 2010, CELL DEATH DIFFER, V17, P1908, DOI 10.1038/cdd.2010.65; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Tran B, 2010, J CLIN NEUROSCI, V17, P417, DOI 10.1016/j.jocn.2009.09.004; Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507; Unterkircher T, 2011, CLIN CANCER RES, V17, P4019, DOI 10.1158/1078-0432.CCR-11-0075; Walczak H, 2000, CANCER RES, V60, P3051; Younes A, 2010, BRIT J CANCER, V103, P1783, DOI 10.1038/sj.bjc.6605987; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zanca C, 2008, J CELL MOL MED, V12, P2416, DOI 10.1111/j.1582-4934.2008.00283.x; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	42	80	84	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4001	4008		10.1038/onc.2012.410	http://dx.doi.org/10.1038/onc.2012.410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964638				2022-12-17	WOS:000323748100008
J	Gusenbauer, S; Vlaicu, P; Ullrich, A				Gusenbauer, S.; Vlaicu, P.; Ullrich, A.			HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors	ONCOGENE			English	Article						HGF; EGFR; resistance; gefitinib; kinase-independent	EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; FACTOR RECEPTOR; ACQUIRED-RESISTANCE; MET AMPLIFICATION; GEFITINIB RESISTANCE; T790M MUTATIONS; C-MET; EXPRESSION; ACTIVATION	The epidermal growth factor receptor (EGFR) is overexpressed and activated in many human cancers and predicts poor patient prognosis. Targeting the kinase domain with specific EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib has been used in anticancer treatments. However, patient response rates in different human cancers were initially low. Only a subgroup of non-small-cell lung cancer (NSCLC) patients harboring EGFR-activating mutations responds to EGFR TKI treatment, but most of these responders relapse and acquire resistance. Recent clinical studies have demonstrated that MET proto-oncogene overexpression correlates with resistance to EGFR TKI treatment. Similarly to MET overexpression, the tumor microenvironment-derived ligand hepatocyte growth factor (HGF) was shown to activate Met and thereby induce short-term resistance to EGFR TKI treatment in gefitinib-sensitive NSCLC cell lines in vitro. However, only little is known about the HGF/Met-induced EGFR TKI resistance mechanism in other human cancer types. Therefore, in order to develop possible new anticancer strategies for diverse human cancers, we screened 12 carcinoma cell lines originating from the breast, kidney, liver and tongue for HGF-induced EGFR tyrosine kinase (TK)-inhibition. In addition, in order to advance our understanding of a TK-inactive EGFR, we used EGFR co-immunoprecipitation, followed by mass spectrometry to identify novel HGF-induced EGFR binding partners, which are potentially involved in tyrosine kinase-independent EGFR signaling mechanisms. Here we show for the first time that HGF-induced EGFR TK-inhibition is a very common mechanism in human cancers, and that the kinase-inactive EGFR directly interacts with and stabilizes several cancer-relevant proteins, including the receptor tyrosine kinases Axl and EphA2, and the CUB domain-containing protein-1. This study has strong implications for the development of new anticancer strategies.	[Gusenbauer, S.; Vlaicu, P.; Ullrich, A.] Max Planck Inst Biochem, Dept Mol Biol, D-85152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18, D-85152 Martinsried, Germany.	ullrich@biochem.mpg.de						Arteaga CL, 2002, ONCOLOGIST, V7, P31; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blagosklonny MV, 2003, CANCER BIOL THER, V2, P137, DOI 10.4161/cbt.2.2.286; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Castillo L, 2004, ANN ONCOL, V15, P1007, DOI 10.1093/annonc/mdh257; Chen HJ, 2009, PATHOL ONCOL RES, V15, P651, DOI 10.1007/s12253-009-9167-8; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104; Gordon AN, 2005, INT J GYNECOL CANCER, V15, P785, DOI 10.1111/j.1525-1438.2005.00137.x; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Huang SM, 1999, INVEST NEW DRUG, V17, P259, DOI 10.1023/A:1006384521198; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Laimer K, 2007, ORAL ONCOL, V43, P193, DOI 10.1016/j.oraloncology.2006.02.009; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Liu LB, 2008, J MED CHEM, V51, P3688, DOI 10.1021/jm800401t; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McDermott U, 2010, CANCER RES, V70, P1625, DOI 10.1158/0008-5472.CAN-09-3620; Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Peghini PL, 2002, CLIN CANCER RES, V8, P2273; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Quesnelle KM, 2007, J CELL BIOCHEM, V102, P311, DOI 10.1002/jcb.21475; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sharma K, 2009, NAT METHODS, V6, P741, DOI [10.1038/nmeth.1373, 10.1038/NMETH.1373]; Spix JK, 2007, EXP CELL RES, V313, P3319, DOI 10.1016/j.yexcr.2007.06.006; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Twombly R, 2005, J NATL CANCER I, V97, P249, DOI 10.1093/jnci/97.4.249; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Weinberger PM, 2005, ARCH OTOLARYNGOL, V131, P707, DOI 10.1001/archotol.131.8.707; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yoshida T, 2010, BIOCHEM PHARMACOL, V80, P613, DOI 10.1016/j.bcp.2010.05.014; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845; Zucali PA, 2008, ANN ONCOL, V19, P1605, DOI 10.1093/annonc/mdn240	53	80	86	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3846	3856		10.1038/onc.2012.396	http://dx.doi.org/10.1038/onc.2012.396			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	23045285				2022-12-17	WOS:000323210200007
J	Del Vecchio, CA; Giacomini, CP; Vogel, H; Jensen, KC; Florio, T; Merlo, A; Pollack, JR; Wong, AJ				Del Vecchio, C. A.; Giacomini, C. P.; Vogel, H.; Jensen, K. C.; Florio, T.; Merlo, A.; Pollack, J. R.; Wong, A. J.			EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms	ONCOGENE			English	Article						EGFRvIII; glioblastoma; HDAC; methylation; amplification	GROWTH-FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITORS; TUMOR-INITIATING CELLS; TRICHOSTATIN-A; IN-VIVO; LUNG CARCINOMAS; HDAC INHIBITORS; BREAST-CANCER; VALPROIC ACID; BRAIN-TUMORS	Amplification and rearrangements of the epidermal growth factor receptor (EGFR) gene are frequently found in glioblastoma multiforme (GBM). The most common variant is EGFR variant III (EGFRvIII). Research suggests that EGFRvIII could be a marker for a cancer stem cell or tumor-initiating population. If amplification and rearrangement are early events in tumorigenesis, this implies that they should be preserved throughout the tumor. However, in primary GBM, EGFRvIII expression is focal and sporadic. Unexpectedly, we found EGFR amplification and rearrangement throughout the tumor, including regions with no EGFRvIII expression, suggesting that mechanisms exist to modulate EGFRvIII expression even in the presence of high gene amplification. To study this phenomenon, we characterized three GBM cell lines with endogenous EGFRvIII. EGFRvIII expression was heterogeneous, with both positive and negative populations maintaining the genetic alterations, akin to primary tumors. Furthermore, EGFRvIII defined a hierarchy where EGFRvIII-positive cells gave rise to additional positive and negative cells. Only cells that had recently lost EGFRvIII expression could re-express EGFRvIII, providing an important buffer for maintaining EGFRvIII-positive cell numbers. Epigenetic mechanisms had a role in maintaining heterogeneous EGFRvIII expression. Demethylation induced a 20-60% increase in the percentage of EGFRvIII-positive cells, indicating that some cells could re-express EGFRvIII. Surprisingly, inhibition of histone deacetylation resulted in a 50-80% reduction in EGFRvIII expression. Collectively, this data demonstrates that EGFR amplification and rearrangement are early events in tumorigenesis and EGFRvIII follows a model of hierarchical expression. Furthermore, EGFRvIII expression is restricted by epigenetic mechanisms, suggesting that drugs that modulate the epigenome might be used successfully in glioblastoma tumors.	[Del Vecchio, C. A.; Wong, A. J.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; [Del Vecchio, C. A.; Giacomini, C. P.; Pollack, J. R.; Wong, A. J.] Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Giacomini, C. P.; Vogel, H.; Jensen, K. C.; Pollack, J. R.] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Jensen, K. C.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; [Florio, T.] Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; [Merlo, A.] Univ Basel, Lab Mol Neurooncol, Dept Clin & Biol Sci, Basel, Switzerland	Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Genoa; University of Basel	Wong, AJ (corresponding author), Stanford Univ, Med Ctr, Dept Neurosurg, Canc Biol Program, 1201 Welch Rd,MSLS P108, Stanford, CA 94305 USA.	ajwong@stanford.edu	Florio, Tullio/A-2211-2012; FLORIO, TULLIO/ABG-3182-2020	Florio, Tullio/0000-0002-2394-996X; Vogel, Otto Hannes/0000-0002-0960-3508; Del Vecchio Fitz, Catherine/0000-0002-9554-411X; Jensen, Kristin/0000-0003-1177-9104	National Defense Science and Engineering Graduate Research Fellowship; National Science Foundation Graduate Research Fellowship; NIH [CA124832, RC2 CA14891]; Lucille Packard Children's Foundation; National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE [R01CA124832, R01CA069495, RC2CA148491] Funding Source: NIH RePORTER	National Defense Science and Engineering Graduate Research Fellowship; National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lucille Packard Children's Foundation; National Brain Tumor Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Neethan Lobo, Dr Siddhartha Mitra, Dr A Hunter Shain and the Stanford FACS facility for technical advice. Additionally, we thank Dana Bangs and Dr Athena Cherry at the Stanford Cytogenetics Laboratory for their assistance with FISH staining and analysis. This work was supported by the National Defense Science and Engineering Graduate Research Fellowship, the National Science Foundation Graduate Research Fellowship, NIH Grants CA124832, RC2 CA14891, the Lucille Packard Children's Foundation and a research grant from the National Brain Tumor Foundation.	Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700; Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bialer M, 2007, NEUROTHERAPEUTICS, V4, P130, DOI 10.1016/j.nurt.2006.11.007; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; BIGNER SH, 1990, CANCER RES, V50, P8017; Camphausen K, 2005, INT J CANCER, V114, P380, DOI 10.1002/ijc.20774; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Frederick L, 2000, NEURO-ONCOLOGY, V2, P159, DOI 10.1093/neuonc/2.3.159; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Jones G, 2001, CANCER RES, V61, P4978; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Porter KR, 2010, NEURO-ONCOLOGY, V12, P520, DOI 10.1093/neuonc/nop066; Schulte A, 2012, CLIN CANCER RES, V18, P1901, DOI 10.1158/1078-0432.CCR-11-3084; Shabason JE, 2011, J CELL MOL MED, V15, P2735, DOI 10.1111/j.1582-4934.2011.01296.x; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Solomon DA, 2009, CANCER RES, V69, P5630, DOI 10.1158/0008-5472.CAN-09-1055; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stockhausen MT, 2011, EXP CELL RES, V317, P1513, DOI 10.1016/j.yexcr.2011.04.001; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Svechnikova I, 2008, INT J ONCOL, V32, P821; Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5; Tang CK, 2000, CANCER RES, V60, P3081; Thomas C, 2001, ACTA NEUROPATHOL, V101, P605; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vogt N, 2004, P NATL ACAD SCI USA, V101, P11368, DOI 10.1073/pnas.0402979101; VONHOFF DD, 1991, CANCER RES, V51, P6273; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Witusik-Perkowska M, 2011, J NEURO-ONCOL, V102, P395, DOI 10.1007/s11060-010-0352-0; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 2008, J CLIN ONCOL S, V26, P2002; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	45	80	82	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2670	2681		10.1038/onc.2012.280	http://dx.doi.org/10.1038/onc.2012.280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22797070	Bronze			2022-12-17	WOS:000319806700008
J	Chaves-Perez, A; Mack, B; Maetzel, D; Kremling, H; Eggert, C; Harreus, U; Gires, O				Chaves-Perez, A.; Mack, B.; Maetzel, D.; Kremling, H.; Eggert, C.; Harreus, U.; Gires, O.			EpCAM regulates cell cycle progression via control of cyclin D1 expression	ONCOGENE			English	Article						EpCAM; EpICD; cyclin D1	BREAST-CANCER; EP-CAM; POTENTIAL TARGET; GENE-EXPRESSION; BETA-CATENIN; STEM-CELLS; FHL2; CARCINOMA; PROTEIN; DIFFERENTIATION	The epithelial cell adhesion molecule (EpCAM) is an integral transmembrane protein that is frequently overexpressed in embryonic stem cells, tissue progenitors, carcinomas and cancer-initiating cells. In cancer cells, expression of EpCAM is associated with enhanced proliferation and upregulation of target genes including c-myc. However, the exact molecular mechanisms underlying the observed EpCAM-dependent cell proliferation remained unexplored. Here, we show that EpCAM directly affects cell cycle progression via its capacity to regulate the expression of cyclin D1 at the transcriptional level and depending on the direct interaction partner FHL2 (four-and-a-half LIM domains protein 2). As a result, downstream events such as phosphorylation of the retinoblastoma protein (Rb) and expression of cyclins E and A are similarly affected. In vivo, EpCAM expression strength and pattern are both positively correlated with the proliferation marker Ki67, high expression and nuclear localisation of cyclin D1, and Rb phosphorylation. Thus, EpCAM enhances cell cycle progression via the classical cyclin-regulated pathway. Oncogene (2013) 32, 641-650; doi:10.1038/onc.2012.75; published online 5 March 2012	[Chaves-Perez, A.; Kremling, H.; Eggert, C.; Gires, O.] Univ Munich, Clin Cooperat Grp Mol Oncol, Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, D-81377 Munich, Germany; [Chaves-Perez, A.; Kremling, H.; Eggert, C.; Gires, O.] Univ Munich, Head & Neck Res Dept, D-81377 Munich, Germany; [Mack, B.; Harreus, U.; Gires, O.] Univ Munich, Dept Otorhinolaryngol Head & Neck Surg, Grosshadern Med Ctr, D-81377 Munich, Germany; [Maetzel, D.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich; Massachusetts Institute of Technology (MIT); Whitehead Institute	Gires, O (corresponding author), Univ Munich, Dept Otorhinolaryngol, Grosshadern Med Ctr, Marchioninistr 15, D-81377 Munich, Germany.	Olivier.gires@med.uni-muenchen.de	Gires, Olivier/V-2689-2017	Gires, Olivier/0000-0002-2292-7064				Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Chen HF, 2011, STEM CELL REV REP, V7, P722, DOI 10.1007/s12015-011-9233-y; Denzel S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-402; Gabriel B, 2006, J SOC GYNECOL INVEST, V13, P69, DOI 10.1016/j.jsgi.2005.10.001; Gabriel B, 2004, ANTICANCER RES, V24, P921; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Gires O, 2009, NAT REV CANCER, V9, P143, DOI 10.1038/nrc2499-c1; Gonzalez B, 2009, STEM CELLS, V27, P1782, DOI 10.1002/stem.97; Guo Z, 2010, MOL CARCINOGEN, V49, P826, DOI 10.1002/mc.20659; Huang HP, 2011, J BIOL CHEM, V286, P33520, DOI 10.1074/jbc.M111.256164; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Labalette C, 2008, J BIOL CHEM, V283, P15201, DOI 10.1074/jbc.M800708200; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Litvinov SV, 1996, AM J PATHOL, V148, P865; Lu TY, 2010, J BIOL CHEM, V285, P8719, DOI 10.1074/jbc.M109.077081; Maaser K, 2008, BRIT J CANCER, V99, P1635, DOI 10.1038/sj.bjc.6604725; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; MICHALIDES R, 1995, CANCER RES, V55, P975; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Munz Markus, 2004, Cancer Genomics Proteomics, V1, P241; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Nasr AF, 2003, ONCOGENE, V22, P1668, DOI 10.1038/sj.onc.1206248; Ng CF, 2011, GENE, V481, P41, DOI 10.1016/j.gene.2011.04.005; Ng VY, 2010, STEM CELLS, V28, P29, DOI 10.1002/stem.221; Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; SCHON MP, 1994, J INVEST DERMATOL, V102, P987, DOI 10.1111/1523-1747.ep12384258; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soucek T, 1997, ONCOGENE, V14, P2251, DOI 10.1038/sj.onc.1201061; Spizzo G, 2006, GYNECOL ONCOL, V103, P483, DOI 10.1016/j.ygyno.2006.03.035; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908; Yanamoto S, 2007, ORAL ONCOL, V43, P869, DOI 10.1016/j.oraloncology.2006.10.010	40	80	81	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					641	650		10.1038/onc.2012.75	http://dx.doi.org/10.1038/onc.2012.75			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22391566	Bronze			2022-12-17	WOS:000316164700011
J	Huang, S; Gulzar, ZG; Salari, K; Lapointe, J; Brooks, JD; Pollack, JR				Huang, S.; Gulzar, Z. G.; Salari, K.; Lapointe, J.; Brooks, J. D.; Pollack, J. R.			Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness	ONCOGENE			English	Article						prostate cancer; genomic profiling; tumor suppressor; chromatin remodeling; cell invasion	MOLECULAR ASPECTS; COPY NUMBER; MUTATIONS; CHROMATIN; ABERRATIONS; REVEALS; ARID1A; FAMILY	Though prostate cancer is often indolent, it is nonetheless a leading cause of cancer death. Defining the underlying molecular genetic alterations may lead to new strategies for prevention or treatment. Towards this goal, we performed array-based comparative genomic hybridization (CGH) on 86 primary prostate tumors. Among the most frequent alterations not associated with a known cancer gene, we identified focal deletions within 5q21 in 15 out of 86 (17%) cases. By high-resolution tiling array CGH, the smallest common deletion targeted just one gene, the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1). Expression of CHD1 was significantly reduced in tumors with deletion (P = 0.03), and compared with normal prostate (P = 0.04). Exon sequencing analysis also uncovered nonsynonymous mutations in 1 out of 7 (14%) cell lines (LAPC4) and in 1 out of 24 (4%) prostate tumors surveyed. RNA interference-mediated knockdown of CHD1 in two nontumorigenic prostate epithelial cell lines, OPCN2 and RWPE-1, did not alter cell growth, but promoted cell invasiveness, and in OPCN2-enhanced cell clonogenicity. Taken together, our findings suggest that CHD1 deletion may underlie cell invasiveness in a subset of prostate cancers, and indicate a possible novel role of altered chromatin remodeling in prostate tumorigenesis. Oncogene (2012) 31, 4164-4170; doi:10.1038/onc.2011.590; published online 19 December 2011	[Huang, S.; Salari, K.; Pollack, J. R.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Gulzar, Z. G.; Brooks, J. D.] Stanford Univ, Dept Urol, Stanford, CA 94305 USA; [Lapointe, J.] McGill Univ, Dept Surg, Div Urol, Montreal, PQ H3A 2T5, Canada	Stanford University; Stanford University; McGill University	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 269 Campus Dr,CCSR 3245A, Stanford, CA 94305 USA.	pollack1@stanford.edu			NIH [CA122246, CA111782, CA130472]; Burroughs Wellcome Fund [1007519]; American Cancer Society [PF-08-078-01-MGO]; Prostate Cancer Canada; Stanford Cancer Center; NATIONAL CANCER INSTITUTE [P30CA124435, F32CA130472, R01CA111782, R01CA122246] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Cancer Society(American Cancer Society); Prostate Cancer Canada; Stanford Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank the members of the Pollack lab for helpful discussion. Supported by grants from the NIH (CA122246 to JRP; CA111782 to JDB; CA130472 to SH), the Burroughs Wellcome Fund (1007519 to JRP), the American Cancer Society (PF-08-078-01-MGO to SH), Prostate Cancer Canada (to JL) and the Stanford Cancer Center (to JRP).	Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Binkley J, 2010, GENOME RES, V20, P142, DOI 10.1101/gr.097121.109; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212; Hall JA, 2007, BIOCHEM CELL BIOL, V85, P463, DOI 10.1139/O07-063; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JH, 2007, CANCER RES, V67, P8229, DOI 10.1158/0008-5472.CAN-07-1297; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Marfella CGA, 2007, MUTAT RES-FUND MOL M, V618, P30, DOI 10.1016/j.mrfmmm.2006.07.012; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Menon T, 2010, MOL ENDOCRINOL, V24, P1165, DOI 10.1210/me.2009-0421; Nagarajan P, 2009, ONCOGENE, V28, P1053, DOI 10.1038/onc.2008.440; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433	28	80	82	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4164	4170		10.1038/onc.2011.590	http://dx.doi.org/10.1038/onc.2011.590			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22179824	Green Accepted			2022-12-17	WOS:000308688900008
J	Bjorkman, M; Ostling, P; Harma, V; Virtanen, J; Mpindi, JP; Rantala, J; Mirtti, T; Vesterinen, T; Lundin, M; Sankila, A; Rannikko, A; Kaivanto, E; Kohonen, P; Kallioniemi, O; Nees, M				Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Mirtti, T.; Vesterinen, T.; Lundin, M.; Sankila, A.; Rannikko, A.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.			Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion	ONCOGENE			English	Article						prostate cancer; epigenetics; histone demethylase; migration; invasion; PHF8	LINKED MENTAL-RETARDATION; ANDROGEN-RECEPTOR; GLOBAL LEVELS; PREDICT RISK; PHD FINGERS; GENE; LYSINE-4; METHYLATION; H3; TRANSCRIPTION	Our understanding of key epigenetic regulators involved in specific biological processes and cancers is still incomplete, despite great progress in genome-wide studies of the epigenome. Here, we carried out a systematic, genome-wide analysis of the functional significance of 615 epigenetic proteins in prostate cancer (PrCa) cells. We used the high-content cell-spot microarray technology and siRNA silencing of PrCa cell lines for functional screening of cell proliferation, survival, androgen receptor (AR) expression, histone methylation and acetylation. Our study highlights subsets of epigenetic enzymes influencing different cancer cell phenotypes. Plant homeo domain (PHD) finger proteins have a key role in cell survival and histone methylation, whereas histone deacetylases were primarily involved in regulating AR expression. In contrast, JumonjiC-domain (JmjC) containing histone lysine demethylases (KDMs) mainly had an impact on cell proliferation. Our results show that the KDMs JARID1B, PHF8, KDM3A, KDM3B and KDM4A were highly expressed in clinical PrCa samples. The PHD-finger protein 8 (PHF8), a transcriptional coactivator with both PHD- and JmjC-domains, was moderately to strongly expressed in 80% of clinical PrCa samples, whereas 76% of normal and benign samples were negative or only showed weak PHF8 expression. Strong PHF8 expression correlated significantly with high Gleason grade and was borderline significant for poor prognosis. The results of functional PHF8 knockdown implicate a role in cell migration and invasion, as shown by cell motility and 3-D invasion assays. Our study suggests that various cellular phenotypes are regulated by distinct subsets of epigenetic enzymes. Proteins interpreting and modifying histone methylation, such as JmjC-domain and particularly PHD-finger proteins like PHF8, are activated in subsets of PrCa's and promote cancer relevant phenotypes. Oncogene (2012) 31, 3444-3456; doi:10.1038/onc.2011.512; published online 28 November 2011	[Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.] VTT Tech Res Ctr Finland, FI-20520 Turku, Varsinais Suomi, Finland; [Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.] Univ Turku, Ctr Biotechnol, FI-20520 Turku, Varsinais Suomi, Finland; [Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.] Abo Akad Univ, FI-20520 Turku, Varsinais Suomi, Finland; [Ostling, P.; Mpindi, J-P; Mirtti, T.; Vesterinen, T.; Lundin, M.; Sankila, A.; Kallioniemi, O.] Univ Helsinki, FIMM, Helsinki, Finland; [Rannikko, A.] Univ Helsinki, Dept Urol, HUSLAB, Helsinki, Finland	VTT Technical Research Center Finland; University of Turku; Abo Akademi University; University of Helsinki; University of Helsinki	Nees, M (corresponding author), VTT Tech Res Ctr Finland, FI-20520 Turku, Varsinais Suomi, Finland.	matthias.nees@vtt.fi	Rannikko, Antti/ABB-8453-2020; Kohonen, Pekka/F-9596-2011; Nees, Matthias/AAT-5577-2020; Kallioniemi, Olli P/H-5111-2011; Vesterinen, Tiina J/O-8922-2016; Nees, Matthias/W-6596-2018	Rannikko, Antti/0000-0002-4261-3484; Kohonen, Pekka/0000-0002-7845-3611; Kallioniemi, Olli P/0000-0002-3231-0332; Nees, Matthias/0000-0002-9034-301X; Ostling, Paivi/0000-0001-5501-466X; Vesterinen, Tiina/0000-0003-2997-0337; Harma, Ville/0000-0001-5767-5226; Mirtti, Tuomas/0000-0003-0455-9891; Rantala, Juha/0000-0002-4999-5585	Academy of Finland [111456]; EU-EPITRON [LSHC-CT-2005-518417]; Marie Curie Canceromics [MEXT-CT-2003-2728]; Cancer Organizations Finland; Sigrid Juselius Foundation	Academy of Finland(Academy of Finland); EU-EPITRON(European Commission); Marie Curie Canceromics(European Commission); Cancer Organizations Finland; Sigrid Juselius Foundation(Sigrid Juselius Foundation)	We thank Professor Tony Kouzarides from The Gurdon Institute, University of Cambridge for valuable suggestions and insights in constructing the epigenetic siRNA library. We thank Daniela Kleine-Kohlbrecher and Professor Kristian Helin from Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark, for insightful discussions, sharing unpublished results and PHF8 over expression construct. We thank Arho Virkki and Elmar Bucher for assistance with gene expression data normalization. This study was supported by grants from Academy of Finland (grant Nr. 111456 to MN, VH), EU-EPITRON (contract # LSHC-CT-2005-518417 to MB, OK), Marie Curie Canceromics (MEXT-CT-2003-2728 to OK), Cancer Organizations Finland and Sigrid Juselius Foundation (JPM, JR).	Abbott A, 2010, NATURE, V463, P596, DOI 10.1038/463596b; Abidi FE, 2007, CLIN GENET, V72, P19, DOI 10.1111/j.1399-0004.2007.00817.x; Baker LA, 2008, MUTAT RES-FUND MOL M, V647, P3, DOI 10.1016/j.mrfmmm.2008.07.004; Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555; Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351; Bjorkman M, 2008, INT J CANCER, V123, P2774, DOI 10.1002/ijc.23885; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662; Feng WJ, 2010, NAT STRUCT MOL BIOL, V17, P445, DOI 10.1038/nsmb.1778; Flamand V, 2010, J CANCER RES CLIN, V136, P1761, DOI 10.1007/s00432-010-0835-6; Fortschegger K, 2010, MOL CELL BIOL, V30, P3286, DOI 10.1128/MCB.01520-09; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Holst CR, 2003, CANCER RES, V63, P1596; Horton JR, 2010, NAT STRUCT MOL BIOL, V17, P38, DOI 10.1038/nsmb.1753; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kleine-Kohlbrecher D, 2010, MOL CELL, V38, P165, DOI 10.1016/j.molcel.2010.03.002; Koivisto AM, 2007, CLIN GENET, V72, P145, DOI 10.1111/j.1399-0004.2007.00836.x; Lange SS, 2008, P NATL ACAD SCI USA, V105, P10320, DOI 10.1073/pnas.0803181105; Laumonnier F, 2005, J MED GENET, V42, P780, DOI 10.1136/jmg.2004.029439; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Loenarz C, 2010, HUM MOL GENET, V19, P217, DOI 10.1093/hmg/ddp480; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Qi HH, 2010, NATURE, V466, P503, DOI 10.1038/nature09261; Qiao Y, 2008, CLIN GENET, V74, P134, DOI 10.1111/j.1399-0004.2008.01028.x; Rantala JK, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-162; Rantala JK, 2010, NEOPLASIA, V12, P877, DOI 10.1593/neo.10548; Rose NR, 2008, J MED CHEM, V51, P7053, DOI 10.1021/jm800936s; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shi XB, 2007, J BIOL CHEM, V282, P2450, DOI 10.1074/jbc.C600286200; Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179; Smith EH, 2007, HUM MOL GENET, V16, P3136, DOI 10.1093/hmg/ddm275; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tuomi S, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000135; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wolf SS, 2007, ARCH BIOCHEM BIOPHYS, V460, P56, DOI 10.1016/j.abb.2007.01.017; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhu ZQ, 2010, CELL RES, V20, P794, DOI 10.1038/cr.2010.75	58	80	84	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3444	3456		10.1038/onc.2011.512	http://dx.doi.org/10.1038/onc.2011.512			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22120715				2022-12-17	WOS:000306566400005
J	Fanale, D; Amodeo, V; Corsini, LR; Rizzo, S; Bazan, V; Russo, A				Fanale, D.; Amodeo, V.; Corsini, L. R.; Rizzo, S.; Bazan, V.; Russo, A.			Breast cancer genome-wide association studies: there is strength in numbers	ONCOGENE			English	Review						FGFR2; GWAS; H19; LSP1; MAP3K1; TNRC9	FIBROBLAST-GROWTH-FACTOR; BRCA2 MUTATION CARRIERS; SUSCEPTIBILITY LOCI; COMMON VARIANTS; GENE-EXPRESSION; CONFER SUSCEPTIBILITY; GERMLINE MUTATIONS; CHROMOSOME 5P12; TUMOR SUBTYPES; RISK	Breast cancer (BC) is a heterogeneous disease that exhibits familial aggregation. Family linkage studies have identified high-penetrance genes, BRCA1, BRCA2, PTEN and TP53, that are responsible for inherited BC syndromes. Moreover, a combination of family-based and population-based approaches indicated that genes involved in DNA repair, such as CHEK2, ATM, BRIP and PALB2, are associated with moderate risk. Therefore, all of these known genes account for only 25% of the familial aggregation cases. Recently, genome wide association studies (GWAS) in BC revealed single nucleotide polymorphisms (SNPs) in five novel genes associated to susceptibility: TNRC9, FGFR2, MAP3K1, H19 and lymphocyte-specific protein 1 (LSP1). The most strongly associated SNP was in intron 2 of the FGFR2 gene that is amplified and overexpressed in 5-10% of BC. rs3803662 of TNRC9 gene has been shown to be the SNP with the strongest association with BC, in particular, this polymorphism seems to be correlated with bone metastases and estrogen receptor positivity. Relevant data indicate that SNP rs889312 in MAP3K1 is correlated with BC susceptibility only in BRCA2 mutation carriers, but is not associated with an increased risk in BRCA1 carriers. Finally, different SNPs in LSP1 and H19 and in minor genes probably were associated with BC risk. New susceptibility allelic variants associated with BC risk were recently discovered including potential causative genes involved in regulation of cell cycle, apoptosis, metabolism and mitochondrial functions. In conclusion, the identification of disease susceptibility loci may lead to a better understanding of the biological mechanism for BC to improve prevention, early detection and treatment. Oncogene (2012) 31, 2121-2128; doi:10.1038/onc.2011.408; published online 26 September 2011	[Fanale, D.; Amodeo, V.; Corsini, L. R.; Rizzo, S.; Bazan, V.; Russo, A.] Univ Palermo, Sect Med Oncol, Dept Surg & Oncol Sci, I-90127 Palermo, Italy; [Bazan, V.; Russo, A.] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	University of Palermo; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Russo, A (corresponding author), Univ Palermo, Sect Med Oncol, Dept Surg & Oncol Sci, Via Vespro 129, I-90127 Palermo, Italy.	lab-oncobiologia@usa.net	Fanale, Daniele/K-8630-2016	Fanale, Daniele/0000-0001-7668-737X				ADNANE J, 1991, ONCOGENE, V6, P659; Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Antoniou AC, 2008, AM J HUM GENET, V82, P937, DOI 10.1016/j.ajhg.2008.02.008; Antoniou AC, 2009, HUM MOL GENET, V18, P4442, DOI 10.1093/hmg/ddp372; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Braun R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002101; Broeks A, 2011, HUM MOL GENET, V20, P3289, DOI 10.1093/hmg/ddr228; Cerhan JR, 2007, BLOOD, V110, P4455, DOI 10.1182/blood-2007-05-088682; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Dite GS, 2003, J NATL CANCER I, V95, P448, DOI 10.1093/jnci/95.6.448; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Easton DF, 2008, HUM MOL GENET, V17, pR109, DOI 10.1093/hmg/ddn287; FitzGerald MG, 1998, ONCOGENE, V17, P727, DOI 10.1038/sj.onc.1201984; Fu YP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-113; Garcia-Closas M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000054; Garcia-Closas M, 2008, CLIN CANCER RES, V14, P8000, DOI 10.1158/1078-0432.CCR-08-0975; Gold B, 2008, P NATL ACAD SCI USA, V105, P4340, DOI 10.1073/pnas.0800441105; Hashimoto T, 1996, J BIOCHEM-TOKYO, V119, P1196; Hirshfield KM, 2010, J ONCOL, V2010, DOI 10.1155/2010/297671; Hollestelle A, 2010, CURR OPIN GENET DEV, V20, P268, DOI 10.1016/j.gde.2010.02.009; Houlston RS, 2004, ONCOGENE, V23, P6471, DOI 10.1038/sj.onc.1207951; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Ingersoll RG, 2001, CYTOGENET CELL GENET, V94, P121, DOI 10.1159/000048802; Kristensen VN, 2008, MOL ONCOL, V2, P12, DOI 10.1016/j.molonc.2008.02.003; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Rosa-Rosa JM, 2009, AM J HUM GENET, V84, P115, DOI 10.1016/j.ajhg.2008.12.013; Marafioti T, 2003, BRIT J HAEMATOL, V120, P671, DOI 10.1046/j.1365-2141.2003.04137.x; Mcinerney N, 2009, BREAST CANCER RES TR, V117, P151, DOI 10.1007/s10549-008-0235-7; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meyer KB, 2008, PLOS BIOL, V6, P1098, DOI 10.1371/journal.pbio.0060108; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moffa AB, 2007, J CELL PHYSIOL, V210, P720, DOI 10.1002/jcp.20880; Nordgard SH, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1784; Orr N, 2008, ADV GENET, V62, P1, DOI 10.1016/S0065-2660(08)00601-9; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peto J, 2002, CANCER CELL, V1, P411, DOI 10.1016/S1535-6108(02)00079-X; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; Ruiz-Narvaez EA, 2010, BREAST CANCER RES TR, V123, P525, DOI 10.1007/s10549-010-0775-5; SIDRANSKY D, 1992, CANCER RES, V52, P2984; Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131; Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064; Tamaru N, 2004, LAB INVEST, V84, P1460, DOI 10.1038/labinvest.3700166; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Wang XS, 2010, HUM MOL GENET, V19, P2886, DOI 10.1093/hmg/ddq174; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang YZ, 1999, GENE, V230, P69, DOI 10.1016/S0378-1119(99)00047-5	57	80	84	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2121	2128		10.1038/onc.2011.408	http://dx.doi.org/10.1038/onc.2011.408			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21996731	Green Published			2022-12-17	WOS:000303415900001
J	Nakatake, M; Monte-Mor, B; Debili, N; Casadevall, N; Ribrag, V; Solary, E; Vainchenker, W; Plo, I				Nakatake, M.; Monte-Mor, B.; Debili, N.; Casadevall, N.; Ribrag, V.; Solary, E.; Vainchenker, W.; Plo, I.			JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms	ONCOGENE			English	Article						JAK2(V617F); p53; MDM2; La protein; myeloproliferative neoplasms	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; HOMOLOGOUS RECOMBINATION; MYELOID METAPLASIA; ESSENTIAL THROMBOCYTHEMIA; PROGNOSTIC-SIGNIFICANCE; HEMATOPOIETIC-CELLS; CANCER-THERAPY; DISORDERS	JAK2(V617F) is a gain of function mutation that promotes cytokine-independent growth of myeloid cells and accounts for a majority of myeloproliferative neoplasms (MPN). Mutations in p53 are rarely found in these diseases before acute leukemia transformation, but this does not rule out a role for p53 deregulation in disease progression. Using Ba/F3-EPOR cells and ex vivo cultured CD34(+) cells from MPN patients, we demonstrate that expression of JAK2(V617F) affected the p53 response to DNA damage. We show that E3 ubiquitin ligase MDM2 accumulated in these cells, due to an increased translation of MDM2 mRNA. Accumulation of the La autoantigen, which interacts with MDM2 mRNA and promotes its translation, was responsible for the increase in MDM2 protein level and the subsequent degradation of p53 after DNA damage. Downregulation of La protein or cell treatment with nutlin-3, a MDM2 antagonist, restored the p53 response to DNA damage and the cytokine-dependence of Ba/F3-EPOR-JAK2(V617F) cells. Altogether, these data indicate that the JAK2(V617F) mutation affects p53 response to DNA damage through the upregulation of La antigen and accumulation of MDM2. They also suggest that p53 functional inactivation accounts for the cytokine hypersensitivity of JAK2(V617F) MPN and might have a role in disease progression. Oncogene ( 2012) 31, 1323-1333; doi:10.1038/onc.2011.313; published online 25 July 2011	[Nakatake, M.; Monte-Mor, B.; Debili, N.; Casadevall, N.; Ribrag, V.; Solary, E.; Vainchenker, W.; Plo, I.] INSERM, UMR 1009, Villejuif, France; [Nakatake, M.; Monte-Mor, B.; Debili, N.; Ribrag, V.; Solary, E.; Vainchenker, W.; Plo, I.] Univ Paris 11, Inst Gustave Roussy, UMR1009, Villejuif, France; [Plo, I.] Inst Gustave Roussy, INSERM, U1009, F-94805 Villejuif, France; [Casadevall, N.] Hop St Antoine, AP HP, Hematol Lab, F-75571 Paris, France; [Casadevall, N.] Univ Paris 06, F-75252 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Plo, I (corresponding author), Inst Gustave Roussy, INSERM, U1009, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	isabelle.plo@igr.fr	Da Costa Reis Monte Mor, Barbara DCR/A-9909-2015; Plo, Isabelle/C-9056-2017; Plo, Isabelle/AAT-6742-2021	Plo, Isabelle/0000-0002-5915-6910; Vainchenker, William/0000-0003-4705-202X; Solary, Eric/0000-0002-8629-1341	Ligue Nationale Contre le Cancer; INCa; INSERM; Fondation pour la Recherche Medicale	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); INCa(Institut National du Cancer (INCA) France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We thank all the patients and the controls who participated in the study, and AstraZeneca for the gift of the JAK2 inhibitor (AZD1480). We are grateful to Drs LT Vassilev and R Fahraeus for fruitful discussion. We also thank Dr F Wendling for critical reading of the manuscript. This work was supported by grants from the Ligue Nationale Contre le Cancer (equipe labellisee 2007-2010 et 2010-2012), INCa (projets libres 2007) and INSERM. IP was a recipient from INCA, MN from the Ligue Nationale Contre le Cancer, BMM from the Fondation pour la Recherche Medicale.	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Barosi G, 1999, BRIT J HAEMATOL, V104, P730, DOI 10.1046/j.1365-2141.1999.01262.x; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Berthebaud M, 2005, BLOOD, V106, P2962, DOI 10.1182/blood-2005-02-0526; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Cummings WJ, 2007, PLOS BIOL, V5, P2145, DOI 10.1371/journal.pbio.0050246; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gaidano G, 1997, GENE CHROMOSOME CANC, V19, P250; Gangat N, 2008, EUR J HAEMATOL, V80, P197, DOI 10.1111/j.1600-0609.2007.01003.x; Goetz AW, 2001, CANCER RES, V61, P7635; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Ishiguro K, 2005, MOL CANCER THER, V4, P1755, DOI 10.1158/1535-7163.MCT-05-0169; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jastrzebski K, 2007, GROWTH FACTORS, V25, P209, DOI 10.1080/08977190701779101; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; Kawamata N, 2008, EXP HEMATOL, V36, P1471, DOI 10.1016/j.exphem.2008.06.006; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Le Scolan E, 2001, ONCOGENE, V20, P5484, DOI 10.1038/sj.onc.1204708; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu R, 2000, ONCOGENE, V19, P571, DOI 10.1038/sj.onc.1203364; Maetens M, 2007, BLOOD, V109, P2630, DOI 10.1182/blood-2006-03-013656; Mendrysa SM, 2001, GENE, V264, P139, DOI 10.1016/S0378-1119(00)00589-8; Michiels JJ, 2000, LEUKEMIA LYMPHOMA, V36, P239, DOI 10.3109/10428190009148845; Perrotti D, 2007, CLIN CANCER RES, V13, P1638, DOI 10.1158/1078-0432.CCR-06-2320; Plo I, 2008, BLOOD, V112, P1402, DOI 10.1182/blood-2008-01-134114; Reilly JT, 2005, SEMIN ONCOL, V32, P359, DOI 10.1053/j.seminoncol.2005.04.007; Seliger B, 1996, EUR J HAEMATOL, V57, P230; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shide K, 2008, LEUKEMIA, V22, P87, DOI 10.1038/sj.leu.2405043; Sieff CA, 2010, BRIT J HAEMATOL, V148, P611, DOI 10.1111/j.1365-2141.2009.07993.x; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tefferi A, 2009, LEUKEMIA RES, V33, P662, DOI 10.1016/j.leukres.2008.09.009; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Tsurumi S, 2002, AM J HEMATOL, V71, P131, DOI 10.1002/ajh.10188; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Zhao R, 2008, NEW ENGL J MED, V359, P2778, DOI 10.1056/NEJMoa0804953; Zhou M, 2000, LEUKEMIA, V14, P61, DOI 10.1038/sj.leu.2401619	49	80	82	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1323	1333		10.1038/onc.2011.313	http://dx.doi.org/10.1038/onc.2011.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785463				2022-12-17	WOS:000301344600011
J	McInnes, N; Sadlon, TJ; Brown, CY; Pederson, S; Beyer, M; Schultze, JL; McColl, S; Goodall, GJ; Barry, SC				McInnes, N.; Sadlon, T. J.; Brown, C. Y.; Pederson, S.; Beyer, M.; Schultze, J. L.; McColl, S.; Goodall, G. J.; Barry, S. C.			FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells	ONCOGENE			English	Article						SATB1; FOXP3; microRNA; gene regulation networks; breast cancer; tumour suppressor	MESSENGER-RNA EXPRESSION; REGULATORY T-CELLS; TARGET GENES; GASTRIC-CANCER; CUTTING EDGE; RECEPTOR; GROWTH; RESISTANCE; REPRESSOR; MIRNAS	The transcription factor FOXP3 has been identified as a tumour suppressor in the breast and prostate epithelia, but little is known about its specific mechanism of action. We have identified a feed-forward regulatory loop in which FOXP3 suppresses the expression of the oncogene SATB1. In particular, we demonstrate that SATB1 is not only a direct target of FOXP3 repression, but that FOXP3 also induces two miRs, miR-7 and miR-155, which specifically target the 30-UTR of SATB1 to further regulate its expression. We conclude that FOXP3-regulated miRs form part of the mechanism by which FOXP3 prevents the transformation of the healthy breast epithelium to a cancerous phenotype. Approaches aimed at restoring FOXP3 function and the miRs it regulates could help provide new approaches to target breast cancer. Oncogene (2012) 31, 1045-1054; doi:10.1038/onc.2011.293; published online 11 July 2011	[McInnes, N.; Sadlon, T. J.; Brown, C. Y.; Pederson, S.; Barry, S. C.] Womens & Childrens Hosp, Womens & Childrens Hlth Res Inst, Mol Immunol Lab, Adelaide, SA 5006, Australia; [McInnes, N.; Pederson, S.; Barry, S. C.] Univ Adelaide, Dept Paediat, Adelaide, SA, Australia; [Beyer, M.; Schultze, J. L.] Univ Bonn, Lab Genom & Immunoregulat, LIMES Inst, Bonn, Germany; [McColl, S.] Univ Adelaide, Dept Immunol, Adelaide, SA, Australia; [Goodall, G. J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Goodall, G. J.] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia; [Barry, S. C.] Womens & Childrens Hosp, Dept Gastroenterol, Adelaide, SA 5006, Australia	University of Adelaide; University of Bonn; University of Adelaide; Centre for Cancer Biology; SA Pathology; University of Adelaide; Womens & Childrens Hospital Australia	Barry, SC (corresponding author), Womens & Childrens Hosp, Womens & Childrens Hlth Res Inst, Mol Immunol Lab, 72 King William Rd, Adelaide, SA 5006, Australia.	simon.barry@adelaide.edu.au	barry, simon/Y-4529-2019; Beyer, Marc/ABE-1408-2021; Schultze, Joachim L./ABA-8176-2020; Schultze, Joachim L/D-7794-2011	barry, simon/0000-0002-0597-7609; Beyer, Marc/0000-0001-9704-148X; Schultze, Joachim L./0000-0003-2812-9853; Schultze, Joachim L/0000-0003-2812-9853; Goodall, Gregory/0000-0003-1294-0692; Pederson, Stephen/0000-0001-8197-3303	NHMRC [565314]; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	We acknowledge the contributions to this research made by the following co-workers: Danika Hill, Silvia Nobbs, Elizabeth Melville, Suzanne Bresatz, Nicola Eastaff-Leung, Bridget Wilkinson and Marlena Sekutowski. This work was funded by NHMRC Grant 565314 (SCB).	Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Brosh R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.65; Brown CY, 2010, HUM GENE THER, V21, P1005, DOI 10.1089/hum.2009.107; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163; Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x; Cheng C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r90; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hanker LC, 2010, BREAST, DOI org/10.1016/j.breast.2010.10.002; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Jung DJ, 2010, J BIOL CHEM, V285, P7995, DOI 10.1074/jbc.M109.047985; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162; Kohwi-Shigematsu T, 2010, J NATL CANCER I, V102, P1879, DOI 10.1093/jnci/djq440; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Ladoire S, 2011, BREAST CANCER RES TR, V125, P65, DOI 10.1007/s10549-010-0831-1; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li QQ, 2010, CANCER SCI, V101, P80, DOI 10.1111/j.1349-7006.2009.01372.x; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Liu Y, 2010, TRENDS GENET, V26, P260, DOI 10.1016/j.tig.2010.03.004; Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010; Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Patani N, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-18; Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191; Re A, 2009, MOL BIOSYST, V5, P854, DOI 10.1039/b900177h; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Richon VM, 2008, NAT BIOTECHNOL, V26, P655, DOI 10.1038/nbt0608-655; Sadlon TJ, 2010, J IMMUNOL, V185, P1071, DOI 10.4049/jimmunol.1000082; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Selcuklu SD, 2009, CANCER GENET CYTOGEN, V189, P15, DOI 10.1016/j.cancergencyto.2008.09.009; Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	57	80	88	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					1045	1054		10.1038/onc.2011.293	http://dx.doi.org/10.1038/onc.2011.293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21743493	Green Published			2022-12-17	WOS:000300709700010
J	Kondratyev, M; Kreso, A; Hallett, RM; Girgis-Gabardo, A; Barcelon, ME; Ilieva, D; Ware, C; Majumder, PK; Hassell, JA				Kondratyev, M.; Kreso, A.; Hallett, R. M.; Girgis-Gabardo, A.; Barcelon, M. E.; Ilieva, D.; Ware, C.; Majumder, P. K.; Hassell, J. A.			Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer	ONCOGENE			English	Article						breast cancer; tumor-initiating cells; cancer stem cells; gamma-secretase inhibitors; Notch signaling; transgenic mouse models	MAMMARY STEM/PROGENITOR CELLS; LYMPHOBLASTIC-LEUKEMIA CELLS; NOTCH SIGNALING PATHWAY; SUSPENSION BIOREACTORS; NEU PROTOONCOGENE; STEM-CELLS; IN-VITRO; FATE; ACTIVATION; EXPRESSION	Human breast tumors comprise a minor sub-population of tumor-initiating cells (TICs), commonly termed cancer stem cells. TICs are thought to sustain tumor growth and to confer resistance to current anticancer therapies. Hence, targeting TIC may be essential to achieving durable cancer cures. To identify molecular targets in breast TIC, we employed a transgenic mouse model of ERBB2 breast cancer; tumors arising in this model comprise a very high frequency of TIC, which is maintained in tumor cell populations propagated in vitro as non-adherent tumor-spheres. The Notch pathway is dysregulated in human breast tumors and overexpression of constitutively active Notch proteins induces mammary tumors in mice. The Notch pathway has also been implicated in stem cell processes including those of mammary epithelial stem cells. Hence, we investigated the potential that the Notch pathway is required for TIC activity. We found that an antagonist of Notch signaling, a gamma (gamma)-secretase inhibitor termed MRK-003, inhibited the survival of tumorsphere-derived cells in vitro and eliminated TIC as assessed by cell transplantation into syngeneic mice. Whereas MRK-003 also inhibited the self-renewal and/or proliferation of mammosphere-resident cells, this effect of the inhibitor was reversible thus suggesting that it did not compromise the survival of these cells. MRK-003 administration to tumor-bearing mice eliminated tumor-resident TIC and resulted in rapid and durable tumor regression. MRK-003 inhibited the proliferation of tumor cells, and induced their apoptosis and differentiation. These findings suggest that MRK-003 targets breast TIC and illustrate that eradicating these cells in breast tumors ensures long-term, recurrence-free survival. Oncogene (2012) 31, 93-103; doi: 10.1038/onc.2011.212; published online 13 June 2011	[Kondratyev, M.; Kreso, A.; Hallett, R. M.; Girgis-Gabardo, A.; Barcelon, M. E.; Ilieva, D.; Hassell, J. A.] McMaster Univ, Dept Biochem & Biomed Sci, Ctr Funct Genom, Hamilton, ON L8N 3Z5, Canada; [Ware, C.] Merck Res Labs, Dept Biomol Markers, Boston, MA USA; [Majumder, P. K.] Merck Res Labs, Dept Oncol, Boston, MA USA; [Majumder, P. K.] Merck Res Labs, Dept Pharmacol, Boston, MA USA	McMaster University; Merck & Company; Merck & Company; Merck & Company	Hassell, JA (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Ctr Funct Genom, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	hassell@mcmaster.ca			Stem Cell Network; Canadian Breast Cancer Foundation (CBCF); Terry Fox Research Institute/Ontario Institute for Cancer Research	Stem Cell Network; Canadian Breast Cancer Foundation (CBCF); Terry Fox Research Institute/Ontario Institute for Cancer Research	The Stem Cell Network, Canadian Breast Cancer Foundation (CBCF) and the Terry Fox Research Institute/Ontario Institute for Cancer Research provided operating grants to JAH to support the research described herein. MK is the recipient of a CBCF fellowship.	Borowsky AD, 2004, COMPARATIVE MED, V54, P258; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Buono KD, 2006, DEV BIOL, V293, P565, DOI 10.1016/j.ydbio.2006.02.043; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Cardiff RD, 2003, COMPARATIVE MED, V53, P250; Cardiff RD, 2001, VET PATHOL, V38, P357, DOI 10.1354/vp.38-4-357; Chang JC, 2005, J CLIN ONCOL, V23, P1169, DOI 10.1200/JCO.2005.03.156; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cullion K, 2009, BLOOD, V113, P6172, DOI 10.1182/blood-2008-02-136762; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Efferson CL, 2010, CANCER RES, V70, P2476, DOI 10.1158/0008-5472.CAN-09-3114; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kurpios NA, 2009, DEV BIOL, V325, P106, DOI 10.1016/j.ydbio.2008.09.033; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Rao SS, 2009, CANCER RES, V69, P3060, DOI 10.1158/0008-5472.CAN-08-4295; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Sawey ET, 2008, CELL CYCLE, V7, P566, DOI 10.4161/cc.7.5.5531; Sawey ET, 2007, P NATL ACAD SCI USA, V104, P19327, DOI 10.1073/pnas.0705953104; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Smalley MJ, 1998, IN VITRO CELL DEV-AN, V34, P711; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Tammam J, 2009, BRIT J PHARMACOL, V158, P1183, DOI 10.1111/j.1476-5381.2009.00389.x; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Youn BS, 2006, BIOTECHNOL PROGR, V22, P801, DOI 10.1021/bp050430z; Youn BS, 2005, BIOTECHNOL PROGR, V21, P984, DOI 10.1021/bp050059f; Zhang P, 2010, ONCOGENE, V29, P2916, DOI 10.1038/onc.2010.62	44	80	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					93	103		10.1038/onc.2011.212	http://dx.doi.org/10.1038/onc.2011.212			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666715				2022-12-17	WOS:000299176200009
J	Gill, RK; Yang, SH; Meerzaman, D; Mechanic, LE; Bowman, ED; Jeon, HS; Chowdhuri, SR; Shakoori, A; Dracheva, T; Hong, KM; Fukuoka, J; Zhang, JH; Harris, CC; Jen, J				Gill, R. K.; Yang, S-H; Meerzaman, D.; Mechanic, L. E.; Bowman, E. D.; Jeon, H-S; Chowdhuri, S. Roy; Shakoori, A.; Dracheva, T.; Hong, K-M; Fukuoka, J.; Zhang, J-H; Harris, C. C.; Jen, J.			Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer	ONCOGENE			English	Article						LKB1 gene; LOH; homozygous deletion; mutation; CISH; primary lung cancer	PEUTZ-JEGHERS-SYNDROME; TUMOR-SUPPRESSOR GENE; SOMATIC MUTATIONS; GLUCOSE-HOMEOSTASIS; LKB1; KINASE; PATHWAYS; KNOCKOUT; PTEN; ADENOCARCINOMA	LKB1/STK11 is a tumor suppressor and a negative regulator of mammalian target of rapamycin signaling. It is inactivated in 30% of lung cancer cell lines but only 5-15% of primary lung adenocarcinomas. There is evidence that homozygous deletion (HD) of chromosome 19p at the LKB locus contributes to the inactivation of the gene in primary human lung cancers. Here, we used several complementary genetic approaches to assess the LKB1 locus in primary non-small cell lung cancers (NSCLCs). We first analyzed 124 NSCLC cases for allelic imbalance using eight microsatellite markers on chromosome 19p, which revealed an overall rate of 65% (80 of 124) loss of heterozygosity (LOH). We next used chromogenic in situ hybridization (CISH) to directly examine the chromosomal status of the LKB1 locus. In all, 65 of 124 LOH tested samples were available for CISH and 58 of those (89%) showed either loss of one copy of chromosome 19p (LOH, 40 of 65 cases, 62%) or both copies (HD 18 of 65 cases, 28%). The occurrence of HD was significantly more frequent in Caucasian (35%) than in African-American patients (6%) (P = 0.04). A total of 62 of 124 samples with LOH at one or both markers immediately flanking the LKB1 gene were further analyzed by directly sequencing the complete coding region, which identified 7 of 62 (11%) tumors with somatic mutations in the gene. Jointly, our data identified total inactivation of the LKB1 gene by either HD or LOH with somatic mutation in 39% of tested samples, whereas loss of chromosome 19p region by HD or LOH at the LKB1 region occured in 90% of NSCLC. Oncogene (2011) 30, 3784-3791; doi:10.1038/onc.2011.98; published online 2 May 2011	[Jen, J.] Mayo Clin Fdn, Div Pulm & Crit Care Med & Microarray Shared Reso, Rochester, MN USA; [Gill, R. K.; Yang, S-H; Mechanic, L. E.; Bowman, E. D.; Jeon, H-S; Shakoori, A.; Dracheva, T.; Fukuoka, J.; Harris, C. C.] NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA; [Meerzaman, D.; Chowdhuri, S. Roy; Hong, K-M; Zhang, J-H] NCI, Lab Populat Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Hong, K-M] Natl Canc Ctr, Res Inst, Goyang, South Korea	Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Korea (NCC)	Jen, J (corresponding author), Mayo Clin, Div Pulm & Crit Care Med & Microarray Shared Reso, Adv Genom Technol Ctr, Stabile 13-74,200 1st St SW, Rochester, MN 55905 USA.	Jen.Jin@mayo.edu	SHAKOORI, ABDUL RAUF/Q-9373-2019; Fukuoka, Junya/AAT-2924-2021	shakoori, abbas/0000-0002-4363-1967; Fukuoka, Junya/0000-0002-2496-3050; Roy-Chowdhuri, Sinchita/0000-0002-9447-7701	Center for Cancer Research at CCR; Mayo Cancer Center; Center for Individualized Medicine, Rochester, MN; NATIONAL CANCER INSTITUTE [Z01CP010164, P30CA015083, ZIABC010874] Funding Source: NIH RePORTER	Center for Cancer Research at CCR; Mayo Cancer Center; Center for Individualized Medicine, Rochester, MN; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank John Cottrell, Ray Jones, Audrey Salabes and Mike Lipsky at University of Maryland Medical Center for tissue collection and clinical information. We thank the members of Dr. Thomas Reid's lab for technical support during the course of this study. We thank Ms Stacy Johnson for editorial and graphical/technical assistance. The current addresses are RKG, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, Bethesda, MD 20892-4258; SHY, Wonkwang University Hospital, Department of Pulmonary and Critical Care Medicine, Iksan, South Korea; HSJ, Laboratory of Biochemistry and Cell Biology, Kyungpook National University, School of Medicine, Deagu, South Korea; SRC, Laboratory of Pathology, National Cancer Institute, Bethesda, MD; AS, Department of Medical Genetics, Tehran University of Medical Sciences, Cancer Institute Hospital, Tehran, Iran; TVD, J. Craig Venter Institute, Rockville, MD; KMH, National Cancer Center, Cancer Cell and Molecular Biology Branch, Goyang, Korea; JF, Toyama University Hospital, Department of Surgical Pathology, Toyama, Japan; and JHZ, St. Jude Children's Research Hospital, Biotechnology, Memphis, TN. This work was supported by intramural research funds from the Center for Cancer Research at CCR and funds for JJ from the Mayo Cancer Center and Center for Individualized Medicine, Rochester, MN.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bignell GR, 1998, CANCER RES, V58, P1384; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Conde E, 2007, HUM PATHOL, V38, P1351, DOI 10.1016/j.humpath.2007.01.022; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Gill RK, 2008, CLIN CANCER RES, V14, P7481, DOI 10.1158/1078-0432.CCR-07-5242; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Gurumurthy S, 2008, CANCER RES, V68, P55, DOI 10.1158/0008-5472.CAN-07-3225; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Koh HJ, 2006, MOL CELL BIOL, V26, P8217, DOI 10.1128/MCB.00979-06; Koivunen JP, 2008, BRIT J CANCER, V99, P245, DOI 10.1038/sj.bjc.6604469; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lim W, 2003, BRIT J CANCER, V89, P308, DOI 10.1038/sj.bjc.6601030; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; Luukko K, 1999, MECH DEVELOP, V83, P187, DOI 10.1016/S0925-4773(99)00050-7; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Mechanic LE, 2005, CARCINOGENESIS, V26, P597, DOI 10.1093/carcin/bgh344; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zhang SM, 2008, CANCER RES, V68, P740, DOI 10.1158/0008-5472.CAN-07-2989; Zhong DS, 2006, LUNG CANCER, V53, P285, DOI 10.1016/j.lungcan.2006.05.018	44	80	85	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3784	3791		10.1038/onc.2011.98	http://dx.doi.org/10.1038/onc.2011.98			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21532627	Green Accepted			2022-12-17	WOS:000294481400005
J	Oh, JH; Cho, MC; Kim, JH; Lee, SY; Kim, HJ; Park, ES; Ban, JO; Kang, JW; Lee, DH; Shim, JH; Han, SB; Moon, DC; Park, YH; Yu, DY; Kim, JM; Kim, SH; Yoon, DY; Hong, JT				Oh, J. H.; Cho, M-C; Kim, J-H; Lee, S. Y.; Kim, H. J.; Park, E. S.; Ban, J. O.; Kang, J-W; Lee, D-H; Shim, J-H; Han, S. B.; Moon, D. C.; Park, Y. H.; Yu, D-Y; Kim, J-M; Kim, S. H.; Yoon, D-Y; Hong, J. T.			IL-32 gamma inhibits cancer cell growth through inactivation of NF-kappa B and STAT3 signals	ONCOGENE			English	Article						IL-32; cytokine; colon cancer; NF-kappa B; STAT3	PROINFLAMMATORY CYTOKINE; TUMOR-METASTASIS; PROSTATE-CANCER; TRANSGENIC MICE; T-CELLS; INTERLEUKIN-10; IL-32; INFLAMMATION; EXPRESSION; IDENTIFICATION	Several studies have shown physiological functions of interleukin (IL)-32, a novel cytokine. However, the role of IL-32 in cancer development has not been reported. In this study, we showed that IL-32 gamma inhibited tumor growth in IL-32 gamma-overexpressing transgenic mice inoculated with melanoma as well as colon tumor growth in xenograft nude mice inoculated with IL-32 gamma-transfected colon cancer cells (SW620). The inhibitory effect of IL-32 gamma on tumor growth was associated with the inhibition of constitutive activated nuclear transcription factor-kappa B (NF-kappa B) and of signal transducer and activator of transcription 3 (STAT3). The expression of antiapoptotic, cell proliferation and tumor-promoting genes (bcl-2, X-chromosome inhibitor of apoptosis protein (IAP), cellular IAP and cellular FADD-like IL-1 beta-converting enzyme-inhibitory protein, cyclin D), cyclin-dependent kinase 4, cycolooxygenase-2 and inducible nitric oxide synthase was decreased, whereas the expression of apoptotic target genes (caspase-3 and -9, bax) increased. In tumor, spleen and blood, the number of cytotoxic CD8(+) T cells and CD57(+) natural killer cells and the levels of IL-10 increased, but that of tumor necrosis factor-alpha (TNF-alpha), IL-1 beta and IL-6 decreased. We also found that forced overexpression of IL-32 gamma inhibited colon cancer cell (SW620 and HCT116) growth accompanied with the inhibition of activated NF-kappa B and STAT3 in vitro. In addition, when IL-32 gamma was knocked down by small interfering RNA (siRNA) or neutralized with an anti-IL-32 gamma antibody, IL-32 gamma-induced colon cancer cell growth inhibition, the IL-32 gamma-induced decrease of TNF-alpha, IL-1 and IL-6 production, and the increase of IL-10 production were abolished. However, siRNA of NF kappa B and STAT3 augmented IL-32 gamma-induced colon cancer cell growth inhibition. These findings indicate significant pathophysiological roles of IL-32 gamma in cancer development. Oncogene (2011) 30, 3345-3359; doi:10.1038/onc.2011.52; published online 21 March 2011	[Oh, J. H.; Cho, M-C; Lee, S. Y.; Park, E. S.; Ban, J. O.; Han, S. B.; Moon, D. C.; Hong, J. T.] Chungbuk Natl Univ, Coll Pharm, Cheongju 361463, Chungbuk, South Korea; [Oh, J. H.; Cho, M-C; Lee, S. Y.; Park, E. S.; Han, S. B.; Moon, D. C.; Hong, J. T.] Chungbuk Natl Univ, Med Res Ctr, Cheongju 361463, Chungbuk, South Korea; [Kim, J-H; Kim, H. J.; Kang, J-W; Lee, D-H; Shim, J-H; Yoon, D-Y] Konkuk Univ, Dept Biosci & Biotechnol, Bio Mol Informat Ctr, Seoul 143701, South Korea; [Park, Y. H.; Yu, D-Y] Korea Res Inst Biosci & Biotechnol, Anim Dis Res Ctr, Taejon, South Korea; [Kim, J-M] Chungnam Natl Univ, Pathol Lab, Taejon, South Korea; [Kim, S. H.] Konkuk Univ, Lab Cytokine Immunol, Med Immunol Ctr, Inst Biomed Sci & Technol, Seoul 143701, South Korea	Chungbuk National University; Chungbuk National University; Konkuk University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Konkuk University; Konkuk University Medical Center	Hong, JT (corresponding author), Chungbuk Natl Univ, Coll Pharm, 12 Gaeshin Dong, Cheongju 361463, Chungbuk, South Korea.	ydy4218@konkuk.ac.kr; jinthong@chungbuk.ac.kr		kim, sunghoon/0000-0002-1570-3230; KIM, JIN MAN/0000-0003-0905-9730; Shim, Jung-Hyun/0000-0002-4062-4016	Korea Research Foundation (MRC) [R13-2008-001-00000-00]; Ministry for Health, Welfare and Family affairs, Republic of Korea [0920080]; National Research Foundation of Korea [2009-0093824, 2010-0019306]; KRIBB Research Initiative	Korea Research Foundation (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)National Research Foundation of Korea); Ministry for Health, Welfare and Family affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea(National Research Foundation of Korea); KRIBB Research Initiative	This work was supported by the Korea Research Foundation Grant (MRC, R13-2008-001-00000-00) and the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0920080). D Yoon was partially from National Research Foundation of Korea (2009-0093824, 2010-0019306) and D Yu from KRIBB Research Initiative Program Grant. We thank Dr Howard P Glauert (University of Kentucky) who provided invaluable assistance with English legal manuscripts.	Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Ban JO, 2009, MOL CANCER THER, V8, P1613, DOI 10.1158/1535-7163.MCT-08-0694; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cacev T, 2008, CARCINOGENESIS, V29, P1572, DOI 10.1093/carcin/bgn164; Calabrese F, 2008, AM J RESP CRIT CARE, V178, P894, DOI 10.1164/rccm.200804-646OC; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Choi JD, 2009, IMMUNOLOGY, V126, P535, DOI 10.1111/j.1365-2567.2008.02917.x; Choi J, 2010, P NATL ACAD SCI USA, V107, P21082, DOI 10.1073/pnas.1015418107; CHOI KC, 2002, CANCER RES, V69, P583; DAHL CA, 1992, J IMMUNOL, V148, P597; Dinarello CA, 2006, ANN RHEUM DIS, V65, P61, DOI 10.1136/ard.2006.058511; Fujimoto J, 2002, ANN ONCOL, V13, P1598, DOI 10.1093/annonc/mdf248; Goda C, 2006, INT IMMUNOL, V18, P233, DOI 10.1093/intimm/dxh339; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; GROSCURTH P, 1990, INT J CANCER, V45, P694, DOI 10.1002/ijc.2910450422; Hardwick JCH, 2001, ONCOGENE, V20, P819, DOI 10.1038/sj.onc.1204162; Hisada M, 2004, CANCER RES, V64, P1152, DOI 10.1158/0008-5472.CAN-03-2084; Hou T, 2008, J BIOL CHEM, V283, P30725, DOI 10.1074/jbc.M805941200; Huang SY, 1996, CLIN CANCER RES, V2, P1969; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; Jenkins BJ, 2005, BLOOD, V105, P3512, DOI 10.1182/blood-2004-09-3751; Kang JW, 2009, IMMUNOLOGY, V128, pe532, DOI 10.1111/j.1365-2567.2008.03025.x; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim KS, 2008, POLYM-KOREA, V32, P38; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Kundu N, 1997, CELL IMMUNOL, V180, P55, DOI 10.1006/cimm.1997.1176; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee J, 1998, CANCER RES, V58, P1478; Lee S, 2010, HYBRIDOMA, V29, P501, DOI 10.1089/hyb.2010.0059; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Lu C, 2004, J CLIN ONCOL, V22, P4575, DOI 10.1200/JCO.2004.01.091; Ma XY, 2010, J IMMUNOL, V184, P4898, DOI 10.4049/jimmunol.1000142; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marcondes AM, 2008, P NATL ACAD SCI USA, V105, P2865, DOI 10.1073/pnas.0712391105; Moretta L, 2000, IMMUNOL TODAY, V21, P420, DOI 10.1016/S0167-5699(00)01673-X; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Nishida A, 2009, J BIOL CHEM, V284, P17868, DOI 10.1074/jbc.M900368200; Nold-Petry CA, 2009, P NATL ACAD SCI USA, V106, P3883, DOI 10.1073/pnas.0813334106; Ray S, 2008, NUCLEIC ACIDS RES, V36, P4510, DOI 10.1093/nar/gkn419; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Seo EH, 2008, J MICROBIOL BIOTECHN, V18, P1606; Shurin MR, 2006, CANCER METAST REV, V25, P333, DOI 10.1007/s10555-006-9010-6; Son DJ, 2007, MOL CANCER THER, V6, P675, DOI 10.1158/1535-7163.MCT-06-0328; Sorrentino C, 2009, AM J RESP CRIT CARE, V180, P769, DOI 10.1164/rccm.200903-0400OC; Wang AG, 2005, J HEPATOL, V43, P836, DOI 10.1016/j.jhep.2005.04.012; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Westbrook AM, 2009, CANCER RES, V69, P4827, DOI 10.1158/0008-5472.CAN-08-4416; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang F, 2009, CELL SIGNAL, V21, P1085, DOI 10.1016/j.cellsig.2009.02.018; Zheng LM, 1996, J EXP MED, V184, P579, DOI 10.1084/jem.184.2.579	54	80	84	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	30					3345	3359		10.1038/onc.2011.52	http://dx.doi.org/10.1038/onc.2011.52			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21423208	Green Published, hybrid			2022-12-17	WOS:000293215700005
J	Chan, SW; Lim, CJ; Huang, C; Chong, YF; Gunaratne, HJ; Hogue, KA; Blackstock, WP; Harvey, KF; Hong, W				Chan, S. W.; Lim, C. J.; Huang, C.; Chong, Y. F.; Gunaratne, H. J.; Hogue, K. A.; Blackstock, W. P.; Harvey, K. F.; Hong, W.			WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ	ONCOGENE			English	Article						TAZ; Wbp2; Hippo pathway; cancer; transcription factors	YES-ASSOCIATED PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR PATHWAY; CELL CONTACT INHIBITION; ORGAN SIZE CONTROL; HIPPO PATHWAY; BREAST-CANCER; TRANSCRIPTIONAL OUTPUT; BANTAM MICRORNA; GROWTH-CONTROL	The transcriptional co-activators YAP and TAZ are downstream targets inhibited by the Hippo tumor suppressor pathway. YAP and TAZ both possess WW domains, which are important protein-protein interaction modules that mediate interaction with proline-rich motifs, most commonly PPXY. The WW domains of YAP have complex regulatory roles as exemplified by recent reports showing that they can positively or negatively influence YAP activity in a cell and context-specific manner. In this study, we show that the WW domain of TAZ is important for it to transform both MCF10A and NIH3T3 cells and to activate transcription of ITGB2 but not CTGF, as introducing point mutations into the WW domain of TAZ (WWm) abolished its transforming and transcription-promoting ability. Using a proteomic approach, we discovered potential regulatory proteins that interact with TAZ WW domain and identified Wbp2. The interaction of Wbp2 with TAZ is dependent on the WW domain of TAZ and the PPXY-containing C-terminal region of Wbp2. Knockdown of endogenous Wbp2 suppresses, whereas overexpression of Wbp2 enhances, TAZ-driven transformation. Forced interaction of WWm with Wbp2 by direct C-terminal fusion of full-length Wbp2 or its TAZ-interacting C-terminal domain restored the transforming and transcription-promoting ability of TAZ. These results suggest that the WW domain-mediated interaction with Wbp2 promotes the transforming ability of TAZ. Oncogene (2011) 30, 600-610; doi: 10.1038/onc.2010.438; published online 25 October 2010	[Chan, S. W.; Lim, C. J.; Huang, C.; Chong, Y. F.; Hong, W.] Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, Singapore 138673, Singapore; [Gunaratne, H. J.; Hogue, K. A.; Blackstock, W. P.] Inst Mol & Cell Biol, Mass Spectrometry & Syst Biol Lab, Singapore 138673, Singapore; [Harvey, K. F.] Peter MacCallum Canc Ctr, Cell Growth & Proliferat Lab, Melbourne, Vic, Australia; [Harvey, K. F.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Hong, W.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Peter Maccallum Cancer Center; University of Melbourne; National University of Singapore	Hong, W (corresponding author), Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbhwj@imcb.a-star.edu.sg	Harvey, Kieran/AAD-5268-2022; HONG, Wanjin/E-9927-2010	Harvey, Kieran/0000-0001-7845-369X	Agency for Science, Technology, and Research (A*STAR), Singapore	Agency for Science, Technology, and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR))	This work is funded by Agency for Science, Technology, and Research (A*STAR), Singapore.	Bandura JL, 2008, DEV CELL, V14, P315, DOI 10.1016/j.devcel.2008.02.010; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen YH, 2007, MOL CELL PROTEOMICS, V6, P2072, DOI 10.1074/mcp.M700395-MCP200; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Lam-Himlin DM, 2006, J GASTROINTEST CANC, V37, P103, DOI 10.1007/s12029-007-0010-8; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney WM, 2005, BIOCHEM J, V388, P217, DOI 10.1042/BJ20041434; Nolo R, 2006, CURR BIOL, V16, P1895, DOI 10.1016/j.cub.2006.08.057; Oh H, 2009, ONCOGENE, V28, P1916, DOI 10.1038/onc.2009.43; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Peng HW, 2009, GENE DEV, V23, P2307, DOI 10.1101/gad.1820009; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wang KN, 2009, BIOCHEM CELL BIOL, V87, P77, DOI 10.1139/O08-114; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997	41	80	82	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2011	30	5					600	610		10.1038/onc.2010.438	http://dx.doi.org/10.1038/onc.2010.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20972459	Green Published, hybrid			2022-12-17	WOS:000286922300008
J	Jenkins, NC; Liu, T; Cassidy, P; Leachman, SA; Boucher, KM; Goodson, AG; Samadashwily, G; Grossman, D				Jenkins, N. C.; Liu, T.; Cassidy, P.; Leachman, S. A.; Boucher, K. M.; Goodson, A. G.; Samadashwily, G.; Grossman, D.			The p16(INK4A) tumor suppressor regulates cellular oxidative stress	ONCOGENE			English	Article						p16; oxidative stress; melanocyte; 8-oxoguanine	REACTIVE OXYGEN; HUMAN MELANOCYTES; P38 MAPK; MELANOMA; SENESCENCE; INHIBITION; GENE; REPAIR; PHOSPHORYLATION; FIBROBLASTS	Mutations or deletions in the cyclin-dependent kinase inhibitor p16(INK4A) are associated with multiple cancer types, but are more commonly found in melanoma tumors and associated with familial melanoma predisposition. Although p16 is thought to function as a tumor suppressor by negatively regulating the cell cycle, it remains unclear why the genetic compromise of p16 predisposes to melanoma over other cancers. Here we describe a novel role for p16 in regulating oxidative stress in several cell types, including melanocytes. Expression of p16 was rapidly upregulated following ultraviolet-irradiation and in response to H2O2-induced oxidative stress in a p38 stress-activated protein kinase-dependent manner. Knockdown of p16 using small interfering RNA increased intracellular reactive oxygen species (ROS) and oxidative (8-oxoguanine) DNA damage, which was further enhanced by H2O2 treatment. Elevated ROS levels were also observed in p16-depleted human keratinocytes and in whole skin and dermal fibroblasts from Cdkn2a-deficient mice. Aberrant ROS and p38 signaling in Cdkn2a-deficient fibroblasts was normalized by expression of exogenous p16. The effect of p16 depletion on ROS was not recapitulated by the knockdown of retinoblastoma protein (Rb) and did not require Rb. Finally, p16-mediated suppression of ROS could not be attributed to the potential effects of p16 on cell cycle phase. These findings suggest a potential alternate Rb-independent tumor-suppressor function of p16 as an endogenous regulator of carcinogenic intracellular oxidative stress. Compared with keratinocytes and fibroblasts, we also found increased susceptibility of melanocytes to oxidative stress in the context of p16 depletion, which may explain why the compromise of p16 predisposes to melanoma over other cancers. Oncogene (2011) 30, 265-274; doi:10.1038/onc.2010.419; published online 13 September 2010	[Jenkins, N. C.; Liu, T.; Cassidy, P.; Leachman, S. A.; Boucher, K. M.; Samadashwily, G.; Grossman, D.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Jenkins, N. C.; Boucher, K. M.; Grossman, D.] Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Cassidy, P.; Leachman, S. A.; Goodson, A. G.; Samadashwily, G.; Grossman, D.] Univ Utah, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT 84112 USA; [Cassidy, P.] Univ Utah, Hlth Sci Ctr, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, 2000 Circle Hope,Suite 5262, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu		Boucher, Kenneth/0000-0003-2833-0127	NIH [AR050102, CA125761]; Department of Dermatology; Huntsman Cancer Foundation;  [P30 CA042014]; NATIONAL CANCER INSTITUTE [R03CA125761, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Dermatology; Huntsman Cancer Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported in part by NIH grants AR050102 and CA125761, the Department of Dermatology, and the Huntsman Cancer Foundation. We acknowledge use of the DNA/peptide and Flow Cytometry core facilities and a pilot project grant supported by P30 CA042014 awarded to Huntsman Cancer Institute. We thank Bryan Welm for providing the pEI2 plasmid and technical support for our lentiviral production and the MMHCC at the National Cancer Institute for providing B6.129-Cdkn2a<SUP>tm1Rdp</SUP> mice.	Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Becker TM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-4; Becker TM, 2001, CLIN CANCER RES, V7, P3282; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Chung JS, 2009, FREE RADICAL RES, V43, P729, DOI 10.1080/10715760903038432; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Cotter MA, 2007, CLIN CANCER RES, V13, P5952, DOI 10.1158/1078-0432.CCR-07-1187; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Eiberger W, 2008, DNA REPAIR, V7, P912, DOI 10.1016/j.dnarep.2008.03.002; Flores JF, 1996, CANCER RES, V56, P5023; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Goldstein AM, 2006, CANCER RES, V66, P9818, DOI 10.1158/0008-5472.CAN-06-0494; Grammatico P, 1998, EXP DERMATOL, V7, P205, DOI 10.1111/j.1600-0625.1998.tb00325.x; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Haferkamp S, 2008, AGING CELL, V7, P733, DOI 10.1111/j.1474-9726.2008.00422.x; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Herrling T, 2006, SPECTROCHIM ACTA A, V63, P840, DOI 10.1016/j.saa.2005.10.013; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Meyskens FL, 2001, PIGM CELL RES, V14, P148, DOI 10.1034/j.1600-0749.2001.140303.x; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Naidu S, 2009, J IMMUNOL, V182, P7048, DOI 10.4049/jimmunol.0900006; Pashaei S, 2008, J CUTAN PATHOL, V35, P525, DOI 10.1111/j.1600-0560.2007.00865.x; Pavel S, 2004, EUR J CANCER, V40, P1423, DOI 10.1016/j.ejca.2003.11.035; Piepkorn M, 2000, J AM ACAD DERMATOL, V42, P741, DOI 10.1067/mjd.2000.103988; Raj D, 2008, CARCINOGENESIS, V29, P194, DOI 10.1093/carcin/bgm219; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; URABE K, 1994, BBA-MOL CELL RES, V1221, P272, DOI 10.1016/0167-4889(94)90250-X; Wang HT, 2010, P NATL ACAD SCI USA, V107, P12180, DOI 10.1073/pnas.1005244107; Welm Bryan E, 2008, Cell Stem Cell, V2, P90, DOI 10.1016/j.stem.2007.10.002; Wood SR, 2006, P NATL ACAD SCI USA, V103, P4111, DOI 10.1073/pnas.0511248103; Zyrek-Betts J, 2008, J CUTAN PATHOL, V35, P651, DOI 10.1111/j.1600-0560.2007.00878.x	43	80	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					265	274		10.1038/onc.2010.419	http://dx.doi.org/10.1038/onc.2010.419			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20838381	Green Accepted			2022-12-17	WOS:000286418800002
J	Wheeler, SE; Suzuki, S; Thomas, SM; Sen, M; Leeman-Neill, RJ; Chiosea, SI; Kuan, CT; Bigner, DD; Gooding, WE; Lai, SY; Grandis, JR				Wheeler, S. E.; Suzuki, S.; Thomas, S. M.; Sen, M.; Leeman-Neill, R. J.; Chiosea, S. I.; Kuan, C-T; Bigner, D. D.; Gooding, W. E.; Lai, S. Y.; Grandis, J. R.			Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation	ONCOGENE			English	Article						head and neck cancer; epidermal growth factor receptor; EGFRvIII; STAT3; cancer cell invasion	CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCERS; MOUSE FIBROBLASTS; EXPRESSION; EGFR; CARCINOMA; TRANSCRIPTION-3; RESISTANCE; PROMOTES; KINASE	Epidermal growth factor receptor (EGFR) is frequently overexpressed in head and neck squamous cell carcinoma (HNSCC) where aberrant signaling downstream of this receptor contributes to tumor growth. EGFR variant III (EGFRvIII) is the most commonly altered form of EGFR and contains a truncated ligand-binding domain. We previously reported that EGFRvIII is expressed in up to 40% of HNSCC tumors where it is associated with increased proliferation, tumor growth and chemoresistance to antitumor drugs including the EGFR-targeting monoclonal antibody cetuximab. Cetuximab was FDA-approved in 2006 for HNSCC but has not been shown to prevent invasion or metastasis. This study was undertaken to evaluate the mechanisms of EGFRvIII-mediated cell motility and invasion in HNSCC. We found that EGFRvIII induced HNSCC cell migration and invasion in conjunction with increased signal transducer and activator of transcription 3 (STAT3) activation, which was not abrogated by cetuximab treatment. Further investigation showed that EGF-induced expression of the STAT3 target gene HIF1-alpha, was abolished by cetuximab in HNSCC cells expressing wild-type EGFR under hypoxic conditions, but not in EGFRvIII-expressing HNSCC cells. These results suggest that EGFRvIII mediates HNSCC cell migration and invasion by increased STAT3 activation and induction of HIF1-alpha, which contribute to cetuximab resistance in EGFRvIII-expressing HNSCC tumors. Oncogene (2010) 29, 5135-5145; doi:10.1038/onc.2009.279; published online 12 July 2010	[Wheeler, S. E.; Suzuki, S.; Thomas, S. M.; Sen, M.; Lai, S. Y.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA; [Wheeler, S. E.; Suzuki, S.; Thomas, S. M.; Sen, M.; Leeman-Neill, R. J.; Chiosea, S. I.; Gooding, W. E.; Lai, S. Y.; Grandis, J. R.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Leeman-Neill, R. J.; Chiosea, S. I.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Kuan, C-T; Bigner, D. D.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Gooding, W. E.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15213 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Univ Pittsburgh, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu	Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Chiosea, Simion/0000-0002-5766-8779; Wheeler, Sarah/0000-0002-7851-9836; Lai, Stephen/0000-0001-8301-7286	American Cancer Society [CRP-08-229-01]; NIH [EY08098];  [RO1 CA77308];  [RO1 CA101840];  [P50 CA097190]; NATIONAL CANCER INSTITUTE [R01CA101840, R37CA011898, R01CA077308, P50CA097190] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008098] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was supported by Grants RO1 CA77308, RO1 CA101840 and P50 CA097190, and an American Cancer Society Clinical Research professorship CRP-08-229-01 (to JRG) and the NIH core Grant EY08098.	Andersen P, 2008, INT J CANCER, V122, P342, DOI 10.1002/ijc.23109; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Besser D, 1999, MOL CELL BIOL, V19, P1401; BIGNER SH, 1990, CANCER RES, V50, P8017; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; DIEDRICH U, 1995, J NEUROL, V242, P683, DOI 10.1007/BF00866920; GARCIA DP, 1993, CANCER RES, V53, P3217; Germain D, 2007, CLIN CANCER RES, V13, P5665, DOI 10.1158/1078-0432.CCR-06-2491; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, J CELL BIOCHEM, P188; Huang M, 2002, ONCOGENE, V21, P8804, DOI 10.1038/sj.onc.1206028; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kira M, 2002, J BIOL CHEM, V277, P12931, DOI 10.1074/jbc.M110795200; Lal A, 2002, CANCER RES, V62, P3335; Leeman RJ, 2006, EXPERT OPIN BIOL TH, V6, P231, DOI 10.1517/14712598.6.3.231; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Li DN, 2007, J CLIN INVEST, V117, P346, DOI 10.1172/JCI30446; Masuda M, 2002, CANCER RES, V62, P3351; Mizoguchi M, 2006, J NEUROPATH EXP NEUR, V65, P1181, DOI 10.1097/01.jnen.0000248549.14962.b2; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Narita Y, 2002, CANCER RES, V62, P6764; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Qiu ZJ, 2007, CANCER SCI, V98, P1099, DOI 10.1111/j.1349-7006.2007.00485.x; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sen M, 2009, CANCER CHEMOTH PHARM, V63, P983, DOI 10.1007/s00280-008-0823-6; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Sok JC, 2006, CLIN CANCER RES, V12, P5064, DOI 10.1158/1078-0432.CCR-06-0913; Sriuranpong V, 2003, CANCER RES, V63, P2948; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tang CY, 2000, J PHARMACOL EXP THER, V293, P453; Thomas SM, 2003, CANCER RES, V63, P5629; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Weppler SA, 2007, RADIOTHER ONCOL, V83, P333, DOI 10.1016/j.radonc.2007.04.025; Xi SC, 2005, ONCOGENE, V24, P970, DOI 10.1038/sj.onc.1208316; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Zhang Q, 2004, CANCER RES, V64, P6166, DOI 10.1158/0008-5472.CAN-04-0504	49	80	89	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	37					5135	5145		10.1038/onc.2009.279	http://dx.doi.org/10.1038/onc.2009.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622897	Green Submitted, Green Accepted			2022-12-17	WOS:000281867200003
J	Kongkham, PN; Northcott, PA; Croul, SE; Smith, CA; Taylor, MD; Rutka, JT				Kongkham, P. N.; Northcott, P. A.; Croul, S. E.; Smith, C. A.; Taylor, M. D.; Rutka, J. T.			The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma	ONCOGENE			English	Article						medulloblastoma; WNT signaling; epigenetics; methylation; tumor suppressor gene	BETA-CATENIN; METHYLATION; ANTAGONIST; MUTATIONS; SUBTYPES; CANCER; BRAIN; CELLS; MYC	Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Dysregulation of WNT signaling occurs in up to 20% of cases. Using a genome-wide approach, we identified the secreted frizzled-related protein 1, 2 and 3 (SFRP1, SFRP2 and SFRP3) family of WNT inhibitors as putative tumor suppressor genes silenced by promoter region methylation in MB. SFRP1, SFRP2 and SFRP3 expression increased after 5-aza-2'-deoxycytidine treatment. SFRP1, SFRP2 and SFRP3 methylation was identified in 23.5, 3.9 and 15.7% of primary MB specimens, respectively, by methylation-specific PCR. Stable SFRP1, SFRP2 and SFRP3 expression reduced phospho-DVL2 levels and hindered MB cell proliferation and colony formation in soft agar in vitro. In 60% of primary tumors, SFRP1 was expressed at levels twofold lower than that in normal cerebellum. SFRP1 expression impaired tumor formation in vivo in flank and orthotopic intracerebellar xenograft models and conferred a significant survival advantage (P<0.0001). We identify for the first time tumor suppressor gene function of SFRP genes in MB, and suggest that loss of WNT pathway inhibition due to SFRP gene silencing is an additional mechanism that may contribute to excessive WNT signaling in this disease. Oncogene (2010) 29, 3017-3024; doi:10.1038/onc.2010.32; published online 8 March 2010	[Kongkham, P. N.; Northcott, P. A.; Smith, C. A.; Taylor, M. D.; Rutka, J. T.] Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; [Kongkham, P. N.; Smith, C. A.; Rutka, J. T.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Northcott, P. A.; Taylor, M. D.] Univ Toronto, Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada; [Croul, S. E.] Univ Toronto, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Arthur & Sonia Labatt Brain Tumor Res Ctr, Suite 1503,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Northcott, Paul A/N-4022-2018	Northcott, Paul A/0000-0002-1220-5252; Kongkham, Paul/0000-0002-1047-9305; Croul, Sidney/0000-0002-2224-5485; Taylor, Michael/0000-0001-7009-3466	Canadian Cancer Society, National Cancer Institute of Canada [019073]; Pediatric Brain Tumor Foundation; Wiley Fund at the Hospital for Sick Children and B.r.a.i.n.child; National Cancer Institute of Canada Terry Fox Foundation; Surgeon Scientist Program (University of Toronto); National Cancer Institute of Canada Terry Fox Foundation clinical research fellowship; RESTRACOMP, The Hospital for Sick Children, Toronto	Canadian Cancer Society, National Cancer Institute of Canada; Pediatric Brain Tumor Foundation; Wiley Fund at the Hospital for Sick Children and B.r.a.i.n.child; National Cancer Institute of Canada Terry Fox Foundation; Surgeon Scientist Program (University of Toronto)(University of Toronto); National Cancer Institute of Canada Terry Fox Foundation clinical research fellowship; RESTRACOMP, The Hospital for Sick Children, Toronto	This work was supported by grants from the Canadian Cancer Society, National Cancer Institute of Canada (019073), the Pediatric Brain Tumor Foundation, the Wiley Fund at the Hospital for Sick Children and B.r.a.i.n.child. James Rutka is a scientist of the Canadian Institutes of Health Research. Paul Kongkham was supported by the Surgeon Scientist Program (University of Toronto), the National Cancer Institute of Canada Terry Fox Foundation clinical research fellowship and a research studentship from RESTRACOMP, The Hospital for Sick Children, Toronto.	Baeza N, 2003, ONCOGENE, V22, P632, DOI 10.1038/sj.onc.1206156; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Chang Q, 2005, HUM PATHOL, V36, P1265, DOI 10.1016/j.humpath.2005.09.004; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Fan X, 2008, J CLIN ONCOL, V26, P2821, DOI 10.1200/JCO.2007.15.2264; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Habas Raymond, 2005, J Biol, V4, P2, DOI 10.1186/jbiol22; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Katoh Y, 2006, INT J MOL MED, V17, P171; Koch A, 2007, INT J CANCER, V121, P284, DOI 10.1002/ijc.22675; Kongkham PN, 2008, CANCER RES, V68, P9945, DOI 10.1158/0008-5472.CAN-08-2169; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lee Y, 2003, CANCER RES, V63, P5428; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Vibhakar R, 2007, NEURO-ONCOLOGY, V9, P135, DOI 10.1215/15228517-2006-038	22	80	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					3017	3024		10.1038/onc.2010.32	http://dx.doi.org/10.1038/onc.2010.32			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208569				2022-12-17	WOS:000277890400012
J	Pillaire, MJ; Selves, J; Gordien, K; Gouraud, PA; Gentil, C; Danjoux, M; Do, C; Negre, V; Bieth, A; Guimbaud, R; Trouche, D; Pasero, P; Mechali, M; Hoffmann, JS; Cazaux, C				Pillaire, M-J; Selves, J.; Gordien, K.; Gouraud, P-A; Gentil, C.; Danjoux, M.; Do, C.; Negre, V.; Bieth, A.; Guimbaud, R.; Trouche, D.; Pasero, P.; Mechali, M.; Hoffmann, J-S; Cazaux, C.			A 'DNA replication' signature of progression and negative outcome in colorectal cancer	ONCOGENE			English	Article						DNA replication; S-phase checkpoint; colorectal cancer; genetic instability; prognosis markers	MINICHROMOSOME-MAINTENANCE PROTEIN-7; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; POLYMERASE-LAMBDA; REPAIR; OVEREXPRESSION; PROLIFERATION; MECHANISMS; GEMININ; DAMAGE	Colorectal cancer is one of the most frequent cancers worldwide. As the tumor-node-metastasis (TNM) staging classi. cation does not allow to predict the survival of patients in many cases, additional prognostic factors are needed to better forecast their outcome. Genes involved in DNA replication may represent an underexplored source of such prognostic markers. Indeed, accidents during DNA replication can trigger 'replicative stress', one of the main features of cancer from earlier stages onward. In this study, we assessed the expression of 47 'DNA replication' genes in primary tumors and adjacent normal tissues from a homogeneous series of 74 patients. We found that genes coding for translesional (TLS) DNA polymerases, initiation of DNA replication, S-phase signaling and protection of replication forks were significantly deregulated in tumors. We also observed that the overexpression of either the MCM7 helicase or the TLS DNA polymerase POLQ (if also associated with a concomitant overexpression of. ring genes) was significantly related to poor patient survival. Our data suggest the existence of a 'DNA replication signature' that might represent a source of new prognostic markers. Such a signature could help in understanding the molecular mechanisms underlying tumor progression in colorectal cancer patients. Oncogene (2010) 29, 876-887; doi:10.1038/onc.2009.378; published online 9 November 2009	[Pillaire, M-J; Bieth, A.; Hoffmann, J-S; Cazaux, C.] Univ Toulouse 3, IPBS, Genet Instabil & Canc Grp, Dept Biol Canc,CNRS,UMR5089, F-31300 Toulouse 4, Midi Pyrenees, France; [Selves, J.; Gordien, K.; Danjoux, M.; Guimbaud, R.] Univ Toulouse 3, INSERM, U563, F-31300 Toulouse 4, Midi Pyrenees, France; [Selves, J.; Gordien, K.; Danjoux, M.; Guimbaud, R.] Univ Toulouse 3, Dept Anatomopathol, F-31300 Toulouse 4, Midi Pyrenees, France; [Gouraud, P-A; Gentil, C.; Do, C.] Univ Toulouse 3, Serv Epidemiol, Fac Med, INSERM,U558, F-31300 Toulouse 4, Midi Pyrenees, France; [Negre, V.] INSERM, U868, aCGH GSO Canceropole Platform, Montpellier, France; [Trouche, D.] Univ Toulouse 3, Lab Cellular & Mol Biol Cell Proliferat Control, CNRS, UMR 5099, F-31300 Toulouse 4, Midi Pyrenees, France; [Pasero, P.; Mechali, M.] CNRS, UPR1142, Inst Human Genet, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Cazaux, C (corresponding author), Univ Toulouse 3, IPBS, Genet Instabil & Canc Grp, Dept Biol Canc,CNRS,UMR5089, 205 Route Narbonne, F-31300 Toulouse 4, Midi Pyrenees, France.	cazaux@ipbs.fr	Gourraud, Pierre-Antoine FD/O-3024-2015; Selves, Janick/M-7719-2014; Hoffmann, Jean-Sebastien/O-9183-2014; GUIMBAUD, Rosine/M-7503-2014; Pillaire, Marie-Jeanne/P-1579-2014; Pasero, Philippe/O-2340-2018	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Pillaire, Marie-Jeanne/0000-0001-6866-7416; Pasero, Philippe/0000-0001-5891-0822; Gourraud, Pierre-Antoine/0000-0003-1131-9554; Trouche, Didier/0000-0003-1398-6481; do, catherine/0000-0002-9796-4345	INCa (Canceropole GSO)	INCa (Canceropole GSO)(Institut National du Cancer (INCA) France)	We thank the 'GSO/3R' Consortium for helpful discussions. We thank B Orsetti for CGH experiments (GSO aCGH platform, CRLCCMontpellier). We also acknowledge JJMaoret (Q-PCR platform, IFR31, Toulouse), as well as F Viala and S Mazeres (IPBS, Toulouse) for iconography and technical assistance, respectively. This study was supported by INCa (Canceropole GSO, grant ACI 'Genetic instability as a negative outcome' 2004/07 and 2008/09 to CC; grants to JS, DT and PP).	Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Betous R, 2009, MOL CARCINOGEN, V48, P369, DOI 10.1002/mc.20509; Braithwaite EK, 2005, J BIOL CHEM, V280, P18469, DOI 10.1074/jbc.M411864200; Brake T, 2003, CANCER RES, V63, P8173; Brondello JM, 2008, ONCOGENE, V27, P6093, DOI 10.1038/onc.2008.212; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Davies RJ, 2002, LANCET, V359, P1917, DOI 10.1016/S0140-6736(02)08739-1; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Facoetti A, 2006, ANTICANCER RES, V26, P3513; Facoetti A, 2006, ANTICANCER RES, V26, P1071; Gonzalez MA, 2004, J PATHOL, V204, P121, DOI 10.1002/path.1625; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Hanawalt PC, 2007, MOL CELL, V28, P702, DOI 10.1016/j.molcel.2007.11.014; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Kawamura K, 2004, INT J CANCER, V109, P9, DOI 10.1002/ijc.11666; Kunkel TA, 2003, CANCER CELL, V3, P105, DOI 10.1016/S1535-6108(03)00027-8; Lemee F, 2007, ONCOGENE, V26, P3387, DOI 10.1038/sj.onc.1210116; Li JQ, 2003, INT J ONCOL, V23, P1537; Lutzmann M, 2008, MOL CELL, V31, P190, DOI 10.1016/j.molcel.2008.07.001; Lutzmann M, 2006, EMBO J, V25, P5764, DOI 10.1038/sj.emboj.7601436; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Mitchell JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8; Nishihara K, 2008, INT J ONCOL, V33, P245, DOI 10.3892/ijo_00000003; Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417; Padmanabhan V, 2004, J CLIN PATHOL, V57, P1057, DOI 10.1136/jcp.2004.016436; Pan QR, 2005, CANCER LETT, V217, P139, DOI 10.1016/j.canlet.2004.07.021; Rey L, 2009, MOL CELL BIOL, V29, P3344, DOI 10.1128/MCB.00115-09; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Seki M, 2004, EMBO J, V23, P4484, DOI 10.1038/sj.emboj.7600424; Shrestha P, 2007, CANCER-AM CANCER SOC, V109, P949, DOI 10.1002/cncr.22474; Sobol RW, 1996, NATURE, V383, P457, DOI 10.1038/383457b0; Sobol RW, 1996, NATURE, V379, P848, DOI 10.1038/379848b0; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Venkatesan RN, 2007, MOL CELL BIOL, V27, P7669, DOI 10.1128/MCB.00002-07; Wang GL, 2008, JNCI-J NATL CANCER I, V100, P1815, DOI 10.1093/jnci/djn385; Wittschieben JP, 2006, CANCER RES, V66, P134, DOI 10.1158/0008-5472.CAN-05-2982; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108	47	80	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					876	887		10.1038/onc.2009.378	http://dx.doi.org/10.1038/onc.2009.378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19901968				2022-12-17	WOS:000274397800010
J	Allende-Vega, N; Sparks, A; Lane, DP; Saville, MK				Allende-Vega, N.; Sparks, A.; Lane, D. P.; Saville, M. K.			MdmX is a substrate for the deubiquitinating enzyme USP2a	ONCOGENE			English	Article						USP2a; MdmX; Mdm2; p53; ubiquitin; deubiquitinating enzyme	P53 ACTIVATION; DNA-DAMAGE; IN-VIVO; EMBRYONIC LETHALITY; UBIQUITIN LIGASE; PROSTATE-CANCER; TARGETING MDM2; CISPLATIN; CELLS; PATHWAY	It has previously been shown that ubiquitin-specific protease 2a (USP2a) is a regulator of the Mdm2/p53 pathway. USP2a binds to Mdm2 and can deubiquitinate Mdm2 without reversing Mdm2-mediated p53 ubiquitination. Overexpression of USP2a causes accumulation of Mdm2 and promotes p53 degradation. We now show that MdmX is also a substrate for USP2a. MdmX associates with USP2a independently of Mdm2. Ectopic expression of wild-type USP2a but not a catalytic mutant prevents Mdm2-mediated degradation of MdmX. This correlates with the ability of wild-type USP2a to deubiquitinate MdmX. siRNA-mediated knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells causes destabilization of MdmX and results in a decrease in MdmX protein levels, showing that endogenous USP2a participates in the regulation of MdmX stability. The therapeutic drug, cisplatin decreases MdmX protein expression. USP2a mRNA and protein levels were also reduced after cisplatin exposure. The magnitude and time course of USP2a downregulation suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin. Knockdown of USP2a increases the sensitivity of NTERA-2 cells to cisplatin, raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy. Oncogene (2010) 29, 432-441; doi:10.1038/onc.2009.330; published online 19 October 2009	[Allende-Vega, N.; Sparks, A.; Lane, D. P.; Saville, M. K.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, CR UK Cell Transformat Res Grp,Div Mol Med, Dundee DD1 9SY, Scotland	University of Dundee	Saville, MK (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, CR UK Cell Transformat Res Grp,Div Mol Med, Level 6, Dundee DD1 9SY, Scotland.	m.k.saville@dundee.ac.uk		Allende-Vega, Nerea/0000-0001-5569-6461; Lane, David/0000-0003-0551-3545	Cancer Research UK	Cancer Research UK(Cancer Research UK)	This work was funded by Cancer Research UK. Professor David P Lane is a Gibb fellow of Cancer Research UK.	Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; EVANS GL, 1992, BIOCHEM BIOPH RES CO, V184, P1, DOI 10.1016/0006-291X(92)91149-K; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Finch RA, 2002, CANCER RES, V62, P3221; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Giglio S, 2005, CANCER RES, V65, P9687, DOI 10.1158/0008-5472.CAN-05-0450; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Gousseva N, 2003, GENE EXPRESSION, V11, P163, DOI 10.3727/000000003108749053; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kruse JJCM, 2007, MUTAT RES-FUND MOL M, V617, P58, DOI 10.1016/j.mrfmmm.2006.12.004; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin HJ, 2001, J BIOL CHEM, V276, P20357, DOI 10.1074/jbc.M008761200; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUNA RMD, 1995, NATURE, V378, P203; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Park KC, 2002, P NATL ACAD SCI USA, V99, P9733, DOI 10.1073/pnas.152011799; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Previati M, 2004, HEARING RES, V196, P8, DOI 10.1016/j.heares.2004.04.009; Priolo C, 2006, CANCER RES, V66, P8625, DOI 10.1158/0008-5472.CAN-06-1374; Renatus M, 2006, STRUCTURE, V14, P1293, DOI 10.1016/j.str.2006.06.012; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wade M, 2009, MOL CANCER RES, V7, P1, DOI 10.1158/1541-7786.MCR-08-0423; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Xia MX, 2008, CELL CYCLE, V7, P1604, DOI 10.4161/cc.7.11.5929; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656	56	80	86	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					432	441		10.1038/onc.2009.330	http://dx.doi.org/10.1038/onc.2009.330			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838211				2022-12-17	WOS:000273793200012
J	Swartling, FJ; Ferletta, M; Kastemar, M; Weiss, WA; Westermark, B				Swartling, F. J.; Ferletta, M.; Kastemar, M.; Weiss, W. A.; Westermark, B.			Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines	ONCOGENE			English	Article						glioma; PDGF; cGMP-dependent protein kinase II; Akt; Sox9; VASP	NITRIC-OXIDE; GROWTH-FACTOR; BRAIN-TUMORS; RECEPTOR GENE; ACTIVATION; MIGRATION; IDENTIFICATION; AMPLIFICATION; PROGRESSION; IMATINIB	Earlier we used a glioma model to identify loci in the mouse genome, which were repeatedly targeted by platelet-derived growth factor (PDGF)-containing Moloney murine leukemia viruses. The gene Prkg2, encoding cyclic guanosine monophosphate (cGMP)-dependent protein kinase II, cGKII, was tagged by retroviral insertions in two brain tumors. The insertions were both situated upstream of the kinase domain and suggested creating a truncated form of the cGKII protein. We transfected different human glioma cell lines with Prkg2 and found an overall reduction in colony formation and cell proliferation compared with controls transfected with truncated Prkg2 (lacking the kinase domain) or empty vector. All glioma cells transfected with the cGKII phosphorylate vasodilator-stimulated phosphoprotein, VASP, after cGMP analog treatment. Glioma cell lines positive for the Sox9 transcription factor showed reduced Sox9 expression when Prkg2 was stably transfected. When cGKII was activated by cGMP analog treatment, Sox9 was phosphorylated, Sox9 protein expression was suppressed and the glioma cell lines displayed loss of cell adhesion, inhibition of Akt phosphorylation and G1 arrest. Sox9 repression by siRNA was similarly shown to reduce glioma cell proliferation. Expression analysis of stem and glial lineage cell markers also suggests that cGKII induces differentiation of glioma cell lines. These findings describe an anti-proliferative role of cGKII in human glioma biology and would further explain the retroviral tagging of the cGKII gene during brain tumor formation in PDGF-induced tumors. Oncogene (2009) 28, 3121-3131; doi: 10.1038/onc.2009.168; published online 22 June 2009	[Westermark, B.] Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; [Swartling, F. J.; Weiss, W. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	Uppsala University; Uppsala University Hospital; University of California System; University of California San Francisco	Westermark, B (corresponding author), Univ Uppsala Hosp, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskjoldsv 20, SE-75185 Uppsala, Sweden.	Bengt.Westermark@genpat.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367; Westermark, Bengt/0000-0001-7153-5545; Weiss, William/0000-0003-2230-9132	Swedish Cancer Foundation; Children's Cancer Foundation; Swedish Research Council; Swedish Foundation for Strategic Research; NATIONAL CANCER INSTITUTE [P50CA097257] Funding Source: NIH RePORTER	Swedish Cancer Foundation; Children's Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the Swedish Cancer Foundation, the Children's Cancer Foundation, the Swedish Research Council and the Swedish Foundation for Strategic Research. We acknowledge Lisa Christiansson for skillful technical assistance.	BUTT E, 1994, J BIOL CHEM, V269, P14509; Cen B, 2008, CANCER RES, V68, P5355, DOI 10.1158/0008-5472.CAN-07-6869; Chen LH, 2004, ARTERIOSCL THROM VAS, V24, P1403, DOI 10.1161/01.ATV.0000134705.39654.53; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Chikuda H, 2004, GENE DEV, V18, P2418, DOI 10.1101/gad.1224204; Cook ALM, 2004, CELL SIGNAL, V16, P253, DOI 10.1016/S0898-6568(03)00134-7; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Dromard C, 2007, STEM CELLS, V25, P340, DOI 10.1634/stemcells.2005-0556; Finzsch M, 2008, DEVELOPMENT, V135, P637, DOI 10.1242/dev.010454; Gambaryan S, 2002, BIOCHEM BIOPH RES CO, V293, P1438, DOI 10.1016/S0006-291X(02)00412-6; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Hagerstrand D, 2006, ONCOGENE, V25, P4913, DOI 10.1038/sj.onc.1209497; Hofmann F, 2006, PHYSIOL REV, V86, P1, DOI 10.1152/physrev.00015.2005; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hou YL, 2006, CANCER LETT, V240, P60, DOI 10.1016/j.canlet.2005.08.035; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Johansson FK, 2005, ONCOGENE, V24, P3896, DOI 10.1038/sj.onc.1208553; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; Kordes U, 2006, J NEURO-ONCOL, V80, P151, DOI 10.1007/s11060-006-9180-7; Lahortiga I, 2007, HAEMATOLOGICA, V93, P49, DOI 10.3324/haematol.11836; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; NISTER M, 1988, CANCER RES, V48, P3910; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Sottile V, 2006, BRAIN RES, V1099, P8, DOI 10.1016/j.brainres.2006.04.127; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Swartling FJ, 2008, UPSALA J MED SCI, V113, P1; Tanaka J, 1997, GLIA, V19, P286; Taylor MK, 2002, J BIOL CHEM, V277, P37242, DOI 10.1074/jbc.M202060200; Uhrbom L, 1998, CANCER RES, V58, P5275; Villalobo A, 2006, FEBS J, V273, P2329, DOI 10.1111/j.1742-4658.2006.05250.x; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Walz C, 2007, HAEMATOLOGICA, V92, P163, DOI 10.3324/haematol.10980; Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang SI, 1997, CANCER RES, V57, P4183; Yin D, 2008, CLIN CANCER RES, V14, P4002, DOI 10.1158/1078-0432.CCR-07-1826; Yoshioka A, 2000, J NEUROCHEM, V74, P633, DOI 10.1046/j.1471-4159.2000.740633.x	43	80	81	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3121	3131		10.1038/onc.2009.168	http://dx.doi.org/10.1038/onc.2009.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19543319	Green Accepted			2022-12-17	WOS:000269515100004
J	Hoenerhoff, MJ; Chu, I; Barkan, D; Liu, ZY; Datta, S; Dimri, GP; Green, JE				Hoenerhoff, M. J.; Chu, I.; Barkan, D.; Liu, Z-y; Datta, S.; Dimri, G. P.; Green, J. E.			BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases	ONCOGENE			English	Article						BMI1; H-RAS; breast cancer; metastasis	MAMMARY EPITHELIAL-CELLS; STEM-CELLS; CARCINOMA; MYC; TUMORIGENESIS; TRASTUZUMAB; EXPRESSION; APOPTOSIS; THERAPY; RENEWAL	B-lymphoma Moloney murine leukaemia virus insertion region-1 (BMI1) is a member of the polycomb group of transcription repressors, which functions in stem cell maintenance and oncogenesis through the inhibition of the INK4A/ARF tumour suppressor locus. Overexpression of BMI1 is associated with poor prognosis in several human cancers, including breast cancer. We have previously shown that BMI1 collaborates with H-RAS to induce transformation of MCF10A human mammary epithelial cells through dysregulation of multiple growth pathways independent of the INK4A/ARF locus. In this study, we show that BMI1 collaborates with H-RAS to promote increased proliferation, invasion and resistance to apoptosis in vitro, and an increased rate of spontaneous metastases from mammary fat pad xenografts including novel metastases to the brain. Furthermore, in collaboration with H-RAS, BMI1 induced fulminant metastatic disease in the lung using a tail vein model of haematogenous spread through accelerated cellular proliferation and inhibition of apoptosis. Finally, we show that knockdown of BMI1 in several established breast cancer cell lines leads to decreased oncogenic behaviour in vitro and in vivo. In summary, BMI1 collaborates with H-RAS to induce an aggressive and metastatic phenotype with the unusual occurrence of brain metastasis, making it an important target for diagnosis and treatment of aggressive breast cancer. Oncogene (2009) 28, 3022-3032; doi:10.1038/onc.2009.165; published online 22 June 2009	[Hoenerhoff, M. J.; Chu, I.; Barkan, D.; Liu, Z-y; Green, J. E.] NCI, Transgen Oncogenesis Grp, Lab Canc Biol & Genet, NIH, Bethesda, MD 20982 USA; [Datta, S.; Dimri, G. P.] Northwestern Univ, N Shore Univ Hlth Syst Res Inst, Feinberg Sch Med, Div Canc Biol, Evanston, IL USA; [Datta, S.; Dimri, G. P.] Northwestern Univ, N Shore Univ Hlth Syst Res Inst, Feinberg Sch Med, Dept Med, Evanston, IL USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Green, JE (corresponding author), NCI, Transgen Oncogenesis Grp, Lab Canc Biol & Genet, NIH, 37 Convent Dr,Bldg 37,Room 4054, Bethesda, MD 20982 USA.	jegreen@nih.gov	Datta, Sonal/AGI-2356-2022; Dimri, Goberdhan/AAO-4210-2021	, Janet/0000-0001-9020-6982; Datta, Sonal/0000-0002-4924-9355; Barkan, Dalit/0000-0003-4714-0580	NIH; Center for Cancer Research; National Cancer Institute [RO1CA 094150]; NATIONAL CANCER INSTITUTE [ZIABC005740, R01CA094150, ZIABC011229] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Max Wicha for providing the shRNA lentiviral constructs, George Dunn, Asa Dorsey and Gail McMullen for animal care, Zi-ayo Liu for lentiviral transductions and Suresh Arya for advice on lentiviral preparation, and Aleksandra Michalowski and the NIH Biostatisitics Branch for assistance with statistical analysis. This work was supported in part by the Intramural Program of the NIH, Center for Cancer Research, National Cancer Institute and by RO1CA 094150 (GD).	Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; Brackstone M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1677; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Clayton AJ, 2004, BRIT J CANCER, V91, P639, DOI 10.1038/sj.bjc.6601970; Datta S, 2007, CANCER RES, V67, P10286, DOI 10.1158/0008-5472.CAN-07-1636; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Dimri GP, 2002, CANCER RES, V62, P4736; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Feng Yan, 2007, Ai Zheng, V26, P154; Fisher B, 2001, J Natl Cancer Inst Monogr, P62; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Glinsky GV, 2005, CELL CYCLE, V4, P1171, DOI 10.4161/cc.4.9.2001; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; He B, 2006, ONCOGENE, V25, P2192, DOI 10.1038/sj.onc.1209248; Huang Kai-hong, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P973; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kang MK, 2007, BRIT J CANCER, V96, P126, DOI 10.1038/sj.bjc.6603529; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Mihic-Probst D, 2007, INT J CANCER, V121, P1764, DOI 10.1002/ijc.22891; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; TSUKADA Y, 1983, CANCER-AM CANCER SOC, V52, P2349, DOI 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Vernon AE, 2007, REV ENDOCR METAB DIS, V8, P199, DOI 10.1007/s11154-007-9041-5; Wallgren A, 2003, J CLIN ONCOL, V21, P1205, DOI 10.1200/JCO.2003.03.130	31	80	82	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3022	3032		10.1038/onc.2009.165	http://dx.doi.org/10.1038/onc.2009.165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543317	Green Accepted			2022-12-17	WOS:000269319000002
J	Confalonieri, S; Quarto, M; Goisis, G; Nuciforo, P; Donzelli, M; Jodice, G; Pelosi, G; Viale, G; Pece, S; Di Fiore, PP				Confalonieri, S.; Quarto, M.; Goisis, G.; Nuciforo, P.; Donzelli, M.; Jodice, G.; Pelosi, G.; Viale, G.; Pece, S.; Di Fiore, P. P.			Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor	ONCOGENE			English	Article						ubiquitin; ubiquitin E3 ligase; cancer; in situ hybridization; tissue microarrays	SQUAMOUS-CELL CARCINOMA; CYCLIN B1; HECT-DOMAIN; BREAST-CANCER; PROTEIN; OVEREXPRESSION; DEGRADATION; CDC6; P53; SUPPRESSOR	Protein ubiquitination is critical for many cellular processes, through its ability to regulate protein degradation and various signaling mechanisms. In the ubiquitin (Ub) system, substrate specificity is achieved through the E3 family of Ub ligases. Because alterations of the ubiquitination machinery have been reported in human cancers, the selective interference with Ub ligases might represent a powerful therapeutic tool. Here, we report the first wide survey of misregulation of Ub ligases in cancer. We analysed 82 Ub ligases in nine types of cancer by in situ hybridization on tissue microarrays. We found 27 instances in which an Ub ligase was altered in a given type of tumor, when compared with normal tissues: 21 cases of overexpression and 6 cases of underexpression. We further analysed selected Ub ligases in large cohorts of breast and non-small-cell lung carcinomas. In five, of six, of these extended analyses (HUWE1, CCNB1IP1, SIAH1 and SIAH2 in breast cancer and CCNB1IP1 in lung cancer), we found that the levels of Ub ligases correlated significantly with relevant prognostic factors, and with clinical outcome. Our findings show that the alteration of Ub ligases is a frequent event in cancer and identify candidate targets for molecular therapies. Oncogene (2009) 28, 2959-2968; doi:10.1038/onc.2009.156; published online 22 June 2009	[Confalonieri, S.; Quarto, M.; Nuciforo, P.; Jodice, G.; Pece, S.; Di Fiore, P. P.] IFOM, Fdn Ist FIRC Oncol Mol, I-20139 Milan, Italy; [Goisis, G.; Donzelli, M.; Pelosi, G.; Viale, G.; Pece, S.; Di Fiore, P. P.] Ist Europeo Oncol, Milan, Italy; [Pelosi, G.; Viale, G.; Pece, S.; Di Fiore, P. P.] Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan	Confalonieri, S (corresponding author), IFOM, Fdn Ist FIRC Oncol Mol, Via Adamello 16, I-20139 Milan, Italy.	stefano.confalonieri@ifom-ieo-campus.it; pierpaolo.difiore@ifom-ieo-campus.it	Nuciforo, Paolo/Q-2885-2019; Confalonieri, Stefano/AAQ-6786-2020; Viale, Giuseppe/AAE-8921-2019; Donzelli, Maddalena/ABD-3774-2020; Di Fiore, Pier Paolo/K-2130-2012; Pece, Salvatore/B-9609-2013; Pelosi, Giuseppe/F-5073-2012	Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Pece, Salvatore/0000-0003-1764-3929; Pelosi, Giuseppe/0000-0003-4725-4692; Nuciforo, Paolo/0000-0003-1380-0990; DONZELLI, MADDALENA/0000-0002-4045-0802; Iodice, Maria Giovanna/0000-0002-6173-1080	AIRC (Associazione Italiana per la Ricerca sul Cancro); AIRC and MIUR; European Community (VI Framework); Ferrari Foundation; Monzino Foundation; CARIPLO Foundation; G Vollaro Foundation	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AIRC and MIUR(Fondazione AIRC per la ricerca sul cancroMinistry of Education, Universities and Research (MIUR)); European Community (VI Framework)(European Commission); Ferrari Foundation; Monzino Foundation; CARIPLO Foundation(Fondazione Cariplo); G Vollaro Foundation	We thank Maria Capra and Maria Tuttoilmondo for TMA database development and TMA analysis, and Sara Volorio for excellent technical assistance. This work was supported by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro) to SC, and from AIRC and MIUR to SP and PPDF; from the European Community (VI Framework), the Ferrari Foundation, the Monzino Foundation and the CARIPLO Foundation to PPDF; and from the G Vollaro Foundation to SP. PN was supported by an AIRC fellowship.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Capra M, 2006, CANCER RES, V66, P8147, DOI 10.1158/0008-5472.CAN-05-3489; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Ciechanover A, 2003, BIOCHEM SOC T, V31, P474, DOI 10.1042/BST0310474; Ciechanover A, 2002, HEPATOLOGY, V35, P3, DOI 10.1053/jhep.2002.30316; Dong YY, 2002, CANCER LETT, V177, P13, DOI 10.1016/S0304-3835(01)00770-4; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173; Hassan KA, 2002, CANCER RES, V62, P6414; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoppe T, 2005, TRENDS BIOCHEM SCI, V30, P183, DOI 10.1016/j.tibs.2005.02.004; Kallijarvi J, 2005, EXP CELL RES, V308, P146, DOI 10.1016/j.yexcr.2005.04.001; Kim M, 2004, ONCOGENE, V23, P1645, DOI 10.1038/sj.onc.1207298; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nicassio F, 2005, J CLIN INVEST, V115, P3015, DOI 10.1172/JCI24862; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Pelizon C, 2003, TRENDS CELL BIOL, V13, P110, DOI 10.1016/S0962-8924(03)00024-2; Scarafia LE, 2000, PHYSIOL GENOMICS, V4, P147, DOI 10.1152/physiolgenomics.2000.4.2.147; Schauvliege R, 2006, FEBS LETT, V580, P4697, DOI 10.1016/j.febslet.2006.07.046; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Soria JC, 2000, CANCER RES, V60, P4000; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Vecchi M, 2008, ONCOGENE, V27, P2148, DOI 10.1038/sj.onc.1210858; Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Ward JO, 2007, PLOS GENET, V3, P1550, DOI 10.1371/journal.pgen.0030139; Weiss A, 2007, FEBS LETT, V581, P5131, DOI 10.1016/j.febslet.2007.09.062; Xia Y, 2007, MOL CELL BIOL, V27, P510, DOI 10.1128/MCB.01355-06; Yasuda M, 2002, J CANCER RES CLIN, V128, P412, DOI 10.1007/s00432-002-0359-9; Yoon SY, 2005, BIOCHEM BIOPH RES CO, V326, P7, DOI 10.1016/j.bbrc.2004.11.004; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	45	80	87	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	2009	28	33					2959	2968		10.1038/onc.2009.156	http://dx.doi.org/10.1038/onc.2009.156			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19543318				2022-12-17	WOS:000269142800004
J	Chen, J; Kobayashi, M; Darmanin, S; Qiao, Y; Gully, C; Zhao, R; Yeung, SC; Lee, MH				Chen, J.; Kobayashi, M.; Darmanin, S.; Qiao, Y.; Gully, C.; Zhao, R.; Yeung, S. C.; Lee, M. H.			Pim-1 plays a pivotal role in hypoxia-induced chemoresistance	ONCOGENE			English	Article						Pim-1; hypoxia; apoptosis; chemoresistance; mitochondrial transmembrane potential	OXYGEN DISTRIBUTION; INHIBITS APOPTOSIS; CANCER-CELLS; HUMAN TUMORS; KINASE; EXPRESSION; PHOSPHORYLATION; ACTIVATION; PROTEIN; DEATH	Hypoxia changes the responses of cancer cells to many chemotherapy agents, resulting in chemoresistance. The underlying molecular mechanism of hypoxia-induced drug resistance remains unclear. Pim-1 is a survival kinase, which phosphorylates Bad at serine 112 to antagonize drug-induced apoptosis. Here we show that hypoxia increases Pim-1 in a hypoxia-inducible factor-1 alpha-independent manner. Inhibition of Pim-1 function by dominant-negative Pim-1 dramatically restores the drug sensitivity to apoptosis induced by chemotherapy under hypoxic conditions in both in vitro and in vivo tumor models. Introduction of siRNAs for Pim-1 also resensitizes cancer cells to chemotherapy drugs under hypoxic conditions, whereas forced overexpression of Pim-1 endows solid tumor cells with resistance to cisplatin, even under normoxia. Dominant-negative Pim-1 prevents a decrease in mitochondrial transmembrane potential in solid tumor cells, which is normally induced by cisplatin (CDDP), followed by the reduced activity of Caspase-3 and Caspase-9, indicating that Pim-1 participates in hypoxia-induced drug resistance through the stabilization of mitochondrial transmembrane potential. Our results demonstrate that Pim-1 is a pivotal regulator involved in hypoxia-induced chemoresistance. Targeting Pim-1 may improve the chemotherapeutic strategy for solid tumors. Oncogene (2009) 28, 2581-2592; doi: 10.1038/onc.2009.124; published online 1 June 2009	[Chen, J.; Qiao, Y.; Gully, C.; Zhao, R.; Lee, M. H.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chen, J.; Darmanin, S.; Qiao, Y.] Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido, Japan; [Chen, J.] Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido, Japan; [Kobayashi, M.] Hokkaido Univ, Div Canc Biol, Inst Med Genet, Sapporo, Hokkaido, Japan; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Gen Internal Med Ambulatory Treatment & Emer, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University; Hokkaido University; Hokkaido University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, MH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.	syeung@mdanderson.org; mhlee@mdanderson.org	Yeung, Sai-Ching/AAI-6178-2021; Yeung, Sai-Ching/AAP-8079-2020	Yeung, Sai-Ching/0000-0001-5170-0822; Lee, Mong-Hong/0000-0001-8675-8215	NIHRO1CA [089266]; Japan Society for the Promotion of Science (JSPS); Japanese Ministry of Education, Culture, Sports, Science and Technology; US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs [DOD SIDA BC062166]; Cancer Center Core [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA089266, R56CA089266] Funding Source: NIH RePORTER	NIHRO1CA; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs(United States Department of Defense); Cancer Center Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the NIHRO1CA (089266 Lee MH), Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (Chen J), Grants-in-Aid for Cancer Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Kobayashi M), US Department of Defense Breast Cancer Research Program of the Office of the Congressionally Directed Medical Research Programs (DOD SIDA BC062166 Yeung SJ & Lee MH) and Cancer Center Core Grant (CA16672). We thank Dr BQ Vuong for providing the pCDNA3.1-His-SOCS1 plasmid. We thank Mrs Shirley Ware-Gully for her assistance in preparing the article.	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Arsham AM, 2004, CANCER RES, V64, P3500, DOI 10.1158/0008-5472.CAN-03-2239; BANDYOPADHYAY RS, 1995, BBA-GENE STRUCT EXPR, V1264, P72, DOI 10.1016/0167-4781(95)00116-X; Cardenas-Navia LI, 2004, CANCER RES, V64, P6010, DOI 10.1158/0008-5472.CAN-03-0947; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; CHEN J, 2009, AM J PATHOL IN PRESS; Comerford KM, 2002, CANCER RES, V62, P3387; CUYPERS HT, 1984, CELL, V37, P141; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Eichmann A, 2000, ONCOGENE, V19, P1215, DOI 10.1038/sj.onc.1203355; GATENBY RA, 1988, INT J RADIAT ONCOL, V14, P831, DOI 10.1016/0360-3016(88)90002-8; KOH WJ, 1992, INT J RADIAT ONCOL, V22, P199, DOI 10.1016/0360-3016(92)91001-4; KOONG AC, 1994, CANCER RES, V54, P1425; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; Liu LL, 2008, CANCER SCI, V99, P121, DOI 10.1111/j.1349-7006.2007.00643.x; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mizukami Y, 2004, CANCER RES, V64, P1765, DOI 10.1158/0008-5472.CAN-03-3017; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; Pierce AC, 2008, J MED CHEM, V51, P1972, DOI 10.1021/jm701248t; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Teh Beng-gwan, 2004, Hokkaido Journal of Medical Science, V79, P19; TEICHER BA, 1981, CANCER RES, V41, P73; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Toffoli S, 2008, FEBS J, V275, P2991, DOI 10.1111/j.1742-4658.2008.06454.x; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VAUPEL P, 1991, CANCER RES, V51, P3316; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383; Yan B, 2003, J BIOL CHEM, V278, P45358, DOI 10.1074/jbc.M307933200; YOSHIDA A, 1989, J SURG ONCOL, V41, P1, DOI 10.1002/jso.2930410104; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zippo A, 2004, BLOOD, V103, P4536, DOI 10.1182/blood-2003-11-3827; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	37	80	82	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2581	2592		10.1038/onc.2009.124	http://dx.doi.org/10.1038/onc.2009.124			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19483729	Green Accepted			2022-12-17	WOS:000268058900004
J	Nabilsi, NH; Broaddus, RR; Loose, DS				Nabilsi, N. H.; Broaddus, R. R.; Loose, D. S.			DNA methylation inhibits p53-mediated survivin repression	ONCOGENE			English	Article						DNA methylation; endometrium; cancer	WILD-TYPE P53; ENDOMETRIAL CARCINOMA; EXPRESSION; GENE; CANCER; CARCINOGENESIS; APOPTOSIS; DIAGNOSIS; REGION; HTERT	The molecular progression of endometrial cancer is poorly understood, and both genetic and epigenetic factors play a role. Survivin is a member of the inhibitor of apoptosis (IAP) gene family and contains a canonical CpG island that has been described as epigenetically regulated. As survivin is overexpressed in endometrial tumors, we hypothesized that hypomethylation could explain this expression pattern. Surprisingly, methylation-specific PCR and pyrosequencing showed that survivin was hypermethylated in endometrial tumors and correlated with increased survivin expression. We speculated that methylation could inhibit the binding of p53, a repressor of survivin expression. Our data indicates that demethylation of the survivin promoter by decitabine results in p53-dependent survivin repression and that p53 binding can be inhibited by DNA methylation. We are the first to report survivin de-repression by DNA methylation. We also present microarray data, which suggest that de-repression by methylation is a general mechanism of p53 regulation. Demethylation induced by decitabine is traditionally thought to be active in tumors by allowing the re-expression of tumor suppressor genes. However, our results indicate that an additional important mechanism is to decrease the expression of oncogenes. Oncogene (2009) 28, 2046-2050; doi:10.1038/onc.2009.62; published online 13 April 2009	[Nabilsi, N. H.; Loose, D. S.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Loose, DS (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, 6431 Fannin St,MSB 5-132A, Houston, TX 77030 USA.	david.s.loose@uth.tmc.edu			NIH [1P50CA098258-01]; Rosalie B Hite Graduate Student Fellowship; NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rosalie B Hite Graduate Student Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Grant NIH 1P50CA098258-01 (SPORE in Endometrial Cancer), and a Rosalie B Hite Graduate Student Fellowship.	Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Erkanli S, 2006, INT J GYNECOL CANCER, V16, P1412, DOI 10.1111/j.1525-1438.2006.00541.x; Erkanli S, 2007, GYNECOL ONCOL, V104, P320, DOI 10.1016/j.ygyno.2006.08.044; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Furlan D, 2006, CLIN CANCER RES, V12, P3329, DOI 10.1158/1078-0432.CCR-05-2679; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hopfer O, 2007, EXP HEMATOL, V35, P712, DOI 10.1016/j.exphem.2007.01.054; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Konno R, 2000, MOL HUM REPROD, V6, P529, DOI 10.1093/molehr/6.6.529; Lehner R, 2002, ACTA OBSTET GYN SCAN, V81, P162, DOI 10.1034/j.1600-0412.2002.810213.x; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Meng RD, 1999, INT J ONCOL, V14, P5; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Prat J, 2007, PATHOLOGY, V39, P72, DOI 10.1080/00313020601136153; Renaud S, 2007, NUCLEIC ACIDS RES, V35, P1245, DOI 10.1093/nar/gkl1125; Renaud S, 2005, NUCLEIC ACIDS RES, V33, P6850, DOI 10.1093/nar/gki989; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Takai N, 2002, CANCER LETT, V184, P105, DOI 10.1016/S0304-3835(02)00190-8; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Xie R, 2007, MODERN PATHOL, V20, P1045, DOI 10.1038/modpathol.3800940; Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828; Zhou XC, 2007, GYNECOL ONCOL, V107, P143, DOI 10.1016/j.ygyno.2007.06.019	26	80	83	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2046	2050		10.1038/onc.2009.62	http://dx.doi.org/10.1038/onc.2009.62			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363521				2022-12-17	WOS:000266023900005
J	Kwek, SS; Roy, R; Zhou, H; Climent, J; Martinez-Climent, JA; Fridlyand, J; Albertson, DG				Kwek, S. S.; Roy, R.; Zhou, H.; Climent, J.; Martinez-Climent, J. A.; Fridlyand, J.; Albertson, D. G.			Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis	ONCOGENE			English	Article						gene amplification; array CGH; breast cancer; 8p12; 11q13; CCND1	CANCER CELL-LINES; 8P11-12 AMPLICON; THERAPEUTIC TARGET; DNA AMPLIFICATION; INSTABILITY; FGFR1; COAMPLIFICATION; REARRANGEMENTS; ABERRATIONS	Co-amplification at chromosomes 8p11-8p12 and 11q12-11q14 occurs often in breast tumors, suggesting possible cooperation between genes in these regions in oncogenesis. We used high-resolution array comparative genomic hybridization (array CGH) to map the minimal amplified regions. The 8p and 11q amplicons are complex and consist of at least four amplicon cores at each site. Candidate oncogenes mapping to these regions were identified by combining copy number and RNA and protein expression analyses. These studies also suggested that CCND1 at 11q13 induced expression of ZNF703 mapping at 8p12, which was subsequently shown to be mediated by the Rb/E2F pathway. Nine candidate oncogenes from 8p12 and four from 11q13 were further evaluated for oncogenic function. None of the genes individually promoted colony formation in soft agar or collaborated with each other functionally. On the other hand, FGFR1 and DDHD2 at 8p12 cooperated functionally with MYC, whereas CCND1 and ZNF703 cooperated with a dominant negative form of TP53. These observations highlight the complexity and functional consequences of the genomic rearrangements that occur in these breast cancer amplicons, including transcriptional cross-talk between genes in the 8p and 11q amplicons, as well as their cooperation with major pathways of tumorigenesis.	[Albertson, D. G.] Univ Calif San Francisco, Canc Res Inst, San Francisco Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Roy, R.; Fridlyand, J.; Albertson, D. G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Climent, J.] Hosp Clin, Dept Hematol & Med Oncol, Valencia, Spain; [Martinez-Climent, J. A.] Univ Navarra, Div Oncol, Ctr Appl Med Res CIMA, E-31080 Pamplona, Spain; [Fridlyand, J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Albertson, D. G.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Navarra; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, San Francisco Comprehens Canc Ctr, 2340 Sutter St,Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu	Martinez-Climent, Jose A/I-9199-2012; Climent, Joan/O-5877-2017	Martinez-Climent, Jose A/0000-0002-7938-3950; Climent, Joan/0000-0002-8927-6614	NIH [CA90421, CA101359]; DOD BCRP [BC021074, DAMD17-03-1-0483]; NATIONAL CANCER INSTITUTE [R01CA101359, R01CA090421] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BCRP(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the UCSF Helen Diller Family Comprehensive Cancer Center Genome Analysis, Informatics, and Microarray Shared Resources for performing the TaqMan assays and printing the custom 8p11q array. This work was supported by NIH Grants CA90421 and CA101359. Serena S Kwek was the recipient of a DOD BCRP fellowship, Grant nos. BC021074, DAMD17-03-1-0483.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Agrawal A, 2006, EXP MOL PATHOL, V81, P115, DOI 10.1016/j.yexmp.2006.07.001; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Climent J, 2007, CANCER RES, V67, P818, DOI 10.1158/0008-5472.CAN-06-3307; Cuny M, 2000, CANCER RES, V60, P1077; ETHIER SP, 1993, CANCER RES, V53, P627; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Haverty PM, 2008, GENE CHROMOSOME CANC, V47, P530, DOI 10.1002/gcc.20558; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Janssen JWG, 2002, INT J CANCER, V102, P608, DOI 10.1002/ijc.10765; Kan CE, 2007, CANCER RES, V67, P9862, DOI 10.1158/0008-5472.CAN-07-0259; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Melchor L, 2007, INT J CANCER, V120, P714, DOI 10.1002/ijc.22354; Mineta H, 1997, ORAL ONCOL, V33B, P42, DOI 10.1016/S0964-1955(96)00039-5; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Patel DM, 2007, AAPS PHARMSCITECH, V8, DOI 10.1208/pt0802030; Paterson AL, 2007, GENE CHROMOSOME CANC, V46, P427, DOI 10.1002/gcc.20424; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Reis JS, 2006, CLIN CANCER RES, V12, P6652, DOI 10.1158/1078-0432.CCR-06-1164; Rodriguez C, 2004, CLIN CANCER RES, V10, P5785, DOI 10.1158/1078-0432.CCR-03-0410; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Tashiro E, 2003, CANCER RES, V63, P424; Wang B, 1997, ANTICANCER RES, V17, P4387; Willmarth NE, 2004, BREAST CANCER RES, V6, pR531, DOI 10.1186/bcr900; Xian W, 2005, J CELL BIOL, V171, P663, DOI 10.1083/jcb.200505098; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2007, INT J CANCER, V121, P1265, DOI 10.1002/ijc.22831; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013	46	80	82	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1892	1903		10.1038/onc.2009.34	http://dx.doi.org/10.1038/onc.2009.34			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330026	Green Accepted			2022-12-17	WOS:000265640600002
J	Nagarajan, P; Onami, TM; Rajagopalan, S; Kania, S; Donnell, R; Venkatachalam, S				Nagarajan, P.; Onami, T. M.; Rajagopalan, S.; Kania, S.; Donnell, R.; Venkatachalam, S.			Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis	ONCOGENE			English	Article						chromatin remodeling; lymphoma; hematopoiesis; mutant mice; tumor suppressor and DNA damage	CHROMATIN REMODELING FACTORS; HISTONE VARIANT EXCHANGE; TUMOR-SUPPRESSOR; CHD1; H2AX; H3; MUTATIONS; COMPLEX; CANCER; FAMILY	The chromodomain helicase DNA-binding proteins (CHDs) are known to affect transcription through their ability to remodel chromatin and modulate histone deacetylation. In an effort to understand the functional role of the CHD2 in mammals, we have generated a Chd2 mutant mouse model. Remarkably, the Chd2 protein appears to play a critical role in the development, hematopoiesis and tumor suppression. The Chd2 heterozygous mutant mice exhibit increased extramedullary hematopoiesis and susceptibility to lymphomas. At the cellular level, Chd2 mutants are defective in hematopoietic stem cell differentiation, accumulate higher levels of the chromatin-associated DNA damage response mediator, gamma H2AX, and exhibit an aberrant DNA damage response after X-ray irradiation. Our data suggest a direct role for the chromatin remodeling protein in DNA damage signaling and genome stability maintenance.	[Nagarajan, P.; Rajagopalan, S.; Venkatachalam, S.] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA; [Onami, T. M.] Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; [Kania, S.; Donnell, R.] Univ Tennessee, Dept Pathobiol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Venkatachalam, S (corresponding author), Univ Tennessee, Dept Biochem & Cell & Mol Biol, M407,Walters Life Sci Bldg, Knoxville, TN 37996 USA.	sundar@utk.edu	Kania, Stephen/ABF-6920-2021; NAGARAJAN, PRABAKARAN/AAA-2881-2020	NAGARAJAN, PRABAKARAN/0000-0001-6124-3274; Kania, Stephen/0000-0002-4490-7347; Donnell, Robert L./0000-0002-6778-954X	University of Tennessee; PMERF; NIH [00293621, AI05771901]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K22AI057719] Funding Source: NIH RePORTER	University of Tennessee; PMERF; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are thankful to Dr Bruce McKee for critically reading the manuscript. This work was supported by the University of Tennessee startup funds, PMERF seed funds, and NIH funds (00293621) to SV and funding from NIH (AI05771901) to TMO.	Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Banath JP, 2003, CANCER RES, V63, P4347; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Brehm A, 2000, EMBO J, V19, P4332, DOI 10.1093/emboj/19.16.4332; BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; Cowell IG, 1997, BBA-PROTEIN STRUCT M, V1337, P198, DOI 10.1016/S0167-4838(96)00165-3; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Feys T, 2007, HAEMATOL-HEMATOL J, V92, P40; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; Fukasawa M, 2006, CYTOGENET GENOME RES, V113, P138, DOI 10.1159/000090825; Gao XC, 2007, AM J HUM GENET, V80, P957, DOI 10.1086/513571; Gonzalez-Billault C, 2000, MOL CELL NEUROSCI, V16, P408, DOI 10.1006/mcne.2000.0880; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Heyworth C, 2002, EMBO J, V21, P3770, DOI 10.1093/emboj/cdf368; Iwasaki H, 2003, IMMUNITY, V19, P451, DOI 10.1016/S1074-7613(03)00242-5; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Jin JJ, 2005, TRENDS BIOCHEM SCI, V30, P680, DOI 10.1016/j.tibs.2005.10.003; Jones DO, 2000, BIOESSAYS, V22, P124, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;124::AID-BIES4&gt;3.0.CO;2-E; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; Kulkarni S, 2008, AM J MED GENET A, V146A, P1117, DOI 10.1002/ajmg.a.32178; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lalani SR, 2006, AM J HUM GENET, V78, P303, DOI 10.1086/500273; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Lusser A, 2005, NAT STRUCT MOL BIOL, V12, P160, DOI 10.1038/nsmb884; Marfella CGA, 2006, J CELL PHYSIOL, V209, P162, DOI 10.1002/jcp.20718; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Ney PA, 2006, CURR OPIN HEMATOL, V13, P203, DOI 10.1097/01.moh.0000231415.18333.2c; Osley MA, 2007, MUTAT RES-FUND MOL M, V618, P65, DOI 10.1016/j.mrfmmm.2006.07.011; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Schuster EF, 2002, MAMM GENOME, V13, P117, DOI 10.1007/s00335-001-3042-6; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Sims RJ, 2005, J BIOL CHEM, V280, P41789, DOI 10.1074/jbc.C500395200; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Takeda Yoshihiko, 2001, Frontiers in Bioscience, V6, pd1412, DOI 10.2741/Takeda; TARGOFF IN, 1985, ARTHRITIS RHEUM, V28, P796, DOI 10.1002/art.1780280711; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tran HG, 2000, EMBO J, V19, P2323, DOI 10.1093/emboj/19.10.2323; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vissers LELM, 2004, NAT GENET, V36, P955, DOI 10.1038/ng1407; Voss AK, 1998, DEV DYNAM, V212, P258; Wang GG, 2007, TRENDS MOL MED, V13, P373, DOI 10.1016/j.molmed.2007.07.004; Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003; Whiteford M L, 2000, J Med Genet, V37, pE11, DOI 10.1136/jmg.37.8.e11; WILSON GN, 1985, J MED GENET, V22, P233, DOI 10.1136/jmg.22.3.233; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang J, 2003, BLOOD, V102, P3938, DOI 10.1182/blood-2003-05-1479; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	64	80	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1053	1062		10.1038/onc.2008.440	http://dx.doi.org/10.1038/onc.2008.440			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137022	Green Accepted			2022-12-17	WOS:000263722900001
J	Kang, J; Rychahou, PG; Ishola, TA; Mourot, JM; Evers, BM; Chung, DH				Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H.			N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma	ONCOGENE			English	Article						angiogenesis; PI3K/Akt; MYCN; VEGF; neuroblastoma	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR; TUMOR ANGIOGENESIS; MAMMALIAN TARGET; DOWN-REGULATION; C-MYC; CELLS; AMPLIFICATION; INHIBITION; PROGRESSION	Angiogenesis in neuroblastoma (NB) correlates with increased expression of vascular endothelial growth factor (VEGF) and a worse clinical outcome. Other cellular markers, such as Akt activation and MYCN amplification, are also associated with poor prognosis in NB; therefore, we sought to determine the role of N-myc in the regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt/ VEGF pathway. PI3K inhibition, using small-molecule inhibitors or phosphatase and tensin homolog adenovirus, led to decreased levels of VEGF mRNA and/or protein by reducing phosphorylation of Akt and mammalian target of rapamycin (mTOR), and attenuating hypoxia-inducible factor 1 alpha expression. Moreover, PI3K inhibition decreased levels of N-myc expression in MYCN-amplified cells. To further clarify the importance of N-myc as a target of PI3K in VEGF regulation, we inhibited N-myc expression by siRNA transfection. MYCN siRNA significantly blocked VEGF secretion, irrespective of serum conditions, in MYCN-amplified NB cells; this effect was enhanced when combined with rapamycin, an mTOR inhibitor. Interestingly, in cells with low-N-myc expression, MYCN siRNA reduction of VEGF secretion was only effective with MYCN overexpression or insulin-like growth factor-1 stimulation. Our results show that N-myc plays an important role in the PI3K-mediated VEGF regulation in NB cells. Targeting MYCN, as a novel effector of PI3K-mediated angiogenesis, has significant potential for the treatment of highly vascularized, malignant NB.	[Kang, J.; Rychahou, P. G.; Ishola, T. A.; Mourot, J. M.; Evers, B. M.; Chung, D. H.] Univ Texas Med Branch, Dept Surg, Galveston, TX 77555 USA; [Chung, D. H.] Univ Texas Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Chung, DH (corresponding author), Univ Texas Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	dhchung@utmb.edu		Rychahou, Piotr/0000-0001-7352-9122	NATIONAL CANCER INSTITUTE [R01CA104748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498, P01DK035608, R01DK061470] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104748, R01 CA104748-04] Funding Source: Medline; NIDDK NIH HHS [R01 DK061470, P01 DK035608-210001, R01 DK061470-05, R01 DK61470, R01 DK48498, P01 DK035608, R01 DK048498, P01 DK35608, R01 DK048498-12, F31 DK079422] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beppu Y, 2005, CANCER RES, V65, P4775, DOI 10.1158/0008-5472.CAN-04-3332; Brodeur GM, 1990, BRAIN PATHOL, V1, P47, DOI 10.1111/j.1750-3639.1990.tb00638.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Fukuzawa M, 2002, J PEDIATR SURG, V37, P1747, DOI 10.1053/jpsu.2002.36712; Goodman LA, 1997, CLIN EXP METASTAS, V15, P130, DOI 10.1023/A:1018448710006; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hatzi E, 2000, ADV EXP MED BIOL, V476, P239; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Kang JH, 2006, BIOCHEM BIOPH RES CO, V351, P192, DOI 10.1016/j.bbrc.2006.10.020; Kang JH, 2007, CANCER LETT, V253, P273, DOI 10.1016/j.canlet.2007.02.007; Kang J, 2006, ANTICANCER RES, V26, P1903; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kurmasheva RT, 2007, MOL CANCER THER, V6, P1620, DOI 10.1158/1535-7163.MCT-06-0646; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Marimpietri D, 2005, ONCOGENE, V24, P6785, DOI 10.1038/sj.onc.1208829; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Nara K, 2007, INT J ONCOL, V30, P1189; Oikawa T, 1996, EUR J PHARMACOL, V318, P93, DOI 10.1016/S0014-2999(96)00864-3; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Pession A, 1997, J PATHOL, V183, P339; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; POWIS G, 1994, CANCER RES, V54, P2419; RASCHELLA G, 1991, CANCER LETT, V56, P45, DOI 10.1016/0304-3835(91)90192-K; Ribatti D, 2002, INT J CANCER, V102, P351, DOI 10.1002/ijc.10742; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; von Rahden BHA, 2006, NEOPLASIA, V8, P702, DOI 10.1593/neo.06277; ZAIZEN Y, 1993, J PEDIATR SURG, V28, P766, DOI 10.1016/0022-3468(93)90321-B	40	80	85	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	28					3999	4007		10.1038/onc.2008.15	http://dx.doi.org/10.1038/onc.2008.15			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18278068	Green Accepted			2022-12-17	WOS:000257089000011
J	Wu, L; Bernard-Trifilo, JA; Lim, Y; Lim, ST; Mitra, SK; Uryu, S; Chen, M; Pallen, CJ; Cheung, NKV; Mikolon, D; Mielgo, A; Stupack, DG; Schlaepfer, DD				Wu, L.; Bernard-Trifilo, J. A.; Lim, Y.; Lim, S-T; Mitra, S. K.; Uryu, S.; Chen, M.; Pallen, C. J.; Cheung, N-K V.; Mikolon, D.; Mielgo, A.; Stupack, D. G.; Schlaepfer, D. D.			Distinct FAK-Src activation events promote alpha 5 beta 1 and alpha 4 beta 1 integrin-stimulated neuroblastoma cell motility	ONCOGENE			English	Article						Src; FAK; alpha 4 integrin; alpha 5 integrin; motility; neuroblastoma	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; FIBRONECTIN MATRIX; MIGRATION; ALPHA; SUBUNIT; CANCER	Signals from. bronectin-binding integrins promote neural crest cell motility during development in part through protein-tyrosine kinase (PTK) activation. Neuroblastoma (NB) is a neural crest malignancy with high metastatic potential. We find that alpha 4 and alpha 5 integrins are present in late-stage NB tumors and cell lines derived thereof. To determine the signaling connections promoting either alpha 4 beta 1or alpha 5 beta 1-initiated NB cell motility, pharmacological, dominant negative and short-hairpin RNA (shRNA) inhibitory approaches were undertaken. shRNA knockdown revealed that alpha 5 beta 1-stimulated NB motility is dependent upon focal adhesion kinase (FAK) PTK, Src PTK and p130Cas adapter protein expression. Cell reconstitution showed that FAK catalytic activity is required for alpha 5 beta 1-stimulated Src activation in part through direct FAK phosphorylation of Src at Tyr-418. Alternatively, alpha 4 beta 1-stimulated NB cell motility is dependent upon Src and p130Cas but FAK is not essential. Catalytically inactive receptor protein-tyrosine phosphatase-alpha overexpression inhibited alpha 4 beta 1-stimulated NB motility and Src activation consistent with alpha 4-regulated Src activity occurringthr ough Src Tyr-529 dephosphorylation. In alpha 4 shRNA-expressingNB cells, alpha 4 beta 1-stimulated Src activation and NB cell motility were rescued by wild type but not cytoplasmic domain-truncated alpha 4 re-expression. These studies, supported by results using reconstituted fibroblasts, reveal that alpha 4 beta 1-mediated Src activation is mechanistically distinct from FAK-mediated Src activation during alpha 5 beta 1-mediated NB migration and support the evaluation of inhibitors to alpha 4, Src and FAK in the control of NB tumor progression.	[Wu, L.; Bernard-Trifilo, J. A.; Lim, Y.; Lim, S-T; Uryu, S.; Schlaepfer, D. D.] Scripps Res Inst, Dept Immunol, La Jolla, CA USA; [Chen, M.; Pallen, C. J.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; [Chen, M.; Pallen, C. J.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada; [Cheung, N-K V.] Mem Sloan Kettering Canc Ctr, Dept Pediat Oncol, New York, NY 10021 USA; [Mikolon, D.; Mielgo, A.; Stupack, D. G.] Moores UCSD Canc Ctr, Dept Pathol, La Jolla, CA 92093 USA	Scripps Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; Memorial Sloan Kettering Cancer Center	Schlaepfer, DD (corresponding author), Moores UCSD Canc Ctr, Dept Reprod Med, 0803 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	dschlaepfer@ucsd.edu	; mostafavi-pour, zohreh/T-5588-2018	Lim, Steve/0000-0003-0323-8607; Pallen, Catherine/0000-0002-3576-5295; mostafavi-pour, zohreh/0000-0002-3779-177X	NATIONAL CANCER INSTITUTE [R01CA075240, R01CA087038, P01CA106450, R01CA107263, R29CA075240, R01CA102310] Funding Source: NIH RePORTER; NCI NIH HHS [CA107263, CA75240, R01 CA102310, P01 CA106450, CA102310, R01 CA075240-11, CA87038, CA106450, R29 CA075240, R01 CA107263, R01 CA087038, R01 CA087038-05, R01 CA102310-06, R01 CA075240] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; Chen M, 2006, J BIOL CHEM, V281, P11972, DOI 10.1074/jbc.M600561200; Geng X, 2005, IMMUNOLOGY, V115, P347, DOI 10.1111/j.1365-2567.2005.02175.x; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Huttenlocher A, 2005, NAT CELL BIOL, V7, P336, DOI 10.1038/ncb0405-336; Ilic D, 2004, J CELL SCI, V117, P177, DOI 10.1242/jcs.00845; Kil SH, 1998, DEV BIOL, V202, P29, DOI 10.1006/dbio.1998.8985; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Na J, 2003, J CELL SCI, V116, P2333, DOI 10.1242/jcs.00445; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pinco KA, 2002, MOL BIOL CELL, V13, P3203, DOI 10.1091/mbc.02-05-0086; Rose DM, 2002, IMMUNOL REV, V186, P118, DOI 10.1034/j.1600-065X.2002.18611.x; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Testaz S, 2001, DEV DYNAM, V222, P127, DOI 10.1002/dvdy.1181; WU CY, 1995, J CELL SCI, V108, P821; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049	25	80	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1439	1448		10.1038/sj.onc.1210770	http://dx.doi.org/10.1038/sj.onc.1210770			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828307	Green Accepted			2022-12-17	WOS:000253548200011
J	Rodrigues, S; De Wever, O; Bruyneel, E; Rooney, RJ; Gespach, C				Rodrigues, S.; De Wever, O.; Bruyneel, E.; Rooney, R. J.; Gespach, C.			Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis	ONCOGENE			English	Article						adenosine A2B receptors; src; apoptosis; caspase-8; hypoxia; cDNA microarrays	NETRIN-1-MEDIATED AXON OUTGROWTH; UBIQUITIN-PROTEASOME PATHWAY; ADENOSINE A2B RECEPTOR; COLORECTAL-CANCER; ACTIVATION; ADHESION; KINASE; GENE; TUMORIGENESIS; EXPRESSION	Deleted in colon cancer (DCC) and UNC5 function as netrin dependence receptors by inducing apoptosis in the absence of their ligand and accordingly were recently designated as putative conditional tumor suppressors. Herein, we determined whether netrin-1 and its receptors are implicated in cancer cell invasion and tumor progression. Expression of DCC, UNC5 and adenosine A2B-receptors (A2B-Rs) was investigated by reverse transcription polymerase chain reaction in human colon cancer cells. The impact of DCC restitution and netrin-1 was evaluated on collagen type I invasion, tumor growth and metastasis in nude mice, cancer cell survival and gene expression pro. ling. Flow cytometry, poly(ADP-ribose)-polymerase-1 and caspase-8 activation were used to evaluate the impact of DCC on cell death. Both netrin-1 and A2B-R activation induced the invasive phenotype through the Rho-Rho kinase axis in DCC-deficient human colorectal cancer cells. Restitution of wild-type DCC blocked invasion induced by netrin-1, A2B-R agonist and other agents. Ectopic expression of netrin-1 led to increased growth of human colon tumor xenografts in athymic mice. Conversely, introduction of wt-DCC in kidney MDCKts. src-ggl cells strongly inhibited metastasis in lymph nodes and lungs and increased sensitivity to apoptosis in hypoxia. DNA microarrays revealed that netrin and DCC had common and divergent impacts on gene expression linked to cell cycle, survival, surface signaling and adhesion. Our findings underscore that netrin is a potent invasion and tumor growth-promoting agent and that DCC is a metastasis suppressor gene targeting both proinvasive and survival pathways in a cumulative manner.	INSERM, U673, F-75571 Paris 12, France; Univ Paris 06, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Genome Explorat Inc, Memphis, TN USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), INSERM, U673, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	de wever, olivier/J-3094-2013	de wever, olivier/0000-0002-5453-760X				Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Bouchard JF, 2004, J NEUROSCI, V24, P3040, DOI 10.1523/JNEUROSCI.4934-03.2004; Chen L, 2005, FEBS J, V272, P2746, DOI 10.1111/j.1742-4658.2005.04694.x; Corset V, 2000, NATURE, V407, P747, DOI 10.1038/35037600; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Grider JR, 2006, GASTROENTEROLOGY, V130, P771, DOI 10.1053/j.gastro.2005.12.026; Hebrok M, 2004, TRENDS CELL BIOL, V14, P153, DOI 10.1016/j.tcb.2004.02.005; Hill A, 2006, ONCOGENE, V25, P6079, DOI 10.1038/sj.onc.1209628; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Hucho TB, 2005, J NEUROSCI, V25, P6119, DOI 10.1523/JNEUROSCI.0285-05.2005; Kadono Y, 1998, CANCER RES, V58, P2240; Kim TH, 2005, J NEUROCHEM, V95, P1, DOI 10.1111/j.1471-4159.2005.03314.x; Kong TQ, 2006, FASEB J, V20, P2242, DOI 10.1096/fj.06-6419com; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Lahti JM, 2006, CANCER RES, V66, P5981, DOI 10.1158/0008-5472.CAN-06-0131; Linden J, 1999, MOL PHARMACOL, V56, P705; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Martin M, 2006, EUR J CELL BIOL, V85, P769, DOI 10.1016/j.ejcb.2006.02.013; Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; MIYAKI M, 1990, CANCER RES, V50, P7166; Miyamoto Y, 2006, P NATL ACAD SCI USA, V103, P10444, DOI 10.1073/pnas.0603914103; Nguyen QD, 2005, ONCOGENE, V24, P8240, DOI 10.1038/sj.onc.1208990; Nguyen QD, 2006, MOL CANCER THER, V5, P2070, DOI 10.1158/1535-7163.MCT-06-0044; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shekarabi M, 2002, MOL CELL NEUROSCI, V19, P1, DOI 10.1006/mcne.2001.1075; Tan EY, 2006, AM J PHYSIOL-CELL PH, V291, pC433, DOI 10.1152/ajpcell.00238.2005; Taniguchi Y, 2003, J BIOL CHEM, V278, P30425, DOI 10.1074/jbc.C300239200; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wilson BD, 2006, SCIENCE, V313, P640, DOI 10.1126/science.1124704; Xie Y, 2006, J BIOL CHEM, V281, P2605, DOI 10.1074/jbc.M512767200; Yebra M, 2003, DEV CELL, V5, P695, DOI 10.1016/S1534-5807(03)00330-7	40	80	90	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5615	5625		10.1038/sj.onc.1210347	http://dx.doi.org/10.1038/sj.onc.1210347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334389				2022-12-17	WOS:000248801900007
J	Fabre, C; Carvalho, G; Tasdemir, E; Braun, T; Ades, L; Grosjean, J; Boehrer, S; Metivier, D; Souquere, S; Pierron, G; Fenaux, P; Kroemer, G				Fabre, C.; Carvalho, G.; Tasdemir, E.; Braun, T.; Ades, L.; Grosjean, J.; Boehrer, S.; Metivier, D.; Souquere, S.; Pierron, G.; Fenaux, P.; Kroemer, G.			NF-kappa B inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; autophagy; caspases; chemotherapy; mitochondria	THERAPEUTIC TARGET; APOPTOSIS; AUTOPHAGY; CANCER; PATHWAY; LINE	CD34(+) bone marrow blasts from high-risk myelodysplastic syndrome (MDS) patients as well as MDS patient-derived cell lines (P39 and MOLM13) constitutively activate the nuclear factor-kappa B (NF-kappa B) pathway and undergo apoptosis when NF-kappa B is inhibited. Here, we show that the combination of conventional chemotherapeutic agents (daunorubicin, mitoxantrone, 5-azacytidine or camptothecin) with the NF-kappa B inhibitor BAY11-7082 did not yield a synergistic cytotoxicity. In contrast, BAY11-7082 (which targets the NF-kappa B-activating I-kappa B kinase (IKK) complex) or knockdown of essential components of the NF-kappa B system (such as the IKK1 and IKK2 subunits of the IKK complex and the p65 subunit of NF-kappa B), by small interfering RNAs sensitized MDS cell lines to starvation-induced apoptosis. The combination of BAY11-7082 and nutrient depletion synergistically killed the acute myeloid leukemia (AML) cell line U937 as well as primary CD34+ bone marrow blasts from AML and high-risk MDS patients. The synergistic killing by BAY11-7082, combined with nutrient depletion, led to cell death accompanied by all hallmarks of apoptosis, including an early loss of the mitochondrial transmembrane potential, the release of cytochrome c and apoptosis-inducing factor (AIF) from mitochondria, activation of caspase-3, phosphatidylserine exposure on the plasma membrane surface and nuclear chromatin condensation. Transmission electron microscopy revealed the presence of numerous autophagic vacuoles in the cytoplasm before cells underwent nuclear apoptosis. Nonetheless, cell death was neither inhibited by the pan-caspase inhibitor z-VAD-fmk nor by knockdown of AIF or of essential components of the autophagy pathway (ATG5, ATG6/ Beclin-1, ATG10, ATG12). In contrast, external supply of glucose, insulin or insulin-like growth factor-I could retard the cell death induced by BAY11-7082 combined with starvation. These results suggest that in MDS cells, NF-kappa B inhibition can precipitate a bioenergetic crisis that leads to an autophagic stress response followed by apoptotic cell death.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; INSERM, Unit Apoptosis Canc & Immun, F-94800 Villejuif, France; Univ Paris 11, Fac Paris Sud, F-94800 Villejuif, France; Univ Paris 11, Hop Paul Brousse, INSERM U542, F-94800 Villejuif, France; Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France; Inst Andre Lwoff, CNRS, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Ades, lionel/T-6882-2019; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Akdemir F, 2006, DEVELOPMENT, V133, P1457, DOI 10.1242/dev.02332; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; CARVALHO G, 2006, ONCOGENE        1016; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Dombret H, 2002, SEMIN HEMATOL, V39, P8, DOI 10.1053/shem.2002.33608; Engedal N, 2003, J BIOL CHEM, V278, P10934, DOI 10.1074/jbc.M211556200; Fenaux P, 2005, SEMIN ONCOL, V32, pS11, DOI 10.1053/j.seminoncol.2005.06.016; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Israel A, 2006, CELL DEATH DIFFER, V13, P685, DOI 10.1038/sj.cdd.4401891; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; NAGAI M, 1984, GANN, V75, P1100; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; Ribrag V, 2003, LEUKEMIA, V17, P319, DOI 10.1038/sj.leu.2402726; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Silverman Lewis R, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS12, DOI 10.1038/ncponc0347; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	36	80	92	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4071	4083		10.1038/sj.onc.1210187	http://dx.doi.org/10.1038/sj.onc.1210187			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213804				2022-12-17	WOS:000247252700003
J	Cosaceanu, D; Budiu, RA; Carapancea, M; Castro, J; Lewensohn, R; Dricu, A				Cosaceanu, D.; Budiu, R. A.; Carapancea, M.; Castro, J.; Lewensohn, R.; Dricu, A.			Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism	ONCOGENE			English	Article						insulin-like growth factor 1 receptor; ionizing radiation; p38 kinase; Ku86; lung cancer	GROWTH-FACTOR-I; HUMAN LUNG-CANCER; PROTEIN-KINASE; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC RADIOSENSITIVITY; SURVIVAL PATHWAY; CARCINOMA-CELLS; S6 KINASE; RECEPTOR	Ionizing radiation exposure results in the activation of several tyrosine kinase receptors that participate in radiation-induced DNA damage response and radioresistance. We previously showed that insulin-like growth factor 1 receptor (IGF-1R) inhibition enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) cells. In this paper, we demonstrate that in U1810 NSCLC cells gamma-radiation activates IGF-1R within 10 min, with a maximal activation effect 2 h post-irradiation. Impairment of IGF-1R tyrosine kinase activity enhances human lung cancer cells radiosensitivity by a mechanism that involves phosphatidylinositol 3-kinase (PI3-K) and p38 kinase. In an active form, IGF-1R binds and activates p38 kinase, promoting receptor signaling. Conversely, inhibition of IGF-1R phosphorylation results in IGF-1R/p38 complex disruption and p38 kinase inactivation. We have also demonstrated that in insulin-like growth factor-1-stimulated cells, Ku-DNA-binding activation is induced by ionizing radiation within 4 h, reaches a maximum level at 12 h and remains active up to 72 h. Blockade of IGF-1R activity or its downstream signaling through p38 kinase induces a decrease in radiation-mediated Ku-DNA-binding activation and downregulates the level of Ku86, without affecting Ku70 expression in the nucleus of U1810 cells. The IGF-1R signaling via PI3-K does not interfere with the p38 signaling, the Ku-DNA-binding activity or the level of Ku86. Our present study demonstrates for the first time that ionizing radiation activates IGF-1R. Inhibition of IGF-1R signaling via p38 kinase induces radiosensitivity by a novel mechanism involving nuclear Ku86.	Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Radiumhemmet Karolinska Inst Hosp, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Dricu, A (corresponding author), Canc Ctr Karolinska, Dept Oncol Pathol, R8-00, S-17176 Stockholm, Sweden.	anica.dricu@ki.se						Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; Bostedt KT, 2001, EXP CELL RES, V271, P368, DOI 10.1006/excr.2001.5388; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bredin CG, 1999, INT J CANCER, V82, P338, DOI 10.1002/(SICI)1097-0215(19990730)82:3<338::AID-IJC6>3.0.CO;2-Y; BRODIN O, 1991, ACTA ONCOL, V30, P967, DOI 10.3109/02841869109088251; CARNEY DN, 1983, CANCER RES, V43, P2806; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Cosaceanu D, 2005, CANCER LETT, V222, P173, DOI 10.1016/j.canlet.2004.10.002; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; Dricu A, 1997, CANCER RES, V57, P543; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fegley AJ, 2003, J SURG RES, V113, P32, DOI 10.1016/S0022-4804(03)00120-3; GIRINSKY T, 1993, INT J RADIAT ONCOL, V25, P3, DOI 10.1016/0360-3016(93)90137-K; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Griffin RJ, 2002, CANCER RES, V62, P1702; Gupta AK, 2004, LUNG, V182, P151, DOI 10.1007/S00408/004/0310-8; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Jung, 1996, Semin Radiat Oncol, V6, P268, DOI 10.1016/S1053-4296(96)80022-1; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; Mazzarelli P, 2003, J INVEST DERMATOL, V121, P628, DOI 10.1046/j.1523-1747.2003.12416.x; Park SJ, 2004, J BIOL CHEM, V279, P6046, DOI 10.1074/jbc.M311054200; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Reiss K, 2006, J CELL PHYSIOL, V206, P295, DOI 10.1002/jcp.20455; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shahrabani-Gargir L, 2004, ENDOCRINOLOGY, V145, P5679, DOI 10.1210/en.2004-0613; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimizu T, 1999, EXP CELL RES, V251, P424, DOI 10.1006/excr.1999.4582; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; SODERDAHL G, 1988, INT J CANCER, V41, P636, DOI 10.1002/ijc.2910410426; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wan YS, 2001, INT J ONCOL, V18, P461; Watanabe H, 2004, INT J RADIAT BIOL, V80, P451, DOI 10.1080/09553000410001702355; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; Yamagishi S, 2003, MOL BRAIN RES, V119, P184, DOI 10.1016/j.molbrainres.2003.09.009; Yu D, 2003, BIOCHEM BIOPH RES CO, V311, P174, DOI 10.1016/j.bbrc.2003.09.195; Yu D, 2002, J RADIAT RES, V43, P325, DOI 10.1269/jrr.43.325; Zingg D, 2004, CANCER RES, V64, P5398, DOI 10.1158/0008-5472.CAN-03-3369	53	80	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2423	2434		10.1038/sj.onc.1210037	http://dx.doi.org/10.1038/sj.onc.1210037			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043647				2022-12-17	WOS:000245831000003
J	Oloumi, A; Syam, S; Dedhar, S				Oloumi, A.; Syam, S.; Dedhar, S.			Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells	ONCOGENE			English	Article						integrin-linked kinase; nuclear beta-catenin; Wnt; signal transduction	GLYCOGEN-SYNTHASE KINASE; AP-1 TRANSCRIPTION FACTOR; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; THERAPEUTIC TARGET; WNT PATHWAY; PROTEIN; ADHESION; CANCER	The Wnt gene family encodes secreted signaling molecules that play important roles in tumorgenesis and embryogenesis. The canonical Wnt signaling pathway regulates target gene expression via the stabilization and nuclear translocation of the cytoplasmic pool of beta-catenin. The activation of integrin-linked kinase (ILK) is also known to regulate the stabilization and subsequent nuclear translocation of beta-catenin in several epithelial cell models. We now report that molecular and pharmacological inhibition of ILK activity in mammalian cells directly modulates Wnt signaling by suppressing the stabilization and nuclear translocation of beta-catenin, as well as beta-catenin/Lef-mediated transcription. Inhibition of ILK activity, but not phosphatidylinositol-3 kinase (PI3K) or MEK activities suppresses nuclear beta-catenin stabilization in cells stably expressing Wnt3a as well as in cells exposed to either Wnt3a conditioned media or purified Wnt3a. Furthermore, ILK inhibition reverses the Wnt3a-induced suppression of beta- catenin phosphorylation that accompanies beta-catenin stabilization. In addition, we show that ILK can be identified in a complex with Wnt pathway components such as adenomatous polyposis coli and GSK-3. Upon treatment of L cells with Wnt3a-CM, glycogen synthase kinase-3 (GSK-3b) becomes highly phosphorylated on Ser 9, which is completely abolished upon inhibition of ILK activity. However, acute exposure of L cells to purified Wnt3a does not result in the stimulation of GSK-3b Ser 9 phosphorylation, despite beta-catenin stabilization. Together our data demonstrate that ILK activity can modulate acute Wnt3a mediated b- catenin phosphorylation, stabilization and nuclear activation in a PI3K-independent manner, as well as the more prolonged PI3K-dependent secondary effects of Wnt signaling on GSK-3 phosphorylation. Finally, we suggest that a novel small molecule inhibitor of ILK, QLT-0267, may be a useful tool in the regulation of pathological Wnt signaling.	British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of British Columbia	Dedhar, S (corresponding author), Univ British Columbia, British Columbia Canc Res Ctr, Dept Biochem, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca		Dedhar, Shoukat/0000-0003-4355-1657				Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Erdodi F, 2003, BIOCHEM BIOPH RES CO, V306, P382, DOI 10.1016/S0006-291X(03)00976-8; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Kang UG, 2004, FEBS LETT, V560, P115, DOI 10.1016/S0014-5793(04)00082-1; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mills J, 2003, J NEUROSCI, V23, P1638; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pevarello P, 2004, J MED CHEM, V47, P3367, DOI 10.1021/jm031145u; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shibamoto S, 1998, GENES CELLS, V3, P659; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yasunaga T, 2005, GENES CELLS, V10, P369, DOI 10.1111/j.1365-2443.2005.00841.x; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	61	80	81	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7747	7757		10.1038/sj.onc.1209752	http://dx.doi.org/10.1038/sj.onc.1209752			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799642				2022-12-17	WOS:000242830800009
J	Pramoonjago, P; Baras, AS; Moskaluk, CA				Pramoonjago, P.; Baras, A. S.; Moskaluk, C. A.			Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells	ONCOGENE			English	Article						adenoid cystic carcinoma; Sox4; RNAi; apoptosis	ADENOID CYSTIC CARCINOMA; TRANSCRIPTIONAL PROFILES; CANCER; GENE; PROTEINS; DEATH; MICE; IDENTIFICATION; ACTIVATION; PATHWAY	Microarray RNA gene expression pro. ling analysis has shown that Sox4 (Sry-related high mobility group (HMG) box 4) is one of the most upregulated genes in adenoid cystic carcinoma (ACC), relative to non-neoplastic tissue of origin. Here, we show that Sox4 protein is similarly upregulated in ACC by immunohistochemistry of 28 primary cancers and 20 normal tissues. To elucidate the functional significance of these findings, RNA interference (RNAi)-mediated RNA silencing was used to down-regulate Sox4 expression in the ACC-derived cell line, ACC3. With confirmed knockdown of Sox4 protein, cell viability was reduced by 51%, with a corresponding increase of apoptosis to 85% as compared to 12% in controls. Apoptosis was confirmed by cell morphology, DNA fragmentation and flow cytometry. Cells could be rescued from the proapoptotic effects of Sox4 RNAi by co-transfection with a construct expressing functional Sox4. Microarray gene expression pro. ling of RNAi knockdown experiments shows that downregulation of Sox4-modulated expression of critical genes involved in apoptosis and cell cycle control. Overall, our findings suggest that Sox4 contributes to the malignant phenotype of ACC cells by promoting cell survival.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, POB 800214, Charlottesville, VA 22908 USA.	cam5p@virginia.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE-14694] Funding Source: Medline; NIGMS NIH HHS [T32 GM007267] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHENG J, 1995, VIRCHOWS ARCH, V426, P577; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; HE RG, 1988, W CHIN J STOMATOL, V6, P1; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kan LX, 2004, DEV BIOL, V269, P580, DOI 10.1016/j.ydbio.2004.02.005; Kimura S, 1999, J BIOCHEM-TOKYO, V125, P406, DOI 10.1093/oxfordjournals.jbchem.a022301; Lu HF, 2004, FOOD CHEM TOXICOL, V42, P1543, DOI 10.1016/j.fct.2003.06.001; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; McCracken S, 1997, ONCOGENE, V15, P2929, DOI 10.1038/sj.onc.1201474; McEleny K, 2004, BJU INT, V94, P402, DOI 10.1111/j.1464-410X.2004.04936.x; Munakata R, 1996, J ORAL PATHOL MED, V25, P441, DOI 10.1111/j.1600-0714.1996.tb00294.x; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Reichling T, 2005, CANCER RES, V65, P166; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schmahl J, 2000, DEVELOPMENT, V127, P65; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Sowter HM, 2001, CANCER RES, V61, P6669; Su AI, 2001, CANCER RES, V61, P7388; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tamm I, 1998, CANCER RES, V58, P5315; Van Huffel S, 2001, J BIOL CHEM, V276, P30216, DOI 10.1074/jbc.M100048200; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vander Poorten VLM, 1999, CANCER, V85, P2255, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2255::AID-CNCR22>3.3.CO;2-4; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Welsh JB, 2001, CANCER RES, V61, P5974; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794	40	80	85	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5626	5639		10.1038/sj.onc.1209566	http://dx.doi.org/10.1038/sj.onc.1209566			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636670				2022-12-17	WOS:000240599100004
J	Arnesen, T; Gromyko, D; Pendino, F; Ryningen, A; Varhaug, J; Lillehaug, J				Arnesen, T.; Gromyko, D.; Pendino, F.; Ryningen, A.; Varhaug, J. E.; Lillehaug, J. R.			Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex	ONCOGENE			English	Article						apoptosis; NATH; hARD1; protein N-acetylation; siRNA; daunorubicin	TERMINAL ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; ARD1 GENE; IDENTIFICATION; ACETYLATION; YEAST; DESTABILIZATION; HIF-1-ALPHA; EXPRESSION; HYPOXIA	Protein N-epsilon-acetylation is recognized as an important modi. cation influencing many biological processes, and protein deacetylase inhibitors leading to N-epsilon-hyperacetylation of histones are being clinically tested for their potential as anticancer drugs. In contrast to N-epsilon-acetyltransferases, the N-alpha-acetyltransferases transferring acetyl groups to the alpha-amino groups of protein N-termini have only been briefly described in mammalians. Human arrest defective 1(hARD1), the only described human enzyme in this class, complexes with N-acetyltransferase human (NATH) and cotranslationally transfers acetyl groups to the N-termini of nascent polypeptides. Here, we demonstrate that knockdown of NATH and/or hARD1 triggers apoptosis in human cell lines. Knockdown of hARD1 also sensitized cells to daunorubicin-induced apoptosis, potentially pointing at the NATH-hARD1 acetyltransferase complex as a novel target for chemotherapy. Our results argue for an essential role of the NATH-hARD1 complex in cell survival and underscore the importance of protein N-alpha-acetylation in mammalian cells.	Univ Bergen, Dept Mol Biol, Bergen High Technol Ctr, N-5020 Bergen, Norway; Univ Bergen, Dept Surg Sci, N-5020 Bergen, Norway; Haukeland Univ Hosp, Dept Med, N-5021 Bergen, Norway	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital	Arnesen, T (corresponding author), Univ Bergen, Dept Mol Biol, Bergen High Technol Ctr, Thormohlensgate 55, N-5020 Bergen, Norway.	thomas.arnesen@mbi.uib.no	Arnesen, Thomas/Q-8117-2019; PENDINO, Frederic/G-6630-2017; Arnesen, Thomas/J-7139-2017	Arnesen, Thomas/0000-0002-3005-147X; Arnesen, Thomas/0000-0002-3005-147X				Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Arnesen T, 2005, THYROID, V15, P1131, DOI 10.1089/thy.2005.15.1131; Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Di Gennaro E, 2004, AMINO ACIDS, V26, P435, DOI 10.1007/s00726-004-0087-3; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Harborth J, 2001, J CELL SCI, V114, P4557; Ingram AK, 2000, MOL BIOCHEM PARASIT, V111, P309, DOI 10.1016/S0166-6851(00)00322-4; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; LEE FJS, 1989, J BACTERIOL, V171, P5795, DOI 10.1128/jb.171.11.5795-5802.1989; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2003, BIOCHEM BIOPH RES CO, V308, P1, DOI 10.1016/S0006-291X(03)01316-0; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Ryningen A, 2005, LEUKEMIA RES, V29, P185, DOI 10.1016/j.leukres.2004.06.008; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Sowter HM, 2001, CANCER RES, V61, P6669; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3	27	80	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4350	4360		10.1038/sj.onc.1209469	http://dx.doi.org/10.1038/sj.onc.1209469			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518407				2022-12-17	WOS:000239240100010
J	Cao, X; Qin, J; Xie, Y; Khan, O; Dowd, F; Scofield, M; Lin, MF; Tu, Y				Cao, X.; Qin, J.; Xie, Y.; Khan, O.; Dowd, F.; Scofield, M.; Lin, M-F; Tu, Y.			Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells	ONCOGENE			English	Article						RGS2; GPCRs; extracellular signal-regulated; kinases; prostate cancer; androgen receptor; androgen independence	PROTEIN-COUPLED RECEPTOR; LOOP-HELIX PHOSPHOPROTEIN; MESSENGER-RNA; NERVOUS-SYSTEM; ALPHA SUBUNITS; SIGNALING RGS; TARGET GENE; LNCAP CELLS; MAP KINASE; EXPRESSION	Hormones acting through G protein-coupled receptors ( GPCRs) can cause androgen-independent activation of androgen receptor ( AR) in prostate cancer cells. Regulators of G-protein signaling ( RGS) proteins, through their GTPase activating protein ( GAP) activities, inhibit GPCR-mediated signaling by inactivating G proteins. Here, we identified RGS2 as a gene specifically downregulated in androgen-independent prostate cancer cells. Expression of RGS2, but not other RGS proteins, abolished androgen-independent AR activity in androgen-independent LNCaP cells and CWR22Rv1 cells. In LNCaP cells, RGS2 inhibited G(q)-coupled GPCR signaling. Expression of exogenous wild-type RGS2, but not its GAP-deficient mutant, significantly reduced AR activation by constitutively activated G(q)Q209L mutant whereas silencing endogenous RGS2 by siRNA enhanced G(q)Q209L-stimulated AR activity. RGS2 had no effect on RGS-insensitive G(q)Q209L/G188S-induced AR activation. Furthermore, extracellular signal-regulated kinase 1/2 ( ERK1/2) was found to be involved in RGS2-mediated regulation of androgen-independent AR activity. In addition, RGS2 functioned as a growth suppressor for androgen-independent LNCaP cells whereas androgen-sensitive LNCaP cells with RGS2 silencing had a growth advantage under steroid-reduced conditions. Finally, RGS2 expression level was significantly decreased in human prostate tumor specimens. Taken together, our results suggest RGS2 as a novel regulator of AR signaling and its repression may be an important step during prostate tumorigenesis and progression.	Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA; Univ Nebraska, Ctr Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	Creighton University; University of Nebraska System	Tu, Y (corresponding author), Creighton Univ, Sch Med, Dept Pharmacol, 2500 Calif Pl, Omaha, NE 68178 USA.	Yat60399@creighton.edu		Khan, Obaid/0000-0002-5596-2122; Scofield, Margaret/0000-0002-9332-1641	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline; NCRR NIH HHS [P20 RR018759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrahamsson PA, 1999, ENDOCR-RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503; Bakin RE, 2003, CANCER RES, V63, P1981; Ben-Josef E, 1999, J UROLOGY, V161, P970, DOI 10.1016/S0022-5347(01)61831-7; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Burchett SA, 1999, J NEUROCHEM, V72, P1529, DOI 10.1046/j.1471-4159.1999.721529.x; Candas B, 2000, PROSTATE, V45, P19; Chay CH, 2002, UROLOGY, V60, P760, DOI 10.1016/S0090-4295(02)01969-6; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cunningham JM, 1996, CANCER RES, V56, P4475; DAAKA Y, 2004, SCI STKE, V216, P2; Dai J, 2002, CLIN CANCER RES, V8, P2399; Denmeade SR, 2003, PROSTATE, V54, P249, DOI 10.1002/pros.10199; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Gioeli D, 1999, CANCER RES, V59, P279; Gohji K, 2001, J UROLOGY, V165, P1033, DOI 10.1016/S0022-5347(05)66597-4; Grillet N, 2003, J NEUROSCI, V23, P10613; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; GUTKIND JS, 2000, SCI STKE, V40, P1; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Hains MD, 2004, METHOD ENZYMOL, V389, P71; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Hobisch A, 1996, PROSTATE, V28, P129; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Ingi T, 1998, J NEUROSCI, V18, P7178; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Karan D, 2001, CLIN CANCER RES, V7, P3472; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Kehrl JH, 2002, INT J BIOCHEM CELL B, V34, P432, DOI 10.1016/S1357-2725(01)00141-8; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; Lee YF, 2002, CANCER RES, V62, P6039; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Nelson JB, 1996, CANCER RES, V56, P663; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Robinet EA, 2001, NEUROREPORT, V12, P1731, DOI 10.1097/00001756-200106130-00043; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Roy AA, 2003, MOL PHARMACOL, V64, P587, DOI 10.1124/mol.64.3.587; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schwable J, 2005, BLOOD, V105, P2107, DOI 10.1182/blood-2004-03-0940; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Taub JS, 2003, CANCER RES, V63, P2037; Tepper CG, 2002, CANCER RES, V62, P6606; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; Tovey SC, 2004, MOL PHARMACOL, V66, P1453, DOI 10.1124/mol.104.005827; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; Weng JS, 2005, INT J CANCER, V113, P811, DOI 10.1002/ijc.20635; Wieland T, 2003, PHARMACOL THERAPEUT, V97, P95, DOI 10.1016/S0163-7258(02)00326-1; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU HK, 1995, LEUKEMIA, V9, P1291; Xia CZ, 2001, ONCOGENE, V20, P5903, DOI 10.1038/sj.onc.1204803; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu LL, 2000, CANCER RES, V60, P6568; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	78	80	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3719	3734		10.1038/sj.onc.1209408	http://dx.doi.org/10.1038/sj.onc.1209408			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449965				2022-12-17	WOS:000238448300011
J	Li, DWC; Liu, JP; Schmid, PC; Schlosser, R; Feng, H; Liu, WB; Yan, Q; Gong, L; Sun, SM; Deng, M; Liu, Y				Li, D. W-C; Liu, J-P; Schmid, P. C.; Schlosser, R.; Feng, H.; Liu, W-B; Yan, Q.; Gong, L.; Sun, S-M; Deng, M.; Liu, Y.			Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities	ONCOGENE			English	Review						p53; PP-1; dephosphorylation; apoptosis; RNAi; phosphorylation and signal transduction	TUMOR-SUPPRESSOR P53; EPITHELIAL-CELL APOPTOSIS; DAMAGE-INDUCED PHOSPHORYLATION; JUN NH2-TERMINAL KINASE; DNA-BINDING FUNCTION; ALPHA-B-CRYSTALLIN; LARGE-T-ANTIGEN; OKADAIC ACID; P53-DEPENDENT APOPTOSIS; IN-VITRO	We have previously demonstrated that the serine/threonine protein phosphatase-1 (PP-1) plays an important role in promoting cell survival. However, the molecular mechanisms by which PP-1 promotes survival remain largely unknown. In the present study, we provide evidence to show that PP-1 can directly dephosphorylate a master regulator of apoptosis, p53, to negatively modulate its transcriptional and apoptotic activities, and thus to promote cell survival. As a transcriptional factor, the function of p53 can be greatly regulated by phosphorylation and dephosphorylation. While the kinases responsible for phosphorylation of the 17 serine/threonine sites have been identified, the dephosphorylation of these sites remains largely unknown. In the present study, we demonstrate that PP-1 can dephosphorylate p53 at Ser-15 and Ser-37 through co-immunoprecipitation, in vitro and in vivo dephosphorylation assays, overexpression and silence of the gene encoding the catalytic subunit for PP-1. We further show that mutations mimicking constitutive dephosphorylation or phosphorylation of p53 at these sites attenuate or enhance its transcriptional activity, respectively. As a result of the changed p53 activity, expression of the downstream apoptosis-related genes such as bcl-2 and bax is accordingly altered and the apoptotic events are either largely abrogated or enhanced. Thus, our results demonstrate that PP-1 directly dephosphorylates p53, and dephosphorylation of p53 has as important impact on its functions as phosphorylation does. In addition, our results reveal that one of the molecular mechanisms by which PP-1 promotes cell survival is to dephosphorylate p53, and thus negatively regulate p53-dependent death pathway.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China	University of Minnesota System; Hunan Normal University	Li, DWC (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	dwli1688@hotmail.com	Gong, Lili/F-8452-2014; Yan, Qin/F-5161-2012; Yan, Qin/K-3539-2013; Deng, Mi/K-8699-2012; Li, David/AAN-9205-2021	Gong, Lili/0000-0002-6533-5333; Yan, Qin/0000-0002-6344-6398; Deng, Mi/0000-0003-4291-0144; 	NEI NIH HHS [EY15765, R01 EY015765] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY015765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bastians H, 1996, J CELL SCI, V109, P2865; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; DEPAOLIROACH AA, 2003, HDB CELLULAR SIGNALI, V1, P613; Dohoney KM, 2004, ONCOGENE, V23, P49, DOI 10.1038/sj.onc.1207005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; FernandezSanchez MT, 1996, FEBS LETT, V398, P106, DOI 10.1016/S0014-5793(96)01192-1; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haneda M, 2004, FEBS LETT, V567, P171, DOI 10.1016/j.febslet.2004.04.066; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; KAIGHN ME, 1979, INVEST UROL, V17, P16; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LASSUS P, 2002, SCI STKE, V147, pPL13; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010; Li DWC, 2003, INVEST OPHTH VIS SCI, V44, P5277, DOI 10.1167/iovs.03-0348; Li DWC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; LI DWC, 2004, INVEST OPHTHALMOL  S, V45, pE401; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Li WC, 1996, FREE RADICAL BIO MED, V20, P301, DOI 10.1016/0891-5849(96)02050-3; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Long X, 2002, APOPTOSIS, V7, P31, DOI 10.1023/A:1013508811252; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Manfredi JJ, 2003, MOL CELL, V11, P552, DOI 10.1016/S1097-2765(03)00106-0; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MELLGREN G, 1993, EXP CELL RES, V205, P293, DOI 10.1006/excr.1993.1089; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; NEVINS JR, 1992, SCIENCE, V258, P424; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; PARK IK, 1994, J BIOL CHEM, V269, P944; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WALTER G, 2003, HDB CELL SIGNALING, V1, P621; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390; Wen-Schaub LB, 1995, MOL CELL BIOL, V15, P3032; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	133	80	87	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3006	3022		10.1038/sj.onc.1209334	http://dx.doi.org/10.1038/sj.onc.1209334			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16501611	Bronze			2022-12-17	WOS:000237950800005
J	Umetani, N; Mori, T; Koyanagi, K; Shinozaki, M; Kim, J; Giuliano, AE; Hoon, DSB				Umetani, N; Mori, T; Koyanagi, K; Shinozaki, M; Kim, J; Giuliano, AE; Hoon, DSB			Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer	ONCOGENE			English	Article						ID4; breast cancer; hypermethylation; lymph node metastasis	EPIGENETIC INACTIVATION; DNA METHYLATION; CUTANEOUS MELANOMA; EXPRESSION; PROTEINS; CELLS; DIFFERENTIATION; CARCINOMA; DISEASE; ID-1	ID4 gene is a member of the inhibitor of DNA-binding ( ID) family, which inhibits DNA binding of basic helix loop-helix transcription factors. Certain human primary breast cancers reportedly have low or no expression of ID4 protein, but its role in carcinogenesis and cancer progression is unknown. To determine its possible role, we examined epigenetic inactivation of ID4 gene by promoter hypermethylation in human breast cell lines and T1 breast cancer tissues. Methylation status of ID4 promoter CpG island was assessed by methylation-specific PCR (MSP); ID4 mRNA level was assessed by quantitative real-time RT-PCR. Of eight cell lines, two were fully methylated, four were partially methylated, and two were not methylated. ID4 mRNA level was suppressed in fully methylated cell lines. ID4 hypermethylation was observed in 16 of 24 (67%) node- positive and seven of 36 (19%) node- negative T1 primary breast cancers matched by patient age and tumor diameter. It was a significant risk factor for nodal metastasis (OR 13.1, P = 0.0004). ID4 mRNA level was suppressed in hypermethylated cancer specimens (P = 0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis.	John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; John Wayne Canc Inst, Joyce Eisenberg Keefer Breast Ctr, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683				Barth A, 1997, CANCER-AM CANCER SOC, V79, P1918, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Brenin DR, 2001, ANN SURG ONCOL, V8, P432, DOI 10.1245/aso.2001.8.5.432; Carter BA, 2000, AM J CLIN PATHOL, V113, P259, DOI 10.1309/7EF8-F1W7-YVNT-H8H5; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FISHER ER, 1984, CANCER-AM CANCER SOC, V54, P3002, DOI 10.1002/1097-0142(19841215)54:12<3002::AID-CNCR2820541231>3.0.CO;2-V; FISHER ER, 1993, CANCER, V71, P2507, DOI 10.1002/1097-0142(19930415)71:8<2507::AID-CNCR2820710813>3.0.CO;2-0; Fitzgibbons PL, 2000, ARCH PATHOL LAB MED, V124, P966; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Holland PA, 1996, BRIT J CANCER, V74, P1643, DOI 10.1038/bjc.1996.602; Hoon DSB, 2004, ONCOGENE, V23, P4014, DOI 10.1038/sj.onc.1207505; Itahana Y, 2003, CANCER RES, V63, P7098; Jen Y, 1996, DEV DYNAM, V207, P235; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7; Lin CQ, 2000, CANCER RES, V60, P1332; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Moore KH, 2004, CANCER-AM CANCER SOC, V100, P929, DOI 10.1002/cncr.20035; PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; Shan L, 2003, AM J PATHOL, V163, P2495, DOI 10.1016/S0002-9440(10)63604-8; Singh J, 2002, ONCOGENE, V21, P1812, DOI 10.1038/sj.onc.1205252; Spugnardi M, 2003, CANCER RES, V63, P1639; Takeuchi H, 2003, CANCER RES, V63, P441; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689; Umetani N, 2004, ONCOGENE, V23, P8292, DOI 10.1038/sj.onc.1208022; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	36	80	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4721	4727		10.1038/sj.onc.1208538	http://dx.doi.org/10.1038/sj.onc.1208538			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897910				2022-12-17	WOS:000230304500010
J	Xiao, Z; Xue, J; Sowin, TJ; Rosenberg, SH; Zhang, HY				Xiao, Z; Xue, J; Sowin, TJ; Rosenberg, SH; Zhang, HY			A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation	ONCOGENE			English	Article						5-fluorouracil (5-FU); antimetabolites; phospho-histone H2A.X; Chk1; premature chromosomal condensation (PCC); mitotic catastrophe	DNA-DAMAGE CHECKPOINT; INDUCED CELL-DEATH; TUMOR-CELLS; NUCLEOSIDE ANALOGS; APOPTOSIS; SURVIVAL; PATHWAY; 5-FLUOROURACIL; INHIBITION; PROTEASE	Chk1 is the major mediator in the activation of cell-cycle checkpoints in response to a variety of genotoxic stresses. We have previously shown that inhibition of Chkl sensitizes tumor cells to topoisomerase inhibitors such as camptothecin and doxorubicin through abrogation of cell-cycle arrest (S or G2/M checkpoints). However, it was not clear whether inhibition of Chkl could potentiate antimetabolites, a mainstay of cancer therapy, which confer genotoxic stress through a different mechanism than topoisomerase inhibitors. 5-Fluorouracil (5-FU) is the most widely used antimetabolite in the treatment of colorectal, breast and other major types of cancers. Here we demonstrate that 5-FU activates Chk1 and induces an early S-phase arrest. Chk1 downregulation abrogates this arrest and dramatically sensitizes tumor cells to the cytotoxic effects of 5-FU. 5-FU confers S-phase arrest through Chk1-mediated Cdc25A proteolysis leading to inhibition of Cdk2. Chkl elimination stabilizes the Cdc25A protein and results in the abrogation of the S checkpoint and resumption of DNA synthesis, which leads to excessive accumulation of double-stranded DNA breaks. As a result, downregulation of Chk1 potentiates 5-FU efficacy through induction of premature chromosomal condensation followed by apoptosis. Interestingly, the profiles of various cell-cycle markers indicate that cells progress to early M phase to induce apoptosis after checkpoint abrogation. Yet, cells fail to increase their DNA content to 4N as revealed by FACS analysis, probably due to the dramatic induction of double-stranded DNA breaks and chromosomal fragmentation. This is significantly different from the cell-cycle profiles observed in the potentiation of topoisomerase inhibitors by Chk1 siRNA, which showed mitotic progression with 4N DNA content leading to mitotic catastrophe after abrogation of the S or G2 checkpoint. Thus, our results illustrate a novel mode of checkpoint abrogation and cell death conferred by Chk1 inhibition. Additionally, we show that Chkl deficiency potentiates 5-FU efficacy through the preferential induction of the caspase-8 pathway and subsequent caspase-3 activation. In conclusion, we have clearly demonstrated that inhibition of Chk1 not only potentiates the toxicity of conventional DNA-damaging agents such as ionizing radiation and topoisomerase inhibitors, but also enhances the toxicity of antimetabolites in cancer cell lines. This discovery reveals novel scope of checkpoint abrogation and will significantly broaden the potential application of Chk1 inhibitors in cancer therapy if they do not potentiate the toxicity of 5-FU in normal cells. Published online 20 December 2004.	Abbott Labs, Canc Res, N Chicago, IL 60064 USA	Abbott Laboratories	Zhang, HY (corresponding author), Abbott Labs, Canc Res, 100 Abbott Pk Rd, N Chicago, IL 60064 USA.	zhan.xiao@abbott.com						Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen ZH, 2003, MOL CANCER THER, V2, P543; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Eastman A, 2002, MOL CANCER THER, V1, P1067; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Johnston PG, 2001, ANTI-CANCER DRUG, V12, P639, DOI 10.1097/00001813-200109000-00001; Koniaras K, 2001, ONCOGENE, V20, P7453, DOI 10.1038/sj.onc.1204942; Liu QH, 2000, GENE DEV, V14, P1448; Lock RB, 1996, CANCER RES, V56, P4006; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwartzberg LS, 2002, CLIN CANCER RES, V8, P2488; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Shi Z, 2001, CANCER RES, V61, P1065; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Torres K, 1998, CANCER RES, V58, P3620; TOUNEKTI O, 1993, CANCER RES, V53, P5462; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	29	80	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1403	1411		10.1038/sj.onc.1208309	http://dx.doi.org/10.1038/sj.onc.1208309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608676				2022-12-17	WOS:000227092600010
J	Blanc, E; Le Roux, G; Benard, J; Raguenez, G				Blanc, E; Le Roux, G; Benard, J; Raguenez, G			Low expression of Wnt-5a gene is associated with high-risk neuroblastoma	ONCOGENE			English	Article						Wnt-5a; metastatic neuroblastoma; retinoic acid; differentiation	KINASE-C-THETA; NEURAL CREST; NEURONAL DIFFERENTIATION; RETINOIC ACID; GROWTH-FACTOR; LUNG-CANCER; CELLS; PROTEIN; SHAPE; OVEREXPRESSION	Disseminated forms of neuroblastoma (NB), a tumor derived from neuroectodermal tissue, pose a major therapeutic challenge for pediatric oncology. By performing a comparative cDNA array analysis of metastatic neuroblasts versus primary xenograft from the human IGR-N-91 NB model, we were able to identify a set of downregulated developmental genes in metastatic neuroblasts. One of these genes was Wnt-5a, a member of the Wnt signaling pathway, known to be involved in the development of neural crest cells. Since we also found a significant decrease in Wnt-5a mRNA in unfavorable versus favorable categories in 37 primary NB tumors (P<0.007), we wondered whether retinoic acid (RA), which has a role in neural crest induction and differentiation, might reverse the aberrant negative regulation of Wnt-5a in metastatic malignant neuroblasts. Following treatment with 10 muM RA for 6 days, the MYCN-amplified IGR-N-91 cell lines underwent neuronal differentiation as assessed by reduced MYCN gene expression and neuritic extension. In these conditions, data showed an upregulation of Wnt-5a and PKC-theta isoform expressions. Our study highlights, for the first time, the involvement of Wnt-5a, which has a role in embryonic and morphogenetic processes, in the response of malignant neuroblasts to RA. In conclusion, we demonstrated that RA, which is used in the treatment of high-risk NB patients with recurrent/residual disease in the bone marrow, is able to upregulate Wnt-5a gene expression.	Univ Paris Sud, Inst Federat Rech 54, Inst Gustave Roussy, CNRS,UMR 8126, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Genet, Dept Biol, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Raguenez, G (corresponding author), Univ Paris Sud, Inst Federat Rech 54, Inst Gustave Roussy, CNRS,UMR 8126, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	raguenez@igr.fr						AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Cha KB, 2004, MECH DEVELOP, V121, P183, DOI 10.1016/j.mod.2003.12.002; Christiansen JH, 2000, CURR OPIN CELL BIOL, V12, P719, DOI 10.1016/S0955-0674(00)00158-7; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FERRANDIS E, 1994, CANCER RES, V54, P2256; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; HUGUET EL, 1995, J BIOL CHEM, V270, P12851, DOI 10.1074/jbc.270.21.12851; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; IOZZO RV, 1995, CANCER RES, V55, P3495; Jansson M, 2001, J CELL SCI, V114, P2043; Jonsson M, 2002, CANCER RES, V62, P409; Katoh M, 1996, ONCOGENE, V13, P873; Katoh M, 2002, INT J MOL MED, V10, P683; KORNER M, 1994, J NEUROCHEM, V62, P1716; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417; PAHLMAN S, 1995, EUR J CANCER, V31A, P453, DOI 10.1016/0959-8049(95)00033-F; Passalacqua M, 1999, BIOCHEM J, V337, P113, DOI 10.1042/0264-6021:3370113; Polakis P, 2000, GENE DEV, V14, P1837; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Slepko N, 1999, J NEUROSCI RES, V57, P33, DOI 10.1002/(SICI)1097-4547(19990701)57:1<33::AID-JNR4>3.0.CO;2-6; Sparatore B, 2000, BIOCHEM BIOPH RES CO, V279, P589, DOI 10.1006/bbrc.2000.3950; Sparatore B, 2000, BIOCHEM BIOPH RES CO, V275, P149, DOI 10.1006/bbrc.2000.3258; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L	40	80	90	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1277	1283		10.1038/sj.onc.1208255	http://dx.doi.org/10.1038/sj.onc.1208255			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592517				2022-12-17	WOS:000226898700015
J	Porta, C; Hadj-Slimane, R; Nejmeddine, M; Pampin, M; Tovey, MG; Espert, L; Alvarez, S; Chelbi-Alix, MK				Porta, C; Hadj-Slimane, R; Nejmeddine, M; Pampin, M; Tovey, MG; Espert, L; Alvarez, S; Chelbi-Alix, MK			Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively	ONCOGENE			English	Article						interferon; p53; IRF1; CD95; apoptosis	INTERACTING PROTEIN KINASE-2; TRANSCRIPTION FACTOR IRF-1; DAMAGE-INDUCED APOPTOSIS; NUCLEAR-BODIES; PREMATURE SENESCENCE; CARCINOMA-CELLS; BREAST-CANCER; HOST-DEFENSE; I INTERFERON; P53 ACTIVITY	Type I interferon (IFN) enhances the transcription of the tumor suppressor gene p53. To elucidate the molecular mechanism mediating IFN-induced apoptosis, we analysed programmed cell death in response to type I (IFNalpha) or type II (IFNgamma) treatment in relation to p53 status. In two cell lines (MCF-7, SKNSH), IFNalpha, but not IFNgamma, enhanced apoptosis in a p53-dependent manner. Furthermore, only IFNalpha upregulated p53 as well as p53 target genes (Noxa, Mdm2 and CD95). The apoptotic response to IFNalpha decreased in the presence of ZB4, an anti-CD95 antibody, suggesting that CD95 is involved in this process. When p53 was inactivated by the E6 viral protein or the expression of a p53 mutant, IFNalpha-induced apoptosis and p53 target genes upregulation were abrogated. Altogether these results demonstrate that p53 plays a pivotal role in the IFNalpha-induced apoptotic response. IFNalpha-induced PML was unable to recruit p53 into nuclear bodies and its downregulation by siRNA did not alter CD95 expression. In contrast, IFNgamma-induced apoptosis is p53-independent. CD95 and IFN-regulatory factor 1 (IRF1) are directly upregulated by this cytokine. Apoptotic response to IFNgamma is decreased in the presence of ZB4 and strongly diminished by IRF1 siRNA, implicating both CD95 and IRF1 in IFNgamma-induced apoptotic response. Taken together, these results show that in two different cell lines, IFNalpha and IFNgamma, induce p53-dependent - independent apoptosis, respectively.	Inst Andre Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France; CEA, CNRS, UMR 217, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS)	Chelbi-Alix, MK (corresponding author), Inst Andre Lwoff, CNRS, UPR 9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.	mchelbi@infobiogen.fr	Espert, Lucile/ABF-5614-2021	Nejmeddine, Mohamed/0000-0003-0160-2727; Tovey, Michael/0000-0002-3058-0494				Abadie A, 2004, ONCOGENE, V23, P4911, DOI 10.1038/sj.onc.1207614; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Chelbi-alix MK, 2003, ONCOGENE, V22, P9121, DOI 10.1038/sj.onc.1207090; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; FAN SJ, 1995, CANCER RES, V55, P1649; Ferbeyre G, 2002, LEUKEMIA, V16, P1918, DOI 10.1038/sj.leu.2402722; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; Koshiji M, 1997, BIOCHEM BIOPH RES CO, V240, P376, DOI 10.1006/bbrc.1997.7657; Li CX, 2004, ONCOGENE, V23, P1608, DOI 10.1038/sj.onc.1207273; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Panaretakis T, 2003, ONCOGENE, V22, P4543, DOI 10.1038/sj.onc.1206503; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pfeffer LM, 1998, CANCER RES, V58, P2489; Prives C, 1999, J PATHOL, V187, P112; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Sandoval R, 2004, J BIOL CHEM, V279, P32275, DOI 10.1074/jbc.M313830200; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STRANDER H, 1986, ADV CANCER RES, V46, pR9; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thyrell L, 2002, ONCOGENE, V21, P1251, DOI 10.1038/sj.onc.1205179; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WADLER S, 1990, CANCER RES, V50, P3473; Wang SH, 2004, ONCOGENE, V23, P928, DOI 10.1038/sj.onc.1207213; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	59	80	85	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					605	615		10.1038/sj.onc.1208204	http://dx.doi.org/10.1038/sj.onc.1208204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580300				2022-12-17	WOS:000226420400008
J	Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD				Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD			The ATM gene is a target for epigenetic silencing in locally advanced breast cancer	ONCOGENE			English	Article						ATM; epigenetics; promoter hypermethylation; breast cancer	PROMOTER; MUTATIONS; RADIATION; HYPERMETHYLATION; METHYLATION; WOMEN	Several epidemiological studies on ataxia-telangiectasia families indicate that obligate ATM heterozygotes display an elevated risk for developing breast cancer. However, a molecular basis for a potential link between diminished ATM function and sporadic breast malignancy remains elusive. Here, we show that 78% (18 out of a panel of 23) of surgically removed breast tumors (stage II or greater) displayed aberrant methylation of the ATM proximal promoter region as judged by methylation-specific PCR. Aberrant methylation of the ATM promoter was independently confirmed in several tumors by bisulfate sequencing. Moreover, bisulfate sequencing indicated that this region of the genome is subject to dense methylation. Further, we found a highly significant correlation (P = 0.0006) between reduced ATM mRNA abundance, as measured by real-time RT-PCR, and aberrant methylation of the ATM gene promoter. These findings indicate that epigenetic silencing of ATM expression occurs in locally advanced breast tumors, and establish a link at the molecular level between reduced ATM function and sporadic breast malignancy.	Dept Biochem & Mol Biol, New Orleans, LA USA; LSU Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA; Dept Surg, New Orleans, LA USA; Dept Pathol, New Orleans, LA USA; Univ Calif San Francisco, UCSF Comprehens Canc Ctr, San Francisco, CA 94143 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Brown, KD (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245,1600 Archer Rd, Gainesville, FL 32610 USA.	kdbrown1@ufl.edu						Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Angele S, 2000, CLIN CANCER RES, V6, P3536; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Esteller M, 2001, CANCER RES, V61, P3225; Fang ZM, 2001, PATHOLOGY, V33, P30; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gueven N, 2003, GENE CHROMOSOME CANC, V38, P157, DOI 10.1002/gcc.10261; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kairouz R, 1999, J CLIN PATHOL-MOL PA, V52, P252, DOI 10.1136/mp.52.5.252; Kim WJ, 2002, ONCOGENE, V21, P3864, DOI 10.1038/sj.onc.1205485; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Shafman TD, 2000, GENE CHROMOSOME CANC, V27, P124, DOI 10.1002/(SICI)1098-2264(200002)27:2<124::AID-GCC2>3.0.CO;2-M; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Vo QN, 2002, J CLIN PATHOL, V55, P669, DOI 10.1136/jcp.55.9.669	21	80	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9432	9437		10.1038/sj.onc.1208092	http://dx.doi.org/10.1038/sj.onc.1208092			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15516988				2022-12-17	WOS:000225764100015
J	Aeder, SE; Martin, PM; Soh, JW; Hussaini, IM				Aeder, SE; Martin, PM; Soh, JW; Hussaini, IM			PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways	ONCOGENE			English	Article						PKC; glioblastoma; mTOR; Akt; proliferation	PROTEIN-KINASE-C; GROWTH-FACTOR; MESSENGER-RNAS; PHAS-I; EXPRESSION; ALPHA; ACTIVATION; PHOSPHORYLATION; DIFFERENTIATION; TRANSLATION	We previously demonstrated that protein kinase C-eta (PKC-eta) mediates a phorbol 12-myristate-13-acetate (PMA)-induced proliferative response in human glioblastoma (GBM) cells. In this report, we show that PMA-stimulated activation of PKC-eta in U-251 GBM cells resulted in activation of both Akt and the mammalian target of rapamycin (mTOR) signaling pathways and an increase in cell proliferation. Expression of a kinase dead PKC-eta (PKC-etaKR) construct reduced the basal and PMA-evoked proliferation of PKC-eta-expressing U-251 GBM cells, as well as abrogated the PMA-induced activation of Akt, mTOR, and the mTOR targets 4E-BP1 and STAT-3. Treatment of cells with the PI-3 kinase inhibitor LY294002 (10 muM) or the mTOR inhibitor rapamycin (10 nM) also reduced PMA-induced proliferation and cell-cycle progression. Expression of a constitutively active PKC-eta (PKC-etaDeltaNPS) construct in a GBM cell line with no endogenous PKC-eta (U-1242) also provided evidence that PKC-eta targets the Akt and mTOR signaling pathways. Moreover, activation of 4E-BP1 and STAT-3 in both PMA-treated U-251 and PKC-etaDeltaNPS-expressing U-1242 GBM cells was inhibited by rapamycin. However, activation of Akt, but not mTOR was inhibited by the PI-3 kinase inhibitor LY294002. This study identifies Akt and mTOR as downstream targets of PKC-eta that are involved in GBM cell proliferation.	Univ Virginia, Dept Pathol & Neurol, Charlottesville, VA 22908 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Virginia; Columbia University	Aeder, SE (corresponding author), Univ Virginia, Dept Pathol, 415 Lane Rd,POB 800904, Charlottesville, VA 22908 USA.	sea4s@virginia.edu			NCI NIH HHS [CA90851] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BENZIL DL, 1992, CANCER RES, V52, P2951; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Choe Y, 2003, J NEUROENDOCRINOL, V15, P508, DOI 10.1046/j.1365-2826.2003.01023.x; COULDWELL WT, 1991, NEUROSURGERY, V29, P880, DOI 10.1227/00006123-199112000-00013; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELDAR H, 1990, J BIOL CHEM, V265, P13290; Fadden P, 1997, J BIOL CHEM, V272, P10240; Fima E, 2001, ONCOGENE, V20, P6794, DOI 10.1038/sj.onc.1204885; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fujisawa H, 1999, AM J PATHOL, V155, P387, DOI 10.1016/S0002-9440(10)65135-8; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GESCHER A, 1992, BRIT J CANCER, V66, P10, DOI 10.1038/bjc.1992.209; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guizzetti M, 1998, EUR J PHARMACOL, V359, P223, DOI 10.1016/S0014-2999(98)00620-7; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Hesselager G, 2003, CANCER RES, V63, P4305; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; Konopka G, 2003, CURR MOL MED, V3, P73, DOI 10.2174/1566524033361609; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Krasagakis K, 2004, J CELL PHYSIOL, V199, P381, DOI 10.1002/jcp.10434; Livneh E, 1996, ONCOGENE, V12, P1545; MAYER M, 1994, DEVELOPMENT, V120, P143; MAYER M, 1993, GLIA, V8, P12, DOI 10.1002/glia.440080103; MCKINNON RD, 1993, GLIA, V7, P245, DOI 10.1002/glia.440070308; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Nakaigawa N, 1996, BIOCHEM BIOPH RES CO, V222, P95, DOI 10.1006/bbrc.1996.0703; NAVE BT, 1999, BIOCHEM J, V1, P427; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Okada Y, 2000, VERH DEUT G, V84, P33; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; Rajan P, 1998, J NEUROSCI, V18, P3620; Resnick MS, 1997, CANCER RES, V57, P2209; Rolli-Derkinderen M, 2003, J BIOL CHEM, V278, P18859, DOI 10.1074/jbc.M211696200; Rooprai HK, 1999, INT J DEV NEUROSCI, V17, P613, DOI 10.1016/S0736-5748(99)00051-9; Sano T, 1999, CANCER RES, V59, P1820; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; TODO T, 1991, NEUROSURGERY, V108, P11; WANG X, 1998, BIOCHEM J, V183, P261; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Weis J, 1999, J NEURO-ONCOL, V44, P243, DOI 10.1023/A:1006303221064; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; Yamamoto M, 2002, ANTICANCER RES, V22, P4265; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	66	80	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9062	9069		10.1038/sj.onc.1208093	http://dx.doi.org/10.1038/sj.onc.1208093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489897				2022-12-17	WOS:000225492800007
J	Cheng, T				Cheng, T			Cell cycle inhibitors in normal and tumor stem cells	ONCOGENE			English	Review						adult stem cell; hematopoietic stem cell; tumor stem cell; tissue regeneration; self-renewal; cell cycle; cyclin-dependent kinase inhibitor; p21; p27; p18; p16; Rb protein	DEPENDENT KINASE INHIBITORS; STAGE-SPECIFIC REGULATION; GROWTH-FACTOR-BETA; CDK-INHIBITORS; IN-VIVO; PROGENITOR CELLS; SELF-RENEWAL; HEMATOPOIETIC PROGENITORS; TRANSFORMING GROWTH-FACTOR-BETA-1; CORD BLOOD	Emerging data suggest that stem cells may be one of the key elements in normal tissue regeneration and cancer development, although they are not necessarily the same entity in both scenarios. As extensively demonstrated in the hematopoietic system, stem cell repopulation is hierarchically organized and is intrinsically limited by the intracellular cell cycle inhibitors. Their inhibitory effects appear to be highly associated with the differentiation stage in stem/progenitor pools. While this negative regulation is important for maintaining homeostasis, especially at the stem cell level under physiological cues or pathological insults, it constrains the therapeutic use of adult stem cells in vitro and restricts endogenous tissue repair after injury. On the other hand, disruption of cell cycle inhibition may contribute to the formation of the so-called 'tumor stem cells' (TSCs) that are currently hypothesized to be partially responsible for tumorigenesis and recurrence of cancer after conventional therapies. Therefore, understanding how cell cycle inhibitors control stem cells may offer new strategies not only for therapeutic manipulations of normal stem cells but also for novel therapies selectively targeting TSCs.	Univ Pittsburgh, Dept Radiat Oncol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cheng, T (corresponding author), Hillman Canc Ctr, Res Pavil,Off Suite 2-42E,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	chengt@msx.upmc.edu		Cheng, Tao/0000-0002-5925-2769	NHLBI NIH HHS [HL70561] Funding Source: Medline; NIDDK NIH HHS [DK02761] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002761] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Becker PS, 1999, EXP HEMATOL, V27, P533, DOI 10.1016/S0301-472X(98)00037-X; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bonfanti L, 2001, CONT NEUROS, P49; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bradford GB, 1997, EXP HEMATOL, V25, P445; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burton PBJ, 1999, DEV BIOL, V216, P659, DOI 10.1006/dbio.1999.9524; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; CARDOSO AA, 1993, P NATL ACAD SCI USA, V90, P8707, DOI 10.1073/pnas.90.18.8707; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cashman JD, 1999, BLOOD, V94, P3722, DOI 10.1182/blood.V94.11.3722.423k20_3722_3729; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheng T, 2001, BLOOD, V98, P3643, DOI 10.1182/blood.V98.13.3643; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; Cunningham JJ, 2001, CELL GROWTH DIFFER, V12, P387; D'Urso G, 2001, COLD SPRING HARBOR M, P61; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Doetsch F, 2002, J NEUROSCI, V22, P2255, DOI 10.1523/JNEUROSCI.22-06-02255.2002; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; Dunnwald M, 2003, J CELL PHYSIOL, V195, P194, DOI 10.1002/jcp.10311; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Gao FB, 1997, CURR BIOL, V7, P152, DOI 10.1016/S0960-9822(06)00060-1; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HARRISON DE, 1991, BLOOD, V78, P1237; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hatzfeld A, 1996, HUM GENE THER, V7, P207, DOI 10.1089/hum.1996.7.2-207; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hirabayashi Y, 2002, EXP BIOL MED, V227, P474, DOI 10.1177/153537020222700711; Horner PJ, 2000, J NEUROSCI, V20, P2218; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Karnezis AN, 2001, J CLIN INVEST, V108, P383, DOI 10.1172/JCI11933; KAY HEM, 1965, LANCET, V2, P418; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Legrier ME, 2001, CELL GROWTH DIFFER, V12, P591; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liu Y, 1996, CANCER RES, V56, P31; Mahmud N, 2001, BLOOD, V97, P3061, DOI 10.1182/blood.V97.10.3061; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marone M, 2000, BRIT J HAEMATOL, V110, P654, DOI 10.1046/j.1365-2141.2000.02227.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Miyazawa K, 2000, J NEUROSCI, V20, P5756, DOI 10.1523/JNEUROSCI.20-15-05756.2000; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Oostendorp RAJ, 2000, BLOOD, V95, P855, DOI 10.1182/blood.V95.3.855.003k41_855_862; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POTTEN MLA, 1997, STEM CELLS CELLULAR; Prost S, 1998, FEBS LETT, V425, P499, DOI 10.1016/S0014-5793(98)00296-8; Qiu JH, 2004, J EXP MED, V199, P937, DOI 10.1084/jem.20031385; Quesenberry PJ, 2002, BLOOD, V100, P4266, DOI 10.1182/blood-2002-04-1246; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Roy V, 1999, EXP HEMATOL, V27, P302, DOI 10.1016/S0301-472X(98)00031-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Shen HM, 1999, J VIROL, V73, P728, DOI 10.1128/JVI.73.1.728-737.1999; Sherr CJ, 2000, CANCER RES, V60, P3689; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Stier S, 2003, BLOOD, V102, P1260, DOI 10.1182/blood-2002-10-3053; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Tong X, 1998, EXP HEMATOL, V26, P684; Tschan MP, 1999, BRIT J HAEMATOL, V106, P644, DOI 10.1046/j.1365-2141.1999.01617.x; Uchida N, 1997, BLOOD, V90, P4354; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Verfaillie CM, 2002, NAT IMMUNOL, V3, P314, DOI 10.1038/ni0402-314; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Yuan YZ, 2003, BLOOD, V102, p855A; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	135	80	90	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7256	7266		10.1038/sj.onc.1207945	http://dx.doi.org/10.1038/sj.onc.1207945			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378085				2022-12-17	WOS:000223998800011
J	Coulombel, L				Coulombel, L			Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays	ONCOGENE			English	Review						hematopoiesis; stem cells; differentiation; self-renewal; transplantation; assays	HUMAN CORD-BLOOD; EX-VIVO EXPANSION; LONG-TERM HEMATOPOIESIS; ACUTE MYELOID-LEUKEMIA; ADULT BONE-MARROW; COMBINED IMMUNODEFICIENCY MICE; IN-VITRO IDENTIFICATION; EMBRYONIC STEM-CELLS; HUMAN T-CELLS; PRO-B CELLS	A major challenge in hematopoiesis is to conceive assays that could bring useful insights into experimental and clinical hematology. This means identifying separately the various classes of hematopoietic progenitors that are produced sequentially during the progression from stem cells to differentiated functional cells. Standardized short-term colony assays easily quantify lineage-committed myeloid precursors, but identification of primitive cells, which have both the ability to repopulate durably myeloid and lymphoid lineages and perhaps to self-renew, still depends on in vivo assays. Whatever the assay, two important requisites have to be solved: one is the definition of appropriate read-outs that will depend solely on the function of these cells, and the second is to evaluate precisely their numbers and proliferative potential in quantitative assays. When evaluating hematopoiesis, three parameters have to be taken into account: (1) the lack of reliable correlation between the phenotype of a given cell and its function. This is especially problematic in post-transplantation situations where cells from transplanted animals are analysed; (2) functionally heterogeneous cells are identified in a single assay; and (3) ontogeny-related changes in hematopoietic cell proliferation and self-renewal that, in human beings, hampers the exploration of adult stem cells. Nevertheless, years of progress in the manipulation of hematopoietic stem cells have recently resulted in the purification of a cell subset that repopulates irradiated recipients with absolute efficiency.	Fac Med, INSERM, U421, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Coulombel, L (corresponding author), Fac Med, INSERM, U421, 8 Rue Gen Sarrail, F-94010 Creteil, France.	coulombel@im3.inserm.fr						ABRAMSON S, 1977, J EXP MED, V145, P1567, DOI 10.1084/jem.145.6.1567; Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; ASH RC, 1981, BLOOD, V58, P309; BARCENA A, 1994, J EXP MED, V180, P123, DOI 10.1084/jem.180.1.123; Barker J, 2000, LEUKEMIA, V14, P1614, DOI 10.1038/sj.leu.2401869; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bennaceur-Griscelli A, 2001, BLOOD, V97, P435, DOI 10.1182/blood.V97.2.435; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; Berardi AC, 1997, BLOOD, V89, P3554, DOI 10.1182/blood.V89.10.3554.3554_3554_3564; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; Bonnet D, 1999, BONE MARROW TRANSPL, V23, P203, DOI 10.1038/sj.bmt.1701564; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Borge OJ, 1997, BLOOD, V90, P2282, DOI 10.1182/blood.V90.6.2282.2282_2282_2292; BREEMS DA, 1994, LEUKEMIA, V8, P1095; Breems DA, 1996, BLOOD, V87, P5370, DOI 10.1182/blood.V87.12.5370.bloodjournal87125370; BROXMEYER HE, 1984, CRC CR REV ONCOL-HEM, V1, P227, DOI 10.1016/S1040-8428(84)80013-X; Brummendorf TH, 1998, J EXP MED, V188, P1117, DOI 10.1084/jem.188.6.1117; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cashman J, 1997, BRIT J HAEMATOL, V98, P1026, DOI 10.1046/j.1365-2141.1997.3233140.x; Cashman JD, 2000, BLOOD, V96, P3979, DOI 10.1182/blood.V96.12.3979.h8003979_3979_3981; CHANG J, 1986, LANCET, V1, P294; CHEN JZ, 1994, CURR OPIN IMMUNOL, V6, P313, DOI 10.1016/0952-7915(94)90107-4; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; COULOMBEL L, 1983, BLOOD, V62, P291; CROISILLE L, 1994, BLOOD, V84, P4116, DOI 10.1182/blood.V84.12.4116.bloodjournal84124116; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; Danet GH, 2001, EXP HEMATOL, V29, P1465, DOI 10.1016/S0301-472X(01)00750-0; Denning-Kendall P, 2003, STEM CELLS, V21, P694, DOI 10.1634/stemcells.21-6-694; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; Eaves A C, 1998, Stem Cells, V16 Suppl 1, P77; EAVES CJ, 1978, BLOOD, V52, P1196; Fluckiger AC, 1998, BLOOD, V92, P4509; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; Gammaitoni L, 2003, EXP HEMATOL, V31, P261, DOI 10.1016/S0301-472X(02)01077-9; Glimm H, 2001, J CLIN INVEST, V107, P199, DOI 10.1172/JCI11519; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; Hao QL, 2001, BLOOD, V97, P3683, DOI 10.1182/blood.V97.12.3683; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; Hao QL, 1998, BLOOD, V91, P4145, DOI 10.1182/blood.V91.11.4145.411a10_4145_4151; Hiramatsu H, 2003, BLOOD, V102, P873, DOI 10.1182/blood-2002-09-2755; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; Hogan CJ, 2002, P NATL ACAD SCI USA, V99, P413, DOI 10.1073/pnas.012336799; Hogan CJ, 1997, BLOOD, V90, P85; Holyoake TL, 1999, EXP HEMATOL, V27, P1418, DOI 10.1016/S0301-472X(99)00078-8; Horn PA, 2003, BLOOD, V102, P4329, DOI 10.1182/blood-2003-01-0082; ISCOVE NN, 1971, BLOOD-J HEMATOL, V37, P1; ISHIHARA S, 1992, JPN J CANCER RES, V83, P320, DOI 10.1111/j.1349-7006.1992.tb00108.x; ISSAAD C, 1993, BLOOD, V81, P2916; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jaleco AC, 2001, J EXP MED, V194, P991, DOI 10.1084/jem.194.7.991; Jetmore A, 2002, BLOOD, V99, P1585, DOI 10.1182/blood.V99.5.1585; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; KELLER G, 1990, J EXP MED, V171, P1407, DOI 10.1084/jem.171.5.1407; Kerre TCC, 2002, BLOOD, V99, P1620, DOI 10.1182/blood.V99.5.1620; Kincade PW, 2000, CURR TOP MICROBIOL, V251, P67; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; LANSDORP PM, 1993, J EXP MED, V178, P787, DOI 10.1084/jem.178.3.787; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; LEARY AG, 1987, BLOOD, V69, P953; LEBIEN TW, 1989, IMMUNOL TODAY, V10, P296, DOI 10.1016/0167-5699(89)90084-4; LEMIEUX ME, 1995, BLOOD, V86, P1339, DOI 10.1182/blood.V86.4.1339.bloodjournal8641339; Lemieux ME, 1996, BLOOD, V88, P1639; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; Lin Q, 1998, J EXP MED, V187, P79, DOI 10.1084/jem.187.1.79; LORD BI, 1993, STEM CELLS, V11, P212, DOI 10.1002/stem.5530110308; MAGLI MC, 1982, NATURE, V295, P527, DOI 10.1038/295527a0; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; MAYANI H, 1993, J CELL PHYSIOL, V157, P579, DOI 10.1002/jcp.1041570318; MCCULLOCH EA, 1964, RADIAT RES, V22, P383, DOI 10.2307/3571667; McNiece I, 2001, EXP HEMATOL, V29, P3, DOI 10.1016/S0301-472X(00)00610-X; METCALF D, 1975, J CELL PHYSIOL, V85, P643, DOI 10.1002/jcp.1040850317; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; Morris JC, 2004, BLOOD, V103, P492, DOI 10.1182/blood-2003-07-2324; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Nakamura K, 2004, J EXP MED, V199, P243, DOI 10.1084/jem.20031193; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Norol F, 2002, BRIT J HAEMATOL, V117, P924, DOI 10.1046/j.1365-2141.2002.03531.x; Ohishi K, 2002, J CLIN INVEST, V110, P1165, DOI 10.1172/JCI200216167; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; PAIGE CJ, 1984, EUR J IMMUNOL, V14, P979, DOI 10.1002/eji.1830141104; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; PETTENGELL R, 1994, BLOOD, V84, P3653, DOI 10.1182/blood.V84.11.3653.bloodjournal84113653; Petzer AL, 1996, J EXP MED, V183, P2551, DOI 10.1084/jem.183.6.2551; Pflumio F, 1996, BLOOD, V88, P3731, DOI 10.1182/blood.V88.10.3731.bloodjournal88103731; PHILLIPS RA, 1980, J SUPRAMOL STR CELL, V14, P77, DOI 10.1002/jss.400140108; PLOEMACHER RE, 1989, BLOOD, V74, P2755; PLOEMACHER RE, 1991, BLOOD, V78, P2527; PLUM J, 1994, BLOOD, V84, P1587; Plum J, 2000, ANN NY ACAD SCI, V917, P724; Punzel M, 1999, BLOOD, V93, P3750, DOI 10.1182/blood.V93.11.3750.411a37_3750_3756; Punzel M, 1999, LEUKEMIA, V13, P92, DOI 10.1038/sj.leu.2401234; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; Rawlings DJ, 1997, EXP HEMATOL, V25, P66; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reynaud D, 2003, BLOOD, V101, P4313, DOI 10.1182/blood-2002-07-2085; Robin C, 1999, BRIT J HAEMATOL, V104, P809, DOI 10.1046/j.1365-2141.1999.01266.x; Robin C, 1999, J EXP MED, V189, P1601, DOI 10.1084/jem.189.10.1601; Rollini P, 2004, BLOOD, V103, P1166, DOI 10.1182/blood-2003-06-1815; Rosenzweig M, 1996, BLOOD, V87, P4040, DOI 10.1182/blood.V87.10.4040.bloodjournal87104040; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sato T, 1999, BLOOD, V94, P2548, DOI 10.1182/blood.V94.8.2548.420k38_2548_2554; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schmitt TM, 2004, NAT IMMUNOL, V5, P410, DOI 10.1038/ni1055; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Shultz LD, 2003, EXP HEMATOL, V31, P551, DOI 10.1016/S0301-472X(03)00076-6; Spanopoulou E, 1996, Int Rev Immunol, V13, P257, DOI 10.3109/08830189609061752; SROUR EF, 1992, BLOOD, V79, P1404; Srour EF, 2001, LEUKEMIA, V15, P1681, DOI 10.1038/sj.leu.2402256; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; SUTHERLAND HJ, 1991, BLOOD, V78, P666, DOI 10.1182/blood.V78.3.666.bloodjournal783666; Sutherland HJ, 1996, BLOOD, V87, P4754, DOI 10.1182/blood.V87.11.4754.bloodjournal87114754; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; SZILVASSY SJ, 1993, BLOOD, V81, P2310; Szilvassy SJ, 2003, EXP HEMATOL, V31, P331, DOI 10.1016/S0301-472X(03)00005-5; Takano H, 2004, J EXP MED, V199, P295, DOI 10.1084/jem.20030929; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; Thiemann FT, 1998, EXP HEMATOL, V26, P612; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; TREVISAN M, 1995, J EXP MED, V181, P93, DOI 10.1084/jem.181.1.93; Uchida N, 2003, EXP HEMATOL, V31, P1338, DOI 10.1016/j.exphem.2003.09.001; VORMOOR J, 1994, BLOOD, V83, P2489; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Weekx SFA, 2000, BLOOD, V95, P2806, DOI 10.1182/blood.V95.9.2806.009k01_2806_2812; WHITLOCK CA, 1984, J IMMUNOL METHODS, V67, P353, DOI 10.1016/0022-1759(84)90475-7; WU AM, 1967, J CELL PHYSIOL, V69, P177, DOI 10.1002/jcp.1040690208; Yokota T, 2003, IMMUNITY, V19, P365, DOI 10.1016/S1074-7613(03)00231-0; Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698; ZANJANI ED, 1994, J CLIN INVEST, V93, P1051, DOI 10.1172/JCI117054; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	145	80	89	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2004	23	43					7210	7222		10.1038/sj.onc.1207941	http://dx.doi.org/10.1038/sj.onc.1207941			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378081				2022-12-17	WOS:000223998800007
J	Senchenko, VN; Liu, J; Loginov, W; Bazov, I; Angeloni, D; Seryogin, Y; Ermilova, V; Kazubskaya, T; Garkavtseva, R; Zabarovska, VI; Kashuba, VI; Kisselev, LL; Minna, JD; Lerman, MI; Klein, G; Braga, EA; Zabarovsky, ER				Senchenko, VN; Liu, J; Loginov, W; Bazov, I; Angeloni, D; Seryogin, Y; Ermilova, V; Kazubskaya, T; Garkavtseva, R; Zabarovska, VI; Kashuba, VI; Kisselev, LL; Minna, JD; Lerman, MI; Klein, G; Braga, EA; Zabarovsky, ER			Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas	ONCOGENE			English	Article						breast cancer; human chromosome 3p; lung cancer; renal carcinoma; tumour suppressor genes; quantitative real-time PCR	TUMOR-SUPPRESSOR GENE; SINGLE-NUCLEOTIDE POLYMORPHISM; HUMAN EPITHELIAL MALIGNANCIES; REAL-TIME PCR; MOLECULAR-GENETICS; CELL CARCINOMA; SHORT ARM; CANCER; 3P; HETEROZYGOSITY	We searched for chromosome 3p homo- and hemizygous losses in 23 lung cancer cell lines, 53 renal cell and 22 breast carcinoma biopsies using 31 microsatellite markers located in frequently deleted 3p regions. In addition, two sequence-tagged site markers (NLJ-003 and NL3-001) located in the Alu-PCR clone 20 region (AP20) and lung cancer (LUCA) regions, respectively, were used for quantitative real-time PCR (QPCR). We found frequent (10-18%) homozygous deletions (HDs) in both 3p2l.3 regions in the biopsies and lung cancer cell lines. In addition, we discovered that amplification of 3p is a very common (15-42.5%) event in these cancers and probably in other epithelial malignancies. QPCR showed that aberrations of either NLJ-003 or NL3-001 were detected in more than 90% of all studied cases. HDs were frequently detected simultaneously both in NLJ-003 or NL3-001 loci in the same tumour (P < 3-10(-7)). This observation suggests that tumour suppressor genes (TSG) in these regions could have a synergistic effect. The exceptionally high frequency of chromosome aberrations in NLJ-003 and NL3-001 loci suggests that multiple TSG(s) involved in different malignancies are located very near to these markers. Precise mapping of 15 independent HDs in the LUCA region allowed us to establish the smallest HD region in 3p21.3C located between D3S1568 (CACNA2D2 gene) and D3S4604 (SEMA3F gene). This region contains 17 genes. Mapping of 19 HDs in the AP20 region resulted in the localization of the minimal region to the interval flanked by D3S1298 and D3S3623 markers. Only four genes were discovered in this interval, namely, APRG1, ITGA9, HYA22 and VILL.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden; Russian Acad Sci, Ctr Bioengn, Moscow 117312, Russia; Russian State Genet Ctr, Moscow 117545, Russia; Natl Canc Inst, Immunobiol Lab, Canc Causing Genes Sect, Ctr Canc Res, Frederick, MD 21702 USA; Russian Acad Med Sci, Blokhin Canc Res Ctr, Moscow 115478, Russia; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	Karolinska Institutet; Research Center of Biotechnology RAS; Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zabarovsky, ER (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden.	eugene.zabarovsky@mtc.ki.se	Kashuba, Vladimir I/N-3732-2017; Braga, Eleonora A./P-5574-2016; Loginov, Vytaliy I/J-9738-2018; Senchenko, Vera N/C-8992-2014; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir/AAO-7742-2020	Kashuba, Vladimir I/0000-0001-9416-8282; Loginov, Vytaliy I/0000-0003-2668-8096; Senchenko, Vera N/0000-0002-3119-515X; Bazov, Igor/0000-0003-4388-1656; Braga, Eleonora/0000-0001-5188-4094; Angeloni, Debora/0000-0002-3850-5392	NATIONAL CANCER INSTITUTE [R01CA071618, Z01BC008579, P50CA070907] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000, CA71618, P50CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; Angeloni D, 2003, MOL CELL PROBE, V17, P55, DOI 10.1016/S0890-8508(02)00115-9; ANGELONI D, 2001, SOURCEBOOK ASBESTOS, V23, P169; Braga E, 2002, INT J CANCER, V100, P534, DOI 10.1002/ijc.10511; Braga E, 1999, FEBS LETT, V454, P215, DOI 10.1016/S0014-5793(99)00807-8; Daigo Y, 1999, DNA Res, V6, P37, DOI 10.1093/dnares/6.1.37; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Erlandsson R, 1998, CANCER GENET CYTOGEN, V104, P1, DOI 10.1016/S0165-4608(97)00384-1; Girard L, 2000, CANCER RES, V60, P4894; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kashuba VI, 1999, GENE, V239, P259, DOI 10.1016/S0378-1119(99)00411-4; KASHUBA VI, 1995, CANCER GENET CYTOGEN, V81, P144, DOI 10.1016/0165-4608(94)00215-W; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lerman MI, 2000, CANCER RES, V60, P6116; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Liu J, 1999, FEBS LETT, V462, P121, DOI 10.1016/S0014-5793(99)01523-9; Phelps RM, 1996, J CELL BIOCHEM, P32; Protopopov A, 2003, CANCER RES, V63, P404; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SEABRIGH.M, 1971, LANCET, V2, P971; Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429; Stewart B.W., 2003, WORLD CANC REPORT; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P59, DOI 10.1002/(SICI)1098-2264(199706)19:2<59::AID-GCC1>3.3.CO;2-O; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Yang QF, 2002, J HUM GENET, V47, P453, DOI 10.1007/s100380200064; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	31	80	97	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5719	5728		10.1038/sj.onc.1207760	http://dx.doi.org/10.1038/sj.onc.1207760			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208675	Bronze			2022-12-17	WOS:000222629800001
J	Worm, J; Christensen, C; Gronbaek, K; Tulchinsky, E; Guldberg, P				Worm, J; Christensen, C; Gronbaek, K; Tulchinsky, E; Guldberg, P			Genetic and epigenetic alterations of the APC gene in malignant melanoma	ONCOGENE			English	Article						melanoma; APC; Wnt signalling; DNA methylation; beta-catenin; RNAi	ADENOMATOUS-POLYPOSIS-COLI; CELL-CYCLE PROGRESSION; BETA-CATENIN GENE; SOMATIC MUTATIONS; EXON 3; SIGNALING PATHWAY; COLORECTAL-CANCER; DNA METHYLATION; S-PHASE; PROMOTER	High levels of beta-catenin and activating mutations in the beta-catenin gene (CTNNB1) have been demonstrated in malignant melanomas, implicating dysregulated Wnt signalling in the pathogenesis of this malignancy. We systematically examined melanoma cell lines for activating CTNNB1 mutations as well as genetic and epigenetic alterations of the adenomatous polyposis coli gene (APC), another key component of the Wnt signalling transduction pathway. Of 40 cell lines tested, one carried a truncating APC mutation and loss of the corresponding wild-type allele, and one carried a CTNNB1 missense mutation. Hypermethylation of APC promoter 1A was present in five of the cell lines (13%) and in nine of 54 melanoma biopsies (17%). Cells with truncating APC or activating CTNNB1 mutations showed increased transcription from endogenous and ectopic beta-catenin/T-cell factor (Tcf)responsive target genes, consistent with the known effects of these alterations on beta-catenin stability and Tcf transactivation. In contrast, cell lines with APC promoter 1A hypermethylation did not show increased Wnt signalling, probably due to residual APC activity expressed from promoter 1B. Suppression of APC transcripts in melanoma cells by stable expression of short hairpin RNAs led to a Wnt signalling-independent increase in cell proliferation, but also reduced the invasive growth in collagen type I. Collectively, our data suggest that the tumour-suppressive function of APC in melanocytic cells is dose dependent. We propose that epigenetic silencing of promoter 1A may contribute to the development of malignant melanoma by reducing the expression of APC to a level that promotes cell proliferation without compromising the invasive capacity.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 7RH, Leics, England	Danish Cancer Society; University of Leicester	Guldberg, P (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	perg@cancer.dk	Tulchinsky, Eugene/ABD-7070-2021	Gronbaek, Kirsten/0000-0002-1535-9601				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Chen C, 2001, J BIOL CHEM, V276, P320, DOI 10.1074/jbc.M007096200; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Cremonesi L, 1997, BIOTECHNIQUES, V22, P326, DOI 10.2144/97222rr01; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Esteller M, 2000, CANCER RES, V60, P4366; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fodde R, 2003, NAT CELL BIOL, V5, P190, DOI 10.1038/ncb0303-190; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Guldberg P, 1997, CANCER RES, V57, P3660; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Miyoshi Y, 1998, CANCER RES, V58, P2524; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Oda H, 1996, CANCER RES, V56, P3320; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Pollock PM, 2002, MELANOMA RES, V12, P183, DOI 10.1097/00008390-200204000-00013; Reifenberger J, 2002, INT J CANCER, V100, P549, DOI 10.1002/ijc.10512; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Usadel H, 2002, CANCER RES, V62, P371; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Worm J, 2001, CLIN CHEM, V47, P1183; Wu R, 2001, CANCER RES, V61, P8247; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; ZEKI K, 1994, J CLIN ENDOCR METAB, V79, P1317, DOI 10.1210/jc.79.5.1317; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	48	80	82	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5215	5226		10.1038/sj.onc.1207647	http://dx.doi.org/10.1038/sj.onc.1207647			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15133491				2022-12-17	WOS:000222382500011
J	Boya, P; Morales, MC; Gonzalez-Polo, RA; Andreau, K; Gourdier, I; Perfettini, JL; Larochette, N; Deniaud, A; Baran-Marszak, F; Fagard, R; Feuillard, J; Asumendi, A; Raphael, M; Pau, B; Brenner, C; Kroemer, G				Boya, P; Morales, MC; Gonzalez-Polo, RA; Andreau, K; Gourdier, I; Perfettini, JL; Larochette, N; Deniaud, A; Baran-Marszak, F; Fagard, R; Feuillard, J; Asumendi, A; Raphael, M; Pau, B; Brenner, C; Kroemer, G			The chemopreventive agent N-(4-hydroxyphenyl) retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family	ONCOGENE			English	Article						4-hydroxyphenylretinamide; Bax; Bcl-2; cell death; chemoprevention; mitochondria	PERMEABILITY TRANSITION PORE; CERAMIDE-INDUCED APOPTOSIS; CELL-DEATH; ENDOPLASMIC-RETICULUM; CANCER-CELLS; CYTOCHROME-C; MEMBRANE PERMEABILIZATION; LOCALIZED INHIBITOR; GD3 GANGLIOSIDE; KAPPA-B	N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction. 4-HPR induces a loss of the mitochondrial transmembrane potential and the mitochondrial release of cytochrome c before caspase activation. Inhibition of mitochondrial membrane permeabilization (MMP) by transfection with Bcl-2 or the Cytomegalovirus UL37 gene product vMIA prevented caspase activation and cell death. In contrast to other retinoid derivatives, 4-HPR has no direct MMP-inducing effects when added to isolated mitochondria or when added to proteoliposomes containing the MMP-regulatory permeability transition pore complex ( PTPC). Moreover, although reactive oxygen species (ROS) overproduction appears to be instrumental for 4-HPR-induced MMP and apoptosis, inhibition of the NF-kappaB or p53-mediated signal transduction pathways failed to modulate 4-HPR-induced apoptosis. 4-HPR was found to cause an antioxidant-inhibitable conformational change of both Bax and Bak, leading to the exposure of their N- termini and to the mitochondrial relocalization of Bax. Cells with a Bax(-/-) Bak(-/-) genotype were resistant against the 4-HPR-induced MMP, overproduction of ROS and cell death. Altogether, these data indicate that 4-HPR induce s MMP through an ROS-mediated pathway that involves the obligatory contribution of the proapopotic Bcl-2 family members Bax and/or Bak.	Inst Gustave Roussy, CNRS, UMR8125, Villejuif, France; Univ Versailles, CNRS, FRE 2445, F-78000 Versailles, France; CHU Kremlin Bicetre, Serv Hematol Biol, U473, Le Kremlin Bicetre, France; Univ Paris 13, APHP, Hop Avicenne, Biochim Lab, Bobigny, France; Univ Paris 13, EA 3406, Bobigny, France; CHU Dupuytren, Hematol Lab, Limoges, France; Univ Basque Country, Sch Med & Dent, Dept Cell Biol & Histol, Leioa 48940, Bizkaia, Spain; CNRS, UMR 5094, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Avicenne - APHP; Universite Paris 13; Universite Paris 13; CHU Limoges; University of Basque Country; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Asumendi, Aintzane/ABF-7001-2021; Kroemer, Guido/AAY-9859-2020; Boya, Patricia/K-2911-2014; Boya, Patricia/P-8345-2019; PERFETTINI, Jean-Luc/N-4699-2017; Deniaud, Aurelien/L-5093-2019; Morales, Maria Celia/AAB-5085-2020; González-Polo, Rosa A./I-6076-2016; LAROCHETTE, Nathanael/R-4298-2017; KROEMER, Guido/B-4263-2013; brenner, catherine/AAE-8632-2020; Feuillard, Jean/O-8587-2016	Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Morales, Maria Celia/0000-0001-5423-3684; González-Polo, Rosa A./0000-0002-0163-2953; LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405; Asumendi, Aintzane/0000-0002-2156-2323; Andreau, Karine/0000-0002-9773-0733; Feuillard, Jean/0000-0001-6223-2454				Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; De Palo G, 2002, GYNECOL ONCOL, V86, P24, DOI 10.1006/gyno.2002.6663; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gourdier I, 2002, FEBS LETT, V529, P232, DOI 10.1016/S0014-5793(02)03347-1; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Hayajneh WA, 2001, VIROLOGY, V279, P233, DOI 10.1006/viro.2000.0726; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Hursting SD, 2002, MOL CARCINOGEN, V33, P16, DOI 10.1002/mc.10020; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Levi MS, 2001, CURR MED CHEM, V8, P1349, DOI 10.2174/0929867013372229; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lim SJ, 2002, INT J CANCER, V101, P243, DOI 10.1002/ijc.10596; Lovat PE, 2002, CANCER RES, V62, P5158; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Marchetti P, 1999, CANCER RES, V59, P6257; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Notario B, 2003, MOL PHARMACOL, V63, P224, DOI 10.1124/mol.63.1.224; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Prinetti A, 2003, J BIOL CHEM, V278, P5574, DOI 10.1074/jbc.M207269200; Raffaghello L, 2003, INT J CANCER, V104, P559, DOI 10.1002/ijc.10991; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shaker MR, 2001, CLIN EXP METASTAS, V18, P429, DOI 10.1023/A:1010905309570; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; Singletary SE, 2002, CLIN CANCER RES, V8, P2835; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Wang HT, 2001, CANCER RES, V61, P5102; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zou CP, 2002, CANCER LETT, V180, P131, DOI 10.1016/S0304-3835(01)00864-3	65	80	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6220	6230		10.1038/sj.onc.1206827	http://dx.doi.org/10.1038/sj.onc.1206827			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679861				2022-12-17	WOS:000185506200012
J	Marcoux, N; Vuori, K				Marcoux, N; Vuori, K			EGF receptor mediates adhesion-dependent activation of the Rac GTPase: a role for phosphatidylinositol 3-kinase and Vav2	ONCOGENE			English	Article						adhesion; cytoskeleton; integrin; kinase; signaling	GROWTH-FACTOR RECEPTORS; GUANOSINE TRIPHOSPHATASES; PLECKSTRIN HOMOLOGY; SIGNALING PATHWAYS; FAMILY PROTEINS; RHO FAMILY; CELL-CYCLE; INTEGRINS; PHOSPHORYLATION; KINASE	Organization of the actin cytoskeleton in eucaryotic cells is controlled by small GTPases of the Rho family. Rac becomes activated by growth factor stimulation and integrin-mediated cell adhesion to extracellular matrix and is known to have a crucial role in lamellipodia formation, cell spreading and migration. At present, the intracellular pathways that connect cell surface receptors to Rac activation are poorly characterized. It has been reported previously that integrin-mediated cell attachment induces activation of the EGF receptor (EGFR) in the absence of EGF. We demonstrate here that this activation is instrumental for integrin-dependent Rac activation. Thus, we found that cells in which EGFR activity had been inhibited failed to spread and form lamellipodia on fibronectin. Failure to spread coincided with inhibition of adhesion-induced GTP loading of Rac and also with inhibition of the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Subsequent studies demonstrated that an activated form of PI 3-kinase restored Rac GTP loading in the presence of EGFR inhibition, while a dominant-negative form of PI 3-kinase blocked Rac GTP loading in fibronectin-adherent cells. Our further functional studies identified Vav2, a known exchange factor for Rac, as a crucial downstream component in EGFR- and PI 3-kinase-dependent Rac activation upon integrin-mediated cell adhesion. Our results provide a mechanistic insight into integrin-dependent Rac activation, and identify a novel role for EGFR, PI 3-kinase and Vav2 in this pathway.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Vuori, K (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	kvuori@burnham.org						Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tamas P, 2003, J BIOL CHEM, V278, P5163, DOI 10.1074/jbc.M207555200; Tamas P, 2001, CELL SIGNAL, V13, P475, DOI 10.1016/S0898-6568(01)00172-3; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6	34	80	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6100	6106		10.1038/sj.onc.1206712	http://dx.doi.org/10.1038/sj.onc.1206712			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955089				2022-12-17	WOS:000185137800019
J	Soejima, K; Fang, WZ; Rollins, BJ				Soejima, K; Fang, WZ; Rollins, BJ			DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras	ONCOGENE			English	Article						DNA methyltransferase; tumor suppressor; lung cancer	TUMOR-SUPPRESSOR GENE; HISTONE DEACETYLASE COMPLEX; HUMAN CANCER-CELLS; CYTOSINE-5 METHYLTRANSFERASES; RENAL-CARCINOMA; LUNG-CANCER; IMMUNODEFICIENCY SYNDROME; HUMAN FIBROBLASTS; CPG METHYLATION; STEM-CELLS	Transcriptional silencing of tumor suppressor genes in association with DNA methylation contributes to malignant transformation. However, the specific DNA methyltransferases that initiate this process are unknown. Here we show that a de novo DNA methyltransferase, DNMT3b, substantially contributes to the oncogenic phenotype in a lung cancer model. Normal human bronchial epithelial (NHBE) cells expressing telomerase, SV40 large T antigen, and activated Ras were immortal, formed colonies in soft agar, and expressed DNMT3b. Antisense suppression of DNMT3b prevented soft agar growth. Furthermore, mouse embryo fibroblasts expressing T antigen and Ras formed soft agar colonies and large tumors, but fibroblasts from Dnmt3b(-/-) mice did not grow in soft agar and were much less tumorigenic in vivo. The tumor suppressor genes, FHIT, TSLC1, and RASSF1A were downregulated in transformed NHBE cells, and antisense DNMT3b treatment resulted in re-expression of FHIT and TSLC1. While expression of TSCL1 correlated with methylation of CpG dinucleotides in its promoter region, the expression of FHIT did not, suggesting that DNMT3b may silence genes by several mechanisms including direct DNA methylation or recruitment of proteins that modify chromatin. Regardless of mechanism, our data indicate that DNMT3b plays an important role in transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rollins, BJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, M430,44 Binney St, Boston, MA 02115 USA.	barrett_rollins@dfci.harvard.edu	Soejima, Kenzo/T-9878-2019	Soejima, Kenzo/0000-0001-9749-995X				Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan MF, 2000, CURR TOP MICROBIOL, V249, P75; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GREGER V, 1994, HUM GENET, V94, P491; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herman JG, 1996, CANCER RES, V56, P722; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Pradhan S, 1998, NUCLEIC ACIDS RES, V26, P1214, DOI 10.1093/nar/26.5.1214; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; RIOS M, 1990, J CELL PHYSIOL, V145, P434, DOI 10.1002/jcp.1041450307; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; SAKAI T, 1991, AM J HUM GENET, V48, P880; SHAPIRO GI, 1995, CANCER RES, V55, P505; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Tanaka H, 1998, CANCER RES, V58, P3429; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	57	80	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4723	4733		10.1038/sj.onc.1206510	http://dx.doi.org/10.1038/sj.onc.1206510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879017				2022-12-17	WOS:000184157000013
J	Bastian, BC				Bastian, BC			Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer	ONCOGENE			English	Article						melanoma; Spitz nevus; genetics; regression; minimal residual disease	SKIN-CANCER; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; SPITZ NEVI; RAS; MUTATIONS; CELLS; DIAGNOSIS; APOPTOSIS; TELOMERE	Analysis of DNA copy number changes using comparative genomic hybridization in melanocytic neoplasms has revealed distinct patterns of chromosomal aberrations between benign melanocytic nevi and melanoma. Whereas the vast majority of melanoma expresses chromosomal aberrations, blue nevi, congenital nevi, and most Spitz nevi typically show no aberrations. A subset of Spitz nevi shows an isolated gain of chromosome 11p, an aberration pattern not observed in melanoma. These Spitz nevi frequently harbor mutations in the HRAS gene located on this chromosomal arm. Comparisons among melanoma types showed that melanomas of the palms, soles, and subungual sites can be distinguished by the presence of multiple gene amplifications that arise very early in their progression. About 50% of these amplifications are found at the cyclin D1 locus. By contrast, amplifications are significantly less frequent in other cutaneous melanoma types and if present arise late in progression. The frequent amplifications in melanomas on acral sites allowed the detection of single basal melanocytes with gene amplifications in the histologically normal appearing skin immediately adjacent to a melanoma. These "field cells" represent subtle melanoma in situ and are likely to represent minimal residual disease that can lead to local recurrences if not excised with safety margins. The high frequency of chromosomal aberrations in melanomas and their relative absence in nevi could indicate that melanocytes of melanomas went through telomeric crisis, whereas melanocytes in nevi did not. Such a scenario would suggest that replicative senescence is a tumor-suppressive mechanism in melanocytic neoplasia. It might also explain part of the phenomenon of regression commonly seen in melanoma. Genomic analysis is a powerful tool to obtain insight in the progression of melanocytic neoplasms with potential clinical applications for classification and detection of minimal residual melanoma.	Univ Calif San Francisco, Ctr Comprehens Canc, Dept Dermatol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Ctr Comprehens Canc, Dept Pathol, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Bastian, BC (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Dept Dermatol, 2340 Sutter St,Rm S434, San Francisco, CA 94115 USA.	bastian@cc.ucsf.edu		Bastian, Boris/0000-0003-1836-6062				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barnhill RL, 1999, HUM PATHOL, V30, P513, DOI 10.1016/S0046-8177(99)90193-4; Bastian BC, 2000, CANCER RES, V60, P1968; Bastian BC, 1999, J INVEST DERMATOL, V113, P1065, DOI 10.1046/j.1523-1747.1999.00787.x; Bastian BC, 1998, CANCER RES, V58, P2170; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; BASTIAN BC, IN PRESS AM J PATHOL; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Brash DE, 1998, CANCER SURV, V32, P69; BRODEUR GM, 1998, GENETIC BASIS HUMAN; Clark W. H., 1990, PATHOLOGY SKIN, P729; DeDavid M, 1997, J AM ACAD DERMATOL, V36, P409, DOI 10.1016/S0190-9622(97)80217-4; Farmer ER, 1996, HUM PATHOL, V27, P528, DOI 10.1016/S0046-8177(96)90157-4; Glover MT, 1997, LANCET, V349, P398, DOI 10.1016/S0140-6736(97)80015-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herlyn M, 1996, AM J PATHOL, V149, P739; JEN J, 1994, CANCER RES, V54, P5523; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Kageshita T, 1999, AM J PATHOL, V154, P745, DOI 10.1016/S0002-9440(10)65321-7; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1111/j.1365-2133.2000.03703.x; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; Pathak S, 2000, INT J ONCOL, V17, P1219; Ramirez Ruben D., 1999, Neoplasia (New York), V1, P42, DOI 10.1038/sj.neo.7900004; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; SAUTER ER, IN PRESS CANC RES, V1, P20; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Straten P, 1996, J CLIN INVEST, V98, P279, DOI 10.1172/JCI118790; vanElsas A, 1996, AM J PATHOL, V149, P883; Veenhuizen KCW, 1997, J PATHOL, V182, P266, DOI 10.1002/(SICI)1096-9896(199707)182:3<266::AID-PATH812>3.0.CO;2-#; WEINBERG RA, 1989, CANCER RES, V49, P3713; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	36	80	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3081	3086		10.1038/sj.onc.1206463	http://dx.doi.org/10.1038/sj.onc.1206463			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789284				2022-12-17	WOS:000183096600009
J	Agathanggelou, A; Dallol, A; Zochbauer-Muller, S; Morrissey, C; Honorio, S; Hesson, L; Martinsson, T; Fong, KM; Kuo, MJ; Yuen, PW; Maher, ER; Minna, JD; Latif, F				Agathanggelou, A; Dallol, A; Zochbauer-Muller, S; Morrissey, C; Honorio, S; Hesson, L; Martinsson, T; Fong, KM; Kuo, MJ; Yuen, PW; Maher, ER; Minna, JD; Latif, F			Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers	ONCOGENE			English	Article						epigenetic inactivation; 3p21.3 region; human cancers	SINGLE NUCLEOTIDE POLYMORPHISM; HUMAN-CHROMOSOME 3P21.3; HIPPEL-LINDAU-DISEASE; CHANNEL SUBUNIT GENE; HUMAN LUNG-CANCER; 3P ALLELE LOSS; NEUROBLASTOMA TUMORS; RENAL-CARCINOMA; BREAST-CANCER; IDENTIFICATION	Many distinct regions of 3p show frequent allelic losses in a wide range of tumour types. Previously, the BLU candidate tumour suppressor gene (TSG) encoded by a gene-rich critical deleted region in 3p21.3 was found to be inactivated rarely in lung cancer, although expression was downregulated in a subset of lung tumour cell lines. To elucidate the role of BLU in tumorigenesis, we analysed BLU promoter methylation status in tumour cell lines and detected promoter region hypermethylation in 39% lung, 42% breast, 50% kidney, 86% neuroblastoma and 80% nasopharyngeal (NPC) tumour cell lines. Methylation of the BLU promoter region correlated with the down-regulation of BLU transcript expression in tumour cell lines. Expression was recovered in tumour cell lines treated with 5-aza 2-deoxycytidine. Exogenous expression of BLU in neuroblastoma (SK-N-SH) and NSCLC (NCI-H1299) resulted in reduced colony formation efficiency, in vitro. Furthermore, methylation of the BLU promoter region was detected in primary sporadic SCLC (14%), NSCLC (19%) and neuroblastoma (41%). As frequent methylation of the RASSF1A 3p21.3 TSG has also been reported in these tumour types, we investigated whether BLU and RASSF1A methylation were independent or related events. No correlation was found between hypermethylation of RASSF1A and BLU promoter region CpG islands in SCLC or neuroblastoma. However, there was association between RASSF1A and BLU methylation in NSCLC (P = 0.0031). Our data suggest that in SCLC and neuroblastoma, RASSF1A and BLU methylations are unrelated events and not a manifestation of a regional alteration in epigenetic status, while in NSCLC there may be a regional methylation effect. Together, these data suggest a significant role for epigenetic inactivation of BLU in the pathogenesis of common human cancers and that methylation inactivation of BLU occurs independent of RASSF1A in SCLC and neuroblastoma tumours.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Gothenburg, Sahlgrenska Hosp Ostra, Dept Clin Genet, S-41685 Gothenburg, Sweden; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Birmingham Childrens Hosp, Birmingham B4 6NH, W Midlands, England; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Birmingham, Sch Med, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Gothenburg; Prince Charles Hospital; University of Birmingham; University of Hong Kong; Cancer Research UK; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Martinsson, Tommy/J-4140-2013; Fong, Kwun M/G-6369-2010; Hesson, Luke/HDM-0311-2022; Dallol, Ashraf/H-8661-2012; Zöchbauer-Müller, Sabine/B-8399-2012; MAHER, EAMONN R/A-9507-2008	Martinsson, Tommy/0000-0002-9403-3123; Dallol, Ashraf/0000-0002-8803-228X; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; MAHER, EAMONN R/0000-0002-6226-6918; Fong, Kwun/0000-0002-6507-1403	NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Angeloni D, 2000, MOL CELL PROBE, V14, P53, DOI 10.1006/mcpr.1999.0277; Angeloni D, 2001, MOL CELL PROBE, V15, P125, DOI 10.1006/mcpr.2000.0341; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Ejeskar K, 1998, BRIT J CANCER, V77, P1787, DOI 10.1038/bjc.1998.297; FEINSTEIN PG, 1995, GENETICS, V140, P573; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Fullwood P, 1999, CANCER RES, V59, P4662; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Honorio S, 2001, MOL CELL PROBE, V15, P391, DOI 10.1006/mcpr.2001.0382; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lerman MI, 2000, CANCER RES, V60, P6116; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Martinez A, 2001, J CLIN PATHOL-MOL PA, V54, P300, DOI 10.1136/mp.54.5.300; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	33	80	90	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1580	1588		10.1038/sj.onc.1206243	http://dx.doi.org/10.1038/sj.onc.1206243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629521				2022-12-17	WOS:000181411900015
J	Salesse, S; Verfaillie, CM				Salesse, S; Verfaillie, CM			BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia	ONCOGENE			English	Review						CML; BCR/ABL; molecular mechanisms; treatments	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; BONE-MARROW-TRANSPLANTATION; FARNESYL-PROTEIN TRANSFERASE; ANTISENSE OLIGODEOXYRIBONUCLEOTIDES SUPPRESS; HEMATOPOIETIC PROGENITOR CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTEGRIN-MEDIATED ADHESION; CYTOTOXIC T-LYMPHOCYTES; RNA ADENOSINE-DEAMINASE		Univ Minnesota, Ctr Canc, Stell Cell Inst, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Dept Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Verfaillie, CM (corresponding author), Univ Minnesota, Ctr Canc, Stell Cell Inst, MMC708,420 Delaware St SE, Minneapolis, MN 55455 USA.	verfa001@tc.umn.edu	Verfaillie, Catherine/H-5148-2013	Verfaillie, Catherine/0000-0001-7564-4079				ACKERMAN SK, 1978, AM J MED, V64, P1061, DOI 10.1016/0002-9343(78)90462-X; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7-1-9; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; ANAFI M, 1993, BLOOD, V82, P3524; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; Apperley JF, 1998, HEMATOL CELL THER, V40, P229; Barrett AJ, 1998, BONE MARROW TRANSPL, V21, P543, DOI 10.1038/sj.bmt.1701131; BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bhatia R, 1999, EXP HEMATOL, V27, P1384, DOI 10.1016/S0301-472X(99)00084-3; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; Bhatia R, 1998, LEUKEMIA, V12, P1708, DOI 10.1038/sj.leu.2401193; BOCCHIA M, 1995, BLOOD, V85, P2680, DOI 10.1182/blood.V85.10.2680.bloodjournal85102680; BOUTIN JA, 1994, INT J BIOCHEM, V26, P1203, DOI 10.1016/0020-711X(94)90091-4; Buchdunger E, 1996, CANCER RES, V56, P100; Calabretta B, 1997, ANTI-CANCER DRUG DES, V12, P373; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; Campbell JDM, 2001, TRENDS IMMUNOL, V22, P88, DOI 10.1016/S1471-4906(00)01857-3; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; Carlo-Stella C, 1999, BLOOD, V93, P3973, DOI 10.1182/blood.V93.11.3973.411k12_3973_3982; CarloStella C, 1996, BLOOD, V88, P3091, DOI 10.1182/blood.V88.8.3091.bloodjournal8883091; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Choudhury A, 1997, BLOOD, V89, P1133, DOI 10.1182/blood.V89.4.1133; Clark RE, 2000, LEUKEMIA, V14, P347, DOI 10.1038/sj.leu.2401677; Clark RE, 2001, LEUKEMIA LYMPHOMA, V42, P871, DOI 10.3109/10428190109097706; Claxton DF, 2001, CRIT REV IMMUNOL, V21, P147; Cobaleda C, 2000, BLOOD, V95, P731, DOI 10.1182/blood.V95.3.731.003k28_731_737; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; COTTER TG, 1995, LEUKEMIA LYMPHOMA, V18, P231, DOI 10.3109/10428199509059612; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dazzi F, 1999, EXP HEMATOL, V27, P1477, DOI 10.1016/S0301-472X(99)00096-X; de Fabritiis P, 1998, BLOOD, V91, P3156, DOI 10.1182/blood.V91.9.3156; deFabritiis P, 1997, LEUKEMIA, V11, P811, DOI 10.1038/sj.leu.2400664; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, CANCER RES, V60, P2049; DIAMOND J, 1995, BLOOD, V85, P2171, DOI 10.1182/blood.V85.8.2171.bloodjournal8582171; Dietrich C, 1996, P NATL ACAD SCI USA, V93, P10815, DOI 10.1073/pnas.93.20.10815; Dou QP, 1999, J PHARMACOL EXP THER, V289, P781; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Emanuel PD, 2000, BLOOD, V95, P639, DOI 10.1182/blood.V95.2.639; End DW, 1999, INVEST NEW DRUG, V17, P241, DOI 10.1023/A:1006380320290; FABER LM, 1995, BLOOD, V86, P2821; FALKENBURG JHF, 1993, J IMMUNOTHER, V14, P305, DOI 10.1097/00002371-199311000-00009; Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; GarciaHernandez B, 1996, MOL MED, V2, P125, DOI 10.1007/BF03402208; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Gibson SA, 1997, MOL BIOTECHNOL, V7, P125, DOI 10.1007/BF02761748; GIRALT S, 1995, BLOOD, V86, P4337, DOI 10.1182/blood.V86.11.4337.bloodjournal86114337; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goodman M, 1998, LEUKEMIA, V12, P1671, DOI 10.1038/sj.leu.2401199; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Hamada M, 1999, FEBS LETT, V461, P77, DOI 10.1016/S0014-5793(99)01367-8; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Hideshima T, 2001, CANCER RES, V61, P3071; Hochhaus A, 1996, BLOOD, V88, P2236, DOI 10.1182/blood.V88.6.2236.bloodjournal8862236; Hochhaus A, 2001, SCIENCE, V293, P2163; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; HONMA Y, 1990, JPN J CANCER RES, V81, P1132, DOI 10.1111/j.1349-7006.1990.tb02524.x; HONMA Y, 1989, CANCER RES, V49, P331; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; James HA, 1998, BLOOD, V91, P371, DOI 10.1182/blood.V91.2.371.371_371_382; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; JIANG YZ, 1995, EXP HEMATOL, V23, P1167; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Karp JE, 2001, BLOOD, V97, P3361, DOI 10.1182/blood.V97.11.3361; Kasper B, 1999, CANCER CHEMOTH PHARM, V44, P433, DOI 10.1007/s002800051001; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAWADA M, 1993, DRUG EXP CLIN RES, V19, P235; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Kuwabara T, 2001, BIOMACROMOLECULES, V2, P1220, DOI 10.1021/bm010107u; Kuwabara T, 2001, BIOMACROMOLECULES, V2, P788, DOI 10.1021/bm010054g; Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4; LANGE W, 1994, FEBS LETT, V338, P175, DOI 10.1016/0014-5793(94)80359-5; LANGE W, 1993, LEUKEMIA, V7, P1786; LANGE W, 1995, KLIN PADIATR, V207, P222, DOI 10.1055/s-2008-1046544; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu M, 1998, CANCER RES, V58, P4947; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; Luger SM, 1996, BLOOD, V87, P1326, DOI 10.1182/blood.V87.4.1326.bloodjournal8741326; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mahon FX, 1995, EXP HEMATOL, V23, P1606; MANDANAS RA, 1993, BLOOD, V82, P1838; Maran A, 1998, BLOOD, V92, P4336, DOI 10.1182/blood.V92.11.4336.423a06_4336_4343; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MELO JV, 1993, BLOOD, V81, P158; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; Mendoza-Maldonado R, 2002, CANCER GENE THER, V9, P71, DOI 10.1038/sj/cgt/7700410; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; NAGASU T, 1995, CANCER RES, V55, P5310; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NIMER SD, 1994, TRANSPLANTATION, V57, P82, DOI 10.1097/00007890-199401000-00015; NOWELL PC, 1960, SCIENCE, V132, P1497; OBRIEN SG, 1994, LEUKEMIA, V8, P2156; ODA T, 1995, LEUKEMIA, V9, P295; OKABE M, 1992, BLOOD, V80, P1330; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAPANDREOU C, 2001, P AN M AM SOC CLIN, V20, pA86; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Peters DG, 2001, BLOOD, V97, P1404, DOI 10.1182/blood.V97.5.1404; Pinilla-Ibarz J, 2000, BLOOD REV, V14, P111, DOI 10.1054/blre.2000.0127; Pinilla-Ibarz J, 2000, BLOOD, V95, P1781, DOI 10.1182/blood.V95.5.1781.005k46_1781_1787; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RATAJCZAK MZ, 1992, INT J CELL CLONING, V10, P205; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; Reichert A, 2001, BLOOD, V97, P1399, DOI 10.1182/blood.V97.5.1399; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Robinson N, 1996, BLOOD, V87, P1249, DOI 10.1182/blood.V87.4.1249.bloodjournal8741249; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley PT, 1996, LEUKEMIA RES, V20, P473, DOI 10.1016/0145-2126(95)00172-7; Rowley PT, 1999, MOL MED, V5, P693, DOI 10.1007/BF03401988; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SanchezGarcia I, 1997, J MOL BIOL, V267, P225, DOI 10.1006/jmbi.1996.0779; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Sawyers C, 2000, BLOOD, V96, p503A; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shah SA, 2001, J CELL BIOCHEM, V82, P110, DOI 10.1002/jcb.1150; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SHORE SK, 1993, ONCOGENE, V8, P3183; SIGURDSSON ST, 1995, TRENDS BIOTECHNOL, V13, P286, DOI 10.1016/S0167-7799(00)88966-0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, P NATL ACAD SCI USA, V94, P3966, DOI 10.1073/pnas.94.8.3966; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; SMETSERS TFCM, 1995, LEUKEMIA, V9, P118; SMETSERS TFCM, 1994, LEUKEMIA, V8, P129; SOIFFER RJ, 1994, BLOOD, V84, P964; Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365-2141.2001.02683.x; SPIERS ASD, 1977, CLIN HAEMATOL, V6, P77; Spiller DG, 1998, ANTISENSE NUCLEIC A, V8, P281, DOI 10.1089/oli.1.1998.8.281; Spiller DG, 1998, BLOOD, V91, P4738, DOI 10.1182/blood.V91.12.4738.412k31_4738_4746; Stinchcombe TE, 2000, BLOOD, V96, p516A; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Tanabe T, 2000, BIOMACROMOLECULES, V1, P108, DOI 10.1021/bm990009x; Tari AM, 1997, BIOCHEM BIOPH RES CO, V235, P383, DOI 10.1006/bbrc.1997.6791; ten Bosch GJA, 1999, BLOOD, V94, P1038, DOI 10.1182/blood.V94.3.1038.415k22_1038_1045; tenBosch GJA, 1996, BLOOD, V88, P3522, DOI 10.1182/blood.V88.9.3522.bloodjournal8893522; TIBERGHIEN P, 1994, BLOOD, V84, P1333; VAERMAN JL, 1995, BLOOD, V86, P3891, DOI 10.1182/blood.V86.10.3891.bloodjournal86103891; Vaerman JL, 1997, BLOOD, V90, P331; VANDERPLAS DC, 1991, LEUKEMIA, V5, P457; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Vey N, 1999, J IMMUNOTHER, V22, P175, DOI 10.1097/00002371-199903000-00009; Warashina M, 1999, CHEM BIOL, V6, P237, DOI 10.1016/S1074-5521(99)80039-8; WARASHINA M, 1997, NUCL AC S SER, V37, P213; Warmuth M, 1999, ANN HEMATOL, V78, P49, DOI 10.1007/s002770050473; Warren EH, 1998, BLOOD, V91, P2197, DOI 10.1182/blood.V91.6.2197; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu YL, 2000, J CELL BIOCHEM, V76, P596; Wu YP, 1999, HUM GENE THER, V10, P2847, DOI 10.1089/10430349950016573; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	197	80	84	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8547	8559		10.1038/sj.onc.1206082	http://dx.doi.org/10.1038/sj.onc.1206082			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476301	Green Published			2022-12-17	WOS:000179734300004
J	Alpaugh, ML; Tomlinson, JS; Kasraeian, S; Barsky, SH				Alpaugh, ML; Tomlinson, JS; Kasraeian, S; Barsky, SH			Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma	ONCOGENE			English	Article						metastasis; lymphovascular invasion; tumor emboli; E-cadherin; sialyl-Lewis X/A; MUC1	POLYMERASE-CHAIN-REACTION; PERIPHERAL-BLOOD; RHOC GTPASE; CANCER; CELLS; EXPRESSION; MODEL; PROLIFERATION; METASTASIS; SELECTIN	Inflammatory breast carcinoma (IBC) is characterized by florid tumor emboli within lymphovascular spaces termed lymphovascular invasion (LVI). Using a human-scid model of IBC (MARY-X), we have demonstrated using retrovirally-mediated dominant-negative E-cadherin mutant approaches (H-2K(d)-E-cad), that the tumor cell embolus (IBC spheroid) forms on the basis of an intact and overexpressed E-cadherin/alpha, beta-catenin axis which mediates tumor cell-tumor cell adhesion analogous to the embryonic blastocyst and accounts for the compactness of the embolus. The tumor cell embolus (IBC spheroid), in contrast, fails to bind the surrounding vascular endothelial cells both in vitro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on its overexpressed MUC1 which are necessary for binding endothelial cell E-selectin. This tumor cell-endothelial cell aversion further contributes to the compactness of the IBC spheroid and its passivity in metastasis dissemination. This passivity is manifested by a dramatic increase in metastatic pulmonary emboli following palpation of the primary tumor. In assessing this passivity of metastatic dissemination, we compared the effects of palpation on MARY-X with the effects of palpation on a derived dominant-negative E-cadherin mutant (H-2K(d)-E-cad), as well as other well known human tumoral xenografts exhibiting no (MCF-7, T47D), low (MDA-MB-231, MDA-MB-468) or high (C8161, M24(met)) levels of spontaneous metastasis but no LVI. Palpation of each xenograft similarly increased intratumoral pressure by 200% (10-->30 mmHg) but dramatically increased the numbers and sizes of pulmonary metastases 10-100-fold (P<0.001) only in MARY-X. The mechanism of this effect was through an immediate post-palpation release of circulating tumor emboli detected 2-3 min after palpation (P<0.01) by human cytokeratin 19 RT-PCR of extracted RNA from 300 mul of murine blood. Although circulating human tumor cell-derived growth factors (IGF-I, IGF-II, TGF-alpha and TGF-beta) and angiogenic factors (VEGF and bFGF) were detected by ELISA in murine serum of MARY-X, palpation did not further increase the circulating levels of these factors (P>0.1). Our findings support the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in IBC.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Barsky, SH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA.	sbarsky@ucla.edu						Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alpaugh ML, 1999, CANCER RES, V59, P5079; Barsky SH, 1997, ONCOGENE, V15, P2077, DOI 10.1038/sj.onc.1201379; Battaglia M, 1998, BONE MARROW TRANSPL, V22, P693, DOI 10.1038/sj.bmt.1701405; BISCHOFF J, 1995, BIOCHEM BIOPH RES CO, V210, P174, DOI 10.1006/bbrc.1995.1643; Bostick PJ, 1998, J CLIN ONCOL, V16, P2632, DOI 10.1200/JCO.1998.16.8.2632; FUJIWARA T, 1993, CANCER RES, V53, P4129; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kleer CG, 2001, MODERN PATHOL, V14, P458, DOI 10.1038/modpathol.3880334; Kruger W, 1996, J CANCER RES CLIN, V122, P679, DOI 10.1007/BF01209032; LEVINE PH, 1985, JNCI-J NATL CANCER I, V74, P291; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1976, CANCER RES, V36, P889; MOORE DH, 1992, GYNECOL ONCOL, V47, P44, DOI 10.1016/0090-8258(92)90073-R; Mori M, 1996, INT J CANCER, V68, P739; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nguyen M, 1997, AM J PATHOL, V150, P1307; NISHIZAKI T, 1990, J SURG RES, V49, P92, DOI 10.1016/0022-4804(90)90116-J; Noun G, 1996, J IMMUNOL, V157, P2455; Rutz HP, 1999, MED HYPOTHESES, V53, P526, DOI 10.1054/mehy.1999.0805; Silverstein M. J., 1997, DUCTAL CARCINOMA SIT; Tomlinson JS, 2001, CANCER RES, V61, P5231; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Wong IN, 1997, BRIT J CANCER, V76, P628, DOI 10.1038/bjc.1997.436; Wyld DK, 1998, INT J CANCER, V79, P288, DOI 10.1002/(SICI)1097-0215(19980619)79:3<288::AID-IJC14>3.0.CO;2-4; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zhu AJ, 1996, J CELL SCI, V109, P3013	29	80	85	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3631	3643		10.1038/sj.onc.1205389	http://dx.doi.org/10.1038/sj.onc.1205389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032865				2022-12-17	WOS:000175793700014
J	Freemantle, SJ; Kerley, JS; Olsen, SL; Gross, RH; Spinella, MJ				Freemantle, SJ; Kerley, JS; Olsen, SL; Gross, RH; Spinella, MJ			Developmentally-related candidate retinoic acid target genes regulated early during neuronal differentiation of human embryonal carcinoma	ONCOGENE			English	Article						retinoic acid; embryonal carcinoma; development; microarray differentiation; mammalian embryogenesis	CELL-LINE; ALL-TRANS; HOMEOBOX GENES; CLONING; IDENTIFICATION; EXPRESSION; MOUSE; CDNA; BIOLOGY; PROTEIN	Embryonal carcinoma is a model of embryonic development as well as tumor cell differentiation. In response to all-trans retinoic acid (RA), the human embryonal carcinoma (EC) cell line, NT2/D1, differentiates toward a neuronal lineage with associated loss of cell growth and tumorigenicity. Through the use of cDNA-based micro-arrays we sought to identify the early downstream targets of RA during differentiation commitment of NT2/D1 cells. A total of 57 genes were induced and 37 genes repressed by RA. RA regulated genes were restricted at 8 h with 27 genes induced and five repressed. The total number of RA-responsive transcripts increased at 24 and 48 h and their pattern of expression was more symmetrical. For a given time point less than 1% of the 128 cDNAs on the expression array were regulated by RA. Many of these gene products are associated with developmental pathways including those of TGF-beta (Lefty A, NMA, follistatin), homeo domain (HoxD1, Meis2, Meis1, Gbx2), IGF (IGFBP3, IGFBP6, CTGF), Notch (manic fringe, ADAM 11), Hedgehog (patched) and Wnt (Frat2, secreted frizzled-related protein 1) signaling. In addition a large cassette of genes induced by RA at 2448 h are associated with cell adhesion, cytoskeletal and matrix remodeling, growth suppression and intracellular signaling cascades. The majority of repressed genes are associated with protein/RNA processing, turnover or metabolism. The early induced genes identified may play a regulatory role in RA-mediated growth suppression and terminal differentiation and may have physiologic or pharmacologic importance during normal human development and retinoid-based cancer therapy or prevention.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Spinella, MJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CA75154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan GJ, 2001, REPRODUCTION, V122, P31, DOI 10.1530/reprod/122.1.31; Altmann CR, 2001, INT REV CYTOL, V203, P447; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Bani-Yaghoub M, 2001, BIOCHEM CELL BIOL, V79, P387, DOI 10.1139/bcb-79-4-387; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUILLET P, 1995, DEV DYNAM, V204, P372, DOI 10.1002/aja.1002040404; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Calvo R, 2000, ANN ONCOL, V11, P207, DOI 10.1023/A:1011152704791; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; DMITROVSKY E, 1990, ONCOGENE, V5, P543; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Edwards DP, 1999, VITAM HORM, V55, P165; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Glass CK, 2000, GENE DEV, V14, P121; Gudas Lorraine J., 1994, P443; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; Heidenreich A, 2000, EUR UROL, V37, P121, DOI 10.1159/000020128; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; INIGUEZ MA, 1994, MOL BRAIN RES, V27, P205, DOI 10.1016/0169-328X(94)90002-7; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kelly DL, 2000, MOL REPROD DEV, V56, P113, DOI 10.1002/(SICI)1098-2795(200006)56:2&lt;113::AID-MRD1&gt;3.0.CO;2-Q; Kerley JS, 2001, BIOCHEM BIOPH RES CO, V285, P969, DOI 10.1006/bbrc.2001.5274; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KURIE JM, 1993, DIFFERENTIATION, V54, P123; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Leypoldt F, 2001, J NEUROCHEM, V76, P806, DOI 10.1046/j.1471-4159.2001.00079.x; Mangelsdorf David J., 1994, P319; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Matin A, 1998, APMIS, V106, P174, DOI 10.1111/j.1699-0463.1998.tb01333.x; MICHIKAWA M, 1993, BIOCHEM BIOPH RES CO, V192, P1312, DOI 10.1006/bbrc.1993.1559; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Nichols J, 2001, DEVELOPMENT, V128, P2333; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; PENG HQ, 1993, CANCER RES, V53, P3574; Pera MF, 2000, J CELL SCI, V113, P5; PERA MF, 1990, CANCER SURV, V9, P243; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; Przyborski SA, 2000, EUR J NEUROSCI, V12, P3521, DOI 10.1046/j.1460-9568.2000.00230.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Satoh J, 2000, J NEUROSCI METH, V94, P155, DOI 10.1016/S0165-0270(99)00143-0; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YUAN SX, 1995, CANCER RES, V55, P3456; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705	66	80	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2880	2889		10.1038/sj.onc.1205408	http://dx.doi.org/10.1038/sj.onc.1205408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973648				2022-12-17	WOS:000175063700013
J	Minamoto, T; Buschmann, T; Habelhah, H; Matusevich, E; Tahara, H; Boerresen-Dale, AL; Harris, C; Sidransky, D; Ronai, Z				Minamoto, T; Buschmann, T; Habelhah, H; Matusevich, E; Tahara, H; Boerresen-Dale, AL; Harris, C; Sidransky, D; Ronai, Z			Distinct pattern of p53 phosphorylation in human tumors	ONCOGENE			English	Article						p53; phosphorylation; human tumor; JNK; ATM; p38 Chk	DNA-DAMAGE; FUNCTION PHENOTYPE; CELL-CYCLE; IN-VITRO; KINASE; ACTIVATION; DOMAIN; BINDING; PROTEIN; MDM2	The protein product of the tumor suppressor gene p53 is phosphorylated on multiple residues by several protein kinases. Using a battery of 10 antibodies developed against different phosphorylated and acetylated residues of p53, we compared the pattern of p53 phosphorylation and acetylation in tumor-derived cell lines, tumor samples, and non-neoplastic cells. Irrespective of tumor types or the presence of p53 mutation, phosphorylation and acetylation of p53 was substantially higher in samples obtained from tumor tissues than those found in non-transformed samples. Among the 10 sites analysed, phosphorylation of residues 15, 81, 392, and acetylation were among the more frequent modifications. Analysis of two of the more abundant phosphorylation or acetylation sites on p53 is sufficient to detect 72% of tumor-derived p53 proteins. The distinct pattern of p53 phosphorylation and acetylation in human tumors may offer a new means to monitor the status and activity of p53 in the course of tumor development and progression.	Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 920, Japan; Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Hiroshima, Japan; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, Oslo, Norway; NCI, Human Carcinogenesis Lab, Bethesda, MD 20892 USA; Johns Hopkins Univ, Baltimore, MD USA	Icahn School of Medicine at Mount Sinai; Kanazawa University; Hiroshima University; University of Oslo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave Levy Pl,Box 1130, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400; Habelhah, Hasem/0000-0003-4097-1007	NCI NIH HHS [CA78419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Buschmann T, 2000, CANCER RES, V60, P896; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Buschmann T, 2000, J MOL BIOL, V295, P1009, DOI 10.1006/jmbi.1999.3387; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Fernandez PL, 1998, J CLIN PATHOL-MOL PA, V51, P305, DOI 10.1136/mp.51.6.305; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALL PA, 1993, ONCOGENE, V8, P203; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PRICE BD, 1995, ONCOGENE, V11, P73; Prives C, 1999, J PATHOL, V187, P112; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542	35	80	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3341	3347		10.1038/sj.onc.1204458	http://dx.doi.org/10.1038/sj.onc.1204458			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423984				2022-12-17	WOS:000169248800004
J	Zhang, HS; Dean, DC				Zhang, HS; Dean, DC			Rb-mediated chromatin structure regulation and transcriptional repression	ONCOGENE			English	Review						chromatin remodeling; cell cycle; Rb	CELL-CYCLE ARREST; HISTONE DEACETYLASE COMPLEX; SWI-SNF COMPLEX; RETINOBLASTOMA PROTEIN; GROWTH ARREST; REMODELING COMPLEX; PRB-FAMILY; S-PHASE; E2F; RECRUITMENT		Washington Univ, Sch Med, Div Mol Oncol, St Louis, MO 63110 USA; Sangamo Biosci Inc, Richmond, CA 94804 USA	Washington University (WUSTL); Sangamo Therapeutics, Inc.	Dean, DC (corresponding author), Washington Univ, Sch Med, Div Mol Oncol, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.							Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Staehling-Hampton K, 1999, GENETICS, V153, P275; Strobeck MW, 2000, ONCOGENE, V19, P1857, DOI 10.1038/sj.onc.1203510; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Takahashi Y, 2000, GENE DEV, V14, P804; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong AKC, 2000, CANCER RES, V60, P6171; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	43	80	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2001	20	24					3134	3138		10.1038/sj.onc.1204338	http://dx.doi.org/10.1038/sj.onc.1204338			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420730				2022-12-17	WOS:000169308500018
J	Kurokawa, K; Iwashita, T; Murakami, H; Hayashi, H; Kawai, K; Takahashi, M				Kurokawa, K; Iwashita, T; Murakami, H; Hayashi, H; Kawai, K; Takahashi, M			Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction	ONCOGENE			English	Article						SNT/FRS2; RET; SHC; GDNF; MEN2	PHOSPHOTYROSINE-DEPENDENT INTERACTION; FIBROBLAST-GROWTH-FACTOR; NEOPLASIA TYPE 2B; NEUROTROPHIC FACTOR; TRANSFORMING ACTIVITY; CELL-DIFFERENTIATION; ADAPTER PROTEINS; INSULIN-RECEPTOR; PC12 CELLS; NPEY MOTIF	SNT/FRS2 is a lipid anchored docking protein that contains an amino-terminal myristylation signal, followed by a phosphotyrosine-binding (PTB) domain and a carboxy-terminal region with multiple tyrosine residues. Here we show that the SNT/FRS2 PTB domain binds to RET receptor tyrosine kinase activated by glial cell line-derived neurotrophic factor (GDNF) or multiple endocrine neoplasia (MEN) 2 mutations. Analyses by site directed-mutagenesis revealed that it binds to tyrosine 1062 in RET that is also known to be a binding site for the SHC adaptor protein. Whereas SHC bound to RET was associated with GRB2 and GAB1 proteins, SNT/FRS2 was associated with GRB2 only, suggesting that SNT/FRS2 is involved mainly in the activation of the RAS/mitogen activated protein kinase (MAPK) pathway but not the phosphatidylinositol 3-kinase (PI3-K)/AKT pathway. In addition, phosphorylated SNT/FRS2 appeared to directly complex with SHP-2 tyrosine phosphatase. These results suggest that tyrosine 1062 in RET provides a site for the interaction of multiple signaling molecules and that the balance of SHC and SNT/FRS2 binding may affect the nature of the intracellular signaling for cell proliferation, differentiation and survival induced by activated RET.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kumi, Kawai/I-6275-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Kumi, Kawai/0000-0002-7772-2605; Takahashi, Masahide/0000-0002-2803-2683; 				Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Califano D, 2000, J BIOL CHEM, V275, P19297, DOI 10.1074/jbc.M905866199; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2000, BIOCHEM BIOPH RES CO, V268, P804, DOI 10.1006/bbrc.2000.2227; Iwashita T, 1996, ONCOGENE, V12, P481; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	30	80	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					1929	1938		10.1038/sj.onc.1204290	http://dx.doi.org/10.1038/sj.onc.1204290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360177				2022-12-17	WOS:000168043800001
J	Kondo, Y; Koga, S; Komata, T; Kondo, S				Kondo, Y; Koga, S; Komata, T; Kondo, S			Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component	ONCOGENE			English	Article						2-5A; antisense; telomerase; prostate cancer; apoptosis	HUMAN TELOMERASE ACTIVITY; MALIGNANT GLIOMA; TARGETING RNA; IN-VITRO; CELLS; INHIBITION; APOPTOSIS; 2-5A; DIFFERENTIATION; CARCINOMA	Prostate cancer is the most common malignancy of elderly men in the United States. Since there is no curative treatment for advanced prostate cancer, exploration of novel modalities of treatment is essential. Telomerase, a ribsnucleoprotein, is detected in the vast majority of prostate cancer, but not in normal or benign prostatic hyperplasin tissues. Thus, telomerase is expected to be a very strong candidate for targeted therapy of prostate cancer. In this study, we synthesized a 19-mer antisense oligonucleotide against the RNA component of human telomerase (hTR) linked to a 2-5A molecule (2-5A-anti-hTR) and examined its cytotoxic effect on prostate cancer cells. The 2-5A antisense strategy relies on the recruitment and activation of RNase L at the site of targeted RNA sequence. We here show that treatment with 2-5A-anti-hTR in the presence of a cationic liposome reduced cell viability of turner cell lines tested to 9-18% within 6 days, In contrast, normal fibroblast cells mere resistant to the treatment. Its effect was mainly due to induction of apoptosis by activated caspase family members. Furthermore, treatment of subcutaneous tumors in nude mice with 2-SA-anti-hTR significantly suppressed the tumor growth through induction of apoptosis (P < 0.001), The treatment with 2-5A-anti-hTR may be a promising strategy for the treatment modality of prostate cancer with telomerase activity.	CUNY, Mt Sinai Med Ctr, Dept Neurosurg, New York, NY 10029 USA; Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondo, S (corresponding author), CUNY, Mt Sinai Med Ctr, Dept Neurosurg, 1 Gustave L Levy Pl,Box 1136, New York, NY 10029 USA.				NCI NIH HHS [1R01CA80233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bacchetti S, 1996, CANCER SURV, V28, P197; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo S, 1996, ONCOGENE, V13, P1279; Lin Y, 1997, J UROLOGY, V157, P1161, DOI 10.1016/S0022-5347(01)65160-7; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Naitoh John, 1998, Cancer Research, V58, P2895; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Shay Jerry W., 1996, Current Opinion in Oncology, V8, P66, DOI 10.1097/00001622-199601000-00012; Sikora K, 1997, BRIT J UROL, V79, P64, DOI 10.1111/j.1464-410X.1997.tb16923.x; Sommerfeld HJ, 1996, CANCER RES, V56, P218; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WINGO PA, 1995, CA CANC J CLIN, V45, P8030; XIAO W, 1994, BIOORG MED CHEM LETT, V4, P2609, DOI 10.1016/S0960-894X(01)80294-8; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	29	80	103	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 27	2000	19	18					2205	2211		10.1038/sj.onc.1203538	http://dx.doi.org/10.1038/sj.onc.1203538			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822370				2022-12-17	WOS:000086974100005
J	Kim, KR; Yoshizaki, T; Miyamori, H; Hasegawa, K; Horikawa, T; Furukawa, M; Harada, S; Seiki, M; Sato, H				Kim, KR; Yoshizaki, T; Miyamori, H; Hasegawa, K; Horikawa, T; Furukawa, M; Harada, S; Seiki, M; Sato, H			Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth	ONCOGENE			English	Article						EB virus; LMP1; MDCK; Ets1; transformation; tubulogenesis	NF-KAPPA-B; FACTOR-RECEPTOR FAMILY; PLASMINOGEN-ACTIVATOR; TRANSCRIPTION FACTOR; CHICK-EMBRYO; LYMPHOCYTE TRANSFORMATION; MATRIX-METALLOPROTEINASE; GENE; MEMBRANE-PROTEIN-1; INDUCTION	The Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) has a significant role in initiating EBV-associated lymphoproliferative disease and EBV-related malignancies, In view of clinical features related to the type of EBV latency, LMP1 may influence invasiveness of EBV associated tumors categorized as types II and III as represented on nasopharyngeal carcinoma (NPC), To screen for genes associated with invasion of epithelial cells transformed by LIMP1, Madin-Darby canine kidney (MDCK) epithelial cells were transformed by LMP1, Stable transfection of a LMP1 gene into MDCK cells induced morphological change from cobblestone to a long spindle-shape, reduced cell-cell adhesion and caused high cell motility, Parental MDCK cells, which form spherical cysts in three-dimensional collagen gel matrix, form branching tubules following exposure to hepatocyte growth factor (HGF). MDCK cells transformed by LMP1 showed invasive growth to form branching tubules into collagen gel without HGF-treatment. mRNA differential display and Northern hybridization identified plasminogen activator inhibitor-1 (PAI-I), urokinase type plasminogen activator (uPA) and ets1 as genes upregulated during transformation by LMP1. Expression of a dominant negative type of Ets1 in LMP1-transformed cells downregulated uPA expression and cell motility, Deletion of LMP1 cytoplasmic carboxy-terminal activating region 1 (CTAR1) domain abolished transformation, but a deletion mutant lacking CTAR2 domain still retained transforming and uPA-inducing ability, Expression of Ets1 was immunolocalized in tumor cells of NPC tissue which frequently express LMP1, Taken together, it is suggested that LMP1 induces expression of Ets1 which may contribute to invasion of NPC by stimulating cell motility and uPA expression.	Kanazawa Univ, Dept Mol Virol & Oncol, Inst Canc Res, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Sch Med, Dept Otolaryngol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 108, Japan	Kanazawa University; Kanazawa University; University of Tokyo	Sato, H (corresponding author), Kanazawa Univ, Dept Mol Virol & Oncol, Inst Canc Res, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015					BAICHWAL VR, 1988, ONCOGENE, V2, P461; BARDELLI A, 1992, ONCOGENE, V7, P1973; BINDAL AK, 1994, J NEURO-ONCOL, V22, P101, DOI 10.1007/BF01052886; D'Orazio D, 1997, GENE, V201, P179, DOI 10.1016/S0378-1119(97)00445-9; Davies G, 1999, ANTICANCER RES, V19, P547; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Devergne O, 1996, MOL CELL BIOL, V16, P7098; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FOEKENS JA, 1994, J CLIN ONCOL, V12, P1648, DOI 10.1200/JCO.1994.12.8.1648; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Grisendi S, 1998, J CELL PHYSIOL, V176, P465, DOI 10.1002/(SICI)1097-4652(199809)176:3<465::AID-JCP3>3.0.CO;2-M; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hiscox S, 1999, ANTICANCER RES, V19, P509; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Kadono Y, 1998, CANCER RES, V58, P2240; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Kieff E, 1996, VIROLOGY, P2343; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Liebowitz David, 1993, P107; LIOTTA LA, 1992, SCI AM, V266, P54, DOI 10.1038/scientificamerican0292-54; MILLER G, 1990, VIROLOGY, P1921; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nabeshima K, 1998, INT J CANCER, V78, P750, DOI 10.1002/(SICI)1097-0215(19981209)78:6<750::AID-IJC13>3.0.CO;2-#; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nakayama T, 1996, AM J PATHOL, V149, P1931; Noritake H, 1999, CLIN EXP METASTAS, V17, P105, DOI 10.1023/A:1006596620406; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUEVA C, 1993, ONCOGENE, V8, P2511; Rickinson AB, 1996, VIROLOGY, P2397; SAPPINO AP, 1991, J CLIN INVEST, V88, P1073, DOI 10.1172/JCI115406; SATO H, 1992, ONCOGENE, V7, P77; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Takeshita H, 1999, J VIROL, V73, P5548, DOI 10.1128/JVI.73.7.5548-5555.1999; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Young L S, 1992, Semin Cancer Biol, V3, P273; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	54	80	88	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1764	1771		10.1038/sj.onc.1203502	http://dx.doi.org/10.1038/sj.onc.1203502			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777210				2022-12-17	WOS:000086292500004
J	Pim, D; Thomas, M; Javier, R; Gardiol, D; Banks, L				Pim, D; Thomas, M; Javier, R; Gardiol, D; Banks, L			HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase	ONCOGENE			English	Article						HPV E6; DLG; ubiquitin	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; P53 IN-VITRO; CERVICAL-CANCER; HUMAN HOMOLOG; PROGNOSTIC-SIGNIFICANCE; MUTATIONAL ANALYSIS; PDZ DOMAINS; CELLS; ONCOPROTEIN	The Discs Large (DLG) tumour suppressor protein is targeted for ubiquitin mediated degradation by the high risk human papillomavirus (HPV) E6 proteins. In this study we have used a mutational analysis of E6 in order to investigate the mechanism by which this occurs. We first show that the differences in the affinities of HPV-16 and of HPV-18 E6 proteins for binding DLG is reflected in their respective abilities to target DLG for degradation. A mutational analysis of HPV-18 E6 has enabled us to define regions within the carboxy terminal half of the protein which are essential for the ability of E6 to direct the degradation of DLG. Mutants within the amino terminal portion of E6 which have lost the ability to bind the E6-AP ubiquitin ligase, as measured by their ability to degrade p53, nonetheless retain the ability to degrade DLG. Significant levels of DLG degradation are also obtained using wheat germ extracts which lack E6-AP. Finally, we show that the transfer of the DLG binding domain onto the low risk HPV-6 E6 confers DLG binding activity to that protein and, most significantly, allows HPV-6 E6 to target DLG for degradation. These results indicate that E6 mediated degradation of DLG does not involve the EB-AP ubiquitin ligase and, in addition, shows that the high and low risk HPV E6 proteins most likely share a common cellular intermediary in the ubiquitin pathway.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Fac Ciencias Bioquim, Inst Mol & Cellular Biol, Dept Microbiol, RA-2000 Rosario, Argentina	International Center for Genetic Engineering & Biotechnology (ICGEB); Baylor College of Medicine	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA58541, R01 CA058541] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BARNES W, 1988, GYNECOL ONCOL, V29, P267, DOI 10.1016/0090-8258(88)90225-9; BURNETT AF, 1992, GYNECOL ONCOL, V47, P343, DOI 10.1016/0090-8258(92)90137-8; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 1998, J GEN VIROL, V79, P1963, DOI 10.1099/0022-1317-79-8-1963; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HIRAIWA A, 1993, VIROLOGY, V192, P102, DOI 10.1006/viro.1993.1012; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Inoue T, 1998, MOL CARCINOGEN, V21, P215; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; THOMAS M, 1995, ONCOGENE, V10, P261; VILLA LL, 1991, VIROLOGY, V181, P374; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; ZHANG JW, 1995, GYNECOL ONCOL, V57, P170, DOI 10.1006/gyno.1995.1120; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	47	80	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					719	725		10.1038/sj.onc.1203374	http://dx.doi.org/10.1038/sj.onc.1203374			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698489				2022-12-17	WOS:000085192100001
J	Ciminale, V; Zotti, L; D'Agostino, DM; Ferro, T; Casareto, L; Franchini, G; Bernardi, P; Chieco-Bianchi, L				Ciminale, V; Zotti, L; D'Agostino, DM; Ferro, T; Casareto, L; Franchini, G; Bernardi, P; Chieco-Bianchi, L			Mitochondrial targeting of the p13(II) protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I)	ONCOGENE			English	Article						HTLV; X region; p13(II); mitochondria; Delta psi	GREEN-FLUORESCENT PROTEIN; CYTOCHROME-C; CYCLOSPORINE-A; MESSENGER-RNA; BCL-2; APOPTOSIS; RELEASE; LOCALIZATION; INFECTIVITY; EXPRESSION	The X region of the HTLV-I genome contains four major open reading frames (ORFs), two of which, termed x-I and x-II, are of still undefined biological significance. By indirect immunofluorescence and dual labeling with marker proteins, we demonstrate that p13(II), an 87-amino acid protein coded by the x-II ORF, is selectively targeted to mitochondria, Mutational analysis revealed that mitochondrial targeting of p13(II) is directed by an atypical 10-amino acid signal sequence that is not cleaved upon import and is able to target the Green Fluorescent Protein to mitochondria, Expression of p13(II) results in specific alterations of mitochondrial morphology and distribution from a typical string-like, dispersed network to round-shaped clusters, suggesting that p13(II) might interfere with processes relying on an intact mitochondrial architecture. Functional studies of mitochondria with the cationic fluorochrome tetramethylrhodamine revealed that a subpopulation of the cells with p13(II)-positive mitochondria show a disruption in the mitochondrial inner membrane potential (Delta psi), an early event observed in cells committed to apoptosis, Taken together, these results suggest novel virus-cell interactions that might be important in HTLV-I replication and/or pathogenicity.	Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy; NCI, Basic Res Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy	IRCCS Istituto Oncologico Veneto (IOV); University of Padua; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Padua	Ciminale, V (corresponding author), Univ Padua, Dept Oncol & Surg Sci, Via Gattamelata 64, I-35128 Padua, Italy.		D'Agostino, Donna/AAW-1765-2021; Ciminale, Vincenzo/L-1416-2016; Bernardi, Paolo/C-3656-2008	D'Agostino, Donna/0000-0002-3451-5622; Ciminale, Vincenzo/0000-0001-6197-1802; Bernardi, Paolo/0000-0001-9187-3736	NATIONAL CANCER INSTITUTE [Z01BC005645, ZIABC005645] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZZONE GF, 1965, P NATL ACAD SCI USA, V53, P1084, DOI 10.1073/pnas.53.5.1084; BENKO D M, 1990, New Biologist, V2, P1111; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1999, IN PRESS PHYSL REV; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Cann A.J., 1996, FIELDS VIROLOGY, P1849; Chen YMA, 1997, INT J CANCER, V71, P196, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;196::AID-IJC12&gt;3.0.CO;2-G; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; DAgostino DM, 1997, J VIROL, V71, P75, DOI 10.1128/JVI.71.1.75-83.1997; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; DIETEL M, 1994, J CANCER RES CLIN, V120, P263, DOI 10.1007/BF01236382; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HICKISH T, 1994, CANCER RES, V54, P2808; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; Mulloy JC, 1996, J VIROL, V70, P3599, DOI 10.1128/JVI.70.6.3599-3605.1996; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Rabson A. B., 1997, P205; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Rojo G, 1998, J VIROL, V72, P7583, DOI 10.1128/JVI.72.9.7583-7588.1998; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SMITH DB, 1994, CURRENT PROTOCOLS MO, V2, P1671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tollefson AE, 1996, VIROLOGY, V220, P152, DOI 10.1006/viro.1996.0295; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida M, 1996, SEMIN VIROL, V7, P349, DOI 10.1006/smvy.1996.0042	42	80	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4505	4514		10.1038/sj.onc.1203047	http://dx.doi.org/10.1038/sj.onc.1203047			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442641	Green Published			2022-12-17	WOS:000081813500012
J	Schmid, M; Malicki, D; Nobori, T; Rosenbach, MD; Campbell, K; Carson, DA; Carrera, CJ				Schmid, M; Malicki, D; Nobori, T; Rosenbach, MD; Campbell, K; Carson, DA; Carrera, CJ			Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16(INK4A) (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC)	ONCOGENE			English	Article						non-small cell lung cancer; MTAP; p16(INK4A); cell-cycle regulation; chromosome 9p21	ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE-4 INHIBITOR GENE; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; ALPHA-INTERFERON; CHROMOSOME 9P; P16/MTS1 GENE; HUMAN GLIOMAS; NECK-CANCER; P18 GENES	Homozygous deletions of the tumor suppressor gene p16(INK4A) and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). To determine the frequency of co-deletion of these two genes, we investigated 50 samples of primary NSCLC using a quantitative PCR-ELISA. All specimens were fixed in formalin, paraffin embedded and stored until assayed. Histologic subtypes included 25 adenocarcinomas (50%), 21 squamous cell carcinomas (42%) and four large cell carcinomas (8%). Homozygous deletions of MTAP exon 8 could be detected in 19 of 50 NSCLC samples (38%). Adenocarcinoma (11 of 25, 44%) showed a higher deletion frequency than squamous cell carcinoma (six of 21, 29%). In contrast, homozygous p16(INK4A) deletions were detected in only nine of 50 (18%) samples using specific primers for p16(INK4A) exon 1 alpha. No difference between the histological subtypes and p16(INK4A) deletion frequency was observed. We further investigated the ten samples with MTAP deletions but intact p16(INK4A) exon 1 alpha with primers specific for p16(INK4A) exon 3, the exon nearest to MTAP exon 8. Interestingly, none of the ten samples had deletion of the p16(INK4A) exon 3 coding region. Fine mapping analysis performed in ten samples showed a frequent breakpoint between MTAP exon 4 and exon 5. In addition, p16 protein expression could not be detected in five out of six samples with intact p16 but deleted MTAP locus. These data show a high frequency of homozygous MTAP deletions in NSCLC which is associated with detectable co-deletion of p16(INK4A) only half of the cases. This result suggests the existence either of another tumor suppressor gene telomeric of p16(INK4A) or of deletions involving 3'-untranslated (3'-UTR) regulatory regions of p16(INK4A) that can interfere with its expression or function.	Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Carrera, CJ (corresponding author), Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [R21 CA 68260, U01 CA 64926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA068260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker FG, 1997, J NEURO-ONCOL, V31, P17, DOI 10.1023/A:1005768910871; Batova A, 1997, CANCER RES, V57, P832; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Carrera C. J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P407; Carrera C J, 1986, Adv Exp Med Biol, V195 Pt B, P643; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; Chen ZH, 1996, CANCER RES, V56, P1083; Costello JF, 1996, CANCER RES, V56, P2405; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DREYLING MH, 1995, CANCER RES, V55, P984; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Herman JG, 1997, CANCER RES, V57, P837; HORI H, 1996, CANCER RES, V56, P5633; Jagasia AA, 1996, CANCER LETT, V105, P77, DOI 10.1016/0304-3835(96)04273-5; KAMATANI N, 1981, BIOCHIM BIOPHYS ACTA, V675, P344, DOI 10.1016/0304-4165(81)90024-6; KAMATANI N, 1982, BLOOD, V60, P1387; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; Kratzke RA, 1996, CANCER RES, V56, P3415; KUBOTA M, 1983, J BIOL CHEM, V258, P7288; Li XS, 1996, CANCER RES, V56, P5055; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1991, CANCER RES, V51, P3193; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; NOBORI T, 1993, CANCER RES, V53, P1098; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLOPADE OI, 1995, P NATL ACAD SCI USA, V92, P6489, DOI 10.1073/pnas.92.14.6489; PEGG AE, 1969, BIOCHEM J, V115, P241, DOI 10.1042/bj1150241; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rao LS, 1997, DIAGN MOL PATHOL, V6, P115, DOI 10.1097/00019606-199704000-00008; Reed AL, 1996, CANCER RES, V56, P3630; REED JA, 1995, CANCER RES, V55, P2713; Rishi AK, 1997, CANCER RES, V57, P5129; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU T, 1995, INT J CANCER, V63, P616, DOI 10.1002/ijc.2910630503; Singh AD, 1996, OPHTHALMIC GENET, V17, P39, DOI 10.3109/13816819609057868; STADLER WM, 1994, CANCER RES, V54, P2060; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; Tran PT, 1997, GENE, V186, P263, DOI 10.1016/S0378-1119(96)00718-4; TRAWEEK ST, 1988, BLOOD, V71, P1568; Ueki K, 1996, CANCER RES, V56, P150; VANDERRIET P, 1994, CANCER RES, V54, P1156; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; WALKER DG, 1995, CANCER RES, V55, P20; Wiest JS, 1997, CANCER RES, V57, P1; Woloschak M, 1996, CANCER RES, V56, P2493; YOSHIDA S, 1995, CANCER RES, V55, P2756; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	63	80	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2669	2675		10.1038/sj.onc.1202205	http://dx.doi.org/10.1038/sj.onc.1202205			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840931				2022-12-17	WOS:000077058900015
J	Dong, JT; Sipe, TW; Hyytinen, ER; Li, CL; Heise, C; McClintock, DE; Grant, CD; Chung, LWK; Frierson, HF				Dong, JT; Sipe, TW; Hyytinen, ER; Li, CL; Heise, C; McClintock, DE; Grant, CD; Chung, LWK; Frierson, HF			PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate	ONCOGENE			English	Article						PTEN/MMAC1; prostate cancer; allelic loss; mutation; homozygous deletion	TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; COWDEN-DISEASE; MICROSATELLITE INSTABILITY; PTEN GENE; CANCER; DELETION; BREAST; CHROMOSOME; FREQUENT	Deletion of the q23-24 region of human chromosome 10 is one of the most frequent genetic alterations in prostate cancer, suggesting that inactivation of a tumor suppressor gene in this region is involved in the development or progression of this carcinoma. A candidate gene, PTEN/MMAC1, has been identified from this chromosomal region; mutations of this gene have been found in various advanced tumors and cell lines including those of prostate cancer. To further define the role of PTEN/MMAC1 in the development of prostate cancer and its spectrum of genetic alterations, we analysed 40 pT2 or pT3 prostate tumors for allelic loss, mutations, and homozygous deletions using PCR-based methods. Six tumors showed loss of heterozygosity for one of the ten markers analysed, while one tumor showed loss of two markers. None of the markers within PTEN/MMAC1 was lost. Direct sequencing of PCR amplified exons and intron/exon junctions of all 40 tumors revealed three sequence variants, one of which was a point mutation in exon 9, while the other two were polymorphisms. Using multiplex PCR, no homozygous deletions were detected in any of the neoplasms. Our results showing a low frequency of alterations of PTEN/MMAC1 in pT2 and pT3 prostate cancers suggest that this gene plays an insignificant role in the development of most low stage carcinomas of the prostate.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Urol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Dong, JT (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA.			Dong, Jin-Tang/0000-0003-2349-5782				*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B; ARPS S, 1993, CANCER GENET CYTOGEN, V66, P93, DOI 10.1016/0165-4608(93)90234-D; ATKIN NB, 1985, HUM GENET, V70, P359, DOI 10.1007/BF00295378; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Cairns P, 1997, CANCER RES, V57, P4997; Cunningham JM, 1996, CANCER RES, V56, P4475; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Dong JT, 1997, GENOMICS, V41, P25, DOI 10.1006/geno.1997.4618; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; LUNDGREN R, 1988, CANCER GENET CYTOGEN, V35, P103, DOI 10.1016/0165-4608(88)90128-8; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Murakami YS, 1996, CANCER RES, V56, P2157; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; NIHEI N, 1995, GENE CHROMOSOME CANC, V14, P112, DOI 10.1002/gcc.2870140205; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Risinger JI, 1997, CANCER RES, V57, P4736; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Trybus TM, 1996, CANCER RES, V56, P2263; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Wang SI, 1997, CANCER RES, V57, P4183	34	80	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1979	1982		10.1038/sj.onc.1202119	http://dx.doi.org/10.1038/sj.onc.1202119			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788441				2022-12-17	WOS:000076423500011
J	Greco, A; Fusetti, L; Villa, R; Sozzi, G; Minoletti, F; Mauri, P; Pierotti, MA				Greco, A; Fusetti, L; Villa, R; Sozzi, G; Minoletti, F; Mauri, P; Pierotti, MA			Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans	ONCOGENE			English	Article						dermatofibrosarcoma; gene rearrangement; transformation; PDGFB gene	SIMIAN SARCOMA-VIRUS; CHRONIC MYELOMONOCYTIC LEUKEMIA; IN-SITU HYBRIDIZATION; SOFT-TISSUE TUMORS; CELL-LINES; TYROSINE KINASES; HUMAN GLIOMA; EXPRESSION; RECEPTORS; PROLIFERATION	As a consequence of a reciprocal translocation t(17;22)(q22;q13) and of supernumerary ring chromosomes derived from the t(17;22), a fusion between the platelet-derived growth factor b-chain (PDGF, c-sis proto-oncogene) and the collagen type 1A1 (COL1A1) genes has been recently described in dermatofibrosarcoma protuberans (DP), an infiltrating skin tumor (Simon ct al,, 1997), Although PDGFB has been implicated in transforming processes via autocrine and paracrine pathways, by the activation of the cognate receptor, no direct evidence of its involvement in neoplastic transformation of human tumours has been so far provided. In this report, we have tested the DNA from four DPs in the classical DNA transfection assay onto NIH3T3 fibroblast cell line. All the DNAs induced the formation of transformed foci in the transfected cultures whose derived cell lines were shown to contain a fused sequence comprising the human COL1A1 and PDGF genes. The relative breakpoint regions have been sequenced revealing that this gene fusion deleted exon 1 of PDGF and released the growth factor from its normal regulation, All the biochemical and biological assays were consistent with the model of an autocrine mechanism for NIH3T3 transformation by the human rearranged PDGFB gene involving the activation of the endogeneous PDGF receptor.	Ist Nazl Tumori, Div Expt Oncol A, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Milan, Italy.		sozzi, gabriella/G-8259-2011; Greco, Angela/C-1953-2017; Pierotti, Marco Alessandro/AAC-4728-2022	sozzi, gabriella/0000-0001-9360-6914; Greco, Angela/0000-0003-2994-0349; Pierotti, Marco Alessandro/0000-0002-7431-8332; Villa, Riccardo/0000-0001-8385-800X				BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CAMBY I, 1994, PROSTATE, V24, P187, DOI 10.1002/pros.2990240404; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chin LS, 1997, CLIN CANCER RES, V3, P771; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; HERMANSON M, 1992, CANCER RES, V52, P3213; KIKUCHI K, 1993, BIOCHEM BIOPH RES CO, V196, P409, DOI 10.1006/bbrc.1993.2264; MAXWELL M, 1986, J CLIN INVEST, P131; MINOLETTI F, 1995, GENE CHROMOSOME CANC, V13, P62, DOI 10.1002/gcc.2870130110; Pedeutour F, 1996, CYTOGENET CELL GENET, V72, P171, DOI 10.1159/000134178; PEDEUTOUR F, 1993, CANCER GENET CYTOGEN, V67, P149, DOI 10.1016/0165-4608(93)90171-H; PERES R, 1987, CANCER RES, V47, P3425; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; Sambrook J, 1989, MOL CLONING LAB MANU; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; TAPLEY P, 1992, ONCOGENE, V7, P371; TSAI LH, 1994, BLOOD, V83, P51; WANG J, 1994, CANCER RES, V54, P560; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; WEINSTEIN IB, 1987, J CELL BIOCHEM, V33, P213, DOI 10.1002/jcb.240330308; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; WESTERMARK B, 1993, CYTOKINES, P1	34	80	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 10	1998	17	10					1313	1319		10.1038/sj.onc.1202051	http://dx.doi.org/10.1038/sj.onc.1202051			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	117VL	9771975				2022-12-17	WOS:000075803300014
J	Dahia, PLM; FitzGerald, MG; Zhang, X; Marsh, DJ; Zheng, ZM; Pietsch, T; von Deimling, A; Haluska, FG; Haber, DA; Eng, C				Dahia, PLM; FitzGerald, MG; Zhang, X; Marsh, DJ; Zheng, ZM; Pietsch, T; von Deimling, A; Haluska, FG; Haber, DA; Eng, C			A highly conserved processed PTEN pseudogene is located on chromosome band 9p21	ONCOGENE			English	Article						MMAC1; TEP1; 9p; Cowden; pseudogene	COWDEN DISEASE; DELETIONS; GENE	PTEN/MMAC1/TEP1, encoding a dual-specificity phosphatase, is a tumor suppressor gene which has recently been cloned and mapped to chromosome 10q23.3. We have shown that germline mutations of PTEN are present in individuals with two hamartoma syndromes: Cowden Syndrome, associated with a predisposition to breast and thyroid cancers, and Bannayan-Zonana syndrome. Somatic mutations of PTEN have been reported in a variety of human cancer cell lines, suggesting a potential role for this gene in the pathogenesis of human malignancies. We report the identification of a highly conserved PTEN processed pseudogene, psi PTEN, which shares over 98% homology with the coding region of functional PTEN, and its localisation to chromosome 9p21. The high sequence homology of psi PTEN with the PTEN transcript may potentially lead to misinterpretation when performing mutation analyses based on cDNA templates. Caution should be exerted when using such screening approaches.	Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Dept Adult Oncol, Translat Res Lab, Boston, MA 02115 USA; Dana Farber Canc Inst, Program Populat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Bonn; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Dept Adult Oncol, Translat Res Lab, SM822, Boston, MA 02115 USA.		von Deimling, Andreas/F-7774-2013; Marsh, Deborah J/I-1491-2014	von Deimling, Andreas/0000-0002-5863-540X; Marsh, Deborah J/0000-0001-5899-4931; Eng, Charis/0000-0002-3693-5145				Dahia PLM, 1997, CANCER RES, V57, P4710; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EINHORN S, 1993, LEUKEMIA LYMPHOMA, V11, P191, DOI 10.3109/10428199309086995; Eng C, 1997, J Genet Couns, V6, P181, DOI 10.1023/A:1025664119494; GOJOBORI T, 1982, J MOL EVOL, V18, P36; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI WH, 1987, J MOL EVOL, V25, P333; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Maestre J, 1995, EMBO J, V14, P6333, DOI 10.1002/j.1460-2075.1995.tb00324.x; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253	18	80	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2403	2406		10.1038/sj.onc.1201762	http://dx.doi.org/10.1038/sj.onc.1201762			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620558				2022-12-17	WOS:000073428000013
J	Kruger, A; Sanchez-Sweatman, OH; Martin, DC; Fata, JE; Ho, AT; Orr, FW; Ruther, U; Khokha, R				Kruger, A; Sanchez-Sweatman, OH; Martin, DC; Fata, JE; Ho, AT; Orr, FW; Ruther, U; Khokha, R			Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line	ONCOGENE			English	Article						TIMP-1; metastasis inhibition; transgenic mice; lacZ tagging	EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; MELANOMA-CELLS; IN-VIVO; EXPRESSION; INVASION; TUMOR; ANGIOGENESIS; SUPPRESSION; PROTEIN	Within the tumor-stromal microenvironment a disrupted balance between matrix metalloproteinases (MMPs) and their inhibitors compromises the integrity of the extracellular matrix and promotes malignancy. Tissue inhibitors of metalloproteinases (TIMPs) have been linked to tumor suppression in studies of genetically altered tissue culture cells and in analyses of clinical specimens in situ. We generated transgenic mice as a model system to test the relationship between TIMP-1 levels in a host organ and susceptibility to experimentally targeted metastasis. Ectopically overexpressed TIMP-1 in the brain resulted in a tissue microenvironment with elevated protein levels of this natural MMP inhibitor. Metastatic challenge provided by lacZ-tagged fibrosarcoma cells permitted high-resolution analysis of metastatic load and pattern. We found that elevated host TIMP-1 imposed resistance to experimental metastasis of fibrosarcoma: In TIMP-1 overexpressing mice, brain metastases were significantly reduced by 75% compared to wild-type littermates. Our findings demonstrate that ectopic TIMP-1 expression efficiently exerts a suppressive effect on metastasizing tumor cells.	Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada; Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Dept Pathol, Toronto, ON M5G 2M9, Canada; Univ Manitoba, Hlth Sci Ctr, Dept Pathol, Winnipeg, MB R3A 1R9, Canada; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; Hannover Medical School	Khokha, R (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada.		Ho, Andrew Tri Van/D-9681-2019	Ho, Andrew Tri Van/0000-0002-5501-6419				BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUGNO M, 1995, SCIENCE, V5, P1; DECLERCK YA, 1992, CANCER RES, V52, P701; DERCOLE AJ, 1994, DEV BRAIN RES, V82, P213; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOOP S, 1995, CANCER RES, V55, P2520; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Martinson I, 1996, J PALLIATIVE CARE, V12, P13, DOI 10.1177/082585979601200303; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MULLER M, 1995, PEDIATR NEUROSURG, V22, P204, DOI 10.1159/000120902; NUOVO GJ, 1995, CANCER RES, V55, P267; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; SanchezSweatman OH, 1996, INT J ONCOL, V8, P371; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0	21	80	88	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2419	2423		10.1038/sj.onc.1201774	http://dx.doi.org/10.1038/sj.onc.1201774			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620561				2022-12-17	WOS:000073428000016
J	Mahony, D; Parry, DA; Lees, E				Mahony, D; Parry, DA; Lees, E			Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells	ONCOGENE			English	Article						Cdk6; cell-cycle	CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA-PROTEIN; GENE-EXPRESSION; G1 PHASE; G(1); INHIBITION; D1; PROGRESSION; IDENTIFICATION; OVEREXPRESSION	We have performed biochemical analyses of cdk6 complexes in T cells. By gel filtration chromatography we observed at least three cdk6 containing complexes in the cell, the most abundant eluting at 450 kDa and 50-70 kDa and a minor complex eluting at 170 kDa. Cyclin D was present in the minor 170 kDa complex which coeluted with the peak of cdk associated in vitro Rb kinase activity, Analysis of proteins that co-immunoprecipitated with cdk6 showed that the 450 kDa complex contained both Hsp90 and CDC37. The 50-70 kDa complex was made up of two moieties, a 66 kDa complex containing cdk6 bound to p19(INK4d) and monomeric cdk6. The subcellular localisation of the cdk6 complexes was analysed by preparing cytoplasmic and nuclear extracts. The 450 kDa complex was shown to be predominantly cytoplasmic, whereas the 170 kDa cyclin D/cdk6 and the 50-70 kDa complexes were present in both nuclear and cytoplasmic compartments. When these same extracts were assayed for cdk6 associated kinase activity, only the nuclear cdk6 complexes were active. These data suggest that even though there are cdk6/cyclin D complexes detectable in both the cytoplasm and nucleus, only the cdk6 that is in the nucleus is active.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Mahony, D (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Cell Signaling, 901 Calif Ave, Palo Alto, CA 94304 USA.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BATES S, 1994, ONCOGENE, V9, P71; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hirai H, 1996, MOL CELL BIOL, V16, P6457; HORI T, 1987, BLOOD, V70, P1069; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, ONCOGENE, V10, P2125; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	42	80	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					603	611		10.1038/sj.onc.1201570	http://dx.doi.org/10.1038/sj.onc.1201570			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482106				2022-12-17	WOS:000071816600005
J	Beham, A; Marin, MC; Fernandez, A; Herrmann, J; Brisbay, S; Tari, AM; LopezBerestein, G; Lozano, G; Sarkiss, M; McDonnell, TJ				Beham, A; Marin, MC; Fernandez, A; Herrmann, J; Brisbay, S; Tari, AM; LopezBerestein, G; Lozano, G; Sarkiss, M; McDonnell, TJ			Bcl-2 inhibits p53 nuclear import following DNA damage	ONCOGENE			English	Article						apoptosis; bcl-2; nuclear import; p53; prostate cancer	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; CARCINOMA-CELLS; LYMPHOID-CELLS; CYCLE ARREST; G(1) ARREST; IN-VIVO; PROTEIN	Bcl-2 is an integral membrane oncoprotein that localizes to membranes of the mitochondria, endoplasmic reticulum, and nuclear envelope, Bcl-2 is a member of a family of cell death regulators and functions to inhibit apoptosis, Using confocal microscopy and immunoblotting we show that the ability of bcl-2 to suppress cell death following genotoxic damage can be a consequence of inhibiting nuclear import of induced wild-type p53 protein, Our data suggests that the ability of bcl-2 to modulate trafficking events is not cell type specific, These data support a 'gatekeeper' mechanism for cell death suppression by bcl-2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MOL PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT IMMUNOBIOL & DRUG CARRIERS,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marín Vieira, María del Carmen/B-8108-2015; Sarkiss, Mona/AAX-1346-2020; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X	NCI NIH HHS [CA09255] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; CAELLES C, 1994, NATURE, V370, P174; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEJONG D, 1994, CANCER RES, V54, P256; ELKIND NB, 1995, ONCOGENE, V11, P841; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jordan J, 1997, J NEUROSCI, V17, P1397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAM D, 1994, P NATL ACAD SCI USA, V9, P6569; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAGASAWA H, 1995, CANCER RES, V55, P1842; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; Wang YS, 1996, ONCOGENE, V12, P2731; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	43	80	83	1	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2767	2772		10.1038/sj.onc.1201464	http://dx.doi.org/10.1038/sj.onc.1201464			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419967				2022-12-17	WOS:A1997YJ80300002
J	Smilenov, LB; Morgan, SE; Mellado, W; Sawant, SG; Kastan, MB; Pandita, TK				Smilenov, LB; Morgan, SE; Mellado, W; Sawant, SG; Kastan, MB; Pandita, TK			Influence of ATM function on telomere metabolism	ONCOGENE			English	Article						telomeric associations; telomere length; telomerase activity; A-T; LZ; PI-3 kinase domain	CHROMOSOME END ASSOCIATIONS; ATAXIA-TELANGIECTASIA GENE; IMMORTAL CELLS; CANCER; LENGTH; SSCP	The ATM gene product, which is defective in the cancer-prone disorder ataxia telangiectasia, has been implicated in mitogenic signal transduction, chromosome condensation, meiotic recombination and cell cycle control. The ATM gene has homology with the TEL1 gene of yeast, mutations of which lead to shortened telomeres. To test the hypothesis that the ATM gene product is involved in telomere metabolism, we examined telomeric associations (TA), telomere length, and telomerase activity in human cells expressing either dominant-negative or complementing fragments of the ATM gene. The phenotype of RKO colorectal tumor cells expressing ATM fragments containing a leucine zipper (LZ) motif mimics that of ataxia telangiectasia (A-T) cells. These transfected RKO cells relative to transfected controls had a higher frequency of cells with TA and shortened telomeres, but no detectable change in telomerase activity. In addition, the percentage of cells with TA after gamma irradiation was higher in the transfected RKO cells with dominant negative activity of the ATM gene, compared to control cells. SV40 transformed fibroblasts derived from an A-T patient and transfected with a complementing carboxyl terminal kinase region of the ATM gene had a reduced frequency of cells with TA, with no effect on the telomere length or telomerase activity. The present studies using isogenic cells with manipulated ATM function demonstrate a role for the ATM gene product in telomere metabolism.	COLUMBIA UNIV, COLL PHYS & SURG, CTR RADIOL RES, NEW YORK, NY 10032 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21205 USA	Columbia University; Johns Hopkins University; Johns Hopkins Medicine			Pandita, Tej K/AAM-9188-2020		NATIONAL CANCER INSTITUTE [R01CA071387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA71387] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BRIDGES BA, 1982, CELLULAR MOL LINK CA; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; Cenci G, 1997, GENE DEV, V11, P863, DOI 10.1101/gad.11.7.863; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; FANG G, 1995, TELOMERES, P69; Freyer GA, 1996, MUTAT RES-FUND MOL M, V357, P237, DOI 10.1016/0027-5107(96)00130-3; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HONGYO T, 1993, NUCLEIC ACIDS RES, V21, P3637, DOI 10.1093/nar/21.16.3637; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRK KE, 1997, NATURE, V275, P1478; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LINDSEY J, 1991, MUTAT RES, V256, P45, DOI 10.1016/0921-8734(91)90032-7; McClintock B, 1941, GENETICS, V26, P234; MEHLE C, 1994, CANCER RES, V54, P236; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Muller H.J., 1938, COLLECTING NET, V13, P181; OLOVNIKOV AM, 1992, IZV AN SSSR BIOL+, P641; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; Pandita TK, 1996, ONCOGENE, V13, P1423; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PANDITA TK, 1993, 53 COLD SPRING HARB, P173; PATHAK S, 1988, CYTOGENET CELL GENET, V47, P227, DOI 10.1159/000132555; PRICE C M, 1992, Current Opinion in Cell Biology, V4, P379, DOI 10.1016/0955-0674(92)90002-T; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	47	80	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	1997	15	22					2659	2665		10.1038/sj.onc.1201449	http://dx.doi.org/10.1038/sj.onc.1201449			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400992				2022-12-17	WOS:A1997YH46800003
J	Cohen, S; Regev, A; Lavi, S				Cohen, S; Regev, A; Lavi, S			Small polydispersed circular DNA (spcDNA) in human cells: Association with genomic instability	ONCOGENE			English	Article						genomic instability; spcDNA; two dimensional electrophoresis gene amplification; cancer; mutator phenotype	HAMSTER EMBRYO CELLS; GENE AMPLIFICATION; MITOCHONDRIAL-DNA; EXTRACHROMOSOMAL DNA; MOUSE 3T6-CELLS; HELA-CELLS; SEQUENCES; ELEMENT; MECHANISMS; SATELLITE	Small Polydispersed Circular DNA (spcDNA) was suggested to be associated with genetically unstable cells. However, until now, qualitative and quantitative research has been limited due to the lack of efficient methods for detection and analysis. We developed a two-dimensional (2-D) neutral-neutral gel electrophoresis assay for the identification, characterisation and quantitation of spcDNA. Using this method, we established the relation of spcDNA to genetic and induced genomic instability in human cells, both in vitro and in vivo. Enhanced amounts of spcDNA were found in genetically unstable cells and tissues. spcDNA was detected in a tumor cell-line (HeLa) and in tumor tissue (colon carcinoma) as well as in fibroblasts derived from patients suffering from the genomic instability disease, Fanconi's Anemia. We failed to detect spcDNA in the genetically stable normal human fibroblasts. However, following treatment with the initiating carcinogen MNNG, an induction of spcDNA was observed. The level of spcDNA was quantified according to mitochondrial DNA (mtDNA) standards. In light of these findings, we discuss the possible role of spcDNA as a marker and an enhancer of genomic instability.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University								ASSUM G, 1993, HUM GENET, V91, P489; BERKOFLINT Y, 1990, MOL CELL BIOL, V10, P75, DOI 10.1128/MCB.10.1.75; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen S, 1996, MOL CELL BIOL, V16, P2002; DELAP RJ, 1978, PLASMID, V1, P508, DOI 10.1016/0147-619X(78)90008-2; FIDLER IJ, 1982, ONCODEV BIOL MED, V4, P161; FLORES SC, 1988, NUCLEIC ACIDS RES, V16, P3889, DOI 10.1093/nar/16.9.3889; FRIEDBERG EC, 1995, DNA REPAIR; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GAUBATZ JW, 1990, MUTAT RES, V237, P29, DOI 10.1016/0921-8734(90)90029-Q; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; GOLDSTEIN S, 1984, MOL CELL BIOCHEM, V64, P15, DOI 10.1007/BF00420924; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HIGUCHI Y, 1995, J BIOL CHEM, V270, P7950, DOI 10.1074/jbc.270.14.7950; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLIS M, 1986, GENE, V46, P153, DOI 10.1016/0378-1119(86)90399-9; JONES RS, 1985, NUCLEIC ACIDS RES, V13, P1027, DOI 10.1093/nar/13.3.1027; KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; KOWALD A, 1993, MUTAT RES, V295, P93, DOI 10.1016/0921-8734(93)90011-Q; KRYSAN PJ, 1991, MOL CELL BIOL, V11, P1464, DOI 10.1128/MCB.11.3.1464; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; KUNISADA T, 1984, GENE, V31, P213, DOI 10.1016/0378-1119(84)90212-9; KUNISADA T, 1987, J MOL BIOL, V198, P557, DOI 10.1016/0022-2836(87)90199-9; KUNISADA T, 1985, MECH AGEING DEV, V29, P89, DOI 10.1016/0047-6374(85)90050-8; KUNISADA T, 1983, PLASMID, V9, P8, DOI 10.1016/0147-619X(83)90027-6; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LAVI S, 1981, CARCINOGENESIS, V2, P417, DOI 10.1093/carcin/2.5.417; LAVI S, 1982, GENE AMPLIFICATION, P225; LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6; LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732; MISRA R, 1989, NUCLEIC ACIDS RES, V17, P8327, DOI 10.1093/nar/17.20.8327; MISRA R, 1987, J MOL BIOL, V196, P233, DOI 10.1016/0022-2836(87)90687-5; MOTEJLEK K, 1993, MUTAT RES, V293, P205, DOI 10.1016/0921-8777(93)90071-N; NEIDLINGER C, 1988, HUM GENET, V79, P286, DOI 10.1007/BF00366254; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; RIABOWOL K, 1985, NUCLEIC ACIDS RES, V3, P5563; RIO DC, 1990, ANNU REV GENET, V24, P543; RUIZ JC, 1989, MOL CELL BIOL, V9, P109, DOI 10.1128/MCB.9.1.109; RUSH MG, 1985, PLASMID, V14, P177, DOI 10.1016/0147-619X(85)90001-0; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SMITH CA, 1972, J MOL BIOL, V69, P163, DOI 10.1016/0022-2836(72)90222-7; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SUNNERHAGEN P, 1986, NUCLEIC ACIDS RES, V14, P7823, DOI 10.1093/nar/14.20.7823; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; TLSTY T, 1982, GENE AMPLIFICATION, P231; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; WAHL GM, 1989, CANCER RES, V49, P1333; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YAMAGISHI H, 1985, MECH AGEING DEV, V29, P101, DOI 10.1016/0047-6374(85)90051-X; YAMAGISHI H, 1986, BIOESSAYS, V4, P218, DOI 10.1002/bies.950040508	56	80	85	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					977	985		10.1038/sj.onc.1200917	http://dx.doi.org/10.1038/sj.onc.1200917			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050997				2022-12-17	WOS:A1997WK34400011
J	Chang, JY; Xia, WY; Shao, RP; Sorgi, F; Hortobagyi, GN; Huang, L; Hung, MC				Chang, JY; Xia, WY; Shao, RP; Sorgi, F; Hortobagyi, GN; Huang, L; Hung, MC			The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer	ONCOGENE			English	Article						HER-2/neu; E1A; gene therapy; adenoviral vector; cationic liposome	PROTEINS INDUCE APOPTOSIS; GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-PRODUCTS; NONHUMAN-PRIMATES; OVARIAN-CANCER; POOR SURVIVAL; EXPRESSION; METASTASIS; CELLS	The HER-2/neu proto-oncogene is frequently amplified or overexpressed in human breast and ovarian cancers, and is significantly correlated with shorter survival, We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can repress HER-2/neu overexpression by repressing HER-2/neu promoter activity, and suppress the tumorigenic potential of HER-2/neu-overexpressing ovarian cancer cells, To examine E1A tumor suppressor function in breast cancer, we transduced E1A in vitro by adenovirus into both HER-2/neu-overexpressing and low expressing human breast cancer cell lines, In HER-2/neu-overexpressing cells, E1A greatly inhibited tumor cell growth in vitro, However, in HER-2/neu low expressing cancer cell lines, E1A had no significant effect on cell growth in culture medium, To test the therapeutic efficacy of E1A, we used both adenovirus-mediated and cationic liposome-mediated E1A gene delivery systems in an orthotopic breast cancer animal model, An advanced breast cancer model was established by inoculation of HER-2/neu-overexpressing human breast cancer cells in mammary fat pad and treated by local injections of either replication-deficient adenovirus expressing EIA, Ad.E1A(+) or a liposome-E1A DNA complex, As controls, mice bearing tumors were also treated with Ad.E1A(-) which is virtually the same adenovirus as Ad.E1A(+) except that EIA is deleted, a liposome-E1A frame-shift mutant DNA complex, or just PBS, In mice bearing a HER-2/neu-overexpressing breast cancer cell line, EIA delivered either by adenovirus or liposome significantly inhibited tumor growth and prolonged mouse survival compared with the controls, In fact, 60-80% of E1A-treated mice lived longer than 2 years versus only 0-20% of control mice (P<0.05), Western blot analysis showed that E1A protein was expressed in tumor tissue and immunohistochemical analysis showed that HER-2/neu p185 protein expression was suppressed, Taken together, our results indicated that both adenovirus and cationic liposome delivery systems were effective in transfering EIA gene for tumor suppression in a HER-2/neu-overexpressing breast cancer model.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BREAST & GYNECOL MED ONCOL,HOUSTON,TX 77030; UNIV PITTSBURGH,DEPT PHARMACOL,PITTSBURGH,PA 15261	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA60856, CA59327, R01-CA58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, P01CA059327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHANG JY, 1996, IN PRESS ONCOGENE; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; HEARING P, 1985, MOL CELL BIOL, V5, P3214, DOI 10.1128/MCB.5.11.3214; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KERN JA, 1990, CANCER RES, V50, P5284; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; PARKER SE, 1995, HUM GENE THER, V6, P575, DOI 10.1089/hum.1995.6.5-575; PATERSON MC, 1991, CANCER RES, V51, P556; PRESS MF, 1993, CANCER RES, V53, P5675; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TEODORO JG, 1995, ONCOGENE, V11, P467; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YONEMURA Y, 1991, CANCER RES, V51, P1034; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P1947	38	80	83	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					561	568		10.1038/sj.onc.1200861	http://dx.doi.org/10.1038/sj.onc.1200861			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053854				2022-12-17	WOS:A1997WF52400007
J	Wang, MH; MonteroJulian, FA; Dauny, I; Leonard, EJ				Wang, MH; MonteroJulian, FA; Dauny, I; Leonard, EJ			Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein	ONCOGENE			English	Article						MSP; RON; PI-3 kinase; migration	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; MET PROTOONCOGENE PRODUCT; HA-RAS MUTATION; TYROSINE KINASE; FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; 3-KINASE; FAMILY	Macrophage stimulating protein (MSP) is a ligand for the RON receptor protein tyrosine kinase. Activation of RON in murine resident macrophages results in cell shape change and migration. We studied cell movement induced by MSP in different types of human epithelial cells and the possible role of phosphatidylinositol-3 (PI-3) kinase in RON-mediated signal transduction. We observed specific and saturable binding of I-125-MSP to RON on several epithelial cell lines. In addition to activation and phosphorylation of RON, MSP also induced tyrosine phosphorylation of the PI-3 kinase p85 subunit in a time-dependent manner, with a peak at 15 min. Moreover, phosphorylated RON formed complex with PI-3 kinase in both HK-NOC keratinocyte and RON cDNA-transfected MDCK cells. An in vitro protein interaction assay confirmed that PI-3 kinase from a lysate of MSP-activated cells bound to pure RON protein. MSP, at a concentration range of 1 to 5 nM, induced migration of three epithelial cell lines. This effect was inhibited by wortmannin, a specific inhibitor for PI-3 kinase, with an IC50 of 10 nM. MSP-induced shape change in murine resident peritoneal macrophages was also abolished by wortmannin. These data suggest that activation of PI-3 kinase is required for MSP-induced epithelial cell migration. The stimulation by MSP of epithelial cell movement may have implications for tissue repair, wound healing, and tumor metastasis.	NCI,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,NIH,FREDERICK,MD 21702; IMMUNOTECH SA,ANTIBODY DEPT,MARSEILLE 9,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ANDO Y, 1993, J CELL PHYSIOL, V156, P487, DOI 10.1002/jcp.1041560308; Banu N, 1996, J IMMUNOL, V156, P2933; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROXMEYER HE, 1996, IN PRESS ANN HEMATOL; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1996, IN PRESS EXP CELL RE; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	50	80	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2167	2175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950984				2022-12-17	WOS:A1996VV14500014
J	Berry, DE; Lu, YM; Schmidt, B; Fallon, PG; OConnell, C; Hu, SX; Xu, HJ; Blanck, G				Berry, DE; Lu, YM; Schmidt, B; Fallon, PG; OConnell, C; Hu, SX; Xu, HJ; Blanck, G			Retinoblastoma protein inhibits IFN-gamma induced apoptosis	ONCOGENE			English	Article						retinoblastoma protein; IFN-gamma; apoptosis	TUMOR-NECROSIS-FACTOR; B-CELL LINES; INTERFERON-GAMMA; FLOW-CYTOMETRY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HUMAN CANCER; DEATH; INDUCTION; ALPHA	Regulation of apoptosis (programmed cell death) is critical for maintaining tissue homeostasis. Recent studies indicate a tight coupling between cellular proliferation and apoptosis as cell cycle regulators such as Cyclin D, E1A and E7 appear to influence both events, Each of these modulators is able to bind to and inhibit the function of the retinoblastoma tumor suppressor protein (RE), RE functions, in part, by binding to and inactivating E2F transcription factors, preventing expression of E2F-activated genes associated with G1/S cell-cycle progression, Loss of functional RB deregulates E2F activity and, depending on cell type and environmental factors, promotes tumorigenesis or apoptotic death, To determine the effect of RB on IFN-gamma induced apoptosis, we treated RB-defective carcinoma cell lines and their respective RB-reconstituted sister clones with IFN-gamma and examined the cells for alterations characteristic of apoptosis, We observed that RB-defective cells, but not the RB-reconstituted clones, decreased in size following IFN-gamma treatment, IFN-gamma treatment caused increased cell detachment in the RB-defective lines but did not affect adherence of the RB-reconstituted clones, Assays for DNA fragmentation revealed lower molecular weight DNA and the apoptosis- associated oligo-nucleosomal ladder following IFN-gamma treatment of the RB-defective cells while higher molecular weight DNA was present in the IFN-gamma treated, RB-reconstituted lines, IFN gamma-induced apoptosis in RB-defective cells was enhanced by serum stimulation, which is also characteristic of p53-dependent E2F-1-mediated apoptosis, However, IFN-gamma induced apoptosis in RB-defective lines does not require wild-type p53 suggesting that, upon IFN-gamma induction, deregulated E2F-mediated apoptosis can also proceed via p53-independent pathways.	UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA; UNIV S FLORIDA, H LEE MOFFITT CANC CTR, COLL MED, TAMPA, FL 33612 USA; BAYLOR COLL MED, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Baylor College of Medicine					NEI NIH HHS [EY06195] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARTEK J, 1990, ONCOGENE, V5, P893; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN PA, 1993, J IMMUNOTHER, V14, P242, DOI 10.1097/00002371-199310000-00012; DETRICK B, 1991, INVEST OPHTH VIS SCI, V32, P1714; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HOON DSB, 1991, CANCER RES, V51, P2002; HOOPER ML, 1994, J CELL SCI, P13; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUSCHTSCHA LI, 1994, EXP CELL RES, V212, P161, DOI 10.1006/excr.1994.1131; IBRAHIM L, 1993, IMMUNOLOGY, V79, P119; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; ISHII H, 1994, ACTA MED OKAYAMA, V48, P73; JO TS, 1995, ANAT RECORD, V241, P70, DOI 10.1002/ar.1092410110; KARASAKI Y, 1992, J INTERFERON RES, V12, P185, DOI 10.1089/jir.1992.12.185; Kelso A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026930; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LOTEM J, 1995, LEUKEMIA, V9, P685; LU Y, 1994, J IMMUNOL, V153, P1495; LU Y, 1996, IN PRESS J IMMUNOL; LU YM, 1994, ONCOGENE, V9, P1015; MARTIN DM, 1993, J NEUROSCI RES, V34, P489, DOI 10.1002/jnr.490340502; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOVELLI F, 1994, J IMMUNOL, V152, P496; OKUBO K, 1991, Kurume Medical Journal, V38, P57; OSBORNE BA, 1994, IMMUNOL REV, V142, P301, DOI 10.1111/j.1600-065X.1994.tb00894.x; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; PANG YB, 1992, BLOOD, V80, P724; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHER RL, 1993, ARCH OTOLARYNGOL, V119, P432; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shimada Shinya, 1993, In Vivo (Attiki), V7, P1; SHINAGAWA T, 1991, J PATHOL, V165, P247, DOI 10.1002/path.1711650309; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TOMITA Y, 1993, AM J PATHOL, V143, P191; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	76	80	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1809	1819						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622902				2022-12-17	WOS:A1996UG45800024
J	Byeon, MK; Westerman, MA; Maroulakou, IG; Henderson, KW; Suster, S; Zhang, XK; Papas, TS; Vesely, J; Willingham, MC; Green, JE; Schweinfest, CW				Byeon, MK; Westerman, MA; Maroulakou, IG; Henderson, KW; Suster, S; Zhang, XK; Papas, TS; Vesely, J; Willingham, MC; Green, JE; Schweinfest, CW			The down-regulated in adenoma (DRA) gene encodes an intestine-specific membrane glycoprotein	ONCOGENE			English	Article						colon; tumorigenesis; sulfate transporter; mucosa; differentiation	HUMAN COLORECTAL-CANCER; HUMAN-COLON CARCINOMA; HEPARAN-SULFATE; P-GLYCOPROTEIN; APC GENE; GASTRIC-CANCER; FREQUENT LOSS; EXPRESSION; MUTATIONS; IDENTIFICATION	The protein product of the DRA gene, a gene whose expression is down-regulated in colon adenomas and adenocarcinomas, is a membrane glycoprotein and a member of a family of sulfate transporters. It is expressed in the intestinal tract (duodenum, ileum, cecum, distal colon), but not in the esophagus or stomach, DRA mRNA expression is restricted to the mucosal epithelium, and DRA protein expression is further limited to the columnar epithelial cells, particularly to the brush border, Consistent with its expression in the differentiated columnar epithelium of the adult human colon, DRA is first expressed in the midgut of developing mouse embryos at day 16.5, corresponding with the time of differentiation of the epithelium of the small intestine, A model for the structure of the DRA protein is proposed and its possible role in colon tumorigenesis is discussed.	MED UNIV S CAROLINA,CTR MOLEC & STRUCT BIOL,HOLLINGS CANC CTR,CHARLESTON,SC 29425; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; MT SINAI MED CTR,DEPT PATHOL & LAB MED,MIAMI BEACH,FL 33140; UNIV MIAMI,SCH MED,MIAMI,FL 33140; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mount Sinai Medical Center; University of Miami; Medical University of South Carolina								ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; DAMICO D, 1992, CANCER RES, V52, P1996; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLEY GG, 1989, ONCOGENE, V4, P963; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FRANSSON LA, 1981, J BIOL CHEM, V256, P3044; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAWAKAMI H, 1981, BIOCHIM BIOPHYS ACTA, V646, P161, DOI 10.1016/0005-2736(81)90283-2; KOI M, 1994, CANCER RES, V54, P4308; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROLLA TA, 1994, SCIENCE, V265, P1092; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAGUCHI T, 1994, GENOMICS, V20, P147; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	50	80	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					387	396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570216				2022-12-17	WOS:A1996TR53800018
J	MUTHUSWAMY, SK; MULLER, WJ				MUTHUSWAMY, SK; MULLER, WJ			ACTIVATION OF SRC FAMILY KINASES IN NEU-INDUCED MAMMARY-TUMORS CORRELATES WITH THEIR ASSOCIATION WITH DISTINCT SETS OF TYROSINE-PHOSPHORYLATED PROTEINS IN-VIVO	ONCOGENE			English	Article						C-YES; FYN; TYROSINE PHOSPHORYLATION; MAMMARY TUMORS	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; HUMAN-BREAST-CANCER; MIDDLE-T-ANTIGEN; SIGNAL-TRANSDUCTION; METASTATIC DISEASE; SH3 DOMAINS; ONCOGENE; SUBSTRATE; MICE	Overexpression and amplification of the erbB-2 (nea) is thought to play a major role in mammary cancer. Although studies suggest that Neu is directly involved in the genesis of mammary tumors, the molecular mechanism by which Neu induces tumors is not well understood. Recently, we have demonstrated that the activity of c-Src tyrosine kinase is elevated in Neu-induced mammary tumors and this elevated activity correlates with its capacity to physically associate with Neu. To explore whether other members of the c-Src family are activated in these mammary tumors, we measured the in vitro kinase activity of the c-Yes and Fyn kinases in protein extracts derived from mammary tumor tissue and morphological normal adjacent tissue. These analyses revealed that c-Yes kinase activity was elevated in Neu-induced tumors by comparison to the adjacent tissue. By contrast, no significant activation of the Fyn kinase was noted in these tumors. Activation of c-Yes tyrosine kinase correlated with the capacity of c-Yes to associate with Neu in vivo in lysates derived from primary tumor samples. Studies with Rat.2 fibroblasts overexpressing activated Neu revealed that c-Src requires the presence of tyrosine phosphoryated Neu for its ability to interact with Neu in vivo. Moreover, analyses using radiolabeled c-Yes SH2 fusion protein revealed that this interaction is Likely occurring in a direct fashion. Although both c-Src and c-Yes kinase associate with Neu in vivo, a tyrosine phosphorylated protein of 89 kd (p89) was found associated with c-Src but not with c-Yes in cell lysates derived from mammary epithelial cells transformed by either Neu or PyV middle T antigen. Furthermore, this tyrosine phosphorylated protein was not detected in c-Src complexes derived from fibroblasts transformed by either Neu or PyV middle T. These observations suggest that p89 associates with c-Src only in mammary epithelial cells and not in fibroblasts.	MCMASTER UNIV, DEPT BIOL, HAMILTON, ON, CANADA; MCMASTER UNIV, INST MOLEC BIOL & BIOTECHNOL, DEPT PATHOL, CANC RES GRP, HAMILTON, ON, CANADA	McMaster University; McMaster University			Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634				BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JANES PW, 1994, ONCOGENE, V9, P3601; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIEFER F, 1994, CURR BIOL, V4, P100, DOI 10.1016/S0960-9822(94)00025-4; KLAGES S, 1993, ONCOGENE, V8, P713; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK JS, 1993, ONCOGENE, V8, P2627; PATERSON MC, 1991, CANCER RES, V51, P556; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1992, ONCOGENE, V7, P1339; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; THOMAS JE, 1993, ONCOGENE, V8, P2521; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZHAN X, 1994, J BIOL CHEM, V269, P20221	58	80	87	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1801	1810						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478608				2022-12-17	WOS:A1995TD09400015
J	LARSON, RC; OSADA, H; LARSON, TA; LAVENIR, I; RABBITTS, TH				LARSON, RC; OSADA, H; LARSON, TA; LAVENIR, I; RABBITTS, TH			THE ONCOGENIC LIM-PROTEIN RBTN2 CAUSES THYMIC DEVELOPMENTAL ABERRATIONS THAT PRECEDE MALIGNANCY IN TRANSGENIC MICE	ONCOGENE			English	Article						RBTN2; LEUKEMIA; THYMUS; HEMATOPOIESIS; TRANSLOCATION	T-CELL ONCOGENE; HUMAN CD2 GENE; THY-1 GENE; BURKITT-LYMPHOMA; EXPRESSION; TRANSLOCATION; LEUKEMIA; TTG-1; RECEPTOR; ANTIGEN	RBTN2 is activated by the chromosomal translocation t(11;14) (P13;p11) in some T cell leukaemias. Histologically similar T cell. tumours develop with long latency in transgenic mice when either CD2 or thy1.1 promoters control rbtn2 expression, During the asymptomatic period, perturbation of T cell differentiation occurs in the thymus. The major anomalies present during this phase are an increase in the percentage of large thymocytes lacking CD4 and CD8 markers and also of small thymocytes express both the T cell marker CD3 and the B cell-specific form of CD45. These abnormal T cell populations can be clonal and thus a primary result of aberrant expression of the LIM-protein Rbtn2 is alteration of T cell differentiation preceding overt malignancy, These data provide a biological explanation for the role of Rbtn2 in tumorigenesis and presumably RBTN2 expression in T cells after the translocation t(11;14) in children has the same effect.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; AICHI CANC CTR,RES INST,CHEMOTHERAPY LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	MRC Laboratory Molecular Biology; Aichi Cancer Center			Osada, Hiroyuki/AAY-6254-2020; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHEN SH, 1987, CELL, V51, P7, DOI 10.1016/0092-8674(87)90005-5; CLARK SS, 1993, J VIROL, V67, P6033, DOI 10.1128/JVI.67.10.6033-6046.1993; Coffman R L, 1982, Immunol Rev, V69, P5; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; FEINBERG AP, 1993, ANAL BIOCHEM, V132, P6; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GORDON JW, 1987, CELL, V50, P445, DOI 10.1016/0092-8674(87)90498-3; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; KAMOUN M, 1991, J EXP MED, V1553, P207; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOLLIAS G, 1987, P NATL ACAD SCI USA, V84, P1492, DOI 10.1073/pnas.84.6.1492; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LARSON RC, 1994, ONCOGENE, V9, P3675; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; NISHIMURA H, 1992, CELL IMMUNOL, V140, P423; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Sperling A I, 1989, Int Immunol, V1, P434, DOI 10.1093/intimm/1.4.434; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yagita H, 1989, INT IMMUNOL, V1, P94, DOI 10.1093/intimm/1.1.94	39	80	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					853	862						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545805				2022-12-17	WOS:A1995RU79800005
J	FINCHAM, VJ; WYKE, JA; FRAME, MC				FINCHAM, VJ; WYKE, JA; FRAME, MC			V-SRC-INDUCED DEGRADATION OF FOCAL ADHESION KINASE DURING MORPHOLOGICAL TRANSFORMATION OF CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Note						V-SRC; MORPHOLOGICAL TRANSFORMATION; FOCAL ADHESION KINASE	PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; CELL-ADHESION; PHOSPHORYLATION; PAXILLIN; PP125FAK	Morphological transformation of cells by the v-Src tyrosine kinase is incompletely understood, However, it is independent of nuclear functions and probably involves phosphorylation of targets associated with the cytoskeleton and focal adhesions, structures which tether the cytoskeleton to the points of cell attachment. v-Src activity both stimulates tyrosine phosphorylation of a tyrosine kinase present in focal adhesions (focal adhesion kinase or pp125(FAK)) and disrupts focal adhesions, leading to cell rounding and detachment. However, pp125(FAK) is also phosphorylated on tyrosine as a result of integrin stimulation which induces quite different biological consequences including the organisation of focal adhesions when cells spread on fibronectin (reviewed in Schaller and Parsons, 1993). To address this paradox, we examined changes in pp125(FAK) during activation and shut-off of temperature sensitive mutant v-Src proteins that induce varying degrees of transformation in chick embryo fibroblasts. An efficiently transforming v-Src mutant initially stimulated pp125(FAK) tyrosine phosphorylation, but induced subsequent pp125(FAK) degradation prior to the onset of cell rounding and detachment. v-Src mutants which are impaired in their ability to induce morphological transformation were much less efficient at inducing degradation of pp125(FAK). Moreover, cell spreading during restitution of normal morphology did not require detectable tyrosine phosphorylation of pp125(FAK), or its potential substrate paxillin, suggesting that pp125(FAK) may function more in the turnover of focal adhesions than in their assembly.			FINCHAM, VJ (corresponding author), BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,BEARSDEN G61 1BD,SCOTLAND.							BADER JP, 1972, J VIROL, V10, P267, DOI 10.1128/JVI.10.2.267-276.1972; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CATLING AD, 1994, J VIROL, V68, P4392, DOI 10.1128/JVI.68.7.4392-4399.1994; CATLING AD, 1993, ONCOGENE, V8, P1875; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCOTTBURDEN T, 1989, J CELL PHYSIOL, V141, P267, DOI 10.1002/jcp.1041410206; TURNER CE, 1993, J CELL SCI, V105, P637; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	25	80	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2247	2252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784071				2022-12-17	WOS:A1995RB70300022
J	HIYAMA, K; ISHIOKA, S; SHIROTANI, Y; INAI, K; HIYAMA, E; MURAKAMI, I; ISOBE, T; INAMIZU, T; YAMAKIDO, M				HIYAMA, K; ISHIOKA, S; SHIROTANI, Y; INAI, K; HIYAMA, E; MURAKAMI, I; ISOBE, T; INAMIZU, T; YAMAKIDO, M			ALTERATIONS IN TELOMERIC REPEAT LENGTH IN LUNG-CANCER ARE ASSOCIATED WITH LOSS OF HETEROZYGOSITY IN P53 AND RB	ONCOGENE			English	Article						LUNG CANCER; TELOMERE; P53; RB; IMMORTALITY; 1P32	CELLULAR SENESCENCE; RETINOBLASTOMA GENE; HUMAN FIBROBLASTS; L-MYC; MUTATIONS; POLYMORPHISM; TUMOR; DNA; IMMORTALIZATION; ADENOCARCINOMA	In the two-stage model of controlling cellular senescence in cultured human fibro blasts, retinoblastoma (Rb) and p53 proteins may be key factors regulating the mortality stage 1 mechanism. In addition, the critical loss of telomeric DNA due to the end-replication problem may result in the mortality stage 2 mechanism, Cells which acquire telomerase activity can overcome the M2 mechanism by stabilizing telomere length and thus become immortal (telomere hypothesis). At present it is known whether cellular immortality is a prerequisite for all human cancers, To investigate this question and the applicability of the two-stage model to human cancers, we analysed the relationship between alterations of telomere length and other genetic changes in lung cancer. Among 60 primary lung cancer tissues, telomere length alterations were observed in 16 tumors (26.7%) including 14 with short and two with elongated telomeres. Ten of them revealed allelic loss of both p53 and Rb genes, and remaining six showed no abnormalities in both genes. We propose that inactivation of both p53 and Rb genes may promote cell divisions causing telomere shortening in lung cancer as in the two-stage model, while there may be another pathway to overcome both M1 and M2 mechanisms, especially for adenocarcinoma.	HIROSHIMA UNIV,SCH MED,DEPT PATHOL 2,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT GEN MED,HIROSHIMA 734,JAPAN	Hiroshima University; Hiroshima University	HIYAMA, K (corresponding author), HIROSHIMA UNIV,SCH MED,DEPT INTERNAL MED 2,HIROSHIMA 734,JAPAN.		Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				ALLSHIRE RC, 1989, NUCLEIC ACIDS RES, V17, P4611, DOI 10.1093/nar/17.12.4611; BERGH JCS, 1990, AM REV RESPIR DIS, V142, pS20, DOI 10.1164/ajrccm/142.6_Pt_2.S20; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOND JA, 1994, ONCOGENE, V9, P1885; BRANDT B, 1992, AM J HUM GENET, V51, P1450; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P4804; CORNELIS RS, 1994, CANCER RES, V54, P4200; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAY JP, 1993, ENVIRON MOL MUTAGEN, V22, P245, DOI 10.1002/em.2850220411; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hermanek P, 1987, TNM CLASSIFICATION M, P69; HIYAMA E, 1992, JPN J CANCER RES, V83, P159, DOI 10.1111/j.1349-7006.1992.tb00081.x; HIYAMA K, 1993, CHEST, V104, P1606, DOI 10.1378/chest.104.5.1606; HIYOSHI H, 1992, JPN J CANCER RES, V83, P101, DOI 10.1111/j.1349-7006.1992.tb02358.x; HORIO Y, 1993, CANCER RES, V53, P1; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KAWASHIMA K, 1992, INT J CANCER, V50, P557, DOI 10.1002/ijc.2910500411; KAYE FJ, 1990, AM REV RESPIR DIS, V142, pS44, DOI 10.1164/ajrccm/142.6_Pt_2.S44; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; MAKELA TP, 1992, HUM MOL GENET, V1, P217, DOI 10.1093/hmg/1.3.217-a; MCGEE TL, 1990, NUCLEIC ACIDS RES, V18, P207, DOI 10.1093/nar/18.1.207-a; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MITSUDOMI T, 1991, CANCER RES, V51, P4999; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1991, NUCLEIC ACIDS RES, V19, P4799, DOI 10.1093/nar/19.17.4799-a; SACHSE R, 1994, ONCOGENE, V9, P39; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SHIROTANI Y, 1994, LUNG CANCER-J IASLC, V11, P29, DOI 10.1016/0169-5002(94)90280-1; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STAMPS AC, 1992, EUR J CANCER, V28A, P1495, DOI 10.1016/0959-8049(92)90552-D; TAKAHASHI N, 1990, MUTAT RES, V234, P61, DOI 10.1016/0165-1161(90)90032-J; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	56	80	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					937	944						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898935				2022-12-17	WOS:A1995QL03800015
J	BASU, T; WARNE, PH; DOWNWARD, J				BASU, T; WARNE, PH; DOWNWARD, J			ROLE OF SHC IN THE ACTIVATION OF RAS IN RESPONSE TO EPIDERMAL GROWTH-FACTOR AND NERVE GROWTH-FACTOR	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; GRB2 ADAPTER PROTEIN; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION; SEVENLESS GENE; PC12 CELLS; PHOSPHORYLATION; DOMAINS; P21RAS	Treatment of the rat pheochromocytoma cell line PC12 with nerve growth factor (NGF) or epidermal growth factor (EGF) is known to result in activation of Ras. In response to EGF treatment, complexes form between Sos, Grb2 and tyrosine phosphorylated She and/or EGF receptor. In response to NGF treatment, complexes form between Sos, Grb2 and tyrosine phosphorylated Shc. While She is also found bound to the activated NGF receptor, Trk, no complexes were detectable that contained both Trk and Grb2 or Sos. In streptolysin O permeabilised cells, a tyrosine phosphopeptide, EGFR-Y1068P, which binds to the SH2 domain of Grb2, totally blocks growth factor induced formation of complexes between Grb2 and She or EGF receptor, and also blocks activation of nucleotide exchange on Ras. At low concentrations, another tyrosine phosphopeptide, TRK-Y490P, which binds to the SH2 domain of She, blocks growth factor induced formation of complexes between Shc and the EGF receptor or Trk, but fails to block activation of nucleotide exchange on Ras. Higher concentrations of TRK-Y490P inhibit tyrosine phosphorylation of She and the formation of She complexes with Grb2: this results in strong inhibition of Ras activation by NGF and partial inhibition of Ras activation by EGF. These data demonstrate that the formation of a trimeric complex between tyrosine phosphorylated Shc, Grb2 and Sos is the key event in the activation of Ras in response to NGF. The binding of Sos to tyrosine phosphorylated receptor, via Grb2 may also contribute to Ras activation by EGF but not NGF, while stable complex formation between She and receptors is not necessary for Ras activation by either growth factor.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Downward, Julian/0000-0002-2331-4729				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MUROYA K, 1992, ONCOGENE, V7, P277; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OUWENS DM, 1993, J CELL BIOCH S A, V17, P237; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	80	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3483	3491						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970708				2022-12-17	WOS:A1994PT39200010
J	BEAUPARLANT, P; KWAN, I; BITAR, R; CHOU, P; KOROMILAS, AE; SONENBERG, N; HISCOTT, J				BEAUPARLANT, P; KWAN, I; BITAR, R; CHOU, P; KOROMILAS, AE; SONENBERG, N; HISCOTT, J			DISRUPTION OF I-KAPPA-B-ALPHA REGULATION BY ANTISENSE RNA EXPRESSION LEADS TO MALIGNANT TRANSFORMATION	ONCOGENE			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; DNA-BINDING SUBUNIT; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE BCL-3; REL ONCOGENE; P65 SUBUNIT; GENE; INHIBITOR; FAMILY	NF-kappa B transcription factors regulate the expression of a variety of genes involved in immune regulation and cell growth. In most cell types NF-kappa B proteins are localized in an inactive form in the cytoplasm coupled to the inhibitory I kappa B proteins. Viruses, cytokines, lipopolysaccharides and other stimulating agents promote the dissociation of the cytosolic NF-kappa B/I kappa B complexes, via phosphorylation and degradation of I kappa B, resulting in the translocation of DNA binding, NF-kappa B complexes to the nucleus. To further understand the association of I kappa B with cell growth regulation, the effect of ectopic expression of sense and antisense I kappa B genes was examined in NIH3T3 cells. Overexpression of I kappa B alpha antisense RNA but not I kappa B gamma antisense RNA decreased the steady state levels of I kappa B alpha protein, altered NF-kappa B DNA binding and gene activity and, most importantly, induced malignant transformation as measured by saturation density, growth in soft agar and tumorigenicity in nude mice. In contrast, overexpression of I kappa B alpha resulted in decreased saturation density, a battened cellular morphology and decreased NF-kappa B dependent reporter gene activity. These results indicate that overexpression of an I kappa B alpha antisense RNA may disrupt the NF-kappa B/I kappa B autoregulatory loop, leading to cellular transformation. Our results raise the interesting possibility that I kappa B alpha represents a potential tumor suppressor activity.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOLEC ONCOL GRP,MONTREAL H3T 1E2,PQ,CANADA; MCGILL UNIV,DEPT MICROBIOL & IMMUNOL,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University								Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LANOIX J, 1994, ONCOGENE, V9, P841; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PEPIN N, 1994, IN PRESS VIROLOGY; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rossi John J., 1993, Methods (Orlando), V5, P1, DOI 10.1006/meth.1993.1001; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; WEINBERG RA, 1989, CANCER RES, V49, P3713	49	80	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3189	3197						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936641				2022-12-17	WOS:A1994PM65800010
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			ELK-1 PROTEINS INTERACT WITH MAP KINASES	ONCOGENE			English	Article							ETS-RELATED PROTEIN; SERUM RESPONSE FACTOR; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; C-FOS; DNA-BINDING; C-ETS-1 PROTOONCOGENE; FACTOR P62TCF; PHOSPHORYLATION; SEQUENCE	Mitogen activated protein kinases (MAP) or extracellular signal regulated protein kinases (ERK) are a family of protein serine/threonine kinases that are activated very rapidly in response to many extracellular stimuli. elk-1, an ets related gene codes for two transcriptional factors elk-1, which regulates c-fos transcription and Delta elk-1, both of which are substrates for MAP kinases. A part of the C-terminal transcriptional activation domain (ETA-2) which is common to both the proteins was previously shown to function as an activator of MAP kinases. In this report, in an attempt to investigate the mechanism of activation of MAP kinases, purified preparations of recombinant elk-1 and P44(mpk)/ERK-1/ERK-2 proteins were used to show the association of elk-1 proteins with MAP kinases, The specific interactions of elk-1 proteins with MAP kinases were confirmed by co-immunoprecipitation studies. Thus elk-1 proteins appear to regulate the activity of MAP kinases by interacting with them ensuring a conformational change and stimulating their autophosphorylation and activation property. The activation was dependent on the presence of ATP and Mg2+. In vitro phosphorylation of elk-1 protein was not regulatory for autonomous DNA binding activity of elk-1 protein. Cells which were exposed to EGF showed a rapid stimulation of an elk-1 specific kinase activity, probably MAP kinase which phosphorylated MBP and was found to be associated with immobilized GST-elk-1. Furthermore, dephosphorylation studies indicate that elk-1 proteins can activate only tyrosine phosphorylated MAP kinase. These results demonstrate the presence of an alternative pathway/mechanism (other than MAP kinase kinase, MAPKK/Mek) for the activation of MAP kinases with tyrosine phosphorylation occurring before serine/threonine autophosphorylation and activation by elk-1 proteins.			RAO, VN (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.				NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEWIS IC, 1991, J BIOL CHEM, V266, P15180; MARIAS R, 1993, CELL, V73, P381; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1993, CANCER RES, V53, P3449; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	36	80	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1855	1860						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208531				2022-12-17	WOS:A1994NR68500007
J	HAWLEY, RG; FONG, AZC; LU, M; HAWLEY, TS				HAWLEY, RG; FONG, AZC; LU, M; HAWLEY, TS			THE HOX11 HOMEOBOX-CONTAINING GENE OF HUMAN LEUKEMIA IMMORTALIZES MURINE HEMATOPOIETIC PRECURSORS	ONCOGENE			English	Article							T-CELL LEUKEMIA; STEM-CELLS; BONE-MARROW; MYELOID-LEUKEMIA; DIFFERENTIATION; EXPRESSION; GROWTH; LINES; MICE; INTERLEUKIN-6	The t(10;14) chromosomal translocation of T-cell acute lymphoblastic leukemia joins the T-cell receptor delta gene to a region upstream of a diverged homeobox-containing gene called HOX11. To better understand the pathogenetic role of HOX11 in leukemogenesis, post 5-fluorouracil-treated murine bone marrow cells were infected with a replication-defective retrovirus bearing the gene. Constitutive expression of HOX11 in hematopoietic precursors yielded cell lines at high frequency consisting of immature cells belonging to the myeloid lineage. HOX11-transformed cell lines displayed a strict dependence on IL-3 for their survival and proliferation in culture and were not leukemogenic. The results support the hypothesis that the transforming capacity of HOX11 derives from its ability to alter the expression of genes regulating hematopoietic differentiation and that secondary mutations promoting cell survival or stimulating proliferation are required for progression to malignancy. The findings further suggest that the oncogenic activity of HOX11 might not be restricted to T-cell leukemias in humans.	UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4N 3M5, ON, CANADA; UNIV OTTAWA, NE ONTARIO REG CANC CTR, SUDBURY P3E 5J1, ON, CANADA; UNIV OTTAWA, DEPT MED, SUDBURY P3E 5J1, ON, CANADA	University of Toronto; University of Ottawa; University of Ottawa	HAWLEY, RG (corresponding author), UNIV TORONTO, SUNNYBROOK MED CTR, DIV CANC RES, REICHMANN RES BLDG, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ON, CANADA.			Hawley, Robert/0000-0003-3512-5818				BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DIBIRDIK I, 1991, BLOOD, V78, P564, DOI 10.1182/blood.V78.3.564.bloodjournal783564; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DUBE ID, 1991, BLOOD, V78, P2996; DUHRSEN U, 1990, BLOOD, V75, P190; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GOODWIN RG, 1991, CYTOKINE HDB, P191; GREEN SM, 1989, ONCOGENE, V4, P737; HARLOW E, 1988, ANTIBODIES LABORATOR; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; HAWLEY RG, 1987, P NATL ACAD SCI USA, V84, P2406, DOI 10.1073/pnas.84.8.2406; HAWLEY RG, 1982, P NATL ACAD SCI-BIOL, V79, P7425, DOI 10.1073/pnas.79.23.7425; HAWLEY RG, 1993, CLIN EXP METASTAS, V11, P213, DOI 10.1007/BF00114979; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; HAWLEY RG, 1993, IN PRESS J EXP MED, V178; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HAWLEY TS, 1991, CYTOKINE, V3, P60, DOI 10.1016/1043-4666(91)90011-2; JUTILA MA, 1988, EUR J IMMUNOL, V18, P1819, DOI 10.1002/eji.1830181125; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER JR, 1989, J IMMUNOL, V143, P4025; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEE JC, 1981, P NATL ACAD SCI-BIOL, V78, P7712, DOI 10.1073/pnas.78.12.7712; LEONARD EJ, 1990, BIOTECHNIQUES, V9, P684; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MILLER BA, 1985, J IMMUNOL, V134, P3286; MING L, 1992, ONCOGENE, V7, P1325; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, J EXP MED, V166, P12, DOI 10.1084/jem.166.1.12; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SABOURIN LA, 1990, J CELL PHYSIOL, V145, P564, DOI 10.1002/jcp.1041450325; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; ZHANG N, 1993, IN PRESS ONCOGENE, V8	61	80	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					1	12						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7905617				2022-12-17	WOS:A1994MW24700001
J	YAMAMOTO, K; SETO, M; KOMATSU, H; IIDA, S; AKAO, Y; KOJIMA, S; KODERA, Y; NAKAZAWA, S; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R				YAMAMOTO, K; SETO, M; KOMATSU, H; IIDA, S; AKAO, Y; KOJIMA, S; KODERA, Y; NAKAZAWA, S; ARIYOSHI, Y; TAKAHASHI, T; UEDA, R			2 DISTINCT PORTIONS OF LTG19/ENL AT 19P13 ARE INVOLVED IN T(11 19) LEUKEMIA	ONCOGENE			English	Article								We previously isolated cDNA clones, MLL-a and MLL-b, derived from the 11q23 breakpoint region and detected gene rearrangements with MLL-b cDNA in infantile leukemia cell lines with 11q23 abnormalities. We also showed chimeric mRNAs between MLL and genes on partner chromosomes such as 4q21 and 19p13. In the present study, we isolated overlapping MLL cDNA clones of 11 kb and demonstrated that MLL-a and MLL-b were derived from the same gene, MLL/ALL-1/HRX. Northern analysis with an MLL cDNA probe detected different signals in t(11;19) cell lines, one being sized 10 kb in two cell lines, KOCL-33 and KOCL-44, and the other being 9.2 kb in the cell line, KOPN-1. To elucidate the molecular basis for the heterogeneity, we isolated cDNA clones of a translocation-associated gene on chromosome 19, LTG19, as well as chimeric cDNAs from KOPN-1. Northern analysis with LTG19 cDNA demonstrated the identical gene, encoding serine/proline rich 559 amino acid polypeptide, to be involved in all three cell lines. Sequence comparison revealed that the LTG19 portion of the predicted chimeric protein of KOPN-1 was fused in frame and contained the C-terminal 189 amino acids. This was shorter by 366 amino acids than those of KOCL-33 and KOCL-44, also fused in frame. Reverse transcriptase-PCR analysis demonstrated complex chimeric mRNAs in cell lines and leukemia samples. Although a chimeric mRNA of KOPN-1 type was rare, its presence suggested that the shared C-terminal portion of 189 amino acids of LTG19 contains important signal(s) for malignant transformation.	AICHI CANC CTR, RES INST,CHEMOTHERAPY LAB,1-1 KANOKODEN,CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, IMMUNOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR HOSP, DEPT HEMATOL & CHEMOTHERAPY, CHIKUSA KU, NAGOYA 464, JAPAN; NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT PEDIAT, NAKAMURA KU, NAGOYA 453, JAPAN; YAMANASHI MED COLL, DEPT PEDIAT, YAMANASHI 40938, JAPAN; NAGOYA FIRST HOSP, JAPANESE RED CROSS, DEPT INTERNAL MED, NAKAMURA KU, NAGOYA 453, JAPAN; OSAKA MED COLL, DEPT ANAT, TAKATSUKI, OSAKA 569, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; University of Yamanashi; Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; Osaka Medical College								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; AKAO Y, 1991, CANCER RES, V51, P6708; AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1992, CANCER RES, V52, P6083; CHEN CS, 1991, BLOOD, V78, P2498; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAIBATA M, 1987, JPN J CANCER RES, V78, P1182; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DAS S, 1992, GENE CHROMOSOME CANC, V5, P244, DOI 10.1002/gcc.2870050312; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HABER DA, 1992, NEW BIOL, V4, P97; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; IIDA S, 1993, JPN J CANCER RES, V84, P532, DOI 10.1111/j.1349-7006.1993.tb00172.x; KANEKO Y, 1986, BLOOD, V67, P484; KATZ F, 1988, BLOOD, V71, P1438; KEARNEY L, 1992, BLOOD, V80, P1659; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUBONISHI I, 1986, CANCER, V58, P1453, DOI 10.1002/1097-0142(19861001)58:7<1453::AID-CNCR2820580713>3.0.CO;2-B; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITANI K, 1989, AM J HEMATOL, V31, P253, DOI 10.1002/ajh.2830310407; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN GJ, 1992, BLOOD, V80, P2172; PRIETO F, 1990, CANCER GENET CYTOGEN, V45, P1, DOI 10.1016/0165-4608(90)90061-E; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SETO M, 1992, ONCOGENE, V7, P1401; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; YAMAMOTO K, 1993, ONCOGENE, V8, P479; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	45	80	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2617	2625						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378076				2022-12-17	WOS:A1993LX34300002
J	NAUMANN, M; NIETERS, A; HATADA, EN; SCHEIDEREIT, C				NAUMANN, M; NIETERS, A; HATADA, EN; SCHEIDEREIT, C			NF-KAPPA-B PRECURSOR P100 INHIBITS NUCLEAR TRANSLOCATION AND DNA-BINDING OF NF-KAPPA-B/REL-FACTORS	ONCOGENE			English	Article							CANDIDATE PROTOONCOGENE BCL-3; PROTO-ONCOGENE; P50 PRECURSOR; CYTOPLASMIC RETENTION; TRANSCRIPTION FACTOR; REL ONCOGENE; V-REL; C-REL; SUBUNIT; CLONING	The NF-kappaB precursor p100 (lyt-10, p97, p98) generates after proteolytic processing a 52 kDa subunit, which can bind to kappaB-motifs. A deregulated form of the p100 gene, which is structurally altered by a t(10;14) translocation, has a potential oncogenic role in certain human B cell lymphomas. In this study p100 was analysed for its ability to interact with its own processing product p52, with p50, the product of the NF-kappaB precursor p105, and with other NF-kappaB/rel-proteins. As demonstrated by a combination of Western blot analysis, band shift analysis and indirect immunofluorescence labelling of transfected cells, p100 itself was localized in the cytoplasm and indiscriminately retained each co-expressed NF-kappaB subunit. Thereby it simultaneously inhibited their DNA binding activities. Thus, a major function of p100 is, like p105, to associate with subunits of the rel multigene family in the cytoplasm in an IkappaB-like fashion. The similarity between p100 and p105 is also reflected by equivalent protein interactions of their processing products: like NF-kappaB-p50, also NF-kappaB-p52 heteromerised promiscuously with all rel-factors tested. Moreover, p52 efficiently interacts with the candidate oncogene product Bcl-3 and also binds to the basic-leucine zipper protein NF-IL6.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,D-14195 DAHLEM,GERMANY	Max Planck Society			Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, EMBO J, V17, P135; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STORMS RW, 1992, VIROLOGY, V188, P765, DOI 10.1016/0042-6822(92)90531-S; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	42	80	80	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2275	2281						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336950				2022-12-17	WOS:A1993LP17100030
J	HOSONO, S; CHOU, MJ; LEE, CS; SHIH, C				HOSONO, S; CHOU, MJ; LEE, CS; SHIH, C			INFREQUENT MUTATION OF P53 GENE IN HEPATITIS-B VIRUS POSITIVE PRIMARY HEPATOCELLULAR CARCINOMAS	ONCOGENE			English	Note							C VIRUS; BREAST-CANCER; LIVER-CANCER; LUNG-CANCER; ALLELE LOSS; CELL-LINES; CHROMOSOME-17; FREQUENT; TAIWAN; HETEROZYGOSITY	Somatic mutation of the p53 oncogene/anti-oncogene allele has been shown to be involved in many different human solid tumors. Recently, there have been reports that p53 mutations are found to occur at high frequency (50%) in aflatoxin-related human primary hepatocellular carcinomas (HCC) (Hsu et al., 1991 Nature, vol 350, p. 427; Bressac et al., 1991 Nature, vol 350, p. 429). Most strikingly, a hotspot G to T mutation at amino acid position 249 was identified. These reports appear to contradict our earlier publications that although p53 mutation is found frequently in human HCC cell lines, it is rarely found in primary tumors. In this paper, we have further examined 20 different primary HCC samples (17 were hepatitis B surface antigen positive) and their adjacent nontumorous tissues, using restriction fragment length polymorphism (RFLP) analyses. Clear loss of heterozygosity (LOH) was found in only 3 out of 20 samples. All three samples were also found to carry a point mutation within the remaining p53 allele. None of these mutations was found to be at the proposed aflatoxin hotspot of amino acid 249. All three point mutations are of somatic origin. Ten samples, randomly chosen from the remaining 17 LOH negative HCC tumors, were analyzed further by DNA sequencing and Western blot analyses. No point mutations of p53 were found. Taken together with our previous report (Hosono et al., 1991, Oncogene vol 6, p. 237-243), we conclude that p53 mutation occurs infrequently, only approximately 18%, in HBV-positive primary hepatomas from Taiwan. Furthermore, p53 mutation appears to be acquired later in tumor development at least in some HCC samples.	UNIV TEXAS,MED BRANCH,SCH MED,DEPT PATHOL,GALVESTON,TX 77550; NATL TAIWAN UNIV,COLL MED,TAIPEI,TAIWAN	University of Texas System; University of Texas Medical Branch Galveston; National Taiwan University			Shih, Chiaho/S-7017-2018		NATIONAL CANCER INSTITUTE [R01CA048198] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA48198, KO4 CA01399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1981, NEW ENGL J MED, V304, P782, DOI 10.1056/NEJM198103263041312; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHEN DS, 1990, J INFECT DIS, V162, P817, DOI 10.1093/infdis/162.4.817; CHIBA I, 1990, ONCOGENE, V5, P1603; DAVIDOFF AM, 1991, J SURG ONCOL, V48, P260, DOI 10.1002/jso.2930480409; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; FUJIMOTO Y, 1992, CANCER RES, V52, P1044; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KONDOLEON S, 1987, NUCLEIC ACIDS RES, V15, P10605, DOI 10.1093/nar/15.24.10605; LAI MY, 1991, PARIS PASTEUR I M HE, P142; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SCORSONE KA, 1992, CANCER RES, V52, P1635; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SLAGLE BL, 1991, CANCER RES, V51, P49; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOGUCHIDA J, 1989, CANCER RES, V49, P6247; WALKER GJ, 1991, CANCER RES, V51, P4367; WANG WL, 1991, CANCER RES, V51, P4971; YAGINUMA Y, 1991, CANCER RES, V51, P6506; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YU MW, 1991, CANCER RES, V51, P5621; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	41	80	81	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					491	496						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8093978				2022-12-17	WOS:A1993KN00600029
J	OELRICHS, RB; REID, HH; BERNARD, O; ZIEMIECKI, A; WILKS, AF				OELRICHS, RB; REID, HH; BERNARD, O; ZIEMIECKI, A; WILKS, AF			NYK/FLK-1 - A PUTATIVE RECEPTOR PROTEIN TYROSINE KINASE ISOLATED FROM E10 EMBRYONIC NEUROEPITHELIUM IS EXPRESSED IN ENDOTHELIAL-CELLS OF THE DEVELOPING EMBRYO	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; DEVELOPING MOUSE-BRAIN; ONCOGENE C-KIT; W-LOCUS; CONSERVED FEATURES; CDNA; SEQUENCE; FAMILY; GENE; DNA	A protein tyrosine kinase (NYK/FLK-1), bearing all the hallmarks of a growth factor receptor, has been isolated from a cDNA library generated from enriched populations of mouse day 10 embryonic neuroepithelium and from day 18 embryonic colon. Sequence analysis of cDNAs covering the entire coding region of this 5.7 kb mRNA predicted the presence of seven immunoglobulin-like domains in the extracellular region of this molecule. This feature, coupled with the detection of an insert domain bisecting the kinase domain of the predicted protein sequence, places NYK/FLK-1 firmly in the Platelet-derived Growth Factor Receptor-related class of molecules. NYK/FLK-1 is expressed at high levels in adult heart, lung, kidney, brain and skeletal muscle, but is also expressed at lower levels in most other adult tissues. In situ hybridization of day 12.5 embryo sections demonstrated NYK/FLK-1 mRNA expression in endothelial cells lining the dorsal aorta and intervertebral veins. In addition, expression was found in cells lining the capillary plexus which surrounds the developing neuroepithelium, and in the endothelial cells which are found within the embryonic lung, spleen, liver and metanephros.	ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of Bern			Bernard, Olivier/J-1133-2014; Wilks, Andrew F/R-5542-2019	Bernard, Olivier/0000-0003-2539-9014; Wilks, Andrew F/0000-0002-8554-2399				BAER T, 1980, ADV ANAT EMBRYOL CEL, V264, P8222; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DRAGO J, 1991, J NEUROSCI METH, V37, P251, DOI 10.1016/0165-0270(91)90031-T; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOVENS CM, 1992, IN PRESS P NATL ACAD; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; REID HH, 1990, THESIS U MELBOURNE; ROSNET O, 1991, ONCOGENE, V6, P1641; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; STEVENSON DA, 1991, P NATL ACAD SCI USA, V88, P6; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	42	80	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					11	18						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423988				2022-12-17	WOS:A1993KN00500002
J	DONGHI, R; SOZZI, G; PIEROTTI, MA; BIUNNO, I; MIOZZO, M; FUSCO, A; GRIECO, M; SANTORO, M; VECCHIO, G; SPURR, NK; DELLAPORTA, G				DONGHI, R; SOZZI, G; PIEROTTI, MA; BIUNNO, I; MIOZZO, M; FUSCO, A; GRIECO, M; SANTORO, M; VECCHIO, G; SPURR, NK; DELLAPORTA, G			THE ONCOGENE ASSOCIATED WITH HUMAN PAPILLARY THYROID-CARCINOMA (PTC) IS ASSIGNED TO CHROMOSOME-10 Q11-Q12 IN THE SAME REGION AS MULTIPLE ENDOCRINE NEOPLASIA TYPE-2A (MEN2A)	ONCOGENE			English	Note									IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; UNIV NAPLES,FAC MED & CHIRURG 2,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,I-80131 NAPLES,ITALY; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LID,HERTS,ENGLAND	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II			sozzi, gabriella/G-8259-2011	sozzi, gabriella/0000-0001-9360-6914; Grieco, Michele/0000-0002-4212-7814; Fusco, Alfredo/0000-0003-3332-5197; Pierotti, Marco Alessandro/0000-0002-7431-8332; , IDA_2/0000-0002-1068-4763; Miozzo, Monica/0000-0002-6523-4575				BAI Y, 1982, ANN HUM GENET, V46, P337, DOI 10.1111/j.1469-1809.1982.tb01584.x; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HECHT F, 1988, CANCER GENET CYTOGEN, V31, P142; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; LEONARD WJ, 1985, SCIENCE, V228, P1547, DOI 10.1126/science.3925551; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; RADICE P, 1988, NUCLEIC ACIDS RES, V18, P5062; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; SOLOMON E, 1976, SOMAT CELL GENET, V2, P125, DOI 10.1007/BF01542626; SOLOMON E, 1979, ANN HUM GENET, V42, P273, DOI 10.1111/j.1469-1809.1979.tb00661.x; SWALLOW DM, 1977, CYTOGENET CELL GENET, V18, P136, DOI 10.1159/000130758; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	16	80	81	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					521	523						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2566146				2022-12-17	WOS:A1989U567700019
J	VARLEY, JM; WALKER, RA; CASEY, G; BRAMMAR, WJ				VARLEY, JM; WALKER, RA; CASEY, G; BRAMMAR, WJ			A COMMON ALTERATION TO THE INT-2 PROTO-ONCOGENE IN DNA FROM PRIMARY BREAST CARCINOMAS	ONCOGENE			English	Article									UNIV LEICESTER,DEPT PATHOL,LEICESTER LE1 7RH,ENGLAND; ICI PLC,DIV PHARMACEUT,RUNCORN,CHESHIRE,ENGLAND	University of Leicester	VARLEY, JM (corresponding author), UNIV LEICESTER,ICI UNIV JOINT LAB,LEICESTER LE1 7RH,ENGLAND.							CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LAW ML, 1987, P NATL ACAD SCI USA, V84, P2877, DOI 10.1073/pnas.84.9.2877; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1984, MOL CELL BIOL, V4, P375, DOI 10.1128/MCB.4.2.375; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHURCH W, 1981, VIRCHOWS ARCH A, V391, P125, DOI 10.1007/BF00437591; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPANDIDOS DA, 1982, EMBO J, V1, P15, DOI 10.1002/j.1460-2075.1982.tb01117.x; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAMAIMI SO, 1987, J PATH, V153, P163; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHOU DJ, 1988, ONCOGENE, V2, P279	26	80	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					87	91						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400012
J	NEPVEU, A; LEVINE, RA; CAMPISI, J; GREENBERG, ME; ZIFF, EB; MARCU, KB				NEPVEU, A; LEVINE, RA; CAMPISI, J; GREENBERG, ME; ZIFF, EB; MARCU, KB			ALTERNATIVE MODES OF C-MYC REGULATION IN GROWTH FACTOR-STIMULATED AND DIFFERENTIATING CELLS	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; NYU,DEPT BIOCHEM,NEW YORK,NY 10016	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Boston University; New York University	NEPVEU, A (corresponding author), SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794, USA.		/AAB-8315-2020	Ziff, Edward/0000-0001-7389-8649	NATIONAL CANCER INSTITUTE [R01CA036246] Funding Source: NIH RePORTER; NCI NIH HHS [CA36246] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COCHET C, 1984, J BIOL CHEM, V259, P2553; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAHRLANDER PD, 1986, ONCOGENES GROWTH CON, P264; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENBERG ME, 1984, NATURE, V311, P438; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MARCU KB, 1987, IN PRESS NUCLEAR ONC; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEDRANO EE, 1980, P NATL ACAD SCI-BIOL, V77, P4123, DOI 10.1073/pnas.77.7.4123; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RAN W, 1986, P NATL ACAD SCI USA, V83, P8216, DOI 10.1073/pnas.83.21.8216; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROZENGURT E, 1985, MOL MECHANISMS TRANS, P429; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	48	80	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					243	250						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	2455262				2022-12-17	WOS:A1987J970500002
J	Domenici, G; Aurrekoetxea-Rodriguez, I; Simoes, BM; Rabano, M; Lee, SY; San Millan, J; Comaills, V; Oliemuller, E; Lopez-Ruiz, JA; Zabalza, I; Howard, BA; Kypta, RM; Vivanco, MD				Domenici, Giacomo; Aurrekoetxea-Rodriguez, Iskander; Simoes, Bruno M.; Rabano, Miriam; Lee, So Young; San Millan, Julia; Comaills, Valentine; Oliemuller, Erik; Lopez-Ruiz, Jose A.; Zabalza, Ignacio; Howard, Beatrice A.; Kypta, Robert M.; Vivanco, Maria d M.			A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells	ONCOGENE			English	Article							MAMMARY STEM; ALDEHYDE DEHYDROGENASE; TRANSCRIPTION FACTOR; WNT PATHWAY; SOX9; RESISTANCE; DIFFERENTIATION; IDENTIFICATION; EXPRESSION; ACTIVATION	Increased cancer stem cell content during development of resistance to tamoxifen in breast cancer is driven by multiple signals, including Sox2-dependent activation of Wnt signalling. Here, we show that Sox2 increases and estrogen reduces the expression of the transcription factor Sox9. Gain and loss of function assays indicate that Sox9 is implicated in the maintenance of human breast luminal progenitor cells. CRISPR/Cas knockout of Sox9 reduces growth of tamoxifen-resistant breast tumours in vivo. Mechanistically, Sox9 acts downstream of Sox2 to control luminal progenitor cell content and is required for expression of the cancer stem cell marker ALDH1A3 and Wnt signalling activity. Sox9 is elevated in breast cancer patients after endocrine therapy failure. This new regulatory axis highlights the relevance of SOX family transcription factors as potential therapeutic targets in breast cancer.	[Domenici, Giacomo; Aurrekoetxea-Rodriguez, Iskander; Simoes, Bruno M.; Rabano, Miriam; Lee, So Young; San Millan, Julia; Comaills, Valentine; Kypta, Robert M.; Vivanco, Maria d M.] CIC BioGUNE, Technol Pk Bizkaia, Derio 48160, Spain; [Oliemuller, Erik; Howard, Beatrice A.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England; [Lopez-Ruiz, Jose A.] Radiodiagnost Serv PreteImagen, Bilbao, Spain; [Zabalza, Ignacio] Galdakao Usansolo Hosp, Dept Pathol, Galdakao, Spain; [Kypta, Robert M.] Imperial Coll London, Dept Surg & Canc, London, England	CIC bioGUNE; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Galdakao Hospital; Imperial College London	Vivanco, MD (corresponding author), CIC BioGUNE, Technol Pk Bizkaia, Derio 48160, Spain.	mdmvivanco@cicbiogune.es	Vivanco, Maria/G-2393-2011; COMAILLS, VALENTINE/AAX-1697-2021; Simoes, Bruno/AAB-2582-2019; Domenici, Giacomo/AAG-6224-2019; Kypta, Robert/F-7699-2011	Vivanco, Maria/0000-0002-9540-247X; COMAILLS, VALENTINE/0000-0001-8857-6976; Simoes, Bruno/0000-0003-1253-6657; Kypta, Robert/0000-0002-2389-310X; Aurrekoetxea-Rodriguez, Iskander/0000-0001-5294-7798; Lee, So Young/0000-0003-3130-785X; Oliemuller Garcia, Erik/0000-0002-4506-0504; Domenici, Giacomo/0000-0002-3947-5930	Spanish Ministry of Education and Science; Institute of Health Carlos III [PI14/01328]; Department of Education of the Government of the Autonomous Community of the Basque Country [PRE_2013_1_991]; Department of Health of the Government of the Autonomous Community of the Basque Country [2014111145]; Department of Industry, Tourism and Trade (Etortek) of the Government of the Autonomous Community of the Basque Country; Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country; RED Nurcamein; Breast Cancer Now;  [SAF2017-84934-R];  [SAF2017-84092-R]	Spanish Ministry of Education and Science(Spanish Government); Institute of Health Carlos III(Instituto de Salud Carlos III); Department of Education of the Government of the Autonomous Community of the Basque Country; Department of Health of the Government of the Autonomous Community of the Basque Country; Department of Industry, Tourism and Trade (Etortek) of the Government of the Autonomous Community of the Basque Country; Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country; RED Nurcamein; Breast Cancer Now; ; 	We are grateful for the generosity of many women and patients that collaborated in this project. We thank the members of the laboratory for helpful discussions and Jessica Cellot for technical help. This work was supported by grants from the Spanish Ministry of Education and Science, the Institute of Health Carlos III (PI14/01328 to M.V.), the Departments of Education (PRE_2013_1_991 to G.D.) and Health (2014111145 to M.V.) of the Government of the Autonomous Community of the Basque Country, the Department of Industry, Tourism and Trade (Etortek) and Department of Innovation Technology of the Government of the Autonomous Community of the Basque Country (to R.K. and M.V.), the RED Nurcamein and SAF2017-84934-R (to M.V.) and SAF2017-84092-R (to R.K.). We thank Breast Cancer Now for funding this work as part of Programme Funding to the Breast Cancer Now Toby Robins Research Centre (to B.H.). We are particularly grateful for the generosity of ACAMBI and all its supporters (to M.V.).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143; Arendt LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111442; Ashkenazi S, 2016, ONCOTARGET, V7, P30166, DOI 10.18632/oncotarget.7379; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Boras-Granic Kata, 2008, Organogenesis, V4, P116; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; Burdelski C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128525; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Canino C, 2015, ONCOTARGET, V6, P12637, DOI 10.18632/oncotarget.3703; Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086; Chang DR, 2013, P NATL ACAD SCI USA, V110, P18042, DOI 10.1073/pnas.1311760110; Chen MH, 2016, CLIN CANCER RES, V22, P4225, DOI 10.1158/1078-0432.CCR-15-1800; Cheng PF, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0594-4; Clayton H, 2004, EXP CELL RES, V297, P444, DOI 10.1016/j.yexcr.2004.03.029; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791; Elizalde C, 2011, STEM CELLS, V29, P141, DOI 10.1002/stem.562; Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Gascoyne DM, 2003, CELL CYCLE, V2, P238, DOI 10.4161/cc.2.3.355; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gonzalez E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083955; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107; Huang YH, 2015, SCI REP-UK, V5, DOI 10.1038/srep10398; Iriondo O, 2015, ONCOTARGET, V6, P31721, DOI 10.18632/oncotarget.5564; Iriondo O, 2015, METHODS MOL BIOL, V1293, P63, DOI 10.1007/978-1-4939-2519-3_3; Jeselsohn R, 2017, P NATL ACAD SCI USA, V114, pE4482, DOI 10.1073/pnas.1620993114; Kang HM, 2016, CELL REP, V14, P861, DOI 10.1016/j.celrep.2015.12.071; KASTAN MB, 1990, BLOOD, V75, P1947; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020636; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Malhotra GK, 2014, BMC DEV BIOL, V14, DOI 10.1186/s12861-014-0047-4; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Martin-Martin N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12595; Matheu A, 2012, CANCER RES, V72, P1301, DOI 10.1158/0008-5472.CAN-11-3660; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411; Poche RA, 2008, J COMP NEUROL, V510, P237, DOI 10.1002/cne.21746; Prevostel C, 2016, ONCOTARGET, V7, P82228, DOI 10.18632/oncotarget.10573; Scott CE, 2010, NAT NEUROSCI, V13, P1181, DOI 10.1038/nn.2646; Seymour PA, 2007, P NATL ACAD SCI USA, V104, P1865, DOI 10.1073/pnas.0609217104; Simoes BM, 2011, FUTURE ONCOL, V7, P995, DOI [10.2217/FON.11.80, 10.2217/fon.11.80]; Simoes BM, 2011, BREAST CANCER RES TR, V129, P23, DOI 10.1007/s10549-010-1169-4; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Thomsen MK, 2008, DEV BIOL, V316, P302, DOI 10.1016/j.ydbio.2008.01.030; Vidal VPI, 2005, CURR BIOL, V15, P1340, DOI 10.1016/j.cub.2005.06.064; Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Vivanco MD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001215; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wang HY, 2013, J BIOL CHEM, V288, P6478, DOI 10.1074/jbc.M112.419184; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Wu F, 2012, CELL SIGNAL, V24, P1989, DOI 10.1016/j.cellsig.2012.07.008; Zhou CH, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-18	68	79	82	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3151	3169		10.1038/s41388-018-0656-7	http://dx.doi.org/10.1038/s41388-018-0656-7			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30622340	Green Published, hybrid			2022-12-17	WOS:000465557200004
J	Zhen, Y; Fang, W; Zhao, M; Luo, R; Liu, Y; Fu, Q; Chen, Y; Cheng, C; Zhang, Y; Liu, Z				Zhen, Y.; Fang, W.; Zhao, M.; Luo, R.; Liu, Y.; Fu, Q.; Chen, Y.; Cheng, C.; Zhang, Y.; Liu, Z.			miR-374a-CCND 1-pPI3KJAKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; LUNG-CANCER; CYCLE PROGRESSION; GENE-EXPRESSION; DOWN-REGULATION; OVARIAN-CANCER; C-MYC; PROLIFERATION; PROMOTES	miR-374a has been reported to function as an oncogene during tumor pathogenesis. In this study, miR-374a is observed to reduce nasopharyngeal carcinoma (NPC) cell proliferation, migration, invasion, metastasis and cisplatin (DDP) resistance in vitro and in vivo. Mechanistic analyses indicate that miR-374a directly targets CCND1 to inactivate pPI3K/pAKT/c-JUN forming a negative feedback loop, as well as suppressing downstream signals related to cell cycle progression and epithelial mesenchymal transition (EMT). Interestingly, we also observed that miR-374a direct targeting of CCND1 is modulated by tumor suppressor PDCD4 via suppressing pPl3K/pAICT/c-JUN signaling. In clinical specimens, miR-374a was positively and negatively correlated with expression of PDCD4 and CCND1, respectively. Our studies are the first to demonstrate that the miR-374a-CCND1-pPl3K/AKT-c-JUN feedback loop induced by PDCD4 supresses NPC cell growth, metastasis and chemotherapy resistance.	[Zhen, Y.; Fang, W.; Luo, R.] Southern Med Univ, TCM Integrated Hosp, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Zhen, Y.] Guangdong Med Univ, Affiliated Hosp, Inst Resp Dis, Zhanjiang, Peoples R China; [Zhen, Y.; Fang, W.; Zhao, M.; Liu, Y.; Fu, Q.; Chen, Y.; Cheng, C.; Liu, Z.] Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China; [Zhang, Y.; Liu, Z.] Guangzhou Med Univ, Sch Basic Med, Dept Pathol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Guangdong Medical University; Southern Medical University - China; Guangzhou Medical University	Fang, W; Liu, Z (corresponding author), Southern Med Univ, Canc Res Inst, Guangzhou 510515, Guangdong, Peoples R China.	fangweiyi1975@163.com; narcissus_jane@163.com			National Nature Science Fund of China [81372184, 81401906]; Outstanding Young Teacher Training Project of Colleges and Universities in Guangdong Province [Yq2013136]; Guangdong Province Education Foundation [2014KTSCX107]; Yangcheng Scholar Research Projects from Universities of Guangzhou [12A011D]	National Nature Science Fund of China(National Natural Science Foundation of China (NSFC)); Outstanding Young Teacher Training Project of Colleges and Universities in Guangdong Province; Guangdong Province Education Foundation; Yangcheng Scholar Research Projects from Universities of Guangzhou	This study was supported by National Nature Science Fund of China (No. 81372184 and No. 81401906) (http://www.nsfc.gov.cn), the Outstanding Young Teacher Training Project of Colleges and Universities in Guangdong Province (No. Yq2013136), Guangdong Province Education Foundation (No. 2014KTSCX107), and Yangcheng Scholar Research Projects from Universities of Guangzhou (No. 12A011D). We are also grateful to Dr Douglas E Linn (Brigham & Women's Hospital, Boston, MA, USA) for critical reading of the manuscript.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bu PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7879; Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871; Cai LM, 2015, ONCOGENE, V34, P2156, DOI 10.1038/onc.2014.341; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; JIANG W, 1993, ONCOGENE, V8, P3447; Ju XM, 2014, CANCER RES, V74, P508, DOI 10.1158/0008-5472.CAN-13-1313; Keklikoglou I, 2015, ONCOGENE, V34, P4867, DOI 10.1038/onc.2014.408; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lei K, 2008, ONCOGENE, V27, P4877, DOI 10.1038/onc.2008.132; Li JY, 2013, ASIAN PAC J CANCER P, V14, P1715, DOI 10.7314/APJCP.2013.14.3.1715; Liao HZ, 2015, ONCOTARGET, V6, P8914, DOI 10.18632/oncotarget.3563; Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Miko E, 2009, EXP LUNG RES, V35, P646, DOI 10.3109/01902140902822312; Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136; Que T, 2015, ONCOGENE, V34, P4952, DOI 10.1038/onc.2014.419; Sorokin AV, 2013, ONCOGENE, V32, P3130, DOI 10.1038/onc.2012.327; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; Vosa U, 2011, GENE CHROMOSOME CANC, V50, P812, DOI 10.1002/gcc.20902; Walsh AM, 2015, MOL CANCER RES, V13, P1227, DOI 10.1158/1541-7786.MCR-14-0183-T; Wang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.122; Wang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.186; Wu AB, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-38; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489; Yu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.153; Zhang PJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6671; Zhao MY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11309; Zhen Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.376; Zhong ZJ, 2010, CANCER RES, V70, P2105, DOI 10.1158/0008-5472.CAN-08-1108; Zhou Y, 2015, ONCOTARGET, V6, P10350, DOI 10.18632/oncotarget.3585	37	79	85	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					275	285		10.1038/onc.2016.201	http://dx.doi.org/10.1038/onc.2016.201			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270423				2022-12-17	WOS:000393938100012
J	Kale, S; Raja, R; Thorat, D; Soundararajan, G; Patil, TV; Kundu, GC				Kale, S.; Raja, R.; Thorat, D.; Soundararajan, G.; Patil, T. V.; Kundu, G. C.			Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha 9 beta 1 integrin	ONCOGENE			English	Article						osteopontin; tumor-associated macrophages; COX-2 and melanoma growth	BREAST-CANCER; ALPHA(V)BETA(3) INTEGRIN; CRUCIAL ROLE; INFILTRATION; METASTASIS; KINASE; PROGRESSION; INHIBITION; PROTEIN; M2	Tumor-associated macrophages (TAMs) have multifaceted roles in tumor development, particularly linked with tumor angiogenesis and invasion, but the molecular mechanism underlying this association remains unclear. In this study, we report that lack of osteopontin (OPN) suppresses melanoma growth in opn -/- mice and macrophages are the crucial component responsible for OPN-regulated melanoma growth. In tumor microenvironment, OPN activates macrophages and influences angiogenesis by enhancing cyclooxygenase-2 (COX-2)-dependent prostaglandin E-2 (PGE(2)) production in an autocrine manner. Furthermore, we identify alpha 9b1 integrin as a functional receptor for OPN that mediates its effect and activates ERK and p38 signaling, which ultimately leads to COX-2 expression in macrophages. The major role played by OPN and PGE(2) in angiogenesis are further amplified by upregulation of MMP-9. OPN-activated macrophages promote the migration of endothelial and cancer cells via PGE(2). These findings provide evidence that TAMs serve as source of key components such as OPN and COX-2-derived PGE(2) and MMP-9 in melanoma microenvironment. Clinical specimens analyses revealed that increased infiltration of OPN-positive TAMs correlate with melanoma growth and angiogenesis. These data provide compelling evidence that OPN and COX-2 expressing macrophages are obligatory factors in melanoma growth. We conclude that OPN signaling is involved in macrophage recruitment into tumor, and our results emphasize the potential role of macrophage in modulation of tumor microenvironment via secretion of OPN, PGE(2) and MMP-9, which trigger angiogenesis and melanoma growth. Thus, blockade of OPN and its regulated signaling network provides unique strategy to eradicate melanoma by manipulating TAMs.	[Kale, S.; Raja, R.; Thorat, D.; Soundararajan, G.; Kundu, G. C.] Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, Pune 411007, Maharashtra, India; [Patil, T. V.] YCM Hosp, Dept Pathol, Pune, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Kundu, Gopal C./ABA-9897-2020; Raja, Remya/GXM-8598-2022	Raja, Remya/0000-0002-7576-6778	Department of Biotechnology (DBT), Government of India; Council of Scientific and Industrial Research (CSIR), Government of India; Indian Council of Medical Research (ICMR), Government of India; Department of Science and Technology (DST), Government of India	Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research (CSIR), Government of India(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research (ICMR), Government of India(Indian Council of Medical Research (ICMR)); Department of Science and Technology (DST), Government of India(Department of Science & Technology (India))	We thank Dr B Ramanamurthy, In-charge, Experimental Animal Facility, National Center for Cell Science, Pune, India for breeding and maintaining the Opn<SUP>-/-</SUP> mice. We also thank Dr S Ghaskabdi and Dr K Pai, Department of Zoology, University of Pune, India for providing the facility for CAM assay. Skillful assistance was provided by Dr S Vishwakarma, Department of Pathology, YCM Hospital, Pune, India for preparation of Cryosections. The project was supported by Department of Biotechnology (DBT) (GCK), Council of Scientific and Industrial Research (CSIR) (SK and GS), Indian Council of Medical Research (ICMR) (RR) and Department of Science and Technology (DST) (DT), Government of India.	Ahmed M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-101; Bachmann IM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-362; BAXEVANIS CN, 1993, CANCER-AM CANCER SOC, V72, P491, DOI 10.1002/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO;2-1; Behera R, 2010, CARCINOGENESIS, V31, P192, DOI 10.1093/carcin/bgp289; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bianchini F, 2007, PROSTAG OTH LIPID M, V83, P320, DOI 10.1016/j.prostaglandins.2007.03.003; BROWN LF, 1994, AM J PATHOL, V145, P610; Chakraborty G, 2008, MOL MED REP, V1, P641, DOI 10.3892/mmr_00000005; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Cheng JS, 2007, CANCER RES, V67, P5141, DOI 10.1158/0008-5472.CAN-06-4763; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; Finetti F, 2009, CIRC RES, V105, P657, DOI 10.1161/CIRCRESAHA.109.203760; Fujimoto J, 2000, CANCER RES, V60, P2632; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; GORELIK E, 1982, INT J CANCER, V29, P575, DOI 10.1002/ijc.2910290514; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889; Hsu HP, 2010, CANCER BIOL THER, V10, P144, DOI 10.4161/cbt.10.2.12160; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Jain S, 2006, CANCER RES, V66, P6638, DOI 10.1158/0008-5472.CAN-06-0661; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Leek RD, 1996, CANCER RES, V56, P4625; LEWIS CE, 1995, J LEUKOCYTE BIOL, V57, P747, DOI 10.1002/jlb.57.5.747; Liguori Manuela, 2011, Cancers (Basel), V3, P3740, DOI 10.3390/cancers3043740; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nakanishi Y, 2011, CARCINOGENESIS, V32, P1333, DOI 10.1093/carcin/bgr128; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; Nemoto H, 2001, J BONE MINER RES, V16, P652, DOI 10.1359/jbmr.2001.16.4.652; Nesbit M, 2001, J IMMUNOL, V166, P6483, DOI 10.4049/jimmunol.166.11.6483; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Nishie A, 1999, CLIN CANCER RES, V5, P1107; Ojalvo LS, 2009, AM J PATHOL, V174, P1048, DOI 10.2353/ajpath.2009.080676; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Salvesen HB, 1999, INT J CANCER, V84, P539; Sharma P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-178; Shin Hun Sub, 2004, Korean Journal of Internal Medicine, V19, P48; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.0.CO;2-M; Vosseler S, 2005, CANCER RES, V65, P1294, DOI 10.1158/0008-5472.CAN-03-3986; Wang S, 2006, J BIOL CHEM, V281, P9439, DOI 10.1074/jbc.M504977200; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509	52	79	81	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2295	2306		10.1038/onc.2013.184	http://dx.doi.org/10.1038/onc.2013.184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23728342				2022-12-17	WOS:000335451800003
J	Cardoso, AP; Pinto, ML; Pinto, AT; Oliveira, MI; Pinto, MT; Goncalves, R; Relvas, JB; Figueiredo, C; Seruca, R; Mantovani, A; Mareel, M; Barbosa, MA; Oliveira, MJ				Cardoso, A. P.; Pinto, M. L.; Pinto, A. T.; Oliveira, M. I.; Pinto, M. T.; Goncalves, R.; Relvas, J. B.; Figueiredo, C.; Seruca, R.; Mantovani, A.; Mareel, M.; Barbosa, M. A.; Oliveira, M. J.			Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y-1086, c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity	ONCOGENE			English	Article						tumor microenvironment; cancer cell invasion; macrophages; invasion-related signaling pathways; colon cancer; gastric cancer	TUMOR-CELL MIGRATION; PHOSPHOLIPASE C-GAMMA-1; GROWTH; INFILTRATION; METASTASIS; INFLAMMATION; INVASIVENESS; ANGIOGENESIS; PROGRESSION; CARCINOMA	The interactions between cancer cells and their microenvironment are crucial for malignant progression, as they modulate invasion-related activities. Tumor-associated macrophages are generally considered allies in the process of tumor progression in several types of cancer, although their role on gastric and colorectal carcinomas is still poorly understood. In this report, we studied the influence of primary human macrophages on gastric and colorectal cancer cells, considering invasion, motility/migration, proteolysis and activated intracellular signaling pathways. We demonstrated that macrophages stimulate cancer cell invasion, motility and migration, and that these effects depend on matrix metalloproteinase (MMP) activity and on the activation of epidermal growth factor receptor (EGFR) (at the residue Y-1086), PLC-gamma (phospholipase C-gamma) and Gab1 (GRB2-associated binding protein-1), as evidenced by siRNA (small interference RNA) experiments. Epidermal growth factor (EGF)-immunodepletion impaired macrophage-mediated cancer cell invasion and motility, suggesting that EGF is the pro-invasive and pro-motile factor produced by macrophages. Macrophages also induced gastric and colorectal cancer cell phosphorylation of Akt, c-Src and ERK1/2, and led to an increase of RhoA and Cdc42 activity. Interestingly, whereas macrophage-mediated cancer cell c-Src and ERK1/2 phosphorylation occurred downstream EGFR activation, Akt phosphorylation seems to be a parallel event, taking place in an EGFR-independent manner. The involvement of EGF, EGFR-downstream signaling partners and MMPs in macrophage-mediated invasion provides novel insights into the molecular crosstalk established between cancer cells and macrophages, opening new perspectives for the design of new and more efficient therapeutic strategies to counteract cancer cell invasion.	[Cardoso, A. P.; Pinto, M. L.; Pinto, A. T.; Oliveira, M. I.; Goncalves, R.; Barbosa, M. A.; Oliveira, M. J.] Univ Porto, Inst Biomed Engn, P-4150180 Oporto, Portugal; [Cardoso, A. P.; Pinto, A. T.] Univ Porto, Fac Engn, P-4150180 Oporto, Portugal; [Pinto, M. L.; Barbosa, M. A.] Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4150180 Oporto, Portugal; [Pinto, M. T.; Figueiredo, C.; Seruca, R.] Univ Porto, Inst Patol & Imunol Mol, P-4150180 Oporto, Portugal; [Relvas, J. B.] Univ Porto, Inst Biol Celular & Mol, P-4150180 Oporto, Portugal; [Relvas, J. B.] Univ Porto, Fac Med, Dept Biol Expt, P-4150180 Oporto, Portugal; [Figueiredo, C.; Seruca, R.; Oliveira, M. J.] Univ Porto, Fac Med, Dept Patol & Oncol, P-4150180 Oporto, Portugal; [Mantovani, A.] Humanitas Clin & Res Ctr, Rozzano, Italy; [Mantovani, A.] Univ Milan, BIOMETRA Dept, Milan, Italy; [Mareel, M.] Ghent Univ Hosp, Expt Cancerol Lab, Ghent, Belgium	Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; IRCCS Humanitas Research Hospital; University of Milan; Ghent University; Ghent University Hospital	Oliveira, MJ (corresponding author), Univ Porto, INEB Inst Engn Biomed, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	mariajo@ineb.up.pt	Pinto, Ana/AAZ-8360-2020; Cardoso, Ana P/G-2150-2017; Mantovani, Alberto/HCI-7449-2022; Gonçalves, Raquel M/C-5940-2012; Pinto, Marta/AAE-4575-2020; Figueiredo, Ceu/B-8776-2008; Relvas, Joao B/A-1142-2008; Pinto, Marta T/J-2519-2013; Barbosa, Mário A/F-5964-2011; Oliveira, Marta I A/M-9386-2013; Oliveira, Maria Jose/K-3275-2013	Pinto, Ana/0000-0003-0974-2206; Cardoso, Ana P/0000-0003-1987-0316; Mantovani, Alberto/0000-0001-5578-236X; Gonçalves, Raquel M/0000-0003-2841-0485; Pinto, Marta/0000-0002-5783-3965; Figueiredo, Ceu/0000-0001-5247-840X; Relvas, Joao B/0000-0001-7636-0924; Pinto, Marta T/0000-0002-8521-2904; Barbosa, Mário A/0000-0003-3568-7482; Oliveira, Marta I A/0000-0002-0578-9202; Oliveira, Maria Jose/0000-0002-0724-0272; Seruca, Raquel/0000-0002-8851-4166	FCT [PTDC-SAU-ONC/112511/2009, SFRH/BD/74144/2010, SFRH/BD/81103/2011, SFRH/BPD/37090/2007]; COMPETE [FCOMP-01-0124-FEDER-010915]; Prize L'Oreal for Women Science (Foundation L'Oreal/FCT/UNESCO); European project DISC Regeneration [NMP3-LA-2008-213904]; AIRC; ERC; Italian Ministry of Health [RF2010]	FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); COMPETE; Prize L'Oreal for Women Science (Foundation L'Oreal/FCT/UNESCO)(L'Oreal Group); European project DISC Regeneration; AIRC(Fondazione AIRC per la ricerca sul cancro); ERC(European Research Council (ERC)European Commission); Italian Ministry of Health(Ministry of Health, Italy)	This work was financially supported by FCT (PTDC-SAU-ONC/112511/2009), COMPETE FCOMP-01-0124-FEDER-010915 and Prize L'Oreal for Women Science (Foundation L'Oreal/FCT/UNESCO). AP Cardoso is a PhD Fellow from the International Iberian Nanotechnology Laboratory (INL). AT Pinto and ML Pinto are PhD Fellows (SFRH/BD/74144/2010, SFRH/BD/81103/2011) and MI Oliveira a Postdoc Fellow (SFRH/BPD/37090/2007) from FCT. MJ Oliveira and MT Pinto are granted by Programa Ciencia2007-FCT. RGoncalves was funded by the European project DISC Regeneration, NMP3-LA-2008-213904 (FP7). A Mantovani is supported by AIRC, ERC and RF2010 Italian Ministry of Health.	Abella JV, 2010, J CELL SCI, V123, P1306, DOI 10.1242/jcs.062570; Allen M, 2011, J PATHOL, V223, P162, DOI 10.1002/path.2803; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chou J, 2003, EXP CELL RES, V287, P47, DOI 10.1016/S0014-4827(03)00119-8; Coffelt SB, 2009, BBA-REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197; Hagemann T, 2007, CANCER CELL, V12, P300, DOI 10.1016/j.ccr.2007.10.005; Hakansson L, 1997, BRIT J CANCER, V75, P374, DOI 10.1038/bjc.1997.61; Humtsoe JO, 2010, ONCOGENE, V29, P1214, DOI 10.1038/onc.2009.419; Ishigami S, 2003, ANTICANCER RES, V23, P4079; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang JC, 2010, J SURG ONCOL, V102, P242, DOI 10.1002/jso.21617; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kuroda T, 2005, CLIN CANCER RES, V11, P7629, DOI 10.1158/1078-0432.CCR-05-0798; Leek RD, 1996, CANCER RES, V56, P4625; Liguori Manuela, 2011, Cancers (Basel), V3, P3740, DOI 10.3390/cancers3043740; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin EY, 2002, J MAMMARY GLAND BIOL, V7, P147, DOI 10.1023/A:1020399802795; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mateus AR, 2007, HUM MOL GENET, V16, P1639, DOI 10.1093/hmg/ddm113; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Ohno S, 2003, ANTICANCER RES, V23, P5015; Ohta M, 2003, INT J ONCOL, V22, P773; Oliveira MJ, 2006, J BIOL CHEM, V281, P34888, DOI 10.1074/jbc.M607067200; Oliveira MI, 2012, EUR CELLS MATER, V24, P136, DOI 10.22203/eCM.v024a10; Oliveira MJ, 2005, J CANCER RES CLIN, V131, P49, DOI 10.1007/s00432-004-0601-8; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sala G, 2008, CANCER RES, V68, P10187, DOI 10.1158/0008-5472.CAN-08-1181; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449	50	79	85	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2123	2133		10.1038/onc.2013.154	http://dx.doi.org/10.1038/onc.2013.154			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23644655				2022-12-17	WOS:000334599100011
J	Nishi, M; Sakai, Y; Akutsu, H; Nagashima, Y; Quinn, G; Masui, S; Kimura, H; Perrem, K; Umezawa, A; Yamamoto, N; Lee, SW; Ryo, A				Nishi, M.; Sakai, Y.; Akutsu, H.; Nagashima, Y.; Quinn, G.; Masui, S.; Kimura, H.; Perrem, K.; Umezawa, A.; Yamamoto, N.; Lee, S. W.; Ryo, A.			Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors	ONCOGENE			English	Article						cancer stem cell; reprogramming factors; oncogenesis; MCF-10A; p16INK4a	EXPRESSION; PHOSPHORYLATION; IMMORTALIZATION; IDENTIFICATION; MARKER; SOX2	Cancer stem cells (CSCs), a small and elusive population of undifferentiated cancer cells within tumors that drive tumor growth and recurrence, are believed to resemble normal stem cells. Although surrogate markers have been identified and compelling CSC theoretical models abound, actual proof for the existence of CSCs can only be had retrospectively. Hence, great store has come to be placed in isolating CSCs from cancers for in-depth analysis. On the other hand, although induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine, concern exists over the inadvertent co-transplantation of partially or undifferentiated stem cells with tumorigenic capacity. Here we demonstrate that the introduction of defined reprogramming factors (OCT4, SOX2, Klf4 and c-Myc) into MCF-10A nontumorigenic mammary epithelial cells, followed by partial differentiation, transforms the bulk of cells into tumorigenic CD44(+)/CD24(low) cells with CSC properties, termed here as induced CSC-like-10A or iCSCL-10A cells. These reprogrammed cells display a malignant phenotype in culture and form tumors of multiple lineages when injected into immunocompromised mice. Compared with other transformed cell lines, cultured iCSCL-10A cells exhibit increased resistance to the chemotherapeutic compounds, Taxol and Actinomycin D, but higher susceptibility to the CSC-selective agent Salinomycin and the Pin1 inhibitor Juglone. Restored expression of the cyclin-dependent kinase inhibitor p16INK4a abrogated the CSC properties of iCSCL-10A cells, by inducing cellular senescence. This study provides some insight into the potential oncogenicity that may arise via cellular reprogramming, and could represent a valuable in vitro model for studying the phenotypic traits of CSCs per se.	[Nishi, M.; Sakai, Y.; Quinn, G.; Ryo, A.] Yokohama City Univ, Sch Med, Dept Microbiol, Yokohama, Kanagawa 2360004, Japan; [Akutsu, H.; Umezawa, A.] Natl Res Inst Child Hlth & Dev, Dept Reprod Biol, Tokyo, Japan; [Nagashima, Y.] Yokohama City Univ, Sch Med, Dept Mol Pathol, Yokohama, Kanagawa 2360004, Japan; [Masui, S.] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan; [Kimura, H.] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan; [Perrem, K.] CSIRO, Dickson, ACT, Australia; [Yamamoto, N.] Natl Univ Singapore, Dept Microbiol, Singapore 117548, Singapore; [Lee, S. W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA; [Lee, S. W.] Harvard Univ, Sch Med, Charlestown, MA USA	Yokohama City University; National Center for Child Health & Development - Japan; Yokohama City University; Kyoto University; National Institute of Infectious Diseases (NIID); Commonwealth Scientific & Industrial Research Organisation (CSIRO); National University of Singapore; Harvard University; Massachusetts General Hospital; Harvard University	Ryo, A (corresponding author), Yokohama City Univ, Sch Med, Dept Microbiol, Kanazawa Ku, 3-9 Fuku Ura, Yokohama, Kanagawa 2360004, Japan.	aryo@yokohama-cu.ac.jp	Nagashima, Yoji/AAA-2591-2021	Masui, Shinji/0000-0001-7417-0019	Japan Health Sciences Foundation; Uehara Memorial Foundation; Takeda Science Foundation; NATIONAL CANCER INSTITUTE [P01CA080058] Funding Source: NIH RePORTER	Japan Health Sciences Foundation; Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank A Kondo, T Taniguchi, Y Kojima, Y Watanabe, M Tanaka and N Sakurai for technical assistance and discussion. This work was in part supported by Grant-in-Aid for Scientific Research on Innovative Areas and the Japan Health Sciences Foundation, and grants from the Uehara Memorial Foundation and Takeda Science Foundation to AR.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033544; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Clark AT, 2007, STEM CELL REV, V3, P49, DOI 10.1007/s12015-007-0002-x; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Cowell JK, 2005, CANCER GENET CYTOGEN, V163, P23, DOI 10.1016/j.cancergencyto.2005.04.019; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Desbaillets I, 2000, EXP PHYSIOL, V85, P645, DOI 10.1017/S0958067000021047; Dey D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005329; Dick JE, 2009, NAT BIOTECHNOL, V27, P44, DOI 10.1038/nbt0109-44; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Nishi M, 2011, J BIOL CHEM, V286, P11593, DOI 10.1074/jbc.M110.187989; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Sarig R, 2010, J EXP MED, V207, P2127, DOI 10.1084/jem.20100797; Scaffidi P, 2011, NAT CELL BIOL, V13, P1051, DOI 10.1038/ncb2308; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Singh SK, 2003, CANCER RES, V63, P5821; SOULE HD, 1990, CANCER RES, V50, P6075; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243; Werbowetski-Ogilvie TE, 2009, NAT BIOTECHNOL, V27, P91, DOI 10.1038/nbt.1516; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	44	79	81	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					643	652		10.1038/onc.2012.614	http://dx.doi.org/10.1038/onc.2012.614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318426	Green Accepted			2022-12-17	WOS:000331125100012
J	Gallagher, SJ; Rambow, F; Kumasaka, M; Champeval, D; Bellacosa, A; Delmas, V; Larue, L				Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Bellacosa, A.; Delmas, V.; Larue, L.			Beta-catenin inhibits melanocyte migration but induces melanoma metastasis	ONCOGENE			English	Article						Wnt; melanoblast; melanoma; MITF; CSK; mouse	SIGNALING PATHWAY; EXPRESSION; PROLIFERATION; ACTIVATION; CANCER; PROGRESSION; MUTATIONS; CADHERIN; TUMORS; CELLS	The canonical Wnt signalling pathway induces the beta-catenin/lymphoid enhancer factor transcription factors. It is activated in various cancers, most characteristically carcinomas, in which it promotes metastatic spread by increasing migration and/or invasion. The Wnt/beta-catenin signalling pathway is frequently activated in melanoma, but the presence of beta-catenin in the nucleus does not seem to be a sign of aggressiveness in these tumours. We found that, unlike its positive role in stimulating migration and invasion of carcinoma cells, beta-catenin signalling decreased the migration of melanocytes and melanoma cell lines. In vivo, beta-catenin signalling in melanoblasts reduced the migration of these cells, causing a white belly-spot phenotype. The inhibition by beta-catenin of migration was dependent on MITF-M, a key transcription factor of the melanocyte lineage, and CSK, an Src-inhibitor. Despite reducing migration, beta-catenin signalling promoted lung metastasis in the NRAS-driven melanoma murine model. Thus, beta-catenin may have conflicting roles in the metastatic spread of melanoma, repressing migration while promoting metastasis. These results highlight that metastasis formation requires a series of successful cellular processes, any one of which may not be optimally efficient. Oncogene (2013) 32, 2230-2238; doi:10.1038/onc.2012.229; published online 4 June 2012	[Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Delmas, V.; Larue, L.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Delmas, V.; Larue, L.] CNRS, UMR3347, F-91405 Orsay, France; [Gallagher, S. J.; Rambow, F.; Kumasaka, M.; Champeval, D.; Delmas, V.; Larue, L.] Univ Paris 11, INSERM, U1021, F-91405 Orsay, France; [Bellacosa, A.] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA; [Bellacosa, A.] Fox Chase Canc Ctr, Epigenet & Progenitor Cells Keystone Program, Philadelphia, PA 19111 USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; Fox Chase Cancer Center; Fox Chase Cancer Center	Larue, L (corresponding author), Inst Curie, Ctr Rech, Bat 110, F-91405 Orsay, France.	lionel.larue@curie.fr	Gallagher, Stuart J/E-6617-2011; Gallagher, Stuart/S-6718-2019; Larue, Lionel/F-7355-2013; Larue, Lionel/I-6532-2016	Gallagher, Stuart J/0000-0003-2651-9671; Gallagher, Stuart/0000-0003-2651-9671; Delmas, veronique/0000-0001-7368-3664; rambow, florian/0000-0002-9727-8986	LNCC; Curie; Ligue Nationale Contre le Cancer (Equipe labellisee); INCa; NATIONAL CANCER INSTITUTE [R01CA078412, P30CA006927] Funding Source: NIH RePORTER	LNCC; Curie; Ligue Nationale Contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); INCa(Institut National du Cancer (INCA) France); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank D Bennett, M Herlyn and F Beermann for kindly providing materials. We thank staff from the animal colony and imaging facilities of Curie, including Y Bourgeois, F Cordelieres and H Harmange in particular. SG was supported by LNCC and Curie. This work was supported by the Ligue Nationale Contre le Cancer (Equipe labellisee) and INCa.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011; Baldus SE, 2004, CLIN CANCER RES, V10, P2790, DOI 10.1158/1078-0432.CCR-03-0163; BENNETT DC, 1989, DEVELOPMENT, V105, P379; Bottomly D, 2010, NUCLEIC ACIDS RES, V38, P5735, DOI 10.1093/nar/gkq363; Brooks SA, 2010, ACTA HISTOCHEM, V112, P3, DOI 10.1016/j.acthis.2008.11.022; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; de Melker AA, 2004, DEV DYNAM, V230, P708, DOI 10.1002/dvdy.20091; Delmas V, 2003, GENESIS, V36, P73, DOI 10.1002/gene.10197; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; Gallagher SJ, 2011, PIGM CELL MELANOMA R, V24, P987, DOI 10.1111/j.1755-148X.2011.00907.x; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Larue L, 1996, DEVELOPMENT, V122, P3185; Larue L, 2007, PIGM CELL RES, V20, P485, DOI 10.1111/j.1600-0749.2007.00411.x; Luciani F, 2011, DEVELOPMENT, V138, P3943, DOI 10.1242/dev.067447; Lugli A, 2007, HISTOPATHOLOGY, V50, P453, DOI 10.1111/j.1365-2559.2007.02620.x; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Murakami T, 2001, BIOCHEM BIOPH RES CO, V288, P8, DOI 10.1006/bbrc.2001.5719; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05; Sinnberg T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023429; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049	32	79	81	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2230	2238		10.1038/onc.2012.229	http://dx.doi.org/10.1038/onc.2012.229			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22665063	Green Accepted			2022-12-17	WOS:000318062800012
J	Yoon, CH; Kim, MJ; Kim, RK; Lim, EJ; Choi, KS; An, S; Hwang, SG; Kang, SG; Suh, Y; Park, MJ; Lee, SJ				Yoon, C-H; Kim, M-J; Kim, R-K; Lim, E-J; Choi, K-S; An, S.; Hwang, S-G; Kang, S-G; Suh, Y.; Park, M-J; Lee, S-J			c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells	ONCOGENE			English	Article						c-Jun N-terminal kinase; glioma stem-like cells; Notch-2; resistance to anticancer treatments	TUMOR-INITIATING CELLS; HUMAN BRAIN-TUMORS; HUMAN GLIOBLASTOMA; GROWTH-FACTOR; NH2-TERMINAL KINASE; NOTCH; CANCER; ACTIVATION; PATHWAY; EXPRESSION	Uncovering the mechanisms that govern the maintenance of stem-like cancer cells is critical for developing therapeutic strategies for targeting these cells. Constitutive activation of c-Jun N-terminal kinase (JNK) has been reported in gliomas and correlates with histological grade. Here, we found that JNK signaling is crucial for the maintenance of 'stemness' in glioma cells. Sphere-cultured glioma cells showed more phosphorylation of JNK compared with serum-containing monolayer cultures. Importantly, blockade of JNK signaling with SP600125 or small interfering RNAs targeting JNK1 or JNK2 significantly reduced the CD133(+)/Nestin(+) population and suppressed sphere formation, colony formation in soft agar, and expression of stem cell markers in sphere-cultured glioma cells. Intriguingly, sphere-cultured glioma cells exhibited enhanced expression of Notch-2, but not Notch-1, -3 or -4, and JNK inhibition almost completely abrogated this increase. Blocking the phosphoinoside 3-kinase (PI3K)/Akt pathway with LY294002 or si-Akt also suppressed the self-renewal of sphere-cultured glioma cells. PI3K, but not Akt, had a role as an upstream kinase in JNK1/2 activation. In addition, treatment with si-JNK greatly increased etoposide- and ionizing radiation (IR)-induced cell death in glioma spheres. Consistent with glioma cell lines, glioma stem-like cells isolated from primary patient glioma cells also had a higher activity of JNK and Notch-2 expression. Importantly, inhibition of JNK2 led to a decrease of Notch-2 expression and suppressed the CD133(+)/Nestin(+) cell population in patient-derived primary glioma cells. Finally, downregulation of JNK2 almost completely suppressed intracranial tumor formation by glioma cells in nude mice. Taken together, these data demonstrate that JNK signaling is crucial for the maintenance of self-renewal and tumorigenicity of glioma stem-like cells and drug/IR resistance, and can be considered a promising target for eliminating stem-like cancer cells in gliomas.	[Hwang, S-G; Park, M-J] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul 139706, South Korea; [Yoon, C-H; Kim, R-K; Lim, E-J; Suh, Y.; Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Dept Chem, Seoul 133791, South Korea; [Kim, M-J] Korea Atom Energy Res Inst, Environm Radiat Res Grp, Dept Radiat Biol, Taejon, South Korea; [Choi, K-S] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Seoul, South Korea; [An, S.] Konkuk Univ, Funct Genoproteome Res Ctr, Seoul, South Korea; [Kang, S-G] Catholic Univ, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea	Korea Institute of Radiological & Medical Sciences; Hanyang University; Korea Atomic Energy Research Institute (KAERI); Sungkyunkwan University (SKKU); Samsung Medical Center; Konkuk University; Catholic University of Korea; Seoul St. Mary's Hospital	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul 139706, South Korea.	mjpark@kcch.re.kr; sj0420@hanyang.ac.kr	Yoon, Changhwan/AAK-7842-2021	Yoon, Changhwan/0000-0002-8420-9818; Kang, Seok-Gu/0000-0001-5676-2037	Korea Research Foundation (KRF); Ministry of Education, Science and Technology (MEST), Korean government [2008-2003935]; Ministry for Health, Welfare and Family affairs, Republic of Korea [1020340]	Korea Research Foundation (KRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology (MEST), Korean government(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Ministry for Health, Welfare and Family affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	We thank Dr Akio Soeda (Department of Neurological Surgery, University of Virginia, USA) for providing patient-derived glioma cells. This work was supported by the Korea Research Foundation (KRF) and Ministry of Education, Science and Technology (MEST), Korean government, through its National Nuclear Technology Program (2008-2003935) and the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (1020340).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Chen JX, 2005, INT J BIOCHEM CELL B, V37, P2273, DOI 10.1016/j.biocel.2005.02.028; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Eyler CE, 2011, CELL, V146, P53, DOI 10.1016/j.cell.2011.06.006; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Frosina G, 2009, MOL CANCER RES, V7, P989, DOI 10.1158/1541-7786.MCR-09-0030; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Hyun KH, 2011, TOXICOL APPL PHARM, V254, P32, DOI 10.1016/j.taap.2011.04.006; Joseph NM, 2005, DEV CELL, V9, P173, DOI 10.1016/j.devcel.2005.07.001; Kanamori M, 2007, J NEUROSURG, V106, P417, DOI 10.3171/jns.2007.106.3.417; Kanzawa T, 2006, ONCOGENE, V25, P3638, DOI 10.1038/sj.onc.1209414; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Li JY, 2008, J NEURO-ONCOL, V88, P11, DOI 10.1007/s11060-008-9529-1; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Mangiola A, 2007, CLIN CANCER RES, V13, P6970, DOI 10.1158/1078-0432.CCR-07-1229; Mishra OP, 2004, NEUROSCIENCE, V123, P179, DOI 10.1016/j.neuroscience.2003.08.008; Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Salmaggi A, 2006, GLIA, V54, P850, DOI 10.1002/glia.20414; Shih AH, 2006, NEOPLASIA, V8, P1072, DOI 10.1593/neo.06526; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tsuiki H, 2003, CANCER RES, V63, P250; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030; Xu P, 2010, J NEURO-ONCOL, V97, P41, DOI 10.1007/s11060-009-0007-1; Yi L, 2007, MODERN PATHOL, V20, P1061, DOI 10.1038/modpathol.3800942; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475; Yu SC, 2008, CANCER LETT, V265, P124, DOI 10.1016/j.canlet.2008.02.010; Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107; Zhang XP, 2008, MOL CELL BIOCHEM, V307, P101, DOI 10.1007/s11010-007-9589-0; Zhong Y, 2007, BIOCHEM BIOPH RES CO, V364, P338, DOI 10.1016/j.bbrc.2007.10.016; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	62	79	80	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	44					4655	4666		10.1038/onc.2011.634	http://dx.doi.org/10.1038/onc.2011.634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249269				2022-12-17	WOS:000310724400001
J	Palmieri, D; D'Angelo, D; Valentino, T; De Martino, I; Ferraro, A; Wierinckx, A; Fedele, M; Trouillas, J; Fusco, A				Palmieri, D.; D'Angelo, D.; Valentino, T.; De Martino, I.; Ferraro, A.; Wierinckx, A.; Fedele, M.; Trouillas, J.; Fusco, A.			Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis	ONCOGENE			English	Article						HMGA; pituitary adenoma; microRNA	NATURAL-KILLER-CELL; MOBILITY GROUP A2; GENE-EXPRESSION; PROTEIN-SYNTHESIS; ADENOMAS; TUMORS; MOUSE; OVEREXPRESSION; TRANSFORMATION; PROLIFERATION	Previous studies have demonstrated that high mobility group A proteins have a critical role on the onset of human pituitary adenomas. Indeed, both high mobility group A (HMGA) genes are overexpressed in pituitary adenomas, and consistently transgenic mice overexpressing either the Hmga1 or the Hmga2 gene develop mixed growth hormone/prolactin (GH-PRL)-secreting pituitary adenomas. Trisomy of chromosome 12, where HMGA2 is located, and/or amplification of the HMGA2 gene locus account for the HMGA2 overexpression in most human prolactinomas. Conversely, HMGA1 over-expression is not associated to any rearrangement or amplification of the HMGA1 locus. We have first identified micro RNAs (miRNAs) able to target both HMGA1 and HMGA2 messenger RNAs. Then, all of these miRNAs have been found downregulated in pituitary adenomas of different histotypes, compared with normal pituitary. Interestingly, their downregulation was also observed in nonfunctioning pituitary adenomas where HMGA2 overexpression is not associated to any alteration of the HMGA2 locus. Functional studies show that all these HMGA-targeting miRNAs inhibit the proliferation of the rat pituitary adenoma cell line GH3. Therefore, these results indicate that the downregulation of the miRNAs able to target the HMGA genes could contribute to increase HMGA protein levels in human pituitary adenomas, and then to pituitary tumorigenesis. Oncogene (2012) 31, 3857-3865; doi:10.1038/onc.2011.557; published online 5 December 2011	[Palmieri, D.; D'Angelo, D.; Valentino, T.; De Martino, I.; Ferraro, A.; Fedele, M.; Fusco, A.] Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale,Fac Med & Chi, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Wierinckx, A.] Univ Lyon, Lyon, France; [Wierinckx, A.] Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France; [Trouillas, J.] CNRS, INSERM, U1028, UMR 5292,Lyon Neurosci Res Ctr,Neurooncol & Neuro, Lyon, France; [Trouillas, J.] Univ Lyon 1, F-69365 Lyon, France; [Ferraro, A.; Fusco, A.] SEMM European Sch Mol Med Naples Site, Naples, Italy; [Ferraro, A.; Fusco, A.] NOGEC Naples Oncogen Ctr CEINGE, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Fusco, A (corresponding author), Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale,Fac Med & Chi, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	alfusco@unina.it	D'Angelo, Daniela/GVT-9143-2022; Ferraro, Angelo/H-3193-2019; Wierinckx, Anne/AAF-5233-2021; Ferraro, Angelo/A-4172-2014; Fedele, Monica/C-1417-2015	Ferraro, Angelo/0000-0002-2044-7569; Wierinckx, Anne/0000-0002-0186-6645; Ferraro, Angelo/0000-0002-2044-7569; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197; Palmieri, Dario/0000-0002-0797-4268	Associazione Italiana Ricerca sul Cancro (AIRC); Fondazione Italiana per la Ricerca sul Cancro (FIRC)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italiana per la Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC). DP is recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC).	ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chiappetta G, 1996, ONCOGENE, V13, P2439; Daly AF, 2006, J CLIN ENDOCR METAB, V91, P4769, DOI 10.1210/jc.2006-1668; Daly AF, 2009, BEST PRACT RES CL EN, V23, P543, DOI 10.1016/j.beem.2009.05.008; De Martino I, 2009, ONCOGENE, V28, P1432, DOI 10.1038/onc.2008.495; De Martino I, 2007, ENDOCR-RELAT CANCER, V14, P875, DOI 10.1677/ERC-07-0036; De Martino I, 2009, CANCER RES, V69, P1844, DOI 10.1158/0008-5472.CAN-08-4133; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 2006, CANCER CELL, V9, P459, DOI 10.1016/j.ccr.2006.04.024; Fedele M, 2010, MOL CELL ENDOCRINOL, V326, P19, DOI 10.1016/j.mce.2010.03.019; Fedele M, 2010, BBA-GENE REGUL MECH, V1799, P48, DOI 10.1016/j.bbagrm.2009.11.007; Fernandez A, 2010, CLIN ENDOCRINOL, V72, P377, DOI 10.1111/j.1365-2265.2009.03667.x; Finelli P, 2002, CANCER RES, V62, P2398; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kaddar T, 2009, BIOL CELL, V101, P511, DOI 10.1042/BC20080213; KOVACS K, 1986, SEMIN DIAGN PATHOL, V3, P18; Lagana A, 2009, DATABASE-OXFORD, DOI 10.1093/database/bap008; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee S, 2011, CELL MOL LIFE SCI, V68, P325, DOI 10.1007/s00018-010-0457-9; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40; Monson JP, 2000, ENDOCR-RELAT CANCER, V7, P29, DOI 10.1677/erc.0.0070029; Pierantoni GM, 2005, ENDOCR-RELAT CANCER, V12, P867, DOI 10.1677/erc.1.01049; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Qian ZR, 2009, MODERN PATHOL, V22, P431, DOI 10.1038/modpathol.2008.202; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Wang EL, 2010, HISTOPATHOLOGY, V56, P501, DOI 10.1111/j.1365-2559.2010.03495.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	41	79	82	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	34					3857	3865		10.1038/onc.2011.557	http://dx.doi.org/10.1038/onc.2011.557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139073				2022-12-17	WOS:000307925000003
J	Taniguchi, H; Jacinto, FV; Villanueva, A; Fernandez, AF; Yamamoto, H; Carmona, FJ; Puertas, S; Marquez, VE; Shinomura, Y; Imai, K; Esteller, M				Taniguchi, H.; Jacinto, F. V.; Villanueva, A.; Fernandez, A. F.; Yamamoto, H.; Carmona, F. J.; Puertas, S.; Marquez, V. E.; Shinomura, Y.; Imai, K.; Esteller, M.			Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer	ONCOGENE			English	Article						epigenetics; histone methyltransferase; EZH2; KLF2	TRANSCRIPTION FACTORS; CELL-GROWTH; POLYCOMB; REPRESSION; PROGRESSION; EXPRESSION; COMPLEX; TARGET	The Kruppel-like factor (KLF) proteins are multitasked transcriptional regulators with an expanding tumor suppressor function. KLF2 is one of the prominent members of the family because of its diminished expression in malignancies and its growth-inhibitory, pro-apoptotic and anti-angiogenic roles. In this study, we show that epigenetic silencing of KLF2 occurs in cancer cells through direct transcriptional repression mediated by the Polycomb group protein Enhancer of Zeste Homolog 2 (EZH2). Binding of EZH2 to the 5'-end of KLF2 is also associated with a gain of trimethylated lysine 27 histone H3 and a depletion of phosphorylated serine 2 of RNA polymerase. Upon depletion of EZH2 by RNA interference, short hairpin RNA or use of the small molecule 3-Deazaneplanocin A, the expression of KLF2 was restored. The transfection of KLF2 in cells with EZH2-associated silencing showed a significant anti-tumoral effect, both in culture and in xenografted nude mice. In this last setting, KLF2 transfection was also associated with decreased dissemination and lower mortality rate. In EZH2-depleted cells, which characteristically have lower tumorigenicity, the induction of KLF2 depletion 'rescued' partially the oncogenic phenotype, suggesting that KLF2 repression has an important role in EZH2 oncogenesis. Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival. Oncogene (2012) 31, 1988-1994; doi:10.1038/onc.2011.387; published online 5 September 2011	[Taniguchi, H.; Jacinto, F. V.; Fernandez, A. F.; Carmona, F. J.; Esteller, M.] Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain; [Taniguchi, H.; Yamamoto, H.; Shinomura, Y.] Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido, Japan; [Taniguchi, H.] Sapporo Med Univ, Sch Med, Tumor Med Examinat & Treatment Ctr, Sapporo, Hokkaido, Japan; [Jacinto, F. V.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; [Villanueva, A.; Puertas, S.] Bellvitge Biomed Res Inst IDIBELL, ICO, Barcelona, Spain; [Marquez, V. E.] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21701 USA; [Imai, K.] Univ Tokyo, Inst Med Sci, Tokyo, Japan; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Sapporo Medical University; Sapporo Medical University; Salk Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via LHosp 199-203, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Esteller, Manel/L-5956-2014; Fernandez, Agustin F./N-7302-2014; Marquez, Victor/AAP-3549-2021; Taniguchi, Hiroaki/AGB-3012-2022	Esteller, Manel/0000-0003-4490-6093; Fernandez, Agustin F./0000-0002-3792-4085; Taniguchi, Hiroaki/0000-0003-0494-5290; Carmona Sanz, F Javier/0000-0001-7904-8493	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; NIH, National Cancer Institute and Center for Cancer Research;  [SAF2007-00027-65134];  [Consolider CSD2006-49]; ICREA Funding Source: Custom	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; NIH, National Cancer Institute and Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; ICREA(ICREA)	We thank O Dominguez for help with the microarray procedures and analysis, F Setien for technical assistance and Miki Kojiya for the flow cytometry analysis. This work was supported by Grants SAF2007-00027-65134, Consolider CSD2006-49, and Lilly Foundation and Dr Josef Steiner Cancer Research Foundation to ME, and the Intramural Research Program of the NIH, National Cancer Institute and Center for Cancer Research to VEM. HT is supported by the Uehara Memorial Foundation and Pancreas Research Foundation of Japan. ME is an ICREA Research Professor.	Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Bhattacharya R, 2005, J BIOL CHEM, V280, P28848, DOI 10.1074/jbc.C500200200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Bureau C, 2009, CURR GENOMICS, V10, P353, DOI 10.2174/138920209788921010; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Duhagon MA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-324; Fernandez-Zapico ME, 2011, BIOCHEM J, V435, P529, DOI 10.1042/BJ20100773; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kannan-Thulasiraman P, 2010, J BIOL CHEM, V285, P19106, DOI 10.1074/jbc.M109.099770; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Pasini D, 2004, CELL CYCLE, V3, P396; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zhao CT, 2005, DEV GROWTH DIFFER, V47, P201	26	79	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1988	1994		10.1038/onc.2011.387	http://dx.doi.org/10.1038/onc.2011.387			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21892211	Green Published, hybrid			2022-12-17	WOS:000302809900010
J	Huertas, D; Soler, M; Moreto, J; Villanueva, A; Martinez, A; Vidal, A; Charlton, M; Moffat, D; Patel, S; McDermott, J; Owen, J; Brotherton, D; Krige, D; Cuthill, S; Esteller, M				Huertas, D.; Soler, M.; Moreto, J.; Villanueva, A.; Martinez, A.; Vidal, A.; Charlton, M.; Moffat, D.; Patel, S.; McDermott, J.; Owen, J.; Brotherton, D.; Krige, D.; Cuthill, S.; Esteller, M.			Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin	ONCOGENE			English	Article						epigenetics; histone; inhibitor	SPINDLE-ASSEMBLY CHECKPOINT; MYELOID-LEUKEMIA CELLS; AURORA-B; MYELODYSPLASTIC SYNDROMES; DEACETYLASE INHIBITORS; THR-3 PHOSPHORYLATION; CANCER THERAPEUTICS; CHROMOSOME COHESION; TUMOR-GROWTH; DRUG TARGET	The approval of histone deacetylase inhibitors for treatment of lymphoma subtypes has positioned histone modifications as potential targets for the development of new classes of anticancer drugs. Histones also undergo phosphorylation events, and Haspin is a protein kinase the only known target of which is phosphorylation of histone H3 at Thr3 residue (H3T3ph), which is necessary for mitosis progression. Mitotic kinases can be blocked by small drugs and several clinical trials are underway with these agents. As occurs with Aurora kinase inhibitors, Haspin might be an optimal candidate for the pharmacological development of these compounds. A high-throughput screening for Haspin inhibitors identified the CHR-6494 compound as being one promising such agent. We demonstrate that CHR-6494 reduces H3T3ph levels in a dose-dependent manner and causes a mitotic catastrophe characterized by metaphase misalignment, spindle abnormalities and centrosome amplification. From the cellular standpoint, the identified small-molecule Haspin inhibitor causes arrest in G2/M and subsequently apoptosis. Importantly, ex vivo assays also demonstrate its anti-angiogenetic features; in vivo, it shows antitumor potential in xenografted nude mice without any observed toxicity. Thus, CHR-6494 is a first-in-class Haspin inhibitor with a wide spectrum of anticancer effects that merits further preclinical research as a new member of the family of mitotic kinase inhibitors. Oncogene (2012) 31, 1408-1418; doi:10.1038/onc.2011.335; published online 1 August 2011	[Huertas, D.; Soler, M.; Moreto, J.; Esteller, M.] Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, Barcelona 08908, Catalonia, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Translat Res Lab, Inst Catala Oncol, Barcelona, Catalonia, Spain; [Martinez, A.] Ctr Biomed Res La Rioja CIBIR, Oncol Area, Logrono, Spain; [Vidal, A.] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Barcelona 08908, Catalonia, Spain; [Charlton, M.; Moffat, D.; Patel, S.; McDermott, J.; Owen, J.; Brotherton, D.; Krige, D.; Cuthill, S.] Chroma Therapeut, Abingdon, Oxon, England; [Esteller, M.] Univ Barcelona, Dept Physiol Sci 2, Sch Med, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, 3rd Floor,Avda Gran Via LHospitalet 199-203, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Martinez, Alfredo/GQH-5998-2022; Vidal, August/N-4662-2016; Soler, Marta/AEW-9527-2022; Soler, Marta/AAF-1232-2021; Esteller, Manel/L-5956-2014	Martinez, Alfredo/0000-0003-4882-4044; Vidal, August/0000-0001-5727-2099; Soler, Marta/0000-0002-6656-957X; Esteller, Manel/0000-0003-4490-6093	European Community [LSHG-CT-2006-037415, SAF2007-00027-65134, CSD2006-49]; Steiner Cancer Research Foundation; ICREA Funding Source: Custom	European Community(European Commission); Steiner Cancer Research Foundation; ICREA(ICREA)	The research leading to these results has received funding from the European Community's Sixth Framework Programme (FP6/2000-2006) under grant agreement no. LSHG-CT-2006-037415-SMARTER project, grant numbers SAF2007-00027-65134, Consolider CSD2006-49 and Dr. Josef Steiner Cancer Research Foundation. ME is an ICREA Research Professor.	Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bryan J, 2010, DRUGS, V70, P1381, DOI 10.2165/11537920-000000000-00000; Carpinelli P, 2008, ADV EXP MED BIOL, V610, P54, DOI 10.1007/978-0-387-73898-7_5; Cheng AY, 1998, CANCER RES, V58, P3611; Chopra P, 2010, EXPERT OPIN INV DRUG, V19, P27, DOI 10.1517/13543780903483191; Cuny GD, 2010, BIOORG MED CHEM LETT, V20, P3491, DOI 10.1016/j.bmcl.2010.04.150; D'Alise AM, 2008, MOL CANCER THER, V7, P1140, DOI 10.1158/1535-7163.MCT-07-2051; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; Dai J, 2006, DEV CELL, V11, P741, DOI 10.1016/j.devcel.2006.09.018; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gleixner KV, 2010, CANCER RES, V70, P1513, DOI 10.1158/0008-5472.CAN-09-2181; Gotze K, 2010, ANN HEMATOL, V89, P841, DOI 10.1007/s00277-010-1015-0; Graham JS, 2009, EUR J CANCER, V45, P1129, DOI 10.1016/j.ejca.2009.01.003; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Higgins JMG, 2001, PROTEIN SCI, V10, P1677, DOI 10.1110/ps.49901; Johnson EF, 2007, BIOCHEMISTRY-US, V46, P9551, DOI 10.1021/bi7008745; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000; Macurek L, 2009, CANCER RES, V69, P4555, DOI 10.1158/0008-5472.CAN-09-0142; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008; Martinez A, 2004, CANCER RES, V64, P6489, DOI 10.1158/0008-5472.CAN-04-0103; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nakai R, 2009, CANCER RES, V69, P3901, DOI 10.1158/0008-5472.CAN-08-4373; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Oke A, 2009, CANCER RES, V69, P4150, DOI 10.1158/0008-5472.CAN-08-3203; Patnaik D, 2008, J BIOMOL SCREEN, V13, P1025, DOI 10.1177/1087057108326081; Rebacz B, 2007, CANCER RES, V67, P6342, DOI 10.1158/0008-5472.CAN-07-0663; Rosasco-Nitcher SE, 2008, SCIENCE, V319, P469, DOI 10.1126/science.1148980; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Stemmann O, 2006, CELL CYCLE, V5, P11, DOI 10.4161/cc.5.1.2296; Takeuchi T, 2009, BIOORGAN MED CHEM, V17, P8113, DOI 10.1016/j.bmc.2009.09.050; Tao YG, 2009, CELL CYCLE, V8, P3172, DOI 10.4161/cc.8.19.9729; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Villa F, 2009, P NATL ACAD SCI USA, V106, P20204, DOI 10.1073/pnas.0908485106; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498; Zubia A, 2009, ONCOGENE, V28, P1477, DOI 10.1038/onc.2008.501	48	79	82	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1408	1418		10.1038/onc.2011.335	http://dx.doi.org/10.1038/onc.2011.335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804608	Green Published, hybrid			2022-12-17	WOS:000301780000008
J	Banerjee, R; Mani, RS; Russo, N; Scanlon, CS; Tsodikov, A; Jing, X; Cao, Q; Palanisamy, N; Metwally, T; Inglehart, RC; Tomlins, S; Bradford, C; Carey, T; Wolf, G; Kalyana-Sundaram, S; Chinnaiyan, AM; Varambally, S; D'Silva, NJ				Banerjee, R.; Mani, R-S; Russo, N.; Scanlon, C. S.; Tsodikov, A.; Jing, X.; Cao, Q.; Palanisamy, N.; Metwally, T.; Inglehart, R. C.; Tomlins, S.; Bradford, C.; Carey, T.; Wolf, G.; Kalyana-Sundaram, S.; Chinnaiyan, A. M.; Varambally, S.; D'Silva, N. J.			The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma	ONCOGENE			English	Article						miR-101; EZH2; rap1GAP; rap1; promoter hypermethylation	GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE; DOWN-REGULATION; E-CADHERIN; SOMATIC MUTATIONS; MOLECULAR-BIOLOGY; PROMOTES INVASION; HIGH EXPRESSION; NECK-CANCER; POLYCOMB	Rap1GAP is a critical tumor suppressor gene that is downregulated in multiple aggressive cancers, such as head and neck squamous cell carcinoma, melanoma and pancreatic cancer. However, the mechanistic basis of rap1GAP downregulation in cancers is poorly understood. By employing an integrative approach, we demonstrate polycomb-mediated repression of rap1GAP that involves Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase in head and neck cancers. We further demonstrate that the loss of miR-101 expression correlates with EZH2 upregulation, and the concomitant downregulation of rap1GAP in head and neck cancers. EZH2 represses rap1GAP by facilitating the trimethylation of histone 3 at lysine 27, a mark of gene repression, and also hypermethylation of rap1GAP promoter. These results provide a conceptual framework involving a microRNA-oncogene-tumor suppressor axis to understand head and neck cancer progression. Oncogene (2011) 30, 4339-4349; doi: 10.1038/onc.2011.141; published online 2 May 2011	[D'Silva, N. J.] Univ Michigan, Sch Dent, Sch Med, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [Mani, R-S; Jing, X.; Palanisamy, N.; Tomlins, S.; Kalyana-Sundaram, S.; Chinnaiyan, A. M.; Varambally, S.; D'Silva, N. J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Mani, R-S; Jing, X.; Cao, Q.; Palanisamy, N.; Tomlins, S.; Kalyana-Sundaram, S.; Chinnaiyan, A. M.; Varambally, S.; D'Silva, N. J.] Univ Michigan, Sch Med, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Tsodikov, A.] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA; [Bradford, C.; Carey, T.; Wolf, G.] Univ Michigan, Sch Med, Dept Otolaryngol, Ann Arbor, MI 48109 USA; [Kalyana-Sundaram, S.] Bharathidasan Univ, Dept Environm Biotechnol, Tiruchirappalli, Tamil Nadu, India; [Chinnaiyan, A. M.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Bharathidasan University; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Sch Med, Dept Periodont & Oral Med, 1011 N Univ Ave,Room 5217, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu	D'Silva, Nisha J/B-4734-2013; Cao, Qi/A-5517-2010; Palanisamy, Nallasivam/ABC-8844-2020; Kalyana-Sundaram, Shanker/F-6860-2012	Cao, Qi/0000-0002-5140-3681; Palanisamy, Nallasivam/0000-0002-0633-9772; Carey, Thomas/0000-0002-5202-7518; Varambally, Sooryanarayana/0000-0002-2277-1127; Kalyana-Sundaram, Shanker/0000-0002-7309-3848; Mani, Ram/0000-0003-3552-7905	Prostate Cancer Foundation; NIDCR [DE16920-01, DE018512-01]; University of Michigan; National Institutes of Health through the University of Michigan's Cancer Center Support [5 P30 CA46592]; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K02DE019513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE016920, R01DE018512] Funding Source: NIH RePORTER	Prostate Cancer Foundation; NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); University of Michigan(University of Michigan System); National Institutes of Health through the University of Michigan's Cancer Center Support; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr T Giardano for tissue, and Dr Khalid Suleman and Vineeta Sharma for technical assistance for the FISH and methylation studies, respectively. R-SM is the recipient of StewartRahr-PCF Young Investigator Award from the Prostate Cancer Foundation. This work was supported by NIDCR DE16920-01, DE018512-01 grants and funding from University of Michigan Head and Neck Specialized Program of Research Excellence (SPORE) (NJD). This research was made possible, in part, by the use of the Cancer Center Flow Cytometry Core, which was supported (in part) by the National Institutes of Health through the University of Michigan's Cancer Center Support Grant (5 P30 CA46592).	Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chin D, 2006, EXPERT REV ANTICANC, V6, P1111, DOI 10.1586/14737140.6.7.1111; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Glazer CA, 2009, ORAL ONCOL, V45, P440, DOI 10.1016/j.oraloncology.2008.05.013; He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031; Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068; Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004; Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Stork PJS, 2005, BLOOD, V106, P2952, DOI 10.1182/blood-2005-03-1062; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Thomas GJ, 2001, CRIT REV ORAL BIOL M, V12, P479, DOI 10.1177/10454411010120060301; Todd R, 1997, J ORAL MAXIL SURG, V55, P613, DOI 10.1016/S0278-2391(97)90495-X; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Tsygankova OM, 2010, MOL CELL BIOL, V30, P3262, DOI 10.1128/MCB.01345-09; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Yang Y, 2010, CANCER GENET CYTOGEN, V200, P127, DOI 10.1016/j.cancergencyto.2010.03.014; Yarbrough WG, 2006, HEAD NECK-J SCI SPEC, V28, P549, DOI 10.1002/hed.20357; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang LZ, 2006, CANCER RES, V66, P898, DOI 10.1158/0008-5472.CAN-05-3025; Zhang ZC, 2006, AM J PATHOL, V168, P585, DOI 10.2353/ajpath.2006.050132; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812	46	79	82	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	42					4339	4349		10.1038/onc.2011.141	http://dx.doi.org/10.1038/onc.2011.141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21532618	Green Accepted			2022-12-17	WOS:000296356400005
J	Xiang, X; Zhuang, X; Ju, S; Zhang, S; Jiang, H; Mu, J; Zhang, L; Miller, D; Grizzle, W; Zhang, HG				Xiang, X.; Zhuang, X.; Ju, S.; Zhang, S.; Jiang, H.; Mu, J.; Zhang, L.; Miller, D.; Grizzle, W.; Zhang, H-G			miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT	ONCOGENE			English	Article						miR-155; tumor metastasis; epithelial-to-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; E-CADHERIN; GENE-EXPRESSION; BHLH FACTORS; CELL; MICRORNA-155; METASTASIS; GROWTH; PROGRESSION	A micro-RNA, miR-155, is overexpressed in many types of cancer cells, including breast cancer, and its role(s) in tumor metastasis has been studied on a very limited basis. Tumor metastasis is a multi-step process with the last step in the process being formation of macroscopic tumor in organs distant from the primary tumor site. This step is the least studied. Here, we report that stable expression of miR-155 in 4T1 breast tumor cells reduces significantly the aggressiveness of tumor cell dissemination as a result of preventing epithelial-to-mesenchymal transition (EMT) of tumor cells in vivo. Further, miR-155 directly suppresses the expression of the transcription factor TCF4, which is an important regulator of EMT. However, when tumor cells are injected directly into the bloodstream, miR-155 remarkably promotes macroscopic tumor formation in the lung. Analysis of gene expression profiling identified a group of genes that are associated with promoting macroscopic tumor formation in the lung. Importantly, most of these genes are overexpressed in epithelial cells. Our findings provide new insight into how miR-155 modulates the development of tumor metastasis. This study suggests that the location of tumor cells overexpressing miR-155 is a critical factor: in mammary fat pads miR-155 prevents tumor dissemination; whereas in the lung miR-155 apparently maintains the epithelial phenotype of tumor cells that is critical for macroscopic tumor formation. Oncogene (2011) 30, 3440-3453; doi:10.1038/onc.2011.54; published online 4 April 2011	[Xiang, X.; Zhuang, X.; Ju, S.; Jiang, H.; Mu, J.; Zhang, L.; Miller, D.; Zhang, H-G] Univ Louisville, James Graham Brown Canc Ctr, Dept Microbiol & Immunol, Louisville, KY 40202 USA; [Zhang, S.; Grizzle, W.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; [Zhang, H-G] Louisville Vet Adm Med Ctr, Louisville, KY USA	University of Louisville; University of Alabama System; University of Alabama Birmingham	Xiang, X (corresponding author), Univ Louisville, Brown Canc Ctr, 505 Hancock St,CTRB 309, Louisville, KY 40202 USA.	x0xian02@louisville.edu; H0Zhan17@louisvile.edu			National Institutes of Health (NIH) [RO1CA137037, R01AT004294, RO1CA107181, RO1CA116092]; Louisville Veterans Administration Medical Center (VAMC); Susan G Komen Breast Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA107181, R01CA116092, R01CA137037] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT004294] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisville Veterans Administration Medical Center (VAMC); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	We thank Dr David L Turner for providing plasmid UAS-luc-miR-155as, Dr David P Bartel for MDH1-PGK-GFP-miR-223 plasmid and Dr Jeffrey Schlom for the AT-3 breast tumor cell line. This work was supported by grants from the National Institutes of Health (NIH) (RO1CA137037, R01AT004294, RO1CA107181 and RO1CA116092), the Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants (H-G Z) and a grant from the Susan G Komen Breast Cancer Foundation. We thank Dr Jerald Ainsworth for editorial assistance.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Aokage K, 2011, INT J CANCER, V128, P1585, DOI 10.1002/ijc.25500; Bukholm IK, 2000, J PATHOL, V190, P15; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Chung KH, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl143; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Grizzle WE, 2002, INT J CANCER, V101, P270, DOI 10.1002/ijc.10606; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Johnson MH, 2009, ANNU REV CELL DEV BI, V25, P483, DOI 10.1146/annurev.cellbio.042308.113348; Katoh M, 2005, INT J ONCOL, V27, P1677; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Logullo AF, 2010, ONCOL REP, V23, P313, DOI 10.3892/or_00000638; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Nakaya Y, 2004, DEV CELL, V7, P425, DOI 10.1016/j.devcel.2004.08.003; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; PULASKI BA, 2001, CURRENT PROTOCOLS IM, V4, pCH20; Ryu JK, 2010, PANCREATOLOGY, V10, P66, DOI 10.1159/000231984; Sobrado VR, 2009, J CELL SCI, V122, P1014, DOI 10.1242/jcs.028241; Soltermann A, 2008, CLIN CANCER RES, V14, P7430, DOI 10.1158/1078-0432.CCR-08-0935; Stewart TJ, 2007, J IMMUNOL, V179, P2851, DOI 10.4049/jimmunol.179.5.2851; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thompson EW, 2008, CLIN EXP METASTAS, V25, P591, DOI 10.1007/s10585-008-9189-8; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047	44	79	90	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	31					3440	3453		10.1038/onc.2011.54	http://dx.doi.org/10.1038/onc.2011.54			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21460854	Green Accepted			2022-12-17	WOS:000293508100005
J	Ehsanian, R; Brown, M; Lu, H; Yang, XP; Pattatheyil, A; Yan, B; Duggal, P; Chuang, R; Doondeea, J; Feller, S; Sudol, M; Chen, Z; Van Waes, C				Ehsanian, R.; Brown, M.; Lu, H.; Yang, X. P.; Pattatheyil, A.; Yan, B.; Duggal, P.; Chuang, R.; Doondeea, J.; Feller, S.; Sudol, M.; Chen, Z.; Van Waes, C.			YAP dysregulation by phosphorylation or Delta Np63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets	ONCOGENE			English	Article						YAP; p53; Delta Np63; p73; apoptosis; cancer	SQUAMOUS-CELL CARCINOMA; YES-ASSOCIATED PROTEIN; NF-KAPPA-B; GROWTH-FACTOR-RECEPTOR; TUMOR-SUPPRESSOR; WW DOMAIN; PROANGIOGENIC CYTOKINES; HIPPO PATHWAY; DNA-DAMAGE; ACTIVATION	Overexpression of the Yes-associated protein (YAP), and TP53 family members Delta Np63 and p73, have been independently detected in subsets of head and neck squamous cell carcinomas (HNSCCs). YAP may serve as a nuclear cofactor with Delta Np63 and p73, but the functional role of YAP and their potential relationship in HNSCCs are unknown. In this study, we show that in a subset of HNSCC lines and tumors, YAP expression is increased but localized in the cytoplasm in association with increased AKT and YAP phosphorylation, and with decreased expression of Delta Np63 and p73. In another subset, YAP expression is decreased but detectable in the nucleus in association with lower AKT and YAP phosphorylation, and with increased Delta Np63 and p73 expression. Inhibiting AKT decreased serine-127 phosphorylation and enhanced nuclear translocation of YAP. Delta Np63 bound to the YAP promoter and suppressed its expression. Transfection of a YAP-serine-127-alanine phosphoacceptor-site mutant or Delta Np63 knockdown significantly increased nuclear YAP and cell death. Conversely, YAP knockdown enhanced cell proliferation, survival, migration and cisplatin chemoresistance. Thus, YAP function as a tumor suppressor may alternatively be dysregulated by AKT phosphorylation at serine-127 and cytoplasmic sequestration, or by transcriptional repression by Delta Np63, in different subsets of HNSCC. AKT and/or Delta Np63 are potential targets for enhancing YAP-mediated apoptosis and chemosensitivity in HNSCCs. Oncogene (2010) 29, 6160-6171; doi:10.1038/onc.2010.339; published online 23 August 2010	[Ehsanian, R.; Brown, M.; Lu, H.; Yang, X. P.; Pattatheyil, A.; Yan, B.; Duggal, P.; Chuang, R.; Chen, Z.; Van Waes, C.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD USA; [Ehsanian, R.] Howard Hughes Med Inst, Natl Inst Hlth Res Scholars Program, Bethesda, MD 20817 USA; [Ehsanian, R.] NIH Oxford Univ Stanford Univ, Sch Med, Grad Partnership Program, NIH, Bethesda, MD USA; [Brown, M.] NIH, NIH Pfizer Clin Res Training Program, Bethesda, MD USA; [Doondeea, J.; Feller, S.] Univ Oxford, Weatherall Inst Mol Med, Oxford, England; [Sudol, M.] Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; Pfizer; University of Oxford; Icahn School of Medicine at Mount Sinai	Van Waes, C (corresponding author), NIDCD, Head & Neck Surg Branch, NIH, 10-5D55,MSC 1419, Bethesda, MD 20892 USA.	vanwaesc@nidcd.nih.gov		/0000-0002-2168-3379; Lu, Hai/0000-0002-4212-3282; Brown, Matthew/0000-0003-0575-3696	NIDCD [Z1ADC-000073, Z1ADC-000074]; Head and Neck Cancer Charity; Pennsylvania Department of Health; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000073] Funding Source: NIH RePORTER	NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Head and Neck Cancer Charity; Pennsylvania Department of Health; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Drs Tsutomu Oka, Maie St John and Ms Cindy Clark for their critical review; Ning Yeh, Dr Liesl Nottingham, Dr Jay Friedman, Dr Yansong Bian and Jonah Cohen for technical assistance; and Dr Paul Albert for assistance with statistical analysis. This study was supported by the NIDCD Intramural project Z1ADC-000073, Z1ADC-000074, Head and Neck Cancer Charity Grant and the Breast Cancer Coalition Grant from the Pennsylvania Department of Health.	Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Amornphimoltham P, 2008, CLIN CANCER RES, V14, P8094, DOI 10.1158/1078-0432.CCR-08-0703; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Barbieri CE, 2006, EXP CELL RES, V312, P695, DOI 10.1016/j.yexcr.2005.11.028; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bertini E, 2009, CELL CYCLE, V8, P49, DOI 10.4161/cc.8.1.7259; Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; CAREY TE, 1993, ANTICANCER RES, V13, P2561; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chen Z, 1999, CLIN CANCER RES, V5, P1369; Danovi SA, 2008, CELL DEATH DIFFER, V15, P217, DOI 10.1038/sj.cdd.4402226; Dong G, 1997, J CELL BIOCHEM, P90; Dong G, 2001, CANCER RES, V61, P4797; Dong G, 2001, CANCER RES, V61, P5911; Downward J, 2008, MOL CELL, V32, P749, DOI 10.1016/j.molcel.2008.12.002; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Friedman J, 2007, CLIN CANCER RES, V13, P6568, DOI 10.1158/1078-0432.CCR-07-1591; Howell M, 2004, J BIOL CHEM, V279, P26300, DOI 10.1074/jbc.M401070200; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lee TL, 2008, INT J CANCER, V122, P1987, DOI 10.1002/ijc.23324; Lee TL, 2007, CLIN CANCER RES, V13, P5680, DOI 10.1158/1078-0432.CCR-07-0670; Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Massarelli E, 2005, CANCER-AM CANCER SOC, V104, P2430, DOI 10.1002/cncr.21476; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Rocco JW, 2006, CELL CYCLE, V5, P936, DOI 10.4161/cc.5.9.2716; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rosenbluth JM, 2008, GENE DEV, V22, P2591, DOI 10.1101/gad.1727408; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Thimmaiah KN, 2005, J BIOL CHEM, V280, P31924, DOI 10.1074/jbc.M507057200; Thurfjell N, 2005, INT J MOL MED, V16, P1065; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Worden B, 2005, CANCER RES, V65, P7071, DOI 10.1158/0008-5472.CAN-04-0989; Yan B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r78; Yu M, 2006, CANCER RES, V66, P6722, DOI 10.1158/0008-5472.CAN-05-3758; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	52	79	83	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6160	6171		10.1038/onc.2010.339	http://dx.doi.org/10.1038/onc.2010.339			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729916	Green Accepted			2022-12-17	WOS:000284356500008
J	Weisberg, E; Sattler, M; Ray, A; Griffin, JD				Weisberg, E.; Sattler, M.; Ray, A.; Griffin, J. D.			Drug resistance in mutant FLT3-positive AML	ONCOGENE			English	Review						drug resistance; AML; FLT3; combination therapy; stroma	ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; INTERNAL TANDEM DUPLICATION; CONSTITUTIVELY ACTIVATED FLT3; ACQUIRED UNIPARENTAL DISOMY; BCR-ABL; IN-VITRO; C-CBL; PTK INHIBITORS; ANTILEUKEMIC THERAPIES	Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target for the therapy of AML. There are several FLT3 inhibitors presently in clinical trials with sufficient efficacy and toxicity features to warrant further testing in combination with standard therapies. However, the transient and partial responses observed in AML patients treated with FLT3 inhibitors, coupled with the discovery of drug-resistant leukemic blast cells in AML patients, have made resistance to FLT3 inhibitors a growing concern. In this study, we provide an overview of the role of mutant FLT3 in AML, FLT3 inhibitors under clinical and preclinical investigation, mechanisms of resistance to FLT3 inhibitors, and possible therapeutic approaches to overcoming this resistance. Oncogene (2010) 29, 5120-5134; doi:10.1038/onc.2010.273; published online 12 July 2010	[Weisberg, E.; Sattler, M.; Ray, A.; Griffin, J. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol Hematol Neoplasia, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Weisberg, E (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	Ellen_Weisberg@dfci.harvard.edu			National Institutes of Health [CA134660-02, CA36167, DK50654]; Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [R37CA036167, R01CA134660, R01CA036167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported in part by the National Institutes of Health Grants (CA134660-02, MS; and CA36167 and DK50654, JDG), and a Leukemia and Lymphoma Society SCOR grant (JDG).	Adam M, 2006, CANCER RES, V66, P3828, DOI 10.1158/0008-5472.CAN-05-2309; Al Shaer L, 2008, BRIT J HAEMATOL, V141, P483, DOI 10.1111/j.1365-2141.2008.07053.x; Albert DH, 2006, MOL CANCER THER, V5, P995, DOI 10.1158/1535-7163.MCT-05-0410; ASHLEY DM, 1994, LEUKEMIA RES, V18, P337, DOI 10.1016/0145-2126(94)90017-5; Auclair D, 2007, LEUKEMIA, V21, P439, DOI 10.1038/sj.leu.2404508; Bagrintseva K, 2005, BLOOD, V105, P3679, DOI 10.1182/blood-2004-06-2459; Bagrintseva K, 2004, BLOOD, V103, P2266, DOI 10.1182/blood-2003-05-1653; Bang SM, 2008, J KOREAN MED SCI, V23, P833, DOI 10.3346/jkms.2008.23.5.833; Barry EV, 2007, BLOOD, V110, P4476, DOI 10.1182/blood-2007-07-101238; Bojko P, 2002, ANN HEMATOL, V81, P522, DOI 10.1007/s00277-002-0535-7; Bradstock K, 1996, LEUKEMIA, V10, P813; Brandts CH, 2005, CANCER RES, V65, P9643, DOI 10.1158/0008-5472.CAN-05-0422; Breitenbuecher F, 2009, BLOOD, V113, P4063, DOI 10.1182/blood-2007-11-126664; Brown P, 2004, BLOOD, V104, P1841, DOI 10.1182/blood-2004-03-1034; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Caligiuri MA, 2007, BLOOD, V110, P1022, DOI 10.1182/blood-2006-12-061176; Chao Q, 2009, J MED CHEM, V52, P7808, DOI 10.1021/jm9007533; Cheng Y, 2008, IDRUGS, V11, P46; Chu SH, 2009, DRUG RESIST UPDATE, V12, P8, DOI 10.1016/j.drup.2008.12.001; Clark JJ, 2004, BLOOD, V104, P2867, DOI 10.1182/blood-2003-12-4446; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; CORTES J, 2008, BLOOD, V2967; Cramer K, 2008, CANCER RES, V68, P6884, DOI 10.1158/0008-5472.CAN-08-1101; Das J, 2006, J MED CHEM, V49, P6819, DOI 10.1021/jm060727j; de Menezes DEL, 2005, CLIN CANCER RES, V11, P5281, DOI 10.1158/1078-0432.CCR-05-0358; Deininger MWN, 2005, BLOOD, V106, p204A; Despars G, 2006, STEM CELLS, V24, P1496, DOI 10.1634/stemcells.2005-0530; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dunbar AJ, 2008, CANCER RES, V68, P10349, DOI 10.1158/0008-5472.CAN-08-2754; Fernandes MS, 2009, BLOOD, V114, P1813, DOI 10.1182/blood-2008-07-172148; Fiedler W, 2005, BLOOD, V105, P986, DOI 10.1182/blood-2004-05-1846; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Galban S, 2009, BIOCHEM J, V417, P765, DOI 10.1042/BJ20081677; Gaul MD, 2007, BIOORG MED CHEM LETT, V17, P4861, DOI 10.1016/j.bmcl.2007.06.046; Gazit A, 2003, BIOORGAN MED CHEM, V11, P2007, DOI 10.1016/S0968-0896(03)00048-8; Giles FJ, 2003, BLOOD, V102, P795, DOI 10.1182/blood-2002-10-3023; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gracias V, 2008, BIOORG MED CHEM LETT, V18, P2691, DOI 10.1016/j.bmcl.2008.03.021; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Grundler R, 2009, J EXP MED, V206, P1957, DOI 10.1084/jem.20082074; Guerrouahen BS, 2010, CLIN CANCER RES, V16, P1149, DOI 10.1158/1078-0432.CCR-09-2416; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; Hunter HM, 2004, BRIT J HAEMATOL, V127, P26, DOI 10.1111/j.1365-2141.2004.05145.x; Ikezoe T, 2006, MOL CANCER THER, V5, P2522, DOI 10.1158/1535-7163.MCT-06-0071; Ishida H, 2008, BIOORG MED CHEM LETT, V18, P5472, DOI 10.1016/j.bmcl.2008.09.031; Jiang JR, 2004, BLOOD, V104, P1855, DOI 10.1182/blood-2004-02-0712; Jin GL, 2009, BIOCHEM BIOPH RES CO, V390, P1001, DOI 10.1016/j.bbrc.2009.10.094; Kancha RK, 2007, EXP HEMATOL, V35, P1522, DOI 10.1016/j.exphem.2007.07.008; Kasper S, 2008, LEUKEMIA RES, V32, P1698, DOI 10.1016/j.leukres.2008.05.003; Kayser S, 2009, BLOOD, V114, P2386, DOI 10.1182/blood-2009-03-209999; Keller O, 2002, SINGLE MOL, V3, P5, DOI 10.1002/1438-5171(200204)3:1<5::AID-SIMO5>3.0.CO;2-6; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kim KT, 2005, BLOOD, V105, P1759, DOI 10.1182/blood-2004-05-2006; Kim KT, 2006, BRIT J HAEMATOL, V134, P500, DOI 10.1111/j.1365-2141.2006.06225.x; Kindler T, 2005, BLOOD, V105, P335, DOI 10.1182/blood-2004-02-0660; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Kiyoi H, 2007, CLIN CANCER RES, V13, P4575, DOI 10.1158/1078-0432.CCR-07-0225; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Kohl TM, 2007, LEUKEMIA, V21, P1763, DOI 10.1038/sj.leu.2404776; Komeno Y, 2005, LEUKEMIA, V19, P930, DOI 10.1038/sj.leu.2403736; Kondo M, 1999, MED PEDIATR ONCOL, V33, P525; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Kornblau SM, 2006, BLOOD, V108, P2358, DOI 10.1182/blood-2006-02-003475; Kornblau SM, 2010, CLIN CANCER RES, V16, P1865, DOI 10.1158/1078-0432.CCR-09-2551; Kumagai MA, 1996, J CLIN INVEST, V97, P755, DOI 10.1172/JCI118474; Kurokawa M, 2008, MOL CELL BIOL, V28, P5494, DOI 10.1128/MCB.00265-08; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lagneaux L, 1999, LEUKEMIA LYMPHOMA, V35, P445, DOI 10.1080/10428199909169609; Lee BD, 2007, LEUKEMIA RES, V31, P1131, DOI 10.1016/j.leukres.2006.11.012; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Libura M, 2003, BLOOD, V102, P2198, DOI 10.1182/blood-2003-01-0162; Lierman E, 2007, HAEMATOL-HEMATOL J, V92, P27, DOI 10.3324/haematol.10692; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Loh ML, 2009, BLOOD, V114, P1859, DOI 10.1182/blood-2009-01-198416; LYMAN SD, 1995, BLOOD, V86, P4091, DOI 10.1182/blood.V86.11.4091.bloodjournal86114091; Makishima H, 2009, J CLIN ONCOL, V27, P6109, DOI 10.1200/JCO.2009.23.7503; Melnick JS, 2006, P NATL ACAD SCI USA, V103, P3153, DOI 10.1073/pnas.0511292103; Meshinchi S, 2003, BLOOD, V102, P1474, DOI 10.1182/blood-2003-01-0137; Meshinchi S, 2008, BLOOD, V111, P4930, DOI 10.1182/blood-2008-01-117770; Meshinchi S, 2006, BLOOD, V108, P3654, DOI 10.1182/blood-2006-03-009233; Metzelder S, 2009, BLOOD, V113, P6567, DOI 10.1182/blood-2009-03-208298; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Mollgard L, 2008, CANCER CHEMOTH PHARM, V62, P439, DOI 10.1007/s00280-007-0623-4; Molyneux G, 2008, INT J EXP PATHOL, V89, P159, DOI 10.1111/j.1365-2613.2008.00580.x; Mony U, 2008, LEUKEMIA, V22, P1395, DOI 10.1038/leu.2008.125; Murata K, 2003, J BIOL CHEM, V278, P32892, DOI 10.1074/jbc.M210405200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Nakao M, 1996, LEUKEMIA, V10, P1911; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Nishioka C, 2008, LEUKEMIA RES, V32, P865, DOI 10.1016/j.leukres.2007.09.017; Nishiyama U, 2006, LEUKEMIA RES, V30, P1541, DOI 10.1016/j.leukres.2006.02.028; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; O'Farrell AM, 2004, LEUKEMIA RES, V28, P679, DOI 10.1016/j.leukres.2003.11.004; O'Farrell AM, 2003, CLIN CANCER RES, V9, P5465; O'Hare T, 2005, CLIN CANCER RES, V11, P6987, DOI 10.1158/1078-0432.CCR-05-0622; Olsson I, 1996, EUR J HAEMATOL, V57, P1; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paraguassu-Braga FH, 2003, CELL DEATH DIFFER, V10, P1101, DOI 10.1038/sj.cdd.4401279; Patch RJ, 2006, BIOORG MED CHEM LETT, V16, P3282, DOI 10.1016/j.bmcl.2006.03.032; Piloto O, 2007, BLOOD, V109, P1643, DOI 10.1182/blood-2006-05-023804; Pollard JA, 2006, BLOOD, V108, P2764, DOI 10.1182/blood-2006-04-012260; Pratz K, 2008, LEUKEMIA LYMPHOMA, V49, P852, DOI 10.1080/10428190801895352; Pratz KW, 2010, BLOOD, V115, P1425, DOI 10.1182/blood-2009-09-242859; Pratz KW, 2009, BLOOD, V113, P3938, DOI 10.1182/blood-2008-09-177030; Ray A, 2007, BLOOD, V109, P5011, DOI 10.1182/blood-2006-01-015347; Recher C, 2005, BLOOD, V105, P2527, DOI 10.1182/blood-2004-06-2494; Reindl C, 2006, BLOOD, V107, P3700, DOI 10.1182/blood-2005-06-2596; Reindl C, 2009, CLIN CANCER RES, V15, P2238, DOI 10.1158/1078-0432.CCR-08-1325; Rivera VM, 2008, BLOOD, V112, P1008; Rocnik JL, 2006, BLOOD, V108, P1339, DOI 10.1182/blood-2005-11-011429; Rodrigues MS, 2008, ANTIOXID REDOX SIGN, V10, P1813, DOI 10.1089/ars.2008.2071; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Sargin B, 2007, BLOOD, V110, P1004, DOI 10.1182/blood-2007-01-066076; Scheijen B, 2004, ONCOGENE, V23, P3338, DOI 10.1038/sj.onc.1207456; Seedhouse CH, 2006, LEUKEMIA, V20, P2130, DOI 10.1038/sj.leu.2404439; Sensintaffar J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-11; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shaked Y, 2005, BLOOD, V105, P4500, DOI 10.1182/blood-2004-08-3210; Shankar DB, 2007, BLOOD, V109, P3400, DOI 10.1182/blood-2006-06-029579; Shiotsu Y, 2009, BLOOD, V114, P1607, DOI 10.1182/blood-2009-01-199307; Siendones E, 2007, HEMATOL ONCOL, V25, P30, DOI 10.1002/hon.805; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Stolzel F, 2010, ANN HEMATOL, V89, P653, DOI 10.1007/s00277-009-0889-1; Stone R. M., 2004, Annals of Hematology, V83, pS89; Stone RM, 2005, BLOOD, V106, p121A; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; TANAKA T, 1997, LEUKEMIA, V1111, P299; Teller S, 2002, LEUKEMIA, V16, P1528, DOI 10.1038/sj.leu.2402630; Thien CBF, 2005, GROWTH FACTORS, V23, P161, DOI 10.1080/08977190500153763; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Tse KF, 2002, LEUKEMIA, V16, P2027, DOI 10.1038/sj.leu.2402674; Tse KF, 2001, LEUKEMIA, V15, P1001, DOI 10.1038/sj.leu.2402199; von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132; von Bubnoff N, 2009, CANCER RES, V69, P3032, DOI 10.1158/0008-5472.CAN-08-2923; Walters DK, 2005, BLOOD, V105, P2952, DOI 10.1182/blood-2004-07-2758; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Weisberg E, 2008, MOL CANCER THER, V7, P1121, DOI 10.1158/1535-7163.MCT-07-2331; Weisberg E, 2008, BLOOD, V111, P3723, DOI 10.1182/blood-2007-09-114454; Weisberg E, 2007, MOL CANCER THER, V6, P1951, DOI 10.1158/1535-7163.MCT-06-0810; Weisberg E, 2009, DRUG RESIST UPDATE, V12, P81, DOI 10.1016/j.drup.2009.04.001; Weisberg E, 2008, BLOOD, V112, P5161, DOI 10.1182/blood-2008-02-138065; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186; WodnarFilipowicz A, 1996, BLOOD, V88, P4493, DOI 10.1182/blood.V88.12.4493.bloodjournal88124493; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Youssoufian H, 2010, CANCER-AM CANCER SOC, V116, P1013, DOI 10.1002/cncr.24787; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034; Zeng ZH, 2006, CANCER RES, V66, P3737, DOI 10.1158/0008-5472.CAN-05-1278; Zeng Z, 2006, MOL CANCER THER, V5, P3113, DOI 10.1158/1535-7163.MCT-06-0228; Zeng ZH, 2009, BLOOD, V113, P6215, DOI 10.1182/blood-2008-05-158311; Zhang WG, 2008, JNCI-J NATL CANCER I, V100, P184, DOI 10.1093/jnci/djm328; Zhou JB, 2008, LEUKEMIA RES, V32, P1091, DOI 10.1016/j.leukres.2007.11.025; Zhou JB, 2009, BLOOD, V113, P4052, DOI 10.1182/blood-2008-05-156422; Zwaan CM, 2003, BLOOD, V102, P2387, DOI 10.1182/blood-2002-12-3627; Zwierzina H, 1999, LEUKEMIA, V13, P553, DOI 10.1038/sj.leu.2401378	164	79	82	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	37					5120	5134		10.1038/onc.2010.273	http://dx.doi.org/10.1038/onc.2010.273			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20622902				2022-12-17	WOS:000281867200002
J	Pandey, RN; Rani, R; Yeo, EJ; Spencer, M; Hu, S; Lang, RA; Hegde, RS				Pandey, R. N.; Rani, R.; Yeo, E-J; Spencer, M.; Hu, S.; Lang, R. A.; Hegde, R. S.			The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells	ONCOGENE			English	Article						EYA; cell migration; cell invasion; metastasis; tyrosine phosphatase	EXTRASKELETAL MYXOID CHONDROSARCOMAS; FATE DETERMINATION FACTOR; TYROSINE-PHOSPHATASE; BREAST-CANCER; ENDOTHELIAL MIGRATION; SIX1 HOMEOPROTEIN; GENE-EXPRESSION; MATRIX ADHESION; GROWTH; DEPHOSPHORYLATION	The Eyes Absent (EYA) proteins combine transactivation, tyrosine phosphatase, and threonine phosphatase activities in their function as part of a conserved regulatory cascade involved in embryonic organ development. EYA tyrosine phosphatase activity contributes to fly eye development, and vertebrate EYA is involved in promoting DNA damage repair subsequent to genotoxic stress. EYAs are known to be expressed at elevated levels in ovarian and breast cancers. Here, we show that the tyrosine phosphatase activity of the EYAs promotes tumor cell migration, invasion, and transformation. These cellular effects are accompanied by alterations of the actin cytoskeleton and increased levels of active Rac and Cdc42. The invasiveness conferred by EYA is reflected in vivo by inhibition of metastasis seen when EYA3 expression is silenced in the invasive breast cancer cell line MDA-MB-231. Together, our data directly associate the tyrosine phosphatase activity of the EYAs with the oncogenesis-associated cellular properties of motility and invasiveness. Oncogene (2010) 29, 3715-3722; doi: 10.1038/onc.2010.122; published online 26 April 2010	[Hegde, R. S.] Cincinnati Childrens Hosp Res Fdn, Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Pandey, R. N.; Rani, R.; Yeo, E-J; Spencer, M.; Hu, S.; Hegde, R. S.] Univ Cincinnati, Dept Pediat, Sch Med, Cincinnati, OH 45221 USA; [Yeo, E-J; Lang, R. A.] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Dept Ophthalmol,Div Pediat Ophthalmol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hegde, RS (corresponding author), Cincinnati Childrens Hosp Res Fdn, Cincinnati Childrens Hosp Med Ctr, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	rashmi.hegde@cchmc.org	Lang, Richard/E-5578-2011; Hu, Shengyong/C-2798-2012	Lang, Richard/0000-0002-5212-254X	NIH [RO1-EY014648, R21-EY19125]; NATIONAL EYE INSTITUTE [R01EY014648, R21EY019125] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Dr Steve Danzer for help with confocal microscopy. Viral vectors were produced by the Viral Vector Core at the Translational Core Laboratories, Cincinnati Children's Hospital Research Foundation. This study was supported by NIH grants RO1-EY014648 and R21-EY19125 to RSH.	Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Bacac M, 2006, J PATHOL, V208, P543, DOI 10.1002/path.1915; Bonini NM, 1997, DEVELOPMENT, V124, P4819; Castiglioni S, 2007, BIOCHEM BIOPH RES CO, V364, P534, DOI 10.1016/j.bbrc.2007.10.022; Christensen KL, 2007, ONCOGENE, V26, P3406, DOI 10.1038/sj.onc.1210122; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Hanson IM, 2001, SEMIN CELL DEV BIOL, V12, P475, DOI 10.1006/scdb.2001.0271; Hisaoka M, 2004, CANCER GENET CYTOGEN, V152, P101, DOI 10.1016/j.cancergencyto.2003.11.011; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Jemc J, 2007, DEV BIOL, V310, P416, DOI 10.1016/j.ydbio.2007.07.024; Kriebel M, 2007, DEV DYNAM, V236, P1526, DOI 10.1002/dvdy.21170; Krishnan N, 2009, J BIOL CHEM, V284, P16066, DOI 10.1074/jbc.C900032200; Laflamme C, 2003, CANCER RES, V63, P449; Larsen M, 2003, NAT REV MOL CELL BIO, V4, P700, DOI 10.1038/nrm1199; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Liang FB, 2005, J BIOL CHEM, V280, P24857, DOI 10.1074/jbc.M502780200; Mariotti M, 2009, INT J BIOCHEM CELL B, V41, P687, DOI 10.1016/j.biocel.2008.08.005; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Pauli T, 2005, DEVELOPMENT, V132, P2771, DOI 10.1242/dev.01841; Rayapureddi JP, 2006, FEBS LETT, V580, P3853, DOI 10.1016/j.febslet.2006.06.009; Rayapureddi JP, 2005, BIOCHEMISTRY-US, V44, P751, DOI 10.1021/bi0481794; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Richert MM, 2005, BREAST CANCER RES, V7, pR819, DOI 10.1186/bcr1292; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Takamatsu N, 1998, Nihon Ronen Igakkai Zasshi, V35, P535; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Winchester C, 2000, J CLIN PATHOL, V53, P212, DOI 10.1136/jcp.53.3.212; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Wu KM, 2007, MOL BIOL CELL, V18, P755, DOI 10.1091/mbc.E06-09-0793; Wu KM, 2006, MOL CELL BIOL, V26, P7116, DOI 10.1128/MCB.00268-06; Xiong WJ, 2009, DEV CELL, V16, P271, DOI 10.1016/j.devcel.2008.12.005; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang L, 2005, CANCER RES, V65, P925; Zhang TY, 2006, DEVELOPMENT, V133, P4881, DOI 10.1242/dev.02669	44	79	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	2010	29	25					3715	3722		10.1038/onc.2010.122	http://dx.doi.org/10.1038/onc.2010.122			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418914	Green Accepted			2022-12-17	WOS:000279108600011
J	Gu, JJ; Wang, Z; Reeves, R; Magnuson, NS				Gu, J. J.; Wang, Z.; Reeves, R.; Magnuson, N. S.			PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis	ONCOGENE			English	Article						PIM1; phosphorylation; ASK1; kinase activity; apoptosis; cell survival	PROSTATE-CANCER CELLS; KINASE 1 ASK1; ACTIVATION; DEATH; PATHWAY; PROTEIN; STRESS; IDENTIFICATION; DISSOCIATION; THIOREDOXIN	The serine/threonine kinase, PIM1, is involved in promoting cell survival in part by phosphorylation and inhibition of proapoptotic proteins. Apoptosis signaling kinase 1 (ASK1), a mitogen-activated protein kinase kinase kinase, is involved in the so-called stress-activated pathways that contribute to apoptotic cell death. Here we show that PIM1 phosphorylates ASK1 specifically on serine residue 83 (Ser83) both in vitro and in vivo and that PIM1 binds to ASK1 in cells by co-immunoprecipitation. Using H1299 cells, our results further demonstrate that PIM1 phosphorylation of ASK1 decreases its kinase activity induced by oxidative stress. PIM1 phosphorylation of ASK1 on Ser83 inhibited ASK1-mediated c-Jun N-terminal kinase phosphorylation as well as p38 kinase phosphorylation. Under H2O2-induced stress conditions that normally lead to apoptosis, these phosphorylation events were associated with inhibition of caspase-3 activation and resulted in reduced cell death. Moreover, knockdown of PIM1 in H1299 cells decreased phosphorylation of endogenous Ser83 of ASK1 and was associated with a decrease in cell viability after H2O2 treatment. Taken together, these data reveal a novel mechanism by which PIM1 promotes cell survival that involves negative regulation of the stress-activated kinase, ASK1. Oncogene (2009) 28, 4261-4271; doi: 10.1038/onc.2009.276; published online 14 September 2009	[Gu, J. J.; Wang, Z.; Reeves, R.; Magnuson, N. S.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Magnuson, NS (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	magnuson@wsu.edu			NIH [R01-CA104470, R01-GM071760]; NATIONAL CANCER INSTITUTE [R01CA104470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071760] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH Grants R01-CA104470 and R01-GM071760. We thank Dr Hidenori Ichijo (Tokyo Medical and Dental University) for providing us the ASK1 constructs (wild type, kinase mutant and deltaN-deleted).	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cross JV, 2006, ANTIOXID REDOX SIGN, V8, P1819, DOI 10.1089/ars.2006.8.1819; CUYPERS HT, 1984, CELL, V37, P141; Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Fujii K, 2004, ONCOGENE, V23, P5099, DOI 10.1038/sj.onc.1207668; Galvan V, 2003, J BIOL CHEM, V278, P13325, DOI 10.1074/jbc.M211398200; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Katakami N, 2004, J BIOL CHEM, V279, P54742, DOI 10.1074/jbc.M409140200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim SD, 2005, BIOCHEM BIOPH RES CO, V328, P326, DOI 10.1016/j.bbrc.2004.11.173; Kumar A, 2005, J MOL BIOL, V348, P183, DOI 10.1016/j.jmb.2005.02.039; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Matsuzawa A, 2008, BBA-GEN SUBJECTS, V1780, P1325, DOI 10.1016/j.bbagen.2007.12.011; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Peng C, 2007, J BIOCHEM, V141, P353, DOI 10.1093/jb/mvm040; Pircher TJ, 2000, ONCOGENE, V19, P3684, DOI 10.1038/sj.onc.1203684; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shah N, 2008, EUR J CANCER, V44, P2144, DOI 10.1016/j.ejca.2008.06.044; Shay KP, 2005, MOL CANCER RES, V3, P170; Teh Beng-gwan, 2004, Hokkaido Journal of Medical Science, V79, P19; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang Z, 2001, J Vet Sci, V2, P167; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Yan W, 2007, BIOCHEM BIOPH RES CO, V355, P1038, DOI 10.1016/j.bbrc.2007.02.064; Zemskova M, 2008, J BIOL CHEM, V283, P20635, DOI 10.1074/jbc.M709479200; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	42	79	84	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4261	4271		10.1038/onc.2009.276	http://dx.doi.org/10.1038/onc.2009.276			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749799	Green Accepted			2022-12-17	WOS:000272876300004
J	Zheng, HQ; Zhou, Z; Huang, J; Chaudhury, L; Dong, JT; Chen, C				Zheng, H-Q; Zhou, Z.; Huang, J.; Chaudhury, L.; Dong, J-T; Chen, C.			Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of broblast growth factor binding protein 1	ONCOGENE			English	Article						KLF5; FGF-BP; proliferation; transcription factor; breast cancer	EPITHELIAL-CELLS; FGF-BP; CANCER-CELLS; SKIN CARCINOGENESIS; TUMOR-GROWTH; LIGASE WWP1; KLF5; EXPRESSION; KRUPPEL-LIKE-FACTOR-5; ACTIVATION	The Kruppel-like factor 5 (KLF5) is a zinc-finger transcription factor promoting cell proliferation, cell-cycle progression and survival. A high expression level of KLF5 mRNA has been shown to be associated with shorter breast cancer patient survival. However, the mechanism of KLF5 action in breast cancer is still not clear. In this study, we found that both KLF5 and its downstream gene. broblast growth factor binding protein 1 (FGF-BP) are co-expressed in breast cell lines and primary tumors. Manipulation of the KLF5 expression can positively regulate the FGF-BP mRNA and protein levels in multiple breast cell lines. In addition, the secreted FGF-BP protein in the conditional medium is also regulated by KLF5. Furthermore, we demonstrated that KLF5 binds and activates the FGF-BP promoter through a GC box by luciferase reporter, oligo pull down and chromatin immunoprecipitation (ChIP) assays. When FGF-BP is depleted by siRNA, KLF5 fails to promote cell proliferation in MCF10A, SW527 and TSU-Pr1. We further demonstrated that overexpression or addition of FGF-BP rescues the KLF5-knockdown-induced growth arrest in MCF10A cells. Finally, KLF5 significantly promotes MCF7 breast cancer cell xenograft growth in athymic nude mice. These findings suggest that KLF5 may promote breast cancer cell proliferation at least partially through directly activating the FGF-BP mRNA transcription. Understanding the mechanism of KLF5 action in breast cancer may result in useful diagnostic and therapeutic targets. Oncogene (2009) 28, 3702-3713; doi: 10.1038/onc.2009.235; published online 10 August 2009	[Zheng, H-Q; Zhou, Z.; Chaudhury, L.; Chen, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Huang, J.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Dong, J-T] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA USA	Albany Medical College; Baylor College of Medicine; Emory University	Chen, C (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MS355,Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	chenc@mail.amc.edu		Zheng, Hanqiu/0000-0002-8062-1215; Dong, Jin-Tang/0000-0003-2349-5782	Susan G Komen Breast Cancer Foundation [BCTR0503705]; American Cancer Society; Department of Defense [W81XWH-07-1-0191]	Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); American Cancer Society(American Cancer Society); Department of Defense(United States Department of Defense)	This work was supported in part by a grant (BCTR0503705) from the Susan G Komen Breast Cancer Foundation, a grant from the American Cancer Society and a grant from the Department of Defense (W81XWH-07-1-0191). We thank Dr Chunhong Yan and Dr Jihe Zhao for providing the pRL-bactin construct and the pBabe-puro retroviral system.	Abuharbeid S, 2006, INT J BIOCHEM CELL B, V38, P1463, DOI 10.1016/j.biocel.2005.10.017; Aigner A, 2001, INT J CANCER, V92, P510, DOI 10.1002/1097-0215(20010515)92:4<510::AID-IJC1227>3.0.CO;2-H; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Chanchevalap S, 2006, NUCLEIC ACIDS RES, V34, P1216, DOI 10.1093/nar/gkl014; Chen C, 2007, ONCOGENE, V26, P2386, DOI 10.1038/sj.onc.1210021; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2007, INT J CANCER, V121, P2834; Chen CH, 2006, INT J CANCER, V118, P1346, DOI 10.1002/ijc.21533; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; Fujiu K, 2005, CIRC RES, V97, P1132, DOI 10.1161/01.RES.0000190613.22565.13; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Kagan BL, 2003, CANCER RES, V63, P1696; Kojima S, 1997, J BIOCHEM, V121, P389; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; Kurtz A, 2004, NEOPLASIA, V6, P595, DOI 10.1593/neo.04214; Kwak MK, 2008, J CANCER RES CLIN, V134, P163, DOI 10.1007/s00432-007-0265-2; Li WM, 2004, CHINESE MED J-PEKING, V117, P621; McConnell BB, 2007, BIOESSAYS, V29, P549, DOI 10.1002/bies.20581; Mohsin SK, 2004, MODERN PATHOL, V17, P1545, DOI 10.1038/modpathol.3800229; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Ray PE, 2006, AM J PHYSIOL-REG I, V290, pR105, DOI 10.1152/ajpregu.00492.2005; Ray R, 2003, CANCER RES, V63, P8085; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Sur I, 2002, EUR J CELL BIOL, V81, P323, DOI 10.1078/0171-9335-00257; Sur I, 2006, J CELL SCI, V119, P3593, DOI 10.1242/jcs.03070; Tassi E, 2006, CANCER RES, V66, P1191, DOI 10.1158/0008-5472.CAN-05-2926; Tong D, 2006, CLIN CANCER RES, V12, P2442, DOI 10.1158/1078-0432.CCR-05-0964; Wan HJ, 2008, DEVELOPMENT, V135, P2563, DOI 10.1242/dev.021964; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; WU DQ, 1991, J BIOL CHEM, V266, P16778; Yang YZ, 2007, FASEB J, V21, P543, DOI 10.1096/fj.06-6694com; Yang YZ, 2005, CANCER BIOL THER, V4, P1216, DOI 10.4161/cbt.4.11.2090; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Zhao Y, 2008, ONCOGENE, V27, P1, DOI 10.1038/sj.onc.1210625	45	79	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3702	3713		10.1038/onc.2009.235	http://dx.doi.org/10.1038/onc.2009.235			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668233				2022-12-17	WOS:000271023200003
J	Laghi, L; Bianchi, P; Malesci, A				Laghi, L.; Bianchi, P.; Malesci, A.			Differences and evolution of the methods for the assessment of microsatellite instability	ONCOGENE			English	Review						microsatellite instability; mismatch repair defects; inherited and sporadic colorectal cancer; molecular diagnosis	NONPOLYPOSIS COLORECTAL-CANCER; ISLAND METHYLATOR PHENOTYPE; MISMATCH REPAIR DEFICIENCY; COLON-CANCER; BETHESDA GUIDELINES; SOMATIC MUTATIONS; MUTATOR PHENOTYPE; LYNCH-SYNDROME; ADJUVANT CHEMOTHERAPY; GENOMIC INSTABILITY	Microsatellite instability (MSI) originates from the systematic accumulation of uncorrected deletion/insertion in repetitive DNA tracts in cancer cells with a deficient mismatch repair system. Among colorectal cancers, the MSI signature identifies hereditary cases arising in patients with germline mutations in hMLH1, hMSH2, PMS2 and a fraction of those with hMSH6 mutations, as well as sporadic cancers with epigenetic hMLH1 promoter hypermethylation. Considering the specific pathogenesis, pathological features, natural history and response to 5-fluoro-uracil-based chemotherapy of the MSI cancers, confusion about the genetic markers for MSI recognition seems surprising. In this clinically relevant field, an agreement has not been reached concerning the use of di- or mononucleotide markers for MSI assessment. The Revised Bethesda Guidelines still recommend a panel of markers consisting of mono- and dinucleotides, despite being questioned whether it is congruous to continue to use dinucleotide markers for MSI identification. In any event, no single marker is accurate enough for MSI testing, and an awareness of their pros and cons is required for proper interpretation of results. In recent years, several papers have reported different prevalence of MSI in unrelated series, largely depending on the detection and classification method, suggesting that MSI test interpretation also requires the understanding of the phenomenon rather than simply the crude satisfaction of panel recommendations. Inaccuracies can otherwise lead to under- or overdiagnosis and inaccurate disease classification, which always have a negative impact on the clinical practice of medicine.	[Laghi, L.; Bianchi, P.; Malesci, A.] IRCCS Ist Clin Humanitas, Dept Gastroenterol, Lab Mol Gastroenterol, I-20089 Milan, Italy; [Malesci, A.] Univ Milan, Dept Internal Med, Milan, Italy	Humanitas University; IRCCS Humanitas Research Hospital; University of Milan	Laghi, L (corresponding author), IRCCS Ist Clin Humanitas, Dept Gastroenterol, Lab Mol Gastroenterol, Via Manzoni 113, I-20089 Milan, Italy.	luigi.laghi@humanitas.it	Bianchi, Paolo/E-7592-2013; Laghi, Luigi/GZM-5831-2022	Bianchi, Paolo/0000-0001-5786-5644; Laghi, Luigi/0000-0003-4187-1059				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Ahuja N, 1997, CANCER RES, V57, P3370; Bocker T, 1997, CANCER RES, V57, P4739; Boland CR, 2007, J CLIN ONCOL, V25, P754, DOI 10.1200/JCO.2006.09.4607; Boland CR, 2005, SEMIN CANCER BIOL, V15, P436, DOI 10.1016/j.semcancer.2005.06.001; Boland CR, 1998, CANCER RES, V58, P5248; Carethers JM, 2004, GASTROENTEROLOGY, V126, P394, DOI 10.1053/j.gastro.2003.12.023; CAWKWELL L, 1995, GASTROENTEROLOGY, V109, P465, DOI 10.1016/0016-5085(95)90334-8; de la Chapelle A, 2003, NEW ENGL J MED, V349, P209, DOI 10.1056/NEJMp038099; Dietmaier W, 1997, CANCER RES, V57, P4749; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Giuffre G, 2005, J MOL DIAGN, V7, P160, DOI 10.1016/S1525-1578(10)60542-9; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Gonzalez-Garcia I, 2000, JNCI-J NATL CANCER I, V92, P544, DOI 10.1093/jnci/92.7.544; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Gruber SB, 2006, GASTROENTEROLOGY, V130, P577, DOI 10.1053/j.gastro.2006.01.031; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hoang JM, 1997, CANCER RES, V57, P300; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jenkins MA, 2007, GASTROENTEROLOGY, V133, P48, DOI 10.1053/j.gastro.2007.04.044; Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907; Kane MF, 1997, CANCER RES, V57, P808; Kim GP, 2007, J CLIN ONCOL, V25, P767, DOI 10.1200/JCO.2006.05.8172; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOI M, 1994, CANCER RES, V54, P4308; Laghi L, 2004, J NATL CANCER I, V96, P1402, DOI 10.1093/jnci/djh280; Laiho P, 2002, CANCER RES, V62, P1166; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LOTHE RA, 1993, CANCER RES, V53, P5849; Loukola A, 2001, CANCER RES, V61, P4545; MADDOX J, 1993, NATURE, V363, P667, DOI 10.1038/363667a0; Malesci A, 2007, CLIN CANCER RES, V13, P3831, DOI 10.1158/1078-0432.CCR-07-0366; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; Muller A, 2006, INT J COLORECTAL DIS, V21, P632, DOI 10.1007/s00384-005-0073-6; *NCBI, 2007, ONLINEMENDELIAN INH; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Ohmiya N, 2001, GENE, V272, P301, DOI 10.1016/S0378-1119(01)00517-0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Pastrello C, 2006, EUR J HUM GENET, V14, P63, DOI 10.1038/sj.ejhg.5201517; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; Perucho M, 1999, CANCER RES, V59, P249; Pyatt R, 1999, AM J PATHOL, V155, P349, DOI 10.1016/S0002-9440(10)65131-0; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Roncalli M, 2000, HEPATOLOGY, V31, P846, DOI 10.1053/he.2000.5790; Samowitz WS, 2001, CANCER EPIDEM BIOMAR, V10, P917; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; STRACHAN T, 1999, HUMAN MOL GENETICS, V2; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Thibodeau SN, 1998, CANCER RES, V58, P1713; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Tomlinson I, 2002, J PATHOL, V197, P6, DOI 10.1002/path.1071; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Truninger K, 2005, GASTROENTEROLOGY, V128, P1160, DOI 10.1053/j.gastro.2005.01.056; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Weinberg R. A., 2006, BIOL CANC; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z; Xicola RM, 2007, JNCI-J NATL CANCER I, V99, P244, DOI 10.1093/jnci/djk033; Yamamoto H, 1997, CANCER RES, V57, P4420; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	76	79	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6313	6321		10.1038/onc.2008.217	http://dx.doi.org/10.1038/onc.2008.217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18679418				2022-12-17	WOS:000260263400001
J	Candeias, MM; Powell, DJ; Roubalova, E; Apcher, S; Bourougaa, K; Vojtesek, B; Bruzzoni-Giovanelli, H; Fahraeus, R				Candeias, M. M.; Powell, D. J.; Roubalova, E.; Apcher, S.; Bourougaa, K.; Vojtesek, B.; Bruzzoni-Giovanelli, H.; Fahraeus, R.			Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation	ONCOGENE			English	Article						p53; p53/47; stress response; alternative translation initiation	RIBOSOME-ENTRY-SITE; TUMOR-SUPPRESSOR; MEDIATED TRANSLATION; PROTEIN; MDM2; INDUCTION; APOPTOSIS; ISOFORM; DOMAIN; STABILITY	P53 controls the growth and survival of cells by acting in response to a multitude of cellular stresses. It is, however, not yet fully understood how different p53 activation pathways result in either cell cycle arrest or apoptosis. We and others have described an N-terminally truncated p53 protein (p53/47) originating from a second translation initiation site in the p53 messenger RNA ( mRNA), which can interact with p53 and impose altered stability and transactivation properties to p53 complexes. Here we show that cap-dependent and cap-independent mechanisms of initiation govern the translation of the p53 mRNA. Changes in synthesis of full-length p53 or p53/47 are regulated through distinct cell stress-induced pathways acting through separate regions of the p53 mRNA. We also show that some cytotoxic drugs require the presence of full-length p53 to induce apoptosis, whereas for others p53/47 is sufficient. This indicates that by harbouring alternative translation initiation sites, the p53 mRNA gives rise to different levels of the p53 isoforms which help to orchestrate the cell biological outcome of p53 activation in response to different types of cell stress. This sheds new light into the way p53 can integrate and differentiate a large multiplicity of changes in the cellular environment.	Hop St Louis, INSERM, Inst Mol Genet, U716, F-75010 Paris, France; Masaryk Mem Canc Inst, Brno, Czech Republic	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Masaryk Memorial Cancer Institute	Fahraeus, R (corresponding author), Hop St Louis, INSERM, Inst Mol Genet, U716, 27 Rue Juliette Dodu, F-75010 Paris, France.	robinfahraeus@yahoo.co.uk	Hajduskova, Eva/G-9780-2014; Powell, Darren Jmaes/GOE-5236-2022; Apcher, Sebastien/P-2590-2018; Apcher, Sebastien/B-6356-2015; fahraeus, robin/K-8726-2014	Powell, Darren Jmaes/0000-0001-9439-5880; Bourougaa, Karima/0000-0003-0339-962X; , robin/0000-0003-0402-8492				Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Herbreteau CH, 2005, NAT STRUCT MOL BIOL, V12, P1001, DOI 10.1038/nsmb1011; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	41	79	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6936	6947		10.1038/sj.onc.1209996	http://dx.doi.org/10.1038/sj.onc.1209996			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16983332				2022-12-17	WOS:000241732300004
J	Pfeffer, S; Voinnet, O				Pfeffer, S.; Voinnet, O.			Viruses, microRNAs and cancer	ONCOGENE			English	Review						virus; RNA silencing; microRNA; cancer; oncogene; cellular transformation	SMALL INTERFERING RNA; RETRACTED ARTICLE. SEE; ANTIVIRAL IMMUNITY; VIRAL SUPPRESSOR; IDENTIFICATION; PROTEINS; EXPRESSION; INFLUENZA; BINDING; LOCUS	Viruses represent one of the main factors that cause normal cells to proliferate and to become malignant: up to 15% of all human cancers are associated with single or multiple virus infections, and several viruses have been recognized as causal agents of specific types of cancer. Viruses have evolved many strategies to prevent infected cells from becoming apoptotic and to evade the innate and adaptive immune responses of their hosts. The recent discovery that Epstein-Barr virus and other herpesviruses produce their own sets of micro (mi) RNAs brings an additional layer of complexity in this ongoing host-virus arms race and changes our initial views of the antiviral roles of RNA silencing in plants and insects. It seems that, rather than being inhibited by this process, many mammalian viruses can usurp or divert the host RNA silencing machinery to their advantage. Viral-encoded miRNAs can act both in cis, to ensure accurate expression of viral genomes, and in trans, to modify the expression of host transcripts. Here, we review the current knowledge on viral miRNAs and discuss how mammalian viruses can also perturb host miRNA expression. Those recent findings provide new insights into the role of viruses and miRNAs in cancer development.	CNRS, Inst Biol Mol Plantes, UPR 2357, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Voinnet, O (corresponding author), CNRS, Inst Biol Mol Plantes, UPR 2357, 12,Rue Gen Zimmer, F-67084 Strasbourg, France.	sebastien.pfeffer@ibmp-ulp.u-strasbg.fr; olivier.voinnet@ibmp-ulp.u-strasbg.fr	Pfeffer, Sébastien/H-3212-2019; Pfeffer, Sebastien/A-6512-2010	Pfeffer, Sébastien/0000-0002-8458-348X; Pfeffer, Sebastien/0000-0002-8458-348X; Voinnet, Olivier/0000-0001-6982-9544				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Andersson MG, 2005, J VIROL, V79, P9556, DOI 10.1128/JVI.79.15.9556-9565.2005; Aparicio O, 2006, J VIROL, V80, P1376, DOI 10.1128/JVI.80.3.1376-1384.2006; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; Bucher E, 2004, J GEN VIROL, V85, P983, DOI 10.1099/vir.0.19734-0; Cai Xuezhong, 2006, PLoS Pathogens, V2, P236, DOI 10.1371/journal.ppat.0020023; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Cai XZ, 2005, P NATL ACAD SCI USA, V102, P5570, DOI 10.1073/pnas.0408192102; Chapman EJ, 2004, GENE DEV, V18, P1179, DOI 10.1101/gad.1201204; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cui C, 2006, J VIROL, V80, P5499, DOI 10.1128/JVI.00200-06; Cullen BR, 2006, NAT IMMUNOL, V7, P563, DOI 10.1038/ni1352; Deleris A, 2006, SCIENCE, V313, P68, DOI 10.1126/science.1128214; Ding SW, 2004, VIRUS RES, V102, P109, DOI 10.1016/j.virusres.2004.01.021; Dunn W, 2005, CELL MICROBIOL, V7, P1684, DOI 10.1111/j.1462-5822.2005.00598.x; Dunoyer P, 2004, PLANT CELL, V16, P1235, DOI 10.1105/tpc.020719; Galiana-Arnoux D, 2006, NAT IMMUNOL, V7, P590, DOI 10.1038/ni1335; Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05; Grey F, 2005, J VIROL, V79, P12095, DOI 10.1128/JVI.79.18.12095-12099.2005; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Khalili K, 2003, ONCOGENE, V22, P5181, DOI 10.1038/sj.onc.1206559; Kieff E, 2001, FIELDS VIROLOGY, V2, P2511; Kliche S, 2001, MOL CELL, V7, P833, DOI 10.1016/S1097-2765(01)00227-1; Lakatos L, 2006, EMBO J, V25, P2768, DOI 10.1038/sj.emboj.7601164; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; Macrae AI, 2001, J VIROL, V75, P5315, DOI 10.1128/JVI.75.11.5315-5327.2001; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Merai Z, 2006, J VIROL, V80, P5747, DOI 10.1128/JVI.01963-05; MOORE PS, 2001, FIELDS VIROLOGY, V2, P2803; Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obbard DJ, 2006, CURR BIOL, V16, P580, DOI 10.1016/j.cub.2006.01.065; Pearce M, 2005, J VIROL, V79, P14457, DOI 10.1128/JVI.79.22.14457-14464.2005; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; Samols MA, 2005, J VIROL, V79, P9301, DOI 10.1128/JVI.79.14.9301-9305.2005; Sano M, 2006, FEBS LETT, V580, P1553, DOI 10.1016/j.febslet.2006.01.085; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Soderberg-Naucler C, 2006, J INTERN MED, V259, P219, DOI 10.1111/j.1365-2796.2006.01618.x; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Speck SH, 1999, CURR OPIN MICROBIOL, V2, P403; Sullivan CS, 2005, NATURE, V435, P682, DOI 10.1038/nature03576; Sullivan CS, 2005, MOL CELL, V20, P3, DOI 10.1016/j.molcel.2005.09.012; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Vargason JM, 2003, CELL, V115, P799, DOI 10.1016/S0092-8674(03)00984-X; Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555; Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694; Watanabe T, 2006, GENE DEV, V20, P1732, DOI 10.1101/gad.1425706; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Ye KQ, 2003, NATURE, V426, P874, DOI 10.1038/nature02213; Yeung ML, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-81	65	79	92	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6211	6219		10.1038/sj.onc.1209915	http://dx.doi.org/10.1038/sj.onc.1209915			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028601				2022-12-17	WOS:000241158900010
J	Chou, YT; Wang, H; Chen, Y; Danielpour, D; Yang, YC				Chou, Y-T; Wang, H.; Chen, Y.; Danielpour, D.; Yang, Y-C			Cited2 modulates TGF-beta-mediated upregulation of MMP9	ONCOGENE			English	Article						Cited2; TGF-beta; MMP9; Smad3; p300	GROWTH-FACTOR-BETA; BREAST-CANCER CELLS; CREB-BINDING-PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; MELANOCYTE-SPECIFIC GENE; MATRIX METALLOPROTEINASES; TRANSFORMING GROWTH-FACTOR-BETA-1; SMAD PROTEINS; TRANSCRIPTIONAL COACTIVATOR; P300/CREB-BINDING PROTEIN	Cited ((C) under bar BP/p300-interacting transactivators with glutamic acid ((E) under bar )n/ aspartic acid ((D) under bar)-rich C-terminal domain) 2, which is a CBP/p300-binding transcription co-activator without typical DNA-binding domains, has been implicated in control of cell growth and malignant transformation in Rat1 cells. In this report, we provide evidence that Cited2 is an important regulator of transforming growth factor (TGF)-beta signaling. Overexpression of Cited2 enhanced TGF-beta-mediated transcription of a Smad-Binding Element-containing luciferase reporter construct, SBE4-Luc. This may occur through a direct physical association of Cited2 with Smads 2 and 3, as supported by co-immunoprecipitation, mammalian two-hybrid and glutathione S-transferase- pull down assays. The transcription factor p300, which binds to Smad3, was shown to further enhance the interaction between Cited2 and Smad3, and the transcriptional responses of Smad3 by Cited2 in reporter assays. Cited2 enhances TGF-beta-mediated upregulation of matrix metalloproteinase 9 (MMP9) in Cited2 inducible mouse embryo. broblasts. Overexpression of Cited2 enhanced TGF-beta-mediated MMP9 promoter reporter activity. Moreover, knockdown of Cited2 in MDA-MB-231 cells attenuated TGF-beta-mediated upregulation of MMP9 and TGF-beta-mediated cell invasion. Chromatin immunoprecipitation showed that Cited2 and Smad3 were recruited to MMP9 promoter upon TGF-beta stimulation. This is the first demonstration that Cited2 functions as a Smad3/p300-interacting transcriptional coactivator in modulating the expression of MMP9, which could affect tumor cell invasion mediated by TGF-beta.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Sch Med, Cleveland, OH 44106 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA	Case Western Reserve University; Case Western Reserve University; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Yang, YC (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 2109 Adelbert Rd,W353, Cleveland, OH 44106 USA.	yxy36@cwru.edu		Chou, Yu-Ting/0000-0001-9274-8603	NATIONAL CANCER INSTITUTE [R01CA078433] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78433] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews JE, 2000, MECH DEVELOP, V95, P305, DOI 10.1016/S0925-4773(00)00362-2; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Braganca J, 2003, J BIOL CHEM, V278, P16021, DOI 10.1074/jbc.M208144200; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dennler S, 2005, ONCOGENE, V24, P1936, DOI 10.1038/sj.onc.1208343; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Futaki S, 2003, J BIOL CHEM, V278, P50691, DOI 10.1074/jbc.M304985200; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guo BL, 2005, KIDNEY INT, V68, P972, DOI 10.1111/j.1523-1755.2005.00491.x; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Ilunga K, 2004, INT J EXP PATHOL, V85, P373, DOI 10.1111/j.0959-9673.2004.00406.x; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MELCHIORI A, 1987, ANTICANCER RES, V7, P475; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Ogawa K, 2004, BIOCHEM J, V381, P413, DOI 10.1042/BJ20040058; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Santibanez JF, 2002, BIOCHEM BIOPH RES CO, V296, P267; SATO H, 1993, ONCOGENE, V8, P395; Selvamurugan N, 2004, J BIOL CHEM, V279, P27764, DOI 10.1074/jbc.M312870200; Selvamurugan N, 2004, J BIOL CHEM, V279, P19327, DOI 10.1074/jbc.M314048200; Selvamurugan N, 2002, FEBS LETT, V532, P31, DOI 10.1016/S0014-5793(02)03620-7; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Shioda T, 1997, GENE, V204, P235, DOI 10.1016/S0378-1119(97)00551-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Tardif G, 2001, J RHEUMATOL, V28, P1631; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tien ES, 2004, J BIOL CHEM, V279, P24053, DOI 10.1074/jbc.M401489200; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Yokota H, 2003, J BIOL CHEM, V278, P47275, DOI 10.1074/jbc.M304652200; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	74	79	84	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5547	5560		10.1038/sj.onc.1209552	http://dx.doi.org/10.1038/sj.onc.1209552			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619037				2022-12-17	WOS:000240370400008
J	Han, SW; Roman, J				Han, S. W.; Roman, J.			Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-kappa B	ONCOGENE			English	Article						fibronectin; PI3-K; NF-kappa B; cell cycle; tumor suppressor gene; human bronchial epithelial cells	TUMOR-SUPPRESSOR PTEN; SMOOTH-MUSCLE-CELLS; C-MYC; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CYCLE PROGRESSION; GENE-EXPRESSION; GROWTH-FACTORS; CANCER CELLS	The extracellular matrix glycoprotein, fibronectin, influences a variety of cellular functions including adhesion, migration, survival, differentiation, and growth. Fibronectin has also been shown to increase the migration and proliferation of human lung carcinoma cells. However, the role of fibronectin in controlling lung airway epithelial cell phenotype remains unknown. Here, we demonstrate that fibronectin stimulates the proliferation of human bronchial epithelial cells (BEAS-2B and 16-HBE). Of note, fibronectin induced the mRNA and protein expression of c-Myc and cyclin D1, while it decreased the expressions of cyclin-dependent kinase inhibitor p21 (WAF-1/CIP1/MDA-6) (p21) and the tumor suppressor gene phosphatase and tensin homolog deleted on chromosome ten ( PTEN). Fibronectin also stimulated the phosphorylation of the phosphatidylinositol 3 kinase (PI3-K) downstream signal Akt. The inhibitor of PI3-K, Wortmannin, and anti-alpha 5 beta 1 integrin antibodies abrogated the effect of fibronectin on c-Myc, cyclin D1, p21, and PTEN expression. The stimulatory effect of. bronectin was mediated by nuclear factor kappaB (NF-kappa B) since. bronectin induced the expression of the p65 component of NF-kappa B and enhanced NF-kappa B DNA binding. Furthermore, we found that p65 small interfering RNA inhibited the effect of. bronectin on c-Myc, cyclin D1, p21, PTEN expression, and on fibronectin-induced cell proliferation. Finally, we found that. bronectin inhibits apoptosis by reducing DNA fragmentation and inhibiting the activities of caspases 3/7. Taken together, our findings demonstrate that fibronectin stimulates human bronchial epithelial cell growth and inhibits apoptosis through activation of NF-kappa B, which, in turn, increases the expression of c-Myc and cyclin D1 and decreases p21 and PTEN via alpha 5 beta 1 integrin-dependent signals that include PI3-K/Akt. Therefore, alternations in the extracellular matrix composition of the lung, with increased. bronectin, might promote epithelial cell growth and thereby contribute to oncogenesis in certain settings.	Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Atlanta, GA 30322 USA; Atlanta Vet Affairs Med Ctr, Atlanta, GA USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Han, SW (corresponding author), Emory Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Whitehead Biomed Res Bldg,615 Michael St,Suite 20, Atlanta, GA 30322 USA.	shan2@emory.edu						AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Aoshiba K, 1997, AM J PHYSIOL-LUNG C, V273, pL684, DOI 10.1152/ajplung.1997.273.3.L684; Arcuri C, 2005, J BIOL CHEM, V280, P4402, DOI 10.1074/jbc.M406440200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Benaud CM, 2001, ONCOGENE, V20, P759, DOI 10.1038/sj.onc.1204152; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Chen F, 2001, J BIOL CHEM, V276, P11414, DOI 10.1074/jbc.M011682200; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2004, CANCER BIOL THER, V3, P47, DOI 10.4161/cbt.3.1.570; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Dai R, 2005, APOPTOSIS, V10, P503, DOI 10.1007/s10495-005-1880-5; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; de Jong-Hesse Y, 2005, GRAEF ARCH CLIN EXP, V243, P695, DOI 10.1007/s00417-004-1116-3; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012; Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003; Garl PJ, 2004, CIRC RES, V94, P175, DOI 10.1161/01.RES.0000109791.69181.B6; Gordon AH, 2005, CANCER RES, V65, P3209, DOI 10.1158/0008-5472.CAN-04-4017; Halder SK, 2005, EXP CELL RES, V307, P231, DOI 10.1016/j.yexcr.2005.03.009; Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040; Han SW, 2004, INT J CANCER, V111, P322, DOI 10.1002/ijc.20281; Han SW, 2003, J CLIN ENDOCR METAB, V88, P713, DOI 10.1210/jc.2002-020876; Han SW, 1996, ENDOCRINOLOGY, V137, P1791, DOI 10.1210/en.137.5.1791; Illario M, 2005, J CLIN ENDOCR METAB, V90, P2865, DOI 10.1210/jc.2004-1520; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Kijima T, 2003, J CELL MOL MED, V7, P157; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Liu B, 2004, J SURG RES, V120, P256, DOI 10.1016/j.jss.2003.12.015; Loeser RF, 2002, BIORHEOLOGY, V39, P119; Moon SK, 2004, ARCH BIOCHEM BIOPHYS, V421, P267, DOI 10.1016/j.abb.2003.11.007; Nasu-Tada K, 2005, GLIA, V52, P98, DOI 10.1002/glia.20224; Orend G, 2003, ONCOGENE, V22, P3917, DOI 10.1038/sj.onc.1206618; Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; TAKIZAWA H, 1991, AM J RESP CELL MOL, V5, P548, DOI 10.1165/ajrcmb/5.6.548; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang CH, 2004, MOL PHARMACOL, V66, P440; Tell G, 2004, ENDOCRINOLOGY, V145, P4660, DOI 10.1210/en.2004-0282; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Wadsworth SJ, 2004, AM J PHYSIOL-LUNG C, V286, pL596, DOI 10.1152/ajplung.00217.2003; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zhao YL, 2002, BRIT J CANCER, V86, P1923, DOI 10.1038/sj.bjc.6600304	49	79	82	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4341	4349		10.1038/sj.onc.1209460	http://dx.doi.org/10.1038/sj.onc.1209460			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518410				2022-12-17	WOS:000239240100009
J	Segrelles, C; Moral, M; Lara, MF; Ruiz, S; Santos, M; Leis, H; Garcia-Escudero, R; Martinez-Cruz, AB; Martinez-Palacio, J; Hernandez, P; Ballestin, C; Paramio, JM				Segrelles, C; Moral, M; Lara, MF; Ruiz, S; Santos, M; Leis, H; Garcia-Escudero, R; Martinez-Cruz, AB; Martinez-Palacio, J; Hernandez, P; Ballestin, C; Paramio, JM			Molecular determinants of Akt-induced keratinocyte transformation	ONCOGENE			English	Article						Akt; myc; CycD; keratinocyte; HNSCC; Wnt pathway	SQUAMOUS-CELL CARCINOMA; GLYCOGEN-SYNTHASE KINASE; MOUSE SKIN CARCINOGENESIS; INTEGRIN-LINKED KINASE; BETA-CATENIN; CYCLIN D1; C-MYC; DEREGULATED EXPRESSION; MAMMALIAN TARGET; TUMOR-SUPPRESSOR	The PI3K/PTEN/Akt signaling pathway has emerged in recent years as a main player in human cancers, increasing proliferation and decreasing apoptosis of transformed cells, and thus becoming a potential target for therapeutic intervention. Our previous data have demonstrated that Akt-mediated signaling is of a key relevance in the mouse skin carcinogenesis system, one of the best-known models of experimental carcinogenesis. Here, we investigated the involvement of several pathways as mediators of Akt-induced increased proliferation and tumorigenesis in keratinocytes. Tumors produced by subcutaneous injection of Akt-transformed keratinocytes showed increased Foxo3a phosphorylation, but no major alterations in p21(Cip1/WAF1), p27(Kip1) or mdm2 expression and/or localization. In contrast, we found increased expression and nuclear localization of Delta Np63, beta-catenin and Lef1. Concomitantly, we also found increased expression of c-myc and CycD1, targets of the beta-catenin/Tcf pathway. Such increase is associated with increased phosphorylation and stabilization of c-myc protein as well as increased translation of c-myc and CycD1 due to mTOR activation. Using immunohistochemistry approaches in samples of oral dysplasias and human head and neck squamous cell carcinomas, we confirmed that increased Akt activation significantly correlates with increased Delta Np63 and CycD expression, c-myc phosphorylation and nuclear accumulation of beta-catenin. Collectively, these results demonstrate that Akt is able to transform keratinocytes by specific mechanisms involving transcriptional and post-transcriptional processes.	CIEMAT, Dept Cell & Mol Biol, E-28040 Madrid, Spain; Hosp 12 Octubre, Dept Pathol, E-28041 Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Hospital Universitario 12 de Octubre	Paramio, JM (corresponding author), CIEMAT, Dept Cell & Mol Biol, Ave Complutense 22, E-28040 Madrid, Spain.	jesusm.paramio@ciemat.es	Santos, Mirentxu/AAA-1727-2020; Segrelles, Carmen/E-3655-2016; Garcia-Escudero, Ramon/A-2735-2012; Paramio, Jesus M/M-8482-2014; Martinez, Jesus/M-3791-2014; Cabanás, María Lara/AAH-3621-2019; Ruiz, Sergio/G-1561-2016	Segrelles, Carmen/0000-0001-9340-2102; Garcia-Escudero, Ramon/0000-0001-5640-6542; Paramio, Jesus M/0000-0001-7520-3177; Martinez, Jesus/0000-0002-9521-8744; Ruiz, Sergio/0000-0002-0177-6965				Ambrosch P, 2000, ANTICANCER RES, V20, P3151; Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Balz V, 2005, ADV OTO-RHINO-LARYNG, V62, P58; Barbieri CE, 2003, J BIOL CHEM, V278, P51408, DOI 10.1074/jbc.M309943200; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Bhatia N, 2005, MOL CARCINOGEN, V42, P213, DOI 10.1002/mc.20077; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Brown J, 2003, CARCINOGENESIS, V24, P171, DOI 10.1093/carcin/24.2.171; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Casanova ML, 2002, CANCER RES, V62, P3402; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Desbois-Mouthon C, 2002, HEPATOLOGY, V36, P1528, DOI 10.1053/jhep.2002.37192; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gotoh J, 2003, CARCINOGENESIS, V24, P435, DOI 10.1093/carcin/24.3.435; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hildesheim J, 2004, ONCOGENE, V23, P1829, DOI 10.1038/sj.onc.1207301; Koga F, 2003, BRIT J CANCER, V88, P740, DOI 10.1038/sj.bjc.6600764; Lawlor MA, 2001, J CELL SCI, V114, P2903; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Ruiz S, 2004, DEV DYNAM, V230, P410, DOI 10.1002/dvdy.20065; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Segrelles C, 2004, CARCINOGENESIS, V25, P1137, DOI 10.1093/carcin/bgh132; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Suzuki A, 2003, CANCER RES, V63, P674; Thurfjell N, 2005, ADV OTO-RHINO-LARYNG, V62, P49; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Warnakulasuriya KAAS, 1998, J ORAL PATHOL MED, V27, P376; YUSPA SH, 1986, CARCINOGENESIS, V7, P949, DOI 10.1093/carcin/7.6.949; Yuspa SH, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P147; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	75	79	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1174	1185		10.1038/sj.onc.1209155	http://dx.doi.org/10.1038/sj.onc.1209155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247457				2022-12-17	WOS:000235537500005
J	Barrier, A; Lemoine, A; Boelle, PY; Tse, C; Brault, D; Chiappini, F; Breittschneider, J; Lacaine, F; Houry, S; Huguier, M; Van der Laan, MJ; Speed, T; Debuire, B; Flahault, A; Dudoit, S				Barrier, A; Lemoine, A; Boelle, PY; Tse, C; Brault, D; Chiappini, F; Breittschneider, J; Lacaine, F; Houry, S; Huguier, M; Van der Laan, MJ; Speed, T; Debuire, B; Flahault, A; Dudoit, S			Colon cancer prognosis prediction by gene expression profiling	ONCOGENE			English	Article						functional genomics; colon cancer; prognosis prediction; non-neoplastic mucosa; cross-validation	CDNA MICROARRAYS; COLORECTAL-CANCER; SURVIVAL; TISSUES; TUMOR; ADENOCARCINOMA; CLASSIFICATION; IDENTIFICATION; FLUOROURACIL; CHEMOTHERAPY	This study assessed the possibility to build a prognosis predictor, based on microarray gene expression measures, in stage II and III colon cancer patients. Tumour ( T) and non-neoplastic mucosa ( NM) mRNA samples from 18 patients ( nine with a recurrence, nine with no recurrence) were pro. led using the Affymetrix HGU133A GeneChip. The k-nearest neighbour method was used for prognosis prediction using T and NM gene expression measures. Six-fold cross-validation was applied to select the number of neighbours and the number of informative genes to include in the predictors. Based on this information, one T-based and one NM-based predictor were proposed and their accuracies were estimated by double cross-validation. In six-fold cross-validation, the lowest numbers of informative genes giving the lowest numbers of false predictions ( two out of 18) were 30 and 70 with the T and NM gene expression measures, respectively. A 30-gene T-based predictor and a 70-gene NM-based predictor were then built, with estimated accuracies of 78 and 83%, respectively. This study suggests that one can build an accurate prognosis predictor for stage II and III colon cancer patients, based on gene expression measures, and one can use either tumour or non-neoplastic mucosa for this purpose.	Univ Paris 06, Hop Tenon, Serv Chirurg Digest, Assistance Publ, F-75020 Paris, France; Univ Paris 06, Fac Med St Antoine, INSERM U444, F-75571 Paris, France; Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA; Univ Paris 11, Hop Paul Brousse, Serv Biochem, INSERM U602, F-94800 Villejuif, France; Univ Paris 06, Hop Tenon, Serv Biochem, Assistance Publ, F-75020 Paris, France; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley	Barrier, A (corresponding author), Univ Paris 06, Hop Tenon, Serv Chirurg Digest, Assistance Publ, F-75020 Paris, France.	barrier@stat.Berkeley.edu	Speed, Terence P/B-8085-2009; Chiappini, Franck/AAB-9894-2021	Speed, Terence P/0000-0002-5403-7998; Chiappini, Franck/0000-0002-2684-1241				Agrawal D, 2002, J NATL CANCER I, V94, P513; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bertucci F, 2004, ONCOGENE, V23, P1377, DOI 10.1038/sj.onc.1207262; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Boland CR, 1998, CANCER RES, V58, P5248; Bustin SA, 2002, TUMOR BIOL, V23, P130, DOI 10.1159/000064029; Cersosimo RJ, 2005, ANN PHARMACOTHER, V39, P128, DOI 10.1345/aph.1E319; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Dudoit S, 2003, STAT SCI, V18, P71, DOI 10.1214/ss/1056397487; Dudoit S, 2003, INTERDISC STAT, P93; Durai R, 2005, INT J COLORECTAL DIS, V20, P203, DOI 10.1007/s00384-004-0675-4; Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356; Frederiksen CM, 2003, J CANCER RES CLIN, V129, P263, DOI 10.1007/s00432-003-0434-x; Hedge P, 2001, CANCER RES, V61, P7792; Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635; Irizarry R. A., 2003, ANAL GENE EXPRESSION, P102; Jiang ZY, 2003, J BIOL CHEM, V278, P31964, DOI 10.1074/jbc.M303314200; Kitahara O, 2001, CANCER RES, V61, P3544; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Notterman DA, 2001, CANCER RES, V61, P3124; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186; Williams NS, 2003, CLIN CANCER RES, V9, P931; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	38	79	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6155	6164		10.1038/sj.onc.1208984	http://dx.doi.org/10.1038/sj.onc.1208984			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16091735	Green Published			2022-12-17	WOS:000231718100009
J	Ruscetti, FW; Akel, S; Bartelmez, SH				Ruscetti, FW; Akel, S; Bartelmez, SH			Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context	ONCOGENE			English	Review						transforming growth factor-beta 1; hematopoiesis; autocrine; stem cells	UMBILICAL-CORD BLOOD; PROTEIN-KINASE PATHWAY; HUMAN MARROW CULTURES; STEM-CELL QUIESCENCE; HUMAN-BONE-MARROW; RECEPTOR-TYPE II; TGF-BETA; SELF-RENEWAL; IN-VIVO; SIGNAL-TRANSDUCTION	Transforming growth factor-beta (TGF-beta) is a pleiotropic regulator of all stages of hematopoieis. The three mammalian isoforms (TGF-beta 1, 2 and 3) have distinct but overlapping effects on hematopoiesis. Depending on the differentiation stage of the target cell, the local environment and the concentration and isoform of TGF-beta, in vivo or in vitro, TGF-beta can be pro- or antiproliferative, pro- or antiapoptotic, pro- or antidifferentiative and can inhibit or increase terminally differentiated cell function. TGF-beta is a major regulator of stem cell quiescence, at least in vitro. TGF-beta can act directly or indirectly through effects on the bone marrow microenvironment. In addition, paracrine and autocrine actions of TGF-beta have overlapping but distinct regulatory effects on hematopoietic stem/progenitor cells. Since TGF-beta can act in numerous steps in the hematopoietic cascade, loss of function mutations in hematopoeitic stem cells (HSC) have different effects on hematopoiesis than transient blockade of autocrine TGF-beta 1. Transient neutralization of autocrine TGF-beta in HSC has therapeutic potential. In myeloid and erythroid leukemic cells, autocrine TGF-beta 1 and/or its Smad signals controls the ability of these cells to respond to various differentiation inducers, suggesting that this pathway plays a role in determining the cell fate of leukemic cells.	NCI, Expt Immunol Lab, Leukocyte Biol Sect, Canc Res Ctr, Frederick, MD 21702 USA; Hashemite Univ, Dept Med Lab Sci, Zarqa, Jordan; Hemogenix Inc, Colorado Springs, CO USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hashemite University	Ruscetti, FW (corresponding author), NCI, Expt Immunol Lab, Leukocyte Biol Sect, Canc Res Ctr, Bldg 567,RM 251, Frederick, MD 21702 USA.	Ruscettif@ncifcrf.gov			NATIONAL CANCER INSTITUTE [Z01BC009264, Z01BC010252] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R44EY028070] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline; NEI NIH HHS [R44 EY028070] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Akel S, 2003, STEM CELLS, V21, P557, DOI 10.1634/stemcells.21-5-557; ALGIETTA M, 1989, EXP HEMATOL, V17, P296; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Bartelmez SH, 2000, BLOOD, V96, p474A; Batard P, 2000, J CELL SCI, V113, P383; Bertoncello Ivan, 2004, Methods Mol Biol, V263, P181; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Birchenall-Roberts MC, 2004, J BIOL CHEM, V279, P25605, DOI 10.1074/jbc.M402790200; Borkowski TA, 1997, J CLIN INVEST, V100, P575, DOI 10.1172/JCI119567; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; CASHMAN JD, 1990, BLOOD, V75, P96; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Chen CZ, 2002, P NATL ACAD SCI USA, V99, P15468, DOI 10.1073/pnas.202614899; Chen CZ, 2003, IMMUNITY, V19, P525, DOI 10.1016/S1074-7613(03)00265-6; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Defacque H, 1999, J CELL PHYSIOL, V178, P109, DOI 10.1002/(SICI)1097-4652(199901)178:1<109::AID-JCP14>3.3.CO;2-O; DEXTER TM, 1979, ACTA HAEMATOL-BASEL, V62, P299, DOI 10.1159/000207593; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DUBOIS CM, 1994, BLOOD, V83, P3138; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; DYBEDAL I, 1995, BLOOD, V86, P949; Dybedal I, 1997, BLOOD, V90, P3395, DOI 10.1182/blood.V90.9.3395; EAVES CJ, 1991, BLOOD, V78, P110; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fan XL, 2002, J IMMUNOL, V168, P755, DOI 10.4049/jimmunol.168.2.755; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Grady WM, 1999, CANCER RES, V59, P320; GREENBERGER JS, 1983, FED PROC, V42, P2762; Hampson J, 1989, GROWTH FACTORS, V1, P193, DOI 10.3109/08977198909029128; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hatzfeld A, 1996, HUM GENE THER, V7, P207, DOI 10.1089/hum.1996.7.2-207; HATZFELD J, 1994, BLOOD CELLS, V20, P430; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; Imbert AM, 1998, EXP HEMATOL, V26, P374; JACOBSEN SEW, 1991, BLOOD, V77, P1706; JACOBSEN SEW, 1994, EXP HEMATOL, V22, P985; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; JACOBSEN SEW, 1992, J EXP MED, V175, P1759, DOI 10.1084/jem.175.6.1759; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Kalina U, 2001, EXP HEMATOL, V29, P602, DOI 10.1016/S0301-472X(01)00628-2; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1990, BLOOD, V75, P596; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; Kitamura K, 2000, BLOOD, V95, P3371, DOI 10.1182/blood.V95.11.3371.011k37_3371_3379; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; KUTER DJ, 1992, BLOOD, V79, P619; Langer JC, 2004, J EXP MED, V199, P5, DOI 10.1084/jem.20030980; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Larsson J, 2005, EXP HEMATOL, V33, P592, DOI 10.1016/j.exphem.2005.02.003; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Laughlin MJ, 2001, BONE MARROW TRANSPL, V27, P1, DOI 10.1038/sj.bmt.1702740; LETTERIO J, 1998, J CLIN INVEST, V98, P2109; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; Lieb E, 2004, TISSUE ENG, V10, P1414, DOI 10.1089/ten.2004.10.1414; LORD BI, 1990, INT J CELL CLONING, V8, P317, DOI 10.1002/stem.5530080501; LU L, 1993, EXP HEMATOL, V21, P1442; Mancini SJC, 2005, BLOOD, V105, P2340, DOI 10.1182/blood-2004-08-3207; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474-9728.2004.00127.x; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NARA N, 1989, LEUKEMIA, V3, P572; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; NOLTA JA, 1990, HUM GENE THER, V1, P257, DOI 10.1089/hum.1990.1.3-257; OGAWA M, 1993, BLOOD, V81, P2844; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OMAY SB, 1995, EXP HEMATOL, V23, P244; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; Pierelli L, 2000, BLOOD, V95, P3001; PLOEMACHER RE, 1993, STEM CELLS, V11, P336, DOI 10.1002/stem.5530110412; Quesenberry PJ, 1998, P NATL ACAD SCI USA, V95, P15155, DOI 10.1073/pnas.95.26.15155; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; ROJNUCKARIN P, 1995, BLOOD, V85, P402; Rooke HM, 1999, LEUKEMIA, V13, P535, DOI 10.1038/sj.leu.2401384; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Ruscetti FW, 2001, INT J HEMATOL, V74, P18, DOI 10.1007/BF02982545; Ruscetti FW, 1999, BLOOD, V94, p466A; Sakamaki S, 1999, BLOOD, V94, P1961, DOI 10.1182/blood.V94.6.1961.418k17_1961_1970; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SING GK, 1988, BLOOD, V72, P1504; Sitnicka E, 1996, BLOOD, V88, P82; Soma T, 1996, BLOOD, V87, P4561, DOI 10.1182/blood.V87.11.4561.bloodjournal87114561; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Sorrentino BP, 2004, NAT REV IMMUNOL, V4, P878, DOI 10.1038/nri1487; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Stier S, 2003, BLOOD, V102, P1260, DOI 10.1182/blood-2002-10-3053; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; TESSIER N, 1988, BLOOD, V72, P159; Tsimberidou Apostolia-Maria, 2002, Expert Rev Anticancer Ther, V2, P437, DOI 10.1586/14737140.2.4.437; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; Verma A, 2002, J BIOL CHEM, V277, P7726, DOI 10.1074/jbc.M106640200; WAEGELL WO, 1994, EXP HEMATOL, V22, P1051; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wiesmann A, 2000, EXP HEMATOL, V28, P128, DOI 10.1016/S0301-472X(99)00141-1; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Witt O, 2000, BLOOD, V95, P2391, DOI 10.1182/blood.V95.7.2391.007k21_2391_2396; WOLF NS, 1993, EXP HEMATOL, V21, P614; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Yang LP, 2005, BLOOD, V105, P2717, DOI 10.1182/blood-2004-06-2159; Yang LP, 2005, J IMMUNOL, V174, P752, DOI 10.4049/jimmunol.174.2.752; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; Yu J, 1998, GENE THER, V5, P1265, DOI 10.1038/sj.gt.3300732; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhu T, 1997, ARCH BIOCHEM BIOPHYS, V339, P210, DOI 10.1006/abbi.1996.9835	141	79	90	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5751	5763		10.1038/sj.onc.1208921	http://dx.doi.org/10.1038/sj.onc.1208921			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123808				2022-12-17	WOS:000231452800010
J	Liu, JW; Chandra, D; Rudd, MD; Butler, AP; Pallotta, V; Brown, D; Coffer, PJ; Tang, DG				Liu, JW; Chandra, D; Rudd, MD; Butler, AP; Pallotta, V; Brown, D; Coffer, PJ; Tang, DG			Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS	ONCOGENE			English	Article						apoptosis; Bim; Bcl-2; ROS; FOXO3a; MnSOD; cancer therapy	BCL-2 FAMILY-MEMBER; REACTIVE OXYGEN; TRANSCRIPTION FACTORS; CELL-SURVIVAL; CYTOCHROME-C; KAPPA-B; ACTIVATION; EXPRESSION; BIM; DEATH	Most cancer therapeutics fails to eradicate cancer because cancer cells rapidly develop resistance to its proapoptotic effects. The underlying mechanisms remain incompletely understood. Here we show that three representative apoptotic stimuli, that is, serum starvation, a mitochondrial toxin, and a DNA-damaging agent (etoposide), rapidly induce several distinct classes of prosurvival molecules, in particular, Bcl-2/Bcl-X-L and superoxide dismutase (SOD; including both MnSOD and Cu/ZnSOD). At the population level, the induction of these prosurvival molecules occurs prior to or concomitant with the induction of proapoptotic molecules such as Bim and Bak. Blocking the induction using siRNAs of the prosurvival or proapoptotic molecules facilitates or inhibits apoptosis, respectively. One master transcription factor, FOXO3a, is involved in the transcriptional activation of some of these prosurvival (e. g., MnSOD) and proapoptotic (e. g., Bim) molecules. Interestingly, in all three apoptotic systems, FOXO3a itself is also upregulated at the transcriptional level. Mechanistic studies indicate that reactive oxygen species (ROS) are rapidly induced upon apoptotic stimulation and that ROS inhibitors/scavengers block the induction of FOXO3a, MnSOD, and Bim. Finally, we show that apoptotic stimuli also upregulate prosurvival molecules in normal diploid human fibroblasts and at subapoptotic concentrations. Taken together, these results suggest that various apoptotic inducers may rapidly mobilize prosurvival mechanisms through ROS-activated master transcription factors such as FOXO3a. The results imply that effective anticancer therapeutics may need to combine both apoptosis-inducing and survival-suppressing strategies.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div 1C, Smithville, TX 78957 USA; Ambion Inc, Austin, TX 78744 USA; Univ Utrecht, Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	University of Texas System; UTMD Anderson Cancer Center; Utrecht University	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020; Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Chandra D, 2003, J BIOL CHEM, V278, P17408, DOI 10.1074/jbc.M300750200; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong Z, 2004, J BIOL CHEM, V279, P9215, DOI 10.1074/jbc.M312225200; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Joshi B, 1999, CANCER RES, V59, P4343; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Liu JW, 2002, CANCER RES, V62, P2976; Martin AG, 2002, J BIOL CHEM, V277, P50834, DOI 10.1074/jbc.M209369200; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Sade H, 2004, CELL DEATH DIFFER, V11, P416, DOI 10.1038/sj.cdd.4401347; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tang DG, 1998, CANCER RES, V58, P3466; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; Valks DM, 2003, J BIOL CHEM, V278, P25542, DOI 10.1074/jbc.M303760200; Zhao YG, 2003, J BIOL CHEM, V278, P2356, DOI 10.1074/jbc.M209681200	45	79	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2020	2031		10.1038/sj.onc.1208385	http://dx.doi.org/10.1038/sj.onc.1208385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674333				2022-12-17	WOS:000227681900006
J	Heidenblad, M; Lindgren, D; Veltman, JA; Jonson, T; Mahlamaki, EH; Gorunova, L; van Kessel, AG; Schoenmakers, EFPM; Hoglund, M				Heidenblad, M; Lindgren, D; Veltman, JA; Jonson, T; Mahlamaki, EH; Gorunova, L; van Kessel, AG; Schoenmakers, EFPM; Hoglund, M			Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic implications	ONCOGENE			English	Article						expression profiling; genomic profiling; microarray; pancreatic cancer	AMPLIFICATION; EXPRESSION; GENES; CARCINOMAS; TUMORS; 18Q; 12P; 15Q	DNA copy number alterations are believed to play a major role in the development and progression of human neoplasms. Although most of these genomic imbalances have been associated with dysregulation of individual genes, their large-scale transcriptional consequences remain unclear. Pancreatic carcinomas frequently display gene copy number variation of entire chromosomes as well as of chromosomal subregions. These changes range from homozygous deletions to high-level amplifications and are believed to constitute key genetic alterations in the cellular transformation of this tumor type. To investigate the transcriptional consequences of the most drastic genomic changes, that is, genomic amplifications, and to analyse the genome-wide transcriptional effects of DNA copy number changes, we performed expression pro. ling of 29 pancreatic carcinoma cell lines and compared the results with matching genomic pro. ling data. We show that a strong association between DNA copy numbers and mRNA expression levels is present in pancreatic cancer, and demonstrate that as much as 60% of the genes within highly amplified genomic regions display associated overexpression. Consequently, we identified 67 recurrently overexpressed genes located in seven precisely mapped commonly amplified regions. The presented findings indicate that more than one putative target gene may be of importance in most pancreatic cancer amplicons.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Tampere, Canc Genet Lab, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland	Lund University; Skane University Hospital; Radboud University Nijmegen; Tampere University; Tampere University; Tampere University Hospital	Heidenblad, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	markus.heidenblad@klingen.lu.se	Veltman, Joris A/F-5128-2010; van Kessel, Ad Geurts/A-2810-2010	Veltman, Joris A/0000-0002-3218-8250; Hoglund, Mattias/0000-0001-9283-4421				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Gorunova L, 1998, GENE CHROMOSOME CANC, V23, P81, DOI 10.1002/(SICI)1098-2264(199810)23:2<81::AID-GCC1>3.0.CO;2-0; HAHN SA, 1995, CANCER RES, V55, P4670; Heidenblad M, 2004, CANCER RES, V64, P3052, DOI 10.1158/0008-5472.CAN-03-3159; Heidenblad M, 2002, GENE CHROMOSOME CANC, V34, P211, DOI 10.1002/gcc.10063; Hyman E, 2002, CANCER RES, V62, P6240; Jonson T, 1999, GENE CHROMOSOME CANC, V24, P62, DOI 10.1002/(SICI)1098-2264(199901)24:1<62::AID-GCC9>3.0.CO;2-4; Mahlamaki EH, 2004, NEOPLASIA, V6, P432, DOI 10.1593/neo.04130; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; Mertens F, 1997, CANCER RES, V57, P2765; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Saal LH, 2002, GENOME BIOL, V3; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01	17	79	83	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1794	1801		10.1038/sj.onc.1208383	http://dx.doi.org/10.1038/sj.onc.1208383			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688027				2022-12-17	WOS:000227345100015
J	Levina, E; Oren, M; Ben-Ze'ev, A				Levina, E; Oren, M; Ben-Ze'ev, A			Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics	ONCOGENE			English	Article						beta-catenin degradation by p53; Axin; beta-catenin-phosphorylation	TRANSCRIPTION FACTOR LEF-1; WNT SIGNALING PATHWAY; APC TUMOR-SUPPRESSOR; COLORECTAL-CANCER; COLON-CARCINOMA; CYCLIN D1; PROTEIN; ACTIVATION; COMPLEX; TARGET	beta-Catenin, a structural component of cell-cell adhesions, is also a potent signaling molecule in the Wnt pathway activating target genes together with Lef/Tcf transcription factors. In colorectal and many other types of cancer, beta-catenin is hyperactive owing to mutations in beta-catenin, or in components regulating beta-catenin degradation. Deregulated beta-catenin can cause the activation of p53, a key tumor suppressor mutated in most cancers. Activated p53 can feed back and downregulate beta-catenin. Here we investigated the mechanisms involved in downregulation of beta-catenin by p53. We found that the p53-mediated reduction in beta-catenin involves enhanced phosphorylation of beta-catenin on key NH2-terminal serines and requires CK1 and GSK-3beta activities, both being components of the beta-catenin degradation machinery. Mutations in these NH2-terminal beta-catenin serines blocked the ability of p53 to enhance the turnover of beta-catenin. p53 also induced a shift in the distribution of the scaffold molecule Axin to a Triton X-100-soluble fraction, and led to depletion of beta-catenin from this Triton-soluble fraction. The majority of Axin and phosphorylated beta-catenin, however, colocalized in Triton X-100-insoluble punctate aggregates near the plasma membrane, and kinetics studies indicated that in the presence of p53 the movement of Axin into and out of the Triton X-100-insoluble fraction is accelerated. These results suggest that p53 induces a faster mobilization of Axin into the degradation complex thereby enhancing beta-catenin turnover as part of a protective mechanism against the development of cancer.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		ben-ze'ev, avri/0000-0001-6113-3921				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hu G, 1999, MOL CELL BIOL, V19, P724; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	48	79	84	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4444	4453		10.1038/sj.onc.1207587	http://dx.doi.org/10.1038/sj.onc.1207587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064706				2022-12-17	WOS:000221661300010
J	Janne, PA; Li, C; Zhao, XJ; Girard, L; Chen, TH; Minna, J; Christiani, DC; Johnson, BE; Meyerson, M				Janne, PA; Li, C; Zhao, XJ; Girard, L; Chen, TH; Minna, J; Christiani, DC; Johnson, BE; Meyerson, M			High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines	ONCOGENE			English	Article						lung neoplasm; non-small cell; small-cell carcinoma; loss of heterozygosity; single-nucleotide polymorphism	GENOME-WIDE DETECTION; GENE-EXPRESSION; TUMOR PROGRESSION; BLADDER-CANCER; ADENOCARCINOMA; CARCINOMAS; CLASSIFICATION; PATTERNS; SURVIVAL; DNA	Chromosomal loss of heterozygosity (LOH) is a common mechanism for the inactivation of tumor suppressor genes in human epithelial cancers. Hybridization to single-nucleotide polymorphism (SNP) arrays is an efficient method to detect genome-wide cancer LOH. Here, we survey LOH patterns in a panel of 33 human lung cancer cell lines using SNP array hybridization containing 1500 SNPs. We compared the LOH patterns generated by SNP array hybridization to those previously obtained by 399 microsatellite markers and find a high degree of concordance between the two methods. A novel informatics platform, dChipSNP, was used to perform hierarchical tumor clustering based on genome-wide LOH patterns. We demonstrate that this method can separate non-small-cell and small-cell lung cancer samples based on their shared LOH. Furthermore, we analysed seven human lung cancer cell lines using a novel 10000 SNP array and demonstrate that this is an efficient and reliable method of high-density allelotyping. Using this array, we identified small regions of LOH that were not detected by lower density SNP arrays or by standard microsatellite marker panels.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Massachusetts General Hospital	Meyerson, M (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Mayer 446,44 Binney St, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Meyerson, Matthew L/E-7123-2012; Wang, Weili/D-1546-2011		NCI NIH HHS [R01CA92824, P50CA70907, 2P30 CA06516-39, 1K12CA87723-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092824, P50CA070907, K12CA087723, P30CA006516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Dumur CI, 2003, GENOMICS, V81, P260, DOI 10.1016/S0888-7543(03)00020-X; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FONG KM, 1994, GENE CHROMOSOME CANC, V10, P183, DOI 10.1002/gcc.2870100306; FONG KM, 1995, CANCER RES, V55, P220; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Girard L, 2000, CANCER RES, V60, P4894; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hoque MO, 2003, CANCER RES, V63, P2216; JANNE PA, 2002, P AM ASS CAN RES, V43, pA3147; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lieberfarb ME, 2003, CANCER RES, V63, P4781; LIN M, 2003, IN PRESS BIOINFORMAT; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Primdahl H, 2002, J NATL CANCER I, V94, P216; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; Tseng JE, 1999, CANCER RES, V59, P4798; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WANG ZC, 2003, IN PRESS CANC RES; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	30	79	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2716	2726		10.1038/sj.onc.1207329	http://dx.doi.org/10.1038/sj.onc.1207329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048096				2022-12-17	WOS:000220714900013
J	Bothos, J; Summers, MK; Venere, M; Scolnick, DM; Halazonetis, TD				Bothos, J; Summers, MK; Venere, M; Scolnick, DM; Halazonetis, TD			The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains	ONCOGENE			English	Article						checkpoint; mitosis; ubiquitination; Chfr; Ubc13	UBIQUITIN LIGASE ACTIVITY; RING-FINGER DOMAIN; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; FHA DOMAIN; STRESS CHECKPOINT; DNA-REPAIR; CPG ISLAND; HYPERMETHYLATION; COMPLEX	We recently described a novel checkpoint pathway that functions early in mitosis to delay chromosome condensation in response to microtubule poisons. The only gene implicated so far in this checkpoint pathway is chfr, whose protein product contains a RING domain and has ubiquitin ligase activity in vitro. The significance of this activity in vivo is unclear. A recent report suggested that the Chfr protein targets itself for proteasome-dependent degradation in mitotic cells through autoubiquitination. However, we observe that in mitosis Chfr exhibits a phosphorylation-dependent electrophoretic mobility shift with no change in overall protein levels. Further analysis of its ubiquitin ligase activity revealed that Chfr can catalyse the formation of noncanonical Lys63-linked polyubiquitin chains with Ubc13-Mms2 acting as the ubiquitin-conjugating enzyme. Ubc13-Mms2 and Lys63-polyubiquitin chains are not associated with targeting proteins to the proteasome, but rather with signaling cellular stress. We propose that Chfr may have a role in signaling the presence of mitotic stress induced by microtubule poisons.	Univ Penn, Wistar Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Program, Philadelphia, PA 19104 USA; Univ Penn, Program Biochem & Biophys, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Halazonetis, TD (corresponding author), Univ Penn, Wistar Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.		Halazonetis, Thanos/D-7923-2011		NCI NIH HHS [CA09171, CA09677, CA89630] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089630, T32CA009677, T32CA009171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; Chaturvedi P, 2002, CANCER RES, V62, P1797; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; Xiao W, 2000, GENETICS, V155, P1633; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	27	79	85	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7101	7107		10.1038/sj.onc.1206831	http://dx.doi.org/10.1038/sj.onc.1206831			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562038				2022-12-17	WOS:000185955000001
J	Tolg, C; Poon, R; Fodde, R; Turley, EA; Alman, BA				Tolg, C; Poon, R; Fodde, R; Turley, EA; Alman, BA			Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive. bromatosis (desmoid tumor)	ONCOGENE			English	Article						aggressive fibromatosis; Rhamm; beta-catenin; transgenic mice; adenomatous polyposis coli; density-dependent proliferation; hyaladherin	ACTIVATED PROTEIN-KINASE; BINDING-PROTEIN; BETA-CATENIN; ADHESION MOLECULES; BREAST-CANCER; MOUSE MODEL; EXPRESSION; FIBROMATOSIS; CELLS; CD44	Aggressive. bromatosis (desmoid tumor) is a locally invasive soft tissue neoplasm associated with mutations resulting in beta-catenin-mediated transcriptional activation. This tumor is composed of cells with histological and molecular characteristics common to proliferating mesenchymal cells of dermal wounds. Using immunohistochemistry and RT-PCR, we show that Rhamm, a protein with an important role in wound healing and neoplastic progression, is also expressed at high levels in aggressive. bromatosis. A mouse harboring a targeted deletion in Rhamm was generated, resulting in viable Rhamm-/- animals. Rhamm-/- mice were crossed with Apc/Apc1638N mice, which harbor a targeted mutation in the Apc gene predisposing animals to gastrointestinal and aggressive. bromatosis tumors. Rhamm deficiency significantly decreased the number of aggressive. bromatosis tumors formed, but did not alter the number of gastrointestinal polyps. Cell culture studies show that Rhamm regulates cell proliferation in both fibroblasts and. bromatosis cells under conditions of low density, but not high density. These results suggest that Rhamm regulates proliferation of cells with sparse cell-cell contacts, such as occurs in aggressive. bromatosis; provides the first genetic evidence implicating Rhamm in tumor pathology; and suggest Rhamm blockade as a potential therapeutic target for this otherwise difficult-to-treat neoplasm.	Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Western Ontario, Dept Oncol, London, ON N6A 3K7, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 3K7, Canada; London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada; Leiden Univ, Med Ctr, MGC Human & Clin Genet, NL-2333 AL Leiden, Netherlands; Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Alman, BA (corresponding author), Hosp Sick Children, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca	Fodde, Riccardo/AAW-9394-2021	Fodde, Riccardo/0000-0001-9839-4324				Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Assmann V, 1999, J CELL SCI, V112, P3943; Assmann V, 2001, J PATHOL, V195, P191, DOI 10.1002/path.941; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Cheung WF, 1999, BIOCHEM SOC T, V27, P135, DOI 10.1042/bst0270135; Crainie M, 1999, BLOOD, V93, P1684, DOI 10.1182/blood.V93.5.1684.405k22_1684_1696; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gares S L, 2000, Dev Immunol, V7, P209, DOI 10.1155/2000/94616; Gerdin B, 1997, J INTERN MED, V242, P49, DOI 10.1046/j.1365-2796.1997.00173.x; Gutierrez-Ruiz MC, 2002, ARCH MED RES, V33, P595, DOI 10.1016/S0188-4409(02)00408-3; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; Hall CL, 1996, ONCOGENE, V13, P2213; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503; Kong QY, 2003, ONCOL REP, V10, P51; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Li H, 2000, INT J ONCOL, V17, P927; Line A, 2002, CANCER IMMUNOL IMMUN, V51, P574, DOI 10.1007/s00262-002-0322-2; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; Lovvorn HN, 1998, J PEDIATR SURG, V33, P1062, DOI 10.1016/S0022-3468(98)90532-2; Lynn BD, 2001, J COMP NEUROL, V439, P315, DOI 10.1002/cne.1353; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Naor D, 1998, CURR TOP MICROBIOL, V231, P143; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PILARSKI LM, 1994, LEUKEMIA LYMPHOMA, V14, P363, DOI 10.3109/10428199409049691; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; SAVANI RC, 1995, J CLIN INVEST, V95, P1158, DOI 10.1172/JCI117764; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; SPICER AP, 1995, GENOMICS, V30, P115, DOI 10.1006/geno.1995.0022; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tejpar S, 2001, BRIT J CANCER, V85, P98, DOI 10.1054/bjoc.2001.1857; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; TURLEY E, 1989, EXP CELL RES, V182, P340, DOI 10.1016/0014-4827(89)90239-5; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1985, J CELL SCI, V78, P133; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; TURLEY EA, 1982, BIOCHEM BIOPH RES CO, V108, P1016, DOI 10.1016/0006-291X(82)92101-5; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Wang C, 1998, CLIN CANCER RES, V4, P567; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342; Zhou RX, 2002, J NEURO-ONCOL, V59, P15, DOI 10.1023/A:1016373015569	56	79	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6873	6882		10.1038/sj.onc.1206811	http://dx.doi.org/10.1038/sj.onc.1206811			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534534				2022-12-17	WOS:000185843400008
J	Clancy, JL; Henderson, MJ; Russell, AJ; Anderson, DW; Bova, RJ; Campbell, IG; Choong, DYH; Macdonald, GA; Mann, GJ; Nolan, T; Brady, G; Olopade, OI; Woollatt, E; Davies, MJ; Segara, D; Hacker, NF; Henshall, SM; Sutherland, RL; Watts, CKW				Clancy, JL; Henderson, MJ; Russell, AJ; Anderson, DW; Bova, RJ; Campbell, IG; Choong, DYH; Macdonald, GA; Mann, GJ; Nolan, T; Brady, G; Olopade, OI; Woollatt, E; Davies, MJ; Segara, D; Hacker, NF; Henshall, SM; Sutherland, RL; Watts, CKW			EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer	ONCOGENE			English	Article						allelic imbalance; amplification; human neoplasms; gene expression; mutation	COMPARATIVE-GENOMIC-HYBRIDIZATION; POSTERIOR UVEAL MELANOMA; SQUAMOUS-CELL CARCINOMA; DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; OVARIAN-TUMORS; COPY NUMBER; FREQUENT MULTIPLICATION; CYTOGENETIC ANALYSIS	EDD (E3 isolated by differential display), located at chromosome 8q22.3, is the human orthologue of the Drosophila melanogaster tumour suppressor gene 'hyperplastic discs' and encodes a HECT domain E3 ubiquitin protein-ligase. To investigate the possible involvement of EDD in human cancer, several cancers from diverse tissue sites were analysed for allelic gain or loss (allelic imbalance, AI) at the EDD locus using an EDD-specific microsatellite, CEDD, and other polymorphic microsatellites mapped in the vicinity of the 8q22.3 locus. Of 143 cancers studied, 38 had AI at CEDD (42% of 90 informative cases). In 14 of these cases, discrete regions of imbalance encompassing 8q22.3 were present, while the remainder had more extensive 8q aberrations. AI of CEDD was most frequent in ovarian cancer (22/47 informative cases, 47%), particularly in the serous subtype (16/22, 73%), but was rare in benign and borderline ovarian tumours. AI was also common in breast cancer (31%), hepatocellular carcinoma (46%), squamous cell carcinoma of the tongue (50%) and metastatic melanoma (18%). AI is likely to represent amplification of the EDD gene locus rather than loss of heterozygosity, as quantitative RT-PCR and immunohistochemistry showed that EDD mRNA and protein are frequently overexpressed in breast and ovarian cancers, while among breast cancer cell lines EDD overexpression and increased gene copy number were correlated. These results demonstrate that AI at the EDD locus is common in a diversity of carcinomas and that the EDD gene is frequently overexpressed in breast and ovarian cancer, implying a potential role in cancer progression.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; NIDCD, Mol Genet Lab, NIH, Rockville, MD USA; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia; Univ Queensland, Populat & Clin Sci Div, Queensland Inst Med Res, Brisbane, Qld, Australia; Univ Queensland, Dept Med, Brisbane, Qld, Australia; Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England; Univ Chicago, Med Ctr, Ctr Med Genet, Chicago, IL 60637 USA; Womens & Childrens Hosp, Ctr Med Genet, Adelaide, SA, Australia; Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Peter Maccallum Cancer Center; QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; University of Sydney; Westmead Institute for Medical Research; University of Manchester; University of Chicago; University of Chicago Medical Center; Womens & Childrens Hospital Australia	Watts, CKW (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		henderson, Michelle/G-6657-2012; Sutherland, Robert L/A-8378-2008; campbell, Ian G/F-6006-2011; Mann, Graham J/G-4758-2014; Macdonald, Graeme A/K-4167-2013	Mann, Graham J/0000-0003-1301-405X; Macdonald, Graeme A/0000-0003-0929-110X; Hacker, Neville/0000-0002-1445-2302; Campbell, Ian/0000-0002-7773-4155				Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Al-Taher A, 2000, YEAST, V17, P201, DOI 10.1002/1097-0061(20000930)17:3<201::AID-YEA30>3.0.CO;2-R; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; Bova RJ, 1999, CLIN CANCER RES, V5, P2810; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Dahiya R, 1998, INT J ONCOL, V12, P811; Diebold J, 1996, LAB INVEST, V75, P473; ElNaggar AK, 1997, AM J SURG PATHOL, V21, P691, DOI 10.1097/00000478-199706000-00009; Fejzo MS, 1998, GENE CHROMOSOME CANC, V22, P105; Forozan F, 2000, CANCER RES, V60, P4519; FUJIWARA Y, 1993, CANCER RES, V53, P857; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Hermsen MAJA, 1997, ORAL ONCOL, V33, P414, DOI 10.1016/S0964-1955(97)00031-6; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Indsto JO, 1998, CANCER GENET CYTOGEN, V100, P68, DOI 10.1016/S0165-4608(97)00016-2; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Knuutila S, 1998, AM J PATHOL, V152, P1107; Lee JD, 2002, DEVELOPMENT, V129, P5697, DOI 10.1242/dev.00159; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Mark HFL, 1997, PATHOBIOLOGY, V65, P184, DOI 10.1159/000164121; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; Mori Y, 2002, CANCER RES, V62, P3641; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NAWROZ H, 1994, CANCER RES, V54, P1152; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nogradi A, 1998, AM J PATHOL, V153, P1, DOI 10.1016/S0002-9440(10)65537-X; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Obata K, 1998, CANCER RES, V58, P2095; Orntoft TF, 2002, MOL CELL PROTEOMICS, V1, P37, DOI 10.1074/mcp.M100019-MCP200; Parrella P, 1999, CANCER RES, V59, P3032; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Pieretti M, 1995, INT J CANCER, V64, P434, DOI 10.1002/ijc.2910640614; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Seute A, 2001, INT J CANCER, V93, P80, DOI 10.1002/ijc.1296.abs; Sisley K, 1997, GENE CHROMOSOME CANC, V19, P22, DOI 10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2; Sutherland R.L., 1999, HUMAN CELL CULTURE, P79; Tsuneizumi M, 2001, CLIN CANCER RES, V7, P3526; vanDekken H, 1997, HISTOCHEM CELL BIOL, V108, P419, DOI 10.1007/s004180050182; Wong N, 1999, AM J PATHOL, V154, P37, DOI 10.1016/S0002-9440(10)65248-0; Wu XT, 1997, MUTAT RES-DNA REPAIR, V385, P13, DOI 10.1016/S0921-8777(97)00035-9; Yamaguchi T, 2001, CANCER RES, V61, P8256; Yokota T, 1999, CANCER LETT, V139, P7, DOI 10.1016/S0304-3835(98)00329-2	53	79	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5070	5081		10.1038/sj.onc.1206775	http://dx.doi.org/10.1038/sj.onc.1206775			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902990				2022-12-17	WOS:000184578900015
J	Franchitto, A; Pichierri, P; Piergentili, R; Crescenzi, M; Bignami, M; Palitti, F				Franchitto, A; Pichierri, P; Piergentili, R; Crescenzi, M; Bignami, M; Palitti, F			The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase	ONCOGENE			English	Article						MSH2; mismatch repair; cell cycle arrest; DSB repair	STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE MSH2; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; GENETIC-RECOMBINATION; NUCLEAR FOCI; HISTONE H2AX; IN-VITRO; S-PHASE	In yeast, MSH2 plays an important role in mismatch repair (MMR) and recombination, whereas the function of the mammalian MSH2 protein in recombinational repair is not completely established. We examined the cellular responses of MSH2-deficient mouse cells to X-rays to clarify the role of MSH2 in recombinational repair. Cell survival, checkpoint functions and relocalization of the recombination-related proteins MRE11 and RAD51 were analysed in embryonic fibroblasts derived from MSH2(+/+) and MSH2(-/-) mice, and in MSH2-proficient and deficient mouse colorectal carcinoma cells. Loss of MSH2 function was found to be associated with reduction in cell survival following radiation, absence of either MRE11 or RAD51 relocalization and a higher level of X-ray-induced chromosomal damage specifically in G2-phase cells. Finally, MSH2(-/-) cells showed an inefficient early G2/M checkpoint, being arrested only transiently after irradiation before progressing into mitosis. Consistent with the premature release from the G2-phase arrest, activation of CHK1 was transient and CHK2 was not phosphorylated in synchronized MSH2-null cells. Our data suggest that an active MSH2 is required for a correct response to ionizing radiation-induced DNA damage in the G2 phase of the cell cycle, possibly connecting DSB repair to checkpoint signalling.	Univ Tuscia, DABAC, Lab Citogenet Mol & Mutagenesi, I-01100 Viterbo, Italy; Ist Super Sanita, Tossicol Comparata & Ecotossicol Lab, I-00161 Rome, Italy	Tuscia University; Istituto Superiore di Sanita (ISS)	Palitti, F (corresponding author), Univ Tuscia, DABAC, Lab Citogenet Mol & Mutagenesi, Via S Camillo Lellis, I-01100 Viterbo, Italy.	palitti@unitus.it	Pichierri, Pietro/AAA-5476-2021; Crescenzi, Marco/J-3603-2018; Franchitto, Annapaola/K-7564-2016	Pichierri, Pietro/0000-0002-2702-3523; Crescenzi, Marco/0000-0003-0156-1494; Franchitto, Annapaola/0000-0003-4232-4727				Aebi S, 1996, CANCER RES, V56, P3087; ALANI E, 1994, GENETICS, V137, P19; Anthoney DA, 1996, CANCER RES, V56, P1374; Aquilina G, 1999, CARCINOGENESIS, V20, P2317, DOI 10.1093/carcin/20.12.2317; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Berry SE, 2001, SEMIN RADIAT ONCOL, V11, P300, DOI 10.1053/S1053-4296(01)80067-9; Boersma AWM, 1996, CYTOMETRY, V24, P123, DOI 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO;2-K; BRADLEY MO, 1979, NUCLEIC ACIDS RES, V7, P793, DOI 10.1093/nar/7.3.793; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen WL, 1999, GENETICS, V151, P1299; Chen WL, 1998, MOL CELL BIOL, V18, P6525, DOI 10.1128/MCB.18.11.6525; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Datta A, 1996, MOL CELL BIOL, V16, P1085; Davis TW, 1998, CANCER RES, V58, P767; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fiumicino S, 2000, INT J CANCER, V85, P590, DOI 10.1002/(SICI)1097-0215(20000215)85:4<590::AID-IJC23>3.0.CO;2-O; Franchitto A, 1998, MUTAGENESIS, V13, P499, DOI 10.1093/mutage/13.5.499; Fritzell JA, 1997, CANCER RES, V57, P5143; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Palitti F, 1999, INT J RADIAT BIOL, V75, P621, DOI 10.1080/095530099140267; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVAGE JRK, 1976, J MED GENET, V13, P103, DOI 10.1136/jmg.13.2.103; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XXS, 2001, CANCER RES, V61, P3775; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yan T, 2001, CANCER RES, V61, P8290; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 2000, CARCINOGENESIS, V21, P1639, DOI 10.1093/carcin/21.9.1639; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	64	79	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2110	2120		10.1038/sj.onc.1206254	http://dx.doi.org/10.1038/sj.onc.1206254			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687013				2022-12-17	WOS:000182066900005
J	Bocchetta, M; Miele, L; Pass, HI; Carbone, M				Bocchetta, M; Miele, L; Pass, HI; Carbone, M			Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells	ONCOGENE			English	Article						SV40; DNA tumor viruses; carcinogenicity; mesothelioma; notch-1	SMALL-T-ANTIGEN; SIMIAN-VIRUS-40; TRANSFORMATION; DIFFERENTIATION; EXPRESSION; ASBESTOS; PROTEIN; SEL-10; TRANSACTIVATION; PATHOGENESIS	We show that SV40 infection of human mesothelial cells directly causes overexpression of Notch-1, a key cell regulatory gene. Notch-1 induction is achieved at the transcriptional level and requires both the SV40 large T-antigen and the small t-antigen. Notch-1 upregulation is maintained in SV40-transformed human mesothelial clones and in SV40-positive mesotheliomas and derived cell lines. Activation of Notch-1 promotes cell cycle progression and it is required for the growth of SV40-transformed mesothelial cells. Our finding is relevant to the process of SV40-mediated human cell transformation, an effect that cannot be accounted for solely by SV40-Tag inhibition of Rb and p53.	Loyola Univ, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Dept Pathol, Maywood, IL 60153 USA; Univ Illinois, Dept Pharmacodynam & Pharmaceut, Chicago, IL USA; Univ Illinois, Ctr Canc, Chicago, IL USA; Wayne State Univ, Aerodigest Program, Karmanos Ctr Inst, Detroit, MI 48201 USA	Loyola University Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Wayne State University	Carbone, M (corresponding author), Loyola Univ, Cardinal Bernardin Canc Ctr, Canc Immunol Program, Dept Pathol, Room 205,2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		Pass, Harvey/0000-0003-3222-3471; Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [R01CA084065, R01CA092657] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA92657, R0-1 CA84065] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Carlesso N, 1999, BLOOD, V93, P838, DOI 10.1182/blood.V93.3.838.403k29_838_848; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Grammatikakis N, 2001, J BIOL CHEM, V276, P27840, DOI 10.1074/jbc.M101987200; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Imperiale MJ, 2001, SEMIN CANCER BIOL, V11, P81, DOI 10.1006/scbi.2000.0349; Jang MS, 2000, CURR OPIN MOL THER, V2, P55; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; KLEIN G, 2000, P NATL ACTA SCI US, V97, P10214; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; MATTHEWS BJ, 1987, J VIROL, V61, P1282, DOI 10.1128/JVI.61.4.1282-1285.1987; McLendon C, 2000, FASEB J, V14, P2383; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mossman BT, 2002, AM J RESP CELL MOL, V26, P167, DOI 10.1165/ajrcmb.26.2.f229; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Pass HI, 1996, CANCER RES, V56, P4044; Pass HI, 1998, J THORAC CARDIOV SUR, V116, P854, DOI 10.1016/S0022-5223(98)00438-3; Porras A, 1996, J VIROL, V70, P6902; Powers A, 2002, CANCER BIOL THER, V1, P348; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Robledo R, 1999, J CELL PHYSIOL, V180, P158, DOI 10.1002/(SICI)1097-4652(199908)180:2<158::AID-JCP3>3.0.CO;2-R; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SCHILLING LJ, 1994, NUCLEIC ACIDS RES, V22, P3061, DOI 10.1093/nar/22.15.3061; Schrump DS, 2001, SEMIN CANCER BIOL, V11, P73, DOI 10.1006/scbi.2000.0348; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Testa JR, 2001, SEMIN CANCER BIOL, V11, P31, DOI 10.1006/scbi.2000.0344; TESTA JR, 2001, CANC PRINCIPLES PRAC, V6, P1937; Toyooka S, 2001, CANCER RES, V61, P5727; Wiman KG, 1997, NAT MED, V3, P839, DOI 10.1038/nm0897-839; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001	52	79	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					81	89		10.1038/sj.onc.1206097	http://dx.doi.org/10.1038/sj.onc.1206097			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527910				2022-12-17	WOS:000180166900009
J	Choi, Y; Zhang, J; Murga, C; Yu, H; Koller, E; Monia, BP; Gutkind, JS; Li, WQ				Choi, Y; Zhang, J; Murga, C; Yu, H; Koller, E; Monia, BP; Gutkind, JS; Li, WQ			PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells	ONCOGENE			English	Article						myeloma; PTEN; SHIP; signal transduction	PROTEIN-KINASE-B; INOSITOL PHOSPHATASE SHIP; POLYPHOSPHATE 5-PHOSPHATASE SHIP; FORKHEAD TRANSCRIPTION FACTOR; MULTIPLE-MYELOMA; PHOSPHOINOSITIDE 3-KINASE; TUMOR SUPPRESSION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; NEGATIVE REGULATION; GLIOBLASTOMA CELLS	Expression of PTEN tumor suppressor gene has been known to dephosphorylate the phosphatidylinositol 3' kinase (PI3K) products on the 3 prime inositol ring, resulting in reduced Akt activation. Loss of PTEN expression in OPM2 and Delta47 human myeloma lines led to high Akt activity toward insulin-like growth factor I (IGF-I). In contrast, mouse plasma cell tumor (PCT) lines, expressing wild type PTEN, did not respond to IGF-I for Akt activation. We demonstrated here that endogenous PTEN played a negative role in controlling Akt activity in both mouse PCT and NIH3T3 fibroblast lines by using anti-sense oligonucleotides against PTEN. To determine the role of src-homology 2-containing inositol 5' phosphatase (SHIP) in regulating the PI3K/Akt pathway, we manipulated its expression by down-regulation and overexpression in myeloma, PCT and NIH3T3 lines and analysed Akt activation. Our results showed that SHIP, unlike PTEN, did not affect Akt activity in all systems analysed, despite its ability to dephosphorylate a PI3K product. Although SHIP2 expression resulted in suppression of interleukin-6-mediated mitogen-activated protein kinase activation, expression of SHIP and SHIP2 in a PTEN-null myeloma line did not suppress Akt activity. Biologically, expression of only PTEN, but not SHIP and SHIP2, resulted in growth inhibition and increased apoptosis in OPM2 myeloma line. Together, our results have established the role of PTEN, but not SHIP and SHIP2, in negatively regulating the PI3K/Akt cascade and in myeloma leukemogenesis.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, Bethesda, MD USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, E407,3970 Reservoir Rd NW,New Res Bldg, Washington, DC 20007 USA.		Gutkind, J. Silvio/J-1201-2016; Murga, Cristina/E-1965-2014; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Brauweiler A, 2000, J EXP MED, V191, P1545, DOI 10.1084/jem.191.9.1545; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DEL PL, 1997, SCIENCE, V278, P687; Desikan K R, 1999, Curr Opin Hematol, V6, P216, DOI 10.1097/00062752-199907000-00004; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feinman R, 1999, BLOOD, V93, P3044; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Helgason CD, 2000, J EXP MED, V191, P781, DOI 10.1084/jem.191.5.781; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kyle RA, 2001, ONCOLOGIST, V6, P119, DOI 10.1634/theoncologist.6-2-119; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li WQ, 2000, CANCER RES, V60, P3909; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; MACHAMA T, 1998, J BIOL CHEM, V273, P13375; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Potter M, 1997, HEMATOL ONCOL CLIN N, V11, P323, DOI 10.1016/S0889-8588(05)70434-2; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rohrschneider LR, 2000, GENE DEV, V14, P505; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Treon SP, 1999, BLOOD, V93, P1287, DOI 10.1182/blood.V93.4.1287.404k14_1287_1298; Urashima M, 1997, BLOOD, V90, P279; Weng LP, 1999, CANCER RES, V59, P5808; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	68	79	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5289	5300		10.1038/sj.onc.1205650	http://dx.doi.org/10.1038/sj.onc.1205650			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149650				2022-12-17	WOS:000177193900010
J	Pugacheva, EN; Ivanov, AV; Kravchenko, JE; Kopnin, BP; Levine, AJ; Chumakov, PM				Pugacheva, EN; Ivanov, AV; Kravchenko, JE; Kopnin, BP; Levine, AJ; Chumakov, PM			Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil	ONCOGENE			English	Article						mutant p53; drug resistance; gain of function	TUMOR-SUPPRESSOR GENE; FUNCTION MUTATIONS; CELLS; CHEMOTHERAPY; PROMOTER; RAS; MODULATION; PHENOTYPE; REQUIRES	Mutated forms of p53 are often expressed in a variety of human tumors. In addition to loss of function of the p53 tumor suppressor, mutant p53s contribute to malignant process by acquisition of novel functions that enhance transformed properties of cells and resistance to anticancer therapy in vitro, and increase tumorigenecity, invasiveness and metastatic ability in vivo. Searching for genes that change expression in response to p53 gain of function mutants may give a clue to the mechanisms underlying their oncogenic effects. Recently by subtraction hybridization cloning we found that the dUTPase gene is transcriptionally upregulated in p53-null mouse fibroblasts expressing the exogenous human tumor-derived His175 p53 mutant. Here we show that conditional expression of His175 and Trp248 hot-spot p53 mutants in p53-negative mouse 10(l) fibroblasts and human SK-OV3 and H1299 tumor cells results in increase in dUTPase gene transcription, an important marker predicting the efficacy of cancer therapy with fluoropyrimidine drugs. Using tetracycline-regulated retroviral vectors for conditional expression of p53 mutants, we found that transcription of the dUTPase gene is increased within 24 h after tetracycline withdrawal, and the cells acquire higher resistance to 5-FU. Additional inactivation of the N-terminal transcription activation domain of mutant p53 (substitutions in amino-acid residues 22 and 23) results in abrogation of both induction of dUTPase transcripts and 5-FU resistance.	Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 117984, Russia; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Russian Canc Res Ctr, Inst Cancerogenesis, Moscow 115478, Russia; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Princeton University	Chumakov, PM (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	chumakp@ccf.org	Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019	Kopnin, Boris/0000-0003-3100-2212; Pugacheva, Elena/0000-0001-9814-7446; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Aherne GW, 1999, CANC DRUG DISC DEV, P409; Benhattar J, 1996, INT J CANCER, V69, P190, DOI 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Bottini A, 2000, CLIN CANCER RES, V6, P2751; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cabelguenne A, 2000, J CLIN ONCOL, V18, P1465, DOI 10.1200/JCO.2000.18.7.1465; CANMAN CE, 1994, CANCER RES, V54, P2296; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HSIAO M, 1994, AM J PATHOL, V145, P702; Kelavkar UP, 1999, P NATL ACAD SCI USA, V96, P4378, DOI 10.1073/pnas.96.8.4378; KOPNIN BP, 1995, ONCOL RES, V7, P299; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Ladner RD, 2000, CANCER RES, V60, P3493; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Peled A, 1996, CANCER RES, V56, P2148; Pugacheva EN, 2000, MOL BIOL+, V34, P127; Sambrook J., 1989, MOL CLONING; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Zheng MH, 1999, J CANCER RES CLIN, V125, P357, DOI 10.1007/s004320050286	41	79	83	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4595	4600		10.1038/sj.onc.1205704	http://dx.doi.org/10.1038/sj.onc.1205704			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096336				2022-12-17	WOS:000176625100001
J	Vasseur, S; Hoffmeister, A; Garcia-Montero, A; Mallo, GV; Feil, R; Kuhbandner, S; Dagorn, JC; Iovanna, JL				Vasseur, S; Hoffmeister, A; Garcia-Montero, A; Mallo, GV; Feil, R; Kuhbandner, S; Dagorn, JC; Iovanna, JL			p8-deficient fibroblasts grow more rapidly and are more resistant to adriamycin-induced apoptosis	ONCOGENE			English	Article						p8; p53; cell-cycle; apoptosis; MEF	TATA-BINDING PROTEIN; CELL-CYCLE CONTROL; WILD-TYPE; P53 BINDS; IN-VITRO; EXPRESSION; STRESS; GENE; P8; TRANSCRIPTION	p8 is a stress-induced DNA-binding protein, biochemically related to the architectural chromatin binding HMG protein family and whose function is presently unknown. We obtained fibroblast from mice lacking p8 and found that p8 is involved in cell growth regulation and in apoptosis. p8(-/-) mouse embryonic fibroblasts (MEFs) grow more rapidly than p8(+/+) MEFs. This might be explained by the higher intracellular level and activity of the Cdk2 and Cdk4 observed in p8-/- MEFs, which in turn may result, at least in part, from the concomitant decrease observed in the amount of cyclin-dependent kinase inhibitor p27. We also report that p8 mRNA expression is strongly activated in fibroblasts after cell growth arrest induced by serum deprivation or confluence. As expected, MEFs expressing pS arrest their growth more rapidly after serum deprivation than MEFs lacking p8, which strongly suggests that p8 overexpression is implicated in cell growth arrest. On the other hand, P8(+/+) MEFs are more sensitive than p8(-/-)MEFs to the apoptosis induced by adriamycin treatment. p53 might be involved, as p8 expression increases its intracellular amount and trans-activation capacity. Finally, demonstration that p53 is a negative transactivator of p8 suggests the presence of a complex autoregulatory loop. In conclusion, p8 is a cell growth inhibitor that facilitates apoptosis induced in fibroblasts by DNA damage.	INSERM, Ctr Rech, F-13009 Marseille, France; Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm)	Iovanna, JL (corresponding author), INSERM, Ctr Rech, EMI 0116,Parc Sci & Technol Luminy,163 Av Luminy, F-13009 Marseille, France.	iovanna@inserm-adr.univ-mrs.fr	Montero, Andres/HGA-9093-2022; vasseur, sophie/O-9803-2017; Garcia-Montero, Andres C/B-6558-2017; Feil, Susanne/AAF-7032-2019; Iovanna, Juan/M-9805-2017; Feil, Robert/B-8918-2014	vasseur, sophie/0000-0002-2339-8854; Garcia-Montero, Andres C/0000-0003-4360-1386; Iovanna, Juan/0000-0003-1822-2237; Feil, Robert/0000-0002-7335-4841				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Bratland A, 2000, CANCER RES, V60, P5578; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Goldschmidt-Clermont PJ, 1999, GENE EXPRESSION, V7, P255; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang YF, 1999, BIOCHEM BIOPH RES CO, V260, P686, DOI 10.1006/bbrc.1999.0953; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Pesch J, 1996, J INTERF CYTOK RES, V16, P595, DOI 10.1089/jir.1996.16.595; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Ree AH, 1999, CANCER RES, V59, P4675; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Su SB, 2001, CLIN CANCER RES, V7, P309; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x; Vasseur S, 1999, BIOCHEM J, V343, P377, DOI 10.1042/0264-6021:3430377; Wang E, 1999, J CELL BIOCHEM, P95; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang LL, 2000, CANCER RES, V60, P3655	41	79	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1685	1694		10.1038/sj.onc.1205222	http://dx.doi.org/10.1038/sj.onc.1205222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896600				2022-12-17	WOS:000174214200007
J	Zur Hausen, H				Zur Hausen, H			Oncogenic DNA viruses	ONCOGENE			English	Review						viruses; cancer; transformation	HUMAN-PAPILLOMAVIRUS INFECTIONS; RENAL-TRANSPLANT RECIPIENTS; CERVICAL-CARCINOMA CELLS; HERPES-SIMPLEX VIRUS; NUCLEAR ANTIGEN-2; SKIN CANCERS; SEQUENCES; AMPLIFICATION; TRANSCRIPTION; APOPTOSIS		Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Zur Hausen, H (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	zurhausen@dkfz-heidelberg.de						Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1111/j.1365-2613.2001.iep178.x; Astori G, 1998, J INVEST DERMATOL, V110, P752, DOI 10.1046/j.1523-1747.1998.00191.x; BACHMANN A, 2001, IN PRESS J VIROL; BEASLEY RP, 1981, LANCET, V2, P1129; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; Boxman ILA, 1997, J INVEST DERMATOL, V108, P712, DOI 10.1111/1523-1747.ep12292090; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; de Villiers EM, 1998, BIOMED PHARMACOTHER, V52, P26, DOI 10.1016/S0753-3322(97)86238-5; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; EVANS AS, 1976, YALE J BIOL MED, V49, P175; GROSS L, 1951, P SOC EXP BIOL MED, V76, P27; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HEILBRONN R, 1989, J VIROL, V63, P3683, DOI 10.1128/JVI.63.9.3683-3692.1989; HEILBRONN R, 1993, P NATL ACAD SCI USA, V90, P11406, DOI 10.1073/pnas.90.23.11406; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jackson S, 2000, ONCOGENE, V19, P592, DOI 10.1038/sj.onc.1203339; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Polack A, 1996, P NATL ACAD SCI USA, V93, P10411, DOI 10.1073/pnas.93.19.10411; SCHLEHOFER JR, 1983, INT J CANCER, V32, P99, DOI 10.1002/ijc.2910320116; SCHMITT J, 1989, VIROLOGY, V172, P73, DOI 10.1016/0042-6822(89)90108-6; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Vonka V, 2000, PHILOS T R SOC B, V355, P1831, DOI 10.1098/rstb.2000.0738; zur Hausen H, 1994, Curr Top Microbiol Immunol, V186, P131; zur Hausen H, 2001, LANCET, V357, P381, DOI 10.1016/S0140-6736(00)03652-7; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	34	79	83	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7820	7823		10.1038/sj.onc.1204958	http://dx.doi.org/10.1038/sj.onc.1204958			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753664				2022-12-17	WOS:000172336500001
J	Besson, A; Davy, A; Robbins, SM; Yong, VW				Besson, A; Davy, A; Robbins, SM; Yong, VW			Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells	ONCOGENE			English	Article						ERK; MAPK; glioma; integrin; migration; PKC	PROTEIN-KINASE-C; IN-VITRO; PATHWAY UPSTREAM; GROWTH-FACTOR; INTEGRIN; INVASION; MOTILITY; TRANSDUCTION; INHIBITION; DOWNSTREAM	Protein kinase C (PKC) is. a family of serine/threonine kinases. involved in. the transduction of a variety of signals. There is increasing evidence to indicate that specific PKC isoforms are involved in the regulation of distinct cellular processes. In glioma, cells, PKC alpha was found to be a critical regulator of proliferation and cell cycle progression, white PKC epsilon was found to regulate adhesion and migration. Herein, we. report that specific PKC isoforms are able to differentially activate extracellular-signal regulated kinase (ERK)! in distinct cellular locations: while PKC alpha induces the activation of nuclear ERK, PKC epsilon induces, the activation of ERK at focal adhesions. Inhibition of the ERK pathway completely abolished the PKC-induced integrin-mediated adhesion and migration. Thus, we present the first evidence that PKC epsilon is able to, activate ERK at focal adhesions to mediate glioma cell adhesion and motility, providing a molecular mechanism to. explain the different biological functions of PKC alpha and epsilon in glioma cells.	Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Yong, VW (corresponding author), 3300 Hosp Dr NW,HMRB 191, Calgary, AB T2N 4N1, Canada.		Besson, Arnaud/J-6254-2014	Besson, Arnaud/0000-0002-9599-3943; Yong, V. Wee/0000-0002-2600-3563; Robbins, Stephen/0000-0001-7475-1665				Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; El-Obeid A, 1997, CANCER RES, V57, P5598; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Friedlander DR, 1996, CANCER RES, V56, P1939; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gillespie GY, 1999, CANCER RES, V59, P2076; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Rigot V, 1998, J CELL SCI, V111, P3119; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Sieg DJ, 1999, J CELL SCI, V112, P2677; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; TYSNES OB, 1993, ANTICANCER RES, V13, P1325; Zhang W, 1997, CANCER LETT, V120, P31, DOI 10.1016/S0304-3835(97)00287-5	26	79	83	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7398	7407		10.1038/sj.onc.1204899	http://dx.doi.org/10.1038/sj.onc.1204899			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704869				2022-12-17	WOS:000171894200012
J	Jung, MS; Yun, J; Chae, HD; Kim, JM; Kim, SC; Choi, TS; Shin, DY				Jung, MS; Yun, J; Chae, HD; Kim, JM; Kim, SC; Choi, TS; Shin, DY			p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor	ONCOGENE			English	Article						p53; p63; p73; cdk1; cyclin B; NF-Y; senescence	WILD-TYPE P53; TATA-BINDING PROTEIN; MAMMALIAN-CELLS; ONCOGENIC RAS; TUMOR-CELLS; IN-VIVO; PREMATURE SENESCENCE; GENE-EXPRESSION; PROMOTER; REPRESSION	Recent studies have identified two p53 homologues, p63 and p73. They activate p53-responsive promoters and induce apoptosis when overexpressed in certain human tumors. Here, we report that p63, like p53 and p73, induces replicative senescence when expressed in a tetracycline-regulated manner in EJ cells lacking a functional p53. In addition to transcription activation of p53-responsive genes, we found that p63 and p73 repress transcription of the cdk1 and cyclin B genes, both of which are irreversibly repressed in senescent human fibroblast. In transient transfection assay, p63 and p73 repress the cdk1 promoter regardless of the presence of a dominant negative mutant form of p53. Furthermore, we found that DNA binding activity of NF-Y transcription factor, which is essential for transcription of the cdk1 and cyclin B genes and inactivated in senescent fibroblast, is significantly decreased by expression of either of p53, p63, or p73. Since NF-Y binds to many promoters besides the cdk1 and cyclin B promoters, inactivation of NF-Y by p53 family genes may be a general mechanism for transcription repression in replicative senescence.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Regulat, Cheonan 330714, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Jongro Gu, Seoul 10300, South Korea; Korea Adv Inst Sci & Technol, Taejon 305333, South Korea; LG Chem LTD, Biotech Res Inst, Taejon 305380, South Korea	Dankook University; Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST); LG Chem	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab Cell Cycle Regulat, Cheonan 330714, South Korea.		Kim, Sun Chang/C-2026-2011; Kim, Sun/GSN-4867-2022; Chae, Hee-Don/D-2620-2011					AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; Chen Kuang Yu, 1997, Frontiers in Bioscience (online), V2, pD417; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Deb D, 1999, INT J ONCOL, V15, P413; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Ferbeyre G, 2000, GENE DEV, V14, P2015; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Good LF, 1996, BIOL SIGNAL, V5, P163; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park M, 2000, CANCER RES, V60, P542; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Shimada A, 1999, CANCER RES, V59, P2781; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	58	79	81	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5818	5825		10.1038/sj.onc.1204748	http://dx.doi.org/10.1038/sj.onc.1204748			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593387				2022-12-17	WOS:000171037200005
J	Coldwell, MJ; deSchoolmeester, ML; Fraser, GA; Pickering, BM; Packham, G; Willis, AE				Coldwell, MJ; deSchoolmeester, ML; Fraser, GA; Pickering, BM; Packham, G; Willis, AE			The p36 isoform of BAG-1 is translated by internal ribosome entry following heat shock	ONCOGENE			English	Article						BAG-1; IRES; translation; internal ribosome entry; heat shock	APOPTOTIC PROTEIN BAG-1; C-MYC; ALTERNATIVE TRANSLATION; NEGATIVE REGULATOR; MAMMALIAN-CELLS; INITIATION; IDENTIFICATION; LOCATION; CLONING; REGION	BAG-1 (also known as RAP46/HAP46) was originally identified as a 46 kDa protein that bound to and enhanced the anti-apoptotic properties of Bcl-2, BAG-1 exists as three major isoforms (designated p50, p46 and p36 or BAG-1L, BAG-1M and BAG-1S respectively) and one minor isoform (p29), which are translated from a common transcript. The differing amino terminus determines both the intracellular location and the repertoire of binding partners of the isoforms which play different roles in a variety of cellular processes including signal transduction, heat shock, apoptosis and transcription. Although in vitro data suggest that the four BAG-1 isoforms are translated by leaky scanning, the patterns of isoform expression in vivo, especially in transformed cells, do not support this hypothesis. We have performed in vivo analysis of the BAG-1 5' untranslated region and shown that translation initiation of the most highly expressed isoform (p36/BAG-1S) can occur by both internal ribosome entry and cap-dependent scanning. Following heat shock, when there is a downregulation of cap-dependent translation, the expression of the p36 isoform of BAG-1 is maintained by internal ribosome entry.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Southampton Gen Hosp, Oncol Unit, Southampton SO16 6YD, Hants, England	University of Leicester; University of Southampton	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	aew5@le.ac.uk		Packham, Graham/0000-0002-9232-5691; Willis, Anne/0000-0002-1470-8531				Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Cuesta R, 2000, GENE DEV, V14, P1460; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; Schneider RJ, 2000, COLD SPRING HARBOR M, V39, P581; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STONELEY M, 1998, THESIS U LEICESTER; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yueh A, 2000, GENE DEV, V14, P414; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	31	79	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4095	4100		10.1038/sj.onc.1204547	http://dx.doi.org/10.1038/sj.onc.1204547			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494137				2022-12-17	WOS:000169681500017
J	Ludwig, T; Fisher, P; Murty, V; Efstratiadis, A				Ludwig, T; Fisher, P; Murty, V; Efstratiadis, A			Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice	ONCOGENE			English	Article						Brca2; mouse mutant; mammary tumors	BREAST-CANCER; TRANSGENIC MICE; DNA-REPAIR; ADENOSQUAMOUS CARCINOMA; GENETIC INSTABILITY; TUMOR-FORMATION; MUTATION; PROTEIN; RAD51; EXPRESSION	Cre-mediated deletion of exons 3 and 4 of the mouse Brca2 gene occurring specifically in mammary epithelial cells of conditional female mutants carrying a combination of loxP-modified and null Brca2 alleles resulted in a high incidence (77%) of breast tumors that were often palpable and developed in one or more glands after long latency (time for median tumor-free survival of similar to1.4 years; total of 40 tumors in 20 animals). These invasive adenocarcinomas were histologically quite uniform, exhibiting predominantly a solid, nodular tumor pattern with very few variants, in striking contrast to the morphological heterogeneity of analogous Brca1-associated tumors. The karyotypes of tumor cells lacking Brca2 had various chromosomal aberrations and ranged from diploid to hypertetraploid, but this wide variability was incongruous with the histological appearance of carcinomas that was comparable between specimens. The implications of these observations in the context of models positing that Brca2 is involved in the maintenance of genomic stability are discussed.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Ludwig, T (corresponding author), Columbia Univ, Dept Anat & Cell Biol, Russ Berrie Med Sci Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.	tl154@columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585	NATIONAL CANCER INSTITUTE [P01CA075553] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75553] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agnarsson BA, 1998, BREAST CANCER RES TR, V47, P121, DOI 10.1023/A:1005853022804; Armes JE, 1999, CANCER RES, V59, P2011; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CARDIFF RD, 1991, AM J PATHOL, V139, P495; Chappuis PO, 2000, SEMIN SURG ONCOL, V18, P287, DOI 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.3.CO;2-X; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Denley H, 2000, HISTOPATHOLOGY, V36, P203; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Friedman LS, 1998, CANCER RES, V58, P1338; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Glover TW, 1998, CANCER RES, V58, P3409; Gretarsdottir S, 1998, CANCER RES, V58, P859; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Ingvarsson S, 1999, CANCER RES, V59, P2682; Kanazawa H, 2000, AM J PATHOL, V156, P1289, DOI 10.1016/S0002-9440(10)64999-1; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; LUDWIG T, 2001, IN PRESS GENES DEV; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Niho S, 1999, JPN J CANCER RES, V90, P1244, DOI 10.1111/j.1349-7006.1999.tb00703.x; Osin P, 1998, EUR J CANCER, V34, P1683, DOI 10.1016/S0959-8049(98)00248-2; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shoker BS, 1999, HISTOPATHOLOGY, V35, P393; Tirkkonen M, 1997, CANCER RES, V57, P1222; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918	56	79	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					3937	3948		10.1038/sj.onc.1204512	http://dx.doi.org/10.1038/sj.onc.1204512			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494122				2022-12-17	WOS:000169681500002
J	Han, DC; Rodriguez, LG; Guan, JL				Han, DC; Rodriguez, LG; Guan, JL			Identification of a novel interaction between integrin beta 1 and 14-3-3 beta	ONCOGENE			English	Article						integrins; 14-3-3 proteins; cell migration; protein-protein interaction	FOCAL ADHESION KINASE; PROTEIN-KINASE; CYTOPLASMIC DOMAIN; SIGNAL-TRANSDUCTION; CELL-MIGRATION; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; FIBRONECTIN RECEPTOR; 14-3-3-PROTEINS	Integrins are cell surface receptors for extracellular matrix, which play important roles ina a variety of biological processes. 14-3-3 proteins are a highly conserved family of cytoplasmic proteins that associate with several intracellular signaling molecules in regulation of various cellular functions. Here, we report identification of an interaction between the integrin beta1 cytoplasmic domain and 14-3-3 beta by using the yeast two-hybrid screen, Like several other proteins, the integrin beta1 cytoplasmic domain associated with 14-3-3 beta by a non-phosphoserine mechanism. The 14-3-3 beta /integrin beta1 interaction was confirmed by iir vitro binding assays as well as to-precipitation in vivo. Furthermore, we found that 14-3-3 beta co-localized with integrin beta1 during the early stage of cell spreading on fibronectin, suggesting a potential role of the 14-3-3 beta /integrin beta1 interaction in the regulation of cell adhesion. Using tetracycline-regulated expression system, we showed that overexpression of 14-3-3 beta stimulated cell spreading and migration on fibronectin but not on poly-L-lysine. However, the induced expression of 14-3-3 beta did not affect tyrosine phosphorylation of FAK or its substrates, p130(cas) and paxillin, suggesting that 14-3-3 beta regulated integrin-mediated cell spreading and migration by FAK-independent mechanisms. Taken together, these results identify an interaction between integrin and 14-3-3 proteins and suggest a potentially novel cellular function for 14-3-3 proteins in the regulation of integrin-mediated cell adhesion and signaling events.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Aplin AE, 1998, PHARMACOL REV, V50, P197; Autieri MV, 1996, CELL GROWTH DIFFER, V7, P1453; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHUN JS, 1993, MOL BIOL CELL, V4, P271; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Craparo A, 1997, J BIOL CHEM, V272, P11663; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Loftus JC, 1997, J CLIN INVEST, V100, pS77; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Meller N, 1996, MOL CELL BIOL, V16, P5782; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORGAN A, 1992, BIOCHEM J, V286, P807, DOI 10.1042/bj2860807; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakanishi Kozo, 1997, Human Antibodies, V8, P189; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	75	79	83	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					346	357		10.1038/sj.onc.1204068	http://dx.doi.org/10.1038/sj.onc.1204068			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313964				2022-12-17	WOS:000166411000009
J	Johnstone, RW; Wei, W; Greenway, A; Trapani, JA				Johnstone, RW; Wei, W; Greenway, A; Trapani, JA			Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16	ONCOGENE			English	Article						transcription; IFI 16; p53; interferon	NUCLEAR DIFFERENTIATION ANTIGEN; TUMOR-SUPPRESSOR P53; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; CELL-PROLIFERATION; PROTEIN P202; INHIBITION; GENE; EXPRESSION; CLUSTER	Interferons are important in regulating cell growth and differentiation, immune function and initiating anti-viral responses. While the pleotrophic actions of interferons have been well documented, the molecular mechanisms underpinning their biological effects have not been fully characterized. IFI 16 is a member of the interferon-inducible HIN-200 family of nuclear proteins, which we have recently shown can function as a potent transcriptional repressor. A murine member of the HIN-200 family, p202, can indirectly interact with p53 via the p53 binding protein (p53bp) and inhibit p53-mediated transcriptional activation. The binding activity of p202 to p53bp was shown to require the conserved MFHATVAT motif present in all 200 amino acid repeat regions of HIN-200 proteins. Given that IFI 16 contains two MFHATVAT motifs, we sought to determine whether IFI 16 may form a complex with p53 and if so to ascertain the functional significance of this interaction. We demonstrate that IFI 16 can directly bind to the C-terminal region of p53 and augment p53-mediated transcriptional activation without altering the steady state levels of p53. Thus, in addition to its ability to directly regulate gene expression, IFI 16 can also modulate the transcription function of other cellular transcription factors. These findings demonstrate a possible link between gene induction following interferon stimulation and p53-mediated cellular events.	Peter MacCallum Canc Inst, Gene Regulat Lab, Canc Immunol Div, Melbourne, Vic 3002, Australia; Macfarlane Burnet Ctr Med Res, Fairfield, Vic 3078, Australia	Peter Maccallum Cancer Center	Johnstone, RW (corresponding author), Peter MacCallum Canc Inst, Gene Regulat Lab, Canc Immunol Div, Smorgon Family Bldg,St Andrews Pl, Melbourne, Vic 3002, Australia.		Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Trapani, Joseph/0000-0003-0983-1532				Arany I, 1996, IN VIVO, V10, P119; BURRUS GR, 1992, J CELL BIOCHEM, V48, P190, DOI 10.1002/jcb.240480210; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DAWSON MJ, 1996, J LEUKOCYTE BIOL, V60, P1; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DUHL DM, 1989, J CELL PHYSIOL, V141, P148, DOI 10.1002/jcp.1041410122; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hobeika AC, 1999, J INTERF CYTOK RES, V19, P1351, DOI 10.1089/107999099312812; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Min W, 1996, MOL CELL BIOL, V16, P359; MIYASHITA T, 1995, CELL, V80, P293; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shaw P, 1996, ONCOGENE, V12, P921; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; WANG ZY, 1993, J BIOL CHEM, V268, P9972; Xie JP, 1998, J CELL BIOCHEM, V70, P489, DOI 10.1002/(SICI)1097-4644(19980915)70:4<489::AID-JCB6>3.0.CO;2-F; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	56	79	85	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					6033	6042		10.1038/sj.onc.1204005	http://dx.doi.org/10.1038/sj.onc.1204005			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146555				2022-12-17	WOS:000165827900010
J	Moren, A; Itoh, S; Moustakas, A; ten Dijke, P; Heldin, CH				Moren, A; Itoh, S; Moustakas, A; ten Dijke, P; Heldin, CH			Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4	ONCOGENE			English	Article						mutation; signal transduction; Smad; TGF-beta-transcription; tumor suppressor gene	GROWTH-FACTOR-BETA; COLON-CANCER CELLS; TGF-BETA; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; DPC4 SMAD4; PROTEINS; PROMOTER; RECEPTOR; GENE	Smads, the intracellular effecters of transforming growth factor-beta (TGF-beta) family members, are somatically mutated at high frequency in particular types of human cancers. Certain of these mutations affect the Smad amino-terminal domain, which, in the case of Smad3 and Smad4, binds DNA. We investigated the functional consequences of four missense mutations in the Smad4 amino-terminal domain found in human tumors. The mutant proteins were found to have impaired abilities to bind DNA although they were fully capable of forming complexes with Smad3, All four Smad4 mutants showed decreased protein stability compared to wild-type Smad3. Two of the Smad4 mutants (G65V and P130S) were translocated to the nucleus and were capable of transactivating a Smad-dependent promoter in a ligand-dependent manner. In contrast, the L43S and R100T mutants were not translocated efficiently to the nucleus and consequently resulted in severely defective transcriptional responses to TGF-beta. Moreover, we demonstrate here the critical importance of two basic residues in the beta-hairpin loop of Smad3 or Smad4 for DNA binding, consistent with predictions from the Smad3 crystal structure. In addition, our results reveal that in the TGF-beta-induced heteromeric signaling complex, loss of DNA binding of Smad4 can be compensated by Smad3, however, both Smad3 and Smad3 are needed for efficient DNA binding and signaling. In conclusion, mutations in the amino-terminal domain of Smad4, that are found in cancer, show loss of multiple functional properties which may contribute to tumorigenesis.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Ludwig Institute for Cancer Research; Netherlands Cancer Institute	Heldin, CH (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Moustakas, Aristidis/0000-0001-9131-3827; Itoh, Susumu/0000-0002-7967-0730				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DECAESTECKER MP, 2000, IN PRESS J NATL CANC; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEDAI J, 1998, CANCER RES, V58, P4592; LEDAI J, 1999, MOL CARCINOG, V26, P37; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; PARDALI K, 2000, IN PRESS J BIOL CHEM; Piek E, 1999, J CELL SCI, V112, P4557; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, V95, P3; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	55	79	81	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4396	4404		10.1038/sj.onc.1203798	http://dx.doi.org/10.1038/sj.onc.1203798			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980615				2022-12-17	WOS:000089271900010
J	Shirasaki, F; Makhluf, HA; LeRoy, C; Watson, DK; Trojanowska, M				Shirasaki, F; Makhluf, HA; LeRoy, C; Watson, DK; Trojanowska, M			Ets transcription factors cooperate with Sp1 to activate the human Tenascin-C promoter	ONCOGENE			English	Article						Tenascin-C; transcriptional regulation; Fli1; GABP; Sp1	EXTRACELLULAR-MATRIX PROTEIN; ALPHA-2(I) COLLAGEN GENE; BINDING-SITES; DNA-BINDING; MONOCLONAL-ANTIBODIES; HUMAN FIBROBLASTS; TISSUE INHIBITOR; MOUSE TENASCIN; GROWTH-FACTORS; FAMILY MEMBER	Tenascin-C (TN-C), an extracellular matrix glycoprotein is expressed during embryonic development, but is present only at low levels in normal adult tissues. TN-C is re-expressed during wound healing, fibrotic diseases and in cancer. To better understand the mechanisms that control TN-C gene expression, we examined the regulation of the human TN-C promoter in human fibroblasts. We demonstrate that a short segment of the TN-C promoter between bp -133 and -27 contains three evolutionarily conserved Ets binding sites (EBS). These three EBSs bind in vitro expressed Fli1 protein and mediate transactivation of the TN-C gene by Fli1. Furthermore, two proximal EBSs contribute significantly to basal activity of the TN-C promoter. GABP, which is present in human fibroblast nuclear extracts, interacts with the two proximal EBSs, In addition, several Spl and Sp3 binding sites have been located in close proximity to the EBSs within this promoter region. The studies performed in Drosophila cells demonstrate that either Fli1 or GABP alpha + beta 1 functionally interact with Spl resulting in a synergistic stimulation of the TN-C promoter activity. In conclusion, this study shows for the first time that the TN-C gene is regulated by Ets proteins, which together with Spl act as potent activators of TN-C expression.	Med Univ S Carolina, Hollings Canc Ctr, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Ctr Mol & Struct Biol, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Trojanowska, M (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Div Rheumatol & Immunol, Dept Med, Charleston, SC 29425 USA.			Trojanowska, Maria/0000-0001-9550-7178	NIAMS NIH HHS [AR42334] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; CHIQUETEHRISMANN R, 1995, BIOESSAYS, V17, P873, DOI 10.1002/bies.950171009; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COPERTINO DW, 1995, P NATL ACAD SCI USA, V92, P2131, DOI 10.1073/pnas.92.6.2131; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Crossin KL, 1996, J CELL BIOCHEM, V61, P592; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FUJIWARA S, 1990, HYBRIDOMA, V9, P559, DOI 10.1089/hyb.1990.9.559; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GHERZI R, 1995, FEBS LETT, V369, P335, DOI 10.1016/0014-5793(95)00778-8; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; Gherzi R, 1997, DNA CELL BIOL, V16, P559, DOI 10.1089/dna.1997.16.559; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Hodge DR, 1996, ONCOGENE, V12, P11; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; JONES FS, 1990, P NATL ACAD SCI USA, V87, P6497, DOI 10.1073/pnas.87.17.6497; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KOIZUMI S, 1990, ONCOGENE, V5, P675; Kusagawa H, 1998, BRIT J CANCER, V77, P98, DOI 10.1038/bjc.1998.15; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Mackie EJ, 1997, INT J BIOCHEM CELL B, V29, P1133, DOI 10.1016/S1357-2725(97)00031-9; Mager AM, 1998, INT J DEV BIOL, V42, P561; Makhluf HA, 1996, J INVEST DERMATOL, V107, P856, DOI 10.1111/1523-1747.ep12331160; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; Meyer D, 1995, INT J DEV BIOL, V39, P909; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RAO VN, 1993, ONCOGENE, V8, P2167; RETTIG WJ, 1994, J CELL SCI, V107, P487; SAKAI T, 1993, BRIT J CANCER, V67, P1058, DOI 10.1038/bjc.1993.194; SETH A, 1993, ONCOGENE, V8, P1783; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHOJI T, 1992, VIRCHOWS ARCH A, V421, P53, DOI 10.1007/BF01607139; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; YAMADA S, 1992, LIVER, V12, P10; Yoshida T, 1997, J PATHOL, V182, P421; YOSHIDA T, 1995, CANCER LETT, V90, P65, DOI 10.1016/0304-3835(94)03679-D; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961; Zhang XK, 1995, HYBRIDOMA, V14, P563, DOI 10.1089/hyb.1995.14.563	59	79	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7755	7764		10.1038/sj.onc.1203360	http://dx.doi.org/10.1038/sj.onc.1203360			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618716	Bronze			2022-12-17	WOS:000084256900005
J	Geijsen, N; Spaargaren, M; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ				Geijsen, N; Spaargaren, M; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ			Association of RACK1 and PKC beta with the common beta-chain of the IL-5/IL3/GM-CSF receptor	ONCOGENE			English	Article						RACK1; PKC; receptor; cytokine; interleukin	COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; INTERLEUKIN-3 RECEPTOR; SIGNAL TRANSDUCTION; HUMAN EOSINOPHILS; PHORBOL ESTERS; MESSENGER-RNA; GM-CSF; EXPRESSION; SUBUNIT	Granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and interleukin-5 (IL-5 belong to a family of cytokines that regulate proliferation, differentiation and function of haematopoietic cells. Their receptor consists of a ligand specific alpha-chain and a signal transducing beta-chain (beta c). While, the role of phosphotyrosine residues in the beta c as mediators of downstream signalling cascades has been established, little is known about non-phosphotyrosine mediated events. To identify proteins interacting with beta c, me screened a yeast two-hybrid library with the intracellular domain of beta c. We found that RACK1, a molecule associating with activated PKC, PLC gamma and Src kinases, associated with the membrane proximal region of beta c in both yeast two-hybrid, immunoprecipitation and GST-pull-down assays. The association of RACK1 was constitutive, demonstrating no alteration upon cellular stimulation. Furthermore, upon stimulation of cells with IL-5 or PMA, a complex of beta c and PKC beta was found. Together, these findings suggest a novel role for RACK1 as a possible adapter molecule associating with the intracellular domain of cytokine receptors.	Univ Utrecht Hosp, Dept Pulm Dis, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Coffer, PJ (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Heidelberglaan 100,POB 85500, NL-3508 GA Utrecht, Netherlands.		Koenderman, Leo/AAE-7870-2020; Spaargaren, Marcel/AAU-1298-2021; Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020	Koenderman, Leo/0000-0002-5636-6453; Spaargaren, Marcel/0000-0002-3135-5109; 				AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; CloudHeflin BA, 1996, EUR J BIOCHEM, V239, P796, DOI 10.1111/j.1432-1033.1996.0796u.x; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; deGroot RP, 1997, J BIOL CHEM, V272, P2319; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FUJISAWA T, 1990, J IMMUNOL, V144, P642; Gale RE, 1998, BLOOD, V91, P54, DOI 10.1182/blood.V91.1.54.54_54_63; Gubina E, 1998, BLOOD, V91, P823, DOI 10.1182/blood.V91.3.823.823_823_829; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI Y, 1995, J IMMUNOL, V155, P2165; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pascale A, 1996, J NEUROCHEM, V67, P2471; Pierce A, 1998, J CELL BIOL, V140, P1511, DOI 10.1083/jcb.140.6.1511; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347	34	79	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5126	5130		10.1038/sj.onc.1202896	http://dx.doi.org/10.1038/sj.onc.1202896			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490850				2022-12-17	WOS:000082497100013
J	Belka, C; Marini, P; Lepple-Wienhues, A; Budach, W; Jekle, A; Los, M; Lang, F; Schulze-Osthoff, K; Gulbins, E; Bamberg, M				Belka, C; Marini, P; Lepple-Wienhues, A; Budach, W; Jekle, A; Los, M; Lang, F; Schulze-Osthoff, K; Gulbins, E; Bamberg, M			The tyrosine kinase Lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation	ONCOGENE			English	Article						caspase-8/FLICE; lymphoma; apoptosis; tyrosine kinase; Lck	DRUG-INDUCED APOPTOSIS; FAS-INDUCED APOPTOSIS; LEUKEMIA-CELLS; CYTOCHROME-C; T-CELLS; LIGAND EXPRESSION; SH2 DOMAIN; B-CELLS; DEATH; PHOSPHORYLATION	Induction of apoptosis is a hallmark of cytostatic drug and radiation-induced cell death in human lymphocytes and lymphoma cells. However, the mechanisms leading to apoptosis are not well understood. We provide evidence that ionizing radiation induces a rapid activation of caspase-8 (FLICE) followed by apoptosis independently of CD95 ligand/receptor interaction. The radiation induced cleavage pattern of procaspase-8 into mature caspase-8 resembled that following CD95 crosslinking and resulted in cleavage of the proapoptotic substrate BID. Overexpression of dominant-negative caspase-8 interfered with radiation-induced apoptosis, Caspase-8 activation by ionizing radiation was not observed in cells genetically defective for the Src-like tyrosine kinase Lck, Cells lacking Lck also displayed a marked resistance towards apoptosis induction upon ionizing radiation. After retransfection of Lck, caspase-8 activation and the capability to undergo apoptosis in response to ionizing radiation was restored. We conclude that radiation activates caspase-8 via an Lck-controlled pathway independently of CD95 ligand expression, This is a novel signaling event required for radiation induced apoptosis in T lymphoma cells.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Physiol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013; Gulbins, Erich/L-6989-2014	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Gulbins, Erich/0000-0002-3117-1342; Jekle, Andreas/0000-0001-9416-2622; Los, Marek/0000-0001-9518-1411				ALDRIDGE DR, 1995, BRIT J CANCER, V71, P571, DOI 10.1038/bjc.1995.111; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JIMENEZ B, 1995, ONCOGENE, V10, P811; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Leverkus M, 1997, EXP CELL RES, V232, P255, DOI 10.1006/excr.1997.3514; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schlottmann KE, 1996, J LEUKOCYTE BIOL, V60, P546, DOI 10.1002/jlb.60.4.546; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Villunger A, 1997, CANCER RES, V57, P3331; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; WADDICK KG, 1993, RADIAT RES, V136, P313, DOI 10.2307/3578542	44	79	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4983	4992		10.1038/sj.onc.1202878	http://dx.doi.org/10.1038/sj.onc.1202878			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490833	Green Published			2022-12-17	WOS:000082321700011
J	Taylor, JK; Zhang, QQ; Monia, BP; Marcusson, EG; Dean, NM				Taylor, JK; Zhang, QQ; Monia, BP; Marcusson, EG; Dean, NM			Inhibition of Bcl-x(L) expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli	ONCOGENE			English	Article						Bcl-x(L); keratinocytes; epithelial cells; apoptosis	BCL-X EXPRESSION; 2ND-GENERATION ANTISENSE OLIGONUCLEOTIDES; C-ALPHA EXPRESSION; MESSENGER-RNA; IMMUNOHISTOCHEMICAL ANALYSIS; EPIDERMAL-KERATINOCYTES; PROTOONCOGENE BCL-2; GENE-EXPRESSION; IN-VIVO; UV-B	The epidermis is continually exposed to harmful mutagens that have the potential to cause DNA damage. To protect the skin from accumulating mutated cells, keratinocytes have developed a highly regulated mechanism of eliminating damaged cells through apoptosis. Bcl-x(L) is a well-described cell survival protein that when overexpressed in skin can protect keratinocytes from UV radiation-induced apoptosis. To begin to unravel the complex mechanisms that keratinocytes use to survive, we wanted to characterize the role of endogenous Bcl-x(L) in protecting cells from death. In this study, we describe the development and characterization of an antisense inhibitor to Bcl-x(L). We show that this inhibitor reduces Bcl-x(L) RNA and protein in a concentration-dependent, sequence-specific manner, Furthermore, treatment of keratinocytes and epithelial cells with this inhibitor sensitizes these cells to UV-B radiation and cisplatinum treatment-induced apoptosis. Thus, these results offer direct evidence that Bcl-x(L) is critical in the protection of skin and epithelial cells from apoptosis and provide a basis for the role of Bcl-x(L) in keratinocyte and epithelial cell survival.	ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc	Dean, NM (corresponding author), ISIS Pharmaceut, Dept Pharmacol, 2280 Faraday Ave, Carlsbad, CA 92008 USA.			Marcusson, Eric/0000-0002-0504-8674				Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Altmann KH, 1996, BIOCHEM SOC T, V24, P630, DOI 10.1042/bst0240630; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CARSON DA, 1995, LANCET, V346, P1009, DOI 10.1016/S0140-6736(95)91693-8; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Cotton J, 1997, RADIAT RES, V147, P148, DOI 10.2307/3579415; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Dassonneville L, 1998, B CANCER, V85, P254; Dean N, 1996, CANCER RES, V56, P3499; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DHANWADA KR, 1995, ONCOGENE, V11, P1947; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; Henseleit U, 1996, ARCH DERMATOL RES, V288, P676, DOI 10.1007/BF02505277; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KAMB A, 1994, NATURE, V372, P730, DOI 10.1038/372730a0; Kirsh EJ, 1998, J UROLOGY, V159, P1348, DOI 10.1016/S0022-5347(01)63614-0; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewski S, 1997, AM J PATHOL, V150, P805; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; MARVEL J, 1994, ONCOGENE, V9, P1117; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; Olopade OI, 1997, CANCER J SCI AM, V3, P230; OLTAVI ZN, 1994, CELL, V79, P189; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Pena JC, 1998, CANCER RES, V58, P2111; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Ramaswamy NT, 1998, ONCOGENE, V16, P1501, DOI 10.1038/sj.onc.1201628; Reed JC, 1997, J NATL CANCER I, V89, P988, DOI 10.1093/jnci/89.14.988; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Saini KS, 1998, MOL CELL BIOCHEM, V178, P9, DOI 10.1023/A:1006891430596; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sermadiras S, 1997, BRIT J DERMATOL, V137, P883, DOI 10.1046/j.1365-2133.1997.19812085.x; Sierakowska H, 1996, P NATL ACAD SCI USA, V93, P12840, DOI 10.1073/pnas.93.23.12840; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALTON MI, 1993, CANCER RES, V53, P1853; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	62	79	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4495	4504		10.1038/sj.onc.1202836	http://dx.doi.org/10.1038/sj.onc.1202836			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442640				2022-12-17	WOS:000081813500011
J	Bennicelli, JL; Advani, S; Schafer, BW; Barr, FG				Bennicelli, JL; Advani, S; Schafer, BW; Barr, FG			PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						PAX3; PAX7; FKHR; transcription factor; chromosomal translocation; fusion protein	PAX3-FKHR FUSION PROTEIN; CHROMOSOMAL TRANSLOCATIONS; GENE; ACTIVATOR; POTENT; ENCODES; CELLS; EWS	The t(2;13) and t(1;13) translocations of alveolar rhabdomyosarcoma (ARMS) result in chimeric PAX3-FKHR or PAX7-FKHR transcription factors, respectively, In each chimera, a PAX DNA-binding domain is fused to the C-terminal FKHR transactivation domain. Previously we demonstrated that PAX3-FKHR is more potent than PAX3 because the FKHR transactivation domain is resistant to repression mediated by the PAX3 N-terminus. Here me test the hypothesis that the cis-acting repression domain is a conserved feature of PAX3 and PAX7 and that PAX7-FKHR gains function similarly, Using PAX-specific DIVA-binding sites, we found that PAX7 was virtually inactive, while PAX7-FKHR exhibited activity 600-fold above background and was comparable to PAX3-FKHR, Deletion analysis showed that the transactivation domains of PAX7 and PAX7-FKHR are each more potent than either full-length protein, and resistance to cis-repression is responsible for the PAX7-FKHR gain of function. Further deletion mapping and domain swapping experiments with PAX3 and PAX7 showed that their transactivation domains exhibit subtle dose-dependent differences in potency, likely due to regions of structural divergence; while their repression domains are structurally and functionally conserved. Thus, the data support the hypothesis and demonstrate that PAX3 and PAX7 utilize a common gain of function mechanism in ARMS.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Philadelphia, PA 19104 USA; Univ Zurich, Dept Pediat, Zurich, Switzerland	University of Pennsylvania; University of Zurich	Bennicelli, JL (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs, Room 506,422 Curie Blvd, Philadelphia, PA 19104 USA.			Schafer, Beat/0000-0001-5988-2915	NATIONAL CANCER INSTITUTE [R01CA064202] Funding Source: NIH RePORTER; NCI NIH HHS [CA64202] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BENNICELLI JL, 1995, ONCOGENE, V11, P119; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Clark J, 1996, ONCOGENE, V12, P229; DAVIS RJ, 1994, CANCER RES, V54, P2869; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fujimura Y, 1996, ONCOGENE, V12, P159; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; KAZ K, 1997, NAT GENET, V15, P170; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Kim J, 1998, ONCOGENE, V16, P1973, DOI 10.1038/sj.onc.1201716; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LI XL, 1994, NATURE, V367, P83, DOI 10.1038/367083a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; Vorobyov E, 1997, GENOMICS, V45, P168, DOI 10.1006/geno.1997.4915; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Xue L, 1996, EMBO J, V15, P3722, DOI 10.1002/j.1460-2075.1996.tb00742.x; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	30	79	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 29	1999	18	30					4348	4356		10.1038/sj.onc.1202812	http://dx.doi.org/10.1038/sj.onc.1202812			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439042				2022-12-17	WOS:000081732700007
J	Robertson, KD; Jones, PA				Robertson, KD; Jones, PA			Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus	ONCOGENE			English	Article						INK4a; ARF; expression patterns; pancreas; alternative splicing	DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL INTERFERENCE; SOMATIC MUTATIONS; DNA METHYLATION; GLOBIN GENE; WILD-TYPE; P16; P53; MDM2	The INK4a/ARF locus on human chromosome 9p resides at the nexus of two critical cell cycle regulatory pathways, the p53 pathway and the retinoblastoma (pRb) gene pathway, Through the use of shared coding regions and alternative reading frames two distinct proteins are produced: INK4a is a cyclin-dependent kinase inhibitor whereas ARF binds the MDM2 protooncogene and stabilizes p53. We have examined the expression patterns of the INK4a/ARF locus at the RNA level in normal human and murine tissues to determine if these genes are coordinately regulated. We found that both INK4a and ARF were expressed in most tissues at lon levels detectable only by RT-PCR, The pancreas was an exception in that it expressed no detectable ARF mRNA but expressed high levels of INK4a mRNA, Furthermore, human pancreas expressed an additional previously unrecognized splice variant of INK4a, termed p12, through the use of an alternative splice donor site within intron 1. The p12 transcript produced a 12 kD protein composed of INK4a exon 1 alpha and a novel intron-derived C-terminus. This novel protein did not interact with cdk4 but was capable of suppressing growth in a pRb-independent manner. The implications of the capacity of the INK4a/ARF locus to encode a third transcript, and for pancreatic cancer, in which the INK4a/ARF locus is nearly always altered, are considered.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California	Jones, PA (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, MS 83,1441 Eastlake Ave, Los Angeles, CA 90033 USA.			Robertson, Keith/0000-0002-7508-3328	NATIONAL CANCER INSTITUTE [R35CA049758, T32CA009320] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 49758-09, T32 CA 09320-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5394; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; Gonzalgo ML, 1998, CANCER RES, V58, P1245; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; IOVANNA JL, 1991, INT J PANCREATOL, V8, P177; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liggett WH, 1996, CANCER RES, V56, P4119; LONGNECKER DS, 1982, AM J PATHOL, V107, P103; MAO L, 1995, CANCER RES, V55, P2995; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; Rozenblum E, 1997, CANCER RES, V57, P1731; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sambrook J, 1989, MOL CLONING LAB MANU; Schutte M, 1997, CANCER RES, V57, P3126; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sewell D. A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P80; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tsubari M, 1997, CANCER RES, V57, P2966; VALES LD, 1989, GENE DEV, V3, P49, DOI 10.1101/gad.3.1.49; VALLE VD, 1997, ONCOGENE, V15, P2475; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; YEAGER T, 1995, CANCER RES, V55, P493; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	49	79	83	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3810	3820		10.1038/sj.onc.1202737	http://dx.doi.org/10.1038/sj.onc.1202737			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445844				2022-12-17	WOS:000081171700002
J	Valentinis, B; Morrione, A; Peruzzi, F; Prisco, M; Reiss, K; Baserga, R				Valentinis, B; Morrione, A; Peruzzi, F; Prisco, M; Reiss, K; Baserga, R			Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion	ONCOGENE			English	Article						anchorage-independence; apoptosis; IGI-I receptor; ras; Akt	GROWTH-FACTOR-I; BREAST-CANCER CELLS; ANCHORAGE-INDEPENDENT GROWTH; ACTIVATED PROTEIN-KINASE; RAS-TRANSFORMED CELLS; MYC-INDUCED APOPTOSIS; ANTISENSE RNA; TUMOR-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; HEMATOPOIETIC-CELLS	The type 1 insulin-like growth factor receptor (IGF-IR) is known to protect cells from a variety of apoptotic injuries. In several instances, the anti-apoptotic effect of the wild type IGF-IR is more evident under conditions of anchorage-independence than in cells in monolayer cultures. We have investigated IGF-IR signaling in cells in anoikis, a form of apoptosis that occurs when cells are denied attachment to the extra-cellular matrix. IGF-I protects mouse embryo fibroblasts (MEF) from anoikis caused by withdrawal of growth factors. Survival is dependent on the concentration of TGF-I and a sufficient number of functional IGF-I receptors. In this model, IGF-I protection correlates best,vith ras activation and cell-to-cell aggregation, while PI3-kinase, Akt and MAP kinases seem to play a lesser, alternative role.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.		Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53484] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 1997, CANCER RES, V57, P2687; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GunnMoore FJ, 1997, BIOCHEM J, V324, P365, DOI 10.1042/bj3240365; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hsing AY, 1996, CANCER RES, V56, P5146; Jung YK, 1996, J BIOL CHEM, V271, P5112; KATO H, 1993, J BIOL CHEM, V268, P2655; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawada M, 1997, BIOCHEM BIOPH RES CO, V231, P735, DOI 10.1006/bbrc.1997.6179; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kuzumaki T, 1996, BBA-MOL CELL RES, V1310, P185, DOI 10.1016/0167-4889(95)00166-2; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee CT, 1996, CANCER RES, V56, P3038; Lin TH, 1997, J BIOL CHEM, V272, P8849; LONG L, 1995, CANCER RES, V55, P1006; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pass HI, 1996, CANCER RES, V56, P4044; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRISCO M, IN PRESS HORMONES ME; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Turner BC, 1997, CANCER RES, V57, P3079; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1996, BIOCHEM BIOPH RES CO, V224, P362, DOI 10.1006/bbrc.1996.1034; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	71	79	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1827	1836		10.1038/sj.onc.1202471	http://dx.doi.org/10.1038/sj.onc.1202471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086337				2022-12-17	WOS:000079090000006
J	Blackshear, PE; Goldsworthy, SM; Foley, JF; McAllister, KA; Bennett, LM; Collins, NK; Bunch, DO; Brown, P; Wiseman, RW; Davis, BJ				Blackshear, PE; Goldsworthy, SM; Foley, JF; McAllister, KA; Bennett, LM; Collins, NK; Bunch, DO; Brown, P; Wiseman, RW; Davis, BJ			Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice.	ONCOGENE			English	Article						Brca1; Brca2; mitosis; meiosis	BREAST-CANCER; SPERMATOGENIC CELLS; EPITHELIAL-CELLS; MESSENGER-RNA; GENE; DIFFERENTIATION; SUSCEPTIBILITY; TISSUES	The mouse homologues of the breast cancer susceptibility genes, Brca1 and Brca2, are expressed in a cell cycle-dependent fashion in vitro and appear to be regulated by similar or overlapping pathways, Therefore, we compared the non isotopic in situ hybridization expression patterns of Brca1 and Brca2 mRNA in vivo in mitotic and meiotic cells during mouse embryogenesis, mammary gland development, and in adult tissues including testes, ovaries, and hormonally altered ovaries, Brca1 and Brca2 are expressed concordantly in proliferating cells of embryos, and the mammary gland undergoing morphogenesis and in most adult tissues, The expression pattern of Brca1 and Brca2 correlates with the localization of proliferating cell nuclear antigen, an indicator of proliferative activity, In the ovary, Brca1 and Brca2 exhibited a comparable hormone-independent pattern of expression in oocytes, granulosa cells and thecal cells of developing follicles, In the testes, Brca1 and Brca2 were expressed in mitotic spermatogonia and early meiotic prophase spermatocytes, Northern analyses of prepubertal mouse testes revealed that the time course of Brca2 expression was delayed in spermatogonia relative to Brca1. Thus, while Brca1 and Brca2 share concordant cell-specific patterns of expression in most proliferating tissues, these observations suggest that they may have distinct roles during meiosis.	NIEHS, Res Triangle Pk, NC 27709 USA; Pathol Associates Int, Durham, NC 27713 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Blackshear, PE (corresponding author), NIEHS, POB 12233, Res Triangle Pk, NC 27709 USA.			Bunch, Donna/0000-0002-3638-0522; Foley, Julie/0000-0001-9726-2821				BELIVE AR, 1977, J CELL BIOL, V74, P68; CLEVELAND DW, 1990, CELL, V60, P701, DOI 10.1016/0092-8674(90)90083-Q; Connor F, 1997, HUM MOL GENET, V6, P291, DOI 10.1093/hmg/6.2.291; DANIEL CWA, 1987, POSTNATAL DEV RODENT; FOLEY J, 1993, ENVIRON HEALTH PERSP, V101, P199, DOI 10.2307/3431868; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; KURIYAMA R, 1992, BIOESSAYS, V14, P81, DOI 10.1002/bies.950140203; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OBRIEN DA, 1989, ENDOCRINOLOGY, V125, P2973, DOI 10.1210/endo-125-6-2973; Phillips KW, 1997, LAB INVEST, V76, P419; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Smith H S, 1991, Basic Life Sci, V57, P329; Stratton MR, 1996, HUM MOL GENET, V5, P1515, DOI 10.1093/hmg/5.Supplement_1.1515; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WELCH JE, 1995, DEV GENET, V16, P179, DOI 10.1002/dvg.1020160210; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Zabludoff SD, 1996, ONCOGENE, V13, P649	30	79	80	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					61	68		10.1038/sj.onc.1201506	http://dx.doi.org/10.1038/sj.onc.1201506			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467943				2022-12-17	WOS:000071236800007
J	Olshan, AF; Weissler, MC; Pei, H; Conway, K; Anderson, S; Fried, DB; Yarbrough, WG				Olshan, AF; Weissler, MC; Pei, H; Conway, K; Anderson, S; Fried, DB; Yarbrough, WG			Alterations of the p16 gene in head and neck cancer: Frequency and association with p53, PRAD-1 and HPV	ONCOGENE			English	Article						head and neck neoplasms; mutation; p53; p16INK44; HPV; PRAD-1	SQUAMOUS-CELL CARCINOMA; CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA-PROTEIN; HOMOZYGOUS DELETIONS; ALTERED EXPRESSION; FAMILIAL MELANOMA; SUPPRESSOR GENES; INHIBITOR GENE; MTS1 GENE; TUMORS	Alterations, especially homozygous deletions, of the putative tumor suppressor gene, p16 (p16(INK4A), MTS1, CDKN2) have been found in tumor cell lines from a variety of neoplasms. Recent studies have reported frequent p16 gene deletions in cell lines from squamous cell carcinomas of the head and neck (SCCHN), although the prevalence of alterations was variable in primary tumors. This study determined the prevalence of point mutations and deletions of the p16 gene in 33 SCCHN. In addition, the association of p16 gene alterations and abnormalities of p53, PRAD-1 (cyclin D1), and the presence of human papillomavirus (HPV) was examined. We found an overall prevalence of p16 alterations of 36% (nine deletions, three single base substitutions, including one polymorphism). Seven tumors (of 29, 24%) had an alteration of p16 and p53; five (of 33, 15%) had alterations of p16 and PRAD-1; three (of 29, 10%) had alterations of all three genes. In addition, of the five tumors with human papillomavirus detected, only one also had a p16 gene alteration. The results indicate a potentially important role for the p16 gene in head and neck tumorigenesis. In addition, the presence of tumors with multiple somatic gene alterations suggest a possible interaction in the dysregulation of the cell cycle.	UNIV N CAROLINA,SCH MED,DIV OTOLARYNGOL HEAD & NECK SURG,CHAPEL HILL,NC 27599; LAB CORP AMER,DEPT MOL BIOL & PATHOL,RES TRIANGLE PK,NC	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Olshan, AF (corresponding author), UNIV N CAROLINA,SCH PUBL HLTH,DEPT EPIDEMIOL,CHAPEL HILL,NC, USA.							AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Bauer HM, 1992, DIAGNOSTIC MOL PATHO, V2, P131; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; GRANA X, 1995, ONCOGENE, V11, P211; GRUIS NA, 1995, AM J PATHOL, V146, P1199; HANNON GJ, 1994, NATURE, V371, P357; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LIU ET, 1993, SEMIN CANCER BIOL, V4, P47; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAWROZ H, 1994, CANCER RES, V54, P1152; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; QUELLE DE, 1995, CELL, V83, P993; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; VANDERRIET P, 1994, CANCER RES, V54, P1156; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Yeudall WA, 1995, ORAL ONCOL, V31B, P291, DOI 10.1016/0964-1955(95)00028-3; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; YOO GH, 1994, CANCER RES, V54, P4603; ZHANG SY, 1994, CANCER RES, V54, P50; ZHOU XL, 1994, ONCOGENE, V9, P3737	49	79	79	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					811	818		10.1038/sj.onc.1200892	http://dx.doi.org/10.1038/sj.onc.1200892			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047388				2022-12-17	WOS:A1997WJ11200007
J	Janknecht, R; Monte, D; Baert, JL; deLaunoit, Y				Janknecht, R; Monte, D; Baert, JL; deLaunoit, Y			The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA	ONCOGENE			English	Article						Ets protein; ERM; phosphorylation; signaling; transcription	ACTIVATED PROTEIN-KINASE; DNA-BINDING; TRANSDUCTION PATHWAYS; C-FOS; MOLECULAR-CLONING; GENE-EXPRESSION; ONCOGENE FAMILY; GROWTH-FACTOR; DOMAIN; PROMOTER	Recent studies support a model for signal transduction from activated receptor tyrosine kinases to Ras which, in turn, activates the pathway of the mitogen-activated protein kinase (MARK), Although some members of the Ets transcription factor family have been shown to be activated by this signaling pathway, no data are available on the activation of the PEA3 group of Ets proteins, This group is composed of three members PEA3, ER81 and ERM - which are very similar in the DNA-binding domain, the ETS domain, in the 32 residue amino-terminal acidic domain and in the 61 residue carboxy-terminal domain, First of all we demonstrated that ERM-transfected cells contain a positive labeling in the nucleus, and rye concluded that a nuclear localization signal might be situated in the ETS domain, We then showed that of four putative reporter plasmids, ERM activated the artificial 3 x TORU plasmid which contains an Ets binding site contiguous to an AP1 one, This transactivation enhancement requires the presence of the ERM amino-terminal domain, In contrast, although the lack of the carboxy-terminal domain induced a decrease in transactivation, this latter domain is not crucial, By using the E74-reporter plasmid system which is not basically activated by ERM, we showed that the activation of the Ras/Raf-1/MAPK pathway significantly enhanced ERM-mediated transactivation, The deletion of the amino-terminal transactivation domain abolished the capacity of stimulated MAPK to activate ERM, We also demonstrated that ERM can also be activated through the protein kinase A (PKA), another signaling pathway, Nevertheless, the MAPK and PKA activation of ERM are not synergistic, Finally, we showed that this Ets transcription factor is in vitro phosphorylated by both activated ERK-2 and activated PKA, ERM has thus been identified as a transcription factor which is a target for two different signaling pathways and might therefore be involved in the mitogenic response of cells.	INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE; HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Hannover Medical School				Janknecht, Ralf/0000-0003-1741-1562; monte, didier/0000-0002-0613-6203				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COFFER P, 1994, ONCOGENE, V9, P911; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; deLaunoit Y, 1996, BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, P115; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; Laget MP, 1996, ONCOGENE, V12, P1325; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RAO VN, 1993, ONCOGENE, V8, P2167; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Stacey D W, 1988, Adv Exp Med Biol, V234, P141; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	40	79	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1745	1754						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895521				2022-12-17	WOS:A1996VM88700020
J	Wang, JW; Shackleford, GM				Wang, JW; Shackleford, GM			Murine Wnt10a and Wnt10b: Cloning and expression in developing limbs, face and skin of embryos and in adults	ONCOGENE			English	Article						breast neoplasms; oncogene; embryonic development; alternative splicing; limb development; Wnt	MAMMARY-TUMOR VIRUS; GENE FAMILY; TRANSGENIC MICE; CELL-LINE; INT-1 PROTOONCOGENE; PROVIRAL INSERTION; ONCOGENE INT-1; MOUSE; WNT-1; TRANSFORMATION	Wnt genes encode a family of secreted proteins having oncogenic potential and important roles in developmental processes, We report the isolation of cDNAs for a novel murine Wnt gene, Wnt10a, and for two alternatively spliced transcripts of Wnt10b, as well as analyses of the expression patterns of these genes in adult and embryonic tissues, Wnt10a and full length Wnt10b encode relatively closely related (62% identity) Wnt proteins containing the 24 cysteines characteristic of most Wnt proteins, The deduced protein encoded by the alternatively spliced Wnt10b transcript lacks a central region encompassing 25% of the full length isoform, Both Wnt genes were widely expressed in the adult, although the levels of expression varied significantly, Wnt10a RNA was most abundant in adult brain with a high concentration in the pituitary gland, and expression of Wnt10b was highest in adult lung and uterus, RNAs of both genes mere detected in thymus and spleen, tissues not previously reported as sites for Wnt gene expression, Wnt10a and Wnt10b expression broadly peaked at approximately 13.5 and 15.5 days of gestation, respectively, and Northern blot analyses of RNAs from dissected embryos revealed that expression of both genes was strongest in the face, limbs and skin and that Wnt10a was also expressed in the Liver, the major site of hematopoiesis in the embryo, These expression patterns suggest that Wnt10a and Wnt10b may function in various tissues of the adult and embryo with notable expression in tissues responsible for the formation and maturation of blood cells, in the pituitary gland (Wnt10a), and in the face, Limbs and skin of developing embryos.	CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,RES INST,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California					NATIONAL CANCER INSTITUTE [R01CA054436] Funding Source: NIH RePORTER; NCI NIH HHS [CA54436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONOHOWER LA, 1995, GENE DEV, V9, P882; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; IOZZO RV, 1995, CANCER RES, V55, P3495; KELLY GM, 1993, DEV BIOL, V158, P113, DOI 10.1006/dbio.1993.1172; KOZAK M, 1983, MICROBIOL REV, V47, P1; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1992, CIBA F SYMP, V165, P199; MOON RT, 1993, DEVELOPMENT, P85; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RUGH R, 1968, MOUSE ITS REPRODUCTI; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; SU SJ, 1995, MOL CELL BIOL, V15, P2625; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAUTZ D, 1992, IN SITU HYBRIDIZATIO, P61; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	49	79	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875992				2022-12-17	WOS:A1996VL38400019
J	Martin, DC; Ruther, U; SanchezSweatman, OH; Orr, FW; Khokha, R				Martin, DC; Ruther, U; SanchezSweatman, OH; Orr, FW; Khokha, R			Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice	ONCOGENE			English	Article						TIMP-1; tumor suppression; T antigen; transgenic mice	B16-F10 MELANOMA-CELLS; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; METALLOPROTEINASE INHIBITOR; CANCER METASTASIS; GENE-EXPRESSION; TUMOR INVASION; GROWTH-FACTOR; ANGIOGENESIS; COLLAGENASE	The potential of tissue inhibitors of metalloproteinases (TIMPs) to inhibit neoplastic progression has been postulated from studies of genetically manipulated cells. To investigate whether the TIMP-1 expressed in a host tissue suppresses cancer in vivo and to identify the affected stages, we developed transgenic mice with constitutive overexpression or reduction of TIMP-1 in the liver. In double transgenic experiments, the TIMP-1 lines were crossed with a second transgenic line which expresses the Simian Virus 40 t/T antigen (TAg). This viral oncogene leads to heritable development of hepatocellular carcinomas with a 100% incidence. Effects of TIMP-1 coexpression on the TAg-induced neoplasms were determined at the tissue and cellular level. Here, we report that overexpression of hepatic TIMP-1 blocked the development of TAg-induced hepatocellular carcinomas. High TIMP-1 levels inhibited not only the later stages in tumor development (growth and angiogenesis), but also events associated with tumor initiation (altered hepatocyte cytology and tissue architecture). We further show that an antisense-mediated reduction of TIMP-1 resulted in a more rapid tumor initiation and progression. These data demonstrate that intrinsic TIMP-1 levels contribute to a tissue's susceptibility to viral oncogene-induced tumorigenesis.	UNIV WESTERN ONTARIO,LONDON REG CANC CTR,DEPT ONCOL,LONDON,ON N6A 4L6,CANADA; UNIV WESTERN ONTARIO,LONDON REG CANC CTR,DEPT BIOCHEM,LONDON,ON N6A 4L6,CANADA; HANNOVER MED SCH,INST MOL BIOL,D-30655 HANNOVER,GERMANY; HAMILTON REG CANC CTR,HAMILTON,ON L8V 5C2,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Hannover Medical School; McMaster University								ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BERTAUX B, 1993, CR SOC BIOL, V187, P192; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BISWAS C, 1995, CANCER RES, V55, P434; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BOUJRAD N, 1995, SCIENCE, V268, P1609, DOI 10.1126/science.7777858; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULLEN JM, 1993, VET PATHOL, V30, P111, DOI 10.1177/030098589303000203; DECLERCK YA, 1992, CANCER RES, V52, P701; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HOGAN B, 1986, MANIPULATING MOUSE E, P153; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KOOP S, 1994, CANCER RES, V54, P4791; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIGNATTI P, 1988, MOL CELLULAR BIOL WO, P497; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MULLER E, 1995, ONCOGENE, V10, P1175; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; RUTHER U, 1993, ONCOGENE, V8, P87; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAKIGAWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1264, DOI 10.1016/0006-291X(90)90822-5; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; WATERHOUSE P, 1993, MOL REPROD DEV, V35, P219, DOI 10.1002/mrd.1080350302; WELGUS HG, 1979, J BIOL CHEM, V254, P1938; WERNERT N, 1994, CANCER RES, V54, P5683; WITTY JP, 1995, CANCER RES, V55, P1401	54	79	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					569	576						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760297				2022-12-17	WOS:A1996VB32800014
J	ALTOMARE, DA; GUO, K; CHENG, JQ; SONODA, G; WALSH, K; TESTA, JR				ALTOMARE, DA; GUO, K; CHENG, JQ; SONODA, G; WALSH, K; TESTA, JR			CLONING, CHROMOSOMAL LOCALIZATION AND EXPRESSION ANALYSIS OF THE MOUSE AKT2 ONCOGENE	ONCOGENE			English	Article						ONCOGENE; GENE MAPPING; DIFFERENTIATION; MUSCLE	FLUORESCENCE INSITU HYBRIDIZATION; MOLECULAR-CLONING; PROTEIN-KINASE; GENE; SUBFAMILY; HOMOLOGY; REGION	We isolated mouse cDNA clones containing the entire coding region of the putative oncogene Akt2, Sequence analysis revealed that, like its human homolog, Akt2 encodes a protein-serine/threonine kinase containing a pleckstrin homology domain at its amino terminus, Fluorescence in situ hybridization of the mouse cDNA to rodent metaphase spreads demonstrated that the Akt2 gene maps to mouse chromosome band 7B1 and rat chromosome 1q22. Expression levels of mouse Akt2 mRNA and Akt2 protein varied among tissues, with the highest levels in skeletal muscle, Akt2 expression was low in a multipotent fibroblast cell line, but it was upregulated when these cells were transformed with Myod and induced to differentiate into myocytes. These data demonstrate that Akt2 expression is activated during cellular differentiation and suggest that it functions in the signaling pathways of some adult tissues.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; TUFTS UNIV,ST ELIZABETHS MED CTR,SCH MED,DEPT CARDIOVASC RES,BOSTON,MA 02135	Fox Chase Cancer Center; St. Elizabeth's Medical Center; Tufts University					NCI NIH HHS [R01 CA077429, CA-06927, P30 CA006927, CA 09035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA077429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COFFER PJ, 1991, EUR J BIOCHEM, V210, P475; DATTA K, 1995, MOL CELL BIOL, V15, P2304; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FRANKE TF, 1994, ONCOGENE, V9, P141; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASLAM RJ, 1993, NATURE, V36, P309; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; Maltais L. J., 1994, Mouse Genome, V92, P62; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROPERS HH, 1991, CYTOGENET CELL GENET, V58, P751, DOI 10.1159/000133179; Sambrook J., 1989, MOL CLONING LAB MANU; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Staal SP, 1988, GENOMICS, V2, P96, DOI 10.1016/0888-7543(88)90114-0; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	79	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1055	1060						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566964				2022-12-17	WOS:A1995RX18000007
J	PARK, NH; GUJULUVA, CN; BAEK, JH; CHERRICK, HM; SHIN, KH; MIN, BM				PARK, NH; GUJULUVA, CN; BAEK, JH; CHERRICK, HM; SHIN, KH; MIN, BM			COMBINED ORAL CARCINOGENICITY OF HPV-16 AND BENZO(A)PYRENE - AN IN-VITRO MULTISTEP CARCINOGENESIS MODEL	ONCOGENE			English	Article						ORAL CANCER; HPV; BENZO(A)PYRENE; MULTISTEP CARCINOGENESIS; TUMOR SUPPRESSOR	PRIMARY HUMAN KERATINOCYTES; HUMAN PAPILLOMAVIRUS; INSITU HYBRIDIZATION; CERVICAL-CARCINOMA; CELLULAR-RESPONSE; ACTIVATED RAS; DNA DAMAGE; CELLS; TRANSFORMATION; EXPRESSION	We previously immortalized normal human oral keratinocytes by transfection with recombinant HPV-16 DNA and subsequently exposed the cells to benzo(a)pyrene for 7 days. The exposure to benzo(a)pyrene modified the immortalized cells: the modified cells (HOK-16B-BaP) proliferated in an ordinary culture medium containing physiological calcium level (1.5 mM), but demonstrated only enhanced proliferation capacity without tumor formation in nude mice and failed to show in vitro anchorage-independency. In this study, we further modified the HOK-16B-BaP cells by subculturing the cells in a medium containing benzo(a)pyrene for 6 months. The cells were further modified with a chronic benzo(a)pyrene exposure and were termed HOK-16B-BaP-T cells (1) demonstrated a malignant phenotype in organotypic 'raft' culture, (2) showed in vitro anchorage-independency, (3) developed tumors in nude mice when injected subcutaneously, (4) contained a significantly higher copy number of intact and integrated HPV-16 DNA; (5) contained higher level of HPV-16 E6/E7 messages and E7 protein, (6) were more resistant to transforming growth factor-beta 1 and (7) secreted higher level of vascular endothelial growth factor with molecular weight of 56 kd than parental HOK-16B-BaP cells. However, the levels of p53 and ras proteins and the levels of p53, c-myc and c-fos transcripts in the HOK-16B-BaP-T cells were not different from those in the HOK-16B-BaP cells. The highly conserved coding regions of the p53, c-Ha-ras1, and c-Ki-ras2 genes of the tumor cells were not mutated. These data indicate that the HPV-immortalized human oral keratinocytes can convert to tumorigenic cells by chronic exposure to benzo(a)pyrene. The tumorigenic conversion seems to be associated with (1) the overexpression of viral oncogenes such as E6 and E7 genes, (2) the higher resistance of cells to transforming growth factor-beta(1) and (3) the high secretion of 56 kd vascular endothelial growth factor from the cells.	UNIV CALIF LOS ANGELES, SCH DENT, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	PARK, NH (corresponding author), UNIV CALIF LOS ANGELES, DENT RES INST, LOS ANGELES, CA 90024 USA.		Min, Byung-Moo/F-2854-2012		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 10049] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAEK JH, 1994, INT J ONCOL, V5, P1023; BIREK C, 1993, AM J PATHOL, V142, P917; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CURRAN T, 1984, CELL, V36, P259; DILUCA D, 1990, J DENT RES, V69, P51; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; FIELD JK, 1990, ANTICANCER RES, V10, P1; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; JOHNSON MA, 1990, J GEN VIROL, V71, P1473, DOI 10.1099/0022-1317-71-7-1473; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM MS, 1993, CANCER RES, V53, P4811; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MEANWELL CA, 1988, CANCER SURV, V7, P481; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; MIN BM, 1991, IN VITRO CELL DEV B, V27, P128; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SCULLY C, 1988, ORAL SURG ORAL MED O, V65, P526, DOI 10.1016/0030-4220(88)90134-X; SHAH KV, 1990, PAPILLOMAVIRUSES HUM, P73; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SYRJANEN S, 1992, SCAND J DENT RES, V100, P17; WEINBERG WC, 1994, CANCER RES, V54, P5584; WOODS KV, 1993, J ORAL PATHOL MED, V22, P101, DOI 10.1111/j.1600-0714.1993.tb01038.x; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; ZURHANSEN H, 1986, LANCET, V3, P489	43	79	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2145	2153						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784058				2022-12-17	WOS:A1995RB70300009
J	ENOMOTO, H; OZAKI, T; TAKAHASHI, E; NOMURA, N; TABATA, S; TAKAHASHI, H; OHNUMA, N; TANABE, M; IWAI, J; YOSHIDA, H; MATSUNAGA, T; SAKIYAMA, S				ENOMOTO, H; OZAKI, T; TAKAHASHI, E; NOMURA, N; TABATA, S; TAKAHASHI, H; OHNUMA, N; TANABE, M; IWAI, J; YOSHIDA, H; MATSUNAGA, T; SAKIYAMA, S			IDENTIFICATION OF HUMAN DAN GENE, MAPPING TO THE PUTATIVE NEUROBLASTOMA TUMOR-SUPPRESSOR LOCUS	ONCOGENE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; N-MYC AMPLIFICATION; CELL-LINES; NEURO-BLASTOMA; SHORT ARM; DELETION; EXPRESSION; CHROMOSOME; TUMORIGENICITY; HETEROZYGOSITY	The expression of DAN gene (previously designated as N03 gene) is significantly reduced in a variety of transformed rat fibroblasts, including v-src- (SR-3Y1), SV40- and v-mos-transformed 3Y1 cells, compared with that in parental 3Y1 cells. Recently, DAN gene has been shown to possess a tumor suppressive activity when it is overexpressed in SR-3Y1 cells (Ozaki & Sakiyama, 1994). To assess the involvement of DAN gene,vith human neoplasms, we have isolated human DAN counterpart from a normal lung cDNA library by using rat DAN cDNA as a probe, and determined its chromosomal location. Human DAN gene mapped to chromosome 1p36.11-p36.13, which is well known to show highly significant linkage with the genesis and/or progression of human neuroblastoma. Southern blot analysis on tumor DNA from 26 patients with neuroblastoma has detected three patients showing genomic rearrangement or deletion within or closely linked to the DAN gene locus. Collectively, we propose that human DAN gene is a possible candidate for a tumor suppressor gene of human neuroblastoma.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHUOH KU,CHIBA 260,JAPAN; NATL INST RADIOL SCI,DIV GENET,INAGE KU,CHIBA 263,JAPAN; NIPPON MED COLL,INST GERONTOL,MOLEC BIOL LAB,NAKAHARA KU,KAWASAKI 211,KANAGAWA,JAPAN; NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIGUSA KU,NAGOYA 464,JAPAN; KAZUSA DNA,RES INST,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center; Chiba University; National Institutes for Quantum Science & Technology; Nippon Medical School; Nagoya University; Kazusa DNA Research Institute								BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BIECHE I, 1993, CANCER RES, V53, P1990; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; FRANCKE U, 1978, BIRTH DEFECTS, V12, P131; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; GILBERT F, 1984, CANCER RES, V44, P5444; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIYAKE K, 1973, AUTONOM NERV SYST JP, V10, P115; MOLEY JF, 1992, CANCER RES, V52, P770; OZAKI T, 1994, CANCER RES, V54, P646; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; SUGIMOTO T, 1986, CANCER RES, V46, P4765; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAHASHI E, 1991, HUM GENET, V88, P119, DOI 10.1007/BF00204942; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TSUCHIDA Y, 1990, FEBS LETT, V263, P191, DOI 10.1016/0014-5793(90)81370-4; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	58	79	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2785	2791						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084583				2022-12-17	WOS:A1994PG82200003
J	HOGG, A; ONADIM, Z; BAIRD, PN; COWELL, JK				HOGG, A; ONADIM, Z; BAIRD, PN; COWELL, JK			DETECTION OF HETEROZYGOUS MUTATIONS IN THE RB1 GENE IN RETINOBLASTOMA PATIENTS USING SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS AND POLYMERASE CHAIN-REACTION SEQUENCING	ONCOGENE			English	Article							BASE-PAIR SUBSTITUTIONS; SUSCEPTIBILITY GENE; POINT MUTATIONS; DNA FRAGMENTS; EXPRESSION; GERMLINE	Several families segregating the autosomal dominant form of the hereditary retinoblastoma predisposition gene have been analysed for the causative mutation. We have used the single-strand conformation polymorphism (SSCP) technique to screen for mutations, exon by exon, in the RBI gene in affected patients from these families. The SSCP technique has proved a rapid and simple technique which relies on the sequence-dependent migration of single-stranded DNA in a non-denaturing polyacrylamide gel. Oligonucleotide primers flanking all 27 exons and the promoter region of the RB1 gene are reported here. The polymerase chain reaction (PCR)amplified products range in size from 212 to 625 bp and include a flanking intron sequence which allows detection of mutations in these regions. The sensitivity of SSCP is optimal when DNA fragments are approximately 200 bp long. Consequently, restriction enzyme sites for each amplified region were identified, reducing the size of the PCR products analysed to less than 250 bp. Bands with aberrant migration patterns were observed on SSCP gels in the lymphocyte DNA from two patients with bilateral, familial retinoblastoma. Sequence analysis of these DNA fragments revealed the causative mutations. These consisted of a 1-bp insertion of a T in the coding strand of exon 20 and a G --> A mutation in the coding strand of exon 14. This approach has proved to be a powerful method for the rapid detection of germline mutations in the RB1 gene, a programme which can be extended to individuals with new mutations.	INST CHILD HLTH,DEPT HAEMATOL & ONCOL,ICRF,ONCOL GRP,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND	University of London; University College London			Onadim, Zerrin/AAX-6490-2021	Onadim, Zerrin/0000-0002-8594-9586; Baird, Paul/0000-0002-1305-3502; Cowell, John/0000-0002-2079-5950				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GANGULY A, 1990, NUCLEIC ACIDS RES, V18, P3933, DOI 10.1093/nar/18.13.3933; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; INNES MA, 1990, PCR PROTOCOLS GUIDE, P54; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAZARS R, 1991, ONCOGENE, V6, P1685; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MURAKAMI Y, 1991, ONCOGENE, V6, P37; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; ONADIM Z, 1991, J MED GENET, V28, P312, DOI 10.1136/jmg.28.5.312; ONADIM ZO, 1990, ARCH DIS CHILD-FETAL, V65, P651, DOI 10.1136/adc.65.7_Spec_No.651; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOGEL W, 1979, HUM GENET, V51, P1; WARTELL RM, 1990, NUCLEIC ACIDS RES, V18, P2699, DOI 10.1093/nar/18.9.2699; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLIAMS JF, 1989, BIOTECHNIQUES, V7, P283; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	31	79	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1445	1451						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1352398				2022-12-17	WOS:A1992HZ97100026
J	SCHEK, N; BARTENSCHLAGER, R; KUHN, C; SCHALLER, H				SCHEK, N; BARTENSCHLAGER, R; KUHN, C; SCHALLER, H			PHOSPHORYLATION AND RAPID TURNOVER OF HEPATITIS-B VIRUS X-PROTEIN EXPRESSED IN HEPG2 CELLS FROM A RECOMBINANT VACCINIA VIRUS	ONCOGENE			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; TRANSFORMED-CELLS; MAMMALIAN-CELLS; DNA; BINDING; GENOME; ANTIBODIES	The human hepatitis B viral (HBV) genome contains a conserved open reading frame known as the X-gene which is capable of encoding a polypeptide of 16.565 kDa. The corresponding protein has so far not been identified directly in HBV-infected cells, but in transient transfection assays the X-gene encodes a product that functions as a transcriptional transactivator. To characterize the subcellular distribution, stability and post-translational modifications of X-protein in human hepatoma HepG2 cells, we have established a vaccinia virus expression system. As the major X-gene product, a protein with an apparent molecular weight of 16 kDa, and reacting with an X-protein-specific antiserum, was expressed from recombinant vaccinia virus. In indirect immunofluorescence assay, X-protein appeared to be distributed throughout the cells, with a tendency to localize at the nuclear periphery and to accumulate in granules as its levels increased. By subcellular fractionation, we found about one-third of X-protein associated with the fraction defined as the nuclear framework. In pulse-chase experiments, X-protein decayed with a bimodal half-life of 15 min and 3 h. X-protein having a half-life of about 15 min was found associated with the Triton X-100 detergent-soluble fraction of HepG2 cells, while that associated with the insoluble fraction turned over more slowly. By metabolic labeling with [P-32]orthophosphate, we show that X-protein is capable of being phosphorylated. Modification by phosphorylation could play an important role in the regulation of X-protein function.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL HEIDELBERG,IM NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Bartenschlager, Ralf/L-2582-2015	Bartenschlager, Ralf/0000-0001-5601-9307				AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BENZEEV A, 1981, VIROLOGY, V111, P475, DOI 10.1016/0042-6822(81)90350-0; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BRANTON PE, 1985, J VIROL, V56, P633, DOI 10.1128/JVI.56.2.633-638.1985; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHISAKA O, 1987, GENE, V60, P183; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DEMAGISTRIS L, 1988, NUCLEIC ACIDS RES, V16, P3141, DOI 10.1093/nar/16.8.3141; ELFASSI E, 1986, P NATL ACAD SCI USA, V83, P2219, DOI 10.1073/pnas.83.7.2219; FRANKE CA, 1989, J VIROL, V63, P4285, DOI 10.1128/JVI.63.10.4285-4291.1989; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES LABORATOR, P460; HESS J, 1988, MED MICROBIOL IMMUN, V177, P195, DOI 10.1007/BF00211219; HILLER G, 1985, J VIROL, V55, P651, DOI 10.1128/JVI.55.3.651-659.1985; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1988, CELL, V55, P123; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KOSHY R, 1989, CURR TOP MICROBIOL, V144, P265; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; MERRIL CR, 1981, SCIENCE, V211, P1436; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENMAN S, 1966, J MOL BIOL, V17, P117, DOI 10.1016/S0022-2836(66)80098-0; PFAFF E, 1987, VIROLOGY, V158, P456, DOI 10.1016/0042-6822(87)90221-2; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEK N, 1991, HEPADNAVIRAL X PROTE, P181; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SEIFER M, 1990, VIROLOGY, V179, P287, DOI 10.1016/0042-6822(90)90297-5; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STAMATOS NM, 1987, J VIROL, V61, P516, DOI 10.1128/JVI.61.2.516-525.1987; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZAHM P, 1988, ONCOGENE, V3, P169	58	79	84	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1735	1744						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923499				2022-12-17	WOS:A1991GX11800003
J	COHEN, DR; CURRAN, T				COHEN, DR; CURRAN, T			ANALYSIS OF DIMERIZATION AND DNA-BINDING FUNCTIONS IN FOS AND JUN BY DOMAIN-SWAPPING - INVOLVEMENT OF RESIDUES OUTSIDE THE LEUCINE ZIPPER BASIC REGION	ONCOGENE			English	Article											COHEN, DR (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110, USA.		Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Cohen, Donna/0000-0002-0419-9542				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1990, IN PRESS SEMINARS CA; AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1989, ONCOGENE, V4, P123; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1984, CELL, V36, P259; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1987, ONCOGENE, V1, P213; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOUGHTON JE, 1989, NATURE, V338, P172, DOI 10.1038/338172a0; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	51	79	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					929	939						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2113670				2022-12-17	WOS:A1990DP55300022
J	ANDRE, C; DAURIOL, L; LACOMBE, C; GISSELBRECHT, S; GALIBERT, F				ANDRE, C; DAURIOL, L; LACOMBE, C; GISSELBRECHT, S; GALIBERT, F			C-KIT MESSENGER-RNA EXPRESSION IN HUMAN AND MURINE HEMATOPOIETIC-CELL LINES	ONCOGENE			English	Note									HOP COCHIN,CNRS,UA 628,INSERM,U152,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	ANDRE, C (corresponding author), HOP ST LOUIS,HEMATOL EXPTL LAB,CNRS,UPR RECOMBINAISONS GENET 41,F-75475 PARIS 10,FRANCE.							BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAURIOL L, 1988, HUM GENET, V78, P374, DOI 10.1007/BF00291740; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; LEBEAU MM, 1986, SCIENCE, V231, P984, DOI 10.1126/science.3484837; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ELIZABETH S., 1966, P351; SEIGNEURIN D, 1987, EXP HEMATOL, V15, P822; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SIEFF CA, 1987, J CLIN INVEST, V79, P1549, DOI 10.1172/JCI112988; SILINI G, 1967, J EMBRYOL EXP MORPH, V17, P303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	21	79	81	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1047	1049						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2474787				2022-12-17	WOS:A1989AJ29700016
J	MARCH, PE; LERNER, CG; AHNN, J; CUI, X; INOUYE, M				MARCH, PE; LERNER, CG; AHNN, J; CUI, X; INOUYE, M			THE ESCHERICHIA-COLI RAS-LIKE PROTEIN (ERA) HAS GTPASE ACTIVITY AND IS ESSENTIAL FOR CELL-GROWTH	ONCOGENE			English	Article											MARCH, PE (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH RUTGERS,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ARMSTRONG KA, 1984, J MOL BIOL, V175, P331, DOI 10.1016/0022-2836(84)90352-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CULLEN SE, 1976, J IMMUNOL, V117, P136; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; FUMIYAMA A, 1986, P NATL ACAD SCI US, V83, P1266; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; INOUYE S, 1976, J BACTERIOL, V127, P555, DOI 10.1128/JB.127.1.555-563.1976; INOUYE S, 1985, NUCLEIC ACIDS RES, V13, P3101, DOI 10.1093/nar/13.9.3101; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; KUSHNER SR, 1971, P NATL ACAD SCI USA, V68, P824, DOI 10.1073/pnas.68.4.824; LUNN CA, 1987, J BIOL CHEM, V262, P8318; MANIATIS T, 1984, MOL CLONING LABORATO; MARCH PE, 1985, J BIOL CHEM, V260, P7206; Miller D L, 1974, Methods Enzymol, V30, P219; NAKAMURA K, 1982, Journal of Molecular and Applied Genetics, V1, P289; OISHI M, 1972, BIOCHEM BIOPH RES CO, V49, P1568, DOI 10.1016/0006-291X(72)90520-7; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; UNO I, 1985, P NATL ACAD SCI USA, V82, P7855, DOI 10.1073/pnas.82.23.7855; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WACHERNAGEL W, 1973, BIOCHEM BIOPH RES CO, V51, P306; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; WURTZEL ET, 1982, J BIOL CHEM, V257, P13685; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	79	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					539	544						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838786				2022-12-17	WOS:A1988N841500002
J	Wang, KX; Ji, WX; Yu, YF; Li, ZM; Niu, XM; Xia, WL; Lu, S				Wang, Kaixuan; Ji, Wenxiang; Yu, Yongfeng; Li, Ziming; Niu, Xiaomin; Xia, Weiliang; Lu, Shun			FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer	ONCOGENE			English	Article							FACTOR RECEPTOR 1; FGFR1 AMPLIFICATION; GROWTH; SOX2; STEM; INHIBITOR; MECHANISMS; SURVIVAL; GENE; EMT	Epithelial-mesenchymal transition (EMT) is an important process for cancer metastasis, drug resistance, and cancer stem cells. Activation of fibroblast growth factor receptor 1 (FGFR1) was found to promote EMT and metastasis in prostate and breast cancers, but the effects and mechanisms in lung cancer was unclear. In this study, we aimed to explore whether and how activation of FGFR1 promotes EMT and metastasis in FGFR1-amplified lung cancer. We show that activation of FGFR1 by its ligand fibroblast growth factor 2 (FGF2) promoted proliferation, EMT, migration, and invasion in FGFR1-amplified lung cancer cell lines H1581 and DMS114, whereas inhibition of FGFR1 suppressed these processes. FGFR1 activation upregulated expression of Sry-related HMG box 2 (SOX2) by downstream phosphorylated ERK1/2; moreover, the upregulation of SOX2 by autophosphorylation variant ERK2_R67S plasmid transfection was not suppressed by FGFR1 inhibitor AZD4547 or MEK/ERK inhibitor AZD6244 in vitro. And SOX2 expression was also significantly upregulated in ERK2_R67S lentivirus-transfected stable cell lines in vivo. Overexpression of SOX2 promoted cell proliferation, EMT, migration, and invasion. Importantly, activation of FGFR1 could not promote these processes in SOX2-silenced stable cell lines. In orthotopic and subcutaneous lung cancer xenograft models, inhibition of FGFR1 suppressed tumor growth, SOX2 expression, EMT, and metastasis in vivo; however, these processes caused by SOX2-overexpressing stable cell lines were not suppressed by FGFR1 inhibition. Higher expression of FGFR1 and SOX2 were positively correlated, and both were associated with shorter survival in lung cancer patients. In conclusion, our findings reveal that activation of FGFR1 promotes cell proliferation, EMT, and metastasis by the newly defined FGFR1-ERK1/2-SOX2 axis in FGFR1-amplified lung cancer.	[Wang, Kaixuan; Ji, Wenxiang; Yu, Yongfeng; Li, Ziming; Niu, Xiaomin; Lu, Shun] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, West Huaihai Rd 241, Shanghai 200030, Peoples R China; [Wang, Kaixuan; Xia, Weiliang] Shanghai Jiao Tong Univ, Sch Biomed Engn, Huashan Rd 1954, Shanghai 200030, Peoples R China; [Wang, Kaixuan; Xia, Weiliang] Shanghai Jiao Tong Univ, MedX Res Inst, Huashan Rd 1954, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Lu, S (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, West Huaihai Rd 241, Shanghai 200030, Peoples R China.; Xia, WL (corresponding author), Shanghai Jiao Tong Univ, Sch Biomed Engn, Huashan Rd 1954, Shanghai 200030, Peoples R China.; Xia, WL (corresponding author), Shanghai Jiao Tong Univ, MedX Res Inst, Huashan Rd 1954, Shanghai 200030, Peoples R China.	wlxia@sjtu.edu.cn; shunlu@sjtu.edu.cn	XIA, WEILIANG/AEA-0835-2022; Lu, Shun/ABF-8341-2021	XIA, WEILIANG/0000-0002-0256-4219; 	National Key R&D Program of China [2016YFC1303300]; National Natural Science Foundation of China [81672272, 81773115]; National Key Grant of China [2016YFC0906400]; Shanghai Health & Family Planning Commission [201540365]; Shanghai Municipal Science & Technology Commission [17431906103]; Shanghai Scientific Research Projects [14140902800]; AstraZeneca	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Grant of China; Shanghai Health & Family Planning Commission; Shanghai Municipal Science & Technology Commission(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Scientific Research Projects; AstraZeneca(AstraZeneca)	This work was funded by the National Key R&D Program of China (2016YFC1303300 to S.L.), the National Natural Science Foundation of China (81672272 to S.L. and 81773115 to W.X.), the National Key Grant of China (2016YFC0906400 to W.X.), the Key Project of Shanghai Health & Family Planning Commission (201540365 to S.L.), Shanghai Municipal Science & Technology Commission Research Project (17431906103 to S.L.), and Shanghai Scientific Research Projects (14140902800 to S.L.) We thank Wangxi Hai and Med-X Ruijin Hospital Micro PET/CT Research Center for the microCT scan and analysis. We thank AstraZeneca Pharmaceutical Company for kindly supply of AZD4547 and AstraZeneca Research Funding.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Adachi Y, 2017, CARCINOGENESIS, V38, P1063, DOI 10.1093/carcin/bgx091; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Brady DC, 2014, NATURE, V509, P492, DOI 10.1038/nature13180; Brewer JR, 2016, GENE DEV, V30, P751, DOI 10.1101/gad.277137.115; Brown WS, 2016, MOL CANCER THER, V15, P2096, DOI 10.1158/1535-7163.MCT-16-0136; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen F, 2017, ONCOGENE, V36, P1384, DOI 10.1038/onc.2016.303; Chen YJ, 2014, BIOMATERIALS, V35, P10058, DOI 10.1016/j.biomaterials.2014.09.003; Datta J, 2017, MOL CANCER THER, V16, P614, DOI 10.1158/1535-7163.MCT-15-1010; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Goke F, 2015, CLIN CANCER RES, V21, P4356, DOI 10.1158/1078-0432.CCR-14-3357; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanna N, 2017, J CLIN ONCOL, V35, P3484, DOI 10.1200/JCO.2017.74.6065; Hu YP, 2016, ONCOTARGET, V7, P87124, DOI 10.18632/oncotarget.13547; Jakobsen KR, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.17; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Ji WX, 2016, ONCOTARGET, V7, P15118, DOI 10.18632/oncotarget.7701; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katoh M, 2016, TRENDS PHARMACOL SCI, V37, P1081, DOI 10.1016/j.tips.2016.10.003; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kim HR, 2017, ANN ONCOL, V28, P1250, DOI 10.1093/annonc/mdx098; Kim HR, 2013, J CLIN ONCOL, V31, P731, DOI 10.1200/JCO.2012.43.8622; Kim M, 2017, ONCOGENE, V36, P5199, DOI 10.1038/onc.2017.4; Kotani H, 2016, ONCOGENE, V35, P3587, DOI 10.1038/onc.2015.426; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lewis DR, 2014, CANCER-AM CANCER SOC, V120, P2883, DOI 10.1002/cncr.28749; Lim SH, 2016, CANCER-AM CANCER SOC, V122, P3024, DOI 10.1002/cncr.30135; Maehara O, 2017, CARCINOGENESIS, V38, P1073, DOI 10.1093/carcin/bgx095; Malchers F, 2017, CLIN CANCER RES, V23, P5527, DOI 10.1158/1078-0432.CCR-17-0478; Malchers F, 2014, CANCER DISCOV, V4, P246, DOI 10.1158/2159-8290.CD-13-0323; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Mandal R, 2016, ONCOGENE, V35, P2547, DOI 10.1038/onc.2015.329; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Paik PK, 2017, CLIN CANCER RES, V23, P5366, DOI 10.1158/1078-0432.CCR-17-0645; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Peng L, 2014, NANOMED-NANOTECHNOL, V10, P1497, DOI 10.1016/j.nano.2014.03.016; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schultheis AM, 2014, MODERN PATHOL, V27, P214, DOI 10.1038/modpathol.2013.141; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singleton KR, 2015, CANCER RES, V75, P4398, DOI 10.1158/0008-5472.CAN-15-0509; Sousa V, 2016, VIRCHOWS ARCH, V469, P173, DOI 10.1007/s00428-016-1954-5; Tan Q, 2016, ONCOTARGET, V7, P18394, DOI 10.18632/oncotarget.7817; Taniguchi J, 2017, NUCLEIC ACIDS RES, V45, P9219, DOI 10.1093/nar/gkx693; Terry S, 2017, MOL ONCOL, V11, P824, DOI 10.1002/1878-0261.12093; Thomas A, 2014, J THORAC ONCOL, V9, P567, DOI 10.1097/JTO.0000000000000089; Toschi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095303; Tripathi SC, 2017, CANCER RES, V77, P4414, DOI 10.1158/0008-5472.CAN-16-2874; Wang L, 2016, ONCOGENE, V35, P867, DOI 10.1038/onc.2015.141; Weina K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-19; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Yuan H, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0534-0; Zhang JC, 2012, CLIN CANCER RES, V18, P6658, DOI 10.1158/1078-0432.CCR-12-2694	68	78	81	1	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5340	5354		10.1038/s41388-018-0311-3	http://dx.doi.org/10.1038/s41388-018-0311-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29858603				2022-12-17	WOS:000445759700007
J	Bailey, JM; Hendley, AM; Lafaro, KJ; Pruski, MA; Jones, NC; Alsina, J; Younes, M; Maitra, A; McAllister, F; Iacobuzio-Donahue, CA; Leach, SD				Bailey, J. M.; Hendley, A. M.; Lafaro, K. J.; Pruski, M. A.; Jones, N. C.; Alsina, J.; Younes, M.; Maitra, A.; McAllister, F.; Iacobuzio-Donahue, C. A.; Leach, S. D.			p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells	ONCOGENE			English	Article							ADULT MICE; CANCER; METASTASIS; ACTIVATION; INDUCTION	Pancreatic cancer is one of the most lethal malignancies, with virtually all patients eventually succumbing to their disease. Mutations in p53 have been documented in >50% of pancreatic cancers. Owing to the high incidence of p53 mutations in PanIN 3 lesions and pancreatic tumors, we interrogated the comparative ability of adult pancreatic acinar and ductal cells to respond to oncogenic Kras and mutant Tp53(R172H) using Hnf1b:CreER(T2) and Mist1:CreER(T2) mice. These studies involved co-activation of a membrane-tethered GFP lineage label, allowing for direct visualization and isolation of cells undergoing Kras and mutant p53 activation. Kras activation in Mist1(+) adult acinar cells resulted in brisk PanIN formation, whereas no evidence of pancreatic neoplasia was observed for up to 6 months following Kras activation in Hnf1beta(+) adult ductal cells. In contrast to the lack of response to oncogenic Kras alone, simultaneous activation of Kras and mutant p53 in adult ductal epithelium generated invasive PDAC in 75% of mice as early as 2.5 months after tamoxifen administration. These data demonstrate that pancreatic ductal cells, whereas exhibiting relative resistance to oncogenic Kras alone, can serve as an effective cell of origin for pancreatic ductal adenocarcinoma in the setting of gain-of-function mutations in p53.	[Bailey, J. M.; Hendley, A. M.; Pruski, M. A.; Jones, N. C.] Univ Texas Hlth Sci Ctr Houston, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, 6431A Fannin St MSB 1-162, Houston, TX 77030 USA; [Lafaro, K. J.; Iacobuzio-Donahue, C. A.; Leach, S. D.] Mem Sloan Kettering Canc Ctr, David Rubenstein Pancreat Canc Res Ctr, 1275 York Ave, New York, NY 10021 USA; [Alsina, J.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Younes, M.] Univ Texas Hlth Sci Ctr Houston, Dept Pathol & Lab Med, Houston, TX 77030 USA; [Maitra, A.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Maitra, A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [McAllister, F.] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [McAllister, F.] Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bailey, JM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, 6431A Fannin St MSB 1-162, Houston, TX 77030 USA.	Jennifer.M.Bailey@uth.tmc.edu	Iacobuzio-Donahue, Christine/ABF-1295-2020; Alsina, Janivette/AAE-9043-2020	Iacobuzio-Donahue, Christine/0000-0002-4672-3023; Younes, Mamoun/0000-0001-9618-3451; Bailey-Lundberg, Jennifer/0000-0002-4750-106X; Hendley, Audrey/0000-0003-0289-2092	NIH [P01 CA134292, R21 CA158898, F32CA157044, T35 DK007676-22]; AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007814] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge Anzer Habibulla, Danielle Blake, Mara Swaim, Jeffery Roeser and Qingfeng Zhu for their help in maintaining mouse colonies and genotyping. We thank Jorge Ferrer for providing the Hnf1b mice. This work was supported by NIH P01 CA134292 and R21 CA158898 (to SDL). JMB was supported by an NIH F32CA157044 and an AACR/Pancreatic Cancer Action Network Pathway to Leadership Award. NCJ was supported by an NIH T35 DK007676-22.	Bailey JM, 2014, GASTROENTEROLOGY, V146, P245, DOI 10.1053/j.gastro.2013.09.050; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Huang H, 2014, ONCOGENE, V33, P532, DOI 10.1038/onc.2012.619; Ji B, 2009, GASTROENTEROLOGY, V137; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Logsdon CD, 2009, CLIN GASTROENTEROL H, V7, pS40, DOI 10.1016/j.cgh.2009.07.040; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Sivere JT, 2008, GASTROENTEROLOGY, V134, P544, DOI 10.1053/j.gastro.2007.11.003; Solar M, 2009, DEV CELL, V17, P849, DOI 10.1016/j.devcel.2009.11.003; Strobel O, 2007, GASTROENTEROLOGY, V133, P1999, DOI 10.1053/j.gastro.2007.09.009; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066	17	78	80	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4282	4288		10.1038/onc.2015.441	http://dx.doi.org/10.1038/onc.2015.441			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26592447				2022-12-17	WOS:000382149800012
J	Hessmann, E; Schneider, G; Ellenrieder, V; Siveke, JT				Hessmann, E.; Schneider, G.; Ellenrieder, V.; Siveke, J. T.			MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies	ONCOGENE			English	Review							BET BROMODOMAIN INHIBITION; SMALL-MOLECULE INHIBITORS; C-MYC; GENE-EXPRESSION; DUCTAL ADENOCARCINOMA; N-MYC; TRANSCRIPTIONAL ACTIVATION; POTENTIAL TARGET; TRANSGENIC MICE; TUMOR	Owing to its aggressiveness, late detection and marginal therapeutic accessibility, pancreatic ductal adenocarcinoma (PDAC) remains a most challenging malignant disease. Despite scientific progress in the understanding of the mechanisms that underly PDAC initiation and progression, the successful translation of experimental findings into effective new therapeutic strategies remains a largely unmet need. The oncogene MYC is activated in many PDAC cases and is a master regulator of vital cellular processes. Excellent recent studies have shed new light on the tremendous functions of MYC in cancer and identified inhibition of MYC as a likewise beneficial and demanding effort. This review will focus on mechanisms that contribute to deregulation of MYC expression in pancreatic carcinogenesis and progression and will summarize novel biological findings from recent in vivo models. Finally, we provide a perspective, how regulation of MYC in PDAC may contribute to the development of new therapeutic approaches.	[Hessmann, E.; Ellenrieder, V.] Univ Med Ctr Goettingen, Clin Gastroenterol & Gastrointestinal Oncol, Gottingen, Germany; [Schneider, G.; Siveke, J. T.] Tech Univ Munich, Klinikum Rechts Isar, Dept Internal Med 2, Med Klin, D-80290 Munich, Germany; [Siveke, J. T.] German Canc Consortium DKTK, Heidelberg, Germany; [Siveke, J. T.] German Canc Res Ctr, Heidelberg, Germany	University of Gottingen; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Siveke, JT (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin, Dept Internal Med 2, Ismaninger St 22, D-81675 Munich, Germany.	jens.siveke@lrz.tum.de	Siveke, Jens/AAQ-6170-2021	Siveke, Jens/0000-0002-8772-4778				Aichler M, 2012, J PATHOL, V226, P723, DOI 10.1002/path.3017; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Bachireddy P, 2012, CLIN EXP IMMUNOL, V167, P188, DOI 10.1111/j.1365-2249.2011.04514.x; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Bisgrovet DA, 2007, P NATL ACAD SCI USA, V104, P13690, DOI 10.1073/pnas.0705053104; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Bonal C, 2009, GASTROENTEROLOGY, V136, P309, DOI 10.1053/j.gastro.2008.10.015; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Cattoretti G, 2013, J PATHOL, V229, P430, DOI 10.1002/path.4141; Cermelli S., 2014, COLD SPRING HARB PER, V4; Chang DK, 2014, CURR OPIN GENET DEV, V24, P74, DOI 10.1016/j.gde.2013.12.001; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Cheng CY, 2014, CELL REP, V6, P1000, DOI 10.1016/j.celrep.2014.02.023; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Elkon R, 2004, NUCLEIC ACIDS RES, V32, P4955, DOI 10.1093/nar/gkh816; Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802; Feldmann G, 2011, CANCER BIOL THER, V12, P598, DOI 10.4161/cbt.12.7.16475; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fukushima N, 2004, ONCOGENE, V23, P9042, DOI 10.1038/sj.onc.1208117; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gamberi G, 1998, J ORTHOP RES, V16, P1, DOI 10.1002/jor.1100160102; Gao YY, 2014, FEBS LETT, V588, P878, DOI 10.1016/j.febslet.2014.02.016; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Grippo PJ, 2012, INT J CANCER, V131, P1243, DOI 10.1002/ijc.27322; Groisman I, 2006, GENE DEV, V20, P2701, DOI 10.1101/gad.1438906; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Gurda GT, 2010, GASTROENTEROLOGY, V139, P609, DOI 10.1053/j.gastro.2010.04.050; Gustafson WC, 2014, CANCER CELL, V26, P414, DOI 10.1016/j.ccr.2014.07.015; Hamacher R, 2007, ONCOL REP, V18, P695; He WL, 2014, J GASTROEN HEPATOL, V29, P1427, DOI 10.1111/jgh.12558; Heiser PW, 2006, DEVELOPMENT, V133, P2023, DOI 10.1242/dev.02366; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hodges LC, 2003, MOL CANCER RES, V1, P300; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Ischenko I, 2014, P NATL ACAD SCI USA, V111, P3466, DOI 10.1073/pnas.1319911111; Jackstadt R, 2015, BBA-GENE REGUL MECH, V1849, P544, DOI 10.1016/j.bbagrm.2014.04.003; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koenig A, 2010, GASTROENTEROLOGY, V138, P1189, DOI 10.1053/j.gastro.2009.10.045; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lee H, 1995, Curr Top Microbiol Immunol, V194, P247; Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; McKeown MR, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014266; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Melisi D, 2008, MOL CANCER THER, V7, P829, DOI 10.1158/1535-7163.MCT-07-0337; Menssen A, 2012, ONCOTARGET, V3, P112, DOI 10.18632/oncotarget.440; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Murtaugh LC, 2005, DEVELOPMENT, V132, P4663, DOI 10.1242/dev.02063; Nakhai H, 2008, DEVELOPMENT, V135, P3191, DOI 10.1242/dev.017137; Nam S, 2013, MOL ONCOL, V7, P369, DOI 10.1016/j.molonc.2012.10.013; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ogami K, 2014, ONCOGENE, V33, P55, DOI 10.1038/onc.2012.548; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Ortiz-Zapater E, 2012, NAT MED, V18, P83, DOI 10.1038/nm.2540; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Palanichamy JK, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00054; Peter S, 2014, EMBO MOL MED, V6, P1525, DOI 10.15252/emmm.201403927; Politi K, 2004, ONCOGENE, V23, P1558, DOI 10.1038/sj.onc.1207275; Puri S, 2015, CELL STEM CELL, V16, P18, DOI 10.1016/j.stem.2014.11.001; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Rojanala S, 2004, MOL CANCER THER, V3, P451; Rooman I, 2012, GUT, V61, P449, DOI 10.1136/gut.2010.235804; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Sabo A, 2014, COLD SPRING HARB PER, V4; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sahai V, 2014, MOL CANCER THER, V13, P1907, DOI 10.1158/1535-7163.MCT-13-0925; Sancho R, 2014, CELL STEM CELL, V15, P139, DOI 10.1016/j.stem.2014.06.019; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Schmitz R, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014282; Schneider Gunter, 2011, J Gastrointest Cancer, V42, P85, DOI 10.1007/s12029-011-9257-1; Schneider Gunter, 2003, Mol Cancer, V2, P15, DOI 10.1186/1476-4598-2-15; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438; Singh SK, 2011, J BIOL CHEM, V286, P28761, DOI 10.1074/jbc.M110.197533; Skoudy Anouchka, 2011, J Gastrointest Cancer, V42, P76, DOI 10.1007/s12029-011-9258-0; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stellas D, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju320; Tazawa H, 2011, EXPERT OPIN BIOL TH, V11, P145, DOI 10.1517/14712598.2011.542749; Ullius A, 2014, NUCLEIC ACIDS RES, V42, P6901, DOI 10.1093/nar/gku312; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang B, 2014, ONCOL REP, V31, P2279, DOI 10.3892/or.2014.3072; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wells JM, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-4; Wiese KE, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014290; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Xu DP, 2013, CANCER BIOL THER, V14, P492, DOI 10.4161/cbt.24343; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yang SB, 2010, EXP MOL MED, V42, P759, DOI 10.3858/emm.2010.42.11.077; Yochum GS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018966; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zadran S, 2013, P NATL ACAD SCI USA, V110, P19160, DOI 10.1073/pnas.1316991110; Zhang JS, 2011, ONCOGENE, V30, P3705, DOI 10.1038/onc.2011.90; Zheng YJ, 2005, J AM CHEM SOC, V127, P17182, DOI 10.1021/ja0558544; Zhou Q, 2007, DEV CELL, V13, P103, DOI 10.1016/j.devcel.2007.06.001; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	139	78	79	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1609	1618		10.1038/onc.2015.216	http://dx.doi.org/10.1038/onc.2015.216			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26119937				2022-12-17	WOS:000373064200001
J	Farria, A; Li, W; Dent, SYR				Farria, A.; Li, W.; Dent, S. Y. R.			KATs in cancer: functions and therapies	ONCOGENE			English	Review							HISTONE ACETYLTRANSFERASE ACTIVITY; BET BROMODOMAIN INHIBITION; CREB-BINDING-PROTEIN; DNA-DAMAGE RESPONSE; T-CELL LEUKEMIA; NF-KAPPA-B; ANDROGEN RECEPTOR; C-MYC; TRANSCRIPTION FACTOR; IN-VIVO	Post-translational acetylation of lysines is most extensively studied in histones, but this modification is also found in many other proteins and is implicated in a wide range of biological processes in both the cell nucleus and the cytoplasm. Like phosphorylation, acetylation patterns and levels are often altered in cancer, therefore small molecule inhibition of enzymes that regulate acetylation and deacetylation offers much potential for inhibiting cancer cell growth, as does disruption of interactions between acetylated residues and 'reader' proteins. For more than a decade now, histone deacetylase inhibitors have been investigated for their ability to increase acetylation and promote expression of tumor suppressor genes. However, emerging evidence suggests that acetylation can also promote cancer, in part by enhancing the functions of oncogenic transcription factors. In this review, we focus on how acetylation of both histone and non-histone proteins may drive cancer, and we will discuss the implications of such changes on how patients are assigned to therapeutic agents. Finally, we will explore what the future holds in the design of small-molecule inhibitors for modulation of levels or functions of acetylation states.	[Farria, A.; Li, W.; Dent, S. Y. R.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Ctr Canc Epigenet, Dept Epigenet & Mol Carcinogenesis, Smithville, TX 78657 USA	University of Texas System; UTMD Anderson Cancer Center	Dent, SYR (corresponding author), Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Ctr Canc Epigenet, Dept Epigenet & Mol Carcinogenesis, Sci Pk, Smithville, TX 78657 USA.	sroth@mdanderson.org	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269; Farria, Aimee/0000-0002-3524-8730; Li, Wenqian/0000-0001-6663-9809	NIH [R01067718]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067718] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Evangelia Koutelou for the critical reading of this manuscript and Andria Schibler for advice and contributions to artwork. This work was partially supported by NIH R01067718 to SYRD.	Ahmad A, 2012, MOL CANCER THER, V11, P2193, DOI 10.1158/1535-7163.MCT-12-0232-T; Ahmad Aamir, 2011, Front Biosci (Elite Ed), V3, P1483; Ahmad A, 2010, J CELL BIOCHEM, V109, P1134, DOI 10.1002/jcb.22492; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Arif M, 2009, J MED CHEM, V52, P267, DOI 10.1021/jm800657z; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200; Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Bedford DC, 2010, EPIGENETICS-US, V5, P9, DOI 10.4161/epi.5.1.10449; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Bhoumik A, 2008, CELL CYCLE, V7, P2341, DOI 10.4161/cc.6388; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Butler JS, 2012, EPIGENOMICS-UK, V4, P163, DOI [10.2217/EPI.12.3, 10.2217/epi.12.3]; Chen GD, 2012, J INVEST DERMATOL, V132, P2632, DOI 10.1038/jid.2012.193; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Chen L, 2013, J BIOL CHEM, V288, P14510, DOI 10.1074/jbc.M113.458737; Chen R, 2012, J BIOL CHEM, V287, P30800, DOI 10.1074/jbc.M111.244780; Chevillard-Briet M, 2014, HUM MOL GENET, V23, P2120, DOI 10.1093/hmg/ddt604; Chimenti F, 2009, J MED CHEM, V52, P530, DOI 10.1021/jm800885d; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coffey K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045539; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Duong MT, 2013, CANCER RES, V73, P5556, DOI 10.1158/0008-5472.CAN-13-0013; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Endo M, 2014, HUM PATHOL, V45, P276, DOI 10.1016/j.humpath.2013.09.003; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Filippakopoulos P, 2012, CELL, V149, P214, DOI 10.1016/j.cell.2012.02.013; Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2003, CANCER RES, V63, P304; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Gao CX, 2014, SCI REP-UK, V4, DOI 10.1038/srep05372; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Gao XN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055481; Gao YN, 2014, INT J CLIN EXP PATHO, V7, P760; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792; Ghizzoni M, 2012, EUR J MED CHEM, V47, P337, DOI 10.1016/j.ejmech.2011.11.001; Ghizzoni M, 2010, BIOORGAN MED CHEM, V18, P5826, DOI 10.1016/j.bmc.2010.06.089; Gong AY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-492; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grayson AR, 2014, ONCOGENE, V33, P1736, DOI 10.1038/onc.2013.126; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Hao JJ, 2013, CELL REP, V4, P898, DOI 10.1016/j.celrep.2013.07.047; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Herrera JE, 1997, J BIOL CHEM, V272, P27253, DOI 10.1074/jbc.272.43.27253; Holmlund T, 2013, LEUKEMIA, V27, P578, DOI 10.1038/leu.2012.265; Ianculescu I, 2012, J BIOL CHEM, V287, P4000, DOI 10.1074/jbc.M111.300194; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Jiang ZH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-88; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Kaeser MD, 2008, J BIOL CHEM, V283, P32254, DOI 10.1074/jbc.M806061200; Kalac M, 2011, BLOOD, V118, P5506, DOI 10.1182/blood-2011-02-336891; Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Kim HJ, 2011, AM J TRANSL RES, V3, P166; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kobayashi J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-34; Krebs AR, 2011, MOL CELL, V44, P410, DOI 10.1016/j.molcel.2011.08.037; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kurdistani SK, 2007, BRIT J CANCER, V97, P1, DOI 10.1038/sj.bjc.6603844; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Kushal S, 2013, P NATL ACAD SCI USA, V110, P15602, DOI 10.1073/pnas.1312473110; Lange M, 2008, GENE DEV, V22, P2370, DOI 10.1101/gad.471408; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lee SO, 2009, PROSTATE, V69, P126, DOI 10.1002/pros.20865; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Li F, 2013, CANCER PREV RES, V6, P843, DOI 10.1158/1940-6207.CAPR-13-0070; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li YY, 2014, CELL, V159, P558, DOI 10.1016/j.cell.2014.09.049; Liao ZW, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-110; Lin RT, 2013, MOL CELL, V51, P506, DOI 10.1016/j.molcel.2013.07.002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Liu YJ, 2013, NAT MED, V19, P1173, DOI 10.1038/nm.3286; Lleonart ME, 2006, ONCOL REP, V16, P603; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lu HM, 2009, FEBS J, V276, P7291, DOI 10.1111/j.1742-4658.2009.07441.x; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; Lv GX, 2014, ONCOL REP, V32, P1021, DOI 10.3892/or.2014.3296; Malatesta M, 2013, CANCER RES, V73, P6323, DOI 10.1158/0008-5472.CAN-12-4660; Marcu MG, 2006, MED CHEM, V2, P169, DOI 10.2174/157340606776056133; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; Miyamoto N, 2008, J BIOL CHEM, V283, P18218, DOI 10.1074/jbc.M802332200; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nagy Z, 2010, CELL MOL LIFE SCI, V67, P611, DOI 10.1007/s00018-009-0199-8; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Nye MD, 2014, J BIOL CHEM, V289, P15495, DOI 10.1074/jbc.M113.545194; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Patel AJ, 2014, CELL REP, V6, P81, DOI 10.1016/j.celrep.2013.12.001; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Pattabiraman DR, 2014, BLOOD, V123, P2682, DOI 10.1182/blood-2012-02-413187; Pattabiraman DR, 2009, MOL CANCER RES, V7, P1477, DOI 10.1158/1541-7786.MCR-09-0070; Prinjha RK, 2012, TRENDS PHARMACOL SCI, V33, P146, DOI 10.1016/j.tips.2011.12.002; Rauh D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3327; Ravindra KC, 2009, J BIOL CHEM, V284, P24453, DOI 10.1074/jbc.M109.023861; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Robles MTS, 2013, J VIROL, V87, P13499, DOI 10.1128/JVI.02658-13; Rotte A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075405; Saadat N, 2012, J ONCOL, V2012, DOI 10.1155/2012/647206; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Santer FR, 2011, MOL CANCER THER, V10, P1644, DOI 10.1158/1535-7163.MCT-11-0182; Santillan DA, 2006, CANCER RES, V66, P10032, DOI 10.1158/0008-5472.CAN-06-2597; Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988; Santos-Rosa H, 2003, NUCLEIC ACIDS RES, V31, P4285, DOI 10.1093/nar/gkg655; Schwer B, 2006, P NATL ACAD SCI USA, V103, P10224, DOI 10.1073/pnas.0603968103; Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008; Secci D, 2014, BIOORGAN MED CHEM, V22, P1680, DOI 10.1016/j.bmc.2014.01.022; Sethi G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-66; Shah M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001258; Shah S, 2012, CANCER RES, V72, P1248, DOI 10.1158/0008-5472.CAN-11-0943; Shi DD, 2009, P NATL ACAD SCI USA, V106, P16275, DOI 10.1073/pnas.0904305106; Shiota M, 2010, PROSTATE, V70, P540, DOI 10.1002/pros.21088; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Stimson L, 2005, MOL CANCER THER, V4, P1521, DOI 10.1158/1535-7163.MCT-05-0135; Sun BF, 2011, CELL RES, V21, P1262, DOI 10.1038/cr.2011.105; Sun YL, 2006, FEBS LETT, V580, P4353, DOI 10.1016/j.febslet.2006.06.092; Sun YL, 2010, CELL CYCLE, V9, P930, DOI 10.4161/cc.9.5.10931; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood-2007-10-117994; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Takeuchi A, 2012, MOL MED REP, V5, P173, DOI 10.3892/mmr.2011.593; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Teiten MH, 2011, INT J ONCOL, V38, P603, DOI 10.3892/ijo.2011.905; Thevenet L, 2004, EMBO J, V23, P3336, DOI 10.1038/sj.emboj.7600352; Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740; Tohyama S, 2012, J ORG CHEM, V77, P9044, DOI 10.1021/jo301534b; Trisciuoglio D, 2012, CLIN CANCER RES, V18, P475, DOI 10.1158/1078-0432.CCR-11-0579; Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418; Van Den Broeck A, 2012, CARCINOGENESIS, V33, P320, DOI 10.1093/carcin/bgr292; Wang F, 2013, CELL MOL LIFE SCI, V70, P3989, DOI 10.1007/s00018-012-1254-4; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Xie X, 2014, ONCOGENE, V33, P1037, DOI 10.1038/onc.2013.25; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yan G, 2013, J INVEST DERMATOL, V133, P2444, DOI 10.1038/jid.2013.187; Yang H, 2013, MOL CANCER THER, V12, P610, DOI 10.1158/1535-7163.MCT-12-0930; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Ye X, 2014, ASIAN PAC J CANCER P, V15, P5001, DOI 10.7314/APJCP.2014.15.12.5001; Yin SM, 2012, CLIN CANCER RES, V18, P6623, DOI 10.1158/1078-0432.CCR-12-0861; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yu SY, 2014, J AGR FOOD CHEM, V62, P2085, DOI 10.1021/jf4037722; Yu XD, 2002, J NATL CANCER I, V94, P504; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zeng L, 2010, NATURE, V466, P258, DOI 10.1038/nature09139; Zhang N, 2014, BBA-GENE REGUL MECH, V1839, P395, DOI 10.1016/j.bbagrm.2014.03.017; Zhao HW, 2012, J BIOL CHEM, V287, P925, DOI 10.1074/jbc.M111.279950; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zheng YJ, 2005, J AM CHEM SOC, V127, P17182, DOI 10.1021/ja0558544; Zhong J, 2014, CANCER RES, V74, P1870, DOI 10.1158/0008-5472.CAN-13-2485; Zimmer SN, 2012, EXP HEMATOL, V40, P295, DOI 10.1016/j.exphem.2011.12.004; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	192	78	80	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4901	4913		10.1038/onc.2014.453	http://dx.doi.org/10.1038/onc.2014.453			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25659580	Green Accepted			2022-12-17	WOS:000361693000001
J	Menon, DR; Das, S; Krepler, C; Vultur, A; Rinner, B; Schauer, S; Kashofer, K; Wagner, K; Zhang, G; Rad, EB; Haass, NK; Soyer, HP; Gabrielli, B; Somasundaram, R; Hoefler, G; Herlyn, M; Schaider, H				Menon, D. Ravindran; Das, S.; Krepler, C.; Vultur, A.; Rinner, B.; Schauer, S.; Kashofer, K.; Wagner, K.; Zhang, G.; Rad, E. Bonyadi; Haass, N. K.; Soyer, H. P.; Gabrielli, B.; Somasundaram, R.; Hoefler, G.; Herlyn, M.; Schaider, H.			A stress-induced early innate response causes multidrug tolerance in melanoma	ONCOGENE			English	Article							ALDEHYDE DEHYDROGENASE; CELL-GROWTH; RESISTANCE; INHIBITION; FAMILY; BRAF; PHOSPHORYLATION; EXPRESSION; KINASES; MARKER	Acquired drug resistance constitutes a major challenge for effective cancer therapies with melanoma being no exception. The dynamics leading to permanent resistance are poorly understood but are important to design better treatments. Here we show that drug exposure, hypoxia or nutrient starvation leads to an early innate cell response in melanoma cells resulting in multidrug resistance, termed induced drug-tolerant cells (IDTCs). Transition into the IDTC state seems to be an inherent stress reaction for survival toward unfavorable environmental conditions or drug exposure. The response comprises chromatin remodeling, activation of signaling cascades and markers implicated in cancer stemness with higher angiogenic potential and tumorigenicity. These changes are characterized by a common increase in CD271 expression concomitantly with loss of differentiation markers such as melan-A and tyrosinase, enhanced aldehyde dehydrogenase (ALDH) activity and upregulation of histone demethylases. Accordingly, IDTCs show a loss of H3K4me3, H3K27me3 and gain of H3K9me3 suggesting activation and repression of differential genes. Drug holidays at the IDTC state allow for reversion into parental cells re-sensitizing them to the drug they were primarily exposed to. However, upon continuous drug exposure IDTCs eventually transform into permanent and irreversible drug-resistant cells. Knockdown of CD271 or KDM5B decreases transition into the IDTC state substantially but does not prevent it. Targeting IDTCs would be crucial for sustainable disease management and prevention of acquired drug resistance.	[Menon, D. Ravindran; Rad, E. Bonyadi; Schaider, H.] Med Univ Graz, Dept Dermatol, Canc Biol Unit, Graz, Austria; [Menon, D. Ravindran; Rinner, B.; Wagner, K.; Rad, E. Bonyadi; Schaider, H.] Med Univ Graz, Med Res Ctr, Graz, Austria; [Menon, D. Ravindran; Rad, E. Bonyadi; Soyer, H. P.; Schaider, H.] Univ Queensland, Translat Res Inst, Sch Med, Dermatol Res Ctr, Brisbane, Qld, Australia; [Das, S.; Schauer, S.; Kashofer, K.; Hoefler, G.] Med Univ Graz, Inst Pathol, Graz, Austria; [Krepler, C.; Vultur, A.; Zhang, G.; Somasundaram, R.; Herlyn, M.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Haass, N. K.; Soyer, H. P.; Gabrielli, B.; Schaider, H.] Univ Queensland, Translat Res Inst, Diamantina Inst, Brisbane, Qld, Australia	Medical University of Graz; Medical University of Graz; University of Queensland; Medical University of Graz; The Wistar Institute; University of Queensland	Schaider, H (corresponding author), Univ Queensland, Translat Res Inst, Sch Med, Dermatol Res Ctr, 37 Kent St, Woolloongabba, Qld 4102, Australia.	h.schaider@uq.edu.au	Soyer, H. Peter/W-3791-2017; Haass, Nikolas K/M-8507-2015; Ravindran Menon, Dinoop/F-9247-2014; Menon, Dinoop Ravindran/AAC-3620-2021; Gabrielli, Brian G/B-3655-2011; Soyer, H. Peter/E-6000-2010; Hoefler, Gerald/H-1796-2016	Soyer, H. Peter/0000-0002-4770-561X; Haass, Nikolas K/0000-0002-3928-5360; Ravindran Menon, Dinoop/0000-0002-6335-9227; Gabrielli, Brian G/0000-0003-3933-1651; Soyer, H. Peter/0000-0002-4770-561X; Schaider, Helmut/0000-0003-3195-2517; Rinner, Beate/0000-0002-6340-4905; Vultur, Adina/0000-0003-0068-9496; Hoefler, Gerald/0000-0002-9056-3063; Somasundaram, Rajasekharan/0000-0002-8444-8472	Medical University of Graz; Austrian Science foundation (FWF) [SFB LIPOTOX F30, W1226]; National Health and Medical Research Council) [APP1003637]; Cancer Council New South Wales [RG 09-08]; NATIONAL CANCER INSTITUTE [P01CA114046, P30CA010815, P01CA025874] Funding Source: NIH RePORTER	Medical University of Graz; Austrian Science foundation (FWF)(Austrian Science Fund (FWF)); National Health and Medical Research Council); Cancer Council New South Wales(Cancer Council New South Wales); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Marcus Absenger (ZMF, Medical University of Graz), Xin Xiao and Palmila Liu (The Wistar Institute, PA, USA) and Maria Grygar (Institute of Pathology, Medical University of Graz, Austria) for technical assistance. This work was supported by the PhD program 'Molecular Medicine' of the Medical University of Graz (to DRM and SD) and the Austrian Science foundation (FWF) projects SFB LIPOTOX F30 and W1226 DK "Metabolic and cardiovascular disease'' (to GH). We thank Dr Atsushi Miyawaki, RIKEN, Wako-city, Japan, for providing the FUCCI constructs. The FUCCI work was supported by project grants APP1003637 (National Health and Medical Research Council) and RG 09-08 (Cancer Council New South Wales) to NKH.	Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Chen YT, 1996, P NATL ACAD SCI USA, V93, P5915, DOI 10.1073/pnas.93.12.5915; Cvitic S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079233; Das Thakur M, 2013, CANCER RES, V73, P6106, DOI 10.1158/0008-5472.CAN-13-1633; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Duan ZF, 2004, MOL CANCER THER, V3, P833; Elliott AM, 2009, MOL CANCER RES, V7, P79, DOI 10.1158/1541-7786.MCR-08-0235; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Furuta J, 2014, J INVEST DERMATOL, V134, P1369, DOI 10.1038/jid.2013.490; Glover S, 2004, J CELL PHYSIOL, V199, P77, DOI 10.1002/jcp.10456; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Haass NK, 2014, PIGM CELL MELANOMA R, V27, P764, DOI 10.1111/pcmr.12274; Haughian JM, 2009, INT J CANCER, V125, P2556, DOI 10.1002/ijc.24633; Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702; Khalil A, 2011, CELL CYCLE, V10, P481, DOI 10.4161/cc.10.3.14713; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207; KWON BS, 1993, J INVEST DERMATOL, V100, pS134, DOI 10.1111/1523-1747.ep12465022; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Moreb JS, 2008, CURR STEM CELL RES T, V3, P237, DOI 10.2174/157488808786734006; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Shakhova O, 2013, CANCER LETT, V338, P74, DOI 10.1016/j.canlet.2012.10.009; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Zou L, 2012, J BIOL CHEM, V287, P7190, DOI 10.1074/jbc.M111.304972	34	78	78	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4448	4459		10.1038/onc.2014.372	http://dx.doi.org/10.1038/onc.2014.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25417704	Green Accepted			2022-12-17	WOS:000360189200004
J	He, W; Wang, Q; Srinivasan, B; Xu, J; Padilla, MT; Li, Z; Wang, X; Liu, Y; Gou, X; Shen, HM; Xing, C; Lin, Y				He, W.; Wang, Q.; Srinivasan, B.; Xu, J.; Padilla, M. T.; Li, Z.; Wang, X.; Liu, Y.; Gou, X.; Shen, H-M; Xing, C.; Lin, Y.			A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy	ONCOGENE			English	Article						autophagy; necroptosis; RIP1; RIP3; c-IAP; apoptosis	MIXED LINEAGE KINASE; INDUCED CELL-DEATH; PROGRAMMED NECROSIS; CANCER CELLS; DOMAIN-LIKE; APOPTOSIS; RIPOPTOSOME; MECHANISMS; CYTOTOXICITY; DOWNSTREAM	Killing cancer cells through the induction of apoptosis is one of the main mechanisms of chemotherapy. However, numerous cancer cells have primary or acquired apoptosis resistance, resulting in chemoresistance. In this study, using a novel chalcone derivative chalcone-24 (Chal-24), we identified a novel anticancer mechanism through autophagy-mediated necroptosis (RIP1- and RIP3-dependent necrosis). Chal-24 potently killed different cancer cells with induction of necrotic cellular morphology while causing no detectable caspase activation. Blocking the necroptosis pathway with either necrostatin-1 or by knockdown of RIP1 and RIP3 effectively blocked the cytotoxicity of Chal-24, suggesting that Chal-24-induced cell death is associated with necroptosis. Chal-24 robustly activated JNK and ERK and blockage of which effectively suppressed Chal-24-induced cytotoxicity. In addition, Chal-24 strongly induced autophagy that is dependent on JNK-mediated phosphorylation of Bcl-2 and Bcl-xL and dissociation of Bcl-2 or Bcl-xL from Beclin-1. Importantly, suppression of autophagy, with either pharmacological inhibitors or small interfering RNAs targeting the essential autophagy components ATG7 and Beclin-1, effectively attenuated Chal-24-induced cell death. Furthermore, we found that autophagy activation resulted in c-IAP1 and c-IAP2 degradation and formation of the Ripoptosome that contributes to necroptosis. These results thus establish a novel mechanism for killing cancer cells that involves autophagy-mediated necroptosis, which may be employed for overcoming chemoresistance.	[He, W.; Wang, Q.; Xu, J.; Padilla, M. T.; Li, Z.; Liu, Y.; Lin, Y.] Lovelace Resp Res Inst, Mol Biol & Lung Canc Program, Albuquerque, NM USA; [He, W.; Gou, X.] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing, Peoples R China; [Wang, Q.; Wang, X.] Sichuan Univ, West China Univ Hosp 2, Lab Mol & Translat Med, Chengdu 610064, Peoples R China; [Srinivasan, B.; Xing, C.] Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; [Shen, H-M] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore	Lovelace Respiratory Research Institute; Chongqing Medical University; Sichuan University; University of Minnesota System; University of Minnesota Twin Cities; National University of Singapore	Xing, C (corresponding author), Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA.	xingx009@umn.edu; ylin@lrri.org	SHEN, Han-Ming/B-5942-2011; Liu, Yushi/A-1533-2014	SHEN, Han-Ming/0000-0001-7369-5227; Liu, Yushi/0000-0003-4185-4187; Xu, Jennings/0000-0002-3068-0559	NIEHS/NIH [R01ES017328]; NCI/NIH [R03CA156301]; Chongqing Health Bureau [2012-2-001]; NATIONAL CANCER INSTITUTE [R03CA156301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES017328] Funding Source: NIH RePORTER	NIEHS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Chongqing Health Bureau; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was partly supported by grants from NIEHS/NIH (R01ES017328), NCI/NIH (R03CA156301), Chongqing Health Bureau (2012-2-001).	Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Christofferson DE, 2010, CELL DEATH DIFFER, V17, P1942, DOI 10.1038/cdd.2010.123; Darding M, 2012, CELL DEATH DIFFER, V19, P58, DOI 10.1038/cdd.2011.163; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Han JH, 2011, NAT IMMUNOL, V12, P1143, DOI 10.1038/ni.2159; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WY, 2012, AUTOPHAGY, V8, P1811, DOI 10.4161/auto.22145; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Imre G, 2011, J MOL CELL BIOL, V3, P324, DOI 10.1093/jmcb/mjr034; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7; Lonning PE, 2010, MOL ONCOL, V4, P284, DOI 10.1016/j.molonc.2010.04.005; Marquez RT, 2012, AM J CANCER RES, V2, P214; Matsuzawa T, 2012, J IMMUNOL, V189, P813, DOI 10.4049/jimmunol.1102041; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mor Gil, 2008, V414, P1; Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015; Ocker M, 2012, EUR SURG RES, V48, P111, DOI 10.1159/000336875; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Seve Pascal, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P73, DOI 10.2174/1568011053352604; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168; Shiao SL, 2011, GENE DEV, V25, P2559, DOI 10.1101/gad.169029.111; Srinivasan B, 2009, J MED CHEM, V52, P7228, DOI 10.1021/jm901278z; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Wang X, 2006, CANCER RES, V66, P1089, DOI 10.1158/0008-5472.CAN-05-2698; Wang X, 2008, MOL CANCER THER, V7, P1156, DOI 10.1158/1535-7163.MCT-07-2183; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Warmka JK, 2012, BIOCHEM BIOPH RES CO, V424, P488, DOI 10.1016/j.bbrc.2012.06.140; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	46	78	85	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3004	3013		10.1038/onc.2013.256	http://dx.doi.org/10.1038/onc.2013.256			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23831571	Green Accepted			2022-12-17	WOS:000337232200007
J	Rajabi, H; Alam, M; Takahashi, H; Kharbanda, A; Guha, M; Ahmad, R; Kufe, D				Rajabi, H.; Alam, M.; Takahashi, H.; Kharbanda, A.; Guha, M.; Ahmad, R.; Kufe, D.			MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition	ONCOGENE			English	Article						MUC1-C; ZEB1; miR-200c; breast cancer; EMT	BREAST-CANCER CELLS; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; DOWN-REGULATION; FEEDBACK LOOP; STEM-CELLS; E-CADHERIN; ZEB1; METASTASIS; FAMILY	The epithelial-mesenchymal transition (EMT) is activated in cancer cells by ZEB1, a member of the zinc finger/homeodomain family of transcriptional repressors. The mucin 1 (MUC1) heterodimeric protein is aberrantly overexpressed in human carcinoma cells. The present studies in breast cancer cells demonstrate that the oncogenic MUC1-C subunit induces expression of ZEB1 by a NF-kappa B (nuclear factor kappa B) p65-dependent mechanism. MUC1-C occupies the ZEB1 promoter with NF-kappa B p65 and thereby promotes ZEB1 transcription. In turn, ZEB1 associates with MUC1-C and the ZEB1/MUC1-C complex contributes to the transcriptional suppression of miR-200c, an inducer of epithelial differentiation. The co-ordinate upregulation of ZEB1 and suppression of miR-200c has been linked to the induction of EMT. In concert with the effects of MUC1-C on ZEB1 and miR-200c, we show that MUC1-C induces EMT and cellular invasion by a ZEB1-mediated mechanism. These findings indicate that (i) MUC1-C activates ZEB1 and suppresses miR-200c with the induction of EMT and (ii) targeting MUC1-C could be an effective approach for the treatment of breast and possibly other types of cancers that develop EMT properties.	[Rajabi, H.; Alam, M.; Takahashi, H.; Kharbanda, A.; Guha, M.; Ahmad, R.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480.	Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Horn G, 2009, EXP CELL RES, V315, P1490, DOI 10.1016/j.yexcr.2009.02.011; Hu XT, 2001, CANCER RES, V61, P6290; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Jin CN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039432; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Rajabi H, 2012, PROSTATE, V72, P1659, DOI 10.1002/pros.22519; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Rajabi Hasan, 2010, Genes Cancer, V1, P62; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998	37	78	83	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1680	1689		10.1038/onc.2013.114	http://dx.doi.org/10.1038/onc.2013.114			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584475	Green Accepted			2022-12-17	WOS:000334344700008
J	Bossuyt, W; Chen, CL; Chen, Q; Sudol, M; McNeill, H; Pan, D; Kopp, A; Halder, G				Bossuyt, W.; Chen, C-L; Chen, Q.; Sudol, M.; McNeill, H.; Pan, D.; Kopp, A.; Halder, G.			An evolutionary shift in the regulation of the Hippo pathway between mice and flies	ONCOGENE			English	Article						Hippo signaling; evolution; Fat; Dachs; Angiomotin; Yap	PLANAR CELL POLARITY; ORGAN SIZE CONTROL; TUMOR-SUPPRESSOR PATHWAY; NUCLEAR-LOCALIZATION; PROTOCADHERINS FAT; SIGNALING-PATHWAY; CRUMBS COMPLEX; YAP PATHWAY; WW DOMAIN; DROSOPHILA	The Hippo pathway plays a key role in controlling organ growth in many animal species and its deregulation is associated with different types of cancer. Understanding the regulation of the Hippo pathway and discovering upstream regulators is thus a major quest. Interestingly, while the core of the Hippo pathway contains a highly conserved kinase cascade, different components have been identified as upstream regulators in Drosophila and vertebrates. However, whether the regulation of the Hippo pathway is indeed different between Drosophila and vertebrates or whether these differences are due to our limited analysis of these components in different organisms is not known. Here we show that the mouse Fat4 cadherin, the ortholog of the Hippo pathway regulator Fat in Drosophila, does not apparently regulate the Hippo pathway in the murine liver. In fact, we uncovered an evolutionary shift in many of the known upstream regulators at the base of the arthropod lineage. In this evolutionary transition, Fat and the adaptor protein Expanded gained novel domains that connected them to the Hippo pathway, whereas the cell-adhesion receptor Echinoid evolved as a new protein. Subsequently, the junctional adaptor protein Angiomotin (Amot) was lost and the downstream effector Yap lost its PDZ-binding motif that interacts with cell junction proteins. We conclude that fundamental differences exist in the upstream regulatory mechanisms of Hippo signaling between Drosophila and vertebrates.	[Bossuyt, W.; Halder, G.] VIB, Ctr Biol Dis, Louvain, Belgium; [Bossuyt, W.; Halder, G.] Kuleuven, Ctr Human Genet, Louvain, Belgium; [Bossuyt, W.; Chen, C-L; Halder, G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Chen, Q.; Pan, D.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; [Sudol, M.] Weis Ctr Res, Geisinger Clin, Lab Signal Transduct, Weis Ctr Res, Danville, PA 17822 USA; [McNeill, H.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Kopp, A.] Univ Calif Davis, Dept Ecol & Evolut, Davis, CA 95616 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Davis	Halder, G (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Herestr 49,Box 602, B-3000 Louvain, Belgium.	georg.halder@vib.be	McNeill, Helen/E-4579-2013; Halder, Georg/F-2966-2015	McNeill, Helen/0000-0003-1126-5154; Halder, Georg/0000-0001-7580-3236	Department of Defense [NF093145, BC093902]; National Institute of Health [GM067997]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067997] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Drs Alfred Handler, Giuliano Gasperi and Stephen Richards of the Medfly Whole Genome Sequencing Consortium for providing the draft genome sequence of Ceratitis capitata. We thank Lisa McCord for assistance with graphical representation, and also Dr Ryan Udan, Dr Maria Willecke and Chunyao Tao for help in performing the screen, experimental input and valuable discussions. This study was supported in part by grants from Department of Defense (NF093145 to DP) and from the National Institute of Health (GM067997 to GH). QC is a recipient of a Breast Cancer Research Postdoctoral Fellowship from the Department of Defense (BC093902). DP is an investigator of the Howard Hughes Medical Institute.	Ambegaonkar AA, 2012, CURR BIOL, V22, P1302, DOI 10.1016/j.cub.2012.05.049; Angus L, 2012, ONCOGENE, V31, P238, DOI 10.1038/onc.2011.224; Avruch J, 2011, BRIT J CANCER, V104, P24, DOI 10.1038/sj.bjc.6606011; Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Bennett FC, 2006, CURR BIOL, V16, P2101, DOI 10.1016/j.cub.2006.09.045; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Bosveld F, 2012, SCIENCE, V336, P724, DOI 10.1126/science.1221071; Brittle A, 2012, CURR BIOL, V22, P907, DOI 10.1016/j.cub.2012.03.053; Bu X, 2005, ONCOGENE, V24, P2398, DOI 10.1038/sj.onc.1208466; Bulgakova NA, 2009, J CELL SCI, V122, P2587, DOI 10.1242/jcs.023648; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; Castillejo-Lopez C, 2004, J BIOL CHEM, V279, P24034, DOI 10.1074/jbc.M313878200; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chen CL, 2010, P NATL ACAD SCI USA, V107, P15810, DOI 10.1073/pnas.1004060107; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Cho E, 2004, DEVELOPMENT, V131, P4489, DOI 10.1242/dev.01315; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Enomoto M, 2013, EMBO REP, V14, P65, DOI 10.1038/embor.2012.185; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Gaffney CJ, 2012, GENE, V509, P215, DOI 10.1016/j.gene.2012.08.025; Genevet A, 2011, BIOCHEM J, V436, P213, DOI 10.1042/BJ20110217; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Grzeschik NA, 2010, CELL CYCLE, V9, P3202, DOI 10.4161/cc.9.16.12633; Grzeschik NA, 2010, CURR BIOL, V20, P573, DOI 10.1016/j.cub.2010.01.055; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Heallen T, 2011, SCIENCE, V332, P458, DOI 10.1126/science.1199010; Hilman D, 2011, MOL BIOL EVOL, V28, P2403, DOI 10.1093/molbev/msr065; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Ishiuchi T, 2009, J CELL BIOL, V185, P959, DOI 10.1083/jcb.200811030; Jaramillo BE, 2004, EXP CELL RES, V297, P247, DOI 10.1016/j.yexcr.2004.03.021; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Langer EM, 2008, DEV CELL, V14, P424, DOI 10.1016/j.devcel.2008.01.005; Lawrence PA, 2008, NAT CELL BIOL, V10, P1379, DOI 10.1038/ncb1208-1379; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Leys SP, 2012, J EXP ZOOL PART B, V318B, P438, DOI 10.1002/jez.b.21442; Ling C, 2010, P NATL ACAD SCI USA, V107, P10532, DOI 10.1073/pnas.1004279107; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu KC, 2012, MOL BIOL CELL, V23, P1675, DOI 10.1091/mbc.E11-04-0358; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; MacDougall N, 2001, DEVELOPMENT, V128, P665; Mao YL, 2011, GENE DEV, V25, P131, DOI 10.1101/gad.610511; Mao YP, 2006, DEVELOPMENT, V133, P2539, DOI 10.1242/dev.02427; Mao YP, 2011, DEVELOPMENT, V138, P947, DOI 10.1242/dev.057166; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Matakatsu H, 2008, CURR BIOL, V18, P1390, DOI 10.1016/j.cub.2008.07.067; Matakatsu H, 2006, DEVELOPMENT, V133, P2315, DOI 10.1242/dev.02401; Matakatsu H, 2012, DEVELOPMENT, V139, P1498, DOI 10.1242/dev.070367; Mauviel A, 2012, ONCOGENE, V31, P1743, DOI 10.1038/onc.2011.363; McCartney BM, 2000, DEVELOPMENT, V127, P1315; Menendez J, 2010, P NATL ACAD SCI USA, V107, P14651, DOI 10.1073/pnas.1009376107; Milton CC, 2010, DEVELOPMENT, V137, P735, DOI 10.1242/dev.042309; Muller HAJ, 2003, MECH DEVELOP, V120, P1231, DOI 10.1016/j.mod.2003.06.001; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Oh H, 2009, DEV BIOL, V335, P188, DOI 10.1016/j.ydbio.2009.08.026; Oh S, 2009, MOL CELL BIOL, V29, P6309, DOI 10.1128/MCB.00551-09; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Oka T, 2009, GENES CELLS, V14, P607, DOI 10.1111/j.1365-2443.2009.01292.x; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Parsons LM, 2010, FLY, V4, P288, DOI 10.4161/fly.4.4.13116; Pellock BJ, 2007, DEV BIOL, V304, P102, DOI 10.1016/j.ydbio.2006.12.021; Polesello C, 2007, CURR BIOL, V17, P1864, DOI 10.1016/j.cub.2007.09.049; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Remue E, 2010, FEBS LETT, V584, P4175, DOI 10.1016/j.febslet.2010.09.020; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rogulja D, 2008, DEV CELL, V15, P309, DOI 10.1016/j.devcel.2008.06.003; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Sebe-Pedros A, 2012, CELL REP, V1, P13, DOI 10.1016/j.celrep.2011.11.004; Silva E, 2006, CURR BIOL, V16, P2081, DOI 10.1016/j.cub.2006.09.004; Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Sopko R, 2009, CURR OPIN CELL BIOL, V21, P717, DOI 10.1016/j.ceb.2009.07.001; Sudol M, 2010, TRENDS BIOCHEM SCI, V35, P627, DOI 10.1016/j.tibs.2010.05.010; Toyoshima F, 2007, EMBO J, V26, P1487, DOI 10.1038/sj.emboj.7601599; Tyler DM, 2007, DEV BIOL, V305, P187, DOI 10.1016/j.ydbio.2007.02.004; Van Hateren NJ, 2011, DEVELOPMENT, V138, P1893, DOI 10.1242/dev.064204; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Viktorinova I, 2009, DEVELOPMENT, V136, P4123, DOI 10.1242/dev.039099; Visser-Grieve S, 2012, ONCOGENE, V31, P1189, DOI 10.1038/onc.2011.318; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Webb C, 2011, BIOCHEMISTRY-US, V50, P3300, DOI 10.1021/bi2001888; Weber KL, 2004, NATURE, V431, P325, DOI 10.1038/nature02834; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Yue T, 2012, DEV CELL, V22, P255, DOI 10.1016/j.devcel.2011.12.011; Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Ziosi M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001140	103	78	79	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1218	1228		10.1038/onc.2013.82	http://dx.doi.org/10.1038/onc.2013.82			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23563179	Green Accepted			2022-12-17	WOS:000332631100002
J	Comstock, CES; Augello, MA; Goodwin, JF; de Leeuw, R; Schiewer, MJ; Ostrander, WF; Burkhart, RA; McClendon, AK; McCue, PA; Trabulsi, EJ; Lallas, CD; Gomella, LG; Centenera, MM; Brody, JR; Butler, LM; Tilley, WD; Knudsen, KE				Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; de Leeuw, R.; Schiewer, M. J.; Ostrander, W. F., Jr.; Burkhart, R. A.; McClendon, A. K.; McCue, P. A.; Trabulsi, E. J.; Lallas, C. D.; Gomella, L. G.; Centenera, M. M.; Brody, J. R.; Butler, L. M.; Tilley, W. D.; Knudsen, K. E.			Targeting cell cycle and hormone receptor pathways in cancer	ONCOGENE			English	Article						PD-0332991; cyclin-dependent kinase; retinoblastoma protein; prostate cancer; tumor explants	DEPENDENT KINASE INHIBITOR; ANDROGEN RECEPTOR; CRYSTAL-STRUCTURE; PHASE-I; CDK4/6 INHIBITION; PD 0332991; PHARMACOLOGICAL INHIBITION; ANTITUMOR-ACTIVITY; DNA-REPAIR; FLAVOPIRIDOL	The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and is aberrant in many human cancers. New nodes of therapeutic intervention are needed that can delay or combat the onset of malignancies. The antitumor properties and mechanistic functions of PD-0332991 (PD; a potent and selective CDK4/6 inhibitor) were investigated using human prostate cancer (PCa) models and primary tumors. PD significantly impaired the capacity of PCa cells to proliferate by promoting a robust G(1)-arrest. Accordingly, key regulators of the G(1)-S cell cycle transition were modulated including G1 cyclins D, E and A. Subsequent investigation demonstrated the ability of PD to function in the presence of existing hormone-based regimens and to cooperate with ionizing radiation to further suppress cellular growth. Importantly, it was determined that PD is a critical mediator of PD action. The anti-proliferative impact of CDK4/6 inhibition was revealed through reduced proliferation and delayed growth using PCa cell xenografts. Finally, first-in-field effects of PD on proliferation were observed in primary human prostatectomy tumor tissue explants. This study shows that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy. Combined, these pre-clinical findings identify selective targeting of CDK4/6 as a bona fide therapeutic target in both early stage and advanced PCa and underscore the benefit of personalized medicine to enhance treatment response.	[Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; de Leeuw, R.; Schiewer, M. J.; Ostrander, W. F., Jr.; McClendon, A. K.; McCue, P. A.; Gomella, L. G.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Burkhart, R. A.; Brody, J. R.] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA; [McCue, P. A.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Trabulsi, E. J.; Lallas, C. D.; Gomella, L. G.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA; [Centenera, M. M.; Butler, L. M.] Univ Adelaide, Dame Roma Mitchell Canc Res Lab, Sch Med, Hanson Inst, Adelaide, SA, Australia; [Tilley, W. D.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; Hanson Institute; University of Adelaide; Jefferson University	Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 South 10th St,BLSB 1008A, Philadelphia, PA 19107 USA.	karen.knudsen@jefferson.edu	Butler, Lisa M/C-9843-2010; Butler, Lisa/AAP-9088-2020; Comstock, Clay/B-6122-2008	Butler, Lisa/0000-0003-2698-3220; Schiewer, Matthew/0000-0002-2325-4228; centenera, margaret/0000-0002-2206-0632; Knudsen, Karen/0000-0002-1301-890X; de Leeuw, Renee/0000-0002-5550-7613; Comstock, Clay/0000-0001-5867-1489; Tilley, Wayne/0000-0003-1893-2626	National Institutes of Health [CA099996, CA159945]; Department of Defense New Investigator Award [PC094507]; Department of Defense Predoctoral Fellowships [PC094596, PC094195]; National Health and Medical Research Council (NHMRC) of Australia [627185]; Cancer Council of South Australia Senior research Fellowship; Prostate Cancer Foundation of Australia; Enabling Grant from the NHMRC; NATIONAL CANCER INSTITUTE [R01CA159945, R01CA099996] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense New Investigator Award(United States Department of Defense); Department of Defense Predoctoral Fellowships(United States Department of Defense); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of South Australia Senior research Fellowship(Cancer Council South Australia); Prostate Cancer Foundation of Australia; Enabling Grant from the NHMRC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the KEK laboratory for ongoing scientific discussions and Dr Tanmayi Mankame for critical reading of the manuscript. We thank Dr Wen-Shuz Yeow (currently at TheGreenCell; Washington, DC) for assistance with the growth and maintenance of the CRPC cell lines. We especially thank Magdalena Potoczek for assistance regarding RB staining. This work was supported, in whole or in part, by: National Institutes of Health Grants: CA099996 and CA159945 (to KEK); Department of Defense New Investigator Award PC094507 (to CESC); and Department of Defense Predoctoral Fellowships: PC094596 (to MAA) and PC094195 (to MJS); National Health and Medical Research Council (NHMRC) of Australia (627185; to WDT and LMB), a Cancer Council of South Australia Senior research Fellowship (to LMB), and an infrastructure grant from the Prostate Cancer Foundation of Australia and an Enabling Grant from the NHMRC (to WDT).	Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Baughn LB, 2006, CANCER RES, V66, P7661, DOI 10.1158/0008-5472.CAN-06-1098; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Centenera MM, 2012, CLIN CANCER RES, V18, P3562, DOI 10.1158/1078-0432.CCR-12-0782; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Collins I, 2005, CURR OPIN PHARMACOL, V5, P366, DOI 10.1016/j.coph.2005.04.009; Comstock CES, 2011, J BIOL CHEM, V286, P8117, DOI 10.1074/jbc.M110.170720; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diaz-Padilla I, 2009, INVEST NEW DRUG, V27, P586, DOI 10.1007/s10637-009-9236-6; Dickson MA, 2009, CURR ONCOL, V16, P120; Drees M, 1997, CLIN CANCER RES, V3, P273; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Freemantle SJ, 2007, J CELL BIOCHEM, V102, P869, DOI 10.1002/jcb.21519; Fry DW, 2004, MOL CANCER THER, V3, P1427; Halvorsen OJ, 2000, CANCER, V88, P416, DOI 10.1002/(SICI)1097-0142(20000115)88:2<416::AID-CNCR24>3.3.CO;2-R; Heijink DM, 2011, ONCOGENE, V30, P2026, DOI 10.1038/onc.2010.578; Ismail A, 2011, CLIN CANCER RES, V17, P4513, DOI 10.1158/1078-0432.CCR-11-0244; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Johnson N, 2010, EXPERT OPIN THER TAR, V14, P1199, DOI 10.1517/14728222.2010.525221; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen KE, 2011, EXPERT REV ENDOCRINO, V6, P483, DOI 10.1586/EEM.11.33; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Korzynska A, 2008, BIOCYBERN BIOMED ENG, V28, P75; Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Liu G, 2004, CLIN CANCER RES, V10, P924, DOI 10.1158/1078-0432.CCR-03-0050; Lolli G, 2004, STRUCTURE, V12, P2067, DOI 10.1016/j.str.2004.08.013; Lu H, 2006, J MED CHEM, V49, P3826, DOI 10.1021/jm0600388; Martin JM, 2011, DRUGS, V71, P1019, DOI 10.2165/11591500-000000000-00000; Marzec M, 2006, BLOOD, V108, P1744, DOI 10.1182/blood-2006-04-016634; Menu E, 2008, CANCER RES, V68, P5519, DOI 10.1158/0008-5472.CAN-07-6404; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Mostaghel EA, 2011, ENDOCRIN METAB CLIN, V40, P625, DOI 10.1016/j.ecl.2011.05.013; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Rivadeneira DB, 2010, GASTROENTEROLOGY, V138, P1920, DOI 10.1053/j.gastro.2010.01.007; Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002; Rodriguez-Otero P, 2011, BRIT J HAEMATOL, V155, P73, DOI 10.1111/j.1365-2141.2011.08812.x; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Schiewer MJ, 2012, MOL CELL ENDOCRINOL, V352, P34, DOI 10.1016/j.mce.2011.06.033; Schiewer MJ, 2012, ENDOCR-RELAT CANCER, V19, P1, DOI 10.1530/ERC-11-0072; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Sutherland JJ, 2011, MOL CANCER THER, V10, P242, DOI 10.1158/1535-7163.MCT-10-0720; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078-0432.CCR-11-1867; Udayakumar T, 2010, SEMIN RADIAT ONCOL, V20, P258, DOI 10.1016/j.semradonc.2010.05.007; Vaughn DJ, 2009, NEW ENGL J MED, V360, P423, DOI 10.1056/NEJMc0808558; Wang L, 2007, BLOOD, V110, P2075, DOI 10.1182/blood-2007-02-071266; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wesierska-Gadek J, 2011, J CELL PHYSIOL, V226, P341, DOI 10.1002/jcp.22426; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Zhang C, 2009, CLIN CANCER RES, V15, P238, DOI 10.1158/1078-0432.CCR-08-0897; Zhang CC, 2012, CLIN CANCER RES, V18, P1303, DOI 10.1158/1078-0432.CCR-11-1433	65	78	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5481	5491		10.1038/onc.2013.83	http://dx.doi.org/10.1038/onc.2013.83			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23708653	hybrid, Green Published			2022-12-17	WOS:000327780800005
J	Wagner, L; Marschall, V; Karl, S; Cristofanon, S; Zobel, K; Deshayes, K; Vucic, D; Debatin, KM; Fulda, S				Wagner, L.; Marschall, V.; Karl, S.; Cristofanon, S.; Zobel, K.; Deshayes, K.; Vucic, D.; Debatin, K-M; Fulda, S.			Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1-and NF-kappa B-dependent manner	ONCOGENE			English	Article						Smac; apoptosis; glioblastoma; temozolomide; RIP1	IRRADIATION-INDUCED APOPTOSIS; MALIGNANT GLIOMA; BETULINIC ACID; ACTIVATION; GAMMA; DEATH; RESISTANCE; CASPASE-8; CIAP1; IAPS	Inhibitor of apoptosis (IAP) proteins are expressed at high levels in many cancers and therefore represent attractive targets for therapeutic intervention. Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma. BV6 and TMZ synergistically reduce cell viability and trigger apoptosis in glioblastoma cells (combination index <0.4-0.8), which is accompanied by increased loss of mitochondrial-membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Analysis of the molecular mechanisms reveals that BV6 causes rapid degradation of clAP1, leading to stabilization of NF-kappa B-inducing kinase and NF-kappa B activation. BV6-stimulated NF-kappa B activation is critically required for sensitization toward TMZ, as inhibition of NF-kappa B by overexpression of the mutant l kappa B alpha super-repressor profoundly reduces loss of mitochondrial membrane potential, cytochrome c release, caspase activation and apoptosis. Of note, BV6-mediated sensitization to TMZ is not associated with increased tumor necrosis factor alpha (TNF alpha) production. Also, TNF alpha, CD95 or TRAIL-blocking antibodies or knockdown of TNFR1 have no or little effect on combination treatment-induced apoptosis. Interestingly, BV6 and TMZ cooperate to trigger the formation of a RIP1 (receptor activating protein 1)/caspase-8/FADD complex. Knockdown of RIP1 by small interfering RNA significantly reduces BV6- and TMZ-induced caspase-8 activation and apoptosis, showing that RIP1 is necessary for apoptosis induction. By demonstrating that BV6 primes glioblastoma cells for TMZ in a NF-kappa B- and RIP1-dependent manner, these findings build the rationale for further (pre)clinical development of Smac mimetics in combination with TMZ. Oncogene (2013) 32, 988-997; doi:10.1038/onc.2012.108; published online 2 April 2012	[Wagner, L.; Karl, S.; Debatin, K-M; Fulda, S.] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Marschall, V.; Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Hesse, Germany; [Zobel, K.; Deshayes, K.; Vucic, D.] Genentech Inc, San Francisco, CA USA	Ulm University; Goethe University Frankfurt; Roche Holding; Genentech	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); IAP6/18; International Graduate School in Molecular Medicine Ulm, Ulm University	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); IAP6/18; International Graduate School in Molecular Medicine Ulm, Ulm University	We thank C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF) and by a scholarship from the International Graduate School in Molecular Medicine Ulm, Ulm University (to LW). Kerry Zobel, Kurt Deshayes, and Domagoj Vucic are employees of Genentech, Inc.	Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Berger R, 2011, MOL CANCER THER, V10, P1867, DOI 10.1158/1535-7163.MCT-11-0218; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Chou T.C., 1991, SYNERGISM ANTAGONISM, P61; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Probst BL, 2010, CELL DEATH DIFFER, V17, P1645, DOI 10.1038/cdd.2010.44; Shirley S., 2010, CANC LETT; Straub CS, 2011, CURR TOP MED CHEM, V11, P291; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vellanki S, 2009, NEOPLASIA, V11, P743, DOI 10.1593/neo.09436; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036	29	78	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					988	997		10.1038/onc.2012.108	http://dx.doi.org/10.1038/onc.2012.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469979				2022-12-17	WOS:000316523200006
J	Papadimitriou, E; Vasilaki, E; Vorvis, C; Iliopoulos, D; Moustakas, A; Kardassis, D; Stournaras, C				Papadimitriou, E.; Vasilaki, E.; Vorvis, C.; Iliopoulos, D.; Moustakas, A.; Kardassis, D.; Stournaras, C.			Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-beta and miR-24: role in epithelial-to-mesenchymal transition	ONCOGENE			English	Article						TGF-beta; Net1A; RhoA; EMT; miR-24	EXCHANGE FACTOR NET1; SMAD PROTEINS; ADHERENS JUNCTIONS; TUMOR-SUPPRESSOR; FAMILY; DYNAMICS; DOWNSTREAM; MECHANISMS; PLASTICITY; RECEPTORS	In the present study we analyzed the regulation of the two isoforms of the RhoA-specific guanine nucleotide exchange factor Net1 by transforming growth factor-beta (TGF-beta) in keratinocytes. We report that short-term TGF-beta treatment selectively induced Net1 isoform2 (Net1A) but not Net1 isoform1. This led to upregulation of cytoplasmic Net1A protein levels that were necessary for TGF-beta-mediated RhoA activation. Smad signaling and the MAPK/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway were involved in Net1A upregulation by TGF-beta. Interestingly, long-term TGF-beta treatment resulted in Net1 mRNA downregulation and Net1A protein degradation by the proteasome. Furthermore, we identified the microRNA miR-24 as a novel post-transcriptional regulator of Net1A expression. Silencing of Net1A resulted in disruption of E-cadherin-and zonula occludens-1 (ZO-1)-mediated junctions, as well as expression of the transcriptional repressor of E-cadherin, Slug and the mesenchymal markers N-cadherin, plasminogen activator inhibitor-1 (PAI-1) and fibronectin, indicating that late TGF-beta-induced downregulation of Net1A is involved in epithelial-to-mesenchymal transition (EMT). Finally, miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-beta-induced breast cancer cell invasiveness through Net1A regulation. Our results emphasize the importance of Net1 isoform2 in the short-and long-term TGF-beta-mediated regulation of EMT. Oncogene (2012) 31, 2862-2875; doi:10.1038/onc.2011.457; published online 10 October 2011	[Papadimitriou, E.; Vasilaki, E.; Kardassis, D.; Stournaras, C.] Univ Crete, Dept Biochem, Sch Med, Iraklion 71003, Crete, Greece; [Vorvis, C.; Iliopoulos, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Vorvis, C.; Iliopoulos, D.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA; [Vasilaki, E.; Moustakas, A.] Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden; [Moustakas, A.] Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Uppsala, Sweden	University of Crete; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research; Uppsala University; Uppsala University	Stournaras, C (corresponding author), Univ Crete, Dept Biochem, Sch Med, POB 2208, Iraklion 71003, Crete, Greece.	cstourn@med.uoc.gr	Vasilaki, Eleftheria/AAY-6392-2020; Iliopoulos, Dimitrios/AAE-9106-2019		PENED program of the Greek Secretariat for Research and Technology [PENED03-688]	PENED program of the Greek Secretariat for Research and Technology	This work was supported by the PENED program of the Greek Secretariat for Research and Technology (Grant no. PENED03-688). We thank Dr EA Papakonstanti for valuable comments.	Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; Carr HS, 2009, J BIOL CHEM, V284, P24269, DOI 10.1074/jbc.M109.029439; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Garcia-Mata R, 2007, MOL CELL BIOL, V27, P8683, DOI 10.1128/MCB.00157-07; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Inoue Y, 2008, CANCER SCI, V99, P2107, DOI 10.1111/j.1349-7006.2008.00925.x; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kardassis D, 2009, FEBS J, V276, P2947, DOI 10.1111/j.1742-4658.2009.07031.x; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lee J, 2010, J BIOL CHEM, V285, P26618, DOI 10.1074/jbc.M109.073155; Lin SC, 2011, ORAL ONCOL, V46, P204; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 2008, FEBS LETT, V582, P2051, DOI 10.1016/j.febslet.2008.03.027; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Piek E, 1999, J CELL SCI, V112, P4557; Qin HJ, 2005, J BIOL CHEM, V280, P7603, DOI 10.1074/jbc.M412141200; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P3717, DOI 10.1091/mbc.12.12.3717; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Sun FY, 2009, BIOCHEM BIOPH RES CO, V380, P660, DOI 10.1016/j.bbrc.2009.01.161; Sun Q, 2008, NUCLEIC ACIDS RES, V36, P2690, DOI 10.1093/nar/gkn032; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Vardouli L, 2008, FEBS J, V275, P4074, DOI 10.1111/j.1742-4658.2008.06549.x; Vasilaki E, 2010, FASEB J, V24, P891, DOI 10.1096/fj.09-134742; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang Q, 2008, BLOOD, V111, P588, DOI 10.1182/blood-2007-05-092718; Xie L, 2011, CLIN BIOCHEM, V44, P216, DOI 10.1016/j.clinbiochem.2010.11.002; Zaidi SK, 2009, CANCER RES, V69, P8249, DOI 10.1158/0008-5472.CAN-09-1567; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	44	78	80	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2862	2875		10.1038/onc.2011.457	http://dx.doi.org/10.1038/onc.2011.457			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986943				2022-12-17	WOS:000305277900006
J	Kim, JH; Yoon, S; Park, M; Park, HO; Ko, JJ; Lee, K; Bae, J				Kim, J-H; Yoon, S.; Park, M.; Park, H-O; Ko, J-J; Lee, K.; Bae, J.			Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W)	ONCOGENE			English	Article						FOXL2; granulosa cell tumor; apoptosis; caspase; BAK; death receptors	OUTER-MEMBRANE PERMEABILIZATION; DEATH RECEPTORS; CYTOCHROME-C; MYELOID-LEUKEMIA; OVARY; COMPLEX; BAX; TRANSCRIPTION; ACTIVATION; REPRESSES	Some mutations in FOXL2 result in premature ovarian failure accompanied by blepharophimosis, ptosis, epicanthus inversus syndrome type I disease, and FOXL2-null mice exhibit developmental defects in granulosa cells. Recently, FOXL2 c.402C>G, a new somatic mutation that leads to a p. C134W change, was found in the majority of adult-type ovarian granulosa cell tumors (GCTs). In this study, we investigated the possible mechanisms by which the C134W mutation contributes to the development of GCTs. Wild-type (WT) and mutant FOXL2 displayed differential apoptotic activities. Specifically, WT FOXL2 induced significant granulosa cell death, but the mutant exhibited minimal cell death. The FOXL2-induced apoptotic response was greatly dependent on caspase 8, BID and BAK because the depletion of any of these three proteins inhibited FOXL2 from eliciting the full apoptotic response. Activation of caspase 8 and subsequent increased production of truncated BID, and oligomerization of BAK, and release of cytochrome c were all associated with the apoptosis induced by WT FOXL2 expression. In contrast, the mutant FOXL2 was unable to elicit the full array of apoptotic signaling responses. In addition, we found differential TNF-R1 (tumor necrosis factor-receptor 1) and Fas (CD95/APO-1) upregulation between the WT and the mutant, and the silencing of TNF-R1 or Fas and the blockage of the death signaling mediated by TNF-R1 or Fas using TNF-Fc or Fas-Fc, respectively, resulted in significant attenuations of FOXL2-induced apoptosis. Moreover, granulosa cells that expressed either WT FOXL2 or mutant exhibited distinct cell death sensitivities on activation of death receptors and deprivation of serum. Thus, the differential activities of FOXL2 and its mutant may partially account for the pathophysiology of GCT development. Oncogene (2011) 30, 1653-1663; doi:10.1038/onc.2010.541; published online 29 November 2010	[Kim, J-H; Yoon, S.; Park, M.; Park, H-O; Ko, J-J; Bae, J.] CHA Univ, Coll Life Sci, Dept Biomed Sci, Songnam 463836, South Korea; [Lee, K.] Chung Ang Univ, Dept Life Sci, Seoul 156756, South Korea	Pochon Cha University; Chung Ang University	Bae, J (corresponding author), CHA Univ, Coll Life Sci, Dept Biomed Sci, 222 Yatap Dong, Songnam 463836, South Korea.	jeehyeon@cha.ac.kr			National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology [2009-0066320, 2009-0093821]; Ministry of Health, Welfare and Family Affairs [A084923]	National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology(National Research Foundation of Korea); Ministry of Health, Welfare and Family Affairs(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by the Basic Science Research Program (2009-0066320) and the Priority Research Centers Program (2009-0093821) through the National Research Foundation of Korea (NRF) of the Ministry of Education, Science and Technology and by a grant (A084923) from the Korea Healthcare Technology R&D Project from the Ministry of Health, Welfare and Family Affairs.	Arnoult D, 2008, METHODS, V44, P229, DOI 10.1016/j.ymeth.2007.11.003; Benayoun BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008789; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963; Crisponi L, 2001, NAT GENET, V27, P159, DOI 10.1038/84781; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Ganju N, 2003, CELL DEATH DIFFER, V10, P652, DOI 10.1038/sj.cdd.4401234; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; Hail N, 2005, APOPTOSIS, V10, P687, DOI 10.1007/s10495-005-0792-8; Jabbour AM, 2009, CELL DEATH DIFFER, V16, P555, DOI 10.1038/cdd.2008.179; Kang BPS, 2003, AM J PHYSIOL-RENAL, V284, pF455, DOI 10.1152/ajprenal.00137.2002; Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688; Kornblau SM, 2010, CLIN CANCER RES, V16, P1865, DOI 10.1158/1078-0432.CCR-09-2551; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI P, 2004, CELL, V116, P57; Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011; Muzio M, 1998, INT J CLIN LAB RES, V28, P141, DOI 10.1007/s005990050035; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Park M, 2010, MOL ENDOCRINOL, V24, P1024, DOI 10.1210/me.2009-0375; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Pisarska MD, 2004, ENDOCRINOLOGY, V145, P3424, DOI 10.1210/en.2003-1141; Schrader KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007988; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Uda M, 2004, HUM MOL GENET, V13, P1171, DOI 10.1093/hmg/ddh124; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	35	78	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	14					1653	1663		10.1038/onc.2010.541	http://dx.doi.org/10.1038/onc.2010.541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21119601				2022-12-17	WOS:000289239400004
J	Chakrabarty, A; Rexer, BN; Wang, SE; Cook, RS; Engelman, JA; Arteaga, CL				Chakrabarty, A.; Rexer, B. N.; Wang, S. E.; Cook, R. S.; Engelman, J. A.; Arteaga, C. L.			H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3	ONCOGENE			English	Article						PIK3CA mutations; HER2 overexpression; HER3; heregulin; breast cancer	HUMAN BREAST-CANCER; TYROSINE KINASE INHIBITORS; GROWTH-FACTOR RECEPTOR; PIK3CA MUTATIONS; PHOSPHOINOSITIDE 3-KINASE; IN-VIVO; TRASTUZUMAB RESISTANCE; EPITHELIAL-CELLS; HIGH-FREQUENCY; PI3K PATHWAY	Hyperactivation of phosphatidylinositol-3 kinase (PI3K) can occur as a result of somatic mutations in PIK3CA, the gene encoding the p110 alpha subunit of PI3K. The HER2 oncogene is amplified in 25% of all breast cancers and some of these tumors also harbor PIK3CA mutations. We examined mechanisms by which mutant PI3K can enhance transformation and confer resistance to HER2-directed therapies. We introduced the PI3K mutations E545K and H1047R in MCF10A human mammary epithelial cells that also overexpress HER2. Both mutants conferred a gain of function to MCF10A/HER2 cells. Expression of H1047R PI3K, but not E545K PI3K, markedly upregulated the HER3/HER4 ligand heregulin (HRG). HRG siRNA inhibited growth of H1047R but not E545K-expressing cells and synergized with the HER2 inhibitors trastuzumab and lapatinib. The PI3K inhibitor BEZ235 markedly inhibited HRG and pAKT levels and, in combination with lapatinib, completely inhibited growth of cells expressing H1047R PI3K. These observations suggest that PI3K mutants enhance HER2-mediated transformation by amplifying the ligand-induced signaling output of the ErbB network. This also counteracts the full effect of therapeutic inhibitors of HER2. These data also suggest that mammary tumors that contain both HER2 gene amplification and PIK3CA mutations should be treated with a combination of HER2 and PI3K inhibitors. Oncogene (2010) 29, 5193-5203; doi:10.1038/onc.2010.257; published online 28 June 2010	[Chakrabarty, A.; Rexer, B. N.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Wang, S. E.; Cook, R. S.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Cook, R. S.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Breast Canc Res Program, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Engelman, J. A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Canc Ctr,Dept Med, Charlestown, MA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Massachusetts General Hospital	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Ingram Canc Ctr, 777 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu		Wang, Shizhen Emily/0000-0002-5036-8175	ACS Clinical Research [CRP-07-234]; Breast Cancer Specialized Program of Research Excellence (SPORE) [P50 CA98131]; Vanderbilt-Ingram Comprehensive Cancer Center [P30 CA68485];  [R01 CA80195]; NATIONAL CANCER INSTITUTE [P30CA068485, P50CA098131, R01CA080195] Funding Source: NIH RePORTER	ACS Clinical Research; Breast Cancer Specialized Program of Research Excellence (SPORE); Vanderbilt-Ingram Comprehensive Cancer Center; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr H Shelton Earp III and Dr Carlos Garcia-Echeverria for providing the HER4 antibody and NVP-BEZ235, respectively. This work was supported by R01 CA80195 (CLA), ACS Clinical Research Professorship Grant CRP-07-234 (CLA), Breast Cancer Specialized Program of Research Excellence (SPORE) P50 CA98131 and Vanderbilt-Ingram Comprehensive Cancer Center Support Grant P30 CA68485.	Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Carson JD, 2008, BIOCHEM J, V409, P519, DOI 10.1042/BJ20070681; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246; Geering B, 2007, BIOCHEM SOC T, V35, P199, DOI 10.1042/BST0350199; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lai YL, 2008, ANN SURG ONCOL, V15, P1064, DOI 10.1245/s10434-007-9751-7; Lee JY, 2007, SCIENCE, V317, P206, DOI 10.1126/science.1146073; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Lerma E, 2008, VIRCHOWS ARCH, V453, P133, DOI 10.1007/s00428-008-0643-4; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li SY, 2006, BREAST CANCER RES TR, V96, P91, DOI 10.1007/s10549-005-9048-0; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Medina PJ, 2008, CLIN THER, V30, P1426, DOI 10.1016/j.clinthera.2008.08.008; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Revillion F, 2008, ANN ONCOL, V19, P73, DOI 10.1093/annonc/mdm431; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	52	78	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5193	5203		10.1038/onc.2010.257	http://dx.doi.org/10.1038/onc.2010.257			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581867	Green Accepted			2022-12-17	WOS:000281867200008
J	Novakova, Z; Hubackova, S; Kosar, M; Janderova-Rossmeislova, L; Dobrovolna, J; Vasicova, P; Vancurova, M; Horejsi, Z; Hozak, P; Bartek, J; Hodny, Z				Novakova, Z.; Hubackova, S.; Kosar, M.; Janderova-Rossmeislova, L.; Dobrovolna, J.; Vasicova, P.; Vancurova, M.; Horejsi, Z.; Hozak, P.; Bartek, J.; Hodny, Z.			Cytokine expression and signaling in drug-induced cellular senescence	ONCOGENE			English	Article						cytokines; JAK/STAT signaling; interleukins; cellular senescence; 5-bromo-2 '-deoxyuridine; distamycin A	ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE RESPONSE; TUMOR SUPPRESSION; PML PROTEIN; HUMAN-CELLS; HELA-CELLS; CANCER; PATHWAY; STRESS; INDUCTION	Cellular senescence guards against cancer and modulates aging; however, the underlying mechanisms remain poorly understood. Here, we show that genotoxic drugs capable of inducing premature senescence in normal and cancer cells, such as 5-bromo-2'-deoxyuridine (BrdU), distamycin A (DMA), aphidicolin and hydroxyurea, persistently activate Janus kinase-signal transducer and activator of transcription (JAK/STAT) signaling and expression of interferon-stimulated genes (ISGs), such as MX1, OAS, ISG15, STAT1, PML, IRF1 and IRF7, in several human cancer cell lines. JAK1/STAT-activating ligands, interleukin 10 (IL10), IL20, IL24, interferon gamma (IFN gamma), IFN beta and IL6, were also expressed by senescent cells, supporting autocrine/paracrine activation of JAK1/STAT. Furthermore, cytokine genes, including proinflammatory IL1, tumor necrosis factor and transforming growth factor families, were highly expressed. The strongest inducer of JAK/STAT signaling, cytokine production and senescence was BrdU combined with DMA. RNA interference-mediated knockdown of JAK1 abolished expression of ISGs, but not DNA damage signaling or senescence. Thus, although DNA damage signaling, p53 and RB activation, and the cytokine/chemokine secretory phenotype are apparently shared by all types of senescence, our data reveal so far unprecedented activation of the IFN beta-STAT1-ISGs axis, and indicate a less prominent causative role of IL6-JAK/STAT signaling in genotoxic drug-induced senescence compared with reports on oncogene-induced or replicative senescence. These results highlight shared and unique features of drug-induced cellular senescence, and implicate induction of cancer secretory phenotype in chemotherapy. Oncogene (2010) 29, 273-284; doi:10.1038/onc.2009.318; published online 5 October 2009	[Novakova, Z.; Hubackova, S.; Kosar, M.; Vancurova, M.; Bartek, J.; Hodny, Z.] Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Genome Integr, CR-14220 Prague, Czech Republic; [Novakova, Z.; Janderova-Rossmeislova, L.; Dobrovolna, J.; Hozak, P.; Hodny, Z.] Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Biol Cell Nucleus, CR-14220 Prague, Czech Republic; [Vasicova, P.] Acad Sci Czech Republ, Inst Microbiol, Vvi, Lab Cell Reprod, CR-14220 Prague, Czech Republic; [Horejsi, Z.] Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Mol Virol, CR-14220 Prague, Czech Republic; [Bartek, J.] Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, DK-2100 Copenhagen O, Denmark; [Bartek, J.] Danish Canc Soc, Inst Canc Biol, Ctr Genotox Stress Res, DK-2100 Copenhagen O, Denmark	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Danish Cancer Society; Danish Cancer Society	Hodny, Z (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Vvi, Dept Genome Integr, Videnska 1083, CR-14220 Prague, Czech Republic.	jb@cancer.dk; hodny@img.cas.cz	Kosar, Martin/B-7143-2018; Bartek, Jiri/G-5870-2014; Rossmeislová, Lenka/D-1931-2013; Vasicova, Pavla/I-2010-2014; Hozak, Pavel/J-4182-2014; Novakova, Zora/G-8665-2014; Hodny, Zdenek/C-9384-2009; Hozak, Pavel/AAB-5359-2021; Vasicova, Pavla/AAL-6466-2021; Dobrovolna, Jana/G-5873-2014	Kosar, Martin/0000-0002-9400-2327; Rossmeislová, Lenka/0000-0002-7611-7585; Hozak, Pavel/0000-0003-1901-1394; Novakova, Zora/0000-0001-9804-6346; Hozak, Pavel/0000-0003-1901-1394; Stemberkova Hubackova, Sona/0000-0002-3454-6840; Vasicova, Pavla/0000-0002-9733-9929; Dobrovolna, Jana/0000-0003-2412-2080; Licenikova Horejsi, Zuzana/0000-0002-9943-1649	Agency of the Academy of Sciences of the Czech Republic [IAA500390501]; Grant Agency of the Czech Republic [204/08/1418]; European Commission [TRIREME]; Ministry of Education, Youth and Sports of the Czech Republic [LC545]; Institutional Grant [AV0Z5039906]	Agency of the Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); European Commission(European CommissionEuropean Commission Joint Research Centre); Ministry of Education, Youth and Sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Institutional Grant	We thank Ondrej Horvath and Michal Koc for assistance, and Jan Fric and Ondrej Stanek for help with ELISA. This work was supported by the Grant Agency of the Academy of Sciences of the Czech Republic (Project IAA500390501), the Grant Agency of the Czech Republic (Project 204/08/1418), the European Commission (project TRIREME), Grant LC545 of the Ministry of Education, Youth and Sports of the Czech Republic, and the Institutional Grant (Project AV0Z5039906).	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chang BD, 1999, CANCER RES, V59, P3761; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Commins S, 2008, J ALLERGY CLIN IMMUN, V121, P1108, DOI 10.1016/j.jaci.2008.02.026; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Engstrom JU, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199/8/9; Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008-5472.CAN-05-3127; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Janderovd-Rossmeislova L, 2007, J STRUCT BIOL, V159, P56, DOI 10.1016/j.jsb.2007.02.008; Kaynor C, 2002, J INTERF CYTOK RES, V22, P1089, DOI 10.1089/10799900260442511; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Michishita E, 1999, J BIOCHEM-TOKYO, V126, P1052; Minagawa S, 2005, EXP CELL RES, V304, P552, DOI 10.1016/j.yexcr.2004.10.036; Moiseeva O, 2006, MOL BIOL CELL, V17, P1583, DOI 10.1091/mbc.E05-09-0858; Mushinski JF, 2009, J BIOL CHEM, V284, P15206, DOI 10.1074/jbc.M806324200; Pamment J, 2002, ONCOGENE, V21, P7776, DOI 10.1038/sj.onc.1205981; Parrinello S, 2005, J CELL SCI, V118, P485, DOI 10.1242/jcs.01635; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ronni T, 1998, J INTERF CYTOK RES, V18, P773, DOI 10.1089/jir.1998.18.773; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667; Suzuki T, 2002, EXP CELL RES, V276, P174, DOI 10.1006/excr.2002.5524; Suzuki T, 2001, EXP CELL RES, V266, P53, DOI 10.1006/excr.2001.5194; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Toussaint O, 2002, BIOCHEM PHARMACOL, V64, P1007, DOI 10.1016/S0006-2952(02)01170-X; van Boxel-Dezaire AHH, 2006, IMMUNITY, V25, P361, DOI 10.1016/j.immuni.2006.08.014; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Yogev O, 2006, J BIOL CHEM, V281, P34475, DOI 10.1074/jbc.M602865200	50	78	82	3	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					273	284		10.1038/onc.2009.318	http://dx.doi.org/10.1038/onc.2009.318			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19802007				2022-12-17	WOS:000273650000010
J	Yalcin, A; Clem, B; Makoni, S; Clem, A; Nelson, K; Thornburg, J; Siow, D; Lane, AN; Brock, SE; Goswami, U; Eaton, JW; Telang, S; Chesney, J				Yalcin, A.; Clem, B.; Makoni, S.; Clem, A.; Nelson, K.; Thornburg, J.; Siow, D.; Lane, A. N.; Brock, S. E.; Goswami, U.; Eaton, J. W.; Telang, S.; Chesney, J.			Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling	ONCOGENE			English	Article						ras; phosphatidic acid; phosphocholine	PHOSPHATIDIC-ACID; HUMAN CANCER; PHOSPHOLIPASE-D; BREAST-CANCER; LUNG-CANCER; TUMOR PROGRESSION; DRUG-RESISTANCE; RAS ACTIVATION; EGF RECEPTOR; CELL-LINES	Choline is an essential anabolic substrate for the synthesis of phospholipids. Choline kinase phosphorylates choline to phosphocholine that serves as a precursor for the production of phosphatidylcholine, the major phospholipid constituent of membranes and substrate for the synthesis of lipid signaling molecules. Nuclear magnetic resonance (NMR)-based metabolomic studies of human tumors have identified a marked increase in the intracellular concentration of phosphocholine relative to normal tissues. We postulated that the observed intracellular pooling of phosphocholine may be required to sustain the production of the pleiotropic lipid second messenger, phosphatidic acid. Phosphatidic acid is generated from the cleavage of phosphatidylcholine by phospholipase D2 and is a key activator of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT survival signaling pathways. In this study we show that the steady-state concentration of phosphocholine is increased by the ectopic expression of oncogenic H-Ras(V12) in immortalized human bronchial epithelial cells. We then find that small interfering RNA (siRNA) silencing of choline kinase expression in transformed HeLa cells completely abrogates the high concentration of phosphocholine, which in turn decreases phosphatidylcholine, phosphatidic acid and signaling through the MAPK and PI3K/AKT pathways. This simultaneous reduction in survival signaling markedly decreases the anchorage-independent survival of HeLa cells in soft agar and in athymic mice. Last, we confirm the relative importance of phosphatidic acid for this pro-survival effect as phosphatidic acid supplementation fully restores MAPK signaling and partially rescues HeLa cells from choline kinase inhibition. Taken together, these data indicate that the pooling of phosphocholine in cancer cells may be required to provide a ready supply of phosphatidic acid necessary for the feed-forward amplification of cancer survival signaling pathways.	[Yalcin, A.; Clem, B.; Makoni, S.; Clem, A.; Nelson, K.; Thornburg, J.; Siow, D.; Lane, A. N.; Brock, S. E.; Goswami, U.; Eaton, J. W.; Telang, S.; Chesney, J.] Univ Louisville, Dept Biochem & Mol Biol, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40202 USA; [Yalcin, A.] Uludag Univ, Dept Biochem, Sch Vet Med, Bursa, Turkey	University of Louisville; Uludag University	Chesney, J (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, James Graham Brown Canc Ctr, Mol Targets Program, 580 S Preston St,204E, Louisville, KY 40202 USA.	jaches03@louisville.edu	Yalcin, Abdullah/ABI-4164-2020; Yalcin, Abdullah/AAA-6938-2022	Yalcin, Abdullah/0000-0001-8519-8375; 	James Graham Brown Cancer Center; NIH [1 R01 CA11642801]; Kentucky Lung Cancer Research Program	James Graham Brown Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kentucky Lung Cancer Research Program	We gratefully acknowledge helpful discussions with Drs Binks Wattenberg, Mary Roth and Otto Grubraw. This work was supported by the James Graham Brown Cancer Center and by the following grants: NIH 1 R01 CA11642801 (JC) and the Kentucky Lung Cancer Research Program (JC).	Ackerstaff E, 2003, J CELL BIOCHEM, V90, P525, DOI 10.1002/jcb.10659; Al-Saffar NMS, 2006, CANCER RES, V66, P427, DOI 10.1158/0008-5472.CAN-05-1338; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Aoyama C, 2002, BIOCHEM J, V363, P777, DOI 10.1042/0264-6021:3630777; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Banez-Coronel M, 2008, CURR CANCER DRUG TAR, V8, P709, DOI 10.2174/156800908786733432; BOS JL, 1989, CANCER RES, V49, P4682; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; de Molina AR, 2004, CANCER LETT, V206, P137, DOI 10.1016/j.canlet.2003.08.031; DEGANI H, 1986, RADIOLOGY, V161, P53, DOI 10.1148/radiology.161.1.3020609; Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; Glunde K, 2005, CANCER RES, V65, P11034, DOI 10.1158/0008-5472.CAN-05-1807; Glunde K, 2007, LANCET ONCOL, V8, P855, DOI 10.1016/S1470-2045(07)70289-9; Glunde K, 2006, EXPERT REV MOL DIAGN, V6, P821, DOI 10.1586/14737159.6.6.821; Grant S, 2008, J CLIN INVEST, V118, P3003, DOI 10.1172/JCI36898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; Iero M, 2008, CELL DEATH DIFFER, V15, P80, DOI 10.1038/sj.cdd.4402237; Ihle NT, 2009, MOL CANCER THER, V8, P1, DOI 10.1158/1535-7163.MCT-08-0801; Iorio E, 2005, CANCER RES, V65, P9369, DOI 10.1158/0008-5472.CAN-05-1146; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Li GP, 1997, J BIOL CHEM, V272, P10337; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; Martinelli Giovanni, 2008, Clin Adv Hematol Oncol, V6, P303; Mazie AR, 2006, J CELL SCI, V119, P1645, DOI 10.1242/jcs.02858; McCubrey JA, 2007, ADV ENZYME REGUL, V47, P64, DOI 10.1016/j.advenzreg.2006.12.013; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Nozawa S, 2005, J BIOL CHEM, V280, P27544, DOI 10.1074/jbc.M411626200; Omerovic J, 2008, ONCOGENE, V27, P2754, DOI 10.1038/sj.onc.1210925; ONODERA K, 1986, JPN J CANCER RES, V77, P1201; Pal SK, 2008, CLIN LUNG CANCER, V9, P340, DOI 10.3816/CLC.2008.n.049; Ramirez de Molina A, 2005, CANCER RES, V65, P5647, DOI 10.1158/0008-5472.CAN-04-4416; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 2002, PHARMACOL THERAPEUT, V94, P35, DOI 10.1016/S0163-7258(02)00170-5; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Telang S, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-77; Thornburg JM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2154; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	57	78	86	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					139	149		10.1038/onc.2009.317	http://dx.doi.org/10.1038/onc.2009.317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19855431				2022-12-17	WOS:000273373500013
J	Akaogi, K; Nakajima, Y; Ito, I; Kawasaki, S; Oie, SH; Murayama, A; Kimura, K; Yanagisawa, J				Akaogi, K.; Nakajima, Y.; Ito, I.; Kawasaki, S.; Oie, S-H; Murayama, A.; Kimura, K.; Yanagisawa, J.			KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ER alpha	ONCOGENE			English	Article						breast cancer; estrogen receptor; KLF4; p53	KRUPPEL-LIKE FACTOR; COLONIC CELL-GROWTH; TUMOR-SUPPRESSOR; NUCLEAR RECEPTOR; GENE-EXPRESSION; DOWN-REGULATION; CYCLE ARREST; DNA-DAMAGE; P53; PROMOTER	Kruppel-like factor 4 (KLF4) is a transcription factor that participates in both tumor suppression and oncogenesis. To determine the association of KLF4 with tumorigenesis, we integrated data assembled in the Oncomine database and discovered a decrease in KLF4 gene transcripts in breast cancers. Further analysis of the database also showed a correlation between KLF4 expression and estrogen receptor-alpha (ER alpha) positivity. Knockdown of KLF4 in MCF-7 cells elevated the growth rate of these cells in the presence of estrogen. Therefore, we examined the interaction between KLF4 and ER alpha, and found that KLF4 bound to the DNA-binding region of ER alpha. KLF4 thus inhibits the binding of ER alpha to estrogen response elements in promoter regions, resulting in a reduction in ER alpha target gene transcription. Earlier studies have reported that KLF4 is transcriptionally activated by p53 following DNA damage. We also showed that activation of p53 decreased the transcriptional activity of ER alpha by elevating KLF4 expression. Our studies discovered a novel molecular network between p53, KLF4 and ER alpha. As both p53 and ER alpha are involved in cell growth and apoptosis, these results may explain why KLF4 possesses both tumor suppressive and oncogenic functions in breast cancers. Oncogene (2009) 28, 2894-2902; doi:10.1038/onc.2009.151; published online 8 June 2009	[Akaogi, K.; Nakajima, Y.; Ito, I.; Kawasaki, S.; Oie, S-H; Murayama, A.; Kimura, K.; Yanagisawa, J.] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Murayama, A.; Yanagisawa, J.] Univ Tsukuba, TARA Ctr, Tsukuba, Ibaraki 3058572, Japan; [Murayama, A.] JST, PRESTO, Kawaguchi, Saitama, Japan	University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST)	Yanagisawa, J (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.	junny@agbi.tsukuba.ac.jp						Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Blanchon L, 2006, BIOCHEM BIOPH RES CO, V343, P745, DOI 10.1016/j.bbrc.2006.03.032; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; DORGAN JF, 1996, CANCER EPIDEM BIOMAR, V5, P33; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Foster KW, 2000, CANCER RES, V60, P6488; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Ghaleb AM, 2007, CANCER RES, V67, P7147, DOI 10.1158/0008-5472.CAN-07-1302; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HENDERSON BE, 1988, CANCER RES, V48, P246; Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; Liu WS, 2006, J BIOL CHEM, V281, P9837, DOI 10.1074/jbc.C600001200; Luo AP, 2004, ONCOGENE, V23, P1291, DOI 10.1038/sj.onc.1207218; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1; Oishi Y, 2008, NAT MED, V14, P656, DOI 10.1038/nm1756; Okumura N, 2002, JPN J CANCER RES, V93, P867, DOI 10.1111/j.1349-7006.2002.tb01331.x; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Patel S, 2006, P NATL ACAD SCI USA, V103, P18668, DOI 10.1073/pnas.0608658103; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 1999, GASTROENTEROLOGY, V116, pA520; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Tateishi Y, 2006, MOL CELL BIOL, V26, P7966, DOI 10.1128/MCB.00713-06; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966; Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	50	78	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2894	2902		10.1038/onc.2009.151	http://dx.doi.org/10.1038/onc.2009.151			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503094				2022-12-17	WOS:000268917100005
J	Wang, Y; Mikhailova, M; Bose, S; Pan, CX; White, RD; Ghosh, PM				Wang, Y.; Mikhailova, M.; Bose, S.; Pan, C-X; White, Rw deVere; Ghosh, P. M.			Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival	ONCOGENE			English	Article						androgen independence; Akt; apoptosis; mTOR; raptor; rictor	SIGNAL-TRANSDUCTION PATHWAYS; MAMMALIAN TARGET; MTOR; KINASE; PHOSPHORYLATION; PROTEIN; GROWTH; RICTOR; CYTOSKELETON; PROGRESSION	The mTOR (mammalian target of rapamycin) inhibit or rapamycin caused growth arrest in both androgen-dependent and androgen-independent prostate cancer cells; however, long-term treatment induced resistance to the drug. The aim of this study was to investigate methods that can overcome this resistance. Here, we show that rapamycin treatment stimulated androgen receptor (AR) transcriptional activity, whereas suppression of AR activity with the antiandrogen bicalutamide sensitized androgen-dependent, as well as AR-sensitive androgen-independent prostate cancer cells, to growth inhibition by rapamycin. Further, the combination of rapamycin and bicalutamide, but not the individual drugs, induced significant levels of apoptosis in prostate cancer cells. The net effect of rapamycin is determined by its individual effects on the mTOR complexes mTORC1 (mTOR/raptor/G beta L) and mTORC2 (mTOR/rictor/sin1/G beta L). Inhibition of both mTORC1 and mTORC2 by rapamycin-induced apoptosis, whereas rapamycin-stimulation of AR transcriptional activity resulted from the inhibition of mTORC1, but not mTORC2. The effect of rapamycin on AR transcriptional activity was mediated by the phosphorylation of the serine/threonine kinase Akt, which also partially mediated apoptosis induced by rapamycin and bicalutamide. These results indicate the presence of two parallel cell-survival pathways in prostate cancer cells: a strong Akt-independent, but rapamycin-sensitive pathway downstream of mTORC1, and an AR-dependent pathway downstream of mTORC2 and Akt, that is stimulated by mTORC1 inhibition. Thus, the combination of rapamycin and bicalutamide induce apoptosis in prostate cancer cells by simultaneously inhibiting both pathways and hence would be of therapeutic value in prostate cancer treatment.	[Wang, Y.; Bose, S.; Pan, C-X; White, Rw deVere; Ghosh, P. M.] VA No Calf Hlth Care Syst, Res Serv, Mather, CA 95655 USA; [Wang, Y.; Pan, C-X; Ghosh, P. M.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; [Mikhailova, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio	Ghosh, PM (corresponding author), VA No Calf Hlth Care Syst, Res Serv, 10535 Hosp Way, Mather, CA 95655 USA.	paramita.ghosh@ucdmc.ucdavis.edu	WANG, YU/E-4655-2013		Department of Veterans Affairs; National Cancer Institute [CA109057]; NATIONAL CANCER INSTITUTE [R21CA109057, R01CA133209] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hsing-Jien Kung for critical reading of the manuscript, Dr Barry Furr, AstraZeneca, Cheshire, UK, for the gift of bicalutamide (Casodex), Dr Bandana Chatterjee, University of Texas Health Science Center at San Antonio (UTHSCSA) for hPSA-luc construct; Dr LuZhe Sun, UTHSCSA, for beta-gal construct and LNAI cell line. We are grateful to Sherra Johnson and Naveen K Krishnegowda for technical assistance in some of the experiments described. This study was supported by a Merit award from the Department of Veterans Affairs and award CA109057 from the National Cancer Institute.	Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Boehmer A, 2005, ANTICANCER RES, V25, P4481; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Edwards J, 2005, BJU INT, V95, P1320, DOI 10.1111/j.1464-410X.2005.05526.x; Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Ghosh PM, 2002, CANCER RES, V62, P2630; Ghosh PM, 2001, AM J PHYSIOL-RENAL, V280, pF972, DOI 10.1152/ajprenal.2001.280.6.F972; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hartig PC, 2002, TOXICOL SCI, V66, P82, DOI 10.1093/toxsci/66.1.82; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kremer CL, 2006, PROSTATE, V66, P1203, DOI 10.1002/pros.20410; Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Petrylak D, 2005, BJU INT, V96, P41, DOI 10.1111/j.1464-410X.2005.05946.x; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sharef S, 2006, J CLIN ONCOL, V24, P14584; Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535-7163.MCT-05-0068; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Wu LC, 2005, CANCER RES, V65, P2825, DOI 10.1158/0008-5472.CAN-04-3137	30	78	81	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7106	7117		10.1038/onc.2008.318	http://dx.doi.org/10.1038/onc.2008.318			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18776922	Green Accepted			2022-12-17	WOS:000261195900005
J	Boisvert-Adamo, K; Aplin, AE				Boisvert-Adamo, K.; Aplin, A. E.			Mutant B-RAF mediates resistance to anoikis via Bad and Bim	ONCOGENE			English	Article						apoptosis; Bad; Bim; B-RAF; melanoma	BCL-2 FAMILY-MEMBERS; MELANOMA-CELLS; MULTIPLE-MYELOMA; EPITHELIAL-CELLS; SURVIVAL SIGNALS; CYCLIN D1; APOPTOSIS; DEATH; PHOSPHORYLATION; PATHWAY	Normal cells undergo anoikis when they lose adhesion to or encounter an inappropriate extracellular matrix. By contrast, oncogenic signaling in tumor cells enables resistance to anoikis, a trait that contributes to tumor progression. The B-RAF serine-threonine kinase is mutated in multiple cancers and functions as an oncogene in melanoma. Previously, we demonstrated that B-RAF and downstream mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) signaling are necessary for protection from anoikis in mutant B-RAF-expressing melanoma cells. Regulation of Bcl-2 family members in melanoma and their role in B-RAF-mediated survival is poorly defined. Here, we provide evidence that B-RAFMEK signaling protects against anoikis through alterations in two proapoptotic Bcl-2 family proteins: Bcl-xL/Bcl-2-associated death promoter ( Bad) and Bcl-2-interacting mediator of cell death (Bim). B-RAF-MEK signaling regulates phosphorylation of the inhibitory serine-75 residue of Bad, and decreases Bad mRNA expression. RNA interference and overexpression experiments demonstrate that Bad contributes to the susceptibility of B-RAF-depleted cells to anoikis. Additionally, B-RAF-MEK signaling regulates the expression of Bim(EL), mainly through control of protein turnover. Increased BimEL levels induce apoptosis in suspended cells and are required for anoikis in B-RAF-depleted cells. Depletion of Bim together with Bad has an additive effect on protecting B-RAF knockdown cells from anoikis. Together, our data show that Bad and Bim are major B-RAF responsive proteins regulating apoptosis in melanoma cells.	[Boisvert-Adamo, K.; Aplin, A. E.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.	aplina@mail.amc.edu			NIGMS NIH HHS [R01 GM067893, GM067893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Berenson JR, 2006, J CLIN ONCOL, V24, P937, DOI 10.1200/JCO.2005.03.2383; Bhatt KV, 2007, ONCOGENE, V26, P1056, DOI 10.1038/sj.onc.1209861; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cowburn AS, 2002, BLOOD, V100, P2607, DOI 10.1182/blood-2001-11-0122; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Eisenmann KM, 2003, CANCER RES, V63, P8330; El Chami N, 2005, J CELL BIOL, V171, P651, DOI 10.1083/jcb.200507076; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06; Kropff MH, 2005, LEUKEMIA RES, V29, P587, DOI 10.1016/j.leukres.2004.11.004; Letai A, 2005, J CLIN INVEST, V115, P2648, DOI 10.1172/JCI26250; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliviero R, 1997, BIOCHEM J, V324, P75, DOI 10.1042/bj3240075; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Quadros MR, 2006, CANCER BIOL THER, V5, P498, DOI 10.4161/cbt.5.5.2567; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Troppmair J, 2003, BIOCHEM PHARMACOL, V66, P1341, DOI 10.1016/S0006-2952(03)00483-0; Wang PB, 2004, J BIOL CHEM, V279, P41280, DOI 10.1074/jbc.C400248200; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	40	78	80	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3301	3312		10.1038/sj.onc.1211003	http://dx.doi.org/10.1038/sj.onc.1211003			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18246127				2022-12-17	WOS:000256111400009
J	Niemantsverdriet, M; Wagner, K; Visser, M; Backendorf, C				Niemantsverdriet, M.; Wagner, K.; Visser, M.; Backendorf, C.			Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character	ONCOGENE			English	Article						14-3-3 zeta siRNA; UV irradiation; c-Jun N-terminal kinase; p38-MAPK; E-cadherin; Oncomine	PROGNOSTIC MARKER; GAMMA-CATENIN; BETA-CATENIN; DNA-DAMAGE; E-CADHERIN; CANCER; EXPRESSION; CARCINOMA; 14-3-3-PROTEINS; IDENTIFICATION	14-3-3 proteins are relevant to cancer biology as they are key regulators of major cellular processes such as proliferation, differentiation, senescence and apoptosis. So far, the sigma isoform (14-3-3 sigma) has most directly been implicated in carcinogenesis and was recognized as a tumour-suppressor gene. The other six members of the mammalian 14-3-3 gene family likely behave as oncogenes, although direct evidence supporting this view is largely circumstantial. In this report, we show that knockdown of 14-3-3 zeta induces at least two isoform-specific phenotypes that are consistent with a potential oncogenic activity during tumorigenesis. Firstly, down-regulation of 14-3-3 zeta sensitized cells to stress-induced apoptosis and JNK/p38 signalling and secondly, it enforced cell-cell contacts and expression of adhesion proteins. Apparently, the zeta isoform restrains both cell adhesion and the cellular propensity for apoptosis, two activities that are also restrained during carcinogenesis. The assumption that 14-3-3 zeta has oncogenic properties was substantiated with a web-based meta-analysis (Oncomine), revealing that 14-3-3 zeta is overexpressed in various types of carcinomas. As the highly conserved human 14-3-3 gene family encodes proteins with either tumour-promoting or tumour-suppressing activities, we infer that the cellular balance between the various 14-3-3 isoforms is crucial for the proper functioning of cells.	[Niemantsverdriet, M.; Wagner, K.; Visser, M.; Backendorf, C.] Leiden Univ, Leiden Inst Chem, Mol Genet Lab, NL-2333 CC Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Backendorf, C (corresponding author), Leiden Univ, Leiden Inst Chem, Mol Genet Lab, Einsteinweg 55, NL-2333 CC Leiden, Netherlands.	backendo@chem.leidenuniv.nl						Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048; Balda MS, 2003, TRENDS CELL BIOL, V13, P310, DOI 10.1016/S0962-8924(03)00105-3; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Clairotte A, 2006, AM J CLIN PATHOL, V125, P119, DOI 10.1309/DKCLN4K2RK0V87YG; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Ghadimi BM, 2003, CLIN CANCER RES, V9, P1808; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hekman M, 2006, J BIOL CHEM, V281, P17321, DOI 10.1074/jbc.M600292200; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jang JS, 2004, ONCOL RES, V14, P491, DOI 10.3727/0965040042380441; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Niemantsverdriet M, 2005, EXP CELL RES, V310, P237, DOI 10.1016/j.yexcr.2005.07.016; Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003; Rhodes DR, 2005, NAT GENET, V37, pS31, DOI 10.1038/ng1570; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Tada K, 2000, CANCER, V88, P268, DOI 10.1002/(SICI)1097-0142(20000115)88:2<268::AID-CNCR4>3.0.CO;2-B; Takeuchi T, 2002, MOL CARCINOGEN, V35, P173, DOI 10.1002/mc.10088; Takihara Y, 2000, CARCINOGENESIS, V21, P2073, DOI 10.1093/carcin/21.11.2073; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; Ueda G, 2006, INT J ORAL MAX SURG, V35, P356, DOI 10.1016/j.ijom.2005.07.023; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Zang L, 2004, J PROTEOME RES, V3, P604, DOI 10.1021/pr034131l	31	78	84	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1315	1319		10.1038/sj.onc.1210742	http://dx.doi.org/10.1038/sj.onc.1210742			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704798				2022-12-17	WOS:000253407000015
J	Safina, A; Vandette, E; Bakin, AV				Safina, A.; Vandette, E.; Bakin, A. V.			ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells	ONCOGENE			English	Article						invasion; metastasis; MMP-9; MAPK; TGF-beta; angiogenesis	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TGF-BETA; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; MOLECULAR-BIOLOGY; METASTASIS; IDENTIFICATION; EXPRESSION	Transforming growth factor beta 1 (TGF-beta 1) is a potent tumor suppressor but, paradoxically, TGF-beta 1 enhances tumor growth and metastasis in the late stages of cancer progression. This study investigated the role of TGF-beta type I receptor, ALK5, and three mitogen-activated protein kinases (MAPKs) in metastasis by breast cancer cell line MDA-MB-231. We show that autocrine TGF-beta signaling in MDA-MB-231 cells is required for tumor cell invasion and tumor angiogenesis. Expression of kinase inactive ALK5 reduces tumor invasion and formation of new blood vessels within the tumor orthotopic xenografts in severe combined immunodeficiency (SCID) mice. In contrast, constitutively active ALK5-T204D enhances tumor invasion and angiogenesis by stimulating expression of matrix metalloproteinase MMP-9/gelatinase-B. Ablation of MMP-9 in ALK5-T204D cells by RNA interference (RNAi) reduces tumor invasion and tumor growth. Importantly, RNAi-MMP-9 reduces tumor neovasculature and increases tumor cell death. Induction of MMP-9 by TGF-beta-ALK5 signaling requires MEK-ERK but not JNK, p38 MAPK or Smad4. Dominant-negative MEK blocks and constitutively active MEK1 enhances MMP-9 expression. However, all three MAPK cascades (ERK, JNK and p38 MAPK) are required for TGF-beta-mediated cell migration. Collectively, our results show that TGF-beta-ALK5-MAPK signaling in tumor cells promotes tumor angiogenesis and MMP-9 is an important component of this program.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org		Bakin, Andrei/0000-0002-7728-1969	NATIONAL CANCER INSTITUTE [R01CA095263, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, R01 CA95263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 2002, J CELL SCI, V115, P3193; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Benckert C, 2003, CANCER RES, V63, P1083; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bhattacharya A, 2004, CLIN CANCER RES, V10, P8005, DOI 10.1158/1078-0432.CCR-04-1306; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Chantrain CF, 2004, CANCER RES, V64, P1675, DOI 10.1158/0008-5472.CAN-03-0160; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dumont N, 2003, BIOCHEM BIOPH RES CO, V301, P108, DOI 10.1016/S0006-291X(02)02977-7; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Farina AR, 1998, INT J CANCER, V75, P721; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Frey RS, 1997, CANCER RES, V57, P628; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Johansson N, 2000, J CELL SCI, V113, P227; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302; PRICE JE, 1990, CANCER RES, V50, P717; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; TARIN D, 1981, CANCER RES, V41, P3604; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	65	78	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2407	2422		10.1038/sj.onc.1210046	http://dx.doi.org/10.1038/sj.onc.1210046			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17072348				2022-12-17	WOS:000245831000002
J	Fulda, S; Debatin, KM				Fulda, S.; Debatin, K-M			5-aza-2 '-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8	ONCOGENE			English	Article						caspase-8; apoptosis; TRAIL; interferon-gamma; resistance	DRUG-INDUCED APOPTOSIS; BREAST-TUMOR CELLS; NEUROBLASTOMA-CELLS; DEATH RECEPTOR; INTERFERON-GAMMA; DNA METHYLATION; DECOY RECEPTORS; CANCER-THERAPY; CD95 APO-1/FAS; EXPRESSION	Resistance of tumors to cytotoxic therapy remains a major obstacle in cancer treatment and is often caused by defects in apoptosis programs. Caspase-8, a key mediator of death receptor-induced apoptosis, has previously been reported to be frequently inactivated by epigenetic silencing in many tumors, for example in neuroblastoma or medulloblastoma. Here, we provide for the first time evidence that combined treatment with suboptimal concentrations of the demethylating agent 5-Aza-2'-deoxycytidine (5-dAzaC) and interferon-gamma (IFN-gamma) cooperated to upregulate caspase-8 expression in neuroblastoma and medulloblastoma cells lacking caspase-8. Consequently, activation of caspase-8 and downstream caspases upon addition of TNF-related apoptosis-inducing ligand (TRAIL) was restored by pretreatment with 5-dAzaC and IFN-gamma. Importantly, pretreatment with 5-dAzaC and IFN-gamma acted in concert to significantly enhance TRAIL-induced apoptosis in neuroblastoma and medulloblastoma cells. Inhibition of caspase-8 by dominant-negative caspase-8 or by the relatively specific caspase-8 inhibitior zIETD.fmk inhibited the increase in apoptosis provided by 5-dAzaC and IFN-gamma, indicating that caspase-8 is a key mediator of this sensitization effect. Thus, by demonstrating that 5-dAzaC and IFN-gamma at relatively low individual concentrations cooperate to restore caspase-8 expression and sensitize resistant neuroblastoma and medulloblastoma cells to TRAIL-induced apoptosis, our findings have important implications for novel strategies targeting defective apoptosis pathways in neuroectodermal tumors.	Univ Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Univ Childrens Hosp, Dept Hematol Oncol, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Banelli B, 2002, NAT MED, V8, P1333, DOI 10.1038/nm1202-1333; Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Casciano I, 2004, CELL DEATH DIFFER, V11, P131, DOI 10.1038/sj.cdd.4401327; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Eggert A, 2001, CANCER RES, V61, P1314; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Fan WM, 1998, ONCOL REP, V5, P1035; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2004, VITAM HORM, V67, P275; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hopkins-Donaldson S, 2003, CELL DEATH DIFFER, V10, P356, DOI 10.1038/sj.cdd.4401157; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kontny HU, 2001, CELL DEATH DIFFER, V8, P506, DOI 10.1038/sj.cdd.4400836; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Yang XZ, 2003, CANCER RES, V63, P1122	35	78	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5125	5133		10.1038/sj.onc.1209518	http://dx.doi.org/10.1038/sj.onc.1209518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607283				2022-12-17	WOS:000240063700005
J	Peduto, L; Reuter, VE; Sehara-Fujisawa, A; Shaffer, DR; Scher, HI; Blobel, CP				Peduto, L.; Reuter, V. E.; Sehara-Fujisawa, A.; Shaffer, D. R.; Scher, H. I.; Blobel, C. P.			ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression	ONCOGENE			English	Article						ADAM12; metalloprotease-disintegrin; prostate cancer; stromal/tumor cell interaction	EPIDERMAL-GROWTH-FACTOR; CELL-PROLIFERATION; CANCER; EGF; RECEPTOR	The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for cells participating in such interactions, and only few genes are known to play a critical role in this process. Here, we describe the identification of ADAM12 (a disintegrin and metalloprotease 12) as a novel marker for a subpopulation of stromal cells that are adjacent to epithelial tumor cells in three mouse carcinoma models (models for prostate, breast and colon cancer). Moreover, we show that ADAM12 is essential for tumor development and progression in the W-10 mouse model for prostate cancer. These results suggest that ADAM12 might be a useful marker for stromal cells in mouse tumors that are likely to participate in stromal/tumor cell crosstalk, and that ADAM12 is a potential target for design of drugs that prevent carcinoma growth.	Cornell Univ, Weill Med Coll, Arthritis & Tissue Degenerat Program, Hosp Special Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10021 USA; Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kyoto, Japan; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Kyoto University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Blobel, CP (corresponding author), Cornell Univ, Weill Med Coll, Arthritis & Tissue Degenerat Program, Hosp Special Surg, Caspary Res Bldg,Room 426,535 E 70th St, New York, NY 10021 USA.	blobelc@hss.edu		Peduto, Lucie/0000-0003-2414-4407	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR012538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064750] Funding Source: NIH RePORTER; NCRR NIH HHS [C06-RR12538-01] Funding Source: Medline; NIGMS NIH HHS [GM64750] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Freeman MR, 1998, J CELL BIOCHEM, V68, P328, DOI 10.1002/(SICI)1097-4644(19980301)68:3<328::AID-JCB4>3.0.CO;2-W; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; MANOVA K, 1992, J NEUROSCI, V12, P4663; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Peduto L, 2005, CANCER RES, V65, P9312, DOI 10.1158/0008-5472.CAN-05-1063; SCHUURMANS ALG, 1988, MOL CELL ENDOCRINOL, V60, P101, DOI 10.1016/0303-7207(88)90124-4; Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Torring N, 2002, BJU INT, V89, P583, DOI 10.1046/j.1464-410X.2002.02665.x	22	78	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5462	5466		10.1038/sj.onc.1209536	http://dx.doi.org/10.1038/sj.onc.1209536			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607276				2022-12-17	WOS:000240144900010
J	Baraz, L; Haupt, Y; Elkin, M; Peretz, T; Vlodavsky, I				Baraz, L.; Haupt, Y.; Elkin, M.; Peretz, T.; Vlodavsky, I.			Tumor suppressor p53 regulates heparanase gene expression	ONCOGENE			English	Article						heparanase; p53; gene expression; promoter activity	WILD-TYPE P53; TATA-BINDING PROTEIN; MAMMALIAN HEPARANASE; TRANSCRIPTIONAL REPRESSION; EXTRACELLULAR-MATRIX; MEDIATED DEGRADATION; MOLECULAR-PROPERTIES; BASEMENT-MEMBRANES; HUMAN FIBROBLASTS; CANCER	Mammalian heparanase degrades heparan sulfate, the most prominent polysaccharide of the extracellular matrix. Causal involvement of heparanase in tumor progression is well documented. Little is known, however, about mechanisms that regulate heparanase gene expression. Mutational inactivation of tumor suppressor p53 is the most frequent genetic alteration in human tumors. p53 is a transcription factor that regulates a wide variety of cellular promoters. In this study, we demonstrate that wild-type (wt) p53 binds to heparanase promoter and inhibits its activity, whereas mutant p53 variants failed to exert an inhibitory effect. Moreover, p53-H175R mutant even activated heparanase promoter activity. Elimination or inhibition of p53 in several cell types resulted in a significant increase in heparanase gene expression and enzymatic activity. Trichostatin A abolished the inhibitory effect of wt p53, suggesting the involvement of histone deacetylation in negative regulation of the heparanase promoter. Altogether, our results indicate that the heparanase gene is regulated by p53 under normal conditions, while mutational inactivation of p53 during cancer development leads to induction of heparanase expression, providing a possible explanation for the frequent increase of heparanase levels observed in the course of tumorigenesis.	Hadassah Univ, Med Ctr, Dept Oncol, Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, Jerusalem, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NCI NIH HHS [R01 CA 106456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allison SJ, 2004, CARCINOGENESIS, V25, P1551, DOI 10.1093/carcin/bgh212; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; de Mestre AM, 2003, J BIOL CHEM, V278, P50377, DOI 10.1074/jbc.M310154200; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkin M, 2003, CANCER RES, V63, P8821; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; Haupt S, 2004, CELL CYCLE, V3, P912; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Koliopanos A, 2001, CANCER RES, V61, P4655; Kosir MA, 1999, J SURG RES, V81, P42, DOI 10.1006/jsre.1998.5519; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Marchetti D, 2000, CANCER RES, V60, P4767; Maxhimer JB, 2005, DIABETES, V54, P2172, DOI 10.2337/diabetes.54.7.2172; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Milyavsky M, 2003, CANCER RES, V63, P7147; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nadav L, 2002, J CELL SCI, V115, P2179; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Rohloff J, 2002, BRIT J CANCER, V86, P1270, DOI 10.1038/sj.bjc.6600232; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zcharia E, 2005, AM J PATHOL, V166, P999, DOI 10.1016/S0002-9440(10)62321-8; Zcharia E, 2001, J MAMMARY GLAND BIOL, V6, P311, DOI 10.1023/A:1011375624902; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	55	78	86	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3939	3947		10.1038/sj.onc.1209425	http://dx.doi.org/10.1038/sj.onc.1209425			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474844				2022-12-17	WOS:000238668800007
J	Chattopadhyay, S; Machado-Pinilla, R; Manguan-Garcia, C; Belda-Iniesta, C; Moratilla, C; Cejas, P; Fresno-Vara, JA; de Castro-Carpeno, J; Nistal, M; Gonzalez-Baron, M; Perona, R				Chattopadhyay, S.; Machado-Pinilla, R.; Manguan-Garcia, C.; Belda-Iniesta, C.; Moratilla, C.; Cejas, P.; Fresno-Vara, J. A.; de Castro-Carpeno, J.; Nistal, M.; Gonzalez-Baron, M.; Perona, R.			MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer	ONCOGENE			English	Article						non-small-cell lung cancer; MKP1; CL100; siRNA; Jun kinase; cisplatin	PROTEIN-KINASE PHOSPHATASE-1; N-TERMINAL KINASE; JUN ACTIVATION DOMAIN; C-JUN; MAP KINASE; OVARIAN-CARCINOMA; MKP-1 EXPRESSION; STRESS; APOPTOSIS; SPECIFICITY	Non-small-cell lung cancer (NSCLC) represents the most frequent and therapy-refractive sub-class of lung cancer. Improving apoptosis induction in NSCLC represents a logical way forward in treating this tumor. Cisplatin, a commonly used therapeutic agent in NSCLC, induces activation of N-terminal-c-Jun kinase (JNK) that, in turn, mediates induction of apoptosis. In analysing surgical tissue samples of NSCLC, we found that expression of MKP1/CL100, a negative regulator of JNK, showed a strong nuclear staining for tumor cells, whereas, in normal bronchial epithelia, MKP1 was localized in the cytoplasm as well as in nuclei. In the NSCLC-derived cell lines H460 and H-23, we found that MKP1 was constitutively expressed. Expressing a small-interfering RNA (siRNA) vector for MKP1 in H-460 cells resulted in a more efficient activation by cisplatin of JNK and p38 than in the parental cells, and this correlated with a 10-fold increase in sensitivity to cisplatin. A similar response was also observed in H-460 and H-23 cells when treated with the MKP1 expression inhibitor RO-31-8220. Moreover, expression of a siRNA-MKP2, an MKP1-related phosphatase, had no effect on H-460 cell viability response to cisplatin. Tumors induced by H-460 cells expressing MKP1 siRNA grew slower in nu(-)/nu(-) mice and showed more susceptibility to cisplatin than parental cells, and resulted in an impaired growth of the tumor in mice. On the other hand, overexpression of MKP1 in the H-1299 NSCLC-derived cell line resulted in further resistance to cisplatin. Overall, the results showed that inhibition of MKP1 expression contributes to a slow down in cell growth in mice and an increase of cisplatin-induced cell death in NSCLC. As such, MKP1 can be an attractive target in sensitizing cells to cisplatin to increase the effectiveness of the drug in treating NSCLC.	UAM, CSIC, Inst Invest Biomed, Translat Oncol Unit, Madrid 28029, Spain; Hosp La Paz, Med Oncol Serv, Madrid, Spain; Hosp La Paz, Serv Anat Patol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz; Hospital Universitario La Paz	Perona, R (corresponding author), UAM, CSIC, Inst Invest Biomed, Translat Oncol Unit, C-Arturo Duperier 4, Madrid 28029, Spain.	RPerona@iib.uam.es	Vara, Juan Ángel Fresno/Y-9928-2019; Fresno Vara, Juan Angel/F-6702-2010	Vara, Juan Ángel Fresno/0000-0003-1527-1252; Fresno Vara, Juan Angel/0000-0003-1527-1252; Belda Iniesta, Cristobal/0000-0003-3254-7492				Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EASTMAN A, 1985, BIOCHEMISTRY-US, V24, P5027, DOI 10.1021/bi00340a011; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kim DH, 2003, CANCER RES, V63, P6206; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVIN WJ, 1994, CHEST, V106, pS372, DOI 10.1378/chest.106.6.372S; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Liao Q, 2003, GASTROENTEROLOGY, V124, P1830, DOI 10.1016/S0016-5085(03)00398-6; Lim EH, 2003, CLIN CANCER RES, V9, P5980; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00; Perona R, 2004, BRIT J CANCER, V90, P573, DOI 10.1038/sj.bjc.6601552; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SLEBOS RJC, 1989, EUR RESPIR J, V2, P461; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Standaert ML, 1999, ENDOCRINOLOGY, V140, P2145, DOI 10.1210/en.140.5.2145; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wiest JS, 1997, J CELL BIOCHEM, P64; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200	34	78	83	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3335	3345		10.1038/sj.onc.1209364	http://dx.doi.org/10.1038/sj.onc.1209364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16462770				2022-12-17	WOS:000237951200012
J	Xia, G; Kumar, SP; Stein, JP; Singh, J; Krasnoperov, V; Zhu, S; Hassanieh, L; Smith, DL; Buscarini, M; Broek, D; Quinn, DI; Weaver, FA; Gill, PS				Xia, G; Kumar, SP; Stein, JP; Singh, J; Krasnoperov, V; Zhu, S; Hassanieh, L; Smith, DL; Buscarini, M; Broek, D; Quinn, DI; Weaver, FA; Gill, PS			EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival	ONCOGENE			English	Article						receptor tyrosine kinase; bladder cancer; cell growth; EphB4	LIGAND EPHRIN-B2; CARCINOMA; PROTEIN; CISPLATIN; P53; CHEMOTHERAPY; METHOTREXATE; GEMCITABINE; VINBLASTINE; PROGRESSION	We sought to evaluate the biological function of the receptor tyrosine kinase EphB4 in bladder cancer. All of the nine bladder cancer cell lines examined express EphB4 and the receptor could be phosphorylated following stimulation with its cognate ligand, EphrinB2. Out of the 15 fresh bladder cancer specimens examined, 14 expressed EphB4 with a mean sevenfold higher level of expression compared to adjacent normal urothelium. EphB4 expression was regulated by several mechanisms: EPHB4 gene locus was amplified in 27% tumor specimens and 33% cell lines studied; inhibition of EGFR signaling downregulated EphB4 levels; and forced expression of wild-type p53 reduced EphB4 expression. EphB4 knockdown using specific siRNA and antisense oligodeoxynucleotides molecules led to a profound inhibition in cell viability associated with apoptosis via activation of caspase-8 pathway and downregulation of anti apoptotic factor, bcl-xl. Furthermore, EphB4 knockdown significantly inhibited tumor cell migration and invasion. EphB4 knockdown in an in vivo murine tumor xenograft model led to a nearly 80% reduction in tumor volume associated with reduced tumor proliferation, increased apoptosis and reduced tumor microvasculature. EphB4 is thus a potential candidate as a predictor of disease outcome in bladder cancer and as target for novel therapy.	Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA USA; VasGene Therapeut Inc, Los Angeles, CA USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Gill, PS (corresponding author), Univ So Calif, Keck Sch Med, Dept Med, 1441 Eastlake Ave,Norris Canc Res,NOR 6330, Los Angeles, CA 90033 USA.	parkashg@usc.edu	Quinn, David I/F-4343-2015; Reever, Larson/H-9685-2019; Singh, J B/ABF-5574-2021; Quinn, David/N-3730-2019	Quinn, David I/0000-0002-1411-0417; Reever, Larson/0000-0002-5692-4793; Singh, J B/0000-0001-9029-2462; Quinn, David/0000-0002-1411-0417; buscarini, maurizio/0000-0002-9228-3348; Smith, Lynne/0000-0003-2400-659X	NCI NIH HHS [R01CA72918] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Berclaz G, 2003, ANN ONCOL, V14, P220, DOI 10.1093/annonc/mdg072; Buscarini M, 2005, BJU INT, V95, P739, DOI 10.1111/j.1464-410X.2005.05393.x; Chatterjee SJ, 2004, J CLIN ONCOL, V22, P1007, DOI 10.1200/JCO.2004.05.174; Chow NH, 2001, CLIN CANCER RES, V7, P1957; COOPER MJ, 1994, ONCOL RES, V6, P569; CUTLER SJ, 1982, AUA MONOGRAPHS BLADD, V1, P35; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; ESRIG D, 1994, NEW ENGL J MED, V331, P1259, DOI 10.1056/NEJM199411103311903; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Gontero P, 2004, EUR UROL, V46, P296, DOI 10.1016/j.eururo.2004.04.001; Hara I, 2001, J UROLOGY, V165, P1769, DOI 10.1016/S0022-5347(05)66411-7; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Holder N, 1999, DEVELOPMENT, V126, P2033; KOSS LG, 1979, HUM PATHOL, V10, P533, DOI 10.1016/S0046-8177(79)80097-0; Lawson ND, 2001, DEVELOPMENT, V128, P3675; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; LOGOTHETIS CJ, 1990, J CLIN ONCOL, V8, P1050, DOI 10.1200/JCO.1990.8.6.1050; LUTZEYER W, 1982, J UROLOGY, V127, P250, DOI 10.1016/S0022-5347(17)53725-8; Mao WG, 2004, CANCER RES, V64, P781, DOI 10.1158/0008-5472.CAN-03-1047; Masood R, 2005, BLOOD, V105, P1310, DOI 10.1182/blood-2004-03-0933; Masood R, 2003, INT J CANCER, V104, P603, DOI 10.1002/ijc.10996; Munarini N, 2002, J CELL SCI, V115, P25; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Oates AC, 1999, MECH DEVELOP, V83, P77, DOI 10.1016/S0925-4773(99)00036-2; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; Sternberg CN, 2001, CANCER, V92, P2993, DOI 10.1002/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2; Takai N, 2001, ONCOL REP, V8, P567; Tickle C, 1999, CURR OPIN GENET DEV, V9, P455, DOI 10.1016/S0959-437X(99)80069-0; Vasala K, 2003, UROLOGY, V62, P952, DOI 10.1016/S0090-4295(03)00660-5; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285; XIA G, 2005, CLIN CANCER RES, V11, P405; Xia GB, 2005, CANCER RES, V65, P4623, DOI 10.1158/0008-5472.CAN-04-2667	42	78	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					769	780		10.1038/sj.onc.1209108	http://dx.doi.org/10.1038/sj.onc.1209108			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205642				2022-12-17	WOS:000235068800012
J	Kuphal, S; Bosserhoff, AK				Kuphal, S; Bosserhoff, AK			Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma	ONCOGENE			English	Article						E-cadherin; NF kappa B; N-cadherin regulation; cell contact	EPITHELIAL-MESENCHYMAL TRANSITION; CELL-ADHESION MOLECULE; UVOMORULIN-CATENIN COMPLEX; BREAST-CANCER CELLS; KAPPA-B; P-CADHERIN; TUMOR PROGRESSION; GASTRIC-CANCER; ALPHA-CATENIN; UP-REGULATION	E-cadherin is known to be an important molecule in epithelial-mesenchymal transition (EMT). Malignant transformation of melanocytes frequently attends with loss of E-cadherin expression and induction of expression of mesenchymal molecules like N-cadherin. The switch of the cadherin class is an interesting phenomenon of melanoma cells and in EMT in general. Therefore, we analysed the capacity of E-cadherin to regulate expression of N-cadherin in melanocytic cells. Our experiments revealed that melanoma cells downregulate endogenous N-cadherin expression after transient transfection of full-length E-cadherin, but also of the cytoplasmic domain of E-cadherin. Therefore, we concluded that the extracellular domain of E-cadherin and cell-cell contacts are not necessary for negative regulation of N-cadherin. Melanoma cells re-expressing full-length or cytoplasmatic E-cadherin have reduced NF kappa B activity in comparison to mock-transfected cells. Downregulation of NF kappa B activity, either directly or by re-expression of E-cadherin, led to a suppression of N-cadherin promoter activity and N-cadherin expression. Consequently, an NF kappa B-binding site in the N-cadherin promoter was characterized. In summary, our results suggest that N-cadherin is directly regulated by E-cadherin. Loss of E-cadherin induces NF kappa B activity and N-cadherin expression in tumorigenic EMT.	Univ Regensburg, Inst Pathol, D-93053 Bavaria, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Bavaria, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bates RC, 2004, EXP CELL RES, V299, P315, DOI 10.1016/j.yexcr.2004.05.033; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1991, EXP SUPPL, V59, P109; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Buckley CD, 1997, MOL MED TODAY, V3, P449, DOI 10.1016/S1357-4310(97)01128-3; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Fukata M, 1999, J CELL SCI, V112, P4491; Furukawa F, 1997, MICROSC RES TECHNIQ, V38, P343; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Haass NK, 2004, J MOL HISTOL, V35, P309; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Huber MA, 2004, CELL CYCLE, V3, P1477, DOI 10.4161/cc.3.12.1280; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kuphal S, 2004, ONCOGENE, V23, P8509, DOI 10.1038/sj.onc.1207831; Li B, 1997, GENE, V191, P7, DOI 10.1016/S0378-1119(97)00006-1; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2001, CANCER RES, V61, P3819; Melki JR, 2000, BLOOD, V95, P3208; NAVARRO P, 1993, J CELL SCI, V105, P923; Nieman MT, 1999, J CELL SCI, V112, P1621; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Soler C, 1998, CELL ADHES COMMUN, V5, P13, DOI 10.3109/15419069809005595; SOMMERS CL, 1994, CANCER RES, V54, P3544; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tomita K, 2000, CANCER RES, V60, P3650; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhu AJ, 1996, J CELL SCI, V109, P3013	58	78	87	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					248	259		10.1038/sj.onc.1209054	http://dx.doi.org/10.1038/sj.onc.1209054			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16132038				2022-12-17	WOS:000234583600009
J	Rogulski, K; Li, YJ; Rothermund, K; Pu, LX; Watkins, S; Yi, FH; Prochownik, EV				Rogulski, K; Li, YJ; Rothermund, K; Pu, LX; Watkins, S; Yi, FH; Prochownik, EV			Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway	ONCOGENE			English	Article						c-Myc; p53; Mdm2; Akt; PTEN; Max; apoptosis; green. fluorescent protein; PI-3 kinase; p19(ARF); shRNA	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; P53 STABILITY; DNA METHYLTRANSFERASES; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; CXXC MOTIF; IN-VITRO; MDM2	The c-Myc oncoprotein is a general transcription factor whose target genes dictate the c-Myc phenotype. One such target of c-Myc, 'onzin', is normally expressed at high levels in myeloid cells and is dramatically downregulated in response to c-Myc overexpression. We show here that short hairpin interfering RNA-mediated knockdown of endogenous onzin results in a reduced growth rate and a proapoptotic phenotype. In contrast, onzin overexpression in fibroblasts is associated with an increased growth rate, resistance to apoptotic stimuli, loss of the G2/M checkpoint, and tumorigenic conversion. Onzin-overexpressing cells fail to induce p53 in response to apoptotic stimuli and contain higher levels of the active, phosphorylated forms of Akt1 and, more strikingly, of Mdm2. Using yeast two-hybrid and coimmunoprecipitation assays, we show that onzin directly interacts with both proteins. Green fluorescent protein tagging also confirms directly that Akt1 and Mdm2 colocalize with onzin, although the precise subcellular distribution of each protein is dependent on its relative abundance. Collectively, our results identify onzin as a novel regulator of several p53-dependent aspects of the c-Myc phenotype via its dramatic effect on Mdm2. This is reminiscent of the c-Myc -> p19(ARF)-vertical bar Mdm2 pathway and might function as a complementary arm to ensure the proper cellular response to oncogenic and/or apoptotic stimuli.	Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Pittsburgh, PA 15213 USA; Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Hematol Oncol Sect, Rangos Res Ctr, Room 2100,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Braspenning J, 1998, ONCOGENE, V16, P1085, DOI 10.1038/sj.onc.1201617; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Collet JF, 2003, J BIOL CHEM, V278, P45325, DOI 10.1074/jbc.M307818200; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; Guo QM, 2000, CANCER RES, V60, P5922; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; KAUFMANN SH, 1998, BIOCHIM BIOPHYS ACTA, V400, P195; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 2001, Harvey Lect, V97, P57; Paez Juan, 2003, Cancer Treat Res, V115, P145; Page C, 2000, ANTICANCER RES, V20, P407; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Prescott JE, 2001, J BIOL CHEM, V276, P48276, DOI 10.1074/jbc.M107357200; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vargas DA, 2003, ADV CANCER RES, V89, P1, DOI 10.1016/S0065-230X(03)01001-7; Voo KS, 2000, MOL CELL BIOL, V20, P2108; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weber JD, 2003, CELL DEATH DIFFER, V10, P409, DOI 10.1038/sj.cdd.4401226; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Willis AE, 1997, CURR TOP MICROBIOL, V224, P269; Wood LJ, 2000, CANCER RES, V60, P4256; Yang CW, 2003, MOL CARCINOGEN, V36, P15, DOI 10.1002/mc.10086; Yi FH, 2003, CANCER RES, V63, P2923; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Yin XY, 2001, CANCER RES, V61, P6487; Yin XY, 2001, ONCOGENE, V20, P4650, DOI 10.1038/sj.onc.1204606; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	83	78	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7524	7541		10.1038/sj.onc.1208897	http://dx.doi.org/10.1038/sj.onc.1208897			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16170375				2022-12-17	WOS:000233333800003
J	Kerley-Hamilton, JS; Pike, AM; Li, N; DiRenzo, J; Spinella, MJ				Kerley-Hamilton, JS; Pike, AM; Li, N; DiRenzo, J; Spinella, MJ			A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma	ONCOGENE			English	Article						cisplatin; microarray; germ cell tumors; p53; teratocarcinoma	HUMAN EMBRYONAL CARCINOMA; TERATOCARCINOMA CELLS; DNA-DAMAGE; P53; APOPTOSIS; CANCER; DIFFERENTIATION; SENSITIVITY; ACTIVATION; GENES	Testicular germ cell cancers remain one of the few solid tumors routinely cured in advanced stages with conventional cisplatin-based chemotherapy. The mechanisms remain largely unknown. Through use of gene-expression array pro. ling we de. ne immediate transcriptional targets in response to cisplatin in testicular germ cell-derived human embryonal carcinoma cells. We report 46 genes upregulated and five genes repressed by cisplatin. Several of these gene products, including FAS, TRAILR3, PHLDA3, LRDD, and IER3 are previously implicated in the apoptotic death receptor pathway, while others including SESN1, FDXR, PLK3, and DDIT4 are known mediators of reactive oxygen species generation. Approximately 54% of the upregulated genes are established or suspected downstream targets of p53. Specific siRNA to p53 prevents cisplatin-mediated activation of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cisplatin cytotoxicity. Interestingly, in p53 knockdown cells nearly the entire set of identified cisplatin targets fail to respond or have a diminished response to cisplatin, suggesting that many are new direct or indirect targets of p53 including GPR87, STK17A, INPP5D, FLJ11259, and EPS8L2. The data indicate that robust transcriptional activation of p53 is linked to the known hypersensitivity of testicular germ cell tumors to chemotherapy. Many of the gene products may participate in the unique curability of this disease.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NCI NIH HHS [R01 CA104312, R01-CA104312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Einhorn Lawrence H, 2002, Chest Surg Clin N Am, V12, P695, DOI 10.1016/S1052-3359(02)00029-7; Fei PW, 2002, CANCER RES, V62, P7316; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Jakupec MA, 2003, REV PHYSIOL BIOCH P, V146, P1, DOI 10.1007/s10254-002-0001-x; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kho PS, 2004, J BIOL CHEM, V279, P21183, DOI 10.1074/jbc.M311912200; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; PENG HQ, 1993, CANCER RES, V53, P3574; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schrader M, 2001, REPROD TOXICOL, V15, P611, DOI 10.1016/S0890-6238(01)00182-4; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Spierings DCJ, 2003, J PATHOL, V200, P137, DOI 10.1002/path.1373; Spinella MJ, 2003, J NUTR, V133, p273S, DOI 10.1093/jn/133.1.273S; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; White KA, 2003, J BIOL CHEM, V278, P43889, DOI 10.1074/jbc.C300374200; Wright MM, 2002, BIOL RES, V35, P223, DOI 10.4067/S0716-97602002000200014; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	31	78	82	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6090	6100		10.1038/sj.onc.1208755	http://dx.doi.org/10.1038/sj.onc.1208755			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940259				2022-12-17	WOS:000231718100003
J	Nicot, C; Harrod, RL; Ciminale, V; Franchini, G				Nicot, C; Harrod, RL; Ciminale, V; Franchini, G			Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions	ONCOGENE			English	Article						HTLV-1; retrovirus; genes; proteins	OPEN READING FRAMES; HTLV-I; P13(II) PROTEIN; LEUKEMIA-LYMPHOMA; VIRAL INFECTIVITY; MESSENGER-RNAS; SH3 DOMAINS; P12(I); EXPRESSION; CREB	The human T-cell leukemia/lymphoma virus (HTLV) genome, in addition to the structural Gag and Env proteins and retroviral enzymes, carries a region at its 30 end originally designated pX. To date, we know that this region encodes two essential transcriptional and post-transcriptional positive regulators of viral expression, the Tax and Rex proteins, respectively (reviewed elsewhere in this issue). Here, we will review current knowledge of the functions of three additional proteins encoded in the pX region, p12(I), p13(II), and p30(II).	NCI, Anim Models & Retroviral Vaccines Sect, Bethesda, MD 20892 USA; Univ Kansas, Med Ctr, Dept Microbiol, Kansas City, KS 66160 USA; So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; Univ Padua, Dept Oncol & Surg Sci, I-35128 Padua, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Kansas; University of Kansas Medical Center; Southern Methodist University; IRCCS Istituto Oncologico Veneto (IOV); University of Padua	Franchini, G (corresponding author), NCI, Anim Models & Retroviral Vaccines Sect, 41-D804, Bethesda, MD 20892 USA.	franchig@mail.nih.gov	Ciminale, Vincenzo/L-1416-2016	Ciminale, Vincenzo/0000-0001-6197-1802	NATIONAL CANCER INSTITUTE [R01CA106258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058944] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106258] Funding Source: Medline; NIAID NIH HHS [R01 AI058944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; Chen HL, 1997, ACTA MED OKAYAMA, V51, P141; Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; D'Agostino DM, 2005, ADV CANCER RES, V94, P87, DOI 10.1016/S0065-230X(05)94003-7; D'Agostino DM, 2005, CELL DEATH DIFFER, V12, P905, DOI 10.1038/sj.cdd.4401576; D'Agostino DM, 2002, J BIOL CHEM, V277, P34424, DOI 10.1074/jbc.M203023200; DAgostino DM, 1997, J VIROL, V71, P75, DOI 10.1128/JVI.71.1.75-83.1997; Dekaban GA, 2000, VIROLOGY, V274, P86, DOI 10.1006/viro.2000.0406; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Ding W, 2001, J VIROL, V75, P7672, DOI 10.1128/JVI.75.16.7672-7682.2001; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; GESSAIN A, 1991, J VIROL, V65, P1628, DOI 10.1128/JVI.65.3.1628-1633.1991; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HIRARAGI H, 2005, IN PRESS J VIROL; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; KORALNIK IJ, 1992, AIDS RES HUM RETROV, V8, P1845, DOI 10.1089/aid.1992.8.1845; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; KORALNIK IJ, 1995, J GEN VIROL, V76, P1909, DOI 10.1099/0022-1317-76-8-1909; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lefebvre L, 2002, J VIROL, V76, P1400, DOI 10.1128/JVI.76.3.1400-1414.2002; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Martins ML, 2002, AIDS RES HUM RETROV, V18, P899, DOI 10.1089/088922202760265560; Mayer BJ, 2001, J CELL SCI, V114, P1253; Michael Bindhu, 2004, Retrovirology, V1, P39, DOI 10.1186/1742-4690-1-39; Mulloy JC, 1996, J VIROL, V70, P3599, DOI 10.1128/JVI.70.6.3599-3605.1996; Nair A, 2005, AIDS RES HUM RETROV, V21, P273, DOI 10.1089/aid.2005.21.273; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; NICOT C, 1993, VIRUS RES, V30, P317, DOI 10.1016/0168-1702(93)90099-9; Nicot C, 2001, BLOOD, V98, P823, DOI 10.1182/blood.V98.3.823; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; Robek MD, 1998, J VIROL, V72, P4458, DOI 10.1128/JVI.72.5.4458-4462.1998; RURUKAWA Y, 2004, AIDS RES HUM RETROV, V20, P1092; Silic-Benussi M, 2004, P NATL ACAD SCI USA, V101, P6629, DOI 10.1073/pnas.0305502101; Silverman LR, 2004, J VIROL, V78, P3837, DOI 10.1128/JVI.78.8.3837-3845.2004; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Trovato R, 1999, J VIROL, V73, P6460, DOI 10.1128/JVI.73.8.6460-6467.1999; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004; Zhang WQ, 2001, J VIROL, V75, P9885, DOI 10.1128/JVI.75.20.9885-9895.2001; Zhang WQ, 2000, J VIROL, V74, P11270, DOI 10.1128/JVI.74.23.11270-11277.2000; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	54	78	83	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6026	6034		10.1038/sj.onc.1208977	http://dx.doi.org/10.1038/sj.onc.1208977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155609	Green Published			2022-12-17	WOS:000231623400012
J	Fazi, F; Travaglini, L; Carotti, D; Palitti, F; Diverio, D; Alcalay, M; McNamara, S; Miller, WH; Lo Coco, F; Pelicci, PG; Nervi, C				Fazi, F; Travaglini, L; Carotti, D; Palitti, F; Diverio, D; Alcalay, M; McNamara, S; Miller, WH; Lo Coco, F; Pelicci, PG; Nervi, C			Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo	ONCOGENE			English	Article						acute promyelocytic leukemia; retinoic acid; DNA methylation; histone deacetylases; differentiation therapy	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; RECEPTOR-BETA GENE; PML/RAR-ALPHA; BREAST-CANCER; MYELOID-LEUKEMIA; RESIDUAL DISEASE; METHYLATION; TRANSCRIPTION; CELLS	The acute promyelocytic leukemia (PML)-retinoic acid receptor alpha (RAR alpha) fusion product recruits histone deacetylase ( HDAC) and DNA methyltransferase (DNMT) activities on retinoic acid (RA)-target promoters causing their silencing and differentiation block. RA treatment induces epigenetic modi. cations at its target loci and restores myeloid differentiation of APL blasts. Using RA-sensitive and RA-resistant APL cell lines and primary blasts, we addressed the functional relevance of the aberrant methylation status at the RA-target promoter RAR beta 2 and the mechanism by which methylation is reversed by RA. RA decreased DNMT expression and activity, which correlated with demethylation at specific sites on RAR beta 2 promoter/exon-1, and the ability of APL blasts to differentiate in vitro and in vivo. None of these events occurred in an RA-resistant APL cell line containing a PML-RAR alpha defective for ligand binding. The specific contribution of the HDAC and DNMT pathways to the response of APL cells to RA was also tested by inhibiting these enzymatic activities with TSA and/or 5-azacytidine. In RA-responsive and RA-resistant APL blasts, TSA and 5-azacytidine induced specific changes on the chromatin state at RA-target sites, increased the RA effect on promoter activity, endogenous RA-target gene expression and differentiation. These results extend the rationale for chromatin-targeted treatment in APL and RA-resistant leukemias.	Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Histol, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Med Embryol, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00128 Rome, Italy; European Inst Oncol, Milan, Italy; IFOM, FIRC, Milan, Italy; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol & Med, Montreal, PQ, Canada; Univ Roma Tor Vergata, Dept Biopathol, I-00173 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; Lady Davis Institute; McGill University; McGill University; University of Rome Tor Vergata	Nervi, C (corresponding author), Univ Roma La Sapienza, San Raffaele Biomed Sci Pk Rome, Via Castel Romano 100, I-00128 Rome, Italy.	clara.nervi@uniroma1.it	Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016; Travaglini, Lorena/AAA-6245-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; Fazi, Francesco/K-5304-2018	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Fazi, Francesco/0000-0003-2910-7912; NERVI, Clara/0000-0001-9341-0188; Travaglini, Lorena/0000-0003-0142-6516; CAROTTI, Daniela/0000-0001-6273-9749				APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Benedetti L, 1996, BLOOD, V87, P1939; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cacciamani T, 2002, GENE, V297, P103, DOI 10.1016/S0378-1119(02)00874-0; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CAROTTI D, 1989, NUCLEIC ACIDS RES, V17, P9219, DOI 10.1093/nar/17.22.9219; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Cote S, 2002, BLOOD, V100, P2586, DOI 10.1182/blood-2002-02-0614; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferrara FF, 2001, CANCER RES, V61, P2; Glass CK, 2000, GENE DEV, V14, P121; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; LANOTTE M, 1991, BLOOD, V77, P1080; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lo Coco F, 2002, CANCER RES, V62, P5618; Lo Coco F, 1999, BLOOD, V94, P12, DOI 10.1182/blood.V94.1.12.413a44_12_22; LOCOCO F, 1992, LANCET, V340, P1437, DOI 10.1016/0140-6736(92)92625-P; Mandelli F, 1997, BLOOD, V90, P1014; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; Melki JR, 1998, LEUKEMIA, V12, P311, DOI 10.1038/sj.leu.2400932; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1993, BLOOD, V82, P1689; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; MUINDI J, 1992, BLOOD, V79, P299; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nervi C, 1998, BLOOD, V92, P2244; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sirchia SM, 2002, CANCER RES, V62, P2455; Stirzaker C, 1997, CANCER RES, V57, P2229; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826	58	78	81	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1820	1830		10.1038/sj.onc.1208286	http://dx.doi.org/10.1038/sj.onc.1208286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688037				2022-12-17	WOS:000227542000002
J	Ramachandran, S; Liu, PB; Young, AN; Yin-Goen, QQ; Lim, SD; Laycock, N; Amin, M; Carney, JK; Marshall, FF; Petros, JA; Moreno, CS				Ramachandran, S; Liu, PB; Young, AN; Yin-Goen, QQ; Lim, SD; Laycock, N; Amin, M; Carney, JK; Marshall, FF; Petros, JA; Moreno, CS			Loss of HOXC6 expression induces apoptosis in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; HOXC6; microarray; siRNA; apoptosis; IGFBP-3; NEP	ALTERNATE READING FRAME; GENE-PRODUCT EXPRESSION; HOMEOBOX GENES; IMMUNOCYTOCHEMICAL DETECTION; RECEPTOR; PROTEIN; GROWTH; NKX3.1; B3; B4	We have performed whole genome expression profiling of 28 patient prostate tumor samples and 12 normal prostate samples and identified 55 upregulated and 60 down-regulated genes significantly changed in prostate tumor samples compared to normal prostate tissues. Among the members of the upregulated gene set was the developmental transcription factor Homeobox C6 (HOXC6). Silencing of HOXC6 expression using small-interfering RNA (siRNA) resulted in decreased proliferation rates for both androgen-dependent LnCaP cells and the LnCaP-derived androgen-independent C4-2 cell line. Flow cytometry and immunoblotting for the caspase-cleaved form of poly-ADP ribose polymerase (PARP) determined that the decrease in cell numbers was due to increased apoptosis. To validate the specificity of the siRNA-induced apoptosis, LnCaP cells were cotransfected with siRNA specific to the HOXC6 3'UTR and a mammalian expression vector containing the HOXC6 open reading frame, but lacking the 3'UTR. Overexpression of HOXC6 rescued the LnCaP cells from HOXC6 siRNA-induced apoptosis, and increased growth of control GFP siRNA-transfected cells. Expression profiling of HOXC6 siRNA transfections and HOXC6 overexpression identified neutral endopeptidase (NEP) and insulin-like growth factor binding protein-3 (IGFBP-3) as potential proapoptotic repression targets of HOXC6. Our data suggest that HOXC6 may be a novel potential therapeutic target for prostate cancer.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Winship Canc Inst,Dept Hematol & Oncol, Atlanta, GA 30322 USA; Atlanta VA Med Ctr, Atlanta, GA USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; Emory University	Moreno, CS (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Winship Canc Inst,Dept Hematol & Oncol, Whitehead Res Bldg,Rm 105J,615 Michael St, Atlanta, GA 30322 USA.	cmoreno@emory.edu	Liu, Pengbo/J-9801-2012; Moreno, Carlos S/B-3863-2009	Liu, Pengbo/0000-0002-5269-2497; Moreno, Carlos S/0000-0002-5582-0028	NCI NIH HHS [K22-CA96560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA096560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; Bodey B, 2000, ANTICANCER RES, V20, P3281; Bodey B, 2000, ANTICANCER RES, V20, P1769; Bodey B, 2000, ANTICANCER RES, V20, P2711; Bodey B, 2000, ANTICANCER RES, V20, P2717; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bowen C, 2000, CANCER RES, V60, P6111; Braasch DA, 2002, BIOCHEMISTRY-US, V41, P4503, DOI 10.1021/bi0122112; CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2; Chariot A, 1996, BIOCHEM J, V319, P91, DOI 10.1042/bj3190091; Chen H, 2002, CANCER RES, V62, P338; Cheng WS, 2003, ENDOCRINOLOGY, V144, P3433, DOI 10.1210/en.2003-0121; CILLO C, 1994, INVAS METAST, V14, P38; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Garcia-Gasca A, 2000, DEV DYNAM, V219, P261, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1048>3.0.CO;2-3; Grimberg A, 2002, INT J ONCOL, V21, P327; Hu GZ, 2001, DEVELOPMENT, V128, P2373; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kim MJ, 2002, CANCER RES, V62, P2999; Krishnan AV, 2003, J CELL BIOCHEM, V88, P363, DOI 10.1002/jcb.10334; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Miller GJ, 2003, CANCER RES, V63, P5879; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9; Stein S, 1996, MECH DEVELOP, V55, P91, DOI 10.1016/0925-4773(95)00494-7; Sumitomo M, 2000, CANCER RES, V60, P6590; Sumitomo M, 2001, CANCER RES, V61, P3294; Thelen P, 2004, INT J ONCOL, V24, P1085; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; WEI H, 2003, UNPUB; Wolfgang CD, 2000, P NATL ACAD SCI USA, V97, P9437, DOI 10.1073/pnas.160270597; Wolfgang CD, 2001, CANCER RES, V61, P8122; Xia XM, 2003, MOL CELL BIOL, V23, P1717, DOI 10.1128/MCB.23.5.1717-1725.2003; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004	52	78	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					188	198		10.1038/sj.onc.1207906	http://dx.doi.org/10.1038/sj.onc.1207906			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637592				2022-12-17	WOS:000226125800021
J	Verrier, F; Deniaud, A; LeBras, M; Metivier, D; Kroemer, G; Mignotte, B; Jan, G; Brenner, C				Verrier, F; Deniaud, A; LeBras, M; Metivier, D; Kroemer, G; Mignotte, B; Jan, G; Brenner, C			Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis	ONCOGENE			English	Article						ADP/ATP carrier; cell death; glutathion-S-transferase; mitochondrion; permeability transition	MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; BCL-2 FAMILY PROTEINS; BENZODIAZEPINE-RECEPTOR; SIGNALING PATHWAY; BAX TRANSLOCATION; OXIDATIVE STRESS; PORE COMPLEX; BH4 DOMAIN	The mitochondrial permeability transition pore complex (PTPC) is involved in the control of the mitochondrial membrane permeabilization during apoptosis, necrosis and autophagy. Indeed, the adenine nucleotide translocator (ANT) and the voltage-dependent anion channel (VDAC), two major components of PTPC, are the targets of a variety of proapoptotic inducers. Using co-immunoprecipitation and proteomic analysis, we identified some of the interacting partners of ANT in several normal tissues and human cancer cell lines. During chemotherapy-induced apoptosis, some of these interactions were constant (e g. ANT-VDAC), whereas others changed strongly concomitantly with the dissipation of the mitochondrial transmembrane potential and until nuclear degradation occurred (e.g. Bax, Bcl-2, subunits of the respiratory chain, a subunit of the phosphatase PP2A, phospholipase PLC beta 4 and IP3 receptor). In addition, a glutathione-S-transferase (GST) interacts with ANT in normal tissue, in colon carcinoma cells and in vitro. This interaction is lost during apoptosis induction, suggesting that GST behaves as an endogenous repressor of PTPC and ANT pore opening. Thus, ANT is connected to mitochondrial proteins as well as to proteins from other organelles such as the endoplasmic reticulum forming a dynamic polyprotein complex. Changes within this ANT interactome coordinate the lethal response of cells to apoptosis induction.	Univ Versailles, CNRS, FRE 2445, F-78035 Versailles, France; Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; INRA, UR 121, Rech Technol Laitiere Lab, F-35042 Rennes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; INRAE	Brenner, C (corresponding author), Univ Versailles, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	Deniaud, Aurelien/L-5093-2019; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Mignotte, Bernard/A-3499-2009; Jan, Gwenael/K-6767-2014	KROEMER, Guido/0000-0002-9334-4405; Mignotte, Bernard/0000-0002-8512-8518; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ARMSTRONG JS, 2002, FASEB J, V7, P7; Belzacq AS, 2003, CURR DRUG TARGETS, V4, P517, DOI 10.2174/1389450033490867; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Bribes E, 2003, IMMUNOL LETT, V85, P13, DOI 10.1016/S0165-2478(02)00177-3; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dorner A, 1997, MOL CELL BIOCHEM, V174, P261, DOI 10.1023/A:1006825028170; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 2000, J BIOENERG BIOMEMBR, V32, P15, DOI 10.1023/A:1005504210587; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Susin SA, 2000, METHOD ENZYMOL, V322, P205; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yin ZM, 2000, CANCER RES, V60, P4053; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	74	78	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8049	8064		10.1038/sj.onc.1208001	http://dx.doi.org/10.1038/sj.onc.1208001			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377997				2022-12-17	WOS:000224692500003
J	Deng, QD; Huang, S				Deng, QD; Huang, S			PRDM5 is silenced in human cancers and has growth suppressive activities	ONCOGENE			English	Article						PRDM5 (PRDM5); PR/SET domain; tumor suppressors; 4q25-q26; PRDM2	HUMAN HEPATOCELLULAR-CARCINOMA; ZINC-FINGER PROTEIN; PR-DOMAIN FAMILY; CPG ISLANDS; SET DOMAIN; HISTONE METHYLTRANSFERASES; GENE-EXPRESSION; CHROMOSOMES 4Q; RIZ1; FREQUENT	Several genes that contain the PR (PRDI-BF1 and RIZ) domain have been linked with human cancers. We describe here a new PR-domain-containing gene designated as PRDM5 (PFM2). A PRDM5 cDNA was isolated based on its homology to the PR domain of RIZ1 (PRDM2). The gene encodes an open reading frame of 630 amino acids and contains a PR domain in the NH-terminal region followed by 16 zinc finger motifs. Radiation hybrid analysis mapped PRDM5 to human chromosome 4q26, a region thought to harbor tumor suppressor genes for breast, ovarian, liver, lung, colon, and other cancers. The gene has a CpG island promoter and is silenced in human breast, ovarian, and liver cancers. A recombinant adenovirus expressing PRDM5 caused G2/M arrest and apoptosis upon infection of tumor cells. These results suggest that inactivation of PRDM5 may play a role in carcinogenesis.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Huang, S (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@burnham.org			NATIONAL CANCER INSTITUTE [R01CA076146] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arribas R, 1999, LAB INVEST, V79, P111; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Cardoso C, 1998, HUM MOL GENET, V7, P679, DOI 10.1093/hmg/7.4.679; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Chou YHW, 1998, CANCER LETT, V123, P1, DOI 10.1016/S0304-3835(97)00276-0; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Du Y, 2001, CANCER RES, V61, P8094; Fang W, 2000, GENE CHROMOSOME CANC, V28, P269, DOI 10.1002/1098-2264(200007)28:3<269::AID-GCC4>3.0.CO;2-K; Fang W, 2001, BRIT J CANCER, V84, P743, DOI 10.1054/bjoc.2000.1667; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; He LS, 1998, CANCER RES, V58, P4238; HEON E, 1995, HUM MOL GENET, V4, P1435, DOI 10.1093/hmg/4.8.1435; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Jiang GL, 2000, HISTOL HISTOPATHOL, V15, P109, DOI 10.14670/HH-15.109; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; Kim KC, 2003, CANCER BIOL THER, V2, P491, DOI 10.4161/cbt.2.5.629; Kim KC, 2003, CANCER RES, V63, P7619; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; MITRA AB, 1994, CANCER RES, V54, P4481; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Piao Z, 1998, INT J CANCER, V79, P356, DOI 10.1002/(SICI)1097-0215(19980821)79:4<356::AID-IJC8>3.0.CO;2-U; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schwendel A, 1998, BRIT J CANCER, V78, P806, DOI 10.1038/bjc.1998.583; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Tirkkonen M, 1997, CANCER RES, V57, P1222; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; Yang XH, 1999, GENOMICS, V61, P319, DOI 10.1006/geno.1999.5967	44	78	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4903	4910		10.1038/sj.onc.1207615	http://dx.doi.org/10.1038/sj.onc.1207615			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077163				2022-12-17	WOS:000222104200011
J	Ren, Y; Chan, HM; Li, Z; Lin, CL; Nicholls, J; Chen, CF; Lee, PY; Lui, V; Bacher, M; Tam, PKH				Ren, Y; Chan, HM; Li, Z; Lin, CL; Nicholls, J; Chen, CF; Lee, PY; Lui, V; Bacher, M; Tam, PKH			Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma	ONCOGENE			English	Article						MIF; N-myc; neuroblastoma; MAPK; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; HUMAN-MELANOMA CELLS; ANGIOGENIC FACTORS; HEPATOCELLULAR-CARCINOMA; TUMOR-GROWTH; FACTOR MIF; RECEPTORS; CANCER; STAGE; ADENOCARCINOMA	Macrophage migration inhibitory factor (MIF) has been linked to fundamental processes such as control of cell proliferation, cell survival, angiogenesis, and tumor progression. The expression of MIF has been reported in several tumors. However, the precise role of MIF in tumor cells remains unclear. In the present study, we investigated the expression pattern and the function of MIF in neuroblastoma. Our results showed that intracellular MIF was upregulated in neuroblastoma tumor tissues and cell lines. MIF protein expression significantly correlated with the grade of tumor differentiation. In addition, we found that MIF induced a significant dose-dependent increase of vascular endothelial growth factor and interleukin-8 secretion. We also observed that an increased MIF expression level correlated with N-Myc protein ( the N-myc oncogene product) expression in neuroblastoma tissues. MIF increased the expression of N-myc mRNA and N-Myc protein and induced N-Myc translocation from the cytoplasm to nucleus in neuroblastoma cell lines. MIF-induced N-Myc expression was found to be dependent on ERK signaling pathways. The inhibition of ERK activation reduced MIF-mediated N-Myc expression. These results suggest that MIF may contribute to the progression of neuroblastoma by ( a) inducing N-Myc expression and ( b) upregulating the expression of angiogenic factors.	Univ Hong Kong, Med Ctr, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Med Ctr, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Med Ctr, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; Univ Marburg, Inst Immunol, D-35032 Marburg, Germany	University of Hong Kong; University of Hong Kong; University of Hong Kong; Philipps University Marburg	Ren, Y (corresponding author), Univ Hong Kong, Med Ctr, Dept Surg, Room L09-56,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	yren@hkucc.hku.hk; paultam@hkucc.hku.hk	Lee, Pui Yue/C-4332-2009; Nicholls, John Malcolm/C-4375-2009; /C-4359-2009; /C-4405-2009	Nicholls, John Malcolm/0000-0001-7217-7444; /0000-0002-1758-8854; /0000-0001-6231-3035				Akbar SMF, 2001, CANCER LETT, V171, P125, DOI 10.1016/S0304-3835(01)00606-1; BERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; Bin Q, 2002, TUMOR BIOL, V23, P123, DOI 10.1159/000064028; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BROWN LF, 1993, CANCER RES, V53, P4727; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chambery D, 1999, CANCER RES, V59, P2898; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Ferrer FA, 2000, J UROLOGY, V164, P1016, DOI 10.1016/S0022-5347(05)67240-0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Mattern J, 1996, BRIT J CANCER, V73, P931, DOI 10.1038/bjc.1996.166; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Misawa A, 2000, CANCER RES, V60, P64; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Rossler J, 1999, INT J CANCER, V81, P113; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; SINGH RK, 1994, CANCER RES, V54, P3242; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Wada RK, 1997, CANCER LETT, V121, P181, DOI 10.1016/S0304-3835(97)00351-0; Yang YB, 2000, J CLIN ENDOCR METAB, V85, P4721, DOI 10.1210/jc.85.12.4721	48	78	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4146	4154		10.1038/sj.onc.1207490	http://dx.doi.org/10.1038/sj.onc.1207490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064733				2022-12-17	WOS:000221520200013
J	Tanaka, T; Akatsuka, S; Ozeki, M; Shirase, T; Hiai, H; Toyokuni, S				Tanaka, T; Akatsuka, S; Ozeki, M; Shirase, T; Hiai, H; Toyokuni, S			Redox regulation of annexin 2 and its implications for oxidative stress-induced renal carcinogenesis and metastasis	ONCOGENE			English	Article						annexin 2; iron; redox regulation; carcinogenesis; metastasis; renal cell carcinoma	TUMOR-SUPPRESSOR GENE; ROUS-SARCOMA-VIRUS; FERRIC NITRILOTRIACETATE; CELL CARCINOMA; WISTAR RATS; INSULIN-RECEPTOR; KINASE SUBSTRATE; RESPONSE GENES; ALLELIC LOSS; II TETRAMER	Ferric nitrilotriacetate (Fe-NTA) induces oxidative renal damage leading to a high incidence of renal cell carcinoma (RCC) in rats. Differential display analysis of such RCCs revealed elevated expression of annexin 2 (Anx2), a substrate for kinases and a receptor for tissue-type plasminogen activator and plasminogen. We conducted this study to clarify the significance of Anx2 in Fenton reaction-based carcinogenesis. Messenger RNA and protein levels of Anx2 were increased time-dependently in the rat kidney after Fe-NTA administration as well as in LLC-PK1 cells after exposure to H2O2. The latter was inhibited by pretreatment with N-acetylcysteine, pyrrolidine dithiocarbamate or catalase. Immunohistochemistry revealed negligible staining in the normal renal proximal tubules, but strong staining in regenerating proximal tubules, karyomegalic cells and RCCs. Metastasizing RCCs showed higher Anx2 protein levels. Anx2 was phosphorylated at serine and tyrosine residues in these cells and coimmunoprecipitated with phosphorylated actin. Overexpression of Anx2 induced a higher cell proliferation rate in LLC-PK1 cells. In contrast, a decrease in proliferation leading to apoptosis was observed after Anx2 antisense treatment to cell lines established from Fe-NTA-induced RCCs. These results suggest that Anx2 is regulated by redox status, and that persistent operation of this adaptive mechanism plays a role in the proliferation and metastasis of oxidative stress-induced cancer.	Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Toyokuni, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 6068501, Japan.	toyokuni@path1.med.kyoto-u.ac.jp	Akatsuka, Shinya/C-9806-2010; Toyokuni, Shinya/C-1358-2010; Toyokuni, Shinya/ABE-7714-2021	Akatsuka, Shinya/0000-0002-9944-8803; Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109				Aarli A, 1997, APMIS, V105, P699, DOI 10.1111/j.1699-0463.1997.tb05073.x; AMES BN, 1991, OXIDATIVE DAMAGE & REPAIR, P181; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Chacko G, 1998, J BIOL CHEM, V273, P19840, DOI 10.1074/jbc.273.31.19840; Chetcuti A, 2001, CANCER RES, V61, P6331; CHIANG YP, 1993, CANCER RES, V53, P6017; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; EBINA Y, 1986, J NATL CANCER I, V76, P107; Emoto K, 2001, ANTICANCER RES, V21, P1339; ERIKSON E, 1981, J BIOL CHEM, V256, P1381; Forman HJ, 2002, MOL CELL BIOCHEM, V234, P49, DOI 10.1023/A:1015913229650; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; Hajjar KA, 1998, J INVEST MED, V46, P364; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HAMAZAKI S, 1988, TOXICOL APPL PHARM, V92, P500, DOI 10.1016/0041-008X(88)90190-1; HAMAZAKI S, 1985, TOXICOL APPL PHARM, V77, P267, DOI 10.1016/0041-008X(85)90326-6; Hiroyasu M, 2002, AM J PATHOL, V160, P419, DOI 10.1016/S0002-9440(10)64860-2; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JONES PG, 1992, J BIOL CHEM, V267, P13993; Konig J, 1998, J BIOL CHEM, V273, P19679, DOI 10.1074/jbc.273.31.19679; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; KUMBLE KD, 1992, CANCER RES, V52, P163; KUMBLE KD, 1992, J CELL SCI, V101, P35; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; LI JL, 1987, CANCER RES, V47, P1867; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu L, 1996, AM J PHYSIOL-LUNG C, V270, pL668, DOI 10.1152/ajplung.1996.270.4.L668; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Nakanishi H, 1996, JPN J CANCER RES, V87, P1218, DOI 10.1111/j.1349-7006.1996.tb03136.x; Nishiyama Y, 1995, JPN J CANCER RES, V86, P1150, DOI 10.1111/j.1349-7006.1995.tb03308.x; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OZAKI T, 1993, ONCOGENE, V8, P1707; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; Ramasamy S, 1998, J LIPID RES, V39, P268; REEVES SA, 1992, CANCER RES, V52, P6871; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Tanaka T, 1997, LAB INVEST, V77, P145; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; TOYOKUNI S, 1990, CANCER RES, V50, P5574; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; TOYOKUNI S, 1994, INT J CANCER, V57, P123, DOI 10.1002/ijc.2910570122; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Toyokuni S, 2003, PATHOL INT, V53, P259, DOI 10.1046/j.1320-5463.2003.01465.x; Toyokuni S, 1997, LAB INVEST, V76, P365; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; Toyokuni S, 1997, FREE RADICAL BIO MED, V22, P1019, DOI 10.1016/S0891-5849(96)00489-3; TOYOKUNI S, 1995, INT J CANCER, V62, P309, DOI 10.1002/ijc.2910620313; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Zhang DX, 1997, CANCER RES, V57, P2410; Zhao WQ, 2003, J BIOL CHEM, V278, P4205, DOI 10.1074/jbc.M210545200; Zhou S, 2003, MUTAGENESIS, V18, P287, DOI 10.1093/mutage/18.3.287	64	78	91	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3980	3989		10.1038/sj.onc.1207555	http://dx.doi.org/10.1038/sj.onc.1207555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15048081				2022-12-17	WOS:000221382000010
J	der-Sarkissian, H; Bacchetti, S; Cazes, L; Londono-Vallejo, JA				der-Sarkissian, H; Bacchetti, S; Cazes, L; Londono-Vallejo, JA			The shortest telomeres drive karyotype evolution in transformed cells	ONCOGENE			English	Article						telomere length heterogeneity; chromosome instability; tumorigenesis	CHROMOSOME INSTABILITY; REPLICATIVE SENESCENCE; LENGTH; IMMORTALIZATION; DYSFUNCTION; CANCER; HETEROGENEITY; DYNAMICS; CRISIS; HUMANS	Maintenance of telomeres is essential for chromosome stability. In the absence of telomerase, telomeres shorten with cell division until they approach a stability threshold, at which point cells enter senescence. When senescence-signaling pathways are inactive, further telomere shortening leads to chromosome instability characterized by telomeric fusions and breakage-fusion-bridge (BFB) cycles. Since the distribution of telomere lengths among chromosome extremities is heterogeneous, we wondered about the impact of such variability on the stability of particular chromosome arms. We correlated the initial length of individual telomeres in telomerase-negative-transformed cells with the stability of the corresponding chromosome arms during the precrisis period. We show that arms carrying the shortest telomeres are the first to become unstable and this instability affects the chromosome homologues with shorter telomeres almost exclusively. The analysis of several postcrisis cell populations, which had stabilized their telomeres by re-expressing telomerase, showed that the karyotypic outcome is strongly influenced by the initial telomere length heterogeneity. The timing of telomerase re-expression also seems to play a role in limiting the extent of karyotypic changes, probably by reducing the frequency of telomeric fusions and hence BFB. Since the distribution of telomere lengths within somatic cells is proper to every individual, our results predict that the risk for a particular chromosome arm of becoming unstable early in tumorigenesis will differ between individuals and contribute directly to the heterogeneity of chromosome aberrations found in tumors.	Ctr Etud Polymorphisme Humain, F-75010 Paris, France; Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy; INSERM, U434, F-75010 Paris, France	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Institut National de la Sante et de la Recherche Medicale (Inserm)	Londono-Vallejo, JA (corresponding author), Ctr Etud Polymorphisme Humain, 27 Rue Julliette Dodu, F-75010 Paris, France.	londono@cephb.fr	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; CHERIF D, 1993, GENE CHROMOSOME CANC, V6, P107, DOI 10.1002/gcc.2870060207; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Der-Sarkissian H, 2002, GENOME RES, V12, P1673, DOI 10.1101/gr.322802; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Graakjaer J, 2003, MECH AGEING DEV, V124, P629, DOI 10.1016/S0047-6374(03)00081-2; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Lansdorp PM, 2000, MECH AGEING DEV, V118, P23, DOI 10.1016/S0047-6374(00)00151-2; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Londono-Vallejo JA, 2001, NUCLEIC ACIDS RES, V29, P3164, DOI 10.1093/nar/29.15.3164; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	33	78	80	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1221	1228		10.1038/sj.onc.1207152	http://dx.doi.org/10.1038/sj.onc.1207152			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14716292				2022-12-17	WOS:000188892200006
J	Guo, GZ; Wang, TL; Gao, Q; Tamae, D; Wong, P; Chen, T; Chen, WC; Shively, JE; Wong, JYC; Li, JJ				Guo, GZ; Wang, TL; Gao, Q; Tamae, D; Wong, P; Chen, T; Chen, WC; Shively, JE; Wong, JYC; Li, JJ			Expression of ErbB2 enhances radiation-induced NF-kappa B activation	ONCOGENE			English	Article						NF-kappa B; ErbB2; breast cancer; radioresistance	HUMAN-BREAST-CANCER; GROWTH-FACTOR RECEPTOR; IONIZING-RADIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; TNF-ALPHA; CYCLIN B1; TRAIL/APO2L-INDUCED APOPTOSIS; SIGNALING PATHWAY	Her-2/neu (ErbB2) oncogene, the second member of the epidermal growth factor receptor (EGFR) family, encodes a transmembrane tyrosine kinase receptor in Her-2-positive tumors. Accumulating evidences demonstrate that signaling networks activated by EGFR and transcription factor NF-kappaB are associated with cell response to ionizing radiation (IR). The present study shows that overexpression of ErbB2 enhanced NF-kappaB activation induced by IR in human breast carcinoma MCF-7 cells transfected with ErbB2 genes (MCF-7/ErbB2). Stable transfection of dominant-negative mutant IkappaB (MCF-7/ErbB2/mIkappaB) or treatment with anti-ErbB2 antibody, Herceptin, inhibited NF-kappaB activation and radiosensitized MCF-7/ErbB2 cells. Consistent with NF-kappaB regulation, basal and IR-induced Akt, a kinase downstream of ErbB2, was activated in MCF-7/ErbB2 cells and inhibited by Herceptin. To identify specific genes affected by ErbB2-mediated NF-kappaB activation, a group of IR-responsive elements Cyclin B1, Cyclin D1, Bcl-2, Bcl/XL, BAD and BAX were evaluated. Basal levels of prosurvival elements Cyclin B1, Cyclin D1, Bcl-2 and Bcl/XL but not apoptotic BAD and BAX were upregulated in MCF-7/ErbB2 cells with striking enhancements in Bcl-2 and Bcl/XL. IR further induced Cyclin B1 and Cyclin D1 expression that was reduced by Herceptin. Bcl-2 kept a high steady level after Herceptin+IR treatment and, in contrast to control MCF-7/Vector cells, Bcl/XL was inhibited in MCF-7/ErbB2 cells by Herceptin+IR treatment. However, all four prosurvival proteins were downregulated by inhibition of NF-kappaB in MCF-7/ErbB/mIkappaB cells. These results thus provide evidence suggesting that overexpression of ErbB2 is able to enhance NF-kappaB response to IR, and that a specific prosurvival network downstream of NF-kappaB is triggered by treatments using anti-ErbB2 antibody combined with radiation.	City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; Biorad Labs, Life Sci Grp, Hercules, CA 94547 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Li, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	jjli@coh.org		Li, Jian Jian/0000-0003-3694-9675				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Bradbury CM, 2001, CANCER RES, V61, P7689; Chen XF, 2002, CANCER RES, V62, P1213; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Daosukho C, 2002, ONCOGENE, V21, P3603, DOI 10.1038/sj.onc.1205448; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Fornace AJ, 1999, GENE EXPRESSION, V7, P387; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Granville DJ, 2000, BLOOD, V95, P256; Grdina DJ, 2002, SEMIN RADIAT ONCOL, V12, P103, DOI 10.1053/srao.2002.31383; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Gupta AK, 2001, CANCER RES, V61, P4278; Hallahan DE, 1998, CANCER RES, V58, P5484; Hassan KA, 2002, CANCER RES, V62, P6414; Hassan KA, 2001, CLIN CANCER RES, V7, P2458; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Herscher LL, 1999, ONCOLOGY-NY, V13, P11; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kurland JF, 2001, INT J CANCER, V96, P327, DOI 10.1002/ijc.1040; Kurokawa H, 2001, CLIN CANCER RES, V7, p4436s; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; LABUDDA K, 1995, VIROLOGY, V206, P269, DOI 10.1016/S0042-6822(95)80042-5; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, CLIN CANCER RES, V7, P682; Lee S, 2002, CANCER RES, V62, P5703; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Liang K, 2003, MOL CANCER THER, V2, P353; Locke JE, 2002, INT J RADIAT BIOL, V78, P493, DOI [10.1080/095530002317577312, 10.1080/09553000110120355]; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; McBride William H, 2002, Mil Med, V167, P66; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; Miyakoshi J, 2000, BRIT J CANCER, V82, P28; Pegram M, 2000, SEMIN ONCOL, V27, P13; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Ravi R, 2002, CANCER RES, V62, P1583; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Schmidt M, 2001, GYNECOL ONCOL, V80, P145, DOI 10.1006/gyno.2000.6040; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Slamon D J, 1990, Cancer Invest, V8, P253, DOI 10.3109/07357909009017573; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soria JC, 2000, CANCER RES, V60, P4000; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047	70	78	82	3	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					535	545		10.1038/sj.onc.1207149	http://dx.doi.org/10.1038/sj.onc.1207149			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724581				2022-12-17	WOS:000188098300024
J	Xiao, Z; Latek, R; Lodish, HF				Xiao, Z; Latek, R; Lodish, HF			An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity	ONCOGENE			English	Article						nuclear localization signal (NLS); nucleocytoplasmic shuttling; R-Smads; Co-Smad; importin alpha	CRYSTAL-STRUCTURE; DNA-BINDING; DOMAIN; TRANSLOCATION; MUTATIONS; ALPHA; RICH	Smad proteins are a class of tumor suppressors that play critical roles in inhibiting the proliferation of a variety of cell types by modulating the transcriptions of target genes. Despite recent advances, the mechanism of their nuclear import is not completely understood. Smad proteins contain a conserved basic motif in their N-terminal MH1 domains that resembles a nuclear localization signal (NLS). Previous studies indicate that in receptor-regulated Smads such as Smad1 and Smad3 this motif determines their interactions with nuclear import receptors and mediates their ligand-induced nuclear translocation. Common-Smads such as Smad4 display constant nucleocytoplasmic shuttling and are capable of autonomous nuclear import and export. Mutations of the basic motif in Smad4 disrupted its nuclear accumulation. However, this motif is not sufficient to confer nuclear translocation to a fused heterologous protein, suggesting that it is only part of the bona fide Smad4 NLS. We mapped the Smad4 NLS by fusing various segments of Smad4 sequence covering the basic motif to GFP and tested the localization of the fusion proteins. We identified an extended NLS, starting from the basic motif and extending into the DNA-binding region (AA 45-110), that is sufficient to confer nuclear localization to GFP. Among the 14 basic residues in the NLS, only four (K45, K46, K48 and R81) are critical for import. This NLS is critical not only for autonomous nuclear import of Smad4, but also for its nuclear translocation in the presence of activated R-Smads, further confirming the functional relevance of the Smad4 NLS in TGF-beta signal transduction. Structural modeling demonstrated that the four critical basic residues are all solvent exposed and map to a single localized segment on one surface of the Smad4 MH1 domain. Their distribution and spacing resemble a classical bipartite NLS. Smad4 displays specific binding to importin alpha through its MR1 domain, which was abrogated by loss-of-function mutations in Smad4 NLS. Finally, the Smad4 NLS is essential for its transcriptional activity since loss-of-function NLS mutants are also transcriptionally inactive.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Gung, Amber/D-9842-2011		NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [CA63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; de Caestecker MP, 2000, J BIOL CHEM, V275, P2115, DOI 10.1074/jbc.275.3.2115; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; NICOLS A, 1991, PROTEINS, V11, P140; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; YING X, 2000, PROTEIN-STRUCT FUNCT, V40, P343	21	78	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1057	1069		10.1038/sj.onc.1206212	http://dx.doi.org/10.1038/sj.onc.1206212			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592392				2022-12-17	WOS:000180926100011
J	Clarke, ID; Dirks, PB				Clarke, ID; Dirks, PB			Human brain tumor-derived PDGFR-alpha deletion mutant is transforming	ONCOGENE			English	Article						PDGFR-alpha; extracellular deletion; brain tumor; transformation	GROWTH-FACTOR RECEPTOR; SIMIAN SARCOMA-VIRUS; GLIOMA CELL-LINES; BETA-RECEPTOR; IN-VIVO; C-JUN; SIGNAL-TRANSDUCTION; HUMAN GLIOBLASTOMAS; V-SIS; MICE	Aberrant receptor tyrosine kinase signaling plays an important role in the molecular pathogenesis of brain tumors. We have been studying a previously identified human glioblastoma-derived PDGFR-alpha mutant that has an in-frame deletion in the extracellular domain, causing loss of exons 8 and 9 (PDGFR-alpha(Delta8,9)). In the primary tumor, this deletion mutant receptor was shown to be amplified and overexpressed. The purpose of this study was to determine the expression, activity, localization, and transformation properties of this deletion mutant. In the absence of serum, or PDGF-AA, PDGFR-alpha(Delta8,9) was phosphorylated on tyrosine residues, indicating ligand-independent autoactivation. Localization by staining and cell surface biotinylation studies revealed expression of the deletion mutant predominantly in the cytoplasm, with very little present on the cell surface. To determine if PDGFR-alpha(Delta8,9) was oncogenic, we transfected wild-type and mutant receptors into Rat1 cells and performed analyses of cell growth, in vitro transformation, and subcutaneous growth in the nude mouse. PDGFR-alpha(Delta8,9)-expressing cells displayed enhanced cell growth and survival in low serum, and formed foci in monolayer cultures. PDGFR-alpha(Delta8,9)-expressing Rat1 cells were also tumorigenic when injected subcutaneously into nude mice. Expression of PDGFR-alpha(Delta8,9) was also associated with increased c-Jun phosphorylation in the absence of PDGF ligand, demonstrating also that the mutant receptor is associated with altered intracellular signaling. These data demonstrate that PDGFR-alpha(Delta8,9) is transforming, and it is the first demonstration of a naturally occurring tumor-derived mutant PDGFR-alpha with oncogenic properties.	Univ Toronto, Div Neurosurg, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Toronto, Program Dev Biol, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Lab, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Dirks, PB (corresponding author), Univ Toronto, Div Neurosurg, Hosp Sick Children, 555 Univ Ave,Suite 1504, Toronto, ON M5G 1X8, Canada.							Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BEJECK BE, 1989, SCIENCE, V245, P1496; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Feldkamp MM, 1999, NEUROSURGERY, V45, P1442, DOI 10.1097/00006123-199912000-00034; FLEMING TP, 1992, CANCER RES, V52, P4550; Fruttiger M, 1999, DEVELOPMENT, V126, P457; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KIM HRC, 1994, J BIOL CHEM, V269, P30604; Kirsch M, 1997, J NEURO-ONCOL, V35, P289, DOI 10.1023/A:1005872718547; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; KUMABE T, 1992, ONCOGENE, V7, P627; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1991, J BIOL CHEM, V266, P16755; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Uhrbom L, 1998, CANCER RES, V58, P5275; Uren A, 1996, J BIOL CHEM, V271, P11051, DOI 10.1074/jbc.271.19.11051; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1995, GLIA, V15, P257, DOI 10.1002/glia.440150307; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YU JC, 1994, J BIOL CHEM, V269, P10668; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479	55	78	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					722	733		10.1038/sj.onc.1206160	http://dx.doi.org/10.1038/sj.onc.1206160			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569364				2022-12-17	WOS:000180642100009
J	Rushton, JJ; Davis, LM; Lei, WL; Mo, XM; Leutz, A; Ness, SA				Rushton, JJ; Davis, LM; Lei, WL; Mo, XM; Leutz, A; Ness, SA			Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins	ONCOGENE			English	Article						microarrays; differentiation; transcription; breast cancer; oncogenes	BREAST-CANCER; ACTIVATION; SYSTEM; FAMILY; CELLS	The c-Myb, A-Myb and B-Myb transcription factors have nearly identical DNA-binding domains, activate the same reporter gene constructs in animal cells, but have different biological roles. The Myb proteins are often coexpressed in the same cells, raising questions about whether they activate similar or distinct gene expression profiles, and whether they cooperate or compete in regulating the same promoters. Here, recombinant adenoviruses were used to express each protein in human mammary cells, and then microarray assays were used to assess global changes in gene expression. Each Myb protein induced a unique and specific set of changes, displaying activities far more complex than revealed by standard reporter gene assays. These results have important implications for the roles of various Myb proteins in normal and transformed human cells, for regulatory pathways that might modify their activities and for the importance of acquired mutations that may qualitatively alter their functions in tumors.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Keck Genom Resource, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA; Exagen Corp, Albuquerque, NM USA; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Ness, SA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.		Leutz, Achim/K-9643-2013; Ness, Scott/AAV-4009-2020	Leutz, Achim/0000-0001-8259-927X; Ness, Scott/0000-0001-6965-8909	NCI NIH HHS [R01 CA58443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Buckhaults P, 2001, CANCER RES, V61, P6996; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GABRIELLI F, 1995, EUR J BIOCHEM, V232, P473, DOI 10.1111/j.1432-1033.1995.473zz.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GUERIN M, 1990, ONCOGENE, V5, P131; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinz S, 2002, GENOMICS, V79, P608, DOI 10.1006/geno.2002.6743; Kamano H, 1995, ONCOGENE, V11, P2575; Kauraniemi P, 2000, CANCER RES, V60, P5323; McClowry TL, 2002, J MED VIROL, V66, P96, DOI 10.1002/jmv.2116; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Stewart H, 1999, OPHTHALMOLOGY, V106, P964, DOI 10.1016/S0161-6420(99)00539-4; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597	25	78	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					308	313		10.1038/sj.onc.1206131	http://dx.doi.org/10.1038/sj.onc.1206131			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527900				2022-12-17	WOS:000180322400016
J	Guo, WH; Weng, LQ; Ito, K; Chen, LF; Nakanishi, H; Tatematsu, M; Ito, Y				Guo, WH; Weng, LQ; Ito, K; Chen, LF; Nakanishi, H; Tatematsu, M; Ito, Y			Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor	ONCOGENE			English	Article						Runx3; tumor suppressor; methylation; gastric cancer	METHYL-N-NITROSOUREA; P53 GENE-MUTATIONS; HISTONE DEACETYLASE; INDUCTION; PROMOTER; LINES; MECP2	We reported recently that the silencing of RUNX3 is causally related to gastric cancer in humans. Here we report that in three of four cell tines derived from N-methyl-N-nitrosourea-induced mouse glandular stomach carcinomas, Runx3 is silenced due to hypermethylation of CpG islands in the promoter region, as we also observed for human gastric cancer cells. Although two of the sites we tested in the promoter of the fourth line were not methylated, in all four cases the silencing of Runx3 could be reversed by treatment of the cells with 5'-azacytidine and trichostatin A. Interestingly, the exogenous expression of RUNX3 in cell lines that do not express the endogenous gene caused an inhibition of growth in soft agar, suggesting that anchorage-independent growth could be used as an assay of RUNX3 activity in vitro. These observations suggest that the mouse system described here may be useful as a model for the study of human gastric carcinogenesis.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Aichi Canc Ctr, Res Inst, Pathol Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Kyoto University; Aichi Cancer Center	Ito, Y (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							AMY SY, 1998, FRONT BIOSCI, V3, P532; Fearon ER, 2000, JNCI-J NATL CANCER I, V92, P515, DOI 10.1093/jnci/92.7.515; Furihata C, 1997, JPN J CANCER RES, V88, P363, DOI 10.1111/j.1349-7006.1997.tb00390.x; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ichinose M, 1998, JPN J CANCER RES, V89, P516, DOI 10.1111/j.1349-7006.1998.tb03292.x; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; TAMURA G, 1991, CANCER RES, V51, P3056; TATEMATSU M, 1993, JPN J CANCER RES, V84, P1258, DOI 10.1111/j.1349-7006.1993.tb02831.x; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6	16	78	90	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8351	8355		10.1038/sj.onc.1206037	http://dx.doi.org/10.1038/sj.onc.1206037			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447699	Green Submitted			2022-12-17	WOS:000179323900014
J	Kim, WJ; Vo, QN; Shrivastav, M; Lataxes, TA; Brown, KD				Kim, WJ; Vo, QN; Shrivastav, M; Lataxes, TA; Brown, KD			Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line	ONCOGENE			English	Article						ataxia-telangiectasia; gene silencing; epigenetics	DNA MISMATCH REPAIR; ATAXIA-TELANGIECTASIA HETEROZYGOTES; IONIZING-RADIATION; BREAST-CANCER; GENE-MUTATIONS; PROTEIN; HYPERMETHYLATION; INACTIVATION; EXPRESSION; PHENOTYPE	Recent findings suggest that DNA alkylating agents trigger cellular responses that overlap those activated after ionizing radiation. Moreover, activation of these responses is dependent upon a functional mismatch repair (MMR) system. These developments led us to test if MMR-deficient cells may be compromised in their ability to activate appropriate cellular signaling pathways after ionizing radiation. An initial experiment to address this notion was to determine the level of radiosensitivity of several MMR-deficient cell lines derived from patients with Hereditary Non-Polyposis Colorectal Cancer (HNPCC). While two of the three HNPCC lines investigated show levels of radiosensitivity consistent with that displayed by normal human fibroblasts, HCT-116 cells display moderate radio sensitivity compared to the other MMR-deficient lines. This increased sensitivity to ionizing radiation correlates with lowered levels of ATM expression in HCT-116. Analysis of genomic DNA from HCT-116 cells determined that these cells possess aberrant methylation of multiple CpG dinucleotides within the proximal promoter region of the ATM gene. The significance of this finding is underscored by our observations that co-culturing HCT-116 cells with the DNA demethylating agent 5-azacytidine reverses promoter methylation, promotes normal levels of ATM expression, and restores normal radiosensitivity. The proximal ATM promoter is a similar to520 bp region shared with the NPAT gene, and current evidence suggests that this region functions as a bi-directional promoter. We found that, unlike ATM, the methylation status of this intergenic region does not effect the expression of the NPAT gene. In sum, these observations indicate that the ATM gene is a novel target for epigentic silencing through inappropriate methylation of its proximal promoter region.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Brown, KD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,Room 7101, New Orleans, LA 70112 USA.							Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Byrd PJ, 1996, HUM MOL GENET, V5, P1785, DOI 10.1093/hmg/5.11.1785; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; Chen XG, 1997, MAMM GENOME, V8, P129, DOI 10.1007/s003359900371; Costello JF, 1996, CANCER RES, V56, P2405; Dork T, 2001, CANCER RES, V61, P7608; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; Ejima Y, 2000, INT J CANCER, V86, P262, DOI 10.1002/(SICI)1097-0215(20000415)86:2<262::AID-IJC17>3.3.CO;2-9; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fritzell JA, 1997, CANCER RES, V57, P5143; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gnarra JR, 1998, J NATL CANCER I, V90, P1685, DOI 10.1093/jnci/90.22.1685; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hiraguri S, 1998, CANCER RES, V58, P1972; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Kane MF, 1997, CANCER RES, V57, P808; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; MORRELL D, 1986, J NATL CANCER I, V77, P89; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PANDITA TK, 1994, MUTAT RES-FUND MOL M, V310, P1, DOI 10.1016/0027-5107(94)90004-3; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Xu Y, 1999, ADV IMMUNOL, V72, P179, DOI 10.1016/S0065-2776(08)60020-6; Yan T, 2001, CANCER RES, V61, P8290; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	48	78	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3864	3871		10.1038/sj.onc.1205485	http://dx.doi.org/10.1038/sj.onc.1205485			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032824				2022-12-17	WOS:000175847200005
J	Guiducci, C; Cerone, MA; Bacchetti, S				Guiducci, C; Cerone, MA; Bacchetti, S			Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability	ONCOGENE			English	Article						telomerase; hTR mutants; telomere malfunction	IN-VITRO; RNA COMPONENT; DNA-DAMAGE; PROTEIN; TRF2; RECONSTITUTION; LENGTH; YEAST; END; INSTABILITY	We have reconstituted wild type or mutant telomerase activity in two human cell lines that lack constitutive expression of both core subunits of the enzyme and maintain telomeres by a telomerase-independent mechanism (ALT cells). Wild type telomerase RNA and four telomerase RNAs with single point mutations in their template domain were used to express enzymes specifying different telomeric DNA sequences, Expression of wild type telomerase for up to 32 days had no detectable effect on cell growth or viability, In contrast, cells expressing mutant telomerases had slower growth rate, abnormal cell cycle and reduced viability. Dramatically aberrant nuclei, typical of cells undergoing mitotic catastrophe, and large numbers of fused chromosomes were also characteristic of these populations, Notably, all phenotypes were apparent within the first few cell divisions after expression of the enzymes. Unlike wild type, mutant telomerase activity was progressively selected against with cell culturing, and this correlated with the disappearance of cells with aberrant phenotypes. Our results suggest that even very limited synthesis of mutated sequences can affect telomere structure in human cells, and that the toxicity of mutant telomerases is due to telomere malfunction.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	McMaster University	Bacchetti, S (corresponding author), McMaster Med Ctr, Room 4H30,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1196; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Evans SK, 2000, J CELL SCI, V113, P3357; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Iijima M, 1996, INT J CANCER, V66, P698; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRK KE, 1997, SCIENCE, V275, P1748; Kurenova EV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1242; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; MCEACHERN M, 1995, NATURE, V376, P404; McEachern MJ, 2000, P NATL ACAD SCI USA, V97, P11409, DOI 10.1073/pnas.210388397; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Namba M, 1981, GANN MONOGR CANCER R, V27, P221; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV A M, 1971, Doklady Biochemistry, V201, P394; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Prescott JC, 2000, MOL CELL BIOL, V20, P2941, DOI 10.1128/MCB.20.8.2941-2948.2000; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	56	78	85	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					714	725		10.1038/sj.onc.1204145	http://dx.doi.org/10.1038/sj.onc.1204145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314005				2022-12-17	WOS:000166806000007
J	Wood, LD; Halvorsen, TL; Dhar, S; Baur, JA; Pandita, RK; Wright, WE; Hande, MP; Calaf, G; Hei, TK; Levine, F; Shay, JW; Wang, JJY; Pandita, TK				Wood, LD; Halvorsen, TL; Dhar, S; Baur, JA; Pandita, RK; Wright, WE; Hande, MP; Calaf, G; Hei, TK; Levine, F; Shay, JW; Wang, JJY; Pandita, TK			Characterization of ataxia telangiectasia fibroblasts with extended life-span through telomerase expression	ONCOGENE			English	Article						ATM; hTERT; senescence; immortal; ionizing radiation	DNA-DAMAGE CHECKPOINT; IONIZING-RADIATION; HUMAN-CELLS; END ASSOCIATIONS; ATM KINASE; KAPPA-B; C-ABL; PROTEIN; CANCER; GENE	Ataxia-telangiectasia (A-T) is an autosomal recessive disease characterized by progressive cerebellar degeneration, immunodeficiencies, genomic instability and gonadal atrophy, A-T patients are hypersensitive to ionizing radiation and have an elevated cancer risk, Cells derived from A-T patients require higher levels of serum factors, exhibit cytoskeletal defects and undergo premature senescence in culture, We show here that expression of the catalytic subunit of telomerase (hTERT) in primary A-T patient fibroblasts can rescue the premature senescence phenotype, Ectopic expression of hTERT does not rescue the radiosensitivity or the telomere fusions in A-T fibroblasts. The hTERT+AT cells also retain the characteristic defects in cell-cycle checkpoints, and show increased chromosome damage before and after ionizing radiation, Although A-T patients have an increased susteptibility to cancer, the expression of hTERT in A-T fibroblasts does not stimulate malignant transformation. These immortalized A-T cells provide a more stable cell system to investigate the molecular mechanisms underlying the cellular phenotypes of Ataxia-telangiectasia.	Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Columbia University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine	Pandita, TK (corresponding author), Columbia Univ, Ctr Radiol Res, VC11-213,630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020; Baur, Joseph A/D-8163-2011; Hande, M. Prakash/B-1645-2008; Wood, Laura/ABF-1531-2020; Shay, Jerry W/F-7878-2011; Levine, Fred/L-2693-2013	Hande, M. Prakash/0000-0002-4511-6256; Levine, Fred/0000-0002-7336-2526; Baur, Joseph/0000-0001-8262-6549	NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, R01 CA043054, CA43054] Funding Source: Medline; NIDDK NIH HHS [DK55065] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner BP, 1999, CANCER RES, V59, P5456; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Harley CB, 1997, CANCER SURV, V29, P263; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; Holt SE, 1996, NAT BIOTECHNOL, V14, P836, DOI 10.1038/nbt0796-836; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pandita TK, 1996, RADIAT RES, V145, P730, DOI 10.2307/3579364; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Pandita TK, 1996, ONCOGENE, V13, P1423; Pandita TK, 2000, ONCOGENE, V19, P1386, DOI 10.1038/sj.onc.1203444; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sawant SG, 1999, FASEB J, V13, P1047, DOI 10.1096/fasebj.13.9.1047; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shay JW, 1996, LEUKEMIA, V10, P1255; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	65	78	81	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					278	288		10.1038/sj.onc.1204072	http://dx.doi.org/10.1038/sj.onc.1204072			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313956				2022-12-17	WOS:000166411000001
J	Parker, GA; Touitou, R; Allday, MJ				Parker, GA; Touitou, R; Allday, MJ			Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis	ONCOGENE			English	Article						EBV; EBNA3C; cell cycle checkpoints; multinucleated cells; p27(KIP1)	CANCER; DNA; P27(KIP1); PROTEIN; TRANSCRIPTION; ONCOPROTEIN	Expression of EBNA3C is essential for the immortalization of B cells by EBV in vitro and, in co-operation with activated ras, EBNA3C has oncogenic activity in primary rodent fibroblasts. This suggested that this viral oncoprotein might disrupt the cyclin/CDK-pRb-E2F pathway, which regulates cell cycle progression at the restriction point (R-point) in G1 of the proliferation cycle. An assay was established in which transfected EBNA3C-positive cells could be sorted and simultaneously analysed for their distribution in the cell cycle, This revealed that in NIH3T3 fibroblasts compelled to arrest by serum-withdrawal. EBNA3C induces nuclear division that is often divorced from cytokinesis and so produces bi- and multinucleated cells. This was confirmed using the ecdysone-inducible system for expression of EBNA3C in human U2OS cells and by microinjection of expression vectors into NIH3T3 and U2OS, Further analysis revealed that in the inducible system, EBNA3C expression inhibits the accumulation of p27(KIP1) but not the dephosphorylation of pRb, Experiments using the microtubule destabilizing drug nocodazole, showed that EBNA3C could abrogate the mitotic spindle checkpoint.	Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Virol & Cell Biol, St Marys Campus,Norfolk Pl, London W2 1PG, England.							Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; KIEFF E, 1996, FIELDS VIROLOGY; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Parker GA, 1996, ONCOGENE, V13, P2541; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Rickinson A. B., 1996, FIELDS VIROLOGY; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	24	78	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					700	709		10.1038/sj.onc.1203327	http://dx.doi.org/10.1038/sj.onc.1203327			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698515				2022-12-17	WOS:000085192000012
J	Eymin, B; Sordet, O; Droin, N; Munsch, B; Haugg, M; Van de Craen, M; Vandenabeele, P; Solary, E				Eymin, B; Sordet, O; Droin, N; Munsch, B; Haugg, M; Van de Craen, M; Vandenabeele, P; Solary, E			Caspase-induced proteolysis of the cyclin-dependent kinase inhibitor p27(Kip1) mediates its anti-apoptotic activity	ONCOGENE			English	Article						p27(Kip1); apoptosis; cell cycle; leukemia; caspase	TOPOISOMERASE-II INHIBITORS; CYTOCHROME-C; CELLS; ACTIVATION; CLEAVAGE; PROTEASE; P27; HYPERPLASIA; DEGRADATION; RESISTANCE	The caspase-mediated cleavage of a limited number of cellular proteins is a common feature of apoptotic cell death. This cleavage usually inhibits the function of the target protein or generates peptides that actively contribute to the death process. In the present study, we demonstrate that the cyclin-dependent kinase inhibitor p27(Kip1) is cleaved by caspases in human leukemic cells exposed to apoptotic stimuli. We have shown recently that p27(Kip1) overexpression delayed leukemic cell death in response to cytotoxic drugs, In transient transfection experiments, the p23 and the p15 N-terminal peptides generated by p27(Kip1) proteolysis demonstrate an anti-apoptotic effect similar to that induced by the wild-type protein, whereas cleavage-resistant mutants have lost their protective effect. Moreover, stable transfection of a cleavage-resistant mutant of p27(Kip1) sensitizes leukemic cells to drug-induced cell death. Altogether, these results indicate that proteolysis of p27(Kip1) triggered by caspases mediates the anti-apoptotic activity of the protein.	Fac Med & Pharm, INSERM, U517, F-21033 Dijon, France; State Univ Ghent VIB, Dept Mol Biol, B-9000 Ghent, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Flanders Institute for Biotechnology (VIB); Ghent University	Solary, E (corresponding author), Fac Med & Pharm, INSERM, U517, 7 Blvd Jeanne Darc, F-21033 Dijon, France.		Sordet, Olivier/M-3271-2014; Droin, Nathalie M/Y-5506-2018; Vandenabeele, Peter/C-8597-2009; eymin, beatrice/U-4670-2019; Vandenabeele, Peter/AAD-5793-2022; Eymin, Beatrice/M-1962-2013	Sordet, Olivier/0000-0001-6027-4925; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Vandenabeele, Peter/0000-0002-6669-8822; Eymin, Beatrice/0000-0002-7311-3810; Solary, Eric/0000-0002-8629-1341				Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cock JGRBD, 1998, APOPTOSIS, V3, P17, DOI 10.1023/A:1009603001888; Dimanche-Boitrel MT, 1998, INT J CANCER, V77, P796, DOI 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2-Z; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HENTGARTNER MO, 1998, NATURE, V391, P441; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAMATA N, 1995, CANCER RES, V55, P2266; KIYOKAWA H, 1996, CELL, V85, P71; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAI A, 1996, NATURE, V380, P262; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Miossec C, 1997, J BIOL CHEM, V272, P13459, DOI 10.1074/jbc.272.21.13459; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ophascharoensuk V, 1998, NAT MED, V4, P575, DOI 10.1038/nm0598-575; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SOLARY E, 1993, BLOOD, V81, P1359; StCroix B, 1996, NAT MED, V2, P1204; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsihlias J, 1998, CANCER RES, V58, P542; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wilhelm S, 1998, EUR J IMMUNOL, V28, P891, DOI 10.1002/(SICI)1521-4141(199803)28:03<891::AID-IMMU891>3.3.CO;2-O; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	46	78	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4839	4847		10.1038/sj.onc.1202860	http://dx.doi.org/10.1038/sj.onc.1202860			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490817				2022-12-17	WOS:000082184800008
J	de Belle, I; Huang, RP; Fan, Y; Liu, CT; Mercola, D; Adamson, ED				de Belle, I; Huang, RP; Fan, Y; Liu, CT; Mercola, D; Adamson, ED			P53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis	ONCOGENE			English	Article						human fibrosarcoma cells; transfection; stable expression; growth; tumorigenicity; UV-C irradiation	TRANSCRIPTION FACTOR EGR-1; FOCAL ADHESION KINASE; DAMAGE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; DNA-DAMAGE; INDUCIBLE APOPTOSIS; FIBROSARCOMA CELLS; GENE-EXPRESSION; PROTEIN-KINASE; C-JUN	The human fibrosarcoma cell line, HT1080, clone H-4, was used to determine if the transformation suppressive functions of p53 and Egr-1 have the same underlying mechanism. This cell Line expresses only mutant p53 and no detectable Egr-1, H4 clones stably expressing Egr-1 are less transformed in proportion to the level of Egr-1 expressed, acting through the induction of the TGF beta 1 gene. Here, H4 cells and the highest Egr-1 expressing clone mere transfected with a vector expressing normal human p53 to derive stable clones expressing p53. The expression of p53 in H4 cells inhibited transformed growth and reduced tumorigenicity. The effect of coexpression of both p53 and Egr-1 was additive, producing cell lines with 30% of normal growth rate and sevenfold reduced tumorigenicity compared with control lines. These results indicated that each factor may act independently by different pathways, although each additively increased the level of p21(WAF1) cell cycle inhibitor. However, exposure of the H4-derived cells to UV-C irradiation produced contrasting effects. Cell cycle analyses shelved that the presence of p53 was associated with loss of the G1 and S cells to apoptosis after irradiation. In contrast, the expression of Egr-1 increased entry into S/G2 phase of the cell cycle with Little apoptosis via a mechanism involving elevated FAK and low caspase activities. Apoptosis was observed only in the cell lines that expressed no Egr-1, especially those expressing wt-p53, and was preceded by high caspase activity. In summary, Egr-1 suppressed transformation and counteracted apoptosis by the coordinated activation of TGF beta 1, FN, p21 and FAK, leading to enhanced cell attachment and reduced caspase activity. In the doubly expressing cell line, the survival effect of Egr-1 was dominant over the apoptotic effect of p53.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; NW Hosp, Seattle, WA 98125 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Adamson, ED (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA76173, CA 67888, CA 63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783, R01CA076173, R01CA067888] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Akagi M, 1996, JPN J CANCER RES, V87, P377, DOI 10.1111/j.1349-7006.1996.tb00233.x; Akamatsu H, 1996, CANCER RES, V56, P4541; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; DelSal G, 1996, ONCOGENE, V12, P177; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dinkel A, 1997, J IMMUNOL, V159, P2678; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Frisch SM, 1996, MUTAT RES-FUND MOL M, V350, P261, DOI 10.1016/0027-5107(95)00103-4; Fuchs EJ, 1997, CANCER RES, V57, P2550; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Globus RK, 1998, J CELL SCI, V111, P1385; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1998, INT J CANCER, V77, P880, DOI 10.1002/(SICI)1097-0215(19980911)77:6<880::AID-IJC14>3.0.CO;2-5; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; HUANG RP, 1994, J CELL BIOCHEM, V56, P469, DOI 10.1002/jcb.240560407; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUANG RP, 1995, ONCOGENE, V10, P467; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; KEYSE SM, 1993, SEMIN CANCER BIOL, V4, P119; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; Landesman Y, 1997, CELL SIGNAL, V9, P291, DOI 10.1016/S0898-6568(97)89890-7; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIN DY, 1991, STAT SINICA, V1, P1; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MERLO GR, 1994, ONCOGENE, V9, P443; Mohiuddin M., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P427; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Park JA, 1998, EUR J BIOCHEM, V257, P242, DOI 10.1046/j.1432-1327.1998.2570242.x; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; Planus E, 1997, J CELL SCI, V110, P1091; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	61	78	79	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	1999	18	24					3633	3642		10.1038/sj.onc.1202696	http://dx.doi.org/10.1038/sj.onc.1202696			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380885				2022-12-17	WOS:000080891700009
J	Moll, U; Lau, R; Sypes, MA; Gupta, MM; Anderson, CW				Moll, U; Lau, R; Sypes, MA; Gupta, MM; Anderson, CW			DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues	ONCOGENE			English	Article						cancer; DNA repair; DNA double-strand breaks; Brca2; Ku autoantigen; tissue-specific gene expression	STRAND-BREAK REPAIR; HUMAN AUTOANTIGEN KU; RNA-POLYMERASE-II; V(D)J RECOMBINATION; IONIZING-RADIATION; BINDING PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CATALYTIC SUBUNIT; GENE-PRODUCT; HUMAN MRE11	DNA-PK is a nuclear, serine/threonine protein kinase required for repairing DNA double-sh and breaks and for V(D)J recombination. To determine the distribution of DNA-PK in human tissues, we assayed paraffin-embedded sections of normal and cancerous tissues for DNA-PKcs and Ku80 by immunohistochemistry. We also assayed for Brca2, a human tumor suppressor gene that is implicated in the repair of DNA strand-breaks. Brca2 was strongly expressed in epithelial cells of the breast, endometrium, and thymus, in tingible body macrophages of follicular germinal centers of lymphoid tissue, and in reticuloendothelial cells in the spleen. DNA-PKcs and Ku80 expression was usually parallel, but both were expressed in a highly cell- and tissue-specific manner. The highest levels were observed in spermatogenic cells (but not in spermatozoa), and in neurons and glial cells of the central and autonomic nervous system. Neither protein was consistently expressed in liver nor in resting mammary epithelium, but lactating breast epithelium was strongly positive for DNA-PKcs and Ku80. In contrast to established human cell cultures, expression between cells in the same tissue was highly selective in the epidermis, exocrine pancreas, renal glomeruli, the red pulp of the spleen, and within cellular compartments of tonsils, lymph nodes, and thymus. Most cancerous tissues were consistently positive for DNA-PKcs and Ku80, except invasive carcinoma of the breast. DNA-PKcs, Ku80, and Ku70 mRNAs were expressed in all normal tissues with relatively little variation in levels. Our results suggest that the apparent absence of DNA-PKcs and Ku80 from some cells or tissues is a consequence of posttranscriptional mechanisms that regulate protein levels.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Anderson, CW (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bernstein C., 1991, AGING SEX DNA REPAIR; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; Chibazakura T, 1997, EUR J BIOCHEM, V247, P1166, DOI 10.1111/j.1432-1033.1997.01166.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Connelly MA, 1998, GENOMICS, V47, P71, DOI 10.1006/geno.1997.5076; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DVIR A, 1993, J BIOL CHEM, V268, P10440; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; EASTMAN A, 1992, CANCER INVEST, V10, P229, DOI 10.3109/07357909209032765; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; GALLOWAY AM, 1998, IN PRESS ONCOGENE; Gellert M, 1994, Semin Immunol, V6, P125, DOI 10.1006/smim.1994.1018; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1996, EUR J BIOCHEM, V241, P931, DOI 10.1111/j.1432-1033.1996.00931.x; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; ILIAKIS G, 1991, BIOESSAYS, V13, P641; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LABHART P, 1995, P NATL ACAD SCI USA, V92, P2934, DOI 10.1073/pnas.92.7.2934; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; LI LL, 1992, EXP CELL RES, V199, P262, DOI 10.1016/0014-4827(92)90433-9; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; Nagasawa M, 1997, CELL STRUCT FUNCT, V22, P585, DOI 10.1247/csf.22.585; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Pfeiffer P, 1996, MUTAT RES-REV GENET, V366, P69, DOI 10.1016/S0165-1110(96)90029-9; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; SATOH M, 1995, EUR J CELL BIOL, V66, P127; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin EK, 1997, J IMMUNOL, V158, P3565; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Smider V, 1997, Semin Immunol, V9, P189, DOI 10.1006/smim.1997.0070; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; THOMPSON LH, 1995, MUTAT RES-DNA REPAIR, V337, P131, DOI 10.1016/0921-8777(95)00018-F; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; Weaver D, 1995, ANN NY ACAD SCI, V764, P99; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Yamamoto A, 1996, MOL GEN GENET, V251, P1; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896	84	78	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3114	3126		10.1038/sj.onc.1202640	http://dx.doi.org/10.1038/sj.onc.1202640			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340383				2022-12-17	WOS:000080388000007
J	Ness, SA				Ness, SA			Myb binding proteins: regulators and cohorts in transformation	ONCOGENE			English	Article						Myb oncogene; transcription; coactivators; protein interactions; transformation	ACUTE PROMYELOCYTIC LEUKEMIA; MURINE HEMATOPOIETIC-CELLS; RECEPTOR-DELTA-ENHANCER; D-TYPE CYCLINS; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; MYELOMONOCYTIC CELLS; MIM-1 GENE	The c-Myb and v-Myb proteins are transcription factors that regulate cell proliferation and differentiation. Both Myb proteins have been shown to interact with a number of cellular proteins, some of which are transcription factors that cooperate to activate specific promoters, while others regulate the transcriptional activity of Myb in specific contexts. By comparing and analysing the types of proteins that bind Myb, and the conserved domains of Myb that interact with other proteins, conclusions can be drawn regarding the role of specific partner proteins in the regulation of gene expression, cell proliferation and disease.	Univ New Mexico, Sch Med, Dept Microbiol & Mol Genet, Albuquerque, NM 87131 USA	University of New Mexico	Ness, SA (corresponding author), Univ New Mexico, Sch Med, Dept Microbiol & Mol Genet, 915 Camino Salud NE, Albuquerque, NM 87131 USA.		Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NCI NIH HHS [CA580443] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Chen Z, 1996, GENE CHROMOSOME CANC, V15, P147, DOI 10.1002/(SICI)1098-2264(199603)15:3<147::AID-GCC1>3.0.CO;2-2; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FERRAO P, 1995, ONCOGENE, V11, P1631; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRIGNANI F, 1993, BLOOD REV, V7, P87, DOI 10.1016/S0268-960X(05)80018-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; IHLE JN, 1990, INT J CELL CLONING, V8, P130, DOI 10.1002/stem.5530080712; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BBA-REV CANCER, V1288, pR123; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; RAMSAY RG, 1991, ONCOGENE, V6, P1815; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sieweke Michael H., 1997, Leukemia (Basingstoke), V11, P486; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; TONG X, 1995, MOL CELL BIOL, V15, P4735; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	62	78	81	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					3039	3046		10.1038/sj.onc.1202726	http://dx.doi.org/10.1038/sj.onc.1202726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378699				2022-12-17	WOS:000080387800013
J	Lomax, ME; Barnes, DM; Hupp, TR; Picksley, SM; Camplejohn, RS				Lomax, ME; Barnes, DM; Hupp, TR; Picksley, SM; Camplejohn, RS			Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members	ONCOGENE			English	Article						p53; Li-Fraumeni syndrome; oligomerization domain; MDM2; apoptosis; transactivation	TUMOR-SUPPRESSOR P53; TETRAMERIZATION DOMAIN; DNA-BINDING; BAX GENE; IN-VIVO; EXPRESSION; CANCER; MDM2; APOPTOSIS; SARCOMAS	p53 is a tumour suppressor gene which functions as a transcription factor to upregulate genes for growth arrest and apoptosis following DNA damage. p53 mutations are associated with Li-Fraumeni and Li-Fraumeni like syndromes. Recently mutations of the oligomerization domain have been isolated from an LFS and an LFL family affecting respectively codon 344 (Leu to Pro) and 337 (Arg to Cys). The present study was designed to determine the affect of these mutations on the function of pJ3 protein, p53 344 Leu to Pro existed only in a monomeric form and could not bind to DIVA. It was inactive at inducing apoptosis, transactivating luciferase from a bax promoter and inhibiting cell growth. In contrast, p53 337 Arg to (Cys could form tetramers and could bind to DNA. However, p53 337 Arg to Cys was not fully active and could only induce apoptosis, transactivate luciferase from a bax promoter and inhibit cell growth with approximate to 60% of the ability of wild-type p53. Both mutant proteins had reduced ability to bind to MDM2, p53 337 Arg to Cys being more reduced than p53 344 Leu to Pro. These results indicate that point mutations in the oligomerization domain can disrupt p53 function. In addition, the value of LFS and LFL families for the further understanding of the biological and biochemical properties of p53 is demonstrated.	United Med & Dent Sch Guys & St Thomas Hosp, Richard Dimbleby Dept Canc Res, London SE1 7EH, England; Guys Hosp, Clin Oncol Unit, ICRF, London SE1 9RT, England; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Dundee; University of Bradford	Camplejohn, RS (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Richard Dimbleby Dept Canc Res, Lambeth Palace Rd, London SE1 7EH, England.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; Casey G, 1996, ONCOGENE, V13, P1971; DAVISON T, UNPUB ONCOGENE SIMUL; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1991, SCIENCE, V251, P1708; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Varley JM, 1997, CANCER RES, V57, P3245; Varley JM, 1996, ONCOGENE, V12, P2437; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	34	78	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					643	649		10.1038/sj.onc.1201974	http://dx.doi.org/10.1038/sj.onc.1201974			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704930				2022-12-17	WOS:000075195300012
J	Care, A; Silvani, A; Meccia, E; Mattia, G; Peschle, C; Colombo, MP				Care, A; Silvani, A; Meccia, E; Mattia, G; Peschle, C; Colombo, MP			Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence	ONCOGENE			English	Article						bFGF; homeobox gene, SkBr3 cell line; retroviral vector; intracrine loop	HOMEOBOX GENES; TUMORS; MICE; LEUKEMIA; PROMOTER; CANCER	Several melanomas, carcinomas, glioblastomas and leukemias showed coordinated expression of HOXB7 and bFGF with exception of the SkBr3 mammary carcinoma that was negative for both. Transduction of HOXB7 gene into SkBr3 cells, induced bFGF expression, increased growth rate, independence from serum withdrawal and ability to form colonies in semisolid medium. ELISA assay showed that most of bFGF was associated to cell lysate when cells were cultured at 1% serum whereas in cells kept to 10% serum bFGF was detected both within cell lysate or secreted into cell supernatants. Antisense oligos to bFGF inhibited the growth of cells cultured in 1%, indicating that beside the possible activation of additional genes other than bFGF by HOXB7 transduction, only bFGF induction accounts for the observed results. Moreover, since inhibition of cell proliferation occurred in cells kept in 1% but not 10% serum, a bFGF intracrine loop appears operative in serum starved SkBr3/HOXB7 cells. Also, these results further indicate bFGF as target of HOXB7.	Ist Nazl Studio & Cura Tumori, Div Expt Oncol D, I-20133 Milan, Italy; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS)	Colombo, MP (corresponding author), Ist Nazl Studio & Cura Tumori, Div Expt Oncol D, Via Venezian 1, I-20133 Milan, Italy.		Colombo, Mario P./V-7166-2017; Silvani, Antonio/AAA-4600-2019; CARE', Alessandra/H-5090-2016; Mattia, Gianfranco/K-5194-2016; felli, nadia/G-2088-2012	Colombo, Mario P./0000-0003-0042-7955; Silvani, Antonio/0000-0002-4791-1042; CARE', Alessandra/0000-0003-4106-3342; Mattia, Gianfranco/0000-0001-7047-6360; felli, nadia/0000-0001-6763-3361; meccia, ettore/0000-0003-2076-5951				CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DEGUCHI Y, 1993, CANCER RES, V53, P373; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FERNIG DG, 1993, INT J CANCER, V54, P629, DOI 10.1002/ijc.2910540418; FLAMME I, 1992, DEVELOPMENT, V116, P435; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; GOOMER RS, 1994, P NATL ACAD SCI USA, V91, P7985, DOI 10.1073/pnas.91.17.7985; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; KERBEL RS, 1992, AM J PATHOL, V141, P519; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; MAVILIO F, 1993, EUR J BIOCHEM, V212, P273, DOI 10.1111/j.1432-1033.1993.tb17660.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; PEYRAT JP, 1992, J STEROID BIOCHEM, V43, P87, DOI 10.1016/0960-0760(92)90191-K; Quaranta MT, 1996, J IMMUNOL, V157, P2462; Sambrook J, 1989, MOL CLONING LAB MANU; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; STCHOWIAK EK, 1997, ONCOGENE, V14, P2201; TREMPE G, 1973, IN VITRO CELL DEV B, V8, P433	28	78	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3285	3289		10.1038/sj.onc.1201875	http://dx.doi.org/10.1038/sj.onc.1201875			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681827				2022-12-17	WOS:000074343600009
J	Keeling, SL; Gad, JM; Cooper, HM				Keeling, SL; Gad, JM; Cooper, HM			Mouse Neogenin, a DCC-like molecule, has four splice variants and is expressed widely in the adult mouse and during embryogenesis	ONCOGENE			English	Article						neogenin; sequence; tumorigenesis; cell adhesion molecule; embryogenesis	TUMOR-SUPPRESSOR GENE; MESSENGER-RNA; FREQUENT LOSS; COLORECTAL-CARCINOMA; N-CAM; HETEROZYGOSITY; CANCERS; NCAM; DIFFERENTIATION; CADHERIN	Neogenin is a member of the N-CAM family of cell adhesion molecules and is closely related to the DCC tumor suppressor gene product, Recently, it has been demonstrated that the DCC/Neogenin subfamily plays a key role in axonal guidance within the embryonic nervous system, however little is known about the function of DCC or Neogenin in non-neuronal tissues in vertebrates. To gain an understanding of Neogenin function outside of the nervous system we have cloned and sequenced the mouse homologue of Neogenin. We describe three alternatively spliced exons within the extracellular domain of Neogenin and a fourth alternatively spliced exon within the cytoplasmic domain, We further demonstrate that three of these alternatively spliced exons are developmentally regulated, Analysis of Neogenin mRNA expression showed that two distinct Neogenin transcripts are expressed at significant levels in a broad spectrum of adult mouse tissues and throughout the mid to late stages of embryogenesis. In situ hybridization studies on day 15.5 mouse embryos revealed that Neogenin is expressed widely throughout the developing mouse embryo, in both neuronal and nonneuronal tissues, These observations suggests that Neogenin may play an integral role in regulating differentiation programmes and/or cell migration events within many embryonic and adult tissues.			Keeling, SL (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, POB 2008, PARKVILLE, VIC 3050, AUSTRALIA.		Cooper, Helen/G-3505-2010; Cooper, Helen M/AAA-2182-2019	Cooper, Helen M/0000-0001-9838-5743				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BOLAM JP, 1992, EXPT NEUROANATOMY PR, P6; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; Cooper HM, 1995, ONCOGENE, V11, P2243; DEVILEE P, 1991, ONCOGENE, V6, P311; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG Y, 1992, CANCER RES, V52, P6525; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Kaufman M.H., 1992, ATLAS MOUSE DEV; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIYAKE K, 1993, BLOOD, V82, P927; OLEARY DDM, 1993, NEURON, V10, P991, DOI 10.1016/0896-6273(93)90049-W; PORFIRI E, 1993, BLOOD, V81, P2696; REALE MA, 1994, CANCER RES, V54, P4493; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAFFELL JL, 1994, J CELL BIOL, V125, P427, DOI 10.1083/jcb.125.2.427; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SMALL SJ, 1990, J CELL BIOL, V111, P2089, DOI 10.1083/jcb.111.5.2089; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; UCHINO S, 1992, CANCER RES, V52, P3099; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Walsh FS, 1996, CURR OPIN CELL BIOL, V8, P707, DOI 10.1016/S0955-0674(96)80113-X; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; ZORN AM, 1992, DEV BIOL, V149, P197, DOI 10.1016/0012-1606(92)90276-M	46	78	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					691	700		10.1038/sj.onc.1201225	http://dx.doi.org/10.1038/sj.onc.1201225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264410	Bronze			2022-12-17	WOS:A1997XP68300009
J	Nitta, M; Okamura, H; Aizawa, S; Yamaizumi, M				Nitta, M; Okamura, H; Aizawa, S; Yamaizumi, M			Heat shock induces transient p53-dependent cell cycle arrest at G1/S	ONCOGENE			English	Article						p53; heat shock; cell cycle arrest	NUCLEAR ACCUMULATION; P53 PROTEIN; DNA-DAMAGE; DEPENDENT KINASES; HUMAN FIBROBLASTS; TUMOR-ANTIGEN; UV; DEGRADATION; REPLICATION; CHECKPOINT	Heat shock (43 degrees C, 45 min) induced transient nuclear accumulation of p53 in primary human fibroblasts without any clonogenically toxic effects, The accumulation of p53 reached a maximal level 3 similar to 5 h after heat shock, and returned to the basal level within 12 h. Following the increase in p53 level, cell cycle arrest at G1/S was observed in normal fibroblasts, whereas neither nuclear accumulation of p53 nor cell cycle arrest were observed in HeLa cells. By comparing cell cycle patterns of heat-treated mouse cells with different genotypes at the p53 locus (+/+, +/-, -/-), the observed cell cycle arrest at G1/S was demonstrated to be p53-dependent, Cell cycle arrest in normal human fibroblasts continued for nearly 24 h, resulting in a one day delay of cell growth compared with non-treated cells, Following enhancement of the p53 level, the amount of p21/WAF1/CIP1 increased, and the high level of p21 was sustained for almost one day in a cell cycle-independent manner, suggesting the involvement of p21 in the inhibition of cell cycle progression by heat shock.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT OBSTET & GYNECOL,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MINISINI MP, 1994, MUTAT RES-DNA REPAIR, V315, P169, DOI 10.1016/0921-8777(94)90016-7; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shivji KK, 1992, CELL, V69, P367, DOI DOI 10.1016/0092-8674(92)90416-A; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; TSUKADA T, 1993, ONCOGENE, V8, P3313; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	32	78	81	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					561	568		10.1038/sj.onc.1201210	http://dx.doi.org/10.1038/sj.onc.1201210			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247309				2022-12-17	WOS:A1997XN25500007
J	Prasad, R; Zhadanov, AB; Sedkov, Y; Bullrich, F; Druck, T; Rallapalli, R; Yano, T; Alder, H; Croce, CM; Huebner, K; Mazo, A; Canaani, E				Prasad, R; Zhadanov, AB; Sedkov, Y; Bullrich, F; Druck, T; Rallapalli, R; Yano, T; Alder, H; Croce, CM; Huebner, K; Mazo, A; Canaani, E			Structure and expression pattern of human ALR, a novel gene with strong homology to ALL-1 involved in acute leukemia and to Drosophila trithorax	ONCOGENE			English	Article						ALL-1; leukemia; SET domain; PHD fingers	BITHORAX COMPLEX; DNA-BINDING; SEQUENCE SIMILARITY; BMI-1 PROTOONCOGENE; PROTEIN; POLYCOMB; DOMAINS; ENCODES; FINGER; TRANSLOCATIONS	The ALL-1 gene is involved in human acute leukemia through chromosome translocations or internal rearrangements. ALL-1 is the human homologue of Drosophila trithorax. The latter is a member of the trithorax group (trx-G) genes which together with the Polycomb group (Pc-G) genes act as positive and negative regulators, respectively, to determine the body structure of Drosophila. We have cloned a novel human gene, ALR, which encodes a gigantic 5262 amino acid long protein containing a SET domain, five PHD fingers, potential zinc fingers, and a very long run of glutamines interrupted by hydrophobic residues, mostly leucine. The SET motif, PDH fingers, zinc fingers and two other regions are most similar to domains of ALL-1 and TRX. The first two motifs are also found in other trx-G and Pc-G proteins. The ALR gene was mapped to chromosome band 12q12-13, adjacent to the VDR gene. This region is involved in duplications and translocations associated with cancer. The analysis of ALR expression showed that its similar to 18 kb long mRNA is expressed, like ALL-1, in most adult tissues, including a variety of hematopoietic cells, with the exception of the liver. Whole mount in situ hybridization to early mouse embryos indicates expression in multiple tissues. Based on similarities in structure and expression pattern, ALR is likely to play a similar role to ALL-1 and trx, although its target genes have yet to be identified.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Weizmann Institute of Science; Jefferson University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [P01CA050507, R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860, CA50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; ASHAR HR, 1995, CELL, V82, P57; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHIANG A, 1995, DEVELOPMENT, V121, P1681; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; FEARMAN A, 1993, DEVELOPMENT, V118, P919; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hermesz E, 1996, DEVELOPMENT, V122, P41; Hobert O, 1996, MECH DEVELOP, V55, P171, DOI 10.1016/0925-4773(96)00499-6; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JIANG JX, 1995, GENOMICS, V30, P91, DOI 10.1006/geno.1995.0015; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Karlin S, 1996, P NATL ACAD SCI USA, V93, P1560, DOI 10.1073/pnas.93.4.1560; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KRAUTER K, 1995, NATURE, V377, P321; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LONIE A, 1994, DEVELOPMENT, V120, P2629; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; MITELMAN F, 1994, CATALOG CHROMOSOME A; NOMURA M, 1994, DIFFERENTIATION, V57, P39, DOI 10.1046/j.1432-0436.1994.5710039.x; Oliver G, 1995, DEVELOPMENT, V121, P4045; OLIVER G, 1995, DEVELOPMENT, V121, P693; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RAIMONDI SC, 1993, BLOOD, V81, P2237; RAJU K, 1993, MECH DEVELOP, V44, P51, DOI 10.1016/0925-4773(93)90016-Q; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9337; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIDMAN RL, 1959, EXP NEUROL, V1, P322, DOI 10.1016/0014-4886(59)90024-X; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; THOMPSON KA, 1994, BIOCHEM BIOPH RES CO, V198, P1143, DOI 10.1006/bbrc.1994.1162; TILLIB S, 1995, MECH DEVELOP, V53, P113, DOI 10.1016/0925-4773(95)00429-7; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZHANDANOV AB, 1995, DEV DYNAM, V202, P354; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	62	78	82	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					549	560		10.1038/sj.onc.1201211	http://dx.doi.org/10.1038/sj.onc.1201211			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247308				2022-12-17	WOS:A1997XN25500006
J	Middeler, G; Zerf, K; Jenovai, S; Thulig, A; TschodrichRotter, M; Kubitscheck, U; Peters, R				Middeler, G; Zerf, K; Jenovai, S; Thulig, A; TschodrichRotter, M; Kubitscheck, U; Peters, R			The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited	ONCOGENE			English	Article						nucleocytoplasmic shuttling; nucleocytoplasmic transport; nuclear import signal; nuclear export signal; subcellular localization	SCANNING MICROPHOTOLYSIS; NUCLEOCYTOPLASMIC FLUX; PROGESTERONE-RECEPTOR; LOCALIZATION SIGNALS; PROTEIN IMPORT; MESSENGER-RNA; GROWTH ARREST; DNA-BINDING; MUTANT P53; IN-VIVO	Human p53 was expressed in E. coli, purified, labeled with fluorescein iodoacetamide (IAF) and characterized for sequence-specific DNA binding and epitope disposition. Injected into the cytoplasm or nuclei of 3T3 cells IAF-p53 was imported into or exported from nuclei within minutes. Import was inhibited by coinjection of the lectin wheat germ agglutinine (WGA). In contrast, the peptide-protein conjugate NLS-HSA carrying the nuclear localization sequence (NLS) of the SV40 T antigen was only imported but not exported. 3T3 polykaryons were injected with IAF-p53 and photobleached by Scanning Microphotolysis in such a manner that only a single nucleus per polykaryon remained non-bleached. IAF-p53 was found to migrate rapidly (halftime similar to 10 min) from non-bleached into bleached nuclei, while NLS-HSA did not. In digitonin permeabilized cells IAF-p53 was imported into nuclei. When removed from the medium after nuclear accumulation IAF-p53 was exported from the nuclei. Nuclear import and export of IAF-p53 both were rapid (halftimes of a few minutes, 22 degrees C) and strongly inhibited by WGA or incubation on ice. NLS-HSA was only imported but not exported. We conclude that the nucleocytoplasmic transport of p53, in contrast to that of NLS-HSA, is bidirectional and that transport in both directions is carrier mediated and energy dependent. These results suggest that p53 contains nuclear export signals (NES) in addition to import signals (NLS) and thus open new views on the potential regulation of p53 cellular fractions.	UNIV MUNSTER,INST MED PHYS & BIOPHYS,D-48149 MUNSTER,GERMANY	University of Munster			Kubitscheck, Ulrich/GPS-8017-2022; Peters, Reiner/E-7352-2011	Kubitscheck, Ulrich/0000-0003-3750-5355				ACKERMANN M, 1991, EXPERIENTIA, V47, pA55; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ADDISON C, 1990, ONCOGENE, V5, P423; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DANG CV, 1989, J BIOL CHEM, V264, P18019; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FRITSCHE M, 1993, ONCOGENE, V8, P3007; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOLDSTEIN L, 1958, EXP CELL RES, V15, P635, DOI 10.1016/0014-4827(58)90118-6; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; GUIOCHONMANTEL A, 1994, BIOCHEM PHARMACOL, V47, P21, DOI 10.1016/0006-2952(94)90433-2; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KUBITSCHECK U, 1994, BIOPHYS J, V67, P948, DOI 10.1016/S0006-3495(94)80596-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANG I, 1986, J CELL BIOL, V102, P1183, DOI 10.1083/jcb.102.4.1183; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MEIER UT, 1992, CELL, V70, P127; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MICHAEL WM, 1995, CELL, V83, P415; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PETERS R, 1984, EMBO J, V3, P1831, DOI 10.1002/j.1460-2075.1984.tb02055.x; PETERS R, 1974, BIOCHIM BIOPHYS ACTA, V367, P282, DOI 10.1016/0005-2736(74)90085-6; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCHMIDT M, 1994, EUR J CELL BIOL, V65, P70; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; TAKAHASHI K, 1994, ONCOGENE, V9, P183; THULIG A, 1994, MOL BIOL CELL, V5, pA458; TschodrichRotter M, 1996, BIOPHYS J, V70, P723, DOI 10.1016/S0006-3495(96)79612-1; WALASCHEWSKI U, 1995, METHOD MOL CELL BIOL, V5, P87; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEDEKIND P, 1994, J MICROSC-OXFORD, V176, P23, DOI 10.1111/j.1365-2818.1994.tb03496.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	62	78	79	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1407	1417		10.1038/sj.onc.1200949	http://dx.doi.org/10.1038/sj.onc.1200949			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136984				2022-12-17	WOS:A1997WT58400003
J	Rossel, M; Pasini, A; Chappuis, S; Geneste, O; Fournier, L; Schuffenecker, I; Takahashi, M; vanGrunsven, LA; Urdiales, JL; Rudkin, BB; Lenoir, GM; Billaud, M				Rossel, M; Pasini, A; Chappuis, S; Geneste, O; Fournier, L; Schuffenecker, I; Takahashi, M; vanGrunsven, LA; Urdiales, JL; Rudkin, BB; Lenoir, GM; Billaud, M			Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations	ONCOGENE			English	Article						MEN 2; RET proto-oncogene; tyrosine kinase; isoforms	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE; PROTOONCOGENE MUTATIONS; CELL-LINE; FMTC; EXPRESSION; RECEPTOR; DISEASE; GENE; SPECIFICITY	Germline mutations of the RET proto-oncogene, which codes for a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). MEN 2 mutations have been shown to result in RET oncogenic activation. The RET gene encodes several isoforms whose biological properties, when altered by MEN 2 mutations, have not been thoroughly addressed yet. In this study, we have introduced a MEN 2A mutation (Cys634-->Arg) and the unique MEN 2B mutation (Met918-->Thr) in two RET isoforms of 1114 and 1072 amino acids which differ in the carboxy-terminus part, Herein, we report that each RET isoform activated by MEN 2A or MEN 2B mutation was transforming in fibroblasts and induced neuronal differentiation of pheochromocytoma PC12 cells. However, among the different RET-MEN 2 mutants, the long RET isoform activated by the MEN 2B mutation stimulated the most prominent neurite outgrowth in PC12 cells, while the short RET isoform counterpart elicited a very weak differentiation effect in PC12 cells. We further demonstrate that the morphological changes of PC12 cells caused by constitutively activated RET oncoproteins involved the engagement of a Ras-dependent pathway. These findings provide evidence that the biological properties of RET-MEN 2 mutants depend on the interplay between the RET isoforms and the nature of the activating MEN 2 mutation.	UNIV LYON 1,GENET LAB,UMR 5641 CNRS,F-69373 LYON 08,FRANCE; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE; NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,UMR 49 CNRS,F-69364 LYON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Nagoya University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			TAKAHASHI, Masahide/I-7244-2014; Urdiales, José Luis/K-1125-2014; van Grunsven, Leo/E-5839-2010; Takahashi, Masahide/AAN-4770-2020; Billaud, Marc N/M-6954-2013	Urdiales, José Luis/0000-0002-2519-9293; van Grunsven, Leo/0000-0002-0990-7034; Takahashi, Masahide/0000-0002-2803-2683; RUDKIN, Brian B./0000-0003-3700-1982; Rossel, Mireille/0000-0003-2275-0817				ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BOLINO A, 1995, ONCOGENE, V10, P2415; BORELLO MG, 1995, ONCOGENE, V11, P2419; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DELELLIS RA, 1995, LAB INVEST, V72, P494; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1994, HUM MOL GENET, V3, P234; FOURNIER E, 1995, ONCOGENE, V11, P921; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS SM, 1995, ONCOGENE, V11, P2039; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSSEL M, 1995, HUM GENET, V95, P403; RUSSO AF, IN PRESS GENETIC MEC; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	55	78	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					265	275		10.1038/sj.onc.1200831	http://dx.doi.org/10.1038/sj.onc.1200831			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018112				2022-12-17	WOS:A1997WD51600002
J	Gallagher, WM; Cairney, M; Schott, B; Roninson, IB; Brown, R				Gallagher, WM; Cairney, M; Schott, B; Roninson, IB; Brown, R			Identification of p53 genetic suppressor elements which confer resistance to cisplatin	ONCOGENE			English	Article						cisplatin; resistance; p53; cell cycle arrest; apoptosis	DNA-BINDING FUNCTION; CELL-LINES; ANTISENSE RNA; EXPRESSION SELECTION; STRUCTURAL ASPECTS; DRUG-RESISTANCE; OVARIAN-CANCER; PROTEIN; DEPENDENCE; SEQUENCES	Loss of p53 function is associated with the acquisition of cisplatin resistance in the human ovarian adenocarcinoma A2780 cell line, Selection for cisplatin resistance of A2780 cells was used to isolate genetic suppressor elements (GSEs) from a retroviral library expressing random fragments of human or murine TP53 cDNA. Six GSEs were identified, encoding either dominant negative mutant peptides or antisense RNA molecules which corresponded to various regions within the TP53 gene, Both types of GSE induced cisplatin resistance when introduced individually into A2780 cells, Expression of antisense GSEs led to decreased intracellular levels of p53 protein, One sense GSE induced loss of p53-mediated activities such as DNA damage induced cell cycle arrest and apoptosis, A synthetic peptide, representing the predicted amino acid sequence of this GSE, conferred resistance to cisplatin when introduced into A2780 cells and inhibited the sequence specific DNA binding activity of p53 protein in vitro. Overall, these results directly indicate that inactivation of p53 function confers cisplatin resistance in these human ovarian tumour cells. We have identified short structural domains of p53 which are capable of independent functional interactions and highlighted the efficacy of this approach to discriminate biologically active GSEs from a random fragment library.	CRC, BEATSON LABS, DEPT MED ONCOL, GLASGOW G61 1BD, LANARK, SCOTLAND; UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA	Beatson Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327; Gallagher, William/0000-0002-4307-5999	NATIONAL CANCER INSTITUTE [R01CA056736, R01CA062099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56736, R01 CA62099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; Anthoney DA, 1996, CANCER RES, V56, P1374; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BAYEVER E, 1994, LEUKEMIA LYMPHOMA, V12, P223, DOI 10.3109/10428199409059593; BI SC, 1994, CANCER RES, V54, P582; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bishop MR, 1996, J CLIN ONCOL, V14, P1320, DOI 10.1200/JCO.1996.14.4.1320; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BROWN R, 1993, ANN ONCOL, V4, P623, DOI 10.1093/oxfordjournals.annonc.a058614; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Coffin J. M., 1990, VIROLOGY, P1437; DENHARDT DT, 1992, ANN NY ACAD SCI, V660, P70, DOI 10.1111/j.1749-6632.1992.tb21059.x; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FAN SJ, 1995, CANCER RES, V55, P1649; GORCZYCA W, 1993, CANCER RES, V53, P3186; GUDKOV AV, 1993, P NATL ACAD SCI USA, V90, P3231, DOI 10.1073/pnas.90.8.3231; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLZMAYER TA, 1992, NUCLEIC ACIDS RES, V20, P711, DOI 10.1093/nar/20.4.711; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MCLAUGHLIN K, 1991, CANCER RES, V51, P2242; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; OSSOVSKAYA V, IN PRESS P NATL ACAD; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PLUMB JA, 1989, CANCER RES, V49, P4435; RONINSON IB, 1995, CANCER RES, V55, P4023; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; Shimamura A, 1996, CLIN CANCER RES, V2, P435; SORENSON CM, 1988, CANCER RES, V48, P4484; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; VASEY PA, 1996, IN PRESS MOL PHARM; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	49	78	82	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	1997	14	2					185	193						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010220				2022-12-17	WOS:A1997WC81800006
J	Rosenberg, JE; Lisle, DK; Burwick, JA; Ueki, K; vonDeimling, A; Mohrenweiser, HW; Louis, DN				Rosenberg, JE; Lisle, DK; Burwick, JA; Ueki, K; vonDeimling, A; Mohrenweiser, HW; Louis, DN			Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval	ONCOGENE			English	Article						chromosome 19; D19S745; glioma; tumor suppressor gene	REGION; ASTROCYTOMAS; CANDIDATE; 19Q13.3; MAP	Allelic loss of chromsome 19q occurs frequently in malignant gliomas, suggesting the presence of a chromosome 19q glioma tumor suppressor gene, Deletion mapping studies have delineated a 3.5 Mb candidate region between D19S219 and HRC, Cloned sequences from the proximal 425 kb of this interval, however, have not shown tumor-specific alterations, To refine the location of the tumor suppressor gene further, we conducted loss of heterozygosity studies on 191 malignant gliomas using nine PCR-based polymorphisms, These included the previously identified and physically mapped markers D19S219, DM, D19S112, HRC and the recently physically mapped polymorphisms at D19S412, STD, D19S596 and GYS. In addition, we isolated a novel microsatellite polymorphism that maps 400 kb telomeric to D19S112, Oligodendroglial tumors showed frequent loss of heterozygosity in all grades, and typically displayed allelic loss at all studied markers, Astrocytomas, however, showed frequent loss primarily in anaplastic astrocytomas and displayed deletion breakpoints within the candidate region, Deletion mapping revealed a minimal region of overlap between D19S412 and STD, a distance of 900 kb, These data suggest that the D19S412-STD interval represents the most likely location for a chromsome 19q glioma tumor suppressor gene involved in astrocytoma, and perhaps oligodendroglioma, tumorigenesis.	MASSACHUSETTS GEN HOSP,DEPT PATHOL NEUROPATHOL,NEUROSURG SERV,MOL NEUROONCOL LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV HOSP,INST NEUROPATHOL,BONN,GERMANY; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Bonn; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X	NATIONAL CANCER INSTITUTE [R01CA057683, R01CA069285] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69285, CA 57683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; DUROCHER F, 1995, GENOMICS, V29, P781, DOI 10.1006/geno.1995.9935; ELBEIN SC, 1994, DIABETES, V43, P1061, DOI 10.2337/diabetes.43.8.1061; GORDON LA, 1995, GENOMICS, V30, P187, DOI 10.1006/geno.1995.9886; Kleihues P, 1993, HISTOLOGICAL TYPING; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LOUIS DN, 1992, AM J PATHOL, V141, P777; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RUBIO MP, 1994, CANCER RES, V54, P4760; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; YONG WH, 1995, J NEUROPATH EXP NEUR, V54, P622, DOI 10.1097/00005072-199509000-00002; YONG WH, 1995, GENOMICS, V29, P533, DOI 10.1006/geno.1995.9972	16	78	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2483	2485						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957092				2022-12-17	WOS:A1996VX10800023
J	Lu, X; Burbidge, SA; Griffin, S; Smith, HM				Lu, X; Burbidge, SA; Griffin, S; Smith, HM			Discordance between accumulated p53 protein level and its transcriptional activity in response to uv radiation	ONCOGENE			English	Article						p53; uv irradiation; protein level; transcription activity	DNA-BINDING FUNCTION; CELLULAR TUMOR-ANTIGEN; TRANSFORMED-CELLS; IRRADIATION; EXPRESSION; MUTATIONS; INDUCTION; ACTIVATE; CANCER	In response to DIVA damage, the transcriptional activity of p53 rises. This has been thought to be due to an increase in the level of p53 protein. By comparing the p53 protein level and its ability to transactivate target genes Waf1/Cip1 and mdm2 in both T22 and NTH3T3 cells irradiated with u.v., a discordance between the p53 protein level and its transcriptional activity was observed. When the cells were irradiated with 10 J/m(2) of u.v., there was a substantial increase in expression of Waf1/Cip1 and mdm2. However, little increase in Waf1/Cip1 and mdm2 expression was observed in T22 and NIH3T3 cells 8 or 9 h after exposure to 50 J/m(2) of u.v., although the p53 protein level accumulated to its highest level under these conditions. Interestingly, a significant increase in Waf1/Cip1 expression was seen 24 h after irradiation in NIH3T3 cells, indicating that the inhibition of p53 transcriptional activity is reversible. Discordance between the transcriptional activity of p53 and its protein level was further studied using a cell line expressing the p53 reporter plasmid RGC Delta fosLacZ. Using double immunofluorescence staining, the coexpression of p53 and beta-galactosidase from the reporter plasmid in the same cells was investigated. The observed lack of correlation between the elevated p53 and beta-galactosidase and expression in u.v. irradiated cells strongly indicates that the ability of p53 to transactivate its target genes is not simply correlated to its protein level. The results indicate that the transcriptional activity of p53 may be negatively regulated.			Lu, X (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LUDWIG INST CANC RES,SCH MED,NORFOLK PL,LONDON W2 1PG,ENGLAND.			Lu, Xin/0000-0002-6587-1152				DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; Fredersdorf S, 1996, AM J PATHOL, V148, P825; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	26	78	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					413	418						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710381				2022-12-17	WOS:A1996VA25200021
J	Hecker, D; Page, G; Lohrum, M; Weiland, S; Scheidtmann, KH				Hecker, D; Page, G; Lohrum, M; Weiland, S; Scheidtmann, KH			Complex regulation of the DNA-binding activity of p53 by phosphorylation: Differential effects of individual phosphorylation sites on the interaction with different binding motifs	ONCOGENE			English	Article						DNA-binding; p53; phosphorylation; okadaic acid; tumor suppressor protein	LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; CELL-CYCLE CONTROL; WILD-TYPE; RAT-CELLS; 3T3 CELLS; TRANSCRIPTION; SEQUENCE; ONCOGENE	The tumor suppressor protein p53 exists in different phosphorylation states depending on the cellular environment and perhaps the stage of the cell cycle. These different phosphorylation states can be mimicked in the baculovirus expression system by employing the phosphatase inhibitor okadaic acid. Hyperphosphorylation of p53, particularly of Ser313 and/or Ser309, stimulated its DNA binding activity (Fuchs, Hecker and Scheidtmann, Eur. J. Biochem. 228, 625, 1995). Here we show that hyperphosphorylation of p53 has different effects on its DNA-binding activity, depending on the phosphorylation sites and the binding motif: (i) Phosphorylation of amino-terminal sites appeared to reduce binding to the RGC consensus motif, whereas additional phosphorylation of both, Ser313 and Ser309 led to enhanced binding. (ii) Upon hyperphosphorylation, binding to the RGC motif was enhanced whereas binding to the p53 response element of the bax1 gene promoter was diminished. (iii) DNA binding was also greatly enhanced by antibodies Pab 122 and 421 directed against the carboxyl terminus, but this latter effect was superimposed by the phosphorylation state of p53. Thus, the DNA binding activity of p53 appears to be regulated in a complex way in that (i) binding to a given sequence motif may be regulated by differential phosphorylation and/or by interaction with other factors; (ii) binding to different motifs may be modulated in opposite ways. Thus, the different genes that are regulated by p53 may be differently affected by these parameters.	UNIV BONN,INST GENET,ABT MOLEK GENET,D-53117 BONN,GERMANY	University of Bonn								BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRAIN R, 1994, ONCOGENE, V9, P1775; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER B, 1995, EMBO J, V14, P4442; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	82	78	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					953	961						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649812				2022-12-17	WOS:A1996UA88400002
J	FORD, HL; ZAIN, SB				FORD, HL; ZAIN, SB			INTERACTION OF METASTASIS-ASSOCIATED MTS1 PROTEIN WITH NONMUSCLE MYOSIN	ONCOGENE			English	Article						MTS1; METASTASIS; PROTEIN-PROTEIN INTERACTIONS; MOTILITY; MYOSIN	CALCIUM-BINDING PROTEINS; MESSENGER-RNA; HEAVY-CHAIN; MOLECULAR-CLONING; CELLULAR MYOSIN; GENE-PRODUCT; EXPRESSION; CELLS; SEQUENCE; FAMILY	The mts1 gene codes for a 101 amino acid protein which belongs to the subfamily of S100 Ca2+-binding proteins and is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, While the Mts1 protein is putatively involved in cytoskeletal-membrane interactions, its exact physiological role is not known, In order to gain insight into the biological function of Mts1, its expression was monitored throughout mouse embryogenesis as well as in normal adult mouse tissues. In situ hybridizations of mouse embryos showed expression of mts1 mRNA to be highest in trophoblast cells of a day 8 old embryo, In normal adult mouse tissues, immunocytochemistry revealed Mts1 expression in a T-cell specific pattern in both the thymus and spleen, These results indicate that the expression of mts1 is prevalent in motile cell types, and to further elucidate the role of Mts1, gel overlay and GST-fusion protein experiments were performed to identify proteins that interact with the Mts1 protein, Nonmuscle myosin II was found to interact with Mts1, suggesting a role for Mts1 in the process of motility and lending credence to the hypothesis that Mtsl may enhance metastatic potential by increasing the motility of cancerous cells.	UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA062376, P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA11198, R01CA62376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGERER LM, 1987, APPL NEUROBIOLOGY, P42; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; DAVIES BR, 1993, ONCOGENE, V8, P999; DELEON M, 1991, J NEUROSCI RES, V29, P155; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; GENBACEV O, 1992, PLACENTA, V13, P439, DOI 10.1016/0143-4004(92)90051-T; GENBACEV O, 1993, PLACENTA, V14, P463, DOI 10.1016/S0143-4004(05)80466-7; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAKIUCHI S, 1981, FEBS LETT, V126, P203, DOI 10.1016/0014-5793(81)80242-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KORCZAK B, 1991, CELL GROWTH DIFFER, V2, P335; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MIZUTANI T, 1993, CANCER, V72, P2083, DOI 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1; NGUYEN HT, 1982, P NATL ACAD SCI-BIOL, V79, P5230, DOI 10.1073/pnas.79.17.5230; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; OVADI J, 1992, CURR TOP CELL REGUL, V33, P105; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; SAHASRABUDHE DM, 1993, J IMMUNOL, V151, P6302; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SENIN VM, 1983, EKSP ONKOL, V5, P35; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TANIGUCHI S, 1990, BIOCHEM BIOPH RES CO, V168, P520, DOI 10.1016/0006-291X(90)92352-Z; TOOTHAKER LE, 1991, BLOOD, V78, P1826; TULCHINSKY E, 1993, ONCOGENE, V8, P79; VALVERDE I, 1979, SCIENCE, V206, P225, DOI 10.1126/science.225798; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WETERMAN MAJ, 1992, CANCER RES, V52, P1291	59	78	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1597	1605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731714				2022-12-17	WOS:A1995QU68100016
J	MARIN, MC; HSU, B; MEYN, RE; DONEHOWER, LA; ELNAGGAR, AK; MCDONNELL, TJ				MARIN, MC; HSU, B; MEYN, RE; DONEHOWER, LA; ELNAGGAR, AK; MCDONNELL, TJ			EVIDENCE THAT P53 AND BCL-2 ARE REGULATORS OF A COMMON CELL-DEATH PATHWAY IMPORTANT FOR IN-VIVO LYMPHOMAGENESIS	ONCOGENE			English	Article							WILD-TYPE P53; THYMOCYTE APOPTOSIS; LYMPHOID-TISSUES; BURKITT-LYMPHOMA; PROTEIN; MUTATIONS; GENE; ONCOGENES; HYPERPLASIA; PROGRESSION	Multistep lymphomagenesis involves the deregulation of oncogenes and inactivation of tumor suppressor genes resulting in altered rates of proliferation as well as apoptotic cell death in tumor cells. The contribution of bcl-2 and p53 to the regulation of cell death during lymphomagenesis is assessed using bcl-2-1g, p53 'knockout' (p53 KO), and p53 KO/bcl-2 hybrid mice. PCR-SSCP and DNA sequence analysis demonstrated that p53 somatic mutations are uncommon in lymphomas arising in bcl-2-Ig transgenic mice. Reduction in tumor latency was not observed in p53 KO/bcl-2 hybrid mice compared to p53 KO mice. Furthermore, overexpressed bcl-2 suppressed wild-type p53 associated apoptosis following gamma-radiation. These findings indicate that bcl-2 and p53 serve a suppressor and effector function, respectively, of a common cell death pathway. These findings also suggest that p53 somatic mutations provide no selective advantage during in vivo multistep lymphomagenesis in the context of bcl-2 gene deregulation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL RADIOTHERAPY,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DIV PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine			Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NATIONAL CANCER INSTITUTE [R01CA062597, R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA62597, CA54897] Funding Source: Medline; NCRR NIH HHS [RR5511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASTER JC, 1992, AM J PATHOL, V141, P291; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARPER JW, 1993, CELL, V75, P805; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LIMPENS J, 1991, ONCOGENE, V6, P2271; LOCOCO F, 1993, BLOOD, V82, P2289; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCDONNELL TJ, 1993, TRANSGENE, V1, P47; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MIYASHITA T, 1992, CANCER RES, V52, P5407; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORI N, 1992, BRIT J HAEMATOL, V81, P235, DOI 10.1111/j.1365-2141.1992.tb08213.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; SANDER CA, 1993, BLOOD, V82, P1994; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	53	78	81	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3107	3112						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936633				2022-12-17	WOS:A1994PM65800002
J	GAO, XA; WU, N; GRIGNON, D; ZACHAREK, A; LIU, H; SALKOWSKI, A; LI, GY; SAKR, W; SARKAR, F; PORTER, AT; CHEN, YQ; HONN, KV				GAO, XA; WU, N; GRIGNON, D; ZACHAREK, A; LIU, H; SALKOWSKI, A; LI, GY; SAKR, W; SARKAR, F; PORTER, AT; CHEN, YQ; HONN, KV			HIGH-FREQUENCY OF MUTATOR PHENOTYPE IN HUMAN PROSTATIC ADENOCARCINOMA	ONCOGENE			English	Article							NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; GENETIC INSTABILITY; CARCINOMA; P53; MUTATIONS; CELLS; SUPPRESSION; ASSOCIATION	Mutator phenotype of nucleotide repeats has been implicated to be involved in human cancer and other diseases. This type of instability may be the direct result of DNA replication and/or repair errors. To examine mutator phenotype during the development of human prostate cancer, we undertook this study to screen 57 patients with prostatic adenocarcinoma for possible mutator phenotype at 18 microsatellite marker loci on 12 chromosomes (3p, 5q, 6p, 7p, 8p, 10q, 11p, 13q, 16q, 17p, 18q and Xq) Overall, in 37 of 57 patients, we have found positive mutator phenotype in at least one of the loci analysed. A significantly greater number of cases mere found to be positive for this phenotype among the poorly differentiated than the moderately- and well-differentiated prostatic adenocarcinomas. Our data suggest that mutator phenotype may play an important role in the development and progression of human prostate cancer.	WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48202; WAYNE STATE UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,DETROIT,MI 48202	Wayne State University; Wayne State University			Chen, Yong Q/AAI-9864-2021	Chen, Yong Q/0000-0003-4747-4708				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANWAR K, 1992, CANCER RES, V52, P5991; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHIARODO A, 1991, CANCER RES, V51, P2498; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GAO X, 1993, CANCER RES, V53, P2723; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISAACS WB, 1991, CANCER RES, V51, P4716; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOTHE RA, 1993, CANCER RES, V53, P5849; MANDEL JL, 1993, NAT GENET, V4, P8, DOI 10.1038/ng0593-8; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, CANCER RES, V53, P5853; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STEVENBOVA G, 1993, CANCER RES, V53, P3869; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	34	78	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2999	3003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084604				2022-12-17	WOS:A1994PG82200027
J	CICCOLINI, F; DIPASQUALE, G; CARLOTTI, F; CRAWFORD, L; TOMMASINO, M				CICCOLINI, F; DIPASQUALE, G; CARLOTTI, F; CRAWFORD, L; TOMMASINO, M			FUNCTIONAL-STUDIES OF E7 PROTEINS FROM DIFFERENT HPV TYPES	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; MUTATIONAL ANALYSIS; CERVICAL-CARCINOMA; ADENOVIRUS E1A; PRIMARY-CELLS; RB PROTEIN; CYCLIN-A; TRANSFORMATION	We have performed comparative studies on the E7 proteins from malignant and non-malignant Human Papillomavirus types (HPV 1, 6, 11, 16, 18, 33). GST/E7 fusion proteins from all these HPV types associate with Rb1, p107 and the cyclin A/CDK2 complex. As has been shown for Rb1, the association with p107 and Cyclin A was weaker for the 'low risk' HPV6 and 11 E7 proteins as compared to 'high risk' HPV16, 18 and 33 E7 proteins. In contrast the E7 protein of the benign type HPV1 bound Rb1, p107 and cyclin A with the same affinity as the 'high risk' E7 proteins. The affinities of the E7/Rb1 interaction have been confirmed in vivo by the 'two hybrid' method in the yeast Saccharomyces cerevisiae. Although HPV1 E7 showed the same affinity in vitro and in vivo for Rb1 as the high risk HPV E7s, it did not have the ability to activate the E2F-1 transcription factor inhibited by Rb1, nor did it have any transforming activity when coexpressed with activated ras in primary rodent cells.	UNIV CAMBRIDGE, DEPT PATHOL, IMPERIAL CANC RES FUND, TUMOUR VIRUS GRP, CAMBRIDGE CB2 1QP, ENGLAND	University of Cambridge				Ciccolini, Francesca/0000-0002-7276-7361				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; STANDIGER M, 1993, J BIOL CHEM, V268, P4608; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TOMMASINO M, 1993, ONCOGENE, V8, P195; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993	38	78	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2633	2638						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058327				2022-12-17	WOS:A1994PC05400023
J	CHATTON, B; BOCCO, JL; GOETZ, J; GAIRE, M; LUTZ, Y; KEDINGER, C				CHATTON, B; BOCCO, JL; GOETZ, J; GAIRE, M; LUTZ, Y; KEDINGER, C			JUN AND FOS HETERODIMERIZE WITH ATFA, A MEMBER OF THE ATF/CREB FAMILY AND MODULATE ITS TRANSCRIPTIONAL ACTIVITY	ONCOGENE			English	Article							ELEMENT-BINDING-PROTEIN; AMP RESPONSE ELEMENT; LEUCINE ZIPPER STRUCTURE; NUCLEAR FACTOR CREB; DNA-BINDING; CYCLIC-AMP; CDNA CLONES; HELA-CELLS; CROSS-TALK; ENHANCER	Three related clones encoding proteins (ATFa1, 2 and 3) with specific ATF/CRE DNA-binding activities have been isolated from HeLa cell cDNA libraries. All three isoforms have weak effects on the basal activity of the adenovirus E2a promoter. We present evidence suggesting that a C-terminal element of the ATFa molecules negatively interferes with the intrinsic activation function of these proteins. We also show that coexpression of ATFa with c-Jun, Jun-B or Jun-D stimulates ATFa-dependent reporter activity, while coexpression of c-Fos has no effect. Deletion analyses indicate that the metal-binding region of ATFa is dispensible for this effect, but that the domain comprising the leucine-zipper region of ATFa is required. Reciprocal co-immunoprecipitation experiments and electrophoretic band-shift assays with in vitro synthesized proteins reveal direct interactions between ATFa and Jun or Fos. The ATFa/c-Jun heterodimers, but not the ATFa/c-Fos complexes, bind efficiently to ATF, CRE or AP1 sites. The detection of ATFa-Jun complexes in crude extracts from HeLa cells transfected with ATFa and c-Jun expression vectors suggests that such ATFa/c-Jun heterodimers also form in vivo. Altogether these results indicate that the ATFa proteins may contribute to the modulation of the activity of the Jun/Fos complexes by altering their DNA-binding and transcriptional properties.	INST CHIM BIOL,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Bocco, Jose Luis/0000-0002-9682-1270				ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ABDELHAFIZ HAM, 1992, MOL ENDO, V6, P2080; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; FLINT KJ, 1991, ONCOGENE, V6, P2019; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAPRINSKI BA, 1992, P NATL ACAD SCI USA, V85, P7192; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1992, J CELL SCI, V103, P9; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; MERMOD N, 1989, CELL, V57, P859; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NOMURA N, 1993, J BIOL CHEM, V268, P4259; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZU YL, 1991, J BIOL CHEM, V35, P24134	62	78	80	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					375	385						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290251				2022-12-17	WOS:A1994MW24800004
J	HANNA, Z; JANKOWSKI, M; TREMBLAY, P; JIANG, XY; MILATOVICH, A; FRANCKE, U; JOLICOEUR, P				HANNA, Z; JANKOWSKI, M; TREMBLAY, P; JIANG, XY; MILATOVICH, A; FRANCKE, U; JOLICOEUR, P			THE VIN-1 GENE, IDENTIFIED BY PROVIRUS INSERTIONAL MUTAGENESIS, IS THE CYCLIN D2	ONCOGENE			English	Article							T(11-14) CHROMOSOME-TRANSLOCATION; INTEGRATION SITE; CELL; DNA; ONCOGENE; BREAKPOINT; LYMPHOMA; BCL-1; PHASE	The Vin-1 gene was initially identified as a gene whose expression is altered by the integration of proviruses in the Vin-1 common site of integration in retrovirus-induced rodent T-cell leukemias. We have now isolated the Vin-1 cDNA. Sequencing of the Vin-1 cDNA and Vin-1 exons revealed that the proviruses are integrated at the 5' end of the Vin-1 gene in an inverse transcriptional orientation. The sequence of the Vin-1 gene is identical to that of the recently identified G1-phase cyclin D2 gene. The human homolog of the Vin-1/cyclin D2 gene (CCND2) was mapped to chromosome 12, band p13.3, by in situ hybridization, confirming previous mapping data. Our results strongly support a role of the cyclin D2 gene in oncogenesis and thereby implicate altered cell cycle regulation in transformation.	CLIN RES INST MONTREAL, MOLEC BIOL LAB, 110 PINE AVE W, MONTREAL H2W 1R7, QUEBEC, CANADA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, QUEBEC, CANADA; MCGILL UNIV, DEPT EXPTL MED, MONTREAL H3G 1A4, PQ, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Howard Hughes Medical Institute; Stanford University; Stanford University; Universite de Montreal; McGill University				Jiang, Xiaoyan/0000-0002-8974-7340	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000298] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00298] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERIKSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4144, DOI 10.1073/pnas.81.13.4144; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LAMMIE GA, 1991, ONCOGENE, V6, P439; Maniatis T., 1982, MOL CLONING; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILATOVICH A, 1991, GENOMICS, V11, P1040, DOI 10.1016/0888-7543(91)90030-I; MITELMAN F, 1988, CATALOG CHROMOSOME A, P515; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PETERS G, 1990, CELL GROWTH DIFFER, V1, P503; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA H, 1992, JCELL, V70, P57; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TREMBLAY PJ, 1992, J VIROL, V66, P1344, DOI 10.1128/JVI.66.3.1344-1353.1992; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VILLEMUR R, 1987, MOL CELL BIOL, V7, P512, DOI 10.1128/MCB.7.1.512; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUNIS JJ, 1976, SCIENCE, V191, P1268, DOI 10.1126/science.1257746	34	78	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1661	1666						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502486				2022-12-17	WOS:A1993LE06400030
J	HAWTHORN, LA; CHAPMAN, R; OSCIER, D; COWELL, JK				HAWTHORN, LA; CHAPMAN, R; OSCIER, D; COWELL, JK			THE CONSISTENT 13Q14 TRANSLOCATION BREAKPOINT SEEN IN CHRONIC B-CELL LEUKEMIA (BCLL) INVOLVES DELETION OF THE D13S25 LOCUS WHICH LIES DISTAL TO THE RETINOBLASTOMA PREDISPOSITION GENE	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR DEFINITION; CHROMOSOME-13; ABNORMALITIES; HYBRID	Structural rearrangements involving chromosome 13 are frequently seen in B-cell chronic lymphocytic leukaemia. The presence of reciprocal translocations involving 13q14 in 10-15% of cases pinpoints the location of a gene important in leukaemogenesis. In order to characterise the exact location of the 13q14 breakpoint, somatic cell hybrids were constructed between mouse 3T3 cells and leukaemic cells from 5 patients with translocations involving chromosome 13. Hybrid pairs were isolated which carried either of the two derivative chromosomes carrying subsections of 13 and the position of the breakpoint investigated using a series of probes along the length of the chromosome. In all cases the translocation breakpoint lay distal to the 13q14.1 breakpoint region associated with rhabdomyosarcoma tumours and proximal to the D13S31 locus which lies in 13q14.3. In three translocations the RB1 gene was deleted as a result of the translocation but in at least one other case the BCLL breakpoint did not involve the RB1 gene, which consistently cosegregated in hybrids carrying other proximal markers. The D13S25 probe, which lies between RB1 and D13S31, however, was deleted in the translocation retaining RB1. It appears therefore that deletion of a gene(s) in this 2Mbp region is a critical event in some cases of BCLL tumorigenesis.	INST CHILD HLTH,ONCOL GRP,ICRF,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; ROYAL BOURNEMOUTH HOSP,DEPT HAEMATOL,BOURNEMOUTH BH7 7DW,ENGLAND	University of London; University College London				Cowell, John/0000-0002-2079-5950; Hawthorn, Lesleyann/0000-0001-8179-0937				ABBOTT C, 1991, GENOMICS, V9, P73, DOI 10.1016/0888-7543(91)90222-Z; BOWCOCK AM, 1991, GENOMICS, V11, P517, DOI 10.1016/0888-7543(91)90058-M; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; COWELL JK, 1987, BRIT J CANCER, V55, P661, DOI 10.1038/bjc.1987.135; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; COWELL JK, 1992, ANN ONCOL, V3, P693, DOI 10.1093/oxfordjournals.annonc.a058319; COWELL JK, 1992, HUMAN CYTOGENETICS P, P202; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; HOGG A, 1992, ONCOGENE, V7, P1444; JULIUSSON G, 1991, LEUKEMIA LYMPHOMA, V5, P21, DOI 10.3109/10428199109103374; JULIUSSON G, 1990, CANCER GENET CYTOGEN, V45, P143, DOI 10.1016/0165-4608(90)90079-P; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; LUI Y, 1992, GENES CHROMS CANCER, V45, P250; MICHALSKI AJ, 1992, ONCOGENE, V7, P1595; MITCHELL CD, 1991, ONCOGENE, V6, P89; MITCHELL CD, 1989, ONCOGENE, V4, P253; MORRIS CM, 1991, GENE CHROMOSOME CANC, V3, P455, DOI 10.1002/gcc.2870030607; NICHOLS J, 1992, BLOOD, V80, P2953; OSCIER D, 1990, BLOOD, V76, P241; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; Sambrook J, 1989, COLD SPRING HARBOR L, V3	21	78	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1415	1419						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502470				2022-12-17	WOS:A1993LE06400003
J	PULVERER, BJ; HUGHES, K; FRANKLIN, CC; KRAFT, AS; LEEVERS, SJ; WOODGETT, JR				PULVERER, BJ; HUGHES, K; FRANKLIN, CC; KRAFT, AS; LEEVERS, SJ; WOODGETT, JR			COPURIFICATION OF MITOGEN-ACTIVATED PROTEIN-KINASES WITH PHORBOL ESTER-INDUCED C-JUN KINASE-ACTIVITY IN U937 LEUKEMIC-CELLS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; ENHANCER ACTIVITY; MAP KINASES; PHOSPHORYLATION; INSULIN; GENES; DIFFERENTIATION; EXPRESSION; TYROSINE; TPA	Phorbol esters, such as phorbol myristate acetate (PMA), cause differentiation of U937 human mono-myelocytic cells along the macrophage pathway. Within 15 min of PMA treatment DNA binding of the c-jun transcription factor is increased and is accompanied by rapid changes in the phosphate content of the c-jun protein. Phorbol esters stimulate phosphorylation of serines 63 and 73 located within the Al transactivation domain of c-Jun that have previously been shown to positively regulate activity. A protein kinase activity is detectable in extracts of phorbol ester-treated U937 cells that specifically targets these two serines. Using novel assays, the protein kinase activity has been purified over 1000-fold. The major portion of protein kinase activity co-chromatographs over three columns with pp42/44 mitogen-activated protein kinases as judged by immunological methods. The significance of these results with respect to mitogen-induced transcription of AP-1-responsive genes is discussed.	PRINCESS MARGARET HOSP, ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV ALABAMA, DEPT HAEMATOL ONCOL, BIRMINGHAM, AL 35294 USA; CHESTER BEATTY LABS, INST CANC RES, LONDON SW3 6JB, ENGLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Alabama System; University of Alabama Birmingham; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODE N, 1992, J BIOL CHEM, V267, P16878; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KRAFT AS, 1989, CANCER RES, V49, P1287; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LALLEMAIN G, 1991, MOL CELL BIOL, V11, P1002, DOI 10.1128/MCB.11.2.1002; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Woodgett J R, 1990, Semin Cancer Biol, V1, P389	45	78	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					407	415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426747				2022-12-17	WOS:A1993KN00600020
J	WHETSELL, L; MAW, G; NADON, N; RINGER, DP; SCHAEFER, FV				WHETSELL, L; MAW, G; NADON, N; RINGER, DP; SCHAEFER, FV			POLYMERASE CHAIN-REACTION MICROANALYSIS OF TUMORS FROM STAINED HISTOLOGICAL SLIDES	ONCOGENE			English	Article							ENZYMATIC AMPLIFICATION; TISSUE-SECTIONS; DNA; HEPATOCARCINOGENESIS; GENE		CHILDRENS MED CTR,HA CHAPMAN RES INST MED GENET,5300 E SKELLY DR,TULSA,OK 74135; SAMUAL ROBERTS NOBLE FDN INC,DIV BIOMED,ARDMORE,OK 73402; UNIV TULSA,DEPT BIOL,TULSA,OK 74104; HILLCREST MED CTR,TULSA,OK 74104	Noble Research Institute; University of Tulsa								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Dukes CE, 1940, J PATHOL BACTERIOL, V50, P527, DOI 10.1002/path.1700500314; FOULDS L, 1954, CANCER RES, V14, P327; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Greer C E, 1991, PCR Methods Appl, V1, P46; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Luna LG, 1968, MANUAL HISTOLOGIC ST; ONADIM Z, 1991, J MED GENET, V28, P312, DOI 10.1136/jmg.28.5.312; RINGER DP, 1990, CANCER RES, V50, P5301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIBATA D, 1988, CANCER RES, V48, P4564; TEEBOR GW, 1971, CANCER RES, V31, P1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	16	78	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2355	2361						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1279500				2022-12-17	WOS:A1992JW66500032
J	METZ, R; ZIFF, E				METZ, R; ZIFF, E			THE HELIX LOOP HELIX PROTEIN-RE12 AND THE C/EBP-RELATED FACTOR-RNFIL-6 BIND TO NEIGHBORING SITES WITHIN THE C-FOS SERUM RESPONSE ELEMENT	ONCOGENE			English	Article							CARDIAC ACTIN GENE; MULTIPLE SEQUENCE ELEMENTS; EPIDERMAL GROWTH-FACTOR; DYAD SYMMETRY ELEMENT; PROTO-ONCOGENE FOS; CYCLIC-AMP; TRANSCRIPTION FACTOR; 3T3 CELLS; 12-O-TETRADECANOYL PHORBOL-13-ACETATE; MOLECULAR-CLONING	We show that members of two major families of transcription factors, the helix-loop-helix and C/EBP families, interact with the c-fos serum response element (SRE). Two cDNA clones encoding SRE binding factors (clones 9 and 21) were isolated by the direct screening of a PC12 lambda-gt11 cDNA library using SRE oligonucleotide sequences as probes. Clone 9 encodes the rat homolog of the human HLH transcription factor, E12 (called here rE12). Clone 21 encodes a b-zip domain polypeptide that is related to the liver transcription factor C/EBP, and is homologous to the human NFIL-6 transcription factor (called here rNFIL-6). Using in vitro-translated products we show that rNFIL-6 recognizes a 'CCAATT' motif which overlaps the c-fos dyad symmetry element (DSE), the binding site for serum regulatory factor (SRF). Factor rE12 binds to an E-box enhancer sequence, 'CATCTG', immediately adjacent to the rNFIL-6 site, within the SRE. Antibodies specific to rE12 and rNFIL-6 disrupt nucleoprotein complexes with these DNA-binding sites, confirming the interaction of native in vivo factors. We present evidence that rNFIL-6 and SRF binding are mutually exclusive, consistent with the overlap of their binding sites. The demonstration that rE12 and rNFIL-6 bind to the SRE at sites adjacent to the major c-fos regulatory element, the DSE, raises the possibility that helix-loop-helix and C/EBP families regulate the SRE and provide a new basis for the multifunctional properties of the SRE, including possible tissue specificity of expression.	NYU MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,550 1ST AVE,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	Howard Hughes Medical Institute; New York University; New York University				Ziff, Edward/0000-0001-7389-8649	NCI NIH HHS [5T32CA09161, CA44042] Funding Source: Medline; NIMH NIH HHS [2P50MH35976] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009161, R01CA044042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH035976] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CURRAN T, 1988, ONCOGENE HDB, P305; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; METZ R, 1988, COLD SPRING HARB SYM, V53, P727, DOI 10.1101/SQB.1988.053.01.083; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; POLL V, 1990, CELL, V63, P643; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SOBCZAK J, 1989, ONCOGENE, V4, P1503; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	77	78	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2165	2178						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766666				2022-12-17	WOS:A1991GX73500001
J	VERSNEL, MA; CLAESSONWELSH, L; HAMMACHER, A; BOUTS, MJ; VANDERKWAST, TH; ERIKSSON, A; WILLEMSEN, R; WEIMA, SM; HOOGSTEDEN, HC; HAGEMEIJER, A; HELDIN, CH				VERSNEL, MA; CLAESSONWELSH, L; HAMMACHER, A; BOUTS, MJ; VANDERKWAST, TH; ERIKSSON, A; WILLEMSEN, R; WEIMA, SM; HOOGSTEDEN, HC; HAGEMEIJER, A; HELDIN, CH			HUMAN-MALIGNANT MESOTHELIOMA CELL-LINES EXPRESS PDGF BETA-RECEPTORS WHEREAS CULTURED NORMAL MESOTHELIAL CELLS EXPRESS PREDOMINANTLY PDGF ALPHA-RECEPTORS	ONCOGENE			English	Article							GROWTH-FACTOR PDGF; SIMIAN SARCOMA-VIRUS; B-CHAIN; CDNA CLONING; A-CHAIN; GENES; IDENTIFICATION; SIS; DIMERIZATION; COEXPRESSION	In human malignant mesothelioma cell lines elevated expression of the platelet-derived growth factor (PDGF) beta-chain (c-sis) gene was previously reported, while normal mesothelial cells barely express this gene. Expression of the PDGF A-chain gene was only slightly elevated in these cell lines compared with normal mesothelial cells. For a putative autocrine function of the produced PDGF, in these cells expression of PDGF receptors is a prerequisite. In this paper we report on the expression of PDGF alpha- and beta-receptors in normal and malignant mesothelial cells. Cultured normal mesothelial cells expressed PDGF alpha-receptor mRNA and protein and had weak to undetectable levels of the PDGF beta-receptor mRNA and protein. In contrast, malignant mesothelioma cell lines were found to express PDGF beta-receptor mRNA and protein, while PDGF alpha-receptor expression was not detectable by Northern blotting and immunoprecipitation. Binding experiments with [I-125]-PDGF-AA and [I-125]PDGF-BB to normal and malignant mesothelial cell lines confirmed these observations. These results suggest that autocrine stimulation of growth may occur both in cultured normal mesothelial cells (PDGF-AA acting via the alpha-receptor) and in malignant mesothelioma cell lines (PDGF-BB acting via the beta-receptor).	ERASMUS UNIV,DEPT PATHOL,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT PULM MED,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS; ACAD HOSP ROTTERDAM DIJKZIGT,ROTTERDAM,NETHERLANDS; LUDWIG INST CANC RES,UPPSALA,SWEDEN; HUBRECHT LAB,UTRECHT,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Ludwig Institute for Cancer Research; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	VERSNEL, MA (corresponding author), ERASMUS UNIV,DEPT IMMUNOL,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.			Van der Kwast, Theodorus/0000-0001-8640-5786				BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLOBEL G, 1975, J CELL BIOL, V67, P837; CLAESSONWELSH L, 1987, P NATL ACAD SCI USA, V84, P8796, DOI 10.1073/pnas.84.24.8796; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GERWIN BI, 1987, CANCER RES, V47, P6180; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STENMAN G, 1989, GENE CHROMOSOME CANC, V1, P155, DOI 10.1002/gcc.2870010208; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; TERRACIO L, 1988, J CELL BIOL, V107, P1947, DOI 10.1083/jcb.107.5.1947; VANDENOUWELAND AMW, 1985, BIOCHIM BIOPHYS ACTA, V825, P140, DOI 10.1016/0167-4781(85)90097-1; VERSNEL MA, 1989, INT J CANCER, V44, P256, DOI 10.1002/ijc.2910440212; VERSNEL MA, 1988, ONCOGENE, V2, P601; WAGNER J C, 1960, Br J Ind Med, V17, P260; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WILLEMSEN R, 1988, ULTRASTRUCT PATHOL, V12, P471, DOI 10.3109/01913128809032232; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	78	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2005	2011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658707				2022-12-17	WOS:A1991GX11900010
J	MOLL, J; SANSIG, G; FATTORI, E; VANDERPUTTEN, H				MOLL, J; SANSIG, G; FATTORI, E; VANDERPUTTEN, H			THE MURINE RAC1 GENE - CDNA CLONING, TISSUE DISTRIBUTION AND REGULATED EXPRESSION OF RAC1 MESSENGER-RNA BY DISASSEMBLY OF ACTIN MICROFILAMENTS	ONCOGENE			English	Note							5' NONCODING REGION; RNA SECONDARY STRUCTURE; MESSENGER-RNA; TRANSLATIONAL EFFICIENCY; EUKARYOTIC RIBOSOMES; CPG ISLANDS; RAS; PROTEIN; FAMILY; SECRETION	A 886 bp cDNA encoding the murine rac1 protein has been isolated. The abundance of rac1 mRNA was determined in fourteen tissues from both mouse and pig. The mRNA 5' non-coding sequence is very rich in G + C, and has the potential to form several stable secondary structures. In addition, this region contains a putative open reading frame of 57 amino acids. Disruption of the actin microfilament network by cytochalasin B in LLC-PK1 cells results in down regulation of rac1 mRNA. In agreement with the proposed role of rac1 in exocytosis, these results could explain the inhibitory effect of cytochalasin B on secretory processes.	CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K 681447,CH-4002 BASEL,SWITZERLAND	Novartis	VANDERPUTTEN, H (corresponding author), CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K 681447,CH-4002 BASEL,SWITZERLAND.							AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BOTTERI FM, 1990, SERINE PROTEASES THE, P105; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; COCKROFT S, 1987, J CELL BIOL, V5105, P2745; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P814; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDSTEIN AL, 1977, P NATL ACAD SCI USA, V74, P725, DOI 10.1073/pnas.74.2.725; KITIYAMA H, 1989, CELL, V56, P77; KNIGHT DE, 1985, NATURE, V317, P719, DOI 10.1038/317719a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PELLETIER J, 1988, J VIROL, V62, P2219, DOI 10.1128/JVI.62.7.2219-2227.1988; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SIMPSON LL, 1981, PHARMACOL REV, V33, P158; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	51	78	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					863	866						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1905006				2022-12-17	WOS:A1991GT82500024
J	COPPOLA, JA; LEWIS, BA; COLE, MD				COPPOLA, JA; LEWIS, BA; COLE, MD			INCREASED RETINOBLASTOMA GENE-EXPRESSION IS ASSOCIATED WITH LATE STAGES OF DIFFERENTIATION IN MANY DIFFERENT CELL-TYPES	ONCOGENE			English	Note									PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	Princeton University								ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BUKOVICH K, 1989, CELL, V58, P1097; CARAVATTI M, 1982, J MOL BIOL, V160, P59, DOI 10.1016/0022-2836(82)90131-0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECAPRIO, 1989, CELL, V54, P275; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; KYRITSIS AP, 1984, NATURE, V307, P471, DOI 10.1038/307471a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TERADA M, 1977, P NATL ACAD SCI USA, V74, P248, DOI 10.1073/pnas.74.1.248	25	78	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1731	1733						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267138				2022-12-17	WOS:A1990EL40100018
J	HORAK, ID; CORCORAN, ML; THOMPSON, PA; WAHL, LM; BOLEN, JB				HORAK, ID; CORCORAN, ML; THOMPSON, PA; WAHL, LM; BOLEN, JB			EXPRESSION OF P60FYN IN HUMAN PLATELETS	ONCOGENE			English	Article									NCI,MED BRANCH,BETHESDA,MD 20892; NCI,USN,BETHESDA,MD 20892; NIDR,IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	HORAK, ID (corresponding author), NCI,TUMOR VIRUS BIOL LAB,BLDG 41,ROOM D-907,900 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; BOLEN JB, 1983, J BIOL CHEM, V258, P11686; COOPER JA, 1989, IN PRESS PEPTIDES PR; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; Huang E. M., 1986, BIOCH PLATELETS, P1; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; OSHAUGHNESSY J, 1987, ONCOGENE RES, V2, P1; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, ONCOGENES, P121	20	78	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					597	602						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183161				2022-12-17	WOS:A1990DB85300021
J	LISCIA, DS; MERLO, GR; GARRETT, C; FRENCH, D; MARIANICOSTANTINI, R; CALLAHAN, R				LISCIA, DS; MERLO, GR; GARRETT, C; FRENCH, D; MARIANICOSTANTINI, R; CALLAHAN, R			EXPRESSION OF INT-2 MESSENGER-RNA IN HUMAN-TUMORS AMPLIFIED AT THE INT-2 LOCUS	ONCOGENE			English	Article									NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892; GEORGE WASHINGTON UNIV,MED CTR,DEPT PATHOL,WASHINGTON,DC 20037; GD ANNUNZIO UNIV,CHIETI,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University; G d'Annunzio University of Chieti-Pescara			Mariani-Costantini, Renato/B-6637-2012	Mariani-Costantini, Renato/0000-0002-4440-1848				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1989, ONCOGENE, V4, P89; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FOLKMAN J, 1986, CANCER RES, V46, P467; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; HALABAN R, 1988, ONCOGENE RES, V3, P177; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; Maniatis T., 1982, MOL CLONING; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RAMM P, 1985, MICROCOMPUTER CELL N, P311; REDMOND SMS, 1988, ONCOGENE, V2, P259; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VARLEY JM, 1988, ONCOGENE, V3, P87; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHOU DJ, 1988, ONCOGENE, V2, P279	31	78	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1219	1224						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2677918				2022-12-17	WOS:A1989AU50800009
J	Luo, LY; Tang, HL; Ling, L; Li, N; Jia, XT; Zhang, ZJ; Wang, XR; Shi, LJ; Yin, J; Qiu, N; Liu, H; Song, Y; Luo, K; Li, HS; He, ZM; Zheng, GP; Xie, XM				Luo, Liyun; Tang, Hailin; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei; Xie, Xiaoming			LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer	ONCOGENE			English	Article							LONG NONCODING RNAS; PROMOTES; METASTASIS; CHEMORESISTANCE; METADHERIN; PROTEIN	Breast cancer is a heterogeneous disease, and triple-negative breast cancer (TNBC) continues to be a serious health problem. The potential involvement of lncRNAs in TNBC progression remains unexplored. Here, we demonstrated that LINC01638 is highly expressed in TNBC tissues and cells. LINC01638 maintains the mesenchymal traits of TNBC cells, including an enriched epithelial-mesenchymal transition (EMT) signature and cancer stem cell-like state. LINC01638 knockdown suppresses tumor proliferation and metastasis both in vitro and in vivo. LINC01638 overexpression predicts a poor outcome of breast cancer patients. Mechanistically, LINC01638 interacts with c-Myc to prevent SPOP-mediated c-Myc ubiquitination and degradation. C-Myc transcriptionally enhances MTDH (metadherin) expression and subsequently activates Twist1 expression to induce EMT. Our findings describe LINC01638-mediated signal transduction and highlight the crucial role of LINC01638 in TNBC progression.	[Luo, Liyun; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China; [Luo, Liyun; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei] Guangzhou Key Lab Translat Med Malignant Tumor Tr, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China; [Luo, Liyun; Ling, Li; Li, Nan; Jia, Xiaoting; Zhang, Zhijie; Wang, Xiaorong; Shi, Lejuan; Yin, Jiang; Qiu, Ni; Liu, Hao; Song, Ying; Luo, Kai; Li, Hongsheng; He, Zhimin; Zheng, Guopei] Guangzhou Med Univ, Prot Modificat & Degradat Lab, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China; [Tang, Hailin; Xie, Xiaoming] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol,Canc Ctr, Dongfeng Rd 651 E, Guangzhou 510060, Guangdong, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; State Key Lab Oncology South China; Sun Yat Sen University	Zheng, GP (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China.; Zheng, GP (corresponding author), Guangzhou Key Lab Translat Med Malignant Tumor Tr, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China.; Zheng, GP (corresponding author), Guangzhou Med Univ, Prot Modificat & Degradat Lab, Hengzhigang Rd 78, Guangzhou 510095, Guangdong, Peoples R China.; Xie, XM (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol,Canc Ctr, Dongfeng Rd 651 E, Guangzhou 510060, Guangdong, Peoples R China.	zhengguopei@126.com; xiexm@sysucc.org.cn	wang, xiao/HGB-7081-2022	wang, xiao/0000-0002-4088-3341	National Natural Science Foundation of China [81672616, 81402196, 81772961, 81401989, 81772825]; Guangdong Natural Science Funds for Distinguished Young Scholars [2016A030306003]; Guangdong Natural Science Funds [2017A030313867]; Science and Technology Program of Guangzhou [201710010100]; Guangzhou Municipal University Scientific Research project [1201610027]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds for Distinguished Young Scholars; Guangdong Natural Science Funds; Science and Technology Program of Guangzhou; Guangzhou Municipal University Scientific Research project	This study was supported by grants from the National Natural Science Foundation of China: No. 81672616 (GZ), No. 81402196 (GZ), No. 81772961 (HT), No. 81401989 (NL) and No. 81772825 (HL); supported by grants from Guangdong Natural Science Funds for Distinguished Young Scholars: No. 2016A030306003 (GZ) and Guangdong Natural Science Funds: No. 2017A030313867 (GZ); supported by grants from Science and Technology Program of Guangzhou: No. 201710010100 (GZ) and Guangzhou Municipal University Scientific Research project: 1201610027 (GZ).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; Blanco MA, 2011, J BIOL CHEM, V286, P19982, DOI 10.1074/jbc.M111.240077; Booy EP, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0679-7; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Cho MH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8821; Emdad L, 2013, ADV CANCER RES, V120, P75, DOI 10.1016/B978-0-12-401676-7.00003-6; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Geng C, 2017, ONCOGENE, V36, P4767, DOI 10.1038/onc.2017.80; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Jiang ZY, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0853-2; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Liu LP, 2010, CANCER RES, V70, P3750, DOI 10.1158/0008-5472.CAN-09-3838; Luo M, 2015, CELL STEM CELL, V16, P426, DOI 10.1016/j.stem.2015.02.002; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Sarkar D, 2013, ADV CANCER RES, V120, P39, DOI 10.1016/B978-0-12-401676-7.00002-4; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wan LL, 2014, CANCER CELL, V26, P92, DOI 10.1016/j.ccr.2014.04.027; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Yin J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073268; Yoo BK, 2010, CANCER RES, V70, P3249, DOI 10.1158/0008-5472.CAN-09-4009; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zheng GP, 2018, CLIN CANCER RES, V24, P1163, DOI 10.1158/1078-0432.CCR-17-2619	37	77	81	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6166	6179		10.1038/s41388-018-0396-8	http://dx.doi.org/10.1038/s41388-018-0396-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	30002443				2022-12-17	WOS:000450883000005
J	Dong, PX; Xiong, Y; Yu, JH; Chen, L; Tao, T; Yi, S; Hanley, SJB; Yue, JM; Watari, H; Sakuragi, N				Dong, Peixin; Xiong, Ying; Yu, Jiehai; Chen, Lin; Tao, Tang; Yi, Song; Hanley, Sharon J. B.; Yue, Junming; Watari, Hidemichi; Sakuragi, Noriaki			Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer	ONCOGENE			English	Article							CELL-PROLIFERATION; MESENCHYMAL TRANSITION; BETA-CATENIN; IFN-GAMMA; INVASION; B7-H1; PROGRESSION; METASTASIS; REVERSES; TARGET	PD-L1, a key inhibitory immune receptor, has crucial functions in cancer immune evasion, but whether PD-L1 promotes the malignant properties of cervical cancer (CC) cells and the mechanism by which PD-L1 is regulated in CC remains unclear. We report that PD-L1 is overexpressed in CC, and shRNA-mediated PD-L1 depletion suppresses the proliferation, invasion, and tumorigenesis of CC cells. Loss of miR-140/142/340/383 contributes to PD-L1 upregulation. miR-18a enhances PD-L1 levels by targeting PTEN, WNK2 (ERK1/2 pathway inhibitor), and SOX6 (Wnt/beta-catenin pathway inhibitor and p53 pathway activator) to activate the PI3K/AKT, MEK/ERK, and Wnt/beta-catenin pathways and inhibit the p53 pathway, and miR-18a also directly suppresses the expression of the tumor suppressors BTG3 and RBSP3 (CTDSPL). miR-18a overexpression in CC cells is triggered by OCT4 overexpression. Our data implicate PD-L1 as a novel oncoprotein and indicate that miR-140/142/340/383 and miR-18a are key upstream regulators of PD-L1 and potential targets for CC treatment.	[Dong, Peixin; Hanley, Sharon J. B.; Sakuragi, Noriaki] Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido 0608638, Japan; [Dong, Peixin; Watari, Hidemichi] Hokkaido Univ, Dept Obstet & Gynecol, Sch Med, Sapporo, Hokkaido 0608638, Japan; [Xiong, Ying; Yu, Jiehai; Chen, Lin] Sun Yat Sen Univ, Dept Gynecol, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Tao, Tang; Yi, Song] Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; [Yue, Junming] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; [Yue, Junming] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Memphis, TN 38163 USA	Hokkaido University; Hokkaido University; State Key Lab Oncology South China; Sun Yat Sen University; Chinese University of Hong Kong; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Dong, PX (corresponding author), Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido 0608638, Japan.; Dong, PX; Watari, H (corresponding author), Hokkaido Univ, Dept Obstet & Gynecol, Sch Med, Sapporo, Hokkaido 0608638, Japan.; Yue, JM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA.; Yue, JM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Memphis, TN 38163 USA.	dpx1cn@gmail.com; jyue@uthsc.edu; watarih@med.hokudai.ac.jp	Dong, Peixin/M-5592-2015	Dong, Peixin/0000-0002-2335-1394	Department of Women's Health Educational System; JSPS [15K10697, 16K11123]; Science and Technology Planning Project of Guangdong Province, China [2014A020212124]	Department of Women's Health Educational System; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Science and Technology Planning Project of Guangdong Province, China	This research was supported by a grant from the Department of Women's Health Educational System, JSPS Grant-in-Aid for Scientific Research (C) (15K10697 and 16K11123) and the Science and Technology Planning Project of Guangdong Province, China (2014A020212124). We thank Dr. Zhujie Xu for experimental assistance.	Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101; Anand M, 2011, HAEMATOL-HEMATOL J, V96, P253, DOI 10.3324/haematol.2010.027086; Cai YH, 2014, CELL SIGNAL, V26, P1204, DOI 10.1016/j.cellsig.2014.02.013; Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615; Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011; Chen LJ, 2017, CELL PHYSIOL BIOCHEM, V42, P2267, DOI 10.1159/000480000; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Deng JH, 2017, MOL MED REP, V15, P1654, DOI 10.3892/mmr.2017.6180; Dong PX, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0415-y; Dong PX, 2016, ONCOTARGET, V7, P20260, DOI 10.18632/oncotarget.7754; Fang F, 2014, INT J CLIN EXP PATHO, V7, P6447; Fujita Y, 2015, MOL THER, V23, P717, DOI 10.1038/mt.2015.10; Gong AY, 2009, J IMMUNOL, V182, P1325, DOI 10.4049/jimmunol.182.3.1325; Guo W, 2015, TUMOR BIOL, V36, P9049, DOI 10.1007/s13277-015-3644-3; He J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10019; Heong V, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e20; Huo WY, 2017, J CANCER, V8, P57, DOI 10.7150/jca.16723; Ihira K, 2017, ONCOTARGET, V8, P13509, DOI 10.18632/oncotarget.14586; Jiang DQ, 2017, ONCOTARGET, V8, P4001, DOI 10.18632/oncotarget.13136; Konno Y, 2014, ONCOTARGET, V5, P6049, DOI 10.18632/oncotarget.2157; Kramer HB, 2016, NUCLEIC ACIDS RES, V44, P582, DOI 10.1093/nar/gkv948; Li CL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12574; Li J, 2017, CELL PHYSIOL BIOCHEM, V41, P907, DOI [10.1159/00460504, 10.1159/000460504]; Liang XJ, 2014, J LEUKOCYTE BIOL, V95, P179, DOI 10.1189/jlb.0613330; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mezache L, 2015, MODERN PATHOL, V28, P1594, DOI 10.1038/modpathol.2015.108; Mitra S, 2010, GENE CHROMOSOME CANC, V49, P155, DOI 10.1002/gcc.20726; Moniz S, 2007, ONCOGENE, V26, P6071, DOI 10.1038/sj.onc.1210706; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Noh KH, 2009, MOL THER, V17, P439, DOI 10.1038/mt.2008.255; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Ribeiro J, 2014, MOL BIOL REP, V41, P1525, DOI 10.1007/s11033-013-2998-0; Ryan BC, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1057-y; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Song X, 2014, ONCOL REP, V31, P1191, DOI 10.3892/or.2013.2955; Su S, 2016, SCI REP-UK, V6, DOI 10.1038/srep20070; Su YL, 2016, ONCOTARGET, V7, P68397, DOI 10.18632/oncotarget.11722; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Wang J, 2016, ONCOGENE, V35, P1692, DOI 10.1038/onc.2015.234; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Wang YH, 2015, MATH PROBL ENG, V2015, DOI 10.1155/2015/687535; Wilting SM, 2013, ONCOGENE, V32, P106, DOI 10.1038/onc.2012.20; Xiong Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0520-6; Xu SH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11406; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; Zheng Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.211	49	77	81	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5257	5268		10.1038/s41388-018-0347-4	http://dx.doi.org/10.1038/s41388-018-0347-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29855617	Green Published, hybrid			2022-12-17	WOS:000445759700001
J	Boussiotis, VA; Charest, A				Boussiotis, Vassiliki A.; Charest, Alain			Immunotherapies for malignant glioma	ONCOGENE			English	Review							CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; CANCER STEM-CELLS; NEWLY-DIAGNOSED GLIOBLASTOMA; CHIMERIC ANTIGEN RECEPTOR; BLOOD-BRAIN-BARRIER; TUMOR-ASSOCIATED MACROPHAGES; IMMUNE CHECKPOINT BLOCKADE; GROWTH-FACTOR RECEPTOR; MICROGLIAL CELLS	Glioblastoma multiforme (GBM) is a highly malignant primary brain cancer with a dreadful overall survival and for which treatment options are limited. Recent breakthroughs in novel immune-related treatment strategies for cancer have spurred interests in usurping the power of the patient's immune system to recognize and eliminate GBM. Here, we discuss the unique properties of GBM's tumor microenvironment, the effects of GBM standard on care therapy on tumor-associated immune cells, and review several approaches aimed at therapeutically targeting the immune system for GBM treatment. We believe that a comprehensive understanding of the intricate micro-environmental landscape of GBM will abound into the development of novel immunotherapy strategies for GBM patients.	[Boussiotis, Vassiliki A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA; [Boussiotis, Vassiliki A.; Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA; [Boussiotis, Vassiliki A.; Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA; [Charest, Alain] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Genet, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA.; Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Canc Ctr, Boston, MA 02115 USA.; Charest, A (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Genet, Boston, MA 02115 USA.	acharest@bidmc.harvard.edu; vboussio@bidmc.harvard.edu			NIH/NCI [CA183605, CA183605S1, CA212605, CA185137, CA179563, CA069246]; DoD [PC140571]; NATIONAL CANCER INSTITUTE [R01CA212605, P01CA069246, R01CA183605, R01CA185137, U19CA179563] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI grants CA183605, CA183605S1, and CA212605 and the DoD grant PC140571 (to V.A.B.) and NIH/NCI grants CA185137, CA179563, and CA069246 (to A.C.)	Acquaviva J, 2011, CANCER RES, V71, P7198, DOI 10.1158/0008-5472.CAN-11-1514; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Alexiou GA, 2013, ACTA NEUROL BELG, V113, P7, DOI 10.1007/s13760-012-0097-y; Alizadeh D, 2010, CLIN CANCER RES, V16, P3399, DOI 10.1158/1078-0432.CCR-09-3087; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Ardon H, 2010, J NEURO-ONCOL, V99, P261, DOI 10.1007/s11060-010-0131-y; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Badie B, 2000, NEUROSURGERY, V46, P957, DOI 10.1097/00006123-200004000-00035; Banissi C, 2009, CANCER IMMUNOL IMMUN, V58, P1627, DOI 10.1007/s00262-009-0671-1; Bardella C, 2016, CANCER CELL, V30, P578, DOI 10.1016/j.ccell.2016.08.017; Bauer M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039956; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Belcaid Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101764; Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Brown CE, 2009, CANCER RES, V69, P8886, DOI 10.1158/0008-5472.CAN-09-2687; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Campanella M, 2014, PEERJ, V2, DOI 10.7717/peerj.497; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; da Fonseca ACC, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/264124; Castriconi R, 2009, J IMMUNOL, V182, P3530, DOI 10.4049/jimmunol.0802845; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Charles N, 2010, CELL CYCLE, V9, P3012, DOI 10.4161/cc.9.15.12710; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen WL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0487-0; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Curtin JF, 2009, PLOS MED, V6, P83, DOI 10.1371/journal.pmed.1000010; Danaila L., 1993, Romanian Journal of Neurology and Psychiatry, V31, P195; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Di Tomaso T, 2010, CLIN CANCER RES, V16, P800, DOI 10.1158/1078-0432.CCR-09-2730; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Ellsworth S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27357; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Fadul CE, 2011, J IMMUNOTHER, V34, P382, DOI 10.1097/CJI.0b013e318215e300; Fadul CE, 2011, NEURO-ONCOLOGY, V13, P393, DOI 10.1093/neuonc/noq204; Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773; Fleurence J, 2016, ONCOTARGET, V7, P41172, DOI 10.18632/oncotarget.9226; FORD AL, 1995, J IMMUNOL, V154, P4309; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Gabrusiewicz K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023902; Galarneau H, 2007, CANCER RES, V67, P8874, DOI 10.1158/0008-5472.CAN-07-0177; Geranmayeh F, 2007, NEUROSURGERY, V60, P159, DOI 10.1227/01.NEU.0000249192.30786.67; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Gielen PR, 2015, J NEUROPATH EXP NEUR, V74, P390, DOI 10.1097/NEN.0000000000000183; Gieryng A, 2017, LAB INVEST, V97, P498, DOI 10.1038/labinvest.2017.19; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hambardzumyan D, 2011, GLIA, V59, P1155, DOI 10.1002/glia.21142; HART DNJ, 1981, J EXP MED, V154, P347, DOI 10.1084/jem.154.2.347; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Heimberger AB, 2008, CLIN CANCER RES, V14, P5166, DOI 10.1158/1078-0432.CCR-08-0320; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hodges TR, 2017, NEURO-ONCOLOGY, V19, P1047, DOI 10.1093/neuonc/nox026; Hou Y, 2016, BLOOD, V127, P1587, DOI 10.1182/blood-2015-10-674531; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Huang JY, 2010, J IMMUNOL, V185, P1450, DOI 10.4049/jimmunol.0901352; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Hussain SF, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-15; Jacobs JFM, 2010, J NEUROIMMUNOL, V225, P195, DOI 10.1016/j.jneuroim.2010.05.020; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Jhaveri N, 2016, CANCER LETT, V380, P545, DOI 10.1016/j.canlet.2014.12.028; Johanns TM, 2016, CANCER DISCOV, V6, P1230, DOI 10.1158/2159-8290.CD-16-0575; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Jun HJ, 2012, ONCOGENE, V31, P3039, DOI 10.1038/onc.2011.474; Kabba JA, 2017, CELL MOL NEUROBIOL, V22; Kakarla S, 2014, CANCER J, V20, P151, DOI 10.1097/PPO.0000000000000032; Kaminska B, 2016, BBA-MOL BASIS DIS, V1862, P339, DOI 10.1016/j.bbadis.2015.10.026; Kamphorst AO, 2013, CURR OPIN IMMUNOL, V25, P381, DOI 10.1016/j.coi.2013.03.003; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kim JE, 2017, CLIN CANCER RES, V23, P124, DOI 10.1158/1078-0432.CCR-15-1535; Kim TG, 2010, CLIN VACCINE IMMUNOL, V17, P143, DOI 10.1128/CVI.00292-09; Kmiecik J, 2013, J NEUROIMMUNOL, V264, P71, DOI 10.1016/j.jneuroim.2013.08.013; Kochenderfer JN, 2015, J CLIN ONCOL, V33, P540, DOI 10.1200/JCO.2014.56.2025; LAFFERTY KJ, 1978, BLOOD CELLS, V4, P395; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; LeBlanc AK, 2016, NEURO-ONCOLOGY, V18, P1209, DOI 10.1093/neuonc/now051; Leung W, 2014, CLIN CANCER RES, V20, P3390, DOI 10.1158/1078-0432.CCR-13-1766; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803; Ling Y, 2007, EUR J HAEMATOL, V79, P310, DOI 10.1111/j.1600-0609.2007.00917.x; Litterman AJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26294; Llaguno SRA, 2015, CANCER CELL, V28, P429, DOI 10.1016/j.ccell.2015.09.007; Lohr J, 2011, CLIN CANCER RES, V17, P4296, DOI 10.1158/1078-0432.CCR-10-2557; Louis DN, 2016, HO CLASSIFICATION TU, V1; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; LOWE J, 1989, J PATHOL, V159, P143, DOI 10.1002/path.1711590209; Maes W, 2011, CANCER IMMUNOL IMMUN, V60, P153, DOI 10.1007/s00262-010-0946-6; Marko AJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015425; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mathios D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag2942; Matyash V, 2010, BRAIN RES REV, V63, P2, DOI 10.1016/j.brainresrev.2009.12.001; Maxwell R, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0754-x; Mendez JS, 2016, J NEURO-ONCOL, V127, P329, DOI 10.1007/s11060-015-2037-1; Mieczkowski J, 2015, ONCOTARGET, V6, P33077, DOI 10.18632/oncotarget.5310; Mineo JF, 2004, BRIT J CANCER, V91, P1195, DOI 10.1038/sj.bjc.6602089; Molofsky AV, 2015, GLIA, V63, P1320, DOI 10.1002/glia.22836; MORRIS CS, 1991, J NEUROL SCI, V101, P47, DOI 10.1016/0022-510X(91)90017-2; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Nagai T, 2009, CANCER IMMUNOL IMMUN, V58, P1577, DOI 10.1007/s00262-009-0667-x; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Oh T, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-107; Olson JJ, 2014, J NEURO-ONCOL, V118, P557, DOI 10.1007/s11060-013-1339-4; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Paff M, 2014, HUM VACC IMMUNOTHER, V10, P3322, DOI 10.4161/21645515.2014.983002; Pallud J, 2015, NEURO-ONCOLOGY, V17, P1609, DOI 10.1093/neuonc/nov126; Parada LF, 2005, COLD SH Q B, V70, P173, DOI 10.1101/sqb.2005.70.025; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Patsoukis N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00330; Perdiguero EG, 2015, NATURE, V518, P547, DOI 10.1038/nature13989; Perng P, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00153; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pitter KL, 2016, BRAIN, V139, P1458, DOI 10.1093/brain/aww046; Placone AL, 2016, TUMOR BIOL, V37, P61, DOI 10.1007/s13277-015-4242-0; Poli A, 2013, ONCOTARGET, V4, P1527, DOI 10.18632/oncotarget.1291; Prados MD, 2015, NEURO-ONCOLOGY, V17, P1051, DOI 10.1093/neuonc/nov031; Priceman SJ, 2015, CURR OPIN ONCOL, V27, P466, DOI 10.1097/CCO.0000000000000232; Prins RM, 2011, CLIN CANCER RES, V17, P1603, DOI 10.1158/1078-0432.CCR-10-2563; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reardon DA, 2017, SEMIN IMMUNOPATHOL, V39, P225, DOI 10.1007/s00281-016-0616-7; Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151; Ribas A, 2016, CANCER IMMUNOL RES, V4, P194, DOI 10.1158/2326-6066.CIR-15-0210; Ridolfi L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-135; Roth P, 2015, NEURO-ONCOL PRACT, V2, P6, DOI 10.1093/nop/npu029; Ruoslahti E, 1996, GLYCOBIOLOGY, V6, P489, DOI 10.1093/glycob/6.5.489; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; Sampson JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031046; Sampson JH, 2011, NEURO-ONCOLOGY, V13, P324, DOI 10.1093/neuonc/noq157; Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Schultze SM, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/S1462399411002109; SEDGWICK JD, 1993, J EXP MED, V177, P1145, DOI 10.1084/jem.177.4.1145; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; SIMS DE, 1986, TISSUE CELL, V18, P153, DOI 10.1016/0040-8166(86)90026-1; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Szatmari T, 2006, CANCER SCI, V97, P546, DOI 10.1111/j.1349-7006.2006.00208.x; Szulzewsky F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116644; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732, DOI 10.1002/jlb.56.6.732; Varga G, 2008, J LEUKOCYTE BIOL, V84, P644, DOI 10.1189/jlb.1107768; Vauleon E, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-41; Vecht CJ, 2014, ONCOLOGIST, V19, P751, DOI 10.1634/theoncologist.2014-0060; Venkatesh HS, 2015, CELL, V161, P803, DOI 10.1016/j.cell.2015.04.012; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284; Wainwright DA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00116; Wainwright DA, 2011, NEURO-ONCOLOGY, V13, P1308, DOI 10.1093/neuonc/nor134; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Ward-Kavanagh LK, 2016, IMMUNITY, V44, P1005, DOI 10.1016/j.immuni.2016.04.019; Wei J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017868; Wei J, 2010, MOL CANCER THER, V9, P67, DOI 10.1158/1535-7163.MCT-09-0734; Weiss T, 2016, EXPERT REV ANTICANC, V16, P1087, DOI 10.1080/14737140.2016.1229600; Wheeler CJ, 2004, CLIN CANCER RES, V10, P5316, DOI 10.1158/1078-0432.CCR-04-0497; Wiendl H, 2002, J IMMUNOL, V168, P4772, DOI 10.4049/jimmunol.168.9.4772; Wierzba-Bobrowicz T, 1994, Folia Neuropathol, V32, P251; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wintterle S, 2003, CANCER RES, V63, P7462; Wong ET, 2015, BRIT J CANCER, V113, P232, DOI 10.1038/bjc.2015.238; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xia M, 1999, CELL MOL LIFE SCI, V55, P1649, DOI 10.1007/s000180050403; Xing KL, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0103-2; Yan D, 2017, ONCOGENE, V36, P6049, DOI 10.1038/onc.2017.261; Yeo AT, 2017, J CELL BIOCHEM, V118, P2516, DOI 10.1002/jcb.25948; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025; Zhai HY, 2011, GLIA, V59, P472, DOI 10.1002/glia.21117; Zhang CF, 2016, J SENSORS, V2016, DOI 10.1155/2016/9307560; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106; Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004	202	77	81	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1121	1141		10.1038/s41388-017-0024-z	http://dx.doi.org/10.1038/s41388-017-0024-z			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242608	Green Submitted, Green Accepted			2022-12-17	WOS:000426505400001
J	Li, S; Liang, X; Ma, L; Shen, L; Li, T; Zheng, L; Sun, A; Shang, W; Chen, C; Zhao, W; Jia, J				Li, S.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Sun, A.; Shang, W.; Chen, C.; Zhao, W.; Jia, J.			MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis	ONCOGENE			English	Article							HELICOBACTER-PYLORI; CANCER DEVELOPMENT; SUPPRESSOR-CELLS; INFLAMMASOME; PROGRESSION; ACTIVATION; MELANOMA; RECEPTOR; DIFFERENTIATION; SUSCEPTIBILITY	Chronic inflammation is the primary cause of gastric cancer (GC). NLRP3, as an important inflammasome component, has crucial roles in initiating inflammation. However, the potential roles of NLRP3 in GC is unknown. Here, we show that NLRP3 expression is markedly upregulated in GC, which promotes NLRP3 inflammasome activation and interleukin-1 beta (IL-1 beta) secretion in macrophages. In addition, NLRP3 binds to cyclin-D1 (CCND1) promoter and promotes its transcription in gastric epithelial cells. Consequently, NLRP3 enhances epithelial cells proliferation and GC tumorigenesis. Furthermore, we identify miR-22, which is constitutively expressed in gastric mucosa, as a suppressor of NLRP3. MiR-22 directly targets NLRP3 and attenuates its oncogenic effects in vitro and in vivo. However, Helicobacter pylori (H. pylori) infection suppresses miR-22 expression, while enhances NLRP3 expression, and that triggers uncontrolled proliferation of epithelial cells and the emergence of GC. Thus, our research describes a mechanism by which miR-22 suppresses NLRP3 and maintains homeostasis of gastric microenvironments and suggests miR-22 as a potential target for the intervention of GC.	[Li, S.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Sun, A.; Shang, W.; Jia, J.] Shandong Univ, Sch Basic Med Sci, Dept Microbiol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Li, S.; Liang, X.; Ma, L.; Shen, L.; Li, T.; Zheng, L.; Sun, A.; Shang, W.; Zhao, W.; Jia, J.] Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China; [Chen, C.] Shandong Univ, Qilu Hosp, Canc Ctr, Jinan, Shandong, Peoples R China; [Zhao, W.] Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University	Jia, J (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Microbiol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Zhao, W; Jia, J (corresponding author), Shandong Univ, Sch Basic Med Sci, Key Lab Infect & Immun Shandong Prov, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Zhao, W (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Immunol, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.	wzhao@sdu.edu.cn; jiajihui@sdu.edu.cn	Li, Shuyan/AAE-5060-2020	zheng, lixin/0000-0003-0760-4176; Zhao, Wei/0000-0001-8440-2274	National Natural Science Foundation of China [81772151, 81571960, 81371781, 81670146, 81470318, 81372680, 81471991, 81501720]; Science Foundation of Shandong Province [2017GSF18194, 2017GSF18109, 2014GSF118114, ZR2014HQ070]; Independent Innovation Foundation of Shandong University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province); Independent Innovation Foundation of Shandong University	This work was supported by the National Natural Science Foundation of China (Nos. 81772151, 81571960, 81371781, 81670146, 81470318, 81372680, 81471991 and 81501720), the Science Foundation of Shandong Province (2017GSF18194, 2017GSF18109, 2014GSF118114 and ZR2014HQ070), and the Independent Innovation Foundation of Shandong University.	Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Allison CC, 2013, J IMMUNOL, V190, P3706, DOI 10.4049/jimmunol.1200591; Amieva M, 2016, GASTROENTEROLOGY, V150, P64, DOI 10.1053/j.gastro.2015.09.004; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516; Bruchard M, 2015, NAT IMMUNOL, V16, P859, DOI 10.1038/ni.3202; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Castano-Rodriguez N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00336; Castano-Rodriguez N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098899; Chochi K, 2008, CLIN CANCER RES, V14, P2909, DOI 10.1158/1078-0432.CCR-07-4467; Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Couturier-Maillard A, 2013, J CLIN INVEST, V123, P700, DOI 10.1172/JCI62236; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Dowling JK, 2012, CRIT REV BIOCHEM MOL, V47, P424, DOI 10.3109/10409238.2012.694844; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guo CS, 2016, IMMUNITY, V45, P802, DOI 10.1016/j.immuni.2016.09.008; Haneklaus M, 2012, J IMMUNOL, V189, P3795, DOI 10.4049/jimmunol.1200312; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108; Huai WW, 2016, P NATL ACAD SCI USA, V113, P11925, DOI 10.1073/pnas.1601556113; Huai WW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5738; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karki R, 2016, NATURE; Lamb A, 2013, J CELL BIOCHEM, V114, P491, DOI 10.1002/jcb.24389; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Nam KT, 2004, CLIN CANCER RES, V10, P8105, DOI 10.1158/1078-0432.CCR-04-0896; Pasqualini L, 2015, MOL ENDOCRINOL, V29, P1037, DOI 10.1210/me.2014-1358; Petrilli V, 2017, CURR OPIN ONCOL, V29, P35, DOI 10.1097/CCO.0000000000000346; Ping PH, 2016, ARCH BIOCHEM BIOPHYS, V604, P20, DOI 10.1016/j.abb.2016.06.001; Qin Y, 2015, PIGM CELL MELANOMA R, V28, P236, DOI 10.1111/pcmr.12348; Semper RP, 2014, J IMMUNOL, V193, P3566, DOI 10.4049/jimmunol.1400362; Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Tatsuta T, 2012, J CLIN PATHOL, V65, P839, DOI 10.1136/jclinpath-2011-200590; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Ungerback J, 2012, CARCINOGENESIS, V33, P2126, DOI 10.1093/carcin/bgs256; van Deventer HW, 2010, CANCER RES, V70, P10161, DOI 10.1158/0008-5472.CAN-10-1921; Verma D, 2012, PIGM CELL MELANOMA R, V25, P506, DOI 10.1111/j.1755-148X.2012.01008.x; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wan WN, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0178-8; Wang X, 2014, BIOCHEM BIOPH RES CO, V445, P175, DOI 10.1016/j.bbrc.2014.01.160; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047; Yang F, 2015, J BIOL CHEM, V290, P6507, DOI 10.1074/jbc.M114.620369; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.297	53	77	85	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					884	896		10.1038/onc.2017.381	http://dx.doi.org/10.1038/onc.2017.381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059152				2022-12-17	WOS:000425281800006
J	Zhou, C; Huang, C; Wang, J; Huang, H; Li, J; Xie, Q; Liu, Y; Zhu, J; Li, Y; Zhang, D; Zhu, Q; Huang, C				Zhou, C.; Huang, C.; Wang, J.; Huang, H.; Li, J.; Xie, Q.; Liu, Y.; Zhu, J.; Li, Y.; Zhang, D.; Zhu, Q.; Huang, C.			LncRNA MEG3 downregulation mediated by DNMT3b contributes to nickel malignant transformation of human bronchial epithelial cells via modulating PHLPP1 transcription and HIF-1 alpha translation	ONCOGENE			English	Article							NONCODING RNA MEG3; DNA METHYLTRANSFERASES; POOR-PROGNOSIS; PROLIFERATION; EXPRESSION; APOPTOSIS; GENE; HYPERMETHYLATION; CARCINOGENESIS; GROWTH	Long noncoding RNAs (lncRNAs) are emerging as key factors in various fundamental cellular biological processes, and many of them are likely to have functional roles in tumorigenesis. Maternally expressed gene 3 (MEG3) is an imprinted gene located at 14q32 that encodes a lncRNA, and the decreased MEG3 expression has been reported in multiple cancer tissues. However, nothing is known about the alteration and role of MEG3 in environmental carcinogen-induced lung tumorigenesis. Our present study, for the first time to the best of our knowledge, discovered that environmental carcinogen nickel exposure led to MEG3 downregulation, consequently initiating c-Jun-mediated PHLPP1 transcriptional inhibition and hypoxia-inducible factor-1 alpha (HIF-1 alpha) protein translation upregulation, in turn resulting in malignant transformation of human bronchial epithelial cells. Mechanistically, MEG3 downregulation was attributed to nickel-induced promoter hypermethylation via elevating DNMT3b expression, whereas PHLPP1 transcriptional inhibition was due to the decreasing interaction of MEG3 with its inhibitory transcription factor c-Jun. Moreover, HIF-1 alpha protein translation was upregulated via activating the Akt/p70S6K/S6 axis resultant from PHLPP1 inhibition in nickel responses. Collectively, we uncover that nickel exposure results in DNMT3b induction and MEG3 promoter hypermethylation and expression inhibition, further reduces its binding to c-Jun and in turn increasing c-Jun inhibition of PHLPP1 transcription, leading to the Akt/p70S6K/S6 axis activation, and HIF-1 alpha protein translation, as well as malignant transformation of human bronchial epithelial cells. Our studies provide a significant insight into understanding the alteration and role of MEG3 in nickel-induced lung tumorigenesis.	[Zhou, C.; Zhu, Q.] Anhui Med Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China; [Zhou, C.; Huang, H.; Xie, Q.; Huang, C.] Wenzhou Med Univ, Sch Life Sci, Zhejiang Prov Key Lab Technol & Applicat Model Or, Wenzhou, Zhejiang, Peoples R China; [Zhou, C.; Huang, C.; Wang, J.; Li, J.; Zhu, J.; Li, Y.; Zhang, D.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA; [Liu, Y.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Wenzhou, Zhejiang, Peoples R China	Anhui Medical University; Wenzhou Medical University; New York University; Wenzhou Medical University	Zhu, Q (corresponding author), Anhui Med Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China.; Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	zqxing@yeah.net; chuanshu.huang@nyumc.org	Zhu, Qixing/AAM-4214-2020; Zhou, Chengfan/AAM-4097-2020		NIH/NCI [CA112557, CA165980, CA177665]; NIH/NIEHS [ES000260]; National Natural Science Foundation of China [81441090, 81229002, 81372946, 81673141, 81371730]; Specialized Research Fund for the Doctoral Program of Higher Education [20133420110001]; Grant for Scientific Research of BSKY from Anhui Medical University [XJ201418]; NATIONAL CANCER INSTITUTE [R01CA177665, R01CA112557, P01CA165980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Grant for Scientific Research of BSKY from Anhui Medical University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We greatly appreciated Dr Shau-Ping Lin (Institute of Biotechnology, National Taiwan University, Taipei, Taiwan) for his generous gifts about shRNA constructs against MEG3 and control vector. This work was supported partially by grants from NIH/NCI CA112557, CA165980 and CA177665, NIH/NIEHS ES000260, National Natural Science Foundation of China (81441090, 81229002, 81372946, 81673141 and 81371730), the Specialized Research Fund for the Doctoral Program of Higher Education (20133420110001), and the Grant for Scientific Research of BSKY (XJ201418) from Anhui Medical University. We also thank Ms Nedda Tichi for her critical reading of the manuscript.	Anwar SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049462; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Benetatos L, 2011, INT J CANCER, V129, P773, DOI 10.1002/ijc.26052; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Field RW, 2012, CLIN CHEST MED, V33, P681, DOI 10.1016/j.ccm.2012.07.001; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154; Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313; Huang HS, 2015, CLIN CANCER RES, V21, P3783, DOI 10.1158/1078-0432.CCR-14-2829; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Kasprzak KS, 2003, MUTAT RES-FUND MOL M, V533, P67, DOI 10.1016/j.mrfmmm.2003.08.021; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1; Li J, 2016, INT J ONCOL, V48, P723, DOI 10.3892/ijo.2015.3285; Li JX, 2004, CANCER RES, V64, P94, DOI 10.1158/0008-5472.CAN-03-0737; Liu LX, 2016, INT J ONCOL, V48, P421, DOI 10.3892/ijo.2015.3248; Lu HT, 2005, MOL CELL BIOCHEM, V279, P45, DOI 10.1007/s11010-005-8215-2; Lu KH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-461; Luo G, 2015, CELL PHYSIOL BIOCHEM, V37, P2209, DOI 10.1159/000438577; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x; Murphy SK, 2003, HUM MUTAT, V22, P92, DOI 10.1002/humu.10237; Newton AC, 2014, ANNU REV PHARMACOL, V54, P537, DOI 10.1146/annurev-pharmtox-011112-140338; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Ouyang WM, 2009, J CELL PHYSIOL, V218, P205, DOI 10.1002/jcp.21590; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Salnikow K, 2008, CHEM RES TOXICOL, V21, P28, DOI 10.1021/tx700198a; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080; Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277-013-1142-z; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Wang PJ, 2012, J CELL BIOCHEM, V113, P1868, DOI 10.1002/jcb.24055; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; WILLEY JC, 1991, CANCER RES, V51, P5370; Xu Z, 2016, NEURO-ONCOLOGY, V18, P830, DOI 10.1093/neuonc/nov298; Yin DD, 2015, TUMOR BIOL, V36, P4851, DOI 10.1007/s13277-015-3139-2; Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k; Yu Y, 2014, ONCOGENE, V33, P996, DOI 10.1038/onc.2013.8; Zhang D, 2012, ACM COMPUT SURV, V44, DOI 10.1145/2071389.2071391; Zhang DY, 2010, CANCER RES, V70, P813, DOI 10.1158/0008-5472.CAN-09-0448; Zhang J, 2016, CANCER BIOL THER, V17, P104, DOI 10.1080/15384047.2015.1108496; Zhao J, 2005, J CLIN ENDOCR METAB, V90, P2179, DOI 10.1210/jc.2004-1848; Zhou YL, 2012, J MOL ENDOCRINOL, V48, pR45, DOI 10.1530/JME-12-0008	50	77	82	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3878	3889		10.1038/onc.2017.14	http://dx.doi.org/10.1038/onc.2017.14			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263966	Green Accepted			2022-12-17	WOS:000404848200008
J	Yu, T; Yang, G; Hou, Y; Tang, X; Wu, C; Wu, XA; Guo, L; Zhu, Q; Luo, H; Du, YE; Wen, S; Xu, L; Yin, J; Tu, G; Liu, M				Yu, T.; Yang, G.; Hou, Y.; Tang, X.; Wu, C.; Wu, X-A; Guo, L.; Zhu, Q.; Luo, H.; Du, Y-E; Wen, S.; Xu, L.; Yin, J.; Tu, G.; Liu, M.			Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance	ONCOGENE			English	Article							BREAST-CANCER; ESTROGEN-RECEPTOR; NUCLEAR EXPORT; OVARIAN-CANCER; PROGNOSTIC VALUE; PLASMA-MEMBRANE; LUNG-CANCER; FDG UPTAKE; GPR30; MICROENVIRONMENT	Multiple drug resistance is a challenging issue in the clinic. There is growing evidence that the G-protein-coupled estrogen receptor (GPER) is a novel mediator in the development of multidrug resistance in both estrogen receptor (ER)-positive and -negative breast cancers, and that cancer-associated fibroblasts (CAFs) in the tumor microenvironment may be a new agent that promotes drug resistance in tumor cells. However, the role of cytoplasmic GPER of CAFs on tumor therapy remains unclear. Here we first show that the breast tumor cell-activated PI3K/AKT (phosphoinositide 3-kinase/AKT) signaling pathway induces the cytoplasmic GPER translocation of CAFs in a CRM1-dependent pattern, and leads to the activation of a novel estrogen/GPER/cAMP/PKA/CREB signaling axis that triggers the aerobic glycolysis switch in CAFs. The glycolytic CAFs feed the extra pyruvate and lactate to tumor cells for augmentation of mitochondrial activity, and this energy metabolically coupled in a 'host-parasite relationship' between catabolic CAFs and anabolic cancer cells confers the tumor cells with multiple drug resistance to several conventional clinical treatments including endocrine therapy (tamoxifen), Her-2-targeted therapy (herceptin) and chemotherapy (epirubicin). Moreover, the clinical data from F-18-fluorodeoxyglucose positron emission tomography/computed tomography further present a strong association between the GPER/cAMP/PKA/CREB pathway of stromal fibroblasts with tumor metabolic activity and clinical treatment, suggesting that targeting cytoplasmic GPER in CAFs may rescue the drug sensitivity in patients with breast cancer. Thus, our data define novel insights into the stromal GPER-mediated multiple drug resistance from the point of reprogramming of tumor energy metabolism and provide the rationale for CAFs as a promising target for clinical therapy.	[Yu, T.; Yang, G.; Wu, C.; Wu, X-A; Guo, L.; Zhu, Q.; Tu, G.] Chongqing Med Univ, Dept Endocrine & Breast Surg, Affiliated Hosp 1, 1 You Yi Rd, Chongqing 400016, Peoples R China; [Yu, T.; Hou, Y.; Tang, X.; Du, Y-E; Wen, S.; Xu, L.; Yin, J.; Liu, M.] Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, 1 You Yi Rd, Chongqing 400016, Peoples R China; [Yu, T.] Jiangxi Canc Hosp, Dept Breast Surg, Nanchang, Jiangxi, Peoples R China; [Luo, H.] Chongqing Med Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 2, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University	Tu, G (corresponding author), Chongqing Med Univ, Dept Endocrine & Breast Surg, Affiliated Hosp 1, 1 You Yi Rd, Chongqing 400016, Peoples R China.; Liu, M (corresponding author), Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, 1 You Yi Rd, Chongqing 400016, Peoples R China.	tugang68@126.com; mliu-hncq@hotmail.com			National Natural Science Foundation of China [NSFC 81372398, NSFC 81472676, NSFC 31171336]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China (NSFC 81372398) (to GT) and by National Natural Science Foundation of China (NSFC 81472676, NSFC 31171336) (to ML).	Ahn S, 2012, TUMOR BIOL, V33, P1573, DOI 10.1007/s13277-012-0411-6; Alvero AB, 2014, ONCOTARGET, V5, P8703, DOI 10.18632/oncotarget.2367; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Bonuccelli G, 2010, CELL CYCLE, V9, P1960, DOI 10.4161/cc.9.10.11601; Cheng SB, 2011, STEROIDS, V76, P892, DOI 10.1016/j.steroids.2011.02.018; Das SK, 2011, SCIENCE, V333, P233, DOI 10.1126/science.1198973; De Francesco EM, 2014, CANCER RES, V74, P4053, DOI 10.1158/0008-5472.CAN-13-3590; De Francesco EM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3458; de Kruijf EM, 2011, BREAST CANCER RES TR, V125, P687, DOI 10.1007/s10549-010-0855-6; DeFranco DB, 2001, CURR BIOL, V11, pR1036, DOI 10.1016/S0960-9822(01)00619-4; Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168; Dennison JB, 2013, CLIN CANCER RES, V19, P3703, DOI 10.1158/1078-0432.CCR-13-0623; Fan L, 2014, LANCET ONCOL, V15, pE279, DOI 10.1016/S1470-2045(13)70567-9; Farace P, 2009, EUR J NUCL MED MOL I, V36, P616, DOI 10.1007/s00259-008-1012-x; Filardo E, 2007, ENDOCRINOLOGY, V148, P3236, DOI 10.1210/en.2006-1605; Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860; Filardo EJ, 2012, ENDOCRINOLOGY, V153, P2953, DOI 10.1210/en.2012-1061; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fujiwara S, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-35; Girgert R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-935; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Huang T, 2012, J NUCL MED, V53, P1262, DOI 10.2967/jnumed.111.098087; Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1; Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6; Ji JY, 2003, CIRC RES, V92, P279, DOI 10.1161/01.RES.0000057753.57106.0B; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kim MY, 2015, NUCLEIC ACIDS RES, V43, P1609, DOI 10.1093/nar/gkv026; Kitajima K, 2016, JPN J RADIOL, V34, P220, DOI 10.1007/s11604-015-0515-1; LaPensee EW, 2009, ENVIRON HEALTH PERSP, V117, P175, DOI 10.1289/ehp.11788; Lin BC, 2009, CANCER RES, V69, P5415, DOI 10.1158/0008-5472.CAN-08-1622; Liu Y, 2015, AM J TRANSL RES, V7, P967; Lombardi M, 2008, J CELL BIOL, V182, P327, DOI 10.1083/jcb.200712125; Luo HJ, 2014, ENDOCR-RELAT CANCER, V21, P355, DOI 10.1530/ERC-13-0237; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Madeo A, 2010, CANCER RES, V70, P6036, DOI 10.1158/0008-5472.CAN-10-0408; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3956, DOI 10.4161/cc.22136; Martinez-Outschoorn UE, 2012, CELL METAB, V15, P4, DOI 10.1016/j.cmet.2011.12.011; Martinez-Outschoorn UE, 2011, CANCER BIOL THER, V12, P924, DOI 10.4161/cbt.12.10.17780; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mo ZQ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3581; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518; Pugachev A, 2005, INT J RADIAT ONCOL, V62, P545, DOI 10.1016/j.ijrobp.2005.02.009; Pupo M, 2013, MOL CELL ENDOCRINOL, V376, P23, DOI 10.1016/j.mce.2013.05.023; Qiu M, 2003, MOL ENDOCRINOL, V17, P628, DOI 10.1210/me.2002-0378; Scaling AL, 2014, HORM CANCER-US, V5, P146, DOI 10.1007/s12672-014-0174-1; Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856; Sotgia F, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2892; Tang X, 2016, CELL DEATH DIFFER, V23, P132, DOI 10.1038/cdd.2015.78; Vivacqua A, 2015, ONCOTARGET, V6, P16573, DOI 10.18632/oncotarget.4117; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Yu TH, 2014, J STEROID BIOCHEM, V143, P392, DOI 10.1016/j.jsbmb.2014.05.003; Zhang GJ, 2015, J NUCL MED, V56, P607, DOI 10.2967/jnumed.114.148254; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zucchetti AE, 2014, HEPATOLOGY, V59, P1016, DOI 10.1002/hep.26752	59	77	82	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2131	2145		10.1038/onc.2016.370	http://dx.doi.org/10.1038/onc.2016.370			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721408				2022-12-17	WOS:000399782500009
J	Luanpitpong, S; Li, J; Manke, A; Brundage, K; Ellis, E; McLaughlin, SL; Angsutararux, P; Chanthra, N; Voronkova, M; Chen, YC; Wang, L; Chanvorachote, P; Pei, M; Issaragrisil, S; Rojanasakul, Y				Luanpitpong, S.; Li, J.; Manke, A.; Brundage, K.; Ellis, E.; McLaughlin, S. L.; Angsutararux, P.; Chanthra, N.; Voronkova, M.; Chen, Y. C.; Wang, L.; Chanvorachote, P.; Pei, M.; Issaragrisil, S.; Rojanasakul, Y.			SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma	ONCOGENE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; BREAST-CANCER; ALDEHYDE DEHYDROGENASE; DEGRADATION; ADENOCARCINOMA; EXPRESSION; GROWTH; IDENTIFICATION	Cancer stem cells (CSCs) are a promising target for cancer therapy, particularly for metastatic lung cancers, but how CSCs are regulated is largely unknown. We identify two proteins, SLUG (encoded by SNAI2 gene) and SOX9, which are associated with advanced stage lung cancers and are implicated in the regulation of CSCs. Inhibition of either SLUG or SOX9 sufficiently inhibits CSCs in human lung cancer cells and attenuates experimental lung metastasis in a xenograft mouse model. Correlation between SLUG and SOX9 levels was observed remarkably, we therefore sought to explore their mechanistic relationship and regulation. SLUG, beyond its known function as an epithelial-mesenchymal transition transcription factor, was found to regulate SOX9 by controlling its stability via a post-translational modification process. SLUG interacts directly with SOX9 and prevents it from ubiquitin-mediated proteasomal degradation. SLUG expression and binding are necessary for SOX9 promotion of lung CSCs and metastasis in a mouse model. Together, our findings provide a novel mechanistic insight into the regulation of CSCs via SLUG-SOX9 regulatory axis, which represents a potential novel target for CSC therapy that may overcome cancer chemoresistance and relapse.	[Angsutararux, P.; Chanthra, N.; Issaragrisil, S.] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Bangkok 10700, Thailand; [Luanpitpong, S.; Manke, A.; Rojanasakul, Y.] W Virginia Univ, Pharmaceut & Pharmacol Sci Program, Morgantwon, WV 26506 USA; [Luanpitpong, S.; Voronkova, M.; Rojanasakul, Y.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantwon, WV 26506 USA; [Li, J.; Pei, M.] W Virginia Univ, Stem Cell & Tissue Engn Lab, Morgantwon, WV 26506 USA; [Brundage, K.] W Virginia Univ, Flow Cytometry Core Facil, Morgantwon, WV 26506 USA; [Ellis, E.; McLaughlin, S. L.] W Virginia Univ, Anim Models & Imaging Facil, Morgantwon, WV 26506 USA; [Chen, Y. C.] Alderson Broaddus Univ, Div Nat Sci, Philippi, WV USA; [Wang, L.] NIOSH, Allergy & Clin Immunol Branch, Morgantown, WV USA; [Chanvorachote, P.] Chulalongkorn Univ, Prod Dev Res Unit, Cell Based Drug & Hlth, Bangkok, Thailand	Mahidol University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Chulalongkorn University	Luanpitpong, S (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Ctr Excellence Stem Cell Res, Bangkok 10700, Thailand.; Luanpitpong, S; Rojanasakul, Y (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantwon, WV 26506 USA.	suidjit@gmail.com; yrojan@hsc.wvu.edu	Li, Jingting/AAA-4598-2020; Luanpitpong, Sudjit/ABF-1962-2021; Pei, Ming/N-8175-2017	Li, Jingting/0000-0002-3576-0320; chanvorachote, pithi/0000-0002-3103-3249; McLaughlin, Sarah/0000-0002-8413-3585; Voronkova, Maria/0000-0001-9778-5032; Luanpitpong, Sudjit/0000-0002-1639-4935	National Institutes of Health (NIH) [R01-ES022968]; National Science Foundation [CBET-1434503]; Mary Babb Randolph Cancer Center (MBRCC) Sara C Allen Lung and James F Allen Comp Lung Cancer Research Fund; NIH [P30 GM103488, P20 RR016440, P30 RR032138/GM103488, S10 RR026378]; MBRCC; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR026378, P20RR016440, P30RR032138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES022968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103488] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Mary Babb Randolph Cancer Center (MBRCC) Sara C Allen Lung and James F Allen Comp Lung Cancer Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MBRCC; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Institutes of Health (NIH; R01-ES022968), National Science Foundation (CBET-1434503) and Mary Babb Randolph Cancer Center (MBRCC) Sara C Allen Lung and James F Allen Comp Lung Cancer Research Fund. Flow cytometric analysis was performed in the WVU Flow Cytometry Core Facility, which is supported in part by the NIH Grant P30 GM103488. Animal experiments were performed in the WVU Animal Models and Imaging Facility, which is supported in part by the MBRCC and NIH Grants P20 RR016440, P30 RR032138/GM103488 and S10 RR026378. We would like to acknowledge the WVU Pathology Laboratory for Translational Medicine for tissue sectioning and staining services and Drs Davor Solter and Barbara Knowles for their comments on the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Cates JMM, 2009, PANCREAS, V38, pE1, DOI 10.1097/MPA.0b013e3181878b7f; Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086; Chakravarty G, 2011, CANCER BIOL THER, V11, P71, DOI 10.4161/cbt.11.1.13952; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Crino L, 2010, ANN ONCOL, V21, pv103, DOI 10.1093/annonc/mdq207; Cronin JC, 2013, CANCER RES, V73, P5709, DOI 10.1158/0008-5472.CAN-12-4620; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Ding GX, 2012, PANMINERVA MED, V54, P219; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Esposito L, 2010, CURR GENOMICS, V11, P513, DOI 10.2174/138920210793175903; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hasan MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082846; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Krueger KE, 2006, MOL CELL PROTEOMICS, V5, P1799, DOI 10.1074/mcp.R600009-MCP200; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Levina V, 2010, CANCER RES, V70, P338, DOI 10.1158/0008-5472.CAN-09-1102; Levina V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003077; Luanpitpong S, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-22; Luanpitpong S, 2013, MOL BIOL CELL, V24, P858, DOI 10.1091/mbc.E12-10-0747; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nurwidya F, 2012, CANCER RES TREAT, V44, P151, DOI 10.4143/crt.2012.44.3.151; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Riihimaki M, 2014, LUNG CANCER, V86, P78, DOI 10.1016/j.lungcan.2014.07.020; Rockich BE, 2013, P NATL ACAD SCI USA, V110, pE4456, DOI 10.1073/pnas.1311847110; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tan YX, 2014, MOL CLIN ONCOL, V2, P111, DOI 10.3892/mco.2013.195; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Turcatel G, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-117; Xu Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034327; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zheng YF, 2011, J BIOL CHEM, V286, P17722, DOI 10.1074/jbc.M110.184739	49	77	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2824	2833		10.1038/onc.2015.351	http://dx.doi.org/10.1038/onc.2015.351			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387547	Green Accepted			2022-12-17	WOS:000377473700002
J	Stindt, MH; Muller, PAJ; Ludwig, RL; Kehrloesser, S; Dotsch, V; Vousden, KH				Stindt, M. H.; Muller, P. A. J.; Ludwig, R. L.; Kehrloesser, S.; Doetsch, V.; Vousden, K. H.			Functional interplay between MDM2, p63/p73 and mutant p53	ONCOGENE			English	Article							P73 FUNCTION; P63; PROTEIN; DEGRADATION; STABILITY; ISOFORMS; ACTIVATION; MUTATIONS; COMPLEX; DOMAIN	Many cancers express mutant p53 proteins that have lost wild-type tumor suppressor activity and, in many cases, have acquired oncogenic functions that can contribute to tumor progression. These activities of mutant p53 reflect interactions with several other proteins, including the p53 family members p63 and p73. Mutations in p53 that affect protein conformation (such as R175H) show strong binding to p63 and p73, whereas p53 mutants that only mildly affect the conformation (such as R273H) bind less well. A previously described aggregation domain of mutant p53 is not required for p63 or p73 binding; indeed, mutations within this region lead to the acquisition of a mutant p53 phenotype-including a conformational shift, p63/p73 binding and the ability to promote invasion. The activity of wild-type p53 is regulated by an interaction with MDM2 and we have investigated the potential role of MDM2 in the mutant p53/p63/p73 interactions. Both mutant p53 and p73 bind MDM2 well, whereas p63 binds much more weakly. We found that MDM2 can inhibit p63 binding to p53R175H but enhances the weaker p53R273H/p73 interaction. These effects on the interactions are reflected in an ability of MDM2 to relieve the inhibition of p63 by p53R175H, but enhance the inhibition of p73 activity by p53R175H and R273H. We propose a model in which MDM2 competes with p63 for binding to p53R175H to restore p63 activity, but forms a trimeric complex with p73 and p53R273H to more strongly inhibit p73 function.	[Stindt, M. H.; Muller, P. A. J.; Ludwig, R. L.; Vousden, K. H.] Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Kehrloesser, S.; Doetsch, V.] Goethe Univ Frankfurt, D-60054 Frankfurt, Germany	Beatson Institute; Goethe University Frankfurt	Vousden, KH (corresponding author), Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.vousden@beatson.gla.ac.uk	Muller, Patricia AJ/AAH-1888-2019	Muller, Patricia AJ/0000-0002-0926-1499; Kehrloesser, Sebastian/0000-0002-6791-2421; Dotsch, Volker/0000-0001-5720-212X	Cancer Research UK; DFG [DO 545/8-1]; Wellcome Trust/the Royal Society; Cluster of Excellence Frankfurt (Macromolecular Complexes); MRC [MC_UP_1203/3] Funding Source: UKRI; Cancer Research UK [18274] Funding Source: researchfish; Medical Research Council [MC_UP_1203/3] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); DFG(German Research Foundation (DFG)); Wellcome Trust/the Royal Society; Cluster of Excellence Frankfurt (Macromolecular Complexes); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Drs Gerry Melino, Caron de Fromentel and Kevin Ryan for plasmids and are grateful to Cancer Research UK, the DFG (DO 545/8-1), The Wellcome Trust/the Royal Society (Sir Henry Dale Fellowship) and the Cluster of Excellence Frankfurt (Macromolecular Complexes) for funding.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Coutandin D, 2009, CELL DEATH DIFFER, V16, P1582, DOI 10.1038/cdd.2009.139; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Deutsch GB, 2011, CELL, V144, P566, DOI 10.1016/j.cell.2011.01.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ethayathulla AS, 2012, P NATL ACAD SCI USA, V109, P6066, DOI 10.1073/pnas.1115463109; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ishimoto O, 2002, CANCER RES, V62, P636; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Joerger AC, 2007, ADV CANCER RES, V97, P1, DOI 10.1016/S0065-230X(06)97001-8; Joerger AC, 2009, P NATL ACAD SCI USA, V106, P17705, DOI 10.1073/pnas.0905867106; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; Luh LM, 2013, CELL DEATH DIFFER, V20, P1008, DOI 10.1038/cdd.2013.23; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Natan E, 2012, J MOL BIOL, V415, P503, DOI 10.1016/j.jmb.2011.11.007; Neilsen PM, 2011, ONCOTARGET, V2, P1203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Santini S, 2014, BBA-GEN SUBJECTS, V1840, P1958, DOI 10.1016/j.bbagen.2014.02.014; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Stindt Maren H, 2011, Cell Cycle, V10, P3176; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Straub WE, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.1; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Trinidad AG, 2013, MOL CELL, V50, P805, DOI 10.1016/j.molcel.2013.05.002; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Wiech M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051426; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zdzalik M, 2010, CELL CYCLE, V9, P4584, DOI 10.4161/cc.9.22.13871; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996	64	77	79	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4300	4310		10.1038/onc.2014.359	http://dx.doi.org/10.1038/onc.2014.359			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417702	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000359494400002
J	Andruska, N; Zheng, X; Yang, X; Helferich, WG; Shapiro, DJ				Andruska, N.; Zheng, X.; Yang, X.; Helferich, W. G.; Shapiro, D. J.			Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor alpha-positive breast cancer	ONCOGENE			English	Article							REGULATED GENE-EXPRESSION; KINASE PERK; STRESS; TRANSCRIPTION; MICROARRAY; RESISTANCE; GRP78/BIP; INHIBITOR; GROWTH; ATF6	In response to cell stress, cancer cells often activate the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). Little was known about the potential role in cancer of a different mode of UPR activation, anticipatory activation of the UPR prior to accumulation of unfolded protein or cell stress. We show that estrogen, acting via estrogen receptor alpha (ER alpha), induces rapid anticipatory activation of the UPR, resulting in increased production of the antiapoptotic chaperone BiP/GRP78, preparing cancer cells for the increased protein production required for subsequent estrogen-ER alpha-induced cell proliferation. In ER alpha-containing cancer cells, the estrogen, 17 beta-estradiol (E-2) activates the UPR through a phospholipase C gamma (PLC gamma)-mediated opening of EnR IP3R calcium channels, enabling passage of calcium from the lumen of the EnR into the cytosol. siRNA knockdown of ER alpha blocked the estrogen-mediated increase in cytosol calcium and UPR activation. Knockdown or inhibition of PLC gamma, or of IP3R, strongly inhibited the estrogen-mediated increases in cytosol calcium, UPR activation and cell proliferation. E-2-ER alpha activates all three arms of the UPR in breast and ovarian cancer cells in culture and in a mouse xenograft. Knockdown of ATF6 alpha, which regulates UPR chaperones, blocked estrogen induction of BiP and strongly inhibited E-2-ER alpha-stimulated cell proliferation. Mild and transient UPR activation by estrogen promotes an adaptive UPR response that protects cells against subsequent UPR-mediated apoptosis. Analysis of data from ER alpha(+) breast cancers demonstrates elevated expression of a UPR gene signature that is a powerful new prognostic marker tightly correlated with subsequent resistance to tamoxifen therapy, reduced time to recurrence and poor survival. Thus, as an early component of the E-2-ER alpha proliferation program, the mitogen estrogen, drives rapid anticipatory activation of the UPR. Anticipatory activation of the UPR is a new role for estrogens in cancer cell proliferation and resistance to therapy.	[Andruska, N.; Zheng, X.; Shapiro, D. J.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; [Andruska, N.; Helferich, W. G.; Shapiro, D. J.] Univ Illinois, Coll Med, Urbana, IL 61801 USA; [Yang, X.; Helferich, W. G.] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; [Helferich, W. G.; Shapiro, D. J.] Univ Illinois, Ctr Canc, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 419 Roger Adams Lab,600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@illinois.edu	Zheng, Xiaobin/F-8994-2018		NIH [RO1DK 071909]; Westcott predoctoral fellowship; Carter predoctoral fellowship; National Center for Complementary & Integrative Health [P50AT006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071909] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Westcott predoctoral fellowship; Carter predoctoral fellowship; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Mr J Hartman for assistance with xenografts, and Dr S Kaufmann and Dr K Korach for cell lines. This work was supported by NIH RO1DK 071909 (to DS) and Westcott and Carter predoctoral fellowships (to NA). Analyses were performed using BRB-ArrayTools, developed by Dr Richard Simon and BRB-ArrayTools Development Team at the National Cancer Institute.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Andruska N, 2012, J BIOMOL SCREEN, V17, P921, DOI 10.1177/1087057112442960; Ariazi EA, 2011, P NATL ACAD SCI USA, V108, P18879, DOI 10.1073/pnas.1115188108; Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cherian MT, 2012, J BIOL CHEM, V287, P23368, DOI 10.1074/jbc.M112.344671; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Ding LH, 2003, NUCLEIC ACIDS RES, V31, P5266, DOI 10.1093/nar/gkg731; Divekar SD, 2011, CANCER RES, V71, P1658, DOI 10.1158/0008-5472.CAN-10-1899; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Dong SY, 2010, MOL CELL BIOCHEM, V341, P195, DOI 10.1007/s11010-010-0450-5; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Gomez BP, 2007, FASEB J, V21, P4013, DOI 10.1096/fj.06-7990com; Graham K, 2010, BRIT J CANCER, V102, P1284, DOI 10.1038/sj.bjc.6605576; Hu CCA, 2009, EMBO J, V28, P1624, DOI 10.1038/emboj.2009.117; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Ju YH, 2002, CANCER RES, V62, P2474; Kretzer NM, 2010, J BIOL CHEM, V285, P41863, DOI 10.1074/jbc.M110.183723; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rutkowski DT, 2007, TRENDS BIOCHEM SCI, V32, P469, DOI 10.1016/j.tibs.2007.09.003; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665; Spiller DG, 2010, NATURE, V465, P736, DOI 10.1038/nature09232; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Teske BF, 2011, MOL BIOL CELL, V22, P4390, DOI 10.1091/mbc.E11-06-0510; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Yue W, 2013, STEROIDS, V78, P161, DOI 10.1016/j.steroids.2012.11.001	42	77	78	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3760	3769		10.1038/onc.2014.292	http://dx.doi.org/10.1038/onc.2014.292			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263449	Green Accepted			2022-12-17	WOS:000358001600002
J	Roesch, A				Roesch, A.			Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma	ONCOGENE			English	Review							ACQUIRED-RESISTANCE; BRAF(V600E) INHIBITION; BRAF INHIBITION; RAF INHIBITION; OXIDATIVE-METABOLISM; METASTATIC MELANOMA; IMPROVED SURVIVAL; MEK INHIBITION; CELLS; VEMURAFENIB	Despite the recent success of MAPK signaling-targeted drugs in melanoma, the majority of patients with metastatic melanoma still undergo disease progression after initial tumor shrinkage indicating gradually developing therapy resistance. This review will give an overview on currently suggested concepts of resistance to MAPK pathway inhibitors in melanoma with particular focus on interand intraindividual as well as intratumor heterogeneity. The high plasticity of melanoma cells promotes both the clonal evolution of genetic resistance, for example, because of mutations in the MAPK or PI3K/AKT/PTEN pathways, and the emergence of cell phenotypes that functionally and metabolically overcome MAPK inhibition. Like a 'moving target', melanoma cells are shifting between different metabolic, cell cycle and differentiation states reflecting a highly dynamic potential to adapt to exogenous stressors including drugs. The introduction of MAPK inhibitors into the clinics has tremendously pushed the field of melanoma research not just because of the historic therapeutic success but also by providing a new tool to study human melanoma in its natural microenvironment.	Univ Hosp Essen, Dept Dermatol, D-45122 Essen, Germany	University of Duisburg Essen	Roesch, A (corresponding author), Univ Hosp Essen, Dept Dermatol, Hufelandstr 55, D-45122 Essen, Germany.	alexander.roesch@uk-essen.de						Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Berridge MV, 2010, MITOCHONDRION, V10, P584, DOI 10.1016/j.mito.2010.08.002; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Corazao-Rozas P, 2013, ONCOTARGET, V4, P1986, DOI 10.18632/oncotarget.1420; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Girnun GD, 2012, SEMIN CELL DEV BIOL, V23, P381, DOI 10.1016/j.semcdb.2012.01.007; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Haferkamp S, 2013, J INVEST DERMATOL, V133, P1601, DOI 10.1038/jid.2013.6; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hartsough E, 2014, J INVEST DERMATOL, V134, P319, DOI 10.1038/jid.2013.358; Hartsough EJ, 2014, MOL CANCER RES, V12, P795, DOI 10.1158/1541-7786.MCR-13-0581; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nathanson KL, 2013, CLIN CANCER RES, V19, P4868, DOI 10.1158/1078-0432.CCR-13-0827; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Romano E, 2013, CLIN CANCER RES, V19, P5749, DOI 10.1158/1078-0432.CCR-13-0661; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Schadendorf D, 2014, NAT REV CLIN ONCOL, V11, P75, DOI 10.1038/nrclinonc.2013.246; Shao Y, 2012, CELL DEATH DIFFER, V19, P2029, DOI 10.1038/cdd.2012.94; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi H, 2013, CANC DISCOV; Shi HB, 2012, CANCER DISCOV, V2, P414, DOI 10.1158/2159-8290.CD-12-0022; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yuan P, 2013, P NATL ACAD SCI USA, V110, P18226, DOI 10.1073/pnas.1317577110	62	77	81	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2951	2957		10.1038/onc.2014.249	http://dx.doi.org/10.1038/onc.2014.249			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25109330				2022-12-17	WOS:000356100500001
J	Zhou, X; Zhang, CZ; Lu, SX; Chen, GG; Li, LZ; Liu, LL; Yi, C; Fu, J; Hu, W; Wen, JM; Yun, JP				Zhou, X.; Zhang, C. Z.; Lu, S-X; Chen, G. G.; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Wen, J-M; Yun, J-P			miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma	ONCOGENE			English	Article							CELL-MIGRATION; VICKZ PROTEINS; C-MYC; EXPRESSION; MICRORNA; TRANSLATION; METASTASIS; FAMILY; INVOLVEMENT; ADHESION	Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies and the third leading cause of cancer-related deaths worldwide. Tumour metastasis is one of the major causes of high mortality. microRNAshave been implicated in HCC metastasis. In this study, we found that miR-625 was frequently downregulated in HCC samples. A decrease in miR-625 was significantly correlated with lymph node anddistance metastasis (P = 0.013), the presence of portal venous invasion (P = 0.036), tumor-nodemetastasis (TNM) stage (P = 0.027) and unfavourable overall survival (P = 0.003). Compared with primary tumours, miR-625 expression was markedly reduced in portal venous metastatic tumours. Re-expression of miR-625 in HCC cells was remarkably effective in suppressing cell migration andinvasiveness in vitro and in vivo. Mechanistically, miR-625 was confirmed to downregulate IGF2 mRNA-binding protein 1(IGF2BP1) directly, the expression of which was inversely correlated with the level of miR-625 in HCC cell lines and tissues. High expression of IGF2BP1 was frequently found in HCC samples, and associated with poor prognosis. Knockdown of endogenous IGF2BP1 by siRNA exhibited similar effects as the overexpression of miR-625, whereas overexpression of IGF2BP1 (without the 3'-UTR) abrogated miR-625-mediated metastasis inhibition. Interference of the PTEN/HSP27 pathway contributed to miR-625-mediated metastasis inhibition. Taken together, our data suggest that miR-625 might function as an antimetastatic miRNA to have an important role in HCC progression by modulating the IGF2BP1/PTEN pathway. The newly identified miR-625/IGF2BP1 axis represents a new potential therapeutic target for HCC treatment.	[Zhou, X.; Zhang, C. Z.; Lu, S-X; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, X.; Zhang, C. Z.; Lu, S-X; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Zhou, X.; Wen, J-M] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Chen, G. G.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese University of Hong Kong; Prince of Wales Hospital	Yun, JP (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.	yunjp@sysucc.org.cn	Chen, George Gong/I-2757-2016; Zhang, Chris Zhiyi/F-9862-2013		National Natural Science Foundation of China [81372572, 81201717]; State Key Laboratory of Oncology in South China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Oncology in South China	This study was supported by grants from the National Natural Science Foundation of China (No. 81372572, 81201717), and the Project of State Key Laboratory of Oncology in South China.	Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; During RL, 2007, EMBO J, V26, P2240, DOI 10.1038/sj.emboj.7601687; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Forner A, 2006, CRIT REV ONCOL HEMAT, V60, P89, DOI 10.1016/j.critrevonc.2006.06.001; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Ioannidis P, 2005, J BIOL CHEM, V280, P20086, DOI 10.1074/jbc.M410036200; Kobel M, 2007, ONCOGENE, V26, P7584, DOI 10.1038/sj.onc.1210563; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lapidus K, 2007, J CELL SCI, V120, P3173, DOI 10.1242/jcs.000638; Leung KM, 2006, NAT NEUROSCI, V9, P1247, DOI 10.1038/nn1775; Li LZ, 2014, CARCINOGENESIS, V35, P469, DOI 10.1093/carcin/bgt330; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oberman F, 2007, RNA, V13, P1558, DOI 10.1261/rna.559507; Read DE, 2009, CELL MOL LIFE SCI, V66, P2975, DOI 10.1007/s00018-009-0057-8; Read DE, 2009, BIOCHEM BIOPH RES CO, V382, P6, DOI 10.1016/j.bbrc.2009.02.114; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Shimizu S, 2010, J HEPATOL, V52, P698, DOI 10.1016/j.jhep.2009.12.024; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Tan S, 2011, FEBS LETT, V585, P2229, DOI 10.1016/j.febslet.2011.05.042; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806; Vainer G, 2008, J PATHOL, V215, P445, DOI 10.1002/path.2376; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Yan Y, 2013, HEPATOLOGY, V57, P667, DOI 10.1002/hep.26071; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; Yao J, 2010, HEPATOLOGY, V51, P846, DOI 10.1002/hep.23443; Yao JQ, 2006, NAT NEUROSCI, V9, P1265, DOI 10.1038/nn1773; Yisraeli JK, 2005, BIOL CELL, V97, P87; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008	35	77	80	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					965	977		10.1038/onc.2014.35	http://dx.doi.org/10.1038/onc.2014.35			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632613				2022-12-17	WOS:000350121300003
J	Nagel, D; Vincendeau, M; Eitelhuber, AC; Krappmann, D				Nagel, D.; Vincendeau, M.; Eitelhuber, A. C.; Krappmann, D.			Mechanisms and consequences of constitutive NF-kappa B activation in B-cell lymphoid malignancies	ONCOGENE			English	Review						NF-kappa B signaling; Hodgkin's lymphoma; MALT lymphoma; DLBCL; multiple myeloma	EPSTEIN-BARR-VIRUS; REED-STERNBERG CELLS; API2-MALT1 FUSION ONCOPROTEIN; CLASSICAL HODGKIN LYMPHOMA; ONCOGENIC CARD11 MUTATIONS; SMALL-MOLECULE INHIBITORS; TUMOR-SUPPRESSOR GENE; MEMBRANE-PROTEIN 1; MULTIPLE-MYELOMA; HELICOBACTER-PYLORI	The discovery of constitutive nuclear factor-kappa B (NF-kappa B) activation in Hodgkin's lymphoma tumor cells almost two decades ago was one of the first reports that directly connected deregulated NF-kappa B signaling to human cancer. Subsequent studies demonstrated that enhanced NF-kappa B signaling is a common hallmark of many lymphoid malignancies, including Hodgkin lymphoma, mucosa-associated lymphoid tissue lymphoma, diffuse large B-cell lymphoma and multiple myeloma. By inducing an anti-apoptotic and pro-proliferative gene program, NF-kappa B is involved in lymphoma survival and growth. Identification of somatic mutations that led to activation of oncogenes and inactivation of tumor suppressor genes in the pathway revealed that specific pathogenic mechanisms are responsible for constitutive NF-kappa B activation in different lymphoma entities. Thus, the identification of distinct oncogenic events is reflecting the diverse cellular origins of the different lymphomas. Further, elucidation of the mechanisms that drive NF-kappa B in lymphoma is of high clinical relevance as it will allow the design of target-directed precision therapy. Indeed, a number of drugs that impair constitutive NF-kappa B activation in lymphoid malignancies are currently in preclinical or clinical development.	[Nagel, D.; Vincendeau, M.; Eitelhuber, A. C.; Krappmann, D.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, D-85764 Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Krappmann, D (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Mol Toxicol & Pharmacol, Res Unit Cellular Signal Integrat, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	daniel.krappmann@helmholtz-muenchen.de	Vincendeau, Michelle/AAD-4320-2022; Krappmann, Daniel/AAT-4354-2021; Krappmann, Daniel/ABF-4038-2021	Krappmann, Daniel/0000-0001-7640-3234; Krappmann, Daniel/0000-0001-7640-3234	Deutsche Krebshilfe; Wilhelm Sander Stiftung	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm Sander Stiftung	We apologize for incomplete citations due to space constraints. We acknowledge support from the Deutsche Krebshilfe and Wilhelm Sander Stiftung to DK.	Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; Brauninger A, 2003, CANCER RES, V63, P1644; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Conze DB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000518; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Copie-Bergman C, 2003, BLOOD, V101, P2756, DOI 10.1182/blood-2002-07-2215; Cormier F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059127; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Du MQ, 2011, HISTOPATHOLOGY, V58, P26, DOI 10.1111/j.1365-2559.2010.03699.x; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Fabre C, 2012, CLIN CANCER RES, V18, P4669, DOI 10.1158/1078-0432.CCR-12-0779; Ferch U, 2009, J EXP MED, V206, P2313, DOI 10.1084/jem.20091167; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Garrison JB, 2009, ONCOGENE, V28, P1584, DOI 10.1038/onc.2009.17; Graham JP, 2010, IMMUNOL REV, V237, P226, DOI 10.1111/j.1600-065X.2010.00932.x; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hailfinger S, 2009, P NATL ACAD SCI USA, V106, P19946, DOI 10.1073/pnas.0907511106; Harhaj EW, 2012, IMMUNOL REV, V246, P107, DOI 10.1111/j.1600-065X.2012.01100.x; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hideshima T, 2006, CLIN CANCER RES, V12, P5887, DOI 10.1158/1078-0432.CCR-05-2501; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; Jeelall YS, 2012, J EXP MED, V209, P1907, DOI 10.1084/jem.20112744; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jourdan M, 2007, BRIT J HAEMATOL, V138, P160, DOI 10.1111/j.1365-2141.2007.06629.x; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kanarek N, 2012, IMMUNOL REV, V246, P77, DOI 10.1111/j.1600-065X.2012.01098.x; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kapatai G, 2007, J CLIN PATHOL, V60, P1342, DOI 10.1136/jcp.2007.050146; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kimm LR, 2007, GENE CHROMOSOME CANC, V46, P1090, DOI 10.1002/gcc.20495; Kingeter LM, 2010, CELL SIGNAL, V22, P9, DOI 10.1016/j.cellsig.2009.09.033; Kloo B, 2011, P NATL ACAD SCI USA, V108, P272, DOI 10.1073/pnas.1008969108; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Kurosaki T, 2009, IMMUNOL REV, V228, P132, DOI 10.1111/j.1600-065X.2008.00748.x; Lake A, 2009, INT J CANCER, V125, P1334, DOI 10.1002/ijc.24502; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lamason RL, 2010, BIOCHEMISTRY-US, V49, P8240, DOI 10.1021/bi101052d; Landgren O, 2009, BLOOD, V113, P5412, DOI 10.1182/blood-2008-12-194241; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lenz G, 2008, P NATL ACAD SCI USA, V105, P13520, DOI 10.1073/pnas.0804295105; Lenz G, 2008, SCIENCE, V319, P1676, DOI 10.1126/science.1153629; Li KX, 2013, BIOORG MED CHEM LETT, V23, P1238, DOI 10.1016/j.bmcl.2013.01.012; Li ZY, 2009, BLOOD, V114, P4158, DOI 10.1182/blood-2008-12-192583; Li ZW, 2008, CURR OPIN HEMATOL, V15, P391, DOI 10.1097/MOH.0b013e328302c7f4; Ling SCW, 2012, HAEMATOL-HEMATOL J, V97, P64, DOI 10.3324/haematol.2011.043331; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Mancao C, 2007, BLOOD, V110, P3715, DOI 10.1182/blood-2007-05-090142; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Mao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060313; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Martin-Subero JI, 2006, BLOOD, V108, P401, DOI 10.1182/blood-2005-09-3843; Mathas S, 2005, BLOOD, V106, P4287, DOI 10.1182/blood-2004-09-3620; McAllister-Lucas LM, 2011, CLIN CANCER RES, V17, P6623, DOI 10.1158/1078-0432.CCR-11-0467; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512; Mortier J, 2010, BIOORG MED CHEM LETT, V20, P4515, DOI 10.1016/j.bmcl.2010.06.027; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; NAUMANN M, 1993, ONCOGENE, V8, P2275; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Noels H, 2007, J BIOL CHEM, V282, P10180, DOI 10.1074/jbc.M611038200; Nogai H, 2013, BLOOD, V122, P2242, DOI 10.1182/blood-2013-06-508028; Nonaka M, 2005, ONCOGENE, V24, P3976, DOI 10.1038/sj.onc.1208564; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Ott G, 1997, CANCER RES, V57, P3944; Otto C, 2012, BRIT J HAEMATOL, V157, P702, DOI 10.1111/j.1365-2141.2012.09113.x; Pang MF, 2009, CELL MOL BIOL LETT, V14, P222, DOI 10.2478/s11658-008-0045-2; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pelzer C, 2013, NAT IMMUNOL, V14, P337, DOI 10.1038/ni.2540; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Ranuncolo SM, 2012, BLOOD, V120, P3756, DOI 10.1182/blood-2012-01-405951; Rawlings DJ, 2006, NAT REV IMMUNOL, V6, P799, DOI 10.1038/nri1944; Re D, 2008, LEUKEMIA LYMPHOMA, V49, P362, DOI 10.1080/10428190701784722; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rosebeck S, 2014, ONCOGENE, V33, P2520, DOI 10.1038/onc.2013.195; Rosebeck S, 2011, FUTURE ONCOL, V7, P613, DOI [10.2217/fon.11.35, 10.2217/FON.11.35]; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Sanchez-Izquierdo D, 2003, BLOOD, V101, P4539, DOI 10.1182/blood-2002-10-3236; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; Schmidt A, 2010, GENE CHROMOSOME CANC, V49, P803, DOI 10.1002/gcc.20789; Schmitz R, 2009, ANNU REV PATHOL-MECH, V4, P151, DOI 10.1146/annurev.pathol.4.110807.092209; Schmitz R, 2009, J EXP MED, V206, P981, DOI 10.1084/jem.20090528; Schwering I, 2003, BLOOD, V101, P1505, DOI 10.1182/blood-2002-03-0839; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Staudt LM, 2005, ADV IMMUNOL, V87, P163, DOI 10.1016/S0065-2776(05)87005-1; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun SC, 2011, CELL RES, V21, P71, DOI 10.1038/cr.2010.177; Thomas RK, 2004, BRIT J HAEMATOL, V126, P50, DOI 10.1111/j.1365-2141.2004.05000.x; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Troen Gunhild, 2013, ISRN Oncol, V2013, P252318, DOI 10.1155/2013/252318; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Ushmorov A, 2006, BLOOD, V107, P2493, DOI 10.1182/blood-2005-09-3765; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Vicente-Duenas C, 2012, P NATL ACAD SCI USA, V109, P10534, DOI 10.1073/pnas.1204127109; Weniger MA, 2007, GENE CHROMOSOME CANC, V46, P406, DOI 10.1002/gcc.20420; Wessendorf S, 2007, LEUKEMIA, V21, P2463, DOI 10.1038/sj.leu.2404919; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wilson WH, 2012, 54 ASH ANN M EXP 8 1; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Ye HT, 2003, BLOOD, V102, P1012, DOI 10.1182/blood-2002-11-3502; Ye HT, 2000, AM J PATHOL, V157, P1147, DOI 10.1016/S0002-9440(10)64630-5; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	149	77	84	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5655	5665		10.1038/onc.2013.565	http://dx.doi.org/10.1038/onc.2013.565			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24469030				2022-12-17	WOS:000346089300001
J	Amelio, I; Markert, EK; Rufini, A; Antonov, AV; Sayan, BS; Tucci, P; Agostini, M; Mineo, TC; Levine, AJ; Melino, G				Amelio, I.; Markert, E. K.; Rufini, A.; Antonov, A. V.; Sayan, B. S.; Tucci, P.; Agostini, M.; Mineo, T. C.; Levine, A. J.; Melino, G.			p73 regulates serine biosynthesis in cancer	ONCOGENE			English	Article						serine; glucose; cancer metabolism; p73; GLS-2; lung adenocarcinoma	PYRUVATE-KINASE M2; CELL-SURVIVAL; P53; METABOLISM; APOPTOSIS; MICE; INSTABILITY; DELTA-NP73; SENESCENCE; DELTANP73	Activation of serine biosynthesis supports growth and proliferation of cancer cells. Human cancers often exhibit overexpression of phosphoglycerate dehydrogenase (PHGDH), the metabolic enzyme that catalyses the reaction that diverts serine biosynthesis from the glycolytic pathway. By refueling serine biosynthetic pathways, cancer cells sustain their metabolic requirements, promoting macromolecule synthesis, anaplerotic flux and ATP. Serine biosynthesis intersects glutaminolysis and together with this pathway provides substrates for production of antioxidant GSH. In human lung adenocarcinomas we identified a correlation between serine biosynthetic pathway and p73 expression. Metabolic profiling of human cancer cell line revealed that TAp73 activates serine biosynthesis, resulting in increased intracellular levels of serine and glycine, associated to accumulation of glutamate, tricarboxylic acid (TCA) anaplerotic intermediates and GSH. However, at molecular level p73 does not directly regulate serine metabolic enzymes, but transcriptionally controls a key enzyme of glutaminolysis, glutaminase-2 (GLS-2). p73, through GLS-2, favors conversion of glutamine in glutamate, which in turn drives the serine biosynthetic pathway. Serine and glutamate can be then employed for GSH synthesis, thus the p73-dependent metabolic switch enables potential response against oxidative stress. In knockdown experiment, indeed, TAp73 depletion completely abrogates cancer cell proliferation capacity in serine/glycine-deprivation, supporting the role of p73 to help cancer cells under metabolic stress. These findings implicate p73 in regulation of cancer metabolism and suggest that TAp73 influences glutamine and serine metabolism, affecting GSH synthesis and determining cancer pathogenesis.	[Amelio, I.; Rufini, A.; Antonov, A. V.; Sayan, B. S.; Tucci, P.; Agostini, M.; Melino, G.] Univ Leicester, Toxicol Unit, Med Res Council, Leicester LE1 9HN, Leics, England; [Markert, E. K.; Levine, A. J.] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [Rufini, A.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 9HN, Leics, England; [Antonov, A. V.] Technol Univ, Mol Pharmacol Lab, St Petersburg, Russia; [Mineo, T. C.] Univ Roma Tor Vergata, Div Thorac Surg, Rome, Italy; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; Institute for Advanced Study - USA; University of Leicester; University of Rome Tor Vergata; University of Rome Tor Vergata	Melino, G (corresponding author), Univ Leicester, Toxicol Unit, Med Res Council, Leicester LE1 9HN, Leics, England.	gm89@le.ac.uk	Agostini, Massimiliano/G-9579-2014; Amelio, Ivano/AAI-4686-2020; Agostini, Massimiliano/AAE-7971-2019	Agostini, Massimiliano/0000-0003-3124-2072; Agostini, Massimiliano/0000-0003-3124-2072; Amelio, Ivano/0000-0002-9126-5391; TUCCI, PAOLA/0000-0002-9349-5203; Sayan, Berna/0000-0003-2305-1970	Medical Research Council, United Kingdom; Ministry of Education and Science of the Russian Federation [11.G34.31.0069, 14.B37.21.1967]; MIUR, MinSan/IDI-IRCCS [RF73, RF57, ACC12]; AIRC [2011-IG11955]; AIRC 5xmille (MCO) [9979]; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ministry of Education and Science of the Russian Federation(Ministry of Education and Science, Russian Federation); MIUR, MinSan/IDI-IRCCS(Ministry of Education, Universities and Research (MIUR)); AIRC(Fondazione AIRC per la ricerca sul cancro); AIRC 5xmille (MCO)(Fondazione AIRC per la ricerca sul cancro); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work has been supported by the Medical Research Council, United Kingdom; MIUR, MinSan/IDI-IRCCS (RF73, RF57), ACC12, AIRC (2011-IG11955), AIRC 5xmille (MCO #9979) to GM Work was supported by Ministry of Education and Science of the Russian Federation (11.G34.31.0069) to GM & (14.B37.21.1967) to AAV.	Adams CM, 2007, J BIOL CHEM, V282, P16744, DOI 10.1074/jbc.M610510200; Al-Bahlani S, 2011, ONCOGENE, V30, P4219, DOI 10.1038/onc.2011.134; ASHIZAWA K, 1991, J BIOL CHEM, V266, P16842; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bantel H, 2010, CELL CYCLE, V9, P2710, DOI 10.4161/cc.9.14.12592; Boren J, 2012, CELL DEATH DIFFER, V19, P1561, DOI 10.1038/cdd.2012.34; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chang JY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.36; Cho JH, 2012, CELL DEATH DIFFER, V19, P703, DOI 10.1038/cdd.2011.142; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Conforti F, 2013, ONCOGENE, V32, P4758, DOI 10.1038/onc.2012.497; Conforti F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.27; Donzelli S, 2012, CELL DEATH DIFFER, V19, P1038, DOI 10.1038/cdd.2011.190; Dulloo I, 2010, P NATL ACAD SCI USA, V107, P4902, DOI 10.1073/pnas.0906782107; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Huang BH, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.180; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kibe R, 2012, CELL DEATH DIFFER, V19, P1139, DOI 10.1038/cdd.2011.203; Leonova KI, 2013, P NATL ACAD SCI USA, V110, pE89, DOI 10.1073/pnas.1216922110; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Masse I, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.62; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Pollari S, 2011, BREAST CANCER RES TR, V125, P421, DOI 10.1007/s10549-010-0848-5; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ravni A, 2010, CELL CYCLE, V9, P1523, DOI 10.4161/cc.9.8.11291; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Sayan BS, 2010, P NATL ACAD SCI USA, V107, P12877, DOI 10.1073/pnas.0911828107; Seo J, 2009, DIABETES, V58, P2565, DOI 10.2337/db09-0335; Soria C, 2010, NATURE, V466, P1076, DOI 10.1038/nature09307; Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Ye JB, 2012, P NATL ACAD SCI USA, V109, P6904, DOI 10.1073/pnas.1204176109	47	77	82	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5039	5046		10.1038/onc.2013.456	http://dx.doi.org/10.1038/onc.2013.456			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24186203	Green Submitted			2022-12-17	WOS:000343768000008
J	Sun, D; Layer, R; Mueller, AC; Cichewicz, MA; Negishi, M; Paschal, BM; Dutta, A				Sun, D.; Layer, R.; Mueller, A. C.; Cichewicz, M. A.; Negishi, M.; Paschal, B. M.; Dutta, A.			Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells	ONCOGENE			English	Article						miRNA cluster; androgen regulation; prostate cancer proliferation	GROWTH-FACTOR-I; CHROMATIN IMMUNOPRECIPITATION; RECEPTOR EXPRESSION; BREAST-CANCER; UP-REGULATION; POLYCOMB; NETWORK; PROTEIN; FAMILY; JMJD3	The androgen receptor (AR) stimulates and represses gene expression to promote the initiation and progression of prostate cancer. Here, we report that androgen represses the miR-99a/let7c/125b-2 cluster through AR and anti-androgen drugs block the androgen-repression of the miRNA cluster. AR directly binds to the host gene of the miR-99a/let7c/125b-2 cluster, LINC00478. Expression of the cluster is repressed or activated by chromatin remodelers EZH2 or JMJD3 in the presence or absence of androgen, respectively. Bioinformatics analysis reveals a significant enrichment of targets of miR-99a, let-7c and miR-125b in androgen-induced gene sets, suggesting that downregulation of the miR-99a/let7c/125b-2 cluster by androgen protects many of their target mRNAs from degradation and indirectly assists in the gene induction. We validated the hypothesis with 12 potential targets of the miR-99a/let7c/125b-2 cluster induced by androgen: 9 out of the 12 mRNAs are downregulated by the microRNA cluster. To ascertain the biological significance of this hypothesis, we focused on IGF1R, a known prostate cancer growth factor that is induced by androgen and directly targeted by the miR-99a/let7c/125b-2 cluster. The androgen-induced cell proliferation is ameliorated to a similar extent as anti-androgen drugs by preventing the repression of the microRNAs or induction of IGF1R in androgen-dependent prostate cancer cells. Expression of a microRNA-resistant form of IGF1R protects these cells from inhibition by the miR-99a/let7c/125b-2 cluster. These results indicate that a thorough understanding of how androgen stimulates prostate cancer growth requires not only an understanding of genes directly induced/repressed by AR, but also of genes indirectly induced by AR through the repression of key microRNAs.	[Sun, D.; Layer, R.; Mueller, A. C.; Cichewicz, M. A.; Negishi, M.; Paschal, B. M.; Dutta, A.] Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Layer, R.] Univ Virginia, Dept Comp Sci, Charlottesville, VA 22908 USA; [Paschal, B. M.] Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Dutta, A (corresponding author), Univ Virginia, Hlth Sci Ctr, Jordan Hall 1240,Box 800733, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Mueller, Adam/0000-0003-2678-0159; Dutta, Anindya/0000-0002-4319-0073	NIH [P01CA104106]; DOD from the US Army DOD [PC094499]; NATIONAL CANCER INSTITUTE [T32CA009109, P01CA104106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD from the US Army DOD; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by P01CA104106 from NIH to AD and BMP and DOD PC094499 from the US Army DOD to DS. We thank members of the Prostate Cancer Research Working group at UVA for helpful discussions.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Antonarakis ES, 2010, CANCER LETT, V291, P1, DOI 10.1016/j.canlet.2009.08.012; Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008-0470; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cardillo MR, 2003, ANTICANCER RES, V23, P3825; Chen ZJ, 2012, ORAL ONCOL, V48, P686, DOI 10.1016/j.oraloncology.2012.02.020; Chlenski A, 2001, PROSTATE, V47, P66; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841; Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009-0310; Ene CI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051407; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Gennigens C, 2006, CRIT REV ONCOL HEMAT, V58, P124, DOI 10.1016/j.critrevonc.2005.10.003; Gommans Willemijn M, 2012, Methods Mol Biol, V822, P1, DOI 10.1007/978-1-61779-427-8_1; Gonit M, 2011, MOL ENDOCRINOL, V25, P621, DOI 10.1210/me.2010-0409; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Guan Y, 2011, INT J CANCER, V128, P2274, DOI 10.1002/ijc.25575; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Jiang JT, 2012, PROSTATE, V72, P225, DOI 10.1002/pros.21430; Jung JW, 2010, CELL MOL LIFE SCI, V67, P1165, DOI 10.1007/s00018-009-0242-9; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kojima S, 2009, INT J UROL, V16, P161, DOI 10.1111/j.1442-2042.2008.02224.x; Lanzino M, 2010, NUCLEIC ACIDS RES, V38, P5351, DOI 10.1093/nar/gkq278; Lee JG, 2009, MOL CARCINOGEN, V48, P141, DOI 10.1002/mc.20462; Liao YD, 2005, HUM PATHOL, V36, P1186, DOI 10.1016/j.humpath.2005.07.023; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mueller AC, 2013, ONCOGENE, V32, P1164, DOI 10.1038/onc.2012.131; Nadiminty N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032832; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nelius T, 2007, INT J CANCER, V121, P999, DOI 10.1002/ijc.22802; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Ngan S, 2009, ONCOGENE, V28, P2051, DOI 10.1038/onc.2009.68; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ozkan EE, 2011, MOL CELL ENDOCRINOL, V344, P1, DOI 10.1016/j.mce.2011.07.002; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Pandini G, 2009, ANN NY ACAD SCI, V1155, P263, DOI 10.1111/j.1749-6632.2009.04361.x; Papatsoris AG, 2005, TRENDS MOL MED, V11, P52, DOI 10.1016/j.molmed.2004.12.005; Piovan C, 2012, MOL ONCOL, V6, P458, DOI 10.1016/j.molonc.2012.03.003; Qin ZHS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-369; Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Richter E, 2007, PROSTATE CANCER P D, V10, P114, DOI 10.1038/sj.pcan.4500936; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Sun JC, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002488; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang WLW, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-58; Wang Y, 2011, GENOMICS, V98, P445, DOI 10.1016/j.ygeno.2011.09.004; Wu JD, 2006, J CELL BIOCHEM, V99, P392, DOI 10.1002/jcb.20929; Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111; Zheng C, 2012, MED ONCOL, V29, P815, DOI 10.1007/s12032-011-9934-8; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	72	77	82	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1448	1457		10.1038/onc.2013.77	http://dx.doi.org/10.1038/onc.2013.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23503464	Green Accepted			2022-12-17	WOS:000332943500012
J	Goicoechea, SM; Garcia-Mata, R; Staub, J; Valdivia, A; Sharek, L; McCulloch, CG; Hwang, RF; Urrutia, R; Yeh, JJ; Kim, HJ; Otey, CA				Goicoechea, S. M.; Garcia-Mata, R.; Staub, J.; Valdivia, A.; Sharek, L.; McCulloch, C. G.; Hwang, R. F.; Urrutia, R.; Yeh, J. J.; Kim, H. J.; Otey, C. A.			Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts	ONCOGENE			English	Article						invasion; GTPases; Cdc42; actin; invadopodia; myofibroblasts	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX DEGRADATION; STROMAL FIBROBLASTS; PODOSOME FORMATION; PROTEIN PALLADIN; BINDING PARTNER; RHO; SRC; CYTOSKELETON; PROGRESSION	The stromal compartment surrounding epithelial-derived pancreatic tumors is thought to have a key role in the aggressive phenotype of this malignancy. Emerging evidence suggests that cancer-associated fibroblasts (CAFs), the most abundant cells in the stroma of pancreatic tumors, contribute to the tumor's invasion, metastasis and resistance to therapy, but the precise molecular mechanisms that regulate CAFs behavior are poorly understood. In this study, we utilized immortalized human pancreatic CAFs to investigate molecular pathways that control the matrix-remodeling and invasion-promoting activity of CAFs. We showed previously that palladin, an actin-associated protein, is expressed at high levels in CAFs of pancreatic tumors and other solid tumors, and also in an immortalized line of human CAFs. In this study, we found that short-term exposure of CAFs to phorbol esters reduced the number of stress fibers and triggered the appearance of individual invadopodia and invadopodial rosettes in CAFs. Molecular analysis of invadopodia revealed that their composition resembled that of similar structures (that is, invadopodia and podosomes) described in other cell types. Pharmacological inhibition and small interfering RNA knockdown experiments demonstrated that protein kinase C, the small GTPase Cdc42 and palladin were necessary for the efficient assembly of invadopodia by CAFs. In addition, GTPase activity assays showed that palladin contributes to the activation of Cdc42. In mouse xenograft experiments using a mixture of CAFs and tumor cells, palladin expression in CAFs promoted the rapid growth and metastasis of human pancreatic tumor cells. Overall, these results indicate that high levels of palladin expression in CAFs enhance their ability to remodel the extracellular matrix by regulating the activity of Cdc42, which in turn promotes the assembly of matrix-degrading invadopodia in CAFs and tumor cell invasion. Together, these results identify a novel molecular signaling pathway that may provide new molecular targets for the inhibition of pancreatic cancer metastasis.	[Goicoechea, S. M.; Garcia-Mata, R.; Staub, J.; Valdivia, A.; Sharek, L.; Otey, C. A.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC USA; [Hwang, R. F.] Univ Toronto, Fac Dent, CIHR Grp Matrix Dynam, Toronto, ON, Canada; [Hwang, R. F.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Urrutia, R.] Mayo Clin, Dept Biochem & Mol Biol, Epigenet & Chromatin Dynam Lab,CIM, Div Gastroenterol & Hepatol,Translat Epigen Progr, Rochester, MN USA; [Yeh, J. J.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA; [Yeh, J. J.; Kim, H. J.; Otey, C. A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Yeh, J. J.; Kim, H. J.] Univ N Carolina, Dept Surg, UNC Sch Med, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Goicoechea, SM (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	Silvia.Goicoechea@utoledo.edu	, Animal Studies Core/ADK-4234-2022; , Animal Studies Core/AAF-4432-2022	Valdivia, Alejandra/0000-0003-1492-5066; Garcia-Mata, Rafael/0000-0002-7116-4411	NIH [GM081505, CA161136, DK52913]; NSF [MCB-1121365]; Elsa U Pardee Foundation; UNC University Cancer Research Fund; CIHR [MOP-36332]; Mayo Clinic Center for Cell Signaling in Gastroenterology [P30DK084567]; Div Of Molecular and Cellular Bioscience [1121365] Funding Source: National Science Foundation; NATIONAL CANCER INSTITUTE [R03CA161136, R01CA140424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, R56DK052913, P30DK084567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081505] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Elsa U Pardee Foundation; UNC University Cancer Research Fund; CIHR(Canadian Institutes of Health Research (CIHR)); Mayo Clinic Center for Cell Signaling in Gastroenterology; Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Angela Mathison (Mayo Clinic College of Medicine) for assistance in generating the imPSCs (imPSC-C2 and imPSC-C3) and Gabriela Herrera for assistance with the AsPC-1 pancreatic tumor cells labeled with firefly luciferase. We also thank Dr Teresa Brentnall (University of Washington) for helpful discussions, and the Lineberger Comprehensive Cancer Center Animal Studies Core for assistance with xenograft experiments. This study was supported by grants from the NIH (GM081505 to CAO; CA161136 to SMG; DK52913 to RU), the NSF (MCB-1121365 to CAO), the Elsa U Pardee Foundation (CAO), the UNC University Cancer Research Fund (SMG), the CIHR (MOP-36332 to CAGM) and the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567 to RU).	Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Alves F, 2001, PANCREAS, V23, P227, DOI 10.1097/00006676-200110000-00002; Arumugam T, 2005, CLIN CANCER RES, V11, P5356, DOI 10.1158/1078-0432.CCR-05-0092; Ayala I, 2009, CANCER RES, V69, P747, DOI 10.1158/0008-5472.CAN-08-1980; Benard V, 2002, METHOD ENZYMOL, V345, P349; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Boukhelifa M, 2006, FEBS J, V273, P26, DOI 10.1111/j.1742-4658.2005.05036.x; Boukhelifa M, 2004, CELL MOTIL CYTOSKEL, V58, P17, DOI 10.1002/cm.10173; Boukhelifa M, 2001, MOL BIOL CELL, V12, P2721, DOI 10.1091/mbc.12.9.2721; Bowden ET, 2001, METHOD CELL BIOL, V63, P613; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Furmaniak-Kazmierczak E, 2007, CIRC RES, V100, P1328, DOI 10.1161/CIRCRESAHA.106.147744; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gimona M, 2003, MOL BIOL CELL, V14, P2482, DOI 10.1091/mbc.E02-11-0743; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Goicoechea S, 2006, J CELL SCI, V119, P3316, DOI 10.1242/jcs.03076; Goicoechea SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010347; Gupta V, PLOS ONE, V6; Hai CM, 2002, EXP CELL RES, V280, P64, DOI 10.1006/excr.2002.5592; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Katz MH, 2003, J SURG RES, V113, P151, DOI 10.1016/S0022-4804(03)00234-8; Kuroiwa M, 2011, J CELL SCI, V124, P1726, DOI 10.1242/jcs.080291; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Luo HJ, 2005, MOL CELL NEUROSCI, V29, P507, DOI 10.1016/j.mcn.2004.12.002; Mathison A, 2010, PANCREATOLOGY, V10, P505, DOI [10.1159/000320540, 10.1016/S1424-3903(10)80035-3]; Micke P, 2005, EXPERT OPIN THER TAR, V9, P1217, DOI 10.1517/14728222.9.6.1217; Mishra PJ, 2009, CANCER RES, V69, P1255, DOI 10.1158/0008-5472.CAN-08-3562; Mizutani K, 2002, CANCER RES, V62, P669; MONSKY WL, 1994, CANCER RES, V54, P5702; Murphy DA, NAT REV MOL CELL BIO, V12, P413; Nakahara H, 2003, GENES CELLS, V8, P1019, DOI 10.1111/j.1365-2443.2003.00695.x; Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Radisky DC, 2007, J CELL BIOCHEM, V101, P830, DOI 10.1002/jcb.21186; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Ronty M, 2005, EXP CELL RES, V310, P88, DOI 10.1016/j.yexcr.2005.06.026; Ronty M, 2007, EXP CELL RES, V313, P2575, DOI 10.1016/j.yexcr.2007.04.030; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salaria SN, 2007, CANCER BIOL THER, V6, P324, DOI 10.4161/cbt.6.3.3904; Tatin F, 2006, J CELL SCI, V119, P769, DOI 10.1242/jcs.02787; TETI A, 1992, AM J PHYSIOL, V263, pC130, DOI 10.1152/ajpcell.1992.263.1.C130; Xiao HL, 2010, MOL CELL BIOL, V30, P5545, DOI 10.1128/MCB.00382-10; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004	52	77	79	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1265	1273		10.1038/onc.2013.68	http://dx.doi.org/10.1038/onc.2013.68			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23524582	Green Accepted, Green Published			2022-12-17	WOS:000332631100007
J	Arensman, MD; Kovochich, AN; Kulikauskas, RM; Lay, AR; Yang, PT; Li, X; Donahue, T; Major, MB; Moon, RT; Chien, AJ; Dawson, DW				Arensman, M. D.; Kovochich, A. N.; Kulikauskas, R. M.; Lay, A. R.; Yang, P-T; Li, X.; Donahue, T.; Major, M. B.; Moon, R. T.; Chien, A. J.; Dawson, D. W.			WNT7B mediates autocrine Wnt/beta-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma	ONCOGENE			English	Article						pancreatic cancer; WNT7B; Wnt/beta-catenin signaling	BETA-CATENIN; HUMAN-DISEASE; TUMOR-CELLS; E-CADHERIN; CANCER; EXPRESSION; PATHWAY; SURVIVAL; TUMORIGENICITY; STABILIZATION	Developmental and cancer models show Wnt/beta-catenin-dependent signaling mediates diverse phenotypic outcomes in the pancreas that are dictated by context, duration and strength of activation. While generally assumed to be pro-tumorigenic, it is unclear to what extent dysregulation of Wnt/beta-catenin signaling impacts tumor progression in pancreatic adenocarcinoma (PDAC). In the present study, Wnt/beta-catenin activity was characterized across a spectrum of PDAC cell lines and primary tumors. Reporter and gene expression-based assays revealed wide heterogeneity in Wnt/beta-catenin transcriptional activity across PDAC cell lines and patient tumors, as well as variable responsiveness to exogenous Wnt ligand stimulation. An experimentally generated, pancreas-specific gene expression signature of Wnt/beta-catenin transcriptional activation was used to stratify pathway activation across a cohort of resected, early-stage PDAC tumors (N = 41). In this cohort, higher Wnt/beta-catenin activation was found to significantly correlate with lymphvascular invasion and worse disease-specific survival (median survival time 20.3 versus 43.9 months, log-rank P = 0.03). Supporting the importance of Wnt ligand in mediating autocrine Wnt signaling, Wnt/beta-catenin activity was significantly inhibited in PDAC cell lines by WLS gene silencing and the small-molecule inhibitor IWP-2, both of which functionally block Wnt ligand processing and secretion. Transcriptional profiling revealed elevated expression of WNT7B occurred in PDAC cell lines with high levels of cell autonomous Wnt/beta-catenin activity. Gene-knockdown studies in AsPC-1 and HPAF-2 cell lines confirmed WNT7B-mediated cell autonomous Wnt/beta-catenin activation, as well as an anchorage-independent growth phenotype. Our findings indicate WNT7B can serve as a primary determinant of differential Wnt/beta-catenin activation in PDAC. Disrupting the interaction between Wnt ligands and their receptors may be a particularly suitable approach for therapeutic modulation of Wnt/beta-catenin signaling in PDAC and other cancer contexts where Wnt activation is mediated by ligand expression rather than mutations in canonical pathway members.	[Arensman, M. D.; Kovochich, A. N.; Lay, A. R.; Li, X.; Dawson, D. W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Kulikauskas, R. M.; Yang, P-T; Moon, R. T.; Chien, A. J.] Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA; [Kulikauskas, R. M.; Yang, P-T; Moon, R. T.; Chien, A. J.] Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA; [Li, X.; Donahue, T.; Dawson, D. W.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Donahue, T.] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Med & Mol & Med Pharmacol, Dept Surg,Div Gen Surg, Los Angeles, CA 90095 USA; [Major, M. B.] Univ North Carolina Chapel Hill, Sch Med, Lineberger Comprehens Canc Ctr, Dept Cell Biol & Physiol, Chapel Hill, NC USA; [Chien, A. J.] Univ Washington, Sch Med, Dept Med, Div Dermatol, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Washington; University of Washington Seattle	Chien, AJ (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	chien@u.washington.edu; ddawson@mednet.ucla.edu	Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019; Dawson, David/I-5917-2014	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Major, Michael/0000-0002-6753-8513	American Cancer Society Research Scholar Grant; American Association for Cancer Research/Pancreatic Cancer Action Network; UCLA Department of Pathology; NCI/NIH [1K08128565]; University of Washington Office of the Provost; UCLA Tumor Biology Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award) [T32 CA009056]; NATIONAL CANCER INSTITUTE [P30CA016042, P01CA163200, K08CA128565, T32CA009056] Funding Source: NIH RePORTER	American Cancer Society Research Scholar Grant(American Cancer Society); American Association for Cancer Research/Pancreatic Cancer Action Network; UCLA Department of Pathology; NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Washington Office of the Provost; UCLA Tumor Biology Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DWD was supported by an American Cancer Society Research Scholar Grant, an American Association for Cancer Research/Pancreatic Cancer Action Network Career Development Award in memory of Seena Magowitz and a Research Services Research Fund Grant from the UCLA Department of Pathology. AJC was supported by a Career Development Award (1K08128565) from the NCI/NIH and Bridge Funding from the University of Washington Office of the Provost. MDA was supported by the UCLA Tumor Biology Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award # T32 CA009056).	American Council of the Teaching of Foreign Language, 2012, CLEARVOICETM TECHN F, P1; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Kovochich AN, 2013, CANCER-AM CANCER SOC, V119, P529, DOI 10.1002/cncr.27725; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978-1-59745-249-6_8; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Chang JT, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-443; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chien AJ, 2007, FRONT BIOSCI-LANDMRK, V12, P448, DOI 10.2741/2074; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Donahue TR, 2012, CLIN CANCER RES, V18, P1352, DOI 10.1158/1078-0432.CCR-11-1539; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Froeling FEM, 2009, AM J PATHOL, V175, P636, DOI 10.2353/ajpath.2009.090131; Gerdes B, 1999, DIGESTION, V60, P544, DOI 10.1159/000007704; Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109; Heiser PW, 2008, GASTROENTEROLOGY, V135, P1288, DOI 10.1053/j.gastro.2008.06.089; Hong SM, 2011, ARCH PATHOL LAB MED, V135, P716, DOI 10.1043/2010-0566-RA.1; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; Lowe AW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000323; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; Port F, 2010, TRAFFIC, V11, P1265, DOI 10.1111/j.1600-0854.2010.01076.x; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607; Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129	38	77	81	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					899	908		10.1038/onc.2013.23	http://dx.doi.org/10.1038/onc.2013.23			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416978	Green Submitted, Green Accepted			2022-12-17	WOS:000331626900011
J	Bhattacharya, A; Schmitz, U; Wolkenhauer, O; Schoenherr, M; Raatz, Y; Kunz, M				Bhattacharya, A.; Schmitz, U.; Wolkenhauer, O.; Schoenherr, M.; Raatz, Y.; Kunz, M.			Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma	ONCOGENE			English	Article						microRNA; melanoma; metastasis; cell cycle	SUPPRESSES TUMORIGENICITY; MICRORNAS; EXPRESSION; GENES; METASTASIS; INHIBITION; MK-1775; PATHWAY; CHK1; P53	WEE1 kinase has been described as a major gate keeper at the G2 cell cycle checkpoint and to be involved in tumour progression in different malignant tumours. Here we analysed the expression levels of WEE1 in a series of melanoma patient samples and melanoma cell lines using immunoblotting, quantitative real-time PCR and immunohistochemistry. WEE1 expression was significantly downregulated in patient samples of metastatic origin as compared with primary melanomas and in melanoma cell lines of high aggressiveness as compared with cell lines of low aggressiveness. Moreover, there was an inverse correlation between the expression of WEE1 and WEE1-targeting microRNA miR-195. Further analyses showed that transfection of melanoma cell lines with miR-195 indeed reduced WEE1 mRNA and protein expression in these cells. Reporter gene analysis confirmed direct targeting of the WEE1 3' untranslated region (3'UTR) by miR-195. Overexpression of miR-195 in SK-Mel-28 melanoma cells was accompanied by WEE1 reduction and significantly reduced stress-induced G2-M cell cycle arrest, which could be restored by stable overexpression of WEE1. Moreover, miR-195 overexpression and WEE1 knockdown, respectively, increased melanoma cell proliferation. miR-195 overexpression also enhanced migration and invasiveness of melanoma cells. Taken together, the present study shows that WEE1 expression in malignant melanoma is directly regulated by miR-195. miR-195-mediated downregulation of WEE1 in metastatic lesions may help to overcome cell cycle arrest under stress conditions in the local tissue microenvironment to allow unrestricted growth of tumour cells.	[Bhattacharya, A.; Schoenherr, M.; Raatz, Y.; Kunz, M.] Univ Leipzig, Dept Dermatol Venereol & Allergol, D-04103 Leipzig, Germany; [Schmitz, U.; Wolkenhauer, O.] Univ Rostock, Dept Syst Biol & Bioinformat, D-18055 Rostock, Germany	Leipzig University; University of Rostock	Bhattacharya, A (corresponding author), Univ Leipzig, Dept Dermatol Venereol & Allergol, Philipp Rosenthal St 23-25, D-04103 Leipzig, Germany.	animesh.bhattacharya@medizin.uni-leipzig.de	Schmitz, Ulf/B-5400-2010	Schmitz, Ulf/0000-0001-5806-4662; Wolkenhauer, Olaf/0000-0001-6105-2937	Deutsche Forschungsgemeinschaft [KU 1320/5-1, WO 991/4-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank T Magin, Translational Centre for Regenerative Medicine (TRM), Division of Cell and Developmental Biology, University of Leipzig, for helpful advice and discussion. This work was supported by the Deutsche Forschungsgemeinschaft, grant number KU 1320/5-1 to MK and grant number WO 991/4-1 to WO.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto O, 2003, MOL CARCINOGEN, V36, P171, DOI 10.1002/mc.10111; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Jewell R, 2010, CLIN CANCER RES, V16, P5211, DOI 10.1158/1078-0432.CCR-10-1521; Bueno MJ, 2011, BBA-MOL BASIS DIS, V1812, P592, DOI 10.1016/j.bbadis.2011.02.002; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Levati L, 2009, INT J ONCOL, V35, P393, DOI 10.3892/ijo_00000352; Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800; Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; Muller DW, 2008, ONCOGENE, V27, P6698, DOI 10.1038/onc.2008.282; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512; Qi JL, 2009, CELL CYCLE, V8, P3729, DOI 10.4161/cc.8.22.10033; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rai D, 2010, P NATL ACAD SCI USA, V107, P3111, DOI 10.1073/pnas.0910667107; Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45; Swarbrick A, 2010, NAT MED, V16, P1134, DOI 10.1038/nm.2227; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Ujifuku K, 2010, CANCER LETT, V296, P241, DOI 10.1016/j.canlet.2010.04.013; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546; Wang YL, 2001, CANCER RES, V61, P8211; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yoshida T, 2004, ANN ONCOL, V15, P252, DOI 10.1093/annonc/mdh073; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	40	77	82	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2013	32	26					3175	3183		10.1038/onc.2012.324	http://dx.doi.org/10.1038/onc.2012.324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22847610				2022-12-17	WOS:000321004600008
J	Little, AS; Smith, PD; Cook, SJ				Little, A. S.; Smith, P. D.; Cook, S. J.			Mechanisms of acquired resistance to ERK1/2 pathway inhibitors	ONCOGENE			English	Review						acquired resistance; BRAF; ERK1/2; MEK1/2; RAS	TYROSINE KINASE INHIBITORS; SIGNAL-REGULATED KINASE; POTENTIAL MECHANISM; AZD6244 ARRY-142886; MEK1/2 INHIBITORS; TUMOR PROGRESSION; DOWN-REGULATION; BRAF GENE; RAF; MUTATIONS	The ERK1/2 (extracellular signal-regulated kinase 1 and 2) pathway, comprising the protein kinases RAF (v-raf-1 murine leukemia viral oncogene homolog 1), MEK1/2 (mitogen-activated protein kinase or ERK kinase 1 and 2) and ERK1/2 is frequently de-regulated in human cancers, due to mutations in RAS or BRAF (v-raf-1 murine leukemia viral oncogene homolog B1). New, highly selective inhibitors of BRAF and MEK1/2 have shown promise in clinical trials, including in previously intractable diseases such as melanoma. However, drug-resistant tumour cells invariably emerge leading to disease progression. It is important to understand the mechanisms underlying such acquired resistance since this may lead to the development of rational strategies either to delay its onset or to overcome it once established. It also offers unique insights into the plasticity of signalling pathways, which may in turn inform our understanding of the basic biology of these pathways and lead to the validation of new drug targets. Several recent reports have identified diverse mechanisms of acquired resistance to MEK1/2 or BRAF inhibitors. In this article, we review these studies, discuss the different mechanisms, identify common themes and consider their therapeutic implications. Oncogene (2013) 32, 1207-1215; doi:10.1038/onc.2012.160; published online 7 May 2012	[Little, A. S.; Cook, S. J.] Babraham Inst, Signalling Lab, Cambridge CB22 3AT, Cambs, England; [Smith, P. D.] AstraZeneca, Oncol iMed, Macclesfield, Cheshire, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; AstraZeneca	Cook, SJ (corresponding author), Babraham Inst, Signalling Lab, Babraham Res Campus, Cambridge CB22 3AT, Cambs, England.	simon.cook@babraham.ac.uk		Cook, Simon/0000-0001-9087-1616	AstraZeneca; BBSRC [BBS/E/B/000C0419, BBS/E/B/000C0417] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0417, BBS/E/B/0000C199, BBS/E/B/000C0419] Funding Source: researchfish; Cancer Research UK [14867] Funding Source: researchfish; Worldwide Cancer Research [12-1259] Funding Source: researchfish	AstraZeneca(AstraZeneca); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	We apologise to colleagues whose work we have not been able to cite due to space limitations. Dr Simon Cook's laboratory was supported by the Babraham Institute, which receives strategic support from the Biotechnology and Biological Sciences Research Council. Work in Dr Cook's laboratory on mechanisms of resistance to ERK1/2 pathway inhibitors was funded by a collaborative research grant from AstraZeneca, which provided Dr Annette Little's salary and research consumables. Neither Dr Cook or Dr Little received any personal renumeration from AstraZeneca. This article is dedicated to the memory of Maureen Cook, a devoted, loving and much-loved mother whose life was blighted by dementia; she is sorely missed.	Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Balmanno K, 2009, INT J CANCER, V125, P2332, DOI 10.1002/ijc.24604; Birtwistle MR, 2011, CELL CYCLE, V10, P2069, DOI 10.4161/cc.10.13.16245; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; BUDAY L, 1995, ONCOGENE, V11, P1327; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delaney AM, 2002, MOL CELL BIOL, V22, P7593, DOI 10.1128/MCB.22.21.7593-7602.2002; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2010, ONCOGENE, V29, P2346, DOI 10.1038/onc.2009.526; Fedorenko IV, 2011, BIOCHEM PHARMACOL, V82, P201, DOI 10.1016/j.bcp.2011.05.015; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gillings AS, 2009, FEBS J, V276, P6050, DOI 10.1111/j.1742-4658.2009.07329.x; Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409; Hammerman PS, 2009, CLIN CANCER RES, V15, P7502, DOI 10.1158/1078-0432.CCR-09-0189; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatzivassiliou G, 2012, MOL CANCER THER, DOI [10.1158/1535-7163, DOI 10.1158/1535-7163]; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; Ji ZY, 2012, TRENDS MOL MED, V18, P27, DOI 10.1016/j.molmed.2011.08.001; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Little AS, 2012, BIOCHEM SOC T, V40, P73, DOI 10.1042/BST20110647; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Meng JR, 2009, CANCER BIOL THER, V8, P2073, DOI 10.4161/cbt.8.21.9844; Milojkovic D, 2009, CLIN CANCER RES, V15, P7519, DOI 10.1158/1078-0432.CCR-09-1068; Modrek B, 2009, MOL CANCER RES, V7, P1244, DOI 10.1158/1541-7786.MCR-08-0532; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nava C, 2007, J MED GENET, V44, P763, DOI 10.1136/jmg.2007.050450; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Paraiso KH, 2012, CLIN CANCER RES, DOI [10.1158/1078-0432, DOI 10.1158/1078-0432]; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Rodriguez-Viciana P, 2008, METHOD ENZYMOL, V438, P277, DOI 10.1016/S0076-6879(07)38019-1; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Smalley KSM, 2008, MOL CANCER THER, V7, P2876, DOI 10.1158/1535-7163.MCT-08-0431; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Tolcher AW, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.2502; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang HS, 2011, CANCER RES, V71, P5535, DOI 10.1158/0008-5472.CAN-10-4351; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Whittaker S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000758; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xi LQ, 2012, BLOOD, V119, P3330, DOI 10.1182/blood-2011-09-379339; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	75	77	81	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2013	32	10					1207	1215		10.1038/onc.2012.160	http://dx.doi.org/10.1038/onc.2012.160			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22562245				2022-12-17	WOS:000316454500001
J	Muramatsu, F; Kidoya, H; Naito, H; Sakimoto, S; Takakura, N				Muramatsu, F.; Kidoya, H.; Naito, H.; Sakimoto, S.; Takakura, N.			microRNA-125b inhibits tube formation of blood vessels through translational suppression of VE-cadherin	ONCOGENE			English	Article						microRNA; mir125b; angiogenesis; VE-cadherin	VASCULAR MORPHOGENESIS; ENDOTHELIAL-CELLS; IN-VIVO; ANGIOGENESIS; EXPRESSION; RECEPTOR; GROWTH; MICE; STEM; SYSTEM	Angiogenesis is controlled positively or negatively by extrinsic and intrinsic molecular cues in endothelial cells (ECs); in the tumor microenvironment, the action of positive regulators exceeds that of negative regulators. Thus, overinduction of negative regulators may inhibit tumor angiogenesis. MicroRNAs (miRNAs or miRs) are endogenous short noncoding RNAs regulating gene expression either through translational inhibition or destabilization of target mRNA. Here, we show that miR-125b expression is transiently induced in ECs on stimulation with vascular endothelial growth factor or by ischemia. miR-125b inhibits translation of vascular endothelial (VE)-cadherin mRNA and in vitro tube formation by ECs. Injection of miR-125b into the tumor inhibited VE-cadherin expression by ECs and induced nonfunctional blood vessel formation, resulting in inhibition of tumor growth. It has been suggested that pro-angiogenic signals in ECs also upregulate anti-angiogenic molecules simultaneously via negative feedback. Because miR-125b induction in ECs is transient after pro-angiogenic stimulation, prolonged overexpression of miR-125b could result in blood vessel regression. Thus, miR-125b may be useful in cancer therapy by causing the collapse of the lumen of ECs. Oncogene (2013) 32, 414-421; doi:10.1038/onc.2012.68; published online 5 March 2012	[Muramatsu, F.; Kidoya, H.; Naito, H.; Sakimoto, S.; Takakura, N.] Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, Suita, Osaka 5650871, Japan; [Takakura, N.] CREST, JST, Tokyo, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takakura, N (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	ntakaku@biken.osaka-u.ac.jp		Naito, Hisamichi/0000-0002-0750-1743	Ministry of Education, Science, Sports, and Culture of Japan	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank S Fukuhara and N Mochizuki for supplying VE-cadherin expression plasmid, and K Fukuhara and N Fujimoto for technical assistance. This work was partly supported by a grant from the Ministry of Education, Science, Sports, and Culture of Japan.	Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Baumer S, 2006, BLOOD, V107, P4754, DOI 10.1182/blood-2006-01-0141; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chen YH, 2003, BIOCHEM BIOPH RES CO, V310, P804, DOI 10.1016/j.bbrc.2003.09.081; Crosby CV, 2005, BLOOD, V105, P2771, DOI 10.1182/blood-2004-06-2244; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gotsch U, 1997, J CELL SCI, V110, P583; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Kidoya H, 2012, ONCOGENE, V31, P3254, DOI 10.1038/onc.2011.489; Kidoya H, 2008, EMBO J, V27, P522, DOI 10.1038/sj.emboj.7601982; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Nagahama Y, 2010, CANCER RES, V70, P1215, DOI 10.1158/0008-5472.CAN-09-3662; Niola F, 2006, CANCER BIOL THER, V5, P174, DOI 10.4161/cbt.5.2.2317; Okamoto R, 2005, BLOOD, V105, P2757, DOI 10.1182/blood-2004-08-3317; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Takakura N, 2006, CANCER SCI, V97, P568, DOI 10.1111/j.1349-7006.2006.00223.x; Vestweber D, 2009, TRENDS CELL BIOL, V19, P8, DOI 10.1016/j.tcb.2008.10.001; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Yamada Y, 2006, J EXP MED, V203, P1055, DOI 10.1084/jem.20050373; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107	36	77	86	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					414	421		10.1038/onc.2012.68	http://dx.doi.org/10.1038/onc.2012.68			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391569				2022-12-17	WOS:000315551300002
J	Samanta, S; Sharma, VM; Khan, A; Mercurio, AM				Samanta, S.; Sharma, V. M.; Khan, A.; Mercurio, A. M.			Regulation of IMP3 by EGFR signaling and repression by ER beta: implications for triple-negative breast cancer	ONCOGENE			English	Article						breast cancer; IMP3; ER beta; EGFR	GROWTH-FACTOR RECEPTOR; RNA-BINDING PROTEIN; ESTROGEN-RECEPTOR; MESSENGER-RNA; CELL-PROLIFERATION; EXPRESSION; CARCINOMA; ACTIVATION; KINASE; BIOMARKER	Insulin-like growth factor II (IGF-II) mRNA-binding protein 3 (IMP3) is emerging as a useful indicator of the progression and outcome of several cancers. IMP3 expression is associated with triple-negative breast carcinomas (TNBCs), which are aggressive tumors associated with poor outcome. In this study, we addressed the hypothesis that signaling pathways, which are characteristic of TNBCs, impact the expression of IMP3 and that IMP3 contributes to the function of TNBCs. The data obtained reveal that IMP3 expression is repressed specifically by estrogen receptor beta (ER beta) and its ligand 3 beta A-diol but not by ER alpha. Epidermal growth factor receptor (EGFR) signaling and consequent activation of the mitogen-activated protein kinase pathway induce IMP3 transcription and expression. Interestingly, we discovered that the EGFR promoter contains an imperfect estrogen response element and that ER beta represses EGFR transcription. These data support a mechanism in which ER beta inhibits IMP3 expression indirectly by repressing the EGFR. This mechanism relates to the biology of TNBC, which is characterized by diminished ER beta and increased EGFR expression. We also demonstrate that IMP3 contributes to the migration and invasion of breast carcinoma cells. Given that IMP3 is an mRNA-binding protein, we determined that it binds several key mRNAs that could contribute to migration and invasion, including CD164 (endolyn) and MMP9. Moreover, expression of these mRNAs is repressed by ER beta and enhanced by EGFR signaling, consistent with our proposed mechanism for the regulation of IMP3 expression in breast cancer cells. Our findings show that IMP3 is an effector of EGFR-mediated migration and invasion and they provide the first indication of how this important mRNA-binding protein is regulated in cancer.	[Samanta, S.; Sharma, V. M.; Mercurio, A. M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Khan, A.] UMass Mem Med Ctr, Dept Pathol, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St,Lazare Res Bldg, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu			NIH [CA80789, 89209]; NATIONAL CANCER INSTITUTE [R01CA080789, R01CA089209] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH Grants CA80789 and 89209 supported this work. We thank Dr Xiofang Yang for her input into this project, and Drs Paul Mak and Hira Lal Goel for their valuable suggestions and technical assistance. We also thank Bryan Pursell for his technical support.	Agrawal A, 2005, ENDOCR-RELAT CANCER, V12, pS135, DOI 10.1677/erc.1.01059; Belotti D, 2003, CANCER RES, V63, P5224; Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305; CASTRO CG, 1993, ARCH GYNECOL OBSTET, V252, P169, DOI 10.1007/BF02426354; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Guerini V, 2005, CANCER RES, V65, P5445, DOI 10.1158/0008-5472.CAN-04-1941; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Havens AM, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-195; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; Irvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034; Jiang Z, 2006, LANCET ONCOL, V7, P556, DOI 10.1016/S1470-2045(06)70732-X; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475; Li CZ, 2007, MODERN PATHOL, V20, P242, DOI 10.1038/modpathol.3800735; Li DW, 2009, ANN SURG ONCOL, V16, P3499, DOI 10.1245/s10434-009-0648-5; Li S, 2011, HEAD NECK-J SCI SPEC, V33, P368, DOI 10.1002/hed.21457; Li Z, 2011, J BIOL CHEM, V286, P21164, DOI 10.1074/jbc.M110.207571; Liao BS, 2011, J BIOL CHEM, V286, P31145, DOI 10.1074/jbc.M111.263913; Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200; Lu D, 2011, AM J SURG PATHOL, V35, P1638, DOI 10.1097/PAS.0b013e31823272d4; Mak P, 2006, NEOPLASIA, V8, P896, DOI 10.1593/neo.06538; Marotti JD, 2010, MODERN PATHOL, V23, P197, DOI 10.1038/modpathol.2009.158; MARTINAZZI M, 1993, J CLIN PATHOL, V46, P1009, DOI 10.1136/jcp.46.11.1009; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; NEWBY JC, 1995, BRIT J CANCER, V71, P1237, DOI 10.1038/bjc.1995.239; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pinton G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014110; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Ryden L, 2010, BREAST CANCER RES TR, V120, P491, DOI 10.1007/s10549-010-0758-6; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Simon R, 2007, HUM PATHOL, V38, P1178, DOI 10.1016/j.humpath.2007.02.001; Suvasini R, 2011, J BIOL CHEM, V286, P25882, DOI 10.1074/jbc.M110.178012; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Van Meter TE, 2004, NEURO-ONCOLOGY, V6, P188, DOI 10.1215/S1152851703000486; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Webb Paul, 2003, Nucl Recept, V1, P4, DOI 10.1186/1478-1336-1-4; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Yantiss RK, 2005, AM J SURG PATHOL, V29, P188, DOI 10.1097/01.pas.0000149688.98333.54; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zeng ZS, 1999, CARCINOGENESIS, V20, P749, DOI 10.1093/carcin/20.5.749; Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458; Zheng WX, 2008, AM J SURG PATHOL, V32, P304, DOI 10.1097/PAS.0b013e3181483ff8	52	77	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4689	4697		10.1038/onc.2011.620	http://dx.doi.org/10.1038/onc.2011.620			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266872	Green Accepted			2022-12-17	WOS:000310724400004
J	Mura, M; Swain, RK; Zhuang, X; Vorschmitt, H; Reynolds, G; Durant, S; Beesley, JFJ; Herbert, JMJ; Sheldon, H; Andre, M; Sanderson, S; Glen, K; Luu, NT; McGettrick, HM; Antczak, P; Falciani, F; Nash, GB; Nagy, Z; Bicknell, R				Mura, M.; Swain, R. K.; Zhuang, X.; Vorschmitt, H.; Reynolds, G.; Durant, S.; Beesley, J. F. J.; Herbert, J. M. J.; Sheldon, H.; Andre, M.; Sanderson, S.; Glen, K.; Luu, N-T; McGettrick, H. M.; Antczak, P.; Falciani, F.; Nash, G. B.; Nagy, Zs; Bicknell, R.			Identification and angiogenic role of the novel tumor endothelial marker CLEC14A	ONCOGENE			English	Article						tumor vasculature; gene expression; cell migration; shear stress	GENE-EXPRESSION; SOLID TUMORS; MAGIC ROUNDABOUT; CELL GENES; FLOW; THROMBOMODULIN; PROGRESSION; RESPONSES; RECEPTOR; SURFACE	Tumor endothelial markers (TEMs) that are highly expressed in human tumor vasculature compared with vasculature in normal tissue hold clear therapeutic potential. We report that the C-type lectin CLEC14A is a novel TEM. Immunohistochemical and immunofluorescence staining of tissue arrays has shown that CLEC14A is strongly expressed in tumor vasculature when compared with vessels in normal tissue. CLEC14A overexpression in tumor vessels was seen in a wide range of solid tumor types. Functional studies showed that CLEC14A induces filopodia and facilitates endothelial migration, tube formation and vascular development in zebrafish that is, CLEC14A regulates pro-angiogenic phenotypes. CLEC14A antisera inhibited cell migration and tube formation, suggesting that anti-CLEC14A antibodies may have anti-angiogenic activity. Finally, in endothelial cultures, expression of CLEC14A increased at low shear stress, and we hypothesize that low shear stress due to poor blood flow in the disorganized tumor vasculature induces expression of CLEC14A on tumor vessels and pro-angiogenic phenotypes. Oncogene (2012) 31, 293-305; doi:10.1038/onc.2011.233; published online 27 June 2011	[Mura, M.; Swain, R. K.; Zhuang, X.; Vorschmitt, H.; Durant, S.; Beesley, J. F. J.; Herbert, J. M. J.; Bicknell, R.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect Sci, Angiogenesis Grp,Ctr Cardiovasc Sci,Inst Biomed R, Birmingham B15 2TT, W Midlands, England; [Mura, M.; Swain, R. K.; Zhuang, X.; Vorschmitt, H.; Durant, S.; Beesley, J. F. J.; Herbert, J. M. J.; Bicknell, R.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Angiogenesis Grp,Ctr Cardiovasc Sci,Inst Biomed R, Birmingham B15 2TT, W Midlands, England; [Reynolds, G.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Liver Labs,Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Sheldon, H.; Andre, M.; Sanderson, S.; Bicknell, R.] Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK Angiogenesis Grp, Oxford OX3 9DU, England; [Glen, K.; Luu, N-T; McGettrick, H. M.; Nash, G. B.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Res, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; [Antczak, P.; Falciani, F.] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; [Nagy, Zs] Univ Birmingham, Coll Med & Dent, Sch Clin & Expt Med, Neurodegenerat & Repair Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Oxford; University of Birmingham; University of Birmingham; University of Birmingham	Bicknell, R (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect Sci, Angiogenesis Grp,Ctr Cardiovasc Sci,Inst Biomed R, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	r.bicknell@bham.ac.uk	Reynolds, Gary/F-8641-2014; Nagy, Zsuzsanna/L-8446-2013; Nash, Gerard B/E-4182-2010; McGettrick, Helen M/H-3442-2011; Antczak, Philipp/L-5879-2019	Reynolds, Gary/0000-0002-3250-0582; Nagy, Zsuzsanna/0000-0002-6700-4829; Nash, Gerard B/0000-0002-5935-2831; McGettrick, Helen M/0000-0002-5950-8840; Antczak, Philipp/0000-0001-9600-7757; Swain, Rajeeb/0000-0003-4815-8221; Sheldon, Helen/0000-0002-0945-5496; Bicknell, Roy/0000-0002-0941-8919; Zhuang, Alan Xiaodong/0000-0002-6870-9003	Cancer Research UK [C4719/A6766, C4719/A9601]; British Heart Foundation; Medical Research Council [G9818340] Funding Source: researchfish; MRC [G9818340] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Professor Maria Grazia Lampugnani, IFOM-FIRC Institute for Molecular Oncology, Milan, for the gift of the BU9 anti-human VE cadherin mouse monoclonal antibody; and Dr Raj Mehta, Cancer Research Technology for helpful discussions. This work was supported by program grant number C4719/A6766 and project grant number C4719/A9601 from the Cancer Research UK to RB. RB and GBN acknowledge financial support from the British Heart Foundation. Umbilical cords were collected with the assistance of the Birmingham Women's Health Care NHS Trust.	Ando J, 2009, CIRC J, V73, P1983, DOI 10.1253/circj.CJ-09-0583; Armstrong LJ, 2008, ARTERIOSCL THROM VAS, V28, P1640, DOI 10.1161/ATVBAHA.108.162511; Bohlson SS, 2005, J IMMUNOL, V175, P1239, DOI 10.4049/jimmunol.175.2.1239; BURROWS FJ, 1993, P NATL ACAD SCI USA, V90, P8996, DOI 10.1073/pnas.90.19.8996; Chaplin DJ, 1997, TUMOUR ANGIOGENESIS, P61; Chen-Konak L, 2003, FASEB J, V17, P2121, DOI 10.1096/fj.02-1151fje; Chinnasamy D, 2010, J CLIN INVEST, V120, P3953, DOI 10.1172/JCI43490; Chu TJ, 2008, PHYSIOL GENOMICS, V34, P185, DOI 10.1152/physiolgenomics.90201.2008; Dachs GU, 1998, SEMIN RADIAT ONCOL, V8, P208, DOI 10.1016/S1053-4296(98)80046-5; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Gomez GA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004994; Gullino PM., 1975, CANCER, V3, P327; He J, 2009, CLIN CANCER RES, V15, P6871, DOI 10.1158/1078-0432.CCR-09-1499; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbert JMJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-153; Ho M, 2003, PHYSIOL GENOMICS, V13, P249, DOI 10.1152/physiolgenomics.00186.2002; HOLTHOFER H, 1982, LAB INVEST, V47, P60; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Huijbers EJM, 2010, FASEB J, V24, P4535, DOI 10.1096/fj.10-163022; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Huminiecki L, 2000, GENOME RES, V10, P1796, DOI 10.1101/gr.150700; JAIN RK, 1988, CANCER RES, V48, P2641; MacFadyen JR, 2005, FEBS LETT, V579, P2569, DOI 10.1016/j.febslet.2005.03.071; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; Matharu NM, 2008, J CELL PHYSIOL, V216, P732, DOI 10.1002/jcp.21457; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Pham VN, 2007, DEV BIOL, V303, P772, DOI 10.1016/j.ydbio.2006.10.030; Porat RM, 2004, CIRC RES, V94, P394, DOI 10.1161/01.RES.0000111803.92923.D6; Reynolds GM, 2002, BRIT J HAEMATOL, V118, P195, DOI 10.1046/j.1365-2141.2002.03575.x; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Sheikh S, 2004, J IMMUNOL METHODS, V288, P35, DOI 10.1016/j.jim.2004.02.005; Siemann DW, 2011, CANCER TREAT REV, V37, P63, DOI 10.1016/j.ctrv.2010.05.001; St Croix B, 2000, SCIENCE, V289, P1197; Sumanas S, 2005, BLOOD, V106, P534, DOI 10.1182/blood-2004-12-4653; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Tomar A, 2009, J CELL SCI, V122, P1852, DOI 10.1242/jcs.046870; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Wasserman SM, 2004, VASC MED, V9, P35, DOI 10.1191/1358863x04vm521ra; Woo KV, 2011, J CLIN INVEST, V121, P1624, DOI 10.1172/JCI42040; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	46	77	82	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					293	305		10.1038/onc.2011.233	http://dx.doi.org/10.1038/onc.2011.233			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21706054				2022-12-17	WOS:000299542100003
J	Bender, A; Opel, D; Naumann, I; Kappler, R; Friedman, L; von Schweinitz, D; Debatin, KM; Fulda, S				Bender, A.; Opel, D.; Naumann, I.; Kappler, R.; Friedman, L.; von Schweinitz, D.; Debatin, K-M; Fulda, S.			PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis	ONCOGENE			English	Article						apoptosis; PI3K; neuroblastoma; chemotherapy	TRAIL-INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; MEMBRANE PERMEABILIZATION; CONFORMATIONAL-CHANGE; PANCREATIC-CARCINOMA; UP-REGULATION; IN-VIVO; CANCER; MCL-1; BAX	We recently identified activation of phosphatidylinositol 30'-kinase (PI3K)/Akt as a novel predictor of poor outcome in neuroblastoma. Here, we investigated the effect of small-molecule PI3K inhibitors on chemosensitivity. We provide first evidence that PI3K inhibitors, for example PI103, synergize with various chemotherapeutics (Doxorubicin, Etoposide, Topotecan, Cisplatin, Vincristine and Taxol) to trigger apoptosis in neuroblastoma cells (combination index: high synergy). Mechanistic studies reveal that PI103 cooperates with Doxorubicin to reduce Mcl-1 expression and Bim(EL) phosphorylation and to upregulate Noxa and BimEL levels. This shifted ratio of pro-and antiapoptotic Bcl-2 proteins results in increased Bax/Bak conformational change, loss of mitochondrial membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Although Mcl-1 knockdown enhances Doxorubicin- and PI103-induced apoptosis, silencing of Noxa, Bax/Bak or p53 reduces apoptosis, underscoring the functional relevance of the Doxorubicin-and PI103-mediated modulation of these proteins for chemosensitization. Bcl-2 overexpression inhibits Bax activation, mitochondrial perturbations, cleavage of caspases and Bid, and apoptosis, confirming the central role of the mitochondrial pathway for chemosensitization. Interestingly, the broad-range caspase inhibitor zVAD.fmk does not interfere with Bax activation or mitochondrial outer membrane permeabilization, whereas it blocks caspase activation and apoptosis, thus placing mitochondrial events upstream of caspase activation. Importantly, PI103 and Doxorubicin cooperate to induce apoptosis and to suppress tumor growth in patients' derived primary neuroblastoma cells and in an in vivo neuroblastoma model, underlining the clinical relevance of the results. Thus, targeting PI3K presents a novel and promising strategy to sensitize neuroblastoma cells for chemotherapy-induced apoptosis, which has important implications for the development of targeted therapies for neuroblastoma. Oncogene (2011) 30, 494-503; doi: 10.1038/onc.2010.429; published online 20 September 2010	[Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Bender, A.; Opel, D.; Naumann, I.; Debatin, K-M] Univ Childrens Hosp, Dept Hematol Oncol, Ulm, Germany; [Kappler, R.; von Schweinitz, D.] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat Surg, Munich, Germany; [Friedman, L.] Genentech Inc, Dept Canc Signaling, San Francisco, CA 94080 USA	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Roche Holding; Genentech	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Kappler, Roland/0000-0002-8581-2803; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; BMBF; Novartis Stiftung fur Therapeutische Forschung; European Community [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); BMBF(Federal Ministry of Education & Research (BMBF)); Novartis Stiftung fur Therapeutische Forschung; European Community(European Commission)	We thank CA Schmitt (Berlin, Germany) for providing mouse Bcl-2 vector, C Haag (Ulm, Germany) for providing Mcl-1 knockdown SH-EP cells, A Dittrich (Ulm, Germany) for providing expert technical assistance and B Welz (Ulm, Germany) for providing excellent secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, BMBF, Novartis Stiftung fur Therapeutische Forschung, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Ammann JU, 2009, INT J CANCER, V124, P1301, DOI 10.1002/ijc.24068; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chiarini F, 2009, CANCER RES, V69, P3520, DOI 10.1158/0008-5472.CAN-08-4884; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fakler M, 2009, BLOOD, V113, P1710, DOI 10.1182/blood-2007-09-114314; Fei PW, 2002, CANCER RES, V62, P7316; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2009, CURR CANCER DRUG TAR, V9, P729, DOI 10.2174/156800909789271521; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Guillard S, 2009, CELL CYCLE, V8, P443, DOI 10.4161/cc.8.3.7643; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Jaboin J, 2002, CANCER RES, V62, P6756; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Niedermeier M, 2009, BLOOD, V113, P5549, DOI 10.1182/blood-2008-06-165068; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Vogler M, 2007, ONCOGENE, V26, P248, DOI 10.1038/sj.onc.1209776; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Vogler M, 2009, CANCER RES, V69, P2425, DOI 10.1158/0008-5472.CAN-08-2436; Warr MR, 2008, CURR MOL MED, V8, P138; Westhoff MA, 2009, ONCOGENE, V28, P3586, DOI 10.1038/onc.2009.215; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200	40	77	79	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					494	503		10.1038/onc.2010.429	http://dx.doi.org/10.1038/onc.2010.429			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856197				2022-12-17	WOS:000286621600011
J	di Martino, E; L'Hote, CG; Kennedy, W; Tomlinson, DC; Knowles, MA				di Martino, E.; L'Hote, C. G.; Kennedy, W.; Tomlinson, D. C.; Knowles, M. A.			Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner	ONCOGENE			English	Article						fibroblast growth factor; FGFR3; bladder; urothelium; signaling	FGFR3 MUTATIONS; DIFFERENTIAL EXPRESSION; BLADDER; ACTIVATION; DYSPLASIA; PHOSPHORYLATION; CARCINOMA; STAT1; ACHONDROPLASIA; UBIQUITYLATION	Although activating mutations of fibroblast growth factor receptor 3 (FGFR3) are frequent in bladder tumors, little information is available on their specific effects in urothelial cells or the basis for the observed mutation spectrum. We investigated the phenotypic and signaling consequences of three FGFR3 mutations (S249C, Y375C, and K652E) in immortalized normal human urothelial cells (TERT-NHUC) and mouse fibroblasts (NIH-3T3). In TERT-NHUC, all mutant forms of FGFR3 induced phosphorylation of FRS2 alpha and ERK1/2, but not AKT or SRC. PLC gamma 1 phosphorylation was only observed in TERT-NHUC expressing the common S249C and Y375C mutations, and not the rare K652E mutation. Cells expressing S249C and Y375C FGFR3 displayed an increased saturation density, related to increased proliferation and viability. This effect was significantly dependent on PLC gamma 1 signaling and undetectable in cells expressing K652E FGFR3, which failed to phosphorylate PLC gamma 1. In contrast to TERT-NHUC, expression of mutant FGFR3 in NIH-3T3 resulted in phosphorylation of Src and Akt. In addition, all forms of mutant FGFR3 were able to phosphorylate Plc gamma 1 and induce morphological transformation, cell proliferation, and anchorage-independent growth. Our results indicate that the effects of mutant FGFR3 are both cell type specific and mutation specific. Mutant FGFR3 may confer a selective advantage in the urothelium by overcoming normal contact inhibition of proliferation. Oncogene (2009) 28, 4306-4316; doi: 10.1038/onc.2009.280; published online 14 September 2009	[di Martino, E.; L'Hote, C. G.; Kennedy, W.; Tomlinson, D. C.; Knowles, M. A.] St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Oncol, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Knowles, MA (corresponding author), St James Univ Hosp, Leeds Inst Mol Med, Sect Expt Oncol, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk		Tomlinson, Darren/0000-0003-4134-7484; di Martino, Erica/0000-0001-6703-1707; Knowles, Margaret/0000-0002-9363-8657	Cancer Research UK [C6228/A5433]	Cancer Research UK(Cancer Research UK)	We acknowledge Dr D Podolsky for donating the FGFR3 IIIb cDNA, and Dr R Agami for the pFB expression vector. This work was funded by a grant from Cancer Research UK (C6228/A5433).	Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; Agazie YM, 2003, ONCOGENE, V22, P6909, DOI 10.1038/sj.onc.1206798; Bernard-Pierrot I, 2006, CARCINOGENESIS, V27, P740, DOI 10.1093/carcin/bgi290; Bonaventure J, 2007, FEBS J, V274, P3078, DOI 10.1111/j.1742-4658.2007.05835.x; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Chen J, 2005, BLOOD, V106, P328, DOI 10.1182/blood-2004-09-3686; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; Davies-Adetugbo AA, 1998, TROP MED INT HEALTH, V3, P9, DOI 10.1046/j.1365-3156.1998.00162.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Gibbs L, 2007, BBA-MOL CELL RES, V1773, P502, DOI 10.1016/j.bbamcr.2006.12.010; Guy M, 2001, BRIT J CANCER, V84, P520, DOI 10.1054/bjoc.2000.1635; Hafner C, 2006, CELL CYCLE, V5, P2723, DOI 10.4161/cc.5.23.3509; Harada D, 2007, BONE, V41, P273, DOI 10.1016/j.bone.2006.11.030; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; Karoui M, 2001, ONCOGENE, V20, P5059, DOI 10.1038/sj.onc.1204651; Korkolopoulou P, 2002, EUR UROL, V41, P274, DOI 10.1016/S0302-2838(02)00003-9; Legeai-Mallet L, 2004, BONE, V34, P26, DOI 10.1016/j.bone.2003.09.002; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Lievens PMJ, 2006, J MOL BIOL, V357, P783, DOI 10.1016/j.jmb.2006.01.058; Lievens PMJ, 2003, J BIOL CHEM, V278, P17344, DOI 10.1074/jbc.M212710200; Martinez-Torrecuadrada JM, 2005, CLIN CANCER RES, V11, P6280, DOI 10.1158/1078-0432.CCR-05-0282; Monsonego-Ornan E, 2002, FEBS LETT, V528, P83, DOI 10.1016/S0014-5793(02)03255-6; Murakami M, 2008, CARDIOVASC RES, V78, P223, DOI 10.1093/cvr/cvm086; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Ornitz DM, 2001, GENOME BIOL, V2; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Sibley K, 2001, ONCOGENE, V20, P4416, DOI 10.1038/sj.onc.1204543; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Tomlinson D, 2007, ONCOGENE, V26, P5889, DOI 10.1038/sj.onc.1210399; Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207; Tomlinson DC, 2005, CANCER RES, V65, P10441, DOI 10.1158/0008-5472.CAN-05-1718; van Oers JMM, 2006, INT J CANCER, V119, P1212, DOI 10.1002/ijc.21958; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Wallerand H, 2005, CARCINOGENESIS, V26, P177, DOI 10.1093/carcin/bgh275; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Wells A, 2003, CLIN EXP METASTAS, V20, P285, DOI 10.1023/A:1024088922957; YAMAMOTO H, 1995, BRIT J CANCER, V71, P1231, DOI 10.1038/bjc.1995.238	46	77	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4306	4316		10.1038/onc.2009.280	http://dx.doi.org/10.1038/onc.2009.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749790	Green Accepted			2022-12-17	WOS:000272876300008
J	Radpour, R; Kohler, C; Haghighi, MM; Fan, AXC; Holzgreve, W; Zhong, XY				Radpour, R.; Kohler, C.; Haghighi, M. M.; Fan, A. X. C.; Holzgreve, W.; Zhong, X. Y.			Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array	ONCOGENE			English	Article						breast cancer; DNA methylation; MALDI-TOF; mass spectrometry	DNA METHYLATION; PROMOTER METHYLATION; COLORECTAL CANCERS; SERUM; LANDSCAPES; PATTERNS; CLEAVAGE	Alterations of DNA methylation patterns have been suggested as biomarkers for diagnostics and therapy of cancers. Every novel discovery in the epigenetic landscape and every development of an improved approach for accurate analysis of the events may offer new opportunity for the management of patients. Using a novel high-throughput mass spectrometry on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) silico-chips, we determined semiquantitative methylation changes of 22 candidate genes in breast cancer tissues. For the first time we analysed the methylation status of a total of 42 528 CpG dinucleotides on 22 genes in 96 different paraffin-embedded tissues (48 breast cancerous tissues and 48 paired normal tissues). A two-way hierarchical cluster analysis was used to classify methylation profiles. In this study, 10 hypermethylated genes (APC, BIN1, BMP6, BRCA1, CST6, ESRb, GSTP1, P16, P21 and TIMP3) were identified to distinguish between cancerous and normal tissues according to the extent of methylation. Individual assessment of the methylation status for each CpG dinucleotide indicated that cytosine hypermethylation in the cancerous tissue samples was mostly located near the consensus sequences of the transcription factor binding sites. These hypermethylated genes may serve as biomarkers for clinical molecular diagnosis and targeted treatments of patients with breast cancer. Oncogene (2009) 28, 2969-2978; doi:10.1038/onc.2009.149; published online 8 June 2009	[Zhong, X. Y.] Univ Basel, Univ Basel Hosp, Womens Hosp, Lab Prenatal Med & Gynecol Oncol,Dept Biomed, CH-4031 Basel, Switzerland; [Haghighi, M. M.] E Tehran Branch, IAU, Fac Sci, Dept Biol, Tehran, Iran; [Holzgreve, W.] Univ Med Ctr Freiburg, Freiburg, Germany	University of Basel; University of Freiburg	Zhong, XY (corresponding author), Univ Basel, Univ Basel Hosp, Womens Hosp, Lab Prenatal Med & Gynecol Oncol,Dept Biomed, Hebelstr 20,Room 416, CH-4031 Basel, Switzerland.	zhongx@uhbs.ch	Fan, Alex X/I-8247-2014; Radpour, Ramin/J-4949-2014	Fan, Alex X/0000-0003-0433-9864; Radpour, Ramin/0000-0002-5632-7833	Swiss National Science Foundation [320000-119722/1]; Swiss Cancer League; Krebsliga Beider Basel; Dr Hans Altschueler Stiftung	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Krebsliga Beider Basel; Dr Hans Altschueler Stiftung	We thank Professor Charles Cantor (SEQUENOM) for reading the manuscript and making critical comments, Vivian Kiefer for her excellent assistance and Regan Geissmann for proofreading the text. We are indebted to the patients for their cooperation. This work was supported in part by Swiss National Science Foundation (320000-119722/1) and Swiss Cancer League, Krebsliga Beider Basel and Dr Hans Altschueler Stiftung.	Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Ehrich M, 2008, P NATL ACAD SCI USA, V105, P4844, DOI 10.1073/pnas.0712251105; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Nakayama H, 2003, INT J CANCER, V105, P491, DOI 10.1002/ijc.11117; Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Stanssens P, 2004, GENOME RES, V14, P126; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Trent JM, 2007, SCIENCE, V318, P1079, DOI 10.1126/science.1151428; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Zhang YJ, 2007, CLIN CANCER RES, V13, P2378, DOI 10.1158/1078-0432.CCR-06-1900; Zou HZ, 2002, CLIN CANCER RES, V8, P188	20	77	82	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2969	2978		10.1038/onc.2009.149	http://dx.doi.org/10.1038/onc.2009.149			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19503099				2022-12-17	WOS:000269142800005
J	Zagurovskaya, M; Shareef, MM; Das, A; Reeves, A; Gupta, S; Sudol, M; Bedford, MT; Prichard, J; Mohiuddin, M; Ahmed, MM				Zagurovskaya, M.; Shareef, M. M.; Das, A.; Reeves, A.; Gupta, S.; Sudol, M.; Bedford, M. T.; Prichard, J.; Mohiuddin, M.; Ahmed, M. M.			EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells	ONCOGENE			English	Article						EGR-1; YAP-1; Bax; prostate cancer; radiation	YES-ASSOCIATED PROTEIN; IONIZING-RADIATION; APOPTOSIS; TRANSCRIPTION; P53; CANCER; DOMAIN; GENE; RESISTANCE; INDUCTION	In this study, we investigated the functional role of early growth response-1 (Egr1 gene) in the regulation of radiation-induced clonogenic inhibition and apoptosis in p53 wild-type and mutant prostate cancer cells 22Rv1 and DU145, respectively. 22Rv1 cells were more sensitive to irradiation compared with DU145 cells, and the sensitivity was enhanced by overexpression of EGR-1 in both cells. Dominant-negative EGR-1 mutant (dnEGR-1) or repressor of EGR-1, NGFIA binding protein 1 (NAB1), increased radioresistance of these cells. Significant activation of caspases 3 and 9 and Bcl2-associated X (Bax) with increased poly(ADP-ribose) polymerase (PARP) cleavage and cytochrome c release was observed in radiation-exposed EGR-1 overexpressing cells. Gel shift analysis and chloramphenicol acetyl transferase (CAT) reporter assays indicate that EGR-1 transactivates the promoter of the Bax gene. Interaction of EGR-1 and Yes kinase-associated protein 1 (YAP-1) through the WW domain of YAP-1 enhances the transcriptional activity of EGR-1 on the Bax promoter as shown by chromatin immunoprecipitation and reporter assays. Irradiation of PC3 cell xenografts that were treated with adenoviral EGR-1 showed significant regression in tumor volume. These findings establish the radiation-induced pro-apoptotic action of EGR-1, in a p53-independent manner, by directly transactivating Bax, and prove that alters the B-cell CLL/lymphoma 2 (Bcl-2)/Bax ratio as one of the mechanisms resulting in significant activation of caspases, leading to cell death through the novel interaction of EGR-1 with YAP-1.	[Das, A.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA; [Bedford, M. T.] Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX USA; [Prichard, J.] Weis Ctr Res, Geisinger Clin, Dept Pathol, Danville, PA 17822 USA; [Mohiuddin, M.] Geisinger Med Clin, Geisinger Fox Chase Canc Ctr, Wilkes Barre, PA USA; [Ahmed, M. M.] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA	Virginia Commonwealth University; University of Texas System; UTMD Anderson Cancer Center; Fox Chase Cancer Center; Geisinger Medical Center; Fox Chase Cancer Center	Ahmed, MM (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.	amansoor@med.miami.edu	Das, Anindita/K-8003-2013; Bedford, Mark T/E-7856-2011; Ahmed, Mansoor/AAK-5988-2020	Das, Anindita/0000-0003-4422-7277; 	NIH [RO1 CA78471, DK62345]; PCRP-DOD [PC 970526, WB1XWH-04-1-0039]; Pennsylvania Department of Health [SAP4100037378]; Welch Foundation [G-1495]; NATIONAL CANCER INSTITUTE [R01CA078471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK062345] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PCRP-DOD; Pennsylvania Department of Health; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants, NIH (RO1 CA78471), PCRP-DOD (PC 970526) and Charlotte Geyer foundation to MMA; post-doctoral training grant, PCRP-DOD (WB1XWH-04-1-0039) to MZ; NIH (DK62345) and Pennsylvania Department of Health Grant (SAP4100037378) to MMS and Welch Foundation Grant (G-1495) to MTB.	Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Ahmed MM, 1997, J BIOL CHEM, V272, P33056, DOI 10.1074/jbc.272.52.33056; Ahmed MM, 1996, J BIOL CHEM, V271, P29231, DOI 10.1074/jbc.271.46.29231; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DAY ML, 1993, CANCER RES, V53, P5597; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eid MA, 1998, CANCER RES, V58, P2461; Espejo Alexsandra, 2004, Methods Mol Biol, V264, P173; Kalkhoven E, 2004, BIOCHEM PHARMACOL, V68, P1145, DOI 10.1016/j.bcp.2004.03.045; KYPRIANOU N, 1994, WORLD J UROL, V12, P299; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; MATHENY C, 1994, J BIOL CHEM, V269, P8176; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Strano S, 2007, MOL CELL, V27, P863, DOI 10.1016/j.molcel.2007.09.004; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030	29	77	80	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	8					1121	1131		10.1038/onc.2008.461	http://dx.doi.org/10.1038/onc.2008.461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137013				2022-12-17	WOS:000263722900007
J	Maliekal, TT; Bajaj, J; Giri, V; Subramayam, D; Krishna, S				Maliekal, T. T.; Bajaj, J.; Giri, V.; Subramayam, D.; Krishna, S.			The role of Notch signaling in human cervical cancer: implications for solid tumors	ONCOGENE			English	Review						Notch; cervical cancer; HPV	HUMAN-PAPILLOMAVIRUS TYPE-16; SUPPRESSOR PATHWAYS; NEOPLASTIC LESIONS; EPITHELIAL-CELLS; CARCINOMA CELLS; GROWTH ARREST; TRANSFORMATION; EXPRESSION; ONCOGENES; E6	The detection of intracellular forms of Notch1 in human cervical cancers more than a decade ago prompted an investigation into the possible role of this pathway in driving these cancers. These tumors are consistently characterized by features of deregulated ligand-dependent signaling. Although Notch signaling complements the function of papillomavirus oncogenes in transformation assays of human keratinocytes, there are dose-dependent effects, which inhibit growth of established cervical cancer cell lines. Two pro-oncogenic effector mechanisms that have been suggested to operate in this context by Notch signaling are the activation of PI3K/Akt pathway and the upregulation of c-Myc. Collectively, there is a complex interplay between Notch signaling and papillomaviruses in the context of cervical carcinogenesis. Better animal model systems and identification of human cervical cancer stem cells should help clarify the possible stage specific and pleiotropic effects and regulation of Notch signaling.	[Maliekal, T. T.; Bajaj, J.; Subramayam, D.; Krishna, S.] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; [Giri, V.] KIDWAI Mem Inst Oncol, Dept Radiotherapy, Bangalore, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); Kidwai Memorial Institute of Oncology	Krishna, S (corresponding author), Tata Inst Fundamental Res, Natl Ctr Biol Sci, GKVK Campus, Bangalore 560065, Karnataka, India.	skrishna@ncbs.res.in		Subramanyam, Deepa/0000-0002-1650-5690; Maliekal, Tessy/0000-0002-7311-7950	Department of Science and Technology and Council for Scientific and Industrial Research; Department of Biotechnology; TIFR	Department of Science and Technology and Council for Scientific and Industrial Research; Department of Biotechnology; TIFR	Maliekal TT and Bajaj J acknowledge Department of Science and Technology and Council for Scientific and Industrial Research, respectively, for financial support. Our research was supported by Department of Biotechnology and by core grants of TIFR.	Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chakrabarti O, 2004, J VIROL, V78, P5934, DOI 10.1128/JVI.78.11.5934-5945.2004; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Jones EE, 2006, CURR MOL MED, V6, P795; Lathion S, 2003, CANCER RES, V63, P8687; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Pett MR, 2004, CANCER RES, V64, P1359, DOI 10.1158/0008-5472.CAN-03-3214; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; REID R, 1983, GYNECOL ONCOL, V15, P239, DOI 10.1016/0090-8258(83)90080-X; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Subramanyam D, 2006, VIROLOGY, V347, P191, DOI 10.1016/j.virol.2005.11.028; Talora C, 2005, EXP CELL RES, V305, P343, DOI 10.1016/j.yexcr.2005.01.015; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Veeraraghavalu K, 2005, J VIROL, V79, P7889, DOI 10.1128/JVI.79.12.7889-7898.2005; Veeraraghavalu K, 2004, J VIROL, V78, P8687, DOI 10.1128/JVI.78.16.8687-8700.2004; Wang L, 2007, INT J GYNECOL CANCER, V17, P1283, DOI 10.1111/j.1525-1438.2007.00927.x; Weijzen S, 2003, J CELL PHYSIOL, V194, P356, DOI 10.1002/jcp.10217; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yugawa T, 2007, MOL CELL BIOL, V27, P3732, DOI 10.1128/MCB.02119-06; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	28	77	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5110	5114		10.1038/onc.2008.224	http://dx.doi.org/10.1038/onc.2008.224			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758479				2022-12-17	WOS:000258914900004
J	Tao, Y; Zhang, P; Girdler, F; Frascogna, V; Castedo, M; Bourhis, J; Kroemer, G; Deutsch, E				Tao, Y.; Zhang, P.; Girdler, F.; Frascogna, V.; Castedo, M.; Bourhis, J.; Kroemer, G.; Deutsch, E.			Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152	ONCOGENE			English	Article						cell cycle; checkpoints; AZD1152 Aurora-B; ionizing radiation; p53	SPINDLE ASSEMBLY CHECKPOINT; MITOTIC CATASTROPHE; DNA-DAMAGE; P53; APOPTOSIS; PHOSPHORYLATION; DIVISION; VX-680; GROWTH; DEATH	Overexpression of the Aurora-B kinase correlates with oncogenic transformation and poor prognosis. We evaluated the effects of the bona. de Aurora-B kinase inhibitor AZD1152 on tumor responses to ionizing radiation (IR). When p53(wt) HCT116 and A549 cells were pretreated with AZD1152-HQPA prior to IR, additive effects were observed. Interestingly, more pronounced tumoricidal effects were observed in p53-deficient HCT116 and HT29 cells, as well as A549 cells treated with the p53 inhibitor cyclic pifithrin-a. In vivo studies on xenografted mice confirmed enhanced tumor growth delay after the combination of IR plus AZD1152-IR as compared to IR alone. Again, this effect was more pronounced with p53(-/-) HCT116 and p53-mutant xenografts. The AZD1152-mediated radiosensitization was mimicked by knockdown of Aurora-B with a short interference RNA or by inhibition of Aurora-B by transfection with an inducible kinase-dead Aurora-B. The radiosensitizing effect of AZD1152 was lost in CHK2(-/-) and 14-3-3(-/-) HCT116 cells. Altogether, these data indicate that AZD1152 can radiosensitize tumor cell lines in vitro and in vivo, the fact that these effects are exacerbated in p53-deficient cancer cells is of potential interest for further clinical development.	[Tao, Y.; Zhang, P.; Frascogna, V.; Bourhis, J.; Deutsch, E.] Inst Gustave Roussy, PRI, Lab UPRES Radiosensit Tumors & Normal Tissues EA2, F-94805 Villejuif, France; [Tao, Y.; Bourhis, J.; Kroemer, G.] Univ Paris 11, Le Kremlin Bicetre, France; [Tao, Y.] Fu Dan Hosp, Canc Hosp, Shanghai, Peoples R China; [Girdler, F.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Castedo, M.; Kroemer, G.] INSERM, U848, Villejuif, France; [Tao, Y.; Zhang, P.; Frascogna, V.; Castedo, M.; Bourhis, J.; Kroemer, G.; Deutsch, E.] Inst Gustave Roussy, Villejuif, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Fudan University; University of Manchester; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Deutsch, E (corresponding author), Inst Gustave Roussy, PRI, Lab UPRES Radiosensit Tumors & Normal Tissues EA2, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	deutsch@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405; deutsch, eric/0000-0002-8223-3697; Bourhis, Jean/0000-0001-5162-1171; Zhang, Ping/0000-0002-3043-8738; tao, yungan/0000-0002-6916-5263				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andrews PD, 2005, ONCOGENE, V24, P5005, DOI 10.1038/sj.onc.1208752; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gadea BB, 2005, MOL BIOL CELL, V16, P1305, DOI 10.1091/mbc.E04-10-0891; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gizatullin F, 2006, CANCER RES, V66, P7668, DOI 10.1158/0008-5472.CAN-05-3353; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Milas L, 1999, SEMIN RADIAT ONCOL, V9, P12; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Wilkinson RW, 2007, CLIN CANCER RES, V13, P3682, DOI 10.1158/1078-0432.CCR-06-2979; Zhang P, 2006, ONCOGENE, V25, P7758, DOI 10.1038/sj.onc.1209744; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	31	77	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3244	3255		10.1038/sj.onc.1210990	http://dx.doi.org/10.1038/sj.onc.1210990			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084327				2022-12-17	WOS:000256111400003
J	Khaleque, M; Bharti, A; Gong, J; Gray, PJ; Sachdev, V; Ciocca, DR; Stati, A; Fanelli, M; Calderwood, SK				Khaleque, Ma; Bharti, A.; Gong, J.; Gray, P. J.; Sachdev, V.; Ciocca, D. R.; Stati, A.; Fanelli, M.; Calderwood, S. K.			Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1	ONCOGENE			English	Article						heat shock factor; metastasis; associated protein	METASTASIS-ASSOCIATED PROTEIN-1; C-FOS; GENE; CANCER; EXPRESSION; PHOSPHORYLATION; 14-3-3-EPSILON; CHAPERONES; COMPLEXES; APOPTOSIS	Heat shock factor 1 (HSF1), the transcriptional activator of the heat shock genes, is increasingly implicated in cancer. We have shown that HSF1 binds to the corepressor metastasis-associated protein 1 (MTA1) in vitro and in human breast carcinoma samples. HSF1-MTA1 complex formation was strongly induced by the transforming ligand heregulin and complexes incorporated a number of additional proteins including histone deacetylases (HDAC1 and 2) and Mi2 alpha, all components of the NuRD corepressor complex. These complexes were induced to assemble on the chromatin of MCF7 breast carcinoma cells and associated with the promoters of estrogen-responsive genes. Such HSF1 complexes participate in repression of estrogen-dependent transcription in breast carcinoma cells treated with heregulin and this effect was inhibited by MTA1 knockdown. Repression of estrogen-dependent transcription may contribute to the role of HSF1 in cancer.	[Khaleque, Ma; Gray, P. J.; Calderwood, S. K.] Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, Boston, MA 02215 USA; [Khaleque, Ma] NS Univ, Dept Biochem, Dhaka, Bangladesh; [Bharti, A.; Gong, J.; Sachdev, V.; Calderwood, S. K.] Boston Univ, Dept Med, Mendoza, Argentina; [Ciocca, D. R.; Stati, A.; Fanelli, M.] Inst Expt Med & Biol Cuyo, Lab Oncol, Mendoza, Argentina	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dept Radiat Oncol, BIDMC, 21-27 Burlington Ave,5th Floor, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu		Khaleque, Md Abdul/0000-0002-6873-9165	NATIONAL CANCER INSTITUTE [R01CA077465] Funding Source: NIH RePORTER; NCI NIH HHS [CA077465] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bewick M, 1999, BONE MARROW TRANSPL, V24, P377, DOI 10.1038/sj.bmt.1701907; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Gago G, 2006, J BACTERIOL, V188, P477, DOI 10.1128/JB.188.2.477-486.2006; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Jones EL, 2004, INT J HYPERTHER, V20, P835, DOI 10.1080/02656730410001721807; Khaleque MA, 2005, ONCOGENE, V24, P6564, DOI 10.1038/sj.onc.1208798; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Neubauer BL, 2003, CANCER RES, V63, P6056; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Wang XZ, 2006, J BIOL CHEM, V281, P782, DOI 10.1074/jbc.M505822200; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Xie Y, 2003, J BIOL CHEM, V278, P4687, DOI 10.1074/jbc.M210189200; Xie Y, 2002, J BIOL CHEM, V277, P11802, DOI 10.1074/jbc.M109296200; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200	24	77	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1886	1893		10.1038/sj.onc.1210834	http://dx.doi.org/10.1038/sj.onc.1210834			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17922035				2022-12-17	WOS:000254150600008
J	Kamranvar, SA; Gruhne, B; Szeles, A; Masucci, MG				Kamranvar, S. A.; Gruhne, B.; Szeles, A.; Masucci, M. G.			Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma	ONCOGENE			English	Article						EBV; Burkitt's lymphoma; chromosome; aberrations; genomic instability	CELL-LINES; CHROMOSOMAL-ABERRATIONS; DNA-REPAIR; C-MYC; GENETIC INSTABILITY; B-CELLS; TELOMERASE; TRANSLOCATIONS; ABNORMALITIES; INFECTION	Epstein-Barr virus (EBV) has been implicated in the pathogenesis of human malignancies but the mechanisms of oncogenesis remain largely unknown. Genomic instability and chromosomal aberrations are hallmarks of malignant transformation. We report that EBV carriage promotes genomic instability in Burkitt's lymphoma (BL). Cytogenetic analysis of EBV-and EBV+ BL lines and their sublines derived by EBV conversion or spontaneous loss of the viral genome revealed a significant increase in dicentric chromosomes, chromosome fragments and chromatid gaps in EBV-carrying cells. Expression of EBV latency I was suf. ficient for this effect, whereas a stronger effect was observed in cells expressing latency III. Telomere analysis by. fluorescent in situ hybridization revealed an overall increase of telomere size and prevalence of telomere fusion and double strand-break fusion in dicentric chromosomes from EBV+ cells. Phosphorylated H2AX, a reporter of DNA damage and ongoing repair, was increased in virus-carrying cells in the absence of exogenous stimuli, whereas efficient activation of DNA repair was observed in both EBV + and EBV- cells following treatment withetopos ide. These. findings point to induction of telomere dysfunction and DNA damage as important mechanisms for EBV oncogenesis.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 275, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria G/B-8588-2009; Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809				BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; Cao J, 2002, MUTAT RES-FUND MOL M, V504, P85, DOI 10.1016/S0027-5107(02)00082-9; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chan WY, 2002, DIAGN MOL PATHOL, V11, P127, DOI 10.1097/00019606-200209000-00001; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; Chen F, 2005, INT J CANCER, V113, P284, DOI 10.1002/ijc.20594; Dolcetti R, 2003, J CELL PHYSIOL, V196, P207, DOI 10.1002/jcp.10263; Dolcetti R, 2006, PROGRESS IN VIRUS RESEARCH, P191; Gualandi G, 2001, MUTAGENESIS, V16, P203, DOI 10.1093/mutage/16.3.203; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; Jox A, 1997, ANN ONCOL, V8, P131, DOI 10.1023/A:1008215207384; Karpova MB, 2006, INT J ONCOL, V28, P605; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; KUHNHALLEK I, 1995, BLOOD, V85, P1289, DOI 10.1182/blood.V85.5.1289.bloodjournal8551289; Liu MT, 2005, ONCOGENE, V24, P2635, DOI 10.1038/sj.onc.1208319; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Mochida A, 2005, ARCH VIROL, V150, P2139, DOI 10.1007/s00705-005-0557-2; O'Nions J, 2003, ONCOGENE, V22, P7181, DOI 10.1038/sj.onc.1206838; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Potter M, 1997, CURR TOP MICROBIOL, V224, P1; Raptis S, 2006, EXP SUPPL, V96, P303; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Shao JY, 2001, ANTICANCER RES, V21, P3021; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; STOLLMANN B, 1985, BRIT J HAEMATOL, V60, P183, DOI 10.1111/j.1365-2141.1985.tb07399.x; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Urushibara A, 2004, BIOCHEM BIOPH RES CO, V313, P1037, DOI 10.1016/j.bbrc.2003.12.039; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; ZattaraCannoni H, 1996, LEUKEMIA LYMPHOMA, V21, P515, DOI 10.3109/10428199609093453; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; Zimonjic DB, 2001, LEUKEMIA, V15, P1582, DOI 10.1038/sj.leu.2402281	36	77	80	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5115	5123		10.1038/sj.onc.1210324	http://dx.doi.org/10.1038/sj.onc.1210324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17325665				2022-12-17	WOS:000248487400010
J	Strefford, JC; Worley, H; Barber, K; Wright, S; Stewart, ARM; Robinson, HM; Bettney, G; van Delft, FW; Atherton, MG; Davies, T; Griffiths, M; Hing, S; Ross, FM; Talley, P; Saha, V; Moorman, AV; Harrison, CJ				Strefford, J. C.; Worley, H.; Barber, K.; Wright, S.; Stewart, A. R. M.; Robinson, H. M.; Bettney, G.; van Delft, F. W.; Atherton, M. G.; Davies, T.; Griffiths, M.; Hing, S.; Ross, F. M.; Talley, P.; Saha, V.; Moorman, A. V.; Harrison, C. J.			Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization	ONCOGENE			English	Article						array; CGH; acute lymphoblastic leukemia; copy number	ACUTE LYMPHOCYTIC-LEUKEMIA; CHROMOSOMAL-ABNORMALITIES; MYELOID-LEUKEMIA; CELL LYMPHOMA; DELETIONS; AMPLIFICATION; MALIGNANCIES; CYTOGENETICS; CGH; IDENTIFICATION	Chromosomal abnormalities are important for the classification and risk stratification of patients with acute lymphoblastic leukemia (ALL). However, approximately 30% of childhood and 50% of adult patients lack abnormalities with clinical relevance. Here, we describe the use of array-based comparative genomic hybridization (aCGH) to identify copy number alterations (CNA) in 58 ALL patients. CNA were identified in 83% of cases, and most frequently involved chromosomes 21 (n = 42), 9 (n = 21), 6 (n = 16), 12 (n = 11), 15 (n = 11), 8 (n = 10) and 17 (n = 10). Deletions of 6q (del(6q)) were heterogeneous in size, in agreement with previous data, demonstrating the sensitivity of aCGH to measure CNA. Although 9p deletions showed considerable variability in both the extent and location, all encompassed the CDKN2A locus. Six patients showed del(12p), with a common region encompassing the ETV6 gene. Complex CNA were observed involving chromosomes 6 (n = 2), 15 (n = 2) and 21 (n = 11) with multiple regions of loss and gain along each chromosome. Chromosome 21 CNA shared a common region of gain, with associated subtelomeric deletions. Other recurrent findings included dim(13q), dim(16q) and enh(17q). This is the first report of genome-wide detection of CNA in ALL patients using aCGH, and it has demonstrated a higher level of karyotype complexity than anticipated from conventional cytogenetic analysis.	Southmead Hosp, S W Reg Cytogenet Ctr, Bristol, Avon, England; Queen Mary Univ London, Inst Canc, Canc Res UK Childrens Canc Grp, London, England; Liverpool Womens Hosp, Merseyside & Cheshire Genet Lab, Liverpool, Merseyside, England; Birmingham Womens Hosp, W Midlands Reg Genet Lab, Birmingham, W Midlands, England; Inst Canc Res, Sect Paediat Oncol, Sutton, Surrey, England; Royal Marsden Hosp, Sutton, Surrey, England; Wessex Reg Genet Lab, Salisbury, Wilts, England; Sheffield Childrens Hosp, Sheffield Reg Cytogenet Serv, Sheffield, S Yorkshire, England; Univ Southampton, Canc Sci Div, Leukaemia Res Cytogenet Grp, Southampton SO9 5NH, Hants, England	Southmead Hospital; Cancer Research UK; University of London; Queen Mary University London; University of Liverpool; Birmingham Women's Hospital; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Southampton	Strefford, JC (corresponding author), Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Leukaemia Res Cytogenet Grp, MP822 Duthie Bldg, Southampton SO16 6YD, Hants, England.	JCS@soton.ac.uk	Moorman, Anthony/F-5518-2010; Strefford, Jonathan/B-2826-2009; Moorman, Anthony/G-1468-2014	Strefford, Jonathan/0000-0002-0972-2881; Moorman, Anthony/0000-0002-9781-6107; Harrison, Christine/0000-0002-0526-6794; van Delft, Frederik Willem/0000-0002-3704-3720; Saha, Vaskar/0000-0002-2916-9649				Attarbaschi A, 2004, LEUKEMIA, V18, P1611, DOI 10.1038/sj.leu.2403471; BEHRENDT H, 1995, LEUKEMIA, V9, P102; Berger R, 2003, LEUKEMIA, V17, P1851, DOI 10.1038/sj.leu.2403061; Bertin R, 2003, GENE CHROMOSOME CANC, V37, P44, DOI 10.1002/gcc.10188; Chung CY, 2000, CANCER, V88, P1359, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1359::AID-CNCR12>3.3.CO;2-H; Clark R, 2000, LEUKEMIA, V14, P241, DOI 10.1038/sj.leu.2401654; Faderl S, 1998, BLOOD, V91, P3995, DOI 10.1182/blood.V91.11.3995; Fioretos T, 1999, BLOOD, V94, P225, DOI 10.1182/blood.V94.1.225.413k24_225_232; Foroni L, 2003, BLOOD, V102, p606A; Haas OA, 1998, LEUKEMIA, V12, P474, DOI 10.1038/sj.leu.2400943; Hann I, 2001, BRIT J HAEMATOL, V113, P103, DOI 10.1046/j.1365-2141.2001.02668.x; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; Harrison CJ, 2005, BRIT J HAEMATOL, V129, P520, DOI 10.1111/j.1365-2141.2005.05497.x; Heerema NA, 2000, J CLIN ONCOL, V18, P3837, DOI 10.1200/JCO.2000.18.22.3837; Heerema NA, 2004, LEUKEMIA, V18, P939, DOI 10.1038/sj.leu.2403327; Horsley SW, 2006, GENE CHROMOSOME CANC, V45, P554, DOI 10.1002/gcc.20317; HOSOYA N, 2006, GENES CHROMOSOMES CA; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; *ISCN, 2005, INT SYST HUM CYT NOM; Jackson A, 2000, CANCER RES, V60, P2775; Jong K, 2004, BIOINFORMATICS, V20, P3636, DOI 10.1093/bioinformatics/bth355; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Larramendy ML, 1998, LEUKEMIA, V12, P1638, DOI 10.1038/sj.leu.2401142; Martinez-Ramirez A, 2005, GENE CHROMOSOME CANC, V42, P287, DOI 10.1002/gcc.20154; Mirebeau D, 2006, HAEMATOL-HEMATOL J, V91, P881; Moorman AV, 2003, BLOOD, V102, P2756, DOI 10.1182/blood-2003-04-1128; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Nakashima Y, 2005, GENE CHROMOSOME CANC, V44, P247, DOI 10.1002/gcc.20245; Paulsson K, 2006, LEUKEMIA, V20, P840, DOI 10.1038/sj.leu.2404145; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PUI CH, 1989, BLOOD, V73, P1963; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Raghavan M, 2005, CANCER RES, V65, P375; Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140; ROMANA SP, 1994, GENE CHROMOSOME CANC, V9, P186, DOI 10.1002/gcc.2870090307; Rubio-Moscardo F, 2005, BLOOD, V105, P4445, DOI 10.1182/blood-2004-10-3907; RUCKER FG, 2006, J CLIN ONCOL; Scheurlen WG, 1999, GENE CHROMOSOME CANC, V25, P230, DOI 10.1002/(SICI)1098-2264(199907)25:3<230::AID-GCC5>3.0.CO;2-E; Scholz I, 2001, CANCER GENET CYTOGEN, V124, P89, DOI 10.1016/S0165-4608(00)00330-7; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sinclair PB, 2004, CANCER RES, V64, P4089, DOI 10.1158/0008-5472.CAN-03-1871; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Strefford JC, 2006, P NATL ACAD SCI USA, V103, P8167, DOI 10.1073/pnas.0602360103; Strehl S, 2003, LEUKEMIA, V17, P1121, DOI 10.1038/sj.leu.2402923; Takeuchi S, 2003, ONCOGENE, V22, P6970, DOI 10.1038/sj.onc.1206974; Tyybakinoja A, 2006, GENE CHROMOSOME CANC, V45, P257, DOI 10.1002/gcc.20288; van Zutven L, 2005, LEUKEMIA, V19, P1281, DOI 10.1038/sj.leu.2403769; VANVLIERBERGHE P, 2006, BLOOD	48	77	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4306	4318		10.1038/sj.onc.1210190	http://dx.doi.org/10.1038/sj.onc.1210190			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17237825				2022-12-17	WOS:000247619900013
J	Cowger, JJM; Zhao, Q; Isovic, M; Torchia, J				Cowger, J. J. M.; Zhao, Q.; Isovic, M.; Torchia, J.			Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence	ONCOGENE			English	Article						ZNF217; zinc-finger; CoREST; breast cancer; CAST	EPITHELIAL-MESENCHYMAL TRANSITIONS; BREAST-CANCER; E-CADHERIN; COREST; COMPONENT; GENE; CTBP; COREPRESSOR; REGION; 20Q13	Zinc-finger protein 217 (ZNF217) is a Kruppel-like zinc-finger protein located at 20q13.2, within a region of recurrent maximal amplification. Here, we demonstrate that ZNF217 is a transcriptional repressor protein and report the purification and characterization of a ZNF217 complex. The purified ZNF217 complex consists of approximately six proteins and contains the transcriptional co-repressors CoREST, BHC110/LSD1, histone deacetylase (HDAC) 2 and C-terminal binding protein (CtBP1). The purified ZNF217 complex possesses deacetylase activity as well as lysine 4 histone H3-specific demethylase activity that is most likely mediated by the BHC110/LSD1 component. To determine if ZNF217 is a sequence-specific binding protein, we have made use of cyclic amplification and selection of targets (CAST) assay and identify for the first time a ZNF217 DNA consensus recognition sequence (CRS) that is highly conserved in the human E-cadherin promoter. Chromatin immunoprecipitation (ChIP) experiments demonstrate that ZNF217, as well as the other components of the ZNF217 complex, are found on the region of the proximal E-cadherin promoter that contains the identified ZNF217 CRS in vivo. Using a combination of transient transfections and small interfering RNA, we demonstrate that ZNF217 represses the E-cadherin promoter. Collectively, our results implicate ZNF217 and its associated proteins in a novel pathway that may have profound effects on cancer progression.	Univ Western Ontario, London Reg Canc Program, Dept Oncol, London, ON N6A 3K7, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 3K7, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Torchia, J (corresponding author), London Reg Canc Program, Canc Res Labs, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	jtorchia@uwo.ca	Zhao, Qingshi/H-9839-2013					Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bukholm IK, 2000, J PATHOL, V190, P15; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dellaire G, 2002, MOL CELL BIOL, V22, P5141, DOI 10.1128/MCB.22.14.5141-5156.2002; Elrod-Erickson M, 1999, J BIOL CHEM, V274, P19281, DOI 10.1074/jbc.274.27.19281; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Nishimura G, 2002, ONCOL REP, V9, P479; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454	30	77	80	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3378	3386		10.1038/sj.onc.1210126	http://dx.doi.org/10.1038/sj.onc.1210126			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130829				2022-12-17	WOS:000246579600007
J	Davies, AJ				Davies, A. J.			Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab	ONCOGENE			English	Review						radioimmunotherapy; non-Hodgkin's lymphoma; tositumomab; ibritumomab; monoclonal antibodies; CD20	NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; CHEMOTHERAPY PLUS RITUXIMAB; HIGH-DOSE THERAPY; MONOCLONAL-ANTIBODY THERAPY; BONE-MARROW-TRANSPLANTATION; RANDOMIZED CONTROLLED-TRIAL; MULTICENTER PHASE-II; REFRACTORY LOW-GRADE; FOLLICULAR LYMPHOMA	Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing - Y-90 ibritumomab tiuxetan and I-131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.	St Bartholomews Hosp, Dept Med Oncol, London EC1A 7BE, England	University of London; Queen Mary University London	Davies, AJ (corresponding author), St Bartholomews Hosp, Dept Med Oncol, 7th Floor Gloucester House, London EC1A 7BE, England.	Andrew.Davies1@Bartsandthelondon.nhs.uk		Davies, Andrew/0000-0002-7517-6938				Andersen NS, 2002, EUR J CANCER, V38, P401, DOI 10.1016/S0959-8049(01)00366-5; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Ansell SM, 2002, J CLIN ONCOL, V20, P3885, DOI 10.1200/JCO.2002.10.143; Apostolidis J, 2000, J CLIN ONCOL, V18, P527, DOI 10.1200/JCO.2000.18.3.527; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; ARMITAGE JO, 1981, CANCER TREAT REP, V65, P413; BARTLETT N, 2002, P AM SOC CLIN ONCOL, V21; Bastion Y, 1997, J CLIN ONCOL, V15, P1587, DOI 10.1200/JCO.1997.15.4.1587; Bennett JM, 2005, BLOOD, V105, P4576, DOI 10.1182/blood-2004-12-4690; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; BUCHSBAUM DJ, 1992, CANCER RES, V52, P637; Chan WC, 1997, BLOOD, V89, P3909; CHATAL JF, 2004, P AM SOC CLIN ONCOL, V22; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Connors JM, 2005, NEW ENGL J MED, V352, P496, DOI 10.1056/NEJMe048291; Conti PS, 2005, J NUCL MED, V46, P1812; Cragg MS, 2004, BLOOD, V103, P2738, DOI 10.1182/blood-2003-06-2031; CULLEN MH, 1979, CANCER, V44, P645, DOI 10.1002/1097-0142(197908)44:2<645::AID-CNCR2820440234>3.0.CO;2-Y; Czuczman M, 2002, BLOOD, V100, p357A; Davies A, 2005, ANN ONCOL, V16, P112; Davies AJ, 2004, J CLIN ONCOL, V22, P1469, DOI 10.1200/JCO.2004.06.055; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; Dosik AD, 2006, CANCER-AM CANCER SOC, V106, P616, DOI 10.1002/cncr.21606; Dreicer R, 2007, J CLIN ONCOL, V25; Fisher RI, 2005, J CLIN ONCOL, V23, P7565, DOI 10.1200/JCO.2004.00.9217; FLINN IW, 2004, BLOOD, V104; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Freedman AS, 1999, BLOOD, V94, P3325, DOI 10.1182/blood.V94.10.3325.422k13_3325_3333; FUNG H, 2003, BLOOD, V102; GALLAGHER CJ, 1986, J CLIN ONCOL, V4, P1470, DOI 10.1200/JCO.1986.4.10.1470; Gopal AK, 2006, BIOL BLOOD MARROW TR, V12, P697, DOI 10.1016/j.bbmt.2006.03.014; Gopal AK, 2002, BLOOD, V99, P3158, DOI 10.1182/blood.V99.9.3158; Gopal AK, 2003, BLOOD, V102, P2351, DOI 10.1182/blood-2003-02-0622; Gordon LI, 2004, BLOOD, V103, P4429, DOI 10.1182/blood-2003-11-3883; GORDON LI, 2003, P AN M AM SOC CLIN, V22, P576; Gregory SA, 2003, BLOOD, V102, p409A; GREGORY SA, 2005, P AN M AM SOC CLIN, V23, P585; GREGORY SA, 2004, P AN M AM SOC CLIN, V22, P6732; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; HORNING SJ, 1993, SEMIN ONCOL, V20, P75; Horning SJ, 2005, J CLIN ONCOL, V23, P712, DOI 10.1200/JCO.2005.07.040; HUBBARD SM, 1982, BLOOD, V59, P258; Hunault-Berger M, 2002, BLOOD, V100, P1141, DOI 10.1182/blood.V100.4.1141.h81602001141_1141_1152; Hussein MA, 2004, BLOOD, V104, p314B, DOI 10.1182/blood.V104.11.4928.4928; Jacobs SA, 2005, CLIN CANCER RES, V11, p7146S, DOI 10.1158/1078-0432.CCR-1004-0003; JOHNSON PWM, 1995, J CLIN ONCOL, V13, P140, DOI 10.1200/JCO.1995.13.1.140; Johnson TA, 2000, INT J CANCER, V85, P104, DOI 10.1002/(SICI)1097-0215(20000101)85:1<104::AID-IJC19>3.0.CO;2-G; Justice TE, 2006, CANCER, V107, P433, DOI 10.1002/cncr.21998; KAMINSKI M, 2001, BLOOD, V98; Kaminski MS, 2007, J CLIN ONCOL, V25; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kaminski MS, 2005, J CLIN ONCOL, V23, P7985, DOI 10.1200/JCO.2005.01.0892; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Knox SJ, 1996, CLIN CANCER RES, V2, P457; Leahy MF, 2006, J CLIN ONCOL, V24, P4418, DOI 10.1200/JCO.2005.05.3470; Leonard JP, 2003, BLOOD, V102, p105A; Leonard JP, 2005, J CLIN ONCOL, V23, P5696, DOI 10.1200/JCO.2005.14.803; Leonard JP, 2001, BLOOD, V98, p133A; Link B, 2004, J CLIN ONCOL, V22, p562S; Liu SY, 1998, J CLIN ONCOL, V16, P3270, DOI 10.1200/JCO.1998.16.10.3270; MacManus MP, 1996, J CLIN ONCOL, V14, P1282, DOI 10.1200/JCO.1996.14.4.1282; Marcus R, 2005, BLOOD, V105, P1417, DOI 10.1182/blood-2004-08-3175; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MONES J, 2004, P AM SOC CLIN ONCOL, V22; MORSCHHAUSER HD, 2004, BLOOD, V104; Nademanee A, 2005, BLOOD, V106, P2896, DOI 10.1182/blood-2005-03-1310; NADLER LM, 1980, CANCER RES, V40, P3147; OKI Y, 2004, BLOOD, V104; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Press OW, 2006, J CLIN ONCOL, V24, P4143, DOI 10.1200/JCO.2006.05.8198; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; Press OW, 2000, BLOOD, V96, P2934; Press OW, 2003, BLOOD, V102, P1606, DOI 10.1182/blood-2003-01-0287; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; Radford JA, 2003, BLOOD, V102, p408A; SCHILDER RJ, 2002, P AN M AM SOC CLIN, V21, P267; Schouten HC, 2003, J CLIN ONCOL, V21, P3918, DOI 10.1200/JCO.2003.10.023; Shah J, 2007, J CLIN ONCOL, V25; SHIPLEY DL, 2005, J CLIN ONCOL, V23; Shipp MA, 1999, J CLIN ONCOL, V17, P423, DOI 10.1200/JCO.1999.17.1.423; Siegel JA, 1998, J NUCL MED, V39, p28S; Siegel JA, 2002, J NUCL MED, V43, P354; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011; Sweetenham JW, 2004, ASH ANN M, V104, P2633; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; VANOERS MH, 2006, BLOOD; Vose JM, 2000, J CLIN ONCOL, V18, P1316, DOI 10.1200/JCO.2000.18.6.1316; Vose JM, 2004, ONCOLOGIST, V9, P160, DOI 10.1634/theoncologist.9-2-160; Vose JM, 2005, J CLIN ONCOL, V23, P461, DOI 10.1200/JCO.2005.05.117; VOSE JM, 1993, J CLIN ONCOL, V11, P1846, DOI 10.1200/JCO.1993.11.10.1846; Wahl RL, 2003, SEMIN ONCOL, V30, P31, DOI 10.1053/sonc.2003.23799; Wahl RL, 1998, J NUCL MED, V39, p21S; Wiseman GA, 2003, J NUCL MED, V44, P465; Wiseman GA, 2002, CANCER, V94, P1349, DOI 10.1002/cncr.10305; Wiseman GA, 2005, CANCER BIOTHER RADIO, V20, P185, DOI 10.1089/cbr.2005.20.185; Wiseman GA, 2002, BLOOD, V99, P4336, DOI 10.1182/blood.V99.12.4336; WITZIG T, 2003, BLOOD, V102; Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Witzig TE, 2003, J CLIN ONCOL, V21, P1263, DOI 10.1200/JCO.2003.08.043; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zelenetz AD, 2006, J CLIN ONCOL, V24, p436S; Zelenetz AD, 2002, BLOOD, V100, p357A	110	77	80	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3614	3628		10.1038/sj.onc.1210378	http://dx.doi.org/10.1038/sj.onc.1210378			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530015				2022-12-17	WOS:000246816100004
J	Ishizawar, RC; Miyake, T; Parsons, SJ				Ishizawar, R. C.; Miyake, T.; Parsons, S. J.			c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function	ONCOGENE			English	Article						c-Src; ErbB2; ErbB3; HRG; PI3-kinase; heterocomplex formation	HUMAN-BREAST-CANCER; GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; PROTEIN; ACTIVATION; ONCOGENE; AUTOPHOSPHORYLATION; PHOSPHORYLATION; INVOLVEMENT	Overexpression and/or gene amplification of c-Src and members of the epidermal growth factor receptor (EGFR/ErbB) family have been implicated in the pathogenesis of breast cancer. Although members of the EGFR family are known to form heterocomplexes with one another, c-Src has also been shown to physically interact with members ofthis family in breast cancer cell lines and tumors. This paper investigates the role of c-Src in modulating the physical and functional interaction between ErbB2 and ErbB3, two family members that preferentially associate with one another and together exhibit high oncogenic potential. We show that overexpressed wild-type c-Src enhances heterocomplex formation of ErbB2 and ErbB3 that results in increased basal and/or heregulin induced activation of recept ors, and their downstream intracellular effectors. Expression of a kinase-inactive form of c-Src (K- c-Src) or pharmacological inhibition of c-Src by PP2 negatively affects these events. Furthermore, cellular motility and anchorage-independent growth promoted by the ErbB2/ ErbB3 heterocomplex are dependent upon c- Src, as demonstrated by the effects of K- c-Src overexpression or treatment with PP2. In contrast to previous studies that de. ned a role for c-Src downstream of ErbB2/ErbB3, the current work suggests an upstream mechanism, whereby c-Src enhances ErbB2/ErbB3 signaling and biological functions by positively modulating the association between ErbB2 and ErbB3.	Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA.	sap@virginia.edu		Ishizawar, Rumey/0000-0001-5952-7884	NCI NIH HHS [CA71449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fan YX, 2004, J BIOL CHEM, V279, P38143, DOI 10.1074/jbc.M405760200; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Sheffield LG, 1998, BIOCHEM BIOPH RES CO, V250, P27, DOI 10.1006/bbrc.1998.9214; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	27	77	82	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3503	3510		10.1038/sj.onc.1210138	http://dx.doi.org/10.1038/sj.onc.1210138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173075				2022-12-17	WOS:000246799200006
J	Bignone, PA; Lee, KY; Liu, Y; Emilion, G; Finch, J; Soosay, AER; Charnock, FML; Beck, S; Dunham, I; Mungall, AJ; Ganesan, TS				Bignone, P. A.; Lee, K. Y.; Liu, Y.; Emilion, G.; Finch, J.; Soosay, A. E. R.; Charnock, F. M. L.; Beck, S.; Dunham, I.; Mungall, A. J.; Ganesan, T. S.			RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovarian cancer; RPS6KA2; chromosome 6q27; tumour suppressor gene	SIGNAL-REGULATED KINASE; COFFIN-LOWRY SYNDROME; RIBOSOMAL S6 KINASE; CELL-CYCLE ARREST; MONOALLELIC EXPRESSION; NUCLEAR TRANSLOCATION; HOMOZYGOUS DELETIONS; CHROMOSOME 6Q27; ALLELE LOSS; MAP	We had previously defined by allele loss studies a minimal region at 6q27 (between D6S264 and D6S297) to contain a putative tumour suppressor gene. The p90 ribosomal S6 kinase-3 gene (p90 Rsk-3, RPS6KA2) maps in this interval. It is a serine-threonine kinase that signals downstream of the mitogen-activated protein kinase pathway. It is expressed in normal ovarian epithelium, whereas reduced or absent in tumours or cell lines. We show that RPS6KA2 is monoallelically expressed in the ovary suggesting that loss of a single expressed allele is sufficient to cause complete loss of expression in cancer cells. Further, we have identified two new isoforms of RPS6KA2 with an alternative start codon. Homozygous deletions were identified within the RPS6KA2 gene in two cell lines. Re-expression of RPS6KA2 in ovarian cancer cell lines suppressed colony formation. In UCI101 cells, the expression of RPS6KA2 reduced proliferation, caused G1 arrest, increased apoptosis, reduced levels of phosphorylated extracellular signal-regulated kinase and altered other cell cycle proteins. In contrast, small interfering RNA against RPS6KA2 showed the opposite effect in 41M cells. The above results suggest that RPS6KA2 is a putative tumour suppressor gene to explain allele loss at 6q27.	John Radcliffe Hosp, Mol Oncol Labs, Ovarian Canc Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Sanger Ctr, Cambridge, England	University of Oxford; Wellcome Trust Sanger Institute	Ganesan, TS (corresponding author), John Radcliffe Hosp, Mol Oncol Labs, Ovarian Canc Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	ganesan@cancer.org.uk	Mungall, Andrew J./U-7067-2018; Bignone, Paola/K-3797-2012; Soosay, Ashley/D-8060-2012; GANESAN, Trivadi Sundaram/AAU-1499-2020	Mungall, Andrew J./0000-0002-0905-2742; Soosay, Ashley/0000-0002-7443-4472; GANESAN, Trivadi Sundaram/0000-0002-4671-8099; Bignone, Paola/0000-0003-2296-7039; Dunham, Ian/0000-0003-2525-5598	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Bruning JC, 2000, P NATL ACAD SCI USA, V97, P2462, DOI 10.1073/pnas.97.6.2462; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUCHTNER C, 1993, GYNECOL ONCOL, V48, P203, DOI 10.1006/gyno.1993.1034; Goldmit M, 2004, IMMUNOL REV, V200, P197, DOI 10.1111/j.0105-2896.2004.00158.x; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin BH, 2001, J FOOD PROD MARK, V6, P63, DOI 10.1300/J038v06n04_06; Liu Y, 2002, ONCOGENE, V21, P387, DOI 10.1038/sj.onc.1205067; Liu Y, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-20; Liu Y, 2002, REPRODUCTION, V123, P341, DOI 10.1530/reprod/123.3.341; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Luedi PP, 2005, GENOME RES, V15, P875, DOI 10.1101/gr.3303505; Modesitt SC, 2001, CLIN CANCER RES, V7, P1765; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; Nikaido L, 2003, GENOME RES, V13, P1402, DOI 10.1101/gr.1055303; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pineau P, 2003, INT J CANCER, V106, P216, DOI 10.1002/ijc.11214; Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602; Rougeulle C, 1997, NAT GENET, V17, P14, DOI 10.1038/ng0997-14; SAITO S, 1992, CANCER RES, V52, P5815; Sano Y, 2001, GENOME RES, V11, P1833, DOI 10.1101/gr.194301; Schinelli S, 2001, J NEUROSCI, V21, P8842, DOI 10.1523/JNEUROSCI.21-22-08842.2001; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Teng DHF, 1997, CANCER RES, V57, P4177; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zeniou M, 2002, HUM MOL GENET, V11, P2929, DOI 10.1093/hmg/11.23.2929; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	69	77	82	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					683	700		10.1038/sj.onc.1209827	http://dx.doi.org/10.1038/sj.onc.1209827			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878154				2022-12-17	WOS:000243902200006
J	Chapman, EJ; Hurst, CD; Pitt, E; Chambers, P; Aveyard, JS; Knowles, MA				Chapman, E. J.; Hurst, C. D.; Pitt, E.; Chambers, P.; Aveyard, J. S.; Knowles, M. A.			Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway	ONCOGENE			English	Article						urothelial; immortalisation; telomerase; p16; p53	HUMAN UROEPITHELIAL CELLS; REPLICATIVE LIFE-SPAN; BLADDER-CANCER; TELOMERASE ACTIVITY; CELLULAR SENESCENCE; ECTOPIC EXPRESSION; COPY NUMBER; 20Q GAIN; P53; PROLIFERATION	The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. Although most UCC express telomerase, inactivation of the p16/Rb pathway is generally required for in vitro immortalisation. This and the involvement of p16 in senescence of normal human urothelial cells (NHUC) suggest that CDKN2A deletion may aid bypass of senescence and allow immortalisation. CDKN2A encodes p16 and p14(ARF) and therefore inactivation of this locus can disrupt both the Rb and p53 tumour suppressor pathways. Retrovirus-mediated transduction was used to specifically modulate the p16/Rband/or p53 tumour suppressor pathways in NHUC and to express human telomerase reverse transcriptase (hTERT). Expression of hTERT bypassed Rb and p53 pathway-dependent barriers to proliferation and immortalised NHUC. TERT-NHUC had normal karyotypes, were non-tumorigenic and unexpectedly retained CDKN2A. Thus, the phenotypic significance of inactivation of CDKN2A in UCC may not be solely related to bypass of senescence. Phenotypic assays in human urothelial cells have relied on cell strains derived from invasive tumours or NHUC immortalised by expression of SV40-large T. The production of genetically normal but immortal NHUC lines now provides a valuable platform for experiments to examine the timing and combination of events necessary for UCC tumorigenesis.	St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Canc Res UK Mutat Detect Facil, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk	Chambers, Philip/AAK-8549-2020; Chapman, Emma/AAD-7425-2019	Chambers, Philip/0000-0002-0926-717X; Chapman, Emma/0000-0003-2859-2020; Knowles, Margaret/0000-0002-9363-8657				Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Aveyard JS, 2004, J MOL DIAGN, V6, P356, DOI 10.1016/S1525-1578(10)60532-6; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Chapman EJ, 2005, CLIN CANCER RES, V11, P5740, DOI 10.1158/1078-0432.CCR-05-0411; Cote RJ, 1998, CANCER RES, V58, P1090; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Diggle CP, 2000, J LIPID RES, V41, P1509; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Esteller M, 2000, CANCER RES, V60, P129; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Harada H, 2003, MOL CANCER RES, V1, P729; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; HUTTON KAR, 1993, J UROLOGY, V150, P721, DOI 10.1016/S0022-5347(17)35597-0; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Markl IDC, 1998, CANCER RES, V58, P5348; Muntoni A, 2003, ONCOGENE, V22, P7804, DOI 10.1038/sj.onc.1207085; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Puthenveettil JA, 1999, ADV EXP MED BIOL, V462, P83; Rahat MA, 1999, CANCER, V85, P919; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sarkar S, 2000, CANCER RES, V60, P3862; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wootton M, 2003, HUM GENE THER, V14, P1473, DOI 10.1089/104303403769211682; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YEAGER T, 1995, CANCER RES, V55, P493; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163	46	77	77	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5037	5045		10.1038/sj.onc.1209513	http://dx.doi.org/10.1038/sj.onc.1209513			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16619045				2022-12-17	WOS:000239921300009
J	Metzler, M; Forster, A; Pannell, R; Arends, MJ; Daser, A; Lobato, MN; Rabbitts, TH				Metzler, M.; Forster, A.; Pannell, R.; Arends, M. J.; Daser, A.; Lobato, M. N.; Rabbitts, T. H.			A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology	ONCOGENE			English	Article						MLL; AF4; chromosomal translocations; invertor model; Cre-loxP; leukaemia	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; RETROVIRAL INSERTION; HUMAN CANCER; WILD-TYPE; CRE-LOXP; MLL-ELL; GENE; MICE	MLL-AF4 fusion is the most common consequence of chromosomal translocations in infant leukaemia and is associated witha poor prognosis. MLL-AF4 is thought to be required in haematopoietic stem cells to elicit leukaemia and may be involved in tumour phenotype specification as it is only found in B-cell tumours in humans. We have employed the invertor conditional technology to create a model of MLL-AF4, in which a floxed AF4 cDNA was knocked into Mll in the opposite orientation for transcription. Cell-specific Cre expression was used to generate Mll-AF4 expression. The mice develop exclusively B-cell lineage neoplasias, whether the Cre gene was controlled by B- or T-cell promoters, but of a more mature phenotype than normally observed in childhood leukaemia. These findings show that the MLL-AF4 fusion protein does not have a mandatory role in multi-potent haematopoietic stem cells to cause cancer and indicates that MLL-AF4 has an instructive function in the phenotype of the tumour.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England	MRC Laboratory Molecular Biology; University of Cambridge	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	thr@mrc-lmb.cam.ac.uk	Metzler, Markus/AAS-2066-2021; Rabbitts, Terence/D-6262-2016	Metzler, Markus/0000-0002-4523-1676; Rabbitts, Terence/0000-0002-4982-2609	Medical Research Council [G0600914] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALBERT H, 1995, PLANT J, V7, P649, DOI 10.1046/j.1365-313X.1995.7040649.x; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Christiansen DH, 2001, LEUKEMIA, V15, P1848, DOI 10.1038/sj.leu.2402246; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; Codrington R, 2005, PLOS BIOL, V3, P1459, DOI 10.1371/journal.pbio.0030242; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; DiMartino JF, 2000, BLOOD, V96, P3887, DOI 10.1182/blood.V96.12.3887.h8003887_3887_3893; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; Forster A, 2005, NAT METHODS, V2, P27, DOI 10.1038/NMETH727; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008-5472.CAN-04-1356; Jamal R, 2001, GENE CHROMOSOME CANC, V31, P187; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Martin ME, 2003, CANCER CELL, V4, P197, DOI 10.1016/S1535-6108(03)00214-9; McCormack MP, 2003, MOL CELL BIOL, V23, P9003, DOI 10.1128/MCB.23.24.9003-9013.2003; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Nakamura T, 1996, ONCOGENE, V13, P2235; Nam CH, 2006, MOL THER, V13, P15, DOI 10.1016/j.ymthe.2005.09.010; Peham M, 2002, BRIT J HAEMATOL, V117, P315, DOI 10.1046/j.1365-2141.2002.03428.x; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUBNITZ JE, 1994, BLOOD, V84, P1747; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100	39	77	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3093	3103		10.1038/sj.onc.1209636	http://dx.doi.org/10.1038/sj.onc.1209636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16607274				2022-12-17	WOS:000237951000001
J	Leivonen, SK; Ala-aho, R; Koli, K; Grenman, R; Peltonen, J; Kahari, VM				Leivonen, SK; Ala-aho, R; Koli, K; Grenman, R; Peltonen, J; Kahari, VM			Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells	ONCOGENE			English	Article						TGF-beta; Smad; matrix metalloproteinase; collagenase; squamous cell carcinoma	GROWTH-FACTOR-BETA; HUMAN GINGIVAL FIBROBLASTS; TGF-BETA; IN-VITRO; MATRIX METALLOPROTEINASE-13; MEDIATED TRANSCRIPTION; SUPPRESSES METASTASIS; HUMAN KERATINOCYTES; GENE-EXPRESSION; KINASE PATHWAY	Squamous cell carcinoma ( SCC) cells of the head and neck specifically express collagenase-3 ( matrix metalloproteinase-13 ( MMP-13)), the expression of which correlates with their invasion capacity. Transforming growth factor-beta ( TGF-beta) enhances MMP-13 and collagenase-1( MMP-1) expression and invasion of SCC cells via p38 mitogen-activated protein kinase. Here, we have examined the role of Smad signaling in regulating MMP-13 expression and in invasion of head and neck SCC cells. Treatment with TGF-beta resulted in activation of Smad2 and Smad3 in SCC cells, but had no effect on their proliferation or viability. Basal activation of Smad3 and p38 was noted in SCC cells without exogenous TGF-beta stimulation, and adenoviral delivery of Smad7 and dominant-negative Smad3 inhibited p38 activation in these cells. Adenoviral overexpression of Smad3 augmented the upregulatory effect of TGF-beta on MMP-13 expression by SCC cells. Disruption of Smad signaling by adenoviral expression of kinase-defective TGF-b type I receptor ( activin-receptor-like kinase-5),Smad7, and dominant-negative Smad3 potently suppressed the basal and TGF-beta-induced expression of MMP-13 and MMP-1 in SCC cells, and inhibited their basal and TGF-beta-induced invasion through Matrigel and type I collagen. Adenoviral overexpression of Smad7 in cutaneous and oral SCC cells significantly inhibited their implantation in skin of SCID mice and growth of xenografts in vivo, as compared to LacZ adenovirus-transduced control cells. Together, these results show that Smad signaling plays an important role in promoting the invasive phenotype of human head and neck SCC cells by upregulating their collagenase expression.	Univ Turku, Dept Dermatol, Dept Med Biochem & Mol Biol, FI-20521 Turku, Finland; Univ Turku, MediCity Res Lab, FI-20521 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FI-20521 Turku, Finland; Univ Helsinki, Dept Virol, Helsinki, Finland; Univ Helsinki, Dept Pathol, Haartman Inst, Helsinki, Finland; Univ Helsinki, Helsinki Univ Hosp, Helsinki, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland	University of Turku; University of Turku; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku; University of Oulu	Kahari, VM (corresponding author), Univ Turku, Dept Dermatol, Dept Med Biochem & Mol Biol, POB 52, FI-20521 Turku, Finland.	veli-matti.kahari@utu.fi	Leivonen, Suvi-Katri/AAK-3096-2021; Peltonen, Juha/O-7159-2019; Kahari, Veli-Matti/E-5144-2011	Peltonen, Juha/0000-0002-5732-4167; Kahari, Veli-Matti/0000-0003-2421-9368; Leivonen, Suvi-Katri/0000-0003-3224-0757				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-aho R, 2004, ONCOGENE, V23, P5111, DOI 10.1038/sj.onc.1207678; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LANSDORF CD, 1999, HUMAN CELL CULTURE, V2; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodeck U, 1999, CANCER RES, V59, P547; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian F, 2003, CANCER RES, V63, P8284; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	61	77	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2588	2600		10.1038/sj.onc.1209291	http://dx.doi.org/10.1038/sj.onc.1209291			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16407850				2022-12-17	WOS:000237099400003
J	Yates, DR; Rehman, I; Meuth, M; Cross, SS; Hamdy, FC; Catto, JWF				Yates, DR; Rehman, I; Meuth, M; Cross, SS; Hamdy, FC; Catto, JWF			Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls	ONCOGENE			English	Article						epigenetic; DNA methylation; bladder cancer; urinalysis	DNA METHYLATION; HYPERMETHYLATION; URINE; GENE; NEOPLASIA	Tumour suppressor gene ( TSG) methylation has been proposed as a diagnostic marker for urothelial cancer (UC). Here, we compare the frequency of urinary TSG methylation in young and elderly patients, with and without UC. Urine samples were obtained prospectively from 35 UC patients, 35 benign controls over the age of 70 years and 34 healthy volunteers under the age of 40 years. Methylation analysis was performed for eight gene promoters using quantitative methylation-specific PCR. Methylation was detected in urine DNA from all three patient groups. The highest frequencies were seen in UC patients. Significantly less methylation was present in control samples than UC cases for RASSF1a and APC ( P < 0.034). The 'methylation index' and level of methylation was highest in the UC group and lowest in the young control group. A marker panel of RASSF1a, E-cad and APC generated a sensitivity of 69%, a specificity of 60% and a diagnostic accuracy of 86%. TSG methylation is detectable in urine DNA from patients with and without bladder cancer. The frequency and extent of methylation appears to increase with age and malignancy. The lack of tumour specificity suggests that further investigation is required before this test is introduced into clinical practice.	Univ Sheffield, Acad Urol Unit, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Inst Canc Studies, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Pathol Unit, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield; University of Sheffield; University of Sheffield	Catto, JWF (corresponding author), Univ Sheffield, Acad Urol Unit, Royal Hallamshire Hosp, K Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	J.Catto@sheffield.ac.uk		catto, james/0000-0003-2787-8828; Hamdy, Freddie/0000-0003-2627-2154; Cross, Simon/0000-0003-2044-1754				Ahuja N, 1998, CANCER RES, V58, P5489; Bornman DM, 2001, AM J PATHOL, V159, P831, DOI 10.1016/S0002-9440(10)61758-0; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; Catto JWF, 2005, J CLIN ONCOL, V23, P2903, DOI 10.1200/JCO.2005.03.163; Chan MWY, 2002, CLIN CANCER RES, V8, P464; Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127; Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; HARNDEN SV, 2003, CLIN CANCER RES, V9, P370; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Maruyama R, 2001, CANCER RES, V61, P8659; Molinie V, 2001, ANN PATHOL, V21, P361; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Usadel H, 2002, CANCER RES, V62, P371	20	77	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1984	1988		10.1038/sj.onc.1209209	http://dx.doi.org/10.1038/sj.onc.1209209			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288222				2022-12-17	WOS:000236224800016
J	Feng, Z; Jin, S; Zupnick, A; Hoh, J; de Stanchina, E; Lowe, S; Prives, C; Levine, AJ				Feng, Z; Jin, S; Zupnick, A; Hoh, J; de Stanchina, E; Lowe, S; Prives, C; Levine, AJ			p53 tumor suppressor protein regulates the levels of huntingtin gene expression	ONCOGENE			English	Article						p53; hungtingtin; Huntington's disease; p53-responsive element; transcription regulation; gene expression	MONOZYGOTIC TWINS	The p53 protein is a transcription factor that integrates various cellular stress signals. The accumulation of the mutant huntingtin protein with an expanded polyglutamine tract plays a central role in the pathology of human Huntington's disease. We found that the huntingtin gene contains multiple putative p53-responsive elements and p53 binds to these elements both in vivo and in vitro. p53 activation in cultured human cells, either by a temperature-sensitive mutant p53 protein or by gamma-irradiation (gamma-irradiation), increases huntingtin mRNA and protein expression. Similarly, murine huntingtin also contains multiple putative p53-responsive elements and its expression is induced by p53 activation in cultured cells. Moreover, gamma-irradiation, which activates p53, increases huntingtin gene expression in the striatum and cortex of mouse brain, the major pathological sites for Huntington's disease, in p53+/+ but not the isogenic p53 -/- mice. These results demonstrate that p53 protein can regulate huntingtin expression at transcriptional level, and suggest that a p53 stress response could be a modulator of the process of Huntington's disease.	Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ USA; Univ Med & Dent New Jersey, Dept Pharmacol, Piscataway, NJ 08854 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Cold Spring Harbor Labs, Cold Spring Harbor, NY USA; Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; Yale University; Cold Spring Harbor Laboratory; Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Einstein Dr, Princeton, NJ 08540 USA.	alevine@ias.edu						Anca MH, 2004, AM J MED GENET A, V124A, P89, DOI 10.1002/ajmg.a.20328; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dixon KT, 2003, GENE EXPRESSION, V11, P221, DOI 10.3727/000000003783992234; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Georgiou N, 1999, MOVEMENT DISORD, V14, P320, DOI 10.1002/1531-8257(199903)14:2<320::AID-MDS1018>3.0.CO;2-Z; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Jin SK, 2001, J CELL SCI, V114, P4139; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Sharp AH, 1996, NEUROBIOL DIS, V3, P3, DOI 10.1006/nbdi.1996.0002; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	20	77	79	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					1	7		10.1038/sj.onc.1209021	http://dx.doi.org/10.1038/sj.onc.1209021			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16278683				2022-12-17	WOS:000234406400001
J	Koinuma, K; Yamashita, Y; Liu, W; Hatanaka, H; Kurashina, K; Wada, T; Takada, S; Kaneda, R; Choi, YL; Fujiwara, SI; Miyakura, Y; Nagai, H; Mano, H				Koinuma, K; Yamashita, Y; Liu, W; Hatanaka, H; Kurashina, K; Wada, T; Takada, S; Kaneda, R; Choi, YL; Fujiwara, SI; Miyakura, Y; Nagai, H; Mano, H			Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability	ONCOGENE			English	Article						epigenetics; colorectal carcinoma; microsatellite instability; AXIN2; MLH1	ISLAND METHYLATOR PHENOTYPE; ADENOMATOUS-POLYPOSIS-COLI; BETA-CATENIN; MISMATCH REPAIR; HMLH1 PROMOTER; DNA METHYLATION; CELL-LINES; CANCER; MUTATIONS; HOMOLOG	Mutation or epigenetic silencing of mismatch repair genes, such as MLH1 and MSH2, results in microsatellite instability (MSI) in the genome of a subset of colorectal carcinomas (CRCs). However, little is yet known of genes that directly contribute to tumor formation in such cancers. To characterize MSI-dependent changes in gene expression, we have now compared transcriptomes between fresh CRC specimens positive or negative for MSI (n= 10 for each) with the use of high-density oligonucleotide microarrays harboring > 44 000 probe sets. Correspondence analysis of the expression patterns of isolated MSI-associated genes revealed that the transcriptome of MSI+ CRCs is clearly distinct from that of MSI- CRCs. Such MSI-associated genes included that for AXIN2, an important component of the WNT signaling pathway. AXIN2 was silenced, apparen tly as a result of extensive methylation of its promoter region, specifi. cally in MSI+ CRC specimens. Forced expression of AXIN2, either by treatment with 50 '-azacytidine or by transfection with AXIN2 cDNA, resul ted in rapid cell death in an MSI+ CRC cell line. These data indicate that epigenetic silencing of AXIN2 is specifically associated with carcinogenesis in MSI+ CRCs.	Jichi Med Sch, Div Funct Genom, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Surg, Minami Kawachi, Tochigi 3290498, Japan; Mayo Clin & Mayo Grad Sch Med, Div Expt Pathol, Rochester, MN USA	Jichi Medical University; Jichi Medical University; Mayo Clinic	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Fujiwara, Shin-ichiro/ABH-2030-2020	Fujiwara, Shin-ichiro/0000-0002-4523-2994; Takada, Shuji/0000-0002-9406-4683				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boland CR, 1998, CANCER RES, V58, P5248; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Cunningham JM, 1998, CANCER RES, V58, P3455; Esteller M, 2000, CANCER RES, V60, P4366; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; Ohki-Kaneda R, 2004, BIOCHEM BIOPH RES CO, V320, P1328, DOI 10.1016/j.bbrc.2004.06.090; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Wu R, 2001, CANCER RES, V61, P8247; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Zysman M, 2002, CANCER RES, V62, P3663	34	77	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					139	146		10.1038/sj.onc.1209009	http://dx.doi.org/10.1038/sj.onc.1209009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247484				2022-12-17	WOS:000234406400015
J	Qiao, W; Li, AG; Owens, P; Xu, X; Wang, XJ; Deng, CX				Qiao, W; Li, AG; Owens, P; Xu, X; Wang, XJ; Deng, CX			Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin	ONCOGENE			English	Article						squamous cell carcinoma; hair follicle cycle; Pten; AKT; cyclin D1	TUMOR-SUPPRESSOR SMAD4/DPC4; TGF-BETA RECEPTOR; TRANSGENIC MICE; CHEMICAL CARCINOGENESIS; JUVENILE POLYPOSIS; CYCLE ARREST; EXPRESSION; GENE; DIFFERENTIATION; DELETION	Smad4 is the common mediator for TGF beta signals, which play important functions in many biological processes. To study the role of Smad4 in skin development and epidermal tumorigenesis, we disrupted this gene in skin using the Cre-loxP approach. We showed that absence of Smad4 blocked hair follicle differentiation and cycling, leading to a progressive hair loss of mutant (MT) mice. MT hair follicles exhibited diminished expression of Lef1, and increased proliferative cells in the outer root sheath. Additionally, the skin of MT mice exhibited increased proliferation of basal keratinocytes and epidermal hyperplasia. Furthermore, we provide evidence that the absence of Smad4 resulted in a block of both TGFb and bone morphogenetic protein (BMP) signaling pathways, including p21, a well-known cyclin-dependent kinase inhibitor. Consequently, all MT mice developed spontaneous malignant skin tumors from 3 months to 13 months of age. The majority of tumors are malignant squamous cell carcinomas. A most notable finding is that tumorigenesis is accompanied by inactivation of phosphatase and tensin homolog deleted on chromosome 10 (Pten), activation of AKT, fast proliferation and nuclear accumulation of cyclin D1. These observations revealed the essential functions of Smad4-mediated signals in repressing skin tumor formation through the TGF beta/BMP pathway, which interacts with the Pten signaling pathway.	Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wang, XJ (corresponding author), Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA.	wangxiao@ohsu.edu	deng, chuxia/N-6713-2016	Owens, Philip/0000-0002-1452-9285	NCI NIH HHS [CA87849] Funding Source: Medline; NIAMS NIH HHS [AR47898] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056012, ZIADK056012] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso L, 2003, P NATL ACAD SCI USA, V100, P11830, DOI 10.1073/pnas.1734203100; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.0.CO;2-P; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Go C, 1999, CANCER RES, V59, P2861; Hahn SA, 1996, CANCER RES, V56, P490; He W, 2001, ONCOGENE, V20, P471, DOI 10.1038/sj.onc.1204117; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Kobielak K, 2003, J CELL BIOL, V163, P609, DOI 10.1083/jcb.200309042; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Kwan KM, 2004, GENESIS, V39, P10, DOI 10.1002/gene.20021; Li AG, 2003, CYTOKINE GROWTH F R, V14, P99, DOI 10.1016/S1359-6101(03)00005-4; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Redman RS, 2005, J ORAL PATHOL MED, V34, P23, DOI 10.1111/j.1600-0714.2004.00246.x; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Takaku K, 1999, CANCER RES, V59, P6113; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wang XJ, 2001, MICROSC RES TECHNIQ, V52, P420, DOI 10.1002/1097-0029(20010215)52:4<420::AID-JEMT1027>3.3.CO;2-Z; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yuhki M, 2004, DEVELOPMENT, V131, P1825, DOI 10.1242/dev.01079	44	77	83	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					207	217		10.1038/sj.onc.1209029	http://dx.doi.org/10.1038/sj.onc.1209029			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16170355				2022-12-17	WOS:000234583600005
J	Tanaka, Y; Kanai, F; Ichimura, T; Tateishi, K; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Imamura, J; Ikenoue, T; Ijichi, T; Kawabe, T; Isobe, T; Omata, M				Tanaka, Y; Kanai, F; Ichimura, T; Tateishi, K; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Imamura, J; Ikenoue, T; Ijichi, T; Kawabe, T; Isobe, T; Omata, M			The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1	ONCOGENE			English	Article						HBV; HBx; AP-1; Jab1; HCC	STABLE RNA INTERFERENCE; COP9 SIGNALOSOME; HBX PROTEIN; C-JUN; TRANSCRIPTION FACTORS; BINDING PROTEIN; GENE-EXPRESSION; CELL-CYCLE; COMPLEX; KINASES	Hepatitis B virus X protein (HBx) has many cellular functions and is a major factor in hepatitis and hepatocellular carcinoma caused by HBV infection. A proteomic approach was used to search for HBx-interacting proteins in order to elucidate the molecular mechanism of hepatocarcinogenesis. HBx was attached to myc and flag tags (MEF tags) and expressed in 293T cells; the protein complex formed within the cells was purified and characterized by mass spectrometry. COP9 signalosome (CSN) subunits 3 and 4 were subsequently identified as HBx-interacting proteins. In addition, CSN subunit 5, Jun activation domain-binding protein 1 (Jab1), was shown to be a novel cellular target of HBx. In vivo and in vitro interactions between HBx and Jab1 were confirmed by standard immunoprecipitation and GST pull-down assays. An analysis of HBx deletion constructs showed that amino acids 30-125 of HBx were responsible for binding to Jab1. Confocal laser microscopy demonstrated that HBx was mainly localized in the cytoplasm, while Jab1 was found mainly in the nucleus and partially in the cytoplasm, and that the two proteins colocalized in the cytoplasm. The cotransfection of HBx and Jab1 resulted in substantial activator protein 1 (AP-1) activation and knockdown of endogenous Jab1 attenuated AP-1 activation caused by HBx. In addition, the coexpression of HBx and Jab1 potentiated phosphorylation of JNK, leading to the subsequent phosphorylation of c-Jun, whereas the level of c-Jun and JNK phosphorylation induced by HBx was decreased in Jab1 knockdown cells. These results suggest that the interaction between HBx and Jab1 enhances HBx-mediated AP-1 activation.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 113, Japan; Tokyo Metropolitan Univ, Dept Chem, Grad Sch Sci, Hachioji, Tokyo 19203, Japan	University of Tokyo; University of Tokyo; Tokyo Metropolitan University	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Isobe, Toshiaki/Q-9279-2017; IJICHI, Hideaki/AGZ-2874-2022; Ijichi, Hideaki/AAE-6692-2022; Asaoka, Yoshinari/ABC-5412-2021	IJICHI, Hideaki/0000-0002-2379-7986; Ijichi, Hideaki/0000-0002-2379-7986; Asaoka, Yoshinari/0000-0002-2805-8226; Tanaka, Yasuo/0000-0002-2917-3365				Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chopra S, 2002, J BIOL CHEM, V277, P32413, DOI 10.1074/jbc.C200311200; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Henkler F, 1998, J GEN VIROL, V79, P2737, DOI 10.1099/0022-1317-79-11-2737; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Ichimura T, 2005, J BIOL CHEM, V280, P13187, DOI 10.1074/jbc.M412884200; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Liu P, 2002, J HEPATOL, V37, P63, DOI 10.1016/S0168-8278(02)00064-8; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Nijhara R, 2001, FEBS LETT, V504, P59, DOI 10.1016/S0014-5793(01)02773-9; Omata M, 1998, NEW ENGL J MED, V339, P114, DOI 10.1056/NEJM199807093390209; Oron E, 2002, DEVELOPMENT, V129, P4399; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Tanaka Y, 2004, BIOCHEM BIOPH RES CO, V318, P461, DOI 10.1016/j.bbrc.2004.04.046; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Zhang SM, 2005, ARCH VIROL, V150, P1579, DOI 10.1007/s00705-005-0521-1; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	54	77	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					633	642		10.1038/sj.onc.1209093	http://dx.doi.org/10.1038/sj.onc.1209093			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16247477				2022-12-17	WOS:000234897400014
J	Weiss, C; Faust, D; Durk, H; Kolluri, SK; Pelzer, A; Schneider, S; Dietrich, C; Oesch, F; Gottlicher, M				Weiss, C; Faust, D; Durk, H; Kolluri, SK; Pelzer, A; Schneider, S; Dietrich, C; Oesch, F; Gottlicher, M			TCDD induces c-jun expression via a novel Ah (dioxin) receptor-mediated p38 MAPK-dependent pathway	ONCOGENE			English	Article						p38 MAP kinase; c-jun; Ah receptor; dioxin; cross-talk; TCDD	GLUCOCORTICOID-RECEPTOR; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; GENE-EXPRESSION; HEPATOMA-CELLS; CROSS-TALK; KAPPA-B; ACTIVATION; AP-1; TOXICITY	The aryl hydrocarbon receptor (AhR) has a fundamental role during postnatal liver development and is essential for mediating dioxin toxicity. However, the genetic programs mediating, both, the toxic and physiological effects downstream of the transcription factor AhR are in major parts unknown. We have identified the proto-oncogene c-jun as a novel target gene of AhR. Induction of c-jun depends on activation of p38-mitogen-activated protein kinase (MAPK) by an AhR-dependent mechanism. None of the kinases that are known to phosphorylate p38-MAPK is activated by AhR. Neither the dephosphorylation rate of p38-MAPK is reduced. Furthermore, increased p38-MAPK phosphorylation in response to dioxins does not require ongoing transcription. These findings establish activating 'cross-talk' with MAPK signaling as a novel principle of AhR action, which is apparently independent of the AhR's function as a DNA-binding transcriptional activator.	Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55131 Mainz, Germany; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany; Burnham Inst, Ctr Canc, La Jolla, CA 92037 USA; Univ Karlsruhe, Dept Food Chem & Toxicol, D-76128 Karlsruhe, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Toxicol, D-85764 Neuherberg, Germany	Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology; Sanford Burnham Prebys Medical Discovery Institute; Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Weiss, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Obere Zahlbacherster 67, D-55131 Mainz, Germany.	weissca@uni-mainz.de; martin.goettlicher@gsf.de	Oesch, Franz/AAA-8746-2020; Göttlicher, Martin/M-7342-2014; Weiss, Carsten/I-1811-2013	Göttlicher, Martin/0000-0003-0619-2181; Weiss, Carsten/0000-0002-5380-3208				Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COUTURE LA, 1990, TERATOLOGY, V42, P619, DOI 10.1002/tera.1420420606; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; ENAN E, 1995, BIOCHEM PHARMACOL, V49, P249, DOI 10.1016/S0006-2952(94)00430-7; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; Noselli S, 2000, SCIENCE, V290, P68, DOI 10.1126/science.290.5489.68; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165, DOI 10.5271/sjweh.2240; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDENHEUVEL JP, 1993, ENVIRON HEALTH PERSP, V100, P189, DOI 10.1289/ehp.93100189; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weiss C, 2004, CELL CYCLE, V3, P111; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; Werling U, 2001, MOL PHARMACOL, V59, P1269, DOI 10.1124/mol.59.5.1269; ZUGERMAN C, 1990, DERMATOL CLIN, V8, P209, DOI 10.1016/S0733-8635(18)30553-9	45	77	82	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4975	4983		10.1038/sj.onc.1208679	http://dx.doi.org/10.1038/sj.onc.1208679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897893				2022-12-17	WOS:000230646500010
J	Perez-Gomez, E; Eleno, N; Lopez, JM; Ramirez, JR; Velasco, B; Letarte, M; Bernabeu, C; Quintanilla, M				Perez-Gomez, E; Eleno, N; Lopez, JM; Ramirez, JR; Velasco, B; Letarte, M; Bernabeu, C; Quintanilla, M			Characterization of murine S-endoglin isoform and its effects on tumor development	ONCOGENE			English	Article						endoglin; TGF-beta; endothelial cells; angiogenesis; carcinogenesis	GROWTH-FACTOR-BETA; HEREDITARY HEMORRHAGIC TELANGIECTASIA; BINDING PROTEIN ENDOGLIN; HUMAN ENDOTHELIAL-CELLS; TGF-BETA; PROSTATE-CANCER; MOUSE SKIN; TRANSFORMING GROWTH-FACTOR-BETA-1; MONOCLONAL-ANTIBODIES; CELLULAR-RESPONSES	Endoglin is a transmembrane glycoprotein that acts as an auxiliary receptor for transforming growth factor-beta (TGF-beta) and modulates cellular responses to this pleiotropic cytokine. Endoglin is strongly expressed in endothelial cells, where it appears to exert a crucial role in vascular development and angiogenesis. Two endoglin isoforms (L and S), differing in their cytoplasmic domains, have been previously characterized in human tissues. We now demonstrate the existence of similar L- and S-endoglin variants in murine tissues with 47 and 35 amino acids, respectively, in their cytoplasmic tail. RT-PCR analysis showed that L is the predominant endoglin isoform expressed in mouse tissues, although S-endoglin mRNA is significantly expressed in liver and lung, as well as in endothelial cell lines. Furthermore, a protein of size equivalent to recombinant S-endoglin expressed in mammalian cells was detected in mouse endothelial cells by Western blot analysis. L- and S-endoglin isoforms can form disulfide-linked heterodimers, as demonstrated by cotransfection of L- and S-endoglin constructs. To address the role of S-endoglin in vivo, an S-Eng(+) transgenic mouse model that targets S-endoglin expression to the endothelium was generated. The lethal phenotype of endoglin-null (Eng(-/-)) mice was not rescued by breeding S-Eng(+) transgenic mice into the endoglin-null background. S-Eng(+) mice exhibited reduced tumor growth and neovascularization after transplantation of Lewis lung carcinoma cells. In addition, S-Eng(+) mice showed a drastic inhibition of benign papilloma formation when subjected to two-stage chemical skin carcinogenesis. These results point to S-endoglin as an antiangiogenic molecule, in contrast to L-endoglin which is proangiogenic.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Salamanca, Dept Fisiol & Farmacol, Edificio Dept, Salamanca 37007, Spain; Hosp Gomez Ulla, Dept Anat Patol, Madrid, Spain; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Univ Toronto, Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	mquintanilla@iib.uam.es	Bernabeu, Carmelo/P-4662-2019; Pérez-Gómez, Eduardo/GYA-5856-2022; Eleno, Nélida/A-5281-2016; Perez-gomez, Eduardo/F-5906-2015; Bernabeu, Carmelo/L-3226-2014; Quintanilla, Miguel/K-9293-2017	Bernabeu, Carmelo/0000-0002-1563-6162; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Eleno, Nélida/0000-0002-9906-2118; Perez-gomez, Eduardo/0000-0003-0160-5565; Bernabeu, Carmelo/0000-0002-1563-6162; Lopez-Novoa, Jose M./0000-0002-6211-7269; Quintanilla, Miguel/0000-0002-2124-7657				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bolontrade MF, 1998, CARCINOGENESIS, V19, P2107, DOI 10.1093/carcin/19.12.2107; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Conley BA, 2004, J BIOL CHEM, V279, P27440, DOI 10.1074/jbc.M312561200; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Duff SE, 2003, FASEB J, V17, P984, DOI 10.1096/fj.02-0634rev; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Fonsatti E, 2001, J CELL PHYSIOL, V188, P1, DOI 10.1002/jcp.1095; Fonsatti Ester, 2004, J Transl Med, V2, P18, DOI 10.1186/1479-5876-2-18; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARUTA Y, 1986, P NATL ACAD SCI USA, V83, P7898, DOI 10.1073/pnas.83.20.7898; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; Huss WJ, 2001, CANCER RES, V61, P2736; Jerkic M, 2004, FASEB J, V18, P609, DOI 10.1096/fj.03-0197fje; JINDAL SK, 1995, BIOL REPROD, V52, P1027, DOI 10.1095/biolreprod52.5.1027; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, INT J CANCER, V76, P541, DOI 10.1002/(SICI)1097-0215(19980518)76:4<541::AID-IJC16>3.0.CO;2-A; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li C, 2003, BRIT J CANCER, V88, P1424, DOI 10.1038/sj.bjc.6600874; Li CG, 2001, MICROSC RES TECHNIQ, V52, P437, DOI 10.1002/1097-0029(20010215)52:4<437::AID-JEMT1029>3.0.CO;2-G; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; OBESO J, 1990, LAB INVEST, V63, P259; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; Portella G, 2003, FASEB J, V17, P1771, DOI 10.1096/fj.02-1129fje; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; Quintanilla M, 2003, ONCOGENE, V22, P5976, DOI 10.1038/sj.onc.1206841; Raab U, 1999, BIOCHEM J, V339, P579, DOI 10.1042/0264-6021:3390579; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Sanz-Rodriguez F, 2004, J BIOL CHEM, V279, P32858, DOI 10.1074/jbc.M400843200; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Takahashi N, 2001, CANCER RES, V61, P7846; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tuxhorn JA, 2002, CANCER RES, V62, P6021; Velasco B, 2001, GENE THER, V8, P897, DOI 10.1038/sj.gt.3301468; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhang HW, 1996, J IMMUNOL, V156, P565	69	77	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4450	4461		10.1038/sj.onc.1208644	http://dx.doi.org/10.1038/sj.onc.1208644			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806144				2022-12-17	WOS:000229976900014
J	Mahtouk, K; Hose, D; Reme, T; De Vos, J; Jourdan, M; Moreaux, J; Fiol, G; Raab, M; Jourdan, E; Grau, V; Moos, M; Goldschmidt, H; Baudard, M; Rossi, JF; Cremer, FW; Klein, B				Mahtouk, K; Hose, D; Reme, T; De Vos, J; Jourdan, M; Moreaux, J; Fiol, G; Raab, M; Jourdan, E; Grau, V; Moos, M; Goldschmidt, H; Baudard, M; Rossi, JF; Cremer, FW; Klein, B			Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells	ONCOGENE			English	Article						amphiregulin; myeloma; EGF receptor	MALIGNANT PLASMA-CELLS; LUNG-CANCER; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; INTERLEUKIN-6; PROLIFERATION; GEFITINIB; SURVIVAL; ERBB2; LINES	A hallmark of plasma cells is the expression of syndecan-1, which has major functions in epithelial cells, in particular as the coreceptor of heparin-binding growth factors. We previously found that heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a growth factor for malignant plasma cells. As amphiregulin (AREG) is another heparin-binding factor of the EGF family, we investigated its role in multiple myeloma (MM). Using Affymetrix DNA microarrays, we show here that the AREG gene was expressed by purified primary myeloma cells from 65 patients and that the expression was higher than in normal bone marrow (BM) plasma cells or plasmablastic cells. AREG stimulated IL-6 production and growth of BM stromal cells. Using real-time reverse transcriptase polymerase chain reaction, we found that MM cells expressed ErbB receptors and that AREG promoted their growth. Furthermore, PD169540 (a pan-ErbB inhibitor) and IRESSA (an ErbB1-specific inhibitor) induced apoptosis of primary myeloma cells from 10/14 and 4/14 patients, respectively, and there was a synergistic effect with dexamethasone. Altogether, our data provide strong evidence that AREG plays an important role in the biology of MM and emphasize the advantages of using ErbB inhibitors, which might target myeloma cells as well as the tumor environment.	INSERM, U475, F-34000 Montpellier, France; Hop St Eloi, CHU Montpellier, Unit Cellular Therapy, F-34000 Montpellier, France; Univ Klinikum Heidelberg, Med Klin & Poliklin 5, D-69115 Heidelberg, Germany; CHU Nimes, Internal Med Dept B, F-30900 Nimes, France; Hop Lapeyronie, CHU Montpellier, Dept Clin Hematol, F-34000 Montpellier, France; Univ Klinikum Heidelberg, Inst Humangenet, D-69120 Heidelberg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg; Universite de Montpellier; CHU de Nimes; Universite de Montpellier; CHU de Montpellier; Ruprecht Karls University Heidelberg	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	De Vos, John/A-5703-2010; J, Moreaux/ABA-2974-2021; moreaux, jerome/HGA-5649-2022	De Vos, John/0000-0003-1880-4130; J, Moreaux/0000-0002-5717-3207; 				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Badache A, 2001, CANCER RES, V61, P383; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Costes V, 1999, HUM PATHOL, V30, P1405, DOI 10.1016/S0046-8177(99)90160-0; Couchman JR, 2003, NAT REV MOL CELL BIO, V4, P926, DOI 10.1038/nrm1257; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; KLEIN B, 1989, BLOOD, V73, P517; LU ZY, 1995, BLOOD, V85, P2521, DOI 10.1182/blood.V85.9.2521.bloodjournal8592521; LU ZY, 1995, BLOOD, V86, P3123; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mahtouk K, 2004, BLOOD, V103, P1829, DOI 10.1182/blood-2003-05-1510; Manegold C, 2003, ADV EXP MED BIOL, V532, P247; Nylander N, 1998, IN VITRO CELL DEV-AN, V34, P182; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; Sakuma T, 1997, J BIOCHEM-TOKYO, V122, P474; Shao JY, 2003, CANCER RES, V63, P5218; Tarte K, 2000, BLOOD, V96, p514A; Trikha M, 2003, CLIN CANCER RES, V9, P4653; UCHIYAMA H, 1993, BLOOD, V82, P3712; Walters DK, 2003, ONCOGENE, V22, P3598, DOI 10.1038/sj.onc.1206512; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; ZHANG XG, 1994, BLOOD, V83, P3654	38	77	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3512	3524		10.1038/sj.onc.1208536	http://dx.doi.org/10.1038/sj.onc.1208536			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735670	Green Accepted, Green Submitted			2022-12-17	WOS:000229038800013
J	Burger, M; Hartmann, T; Burger, JA; Schraufstatter, I				Burger, M; Hartmann, T; Burger, JA; Schraufstatter, I			KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway	ONCOGENE			English	Article						chemokine receptor; signal transduction; CXCR2; KSHV-GPCR; STAT-3	PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-8 RECEPTORS; ENDOTHELIAL-CELLS; SIGNAL TRANSDUCER; IN-VIVO; EXPRESSION; STAT3	The Kaposi's sarcoma herpesvirus encodes a G-protein-coupled chemokine receptor termed KSHV-GPCR. Expression of this constitutively active GPCR leads to cell transformation and vascular overgrowth characteristic of Kaposi's sarcoma. Previously, we have shown that CXCR2, the closest human homolog, is similarly able to transform cells if continuously stimulated or constitutively activated by amino-acid exchange D138V of the DRY sequence. Here, we demonstrate that STAT3 activation is a prerequisite for transformation in KSHV-GPCR and CXCR2 transfected NIH 3T3 cells. In KSHV-GPCR and D138V transfected cells, STAT-3 is constitutively phosphorylated on Tyr(705). In CXCR2 transfected NIH 3T3 cells and human microvascular endothelial cells (HMEC), which express the CXCR2 constitutively, STAT3 is phosphorylated upon stimulation with IL-8 (CXCL8). Focus formation in NIH 3T3 cells transfected with the KSHV-GPCR, CXCR2, or the D138V mutant, was blocked by the specific JAK2 inhibitor AG490. Typical functions of the CXCR2 including actin stress fiber formation, haptotaxis, and the angiogenic response in HMEC shown by tube formation in Matrigel were blocked by AG490. These data suggest that the transforming capacity and migratory responses that are involved in tumor development, metastasis, and angiogenesis in KSHV or CXCR2-expressing cells is at least partially mediated through a JAK2-STAT3 dependent pathway.	Freiburg Univ Hosp, Dept Internal Med, D-79106 Freiburg, Germany; La Jolla Inst Mol Med, Dept Canc Biol, San Diego, CA USA	University of Freiburg	Burger, M (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burgerm@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bellocq A, 1998, AM J PATHOL, V152, P83; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Greene GF, 1997, AM J PATHOL, V150, P1571; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Korff T, 1999, J CELL SCI, V112, P3249; LEE J, 1992, J BIOL CHEM, V267, P16283; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mellado M, 1998, J IMMUNOL, V161, P805; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Miller LJ, 1998, ANTICANCER RES, V18, P77; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Norgauer J, 1996, J IMMUNOL, V156, P1132; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Offermann MK, 1996, TRENDS MICROBIOL, V4, P383, DOI 10.1016/0966-842X(96)10060-3; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; Richards BL, 1997, AM J SURG, V174, P507; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Scholz A, 2003, GASTROENTEROLOGY, V125, P891, DOI 10.1016/S0016-5085(03)01064-3; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Schraufstatter IU, 2003, J IMMUNOL, V171, P6714, DOI 10.4049/jimmunol.171.12.6714; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shao H, 2003, CANCER RES, V63, P3923; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041; Soriano SF, 2003, EUR J IMMUNOL, V33, P1328, DOI 10.1002/eji.200323897; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Van Rompaey L, 2002, BIOCHEM BIOPH RES CO, V291, P820, DOI 10.1006/bbrc.2002.6513; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; WIGLER M, 1978, CANCER RES, V38, P1434; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	54	77	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					2067	2075		10.1038/SJ.ONC.1208442	http://dx.doi.org/10.1038/SJ.ONC.1208442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688008				2022-12-17	WOS:000227681900011
J	Esufali, S; Bapat, B				Esufali, S; Bapat, B			Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation	ONCOGENE			English	Article						Rac1; beta-catenin; TCF-mediated transcription; Wnt signaling; PBR	ADENOMATOUS POLYPOSIS-COLI; FACTOR-KAPPA-B; RHO-GTPASES; CARCINOMA-CELLS; CYCLIN D1; PROTEIN; CANCER; CDC42; TCF; ADHESION	Aberrant activation of the Wnt pathway is observed in numerous cancers, and is particularly important in colon cancer. We demonstrate that Rac1 GTPase can significantly increase the signaling activity of beta-catenin in cells with inherent dysregulation of the canonical Wnt signaling pathway. Expression of dominant-negative (N17)Rac1 mutant in colon cancer cells caused a marked inhibition of Wnt signaling, as determined by the TCF/LEF-responsive (TOPFLASH) transcription assay. Expression of a constitutively active (V12)Rac1 mutant caused up to 40-fold induction from the TOPFLASH promoter, and this was dependent on the presence of stabilized beta-catenin. This induction was completely blocked by the expression of dominant-negative TCF-4, suggesting that beta-catenin and TCF-4 complex formation is required for Rac1-mediated transcription. Furthermore, we show that Cyclin D1, an important biological Wnt target gene, is regulated by Rac1 in a beta-catenin/TCF-dependent manner. We observed that Rac1 co-immunoprecipitates with beta-catenin and TCF-4 only in its active GTP-bound form. Both cell fractionation studies and fluorescence microscopy indicate that overexpression of V12Rac1 results in increased cytosolic and nuclear expression of beta-catenin. Interestingly, mutation of the polybasic region of Rac1, which prevents its nuclear localization, also caused an appreciable decrease in nuclear localization of beta-catenin, and effectively abolished its beta-catenin-dependent transcription co-activator function. Taken together, our data demonstrate a novel mechanism of Wnt pathway regulation whereby activation of Rac1 amplifies the signaling activity of stabilized/mutated beta-catenin by promoting its accumulation in the nucleus, and synergizing with beta-catenin to augment TCF/LEF-dependent gene transcription.	Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Bapat, B (corresponding author), Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Pathol & Lab Med, 9th Floor,Room 992B,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	bapat@mshri.on.ca	Bapat, Bharati/B-5839-2014					Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Polakis P, 2000, GENE DEV, V14, P1837; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	39	77	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8260	8271		10.1038/sj.onc.1208007	http://dx.doi.org/10.1038/sj.onc.1208007			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15377999				2022-12-17	WOS:000224749500008
J	de Souza-Pinto, NC; Harris, CC; Bohr, VA				de Souza-Pinto, NC; Harris, CC; Bohr, VA			p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria	ONCOGENE			English	Article						p53; mitochondrial DNA; DNA repair; BER; uracil	MICROSATELLITE INSTABILITY; POLYMERASE-GAMMA; LYASE ACTIVITY; NUCLEAR-DNA; URACIL; IDENTIFICATION; INVOLVEMENT; INCISION; BINDING; PROTEIN	The tumor suppressor p53 protein stimulates nuclear base excision repair (BER) in vitro. In response to certain cellular stresses, p53 translocates to mitochondria, where it can trigger an apoptotic response. However, a potential role for p53 in modulating mitochondrial DNA repair has not yet been examined. In this study, we show that p53 also modulates mitochondrial BER. Uracil-initiated BER incorporation, which measures flux through the entire BER pathway, was lower in mitochondrial extracts from nonstressed p53 knockout mice than in wild type. The addition of recombinant p53 complemented the BER incorporation in p53 knockout extracts and stimulated BER in wt extracts. The activities of three major mitochondrial DNA glycosylases were similar in extracts from wild-type and knockout animals. Likewise, AP endonuclease activity was unaffected by the absence of p53. Gel shift experiments with recombinant p53 demonstrated that p53 did not bind to the uracil-containing substrate used in the repair assay. Polymerase gamma gap-filing activity was less efficient in p53 knockout extracts, but it was complemented with the addition of recombinant p53. Thus, we conclude that p53 may participate in mtBER by stimulating the repair synthesis incorporation step.	NIA, Lab Mol Gerontol, GRC,IRP, NIH, Baltimore, MD 21224 USA; NCI, Human Carcinogenesis Lab, CTR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, GRC,IRP, NIH, 5600 Nathon Shock Dr,Box 1, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000733, Z01AG000733] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; EVANS MK, 1993, CANCER RES, V53, P5377; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; Karahalil B, 2003, J BIOL CHEM, V278, P33701, DOI 10.1074/jbc.M301617200; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Krokan HE, 1997, BIOCHEM J, V325, P1; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Meira LB, 1997, NAT GENET, V17, P145, DOI 10.1038/ng1097-145; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; NILSEN H, 1997, NUCLEIC ACIDS RES, V21, P2579; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sobol RW, 2003, J BIOL CHEM, V278, P39951, DOI 10.1074/jbc.M306592200; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712; Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje; TAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V216, P715, DOI 10.1006/bbrc.1995.2680; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Yamada NA, 2002, CANCER RES, V62, P6061; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186	38	77	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6559	6568		10.1038/sj.onc.1207874	http://dx.doi.org/10.1038/sj.onc.1207874			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208669				2022-12-17	WOS:000223530800003
J	Tong, XJ; O'Kelly, J; Xie, D; Mori, A; Lemp, N; McKenna, R; Miller, CW; Koeffler, HP				Tong, XJ; O'Kelly, J; Xie, D; Mori, A; Lemp, N; McKenna, R; Miller, CW; Koeffler, HP			Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway	ONCOGENE			English	Article						Cyr61; beta-catenin; c-myc; p53; p21; p130	HUMAN-PAPILLOMAVIRUS TYPE-16; IMMEDIATE-EARLY GENE; GLYCOGEN-SYNTHASE KINASE; WILD-TYPE P53; BETA-CATENIN; C-MYC; TUMOR-SUPPRESSOR; BREAST-CANCER; P53-DEPENDENT APOPTOSIS; FUNCTIONAL INTERACTION	Cysteine-rich protein 61 (Cyr61) is a growth factor-inducible, immediate-early gene that has multifaceted activities in various cancers. In a previous study, we found that Cyr61 inhibited the growth of the H520 and H460 non-small-cell lung cancer (NSCLC) cell lines. In further studies, we now report that p53 plays a pivotal role in Cyr61-dependent cellular growth arrest. Blockin g Cyr61 with a Cyr61 antibody resulted in the downregulation of expression of p53 and p21, as well as partially reversing the growth suppression of H520-Cyr61 cells. Proliferation of NSCLC cell lines (NCI-H157, H125, H1299), having a mutant p53, were not suppressed by Cyr61. Inhibition of wild-type p53, by either human papilloma virus type 16 E6 or a dominant-negative p53, resulted in the rescue of the growth suppression mediated by Cyr61 in the H520-Cyr61 cells. The enhanced levels of p21(WAF1) and p130/RB2, in the Cyr61-expressing H520-Cyr61 cells, were also inhibited by blocking p53 showing that p21 and p130 were induced by p53 in these cells. In addition, levels of both c-myc and beta-catenin increased in Cyr61 stably transfected H520 cells. Moreover, beta-catenin was translocated into the nucleus in these cells. Inhibition of c-myc expression in the H520-Cyr61 cells with antisense c-myc resulted in their decreased levels of p53. Transfecting cells with a dominant-negative T-cell factor (TCF4), the specific inhibitor of the beta-catenin/TCF4 complex, downregulated the expression of c-myc. Taken together, the data suggest that Cyr61 suppressed the growth of NSCLC cells by triggering a signal transduction pathway through beta-catenin. In this pathway, Cyr61 activated the beta-catenin/TCF4 complex, which promoted the expression of c-myc and the latter induced expression of p53, and p53 upregulated p21(WAF1) and p130/RB2, resulting in growth arrest.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Surg, Los Angeles, CA 90048 USA; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Chinese Acad Sci, Inst Nutr Sci, Shanghai, Peoples R China	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Peking University; Chinese Academy of Sciences	O'Kelly, J (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.	okellyj@cshs.org		Xie, Dong/0000-0002-1150-8657	NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NCI NIH HHS [CA90388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; BODNER SM, 1992, ONCOGENE, V7, P743; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Clevers H, 2000, NAT CELL BIOL, V2, pE177, DOI 10.1038/35036424; Cox RT, 1998, CURR BIOL, V8, pR140, DOI 10.1016/S0960-9822(98)70081-8; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dang CV, 1999, MOL CELL BIOL, V19, P1; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARPER JW, 1993, CELL, V75, P805; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huang SL, 2001, CANCER RES, V61, P3373; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1992, NEW ENGL J MED, V326, P1350, DOI 10.1056/NEJM199205143262008; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marutani M, 1999, CANCER RES, V59, P4765; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Pilarsky CP, 1998, PROSTATE, V36, P85; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Sampath D, 2001, J CLIN ENDOCR METAB, V86, P1707, DOI 10.1210/jc.86.4.1707; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Seewaldt VL, 2001, CANCER RES, V61, P616; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shih IM, 2000, CANCER RES, V60, P1671; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Tsai MS, 2000, CANCER RES, V60, P5603; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waikel RL, 2001, NAT GENET, V28, P165, DOI 10.1038/88889; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	81	77	96	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4847	4855		10.1038/sj.onc.1207628	http://dx.doi.org/10.1038/sj.onc.1207628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077166				2022-12-17	WOS:000222104200005
J	Cronauer, MV; Schulz, WA; Burchardt, T; Ackermann, R; Burchardt, M				Cronauer, MV; Schulz, WA; Burchardt, T; Ackermann, R; Burchardt, M			Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines	ONCOGENE			English	Article						androgen receptor; p53; prostate cancer; pifithrin; MDM2; probasin promoter	WILD-TYPE P53; CARCINOMA-CELLS; TRANSCRIPTIONAL ACTIVITY; GLUCOCORTICOID-RECEPTOR; MUTATIONS; PROTEIN; GROWTH; EXPRESSION; ADENOVIRUS; APOPTOSIS	Current therapy for advanced prostate cancer is mainly based on androgen deprivation, although most patients relapse to androgen-insensitive disease. Several mechanisms contributing to androgen-independent growth including alterations in the structure or expression of the androgen receptor (AR) and its cofactors have been identified. Recent evidence suggests that p53 is involved in androgen signaling. The analysis of the effect of p53 on androgen signaling was performed in 22Rv1 and LNCaP prostate cancer cells that express both p53 and AR. The overexpression of p53 diminished the androgenic response in both cell lines in a reporter gene assay. Conversely, the inhibition of p53 by three different p53 inhibitors, Pifithrin-1alpha (PFT-1alpha), an inhibitor of p53-dependent transactivation; MDM2, a regulator of p53 expression; and a dominant-negative N-terminally truncated p53 gene also reduced transactivation of androgen-dependent reporter genes. The inactivation of p53 by PFT-1alpha decreased AR-protein expression in both 22Rv1 and LNCaP cells. Our findings confirm that the overexpression of wild-type p53 decreases androgen function, whereas p53 expression at physiological levels stabilizes AR signaling. Thus, our findings suggest that there is a balance of AR and p53 expression during the androgen-dependent growth of prostate cancer, which is obliterated during further progression of the disease.	Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Burchardt, M (corresponding author), Univ Dusseldorf, Dept Urol, D-40225 Dusseldorf, Germany.	mb706@hotmail.com	Schulz, Wolfgang A./A-6523-2008; Cronauer, Marcus/AAG-7457-2021; Schulz, Wolfgang/N-3402-2019	Schulz, Wolfgang/0000-0002-2196-463X				Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; APRIKIAN AG, 1994, J UROLOGY, V151, P1276, DOI 10.1016/S0022-5347(17)35231-X; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Burchardt M, 2001, PROSTATE, V48, P225, DOI 10.1002/pros.1101; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen TS, 2000, CANCER RES, V60, P2132; Coffey RNT, 2002, PROSTATE, V53, P300, DOI 10.1002/pros.10159; Coursen JD, 1997, MOL CARCINOGEN, V19, P191; Cronauer MV, 2000, BRIT J CANCER, V82, P39; Cronauer MV, 1997, IN VITRO CELL DEV-AN, V33, P742; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Culig Z, 2002, MOL CELL ENDOCRINOL, V197, P231, DOI 10.1016/S0303-7207(02)00263-0; Eastham JA, 1995, CLIN CANCER RES, V1, P1111; Eastham JA, 2000, J UROLOGY, V164, P814, DOI 10.1016/S0022-5347(05)67320-X; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Freedland SJ, 2003, PROSTATE, V55, P299, DOI 10.1002/pros.10226; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gurova KV, 2002, ONCOGENE, V21, P153, DOI 10.1038/sj.onc.1205001; HASSE A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P16, DOI 10.1016/0167-4781(92)90092-E; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; Hobisch A, 1998, CANCER RES, V58, P4640; ISAACS WB, 1991, CANCER RES, V51, P4716; Jacobberger JW, 1999, CYTOMETRY, V38, P201, DOI 10.1002/(SICI)1097-0320(19991015)38:5<201::AID-CYTO2>3.0.CO;2-F; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Lee YG, 2001, IN VIVO, V15, P157; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; Makri D, 1998, INT J ONCOL, V12, P621; MARTH C, 1990, CANCER RES, V50, P7037; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Osman I, 1999, CLIN CANCER RES, V5, P2082; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Peehl DM, 1994, ATLAS HUMAN TUMOR CE, P387; Pocard M, 1996, ONCOGENE, V12, P875; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; RUNNEBAUM IB, 1994, FEBS LETT, V353, P29, DOI 10.1016/0014-5793(94)00953-8; Schumacher G, 2001, INT J CANCER, V91, P159, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1026>3.3.CO;2-E; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shi XB, 2002, PROSTATE, V51, P59, DOI 10.1002/pros.10072; Sinisl AA, 2002, IN VITRO CELL DEV-AN, V38, P165; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; Steinhoff C, 2002, INT J ONCOL, V21, P1033; Tepper CG, 2002, CANCER RES, V62, P6606; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9	57	77	78	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3541	3549		10.1038/sj.onc.1207346	http://dx.doi.org/10.1038/sj.onc.1207346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077179				2022-12-17	WOS:000221101700005
J	Watson, JEV; Doggett, NA; Albertson, DG; Andaya, A; Chinnaiyan, A; van Dekken, H; Ginzinger, D; Haqq, C; James, K; Kamkar, S; Kowbel, D; Pinkel, D; Schmitt, L; Simko, JP; Volik, S; Weinberg, VK; Paris, PL; Collins, C				Watson, JEV; Doggett, NA; Albertson, DG; Andaya, A; Chinnaiyan, A; van Dekken, H; Ginzinger, D; Haqq, C; James, K; Kamkar, S; Kowbel, D; Pinkel, D; Schmitt, L; Simko, JP; Volik, S; Weinberg, VK; Paris, PL; Collins, C			Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer	ONCOGENE			English	Article						prostate cancer; chromosome 16q; array CGH; tumor suppressor genes	FRAGILE SITE FRA16D; ALLELIC IMBALANCE; GROWTH; CARCINOMAS; BREAST; TRANSLOCATION; DYSREGULATION; MICROARRAYS; DELETIONS; SEQUENCE	We have constructed a high-resolution genomic microarray of human chromosome 16q, and used it for comparative genomic hybridization analysis of 16 prostate tumors. We demarcated 10 regions of genomic loss between 16q23.1 and 16qter that occurred in five or more samples. Mining expression array data from four independent studies allowed us to identify 11 genes that were frequently underexpressed in prostate cancer and that co-localized with a region of genomic loss. Quantitative expression analyses of these genes in matched tumor and benign tissue from 13 patients showed that six of these 11 (WWOX, WFDC1, MAF, FOXF1, MVD and the predicted novel transcript Q9H0B8 (NM_031476)) had significant and consistent downregulation in the tumors relative to normal prostate tissue expression making them candidate tumor suppressor genes.	Univ Calif San Francisco, Ctr Comprehens Canc, Collins Lab, San Francisco, CA 94143 USA; Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Med Ctr, Erasmus Med Ctr, Rotterdam, Netherlands	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Los Alamos National Laboratory; University of Michigan System; University of Michigan; Erasmus University Rotterdam; Erasmus MC	Watson, JEV (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Collins Lab, 2340 Sutter St, San Francisco, CA 94143 USA.	vwatson@cc.ucsf.edu			NCI NIH HHS [CA89520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednarek AK, 2001, CANCER RES, V61, P8068; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Chu LW, 2003, GENE CHROMOSOME CANC, V36, P303, DOI 10.1002/gcc.10171; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Elo JP, 1999, BRIT J CANCER, V79, P156, DOI 10.1038/sj.bjc.6690025; Giese A, 2002, GENE, V299, P101, DOI 10.1016/S0378-1119(02)01018-1; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Han CS, 2000, GENOME RES, V10, P714, DOI 10.1101/gr.10.5.714; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kochetkova M, 2002, CANCER RES, V62, P4599; Larsen M, 1998, J BIOL CHEM, V273, P4574, DOI 10.1074/jbc.273.8.4574; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Paris PL, 2000, CANCER RES, V60, P3645; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Rhodes DR, 2002, CANCER RES, V62, P4427; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; ROWLEY DR, 1995, J BIOL CHEM, V270, P22058, DOI 10.1074/jbc.270.37.22058; Ruijter ETG, 1999, J PATHOL, V188, P271, DOI 10.1002/(SICI)1096-9896(199907)188:3<271::AID-PATH359>3.0.CO;2-K; Smith DM, 2001, MECH DEVELOP, V102, P223, DOI 10.1016/S0925-4773(01)00293-3; Strup SE, 1999, J UROLOGY, V162, P590, DOI 10.1016/S0022-5347(05)68631-4; Toyooka KO, 2001, CANCER RES, V61, P4556; Van Dekken H, 2000, ACTA HISTOCHEM, V102, P85, DOI 10.1078/0065-1281-00540; Verhage BAJ, 2003, PROSTATE, V54, P50, DOI 10.1002/pros.10148; Wadhwa R, 2003, BIOCHEM BIOPH RES CO, V302, P735, DOI 10.1016/S0006-291X(03)00226-2; Welsh JB, 2001, CANCER RES, V61, P5974	33	77	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	2004	23	19					3487	3494		10.1038/sj.onc.1207474	http://dx.doi.org/10.1038/sj.onc.1207474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15007382				2022-12-17	WOS:000220975000024
J	Scapoli, L; Ramos-Nino, ME; Martinelli, M; Mossman, BT				Scapoli, L; Ramos-Nino, ME; Martinelli, M; Mossman, BT			Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos	ONCOGENE			English	Article						mitogen-activated protein kinases; asbestos; activator protein-1	EPIDERMAL-GROWTH-FACTOR; FACTOR-RECEPTOR PROTEIN; SIGNAL-TRANSDUCTION; TYROSINE KINASES; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; IDENTIFICATION; MECHANISMS; BMK1/ERK5	Crocidolite asbestos elicits oxidative stress and cell proliferation, but the signaling cascades linked to these outcomes are unclear. To determine the role of mitogen-activated protein kinases ( MAPK) in asbestos-induced cell signaling, we evaluated the effects of crocidolite asbestos, EGF and H2O2, on MAPK activation in murine lung epithelial cells (C10 line). In contrast to rapid and transient activation of extracellular signal-regulated kinase 5 (ERK5) by EGF or H2O2, asbestos caused protracted oxidant-dependent ERK5 activation that was inhibited by an Src kinase inhibitor (PP2), but not by an inhibitor of epidermal growth factor receptor ( EGFR) phosphorylation (AG1478). ERK1/2 activation by asbestos was inhibited by either PP2 or AG1478. To confirm the involvement of Src in ERK1/2 and ERK5 activation, a dominant-negative Src construct was used. These experiments showed that Src was essential for ERK1/2and also ERK5 phosphorylation by asbestos. Time frame studies indicated immediate activation of Src by asbestos fibers, whereas EGFR phosphorylation occurred subsequently. Data suggest that asbestos causes activation of ERK5 through an EGFR-independent pathway, whereas ERK1/ 2 activation is dependent on Src through a mechanism involving phosphorylation of the EGFR. Furthermore, Src, ERK1/ 2 and ERK5 activation are essential for cell proliferation by asbestos. The use of a dominant-negative ERK5 construct caused selective downregulation of c-jun expression, whereas inhibition of Src by PP2 or MEK1 by PD98059 caused decreases in c-fos, fra-1 and c-jun expression in asbestos-exposed C10 cells. These observations may have broad relevance to cell proliferation by carcinogenic mineral fibers and oxidants.	Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA	University of Vermont	Mossman, BT (corresponding author), Univ Vermont, Coll Med, Dept Pathol, 89 Beaumont Ave, Burlington, VT 05405 USA.	Brooke.Mossman@uvm.edu	Scapoli, Luca/C-6152-2008; Scapoli, Luca/I-7609-2019	Scapoli, Luca/0000-0003-4006-9910; Scapoli, Luca/0000-0003-4006-9910	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009213] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL67005] Funding Source: Medline; NIEHS NIH HHS [R01 ES/HL09213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abe MK, 1999, MOL CELL BIOL, V19, P1301; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BeruBe KA, 1996, AM J RESP CELL MOL, V15, P141, DOI 10.1165/ajrcmb.15.1.8679218; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Buder-Hoffmann S, 2001, AM J RESP CELL MOL, V24, P405, DOI 10.1165/ajrcmb.24.4.4290; CAMPBELL WJ, 1980, 8452 US BUR MIN; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kamp DW, 1995, TOXICOL PATHOL, V23, P689, DOI 10.1177/019262339502300606; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Malkinson AM, 1997, TOXICOLOGY, V123, P53, DOI 10.1016/S0300-483X(97)00108-X; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Mossman BT, 2000, INHAL TOXICOL, V12, P307, DOI 10.1080/08958378.2000.11463240; Pache JC, 1998, AM J PATHOL, V152, P333; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Ramos-Nino ME, 2002, MOL CELL BIOCHEM, V234, P111, DOI 10.1023/A:1015924413043; Robledo RF, 2000, AM J PATHOL, V156, P1307, DOI 10.1016/S0002-9440(10)65001-8; Shukla A, 2001, CANCER RES, V61, P1791; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Zanella CL, 1996, CANCER RES, V56, P5334; Zanella CL, 1999, AM J PHYSIOL-LUNG C, V277, pL684, DOI 10.1152/ajplung.1999.277.4.L684; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	32	77	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					805	813		10.1038/sj.onc.1207163	http://dx.doi.org/10.1038/sj.onc.1207163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737115				2022-12-17	WOS:000188304900019
J	Pennati, M; Binda, M; Colella, G; Zoppe', M; Folini, M; Vignati, S; Valentini, A; Citti, L; De Cesare, M; Pratesi, G; Giacca, M; Daidone, MG; Zaffaroni, N				Pennati, M; Binda, M; Colella, G; Zoppe', M; Folini, M; Vignati, S; Valentini, A; Citti, L; De Cesare, M; Pratesi, G; Giacca, M; Daidone, MG; Zaffaroni, N			Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells	ONCOGENE			English	Article						survivin; ribozyme; prostate cancer; apoptosis; tumorigenicity	HUMAN-MELANOMA CELLS; DOWN-REGULATION; GENE-THERAPY; TUMOR-GROWTH; DEATH; PHOSPHORYLATION; PROGRESSION; RESISTANCE; RECEPTOR; BCL-2	Survivin is a member of the inhibitor of apoptosis protein (IAP) family, which has been implicated in inhibition of apoptosis and control of mitotic progression. The finding that survivin is overexpressed in most human tumors but absent in normal adult tissues has led to the proposal of survivin as a promising therapeutic target for anticancer therapies. We decided to evaluate the effects of a ribozyme-based strategy for survivin inhibition in androgen-independent human prostate cancer cells. We constructed a Moloney-based retroviral vector expressing a ribozyme targeting the 3' end of the CUA(110) triplet in survivin mRNA, encoded as a chimeric RNA within adenoviral VA1 RNA. Polyclonal cell populations obtained by infection with the retroviral vector of two androgen-independent human prostate cancer cell lines (DU145 and PC-3) were selected for the study. Ribozyme-expressing prostate cancer cells were characterized by a significant reduction of survivin expression compared to parental cells transduced with a control ribozyme; the cells became polyploid, underwent caspase-9-dependent apoptosis and showed an altered pattern of gene expression, as detected by oligonucleotide array analysis. Survivin inhibition also increased the susceptibility of prostate cancer cells to cisplatin-induced apoptosis and prevented tumor formation when cells were xenografted in athymic nude mice. These findings suggest that manipulation of the antiapoptotic survivin pathway may provide a novel approach for the treatment of androgen-independent prostate cancer.	Ist Nazl Studio & Cura Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy; CNR, Ist Fisiol Clin, I-56100 Pisa, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); International Center for Genetic Engineering & Biotechnology (ICGEB)	Zaffaroni, N (corresponding author), Ist Nazl Tumori, Dipartimento Oncol Sperimentale, Unita Operat 10, Via Venezian 1, I-20133 Milan, Italy.	nadia.zaffaroni@istitutotumori.mi.it	De Cesare, Michelandrea/M-6667-2017; Folini, Marco/B-9607-2017; Daidone, Maria Grazia/E-9232-2017; Zaffaroni, Nadia/J-8178-2016; Giacca, Mauro/J-9287-2016; Pennati, Marzia/K-2554-2016	De Cesare, Michelandrea/0000-0001-9687-0753; Folini, Marco/0000-0002-1811-4407; Daidone, Maria Grazia/0000-0002-4786-1321; Zaffaroni, Nadia/0000-0002-4669-0890; Giacca, Mauro/0000-0003-2927-7225; Pennati, Marzia/0000-0002-6181-2681; ZOPPE', Monica/0000-0003-4590-0718; Colella, Gennaro/0000-0001-9132-8375				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Cagnon L, 2000, ANTISENSE NUCLEIC A, V10, P251, DOI 10.1089/108729000421439; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Denmeade SR, 1996, PROSTATE, V28, P251; Dennis LK, 2000, PROSTATE, V42, P247; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Giodini A, 2002, CANCER RES, V62, P2462; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Honda T, 2001, ANTICANCER RES, V21, P3141; Howell SB, 2000, MOL UROL, V4, P225; Kore AR, 1998, NUCLEIC ACIDS RES, V26, P4116, DOI 10.1093/nar/26.18.4116; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Mendoza-Maldonado R, 2002, CANCER GENE THER, V9, P71, DOI 10.1038/sj/cgt/7700410; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Olie RA, 2000, CANCER RES, V60, P2805; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Pennati M, 2002, J CLIN INVEST, V109, P285; Prislei S, 1997, RNA, V3, P677; Somia NV, 2000, J VIROL, V74, P4420, DOI 10.1128/JVI.74.9.4420-4424.2000; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wall NR, 2003, CANCER RES, V63, P230; Workman P, 1998, BRIT J CANCER, V77, P1; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3	37	77	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					386	394		10.1038/sj.onc.1207071	http://dx.doi.org/10.1038/sj.onc.1207071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724567				2022-12-17	WOS:000188098300008
J	Mallette, FA; Goumard, S; Gaumont-Leclerc, MF; Moiseeva, O; Ferbeyre, G				Mallette, FA; Goumard, S; Gaumont-Leclerc, MF; Moiseeva, O; Ferbeyre, G			Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence	ONCOGENE			English	Article						senescence; nuclear bodies; E6; E7; Rb; p53; PML	PAPILLOMAVIRUS TYPE-16 E7; HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE ARREST; ONCOGENIC RAS; RETINOBLASTOMA PROTEIN; REPLICATIVE SENESCENCE; PREMATURE SENESCENCE; TELOMERASE ACTIVITY; G(1) CONTROL; IMMORTALIZATION	Cellular senescence is a permanent cell cycle arrest that can be triggered by a variety of stresses including short telomeres and activated oncogenes. Promyelocytic leukemia protein (PML) is a central component of the senescence response, and is able to trigger the process when overexpressed in human diploid fibroblasts (HDFs). Senescence induced by PML in HDFs is characterized by a modest increase in p53 levels and activity, the accumulation of hypophosphorylated Rb and a reduced expression of E2F-dependent genes. To dissect the p53 and Rb family requirements for PML-induced senescence, we used the oncoproteins E6 and E7 from human papillomavirus type 16. We found that the coexpression of E6 and E7 inhibited the growth arrest and senescence induced by PML. In addition, these viral oncoproteins blocked the formation of PML bodies and excluded both p53 and Rb from PML bodies. Expression of dominant-negative p53 alone failed to block PML-induced senescence and expression of E6 only delayed the process. On the other hand, expression of E7 was sufficient to block PML-induced senescence, while an E7 mutant unable to bind Rb did not. Together, these data indicate that PML-induced senescence engages the Rb tumor-suppressor pathway predominantly.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Ferbeyre, G (corresponding author), Univ Montreal, Dept Biochim, E-515,CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	g.ferbeyre@umontreal.ca	Ferbeyre, Gerardo/A-1569-2010; Moiseeva, Olga/Q-4848-2016; Mallette, Frédérick A./J-6646-2019	Mallette, Frédérick A./0000-0001-7932-0338				Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2000, GENE DEV, V14, P2015; Franco EL, 2001, CAN MED ASSOC J, V164, P1017; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haq R, 2002, CANCER RES, V62, P5076; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heidebrecht HJ, 2001, LAB INVEST, V81, P1163, DOI 10.1038/labinvest.3780328; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Medcalf ASC, 1996, CANCER RES, V56, P4582; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	53	77	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					91	99		10.1038/sj.onc.1206886	http://dx.doi.org/10.1038/sj.onc.1206886			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712214				2022-12-17	WOS:000187895300010
J	Mateo-Lozano, S; Tirado, OM; Notario, V				Mateo-Lozano, S; Tirado, OM; Notario, V			Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation	ONCOGENE			English	Article						mTOR; rapamycin; EWS/FLI-1; Ewing's sarcoma	TRANSFORMING-GROWTH-FACTOR; II RECEPTOR; EWS-FLI1; FAMILY; EXPRESSION; TARGET; EWS; ONCOPROTEINS; PATHWAY	Ewing's sarcoma (ES) is the prototype of a family of tumors (ESFT) of neuroectodermal origin formed by small, round cells with limited neural differentiation, which arise most frequently within bones in children or adolescents. The proliferation of ESFT cells is highly dependent on the establishment of, and signaling through several growth factor-mediated autocrine loops. The mammalian target of rapamycin (mTOR) is a central regulator of translation and cell proliferation, involved in the cellular response to various nutritional, stress and mitogenic effectors. As mTOR has recently been associated with certain human cancers, we investigated the possibility that mTOR played a role in the regulation of ES cell proliferation. Results showed that ES cell lines carrying EWS/FLI-1 alleles of different types expressed different levels of total and phosphorylated mTOR protein. We demonstrate that rapamycin, an mTOR inhibitor, efficiently blocked the proliferation of all cell lines by promoting cell cycle arrest at the G(1) phase. This was paralleled by the downregulation of the levels of the EWS/FLI-1 proteins, regardless of their fusion type, and the concomitant restoration of the expression of the TGF-beta type 2 receptor (TGFbeta RII), which is known to be repressed by several EWS-ETS fusion proteins. The expression of a rapamycin-resistant mTOR construct prevented both the proliferation blockade and the EWS/FLI-1 downregulation. These data demonstrate that mTOR signaling plays a central role in ES cell pathobiology and strongly suggest that the use of rapamycin as a cytostatic agent may be an efficient tool for the treatment of ES patients.	Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Washington, DC 20057 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20057 USA.	notariov@georgetown.edu	Tirado, Oscar Martínez/R-9604-2019; /AAB-6461-2022; /AFP-0764-2022	Tirado, Oscar Martínez/0000-0002-4666-2822; Mateo, Silvia/0000-0002-2365-1573	NCI NIH HHS [P01-CA74175, P30-CA51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Aryee DNT, 2000, LAB INVEST, V80, P1833, DOI 10.1038/labinvest.3780194; Benini S, 2001, CLIN CANCER RES, V7, P1790; Daniels G A, 2001, Expert Rev Anticancer Ther, V1, P211, DOI 10.1586/14737140.1.2.211; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Im YH, 2000, CANCER RES, V60, P1536; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Kovar H, 2001, CANCER RES, V61, P5992; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lin PP, 1999, CANCER RES, V59, P1428; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Sausville EA, 1999, PHARMACOL THERAPEUT, V82, P285, DOI 10.1016/S0163-7258(98)00062-X; Scotlandi K, 1998, CANCER RES, V58, P4127; Seufferlein T, 1996, CANCER RES, V56, P3895; Shah SA, 2001, J SURG RES, V97, P123, DOI 10.1006/jsre.2001.6145; Toretsky JA, 1999, CANCER RES, V59, P5745; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; van der Poel HG, 2003, UROL RES, V30, P380, DOI 10.1007/s00240-002-0282-1; Visner GA, 2003, CIRCULATION, V107, P911, DOI 10.1161/01.CIR.0000048191.75585.60; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	35	77	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9282	9287		10.1038/sj.onc.1207081	http://dx.doi.org/10.1038/sj.onc.1207081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681687				2022-12-17	WOS:000187400400010
J	Conte, N; Delaval, B; Ginestier, C; Ferrand, A; Isnardon, D; Larroque, C; Prigent, C; Seraphin, B; Jacquemier, J; Birnbaum, D				Conte, N; Delaval, B; Ginestier, C; Ferrand, A; Isnardon, D; Larroque, C; Prigent, C; Seraphin, B; Jacquemier, J; Birnbaum, D			TACC1-chTOG-Aurora A protein complex in breast cancer	ONCOGENE			English	Article						Aurora kinase; breast cancer; cell division; chTOG protein; microtubule; SM proteins; TACC protein; tissue microarray; RNAi	DROSOPHILA AURORA-A; SM-LIKE PROTEIN; MESSENGER-RNA; COILED-COIL; TRANSLATIONAL CONTROL; D-TACC; SERINE/THREONINE KINASE; EXPRESSION ANALYSIS; TUMOR SUPPRESSOR; GENE FAMILY	The three human TACC (transforming acidic coiled-coil) genes encode a family of proteins with poorly defined functions that are suspected to play a role in oncogenesis. A Xenopus TACC homolog called Maskin is involved in translational control, while Drosophila D-TACC interacts with the microtubule-associated protein MSPS (Mini SPindleS) to ensure proper dynamics of spindle pole microtubules during cell division. We have delineated here the interactions of TACC1 with four proteins, namely the microtubule-associated chTOG (colonic and hepatic tumor-overexpressed gene) protein (ortholog of Drosophila MSPS), the adaptor protein TRAP (tudor repeat associator with PCTAIRE2), the mitotic serine/threonine kinase Aurora A and the mRNA regulator LSM7 (Like-Sm protein 7). To measure the relevance of the TACC1-associated complex in human cancer we have examined the expression of the three TACC, chTOG and Aurora A in breast cancer using immunohistochemistry on tissue microarrays. We show that expressions of TACC1, TACC2, TACC3 and Aurora A are significantly correlated and downregulated in a subset of breast tumors. Using siRNAs, we further show that depletion of chTOG and, to a lesser extent of TACC1, perturbates cell division. We propose that TACC proteins, which we also named 'Taxins', control mRNA translation and cell division in conjunction with microtubule organization and in association with chTOG and Aurora A, and that these complexes and cell processes may be affected during mammary gland oncogenesis.	Inst J Paoli I Calmettes, INSERM, U119, IFR57,Dept Mol Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Imaging Core Facil, F-13009 Marseille, France; CRLC Val Aurelle Paul Lamarque, INSERM, E229, Montpellier, France; Fac Med, CNRS, UMR 6061, IFR 97,Lab Cycle Cellulaire, Rennes, France; Ctr Genet Mol, Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, U119, IFR57,Dept Mol Oncol, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017	Ginestier, Christophe/0000-0002-7477-3837; Birnbaum, Daniel/0000-0001-7920-9883; Conte, Nathalie/0000-0002-1010-3121; Seraphin, Bertrand/0000-0002-5168-1921				Aitola M, 2003, J HISTOCHEM CYTOCHEM, V51, P455, DOI 10.1177/002215540305100407; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Barbarese E, 2002, J NEUROCHEM, V81, P93; Barbee SA, 2002, CURR BIOL, V12, P1502, DOI 10.1016/S0960-9822(02)01111-9; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cremet JY, 2003, MOL CELL BIOCHEM, V243, P123, DOI 10.1023/A:1021608012253; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GREGELY F, 2003, GENE DEV, V17, P336; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Hao ZL, 2002, MOL REPROD DEV, V63, P291, DOI 10.1002/mrd.90012; Hirose T, 1997, EUR J BIOCHEM, V249, P481, DOI 10.1111/j.1432-1033.1997.t01-1-00481.x; Hirose T, 2000, EUR J BIOCHEM, V267, P2113, DOI 10.1046/j.1432-1327.2000.01218.x; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lauffart B, 2003, GENOMICS, V81, P192, DOI 10.1016/S0888-7543(02)00039-3; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Line A, 2002, CANCER GENET CYTOGEN, V139, P78, DOI 10.1016/S0165-4608(02)00607-6; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mack GJ, 2000, MICROSC RES TECHNIQ, V49, P409, DOI 10.1002/(SICI)1097-0029(20000601)49:5<409::AID-JEMT2>3.0.CO;2-V; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nonet GH, 2001, CANCER RES, V61, P1250; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Popovici C, 2001, BIOCHEM BIOPH RES CO, V288, P362, DOI 10.1006/bbrc.2001.5794; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; Roghi C, 1998, J CELL SCI, V111, P557; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schweinfest CW, 1997, CANCER RES, V57, P2961; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Spittle C, 2000, J BIOL CHEM, V275, P20748, DOI 10.1074/jbc.M002597200; STEADMAN BT, 2002, J BIOL CHEM, V363, P195; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Theurkauf WE, 2001, NAT CELL BIOL, V3, pE159, DOI 10.1038/35083110; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	71	77	86	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8102	8116		10.1038/sj.onc.1206972	http://dx.doi.org/10.1038/sj.onc.1206972			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603251				2022-12-17	WOS:000186403400005
J	Sansom, OJ; Zabkiewicz, J; Bishop, SM; Guy, J; Bird, A; Clarke, AR				Sansom, OJ; Zabkiewicz, J; Bishop, SM; Guy, J; Bird, A; Clarke, AR			MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine	ONCOGENE			English	Article						MBD4; mismatch repair; apoptosis; DNA methylation; p53	MISMATCH REPAIR PROTEIN; MED1 MBD4; CPG SITES; MICE; GENE; MUTATION; CANCER; CELLS; DEATH; P53	MBD4 was originally identified through its methyl binding domain, but has more recently been characterized as a thymine DNA glycosylase that interacts with the mismatch repair (MMR) protein MLH1. In vivo, MBD4 functions to reduce the mutability of methyl-CpG sites in the genome and mice deticient in MBD4 show increased intestinal tumorigenesis on an Apc(Min/)+ background. As MLH1 and other MMR proteins have been functionally linked to apoptosis, we asked whether MBD4 also plays a role in mediating the apoptotic response within the murine small intestine. Mice deficient for MBD4 showed significantly reduced apoptotic responses 6 h following treatment with a range of cytotoxic agents including gamma-irradiation, cisplatin, temozolomide and 5-fluorouracil (5-FU). This leads to increased clonogenic survival in vivo in Mbd4(-/-) mice following exposure to either 5-FU or cisplatin. We next analysed the apoptotic response to 5FU and temozolomide in doubly mutant Mbd4(-/-), Mlh1(-/-) mice but observed no additive decrease. The results imply that MBD4 and MLH1 lie in the same pathway and therefore that MMR-dependent apoptosis is mediated through MBD4. MBD4 deficiency also reduced the normal apoptotic response to gamma-irradiation, which we show is independent of Mlh1 status (at least in the murine small intestine), so suggesting that the reliance upon MBD4 may extend beyond MMR-mediated apoptosis. Our results establish a novel functional role for MBD4 in the cellular response to DNA damage and may have implications for its role in suppressing neoplasia.	Cardiff Univ, Cardiff Business Sch, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Business Sch, POB 911, Cardiff CF10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Sansom, Owen J./0000-0001-9540-3010; Guy, Jacky/0000-0002-8440-5667; Bird, Adrian/0000-0002-8600-0372; Clarke, Alan/0000-0002-4281-426X				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, J CELL PHYSIOL, V187, P137, DOI 10.1002/jcp.1064; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Drummond JT, 2001, NUCLEIC ACIDS RES, V29, P2234, DOI 10.1093/nar/29.11.2234; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Meyers M, 2001, CANCER RES, V61, P5193; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; Pritchard DM, 1998, CANCER RES, V58, P5453; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911	27	77	81	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7130	7136		10.1038/sj.onc.1206850	http://dx.doi.org/10.1038/sj.onc.1206850			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562041				2022-12-17	WOS:000185955000004
J	Oshiro, MM; Watts, GS; Wozniak, RJ; Junk, DJ; Munoz-Rodriguez, JL; Domann, FE; Futscher, BW				Oshiro, MM; Watts, GS; Wozniak, RJ; Junk, DJ; Munoz-Rodriguez, JL; Domann, FE; Futscher, BW			Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression	ONCOGENE			English	Article						methylation; p53; tumor suppressor; azacytidine; breast cancer; maspin	HUMAN BREAST CARCINOMAS; CLONAL CHROMOSOME-ABNORMALITIES; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; CELL-LINES; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; BINDING PROTEIN; MASPIN GENE; CANCER	p53 is an important transcriptional regulator that is frequently mutated in cancer. Gene-profiling experiments of breast cancer cells infected with wt p53 revealed both MASPIN and desmocollin 3 (DSC3) to be p53-target genes, even though both genes are silenced in association with aberrant cytosine methylation of their promoters. Despite the transcriptional repression of these genes by aberrant DNA methylation, restoration of p53 resulted in the partial reactivation of both genes. This reactivation is a result of wt p53 binding to its consensus DNA-binding sites within the MASPIN and DSC3 promoters, stimulating histone acetylation, and enhancing chromatin accessibility of their promoters. Interestingly, wt p53 alone did not affect the methylation status of either promoter, suggesting that p53 itself can partially overcome the repressive barrier of DNA methylation. Pharmacologic inhibition of DNA methylation with 5-aza-2'-deoxycytidine in combination with restoration of wt p53 status resulted in a synergistic reactivation of these genes to near-normal levels. These results suggest that cancer treatments that target both genetic and epigenetic facets of gene regulation may be a useful strategy towards the therapeutic transcriptional reprogramming of cancer cells.	Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Iowa; University of Iowa	Futscher, BW (corresponding author), Univ Arizona, Arizona Canc Ctr, Bone Marrow Transplant Program, Tucson, AZ 85724 USA.		Rodríguez, Jose Manuel JMMR Muñoz/A-7323-2016	Rodríguez, Jose Manuel JMMR Muñoz/0000-0002-4688-6420; Junk, Damian/0000-0002-9251-3799; Domann, Frederick/0000-0002-0489-2179	NCI NIH HHS [P30 CA023074] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan J, 1998, CANCER RES, V58, P5009; Klus GT, 2001, INT J ONCOL, V19, P169; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; MELTZER P, 1991, BRIT J CANCER, V63, P727, DOI 10.1038/bjc.1991.164; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Seftor REB, 1998, CANCER RES, V58, P5681; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Streuli CH, 2002, BREAST CANCER RES, V4, P137, DOI 10.1186/bcr437; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhao RB, 2000, GENE DEV, V14, P981; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	44	77	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3624	3634		10.1038/sj.onc.1206545	http://dx.doi.org/10.1038/sj.onc.1206545			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789271				2022-12-17	WOS:000183399200013
J	Iizuka, N; Oka, M; Yamada-Okabe, H; Mori, N; Tamesa, T; Okada, T; Takemoto, N; Hashimoto, K; Tangoku, A; Hamada, K; Nakayama, H; Miyamoto, T; Uchimura, S; Hamamoto, Y				Iizuka, N; Oka, M; Yamada-Okabe, H; Mori, N; Tamesa, T; Okada, T; Takemoto, N; Hashimoto, K; Tangoku, A; Hamada, K; Nakayama, H; Miyamoto, T; Uchimura, S; Hamamoto, Y			Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis	ONCOGENE			English	Article						DNA chip; gene expression profiles; HCC; HBV; liver cirrhosis	HEPATITIS-B; CDNA MICROARRAY; CANCER; IDENTIFICATION; APOPTOSIS; PROFILES; CARCINOGENESIS; PROGRESSION; INTERACTS; BINDING	Using oligonucleotide microarray data of 45 hepatocellular carcinoma (HCC) samples, we evaluated gene expression in hepatitis B virus-positive and hepatitis C virus-positive HCCs (HBV- and HCV-HCCs) for an association with liver cirrhosis (LC). In all, 89 genes were expressed differentially between HBV-HCCs associated with LC and those not associated with LC. Among them, tumors from LC patients showed significantly lower expression levels of 72 genes and significantly higher levels of 17 genes than the levels found in tumors from non-LC patients. The former included genes responsible for signal transduction, transcription, metabolism, and cell growth. The latter included a tumor suppressor gene and a cell-growth-related gene. Only eight genes were expressed differentially between HCV-HCCs associated with and without LC. Our findings provide as a framework for clarifying the role of LC in HBV- and HCV-related hepatocarcinogenesis.	Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Bioregulat Funct, Yamaguchi 7558505, Japan; Nippon Roche Res Ctr, Dept Oncol, Kanagawa 2478530, Japan; Yamaguchi Univ, Fac Engn, Dept Comp Sci & Syst Engn, Yamaguchi 7558611, Japan	Yamaguchi University; Yamaguchi University; Roche Holding; Yamaguchi University	Oka, M (corresponding author), Yamaguchi Univ, Sch Med, Dept Surg 2, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.							Bode BP, 1999, JPEN-PARENTER ENTER, V23, pS33, DOI 10.1177/014860719902300509; Delpuech O, 2002, ONCOGENE, V21, P2926, DOI 10.1038/sj.onc.1205392; Goldenberg D, 2002, MOL CARCINOGEN, V33, P113, DOI 10.1002/mc.10027.abs; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; Huang CJ, 2000, J BIOMED SCI, V7, P160, DOI 10.1159/000025442; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; IIZUKA N, 1995, CANCER RES, V55, P652; Iizuka N, 2002, INT J CANCER, V99, P286, DOI 10.1002/ijc.10338; Iizuka N, 2002, CANCER RES, V62, P3939; Kao JH, 2000, GASTROENTEROLOGY, V118, P554, DOI 10.1016/S0016-5085(00)70261-7; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Kim JS, 2002, CANCER RES, V62, P2744; Koike K, 2002, ONCOLOGY-BASEL, V62, P29, DOI 10.1159/000048273; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lau WY, 2000, ONCOL RES, V12, P59; Luo J, 2001, CANCER RES, V61, P4683; Okabe H, 2001, CANCER RES, V61, P2129; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith TAD, 1999, BRIT J BIOMED SCI, V56, P285; Sobin L, 2002, TNM CLASSIFICATION M, P81; van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037; Xu L, 2001, CANCER RES, V61, P3176; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398	26	77	86	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					3007	3014		10.1038/sj.onc.1206401	http://dx.doi.org/10.1038/sj.onc.1206401			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771952				2022-12-17	WOS:000182824800016
J	Baba, M; Hirai, S; Yamada-Okabe, H; Hamada, K; Tabuchi, H; Kobayashi, K; Kondo, K; Yoshida, M; Yamashita, A; Kishida, T; Nakaigawa, N; Nagashima, Y; Kubota, Y; Yao, M; Ohno, S				Baba, M; Hirai, S; Yamada-Okabe, H; Hamada, K; Tabuchi, H; Kobayashi, K; Kondo, K; Yoshida, M; Yamashita, A; Kishida, T; Nakaigawa, N; Nagashima, Y; Kubota, Y; Yao, M; Ohno, S			Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor	ONCOGENE			English	Article						VHL; tumor suppressor; contact inhibition; renal cell carcinoma; cyclinDl; HIF	TUMOR-SUPPRESSOR GENE; TRANSFORMING-GROWTH-FACTOR; RENAL-CARCINOMA CELLS; UBIQUITIN LIGASE; HIF-ALPHA; G1 PHASE; VHL; CYCLE; COMPLEX; FIBROBLASTS	Loss of the von Hippel-Lindau gene (VHL) expression causes deregulation of contact inhibition of cell growth, which might be one of the bases of the tumor suppressor function of VHL. Here we show that this function of the VHL gene product (pVHL) depends on cell autonomous events. To identify the target gene of pVHL, which is directly involved in the contact inhibition, we compared the gene expression profile between VHL-deficient renal carcinoma 786-O cells and those infected with an adenovirus vector encoding VHL. In addition to known pVHL-regulated genes, such as vascular endothelial growth factor and carbonic anhydrase, we found cyclinD1 as a new target of pVHL at a high cell density. In VHL-expressing cells (VHL (+) cells), the cyclinD1 mRNA expression level diminishes at a high cell density, while it remains at a relatively high level in VHL-deficient cells (VHL (-) cells). The cyclinD1 expression level was also abnormally high in VHL (-) cells at a high cell density. Consequently, the phosporylation level of the retinoblastoma (Rb) protein remained high in these cells, whereas there was no phosporylated Rb in VHL (+) cells under the contact inhibition. The abnormal expression of cyctinD1 at a high cell density was observed even in VHL (+) cells under the hypoxic state. Moreover, ectopic expression of a HIF mutant resistant to pVHL-mediated proteolysis causes the abnormal cyclinD1 expression in VHL (+) cells. Taken together, these observations indicate that VHL is required for the downregulation of cyclinD1 at a high cell density through HIF.	Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Urol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Pathol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Chugai Res Ctr, Pharmacol Res Dept 4, Kamakura, Kanagawa 2473590, Japan	Yokohama City University; Yokohama City University; Yokohama City University; Chugai Pharmaceutical Co., Ltd.	Hirai, S (corresponding author), Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, 3-9 Fuko Ura, Yokohama, Kanagawa 2360004, Japan.		Baba, Masaya/ABE-4893-2020; Ohno, Shigeo/B-1768-2010; Baba, Masaya/L-7490-2013; Nagashima, Yoji/AAA-2591-2021	Ohno, Shigeo/0000-0002-1294-5269; Baba, Masaya/0000-0002-5308-6683; 				Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Bindra RS, 2002, CANCER RES, V62, P3014; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; Iizuka N, 2002, CANCER RES, V62, P3939; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; JIANG W, 1993, ONCOGENE, V8, P3447; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Knebelmann B, 1998, CANCER RES, V58, P226; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Kondo K, 2002, GENE CHROMOSOME CANC, V34, P58, DOI 10.1002/gcc.10054; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; PAPADIMITRIOU E, 1993, J IMMUNOL METHODS, V162, P41, DOI 10.1016/0022-1759(93)90405-V; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sellers WR, 1996, BBA-REV CANCER, V1288, pM1, DOI 10.1016/0304-419X(96)00014-5; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; Vinals F, 1999, MOL CELL BIOL, V19, P2763; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Yao M, 2002, JNCI-J NATL CANCER I, V94, P1569; Zatyka M, 2002, CANCER RES, V62, P3803	43	77	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2728	2738		10.1038/sj.onc.1206373	http://dx.doi.org/10.1038/sj.onc.1206373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743597				2022-12-17	WOS:000182569300004
J	Clark, J; Edwards, S; Feber, A; Flohr, P; John, M; Giddings, I; Crossland, S; Stratton, MR; Wooster, R; Campbell, C; Cooper, CS				Clark, J; Edwards, S; Feber, A; Flohr, P; John, M; Giddings, I; Crossland, S; Stratton, MR; Wooster, R; Campbell, C; Cooper, CS			Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays	ONCOGENE			English	Article							DNA COPY-NUMBER; LOCALLY WEIGHTED REGRESSION; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; GROWTH-ARREST; CELL-LINES; STAT3; DIFFERENTIATION; PROTEIN; IDENTIFICATION	We demonstrate that comparative genomic hybridization (CGH) onto cDNA microarrays may be used to carry out genome-wide screens for regions of genetic loss, including homozygous (complete) deletions that may represent the possible location of tumour suppressor genes in human cancer. Screening of the prostate cancer cell lines LNCaP, PC3 and DU145 allowed the mapping of specific regions where genome copy number appeared altered and led to the identification of two novel regions of complete loss at 17q21.31 (500 kb spanning STAT3) and at 10q23.1 (50-350 kb spanning SFTPA2) in the PC3 cell line.	Inst Canc Res, Male Urol Canc Res Ctr, Mol Carcinogenesis Sect, Surrey, England; Inst Canc Res, Male Urol Canc Res Ctr, Canc Res UK DNA Microarray Facil, Surrey, England; Wellcome Trust Sanger Inst, Cambridge, England; Univ Bristol, Adv Comp Res Ctr, Bristol BS8 1TH, Avon, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Wellcome Trust Sanger Institute; University of Bristol	Cooper, CS (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, Mol Carcinogenesis Sect, Surrey, England.			Giddings, Ian/0000-0003-1078-5780; Feber, Andrew/0000-0001-5282-0498				Aurich-Costa J, 2001, GENE CHROMOSOME CANC, V30, P143, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E; Bednarek AK, 2001, CANCER RES, V61, P8068; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chekmareva MA, 1997, PROSTATE, V33, P271; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Forozan F, 2000, CANCER RES, V60, P4519; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Heiskanen MA, 2000, CANCER RES, V60, P799; Hyytinen ER, 2002, GENE CHROMOSOME CANC, V34, P306, DOI 10.1002/gcc.10065; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Khubchandani KR, 2001, FASEB J, V15, P59, DOI 10.1096/fj.00-0318rev; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; MORTON RA, 1993, CANCER RES, V53, P3585; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Uchida T, 1999, INT J CANCER, V84, P19, DOI 10.1002/(SICI)1097-0215(19990219)84:1<19::AID-IJC4>3.0.CO;2-S; Yang Y H, 2001, Brief Bioinform, V2, P341, DOI 10.1093/bib/2.4.341	33	77	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1247	1252		10.1038/sj.onc.1206247	http://dx.doi.org/10.1038/sj.onc.1206247			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606952				2022-12-17	WOS:000181249700014
J	Fu, WN; Bertoni, F; Kelsey, SM; McElwaine, SM; Cotter, FE; Newland, AC; Jia, L				Fu, WN; Bertoni, F; Kelsey, SM; McElwaine, SM; Cotter, FE; Newland, AC; Jia, L			Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia	ONCOGENE			English	Article						Apaf-1; apoptosis; methylation; CpG island; real-time polymerase chain reaction	CYTOCHROME-C; INDUCED APOPTOSIS; LEUKEMIC-CELLS; CANCER; INACTIVATION; EPIGENETICS; ACTIVATION; CASPASE-9; DEATH	Apaf-1 protein deficiency occurs in human leukaemic blasts and confers resistance to cytochrome-c-dependent apoptosis. Demethylation treatment with 5-aza-2-deoxycytidine (5aza2dc) increased the sensitivity of the K562 leukaemic cell line to UV light-induced apoptosis in association with increased Apaf-1 protein levels. There was no correlation between Apaf-1 protein expression and Apaf-1 mRNA levels after the demethylation treatment. Methylation-specific polymerase chain reaction was used to show that the methylation can occur within the Apaf-1 promoter region in leukaemic blasts. Apaf-1 DNA methylation was demonstrated in acute myeloid leukaemia, chronic myeloid leukaemia and acute lymphoid leukaemia, suggesting that it is not specific to a particular leukaemia subtype. Apaf-1 protein expression did not correlate with Apaf-1 mRNA levels in human leukaemic blasts. Some leukaemic cells expressed high levels of Apaf-1 mRNA but low levels of Apaf-1 protein. This study suggests that Apaf-1 DNA promoter methylation might contribute to the inactivation of Apaf-1 expression. However, Apaf-1 protein levels might also be controlled at post-transcription level.	St Bartholomews & Royal London Sch Med & Dent, Dept Haematol Oncol, London E1 2AD, England; Osped San Giovanni Bellinzona, Oncol Inst So Switzerland, Bellinzona, Switzerland	University of London; Queen Mary University London; Institute of Oncology Research (IOR); Regional Hospital of Bellinzona & Valleys, San Giovanni	Jia, L (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Haematol Oncol, Turner St, London E1 2AD, England.		Bertoni, Francesco/G-6922-2014	Bertoni, Francesco/0000-0001-5637-8983; Jia, Li/0000-0002-6076-8455				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Chitnis S, 2000, ARTHRITIS RES, V2, P399, DOI 10.1186/ar118; Feinberg AP, 2001, P NATL ACAD SCI USA, V98, P392, DOI 10.1073/pnas.98.2.392; Fu WN, 2001, BIOCHEM BIOPH RES CO, V282, P268, DOI 10.1006/bbrc.2001.4575; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jia L, 2001, ONCOGENE, V20, P4817, DOI 10.1038/sj.onc.1204628; Jia L, 2001, BLOOD, V98, P414, DOI 10.1182/blood.V98.2.414; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu FT, 2002, BRIT J HAEMATOL, V117, P333, DOI 10.1046/j.1365-2141.2002.03418.x; Lopatina N, 2002, J CELL BIOCHEM, V84, P324, DOI 10.1002/jcb.10015; Perkins C, 1998, CANCER RES, V58, P4561; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Shinoura N, 2001, INT J CANCER, V93, P252, DOI 10.1002/ijc.1327; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; van Noesel MM, 2002, CANCER RES, V62, P2157; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	22	77	89	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					451	455		10.1038/sj.onc.1206147	http://dx.doi.org/10.1038/sj.onc.1206147			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545166				2022-12-17	WOS:000180379100014
J	Elez, R; Piiper, A; Kronenberger, B; Kock, M; Brendel, M; Hermann, E; Pliquett, U; Neumann, E; Zeuzem, S				Elez, R; Piiper, A; Kronenberger, B; Kock, M; Brendel, M; Hermann, E; Pliquett, U; Neumann, E; Zeuzem, S			Tumor regression by combination antisense therapy against Plk1 and Bcl-2	ONCOGENE			English	Article						polo-like kinase 1 (PLK1); BCL-2; antisense therapy; electroporation; cell cycle; mitotic catastrophe	POLO-LIKE KINASE; PROGNOSTIC-SIGNIFICANCE; DNA-DAMAGE; MITOTIC CATASTROPHE; MALIGNANT-MELANOMA; DROSOPHILA POLO; PROTEIN-KINASE; EXPRESSION; INHIBITION; CANCER	Increased expression of the cell proliferation-associated polo-like kinase 1 (PLK1) and apoptosis-associated BCL-2 genes has been observed in different human malignancies. Inhibition of cell proliferation and reactivation of apoptosis are basic principles in anticancer therapy. The efficiency of this approach is often limited by insufficient targeting and delivery of anticancer drugs into the tumors. Phosphorothioate antisense oligodeoxynucleotides (ODNs) directed against PLK1 and BCL-2 were administered systemically via the tail vein into nude mice bearing A549, MDA-MB-435, and Detroit562 xenografts. To enhance tumor-specific uptake and to reduce systemic toxicity of antisense ODNs membrane electroporation transfer was applied in vivo. Northern and Western blot analyses were used to assess PLK1 and BCL-2 expression. Tumor mass was assessed after resection of tumors. All three cell lines and corresponding xenografts expressed high levels of PLK1 and were sensitive towards antisense PLK1 treatment. Antisense BCL-2 therapy was effective in tumors expressing high levels of BCL-2, but not in A549 cells and corresponding xenografts, which express low levels of BCL-2. Administration of antisense ODNs in a dose of 5mg/kg, twice weekly during four weeks supported by the membrane electroporation transfer, eradicated 60-100% of the xenografted tumors. Antitumor effect in BCL-2 overexpressing MDA-MB-435 cells was synergistic for BCL-2 and PLK1 combination therapy. This study provides evidence that combined systemic administration of antisense ODNs against proliferation and pro- survival associated targets and in vivo electroporation of tumors represents a promising antitumor therapeutic approach.	Univ Saarland, Dept Internal Med 2, Mol Oncol Unit, D-66422 Homburg, Germany; Univ Frankfurt, Dept Internal Med, D-60590 Frankfurt, Germany; Univ Frankfurt, Anim Res Facil, Sch Med, D-6000 Frankfurt, Germany; Univ Frankfurt, Inst Microbiol, Frankfurt, Germany; Univ Bielefeld, Fac Chem, D-4800 Bielefeld, Germany	Saarland University; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; University of Bielefeld	Elez, R (corresponding author), Univ Saarland, Dept Internal Med 2, Mol Oncol Unit, D-66422 Homburg, Germany.		Zeuzem, Stefan/AAE-7435-2019; Neumann, Eberhard/AAU-6955-2020	Neumann, Eberhard/0000-0003-0861-072X; Brendel, Martin/0000-0002-7716-7576				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Donaldson MM, 2001, J CELL SCI, V114, P2357; Draghia-Akli R, 1999, NAT BIOTECHNOL, V17, P1179, DOI 10.1038/70718; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Heller R, 1998, CANCER-AM CANCER SOC, V83, P148, DOI 10.1002/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W; Heller R, 1996, CANCER-AM CANCER SOC, V77, P964, DOI 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Khaled Z, 1996, NUCLEIC ACIDS RES, V24, P737, DOI 10.1093/nar/24.4.737; Knecht R, 1999, CANCER RES, V59, P2794; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lebleu B., 1993, ANTISENSE RES APPL; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIR LM, 1991, CR ACAD SCI III-VIE, V313, P613; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; Neumann E, 1999, BIOELECTROCH BIOENER, V48, P3, DOI 10.1016/S0302-4598(99)00008-2; Neumann E, 2000, METH MOLEC MED, V37, P1, DOI 10.1385/1-59259-080-2:1; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sambrook J, 1989, MOL CLONING LAB MANU; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sheehan JP, 1998, BLOOD, V92, P1617, DOI 10.1182/blood.V92.5.1617.417k13_1617_1625; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119; SWANSON PE, 1995, AM J PATHOL, V146, P963; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862	46	77	88	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					69	80		10.1038/sj.onc.1206038	http://dx.doi.org/10.1038/sj.onc.1206038			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527909				2022-12-17	WOS:000180166900008
J	Pazzaglia, S; Mancuso, M; Atkinson, MJ; Tanori, M; Rebessi, S; Di Majo, V; Covelli, V; Hahn, H; Saran, A				Pazzaglia, S; Mancuso, M; Atkinson, MJ; Tanori, M; Rebessi, S; Di Majo, V; Covelli, V; Hahn, H; Saran, A			High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice	ONCOGENE			English	Article						patched-knockout mice; X-rays; medulloblastoma; LOH	CELL CARCINOMA SYNDROME; HUMAN HOMOLOG; GORLIN SYNDROME; UNITED-STATES; PATCHED GENE; MUTATIONS; CANCER; P53	Individuals affected with the Gorlin syndrome inherit a germ-line mutation of the patched (Ptc1) developmental gene and, analogously to Ptc1 heterozygous mice, show an increased susceptibility to spontaneous tumor development. Human and mouse Ptc1 heterozygotes (Ptc1(+/-)) are also hypersensitive to ionizing radiation (IR)-induced tumorigenesis in terms of basal cell carcinoma (BCC) induction. We have analysed the involvement of Ptc1 in the tumorigenic response to a single dose of 3 Gy X-rays in neonatal and adult Ptc1 heterozygous and wild type mice. We report that irradiation dramatically increased the incidence of medulloblastoma development (51%) over the spontaneous rate (7%) in neonatal but not adult Ptc1 heterozygotes, indicating that medulloblastoma induction by IR is subjected to temporal restriction. Analysis of Ptc1 allele status in the tumors revealed loss of the wild type allele in 17 of 18 medulloblastomas from irradiated mice and in two of three spontaneous medulloblastomas. To our knowledge, irradiated newborn Ptc1(+/-) heterozygous mice constitute the first mouse model of IR-induced medulloblastoma tumorigenesis, providing a useful tool to elucidate the molecular basis of medulloblastoma development.	ENEA, CR Casaccia, Biotechnol Unit, I-00060 Rome, Italy; GSF Munich, Natl Res Ctr, Inst Pathol, Munich, Germany; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; ENEA, CR Casaccia, Radiat Protect Unit, I-00060 Rome, Italy; Univ Goettingen, Inst Human Genet, Gottingen, Germany	Italian National Agency New Technical Energy & Sustainable Economics Development; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Fondazione IRCCS Istituto Nazionale Tumori Milan; Italian National Agency New Technical Energy & Sustainable Economics Development; University of Gottingen	Pazzaglia, S (corresponding author), ENEA, CR Casaccia, Biotechnol Unit, Via Anguillarese 301, I-00060 Rome, Italy.	pazzaglia@casaccia.enea.it	Atkinson, Michael J/E-5537-2011; Atkinson, Michael/AAU-5127-2020	Atkinson, Michael J/0000-0003-3358-2089; Atkinson, Michael/0000-0003-3358-2089; Saran, Anna/0000-0002-5587-064X				Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Chidambaram A, 1996, CANCER RES, V56, P4599; COREY R, 1997, CANCER RES, V57, P842; Cowan R, 1997, BRIT J CANCER, V76, P141, DOI 10.1038/bjc.1997.354; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; LACOMBE D, 1990, Genetic Counseling, V1, P273; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Unden AB, 1996, CANCER RES, V56, P4562; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; Wicking C, 1997, AM J HUM GENET, V60, P21; Xie JW, 1997, CANCER RES, V57, P2369; ZURAWEL RH, 1997, CANCER RES, V577, P842; ZURAWEL RH, 2000, GENES CHROMOSOMES CA, V28	24	77	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7580	7584		10.1038/sj.onc.1205973	http://dx.doi.org/10.1038/sj.onc.1205973			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386820				2022-12-17	WOS:000178618200013
J	Devilard, E; Bertucci, F; Trempat, P; Bouabdallah, R; Loriod, B; Giaconia, A; Brousset, P; Granjeaud, S; Nguyen, C; Birnbaum, D; Birg, F; Houlgatte, R; Xerri, L				Devilard, E; Bertucci, F; Trempat, P; Bouabdallah, R; Loriod, B; Giaconia, A; Brousset, P; Granjeaud, S; Nguyen, C; Birnbaum, D; Birg, F; Houlgatte, R; Xerri, L			Gene expression profiling defines molecular subtypes of classical Hodgkin's disease	ONCOGENE			English	Article						cDNA array; gene expression profiling; mRNA; Hodgkin's disease	REED-STERNBERG CELLS; NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CLASSIFICATION; LYMPHOMA; CANCER; PTEN; ACTIVATION; BREAST	Although the prognosis of Hodgkin's disease is relatively good, around 20% of patients do not benefit from current therapies and succumb to their disease. A large-scale molecular characterization of disease might help improve HD management. Using cDNA arrays, we studied the mRNA expression levels of similar to 1000 selected genes in 34 benign and malignant lymphoid samples including 21 classical Hodgkin's disease (HD) tissue samples. Hierarchical clustering identified three main molecular groups of HD tumours relevant with respect to histology and clinical outcome (response to therapy and survival). Samples from all bad outcome HD (BOHD) patients clustered in one group whereas the two other groups contained most good outcome HD (GOHD) cases. The nodular sclerosis GOHD samples overexpressed genes involved in apoptotic induction and cell signalling, including cytokines, while the BOHD samples were characterized by the upregulation of genes involved in fibroblast activation, angiogenesis, extracellular matrix remodelling, cell proliferation, and the downregulation of tumour suppressor genes. Our results establish a molecular taxonomy of HD correlating with response to therapy and clinical outcome, thereby suggesting the possibility of improving the current prognostic classification.	Inst Paoli Calmettes, Dept Pathol, Marseille, France; Inst Paoli Calmettes, TAGC, Marseille, France; Inst Paoli Calmettes, Dept Haematol, Marseille, France; Inst Paoli Calmettes, INSERM, U119, IFR 57, Marseille, France; Univ Mediterranee, Marseille, France; CHU Purpan, Toulouse, France	UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; CHU de Toulouse	Xerri, L (corresponding author), 232 Blvd St Marguerite,BP 156, F-13273 Marseille 9, France.	xerril@marseille.fnclcc.fr	Houlgatte, Remi/P-3020-2017; Granjeaud, Samuel/AAE-6488-2022; Nguyen, Catherine/M-4119-2016; loriod, beatrice bl/L-2948-2016	Granjeaud, Samuel/0000-0001-9245-1535; Nguyen, Catherine/0000-0001-9376-6360; loriod, beatrice bl/0000-0001-5801-2264; Bertucci, Francois/0000-0002-0157-0959				Alizadeh AA, 2000, CURR OPIN IMMUNOL, V12, P219, DOI 10.1016/S0952-7915(99)00078-3; Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; [Anonymous], 1999, NAT GENET S, V21, P1; Bartlett N L, 2000, Curr Oncol Rep, V2, P163, DOI 10.1007/s11912-000-0089-6; Bertucci F, 1999, ONCOGENE, V18, P3905, DOI 10.1038/sj.onc.1202731; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Brice P, 1996, CANCER-AM CANCER SOC, V78, P1293, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Chan WC, 2001, HEMATOL ONCOL, V19, P1; Chen HL, 2001, J VIROL, V75, P2929, DOI 10.1128/JVI.75.6.2929-2937.2001; Cossman J, 1999, BLOOD, V94, P411, DOI 10.1182/blood.V94.2.411; Cossman J, 1998, LAB INVEST, V78, P229; Cossman J, 2001, J HISTOCHEM CYTOCHEM, V49, P799, DOI 10.1177/002215540104900617; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dales JP, 2001, J CLIN PATHOL-MOL PA, V54, P17; DREXLER HG, 1993, LEUKEMIA LYMPHOMA, V9, P1, DOI 10.3109/10428199309148499; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Granjeaud S, 1999, BIOESSAYS, V21, P781, DOI 10.1002/(SICI)1521-1878(199909)21:9<781::AID-BIES10>3.0.CO;2-2; HARRIS NL, 1994, BLOOD, V84, P1361; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Izban KF, 2001, MODERN PATHOL, V14, P297, DOI 10.1038/modpathol.3880306; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Kennedy BJ, 1998, CANCER-AM CANCER SOC, V83, P1041, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1041::AID-CNCR31>3.0.CO;2-5; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li SY, 2001, AM J PATHOL, V158, P1231, DOI 10.1016/S0002-9440(10)64073-4; LOHRI A, 1991, BLOOD, V77, P2292; Messineo C, 1998, BLOOD, V91, P2443, DOI 10.1182/blood.V91.7.2443.2443_2443_2451; Morente MM, 1997, BLOOD, V90, P2429; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; POPPEMA S, 2000, LAB INVEST, V78, P229; Prolla TA, 1998, CURR OPIN CELL BIOL, V10, P311, DOI 10.1016/S0955-0674(98)80005-7; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Staudt LM, 2000, J EXP MED, V191, P207, DOI 10.1084/jem.191.2.207; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Theil J, 2001, BLOOD, V97, P3191, DOI 10.1182/blood.V97.10.3191; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; Wakkach A, 2000, EUR CYTOKINE NETW, V11, P153; Warzocha K, 1998, BRIT J CANCER, V77, P2357, DOI 10.1038/bjc.1998.391; Wellmann A, 2000, BLOOD, V96, P398; XERRI L, 1994, HUM PATHOL, V25, P449, DOI 10.1016/0046-8177(94)90116-3; Xerri L, 2000, J PATHOL, V192, P194, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH685>3.0.CO;2-M; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	54	77	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3095	3102		10.1038/sj.onc.1205418	http://dx.doi.org/10.1038/sj.onc.1205418			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082542				2022-12-17	WOS:000175262700019
J	David, M; Ford, D; Bertoglio, J; Maizel, AL; Pierre, J				David, M; Ford, D; Bertoglio, J; Maizel, AL; Pierre, J			Induction of the IL-13 receptor alpha 2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways	ONCOGENE			English	Article						keratinocytes; MAP kinase; inhibitors; IL-4; IL-13; cytokine receptor chain; transduction	INTERLEUKIN-13 RECEPTOR; MESSENGER-RNA; KINASE PATHWAY; CELL RESPONSE; ALPHA CHAIN; PROTEIN; GENE; INHIBITOR; CLONING; BINDING	IL-4 and IL-13 are related cytokines which induce both pro- and anti-inflammatory effects depending on the cell type they act upon and the nature of the receptors expressed. The type I receptor complex is composed of the IL-4R alpha and gammac and only binds IL-4, whereas, in the type II receptor, IL-4R alpha dimerizes with IL-13R alpha1 upon either IL-4 or IL-13 binding. Another ligand binding chain potentially implicated in the IL-4/M-13 receptor has been described, the IL-13R alpha2, but the regulation of its expression and its role in IL-4/IL-13 transduction is poorly understood. In this study we report that IL-4 and IL-13 upregulate IL-13R alpha2 at both the mRNA and protein levels in the keratinocyte cell line HaCaT. In these cells, IL-4 or IL-13 were shown to activate the Janus Kinases JAK1 and JAK2, the transcription factor STAT6, and the ERK and p38 mitogen-activated protein kinases. We show that IL-4 or IL-13-induced IL-13R alpha2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580. Moreover, expression of a constitutive active mutant of STAT6 alone did not modify IL-13R alpha2 mRNA expression, but potentiated the effects of IL-4 or 11-13 on IL-13 alpha2 expression. The constitutive active mutants of MEK1 or MKK6 increased the level of expression of IL-13R alpha2 mRNA even in absence of stimulation. Our findings demonstrate, for the first time, that IL-4 and IL-13 can induce IL-13R alpha2 expression in keratinocytes, and that the ERK and p38 MAPK together with JAK2 and STAT6 play a critical role in this process.	INSERM, Fac Pharm, U461, F-92296 Chatenay Malabry, France; Boston Univ, Sch Med, Roger Williams Med Ctr, Providence, RI 02908 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Boston University; Roger Williams Medical Center	Pierre, J (corresponding author), INSERM, Fac Pharm, U461, 5,Rue JB Clement, F-92296 Chatenay Malabry, France.		David, Muriel/F-9592-2012	David, Muriel/0000-0003-1392-2701				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRUNET A, 1994, ONCOGENE, V9, P3379; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COLOTTA F, 1992, CYTOKINE, V4, P24, DOI 10.1016/1043-4666(92)90032-M; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Daniel C, 2000, J BIOL CHEM, V275, P14255, DOI 10.1074/jbc.C000129200; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DEROCQ JM, 1994, FEBS LETT, V343, P32, DOI 10.1016/0014-5793(94)80601-2; Ezernieks J, 1996, EUR J BIOCHEM, V240, P667, DOI 10.1111/j.1432-1033.1996.0667h.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feng NP, 1998, LAB INVEST, V78, P591; Ford D, 1999, J IMMUNOL, V163, P3185; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; Graber P, 1998, EUR J IMMUNOL, V28, P4286, DOI 10.1002/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H; HARELBELLAN A, 1986, J IMMUNOL, V136, P2463; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Ogata H, 1998, J BIOL CHEM, V273, P9864, DOI 10.1074/jbc.273.16.9864; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Wang LH, 1999, J IMMUNOL, V162, P3897; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	40	77	80	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6660	6668		10.1038/sj.onc.1204629	http://dx.doi.org/10.1038/sj.onc.1204629			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709700				2022-12-17	WOS:000171551600002
J	Ross, J; Lemm, I; Berberet, B				Ross, J; Lemm, I; Berberet, B			Overexpression of an mRNA-binding protein in human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; tumor marker; c-myc	MYC MESSENGER-RNA; CODING REGION; KH-DOMAIN; EXPRESSION; GENE; FAMILY; CELLS; PURIFICATION; CARCINOMA; ONCOGENE	A Coding Region instability Determinant-Binding Protein (CRD-BP) binds in vitro to c-myc mRNA and appears to stabilize the mRNA. The CRD-BP gene is amplified in one-third of human breast cancer cases, and the CRD-BP appears to be an oncofetal protein. To analyse CRD-BP expression in human cancer tissue, paired extracts of cancer and normal colon specimens from 21 patients were analysed by immunoblotting and/or reverse transcriptase-polymerase chain reaction. Seventeen cancer specimens out of 21 (81%) were positive for CRD-BP expression by one or both assays. With one exception, normal colon specimens were negative for CRD-BP expression; specimens of inflammatory bowel and a villous adenoma also had no detectable CRD-BP. The lack of CRD-BP expression in normal colon did not result from indiscriminate protein or RNA degradation. c-myc mRNA levels appeared to be elevated in tumor specimens. We conclude that the CRD-BP is scarce or absent from normal colon but is overexpressed in colorectal cancer. The CRD-BP might be a novel human tumor marker.	Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ross, J (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.	ross@oncology.wisc.edu			NATIONAL CANCER INSTITUTE [R01CA078710] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA78710] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander RJ, 1998, DIGEST DIS SCI, V43, P2652, DOI 10.1023/A:1026699126899; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Castells A, 1998, BRIT J CANCER, V78, P1368, DOI 10.1038/bjc.1998.686; Compton C, 2000, CANCER-AM CANCER SOC, V88, P1739, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; Doyle GA, 2000, CANCER RES, V60, P2756; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; FINLEY GG, 1989, ONCOGENE, V4, P963; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; IMASEKI H, 1989, CANCER, V64, P704, DOI 10.1002/1097-0142(19890801)64:3<704::AID-CNCR2820640323>3.0.CO;2-S; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Nielsen J, 2000, MECH DEVELOP, V96, P129, DOI 10.1016/S0925-4773(00)00383-X; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; NUSSBAUM NL, 1995, METABOLIC BASIS INHE, P759; PFAFF SL, 1992, DEV BIOL, V151, P306, DOI 10.1016/0012-1606(92)90235-9; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; SCHER HI, 2000, CLIN ONCOLOGY, P1823; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101	26	77	80	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6544	6550		10.1038/sj.onc.1204838	http://dx.doi.org/10.1038/sj.onc.1204838			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641779				2022-12-17	WOS:000171404200007
J	Zhang, ZH; DuBois, RN				Zhang, ZH; DuBois, RN			Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor	ONCOGENE			English	Article						cyclo-oxygenase-2; NSAID; colon cancer; subtraction cloning	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; PROTEIN-TYROSINE-PHOSPHATASE; COLORECTAL-CANCER CELLS; CYCLOOXYGENASE-2 INHIBITOR; MOLECULAR-CLONING; MESSENGER-RNA; CDNA CLONING; TUMOR-GROWTH; MOUSE MODEL	Numerous reports suggest that use of nonsteroidal anti-inflammatory drugs (NSAIDs) decrease mortality from colorectal cancer. To better understand all of the mechanisms underlying this effect, the global pattern of gene expression in colon carcinoma cells following treatment with NS-398, a selective cyclooxygenase-2 inhibitor was evaluated. We utilized suppression subtractive hybridization combined with differential screening to identify genes whose expression was affected following treatment. Among the subtracted cDNA fragments confirmed as differentially expressed, there were two which are known to be involved in the regulation of cell adhesion (human FAT and proto-cadherin-7). We identified two other genes whose levels were decreased and these are known to be involved in the regulation of cell proliferation (cyclin K and p-100). We identified additional genes which are involved in different signaling pathways which regulate programmed cell death (Dynamin 2, Pdcd4 and LIP.1). These results provide evidence that some of the effects of NS-398 on carcinoma cells may be due to modulation of genes which regulate programmed cell death, cell proliferation and cell-cell communication. Additional studies are underway to determine the biological function of the novel genes that were identified.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NATIONAL CANCER INSTITUTE [P30CA068485, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK047297, R01DK047297] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA68485, P0 CA77839] Funding Source: Medline; NIDDK NIH HHS [DK 47297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Drmanac R, 1999, METHOD ENZYMOL, V303, P165; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUNNE J, 1995, GENOMICS, V30, P207, DOI 10.1006/geno.1995.9884; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hara A, 1997, JPN J CANCER RES, V88, P600; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Heidebrecht HJ, 1997, BLOOD, V90, P226; Jacoby RF, 2000, CANCER RES, V60, P5040; Jones MK, 1999, NAT MED, V5, P1418; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kuang WW, 1998, NUCLEIC ACIDS RES, V26, P1116, DOI 10.1093/nar/26.4.1116; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu XH, 1998, CANCER RES, V58, P4245; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MASER RL, 1995, SEMIN NEPHROL, V15, P29; McGinty A, 2000, J BIOL CHEM, V275, P12095, DOI 10.1074/jbc.275.16.12095; Nagase T, 1995, DNA Res, V2, P51, DOI 10.1093/dnares/2.1.51; Nakagawa N, 2000, BIOCHEM BIOPH RES CO, V272, P505, DOI 10.1006/bbrc.2000.2787; Nishimura G, 1999, JPN J CANCER RES, V90, P1152, DOI 10.1111/j.1349-7006.1999.tb00690.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Rioux N, 1998, CANCER RES, V58, P5354; Sawaoka H., 1998, AM J PHYSIOL, V274, P1061; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tsuji S, 1996, PROSTAG LEUKOTR ESS, V55, P179, DOI 10.1016/S0952-3278(96)90095-2; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Wang X, 2000, ONCOGENE, V19, P2346, DOI 10.1038/sj.onc.1203558; Watanabe K, 1999, CANCER RES, V59, P5093; Wechter WJ, 1997, CANCER RES, V57, P4316; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yoshida K, 1998, GENOMICS, V49, P458, DOI 10.1006/geno.1998.5271; Yoshimi N, 1999, JPN J CANCER RES, V90, P406, DOI 10.1111/j.1349-7006.1999.tb00762.x; ZENG J, 1994, NUCLEIC ACIDS RES, V22, P4381, DOI 10.1093/nar/22.21.4381; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	60	77	92	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4450	4456		10.1038/sj.onc.1204588	http://dx.doi.org/10.1038/sj.onc.1204588			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494140				2022-12-17	WOS:000170074900002
J	Wang, LL; Hiebert, SW				Wang, LL; Hiebert, SW			TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3	ONCOGENE			English	Article						HDAC3; TEL; tumor suppressor; stromelysin-1; mSin3; N-CoR	ACUTE LYMPHOBLASTIC-LEUKEMIA; NUCLEAR RECEPTOR COREPRESSORS; TRANSCRIPTIONAL REPRESSION; N-COR; TUMOR-SUPPRESSOR; ETS-FAMILY; FREQUENT LOSS; CLASS-I; GENE; COMPLEX	TEL (Translocation-ETS-Leukemia or ETV 6) is disrupted by multiple chromosomal translocations in acute leukemia. The loss of heterozygosity at the TEL locus in leukemias and the hemizygous deletion of TEL that is observed in various tumors, suggests that TEL is tumor suppressor, Overexpression of TEL alters cellular morphology and represses the expression of the matrix metalloproteinase stromelysin-1. Based on these studies, deletion analysis was used to define the minimal repression domains of TEL, TEL-mediated repression required both the N-terminal pointed domain and a central region composed of amino acids 268-303, The mSin3A and N-CoR corepressors bind to the pointed domain and the central repression domain of TEL, respectively. Unexpectedly, histone deacetylase-3, but not other histone deacetylases, also associates with the central region of TEL, Histone deacetylase-3 interacts with a TEL mutant that cannot bind N-CoR, suggesting that this is a direct interaction with TEL, In addition, histone H3 was under-acetylated near the TEL-binding sites in the endogenous stromelysin-1 promoter when TEL was expressed. Furthermore, trichostatin A, a potent histone deacetylase inhibitor, impaired TEL-dependent repression of the stromelysin-1 promoter. Finally, while TEL-expression induced cellular aggregation of Ras-transformed cells, Trichostatin A reversed the TEL-induced cellular aggregation phenotype, Thus, the cumulative data suggests that histone deacetylase-3 activity is required for the transcriptional functions of TEL.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Room 512,Med Res Bldg 2, Nashville, TN 37232 USA.		Hiebert, Scott W/C-9979-2010		NCI NIH HHS [CA68465, R01-CA77274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068465, R01CA077274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, GENE DEV, V14, P1021; Guenther MG, 2000, GENE DEV, V14, P1048; Guidez F, 2000, BLOOD, V96, P2557; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Javed A, 2000, J CELL SCI, V113, P2221; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kao HY, 2000, GENE DEV, V14, P55; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; Luo RX, 1999, J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Mahlknecht U, 1999, CYTOGENET CELL GENET, V86, P237, DOI 10.1159/000015347; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Rao G, 1996, ONCOGENE, V12, P1165; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Romana SP, 1996, LEUKEMIA, V10, P167; SCHOLZ H, 1993, GENETICS, V135, P455; Spirin KS, 1996, CANCER RES, V56, P2400; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wiesen JF, 1996, ENZYME PROTEIN, V49, P174, DOI 10.1159/000468624; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	70	77	79	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3716	3725		10.1038/sj.onc.1204479	http://dx.doi.org/10.1038/sj.onc.1204479			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439334				2022-12-17	WOS:000169400200012
J	Karayan, L; Riou, JF; Seite, P; Migeon, J; Cantereau, A; Larsen, CJ				Karayan, L; Riou, JF; Seite, P; Migeon, J; Cantereau, A; Larsen, CJ			Human ARF protein interacts with Topoisomerase I and stimulates its activity	ONCOGENE			English	Article						p14(ARF); Topoisomerase I; protein interactions	TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; BETA-TRANSCRIPT; DNA; P19(ARF); MDM2; GENE; LOCUS; PRODUCT	The ARF gene (p19(ARF) in mouse and p14(ARF) in man) has become a central actor of the cell cycle regulation process as it participates to the ARF-MDM2-p53 pathway and the Rh-E2F-1 pathway. By use of immunoprecipitation and Western blotting (IP/WB), we now show that ARF physically associates with Topoisomerase I(Topo I), ARF-Topo I immune complexes were detected in SF9 insect cells infected with recombinant baculoviruses encoding the two genes as well as in 293 cells that express endogeneously these proteins. Preparations of a GST-ARF recombinant protein stimulated the DNA relaxation activity of Topo I but, in contrast, had no effect an the decatenation activity of Topo TT, The Topo I stimulation was also detected in cell extracts of SF9 cells expressing both proteins, A confocal microscopy study indicated that part of ARF and Topo I colocalized in the granular component structure of the nucleolus. As a whole, our data indicate that Topo I is a new partner of ARF and suggest that ARF is involved in cell reactions that require Topo I.	CHU Poitiers, Lab Biochim Prot, Poitiers, France; Oncol Mol Lab, CNRS, FRE 2224, Poitiers, France; IFR Commun Intercellulaire, CNRS, UMR 6558, Serv Cytofluorometrie, F-86021 Poitiers, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Aventis Pharma, F-94403 Vitry Sur Seine, France	CHU Poitiers; Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Sanofi-Aventis; Sanofi France	Larsen, CJ (corresponding author), CHU Poitiers, Lab Biochim Prot, Poitiers, France.			riou, jean-francois/0000-0002-0055-6506; Seite, Paule/0000-0002-7809-7610				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Becker T., 1902, MITTEILUNGEN ZOOLOGI, V2, P1, DOI [10.1002/mmnz.4830020237, DOI 10.1002/MMNZ.4830020237]; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Castano IB, 1996, GENE DEV, V10, P2564, DOI 10.1101/gad.10.20.2564; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DURO D, 1995, ONCOGENE, V11, P21; EYMIN B, 2000, IN PRESS ONCOGENE; Gazzeri S, 1998, CANCER RES, V58, P3926; Gimenez-Abian JF, 2000, CHROMOSOMA, V109, P235, DOI 10.1007/s004120000065; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; GULDNER HH, 1986, CHROMOSOMA, V94, P132, DOI 10.1007/BF00286991; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hao YW, 1997, BIOCHEM BIOPH RES CO, V234, P194, DOI 10.1006/bbrc.1997.6539; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kill IR, 1996, J CELL SCI, V109, P1253; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Kwon Y, 2000, J BIOL CHEM, V275, P18503, DOI 10.1074/jbc.M002081200; Larsen A K, 1999, Pathol Oncol Res, V5, P171, DOI 10.1053/paor.1999.0209; LARSEN CJ, 1997, PROGR CELL CYCLE RES, P109; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; MAO L, 1995, CANCER RES, V55, P2995; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; NITISS JL, 1996, DNA TOPOISOMERASE DN; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; RUAS, 1998, BIOCH BIPHYS ACTA, V1378, P115; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; TAN KB, 1992, CANCER RES, V52, P231; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tazi J, 1997, J MOL MED, V75, P786, DOI 10.1007/s001090050168; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	77	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2001	20	7					836	848		10.1038/sj.onc.1204170	http://dx.doi.org/10.1038/sj.onc.1204170			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314011				2022-12-17	WOS:000166924400007
J	Weiner, LM; Adams, GP				Weiner, LM; Adams, GP			New approaches to antibody therapy	ONCOGENE			English	Article						antibody therapy; radioimmunotherapy; bispecific antibodies	SINGLE-CHAIN FV; BISPECIFIC MONOCLONAL-ANTIBODY; PHASE-I TRIAL; B-CELL LYMPHOMA; ENZYME PRODRUG THERAPY; FUSION PROTEIN; RADIOLABELED-ANTIBODY; TARGETING C-ERBB-2; OVARIAN-CARCINOMA; COLORECTAL-CANCER	Antibody-based therapy of human cancers has led to several remarkable outcomes, particularly in the therapy of breast cancer and lymphoma. Many solid tumors have proven less responsive, due in part to difficulties in the tumor-selective delivery of antibodies and potential cytolytic effecters. However, antibodies that directly perturb signaling mechanisms in cells derived from epithelial malignancies have shown benefit; examples include antibodies directed against the extracellular domains of HER2/neu and epidermal growth factor receptor. A long-term goal of immunotherapy has been to induce anti-tumor inflammatory responses that can directly cause tumor regression or induct adaptive responses against tumor-related antigens. This review focuses on the use of antibodies to provide a means for initiating anti-tumor immune responses, and on the use of antibodies as delivery vehicles of radionuclides.	Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Weiner, LM (corresponding author), Fox Chase Canc Ctr, Dept Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Adams, Gregory/ABE-8245-2020		NATIONAL CANCER INSTITUTE [P30CA006927, R01CA050633, R01CA065559] Funding Source: NIH RePORTER; NCI NIH HHS [CA65559, CA06927, CA50633] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 1998, CANCER RES, V58, P485; ADAMS GP, 1993, CANCER RES, V53, P4026; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; ADAMS GP, 1995, CANCER IMMUNOL IMMUN, V40, P299, DOI 10.1007/BF01519629; Alpaugh RK, 1998, CLIN CANCER RES, V4, P1903; ANDERSON WT, 1987, NATL CANCER I MONOGR, V3, P149; Axworthy D, 1996, TUMOR TARGET, V2, P156; Bagshawe K D, 1993, Adv Pharmacol, V24, P99, DOI 10.1016/S1054-3589(08)60935-7; BAGSHAWE KD, 1991, DIS MARKERS, V9, P233; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; CANEVARI S, 1995, JNCI-J NATL CANCER I, V87, P1463, DOI 10.1093/jnci/87.19.1463; Challita-Eid PM, 1998, J IMMUNOL, V161, P3729; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Clark JI, 1997, CANCER IMMUNOL IMMUN, V44, P265, DOI 10.1007/s002620050382; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; COLCHER D, 1988, CANCER RES, V48, P4597; Curnow RT, 1997, CANCER IMMUNOL IMMUN, V45, P210, DOI 10.1007/s002620050435; DEPALAZZO IG, 1990, CANCER RES, V50, P7123; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; GALLINGER S, 1993, CANCER RES, V53, P271; Giantonio BJ, 1997, J CLIN ONCOL, V15, P1994, DOI 10.1200/JCO.1997.15.5.1994; GILLIES SD, 1992, P NATL ACAD SCI USA, V89, P1428, DOI 10.1073/pnas.89.4.1428; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOODWIN DA, 1988, J NUCL MED, V29, P226; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Hu SZ, 1996, CANCER RES, V56, P3055; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JAIN RK, 1987, CANCER RES, V47, P3039; JUWEID M, 1992, CANCER RES, V52, P5144; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Knox SJ, 2000, CLIN CANCER RES, V6, P406; KUDO T, 1991, J IMMUNOL METHODS, V145, P119, DOI 10.1016/0022-1759(91)90317-9; LANZAVECCHIA A, 1987, EUR J IMMUNOL, V17, P105, DOI 10.1002/eji.1830170118; LI S, 1986, J IMMUNOL, V137, P3378; LINK BK, 1993, BLOOD, V81, P3343; Link BK, 1998, INT J CANCER, V77, P251, DOI 10.1002/(SICI)1097-0215(19980717)77:2<251::AID-IJC14>3.0.CO;2-E; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; MALONEY DG, 1994, BLOOD, V84, P2457; Martin J, 1997, CANCER CHEMOTH PHARM, V40, P189, DOI 10.1007/s002800050646; NITTA T, 1990, LANCET, V335, P368, DOI 10.1016/0140-6736(90)90205-J; OBRIST R, 1988, BIOCHEM BIOPH RES CO, V155, P1139, DOI 10.1016/S0006-291X(88)81259-2; ORDER SE, 1986, INT J RADIAT ONCOL, V12, P277, DOI 10.1016/0360-3016(86)90110-0; PAGANELLI G, 1988, INT J CANCER, P121; PRESS OW, 1993, NEW ENGL J MED, V329, P1219, DOI 10.1056/NEJM199310213291702; PRESSMAN D, 1953, CANCER, V6, P619, DOI 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y; RENNER C, 1995, EUR J IMMUNOL, V25, P2027, DOI 10.1002/eji.1830250734; SABZEVARI H, 1994, P NATL ACAD SCI USA, V91, P9626, DOI 10.1073/pnas.91.20.9626; SCHEINBERG DA, 1991, J CLIN ONCOL, V9, P478, DOI 10.1200/JCO.1991.9.3.478; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCHIER R, 1995, IMMUNOTECHNOLOGY, V1, P73, DOI 10.1016/1380-2933(95)00007-0; SCONOCCHIA G, 1994, J IMMUNOL, V153, P5473; SEGAL DM, 1988, CANCER INVEST, V6, P83, DOI 10.3109/07357908809077031; Siemers NO, 1997, BIOCONJUGATE CHEM, V8, P510, DOI 10.1021/bc9700751; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; SILVERSTEIN AM, 1994, CELL IMMUNOL, V158, P1, DOI 10.1006/cimm.1994.1253; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA377; STEPLEWSKI Z, 1983, SCIENCE, V221, P865, DOI 10.1126/science.6879183; Thomas MC, 1998, HUM GENE THER, V9, P835, DOI 10.1089/hum.1998.9.6-835; TIBBEN JG, 1993, J NATL CANCER I, V85, P1003, DOI 10.1093/jnci/85.12.1003; VADHANRAJ S, 1988, J CLIN ONCOL, V6, P1636, DOI 10.1200/JCO.1988.6.10.1636; Valerius T, 1997, BLOOD, V90, P4485, DOI 10.1182/blood.V90.11.4485.4485_4485_4492; VALONE FH, 1995, J CLIN ONCOL, V13, P2281, DOI 10.1200/JCO.1995.13.9.2281; WEINER GJ, 1994, J IMMUNOL, V152, P2385; WEINER LM, 1995, CANCER RES, V55, P4586; WEINER LM, 1993, CANCER RES, V53, P94; WEINER LM, 1993, J IMMUNOL, V151, P2877; WEINER LM, 1995, TUMOR TARGET, V1, P51; Weinstein S., 1986, MODERN MED, V1, P5; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Wu AM, 1996, IMMUNOTECHNOLOGY, V2, P21, DOI 10.1016/1380-2933(95)00027-5	72	77	85	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6144	6151		10.1038/sj.onc.1204000	http://dx.doi.org/10.1038/sj.onc.1204000			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156528				2022-12-17	WOS:000166121400008
J	Vaillant, F; Blyth, K; Terry, A; Bell, M; Cameron, ER; Neil, J; Stewart, M				Vaillant, F; Blyth, K; Terry, A; Bell, M; Cameron, ER; Neil, J; Stewart, M			A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with MYC	ONCOGENE			English	Article						Cbfa1; myc; T-cell lymphoma; apoptosis	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR OSF2/CBFA1; CD2-MYC TRANSGENIC MICE; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; RUNT DOMAIN; TGF-BETA; DEFINITIVE HEMATOPOIESIS; NERVOUS-SYSTEM; DNA-BINDING	The C6fa1/PEBP2 alpha A/AML3 gene plays an essential role in osteogenesis but is also expressed in the T-cell lineage where it has been implicated in lymphoma development as a target for retroviral insertional mutagenesis. As lymphoma cells with til-1 insertion express at least five distinct Cbfa1 isoforms, it is important to establish which, if any, have intrinsic oncogenic potential. We have generated transgenic mice in which the most abundant lymphoma isoform (G1/p57) is expressed under the control of the CD2 locus control region. Co-precipitation analysis of transgenic thymus revealed high levels of Cbfa1 protein in an abundant complex containing the binding cofactor Cbfb. CD2-Cbfa1-G1 mice displayed abnormal T-cell development, with a pronounced skew towards CD8 SP cells in the thymus and developed a low incidence of spontaneous lymphomas (6% at 12 months) with cells of similar phenotype. Strongly synergistic tumour development was seen when CD2-Cbfa1-G1 mice were crossed with lines carrying myc transgenes (CD2-myc or tamoxifen-regulatable CD2-mycER(TM)) and Cbfa1 was found to rescue expression of the CD2-myc transgene in preleukaemic mice. However, synergy did not appear to be due to a dominant block of myc-induced apoptosis by Cbfa1 as explanted primary tumours and cell lines from CD2-Cbfa1-G1/CD2-mycER(TM) mice showed accelerated death on induction with tamoxifen at similar rates to CD2-mycER(TM) controls. Moreover, thymocytes from preleukaemic CD2-Cbfa1-G1 mice showed reduced survival in vitro and increased sensitivity to the inhibitory effects of TGF-beta. This study demonstrates that a full-length Cbf alpha-chain gene can act as an oncogene without fusion to a heterologous protein.	Univ Glasgow, Sch Vet, Dept Vet Pathol, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Sch Vet, Div Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Stewart, M (corresponding author), Univ Glasgow, Sch Vet, Dept Vet Pathol, Mol Oncol Lab, Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.			Blyth, Karen/0000-0002-9304-439X				Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.3.CO;2-Y; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BLYTH K, 1995, ONCOGENE, V10, P1717; Cameron ER, 1996, BRIT J CANCER, V73, P13, DOI 10.1038/bjc.1996.3; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; STEWART M, 1993, INT J CANCER, V53, P1023; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	77	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7124	7134		10.1038/sj.onc.1203202	http://dx.doi.org/10.1038/sj.onc.1203202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597314				2022-12-17	WOS:000083901900020
J	Sakisaka, T; Nakanishi, H; Takahashi, K; Mandai, K; Miyahara, M; Satoh, A; Takaishi, K; Takai, Y				Sakisaka, T; Nakanishi, H; Takahashi, K; Mandai, K; Miyahara, M; Satoh, A; Takaishi, K; Takai, Y			Different behavior of l-afadin and Neurabin-II during the formation and destruction of cell-cell adherens junction	ONCOGENE			English	Article						1-afadin; Neurabin-II; ZO-1; E-cadherin; cell-cell adherens junction	FILAMENT-BINDING PROTEIN; EPITHELIAL-CELLS; TIGHT JUNCTIONS; CYTOPLASMIC DOMAIN; ADHESION COMPLEX; CDNA CLONING; E-CADHERIN; ACTIN; CATENIN; ZO-1	We have recently isolated two novel actin filament-binding proteins, l-afadin and neurabin-II and shown that they are localized at cell-cell adherens junction (AJ) in epithelial cells. We found here that l-afadin, neurabin-II, ZO-1, and E-cadherin showed similar and different behavior during the formation and destruction of cell-cell AJ in MDCK cells. In MDCK cells, the accumulation of both l-afadin and E-cadherin, but not that of ZO-1, changed in parallel depending on Rac small G protein activity. Dissociation of MDCK cells by culturing the cells at 2 mu M Ca2+ caused rapid endocytosis of E-cadherin, but not that of l-afadin or ZO-1, Addition of phorbol 12-myristate 13-acetate to these dissociated cells formed a tight junction-like structure where ZO-1 and l-afadin, but not neurabin-II or E-cadherin, accumulated. We furthermore found that, in nonepithelial EL cells, which expressed E-cadherin and attached to each other, l-afadin, neurabin-II, ZO-1 and E-cadherin were all localized at AJ. In cadherin-deficient L cells, l-afadin was mainly localized at cell-cell contact sites, but ZO-1 was mainly localized at the tip area of cell processes. Neurabin-II did not accumulate at the plasma membrane area. Neither l-afadin nor neurabin-II significantly interacted with alpha-, beta-catenin, E-cadherin, ZO-1 or occludin.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CIMINO G, 1991, CANCER RES, V51, P6712; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Papkoff J, 1997, J BIOL CHEM, V272, P4536; PRASAD R, 1993, CANCER RES, V53, P5624; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	36	77	77	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1609	1617		10.1038/sj.onc.1202451	http://dx.doi.org/10.1038/sj.onc.1202451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102631				2022-12-17	WOS:000078770700011
J	Amundson, SA; Zhan, Q; Penn, LZ; Fornace, AJ				Amundson, SA; Zhan, Q; Penn, LZ; Fornace, AJ			Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents	ONCOGENE			English	Article						gadd45; myc; transcriptional repression	C-MYC; REPRESSES TRANSCRIPTION; INDUCED APOPTOSIS; RAT FIBROBLASTS; CELL-GROWTH; P53; ACTIVATION; PROMOTER; RADIATION; PATHWAY	The growth arrest and DNA damage inducible (gadd) genes are induced by various genotoxic and nongenotoxic stresses such as serum starvation, ultraviolet irradiation and treatment with alkylating agents. Their coordinate induction is a growth arrest signal which may play an important role in the response of cells to DNA damage. Conversely, c-myc is a strong proliferative signal, and overexpression of Myc is frequently observed in cancer cells, We have found that ectopic expression of v-myc in RAT-I cells results in an attenuated induction of the three major gadd transcripts by methyl methanesulfonate (MMS), and almost completely blocks the response to ultraviolet (UV) radiation. Myc acts in part by reducing the stress-responsiveness of the gadd45 promoter, as a c-myc expression vector strongly suppressed activation of gadd-reporter constructs. This activity of Myc localizes to a recently described CC-rich binding site within the gadd45 promoter. These results indicate that a coordinate down-regulation of the gadd gene response is one mechanism by which Myc can circumvent growth arrest and contribute to the neoplastic phenotype.	NCI, NIH, Bethesda, MD 20892 USA; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Fornace, AJ (corresponding author), NCI, NIH, 37 Convent Dr,Bldg,37 Room 5C09, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Penn, Linda/0000-0001-8133-5459				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Chen CH, 1996, ONCOGENE, V13, P1659; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRABHAKAR NR, 1995, BRAIN RES, V697, P266, DOI 10.1016/0006-8993(95)00994-2; WANG ZY, 1995, ONCOGENE, V10, P1243; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	28	77	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2149	2154		10.1038/sj.onc.1202136	http://dx.doi.org/10.1038/sj.onc.1202136			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811446				2022-12-17	WOS:000076698200001
J	Suzuki, R; Sakamoto, H; Yasukawa, H; Masuhara, M; Wakioka, T; Sasaki, A; Yuge, K; Komiya, S; Inoue, A; Yoshimura, A				Suzuki, R; Sakamoto, H; Yasukawa, H; Masuhara, M; Wakioka, T; Sasaki, A; Yuge, K; Komiya, S; Inoue, A; Yoshimura, A			CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells	ONCOGENE			English	Article						interleukin 6; STAT; JAK; tyrosine kinase; regulation	GROWTH ARREST; TRANSCRIPTIONAL ACTIVATION; TERMINAL DIFFERENTIATION; INHIBITORY FACTOR; DNA-DAMAGE; C-MYC; RECEPTOR; PATHWAYS; PROTEIN; FAMILY	We have reported JAK-signaling modulators, CIS1 (cytokine-inducible SH2 protein-1), CIS3 and JAB (JAK2 binding protein), which are structurally related. In M1 myeloid leukemia cells, CIS3 was induced by neither interleukin 6 (IL6) nor interferon gamma (IFN gamma), while JAB was induced strongly by IFN gamma and slightly by IL6 and leukemia inhibitory factor (ILF), Forced expression of CIS3 and JAB in Mi cells prevented IL6- or LIF-induced growth arrest and differentiation, even when their expression levels were comparable to endogenous ones in several cell lines such as HEL, UT-7, IFN gamma-treated Mi, and CTLL2 cells, Pretreatment of parental Mi cells with IFN gamma but not IFN beta resulted in suppression of LIF-induced STAT3 activation and differentiation, further supporting that physiological level of JAB is sufficient to inhibit LIF-signaling. However, unlike JAB, CIS3 did not inhibit IFN gamma-induced growth arrest, suggesting a difference in cytokine specificity between CIS3 and JAB. CIS3 inhibited STAT3 activation with slower kinetics than JAB and allowed rapid c-fos induction and partial Fc gamma RI expression in response to IL6, In 293 cells, CIS3 as well as JAB bound to JAK2 tyrosine kinase domain (JH1), and inhibited its kinase activity, however, the effect of CIS3 an tyrosine kinase activity was weaker than that of JAB, indicating that CIS3 possesses lower affinity to JAK kinases than JAB, These findings suggest that CIS3 is a weaker inhibitor than JAB against JAK signaling, and JAB and CIS3 possess different regulatory roles in cytokine signaling.	Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Fac Med, Dept Internal Med 3, Kurume, Fukuoka 8300011, Japan	Kurume University; Kurume University	Yoshimura, A (corresponding author), Kurume Univ, Inst Life Sci, Aikawa Machi 2432-3, Kurume, Fukuoka 8390861, Japan.			Sasaki, Atsuo/0000-0003-2963-4501				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; YAMAMURA Y, 1992, EMBO J, V11, P4909, DOI 10.1002/j.1460-2075.1992.tb05597.x; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	26	77	79	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2271	2278		10.1038/sj.onc.1202143	http://dx.doi.org/10.1038/sj.onc.1202143			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811457				2022-12-17	WOS:000076698200012
J	Di Como, CJ; Prives, C				Di Como, CJ; Prives, C			Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay	ONCOGENE			English	Review						p53; tumor-derived mutants; transactivation; Saccharomyces cerevisiae; FASAY	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION DOMAIN; C-TERMINAL DOMAIN; DNA-BINDING; MUTANT P53; CELL-LINES; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; GROWTH ARREST; FISSION YEAST	p53 is a sequence-specific transcriptional activator with a number of known target genes which contain p53-responsive elements. Mutations in p53 have been identified ,within its sequence-specific DNA binding domain in more than half of all human tumors, although a subset of tumor-derived p53 mutants have retained the ability to bind DNA and activate transcription under certain conditions. In order to broaden our understanding of this transactivating ability, we examined the efficacy by which p53 mutants bind to and activate reporters in an Saccharomyces cerevisiae-based assay. Analysis of 19 human tumor-derived p53 mutants, spanning the DNA binding domain of p53 and including the 'hot-spot' class, revealed a broad array of transcriptional transactivation abilities at 24 degrees C, 30 degrees C and 37 degrees C, despite the fact that each mutant had originally been identified as being inactive for transactivation in yeast against a single p53-responsive RGC site-containing reporter. One class of mutants (P177L, R267W, C277Y and R283H) retained wild-type or near wild-type activity that is binding site-selective, even at physiological temperature (37 degrees C). Another class of mutants (V143A, M160I/A161T, H193R, Y220C and I254F), all positioned for maintaining the beta-scaffold of p53, also retained selective activity, but preferentially at sub-physiological temperatures (24 degrees and 30 degrees C). Strikingly, however, in contrast to the other tumor derived mutants, all of the previously identified 'hot-spot' mutants were completely inactive with all sites tested. Moreover, a double mutant, L22E/W23S, located within the activation region and previously shown to be transcriptionally inactive in fibroblasts, retained wildtype or near wild-type binding site-selective activity in yeast. Finally, we found that transcriptional activity in vivo does not necessarily correlate with DNA binding in vitro.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			DiComo, Charles/0000-0003-2818-9215				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BRAIN R, 1994, ONCOGENE, V9, P1775; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DICOMO CJ, 1995, MOL CELL BIOL, V15, P1835; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUTHRIE JA, 1991, METHODS ENZYMOLOGY, V194; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOVAR H, 1993, ONCOGENE, V8, P2683; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LEGROS Y, 1994, ONCOGENE, V9, P2071; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MILLER CW, 1993, ONCOGENE, V8, P1815; MIYASHITA T, 1995, CELL, V80, P293; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; PIENTENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rose M, 1990, LAB COURSE MANUAL ME; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Scolnick DM, 1997, CANCER RES, V57, P3693; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; Shaw P, 1996, ONCOGENE, V12, P921; SIEGEL J, 1995, ONCOGENE, V11, P1363; Silhavy T.J., 1984, EXPT GENE FUSIONS; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	110	77	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	1998	16	19					2527	2539						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627118				2022-12-17	WOS:000073672300010
J	Andres, JL; Fan, SJ; Turkel, GJ; Wang, JA; Twu, NF; Yuan, RQ; Lamszus, K; Goldberg, ID; Rosen, EM				Andres, JL; Fan, SJ; Turkel, GJ; Wang, JA; Twu, NF; Yuan, RQ; Lamszus, K; Goldberg, ID; Rosen, EM			Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents	ONCOGENE			English	Article						breast cancer; BRCA1; BRCA2; MCF-7; DNA damage; adriamycin	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTIONAL ACTIVATION; OVARIAN-CANCER; SUSCEPTIBILITY GENE; IN-VIVO; P53; PROGRESSION; INHIBITION; INTERACTS; GROWTH	Germline mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 have been linked Ito the development of breast cancer, ovarian cancer, and other malignancies. Recent studies suggest that the BRCA1 and BRCA2 gene products may function in the sensing and/or repair of DNA damage. To investigate this possibility, we determined the effects of various DNA-damaging agents and other cytotoxic agents on the mRNA levels of BRCA1 and BRCA2 in the MCF-7 and other human breast cancer cell lines. We found that several agents, including adriamycin (a DNA intercalator and inhibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation induced significant decreases in BRCA1 and BRCA2 mRNA levels. Decreased levels of BRCA1 and BRCA2 mRNAs were observed within 6-12 h after treatment with adriamycin and persisted for at least 72 h. Adriamycin also induced decreases in BRCA1 protein levels; but these decreases required several days. U.V. radiation induced dose-dependent down-regulation of BRCA1 and BRCA2 mRNAs, with significant decreases in both mRNAs at doses as low as 2.5 J/m(2), a dose that yielded very little cytotoxicity. Adriamycin-induced down-regulation of BRCA1 and BRCA2 mRNAs was first observed at doses that yielded relatively little cytotoxicity and little or no apoptotic DNA fragmentation, Adriamycin and U.V. radiation induced distinct dose- and time-dependent alterations in the cell cycle distribution; but these alterations did not correlate well with corresponding changes in BRCA1 and BRCA2 mRNA levels. However, the adriamycin-induced reduction in BRCA1 and BRCA2 mRNA levels was correlated with p53 functional status. MCF-7 cells transfected with a dominant negative mutant p53 (143 val-->ala) required at least tenfold higher doses of adriamycin to down-regulate BRCA1 and BRCA2 mRNAs than did parental MCF-7 cells or control-transfected MCF-7 clones. These results suggest that BRCA1 and BRCA2 may play roles in the cellular response to DNA-damaging agents and that there may be a p53-sensitive component to the regulation of BRCA1 and BRCA2 mRNA expression.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA	Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.				NATIONAL CANCER INSTITUTE [R01CA064869] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; EASTON DF, 1993, AM J HUM GENET, V52, P678; FAN SJ, 1995, CANCER RES, V55, P1649; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GUDAS J, 1996, CELL GROWTH DIFFER, V7, P712; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Larson JS, 1997, CANCER RES, V57, P3351; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; ROSEN EM, 1991, CANCER RES, V51, P5315; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Shao NS, 1996, ONCOGENE, V13, P1; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Spillman MA, 1996, ONCOGENE, V13, P1639; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395	42	77	77	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2229	2241		10.1038/sj.onc.1201752	http://dx.doi.org/10.1038/sj.onc.1201752			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619832				2022-12-17	WOS:000073298000008
J	Kashiwazaki, H; Tonoki, H; Tada, M; Chiba, I; Shindoh, M; Totsuka, Y; Iggo, R; Moriuchi, T				Kashiwazaki, H; Tonoki, H; Tada, M; Chiba, I; Shindoh, M; Totsuka, Y; Iggo, R; Moriuchi, T			High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay	ONCOGENE			English	Article						p53 mutations; oral squamous cell carcinoma; premalignant lesions; ethnic origin; yeast functional assay	POLYMERASE CHAIN-REACTION; TUMOR-SUPPRESSOR GENE; LUNG-CANCER; PROTEIN EXPRESSION; BREAST-CANCER; CAVITY; IMMUNOHISTOCHEMISTRY; OVEREXPRESSION; TRANSFORMATION; ONCOGENE	To determine the timing and actual incidence of p53 mutations in oral epithelial lesions, we examined 33 primary squamous cell carcinomas (SCCs), 14 dysplasias and six hyperplasias from Japanese patients by a combination of yeast functional assay and DNA sequencing, The assay detects mutations of p53 mRNA between codons 67 and 347 on the basis of the DNA-binding activity of the protein, Twenty-six SCCs (79%) and five dysplasias (36%) were positive for p53 mutation, while all six hyperplasias were negative for the mutation, Human papillomavirus type 16 E6 mRNA was detected in one of seven p53 mutation-negative SCCs by reverse transcription polymerase chain reaction (RT-PCR), We further examined p53 mutations in 17 Sri Lankan oral SCCs using the yeast functional assay and the single-strand conformation polymorphism analysis of PCR-amplified DNA fragments (PCR-SSCP) of exon 5-8. The mutations were confirmed by DNA sequencing and the detection sensitivity was compared between the two methods, Six samples (35%) were positive for p53 mutation in PCR-SSCP analysis, while nine samples (53%) were positive in yeast functional assay, This suggests that the incidence of p53 mutations has been considerably underestimated in the conventional SSCP analysis, The present data indicate that p53 mutations are extremely frequent in oral cancers in the Japanese, and suggest that the timing and significance of p53 mutation in oral tumor progression vary in different ethnic populations and areas.	HOKKAIDO UNIV,SCH MED,INST CANC,DIV CELL BIOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT NEUROSURG,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH DENT,DEPT ORAL SURG 1,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH DENT,DEPT ORAL SURG 2,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH DENT,DEPT ORAL PATHOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; SWISS INST EXPT CANC RES,ONCOGENE GRP,CH-1066 EPALINGES,SWITZERLAND	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University; Swiss Institute Experimental Cancer Research			Iggo, Richard/G-3546-2014; Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BENNETT WP, 1992, CANCER RES, V52, P6092; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CASSON AG, 1991, CANCER RES, V51, P4495; CESARMAN E, 1993, AM J PATHOL, V143, P845; Chiba I, 1996, ONCOGENE, V12, P1663; CHIBA I, 1990, ONCOGENE, V5, P1603; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1991, BRIT J CANCER, V64, P573, DOI 10.1038/bjc.1991.352; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HERMANEK P, 1987, TNM CLASSIFICATION M, P1; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Kusama K, 1996, J PATHOL, V178, P415; LAZARUS P, 1995, INT J CANCER, V60, P458, DOI 10.1002/ijc.2910600406; Lazarus P, 1996, CARCINOGENESIS, V17, P733, DOI 10.1093/carcin/17.4.733; MAESTRO R, 1992, ONCOGENE, V7, P1159; MAITLAND NJ, 1989, BRIT J CANCER, V59, P698, DOI 10.1038/bjc.1989.146; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOYRET C, 1994, ONCOGENE, V9, P1739; Munirajan AK, 1996, INT J CANCER, V66, P297; OGDEN GR, 1992, J PATHOL, V166, P389, DOI 10.1002/path.1711660411; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORRWEAVER TL, 1983, METHOD ENZYMOL, V101, P228; Paterson IC, 1996, ORAL ONCOL, V32B, P150, DOI 10.1016/0964-1955(95)00065-8; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SARANATH D, 1993, ORAL ONCOL, V29B, P107, DOI 10.1016/0964-1955(93)90031-9; SAUTER ER, 1992, AM J SURG, V164, P651, DOI 10.1016/S0002-9610(05)80727-5; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SILVERMAN S, 1984, CANCER, V53, P563; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SOZZI G, 1992, CANCER RES, V52, P6079; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; Tada M, 1996, INT J CANCER, V67, P447, DOI 10.1002/(SICI)1097-0215(19960729)67:3<447::AID-IJC22>3.0.CO;2-3; Tada M, 1997, MOL CARCINOGEN, V18, P171, DOI 10.1002/(SICI)1098-2744(199703)18:3<171::AID-MC6>3.3.CO;2-2; WAHI PN, 1971, INT HISTOLOGICAL CLA, P15; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	43	77	78	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2667	2674		10.1038/sj.onc.1201438	http://dx.doi.org/10.1038/sj.onc.1201438			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400993				2022-12-17	WOS:A1997YH46800004
J	Xie, KP; Wang, YF; Huang, SY; Xu, L; Bielenberg, D; Salas, T; McConkey, DJ; Jiang, WD; Fidler, IJ				Xie, KP; Wang, YF; Huang, SY; Xu, L; Bielenberg, D; Salas, T; McConkey, DJ; Jiang, WD; Fidler, IJ			Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2	ONCOGENE			English	Article						metastasis; nitric oxide; Bcl-2; apoptosis	VASCULAR ENDOTHELIAL-CELLS; L-ARGININE; CANCER METASTASIS; HUMAN PLATELETS; B-LYMPHOCYTES; TUMOR-CELLS; DEATH; MACROPHAGES; INDUCTION; PATHWAY	Recent studies have shown that the treatment of nonmetastatic K-1735 murine melanoma cells with cytokines induces the production of nitric oxide (NO) and hence cell death, The purpose of this study was to determine the mechanism of this cytokine-induced NO-mediated apoptosis. Incubation of nonmetastatic K-1735 cells with interleukin-1 alpha (IL-1 alpha) and interferon-gamma (IFN-gamma) induced high NO production, Bcl-2 downregulation, and apoptotic cell death, In contrast, incubation of metastatic K-1735 cells with IL-1 alpha. and IFN-gamma did not induce significant production of NO, downregulation of Bcl-2, or cell death. The exposure to exogenous NO derived from the NO donors, sodium nitroprusside (SNP), or GEA5024 produced a dose-dependent apoptotic cell death in both the metastatic and nonmetastatic K-1735 cells, which was associated with downregulation of Bcl-2 at the mRNA level and, to a lesser extent, at the protein level, Nonmetastatic and metastatic K-1735 cells transfected with the Bcl-2 gene were more resistant to apoptosis mediated by both endogenous and exogenous NO, Subsequent to intravenous injection, the tumor cells transfected with the Bcl-2 gene had an increased survival rate in the lungs of nude mice and produced a higher number of experimental lung metastases, These data suggest that NO-induced apoptosis in K-1735 melanoma cells is associated with downregulation of Bcl-2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Xu, Lei/GRR-9174-2022		NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKERMAN SL, 1986, JNCI-J NATL CANCER I, V77, P915; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BERGELSON S, 1994, CANCER RES, V54, P36; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Brune B, 1995, TOXICOL LETT, V82-3, P233, DOI 10.1016/0378-4274(95)03481-1; CHUN SY, 1995, ENDOCRINOLOGY, V136, P2121; CORRALIZA IM, 1993, BIOCHEM BIOPH RES CO, V196, P342, DOI 10.1006/bbrc.1993.2254; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DING AH, 1988, J IMMUNOL, V141, P2407; DONG ZY, 1994, CANCER RES, V54, P789; ELMORE L, 1996, P AACR ANN M, V37, pA119; FANG W, 1995, J IMMUNOL, V155, P66; FIDLER IJ, 1985, CANCER RES, V45, P4714; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FIDLER IJ, 1986, CANCER RES, V46, P5167; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Geng YJ, 1996, CANCER RES, V56, P866; GLAVES D, 1986, INVAS METAST, V6, P101; HANNA N, 1980, J NATL CANCER I, V65, P801, DOI 10.1093/jnci/65.4.801; Herberman R B, 1989, Prog Clin Biol Res, V288, P161; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; Hockenbery D M, 1992, Semin Immunol, V4, P413; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFMANN M, 1991, CANCER RES, V51, P5292; Huang SY, 1996, ONCOGENE, V13, P2339; IGNARRO LJ, 1990, P NATL ACAD SCI USA, V87, P5193; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANETO H, 1995, DIABETES, V44, P733, DOI 10.2337/diabetes.44.7.733; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LEWISMOLOCK Y, 1994, AM J RESP CELL MOL, V10, P133, DOI 10.1165/ajrcmb.10.2.8110468; LI L, 1991, CANCER RES, V51, P245; LI LM, 1991, CANCER RES, V51, P2531; LIN JK, 1992, CANCER RES, V52, P385; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MartinSanz P, 1996, HEPATOLOGY, V23, P1200; McConkey DJ, 1996, J IMMUNOL, V156, P2624; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PRICE JE, 1986, CANCER RES, V46, P5172; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RADINSKY R, 1994, ONCOGENE, V9, P1977; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1990, BRIT J PHARMACOL, V101, P325, DOI 10.1111/j.1476-5381.1990.tb12709.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Sato H., 1976, FUNDAMENTAL ASPECTS, V11, P311; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SUGIMOTO Y, 1987, CANCER RES, V47, P4396; TALMADGE JE, 1982, SCIENCE, V217, P361, DOI 10.1126/science.6953592; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSURUO T, 1986, CLIN EXP METASTAS, V7, P25; WEISS L, 1986, Cancer Reviews, V3, P1; WEISS L, 1986, J THEOR BIOL, V121, P307, DOI 10.1016/S0022-5193(86)80110-2; WHITWORTH PW, 1990, CANCER METAST REV, V8, P319, DOI 10.1007/BF00052607; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILTROUT RH, 1979, CANCER RES, V39, P4034; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Xie KP, 1997, J NATL CANCER I, V89, P421, DOI 10.1093/jnci/89.6.421; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1996, J LEUKOCYTE BIOL, V59, P797, DOI 10.1002/jlb.59.6.797; XIE KP, 1993, INT J ONCOL, V3, P1043; Xie KP, 1996, CANCER IMMUNOL IMMUN, V43, P109, DOI 10.1007/s002620050310; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	70	77	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					771	779		10.1038/sj.onc.1201239	http://dx.doi.org/10.1038/sj.onc.1201239			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266963				2022-12-17	WOS:A1997XQ11700003
J	Takahashi, K; Suzuki, K; Tsukatani, Y				Takahashi, K; Suzuki, K; Tsukatani, Y			Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence	ONCOGENE			English	Article						tyrosine phosphorylated beta-catenin; EGF receptor; tryptic digestion; dissociation of alpha-catenin; dysfunction of E-cadherin; normal human breast epithelial cells	EPIDERMAL GROWTH-FACTOR; E-CADHERIN EXPRESSION; ADHESION MOLECULE UVOMORULIN; BREAST EPITHELIAL-CELLS; HUMAN CARCINOMA-CELLS; ALPHA-CATENIN; CYTOPLASMIC DOMAIN; COMPLEX; PROTEIN; CANCER	Normal human breast epithelial (HBE) cells which reached confluence ceased growth and tightly adhered to each other, forming a monolayer, In quiescent cells thus arrested by density, E-cadherin colocalized and coimmunoprecipitated with alpha- and beta-catenins in the boundary region between adjacent cells, By contrast, immunocytostaining and Western blot analyses revealed that E-cadherin colocalized and coprecipitated with beta-catenin but not with alpha-catenin in exponentially growing cells at low density. As a comparable amount of alpha-catenin was detected in the total cell lysate of cells at different densities, it is suggested that alpha-catenin is present but dissociates from the E-cadherin-beta-catenin complex in growing cells, beta-Catenin was tyrosine phosphorylated in growing cells at low density but not in quiescent cells at confluence, Tyrosine phosphorylation of beta-catenin was concomitantly induced with association of beta-catenin with EGF receptor (EGFR) when quiescent cells at confluence were dissociated into single cells by tryptic digestion, being accompanied by dissociation of alpha-catenin from E-cadherin, Both tyrosine phosphorylation and association of beta-catenin with EGFR were inhibited by tyrphostin, a specific inhibitor of the EGFR tyrosine kinase, whereas dissociation of beta-catenin from E-cadherin was not, The results suggest that tyrosine phosphorylation of beta-catenin is achieved by EGFR upon tryptic digestion of cells and concurrent with but independent of dissociation of alpha-catenin from E-cadherin, beta-Catenin thus phosphorylated at tyrosine is suggested to play the role in preventing alpha-catenin once dissociated from reassociating with E-cadherin until cells reach confluence.			Takahashi, K (corresponding author), KANAGAWA CANC CTR,RES INST,DEPT BIOCHEM,ASAHI KU,1-1-2 NAKAO,YOKOHAMA,KANAGAWA 241,JAPAN.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KADOWAKI T, 1994, CANCER RES, V54, P291; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LINDBLOM A, 1993, CANCER RES, V53, P3707; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1994, DEV GROWTH DIFFER, V36, P59; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PERCEALL WE, 1995, ONCOGENE, V11, P1319; SATO T, 1990, CANCER RES, V50, P7184; SCHIPPER JH, 1991, CANCER RES, V51, P6328; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAKAHASHI K, 1989, INT J CANCER, V43, P870, DOI 10.1002/ijc.2910430522; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	43	77	78	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					71	78		10.1038/sj.onc.1201160	http://dx.doi.org/10.1038/sj.onc.1201160			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233779				2022-12-17	WOS:A1997XH58600008
J	Yu, YJ; Li, CY; Little, JB				Yu, YJ; Li, CY; Little, JB			Abrogation of p53 function by HPV16 E6 gene delays apoptosis and enhances mutagenesis but does not alter radiosensitivity in TK6 human lymphoblast cells	ONCOGENE			English	Article						p53; HPV16 E6; radiosensitivity; apoptosis; mutability	WILD-TYPE P53; INDUCED G(1) ARREST; SV40 T-ANTIGEN; DNA-DAMAGE; CHROMOSOMAL-ABERRATIONS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CYCLE PROGRESSION; X-IRRADIATION; SINGLE-DONOR	In order to gain a better understanding of the role of p53 in radiation-induced mitotic failure, apoptosis and mutagenesis, we introduced the HPV16 E6 gene via a retroviral vector into the TK6 human lymphoblast cell line which expresses wild type p53. Abrogation of p53 function by E6 resulted in a delayed and reduced apoptotic response and a moderate increase in the frequency of mutations at the thymidine kinase (tk) locus following gamma-irradiation, but failed to alter radiosensitivity. The apoptotic response of the E6-transduced line was intermediate between that of wild type TK6 and the WTK1 cell line. WTK1 is derived from the same parental cell line as TK6 but expresses mutant p53. The spontaneous and gamma-ray-induced mutation frequencies in E6-transduced TK6 cells, although higher than that of the parental TK6 cell line, were still much lower than that of the WTK1 line. No effect on apoptosis, radiosensitivity or mutability was observed when the HPV16 E6 gene was introduced into the WTK1 cells. These results indicate that p53 does not regulate the radiosensitivity of TK6 cells through the apoptotic pathway. Furthermore, the previously observed enhanced radioresistance and mutability in WTK1 cells must be attributed to a more complex mechanism than p53 status alone.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Li, Chuan-Yuan/H-4148-2013		NCI NIH HHS [CA-09078, CA-47542] Funding Source: Medline; NIEHS NIH HHS [ES-00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMUNDSON SA, 1993, MUTAT RES, V286, P233, DOI 10.1016/0027-5107(93)90188-L; BRACHMAN DG, 1993, CANCER RES, V53, P3667; CARRIER F, 1994, J BIOL CHEM, V269, P32672; Carrier F, 1996, MUTAT RES-FUND MOL M, V352, P79, DOI 10.1016/0027-5107(95)00255-3; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Gottlieb E, 1996, CELL GROWTH DIFFER, V7, P301; Gupta N, 1996, RADIAT RES, V145, P289, DOI 10.2307/3578984; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUANG H, 1996, IN PRESS INT J RAD B; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1995, ONCOGENE, V10, P2001; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVY JA, 1968, CANCER-AM CANCER SOC, V22, P517, DOI 10.1002/1097-0142(196809)22:3<517::AID-CNCR2820220305>3.0.CO;2-A; LI CY, 1995, ONCOGENE, V11, P1885; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI CY, 1995, INT J ONCOL, V7, P223; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LITTLE JB, 1985, RADIAT RES, V101, P81, DOI 10.2307/3576305; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIVINGSTONE LR, 1992, CELL, V70, P925; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACILWRATH AJ, 1994, CANCER RES, V54, P3718; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; MURNANE JP, 1993, NATURE, V365, P22, DOI 10.1038/365022a0; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ JL, 1995, MUTAGENESIS, V10, P227, DOI 10.1093/mutage/10.3.227; SLICHENMYER WJ, 1993, CANCER RES, V53, P5164; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SU LN, 1992, INT J RADIAT BIOL, V62, P201, DOI 10.1080/09553009214552021; SU LN, 1992, INT J RADIAT BIOL, V62, P461, DOI 10.1080/09553009214552341; TSANG NM, 1995, ONCOGENE, V10, P2403; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS AC, 1995, ONCOGENE, V11, P141; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHEN W, 1995, MUTAT RES LETT, V346, P85, DOI 10.1016/0165-7992(95)90055-1; Zhen W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P602	52	77	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1661	1667		10.1038/sj.onc.1201026	http://dx.doi.org/10.1038/sj.onc.1201026			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135067				2022-12-17	WOS:A1997WR89300004
J	Langenfeld, J; Lonardo, F; Kiyokawa, H; Passalaris, T; Ahn, MJ; Rusch, V; Dmitrovsky, E				Langenfeld, J; Lonardo, F; Kiyokawa, H; Passalaris, T; Ahn, MJ; Rusch, V; Dmitrovsky, E			Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation	ONCOGENE			English	Article						retinoic acid; bronchial epithelial cells; transformation; cyclin E	ACUTE PROMYELOCYTIC LEUKEMIA; 13-CIS-RETINOIC ACID; NEOPLASTIC TRANSFORMATION; DIFFERENTIATION THERAPY; INTERFERON ALPHA-2A; PHASE-TRANSITION; LUNG-CANCER; VITAMIN-A; EXPRESSION; CARCINOMA	The retinoids are reported to reduce second primary aerodigestive tract tumors in patients with prior lung or head and neck carcinomas. Yet, the optimal retinoid useful for chemoprevention and those mechanisms linked to this chemoprevention are not identified. This study reports an in vitro model for carcinogen-induced transformation of immortalized human bronchial epithelial (BEAS-2B) cells that was adapted to study the anticarcinogenic effects of all-trans-retinoic acid (RA). Following exposure to carcinogens: cigarette smoke condensate (CSC) or N-nitrosamine-4-(methylnitrosamino)-1-(3 pyridyl)-1-butanone (NNK), BEAS-2B cells exhibited evidence of transformation. This included an increased anchorage independent growth or acquired ability to form tumors in athymic mice. This transformation was inhibited by RA as demonstrated by a lack of augmented anchorage independent growth or tumor formation in athymic mice for the cells treated with RA. The BEAS-2B cells transformed by NNK exhibited an increase in cyclin E expression which was associated with an increase in the cyclin E-Cdk2 kinase activity. Over-expression of human cyclin E by transfection shows cyclin E enhances the basal clonal growth of BEAS-2B cells. In both the parental and transformed BEAS-2B cells, RA down-regulated cyclin E protein levels which was associated with an inhibition of growth and an accumulation of cells in G1. The data reported here suggest the decline of cyclin E expression represents a potential mechanism for the RA-induced growth suppression which is linked to the anti-carcinogenic effects of RA. Thus, this study reports the adaption of an in vitro model of lung carcinogenesis suitable to test the activity of chemoprevention agents.	MEM SLOAN KETTERING CANC CTR,DEPT MED,MOL MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT SURG,THORAC SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MEM HOSP,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOL PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Kiyokawa, Hiroaki/0000-0002-7942-6455	NCI NIH HHS [K12-CA01712, R01-CA5 4494-04, T32-CA09512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494, K12CA001712, T32CA009512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; BASELGA J, 1993, ONCOGENE, V8, P3257; BURGER C, 1994, J CELL SCI, V107, P2047; CASTAIGNE S, 1990, BLOOD, V76, P1704; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gudas Lorraine J., 1994, P443; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEYOMARSI K, 1994, CANCER RES, V54, P380; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MAHAFFEY DT, 1995, FEBS LETT, V370, P109, DOI 10.1016/0014-5793(95)00799-F; MERRIMAN RL, 1979, CANCER RES, V39, P1661; MOASSER MM, 1995, ONCOGENE, V10, P1537; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; REDDEL RR, 1988, CANCER RES, V48, P1904; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; 1994, NEW ENGL J MED, V330, P1029	35	77	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1983	1990						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934545				2022-12-17	WOS:A1996VR79500018
J	Fueyo, J; GomezManzano, C; Bruner, JM; Saito, Y; Zhang, BH; Zhang, W; Levin, VA; Yung, WKA; Kyritsis, AP				Fueyo, J; GomezManzano, C; Bruner, JM; Saito, Y; Zhang, BH; Zhang, W; Levin, VA; Yung, WKA; Kyritsis, AP			Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas	ONCOGENE			English	Article						p16/CDKN2; glioma; methylation; tumor suppressor genes	CHRONIC MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; P16(INK4) EXPRESSION; BRAIN-TUMORS; RETINOBLASTOMA; DELETION; CANCERS; P16	There is considerable evidence that lack of p16 protein expression is a frequent event in human gliomas. Nevertheless, the molecular mechanisms underlying this absence of p16 protein expression are not completely understood. In some gliomas, homozygous deletions are the main cause of p16/CDKN2 gene inactivation. However, other gliomas lacking p16 expression exhibit intact p16/CDKN2 gene, suggesting that p16/CDKN2 is down-regulated at the transcriptional level. In this study we investigated whether aberrant p16/CDKN2 gene methylation correlated with absence of p16 expression in the latter group of gliomas. In a series of 27 gliomas, 12 malignant tumors exhibited loss of p16/CDKN2 expression but not gene deletion. Methylation analysis of the CpG island in the 5' region of the p16/CDKN2 gene showed that exon 1 was extensively methylated in six and partially methylated in the other six of the 12 malignant gliomas. In contrast, no methylation was observed in four other malignant gliomas and two low-grade gliomas that expressed p16 protein. These results indicate that abnormal hypermethylation of the CpG island encompassing the 5' end of the p16/CDKN2 gene may be a mechanism of transcriptional silencing in gliomas without homozygous deletions.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030, USA.			Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, 1995, CANCER RES, V55, P1351; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BURGER PC, 1991, SURGICAL PATHOLOGY N, P193; Fueyo J, 1996, ONCOGENE, V12, P103; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JEN J, 1994, CANCER RES, V54, P6353; JUNG JM, 1995, ONCOGENE, V11, P2021; Kyritsis AP, 1996, ONCOGENE, V12, P63; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NELKIN BD, 1991, BLOOD, V77, P2431; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Sambrook J, 1989, MOL CLONING LAB MANU; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; Ueki K, 1996, CANCER RES, V56, P150; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; YEAGER T, 1995, CANCER RES, V55, P493; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	28	77	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1615	1619						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895506				2022-12-17	WOS:A1996VM88700005
J	Rehman, I; Takata, M; Wu, YY; Rees, JL				Rehman, I; Takata, M; Wu, YY; Rees, JL			Genetic change in actinic keratoses	ONCOGENE			English	Article						loss of heterozygosity; allelotype; squamous cell carcinoma; p21(WAF1/CIP1); p53; Ki67	SQUAMOUS-CELL CARCINOMA; P53 MUTATIONS; SOLAR KERATOSES; BREAST-CANCER; SKIN-CANCER; ALLELOTYPE; BIOLOGY; PROGRESSION; COMMON	Actinic keratoses (AKs) are small scaly red areas of skin characterised histologically by dysplasia, a minority of which are thought to be precursors of squamous cell carcinoma (SCC), and which show a high frequency of regression. Surprisingly, in view of their benign clinical course, they show a high frequency of loss of heterozygosity (LOH) with a median loss of four loci with almost 20% of lesions showing loss of eight or more alleles, as well as frequent p53 mutation. Loss was common on 3p (31%), 9p (39%), 9q (22%), 13q (52%), 17p (64%) and 17q (46%), and allele loss correlated with dysplasia. Topological disturbance of p21(WAF1/CIP1) expression correlated with allele loss but was also seen together with increased wild-type p53 expression and an increase in the fraction of cycling cells in the absence of allele loss or p53 mutation, and is likely to represent an early change, P21(WAF1/CIP1) expression appeared independent of p53 status. The frequency of LOH in AKs exceeded that of (invasive) SCCs suggesting that the relation between the accumulation of genetic change and behaviour for non-melanoma skin cancer is not straightforward.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK								AHSEE KW, 1994, CANCER RES, V54, P1617; ANTONIADES HN, 1994, J CLIN INVEST, V93, P2206, DOI 10.1172/JCI117217; BOYLE JO, 1993, CANCER RES, V53, P4477; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN DC, 1990, HISTOPATHOLOGY, V17, P489, DOI 10.1111/j.1365-2559.1990.tb00788.x; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; CAMPBELL C, 1993, SKIN CANC, V8, P245; CLIBY W, 1993, CANCER RES, V53, P2393; COLES C, 1992, CANCER RES, V52, P5291; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GALLAGHER RP, 1990, J AM ACAD DERMATOL, V23, P413, DOI 10.1016/0190-9622(90)70234-9; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; HEALY E, 1994, J INVEST DERMATOL, V103, P493, DOI 10.1111/1523-1747.ep12395637; HEALY E, 1994, J INVEST DERMATOL, V105, P274; JACKSON DP, 1995, PCR PRACTICAL APPROA, P29; JIANG HP, 1994, ONCOGENE, V9, P3397; KNOWLES MA, 1994, CANCER RES, V54, P531; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; LEE YS, 1994, CANCER-AM CANCER SOC, V73, P2317, DOI 10.1002/1097-0142(19940501)73:9<2317::AID-CNCR2820730913>3.0.CO;2-0; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; MARKS R, 1991, ARCH DERMATOL, V127, P1031, DOI 10.1001/archderm.127.7.1031; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; MOLES JP, 1993, J INVEST DERMATOL, V101, P100, DOI 10.1111/1523-1747.ep12360920; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NAWROZ H, 1994, CANCER RES, V54, P1152; NEWTON JA, 1987, BRIT J DERMATOL, V117, P169, DOI 10.1111/j.1365-2133.1987.tb04113.x; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; QUINN AG, 1994, GENE CHROMOSOME CANC, V11, P222, DOI 10.1002/gcc.2870110404; QUINN AG, 1994, CANCER RES, V54, P4756; REES J, 1994, J INVEST DERMATOL, V103, P747, DOI 10.1111/1523-1747.ep12412256; REES JL, 1995, J INVEST DERMATOL, V104, P883, DOI 10.1111/1523-1747.ep12606149; REHMAN I, 1994, LANCET, V344, P788, DOI 10.1016/S0140-6736(94)92343-4; REID T, 1994, CANCER RES, V54, P1801; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1990, CANCER RES, V50, P7184; SMITH MD, 1995, BRIT J DERMATOL, V132, P359, DOI 10.1111/j.1365-2133.1995.tb08668.x; SOBER AJ, 1995, CANCER, V75, P645, DOI 10.1002/1097-0142(19950115)75:2+<645::AID-CNCR2820751405>3.0.CO;2-1; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VANDERRIET P, 1994, CANCER RES, V54, P25; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	53	77	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2483	2490						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700506				2022-12-17	WOS:A1996UW48700001
J	McKenna, WG; Bernhard, EJ; Markiewicz, DA; Rudoltz, MS; Maity, A; Muschel, RJ				McKenna, WG; Bernhard, EJ; Markiewicz, DA; Rudoltz, MS; Maity, A; Muschel, RJ			Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: Influence of H-ras on the G2 delay	ONCOGENE			English	Article						apoptosis; G2 delay; X-rays; cyclin B1	IRRADIATED MURINE TUMORS; INDUCED MITOTIC DELAY; HAMSTER OVARY CELLS; DNA STRAND BREAKS; IONIZING-RADIATION; EMBRYO CELLS; HELA-CELLS; V-MYC; SACCHAROMYCES-CEREVISIAE; P34CDC2 KINASE	Primary fibroblasts, after serum withdrawal or after irradiation, do not undergo apoptosis. Myc-transfected fibroblasts, in contrast, undergo apoptosis upon serum withdrawal and after irradiation. We have studied the relationship of apoptosis induction to effects on the G2 phase cell cycle in a series of rat embryo cells transformed by ras(H) plus myc or immortalized by myc alone. In this system, while the presence of ras(H) had little effect on the extent of apoptosis induction by serum withdrawal, ras(H) greatly suppressed the apoptotic response of myc-transfected cells to X-rays. The cells into which ras(H) had been introduced showed a profound G2 arrest associated with suppression of cyclin B1 mRNA expression. In contrast, cells with myc alone had a minimal G2 delay after irradiation and no suppression of cyclin B1 mRNA expression, We hypothesize that ras(H), by influencing the G2 response of cells to X-rays, exerts an anti-apoptotic effect. In support of this hypothesis; we found that treatment of cells with caffeine, an agent that relieves the G2 delay after irradiation resulted in increased apoptosis in the irradiated cells, but not in control cells.	UNIV PENN,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Maity, Amit/0000-0001-7151-2845	NATIONAL CANCER INSTITUTE [R01CA064227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [CA64227] Funding Source: Medline; NIGMS NIH HHS [GM47439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BERNHARD EJ, 1994, RADIAT RES, V140, P393, DOI 10.2307/3579118; BRACEY TS, 1995, ONCOGENE, V10, P2391; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; ELDIERY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS DL, 1993, CANCER RES, V53, P2133; FAN SJ, 1995, CANCER RES, V55, P1649; GORCZYCA W, 1993, CANCER RES, V53, P1945; GORCZYCA W, 1993, LEUKEMIA, V7, P659; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HURWITZ C, 1969, BIOPHYS J, V9, P607, DOI 10.1016/S0006-3495(69)86407-6; ILIAKIS G, 1990, CANCER RES, V50, P6575; KARBANDA S, 1994, ONCOGENE, V9, P3005; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LING CC, 1994, RADIOTHER ONCOL, V32, P129; LING CC, 1994, RADIOTHER ONCOL, V33, P17; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOCK RB, 1990, CANCER RES, V50, P3767; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAITY A, 1994, BIOCHEM BIOPH RES CO, V202, P908, DOI 10.1006/bbrc.1994.2016; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MCKENNA WG, 1990, CANCER RES, V50, P97; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; MCKENNA WG, 1981, J BIOL CHEM, V265, P6435; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1986, CANCER RES, V46, P4104; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; MUSHCEL R, 1985, AM J PATHOL, V121, P1; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; POWELL SN, 1995, CANCER RES, V55, P1643; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; RODEMANN HP, 1991, SCANNING MICROSCOPY, V5, P1135; ROWLEY R, 1992, RADIAT RES, V132, P144, DOI 10.2307/3578519; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STEPHENS LC, 1991, RADIAT RES, V127, P308, DOI 10.2307/3577946; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHEN WN, 1995, RADIAT RES, V141, P170, DOI 10.2307/3579044	65	77	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					237	245						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570201				2022-12-17	WOS:A1996TR53800003
J	BENNICELLI, JL; FREDERICKS, WJ; WILSON, RB; RAUSCHER, FJ; BARR, FG				BENNICELLI, JL; FREDERICKS, WJ; WILSON, RB; RAUSCHER, FJ; BARR, FG			WILD-TYPE PAX3 PROTEIN AND THE PAX3-FKHR FUSION PROTEIN OF ALVEOLAR RHABDOMYOSARCOMA CONTAIN POTENT, STRUCTURALLY DISTINCT TRANSCRIPTIONAL ACTIVATION DOMAINS	ONCOGENE			English	Article						PAX3; FKHR; FUSION PROTEIN; TRANSCRIPTION FACTOR; CHROMOSOMAL TRANSLOCATION	DNA-BINDING DOMAIN; MAMMALIAN-CELLS; GENE-EXPRESSION; EWINGS-SARCOMA; PRE-B; TRANSLOCATION; VIRUS; RNA; LIPOSARCOMA; E2A-PBX1	Alveolar rhabdomyosarcoma (ARMS) is characterized cytogenetically by a t(2;13)(q35;q14) chromosomal translocation involving two transcription factor genes: PAX3 and FKHR. ARMS cells express a PAX3-FKHR fusion protein containing the complete N-terminal, DNA-binding domain of PAX3 and the C-terminus of FKHR. Recently we demonstrated that PAX3-FKHR is a more potent transcriptional activator than PAX3 despite impaired binding to canonical PAX3 binding sites. Therefore, we propose that the gene fusion results in snitching of PAX3 and FKHR transactivation domains with distinct structure, potency or function. To compare the PAX3 and putative PAX3-FKHR transactivation domains, we fused C-terminal test fragments to the heterologous GAL4 DNA-binding domain and tested activation of a reporter gene co-transfected into four cell types. GAL4-PAX3 and GAL4-PAX3-FKHR were found to be potent activators exhibiting different concentration-dependent transactivation profiles and distinct structural motifs. Deletion mapping demonstrated essential acidic and/or serine/threonine-rich domains in the extreme 3' ends of their respective coding regions and positive modifying elements in adjacent 5' sequences. These data demonstrate that PAX3 and PAX3-FKHR contain structurally distinct transcriptional activation domains and suggest that a consequent difference in function is important for oncogenesis.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; The Wistar Institute					NATIONAL CANCER INSTITUTE [P01CA047983, R01CA064202] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002871] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47983, CA 64202] Funding Source: Medline; NHLBI NIH HHS [K08 HL02871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; DENECKE B, 1993, J BIOL CHEM, V268, P18076; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Manet Evelyne, 1993, Gene Expression, V3, P49; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OHNO T, 1993, CANCER RES, V53, P5859; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; TASSABEHJI M, 1994, HUM MOL GENET, V3, P1069, DOI 10.1093/hmg/3.7.1069; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VANDIJK MA, 1989, P NATL ACAD SCI USA, V90, P6061; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	39	77	77	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					119	130						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624119				2022-12-17	WOS:A1995RJ29500015
J	LIU, M; PELLING, JC				LIU, M; PELLING, JC			UV-B/A IRRADIATION OF MOUSE KERATINOCYTES RESULTS IN P53-MEDIATED WAF1/CIP1 EXPRESSION	ONCOGENE			English	Article						UV IRRADIATION; P53; WAF1/CIP1; KERATINOCYTE; SKIN CANCER	P53 MUTATIONS; ATAXIA-TELANGIECTASIA; SKIN-CANCER; DNA-DAMAGE; WILD-TYPE; CELL; RADIATION; PROTEIN; INDUCTION; ULTRAVIOLET	The tumor suppressor gene p53 is involved in controlling cell cycle checkpoint or triggering apoptosis. p53 may accomplish these roles by acting as a sequence-specific transcription factor, One of the downstream targets of p53 transcription control is the WAF1/CIP1 gene, whose gene product p21 interacts with several cyclins and cyclin-dependent kinases, resulting in inhibition of these kinases. Tn our previous studies, we have shown that the p53 protein level in mouse keratinocytes was elevated following UV-B/A irradiation. In this paper we further investigated the consequences of increased p53 protein level by characterizing p53 DNA-binding level and WAF1/CIP1 gene expression in UV-B/A-irradiated mouse keratinocytes. Consistent with the increased level of p53 protein, both p53 DNA-binding level and steady-state level of WAFI/CIP1 mRNA were elevated. We have demonstrated that the induction of WAF1/CIP1 mRNA was mediated by p53, since no WAF1/CIP1 induction was observed in p53-deficient cells upon W-B exposure. These observations suggest an important role for the tumor suppressor gene p53 in the response of keratinocytes to the biologically relevant W-BIA irradiation and in suppressing UV-induced skin cancer.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA040847, P30CA036727] Funding Source: NIH RePORTER; NCI NIH HHS [CA36727-07, CA40847] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOL MOL; BEER JZ, 1993, PHOTOCHEM PHOTOBIOL, V58, P676, DOI 10.1111/j.1751-1097.1993.tb04951.x; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, CANCER RES, V53, P2697; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DANNO K, 1987, PHOTOCHEM PHOTOBIOL, V45, P683, DOI 10.1111/j.1751-1097.1987.tb07401.x; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINALY CA, 1989, CELL, V57, P1083; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; HERRLICH P, 1984, ADV ENZYME REGUL, V25, P485; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSON BE, 1984, PHYSL PATHOPHYSIOLOG, V8, P2414; KANJILAL S, 1993, CANCER RES, V53, P2961; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KOONE MD, 1986, J INVEST DERMATOL, V87, P343, DOI 10.1111/1523-1747.ep12524440; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LOGANZO JF, 1994, MOL CELL DIFF, V2, P23; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHIELI P, 1994, CANCER RES, V54, P3391; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRICE BD, 1993, ONCOGENE, V8, P3055; Romerdahl C A, 1989, Cancer Commun, V1, P209; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; URBACH F, 1984, TOPICS PHOTOMEDICINE, P67; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG W, 1994, CANCER RES, V54, P4448; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0; [No title captured]	48	77	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1955	1960						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761096				2022-12-17	WOS:A1995QZ92600009
J	ZHANG, YJ; YU, DH; XIA, WY; HUNG, MC				ZHANG, YJ; YU, DH; XIA, WY; HUNG, MC			HER-2/NEU-TARGETING CANCER-THERAPY VIA ADENOVIRUS-MEDIATED E1A DELIVERY IN AN ANIMAL-MODEL	ONCOGENE			English	Article						HER-2/NEU; GENE THERAPY; E1A; ADENOVIRAL VECTOR	NEGATIVE BREAST-CANCER; GROWTH-FACTOR RECEPTOR; NECROSIS-FACTOR-ALPHA; HUMAN TUMOR-CELLS; OVARIAN-CANCER; NEU ONCOGENE; GENE-PRODUCTS; RECURRENT DISEASE; INCREASED RISK; POOR SURVIVAL	Overexpression of HER-2/neu has been demonstrated in human ovarian cancer and correlated with poor prognosis. We previously found that the adenovirus type 5 early region 1A (EIA) gene product can repress overexpression and suppress the tumorigenic potential of the HER-2/neu-overexpressing cancer cells. To develop an efficient HER-2/neu-targeting gene therapy with EIA, a replication-deficient adenovirus containing the E1A gene, Ad.E1A(+), was used to transduce the HER-2/neu-overexpressing human ovarian cancer cell line SK-OV3.ip1. Tumor cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction. To test therapeutic efficacy in vivo, tumor-bearing mice were established by i.p. injection with ovarian cancer cells and treated by i.p. injection of 10(8) PFU viral solution containing either replication-deficient Ad.E1A(+); control virus Ad.E1A(-) which is the same adenovirus as Ad.E1A(+) except for E1A deletion, or just PBS. Ad.E1A(+) significantly prolonged survival in treated mice for 1 year (80%) whereas in control groups, ah mice died of cancer within 4.5 months. Immunohistochemistry analysis indicated that Ad.E1A protein was expressed in tumor tissue and expression of HER-2/neu p185 protein was suppressed in vivo. As a control, another ovarian cancer cell Une 2774, in which HER-2/neu is expressed at a basal level, was also inoculated i.p. following the same therapeutic procedure. Ad.E1A(+) could not prolong survival of 2774 cells, indicating that Ad.E1A(+) specifically targeted HER-2/neu-overexpressing tumor cells and functioned as an antitumor agent.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58880, R01-CA60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; BORG A, 1990, CANCER RES, V50, P4332; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1990, ONCOGENE, V5, P75; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KENYON DJ, 1991, VIROLOGY, V180, P818, DOI 10.1016/0042-6822(91)90099-W; KERN JA, 1990, CANCER RES, V50, P5284; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MITRA AB, 1994, CANCER RES, V54, P637; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PARK JB, 1989, CANCER RES, V49, P6605; PATERSON MC, 1991, CANCER RES, V51, P556; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1993, CANCER RES, V53, P4960; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAWADA Y, 1986, J EXP MED, V163, P563, DOI 10.1084/jem.163.3.563; SAWADA Y, 1994, INT J CANCER, V57, P598, DOI 10.1002/ijc.2910570426; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V23, P177; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAN DH, 1991, ONCOGENE, V6, P343; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YONEMURA Y, 1991, CANCER RES, V51, P1034; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG X, 1989, ONCOGENE, V4, P985	55	77	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1947	1954						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761095				2022-12-17	WOS:A1995QZ92600008
J	BROWN, AD; LOPEZTERRADA, D; DENNY, C; LEE, KAW				BROWN, AD; LOPEZTERRADA, D; DENNY, C; LEE, KAW			PROMOTERS CONTAINING ATF-BINDING SITES ARE DE-REGULATED IN CELLS THAT EXPRESS THE EWS/ATF1 ONCOGENE	ONCOGENE			English	Article						ONCOGENES; TRANSCRIPTION, CAMP	TRANSCRIPTION FACTOR CREB; MULTIPLE SEQUENCE ELEMENTS; C-FOS PROMOTER; CYCLIC-AMP; MALIGNANT-MELANOMA; RESPONSE ELEMENT; SOMATOSTATIN GENE; PROTEIN-KINASE; FRTL5 CELLS; SOFT PARTS	Chromosomal translocations that fuse the N-terminal region of the Ewings sarcoma oncogene (EWS) to the C-terminal region (including the DNA-binding domain) of the cellular transcription factor ATF1 are associated with a tumour type termed malignant melanoma of soft parts (MMSP). It is envisioned that transformation by the EWS/ATF1 fusion protein results from aberrant transcriptional regulation of genes that are normally regulated by ATF1. To examine this hypothesis we have expressed exogenous EWS-ATF1 in JEG3 cells and tested its ability to activate several promoters that contain binding sites for ATF1. We show that EWS-ATF1 is a strong constitutive activator of some promoters tested but represses others. Significantly, the ability of particular promoters to be activated by EWS/ATF1 in JEG3 cells correlates with promoter activity in two MMSP-derived cell lines (SU-CCS-1 and DTC1). Our results therefore provide evidence that endogenous EWS/ATF1 can de-regulate transcription and that this capacity may contribute to transformation in MMSP.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV SO CALIF,CHILDRENS HOSP,DEPT PATHOL,LOS ANGELES,CA 90027; UNIV CALIF LOS ANGELES,MED CTR,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	Children's Hospital Los Angeles; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN AL, 1984, CANCER RES, V44, P1265; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRIGNANI F, 1994, BLOOD, V83, P10; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERBER B, 1994, ONCOGENE, V9, P1295; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; JIN S, 1986, ENDOCRINOLOGY, V119, P802, DOI 10.1210/endo-119-2-802; JONES C, 1991, MOL CELL BIOL, V11, P4297, DOI 10.1128/MCB.11.9.4297; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; LADANYI M, 1994, CANCER RES, V54, P2837; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE KAW, 1989, MOL CELL BIOL, V9, P4390, DOI 10.1128/MCB.9.10.4390; LEE KAW, 1987, EMBO J, V6, P1345, DOI 10.1002/j.1460-2075.1987.tb02374.x; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; MACARTHUR H, 1984, J VIROL, V483, P84; MAO XH, 1994, J BIOL CHEM, V269, P18216; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MASSON N, 1993, NUCLEIC ACIDS RES, V5, P1163; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	77	77	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1749	1756						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753552				2022-12-17	WOS:A1995QX46900008
J	MURTY, VVVS; BOSL, GJ; HOULDSWORTH, J; MEYERS, M; MUKHERJEE, AB; REUTER, V; CHAGANTI, RSK				MURTY, VVVS; BOSL, GJ; HOULDSWORTH, J; MEYERS, M; MUKHERJEE, AB; REUTER, V; CHAGANTI, RSK			ALLELIC LOSS AND SOMATIC DIFFERENTIATION IN HUMAN MALE GERM-CELL TUMORS	ONCOGENE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; CYTOGENETIC ANALYSIS; SUPPRESSOR GENES; KIT RECEPTOR; LONG ARM; METASTASIS; EXPRESSION; CANCER; CHROMOSOME-12; MUTATIONS	The complex but poorly understood human male germ cell tumors offer unusual opportunities for the genetic analysis of malignant transformation and embryonal differentiation in a pluripotential stem cell Lineage. Histologically, these tumors are divided into two major subgroups, seminomas which are characterized by inability to express embryonal differentiation, and nonseminomas which are characterized by ability to express embryonal as well as extraembryonal patterns of differentiation. To understand the role of genetic factors in the development of these tumors and the regulation of differentiation expressed by them, we carried out a detailed allelotype analysis by the loss of heterozygosity assay. This analysis revealed frequent deletions in known tumor suppressor genes (RB1, DCC, NME), a number of previously described sites of candidate tumor suppressor genes (3p, 9p, 9q, 10q, 11p, 11q and 17p), as well as several novel sites (2p, 3q, 5p, 12q, 18p and 20p). Our results also showed that well differentiated teratomas exhibit a significantly higher level of allelic loss compared to the less differentiated embryonal carcinomas. In addition, certain loci and genes exhibited frequent non-random deletion in teratomas (D3S32, D3S42, D5S12, D10S25, D11S12, RB1, TP53, NME1, NME2, D17S4, D18S6 and D20S6) and embryonal carcinomas (IFNB, D9S27). Among these loci, the NME genes were notable for a high degree of genetic loss (> 70%) in teratomas. These results suggested that nonrandom loss or inactivation of certain genes may be associated with tumor development and loss or inactivation of other genes mag be associated with somatic differentiation.	MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CYTOGENET SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR,NEW YORK,NY 10021; FORDHAM UNIV,DEPT BIOL SCI,NEW YORK,NY 10458	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Fordham University	MURTY, VVVS (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P01CA005826, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA-05826, CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1993, ONCOGENE, V8, P497; COLLINS D. H., 1964, BRIT J UROL, V36, P1; CUTICCHIA AJ, 1993, GENOME PRIORITY REPO, V1; DMITROVSKY E, 1990, ONCOGENE, V5, P543; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GODDARD AD, 1993, ADV HUM GENET, V21, P321; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; MANOVA K, 1993, DEV BIOL, V157, P85, DOI 10.1006/dbio.1993.1114; MATHEW S, 1992, GENOMICS, V14, P775, DOI 10.1016/S0888-7543(05)80184-3; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1990, CANCER GENET CYTOGEN, V50, P67, DOI 10.1016/0165-4608(90)90239-7; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; PENG HQ, 1993, CANCER RES, V53, P3574; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; PUGH RCB, 1976, PATHOLOGY TESTIS, P245; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; RODRIGUEZ E, 1994, IN PRESS CANCER RES; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STROHMEYER T, 1991, P NATL ACAD SCI USA, V88, P6662, DOI 10.1073/pnas.88.15.6662; STROHMEYER T, 1991, CANCER RES, V51, P1811; ULBRIGHT TM, 1987, SEMIN DIAGN PATHOL, V4, P304; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG N, 1981, CANCER RES, V41, P2135	27	77	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2245	2251						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518576				2022-12-17	WOS:A1994NX62900016
J	HUANG, RP; DARLAND, T; OKAMURA, D; MERCOLA, D; ADAMSON, ED				HUANG, RP; DARLAND, T; OKAMURA, D; MERCOLA, D; ADAMSON, ED			SUPPRESSION OF V-SIS-DEPENDENT TRANSFORMATION BY THE TRANSCRIPTION FACTOR, EGR-1	ONCOGENE			English	Article							WILMS-TUMOR GENE; EMBRYONAL CARCINOMA-CELLS; DNA-BINDING DOMAINS; C-FOS; CULTURED-CELLS; GROWTH-FACTORS; RETINOIC ACID; CHAIN GENE; PROTEIN; EXPRESSION	The transcription factor Egr-1, stimulates the activity of a number of genes and inhibits other genes, by binding to the sequence GCGGGGGCG in 5' enhancer regions, However, the functions of Egr-1 are obscure in spite of its rather ubiquitous expression. Egr-1 may play a role in proliferation in mitogen-stimulated cells but its expression is also correlated with the differentiated state in teratocarcinoma cells. The constitutive expression of Egr-1 appears to have little effect on the growth rate of normal immortalized cell-lines. We show that in NIH3T3 cells that are conditionally transformed by the expression of v-sis, the presence of Egr-1 is inhibitory to the production of transformed colonies (foci) and to growth in soft agar. In addition, the first appearance of tumors in nu/nu mice is delayed in tumorigenicity tests with cells that over-express Egr-1 and tumor growth is suppressed compared to control cells. We used a series of fragments of Egr-1 cloned into expression vectors to show that not only full length, but also truncated Egr-1 fragments inhibit colony formation. Using deletion mutants, we observed that this inhibitory activity is dependent on the presence of the DNA-binding 'zinc-finger' region. Wilm's tumor protein, WT1, (known to be a tumor suppressor gene) that exhibits the same DNA binding activity is also inhibitory. In contrast, colony formation is stimulated by an Egr-1 antisense RNA-expressing plasmid, since colonies grow rapidly and the colony-forming frequency is higher than in the presence of v-sis alone. We conclude that proteins containing the Egr-1 'zinc-finger' domain can bind to the regulatory regions of one or more genes that are required for the transformation of fibroblasts by v-sis thus inhibiting transformation. One function for Egr-1 implied by these results is the restraint of transformed growth in mitogen-stimulated cells.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037; SAN DIEGO REG CANC CTR,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego			mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA 49963] Funding Source: Medline; NICHD NIH HHS [HD 28025, HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028025, R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DEWALD GW, 1985, BLOOD, V66, P189; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GINSBERG D, 1991, ONCOGENE, V6, P669; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVIIN WJ, 1992, J CELL BIOCHEM, V16, pA240; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MERCOLA D, 1993, FRONTIERS OF OSTEOSARCOMA RESEARCH, P375; MERCOLA D, 1992, ONCOGENE, V7, P1793; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAGONA G, 1991, DNA CELL BIOL, V10, P61, DOI 10.1089/dna.1991.10.61; Sambrook J., 1989, MOL CLONING, V1; Sambrook J., 1989, MOL CLONING, V2; Sambrook J, 1989, MOL CLONING, V3; SHAM MH, 1993, CELL, V72, P83; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VESQUE C, 1992, NUCLEIC ACIDS RES, V20, P2485, DOI 10.1093/nar/20.10.2485; WANG ZY, 1992, J BIOL CHEM, V267, P21999	47	77	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1367	1377						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152797				2022-12-17	WOS:A1994NH40100008
J	DSOUZA, B; BERDICHEVSKY, F; KYPRIANOU, N; TAYLORPAPADIMITRIOU, J				DSOUZA, B; BERDICHEVSKY, F; KYPRIANOU, N; TAYLORPAPADIMITRIOU, J			COLLAGEN-INDUCED MORPHOGENESIS AND EXPRESSION OF THE ALPHA-2-INTEGRIN SUBUNIT IS INHIBITED IN C-ERBB2-TRANSFECTED HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article							MONOCLONAL-ANTIBODIES; C-ERBB-2 PROTEIN; BREAST; TUMORS; GLAND; GENE; ADENOCARCINOMA; AMPLIFICATION; KERATIN-19; DISTINCT	The c-erbB2 (or Her2) oncogene is amplified and/or overexpressed in a significant proportion of breast cancers. To assess the role of the c-erbB2 oncogene in mammary tumorigenesis, we have transfected the corresponding human c-erbB2 cDNA into an immortalized human mammary epithelial cell line, MTSV1-7, that was derived from luminal epithelial cells cultured from milk. Three transfectants expressing different levels of the c-erbB2 gene product have been isolated which form colonies in agar and produce tumours in nude mice with high efficiency. We have observed that MTSV1-7 cells form three-dimensional structures in collagen gels and that alpha2beta1-integrin plays a crucial role in the process of morphogenesis. We now find that the c-erbB2 transfectants exhibit an impaired ability to undergo morphogenesis in collagen gets as compared with the parental cell line or the control neomycin transfectant, and that the degree of impairment is related to the level of c-erbB2 expression. Moreover, overexpression of the c-erbB2 product was found to be correlated with a specific decrease in the expression of alpha2beta1-integrin subunit and in the alpha2-mRNA. The breast cancer cell line SKBr3, which carries multiple copies of the c-erbB2 gene and overexpresses the 185-kDa product, was also found to express very low levels of the alpha2-integrin protein and mRNA. Our results confirm the involvement of the alpha2beta1-integrin in collagen-induced morphogenesis of mammary epithelial cells and suggest that the c-erbB2 gene product may inhibit this morphogenesis by inhibiting the expression of the alpha2-integrin subunit.	IMPERIAL CANC RES FUND,POB 123,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND; UNIV MARYLAND HOSP,DEPT SURG,DIV UROL,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Cancer Research UK; University System of Maryland; University of Maryland Baltimore; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BARTEK J, 1986, EUR J CANCER CLIN ON, V22, P1441, DOI 10.1016/0277-5379(86)90077-5; BARTEK J, 1985, J CELL SCI, V75, P17; BARTEK J, 1985, INT J CANCER, V36, P299, DOI 10.1002/ijc.1985.36.3.299; BERDICHEVSKY F, 1991, EXP CELL RES, V194, P267, DOI 10.1016/0014-4827(91)90364-Z; BERDICHEVSKY F, 1992, J CELL SCI, V102, P437; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KYPRIANOU N, 1991, ONCOGENE, V7, P77; LONARDO F, 1990, New Biologist, V2, P992; Maniatis T., 1982, MOL CLONING; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHEARER M, 1992, INT J CANCER, V51, P602, DOI 10.1002/ijc.2910510417; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Taylor-Papadimitriou J., 1987, The mammary gland. Development, regulation, and function., P181; TAYLORPAPADIMIT.J, 1992, BREAST CANCER CELLUL, V3, P355; TAYLORPAPADIMIT.J, 1987, GROWTH DIFFERENTIATI, P1; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; ZUTTER MM, 1990, AM J PATHOL, V137, P863	33	77	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1797	1806						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8099725				2022-12-17	WOS:A1993LG68200011
J	SU, ZZ; AUSTIN, VN; ZIMMER, SG; FISHER, PB				SU, ZZ; AUSTIN, VN; ZIMMER, SG; FISHER, PB			DEFINING THE CRITICAL GENE-EXPRESSION CHANGES ASSOCIATED WITH EXPRESSION AND SUPPRESSION OF THE TUMORIGENIC AND METASTATIC PHENOTYPE IN HA-RAS-TRANSFORMED CLONED RAT EMBRYO FIBROBLAST CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; GTPASE ACTIVATING PROTEIN; HUMAN COLORECTAL TUMORS; ADENOVIRUS TYPE-5; MESSENGER-RNA; DROSOPHILA GENE; HUMAN CANCER; E1A GENE; NM23; PROGRESSION	Carcinogenesis requires a complex series of genetic changes often involving multiple oncogenes and the inactivation of multiple tumor-suppressor genes. We presently examined the effect of the Krev-1 tumor-suppressor gene on the tumorigenic and metastatic potential of Ha-ras-transformed cloned rat embryo fibroblast (CREF) cells. Ha-ras-transformed CREF cells are morphologically transformed and anchorage independent, produce reduced levels of nm23-H1 (a putative metastasis-suppressor gene product) and TIMP-1 (tissue inhibitor of metalloproteinase 1) transcripts and mRNA compared with CREF cells; produce increased levels of cripto, 94-kDa gelatinase/type IV collagenase (94-kDa GEL), osteopontin (OPN) and transin/stromelysin transcripts and mRNA compared with CREF cells; and are tumorigenic and metastatic in both nude mice and syngeneic rats. Ha-ras-transformed CREF cells coexpressing the Krev-1 gene display a reversion in cellular phenotype and gene expression to that of untransformed CREF cells. However, Ha-ras/Krev-1-coexpressing CREF cells retain, albeit with extended latency periods, both tumorigenic and metastatic potential that is not related directly to the final level of Ha-ras or Krev-1 mRNA or the Ha-ras p21 transforming protein. Development of metastatic potential is, however, directly correlated with a reduction in nm23-H1 and TIMP-1 transcription and mRNA levels and an enhanced expression of cripto, 94-kDa GEL, osteopontin and transin. In contrast, expression of additional tumor-suppressor genes, such as the RB gene and p53, or genes associated with tumorigenesis in other model systems, such as major excreted glycoprotein (MEP), 72-kDa gelatinase/type IV collagenase (72-kDa GEL), fibronectin (FIB), tenascin and intracellular adhesion molecule 1 (ICAM-1) is not altered in a consistent manner during in vitro transformation suppression or escape from tumorigenic and metastatic suppression. These results indicate that Krev-1 suppression of the Ha-ras-transformed/oncogenic phenotype is associated with a distinct program of gene expression changes manifested by altered rates of transcription and steady-state mRNA levels of specific oncogenic-suppressing and oncogenic-inducing genes. These data support a model of Ha-ras-induced metastasis in CREF cells that involves a direct modulation in the expression/suppression of specific combinations of oncogenic-suppressor genes and metastasis-promoting genes that are regulated coordinately in the process of tumor progression.	COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,INST CANC RES,CTR COMPREHENS CANC,650 W 168TH ST,NEW YORK,NY 10032; UNIV KENTUCKY,MED CTR,DEPT MED MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,INST CANC RES,CTR COMPREHENS CANC,NEW YORK,NY 10032	Columbia University; University of Kentucky; Columbia University					NCI NIH HHS [CA33434, CA43208, CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208, R01CA033434] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; Bar-Sagi D, 1992, Semin Cell Biol, V3, P93; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BOYLAN JF, 1992, MOL CARCINOGEN, P118; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1979, CANCER RES, V39, P3051; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KERBEL RS, 1988, CANCER SURV, V7, P597; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKKA R, 1991, J CANCER RES CLIN, V117, P333, DOI 10.1007/BF01630716; KITAYAMA H, 1990, JPN J CANCER RES, V81, P445, DOI 10.1111/j.1349-7006.1990.tb02589.x; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUBOTA S, 1991, BIOCHEM BIOPH RES CO, V181, P1539, DOI 10.1016/0006-291X(91)92114-Y; KUNIYASU H, 1991, JPN J CANCER RES, V82, P969, DOI 10.1111/j.1349-7006.1991.tb01929.x; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1991, CANCER RES, V51, P2490; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCCORMICK F, 1992, PHILOS T ROY SOC B, V336, P43, DOI 10.1098/rstb.1992.0042; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NICHOLSON GL, 1988, CANCER METAST REV, V7, P143; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEEG PS, 1991, CANCER CELL-MON REV, V3, P257; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SU ZZ, 1992, POLY ADP RIBOSYLATIO, P203; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	63	77	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1211	1219						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479744				2022-12-17	WOS:A1993KY32800012
J	CORNELIS, RS; DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; KERSENMAEKER, A; BARDOEL, A; KHAN, PM; CORNELISSE, CJ				CORNELIS, RS; DEVILEE, P; VANVLIET, M; KUIPERSDIJKSHOORN, N; KERSENMAEKER, A; BARDOEL, A; KHAN, PM; CORNELISSE, CJ			ALLELE LOSS PATTERNS ON CHROMOSOME-17Q IN 109 BREAST CARCINOMAS INDICATE AT LEAST 2 DISTINCT TARGET REGIONS	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; P53 MUTATIONS; CANCER; CARCINOGENESIS; HETEROZYGOSITY; ASSOCIATION; PROGRESSION; MECHANISMS; DELETION; PROTEIN	Loss of heterozygosity (LOH) of markers for chromosome 17 is the most frequent genetic change observed in breast cancer to date. To assess whether the location of several candidate target genes is compatible with patterns of allele losses in the individual tumors, we examined the LOH status of chromosome 17 in 109 primary breast tumors with 15 polymorphic DNA markers (three for 17p and 12 for 17q). Allelic imbalance (AI) at 17q was observed in 44 of the 97 informative cases. A significant correlation was found between Al at the long arm and Al at the short arm of chromosome 17. The patterns of Al on 17q in the tumors differed and were highly complex in some cases. A number of tumors showed AI distal to the growth hormone locus, whereas others showed Al exclusively proximal of this marker. These results indicate that there are at least two different regions of allele loss on 17q.	LEIDEN UNIV,FAC MED,DEPT PATHOL,2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	CORNELIS, RS (corresponding author), LEIDEN UNIV,FAC MED,DEPT HUMAN GENET,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS.		DEVILEE, PETER/ABR-2140-2022					ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; BAKER SJ, 1990, CANCER RES, V50, P7717; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BORRESEN AL, 1991, AM J HUM GENET, V49, P44; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1991, CANCER RES, V51, P1020; DEVILEE P, 1991, ONCOGENE, V6, P311; DEVILEE P, 1990, CANCER SURV, V9, P605; DEVILEE P, 1991, INT J CANCER, V47, P817, DOI 10.1002/ijc.2910470604; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EASTON DF, 1993, IN PRESS AM J HUM GE; GELEICK D, 1990, CANCER GENET CYTOGEN, V46, P217, DOI 10.1016/0165-4608(90)90107-L; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P138; HALL JM, 1992, AM J HUM GENET, V50, P1235; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1989, BRIT J CANCER, V59, P661, DOI 10.1038/bjc.1989.137; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LEONE A, 1991, CANCER RES, V51, P2490; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; OSBORNE RJ, 1991, CANCER RES, V51, P6194; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; PONDER B, 1989, NATURE, V340, P264, DOI 10.1038/340264a0; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1990, ONCOGENE, V5, P1573; SASTREGARAU X, 1992, INT J CANCER, V50, P533, DOI 10.1002/ijc.2910500406; SATO T, 1991, CANCER RES, V51, P5794; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SOLOMON E, 1991, CYTOGENET CELL GENET, V51; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1991, ONCOGENE, V6, P413; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WHITE JJ, 1991, GENOMICS, V11, P228, DOI 10.1016/0888-7543(91)90126-Y	44	77	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					781	785						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437862				2022-12-17	WOS:A1993KN00800031
J	LANZI, C; BORRELLO, MG; BONGARZONE, I; MIGLIAZZA, A; FUSCO, A; GRIECO, M; SANTORO, M; GAMBETTA, RA; ZUNINO, F; DELLAPORTA, G; PIEROTTI, MA				LANZI, C; BORRELLO, MG; BONGARZONE, I; MIGLIAZZA, A; FUSCO, A; GRIECO, M; SANTORO, M; GAMBETTA, RA; ZUNINO, F; DELLAPORTA, G; PIEROTTI, MA			IDENTIFICATION OF THE PRODUCT OF 2 ONCOGENIC REARRANGED FORMS OF THE RET PROTOONCOGENE IN PAPILLARY THYROID CARCINOMAS	ONCOGENE			English	Article							TYROSINE KINASE; AFFINITY-CHROMATOGRAPHY; PHOSPHORYLATION; NEUROBLASTOMA; ACTIVATION; PROTEINS; PTC; PROTOONCOGENE; EXPRESSION; RECEPTOR	In papillary thyroid carcinomas, we have identified two tumor-specific rearrangements of the RET protooncogene leading to the formation of different transforming fusion products sharing the tyrosine kinase (tk) domain of the proto-oncogene and designated ptc-1 and ptc-2. We have analysed ptc-1 and ptc-2 products by immunoprecipitation with specific anti-RET antibodies followed by immunoblotting with the same reagent or with antibodies specific for phosphotyrosine (P-tyr) residues. The anti-RET antibodies were reactive with 64-kDa (p64ptc-1) and 81-kDa (p81ptc-2) proteins from lysates of ptc-1 and ptc-2 transformed cells, respectively, and identified two proteins of 140 kDa and 160 kDa from extracts of SK-N-SH, a neuroblastoma cell line previously shown to express two differently glycosylated forms of the normal RET product. The anti P-tyr antibodies, while detecting the same p64ptc-1 and p81ptc-2 proteins from ptc-1 and ptc-2 extracts, did not show any specific band in the neuroblastoma lysates. An additional set of experiments led us to conclude that, whereas the normal product of the RET proto-oncogene is a membrane-associated receptor-like molecule not intrinsically phosphorylated on tyrosine, both oncogenic forms of RET, ptc-1 and ptc-2, are constitutively phosphorylated on tyrosine, display an 'in vitro' autophosphorylation activity, are translocated from the membrane to the cytoplasm and are apparently unaffected by protein kinase C modulation.	IST NAZL TUMORI, DIV ONCOL SPERIMENTALE B, VIA G VENEZIAN 1, I-20133 MILAN, ITALY; NAPLES UNIV, DIPARTIMENTO BIOL PATOL CELLULARE & MOLEC, CNR, I-80134 NAPLES, ITALY; IST NAZL TUMORI, DIV ONCOL SPERIMENTALE A, I-20133 MILAN, ITALY; UNIV REGGIO CALABRIA, FAC MED & CHIRURG CATANZARO, DIPARTIMENTO MED SPERIMENTALE & CLIN, CALABRIA, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Fondazione IRCCS Istituto Nazionale Tumori Milan; Universita Mediterranea di Reggio Calabria			Borrello, Maria Grazia/C-3161-2017; Lanzi, Cinzia/J-6539-2016; Pierotti, Marco Alessandro/AAC-4728-2022; Bongarzone, Italia/B-9544-2017	Borrello, Maria Grazia/0000-0002-6854-2848; Lanzi, Cinzia/0000-0002-4480-9413; Pierotti, Marco Alessandro/0000-0002-7431-8332; Bongarzone, Italia/0000-0003-2530-9170; Fusco, Alfredo/0000-0003-3332-5197; Grieco, Michele/0000-0002-4212-7814				BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CIRILLO DM, 1986, MOL CELL BIOL, V6, P4641, DOI 10.1128/MCB.6.12.4641; DONGHI R, 1989, ONCOGENE, V4, P521; DUCLOS B, 1991, METHOD ENZYMOL B, V201, P10; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT M, 1978, BIOCHEMISTRY-US, V17, P915, DOI 10.1021/bi00598a027; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; SANTORO M, 1992, IN PRESS J CLIN INVE, V3; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SOZZI G, 1991, ONCOGENE, V6, P339; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588	29	77	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2189	2194						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437145				2022-12-17	WOS:A1992JW66500011
J	RAO, VN; REDDY, ESP				RAO, VN; REDDY, ESP			A DIVERGENT ETS-RELATED PROTEIN, ELK-1, RECOGNIZES SIMILAR C-ETS-1 PROTOONCOGENE TARGET SEQUENCES AND ACTS AS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							LONG TERMINAL REPEAT; AVIAN LEUKEMIA-VIRUS; DNA-BINDING; V-ETS; ERG GENE; C-ETS; CELLS; E26; TRANSLOCATION; LOCALIZATION	The ets oncogene superfamily consists of a family of sequence-specific DNA-binding proteins that activate transcription. We have previously identified two new members of the ets oncogene superfamily, namely elk-1 and elk-2. In this report we show that the recombinant elk-1 protein expressed in bacteria, like the c-ets-1 proto-oncogene, binds in a sequence-specific manner to Moloney murine sarcoma virus long terminal repeat, E74 target sequences and the PEA3 motif (polyoma enhancer), but does not bind to PU box sequences. Thus analysis of the DNA-binding specificity of ets-related proteins supports the view that different members show similar DNA-binding specificity, which is a general feature of the homeobox proteins. Our data using the chloramphenicol acetyltransferase gene linked to a thymidine kinase promoter containing multimers of the elk-1 target sequence indicates that elk-1 functions as a transcriptional activator. Interestingly, although elk-1 is the most divergent of all the members of the ets gene family, it shows very close similarities with c-ets-1 in some of its sequence-specific DNA-binding specificities. Here, we propose a new function for the elk-1 gene to act as a transcriptional activator of retroviruses and DNA tumor viruses.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DIAZ MO, 1986, SCIENCE, V231, P265, DOI 10.1126/science.3455787; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, IN PRESS ONCOGENE, V6; REDDY ESP, 1991, ERG ELK 1 ELK 2 GUID; REDDY ESP, 1990, CANCER RES, V50, P5013; Sambrook J., 1989, MOL CLONING LAB MANU; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK D, 1990, NATURE, V3346, P191; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	43	77	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					65	70						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741166				2022-12-17	WOS:A1992HC22700009
J	HANNINK, M; TEMIN, HM				HANNINK, M; TEMIN, HM			STRUCTURE AND AUTOREGULATION OF THE C-REL PROMOTER	ONCOGENE			English	Article							VIRUS STRAIN-T; AVIAN RETICULOENDOTHELIOSIS VIRUS; CHICKEN SPLEEN-CELLS; PROTO-ONCOGENE; MESSENGER-RNA; SUPPRESSES TRANSFORMATION; CELLULAR HOMOLOG; MAMMALIAN-CELLS; RECEPTOR GENE; GROWTH-FACTOR	Precise regulation of proto-oncogene expression appears to be essential for the proper growth and development of multi-cellular organisms. One aspect of this regulation is at the level of transcription from the proto-oncogene promoter(s). In order to characterize the promoter for the chicken c-rel proto-oncogene, we have isolated and sequenced genomic DNA containing the first exon of the chicken c-rel proto-oncogene. The c-rel promoter is structurally similar to the promoters of the so-called housekeeping genes, lacking the CAATT and TATA elements found in some cellular genes, but containing a G/C-rich box near the transcription start sites. There are multiple transcription start sites for the c-rel mRNA, which map near putative binding sites for the transcription factors HIP-1 and NF-kB. The c-rel promoter was functionally characterized by its ability to support expression of the firefly luciferase gene. The c-rel promoter is a relatively weak promoter, 100-times less active than the promoter within the spleen necrosis virus long terminal repeat (LTR). We have defined the c-rel promoter by analysis of a series of 5' deletion mutants of the c-rel promoter fused to the firefly luciferase gene. A DNA fragment containing 97 bp of 5' flanking sequence and 72 bp of 3' flanking sequence is sufficient for c-rel promoter function. Co-transfection of the c-rel promoter with a retroviral vector expressing the c-rel protein resulted in a decrease in expression from the minimal c-rel promoter. These results indicate that expression of the c-rel proto-oncogene is tightly regulated both at the level of basal promoter activity and by autoregulation of transcription by the c-rel protein.	UNIV WISCONSIN, MCARDLE LAB CANC RES, DEPT BIOCHEM, M121 MED SCI BLDG, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA-22443, CA-07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443, P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLARD DW, 1990, UNPUB; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN ISY, 1982, CELL, V31, P111, DOI 10.1016/0092-8674(82)90410-X; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; GELINAS C, 1988, ONCOGENE, V3, P349; GHOSH S, 1990, IN PRESS CELL; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALEY J, 1987, ONCOGENE RES, V1, P375; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIERAN M, 1990, IN PRESS CELL; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MORRISON LE, 1989, ONCOGENE, V4, P677; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STINSKI MF, 1985, J VIROL, V55, P431, DOI 10.1128/JVI.55.2.431-441.1985; THEILEN G, 1966, JNCI-J NATL CANCER I, V37, P747; TUNG HYL, 1988, P NATL ACAD SCI USA, V80, P6229; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984	55	77	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1990	5	12					1843	1850						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284104				2022-12-17	WOS:A1990ET43600016
J	RAZZAQUE, A				RAZZAQUE, A			ONCOGENIC POTENTIAL OF HUMAN HERPESVIRUS-6 DNA	ONCOGENE			English	Article											RAZZAQUE, A (corresponding author), US FDA,CBER,DIV VIROL,DNA VIRUS RES LAB,BETHESDA,MD 20892, USA.							ABLASHI DV, 1988, INT J CANCER, V42, P787, DOI 10.1002/ijc.2910420526; ABLASHI DV, 1988, J VIROL METHODS, V21, P29, DOI 10.1016/0166-0934(88)90050-X; ALBRECHT T, 1973, VIROLOGY, V55, P53, DOI 10.1016/S0042-6822(73)81007-4; CAMERON IR, 1985, J GEN VIROL, V66, P517, DOI 10.1099/0022-1317-66-3-517; DUFF R, 1971, NATURE-NEW BIOL, V233, P48, DOI 10.1038/newbio233048a0; DUFF R, 1973, J VIROL, V12, P209, DOI 10.1128/JVI.12.2.209-217.1973; EFSTATHIOU S, 1988, LANCET, V1, P8575; ELBEIK T, 1986, J VIROL, V60, P645, DOI 10.1128/JVI.60.2.645-652.1986; GALLOWAY DA, 1984, P NATL ACAD SCI-BIOL, V81, P4736, DOI 10.1073/pnas.81.15.4736; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; GALLOWAY DA, 1981, J VIROL, V38, P749, DOI 10.1128/JVI.38.2.749-760.1981; GALLOWAY DA, 1986, CANCER CELL, V4, P355; GEDER L, 1976, SCIENCE, V192, P1134, DOI 10.1126/science.179143; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JARRETT RF, 1988, LEUKEMIA, V2, P496; JOSEPHS SF, 1988, LEUKEMIA, V2, P132; JOSEPHS SF, 1986, SCIENCE, V234, P601, DOI 10.1126/science.3020691; JOSEPHS SF, 1988, J VIROL METHODS, V21, P179, DOI 10.1016/0166-0934(88)90064-X; KISHI M, 1988, J VIROL, V62, P4824, DOI 10.1128/JVI.62.12.4824-4827.1988; LOPEZ C, 1988, J INFECT DIS, V157, P1271, DOI 10.1093/infdis/157.6.1271; LUMBARDI L, 1987, CELL, V49, P161; LUSSO P, 1987, LANCET, V2, P743; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MACNAB JCM, 1987, J GEN VIROL, V68, P2525, DOI 10.1099/0022-1317-68-10-2525; MILLER G, 1971, P SOC EXP BIOL MED, V137, P1459; NELSON JA, 1984, J VIROL, V49, P109, DOI 10.1128/JVI.49.1.109-115.1984; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; RAZZAQUE A, 1988, P NATL ACAD SCI USA, V85, P5709, DOI 10.1073/pnas.85.15.5709; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPECTOR SA, 1985, CLIN CHEM, V31, P1514; TEDDER RS, 1987, LANCET, V2, P390; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; YAMANISHI K, 1988, LANCET, V1, P1065; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	36	77	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1365	1370						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2170897				2022-12-17	WOS:A1990EC24100013
J	ACKRILL, AM; BLAIR, GE				ACKRILL, AM; BLAIR, GE			REGULATION OF MAJOR HISTOCOMPATIBILITY CLASS-I GENE-EXPRESSION AT THE LEVEL OF TRANSCRIPTION IN HIGHLY ONCOGENIC ADENOVIRUS TRANSFORMED RAT-CELLS	ONCOGENE			English	Article									UNIV LEEDS, DEPT BIOCHEM, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds			Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795				ANTONIOU M, 1986, HUMAN GENETIC DISEAS, P65; BERNARDS R, 1987, TRENDS GENET, V3, P298, DOI 10.1016/0168-9525(87)90272-1; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BRICKELL PM, 1985, NATURE, V316, P162, DOI 10.1038/316162a0; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; GRAND RJA, 1987, INT J CANCER, V40, P213, DOI 10.1002/ijc.2910400215; HAMMERLING GJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P245, DOI 10.1016/0304-419X(87)90008-4; HARWOOD LMJ, 1975, INT J CANCER, V16, P498, DOI 10.1002/ijc.2910160317; HAYASHI H, 1985, CELL, V43, P263, DOI 10.1016/0092-8674(85)90031-5; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KUSHTAI G, 1988, ONCOGENE, V2, P119; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MANIATIS T, 1982, MOL CLONING LABORATO; Mellor A L, 1986, Oxf Surv Eukaryot Genes, V3, P95; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; RASKA K, 1980, INT J CANCER, V26, P79, DOI 10.1002/ijc.2910260113; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Roeder R.G., 1976, RNA POLYMERASE, P285; ROSA IM, 1986, INTERFERON, V7, P47; SAWADA Y, 1985, VIROLOGY, V147, P413, DOI 10.1016/0042-6822(85)90143-6; SAWADA Y, 1986, J EXP MED, V163, P563, DOI 10.1084/jem.163.3.563; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; TANAKA K, 1986, P NATL ACAD SCI USA, V83, P8723, DOI 10.1073/pnas.83.22.8723; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VAESSEN RTMJ, 1987, SCIENCE, V235, P1486, DOI 10.1126/science.3823900; VANDERMEIDE PH, 1986, J GEN VIROL, V67, P1059, DOI 10.1099/0022-1317-67-6-1059; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WEISS E, 1983, EMBO J, V2, P453, DOI 10.1002/j.1460-2075.1983.tb01444.x; ZAIDELBLAIR ME, 1981, NUCLEIC ACIDS RES, V9, P4547, DOI 10.1093/nar/9.18.4547	39	77	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1988	3	4					483	487						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2484015				2022-12-17	WOS:A1988Q773900019
J	WATSON, RJ				WATSON, RJ			A TRANSCRIPTIONAL ARREST MECHANISM INVOLVED IN CONTROLLING CONSTITUTIVE LEVELS OF MOUSE C-MYB MESSENGER-RNA	ONCOGENE			English	Article											WATSON, RJ (corresponding author), ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND LABS,DOMINION HOUSE,BARTHOLOMEW CLOSE,LONDON EC1A 7BE,ENGLAND.							BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BISHOP JM, 1985, MOL BIOL TUMOR VIR 4, P351; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; CRAIG RW, 1984, CANCER RES, V44, P442; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PAUZA CD, 1987, MOL CELL BIOL, V7, P342, DOI 10.1128/MCB.7.1.342; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SPANDIDOS DA, 1982, EMBO J, V1, P15, DOI 10.1002/j.1460-2075.1982.tb01117.x; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194	33	77	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					267	272						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281094				2022-12-17	WOS:A1988M593100009
J	Yang, B; Feng, XD; Liu, H; Tong, RL; Wu, JB; Li, CB; Yu, HX; Chen, YH; Cheng, QY; Chen, JR; Cai, XL; Wu, WX; Lu, YJ; Hu, JT; Liang, KJ; Lv, Z; Wu, J; Zheng, SS				Yang, Beng; Feng, Xiaode; Liu, Hua; Tong, Rongliang; Wu, Jingbang; Li, Changbiao; Yu, Hanxi; Chen, Yunhao; Cheng, Qiyang; Chen, Junru; Cai, Xianlei; Wu, Wenxuan; Lu, Yuejie; Hu, Jiating; Liang, Kejiong; Lv, Zhen; Wu, Jian; Zheng, Shusen			High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULATING TUMOR-CELLS; EXTRACELLULAR VESICLES; EVOLUTIONARY; GENETICS; ROLES; EXPRESSION; BIOLOGY	Exosomes play an important role in intercellular communication and metastatic progression of hepatocellular carcinoma (HCC). However, cellular communication between heterogeneous HCC cells with different metastatic potentials and the resultant cancer progression are not fully understood in HCC. Here, HCC cells with high-metastatic capacity (97hm and Huhm) were constructed by continually exerting selective pressure on primary HCC cells (MHCC-97H and Huh7). Through performing exosomal miRNA sequencing in HCC cells with different metastatic potentials (MHCC-97H and 97hm), many significantly different miRNA candidates were found. Among these miRNAs, miR-92a-3p was the most abundant miRNA in the exosomes of highly metastatic HCC cells. Exosomal miR92a-3p was also found enriched in the plasma of HCC patient-derived xenograft mice (PDX) model with high-metastatic potential. Exosomal miR-92a-3p promotes epithelial-mesenchymal transition (EMT) in recipient cancer cells via targeting PTEN and regulating its downstream Akt/Snail signaling. Furthermore, through mRNA sequencing in HCC cells with different metastatic potentials and predicting potential transcription factors of miR92a-3p, upregulated transcript factors E2F1 and c-Myc were found in high-metastatic HCC cells promote the expression of cellular and exosomal miR-92a-3p in HCC by directly binding the promoter of its host gene,miR17HG. Clinical data showed that a high plasma exosomal miR92a-3p level was correlated with shortened overall survival and disease-free survival, indicating poor prognosis in HCC patients. In conclusion, hepatoma-derived exosomal miR92a-3p plays a critical role in the EMT progression and promoting metastasis by inhibiting PTEN and activating Akt/Snail signaling. Exosomal miR92a-3p is a potential predictive biomarker for HCC metastasis, and this may provoke the development of novel therapeutic and preventing strategies against metastasis of HCC.	[Yang, Beng; Feng, Xiaode; Liu, Hua; Tong, Rongliang; Wu, Jingbang; Li, Changbiao; Chen, Yunhao; Cheng, Qiyang; Chen, Junru; Cai, Xianlei; Wu, Wenxuan; Lu, Yuejie; Hu, Jiating; Lv, Zhen; Wu, Jian; Zheng, Shusen] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Div Hepatobiliary & Pancreat Surg,Dept Surg, Hangzhou, Zhejiang, Peoples R China; [Yang, Beng; Liu, Hua; Cheng, Qiyang; Wu, Jian; Zheng, Shusen] NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Zhejiang, Peoples R China; [Yang, Beng; Chen, Junru; Wu, Jian; Zheng, Shusen] CAMS, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Zhejiang, Peoples R China; [Yang, Beng; Chen, Yunhao; Wu, Jian; Zheng, Shusen] Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China; [Yu, Hanxi] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gynecol & Obstet, Hangzhou, Zhejiang, Peoples R China; [Liang, Kejiong] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Orthoped, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Zhejiang University	Wu, J; Zheng, SS (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Div Hepatobiliary & Pancreat Surg,Dept Surg, Hangzhou, Zhejiang, Peoples R China.; Wu, J; Zheng, SS (corresponding author), NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Zhejiang, Peoples R China.; Wu, J; Zheng, SS (corresponding author), CAMS, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Zhejiang, Peoples R China.; Wu, J; Zheng, SS (corresponding author), Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China.	drwujian@zju.edu.cn; shusenzheng@zju.edu.cn	Yang, Beng/GRX-9557-2022		Innovative Research Groups of National Natural Science Foundation of China [81721091]; Major program of National Natural Science Foundation of China [91542205]; National Natural Science Foundation of China [81874228]; National ST Major Project [2017ZX10203205]; Zhejiang International Science and Technology Cooperation Project [2016C04003]; Natural Science Foundation of Zhejiang Province [LQ20H160037, LQ18H160011]	Innovative Research Groups of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National ST Major Project; Zhejiang International Science and Technology Cooperation Project; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This work was supported by Innovative Research Groups of National Natural Science Foundation of China (No. 81721091), Major program of National Natural Science Foundation of China (No. 91542205), the National Natural Science Foundation of China (No. 81874228), National S&T Major Project (No. 2017ZX10203205) and Zhejiang International Science and Technology Cooperation Project (No. 2016C04003), Natural Science Foundation of Zhejiang Province (LQ20H160037, LQ18H160011).	Alix-Panabieres C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483; Andela VB, 2003, CLIN ORTHOP RELAT R, pS75, DOI 10.1097/01.blo.0000093048.96273.aa; [Anonymous], 2019, J ASIAN NAT PROD RES; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Casadei L, 2017, CANCER RES, V77, P3846, DOI 10.1158/0008-5472.CAN-16-2984; Chen JA, 2019, HEPATOB PANCREAT DIS, V18, P321, DOI 10.1016/j.hbpd.2018.09.016; Crespi B, 2005, TRENDS ECOL EVOL, V20, P545, DOI 10.1016/j.tree.2005.07.007; Crichton MB, 1996, MOL CELL ENDOCRINOL, V118, P215, DOI 10.1016/0303-7207(96)03761-6; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Dudas J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00044; Fang JH, 2018, HEPATOLOGY, V68, P1459, DOI 10.1002/hep.29920; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Finn RS, 2018, HEPATOLOGY, V67, P422, DOI 10.1002/hep.29486; Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Lakkaraju A, 2008, TRENDS CELL BIOL, V18, P199, DOI 10.1016/j.tcb.2008.03.002; Lehmann BD, 2008, CANCER RES, V68, P7864, DOI 10.1158/0008-5472.CAN-07-6538; Lynch M, 2016, NAT REV GENET, V17, P704, DOI 10.1038/nrg.2016.104; Makohon-Moore A, 2016, NAT REV CANCER, V16, P553, DOI 10.1038/nrc.2016.66; Martincorena I, 2018, CELL, V173, P1823, DOI 10.1016/j.cell.2018.06.001; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Moi L, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2086-x; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Reiter JG, 2019, NAT REV CANCER, V19, P639, DOI 10.1038/s41568-019-0185-x; Singal AG, 2015, CLIN GASTROENTEROL H, V13, P2140, DOI 10.1016/j.cgh.2015.08.014; Song H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111799; Strilic B, 2017, CANCER CELL, V32, P282, DOI 10.1016/j.ccell.2017.07.001; Tang J, 2018, MINERVA MED, V109, P15, DOI 10.23736/S0026-4806.17.05167-9; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; Uchino K, 2011, CANCER-AM CANCER SOC, V117, P4475, DOI 10.1002/cncr.25960; Wan ZH, 2019, HEPATOB PANCREAT DIS, V18, P525, DOI 10.1016/j.hbpd.2019.09.005; Wang HW, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/864894; Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841; Weng XY, 2019, EBIOMEDICINE, V44, P225, DOI 10.1016/j.ebiom.2019.05.029; Xue XF, 2018, BIOCHEM BIOPH RES CO, V502, P515, DOI 10.1016/j.bbrc.2018.05.208; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Yang B, 2019, J MATER CHEM B, V7, P6476, DOI 10.1039/c9tb01299k; Yang B, 2018, INT J ONCOL, V52, P1235, DOI 10.3892/ijo.2018.4292; Yin ZY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0782-x; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Zhang G, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0829-6; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376	50	76	77	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6529	6543		10.1038/s41388-020-01450-5	http://dx.doi.org/10.1038/s41388-020-01450-5		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32917956	Green Published, hybrid			2022-12-17	WOS:000568475200001
J	Han, Y; Kim, B; Cho, U; Park, IS; Kim, SI; Dhanasekaran, DN; Tsang, BK; Song, YS				Han, Youngjin; Kim, Boyun; Cho, Untack; Park, In Sil; Kim, Se Ik; Dhanasekaran, Danny N.; Tsang, Benjamin K.; Song, Yong Sang			Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells	ONCOGENE			English	Article							INDUCED MIGRATION; DYNAMICS; DRP1; PHOSPHORYLATION; METASTASIS; SURVIVAL; P53; TRAFFICKING; STRESS; FUSION	Mitochondria undergo fission and fusion continually for survival through the course of cellular adaption processes in response to changes in the surrounding environment. Dysregulated mitochondria' dynamics has been reported in various diseases including cancer. Under hypoxic conditions (<1% O-2), the relationship between mitochondrial dynamics and sensitivity to cisplatin (CDDP) was examined in ovarian cancer cells. We found that hypoxia promoted mitochondria' fission and CDDP resistance in ovarian cancer cells. Hypoxia-induced reactive oxygen species (ROS) caused an increase in mitochondrial fission, a response abolished by free radical scavenging with N-acetylcysteine (NAC) and Trolox. Also, treatment of hydrogen peroxide (H2O2) decreased inhibitory p-Drp1 (Ser637) content and increased mitochondrial fission. Suppression of mitochondrial fission enhanced the CDDP sensitivity of hypoxic ovarian cancer cells. Lastly, in tumor spheroids from malignant ascites or tissues of patients with advanced-stage ovarian cancer, pretreatment with Mdivi-1 increased the CDDP sensitivity. Taken together, our results implicate that hypoxia-induced ROS trigger mitochondrial fission and CDDP resistance through downregulation of p-Drpl (Ser637) and Mfn1 in ovarian cancer cells. Inhibition of Drp1 by Mdivi-1 treatment or si-Drpl transfection increased CDDP sensitivity of ovarian cancer cells under hypoxia. Therefore, mitochondrial dynamics of cancer cells adapting to the hypoxic tumor microenvironment could be a potential target for anticancer therapy.	[Han, Youngjin; Song, Yong Sang] Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat, Seoul 08826, South Korea; [Han, Youngjin; Kim, Boyun; Cho, Untack; Park, In Sil; Song, Yong Sang] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea; [Kim, Boyun] Univ Texas Hlth Sci Ctr Houston, Dept Anesthesiol, McGovern Med Sch, Houston, TX 77030 USA; [Cho, Untack; Song, Yong Sang] Seoul Natl Univ, Interdisciplinary Program Canc Biol, Seoul 03080, South Korea; [Park, In Sil] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea; [Kim, Se Ik; Song, Yong Sang] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 03080, South Korea; [Dhanasekaran, Danny N.] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK 73012 USA; [Tsang, Benjamin K.] Univ Ottawa, Dept Obstet & Gynecol, Ottawa, ON K1H 8L6, Canada; [Tsang, Benjamin K.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; [Tsang, Benjamin K.] Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON K1H 8L6, Canada; [Tsang, Benjamin K.] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau Inst Appl Res Med & Hlth, Macau, Peoples R China	Seoul National University (SNU); Seoul National University (SNU); University of Texas System; University of Texas Health Science Center Houston; Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Macau University of Science & Technology	Song, YS (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, WCU Biomodulat, Seoul 08826, South Korea.; Song, YS (corresponding author), Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 03080, South Korea.; Song, YS (corresponding author), Seoul Natl Univ, Interdisciplinary Program Canc Biol, Seoul 03080, South Korea.; Song, YS (corresponding author), Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 03080, South Korea.	yssong@snu.ac.kr		Han, Youngjin/0000-0002-3778-2056; SONG, YONGSANG/0000-0001-7115-4021; Kim, Se Ik/0000-0002-9790-6735	BK21 Plus Program of the Department of Agricultural Biotechnology, Seoul National University (Seoul, Korea); Korea Health Technology R&D Project through the Korea Health Industry Development R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI16C2037]; Seoul National University Hospital (SNUH) research fund [04-2017-0530]; Canadian Institutes of Health Research [MOP-126144]	BK21 Plus Program of the Department of Agricultural Biotechnology, Seoul National University (Seoul, Korea); Korea Health Technology R&D Project through the Korea Health Industry Development R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; Seoul National University Hospital (SNUH) research fund; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This research was supported by the BK21 Plus Program of the Department of Agricultural Biotechnology, Seoul National University (Seoul, Korea), a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number HI16C2037], and Seoul National University Hospital (SNUH) research fund [grant number 04-2017-0530], as well as a grant from the Canadian Institutes of Health Research [grant number MOP-126144]. Also, we would like to thank Prof. Woo Ho Kim (Seoul National University, Republic of Korea) and his lab members for technical assistance in this study.	Akbarzadeh M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16940-y; Altieri DC, 2017, BRIT J CANCER, V117, P301, DOI 10.1038/bjc.2017.201; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Braicu EI, 2014, ONCOTARGETS THER, V7, P1563, DOI 10.2147/OTT.S65373; Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112; Capriglione S, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1026-y; Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582-4934.2011.01258.x; Casciello F, 2017, P NATL ACAD SCI USA, V114, P7077, DOI 10.1073/pnas.1618706114; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Chen Y, 2012, INT J MOL SCI, V13, P13264, DOI 10.3390/ijms131013264; Cheng CT, 2016, CANCER RES, V76, P5006, DOI 10.1158/0008-5472.CAN-15-2921; Cho U, 2018, MOL CARCINOGEN, V57, P235, DOI 10.1002/mc.22750; Coburn SB, 2017, INT J CANCER, V140, P2451, DOI 10.1002/ijc.30676; Cocola C, 2017, J CELL BIOCHEM, V118, P570, DOI 10.1002/jcb.25737; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Farrand L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074008; Ferree A, 2012, ADV EXP MED BIOL, V748, P13, DOI 10.1007/978-1-4614-3573-0_2; Ferreira-da-Silva A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122308; Girda E, 2017, INT J GYNECOL CANCER, V27, P1701, DOI 10.1097/IGC.0000000000001061; Gjorevski N, 2016, NATURE, V539, P359, DOI 10.1038/nature20168; Han XJ, 2015, INT J ONCOL, V46, P691, DOI 10.3892/ijo.2014.2781; Han Y, 2018, FREE RADICAL RES, V52, P1271, DOI 10.1080/10715762.2018.1459594; Hong YH, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00167; Humpton TJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026146; Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006; Jabs J, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20177697; Kang J, 2018, CANCER RES, V78, P1184, DOI 10.1158/0008-5472.CAN-17-2506; Kim B, 2013, AM J PHYSIOL-REG I, V305, pR927, DOI 10.1152/ajpregu.00502.2012; Kim B, 2017, ONCOTARGET, V8, P60299, DOI 10.18632/oncotarget.19140; Kim B, 2017, CANCER RES TREAT, V49, P338, DOI 10.4143/crt.2016.175; Kim S, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0063-0; Kim S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31097-y; Kong B, 2015, ANN NY ACAD SCI, V1350, P1, DOI 10.1111/nyas.12883; Lee JH, 2012, J BIOL CHEM, V287, P20898, DOI 10.1074/jbc.M111.336875; Lee JY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1077-4; Li PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22831; Matz M, 2017, GYNECOL ONCOL, V144, P396, DOI 10.1016/j.ygyno.2016.11.019; Oettinghaus B, 2016, BBA-BIOENERGETICS, V1857, P1267, DOI 10.1016/j.bbabio.2016.03.016; Otera H, 2016, J CELL BIOL, V212, P531, DOI 10.1083/jcb.201508099; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Park HK, 2017, CANCER EPIDEM BIOMAR, V26, P1511, DOI 10.1158/1055-9965.EPI-17-0290; Parone PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003257; Pletjushkina OY, 2006, BBA-BIOENERGETICS, V1757, P518, DOI 10.1016/j.bbabio.2006.03.018; Ren YA, 2016, CANCER RES, V76, P2206, DOI 10.1158/0008-5472.CAN-15-1046; Seo JA, 2016, CANCER LETT, V371, P30, DOI 10.1016/j.canlet.2015.11.021; Shen YL, 2018, INT J MOL MED, V41, P2317, DOI 10.3892/ijmm.2018.3385; Soragni A, 2016, CANCER CELL, V29, P90, DOI 10.1016/j.ccell.2015.12.002; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Turco MY, 2017, NAT CELL BIOL, V19, P568, DOI 10.1038/ncb3516; Wan YY, 2014, ONCOL REP, V32, P619, DOI 10.3892/or.2014.3235; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Xu SC, 2016, J PINEAL RES, V60, P291, DOI 10.1111/jpi.12310; Zhang D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197266	53	76	77	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7089	7105		10.1038/s41388-019-0949-5	http://dx.doi.org/10.1038/s41388-019-0949-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409904				2022-12-17	WOS:000495878400005
J	Dou, CW; Zhou, ZY; Xu, QR; Liu, ZK; Zeng, YQ; Wang, YF; Li, Q; Wang, L; Yang, W; Liu, QG; Tu, KS				Dou, Changwei; Zhou, Zhenyu; Xu, Qiuran; Liu, Zhikui; Zeng, Yuqun; Wang, Yufeng; Li, Qing; Wang, Liang; Yang, Wei; Liu, Qingguang; Tu, Kangsheng			Hypoxia-induced TUFT1 promotes the growth and metastasis of hepatocellular carcinoma by activating the Ca2+/PI3K/AKT pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR HYPOXIA; CANCER CELLS; EXPRESSION; TUFTELIN; INDUCTION; PROTEIN; GENE; RESISTANCE; HALLMARKS	Tuftelin1 (TUFT1), an acidic protein constituent of developing and mineralizing tooth tissues, is regulated by hypoxia and the Hedgehog signaling pathway. We investigated the role of TUFT1 in hepatocellular carcinoma (HCC). qRT-PCR, immunohistochemistry and western blot were employed to evaluate TUFT1 level in HCC. MTT, BrdU, 3D culture and Transwell assays were used to assess cell viability, proliferation, in vitro growth, migration, and invasion. Subcutaneous and tail vein injection models were established to investigate in vivo growth and metastasis. Chromatin immunoprecipitation was performed to assess binding of hypoxia-inducible factor 1 alpha (HIF-1 alpha) to TUFT1 promoter. A microRNA array was used to identify hypoxia-related microRNAs. TUFT1 was elevated in HCC, and correlated with unfavorable clinicopathologic characteristics and poor survival. TUFT1 promoted HCC cell growth, metastasis and epithelial-mesenchymal transition in vitro and in vivo via activation of Ca2+/PI3K/AKT pathway. Hypoxia induced TUFT1 expression in an HIF-1 alpha dependent manner, and TUFT1 expression was positively correlated with HIF-1a level in HCC tissues. Hypoxiaenhanced TUFT1 expression by downregulating miR-671-5p rather than by directly promoting the binding of HIF-1 alpha to TUFT1 promoter. MiR-671-5p interacted with the 3'-UTR of TUFT1 mRNA and subsequently inhibited TUFT1 expression. Consequently, knockdown of TUFT1 blocked the effects of hypoxia in promoting HCC progression. TUFT1 promoted the growth, metastasis and EMT of HCC cells through activating Ca2+/PI3K/AKT pathway. The hypoxic microenvironment increased the expression of TUFT1 via downregulation of miR-671-5p. TUFT1 may function as a potential therapeutic target for the intervention and treatment of HCC.	[Dou, Changwei; Liu, Zhikui; Wang, Yufeng; Li, Qing; Wang, Liang; Yang, Wei; Liu, Qingguang; Tu, Kangsheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian 710061, Shaanxi, Peoples R China; [Dou, Changwei] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Hepatopancreatobiliary Surg & Minimally Inva, Hangzhou, Zhejiang, Peoples R China; [Zhou, Zhenyu] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 510120, Guangdong, Peoples R China; [Xu, Qiuran] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Key Lab Tumor Mol Diag & Individualized Med Zheji, Hangzhou 310014, Zhejiang, Peoples R China; [Zeng, Yuqun] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Nephrol, Hangzhou 310014, Zhejiang, Peoples R China	Xi'an Jiaotong University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Sun Yat Sen University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Hangzhou Medical College; Zhejiang Provincial People's Hospital	Liu, QG; Tu, KS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian 710061, Shaanxi, Peoples R China.	liuqingguang@vip.sina.com; tks0912@foxmail.com	dou, dou/ABB-4731-2020	Xu, Qiuran/0000-0003-2171-9279; Tu, Kangsheng/0000-0002-0032-1459; Zhou, Zhenyu/0000-0002-7934-4425	National Natural Science Foundation of China [81874049, 81773123, 81572847, 81502092]; Innovation Capacity Support Plan in Shaanxi Province of China [2018KJXX-045]; Fundamental Research Funds for the Central Universities [7N010011015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Capacity Support Plan in Shaanxi Province of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This study was supported by grants from the National Natural Science Foundation of China (81874049, 81773123, 81572847, 81502092); Innovation Capacity Support Plan in Shaanxi Province of China (2018KJXX-045); the Fundamental Research Funds for the Central Universities (7N010011015).	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Carnero A, 2016, BIOESSAYS, V38, pS65, DOI 10.1002/bies.201670911; Chang YN, 2016, GENE, V575, P1, DOI 10.1016/j.gene.2015.08.049; Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003; Davis FM, 2014, ONCOGENE, V33, P2307, DOI 10.1038/onc.2013.187; Deutsch D, 1998, EUR J ORAL SCI, V106, P315, DOI 10.1111/j.1600-0722.1998.tb02192.x; DEUTSCH D, 1995, INT J DEV BIOL, V39, P135; Dou CW, 2016, CANCER LETT, V381, P380, DOI 10.1016/j.canlet.2016.08.011; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Giatromanolaki A, 2001, ANTICANCER RES, V21, P4317; Gwak GY, 2005, J HEPATOL, V42, P358, DOI 10.1016/j.jhep.2004.11.020; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Jubb A, 2005, J CLIN PATHOL, V58, P1344; Kawasaki N, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-017-0001-2; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Leiser Y, 2007, ANAT REC, V290, P449, DOI 10.1002/ar.20512; Leiser Y, 2011, J CELL PHYSIOL, V226, P165, DOI 10.1002/jcp.22318; Li XH, 2012, ONCOL REP, V28, P77, DOI 10.3892/or.2012.1769; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Mao ZK, 2001, GENE, V279, P181, DOI 10.1016/S0378-1119(01)00749-1; Meng H, 2015, AM J CANCER RES, V5, P1062; Oliveira FS, 2012, J CELL BIOCHEM, V113, P204, DOI 10.1002/jcb.23345; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Sliz E, 2017, TUFT1 NOVEL CANDIDAT, V12; Sliz E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175474; Soni S, 2017, ACTA ONCOL, V56, P503, DOI 10.1080/0284186X.2017.1301680; Tan XH, 2016, ONCOTARGET, V7, P293, DOI 10.18632/oncotarget.6344; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wen L, 2016, SCI REP-UK, V6, DOI 10.1038/srep23269; Wu XZ, 2007, J GASTROEN HEPATOL, V22, P1178, DOI 10.1111/j.1440-1746.2007.04997.x; Xu S, 2016, CELL CYCLE, V15, P2920, DOI 10.1080/15384101.2016.1224043; Zhang YH, 2017, LAB INVEST, V97, P53, DOI 10.1038/labinvest.2016.127; Zheng X, 2013, ONCOL REP, V30, P2020, DOI 10.3892/or.2013.2690; Zheng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049581; Zhou B, 2016, CANCER LETT, V382, P11, DOI 10.1016/j.canlet.2016.08.017	45	76	82	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1239	1255		10.1038/s41388-018-0505-8	http://dx.doi.org/10.1038/s41388-018-0505-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30250300				2022-12-17	WOS:000459249800007
J	Chen, XW; Yu, TJ; Zhang, J; Li, Y; Chen, HL; Yang, GF; Yu, W; Liu, YZ; Liu, XX; Duan, CF; Tang, HL; Qiu, M; Wang, CL; Zheng, H; Yue, J; Guo, AM; Yang, J				Chen, X. W.; Yu, T. J.; Zhang, J.; Li, Y.; Chen, H. L.; Yang, G. F.; Yu, W.; Liu, Y. Z.; Liu, X. X.; Duan, C. F.; Tang, H. L.; Qiu, M.; Wang, C. L.; Zheng, H.; Yue, J.; Guo, A. M.; Yang, J.			CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis	ONCOGENE			English	Article							MARROW-DERIVED CELLS; PREMETASTATIC NICHE; CANCER METASTASIS; LUNG METASTASIS; POLARIZATION; RECRUITMENT; GROWTH; ACTIVATION; ENZYMES; MATRIX-METALLOPROTEINASE-9	Tumor-associated macrophages (TAMs) play an essential role in metastasis. However, what enables TAMs to have a superior capacity to establish pre-metastatic microenvironment in distant organs is unclear. Here we have begun to uncover the effects of cytochrome P450 (CYP) 4A in TAMs on lung pre-metastatic niche formation and metastasis. CYP4A(+) TAM infiltration was positively associated with metastasis, pre-metastatic niche formation and poor prognosis in breast cancer patients. The pharmacological inhibition of CYP4A reduced lung pre-metastatic niche formation (evidenced by a decrease in vascular endothelial growth factor receptor 1 positive (VEGFR1(+)) myeloid cell recruitment and pro-metastatic protein expression) and metastatic burden, accompanied with TAM polarization away from the M2 phenotype in spontaneous metastasis models of 4T1 breast cancer and B16F10 melanoma. Co-implantation of 4T1 cells with CYP4A10(high) macrophages promoted lung pre-metastatic niche formation and metastasis. Depletion of TAMs disrupted lung pre-metastatic niches and thereby prevented metastasis. Treatment with the CM from CYP4A10(high) M2 macrophages (M2) increased pre-metastatic niche formation and metastatic burden in the lungs, whereas CYP4A inhibition attenuated these effects. In vitro TAM polarization away from the M2 phenotype induced by CYP4A inhibition decreased VEGFR1(+) myeloid cell migration and fibronectin expression, accompanied with downregulation of STAT3 signaling. Conversely, overexpression of CYP4A or exogenous addition of 2'-hydroxyeicosatetraenoic acid promoted M2 polarization and cytokine production of macrophages and thereby enhanced migration of VEGFR1(+) myeloid cells, which were reversed by siRNA or pharmacological inhibition of STAT3. Importantly, a combined blocking M2 macrophage-derived factors TGF-beta, VEGF and SDF-1 abolished VEGFR1(+) myeloid cell migration and fibroblast activation induced by CYP4A. In summary, CYP4A in TAMs is crucial for lung pre-metastatic niche formation and metastasis, and may serve as a potential therapeutic target in human cancer.	[Chen, X. W.; Yu, T. J.; Li, Y.; Liu, Y. Z.; Liu, X. X.; Duan, C. F.; Tang, H. L.; Qiu, M.; Wang, C. L.; Zheng, H.; Yue, J.; Yang, J.] Wuhan Univ, Sch Basic Med Sci, Dept Pharmacol, Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Zhang, J.] Wuhan Univ, Anim Expt Ctr, Wuhan, Hubei, Peoples R China; [Chen, H. L.] Wuhan Univ, Sch Basic Med Sci, Dept Pathol & Pathophysiol, Wuhan, Hubei, Peoples R China; [Yang, G. F.] Wuhan Univ, Zhongnan Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China; [Yu, W.] China Three Gorges Univ, Dept Oncol, Coll Clin Med 1, Yichang, Peoples R China; [Guo, A. M.] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA	Wuhan University; Wuhan University; Wuhan University; Wuhan University; China Three Gorges University; New York Medical College	Yang, J (corresponding author), Wuhan Univ, Sch Basic Med Sci, Dept Pharmacol, Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	yangjingliu2013@163.com		yang, jing/0000-0003-2733-8629	National Natural Science Foundation of China [30973552, 81272464, 81173089, 81402958, 81201261]; Fundamental Research Funds for the Central Universities [2014301020201]; Hubei Key Laboratory of Medical Information Analysis & Tumor Diagnosis and Treatment [PJS140011508]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Hubei Key Laboratory of Medical Information Analysis & Tumor Diagnosis and Treatment	This work was supported by the National Natural Science Foundation of China (grant nos 30973552, 81272464, 81173089 (to JY), 81402958 (to WY) and 81201261 (to JZ)), the Fundamental Research Funds for the Central Universities (grant no. 2014301020201) (to XC) and Hubei Key Laboratory of Medical Information Analysis & Tumor Diagnosis and Treatment (PJS140011508) (to CW).	Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008-5472.CAN-05-2502; Alexanian A, 2013, ONCOTARGETS THER, V6, P243, DOI 10.2147/OTT.S31586; Alexanian A, 2012, CANCER GENOM PROTEOM, V9, P163; Borin TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116247; Chen PW, 2013, INT REV CEL MOL BIO, V301, P1, DOI 10.1016/B978-0-12-407704-1.00001-4; Chen YK, 2015, ONCOTARGET, V6, P32575, DOI 10.18632/oncotarget.5331; Cirri P, 2011, AM J CANCER RES, V1, P482; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Dayer C, 2015, J BIOL CHEM, V290, P13763, DOI 10.1074/jbc.M114.622274; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Ding L, 2015, ONCOTARGET, V6, P36441, DOI 10.18632/oncotarget.5541; Edson KZ, 2013, CURR TOP MED CHEM, V13, P1429; Fang WY, 2014, CARCINOGENESIS, V35, P1780, DOI 10.1093/carcin/bgu060; Gil-Bernabe AM, 2012, BLOOD, V119, P3164, DOI 10.1182/blood-2011-08-376426; Giles AJ, 2016, CANCER RES, V76, P1335, DOI 10.1158/0008-5472.CAN-15-0204; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Jia XM, 2014, BREAST CANCER RES TR, V148, P291, DOI 10.1007/s10549-014-3164-7; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kroetz DL, 2005, ANNU REV PHARMACOL, V45, P413, DOI 10.1146/annurev.pharmtox.45.120403.100045; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Pal SK, 2015, MOL CANCER THER, V14, P2896, DOI 10.1158/1535-7163.MCT-15-0367; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Sharma SK, 2015, J IMMUNOL, V194, P5529, DOI 10.4049/jimmunol.1403215; Sun QZ, 2016, CELL SIGNAL, V28, P307, DOI 10.1016/j.cellsig.2016.01.004; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wei J, 2015, J SURG RES, V197, P126, DOI 10.1016/j.jss.2015.03.023; Wu CF, 2015, INT J CANCER, V137, P837, DOI 10.1002/ijc.29444; Yu W, 2011, CANCER CHEMOTH PHARM, V68, P619, DOI 10.1007/s00280-010-1521-8; Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078-0432.CCR-09-2904; Zhao HX, 2014, TOXICOL APPL PHARM, V279, P311, DOI 10.1016/j.taap.2014.07.001; Zheng H, 2014, TOXICOL APPL PHARM, V280, P10, DOI 10.1016/j.taap.2014.07.018	39	76	79	4	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5045	5057		10.1038/onc.2017.118	http://dx.doi.org/10.1038/onc.2017.118			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28481877	Green Published, hybrid			2022-12-17	WOS:000408768800009
J	Chen, F; Zhang, Y; Parra, E; Rodriguez, J; Behrens, C; Akbani, R; Lu, Y; Kurie, JM; Gibbons, DL; Mills, GB; Wistuba, II; Creighton, CJ				Chen, F.; Zhang, Y.; Parra, E.; Rodriguez, J.; Behrens, C.; Akbani, R.; Lu, Y.; Kurie, J. M.; Gibbons, D. L.; Mills, G. B.; Wistuba, I. I.; Creighton, C. J.			Multiplatform-based molecular subtypes of non-small-cell lung cancer	ONCOGENE			English	Article							GENE-EXPRESSION; CARCINOMA	Non-small-cell lung cancer (NSCLC) demonstrates remarkable molecular diversity. With the completion of The Cancer Genome Atlas (TCGA), there is opportunity for systematic analyses of the entire TCGA NSCLC cohort, including comparisons and contrasts between different disease subsets. On the basis of multidimensional and comprehensive molecular characterization (including DNA methylation and copy, and RNA and protein expression), 1023 NSCLC cases-519 from TCGA adenocarcinoma (AD) project and 504 from TCGA squamous cell carcinoma (SQCC) project-were classified using a 'cluster-of-clusters' analytic approach. Patterns from TCGA NSCLC subsets were examined in independent external databases, including the PROSPECT (Profiling of Resistance patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax) NSCLC data set. Nine genomic subtypes of NSCLC were identified, three within SQCC and six within AD. SQCC subtypes were associated with transcriptional targets of SOX2 or p63. One predominately AD subtype (with a large proportion of SQCC) shared molecular features with neuroendocrine tumors. Two AD subtypes manifested a CpG island methylator phenotype. Three AD subtypes showed high p38 and mTOR pathway activation. AD subtypes associated with low differentiation showed relatively worse prognosis. SQCC subtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes expressed several immune checkpoint genes including PDL1 and PDL2, corresponding with patterns of greater immune cell infiltration. Subtype associations for several immune-related markers -including PD1, PDL1, CD3 and CD8-were confirmed in the PROSPECT cohort using immunohistochemistry. NSCLC molecular subtypes have therapeutic implications and lend support to a personalized approach to NSCLC management based on molecular characterization.	[Chen, F.; Zhang, Y.; Creighton, C. J.] Baylor Coll Med, Div Biostat, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Parra, E.; Rodriguez, J.; Behrens, C.; Wistuba, I. I.] Univ Texas MD Anderson Canc, Dept Translat Mol Pathol, Houston, TX USA; [Akbani, R.; Creighton, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Kurie, J. M.; Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, Houston, TX 77030 USA; [Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, One Baylor Plaza MS305, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Creighton, CJ (corresponding author), Baylor Coll Med, Dept Med, One Baylor Plaza MS305, Houston, TX 77030 USA.	creighto@bcm.edu		Mills, Gordon/0000-0002-0144-9614	National Institutes of Health (NIH) [2R01CA125123-09]; MD Anderson's Institutional Tissue Bank Award [2P30CA016672]; University of Texas Lung Specialized Programs of Research Excellence grant [P50CA70907]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP120713, RP150405]; Department of Defense PROSPECT grant [W81XWH-07-1-0306]; NATIONAL CANCER INSTITUTE [P30CA125123, U24CA210950, U24CA143883, P30CA016672, P50CA070907, U24CA210949, U24CA199461] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson's Institutional Tissue Bank Award; University of Texas Lung Specialized Programs of Research Excellence grant; Cancer Prevention and Research Institute of Texas (CPRIT); Department of Defense PROSPECT grant(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the following grants from the National Institutes of Health (NIH) grant 2R01CA125123-09 (C. Creighton), MD Anderson's Institutional Tissue Bank Award (2P30CA016672, I. Wistuba), and The University of Texas Lung Specialized Programs of Research Excellence grant (P50CA70907, I. Wistuba), Cancer Prevention and Research Institute of Texas (CPRIT) grant RP120713 C2 (C. Creighton) and P2 (D. Gibbons), and RP150405 (D. Gibbons) and Department of Defense PROSPECT grant (W81XWH-07-1-0306, I. Wistuba).	Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Chae YK, 2016, CLIN LUNG CANCER, V17, P350, DOI 10.1016/j.cllc.2016.03.011; Chen FJ, 2016, CELL REP, V14, P2476, DOI 10.1016/j.celrep.2016.02.024; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Chiriva-Internati M, 2012, INT REV IMMUNOL, V31, P321, DOI 10.3109/08830185.2012.723512; Ciuffreda L, 2014, CURR PHARM DESIGN, V20, P3944, DOI 10.2174/13816128113196660763; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Creighton Chad J, 2013, Cancer Manag Res, V5, P187, DOI 10.2147/CMAR.S35171; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Iyoda A, 2014, GEN THORAC CARDIOVAS, V62, P351, DOI 10.1007/s11748-014-0379-9; Lou YY, 2016, CLIN CANCER RES, V22, P3630, DOI 10.1158/1078-0432.CCR-15-1434; Mo QX, 2013, P NATL ACAD SCI USA, V110, P4245, DOI 10.1073/pnas.1208949110; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Thomas A, 2015, NAT REV CLIN ONCOL, V12, P511, DOI 10.1038/nrclinonc.2015.90; Watanabe H, 2014, J CLIN INVEST, V124, P1636, DOI 10.1172/JCI71545; Wilkerson MD, 2010, CLIN CANCER RES, V16, P4864, DOI 10.1158/1078-0432.CCR-10-0199; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096	25	76	78	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2017	36	10					1384	1393		10.1038/onc.2016.303	http://dx.doi.org/10.1038/onc.2016.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2TG	27775076	Green Accepted			2022-12-17	WOS:000395862500007
J	Musa, J; Orth, MF; Dallmayer, M; Baldauf, M; Pardo, C; Rotblat, B; Kirchner, T; Leprivier, G; Grunewald, TGP				Musa, J.; Orth, M. F.; Dallmayer, M.; Baldauf, M.; Pardo, C.; Rotblat, B.; Kirchner, T.; Leprivier, G.; Gruenewald, T. G. P.			Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis	ONCOGENE			English	Review							RAPAMYCIN SIGNALING PATHWAY; CAP-BINDING PROTEIN; INTERNAL RIBOSOMAL ENTRY; CELL-CYCLE PROGRESSION; RAT EMBRYO FIBROBLASTS; FACTOR 4E; MAMMALIAN TARGET; BREAST-CANCER; MTOR PATHWAY; POOR-PROGNOSIS	Protein synthesis activity is abnormally enhanced in cancer cells to support their uncontrolled growth. However, this process needs to be tightly restricted under metabolic stress - a condition often found within the tumor microenvironment - to preserve cell viability. mTORC1 is critical to link protein synthesis activity to nutrient and oxygen levels, in part by controlling the 4E-BP1-eIF4E axis. Whereas mTORC1 and eIF4E are known pro-tumorigenic factors, whose expression or activity is increased in numerous cancers, the role of 4E-BP1 in cancer is not yet definitive. On the one hand, 4E-BP1 has tumor suppressor activity by inhibiting eIF4E and, thus, blocking mRNA translation and proliferation. This is corroborated by elevated levels of phosphorylated and hence inactive 4E-BP1, which are detected in various cancers. On the other hand, 4E-BP1 has pro-tumorigenic functions as it promotes tumor adaptation to metabolic and genotoxic stress by selectively enhancing or preventing the translation of specific transcripts. Here we describe the molecular and cellular functions of 4E-BP1 and highlight the distinct roles of 4E-BP1 in cancer depending on the microenvironmental context of the tumor.	[Musa, J.; Orth, M. F.; Dallmayer, M.; Baldauf, M.; Gruenewald, T. G. P.] Ludwig Maximilians Univ Munchen, Inst Pathol, Lab Pediat Sarcoma Biol, Thalkirchner Str 36, D-80337 Munich, Germany; [Pardo, C.; Rotblat, B.; Leprivier, G.] Ben Gurion Univ Negev, Dept Life Sci, Beer Sheva, Israel; [Kirchner, T.] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany; [Kirchner, T.] German Canc Consortium DKTK, Heidelberg, Germany; [Kirchner, T.] German Canc Res Ctr, Heidelberg, Germany; [Leprivier, G.] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, Beer Sheva, Israel	University of Munich; Ben Gurion University; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ben Gurion University	Grunewald, TGP (corresponding author), Ludwig Maximilians Univ Munchen, Inst Pathol, Lab Pediat Sarcoma Biol, Thalkirchner Str 36, D-80337 Munich, Germany.	thomas.gruenewald@med.uni-muenchen.de	Grünewald, Thomas G. P./O-2317-2013; Rotblat, Barak/H-5970-2019	Grünewald, Thomas G. P./0000-0003-0920-7377; Rotblat, Barak/0000-0003-2985-7115; Dallmayer, Marlene/0000-0002-6877-7268; Orth, Martin/0000-0002-1789-6427; Musa, Julian/0000-0002-9138-1819	Bundesministerium fur Bildung und Forschung (BMBF); LMU Munich; Deutsche Stiftung fur Junge Erwachsene mit Krebs; Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; Reinhard Frank Foundation; LMU Munich's Institutional Strategy LMUexcellent within German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder - Bettina-Brau-Stiftung; Fritz-Thyssen Foundation [FTF-40.15.0.030MN]; Deutsche Forschungsgemeinschaft [DFG GR3728/2-1]; German Cancer Aid [DKH-111886]	Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); LMU Munich; Deutsche Stiftung fur Junge Erwachsene mit Krebs; Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed); Daimler and Benz Foundation; Reinhard Frank Foundation; LMU Munich's Institutional Strategy LMUexcellent within German Excellence Initiative; Mehr LEBEN fur krebskranke Kinder - Bettina-Brau-Stiftung; Fritz-Thyssen Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe)	JM is supported by a scholarship in frame of the 'Deutschlandstipendium' program of the Bundesministerium fur Bildung und Forschung (BMBF) and the LMU Munich. MD is supported by a grant of the 'Deutsche Stiftung fur Junge Erwachsene mit Krebs'. TGPG is supported by a grant from the 'Verein zur Forderung von Wissenschaft und Forschung an der Medizinischen Fakultat der LMU Munchen (WiFoMed)', the Daimler and Benz Foundation in cooperation with the Reinhard Frank Foundation, by LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative, the 'Mehr LEBEN fur krebskranke Kinder - Bettina-Brau-Stiftung', the Fritz-Thyssen Foundation (FTF-40.15.0.030MN), the Deutsche Forschungsgemeinschaft (DFG GR3728/2-1) and by the German Cancer Aid (DKH-111886).	Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Bidinosti M, 2010, J BIOL CHEM, V285, P19402, DOI 10.1074/jbc.M110.120774; Bidinosti M, 2010, MOL CELL, V37, P797, DOI 10.1016/j.molcel.2010.02.022; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cai WJ, 2014, ONCOTARGET, V5, P6015, DOI 10.18632/oncotarget.2109; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Cen L, 2007, MODERN PATHOL, V20, P936, DOI 10.1038/modpathol.3800834; Chao MW, 2015, ONCOTARGET, V6, P24092, DOI 10.18632/oncotarget.4483; Chaux A, 2013, HUM PATHOL, V44, P2323, DOI 10.1016/j.humpath.2013.05.014; Chaux A, 2013, UROLOGY, V81, P116, DOI 10.1016/j.urology.2012.09.007; Chen CN, 2004, J SURG ONCOL, V86, P22, DOI 10.1002/jso.20037; Chen J, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-30; Chen S, 2009, BRIT J DERMATOL, V161, P357, DOI 10.1111/j.1365-2133.2009.09179.x; Chen SJ, 2009, BRIT J DERMATOL, V160, P442, DOI 10.1111/j.1365-2133.2008.08903.x; Chen WN, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-292; Clark C, 2010, LARYNGOSCOPE, V120, P1159, DOI 10.1002/lary.20917; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Dai B, 2009, BJU INT, V104, P1009, DOI 10.1111/j.1464-410X.2009.08538.x; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Darb-Esfahani S, 2009, J CANCER RES CLIN, V135, P933, DOI 10.1007/s00432-008-0529-5; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Martino MC, 2014, ENDOCR-RELAT CANCER, V21, P601, DOI 10.1530/ERC-13-0112; Demicco EG, 2012, MODERN PATHOL, V25, P212, DOI 10.1038/modpathol.2011.148; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Dubois L, 2009, INT J RADIAT ONCOL, V73, P1219, DOI 10.1016/j.ijrobp.2008.12.003; Efeyan A, 2013, NATURE, V493, P679, DOI 10.1038/nature11745; Eguchi S, 2006, GENES CELLS, V11, P757, DOI 10.1111/j.1365-2443.2006.00977.x; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fonseca BD, 2015, J BIOL CHEM, V290, P15996, DOI 10.1074/jbc.M114.621730; Fonseca BD, 2014, SEMIN CELL DEV BIOL, V36, P102, DOI 10.1016/j.semcdb.2014.09.014; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Grunewald TGP, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-79; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Haddad AQ, 2015, CANCER-AM CANCER SOC, V121, P43, DOI 10.1002/cncr.28976; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Italiano A, 2012, CANCER-AM CANCER SOC, V118, P5878, DOI 10.1002/cncr.27614; Izycka-Swieszewska E, 2010, POL J PATHOL, V61, P192; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jiang H, 2008, ONCOGENE, V27, P5729, DOI 10.1038/onc.2008.180; Jiao XD, 2013, HEPATO-GASTROENTEROL, V60, P921, DOI 10.5754/hge12865; Karlsson E, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3557; Karlsson E, 2011, GENE CHROMOSOME CANC, V50, P775, DOI 10.1002/gcc.20900; Kasajima A, 2011, ENDOCR-RELAT CANCER, V18, P181, DOI 10.1677/ERC-10-0126; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Korkolopoulou P, 2012, HISTOPATHOLOGY, V61, P293, DOI 10.1111/j.1365-2559.2012.04236.x; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Kouvaraki MA, 2011, SURGERY, V150, P1258, DOI 10.1016/j.surg.2011.09.022; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kremer CL, 2006, PROSTATE, V66, P1203, DOI 10.1002/pros.20410; Kuang XH, 2009, BIOCHEM BIOPH RES CO, V383, P368, DOI 10.1016/j.bbrc.2009.04.019; Lahat G, 2010, ANN SURG, V251, P1098, DOI 10.1097/SLA.0b013e3181dbb75a; Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laplante M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011593; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Lee HW, 2015, INT J CLIN EXP PATHO, V8, P3955; Lee VHY, 2008, FEBS J, V275, P2185, DOI 10.1111/j.1742-4658.2008.06372.x; Leprivier G, 2015, BBA-GENE REGUL MECH, V1849, P845, DOI 10.1016/j.bbagrm.2014.11.002; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li N, 2012, INT J CLIN EXP PATHO, V5, P660; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; Mueller S, 2012, NEURO-ONCOLOGY, V14, P1146, DOI 10.1093/neuonc/nos140; Nemes K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059335; Nishikawa M, 2015, UROL ONCOL, V33; No JH, 2011, GYNECOL ONCOL, V121, P8, DOI 10.1016/j.ygyno.2010.12.364; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; Peng JZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107362; Perrone F, 2010, EUR J CANCER, V46, P2837, DOI 10.1016/j.ejca.2010.06.130; Petricoin EF, 2007, CANCER RES, V67, P3431, DOI 10.1158/0008-5472.CAN-06-1344; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rice LW, 2006, AM J OBSTET GYNECOL, V194, P1119, DOI 10.1016/j.ajog.2005.12.020; Righi L, 2010, ENDOCR-RELAT CANCER, V17, P977, DOI 10.1677/ERC-10-0157; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; Roh MS, 2015, VIRCHOWS ARCH, V467, P667, DOI 10.1007/s00428-015-1860-2; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Rosenwald IB, 2001, CANCER-AM CANCER SOC, V92, P2164, DOI 10.1002/1097-0142(20011015)92:8<2164::AID-CNCR1559>3.0.CO;2-A; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Ruys AT, 2014, ANN SURG ONCOL, V21, P487, DOI 10.1245/s10434-013-3286-x; Salehi Z, 2006, CLIN BIOCHEM, V39, P404, DOI 10.1016/j.clinbiochem.2005.11.007; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schultz L, 2011, AM J SURG PATHOL, V35, P1549, DOI 10.1097/PAS.0b013e31822895e5; Schultz L, 2010, CANCER-AM CANCER SOC, V116, P5517, DOI 10.1002/cncr.25502; Shantz LM, 1996, CANCER RES, V56, P3265; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Siddiqui N, 2012, J MOL BIOL, V415, P781, DOI 10.1016/j.jmb.2011.12.002; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sunavala-Dossabhoy G, 2011, LARYNGOSCOPE, V121, P2136, DOI 10.1002/lary.22144; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tejada S, 2009, J HISTOCHEM CYTOCHEM, V57, P503, DOI 10.1369/jhc.2009.952929; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860; Thumma SC, 2007, CANCER LETT, V258, P1, DOI 10.1016/j.canlet.2007.08.022; Topisirovic I, 2015, BBA-GENE REGUL MECH, V1849, P751, DOI 10.1016/j.bbagrm.2015.05.004; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Truitt ML, 2015, CELL, V162, P59, DOI 10.1016/j.cell.2015.05.049; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; Wang WY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106098; Wang Z, 2012, NEOPLASMA, V59, P137, DOI 10.4149/neo_2012_018; Yamada Y, 2014, CANCER-AM CANCER SOC, V120, P864, DOI 10.1002/cncr.28506; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112; Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056	178	76	77	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4675	4688		10.1038/onc.2015.515	http://dx.doi.org/10.1038/onc.2015.515			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26829052				2022-12-17	WOS:000383324700001
J	Wu, YC; Tang, SJ; Sun, GH; Sun, KH				Wu, Y-C; Tang, S-J; Sun, G-H; Sun, K-H			CXCR7 mediates TGF beta 1-promoted EMT and tumor-initiating features in lung cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA; CHEMOKINE RECEPTOR; STEM-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; BREAST; EXPRESSION; MIGRATION; SURVIVAL; ADHESION	In the tumor microenvironment, chemokine system has a critical role in tumorigenesis and metastasis. The acquisition of stem-like properties by cancer cells is involved in metastasis and drug resistance, which are pivotal problems that result in poor outcomes in patients with lung cancer. Patients with advanced lung cancer present high plasma levels of transforming growth factor-beta 1 (TGF beta 1), which correlate with poor prognostic features. Therefore, TGF beta 1 may be important in the tumor microenvironment, where chemokines are widely expressed. However, the role of chemokines in TGF beta 1-induced tumor progression still remains unclear. In our study, TGF beta 1 upregulated CXC chemokine receptor expression, migration, invasion, epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) formation in lung adenocarcinoma. We found that CXCR7 was the most upregulated chemokine receptor induced by TGF beta 1. CXCR7 knockdown resulted in reduction of migration, invasion and EMT induced by TGF beta 1, whereas CXCR4 knockdown did not reverse TGF beta 1-promoted EMT. CXCR7 silencing significantly decreased cancer sphere-forming capacity, stem-like properties, chemoresistance and TGF beta 1-induced CSC tumor initiation in vivo. In clinical samples, high TGF beta 1 and CXCR7 expression was significantly associated with the late stages of lung adenocarcinoma. Moreover, TGF beta 1 and CXCR7 coexpression was positively correlated with the CSC marker, CD44, which is associated with lymph node metastasis. Besides, patients with high expression of both CXCR7 and TGF beta 1 presented a significantly worse survival rate. These results suggest that the TGF beta 1-CXCR7 axis may be a prognostic marker and may provide novel targets for combinational therapies to be used in the treatment of advanced lung cancer in the future.	[Wu, Y-C; Sun, K-H] Natl Yang Ming Univ, Taipei City Hosp, Dept Educ & Res, Dept Biotechnol & Lab Sci Med, Taipei 112, Taiwan; [Tang, S-J] Natl Taiwan Ocean Univ, Inst Marine Biotechnol, Keelung, Taiwan; [Sun, G-H] Triserv Gen Hosp, Dept Surg, Div Surg, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan; [Sun, G-H] Natl Def Med Ctr, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan	National Yang Ming Chiao Tung University; Taipei City Hospital; National Taiwan Ocean University; Tri-Service General Hospital; National Defense Medical Center	Sun, GH (corresponding author), Triserv Gen Hosp, Dept Surg, Div Surg, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan.; Sun, GH (corresponding author), Natl Def Med Ctr, 325,Sect 2,Chenggong Rd, Taipei 114, Taiwan.; Sun, KH (corresponding author), Natl Yang Ming Univ, Dept Biotechnol & Lab Sci Med, 155,Sect 2,Linong St, Taipei 11221, Taiwan.; Sun, KH (corresponding author), Taipei City Hosp, Dept Educ & Res, 155,Sect 2,Linong St, Taipei 11221, Taiwan.	ghsun@ndmctsgh.edu.tw; khsun@ym.edu.tw			Ministry of Science and Technology (MOST) [103-2320-B-010-039-MY3, 103-2321-B-010-029]; Ministry of Education (Aim for the Top University Plan); Tri-Service General Hospital; National Defense Medical Center [TSGHC-C103-062, TSGH-104-507]; Taipei City Hospital, Taiwan	Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China); Ministry of Education (Aim for the Top University Plan)(Ministry of Education, Taiwan); Tri-Service General Hospital; National Defense Medical Center; Taipei City Hospital, Taiwan	This study was supported by the Ministry of Science and Technology (MOST 103-2320-B-010-039-MY3, 103-2321-B-010-029), the Ministry of Education (Aim for the Top University Plan), the Tri-Service General Hospital and the National Defense Medical Center (TSGHC-C103-062, TSGH-104-507) and the Taipei City Hospital, Taiwan.	Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Bareschino Maria Anna, 2011, J Thorac Dis, V3, P122, DOI 10.3978/j.issn.2072-1439.2010.12.08; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bertran E, 2009, CELL SIGNAL, V21, P1595, DOI 10.1016/j.cellsig.2009.06.006; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x; Guo Y, 2005, STEM CELLS, V23, P1324, DOI 10.1634/stemcells.2005-0085; Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621; Hasegawa Y, 2001, CANCER-AM CANCER SOC, V91, P964, DOI 10.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O; Hou YL, 2013, CANCER EPIDEMIOL, V37, P750, DOI 10.1016/j.canep.2013.04.013; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang Xiefang, 2010, Zhongguo Fei Ai Za Zhi, V13, P451, DOI 10.3779/j.issn.1009-3419.2010.05.14; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Maksym RB, 2009, EUR J PHARMACOL, V625, P31, DOI 10.1016/j.ejphar.2009.04.071; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Pirozzi G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021548; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Sakaki-Yumoto M, 2013, BBA-GEN SUBJECTS, V1830, P2280, DOI 10.1016/j.bbagen.2012.08.008; Sanchez-Martin L, 2013, TRENDS MOL MED, V19, P12, DOI 10.1016/j.molmed.2012.10.004; Schaeffer D, 2014, MOL CELL BIOL, V34, P3486, DOI 10.1128/MCB.00694-14; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Su LP, 2005, CLIN CANCER RES, V11, P8273, DOI 10.1158/1078-0432.CCR-05-0537; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Suzuki M, 2008, INT J ONCOL, V33, P113; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Xu CC, 2011, MOL MED REP, V4, P1007, DOI 10.3892/mmr.2011.530; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhao XP, 2010, ACTA PHARMACOL SIN, V31, P347, DOI 10.1038/aps.2009.204; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	41	76	78	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2123	2132		10.1038/onc.2015.274	http://dx.doi.org/10.1038/onc.2015.274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26212008				2022-12-17	WOS:000374505600011
J	Owens, P; Pickup, MW; Novitskiy, SV; Giltnane, JM; Gorska, AE; Hopkins, CR; Hong, CC; Moses, HL				Owens, P.; Pickup, M. W.; Novitskiy, S. V.; Giltnane, J. M.; Gorska, A. E.; Hopkins, C. R.; Hong, C. C.; Moses, H. L.			Inhibition of BMP signaling suppresses metastasis in mammary cancer	ONCOGENE			English	Article							BONE MORPHOGENETIC PROTEIN-6; TUMOR-ASSOCIATED MACROPHAGES; TGF-BETA RECEPTOR; BREAST-CANCER; PROSTATE-CANCER; GERMLINE MUTATIONS; JUVENILE POLYPOSIS; EPITHELIAL-CELLS; HAIR-FOLLICLES; EXPRESSION	Bone morphogenetic proteins (BMPs) are secreted cytokines/growth factors that have differing roles in cancer. BMPs are overexpressed in human breast cancers, but loss of BMP signaling in mammary carcinomas can accelerate metastasis. We show that human breast cancers display active BMP signaling, which is rarely downregulated or homozygously deleted. We hypothesized that systemic inhibition of BMP signaling in both the tumor and the surrounding microenvironment could prevent tumor progression and metastasis. To test this hypothesis, we used DMH1, a BMP antagonist, in MMTV. PyVmT expressing mice. Treatment with DMH1 reduced lung metastasis and the tumors were less proliferative and more apoptotic. In the surrounding tumor microenvironment, treatment with DMH1 altered fibroblasts, lymphatic vessels and macrophages to be less tumor promoting. These results indicate that inhibition of BMP signaling may successfully target both the tumor and the surrounding microenvironment to reduce tumor burden and metastasis.	[Owens, P.; Pickup, M. W.; Novitskiy, S. V.; Gorska, A. E.; Moses, H. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Owens, P.; Pickup, M. W.; Novitskiy, S. V.; Gorska, A. E.; Moses, H. L.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Giltnane, J. M.; Moses, H. L.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Hopkins, C. R.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA; [Hopkins, C. R.] Vanderbilt Univ, Coll Arts & Sci, Dept Chem, Nashville, TN 37235 USA; [Hong, C. C.] Vet Affairs TVHS, Res Med, Nashville, TN USA; [Hong, C. C.] Vanderbilt Univ, Sch Med, Div Cardiovasc Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Owens, P (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 2220 Pierce Ave,Preston Res Bldg 692, Nashville, TN 37232 USA.	philip.owens@vanderbilt.edu			DoD BCRP postdoctoral fellowship [W81XWH-09-1-0421]; NIH/NHLBI [RO1HL104040]; VA Merit Award [101BX000771]; NIH [CA085492, CA102162]; Robert J and Helen C Kleberg Foundation; TJ Martell Foundation;  [CA068485]; NATIONAL CANCER INSTITUTE [R01CA085492, R01CA102162, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL104040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115305] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000771] Funding Source: NIH RePORTER	DoD BCRP postdoctoral fellowship; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); VA Merit Award(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert J and Helen C Kleberg Foundation; TJ Martell Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We would like to thank the members of the Moses laboratory for critically reading the manuscript. We thank Dr Connor Lynch for help with tissue acquisition. PO has been supported by DoD BCRP postdoctoral fellowship grant number W81XWH-09-1-0421. CCH is supported by NIH/NHLBI grants RO1HL104040 and VA Merit Award # 101BX000771. This work is supported by NIH grants CA085492, CA102162, the Robert J and Helen C Kleberg Foundation and the TJ Martell Foundation to HLM. Grant number CA068485 provided core laboratory support.	Alarmo EL, 2008, ANN ONCOL, V19, P308, DOI 10.1093/annonc/mdm453; Alarmo EL, 2006, GENE CHROMOSOME CANC, V45, P411, DOI 10.1002/gcc.20307; Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549-006-9362-1; Alarmo EL, 2013, MODERN PATHOL, V26, P10, DOI 10.1038/modpathol.2012.128; Alarmo EL, 2010, ENDOCR-RELAT CANCER, V17, pR123, DOI 10.1677/ERC-09-0273; Alarmo EL, 2009, CANCER LETT, V275, P35, DOI 10.1016/j.canlet.2008.09.028; Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Balboni AL, 2013, CANCER RES, V73, P1020, DOI 10.1158/0008-5472.CAN-12-2862; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Calva-Cerqueira D, 2010, HUM MOL GENET, V19, P4654, DOI 10.1093/hmg/ddq396; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen JC, 2013, INT J MOL SCI, V14, P88, DOI 10.3390/ijms14010088; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Cross EE, 2011, ACS CHEM BIOL, V6, P952, DOI 10.1021/cb200205z; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Ehata S, 2013, PATHOL INT, V63, P287, DOI 10.1111/pin.12067; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goto K, 2007, J BIOL CHEM, V282, P20603, DOI 10.1074/jbc.M702100200; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hao J, 2010, ACS CHEM BIOL, V5, P245, DOI 10.1021/cb9002865; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hill CR, 2012, CELL SIGNAL, V24, P1012, DOI 10.1016/j.cellsig.2011.12.022; Hollosi P, 2009, INT J CANCER, V125, P318, DOI 10.1002/ijc.24308; Hong JH, 2009, IMMUNOLOGY, V128, pe442, DOI 10.1111/j.1365-2567.2008.02998.x; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Ketolainen JM, 2010, BREAST CANCER RES TR, V124, P377, DOI 10.1007/s10549-010-0808-0; Kobielak K, 2003, J CELL BIOL, V163, P609, DOI 10.1083/jcb.200309042; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kwan KM, 2004, GENESIS, V39, P10, DOI 10.1002/gene.20021; Kwon SJ, 2009, IMMUNOLOGY, V128, pe758, DOI 10.1111/j.1365-2567.2009.03079.x; Langenfeld E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061256; Laoui D, 2011, INT J DEV BIOL, V55, P861, DOI 10.1387/ijdb.113371dl; Lee GT, 2011, MOL IMMUNOL, V48, P1540, DOI 10.1016/j.molimm.2011.04.019; Lee GT, 2010, J BIOL CHEM, V285, P39401, DOI 10.1074/jbc.M110.103705; Lee JH, 2013, CANCER RES, V73, P3604, DOI 10.1158/0008-5472.CAN-12-4563; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836; Nishimori H, 2012, J BIOL CHEM, V287, P20037, DOI 10.1074/jbc.M112.353094; Novitskiy SV, 2012, J LEUKOCYTE BIOL, V92, P641, DOI 10.1189/jlb.1211639; Novitskiy SV, 2011, CANCER DISCOV, V1, P430, DOI 10.1158/2159-8290.CD-11-0100; Owens P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067533; Owens P, 2012, P NATL ACAD SCI USA, V109, P2814, DOI 10.1073/pnas.1101139108; Owens P, 2010, AM J PATHOL, V176, P122, DOI 10.2353/ajpath.2010.090081; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Pickup MW, 2013, CANCER RES, V73, P5336, DOI 10.1158/0008-5472.CAN-13-0012; Rodriguez-Martinez A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-80; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Su JL, 2007, BRIT J CANCER, V96, P541, DOI 10.1038/sj.bjc.6603487; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Vogt J, 2011, CELL SIGNAL, V23, P1831, DOI 10.1016/j.cellsig.2011.06.019; Wiley DM, 2011, NAT CELL BIOL, V13, P686, DOI 10.1038/ncb2232; Yang S, 2008, CANCER RES, V68, P198, DOI 10.1158/0008-5472.CAN-07-5074; Yuhki M, 2004, DEVELOPMENT, V131, P1825, DOI 10.1242/dev.01079	59	76	78	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2437	2449		10.1038/onc.2014.189	http://dx.doi.org/10.1038/onc.2014.189			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998846	Green Accepted			2022-12-17	WOS:000354190400003
J	Jin, JK; Tien, PC; Cheng, CJ; Song, JH; Huang, C; Lin, SH; Gallick, GE				Jin, J-K; Tien, P-C; Cheng, C-J; Song, J. H.; Huang, C.; Lin, S-H; Gallick, G. E.			Talin1 phosphorylation activates beta 1 integrins: a novel mechanism to promote prostate cancer bone metastasis	ONCOGENE			English	Article							INTEGRIN EXPRESSION; BINDING; PROGRESSION; ADHESION; CARCINOMA; SUBUNIT; DOMAIN; TAILS; SITES; CELLS	Talins are adaptor proteins that regulate focal adhesion signaling by conjugating integrins to the cytoskeleton. Talins directly bind integrins and are essential for integrin activation. We previously showed that beta 1 integrins are activated in metastatic prostate cancer (PCa) cells, increasing PCa metastasis to lymph nodes and bone. However, how beta 1 integrins are activated in PCa cells is unknown. In this study, we identified a novel mechanism of beta 1 integrin activation. Using knockdown experiments, we first demonstrated that talin1, but not talin2, is important in beta 1 integrin activation. We next showed that talin1 S425 phosphorylation, but not total talin1 expression, correlates with metastatic potential of PCa cells. Expressing a non-phosphorylatable mutant, talin1(S425A), in talin1-silenced PC3-MM2 and C4-2B4 PCa cells, decreased activation of beta 1 integrins, integrin-mediated adhesion, motility and increased the sensitivity of the cells to anoikis. In contrast, reexpression of the phosphorylation-mimicking mutant talin1(S425D) led to increased beta 1 integrin activation and generated biologic effects opposite to talin1(S425A) expression. In the highly metastatic PC3-MM2 cells, expression of a non-phosphorylatable mutant, talin1(S425A), in talin1-silenced PC3-MM2 cells, abolished their ability to colonize in the bone following intracardiac injection, while reexpression of phosphorylation-mimicking mutant talin1(S425D) restored their ability to metastasize to bone. Immunohistochemical staining demonstrated that talin S425 phosphorylation is significantly increased in human bone metastases when compared with normal tissues, primary tumors or lymph node metastases. We further showed that p35 expression, an activator of Cdk5, and Cdk5 activity were increased in metastatic tumor cells, and that Cdk5 kinase activity is responsible for talin1 phosphorylation and subsequent beta 1 integrin activation. Together, our study reveals Cdk5-mediated phosphorylation of talin1 leading to beta 1 integrin activation is a novel mechanism that increases metastatic potential of PCa cells.	[Jin, J-K; Tien, P-C; Song, J. H.; Lin, S-H; Gallick, G. E.] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Genitourinary Med Oncol, Unit 18 4, Houston, TX 77030 USA; [Jin, J-K; Lin, S-H; Gallick, G. E.] Univ Texas Houston, Grad Sch Biomed Sci, Program Canc Metastasis, Houston, TX USA; [Cheng, C-J] Taipei Med Univ, Dept Pathol, Coll Med, Taipei, Taiwan; [Huang, C.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Lexington, KY USA; [Lin, S-H] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Translat Mol Pathol, Unit 89, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Taipei Medical University; University of Kentucky; University of Texas System; UTMD Anderson Cancer Center	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Translat Mol Pathol, Unit 89, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slin@mdanderson.org; ggallick@mdanderson.org	Jin, Jungkang/H-6285-2011	Tien, Pei-Chieh/0000-0002-0012-0155	National Institutes of Health (NIH) [P50 CA140388, RO-1 CA174798, CA16672]; Prostate Cancer Foundation Challenge Award; DOD [PC093132]; Cancer Prevention and Research Institute of Texas [CPRIT RP110327]; NATIONAL CANCER INSTITUTE [R01CA174798, P30CA016672, P50CA140388] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation Challenge Award; DOD(United States Department of Defense); Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Joseph H McCarty for critically reviewing the manuscript. This work was supported by the National Institutes of Health (NIH) P50 CA140388 (GEG, S-HL), a Prostate Cancer Foundation Challenge Award (GEG, S-HL), NIH RO-1 CA174798 (S-HL), DOD PC093132 (S-HL), a Cancer Prevention and Research Institute of Texas, CPRIT RP110327 (S-HL) and NIH CA16672 (CCSG, M. D. Anderson Cancer Center core grant).	American Cancer Society, 2013, CANC FACTS FIG; Barthel SR, 2013, CANCER RES, V73, P942, DOI 10.1158/0008-5472.CAN-12-3264; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2013, NAT REV MOL CELL BIO, V14, P503, DOI 10.1038/nrm3624; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chang SK, 2011, P NATL ACAD SCI USA, V108, P8402, DOI 10.1073/pnas.1019437108; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Critchley DR, 2008, J CELL SCI, V121, P1345, DOI 10.1242/jcs.018085; Das M, 2014, BBA-BIOMEMBRANES, V1838, P579, DOI 10.1016/j.bbamem.2013.07.017; Debrand E, 2009, FEBS J, V276, P1610, DOI 10.1111/j.1742-4658.2009.06893.x; Desiniotis A, 2011, INT REV CEL MOL BIO, V289, P117, DOI 10.1016/B978-0-12-386039-2.00004-3; Edlund M, 2001, CELL GROWTH DIFFER, V12, P99; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Goult BT, 2013, J STRUCT BIOL, V184, P21, DOI 10.1016/j.jsb.2013.05.014; Hall CL, 2006, CANCER RES, V66, P8648, DOI 10.1158/0008-5472.CAN-06-1544; Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024; Lai MT, 2011, J PATHOL, V224, P367, DOI 10.1002/path.2867; Lang SH, 1997, CLIN EXP METASTAS, V15, P218, DOI 10.1023/A:1018465213641; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lin TH, 2013, BBA-GEN SUBJECTS, V1830, P4917, DOI 10.1016/j.bbagen.2013.06.033; Manso AM, 2013, J BIOL CHEM, V288, P4252, DOI 10.1074/jbc.M112.427484; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Ratnikov B, 2005, J CELL SCI, V118, P4921, DOI 10.1242/jcs.02682; Sakamoto S, 2010, CANCER RES, V70, P1885, DOI 10.1158/0008-5472.CAN-09-2833; Sayeed A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076513; Song XQ, 2012, CELL RES, V22, P1533, DOI 10.1038/cr.2012.97; Sottnik JL, 2013, CLIN EXP METASTAS, V30, P569, DOI 10.1007/s10585-012-9561-6; Stachurska A, 2012, CELL BIOL INT, V36, P883, DOI 10.1042/CBI20110522; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207; Tang HS, 2013, INT J MOL MED, V32, P381, DOI 10.3892/ijmm.2013.1400; THALMANN GN, 1994, CANCER RES, V54, P2577; Trerotola M, 2013, CANCER RES, V73, P3155, DOI 10.1158/0008-5472.CAN-12-3266; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405; Varkaris A, 2013, INT J CANCER, V133, P1536, DOI 10.1002/ijc.28169; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Ye F, 2011, J THROMB HAEMOST, V9, P20, DOI 10.1111/j.1538-7836.2011.04355.x; Ye F, 2013, CURR BIOL, V23, P2288, DOI 10.1016/j.cub.2013.09.050; Zheng DQ, 1999, CANCER RES, V59, P1655	44	76	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1811	1821		10.1038/onc.2014.116	http://dx.doi.org/10.1038/onc.2014.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24793790	Green Accepted			2022-12-17	WOS:000352158000008
J	Cappello, P; Blaser, H; Gorrini, C; Lin, DCC; Elia, AJ; Wakeham, A; Haider, S; Boutros, PC; Mason, JM; Miller, NA; Youngson, B; Done, SJ; Mak, TW				Cappello, P.; Blaser, H.; Gorrini, C.; Lin, D. C. C.; Elia, A. J.; Wakeham, A.; Haider, S.; Boutros, P. C.; Mason, J. M.; Miller, N. A.; Youngson, B.; Done, S. J.; Mak, T. W.			Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells	ONCOGENE			English	Article						kinase; aneuploidy; cell cycle; breast cancer; cell death; metastasis	POTENTIAL THERAPEUTIC TARGET; HISTONE H3 PHOSPHORYLATION; PROTEIN-KINASE; SPINDLE CHECKPOINT; TUMORIGENIC GROWTH; CYCLE REGULATION; EXPRESSION; NIMA; REGULATOR; SURVIVAL	Breast cancer is the most common solid tumor and the second most common cause of death in women. Despite a large body of literature and progress in breast cancer research, many molecular aspects of this complex disease are still poorly understood, hindering the design of specific and effective therapeutic strategies. To identify the molecules important in breast cancer progression and metastasis, we tested the in vivo effects of inhibiting the functions of various kinases and genes involved in the regulation/modulation of the cytoskeleton by downregulating them in mouse PyMT mammary tumor cells and human breast cancer cell lines. These kinases and cytoskeletal regulators were selected based on their prognostic values for breast cancer patient survival. PyMT tumor cells, in which a selected gene was stably knocked down were injected into the tail veins of mice, and the formation of tumors in the lungs was monitored. One of the several genes found to be important for tumor growth in the lungs was NIMA-related kinases 2 (Nek2), a cell cycle-related protein kinase. Furthermore, Nek2 was also important for tumor growth in the mammary fat pad. In various human breast cancer cell lines, Nek2 knockdown induced aneuploidy and cell cycle arrest that led to cell death. Significantly, the breast cancer cell line most sensitive to Nek2 depletion was of the triple negative breast cancer subtype. Our data indicate that Nek2 has a pivotal role in breast cancer growth at primary and secondary sites, and thus may be an attractive and novel therapeutic target for this disease	[Cappello, P.; Blaser, H.; Gorrini, C.; Elia, A. J.; Wakeham, A.; Done, S. J.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada; [Cappello, P.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Lin, D. C. C.; Mason, J. M.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, MaRS Ctr, Toronto, ON M5G 2M9, Canada; [Haider, S.; Boutros, P. C.] Ontario Inst Canc Res, Informat & Biocomp Platform, Toronto, ON, Canada; [Miller, N. A.; Youngson, B.; Done, S. J.] Univ Hlth Network, Lab Med Program, Toronto, ON M5G 2M9, Canada; [Miller, N. A.; Youngson, B.; Done, S. J.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turin; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2M9, Canada.	tmak@uhnresearch.ca	Cappello, Paola/J-3127-2018	Cappello, Paola/0000-0002-5321-7794; Done, Susan/0000-0002-1770-988X; Gorrini, Chiara/0000-0002-5239-6671; Boutros, Paul/0000-0003-0553-7520; Youngson, Bruce/0000-0001-6526-8081	Canadian Institutes of Health Research [179815]; Ontario Institute for Cancer Research through Government of Ontario	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research through Government of Ontario	We thank Dr Mary Saunders for the insightful scientific editing. This work was supported by grant no. 179815 from the Canadian Institutes of Health Research to TWM. This work was also performed with the support of the Ontario Institute for Cancer Research to PCB through funding provided by the Government of Ontario.	Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Chia SK, 2007, CANCER, V110, P973, DOI 10.1002/cncr.22867; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Dey N, 2012, CURR DRUG TARGETS, V13, P1510, DOI 10.2174/138945012803530116; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Du J, 2008, ONCOGENE, V27, P4107, DOI 10.1038/onc.2008.34; Ferretti C, 2010, CELL CYCLE, V9, P4174, DOI 10.4161/cc.9.20.13457; Fiskus W, 2012, BREAST CANCER RES TR, V135, P433, DOI 10.1007/s10549-012-2171-9; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2012, J CELL SCI, V125, P4423, DOI 10.1242/jcs.111195; Gennari A, 2005, CANCER, V104, P1742, DOI 10.1002/cncr.21359; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Hayward DG, 2010, J BIOMOL SCREEN, V15, P918, DOI 10.1177/1087057110376537; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Hu KJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3107; Ikui AE, 2005, CELL CYCLE, V4, P1385, DOI 10.4161/cc.4.10.2061; Innocenti P, 2012, J MED CHEM, V55, P3228, DOI 10.1021/jm201683b; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Kokuryo T, 2007, CANCER RES, V67, P9637, DOI 10.1158/0008-5472.CAN-07-1489; Kolodner RD, 2011, SCIENCE, V333, P942, DOI 10.1126/science.1211154; Komatsu M, 2013, INT J ONCOL, V42, P478, DOI 10.3892/ijo.2012.1744; Lee J, 2013, INT J ONCOL, V42, P839, DOI 10.3892/ijo.2013.1788; Liu QD, 2010, EXP MOL PATHOL, V88, P225, DOI 10.1016/j.yexmp.2009.12.004; Loddo M, 2009, BRIT J CANCER, V100, P959, DOI 10.1038/sj.bjc.6604924; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mardin BR, 2012, J CELL BIOL, V197, P11, DOI 10.1083/jcb.201108006; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; Reddy KB, 2011, CURR ONCOL, V18, pE173; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Romanelli A, 2012, MOL CANCER THER, V11, P2693, DOI 10.1158/1535-7163.MCT-12-0441-T; Shaukat Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047447; Shibata H, 2011, CANCER SCI, V102, P1882, DOI 10.1111/j.1349-7006.2011.02016.x; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Tryfonopoulos D, 2011, ANN ONCOL, V22, P2234, DOI 10.1093/annonc/mdq757; Tsunoda N, 2009, CANCER SCI, V100, P111, DOI 10.1111/j.1349-7006.2008.01007.x; Wang SL, 2012, J CELL BIOCHEM, V113, P1904, DOI 10.1002/jcb.24059; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001	45	76	79	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2375	2384		10.1038/onc.2013.183	http://dx.doi.org/10.1038/onc.2013.183			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708664	Green Submitted			2022-12-17	WOS:000335451800010
J	Shin, S; Wolgamott, L; Tcherkezian, J; Vallabhapurapu, S; Yu, Y; Roux, PP; Yoon, SO				Shin, S.; Wolgamott, L.; Tcherkezian, J.; Vallabhapurapu, S.; Yu, Y.; Roux, P. P.; Yoon, S-O			Glycogen synthase kinase-3 beta positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1	ONCOGENE			English	Article						GSK-3; translation; 4E-BP1	NEGATIVE BREAST-CANCER; S6 KINASE; HIERARCHICAL PHOSPHORYLATION; 4E-BP1 PHOSPHORYLATION; DIABETES-MELLITUS; RAPAMYCIN; INHIBITION; SURVIVAL; GSK3-BETA; PATHWAY	Protein synthesis has a key role in the control of cell proliferation, and its deregulation is associated with pathological conditions, notably cancer. Rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1), was known to inhibit protein synthesis. However, it does not substantially inhibit protein synthesis and cell proliferation in many cancer types. We were interested in finding a novel target in rapamycin-resistant cancer. The rate-limiting factor for translation is eukaryotic translation initiation factor 4E (eIF4E), which is negatively regulated by eIF4E-binding protein 1 (4E-BP1). Here, we provide evidence that glycogen synthase kinase (GSK)-3 beta promotes cell proliferation through positive regulation of protein synthesis. We found that GSK-3 beta phosphorylates and inactivates 4E-BP1, thereby increasing eIF4E-dependent protein synthesis. Considering the clinical relevance of pathways regulating protein synthesis, our study provides a promising new strategy and target for cancer therapy.	[Shin, S.; Wolgamott, L.; Vallabhapurapu, S.; Yoon, S-O] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA; [Tcherkezian, J.; Roux, P. P.] Univ Montreal, Inst Res Immunol & Canc, Dept Pathol & Cell Biol, Montreal, PQ, Canada; [Yu, Y.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	University System of Ohio; University of Cincinnati; Universite de Montreal; University of Texas System; University of Texas Southwestern Medical Center Dallas	Yoon, SO (corresponding author), Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	yoonsh@ucmail.uc.edu	Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250	University of Cincinnati College of Medicine; Marlene Harris-Ride Cincinnati Breast Cancer Pilot Grant Program; Canadian Cancer Society Research Institute; Cancer Research Society; Cancer Prevention and Research Institute of Texas [R1103]; Welch Foundation [I-1800]; University of Texas Southwestern Medical Center	University of Cincinnati College of Medicine; Marlene Harris-Ride Cincinnati Breast Cancer Pilot Grant Program; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Cancer Prevention and Research Institute of Texas; Welch Foundation(The Welch Foundation); University of Texas Southwestern Medical Center	We thank Drs John Blenis, Do-Hyung Kim, Andrew L Kung, David Baltimore and Anne E Willis for generously providing reagents. We also thank Dr Belinda Peace for editing this manuscript and Teng Teng for polysome analysis. This work was supported by a start-up fund from the University of Cincinnati College of Medicine and the Marlene Harris-Ride Cincinnati Breast Cancer Pilot Grant Program (S-OY), by the Canadian Cancer Society Research Institute and the Cancer Research Society (PPR), and by the Cancer Prevention and Research Institute of Texas (R1103), the Welch Foundation (I-1800), and a start-up fund from the University of Texas Southwestern Medical Center (YY). PP Roux holds a Canada Research Chair in Signal Transduction and Proteomics and Y Yu is a CPRIT scholar in Cancer Research and a Virginia Murchison Linthicum Scholar in Medical Research.	Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27; Ayuso MI, 2010, J BIOL CHEM, V285, P34355, DOI 10.1074/jbc.M110.135103; Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824; Birch NW, 2010, CANCER CELL, V17, P529, DOI 10.1016/j.ccr.2010.05.017; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Chen YQ, 2010, CAN J PHYSIOL PHARM, V88, P285, DOI 10.1139/Y10-010; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870; Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Keshwani MM, 2011, J BIOL CHEM, V286, P23552, DOI 10.1074/jbc.M111.258004; Kim George R., 2008, P635, DOI 10.1007/978-0-387-69252-4_37; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee JS, 2007, DIABETES RES CLIN PR, V77, pS49, DOI 10.1016/j.diabres.2007.01.033; Liu TR, 2011, MOL CANCER THER, V10, P1460, DOI 10.1158/1535-7163.MCT-10-0925; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Mai W, 2009, CLIN CANCER RES, V15, P6810, DOI 10.1158/1078-0432.CCR-09-0973; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; Mir MA, 2008, EMBO J, V27, P3129, DOI 10.1038/emboj.2008.228; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Miyashita K, 2009, ANTI-CANCER AGENT ME, V9, P1114, DOI 10.2174/187152009789734982; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Ougolkov Andrei V, 2006, Future Oncol, V2, P91, DOI 10.2217/14796694.2.1.91; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Patel S, 2008, CANCER CELL, V14, P351, DOI 10.1016/j.ccr.2008.10.013; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rocques N, 2007, MOL CELL, V28, P584, DOI 10.1016/j.molcel.2007.11.009; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041; Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x; Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Tabares-Seisdedos R, 2011, LANCET ONCOL, V12, P604, DOI 10.1016/S1470-2045(11)70041-9; Tullai JW, 2011, CELL CYCLE, V10, DOI 10.4161/cc.10.18.17321; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Wang XM, 2007, METHOD ENZYMOL, V431, P113, DOI 10.1016/S0076-6879(07)31007-0; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Wolf I, 2005, LANCET ONCOL, V6, P103, DOI 10.1016/S1470-2045(05)01736-5; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zeng Q, 2010, EUR J CANCER, V46, P1132, DOI 10.1016/j.ejca.2010.01.014; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096	60	76	79	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1690	1699		10.1038/onc.2013.113	http://dx.doi.org/10.1038/onc.2013.113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584478				2022-12-17	WOS:000334344700009
J	Park, MH; Lee, HS; Lee, CS; You, ST; Kim, DJ; Park, BH; Kang, MJ; Heo, WD; Shin, EY; Schwartz, MA; Kim, EG				Park, M-H; Lee, H-S; Lee, C-S; You, S. T.; Kim, D-J; Park, B-H; Kang, M. J.; Heo, W. D.; Shin, E-Y; Schwartz, M. A.; Kim, E-G			p21-Activated kinase 4 promotes prostate cancer progression through CREB	ONCOGENE			English	Article						prostate cancer; p21-activated kinase 4; protein kinase A; CREB; neuroendocrine differentiation; chemoresistance	PROTEIN-KINASE; CELL-MIGRATION; IN-VITRO; PAK4; ACTIVATION; DOMAIN; BCL-2; TRANSDIFFERENTIATION; DIFFERENTIATION; EXPRESSION	Prostate cancer is initially androgen-dependent but, over time, usually develops hormone-and chemo-resistance. The present study investigated a role for p21-activated kinase 4 (PAK4) in prostate cancer progression. PAK4 activation was markedly inhibited by H89, a specific protein kinase A (PKA) inhibitor, and PAK4 was activated by the elevation of cAMP. The catalytic subunit of PKA interacted with the regulatory domain of PAK4, and directly phosphorylated PAK4 at serine 474 (S474). Catalytically active PAK4 enhanced the transcriptional activity of CREB independent of S133 phosphorylation. Stable knockdown of PAK4 in PC-3 and DU145 prostate cancer cells inhibited tumor formation in nude mice. Decreased tumorigenicity correlated with decreased expression of CREB and its targets, including Bcl-2 and cyclin A1. Additionally, in androgen-dependent LNCap-FGC cells, PAK4 regulated cAMP-induced neuroendocrine differentiation, which is known to promote tumor progression. Finally, PAK4 enhanced survival and decreased apoptosis following chemotherapy. These results suggested that PAK4 regulates progression toward hormone-and chemo-resistance in prostate cancer, and this study identified both a novel activation mechanism and potential downstream effector pathways. Therefore, PAK4 may be a promising therapeutic target in prostate cancer.	[Park, M-H; Lee, C-S; You, S. T.; Kim, D-J; Shin, E-Y; Kim, E-G] Chungbuk Natl Univ, Coll Med, Dept Biochem, Chonju 361763, Chungbuk, South Korea; [Park, M-H; Lee, C-S; You, S. T.; Kim, D-J; Shin, E-Y; Kim, E-G] Chungbuk Natl Univ, Coll Med, Med Res Ctr, Chonju 361763, Chungbuk, South Korea; [Lee, H-S; Park, B-H] Chonbuk Natl Univ, Sch Med, Dept Biochem, Jeonju, Jeonbuk, South Korea; [Kang, M. J.] Chonbuk Natl Univ, Sch Med, Dept Pathol, Jeonju, Jeonbuk, South Korea; [Heo, W. D.] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Schwartz, M. A.] Yale Univ, Sch Med, Yale Cardiovasc Res Ctr, Dept Med, New Haven, CT USA; [Schwartz, M. A.] Yale Univ, Sch Med, Yale Cardiovasc Res Ctr, Dept Cell Biol, New Haven, CT USA	Chungbuk National University; Chungbuk National University; Jeonbuk National University; Jeonbuk National University; Korea Advanced Institute of Science & Technology (KAIST); Yale University; Yale University	Kim, EG (corresponding author), Chungbuk Natl Univ, Coll Med, Med Res Ctr, Chonju 361763, Chungbuk, South Korea.	eyshin@chungbuk.ac.kr; egkim@chungbuk.ac.kr	Heo, Won-Do/C-1696-2011	schwartz, martin/0000-0002-2071-1243	National Research Foundation of Korea [2012-0005747]; USPHS [RO1 CA14397]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075092] Funding Source: NIH RePORTER	National Research Foundation of Korea(National Research Foundation of Korea); USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	CRE-luciferase reporter gene containing 6x CRE binding sites was gift from Dr Jung EB at Chungbuk National University (Cheongju, Korea). This work was supported by a grant of the National Research Foundation of Korea (2012-0005747). MAS was supported by USPHS grant RO1 CA14397.	Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; Bagchi G, 2008, CANCER RES, V68, P3225, DOI 10.1158/0008-5472.CAN-07-5026; Baldassa S, 2010, J CELL PHYSIOL, V224, P722, DOI 10.1002/jcp.22172; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022-5347(05)68241-9; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Donkena KV, 2010, CURR CANCER DRUG TAR, V10, P402, DOI 10.2174/156800910791208544; Eswaran J, 2007, STRUCTURE, V15, P201, DOI 10.1016/j.str.2007.01.001; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Lee KH, 2010, P NATL ACAD SCI USA, V107, P3412, DOI 10.1073/pnas.0911262107; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Murray BW, 2010, P NATL ACAD SCI USA, V107, P9446, DOI 10.1073/pnas.0911863107; Paliouras GN, 2009, MOL CELL BIOL, V29, P3018, DOI 10.1128/MCB.01286-08; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; RAFFO AJ, 1995, CANCER RES, V55, P4438; Shaywitz AJ, 1995, ANNU REV BIOCHEM, V68, P821; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Wells CM, 2010, J CELL SCI, V123, P1663, DOI 10.1242/jcs.055707; Wells CM, 2010, BIOCHEM J, V425, P465, DOI 10.1042/BJ20091173; Wells CM, 2002, J CELL SCI, V115, P3947, DOI 10.1242/jcs.00080; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Xiao X, 2010, CURR CANCER DRUG TAR, V10, P384, DOI 10.2174/156800910791208535; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061	33	76	79	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2475	2482		10.1038/onc.2012.255	http://dx.doi.org/10.1038/onc.2012.255			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22710715				2022-12-17	WOS:000318694900011
J	Paris, O; Ferraro, L; Grober, OMV; Ravo, M; De Filippo, MR; Giurato, G; Nassa, G; Tarallo, R; Cantarella, C; Rizzo, F; Di Benedetto, A; Mottolese, M; Benes, V; Ambrosino, C; Nola, E; Weisz, A				Paris, O.; Ferraro, L.; Grober, O. M. V.; Ravo, M.; De Filippo, M. R.; Giurato, G.; Nassa, G.; Tarallo, R.; Cantarella, C.; Rizzo, F.; Di Benedetto, A.; Mottolese, M.; Benes, V.; Ambrosino, C.; Nola, E.; Weisz, A.			Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer	ONCOGENE			English	Article						estrogen receptor beta; microRNA; breast cancer; hormones; gene transcription	CELLS; ALPHA; NUCLEAR; COMPLEX; SIGNATURE; MULTIPLE; NETWORK; TARGETS; PROTEIN; TUMORS	Estrogen effects on mammary epithelial and breast cancer (BC) cells are mediated by the nuclear receptors ER alpha and ER beta, transcription factors that display functional antagonism with each other, with ER beta acting as oncosuppressor and interfering with the effects of ER alpha on cell proliferation, tumor promotion and progression. Indeed, hormone-responsive, ER alpha + BC cells often lack ER beta, which when present associates with a less aggressive clinical phenotype of the disease. Recent evidences point to a significant role of microRNAs (miRNAs) in BC, where specific miRNA expression profiles associate with distinct clinical and biological phenotypes of the lesion. Considering the possibility that ER beta might influence BC cell behavior via miRNAs, we compared miRNome expression in ER beta + vs ER beta- hormone-responsive BC cells and found a widespread effect of this ER subtype on the expression pattern of these non-coding RNAs. More importantly, the expression pattern of 67 miRNAs, including 10 regulated by ER beta in BC cells, clearly distinguishes ER beta+, node-negative, from ER beta-, metastatic, mammary tumors. Molecular dissection of miRNA biogenesis revealed multiple mechanisms for direct regulation of this process by ER beta+ in BC cell nuclei. In particular, ER beta downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ER alpha on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. These results indicate that cell autonomous regulation of miRNA expression is part of the mechanism of action of ER beta in BC cells and could contribute to establishment or maintenance of a less aggressive tumor phenotype mediated by this nuclear receptor.	[Ravo, M.; De Filippo, M. R.; Giurato, G.; Nassa, G.; Tarallo, R.; Cantarella, C.; Rizzo, F.; Weisz, A.] Univ Salerno, Lab Mol Med & Genom, I-84081 Baronissi, SA, Italy; [Paris, O.; Ferraro, L.; De Filippo, M. R.; Giurato, G.; Nola, E.; Weisz, A.] Univ Naples 2, Dept Gen Pathol, Naples, Italy; [Di Benedetto, A.; Mottolese, M.] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Benes, V.] European Mol Biol Lab, Genom Core Facil, Heidelberg, Germany; [Ambrosino, C.] Univ Sannio, Dept Biol & Environm Sci, Benevento, Italy; [Weisz, A.] Univ Salerno, SS Giovanni Dio & Ruggi Aragona Hosp, Div Mol Pathol & Med Genom, I-84100 Salerno, Italy	University of Salerno; Universita della Campania Vanvitelli; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; European Molecular Biology Laboratory (EMBL); University of Sannio; University of Salerno	Weisz, A (corresponding author), Univ Salerno, Lab Mol Med & Genom, Via Allende, I-84081 Baronissi, SA, Italy.	aweisz@unisa.it	Rizzo, Francesca/K-3057-2016; Giurato, Giorgio/K-3859-2018; ambrosino, concetta/AAB-3452-2019; Nassa, Giovanni/AAB-2059-2022; Weisz, Alessandro/A-1317-2014; Tarallo, Roberta/C-2600-2014	Rizzo, Francesca/0000-0003-1783-5015; Giurato, Giorgio/0000-0002-0538-8978; Weisz, Alessandro/0000-0003-0455-2083; Tarallo, Roberta/0000-0001-9668-3632; Di Benedetto, Anna/0000-0002-9853-8671; Benes, Vladimir/0000-0002-0352-2547; Ravo, Maria/0000-0003-1003-2922	Italian Association for Cancer Research [IG-8586, IG-8706]; European Union (CRESCENDO IP) [LSHM-CT2005-018652]; Italian Ministry for Education, University and Research [PRIN 2008CJ4SYW_004]; University of Salerno (Fondi FARB); Fondazione con il Sud [2009-PdP-22]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); European Union (CRESCENDO IP)(European Commission); Italian Ministry for Education, University and Research(Ministry of Education, Universities and Research (MIUR)); University of Salerno (Fondi FARB); Fondazione con il Sud	We thank Manuela Ferracin and Massimo Negrini for help with analysis of miRNA expression data from primary tumor samples and useful suggestions, and Luigi Cicatiello, Margherita Mutarelli and Maria Francesca Papa for technical assistance. Work supported by: Italian Association for Cancer Research (grants IG-8586 to AW and IG-8706 to MM), European Union (CRESCENDO IP, contract number LSHM-CT2005-018652), Italian Ministry for Education, University and Research (grant PRIN 2008CJ4SYW_004), University of Salerno (Fondi FARB 2011) and Fondazione con il Sud (grant 2009-PdP-22). CC, FR, GN, MR and RT are fellows of Fondazione con il Sud.	Ambrosino C, 2010, MOL CELL PROTEOMICS, V9, P1352, DOI 10.1074/mcp.M900519-MCP200; [Anonymous], 2003, WHO CLASSIFICATION T; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Cicatiello L, 2000, MOL CELL ENDOCRINOL, V165, P199, DOI 10.1016/S0303-7207(00)00243-4; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Fejes AP, 2008, BIOINFORMATICS, V24, P1729, DOI 10.1093/bioinformatics/btn305; Ferraro L, 2011, HORM CANC IN PRESS; Ferraro L, 2010, AM J PATHOL, V177, pS34; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Nakamura T, 2007, P NATL ACAD SCI USA, V104, P10980, DOI 10.1073/pnas.0704559104; Nassa G, 2011, PROTEOMICS, V11, P159, DOI 10.1002/pmic.201000344; Newman MA, 2010, GENE DEV, V24, P1086, DOI 10.1101/gad.1919710; Novelli F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2139; Okamura K, 2008, NAT STRUCT MOL BIOL, V15, P354, DOI 10.1038/nsmb.1409; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Ravo M, 2008, LAB INVEST, V88, P430, DOI 10.1038/labinvest.2008.11; Roger P, 2001, CANCER RES, V61, P2537; Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528; Sugiura H, 2007, JPN J CLIN ONCOL, V37, P820, DOI 10.1093/jjco/hym114; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yamagata K, 2009, MOL CELL, V36, P340, DOI 10.1016/j.molcel.2009.08.017; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028	43	76	78	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4196	4206		10.1038/onc.2011.583	http://dx.doi.org/10.1038/onc.2011.583			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22231442				2022-12-17	WOS:000308975800003
J	Wang, L; Wang, J				Wang, L.; Wang, J.			MicroRNA-mediated breast cancer metastasis: from primary site to distant organs	ONCOGENE			English	Review						miRNA; breast cancer; metastasis; EMT/MET; stemness	EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; REGULATORY FEEDBACK LOOP; FACTOR-KAPPA-B; STEM-CELLS; MIR-200 FAMILY; GENE-EXPRESSION; SELF-RENEWAL; E-CADHERIN; REPRESSORS ZEB1	The recent upsurge of interest in microRNA (miRNA) is partly attributed to the discovery of the novel roles of miRNAs in many physiological and pathological processes, including tumor development. Research on breast cancer metastasis has also focused on the concept of miRNA, which can act either as promoters or as suppressors of metastases. This review will focus on a series of recent studies that demonstrate the involvement of miRNAs in breast cancer metastasis and will briefly describe various pathways of miRNA-regulated metastasis. Finally, future prospects will be discussed for the potential role of miRNAs as predictive markers and therapeutic agents for patients with breast cancer metastases. Oncogene (2012) 31, 2499-2511; doi:10.1038/onc.2011.444; published online 3 October 2011	[Wang, L.; Wang, J.] Gen Hosp Guangzhou Mil Command, Dept Med Res, Guangzhou 510010, Guangdong, Peoples R China; [Wang, L.] S China Univ Technol, Sch Biosci & Bioengn, Guangzhou, Guangdong, Peoples R China	Southern Theater Command General Hospital; South China University of Technology	Wang, J (corresponding author), Gen Hosp Guangzhou Mil Command, Dept Med Res, Liuhua Rd, Guangzhou 510010, Guangdong, Peoples R China.	jiew@tom.com	Xie, Huangming/B-2260-2012	Wang, Li/0000-0001-8321-102X				Adams BD, 2009, MOL ENDOCRINOL, V23, P1215, DOI 10.1210/me.2009-0062; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Berezikov E, 2006, NAT GENET, V38, pS2, DOI 10.1038/ng1794; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cabodi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2563; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139; Connolly EC, 2010, MOL CANCER RES, V8, P691, DOI 10.1158/1541-7786.MCR-09-0465; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102; Divijendra S, 2009, CANCER RES, V69, P5639, DOI 10.1158/0008-5472.CAN-09-0898; Du J, 2009, CELL RES, V19, P487, DOI 10.1038/cr.2009.34; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; FIDLER IJ, 1975, CANCER RES, V35, P218; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Forstemann K, 2007, CELL, V130, P287, DOI 10.1016/j.cell.2007.05.056; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Hedley BD, 2009, ADV CANCER RES, V102, P67, DOI 10.1016/S0065-230X(09)02003-X; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Horikawa T, 2007, CANCER RES, V67, P1970, DOI 10.1158/0008-5472.CAN-06-3933; Hoser M, 2007, J NEUROSCI, V27, P5495, DOI 10.1523/JNEUROSCI.1384-07.2007; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Hurst DR, 2008, J BIOL CHEM, V283, P7438, DOI 10.1074/jbc.M709446200; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Jin ZG, 2007, CURR BIOL, V17, P539, DOI 10.1016/j.cub.2007.01.050; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Khraiwesh B, 2010, CELL, V140, P111, DOI 10.1016/j.cell.2009.12.023; Kim DH, 2008, P NATL ACAD SCI USA, V105, P16230, DOI 10.1073/pnas.0808830105; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li SW, 2009, MOL ENDOCRINOL, V23, P901, DOI 10.1210/me.2008-0368; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372; Lin SL, 2008, RNA, V14, P417, DOI 10.1261/rna.874808; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Moriarty CH, 2010, J BIOL CHEM, V285, P20541, DOI 10.1074/jbc.M110.121012; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Pawelek JM, 2008, NAT REV CANCER, V8, P377, DOI 10.1038/nrc2371; Phadke PA, 2008, AM J PATHOL, V172, P809, DOI 10.2353/ajpath.2008.070772; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Sempere LF, 2010, CLIN CANCER RES, V16, P4246, DOI 10.1158/1078-0432.CCR-10-1152; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862; Spizzo R, 2010, CELL DEATH DIFFER, V17, P246, DOI 10.1038/cdd.2009.117; Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Vaidya KS, 2008, J BIOL CHEM, V283, P28354, DOI 10.1074/jbc.M710068200; Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410; Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; WAGHORNE C, 1988, CANCER RES, V48, P6109; Wang K, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-12; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	138	76	81	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2499	2511		10.1038/onc.2011.444	http://dx.doi.org/10.1038/onc.2011.444			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21963843				2022-12-17	WOS:000304191800001
J	Regan, JL; Kendrick, H; Magnay, FA; Vafaizadeh, V; Groner, B; Smalley, MJ				Regan, J. L.; Kendrick, H.; Magnay, F-A; Vafaizadeh, V.; Groner, B.; Smalley, M. J.			c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer	ONCOGENE			English	Article						Brca1; c-Kit; mammary; progenitor	PROTEIN-TYROSINE KINASE; FUNCTIONAL MAMMARY-GLAND; ESTROGEN-RECEPTOR-ALPHA; 2 SPLICE FORMS; STEM-CELLS; SIGNAL-TRANSDUCTION; LINEAGE-COMMITMENT; BRCA1; ACTIVATION; MOUSE	BRCA1 mutation-associated breast cancer originates in oestrogen receptor-alpha-negative (ER-) progenitors in the mammary luminal epithelium. These cells also express high levels of the Kit gene and a recent study demonstrated a correlation between Brca1 loss and Kit over-expression in the mammary epithelium. However, the functional significance of c-Kit expression in the mammary gland is unknown. To address this, c-Kit(-) and c-Kit(+) mammary epithelial subsets were isolated by flow cytometry, characterised for expression of lineage-specific cell markers and functionally analysed by in vitro colony forming and in vivo transplantation assays. The results confirm that the majority of luminal ER- progenitors are c-Kit(+), but also that most stem cells and the differentiated cell populations are c-Kit(-). A subset of c-Kit(+) cells with high proliferative potential was found in the luminal ER+ population, however, suggesting the existence of a distinct luminal ER+ progenitor cell type. Analysis of mouse Brca1 mammary tumours demonstrated that they expressed Kit and its downstream effector Lyn at levels comparable to the most strongly c-Kit(+) luminal ER- progenitors. Consistent with c-Kit being a progenitor cell marker, in vitro threedimensional differentiation of c-Kit(+) cells resulted in a loss of c-Kit expression, whereas c-Kit over-expression prevented normal differentiation in vivo. Furthermore, c-Kit was a functional marker of proliferative potential, as c-Kit inhibition by short hairpin knockdown prevented normal epithelial growth and caused cells to undergo apoptosis. Therefore, c-Kit defines distinct progenitor populations in the mammary epithelium and is critical for mammary progenitor survival and proliferation. Importantly, c-Kit is only the second mammary epithelial stem/progenitor marker to be shown to have a functional role in the mammary epithelium and the first marker to be shown to be required for progenitor cell function. The c-Kit signalling network has potential as a target for therapy and/or prevention in BRCA1-associated breast cancer. Oncogene (2012) 31, 869-883; doi:10.1038/onc.2011.289; published online 18 July 2011	[Regan, J. L.; Kendrick, H.; Magnay, F-A; Smalley, M. J.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Vafaizadeh, V.; Groner, B.] Georg Speyer Haus, Inst Biomed Res, Frankfurt, Germany	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Octapharma	Smalley, MJ (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	matthew.smalley@icr.ac.uk	Regan, Joseph/K-4188-2019; Smalley, Matthew J/M-7000-2015	Regan, Joseph/0000-0001-9987-7942; Smalley, Matthew J/0000-0001-9540-1146; Vafaizadeh, Vida/0000-0002-0875-6246	Breakthrough Breast Cancer; NHS	Breakthrough Breast Cancer; NHS	We thank Eric So for the c-Kit cDNA, Fredrik Wallberg for help with flow cytometry analysis and Jorge Reis-Filho and Arno Gauthier for assistance with assessment of Lyn staining on mouse tumours. This work was funded by Breakthrough Breast Cancer. We acknowledge NHS funding to the NIHR Biomedical Research Centre. This work was funded by Breakthrough Breast Cancer. We acknowledge NHS funding to the NIHR Biomedical Research Centre.	Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Arendt LM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2819; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Barton J, 2006, J CLIN ONCOL, V24, P10716; Baxter LL, 2004, PIGM CELL RES, V17, P215, DOI 10.1111/j.1600-0749.2004.00147.x; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; Britt KL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2245; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Chew HK, 2006, J CLIN ONCOL S18, V24, P10529; Chin H, 1998, BLOOD, V91, P3734; Clarke RB, 1997, CANCER RES, V57, P4987; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Driessen RL, 2003, EXP HEMATOL, V31, P1284, DOI 10.1016/j.exphem.2003.08.015; Fernandez-Gonzalez R, 2009, INTEGR BIOL, V1, P80, DOI 10.1039/b816933k; Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014-5793(00)02430-3; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Gommerman JL, 2000, BLOOD, V96, P3734, DOI 10.1182/blood.V96.12.3734.h8003734_3734_3742; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Haley BB, 2007, J CLIN ONCOL, V25; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; Huang S, 2007, DEV BIOL, V305, P695, DOI 10.1016/j.ydbio.2007.02.036; Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591; Kent D, 2008, CLIN CANCER RES, V14, P1926, DOI 10.1158/1078-0432.CCR-07-5134; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lilla JN, 2010, DEV BIOL, V337, P124, DOI 10.1016/j.ydbio.2009.10.021; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Mansson R, 2007, IMMUNITY, V26, P407, DOI 10.1016/j.immuni.2007.02.013; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Molyneux G, 2007, CELL MOL LIFE SCI, V64, P3248, DOI 10.1007/s00018-007-7391-5; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shivakrupa R, 2005, CELL SIGNAL, V17, P103, DOI 10.1016/j.cellsig.2004.06.004; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Smart CE, 2011, ONCOGENE, V30, P1597, DOI 10.1038/onc.2010.538; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Vafaizadeh V, 2010, STEM CELLS, V28, P928, DOI 10.1002/stem.407; Vidarsson H, 2002, FEBS LETT, V532, P247, DOI 10.1016/S0014-5793(02)03684-0; Voytyuk O, 2003, J BIOL CHEM, V278, P9159, DOI 10.1074/jbc.M211726200; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WATERHOUSE DM, 2008, J CLIN ONCOL S, V26; Westbury CB, 2009, J PATHOL, V219, P131, DOI 10.1002/path.2581; Young SM, 2007, CELL SIGNAL, V19, P2572, DOI 10.1016/j.cellsig.2007.08.004; Yu M, 2006, J BIOL CHEM, V281, P28615, DOI 10.1074/jbc.M603742200	56	76	77	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					869	883		10.1038/onc.2011.289	http://dx.doi.org/10.1038/onc.2011.289			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21765473				2022-12-17	WOS:000300615800006
J	Szabo, R; Rasmussen, AL; Moyer, AB; Kosa, P; Schafer, JM; Molinolo, AA; Gutkind, JS; Bugge, TH				Szabo, R.; Rasmussen, A. L.; Moyer, A. B.; Kosa, P.; Schafer, J. M.; Molinolo, A. A.; Gutkind, J. S.; Bugge, T. H.			c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase	ONCOGENE			English	Article						hepatocyte growth factor; head and neck carcinoma; mTor; protease-activated signaling; cell surface proteases	HEPATOCYTE GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; PLASMINOGEN-ACTIVATOR; IN-VIVO; FACTOR/SCATTER FACTOR; BARRIER FUNCTION; CANCER; MICE; RAPAMYCIN; RECEPTOR	The progression and negative outcome of a variety of human carcinomas are intimately associated with aberrant activity of the c-Met oncogene. The underlying cause of this dysregulation, however, remains a subject of discussion, as the majority of cancer patients do not present with activating mutations in c-Met receptor itself. In this study, we show that the oncogenic protease matriptase is ubiquitously co-expressed with the c-Met in human squamous cell carcinomas and amplifies migratory and proliferative responses of primary epithelial cells to the cognate ligand for c-Met, pro-hepatocyte growth factor/scatter factor (proHGF/SF), through c-Met and Gab1 signaling. Furthermore, the selective genetic ablation of c-Met from matriptase-expressing keratinocytes completely negates the oncogenic potential of matriptase. In addition, matriptase-dependent carcinoma formation could be blocked by the pharmacological inhibition of the Akt-mammalian target of Rapamycin (mTor) pathway. Our data identify matriptase as an initiator of c-Met-Akt-mTor-dependent signaling axis in tumors and reveal mTor activation as an essential component of matriptase/ c-Met-induced carcinogenesis. The study provides a specific example of how epithelial transformation can be promoted by epigenetic acquisition of the capacity to convert a widely available paracrine growth factor precursor to its signaling competent state. Oncogene (2011) 30, 2003-2016; doi:10.1038/onc.2010.586; published online 10 January 2011	[Szabo, R.; Rasmussen, A. L.; Moyer, A. B.; Kosa, P.; Schafer, J. M.; Molinolo, A. A.; Gutkind, J. S.; Bugge, T. H.] NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), NIDCR, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NIDCR; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000558, ZIADE000551, ZIADE000699] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Snorri Thorgeirsson for floxed Hgfr mice. Supported by NIDCR Intramural Research Program. We thank Dr Mary Jo Danton for critically reviewing this manuscript.	Amornphimoltham P, 2005, CANCER RES, V65, P9953, DOI 10.1158/0008-5472.CAN-05-0921; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Camerer E, 2010, DEV CELL, V18, P25, DOI 10.1016/j.devcel.2009.11.014; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Dai CS, 2010, KIDNEY INT, V77, P962, DOI 10.1038/ki.2010.40; Gailani D, 1997, BLOOD COAGUL FIBRIN, V8, P134, DOI 10.1097/00001721-199703000-00008; Gherardi E, 2006, P NATL ACAD SCI USA, V103, P4046, DOI 10.1073/pnas.0509040103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartmann G, 1998, CURR BIOL, V8, P125, DOI 10.1016/S0960-9822(98)70059-4; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Itoh H, 2004, GASTROENTEROLOGY, V127, P1423, DOI 10.1053/j.gastro.2004.08.027; Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x; Kang JY, 2003, CANCER RES, V63, P1101; Kirchhofer D, 2007, P NATL ACAD SCI USA, V104, P5306, DOI 10.1073/pnas.0700184104; Knudsen BS, 2008, CURR OPIN GENET DEV, V18, P87, DOI 10.1016/j.gde.2008.02.001; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; LICHTI U, 1993, J INVEST DERMATOL, V101, pS124, DOI 10.1111/1523-1747.ep12363165; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Ma H, 2009, KIDNEY INT, V76, P868, DOI 10.1038/ki.2009.304; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Molinolo AA, 2009, ORAL ONCOL, V45, P324, DOI 10.1016/j.oraloncology.2008.07.011; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Owen KA, 2010, BIOCHEM J, V426, P219, DOI 10.1042/BJ20091448; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pauer HU, 2004, THROMB HAEMOSTASIS, V92, P503, DOI 10.1160/TH04-04-0250; Peek M, 2002, J BIOL CHEM, V277, P47804, DOI 10.1074/jbc.M209778200; Raimondi AR, 2009, CANCER RES, V69, P4159, DOI 10.1158/0008-5472.CAN-08-4645; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Seiwert TY, 2009, CANCER RES, V69, P3021, DOI 10.1158/0008-5472.CAN-08-2881; Shanmukhappa K, 2009, J BIOL CHEM, V284, P12917, DOI 10.1074/jbc.M807313200; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Szabo R, 2008, INT J BIOCHEM CELL B, V40, P1297, DOI 10.1016/j.biocel.2007.11.013; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Williams-Simons L, 1999, TRANSGENIC RES, V8, P253, DOI 10.1023/A:1008994831937; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	50	76	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2003	2016		10.1038/onc.2010.586	http://dx.doi.org/10.1038/onc.2010.586			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217780	Green Accepted			2022-12-17	WOS:000289977400004
J	Hrstka, R; Nenutil, R; Fourtouna, A; Maslon, MM; Naughton, C; Langdon, S; Murray, E; Larionov, A; Petrakova, K; Muller, P; Dixon, MJ; Hupp, TR; Vojtesek, B				Hrstka, R.; Nenutil, R.; Fourtouna, A.; Maslon, M. M.; Naughton, C.; Langdon, S.; Murray, E.; Larionov, A.; Petrakova, K.; Muller, P.; Dixon, M. J.; Hupp, T. R.; Vojtesek, B.			The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers	ONCOGENE			English	Article						AGR2; tamoxifen; letrozole; estrogen receptor; breast cancer	HUMAN ESTROGEN-RECEPTOR; PROGESTERONE RECEPTORS; RESPONSE ELEMENT; HUMAN HOMOLOG; GENE XAG-2; CELL-LINES; EXPRESSION; AGR2; RESISTANCE; HYBRIDIZATION	Transcriptomic screens in breast cancer cell lines have identified a protein named anterior gradient-2 (AGR2) as a potentially novel oncogene overexpressed in estrogen receptor (ER) positive tumours. As targeting the ER is responsible for major improvements in cure rates and prevention of breast cancers, we have evaluated the prooncogenic function of AGR2 in anti-hormone therapeutic responses. We show that AGR2 expression promotes cancer cell survival in clonogenic assays and increases cell proliferation and viability in a range of cancer cell lines. Chromatin immunoprecipitation and reporter assays indicate that AGR2 is transcriptionally activated by estrogen through ER alpha. However, we also found that AGR2 expression is elevated rather than inhibited in response to tamoxifen, thus identifying a novel mechanism to account for an agonistic effect of the drug on a specific pro-oncogenic pathway. Consistent with these data, clinical analysis indicates that AGR2 expression is related to treatment failure in ER alpha-positive breast cancers treated with tamoxifen. In contrast, AGR2 is one of the most highly suppressed genes in cancers of responding patients treated with the anti-hormonal drug letrozole. These data indicate that the AGR2 pathway represents a novel pro-oncogenic pathway for evaluation as anti-cancer drug developments, especially therapies that by-pass the agonist effects of tamoxifen. Oncogene (2010) 29, 4838-4847; doi:10.1038/onc.2010.228; published online 7 June 2010	[Hrstka, R.; Nenutil, R.; Petrakova, K.; Muller, P.; Vojtesek, B.] Masaryk Mem Canc Inst, Dept Oncol & Expt Pathol, Brno 65653, Czech Republic; [Fourtouna, A.; Maslon, M. M.; Naughton, C.; Langdon, S.; Murray, E.; Hupp, T. R.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Fourtouna, A.; Maslon, M. M.; Naughton, C.; Langdon, S.; Murray, E.; Hupp, T. R.] Univ Edinburgh, Canc Res UK Signal Transduct Labs P53, Edinburgh, Midlothian, Scotland; [Larionov, A.; Dixon, M. J.] Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Masaryk Memorial Cancer Institute; University of Edinburgh; University of Edinburgh; University of Edinburgh	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Dept Oncol & Expt Pathol, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Muller, Petr/AAK-5014-2021; Maslon, Magdalena/AAC-4790-2022; RASOR, Scotland/A-3274-2011; Maslon, Magdalena/AAB-9609-2020; Muller, Petr/F-7762-2015; Hrstka, Roman/AAM-4430-2020; Larionov, Alexey/A-5088-2010	Muller, Petr/0000-0002-8404-4494; Muller, Petr/0000-0002-8404-4494; Hrstka, Roman/0000-0002-6139-2664; Larionov, Alexey/0000-0001-6374-9391; Nenutil, Rudolf/0000-0003-0068-9760; Maslon, Magdalena/0000-0002-1050-1306; Naughton, Catherine/0000-0002-9576-5983	GACR [P301/10/1615]; IGA MZCR [NS/9812-4, MZ0MOU2005]; Cancer Research UK [C483/A10706, C483/A6354]; Breast Cancer Campaign Garfield Weston PhD studentship on AGR2 pathway regulation; BBSRC; Breakthrough Breast Cancer	GACR(Grant Agency of the Czech Republic); IGA MZCR; Cancer Research UK(Cancer Research UK); Breast Cancer Campaign Garfield Weston PhD studentship on AGR2 pathway regulation; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Breakthrough Breast Cancer	We thank Tamara Smerdova and Sona Babcanova for their excellent technical assistance and Larry Hayward for critical discussions. This work was supported by the GACR P301/10/1615, IGA MZCR NS/9812-4 and MZ0MOU2005. Ted Hupp was supported by grants C483/A10706 and C483/A6354 from the Cancer Research UK, a Breast Cancer Campaign Garfield Weston PhD studentship on AGR2 pathway regulation (AF), and the BBSRC (EM). Mike Dixon was supported by Breakthrough Breast Cancer.	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Anderson I, 2000, BIOCHEMISTRY-US, V39, P3842, DOI 10.1021/bi9924516; Barraclough DL, 2009, AM J PATHOL, V175, P1848, DOI 10.2353/ajpath.2009.090246; Barraclough DL, 2010, CELL ONCOL, V32, P87, DOI 10.3233/CLO-2009-0499; Brunner N, 1997, CANCER RES, V57, P3486; Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106; Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740; Fritzsche FR, 2006, CLIN CANCER RES, V12, P1728, DOI 10.1158/1078-0432.CCR-05-2057; Goetz MP, 2003, JNCI-J NATL CANCER I, V95, P1734, DOI 10.1093/jnci/djg129; Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008; Gunthert AR, 2005, EUR J ENDOCRINOL, V153, P613, DOI 10.1530/eje.1.01996; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Innes HE, 2006, BRIT J CANCER, V94, P1057, DOI 10.1038/sj.bjc.6603065; JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004; Kim NS, 2007, J BIOCHEM MOL BIOL, V40, P212; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Kondrakhin Yury V, 2008, In Silico Biol, V8, P383; Kumar A, 2007, SCIENCE, V318, P772, DOI 10.1126/science.1147710; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lee S, 2006, ONCOL REP, V16, P747; Liu D, 2005, CANCER RES, V65, P3796, DOI 10.1158/0008-5472.CAN-04-3823; Mackay A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1732; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Normanno N, 2005, ENDOCR-RELAT CANCER, V12, P721, DOI 10.1677/erc.1.00857; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Petek E, 2000, CYTOGENET CELL GENET, V89, P141, DOI 10.1159/000015594; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Ramachandran V, 2008, CANCER RES, V68, P7811, DOI 10.1158/0008-5472.CAN-08-1320; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Robertson JFR, 1996, INT J BIOL MARKER, V11, P29, DOI 10.1177/172460089601100106; Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330; Stendahl M, 2004, BRIT J CANCER, V90, P1942, DOI 10.1038/sj.bjc.6601831; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; Tyulmenkov VV, 2001, MOL CELL ENDOCRINOL, V182, P109, DOI 10.1016/S0303-7207(01)00508-1; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang Z, 2008, CANCER RES, V68, P492, DOI 10.1158/0008-5472.CAN-07-2930; Zhang Y, 2007, PROSTATE CANCER P D, V10, P293, DOI 10.1038/sj.pcan.4500960; Zheng W, 2006, GENES IMMUN, V7, P11, DOI 10.1038/sj.gene.6364263; Zhu H, 2007, CANCER LETT, V245, P303, DOI 10.1016/j.canlet.2006.01.020; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	43	76	79	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4838	4847		10.1038/onc.2010.228	http://dx.doi.org/10.1038/onc.2010.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20531310				2022-12-17	WOS:000281326400009
J	Cobbold, LC; Wilson, LA; Sawicka, K; King, HA; Kondrashov, AV; Spriggs, KA; Bushell, M; Willis, AE				Cobbold, L. C.; Wilson, L. A.; Sawicka, K.; King, H. A.; Kondrashov, A. V.; Spriggs, K. A.; Bushell, M.; Willis, A. E.			Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1	ONCOGENE			English	Article						translation; IRES; c-myc; protein synthesis	BINDING-PROTEIN; SITE FUNCTION; CELL-LINE; SEGMENT; TRANSLATION; INITIATION; IDENTIFICATION; MECHANISM; FAMILY; GROWTH	The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment (IRES) and c-myc translation can therefore be initiated by internal ribosome entry as well as by cap-dependent mechanisms. It has been shown previously that in patients with multiple myeloma (MM) and in MM-derived cell lines there is a C to T mutation in the c-myc IRES that increases IRES activity and the corresponding synthesis of c-myc protein although it is not fully understood how this occurs. Our data show that two recently identified c-myc IRES transacting factors, Y-box binding protein 1 (YB-1) and polypyrimidine tract-binding protein 1 (PTB-1), bind more strongly (approximately 3.5- and 2-fold respectively) to the mutated version of the c-myc IRES and in vitro these proteins exert their effect synergistically to stimulate IRES activity of the mutant IRES 4.5-fold more than the wild-type version. Importantly, we show that there is a strong correlation between the expression of PTB-1, YB-1 and c-myc in MM-derived cell lines, suggesting that by reducing either PTB-1 or YB-1 protein levels it is possible to decrease c-myc expression and inhibit cell proliferation of MM-derived cell lines. Oncogene (2010) 29, 2884-2891; doi: 10.1038/onc.2010.31; published online 1 March 2010	[Cobbold, L. C.; Wilson, L. A.; Sawicka, K.; King, H. A.; Kondrashov, A. V.; Spriggs, K. A.; Bushell, M.; Willis, A. E.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England	University of Nottingham	Willis, AE (corresponding author), Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Univ Pk, Nottingham NG7 2RD, England.	anne.willis@nottingham.ac.uk		Sawicka, Kirsty/0000-0003-4195-6327; Willis, Anne/0000-0002-1470-8531; Kondrashov, Alexander/0000-0003-3428-5975	BBSRC; CRUK; Biotechnology and Biological Sciences Research Council [BB/F006926/1] Funding Source: researchfish; Medical Research Council [MC_UP_A600_1023] Funding Source: researchfish; BBSRC [BB/F006926/1] Funding Source: UKRI; MRC [MC_UP_A600_1023] Funding Source: UKRI	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); CRUK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by grants from the BBSRC (LCC, HAK) and CRUK (LAW, AVK). Martin Bushell is a BBSRC David Philips fellow and Anne Willis holds a BBSRC professorial fellowship. We thank Professor Dalton (Moffitt Cancer Center, Florida, USA) for providing the cell line 8226/R5.	Bader AG, 2008, ONCOGENE, V27, P1179, DOI 10.1038/sj.onc.1210719; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boutz PL, 2007, GENE DEV, V21, P71, DOI 10.1101/gad.1500707; Chappell SA, 2000, ONCOGENE, V19, P4437, DOI 10.1038/sj.onc.1203791; Chatterjee M, 2008, BLOOD, V111, P3714, DOI 10.1182/blood-2007-05-089151; Cobbold LC, 2008, MOL CELL BIOL, V28, P40, DOI 10.1128/MCB.01298-07; DALTON WS, 1986, CANCER RES, V46, P5125; Drach J, 2000, J CANCER RES CLIN, V126, P441, DOI 10.1007/s004320050011; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; He X, 2007, ONCOGENE, V26, P4961, DOI 10.1038/sj.onc.1210307; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Ho P Joy, 2002, Rev Clin Exp Hematol, V6, P276, DOI 10.1046/j.1468-0734.2002.00081.x; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Mitchell SA, 2005, GENE DEV, V19, P1556, DOI 10.1101/gad.339105; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spriggs KA, 2009, MOL CELL BIOL, V29, P1565, DOI 10.1128/MCB.01283-08; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang C, 2008, J BIOL CHEM, V283, P20277, DOI 10.1074/jbc.M803682200	33	76	80	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2884	2891		10.1038/onc.2010.31	http://dx.doi.org/10.1038/onc.2010.31			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190818				2022-12-17	WOS:000277591900013
J	Soto-Reyes, E; Recillas-Targa, F				Soto-Reyes, E.; Recillas-Targa, F.			Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines	ONCOGENE			English	Article						tumor suppressor gene; CTCF; epigenetics; DNA methylation; p53 human promoter and histone covalent modifications	TUMOR-SUPPRESSOR; DNA METHYLATION; HUMAN GENOME; PROTEIN CTCF; CANCER; BINDING; EXPRESSION; INSULATOR; REGION; DOMAIN	Epigenetic silencing of tumor suppressor gene promoters has become a more frequent phenomenon in cancer than previously anticipated. In this study we addressed the mechanisms involved in the protection of the p53 tumor suppressor gene against epigenetic silencing in human transformed cell lines. We characterized a binding site for the CCCTC-binding factor (CTCF) in the human p53 gene promoter that contributes to its transcriptional expression, and has the ability to maintain this regulatory element in a local open chromatin configuration. In the absence of CTCF we observe the incorporation of repressive histone marks, such as H3K9me3, H3K27me3 and H4K20me3, in different sub-domains of the upstream regulatory sequence. This evidence suggests that CTCF protects the p53 gene promoter against repressive histone marks. Notably, no apparent direct correlation between repression and DNA hypermethylation has been detected. Together, we present evidence supporting the relevant role of CTCF in the epigenetic regulation of tumor suppressor genes and cancer. We propose that CTCF is a strategic component responsible for the maintenance and segregation of epigenetic traits. Oncogene (2010) 29, 2217-2227; doi: 10.1038/onc.2009.509; published online 25 January 2010	[Soto-Reyes, E.; Recillas-Targa, F.] Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Recillas-Targa, F (corresponding author), Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Apartado Postal 70-242, Mexico City 04510, DF, Mexico.	frecilla@ifc.unam.mx	Xie, Huangming/B-2260-2012	Soto-Reyes, Ernesto/0000-0002-4219-6406	Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Mexico [IN209403, IN214407]; Consejo Nacional de Ciencia y Tecnologia (CONACyT) [42653-Q, 58767, 181389]; Fundacion Miguel Aleman, AC; Direccion General de estudios de Posgrado-Universidad Nacional Autonoma de Mexico (DGEP); Doctorado en Ciencias Biomedicas	Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Mexico(Universidad Nacional Autonoma de Mexico); Consejo Nacional de Ciencia y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Fundacion Miguel Aleman, AC; Direccion General de estudios de Posgrado-Universidad Nacional Autonoma de Mexico (DGEP)(Universidad Nacional Autonoma de Mexico); Doctorado en Ciencias Biomedicas	We thank Inti Alberto de la Rosa-Velazquez, Catherine Farrell, Mayra Furlan-Magaril, Francisco Antequera, Abrahan Hernandez-Hernandez, Martin Escamilla-del-Arenal and Hector Rincon-Arano for suggestions and constant scientific discussions. We are particularly indebted with the excellent technical assistance of Georgina Guerrero Avendano, members of the Felix Recillas-Targa laboratory, Dr JA Garcia-Sainz and the Instituto de Fisiologia Celular, UNAM. We thank L Ongay, G Codiz and M Mora from the Unidad de Biologia Molecular, IFC-UNAM, for DNA sequencing. This work was supported by the Direccion General de Asuntos del Personal Academico-Universidad Nacional Autonoma de Mexico (IN209403 and IN214407), Consejo Nacional de Ciencia y Tecnologia (CONACyT: 42653-Q and 58767) and Fundacion Miguel Aleman, AC. E Soto-Reyes is supported by a PhD fellowship from CONACyT (181389) and Direccion General de estudios de Posgrado-Universidad Nacional Autonoma de Mexico (DGEP). Additional support was provided by the PhD Graduate Program of Doctorado en Ciencias Biomedicas.	Amatya VJ, 2005, ACTA NEUROPATHOL, V110, P178, DOI 10.1007/s00401-005-1041-5; Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002; Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324; De la Rosa-Velazquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024; Docquier F, 2009, CLIN CANCER RES, V15, P5762, DOI 10.1158/1078-0432.CCR-09-0329; El-Kady A, 2005, FEBS LETT, V579, P1424, DOI 10.1016/j.febslet.2005.01.044; Escamilla-Del-Arenal M, 2008, MOL CELL BIOL, V28, P575, DOI 10.1128/MCB.00943-07; Filippova GN, 2008, CURR TOP DEV BIOL, V80, P337, DOI 10.1016/S0070-2153(07)80009-3; Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Ishihara K, 2006, MOL CELL, V23, P733, DOI 10.1016/j.molcel.2006.08.008; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jelinic P, 2006, PLOS BIOL, V4, P1910, DOI 10.1371/journal.pbio.0040355; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Kim TH, 2007, CELL, V128, P1231, DOI 10.1016/j.cell.2006.12.048; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; Mahmoudi S, 2009, MOL CELL, V33, P462, DOI 10.1016/j.molcel.2009.01.028; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Nguyen P, 2008, CANCER RES, V68, P5546, DOI 10.1158/0008-5472.CAN-08-1005; Pogribny IP, 2000, CANCER RES, V60, P588; Recillas-Targa F, 2006, J CELL MOL MED, V10, P554, DOI 10.1111/j.1582-4934.2006.tb00420.x; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Su CH, 2009, MOL CELL BIOL, V29, P93, DOI 10.1128/MCB.00704-08; Sun LC, 2008, CANCER RES, V68, P2726, DOI 10.1158/0008-5472.CAN-07-6654; Valadez-Graham V, 2004, NUCLEIC ACIDS RES, V32, P1354, DOI 10.1093/nar/gkh301; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Williams A, 2008, J EXP MED, V205, P747, DOI 10.1084/jem.20080066; Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426	41	76	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2217	2227		10.1038/onc.2009.509	http://dx.doi.org/10.1038/onc.2009.509			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101205				2022-12-17	WOS:000276685200007
J	Ebi, H; Sato, T; Sugito, N; Hosono, Y; Yatabe, Y; Matsuyama, Y; Yamaguchi, T; Osada, H; Suzuki, M; Takahashi, T				Ebi, H.; Sato, T.; Sugito, N.; Hosono, Y.; Yatabe, Y.; Matsuyama, Y.; Yamaguchi, T.; Osada, H.; Suzuki, M.; Takahashi, T.			Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers	ONCOGENE			English	Article						small-cell lung cancer; DNA damage response; miRNA; RB; reactive oxygen species	CHECKPOINT IMPAIRMENT; E2F1; IDENTIFICATION; EXPRESSION; MICRORNAS; APOPTOSIS; PATHWAY; DELETION; MIR-20A; CLUSTER	Small-cell lung cancer (SCLC) is a highly aggressive disease that exhibits rapid growth and genetic instability. We found earlier frequent overexpression of the miR-17-92 microRNA cluster, and showed that SCLC cells were addicted to continued expressions of miR-17-5p and miR-20a, major components of this microRNA cluster. In this study, we identified the frequent presence of constitutively phosphorylated H2AX (gamma-H2AX), which reflects continuing DNA damage, preferentially in SCLC. Knockdown of RB induced gamma-H2AX foci formation in non-small cell lung cancer (NSCLC) cells with wild-type RB, in association with growth inhibition and reactive oxygen species (ROS) generation, which was canceled by overexpression of miR-17-92. Conversely, induction of gamma-H2AX was observed in a miR-17-92-overexpressing SCLC cell line with miR-20a antisense oligonucleotides. These findings suggest that miR-17-92 overexpression may serve as a fine-tuning influence to counterbalance the generation of DNA damage in RB-inactivated SCLC cells, thus reducing excessive DNA damage to a tolerable level and consequently leading to genetic instability. Therefore, miR-17-92 may be an excellent therapeutic target candidate to elicit excessive DNA damage in combination with DNA-damaging chemotherapeutics. Oncogene (2009) 28, 3371-3379; doi: 10.1038/onc.2009.201; published online 13 July 2009	[Ebi, H.; Sato, T.; Sugito, N.; Hosono, Y.; Matsuyama, Y.; Yamaguchi, T.; Suzuki, M.; Takahashi, T.] Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc,Showa Ku, Nagoya, Aichi 4668550, Japan; [Yatabe, Y.] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diag, Showa Ku, Nagoya, Aichi 464, Japan; [Osada, H.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Showa Ku, Nagoya, Aichi 464, Japan	Nagoya University; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Div Mol Carcinogenesis, Ctr Neurol Dis & Canc,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	tak@med.nagoya-u.ac.jp	Hosono, Yasuyuki/J-4295-2019; Hosono, Yasuyuki/GOP-1342-2022; Ebi, Hiromichi/AAA-7358-2019; Suzuki, Motoshi/I-7246-2014; YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Yamaguchi, Tomoya/AAN-7524-2020	Ebi, Hiromichi/0000-0003-3155-7576; Suzuki, Motoshi/0000-0003-0682-5006; YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Yamaguchi, Tomoya/0000-0001-6933-543X	Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science; Princess Takamatsu Cancer Research Fund [07-23903]; International Association for the Study of Lung Cancer (IASLC)	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Princess Takamatsu Cancer Research Fund; International Association for the Study of Lung Cancer (IASLC)	This work was financially supported in part by a Grant-in-Aid for Scientific Research on priority areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, and a Grant (07-23903) from the Princess Takamatsu Cancer Research Fund. HE was supported by the IASLC fellowship of the International Association for the Study of Lung Cancer (IASLC) during this study.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Ebi H, 2007, CANCER RES, V67, P11158, DOI 10.1158/0008-5472.CAN-07-1749; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Konishi H, 2002, CANCER RES, V62, P271; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Nakagawa T, 2004, CANCER RES, V64, P4826, DOI 10.1158/0008-5472.CAN-04-0871; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pickering MT, 2009, ONCOGENE, V28, P140, DOI 10.1038/onc.2008.372; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Taguchi A, 2008, CANCER RES, V68, P5540, DOI 10.1158/0008-5472.CAN-07-6460; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	28	76	81	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3371	3379		10.1038/onc.2009.201	http://dx.doi.org/10.1038/onc.2009.201			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19597473				2022-12-17	WOS:000270103300004
J	Knight, AS; Notaridou, M; Watson, RJ				Knight, A. S.; Notaridou, M.; Watson, R. J.			A Lin-9 complex is recruited by B-Myb to activate transcription of G(2)/M genes in undifferentiated embryonal carcinoma cells	ONCOGENE			English	Article						cell cycle; mitosis; transcription; B-Myb; Lin-9; LINC	MUVB/DREAM COMPLEX; REPRESSOR COMPLEX; DROSOPHILA MYB; EXPRESSION; PROTEINS; PHOSPHORYLATION; PROGRESSION; DISTINCT; KINASE; CANCER	It has recently been discovered that cell-cycle gene transcription is regulated by a core complex named LINC that switches from a transcriptionally repressive complex in G(0)-G(1) with the p130 or p107 pocket proteins and E2F4 to a transcriptionally active complex in S-G(2) containing B-Myb. We have studied the function of LINC in F9 embryonal carcinoma cells, which are distinguished by a rapid cell cycle resulting from an extremely short G(1) phase. We show that suppressing expression of the LINC component, Lin-9, in F9 cells causes arrest in mitosis, and we have used this system to screen for transcriptional targets. In these cells, B-Myb was found in complexes with Lin-9 and several other LINC constituents, however, the pocket proteins did not associate with LINC unless F9 cells were differentiated. Lin-9 and B-Myb were both required for transcription of G(2)/M genes such as Cyclin B1 and Survivin. Moreover, B-Myb was demonstrated to recruit Lin-9 to the Survivin promoter through multiple Myb-binding sites. The demonstration that a B-Myb/LINC complex is vital for progression through mitosis in cells lacking a G(1)/S checkpoint has implications for both undifferentiated embryonal cells and for cancers in which pocket protein function is compromised.	[Knight, A. S.; Notaridou, M.; Watson, R. J.] Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, London W2 1PG, England	Imperial College London	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, St Marys Campus,Norfolk Pl, London W2 1PG, England.	r.watson@imperial.ac.uk			Association for International Cancer Research [06-030]	Association for International Cancer Research	We thank Stephan Gaubatz and Alexander Brehm for the kind gifts of LINC antibodies and human Lin-9 cDNA, respectively. This work was supported by a project grant from the Association for International Cancer Research (06-030).	Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Georlette D, 2007, GENE DEV, V21, P2880, DOI 10.1101/gad.1600107; Harrison MM, 2006, P NATL ACAD SCI USA, V103, P16782, DOI 10.1073/pnas.0608461103; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tarasov KV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002478; Tavner F, 2007, ONCOGENE, V26, P2727, DOI 10.1038/sj.onc.1210087; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Wen H, 2008, GENE DEV, V22, P601, DOI 10.1101/gad.1626308; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Yamauchi T, 2008, EMBO J, V27, P1852, DOI 10.1038/emboj.2008.118; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	26	76	77	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	2009	28	15					1737	1747		10.1038/onc.2009.22	http://dx.doi.org/10.1038/onc.2009.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19252525				2022-12-17	WOS:000265640400001
J	Maroto, B; Ye, MB; von Lohneysen, K; Schnelzer, A; Knaus, UG				Maroto, B.; Ye, M. B.; von Lohneysen, K.; Schnelzer, A.; Knaus, U. G.			P21-activated kinase is required for mitotic progression and regulates Plk1	ONCOGENE			English	Article						p21-activated kinase; Plk1; cell cycle	POLO-LIKE KINASE-1; BREAST-CANCER CELLS; SPINDLE POLES; HISTONE H3; AURORA-A; PHOSPHORYLATION; PAK1; ACTIVATION; LOCALIZATION; CYTOKINESIS	P21-activated kinases (Paks), a family of serine/threonine kinases, are effectors of the Rho GTPases Cdc42 and Rac1. Mammalian Pak1 and Pak homologs in simple eukaryotes are implicated in controlling G2/M transition and/or mitosis. Another serine/threonine kinase, polo-like kinase 1 (Plk1), is an important regulator of mitotic events, such as centrosome maturation, mitotic entry, spindle formation, sister chromatid cohesion and cytokinesis. Plk1 phosphorylation is thought to be one of the critical regulatory events leading to these Plk1-mediated functions. We show here that Pak1 is required for cell proliferation, mitotic progression and Plk1 activity in HeLa cells. Gain or loss of Pak function directly impacted phosphorylation and activity of Plk1. Phosphorylation of Plk1 on Ser 49 is important for metaphase-associated events. Inhibition of Pak activity leads to delay in G2/M progression and abnormal spindle formation, mirroring some attributes of Plk1 deregulation. Our results reveal a role for Pak in regulating Plk1 activity and mitotic progression, and connect Pak to the complex protein interaction network enabling cell division.	[Maroto, B.; Ye, M. B.; von Lohneysen, K.; Schnelzer, A.; Knaus, U. G.] Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Knaus, UG (corresponding author), Scripps Res Inst, Dept Immunol, IMM28,10550 N Torrey Pines Rd,R203, La Jolla, CA 92037 USA.	uknaus@scripps.edu		Schnelzer, Andreas/0000-0002-5410-3561	NIH [AI35947, AI24838, AI07244-22]; University of California [8FB-0026]; German Academic Exchange; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244, R01AI035947, R01AI024838] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California(University of California System); German Academic Exchange(Deutscher Akademischer Austausch Dienst (DAAD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank E Nishida for Plk wild-type constructs, the laboratories of G Bokoch and S Reed for sharing antibodies, J Birkenfeld for advice and K Schreiber for illustrations and administrative assistance. This work was supported by NIH (AI35947, AI24838 to UGK), by funds from the California Breast Cancer Research Program of the University of California 8FB-0026 (BM), NIH training grant T32 AI07244-22 (MY) and a German Academic Exchange (DAAD) fellowship (AS).	Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; BODE AM, 2005, SCI STKE, pRE4; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; De Luca M, 2006, CELL CYCLE, V5, P296; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Glover DM, 2005, ONCOGENE, V24, P230, DOI 10.1038/sj.onc.1208279; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Nheu T, 2004, CELL CYCLE, V3, P71; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Seong YS, 2002, J BIOL CHEM, V277, P32282, DOI 10.1074/jbc.M202602200; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thullberg M, 2007, ONCOGENE, V26, P1820, DOI 10.1038/sj.onc.1209983; Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005; van de Weerdt BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/cc.5.8.2692; van de Weerdt BCM, 2005, MOL CELL BIOL, V25, P2031, DOI 10.1128/MCB.25.5.2031-2044.2005; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	36	76	76	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4900	4908		10.1038/onc.2008.131	http://dx.doi.org/10.1038/onc.2008.131			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18427546				2022-12-17	WOS:000258596900004
J	Jiemjit, A; Fandy, TE; Carraway, H; Bailey, KA; Baylin, S; Herman, JG; Gore, SD				Jiemjit, A.; Fandy, T. E.; Carraway, H.; Bailey, K. A.; Baylin, S.; Herman, J. G.; Gore, S. D.			p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage	ONCOGENE			English	Article; Proceedings Paper	96th Annual Meeting of the American-Association-for-Cancer-Research	APR 16-20, 2005	Anaheim, CA	Amer Assoc Canc Res		decitabine; apoptosis; DNA methyltransferase inhibitors; histone deacetylase inhibitors; epigenetics; p21	HISTONE DEACETYLASE INHIBITION; ACUTE MYELOID-LEUKEMIA; 5-AZA-2'-DEOXYCYTIDINE DECITABINE; HEMATOPOIETIC MALIGNANCIES; FUNDAMENTAL ROLE; GENE-EXPRESSION; CANCER-CELLS; METHYLATION; DEMETHYLATION; APOPTOSIS	Decitabine (DAC) and 5-azacitidine have recently been approved for the treatment of myelodysplastic syndrome. The pharmacodynamic effects of DAC and 5-azacitidine outside their known activity as inhibitors of DNA methyltransferases (DNMTs) require further investigation. The purpose of this study was to investigate the effect of DAC on the expression of p21(WAF1/CIP1), a gene with a putative CpG island surrounding its promoter region. Promoter methylation analysis of p21(WAF1/CIP1) in leukemia cells revealed the absence of CpG methylation. However, DAC upregulated p21(WAF1/CIP1) expression in a dose-dependent manner (ED(50) = 103.34 nM) and induced G2/M cell cycle arrest in leukemia cells. Sequential application of DAC followed by different histone deacetylase inhibitors induced expression of p21(WAF1/CIP1) synergistically. Upregulation of p21(WAF1/CIP1) paralleled DAC-induced apoptosis (ED50 = 153 nM). Low doses of DAC induced gamma-H2AX expression (ED(50) =16.5 nM) and upregulated p21(WAF1/CIP1) in congenic HCT 116 colon cancer cells in a DNMT-independent and p53-dependent fashion. Inhibition of p53 transactivation by pifithrin-alpha or the kinase activity of ATM by either the specific ATM inhibitor KU-5593 or caffeine abrogated p21(WAF1/CIP1) upregulation, indicating that DAC upregulation of p21(WAF1/CIP1) was p53- and ATM-dependent in leukemia cells. In conclusion, DAC upregulates p21(WAF1/CIP1) in DNMT-independent manner via the DNA damage/ATM/p53 axis.	[Jiemjit, A.; Fandy, T. E.; Carraway, H.; Bailey, K. A.; Baylin, S.; Herman, J. G.; Gore, S. D.] Sidney Kimmel Comprehens Canc Ctr John Hopkins, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Gore, SD (corresponding author), Sidney Kimmel Comprehens Canc Ctr John Hopkins, 1650 Orleans St, Baltimore, MD 21231 USA.	gorest@jhmi.edu	Carraway, Hetty/AAR-4977-2020; Bailey, Kayleen/G-7716-2018	Carraway, Hetty/0000-0001-5241-3614; Bailey, Kayleen/0000-0002-8193-642X	NCI NIH HHS [R01 CA125635, L30 CA111124-01, P30 CA006973, K24CA111717, L30 CA111124, K24 CA111717, P30 CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006973, K24CA111717, R01CA125635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brakensiek K, 2005, LEUKEMIA RES, V29, P1357, DOI 10.1016/j.leukres.2005.04.012; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHOU TC, 1977, J BIOL CHEM, V252, P6438; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Galm O, 2004, LEUKEMIA, V18, P1687, DOI 10.1038/sj.leu.2403434; Gartel AL, 2005, LEUKEMIA RES, V29, P1237, DOI 10.1016/j.leukres.2005.04.023; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Ju R, 2003, CANCER RES, V63, P2891; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KASTAN MB, 1991, CANCER RES, V51, P6304; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sarkaria JN, 1999, CANCER RES, V59, P4375; Schmelz K, 2005, LEUKEMIA, V19, P103, DOI 10.1038/sj.leu.2403552; Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Tamm I, 2005, ANN HEMATOL, V84, P47, DOI 10.1007/s00277-005-0013-0; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970	33	76	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2008	27	25					3615	3623		10.1038/sj.onc.1211018	http://dx.doi.org/10.1038/sj.onc.1211018			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223691	Green Accepted			2022-12-17	WOS:000256468500013
J	Miyamoto, D; Miyamoto, M; Takahashi, A; Yomogita, Y; Higashi, H; Kondo, S; Hatakeyama, M				Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M.			Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors	ONCOGENE			English	Article						SHP-2; gain-of-function mutation; NIH3T3; solid tumor; oncogenic RAS	PROTEIN-TYROSINE-PHOSPHATASE; HELICOBACTER-PYLORI CAGA; CAUSE NOONAN-SYNDROME; JUVENILE MYELOMONOCYTIC LEUKEMIA; SOMATIC PTPN11 MUTATIONS; FACIO-CUTANEOUS SYNDROME; GROWTH-FACTOR RECEPTOR; GERMLINE MUTATIONS; LEUKEMOGENESIS; ACTIVATION	SHP-2 protein tyrosine phosphatase plays an important role in activation of the RAS-dependent signaling. Gain-of-function mutations in the PTPN11 gene, which encodes SHP-2, have been found in the leukemia-prone developmental disorder Noonan syndrome as well as sporadic childhood leukemias, indicating that SHP-2 is a bona. de human oncoprotein. However, the role of SHP-2 mutations in non-hematological malignancies remains obscure. Here, we screened for PTPN11 mutations in primary solid tumors and identified a 1520C > A mutation that causes threonine-507 to lysine (T507K) substitution in the phosphatase domain of SHP-2 in a case of hepatocellular carcinoma. T507K SHP-2 exhibited altered substrate specificity with slightly elevated basal phosphatase activity. Upon expression in NIH3T3 cells, T507K SHP-2 induced transformed foci, which was not observed with wild type, Noonan-specific or leukemia-specific SHP-2. Furthermore, NIH3T3 cells transformed by T507K SHP-2 showed anchorage-independent growth and developed tumors in nude mice. These results indicate that quantitative and/or qualitative alteration in phosphatase activity determines the transforming potential as well as target cell/tissue spectrum of individual SHP-2 mutants as oncoproteins. Although rare in solid tumors, the identified T507K SHP-2 represents a distinct class of SHP-2 mutants with oncogenic RAS-like transforming activity, which could contribute to the development of solid tumors.	[Hatakeyama, M.] Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan; [Miyamoto, D.; Miyamoto, M.; Kondo, S.] Hokkaido Univ, Grad Sch Med, Div Surg Oncol, Sapporo, Hokkaido 0600815, Japan	Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Div Mol Oncol, Inst Med Genet, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp	Higashi, Hideaki/F-6872-2012	Kanemitsu, Atsushi/0000-0002-4156-9522				Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Aoki Y, 2005, NAT GENET, V37, P1038, DOI 10.1038/ng1641; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chen YY, 2006, GENE CHROMOSOME CANC, V45, P583, DOI 10.1002/gcc.20322; Choong K, 1999, J PEDIAT HEMATOL ONC, V21, P523, DOI 10.1097/00043426-199911000-00014; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Digilio MC, 2002, AM J HUM GENET, V71, P389, DOI 10.1086/341528; Gelb BD, 2006, HUM MOL GENET, V15, pR220, DOI 10.1093/hmg/ddl197; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Higashi H, 2004, J BIOL CHEM, V279, P17205, DOI 10.1074/jbc.M309964200; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kosaki K, 2002, J CLIN ENDOCR METAB, V87, P3529, DOI 10.1210/jc.87.8.3529; Lauchle JO, 2006, PEDIATR BLOOD CANCER, V46, P579, DOI 10.1002/pbc.20644; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martinelli S, 2006, CANCER GENET CYTOGEN, V166, P124, DOI 10.1016/j.cancergencyto.2005.10.003; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Roberts AE, 2007, NAT GENET, V39, P70, DOI 10.1038/ng1926; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tartaglia M, 2007, NAT GENET, V39, P75, DOI 10.1038/ng1939; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006	37	76	80	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3508	3515		10.1038/sj.onc.1211019	http://dx.doi.org/10.1038/sj.onc.1211019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223690				2022-12-17	WOS:000256468500002
J	Wagner, N; Michiels, JF; Schedl, A; Wagner, KD				Wagner, N.; Michiels, J. F.; Schedl, A.; Wagner, K-D			The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo	ONCOGENE			English	Article						cancer; endothelial cells; RNAi	TRANSCRIPTION FACTOR ETS-1; INDUCIBLE FACTOR-I; NESTIN EXPRESSION; ANGIOGENESIS; GENE; ACTIVATION; INTRON; KIDNEY; MOUSE	Vascularization is an important step in tumour growth. Although a variety of molecules, for example, VEGF, ETS-1 or nestin have been implicated in tumour angiogenesis, the molecular mechanisms of vessel formation are not fully characterized. We showed that the Wilms' tumour suppressor WT1 activates nestin during development. Here we tested whether WT1 might also be involved in tumour angiogenesis. Endothelial WT1 expression was detected in 95% of 113 tumours of different origin. To analyse the function of WT1 in endothelial cells, we used an RNAi approach in vitro and showed that inhibition of WT1 reduces cell proliferation, migration and endothelial tube formation. On a molecular level, WT1 silencing diminished expression of the ETS-1 transcription factor. WT1 and ETS-1 shared an overlapping expression in tumour endothelia. The ETS-1 promoter was stimulated approximately 10-fold by transient co-transfection of a WT1 expression construct and WT1 bound to the ETS-1 promoter in chromatin immunoprecipitation and electrophoretic mobility shift assays. Deletion of the identified WT1-binding site abolished stimulation of the ETS-1 promoter by WT1. These findings suggest that transcriptional activation of ETS-1 by the Wilms' tumour suppressor WT1 is a crucial step in tumour vascularization via regulation of endothelial cell proliferation and migration.	[Wagner, N.; Wagner, K-D] INSERM, U907, Fac Med, PACA, F-06107 Nice, France; [Wagner, N.; Michiels, J. F.; Schedl, A.; Wagner, K-D] Univ Nice Sophia Antipolis, Nice, France; [Michiels, J. F.] Univ Nice Sophia Antipolis, Dept Pathol, Nice, France; [Schedl, A.] INSERM, U636, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Wagner, KD (corresponding author), INSERM, U907, Fac Med, PACA, 28 Ave Valombrose, F-06107 Nice, France.	kwagner@unice.fr	Wagner, Kay-Dietrich/E-6119-2016; Schedl, Andreas/GOP-3427-2022; Schedl, Andreas/F-8823-2015	Wagner, Kay-Dietrich/0000-0001-5483-7760; Schedl, Andreas/0000-0001-9380-7396; Wagner, Nicole/0000-0002-2746-0707				Aihara M, 2004, LAB INVEST, V84, P1581, DOI 10.1038/labinvest.3700186; Amoh Y, 2005, CANCER RES, V65, P5352, DOI 10.1158/0008-5472.CAN-05-0821; Brown C, 2004, J BIOL CHEM, V279, P12794, DOI 10.1074/jbc.M308593200; Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005; Cohen MM, 2006, AM J MED GENET A, V140A, P2013, DOI 10.1002/ajmg.a.31333; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Gao XB, 2005, DEVELOPMENT, V132, P5437, DOI 10.1242/dev.02095; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hasegawa Y, 2004, BIOCHEM BIOPH RES CO, V316, P52, DOI 10.1016/j.bbrc.2004.02.019; Hashiya N, 2004, CIRCULATION, V109, P3035, DOI 10.1161/01.CIR.0000130643.41587.DB; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jorcyk CL, 1997, CELL MOL BIOL, V43, P211; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Labrecque L, 2003, MOL BIOL CELL, V14, P334, DOI 10.1091/mbc.E02-07-0379; Mikami S, 2006, CANCER SCI, V97, P875, DOI 10.1111/j.1349-7006.2006.00268.x; Mokry J, 2004, STEM CELLS DEV, V13, P658, DOI 10.1089/scd.2004.13.658; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Timar J, 2005, HISTOPATHOLOGY, V47, P67, DOI 10.1111/j.1365-2559.2005.02169.x; Wagner KD, 2003, FASEB J, V17, P1364, DOI 10.1096/fj.02-1065fje; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wagner N, 2006, AM J PHYSIOL-REG I, V291, pR779, DOI 10.1152/ajpregu.00219.2006; WERNERT N, 1992, AM J PATHOL, V140, P119	27	76	78	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3662	3672		10.1038/sj.onc.1211044	http://dx.doi.org/10.1038/sj.onc.1211044			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18212735				2022-12-17	WOS:000256659300003
J	Ticchioni, M; Essafi, M; Jeandel, PY; Davi, F; Cassuto, JP; Deckert, M; Bernard, A				Ticchioni, M.; Essafi, M.; Jeandel, P. Y.; Davi, F.; Cassuto, J. P.; Deckert, M.; Bernard, A.			Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a	ONCOGENE			English	Article						B-CLL; chemokines; survival; akt; FOXO3a	FACTOR-I; UP-REGULATION; APOPTOSIS; ACTIVATION; KINASE; INHIBITION; EXPRESSION; MIGRATION; PATHWAY; DIFFERENTIATION	B-chronic lymphocytic leukemia (B-CLL) cell is characterized by the accumulation of long-lived CD5+ B lymphocytes, whose survival in vivo is in part dependent on exogenous factors such as cytokines and/or extracellular matrix proteins. Homeostatic chemokines are critical mediators of lymphoid cell trafficking. However, how they function in cell signaling and survival remains ill-defined. In this study, we have investigated the role of the homeostatic chemokines, CXCL12, CCL21, CCL19 and CXCL13, in B-CLL cell survival. Using primary leukemic cells isolated from 26 patients, we observed that each chemokine enhances cell survival. Chemokines induced the phosphorylation of ERK1/2 and p90RSK, and of Akt and its effectors GSK3 and FOXO3a. Consistently, inhibitors against mitogen-activated protein kinase/extracellular signal-regulated kinase and phosphatidylinositol 3-kinase inhibited chemokine-induced survival. Moreover, using a constitutively active mutated form of FOXO3a or siRNAs against FOXO3a in transfection experiments performed in primary B-CLL cells, we directly demonstrated the critical role of FOXO3a in both spontaneous and chemokine-induced B-CLL cell survival. Overall, our data support the notion that homeostatic chemokines contribute to B-CLL resistance to cell death through inactivation of the transcription factor FOXO3a, which may represent a novel therapeutic target in this hematopoietic malignancy.	Univ Nice, Hop Archet, Dept Immunol, Immunol Lab, F-06202 Nice 3, France; Hop Archet, INSERM, UMR576, F-06202 Nice, France; Univ Nice, Hop Archet, Dept Med Interne, F-06202 Nice 3, France; Univ Paris 06, Grp Hosp Pitie Salpetriere, Dept Hematol, Paris, France; Univ Nice, Hop Archet, Dept Hematol, F-06202 Nice 3, France	CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur	Ticchioni, M (corresponding author), Univ Nice, Hop Archet, Dept Immunol, Immunol Lab, Route St Antoine Ginestiere, F-06202 Nice 3, France.	michel.ticchioni@unice.fr; deckert@unice.fr	Deckert, Marcel/M-4998-2016; Ticchioni, Michel/P-8095-2016; Jeandel, Pierre-Yves/ABD-6658-2020; Deckert, Marcel/T-3566-2019; Essafi, Makram/V-8411-2019	Deckert, Marcel/0000-0003-2094-559X; 				AUBIN J, 1995, LEUKEMIA, V9, P471; Baccarini M, 2002, CELL DEATH DIFFER, V9, P783, DOI 10.1038/sj.cdd.4401070; Birkenkamp KU, 2003, J IMMUNOL, V171, P1623, DOI 10.4049/jimmunol.171.4.1623; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burger JA, 2000, BLOOD, V96, P2655; Burger M, 2005, BLOOD, V106, P1824, DOI 10.1182/blood-2004-12-4918; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778; Colamussi ML, 2001, J LEUKOCYTE BIOL, V69, P263; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Durig J, 2002, LEUKEMIA, V16, P30, DOI 10.1038/sj.leu.2402339; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Glimm H, 2002, BLOOD, V99, P3454, DOI 10.1182/blood.V99.9.3454; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Kamiguti AS, 2003, ONCOGENE, V22, P2272, DOI 10.1038/sj.onc.1206398; Kipps TJ, 2003, CURR OPIN HEMATOL, V10, P312, DOI 10.1097/00062752-200307000-00010; Lataillade JJ, 2002, BLOOD, V99, P1117, DOI 10.1182/blood.V99.4.1117; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Leupin N, 2003, BRIT J HAEMATOL, V121, P97, DOI 10.1046/j.1365-2141.2003.04227.x; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Majka M, 2000, BLOOD, V96, P4142, DOI 10.1182/blood.V96.13.4142.h8004142_4142_4151; Mori M, 2003, J CELL PHYSIOL, V195, P290, DOI 10.1002/jcp.10245; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood-2004-03-0889; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Pepper C, 2003, BLOOD, V101, P2454, DOI 10.1182/blood-2002-07-1984; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Suzuki Y, 2001, J IMMUNOL, V167, P3064, DOI 10.4049/jimmunol.167.6.3064; Ticchioni M, 2002, BLOOD, V99, P3111, DOI 10.1182/blood.V99.9.3111; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407	35	76	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2007	26	50					7081	7091		10.1038/sj.onc.1210519	http://dx.doi.org/10.1038/sj.onc.1210519			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228GF	17496928				2022-12-17	WOS:000250715000002
J	Marzec, M; Kasprzycka, M; Liu, X; El-Salem, M; Halasa, K; Raghunath, PN; Bucki, R; Wlodarski, P; Wasik, MA				Marzec, M.; Kasprzycka, M.; Liu, X.; El-Salem, M.; Halasa, K.; Raghunath, P. N.; Bucki, R.; Wlodarski, P.; Wasik, M. A.			Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway	ONCOGENE			English	Article						anaplastic lymphoma kinase (ALK); mammalian target of rapamycin (mTOR); mitogen-activated protein kinase pathway (MAPK); protein kinase B (PKB/Akt)	TRANSFORMED B-LYMPHOCYTES; NON-HODGKINS-LYMPHOMA; T-CELL LYMPHOMA; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; ANAPLASTIC LYMPHOMA; S6 KINASE; MEDIATED LYMPHOMAGENESIS; AMINO-ACIDS; IN-VITRO	The mechanisms of cell transformation mediated by the nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) tyrosine kinase are only partially understood. Here, we report that cell lines and native tissues derived from the NPM/ALK-expressing T-cell lymphoma display persistent activation of mammalian target of rapamycin ( mTOR) as determined by phosphorylation of mTOR targets S6rp and 4E-binding protein 1 (4E-BP1). The mTOR activation is serum growth factor-independent but nutrient-dependent. It is also dependent on the expression and enzymatic activity of NPM/ALK as demonstrated by cell transfection with wild-type and functionally deficient NPM/ALK, small interfering RNA (siRNA)-mediated NPM/ALK depletion and kinase activity suppression using the inhibitor WHI-P154. The NPM/ALK-induced mTOR activation is transduced through the mitogen-induced extracellular kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway and, to a much lesser degree, through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway. Accordingly, whereas the low-dose PI3K inhibitor wortmannin and Akt inhibitor III profoundly inhibited Akt phosphorylation, they had a very modest effect on S6rp and 4E-BP1 phosphorylation. In turn, MEK inhibitors U0126 and PD98059 and siRNA-mediated depletion of either ERK1 or ERK2 inhibited S6rp phosphorylation much more effectively. Finally, the mTOR inhibitor rapamycin markedly decreased proliferation and increased the apoptotic rate of ALK+TCL cells. These findings identify mTOR as a novel key target of NPM/ALK and suggest that mTOR inhibitors may prove effective in therapy of ALK-induced malignancies.	Univ Penn, Med Ctr, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Wasik, MA (corresponding author), Univ Penn, Med Ctr, Dept Pathol, 3400 Spruce St,7-106 Founders Pavil, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Bucki, Robert/0000-0001-7664-9226; Wlodarski, Pawel/0000-0002-0683-1791	NCI NIH HHS [R01 CA96856] Funding Source: Medline; NIDCR NIH HHS [R01-DE-017337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arvisais EW, 2006, J BIOL CHEM, V281, P26904, DOI 10.1074/jbc.M605371200; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Majewski M, 2003, TRANSPLANTATION, V75, P1710, DOI 10.1097/01.TP.0000063934.89714.19; Majewski M, 2000, P NATL ACAD SCI USA, V97, P4285, DOI 10.1073/pnas.080068597; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sakata A, 1999, IMMUNOL LETT, V68, P301, DOI 10.1016/S0165-2478(99)00053-X; Sekulic A, 2000, CANCER RES, V60, P3504; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shillingford JM, 2006, P NATL ACAD SCI USA, V103, P5466, DOI 10.1073/pnas.0509694103; SHIOTA M, 1994, ONCOGENE, V9, P1567; Slupianek A, 2001, CANCER RES, V61, P2194; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Vega F, 2006, CANCER RES, V66, P6589, DOI 10.1158/0008-5472.CAN-05-3018; WASIK MA, 2002, J CLIN PATHOL S, V118, pS81; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	41	76	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5606	5614		10.1038/sj.onc.1210346	http://dx.doi.org/10.1038/sj.onc.1210346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353907				2022-12-17	WOS:000248801900006
J	Concannon, CG; Koehler, BF; Reimertz, C; Murphy, BM; Bonner, C; Thurow, N; Ward, MW; Villunger, A; Strasser, A; Kogel, D; Prehn, JHM				Concannon, C. G.; Koehler, B. F.; Reimertz, Claus; Murphy, B. M.; Bonner, C.; Thurow, N.; Ward, M. W.; Villunger, A.; Strasser, A.; Koegel, D.; Prehn, J. H. M.			Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway	ONCOGENE			English	Article						proteasome; apoptosis; epoxomicin; Bcl-2 family; BH3-only protein; p53	NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; PHASE-I TRIAL; BH3-ONLY PROTEINS; MULTIPLE-MYELOMA; TARGET GENES; GLIOMA-CELLS; SOLID TUMORS; C-MYC; P53	The proteasome has emerged as a novel target for antineoplastic treatment of hematological malignancies and solid tumors, including those of the central nervous system. To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). Prolonged exposure to Epoxo was associated with increased levels of poly-ubiquitinylated proteins and p53, release of cytochrome c from the mitochondria, and activation of caspases. Analysis of global gene expression using high-density oligonucleotide microarrays revealed that Epoxo triggered transcriptional activation of the two Bcl-2-homology domain-3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim. Subsequent studies in PUMA- and Bim-deficient cells indicated that Epoxo-induced caspase activation and apoptosis was predominantly PUMA- dependent. Further characterization of the transcriptional response to Epoxo in HCT116 human colon cancer cells demonstrated that PUMA induction was p53-dependent; with deficiency in either p53 or PUMA significantly protected HCT116 cells against Epoxo-induced apoptosis. Our data suggest that p53 activation and the transcriptional induction of its target gene PUMA play an important role in the sensitivity of cancer cells to apoptosis induced by proteasome inhibition, and imply that antineoplastic therapies with PIs might be especially useful in cancers with functional p53.	Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; Johann Wolfgang Goethe Univ Clin, Ctr Neurol & Neurosurg, Frankfurt, Germany; Innsbruck Med Univ, Bioctr, Div Expt Pathophysiol & Immunol, Innsbruck, Austria; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal College of Surgeons - Ireland; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Medical University of Innsbruck; Walter & Eliza Hall Institute	Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	prehn@rcsi.ie	Strasser, Andreas/C-7581-2013; Murphy, Brona/P-2544-2019; Prehn, Jochen HM/A-3928-2010; Concannon, Caoimhin/B-2075-2010; Murphy, Brona/D-4873-2012; Pattou, Francois/O-6151-2017; Bonner, Caroline/A-9819-2015	Strasser, Andreas/0000-0002-5020-4891; Murphy, Brona/0000-0002-6740-8858; Prehn, Jochen HM/0000-0003-3479-7794; Murphy, Brona/0000-0002-6740-8858; Pattou, Francois/0000-0001-8388-3766; Bonner, Caroline/0000-0002-4430-8280; Ward, Manus/0000-0002-7085-9668; Kogel, Donat/0000-0003-1209-0210				Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Aghajanian C, 2002, CLIN CANCER RES, V8, P2505; Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Biswas SC, 2005, NEUROCHEM RES, V30, P839, DOI 10.1007/s11064-005-6877-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Ceballos E, 2005, ONCOGENE, V24, P4559, DOI 10.1038/sj.onc.1208652; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; HANADA M, 1992, J ANTIBIOT, V45, P1746, DOI 10.7164/antibiotics.45.1746; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kikuchi S, 2003, BRAIN RES, V964, P228, DOI 10.1016/S0006-8993(02)04030-1; Kurland JF, 2001, INT J CANCER, V96, P327, DOI 10.1002/ijc.1040; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Masdehors P, 2000, BLOOD, V96, P269, DOI 10.1182/blood.V96.1.269.013k10_269_274; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MITSIADES N, 2002, MOL SEQUELAE PROTEAS, V99, P14374; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nikrad M, 2005, MOL CANCER THER, V4, P443; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106; Park DJ, 2004, ANN MED, V36, P296, DOI 10.1080/07853890410029031; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132; Wagenknecht B, 2000, J NEUROCHEM, V75, P2288, DOI 10.1046/j.1471-4159.2000.0752288.x; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	55	76	79	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1681	1692		10.1038/sj.onc.1209974	http://dx.doi.org/10.1038/sj.onc.1209974			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983338				2022-12-17	WOS:000244955600002
J	Roversi, G; Pfundt, R; Moroni, RF; Magnani, I; van Reijmersdal, S; Pollo, B; Straatman, H; Larizza, L; Schoenmakers, EFPM				Roversi, G; Pfundt, R; Moroni, RF; Magnani, I; van Reijmersdal, S; Pollo, B; Straatman, H; Larizza, L; Schoenmakers, EFPM			Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines	ONCOGENE			English	Article						glioma; array-based CGH; copy number changes; chromosome 19	TUMOR-SUPPRESSOR GENE; BRAIN-TUMORS; COPY NUMBER; CHROMOSOMAL IMBALANCES; MOLECULAR SUBTYPES; ARRAY-CGH; HYBRIDIZATION; EXPRESSION; CANCER; REGION	Identification of genetic copy number changes in glial tumors is of importance in the context of improved/refined diagnostic, prognostic procedures and therapeutic decision-making. In order to detect recurrent genomic copy number changes that might play a role in glioma pathogenesis and/or progression, we characterized 25 primary glioma cell lines including 15 non glioblastoma (non GBM) (I-III WHO grade) and 10 GBM (IV WHO grade), by array comparative genomic hybridization, using a DNA microarray comprising approx. 3500 BACs covering the entire genome with a 1Mb resolution and additional 800 BACs covering chromosome 19 at tiling path resolution. Combined evaluation by single clone and whole chromosome analysis plus 'moving average (MA) approach' enabled us to confirm most of the genetic abnormalities previously identified to be associated with glioma progression, including +1q32, +7, -10, -22q, PTEN and p16 loss, and to disclose new small genomic regions, some correlating with grade malignancy. Grade I-III gliomas exclusively showed losses at 3p26 (53%), 4q13-21 (33%) and 7p15-p21 (26%), whereas only GBMs exhibited 4p16.1 losses (40%). Other recurrent imbalances, such as losses at 4p15, 5q22-q23, 6p23-25, 12p13 and gains at 11p11-q13, were shared by different glioma grades. Three intervals with peak of loss could be further refined for chromosome 10 by our MA approach. Data analysis of full-coverage chromosome 19 highlighted two main regions of copy number gain, never described before in gliomas, at 19p13.11 and 19q13.13-13.2. The well-known 19q13.3 loss of heterozygosity area in gliomas was not frequently affected in our cell lines. Genomic hotspot detection facilitated the identification of small intervals resulting in positional candidate genes such as PRDM2 (1p36.21), LRP1B (2q22.3), ADARB2 (10p15.3), BCCIP (10q26.2) and ING1 (13q34) for losses and ECT2 (3q26.3), MDK, DDB2, IG20 (11p11.2) for gains. These data increase our current knowledge about cryptic genetic changes in gliomas and may facilitate the further identification of novel genetic elements, which may provide us with molecular tools for the improved diagnostics and therapeutic decision-making in these tumors.	Univ Milan, Dept Biol & Genet Med Sci, I-20133 Milan, Italy; Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands; Ist Neurol Besta, Milan, Italy; Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat, Nijmegen, Netherlands	University of Milan; Radboud University Nijmegen; IRCCS Istituto Neurologico Besta; Radboud University Nijmegen	Larizza, L (corresponding author), Univ Milan, Dept Biol & Genet Med Sci, Via Viotti 3-5, I-20133 Milan, Italy.	lidia.larizza@unimi.it	Pollo, Bianca/K-5347-2018; van Reijmersdal, Simon V/E-9529-2016; Pfundt, Rolph/L-4576-2015	Pollo, Bianca/0000-0002-5523-4256; Moroni, Ramona Frida/0000-0002-0461-3213				Bakir A, 1998, CANCER GENET CYTOGEN, V103, P46, DOI 10.1016/S0165-4608(97)00364-6; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; BIGNER SH, 1987, CANCER GENET CYTOGEN, V24, P163, DOI 10.1016/0165-4608(87)90094-X; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Buschges R, 1999, BRAIN PATHOL, V9, P435; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Chernova OB, 2001, ONCOGENE, V20, P5378, DOI 10.1038/sj.onc.1204694; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337; Cowell JK, 2004, CANCER GENET CYTOGEN, V151, P36, DOI 10.1016/j.cancergencyto.2003.09.012; Cowell JK, 2004, J NEUROPATH EXP NEUR, V63, P151, DOI 10.1093/jnen/63.2.151; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; FISCHER H, 1985, CANCER GENET CYTOGEN, V17, P257, DOI 10.1016/0165-4608(85)90017-2; Hackett CS, 2003, CANCER RES, V63, P5266; Harada K, 2000, GENOMICS, V67, P268, DOI 10.1006/geno.2000.6257; Hartmann C, 2002, CANCER RES, V62, P4100; Hawkins CJ, 2004, VITAM HORM, V67, P427; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Ino Y, 2001, CLIN CANCER RES, V7, P839; Jeuken JWM, 2004, J NEURO-ONCOL, V70, P161, DOI 10.1007/s11060-004-2748-1; Kanno H, 1997, CANCER RES, V57, P1035; Kitange G, 2005, GENE CHROMOSOME CANC, V42, P68, DOI 10.1002/gcc.20108; Kitange GJ, 2003, CURR OPIN ONCOL, V15, P197, DOI 10.1097/00001622-200305000-00003; Kleihues P, 2000, P ICMTS2000 MARCH MO, P99; Kohler B, 2004, INT J CANCER, V111, P644, DOI 10.1002/ijc.20302; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Liu CX, 2000, CANCER RES, V60, P1961; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Magnani I, 2005, CANCER GENET CYTOGEN, V161, P140, DOI 10.1016/j.cancergencyto.2005.02.010; Magnani I, 1999, CANCER GENET CYTOGEN, V110, P82, DOI 10.1016/S0165-4608(98)00190-3; MAGNANI I, 1994, CANCER GENET CYTOGEN, V75, P77, DOI 10.1016/0165-4608(94)90157-0; Manni I, 2002, BRIT J CANCER, V86, P477, DOI 10.1038/sj.bjc.6600065; Marschang P, 2004, MOL CELL BIOL, V24, P3782, DOI 10.1128/MCB.24.9.3782-3793.2004; Meng XB, 2004, CELL CYCLE, V3, P343; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mitelman F, 1995, INT SYSTEM HUMAN CYT; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; Noble M, 2004, TRENDS NEUROSCI, V27, P148, DOI 10.1016/j.tins.2003.12.007; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; Pandita A, 2004, GENE CHROMOSOME CANC, V39, P29, DOI 10.1002/gcc.10300; PEREGO P, 1994, J CANCER RES CLIN, V120, P585, DOI 10.1007/BF01212812; REY JA, 1989, CANCER GENET CYTOGEN, V41, P175, DOI 10.1016/0165-4608(89)90244-6; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; Rong Y, 2005, CANCER RES, V65, P1406, DOI 10.1158/0008-5472.CAN-04-3376; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Schraders M, 2005, BLOOD, V105, P1686, DOI 10.1182/blood-2004-07-2730; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Shapiro JR, 2002, AM J MED GENET, V115, P194, DOI 10.1002/ajmg.10690; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; Smith JS, 1999, ONCOGENE, V18, P4144, DOI 10.1038/sj.onc.1202759; Sun CL, 2005, MOL PHARMACOL, V67, P1307, DOI 10.1124/mol.104.008797; Tallen G, 2004, INT J CANCER, V109, P476, DOI 10.1002/ijc.11715; Veltman JA, 2003, CANCER RES, V63, P2872; Veltman JA, 2003, AM J HUM GENET, V72, P1578, DOI 10.1086/375695; Vissers LELM, 2003, AM J HUM GENET, V73, P1261, DOI 10.1086/379977; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; Weber RG, 1996, ONCOGENE, V13, P983; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	64	76	79	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1571	1583		10.1038/sj.onc.1209177	http://dx.doi.org/10.1038/sj.onc.1209177			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16247447	Green Published			2022-12-17	WOS:000235890400014
J	Anderson, CJ; Hoare, SF; Ashcroft, M; Bilsland, AE; Keith, WN				Anderson, CJ; Hoare, SF; Ashcroft, M; Bilsland, AE; Keith, WN			Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms	ONCOGENE			English	Article						telomerase; hTR; hTERT; hypoxia; RNA splicing; chromatin	STRESS-INDUCED APOPTOSIS; HUMAN CANCER-CELLS; INDUCIBLE FACTOR-1-ALPHA; BACTERIAL NITROREDUCTASE; REVERSE-TRANSCRIPTASE; TUMOR-GROWTH; LIFE-SPAN; IN-VIVO; ACTIVATION; HTERT	Basal telomerase activity is dependent on expression of the hTERT and hTR genes and upregulation of telomerase gene expression is associated with tumour development. It is therefore possible that signal transduction pathways involved in tumour development and features of the tumour environment itself may influence telomerase gene regulation. The majority of solid tumours contain regions of hypoxia and it has recently been demonstrated that hypoxia can increase telomerase activity by mechanisms that are still poorly defined. Here, we show that hypoxia induces the transcriptional activity of both hTR and hTERT gene promoters. While endogenous hTR expression is regulated at the transcriptional level, hTERT is subject to regulation by alternative splicing under hypoxic conditions, which involves a switch in the splice pattern in favour of the active variant. Furthermore, analysis of the chromatin landscape of the telomerase promoters reveals dynamic recruitment of a transcriptional complex involving the hypoxia- inducible factor-1 transcription factor, p300, RNA polymerase II and TFIIB, to both promoters during hypoxia, which traffics along and remains associated with the hTERT gene as transcription proceeds. These studies show that hTERT and hTR are subject to similar controls under hypoxia and highlight the rapid and dynamic regulation of the telomerase genes in vivo.	Univ Glasgow, Canc Res UK, Beatson Labs, Ctr Oncol & Appl Pharmacol, Glasgow G61 1BD, Lanark, Scotland; Inst Canc Res, Canc Res UK, Ctr Canc Therapeut, Sutton, Surrey, England	Beatson Institute; Cancer Research UK; University of Glasgow; Cancer Research UK; University of London; Institute of Cancer Research - UK	Keith, WN (corresponding author), Univ Glasgow, Canc Res UK, Beatson Labs, Ctr Oncol & Appl Pharmacol, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.	n.keith@beatson.gla.ac.uk	Cairney, Claire/H-6989-2012; Bilsland, Alan/G-2629-2010; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Cairney, Claire/0000-0001-6531-245X; Bilsland, Alan/0000-0003-0957-3908				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; ASHCROFT M, 2004, BIOESSAYS, V26, P262; ATKINSON SP, 2005, IN PRESS CANC RES; Bilsland AE, 2003, ONCOGENE, V22, P370, DOI 10.1038/sj.onc.1206168; Blasco MA, 2003, TRENDS CELL BIOL, V13, P289, DOI 10.1016/S0962-8924(03)00085-0; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; Elsby LM, 2004, BIOCHEM SOC T, V32, P1098, DOI 10.1042/BST0321098; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; GRAVEN KK, 1994, J BIOL CHEM, V269, P24446; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kornblihtt AR, 2004, RNA, V10, P1489, DOI 10.1261/rna.7100104; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Minamino T, 2001, MOL CELL BIOL, V21, P3336, DOI 10.1128/MCB.21.10.3336-3342.2001; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Munch C, 2003, J NEUROSCI RES, V71, P819, DOI 10.1002/jnr.10536; Nishi H, 2004, MOL CELL BIOL, V24, P6076, DOI 10.1128/MCB.24.13.6076-6083.2004; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Reynolds TY, 1996, CANCER RES, V56, P5754; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Seimiya H, 1999, BIOCHEM BIOPH RES CO, V260, P365, DOI 10.1006/bbrc.1999.0910; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Ulaner GA, 1998, CANCER RES, V58, P4168; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Zaffaroni N, 2002, J PATHOL, V198, P37, DOI 10.1002/path.1178; Zhang C, 2003, J BIOL CHEM, V278, P35325, DOI 10.1074/jbc.M305191200; Zhang LQ, 2003, CANCER RES, V63, P4552	34	76	81	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					61	69		10.1038/sj.onc.1209011	http://dx.doi.org/10.1038/sj.onc.1209011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16170363				2022-12-17	WOS:000234406400007
J	Raffaghello, L; Prigione, I; Bocca, P; Morandi, F; Camoriano, M; Gambini, C; Wang, XH; Ferrone, S; Pistoia, V				Raffaghello, L; Prigione, I; Bocca, P; Morandi, F; Camoriano, M; Gambini, C; Wang, XH; Ferrone, S; Pistoia, V			Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications	ONCOGENE			English	Article						pediatric tumor; antigen-processing machinery; MHC downregulation; immune evasion	HLA-CLASS-I; MHC CLASS-I; NEURONAL CELL-LINES; MONOCLONAL-ANTIBODIES; FLOW-CYTOMETRY; HEAVY-CHAINS; ENDOPLASMIC-RETICULUM; KILLER-CELLS; EXPRESSION; INTERFERON	Low expression of human leukocyte antigen (HLA) class I in human tumors may be related to defects of the antigen-processing machinery (APM) components. Neuroblastoma cells are virtually HLA class I negative, but (i) the underlying mechanisms are unknown, and (ii) expression of the APM components has never been investigated. Here we have used a panel of novel monoclonal antibodies to proteasomal and immunoproteasomal components, chaperons and transporter associated with antigen processing (TAP) to characterize 24 stroma-poor neuroblastoma tumors and six neuroblastoma cell lines. Primary tumors showed defects in the expression of zeta, tapasin, TAP1 or TAP2, HLA class I heavy chain and 2 microglobulin, LMP2 and LMP7, as compared to normal adrenal medulla. Neuroblastoma cell lines displayed roughly similar patterns of APM expression in comparison to primary tumors. Incubation of neuroblastoma cell lines with interferon-gamma caused upregulation of HLA class I molecules and reduced lysis by killer inhibitory receptor HLA ligand-matched NK cells. Defects in APM components explain reduced peptide loading on HLA class I molecules, their instability and failure to be expressed on the cell surface. HLA class I upregulation by interferon-gamma, although enhancing neuroblastoma cell recognition by cytotoxic T cells, dampens their susceptibility to NK cells.	G Gaslini Inst Children, Lab Oncol, Genoa, Italy; G Gaslini Inst Children, Pathol Lab, Genoa, Italy; Roswell Pk Canc Ctr, Dept Immunol, Buffalo, NY USA	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini; Roswell Park Cancer Institute	Raffaghello, L (corresponding author), G Gaslini Inst Children, Lab Oncol, Largo G Gaslini, Genoa, Italy.	lizziaraffaghello@ospedale-gaslini.ge.it	Bocca, Paola/AAB-3381-2021; Prigione, Ignazia/K-3011-2016; Morandi, Fabio/I-1185-2012	Bocca, Paola/0000-0002-7498-209X; Prigione, Ignazia/0000-0002-0877-6255; Morandi, Fabio/0000-0002-2849-7595; Raffaghello, Lizzia/0000-0003-2357-0607	NCI NIH HHS [R01 CA 67108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Airoldi I, 2004, BRIT J CANCER, V90, P2210, DOI 10.1038/sj.bjc.6601842; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Corrias MV, 2001, TISSUE ANTIGENS, V57, P110, DOI 10.1034/j.1399-0039.2001.057002110.x; Desai SA, 2000, J IMMUNOL, V165, P3275, DOI 10.4049/jimmunol.165.6.3275; Facchetti P, 1996, CANCER IMMUNOL IMMUN, V42, P170, DOI 10.1007/s002620050267; Facchetti P, 1999, EXP CELL RES, V253, P440, DOI 10.1006/excr.1999.4697; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; HEDLEY DW, 1985, CYTOMETRY, V6, P327, DOI 10.1002/cyto.990060409; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kageshita T, 1999, AM J PATHOL, V154, P745, DOI 10.1016/S0002-9440(10)65321-7; Kishore R, 1998, TISSUE ANTIGENS, V51, P129; LAMPSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P6476, DOI 10.1073/pnas.81.20.6476; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; LAMPSON LA, 1986, J INTERFERON RES, V6, P257, DOI 10.1089/jir.1986.6.257; MAROZZI A, 1993, SCAND J IMMUNOL, V37, P661, DOI 10.1111/j.1365-3083.1993.tb01680.x; Moretta A, 1996, ANNU REV IMMUNOL, V14, P619, DOI 10.1146/annurev.immunol.14.1.619; Neal ZC, 2004, CANCER IMMUNOL IMMUN, V53, P41, DOI 10.1007/s00262-003-0435-2; Ogino T, 2003, TISSUE ANTIGENS, V62, P385, DOI 10.1034/j.1399-0039.2003.00114.x; Ogino T, 2003, J IMMUNOL METHODS, V278, P33, DOI 10.1016/S0022-1759(03)00224-2; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; Passoni L, 2002, BLOOD, V99, P2100, DOI 10.1182/blood.V99.6.2100; PICKL WF, 1993, J IMMUNOL, V151, P2613; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PONZONI M, 1993, INT J CANCER, V55, P817, DOI 10.1002/ijc.2910550521; Puppo F, 1999, TISSUE ANTIGENS, V53, P253, DOI 10.1034/j.1399-0039.1999.530305.x; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Sarkar AK, 2000, CANCER RES, V60, P1908; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Seliger B, 2002, SEMIN CANCER BIOL, V12, P3, DOI 10.1006/scbi.2001.0404; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; STAM NJ, 1986, J IMMUNOL, V137, P2299; Tanaka K, 1998, IMMUNOL REV, V163, P161; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; THIELE CJ, 1999, NEUROBLASTOMA, P21; Tonini GP, 1997, J CLIN ONCOL, V15, P85, DOI 10.1200/JCO.1997.15.1.85; Vertuani S, 2003, CANCER RES, V63, P8006; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Wolfl M, 2005, CANCER IMMUNOL IMMUN, V54, P400, DOI 10.1007/s00262-004-0603-z; Zarling AL, 2003, J IMMUNOL, V171, P5287, DOI 10.4049/jimmunol.171.10.5287; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	45	76	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2005	24	29					4634	4644		10.1038/sj.onc.1208594	http://dx.doi.org/10.1038/sj.onc.1208594			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897905				2022-12-17	WOS:000230304500003
J	Hesson, LB; Wilson, R; Morton, D; Adams, C; Walker, M; Maher, ER; Latif, F				Hesson, LB; Wilson, R; Morton, D; Adams, C; Walker, M; Maher, ER; Latif, F			CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations	ONCOGENE			English	Article						RASSF2; colorectal cancer; epigenetic inactivation; K-ras	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; COLORECTAL-CANCER; LUNG-CANCER; EPIGENETIC INACTIVATION; IDENTIFICATION; METHYLATION; NORE1; REGION; TUMORIGENESIS	We report in silico identification and characterisation of a novel member of the ras association domain family 1 (RASSF1)/NORE1 family, namely, RASSF2, located at chromosomal region 20p13. It has three isoforms, all contain a ras association domain in the C-terminus. The longest isoform RASSF2A contains a 5' CpG island. RASSF2A was cloned from a brain cDNA library and directly sequenced, confirming the genomic gene structure. In previous reports, we and others have demonstrated that RASSF1A is epigenetically inactivated in a variety of cancers, including sporadic colorectal cancer (CRC). In the present report, we analysed the methylation status of RASSF2A promoter region CpG island in sporadic CRC and compared it to K-ras mutation status. RASSF2A promoter region CpG island was hypermethylated in a majority of colorectal tumour cell lines (89%) and in primary colorectal tumours (70%), while DNA from matched normal mucosa was found to be unmethylated (tumour-specific methylation). RASSF2A expression was reactivated in methylated tumour cell lines after treatment with 5-aza 2-deoxycytidine. RASSF2A methylation is an early event, detectable in 7/8 colon adenomas. Furthermore, 75% of colorectal tumours with RASSF2A methylation had no K-ras mutations (codons, 12 and 13) (P = 0.048), Fisher's exact test). Our data demonstrate that RASSF2A is frequently inactivated in CRCs by CpG island promoter hypermethylation, and that epigenetic (RASSF2A) and genetic (K-ras) changes are mutually exclusive and provide alternative pathways for affecting Ras signalling.	Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Hesson, Luke/HDM-0311-2022; MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918				Agathanggelou A, 2003, CANCER RES, V63, P5344; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; AGATHANGGELOU A, 2005, IN PRESS CANC RES; Behn M, 1998, CLIN CANCER RES, V4, P361; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Herman JG, 2002, GASTROENTEROL CLIN N, V31, P945, DOI 10.1016/S0889-8553(02)00058-4; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Muller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922	30	76	95	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3987	3994		10.1038/sj.onc.1208566	http://dx.doi.org/10.1038/sj.onc.1208566			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15806169				2022-12-17	WOS:000229435300014
J	Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I				Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I			Prediction of high risk Ewing's sarcoma by gene expression profiling	ONCOGENE			English	Article						Ewing's sarcoma; high risk; gene expression signature; prediction; prognosis	METASTASIS-ASSOCIATED GENE; HUMAN MTA1 GENE; BREAST-CANCER; CADHERIN EXPRESSION; CELL-LINES; TUMORS; INVASION; DIFFERENTIATION; OVEREXPRESSION; CLASSIFICATION	Ewing's sarcoma (ES) is the second most common primary malignant bone tumor in children and adolescents. Currently accepted clinical prognostic factors fail to classify ES patients' risk to relapse at diagnosis. We aimed to find a new strategy to distinguish between poor and good prognosis ES patients already at diagnosis. We analysed the gene expression profiles of 14 primary tumor specimens and six metastases from ES patients, using oligonucleotide microarray analysis. The over-expression of two genes was validated by quantitative PCR using the LightCycler system. We identified two distinct gene expression signatures distinguishing high-risk ES patients that are likely to progress from low-risk ES patients with a favorable prognosis of long-term progression-free survival. The microarray-based classification was superior to currently used prognostic parameters. Over-expressed genes in the poor prognosis patients included genes regulating the cell cycle and genes associated with invasion and metastasis, while among the downregulated genes were tumor suppressor genes and inducers of apoptosis. Our results indicate the existence of a specific gene expression signature of outcome in ES already at diagnosis, and provide a strategy to select patients who would benefit from risk-adapted improved therapy.	Schneider Childrens Med Ctr Israel, Mol Oncol Lab, IL-49202 Petah Tiqwa, Israel; Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Biol Serv, DNA Array Unit, IL-76100 Rehovot, Israel; Sourasky Med Ctr, IL-64239 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Avigad, S (corresponding author), Schneider Childrens Med Ctr Israel, Mol Oncol Lab, 14 Kaplan St, IL-49202 Petah Tiqwa, Israel.	savigad@post.tau.ac.il	Cohen, Ian/H-3358-2013					Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Burchill SA, 2003, J CLIN PATHOL, V56, P96, DOI 10.1136/jcp.56.2.96; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fouts RL, 2003, CANCER-AM CANCER SOC, V97, P1447, DOI 10.1002/cncr.11201; GINSBERG JP, 2002, PRINCIPLES PRACTICE, P973; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Iguchi H, 2000, INT J ONCOL, V16, P1211; Im YH, 2000, CANCER RES, V60, P1536; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Markus MA, 1999, J PATHOL, V187, P164, DOI 10.1002/(SICI)1096-9896(199901)187:2<164::AID-PATH208>3.0.CO;2-3; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; NAWA A, 2000, INT J MED BIOL ENV, V28, P33; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; Park BW, 2003, BREAST CANCER RES TR, V80, P79, DOI 10.1023/A:1024406223619; Pishvaian MJ, 1999, CANCER RES, V59, P947; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schulz S, 2000, J PATHOL, V191, P162; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; Shing DC, 2003, CANCER RES, V63, P4568; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Terrier P, 1996, SEMIN DIAGN PATHOL, V13, P250; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.0.CO;2-4; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6	36	76	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8997	9006		10.1038/sj.onc.1208060	http://dx.doi.org/10.1038/sj.onc.1208060			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467746				2022-12-17	WOS:000225354600016
J	Rozier, L; El-Achkar, E; Apiou, F; Debatisse, M				Rozier, L; El-Achkar, E; Apiou, F; Debatisse, M			Characterization of a conserved aphidicolin-sensitive common fragile site at human 4q22 and mouse 6C1: possible association with an inherited disease and cancer	ONCOGENE			English	Article						common fragile site; hepatic carcinogenesis; inherited disease, chromosome rearrangement; grid2; aphidicolin	DELTA-2 GLUTAMATE-RECEPTOR; MAMMALIAN GENE AMPLIFICATION; BONE-MARROW CELLS; HEPATOCELLULAR-CARCINOMA; OVARIAN-CANCER; MORTALITY GENE(S); TUMOR PROGRESSION; HUMAN-CHROMOSOMES; POTENTIAL ROLE; BREAST-CANCER	Fragile sites are classified as common or rare depending on their occurrence in the populations. While rare sites are mainly associated with inherited diseases, common sites have been involved in somatic rearrangements found in the chromosomes of cancer cells. Here we study a mouse locus containing the ionotropic glutamate receptor delta 2 (grid2) gene in which spontaneous chromosome rearrangements occur frequently, giving rise to mutant animals in inbred populations. We identify and clone common fragile sites overlapping the mouse grid2 gene and its human ortholog GRID2, lying respectively at bands 6C1 and 4q22 in a 7-Mb-long region of synteny. These results show a third example of orthologous common sites conserved at the molecular level, and reveal an unexpected link between an inherited disease and an aphidicolin-sensitive region. Recurrent deletions of subregions of band 4q22 have been previously described in human hepatocellular carcinomas. This 15-Mb-long region appears precisely centered on the site described here, which strongly suggests that it also plays a specific role in hepatic carcinogenesis.	Inst Curie, CNRS, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Debatisse, M (corresponding author), Inst Curie, CNRS, FRE2584,26 Rue Ulm, F-75248 Paris 05, France.	michelle.debatisse@curie.fr						Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Bryce SD, 2002, NEOPLASIA, V4, P544, DOI 10.1038/sj.neo.7900268; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Callahan G, 2003, ONCOGENE, V22, P590, DOI 10.1038/sj.onc.1206171; CAPOROSSI D, 1995, HUM GENET, V96, P269; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Coquelle A, 2002, ONCOGENE, V21, P7671, DOI 10.1038/sj.onc.1205880; DeJager PL, 1997, GENOME RES, V7, P736, DOI 10.1101/gr.7.7.736; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Denison SR, 2002, GENE CHROMOSOME CANC, V34, P406, DOI 10.1002/gcc.10084; ELDER FFB, 1989, CHROMOSOMA, V97, P459, DOI 10.1007/BF00295030; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Forsyth NR, 2002, ONCOGENE, V21, P5135, DOI 10.1038/sj.onc.1205688; FURUYA T, 1989, CANCER GENET CYTOGEN, V43, P131, DOI 10.1016/0165-4608(89)90136-2; Gericke GS, 1996, AM J MED GENET, V67, P25, DOI 10.1002/(SICI)1096-8628(19960216)67:1<25::AID-AJMG4>3.0.CO;2-R; Ginestier C, 2003, INT J CANCER, V107, P854, DOI 10.1002/ijc.11462; Glover TW, 1998, CANCER RES, V58, P3409; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; HSU YY, 2002, J BIOL CHEM, V5, P5; Hu W, 1998, GENOMICS, V47, P143, DOI 10.1006/geno.1997.5108; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Jones C, 2000, HUM MOL GENET, V9, P1201, DOI 10.1093/hmg/9.8.1201; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Lalouette A, 2001, NEUROSCIENCE, V105, P443, DOI 10.1016/S0306-4522(01)00193-2; Lalouette A, 1998, GENOMICS, V50, P9, DOI 10.1006/geno.1998.5314; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; MITRA AB, 1994, CANCER RES, V54, P4481; MURANO I, 1989, HUM GENET, V84, P71, DOI 10.1007/BF00210675; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nowaczyk MJM, 1997, AM J MED GENET, V69, P400, DOI 10.1002/(SICI)1096-8628(19970414)69:4<400::AID-AJMG12>3.3.CO;2-3; Pekarsky Y, 1998, CANCER RES, V58, P3401; Perucca-Lostanlen D, 1997, CYTOGENET CELL GENET, V79, P88, DOI 10.1159/000134689; Simonic I, 1997, AM J MED GENET, V74, P331, DOI 10.1002/(SICI)1096-8628(19970531)74:3<331::AID-AJMG16>3.3.CO;2-1; Smit AFA, 1999, CURR OPIN GENET DEV, V9, P657, DOI 10.1016/S0959-437X(99)00031-3; Smith DI, 1998, INT J ONCOL, V12, P187; Sutherland GR, 2000, CLIN GENET, V58, P157, DOI 10.1034/j.1399-0004.2000.580301.x; Terada Y, 2001, AM J MED GENET, V103, P176, DOI 10.1002/ajmg.1521; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Wang Y, 2003, EUR J NEUROSCI, V17, P1581, DOI 10.1046/j.1460-9568.2003.02595.x; Wong N, 2000, CLIN CANCER RES, V6, P4000; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Yuzaki M, 2003, NEUROSCI RES, V46, P11, DOI 10.1016/S0168-0102(03)00036-1	56	76	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6872	6880		10.1038/sj.onc.1207809	http://dx.doi.org/10.1038/sj.onc.1207809			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286716				2022-12-17	WOS:000223750700004
J	Kawakami, T; Zhang, C; Taniguchi, T; Kim, CJ; Okada, Y; Sugihara, H; Hattori, T; Reeve, AE; Ogawa, O; Okamoto, K				Kawakami, T; Zhang, C; Taniguchi, T; Kim, CJ; Okada, Y; Sugihara, H; Hattori, T; Reeve, AE; Ogawa, O; Okamoto, K			Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells	ONCOGENE			English	Article						X inactivation; Klinefelter syndrome; female-derived cancer	SEX-CHROMOSOMES; XIST EXPRESSION; CHROMATIN; TUMORS; BREAST; GENE; STR; CARCINOMA; BRCA1; LINE	The increased risk of several types of cancer in Klinefelter syndrome (47XXY) suggests that the extra X chromosome may be involved in the tumorigenesis associated with this syndrome. Here, we show that cancer cells (PSK-1) derived from a patient with Klinefelter syndrome (47XXY) showing loss of an inactive X chromosome subsequently gained active X chromosomes. We found that this abnormal X chromosome composition in PSK-1 is caused by a loss of an inactive X chromosome followed by multiplication of identical active X chromosomes, not by reactivation of an inactive X chromosome. Furthermore, we extended the characterization of loss-of-inactive X in a series of 22 female-derived cancer cell lines (eight breast cancer cell lines, seven ovarian cancer cell lines, and seven cervical cancer cell lines). The data demonstrate that loss-of-inactive X in the female-derived cancer cells is mainly achieved by loss of an inactive X chromosomes followed by multiplication of an identical active X chromosomes. However, distinctive pathways, including reactivation of an inactive X chromosome, are also involved in the mechanisms for loss-of-inactive X and gain-of-active X in female-derived cancer cells. The biological significance of the loss-of-inactive X and gain-of-active X in the oncogenesis of Klinefelter syndrome and female-derived cancer cells are discussed.	Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan; Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan; Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 52021, Japan; Univ Otago, Dept Biochem, Dunedin, New Zealand; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan	Shiga University of Medical Science; Asahikawa Medical College; Shiga University of Medical Science; University of Otago; Kyoto University	Okamoto, K (corresponding author), Shiga Univ Med Sci, Dept Urol, Shiga 5202192, Japan.	keisei@belle.shiga-med.ac.jp						Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; DUTRILLAUX B, 1986, INT J CANCER, V38, P475, DOI 10.1002/ijc.2910380404; Edelmann J, 2002, FORENSIC SCI INT, V125, P217, DOI 10.1016/S0379-0738(02)00005-1; Edelmann J, 2001, INT J LEGAL MED, V114, P301, DOI 10.1007/s004140000188; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Giordano SH, 2002, ANN INTERN MED, V137, P678, DOI 10.7326/0003-4819-137-8-200210150-00013; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HOPMAN AHN, 1989, AM J PATHOL, V135, P1105; Huang DX, 2003, FORENSIC SCI INT, V133, P246, DOI 10.1016/S0379-0738(03)00077-X; Huang KC, 2002, MOL CANCER THER, V1, P769; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7; Kawakami T, 2003, GENE CHROMOSOME CANC, V38, P97, DOI 10.1002/gcc.10234; Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a; Kim CJ, 2000, PROSTATE, V42, P287; KIRCHGESSNER CU, 1995, J MED GENET, V32, P925, DOI 10.1136/jmg.32.12.925; KOKALJVOKAC N, 1991, CYTOGENET CELL GENET, V57, P11, DOI 10.1159/000133103; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; McDonald HL, 2000, GENE CHROMOSOME CANC, V28, P246, DOI 10.1002/1098-2264(200007)28:3<246::AID-GCC2>3.3.CO;2-S; Melki JR, 1999, CANCER RES, V59, P3730; MULERIS M, 1990, GENE CHROMOSOME CANC, V1, P221, DOI 10.1002/gcc.2870010306; PERRY M, 1972, BRIT J SURG, V59, P731, DOI 10.1002/bjs.1800590912; SAVINO A, 1971, ACTA CYTOL, V15, P372; Smyth CM, 1998, ARCH INTERN MED, V158, P1309, DOI 10.1001/archinte.158.12.1309; Son JY, 2002, INT J LEGAL MED, V116, P317, DOI 10.1007/s00414-002-0307-x; Stone C, 2003, CURR BIOL, V13, pR63, DOI 10.1016/S0960-9822(02)01430-6; THERMAN E, 1985, CANCER GENET CYTOGEN, V16, P1, DOI 10.1016/0165-4608(85)90072-X	28	76	81	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6163	6169		10.1038/sj.onc.1207808	http://dx.doi.org/10.1038/sj.onc.1207808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195139				2022-12-17	WOS:000223261000016
J	Logan, N; Delavaine, L; Graham, A; Reilly, C; Wilson, J; Brummelkamp, TR; Hijmans, EM; Bernards, R; La Thangue, NB				Logan, N; Delavaine, L; Graham, A; Reilly, C; Wilson, J; Brummelkamp, TR; Hijmans, EM; Bernards, R; La Thangue, NB			E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains	ONCOGENE			English	Article						E2F; repression; cancer; cell cycle; transcription factor	TRANSCRIPTION FACTOR E2F-1; PROTEIN; DAMAGE; INDUCTION; LEADS; MICE; ATM	The E2F family of transcription factors play an important role in regulating cell cycle progression. We report here the characterization and functional properties of a new member of the human E2F family, referred to as E2F-7. E2F-7 has two separate DNA-binding domains, a feature that distinguishes E2F-7 from other mammalian E2F proteins, but resembling the organization of recently isolated E2F-like proteins from Arabidopsis. E2F-7 binds to DNA independently of a DP partner and delays cell cycle progression. Interestingly, E2F-7 modulates the transcription properties of other E2F proteins. A mutational analysis indicates that the integrity of both DNA-binding domains is required for cell cycle delay and transcriptional modulation. Biochemical results and protein modelling studies suggest that in binding to DNA interactions occur between the two DNA-binding domains, most probably as a homodimer, thereby mimicking the organization of an E2F/DP heterodimer. These structural and functional properties of E2F-7 imply a unique role in regulating cellular proliferation.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	University of Glasgow; MRC National Institute for Medical Research; Netherlands Cancer Institute	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	n.lathangue@bio.gla.ac.uk	Wilson, Jon R/B-7362-2019	Wilson, Jon R/0000-0002-5157-5432; Bernards, Rene/0000-0001-8677-3423; Hijmans, Marielle/0000-0003-4847-9412	MRC [G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; delaLuna S, 1996, J CELL SCI, V109, P2443; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; Komori H, 1999, EMBO J, V18, P4597, DOI 10.1093/emboj/18.17.4597; Kosugi S, 2002, J BIOL CHEM, V277, P16553, DOI 10.1074/jbc.M200913200; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; Lee JK, 1997, P NATL ACAD SCI USA, V94, P8427, DOI 10.1073/pnas.94.16.8427; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	33	76	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5138	5150		10.1038/sj.onc.1207649	http://dx.doi.org/10.1038/sj.onc.1207649			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15133492	Green Published			2022-12-17	WOS:000222382500004
J	Pan, Y; Oprysko, PR; Asham, AM; Koch, CJ; Simon, MC				Pan, Y; Oprysko, PR; Asham, AM; Koch, CJ; Simon, MC			p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment	ONCOGENE			English	Article						hypoxia; anoxia; p53; HIF; tumor cells	INDUCIBLE FACTOR 1-ALPHA; LOW-OXYGEN CONDITIONS; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS; PROTEIN; CELLS; MDM2; GENE; DEGRADATION; ACTIVATION	Solid tumors frequently contain hypoxic subregions due to insufficient blood supply. In these domains, cells can undergo p53-dependent apoptosis. Therefore, hypoxia has been implicated as a physiological stimulus for p53 accumulation and activation. In such an environment, p53 mutant cells exhibit a selective growth advantage. Hypoxic regulation of p53 has been proposed to be hypoxia inducible factor (HIF) dependent; however, controversy remains over whether and to what extent low oxygen (O-2) tension by itself enhances p53 protein stability. Here, we examined the p53 response to hypoxia and hypoxia mimetics in several cell lines expressing different HIF-alpha proteins. Most cells exhibited elevated levels of p53 in response to hypoxia mimetics such as deferoxamine mesylate and CoCl2, regardless of their HIF-alpha protein expression profile. However, over a range of O-2 levels, from 1.5% to less than 0.02%, we failed to observe p53 accumulation or p53 nuclear translocation in any cell lines tested. Only after treatment with a combination of hypoxia and acidosis/nutrient deprivation did some cells exhibit p53 induction. Our results suggest that, although hypoxia induces p53 accumulation in vivo, secondary effects such as acidosis caused by a hypoxic Pasteur effect ( instead of low O-2 by itself) are necessary for p53 accumulation. Therefore, the expression of HIF-1alpha and p53 proteins is not coupled during the cellular hypoxia response.	Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Simon, MC (corresponding author), Univ Penn, Howard Hughes Med Inst, Abramson Family Canc Res Inst, BRB 2-3 Rm 456,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021		NATIONAL CANCER INSTITUTE [P01CA079862] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA79862] Funding Source: Medline; PHS HHS [66310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Alarcon R, 1999, CANCER RES, V59, P6046; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Denko NC, 2000, EXP CELL RES, V258, P82, DOI 10.1006/excr.2000.4928; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; Kim CY, 1997, CANCER RES, V57, P4200; Koch CJ, 2002, METHOD ENZYMOL, V352, P3; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maya R, 2000, ONCOGENE, V19, P3213, DOI 10.1038/sj.onc.1203658; Ohtsubo T, 1997, CANCER RES, V57, P3910; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ravi R, 2000, GENE DEV, V14, P34; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Sax JK, 2002, CELL CYCLE, V1, P90, DOI 10.4161/cc.1.1.105; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2002, INTERNAL MED, V41, P79, DOI 10.2169/internalmedicine.41.79; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 1996, NATURE, V380, P100, DOI 10.1038/380100d0; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhong H, 1999, CANCER RES, V59, P5830; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	58	76	86	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4975	4983		10.1038/sj.onc.1207657	http://dx.doi.org/10.1038/sj.onc.1207657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15107830				2022-12-17	WOS:000222237300003
J	Jin, SQ; Mazzacurati, L; Zhu, XC; Tong, T; Song, YM; Shao, SJ; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM				Jin, SQ; Mazzacurati, L; Zhu, XC; Tong, T; Song, YM; Shao, SJ; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM			Gadd45a contributes to p53 stabilization in response to DNA damage	ONCOGENE			English	Article						p53; Gadd45a; DNA damage	CELL-CYCLE CHECKPOINT; P53-REGULATED PROTEIN GADD45; TUMOR-SUPPRESSOR P53; INDUCED PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; KINASE-ACTIVITY; ACTIVATES P53; MDM2; ARREST; INHIBITION	p53 is an important molecule in cellular response to DNA damage. After genotoxic stress, p53 protein stabilizes transiently and accumulates in the nucleus, where it functions as a transcription factor and upregulates multiple downstream-targeted genes, including p21(Waf1/Cip1), Gadd45a and Bax. However, regulation of p53 stabilization is complex and may mainly involve post-translational modification of p53, such as phosphorylation and acetylation. Using mouse embryonic fibroblasts (MEFs) derived from Gadd45a knockouts, we found that disruption of Gadd45a greatly abolished p53 protein stabilization following UVB treatment. Phosphorylation of p53 at Ser-15 was substantially reduced in Gadd45a-/- MEFs. In addition, p53 induction by UVB was shown to be greatly abrogated in the presence of p38 kinase inhibitor, but not c-Jun N-terminal kinase (JNK) and extracellular-signal regulated kinase (ERK), suggesting that p38 protein kinase is involved in the regulation of p53 induction. Along with the findings presented above, inducible expression of Gadd45a enhanced p53 accumulation after cell exposure to UVB. Taken together, the current study demonstrates that Gadd45a, a conventional downstream gene of p53, may play a role as an upstream effector in p53 stabilization following DNA damage, and thus has defined a positive feedback signal in the activation of the p53 pathway.	Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College	Zhan, QM (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, UPCI Res Pavil,Suite G5,5117 Ctr Ave, Pittsburgh, PA 15213 USA.			mazzacurati, lucia/0000-0002-8336-8032; song, yongmei/0000-0002-7789-0158	NCI NIH HHS [R01 CA-83874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang XH, 2001, TRIBOL LETT, V11, P15, DOI 10.1023/A:1016677321278; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	48	76	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8536	8540		10.1038/sj.onc.1206907	http://dx.doi.org/10.1038/sj.onc.1206907			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627995				2022-12-17	WOS:000186650300018
J	Kim, SH; Gunnery, S; Choe, JK; Mathews, MB				Kim, SH; Gunnery, S; Choe, JK; Mathews, MB			Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR	ONCOGENE			English	Article						PKR; interferon; melanoma; colon; cancer	SQUAMOUS-CELL CARCINOMA; NF-KAPPA-B; MALIGNANT TRANSFORMATION; HEPATOCELLULAR-CARCINOMA; CUTANEOUS MELANOMA; CATALYTIC DOMAIN; TUMOR-SUPPRESSOR; C-MYC; ACTIVATION; P68	The interferon-inducible, double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays key roles in regulation of cell growth and differentiation, and has been postulated as a tumor suppressor. Downstream effectors of PKR include the translation initiation factor, eIF2alpha, and the transcription factor, NF-kappaB. We found elevated levels of PKR protein, dsRNA-dependent PKR autophosphorylation activity, and phosphorylated eIF2a in melanoma cells compared to nontransformed melanocytes in culture. Treatment with interferon-alpha2b further induced PKR expression and activity. Immunohistochemical analysis of primary melanomas demonstrated minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR protein. Furthermore, analysis of colon cancer specimens revealed that transformation from normal mucosa to adenomas and carcinomas was coincident with an increase in PKR expression. These data do not support the concept of PKR as a classic tumor suppressor but instead suggest that PKR upregulation occurs at defined steps in cancer progression, probably as a cellular response to neoplasia.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; VA New Jersey Healthcare Syst, Pathol & Lab Med Serv, E Orange, NJ 07018 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; VA New Jersey Healthcare Syst, Surg Serv, E Orange, NJ 07018 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; New Jersey Department of Health & Senior Services; Rutgers State University New Brunswick; Rutgers State University Medical Center; New Jersey Department of Health & Senior Services	Kim, SH (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.				NIAID NIH HHS [AI34552] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Delhem N, 2001, ONCOGENE, V20, P5836, DOI 10.1038/sj.onc.1204744; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HAINES GK, 1993, VIRCHOWS ARCH B, V63, P289, DOI 10.1007/BF02899275; HAINES GK, 1992, VIRCHOWS ARCH B, V62, P151, DOI 10.1007/BF02899677; Haines GK, 1996, TUMOR BIOL, V17, P5, DOI 10.1159/000217961; Haines GK, 1998, TUMOR BIOL, V19, P52, DOI 10.1159/000029974; HAINES GK, 1993, ARCH OTOLARYNGOL, V119, P1142; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; Kim SH, 2000, ONCOGENE, V19, P3086, DOI 10.1038/sj.onc.1203632; KIM SH, 1998, CUTANEOUS ONCOLOGY, P303; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mathews Michael B., 2001, Trends in Biochemical Sciences, V26, P585, DOI 10.1016/S0968-0004(01)01971-5; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; OLDFIELD S, 1994, EUR J BIOCHEM, V221, P399, DOI 10.1111/j.1432-1033.1994.tb18752.x; Pataer A, 2002, CANCER RES, V62, P2239; Pehamberger H, 1998, J CLIN ONCOL, V16, P1425, DOI 10.1200/JCO.1998.16.4.1425; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Savinova O, 1999, INT J BIOCHEM CELL B, V31, P175, DOI 10.1016/S1357-2725(98)00140-X; Shang YF, 1998, J BIOL CHEM, V273, P30608, DOI 10.1074/jbc.273.46.30608; Shimada A, 1998, CANCER RES, V58, P4434; Sieber OM, 2000, MOL MED TODAY, V6, P462; SINGH C, 1995, TUMOR BIOL, V16, P281, DOI 10.1159/000217945; Sudhakar A, 2000, BIOCHEMISTRY-US, V39, P12929, DOI 10.1021/bi0008682; Terada T, 2000, HUM PATHOL, V31, P817, DOI 10.1053/hupa.2000.8443; Terada W, 2000, LIVER, V20, P450, DOI 10.1034/j.1600-0676.2000.020006450.x; WILLIAMS BR, 2001, SCI STKE RE, V2; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zamanian-Daryoush M, 1999, ONCOGENE, V18, P315, DOI 10.1038/sj.onc.1202293; Zhou U, 1998, EUR J CANCER, V34, P2046, DOI 10.1016/S0959-8049(98)00292-5	50	76	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 12	2002	21	57					8741	8748		10.1038/sj.onc.1205987	http://dx.doi.org/10.1038/sj.onc.1205987			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483527				2022-12-17	WOS:000179734400008
J	Song, CH; Satoh, T; Edamatsu, H; Wu, DM; Tadano, M; Gao, XL; Kataoka, T				Song, CH; Satoh, T; Edamatsu, H; Wu, DM; Tadano, M; Gao, XL; Kataoka, T			Differential roles of Ras and Rap1 in growth factor-dependent activation of phospholipase C epsilon	ONCOGENE			English	Article						PLC epsilon; Ras; Rap1	PROTEIN-KINASE-C; GOLGI-COMPLEX; GTPASE; RECEPTOR; IDENTIFICATION; ASSOCIATION; EFFECTOR; ADHESION; PRODUCT; PATHWAY	Phospholipase Cepsilon is a phosphoinositide-specific phospholipase C that selectively associates with Ras and Rap small GTPases as a target. Here we explored the molecular basis of the Rap1- as well as Ras-mediated regulation of phospholipase Cepsilon upon platelet-derived growth factor stimulation by using a receptor mutant deficient in its ability to phosphorylate and activate phospholipase Cgamma. Following platelet-derived growth factor treatment, this receptor induces persistent activation of ectopically expressed PLCepsilon through activation of Ras and Rap1. The rapid and initial phase of the activation is mediated by Ras, whereas Rap1 is responsible for the prolonged activation. We further demonstrate that the CDC25 homology domain, which exhibits guanine nucleotide exchange factor activity toward Rap1, but not Ras, is critical for the prolonged activation of phospholipase Cepsilon. Platelet-derived growth factor prevented the hematopoietic BaF3 cells containing the mutant receptor from undergoing apoptosis, and enabled these cells to proliferate, only when phospholipase Cepsilon was expressed. Therefore, the phospholipase C signal is suggested to be critical for survival and growth of BaF3 cells.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.		song, chunhua/K-7882-2016; Satoh, Takaya/K-2628-2014; song, chunhua/K-7882-2016	song, chunhua/0000-0001-7563-0339; song, chunhua/0000-0002-4081-2543; Edamatsu, Hironori/0000-0002-1335-4217				Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; JOHNSON DE, 1998, FRONT BIOSCI, V3, P313; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Shima F, 1997, MOL CELL BIOL, V17, P1057, DOI 10.1128/MCB.17.3.1057; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Wienecke R, 1996, ONCOGENE, V13, P913; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	30	76	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8105	8113		10.1038/sj.onc.1206003	http://dx.doi.org/10.1038/sj.onc.1206003			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444546				2022-12-17	WOS:000179231400004
J	Carlson, H; Ota, S; Song, YS; Chen, YW; Hurlin, PJ				Carlson, H; Ota, S; Song, YS; Chen, YW; Hurlin, PJ			Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation	ONCOGENE			English	Article						T-box; Tbx3; Myc; Ras; pl9ARF; p53	T-BOX GENES; FOOT MALFORMATION; MAMMARY SYNDROME; TYROSINE KINASE; P63 GENE; C-ABL; MUTATIONS; P19(ARF); MYC; EXPRESSION	Tbx3 is a member of the T-box family of transcription factors. Mutations in Tbx3 cause ulnar-mammary syndrome, an autosomal dominant disorder characterized by upper limb defects, apocrine-gland defects including mammary hypoplasia, and tooth, hair and genital defects. In cell culture, Tbx3 and its close relative Tbx2 are capable of immortalizing mouse embryo fibroblasts. We show that expression of Tbx3 together with Myc or oncogenic Ras (H-Ras(Val17)) leads to efficient transformation of mouse embryo fibroblasts. Oncogene cooperation by Tbx3 correlates with an ability of Tbx3 to suppress the induction of p19ARF and p53 that is typically caused by overexpression Myc and Ras, and to protect against Myc-induced apoptosis. Whereas Tbx3 is capable of interfering with apoptosis caused by excessive Myc levels, a Tbx3 mutant lacking its C-terminal repression domain shows no anti-apoptotic activity and fails to repress levels of p19ARF or p53. Consistent with an ability to suppress p53 pathway function, we find that Tbx3, but not a Tbx3 C-terminal mutant, efficiently blocks myogenic differentiation of C2C12 myoblasts. Our results support the idea that deregulation and/or excessive levels of Tbx3 may have oncogenic potential in vivo.	Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Hurlin, PJ (corresponding author), Oregon Hlth & Sci Univ, Shriners Hosp Children, 3101 Sam Jackson Pk Rd, Portland, OR 97201 USA.	pjh@shcc.org		Song, Youngsup/0000-0002-6268-5223				Agulnik SI, 1996, GENETICS, V144, P249; Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Bamshad M, 1999, AM J HUM GENET, V64, P1550, DOI 10.1086/302417; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Braybrook C, 2001, NAT GENET, V29, P179, DOI 10.1038/ng730; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cerone MA, 2000, CELL DEATH DIFFER, V7, P506, DOI 10.1038/sj.cdd.4400676; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gibson-Brown JJ, 1998, MECH DEVELOP, V74, P165, DOI 10.1016/S0925-4773(98)00056-2; He ML, 1999, P NATL ACAD SCI USA, V96, P10212, DOI 10.1073/pnas.96.18.10212; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HURLIN PJ, 1987, CANCER RES, V47, P5752; Ianakiev P, 2000, AM J HUM GENET, V67, P59, DOI 10.1086/302972; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Li QY, 1997, NAT GENET, V15, P21; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Schinke M, 2001, NAT GENET, V27, P238, DOI 10.1038/85784; SCHINZEL A, 1987, J MED GENET, V24, P778, DOI 10.1136/jmg.24.12.778; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	76	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3827	3835		10.1038/sj.onc.1205476	http://dx.doi.org/10.1038/sj.onc.1205476			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032820				2022-12-17	WOS:000175847200001
J	Scandura, JM; Boccuni, P; Cammenga, J; Nimer, SD				Scandura, JM; Boccuni, P; Cammenga, J; Nimer, SD			Transcription factor fusions in acute leukemia: variations on a theme	ONCOGENE			English	Review						leukemia; transcription; PML; RAR alpha; TGF beta; NUP98; AML1/ETO; CBF beta	ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR-BETA; ACUTE PROMYELOCYTIC LEUKEMIA; RETINOIC ACID RECEPTOR; ACUTE MYELOGENOUS LEUKEMIA; CORE BINDING-FACTOR; PML-RAR-ALPHA; MYOSIN HEAVY-CHAIN; HISTONE DEACETYLASE COMPLEX; MULTIPLE CHROMOSOMAL TRANSLOCATIONS	The leukemia-associated fusion proteins share several structural or functional similarities, suggesting that they may impart a leukemic phenotype through common modes of transcriptional dysregulation. The fusion proteins generated by these translocations usually contain a DNA-binding domain, domains responsible for homo- or hetero-dimerization, and domains that interact with proteins involved in chromatin remodeling (e.g., corepressor molecules or co-activator molecules). It is these shared features that constitute the 'variations on the theme' that underling the aberrant growth and differentiation that is the hallmark of acute leukemia cells.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, 1275 York Ave, New York, NY 10021 USA.	s-nimer@mskcc.org		Scandura, Joseph/0000-0002-9525-143X	NATIONAL CANCER INSTITUTE [T32CA009512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER; NCI NIH HHS [CA09512] Funding Source: Medline; NIDDK NIH HHS [R01 DK 52208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Ahn MY, 1998, P NATL ACAD SCI USA, V95, P1812, DOI 10.1073/pnas.95.4.1812; Ahuja HG, 2000, CANCER RES, V60, P6227; Ahuja HG, 1999, BLOOD, V94, P3258, DOI 10.1182/blood.V94.9.3258.421a40_3258_3261; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Andrieu V, 1996, BRIT J HAEMATOL, V92, P855, DOI 10.1046/j.1365-2141.1996.415954.x; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Babichuk CK, 1997, J BIOL CHEM, V272, P18564, DOI 10.1074/jbc.272.30.18564; Baer MR, 1997, BLOOD, V90, P1643, DOI 10.1182/blood.V90.4.1643.1643_1643_1648; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Batard P, 2000, J CELL SCI, V113, P383; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bloomfield CD, 1998, CANCER RES, V58, P4173; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BREEN TR, 1991, MECH DEVELOP, V35, P113, DOI 10.1016/0925-4773(91)90062-B; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Broeker PL, 1996, CURR TOP MICROBIOL, V211, P259; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; BYRD JC, 1994, CANCER, V73, P2107, DOI 10.1002/1097-0142(19940415)73:8<2107::AID-CNCR2820730815>3.0.CO;2-W; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Cashman JD, 1999, BLOOD, V94, P3722, DOI 10.1182/blood.V94.11.3722.423k20_3722_3729; CASTAIGNE S, 1990, BLOOD, V76, P1704; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dann EJ, 2001, BEST PRACT RES CL HA, V14, P119, DOI 10.1053/beha.2000.0119; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DUBOIS CM, 1994, BLOOD, V83, P3138; Ducos K, 2000, J CELL PHYSIOL, V184, P80, DOI 10.1002/(SICI)1097-4652(200007)184:1<80::AID-JCP8>3.0.CO;2-Q; Dybedal I, 1997, BLOOD, V90, P3395, DOI 10.1182/blood.V90.9.3395; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Engel ME, 1998, J CELL BIOCHEM, P111; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Faretta M, 2001, SEMIN HEMATOL, V38, P42, DOI 10.1053/shem.2001.20866; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; FEINSTEIN PG, 1995, GENETICS, V140, P573; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; Fontoura BMA, 1999, J CELL BIOL, V144, P1097, DOI 10.1083/jcb.144.6.1097; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fortunel NO, 2000, BLOOD, V96, P2022; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grimwade D, 2001, BLOOD, V98, P1312, DOI 10.1182/blood.V98.5.1312; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Horiike S, 1997, LEUKEMIA, V11, P1442, DOI 10.1038/sj.leu.2400770; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; JACOBSEN RJ, 1984, BRIT J HAEMATOL, V57, P539, DOI 10.1111/j.1365-2141.1984.tb02928.x; JACOBSEN SEW, 1993, J IMMUNOL, V151, P4534; JACOBSEN SEW, 1991, BLOOD, V77, P1706; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jochum W, 1999, Verh Dtsch Ges Pathol, V83, P216; Joh T, 1996, ONCOGENE, V13, P1945; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Jones KA, 2000, GENE DEV, V14, P1992; KALWINSKY DK, 1990, J CLIN ONCOL, V8, P75, DOI 10.1200/JCO.1990.8.1.75; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kasper LH, 1999, MOL CELL BIOL, V19, P764; KEATING MJ, 1988, LEUKEMIA, V2, P403; Kim JH, 1999, INT J BIOCHEM CELL B, V31, P933, DOI 10.1016/S1357-2725(99)00048-5; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; LAI JL, 1995, LEUKEMIA, V9, P370; Langabeer SE, 1997, BRIT J HAEMATOL, V99, P925, DOI 10.1046/j.1365-2141.1997.4663270.x; Langabeer SE, 1997, BRIT J HAEMATOL, V96, P736, DOI 10.1046/j.1365-2141.1997.d01-2096.x; Lardon F, 1996, LEUKEMIA, V10, P1937; LARSON RA, 1986, BLOOD, V68, P1242; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Leith CP, 1997, BLOOD, V89, P3323; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LONGO L, 1993, LEUKEMIA LYMPHOMA, V11, P405, DOI 10.3109/10428199309067933; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; LU J, 1995, MOL CELL BIOL, V15, P1651; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luo RT, 2001, MOL CELL BIOL, V21, P5678, DOI 10.1128/MCB.21.16.5678-5687.2001; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Mahmud N, 1999, BRIT J HAEMATOL, V105, P470, DOI 10.1046/j.1365-2141.1999.01324.x; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mao SF, 1999, MOL CELL BIOL, V19, P3635; MARLTON P, 1995, LEUKEMIA, V9, P965; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McLarren KW, 2000, J BIOL CHEM, V275, P530, DOI 10.1074/jbc.275.1.530; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; McLean TW, 1996, BLOOD, V88, P4252; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; McNeil S, 2000, J CELL BIOCHEM, V79, P103, DOI 10.1002/1097-4644(2000)79:1<103::AID-JCB100>3.0.CO;2-B; Megonigal MD, 1998, ONCOGENE, V16, P1351, DOI 10.1038/sj.onc.1201637; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mrozek K, 2001, BEST PRACT RES CL HA, V14, P19, DOI 10.1053/beha.2000.0114; Mrozek K, 1997, SEMIN ONCOL, V24, P17; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Nakamura T, 1999, BLOOD, V94, P741, DOI 10.1182/blood.V94.2.741.414k04_741_747; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakao M, 1996, LEUKEMIA, V10, P1911; Nishiyama M, 1999, GENE CHROMOSOME CANC, V26, P215, DOI 10.1002/(SICI)1098-2264(199911)26:3<215::AID-GCC5>3.3.CO;2-T; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Padua RA, 1998, LEUKEMIA, V12, P887, DOI 10.1038/sj.leu.2401044; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; PEARSONWHITE S, 1995, BLOOD, V86, P2146, DOI 10.1182/blood.V86.6.2146.bloodjournal8662146; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Pierelli L, 2000, BLOOD, V95, P3001; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Raimondi SC, 1999, BLOOD, V94, P3707; Rasio D, 1996, CANCER RES, V56, P1766; Raza-Egilmez SZ, 1998, CANCER RES, V58, P4269; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rhoades KL, 2000, BLOOD, V96, P2108; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; Rogaia D, 1997, CANCER RES, V57, P799; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Rozovskaia T, 2000, ONCOGENE, V19, P351, DOI 10.1038/sj.onc.1203307; RUBNITZ JE, 1994, BLOOD, V84, P1747; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SARGIACOMO M, 1991, ANN NY ACAD SCI, V628, P84, DOI 10.1111/j.1749-6632.1991.tb17226.x; Satake N, 1999, LEUKEMIA, V13, P1013, DOI 10.1038/sj.leu.2401439; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; SHEN WPV, 1987, ONCOGENE, V1, P157; Shikami M, 1999, LEUKEMIA, V13, P358, DOI 10.1038/sj.leu.2401343; Shimada H, 2000, BLOOD, V96, P655; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; Soignet S, 1997, CANCER CHEMOTH PHARM, V40, pS25, DOI 10.1007/s002800051057; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Stein GS, 2000, J CELL BIOCHEM, P84; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; SUPER HJG, 1994, BLOOD, V83, P641; SWIRSKY DM, 1984, BRIT J HAEMATOL, V56, P199, DOI 10.1111/j.1365-2141.1984.tb03948.x; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TESTA U, 1993, J IMMUNOL, V150, P2418; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Turley JM, 1996, CELL GROWTH DIFFER, V7, P1535; Uchida H, 1997, J IMMUNOL, V158, P2251; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; VAN DJ, 1995, P NATL ACAD SCI USA, V92, P7376; VanRanst PCF, 1996, EXP HEMATOL, V24, P1509; Visani G, 2001, LEUKEMIA, V15, P903, DOI 10.1038/sj.leu.2402142; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang LL, 2001, ONCOGENE, V20, P3716, DOI 10.1038/sj.onc.1204479; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1996, ANNU REV MED, V47, P555, DOI 10.1146/annurev.med.47.1.555; Weekx SFA, 1999, LEUKEMIA, V13, P1266, DOI 10.1038/sj.leu.2401462; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1996, LEUKEMIA, V10, P735; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang R, 1999, BLOOD, V93, P2067; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	289	76	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3422	3444		10.1038/sj.onc.1205315	http://dx.doi.org/10.1038/sj.onc.1205315			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032780				2022-12-17	WOS:000175633300015
J	Hsu, JH; Shi, YJ; Hu, LP; Fisher, M; Franke, TF; Lichtenstein, A				Hsu, JH; Shi, YJ; Hu, LP; Fisher, M; Franke, TF; Lichtenstein, A			Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses	ONCOGENE			English	Article						multiple myeloma; AKT; interleukin-6	PHOSPHATIDYLINOSITOL 3-KINASE; CELL-GROWTH; MONOCLONAL-ANTIBODY; INDUCED APOPTOSIS; PLASMA-CELLS; INTERLEUKIN-6; ACTIVATION; EXPRESSION; ONCOGENE; PROTOONCOGENE	IL-6 is an established growth factor for multiple myeloma tumor cells, stimulating proliferative and survival responses. Recent work indicates that IL-6 can activate the AKT kinase in myeloma cells. Thus, to test a potential role for AKT in IL-6-induced cellular responses, we transfected myeloma cell lines with an active 'E40K' or dominant negative 'PH' AKT construct using an adenoviral vector. Transfection of the E40K into myeloma cells resulted in enhanced tumor cell growth and expression of the PH dominant negative AKT resulted in both inhibition of the IL-6-dependent proliferative response and a decrease in S phase distribution. While transfection of E40K protected myeloma cells front dexamethasone-induced apoptosis, the dominant negative PH had no effect on the ability of IL-6 to protect these cells front dexamethasone. These results clearly demonstrate that AKT activation is critical for the IL-6 proliferative response. In addition, although the level of AKT activation can regulate sensitivity to dexamethasone-induced apoptosis, additional cytokine-induced AKT-independent pathways can mediate IL-6 protection against dexamethasone.	Univ Calif Los Angeles, Med Ctr, Dept Med & Pathol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Columbia University	Lichtenstein, A (corresponding author), VA West LA Hosp, W111H 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	alichten@ucla.edu						ANDERSON KC, 1989, BLOOD, V73, P1915; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aparicio A, 1998, LEUKEMIA, V12, P220, DOI 10.1038/sj.leu.2400892; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HSU JH, 2001, IN PRESS BLOOD; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jin Z., 1994, OCEANOLOGY CHINA SEA, P179, DOI DOI 10.1007/978-94-011-0862-1_19; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Prince HM, 1998, EXP HEMATOL, V26, P27; REIBNEGGER G, 1991, CANCER RES, V51, P6250; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sekulic A, 2000, CANCER RES, V60, P3504; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; SOONYANG Z, 1997, P NATL ACAD SCI USA, V94, P11345; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Teoh G, 1998, BLOOD, V92, P4591, DOI 10.1182/blood.V92.12.4591.424k08_4591_4601; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tu YP, 2000, CANCER RES, V60, P6763; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251	44	76	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1391	1400		10.1038/sj/onc/1205194	http://dx.doi.org/10.1038/sj/onc/1205194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857082				2022-12-17	WOS:000173861000009
J	Ackler, S; Ahmad, S; Tobias, C; Johnson, MD; Glazer, RI				Ackler, S; Ahmad, S; Tobias, C; Johnson, MD; Glazer, RI			Delayed mammary gland involution in MMTV-AKT1 transgenic mice	ONCOGENE			English	Article						AKT1; transgenic; mammary gland; cyclin D1	BREAST-CANCER CELLS; AKT/PROTEIN KINASE-B; TRANSCRIPTION FACTOR FKHR; GROWTH-FACTOR PROTECTS; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIN D1; AKT ACTIVATION; INDUCED APOPTOSIS; FACTOR I; KAPPA-B	AKT1/protein kinase B alpha is a protein-serine/threonine kinase that regulates multiple targets involved in cell survival and cell cycle progression in a variety of cell types including breast cancer cells. To explore the role of Akt1 in mammary gland function and tumorigenesis, transgenic mice were generated that express human AKT1 under the control of the MMTV promoter. Virgin transgenic mice did not exhibit a dominant phenotype, but upon cessation of lactation, a notable delay in involution occurred compared to age-matched nontransgenic mice. The delay in involution coincided with increased hyperplasia as evidenced by an increased number of binucleated epithelial cells and a marked elevation in cyclin D1 expression in mammary epithelium. The delayed involution phenotype corresponded to increased phosphorylation of Thr308 in AKT1 and Ser136 in BAD, but not phosphorylation of Ser21 in GSK-3 alpha. There was no evidence of mammary dysplasia or neoplasia during the lifespan of multiparous transgenic mice. These data suggest that AKT1 is involved in cell survival in the lactating and involuting mammary gland, but that overexpression of AKT1 alone is insufficient to induce transformation.	Georgetown Univ, Sch Med, Dept Pharmacol, Washington, DC 20007 USA; Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Oncol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Glazer, RI (corresponding author), Georgetown Univ, Sch Med, Dept Pharmacol, 3970 Reservoir Rd NW,Res Bldg,Room W318, Washington, DC 20007 USA.	glazerr@georgetown.edu			NATIONAL CANCER INSTITUTE [P50CA058185, P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA51008, P50-CA58185, R01 CA881565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bowers DC, 2000, CANCER RES, V60, P4277; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; HAYCOCK JW, 1993, ANAL BIOCHEM, V208, P397, DOI 10.1006/abio.1993.1068; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Krane IM, 1996, ONCOGENE, V12, P1781; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SMITH GH, 1995, AM J PATHOL, V147, P1081; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	47	76	77	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					198	206		10.1038/sj.onc.1205052	http://dx.doi.org/10.1038/sj.onc.1205052			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803463				2022-12-17	WOS:000173026200004
J	Pierantoni, GM; Fedele, M; Pentimalli, F; Benvenuto, G; Pero, R; Viglietto, G; Santoro, M; Chiariotti, L; Fusco, A				Pierantoni, GM; Fedele, M; Pentimalli, F; Benvenuto, G; Pero, R; Viglietto, G; Santoro, M; Chiariotti, L; Fusco, A			High mobility group I (Y) proteins bind HIPK2, a serine-threonine kinase protein which inhibits cell growth	ONCOGENE			English	Article						HMGI(Y); HIPK2; serine-threonine kinase; growth inhibition; yeast two-hybrid screening	IFN-BETA GENE; EXPRESS HIGH-LEVELS; FACTOR HMGI-C; SERINE/THREONINE KINASE; TRANSCRIPTION FACTORS; NUCLEAR PROTEINS; VIRUS INDUCTION; THYROID-CELLS; DNA-BINDING; SEQUENCE	The HMGI proteins (HMGI, HMGY and HMGI-C) have an important role in the chromatin organization and interact with different transcriptional factors. The HMGI genes are expressed at very low levels in normal adult tissues, whereas they are very abundant during embryonic development and in several experimental and human tumours. In order to isolate proteins interacting with the HMGI(Y) proteins, a yeast two-hybrid screening was performed using the HMGI(Y) protein as bait. This analysis led to the isolation of homeodomain-interacting protein kinase-2 (HIPK2), a serine/threonine nuclear kinase. HIPK2 co-immunoprecipitates with the HMGI(Y) protein in 293T cells. The interaction between HIPK2 and HMGI(Y) occurs through the PEST domain of HIPK2 and it is direct because in vitro translated HIPK2 binds HMGI(Y). We also show that HIPK2 is able to phosphorylate the HMGI(Y) protein by an in vitro kinase assay. In order to understand a possible role of HIPK2 gene in cell growth we performed a colony assay which showed an impressive HIPK2 inhibitory effect on normal thyroid cells. Flow cytometric analysis would indicate the block of cell growth at the G2/M phase of the cell cycle. Since normal thyroid cells do not express detectable HMGI(Y) protein levels, we assume that the HIPK2 inhibitory effect is independent from the interaction with the HMGI(Y) protein.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fondaz Senatore Pascale, Ist Nazl Tumori, I-80131 Naples, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	University of Naples Federico II; IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.		Fedele, Monica/C-1417-2015; Pentimalli, Francesca/K-4936-2014; Pierantoni, Giovanna Maria/O-7527-2015; Pero, Raffaela/L-1461-2015; Viglietto, Giuseppe/AAC-2852-2019; Chiariotti, Lorenzo/AAC-5262-2022	Fedele, Monica/0000-0002-9171-1312; Pentimalli, Francesca/0000-0003-4740-6801; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Pero, Raffaela/0000-0003-2182-5530; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197; BENVENUTO, Giovanna/0000-0001-7155-2935; CHIARIOTTI, Lorenzo/0000-0001-6097-4171				Abe N, 2000, CANCER RES, V60, P3117; ABE N, 1999, CANCER RES, V56, P1896; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Fedele M, 1996, CANCER RES, V56, P1896; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Li X, 2000, BIOCHEM BIOPH RES CO, V277, P513, DOI 10.1006/bbrc.2000.3700; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; ROGERS S, 1986, SCIENCE, V234, P3674; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	76	84	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6132	6141		10.1038/sj.onc.1204635	http://dx.doi.org/10.1038/sj.onc.1204635			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593421	Bronze			2022-12-17	WOS:000171206300004
J	Tsukasaki, K; Miller, CW; Greenspun, E; Eshaghian, S; Kawabata, H; Fujimoto, T; Tomonaga, M; Sawyers, C; Said, JW; Koeffler, HP				Tsukasaki, K; Miller, CW; Greenspun, E; Eshaghian, S; Kawabata, H; Fujimoto, T; Tomonaga, M; Sawyers, C; Said, JW; Koeffler, HP			Mutations in the mitotic check point gene, MAD1L1, in human cancers	ONCOGENE			English	Article						MAD1L1; mitotic checkpoint; chromosomal instability; prostate cancer; breast cancer; adult T-cell leukemia/lymphoma	HUMAN LUNG CANCERS; VIRUS TYPE-I; SPINDLE CHECKPOINT; INSTABILITY; LYMPHOMA; CELLS; FRESH	Aneuploidy is a characteristic of the majority of human cancers, and recent studies suggest that defects of mitotic checkpoints play a role in carcinogenesis. MAD1L1 is a checkpoint gene, and its dysfunction is associated with chromosomal instability. Rare mutations of this gene have been reported in colon and lung cancers. We examined a total of 44 cell lines (hematopoietic, prostate, osteosarcoma, breast, glioblastoma and lung) and 133 fresh cancer cells (hematopoietic, prostate, breast and glioblastoma) for alterations of MAD1L1 by RT-PCR-SSCP and nucleotide sequencing. Eight mutations consisting of missense, nonsense and frameshift mutations were found, together with a number of nucleotide polymorphisms. All the alterations in cell lines were heterozygous, Frequency of mutations was relatively high in prostate cancer (2/7 cell lines and 2/33 tumor specimens). We placed a mutant truncated MAD1L1, found in a lymphoma sample, into HOS, Ht161 and SJSA cell lines and found that it was less inhibitory than wild type MAD1L1 at decreasing cell proliferation. Go-expression experiments showed that the mutant form had a dominant-negative effect. Furthermore, this mutant impaired the mitotic checkpoint as shown by decreased mitotic indices in HOS cells expressing mutant MAD1L1 after culture with the microtubule-disrupting agent, nocodazole, Our results suggest a pathogenic role of MAD1L1 mutations in various types of human cancer.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA; Nagasaki Univ, Sch Med, Atom Bomb Dis Inst, Dept Hematol, Nagasaki 852, Japan; Univ Calif Los Angeles, Sch Med, Hlth Sci Ctr, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Hlth Sci Ctr, Dept Pathol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Nagasaki University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Tsukasaki, K (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Sawyers, Charles/G-5327-2016					Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Cunningham JM, 1996, CANCER RES, V56, P4475; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GOMBART AF, 1995, BLOOD, V86, P1534, DOI 10.1182/blood.V86.4.1534.bloodjournal8641534; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMIHIRA S, 1994, LEUKEMIA RES, V18, P79, DOI 10.1016/0145-2126(94)90122-8; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Said JW, 1996, BLOOD, V87, P4937, DOI 10.1182/blood.V87.12.4937.bloodjournal87124937; Sciavolino PJ, 1998, ANN MED, V30, P357, DOI 10.3109/07853899809029935; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tsukasaki K, 1999, BRIT J HAEMATOL, V105, P369, DOI 10.1111/j.1365-2141.1999.01323.x; Tsukasaki K, 2000, BEST PRACT RES CL HA, V13, P231, DOI 10.1053/beha.1999.0070	22	76	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3301	3305		10.1038/sj.onc.1204421	http://dx.doi.org/10.1038/sj.onc.1204421			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423979				2022-12-17	WOS:000169163500013
J	Yasui, Y; Goto, H; Matsui, S; Manser, E; Lim, L; Nagata, K; Inagaki, M				Yasui, Y; Goto, H; Matsui, S; Manser, E; Lim, L; Nagata, K; Inagaki, M			Protein kinases required for segregation of vimentin filaments in mitotic process	ONCOGENE			English	Article						mitosis; vimentin; phosphorylation; Rho-kinase; protein kinase C (PKC); vimentin-Ser72 kinase	RHO-ASSOCIATED KINASE; CELL-CYCLE CONTROL; POLO-LIKE KINASES; INTERMEDIATE-FILAMENTS; CLEAVAGE FURROW; PHOSPHORYLATION; CYTOKINESIS; MITOSIS; SITE; CYTOSKELETON	Vimentin, one of type III intermediate filament (IF) proteins, is expressed not only in mesenchymal cells but also in most types of tumor cells. In the present study, rye introduced several types of vimentin mutated at putative phosphorylation sites in its amino-terminal head domain into type III IF-negative T24 cells. Site-specific mutation induced the formation of an unusually long bridge-like IF structure between the unseparated daughter cells, although these mutants formed the filament network similar to wild type in interphase cells. Together with sites phosphorylated by Rho-kinase and protein kinase C (PKC), vimentin-Ser72, which can not be phosphorylated by any known vimentin kinase, was one of the mutation sites essential for this phenotype, We further demonstrated that vimentin-Ser72 was phosphorylated specifically at the cleavage furrow during cytokinesis. These observations suggest the existence of a novel protein kinase responsible for vimentin filament separation through the cleavage furrow-specific vimentin phosphorylation, We propose that Rho-kinase, PKC, and an unidentified vimentin-Ser72 kinase may play important roles in vimentin filament separation during cytokinesis, Oncogene (2001) 20, 3868-2876.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 117609, Singapore; Nagoya City Univ, Fac Pharmaceut Sci, Dept Biol Chem, Nagoya, Aichi 4678603, Japan; UCL, Inst Neurol, London WC1N 1PJ, England	Aichi Cancer Center; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; Nagoya City University; University of London; University College London	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016; Manser, Edward/ABD-2301-2020	Goto, Hidemasa/0000-0002-6796-4467				Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; EVANS RM, 1984, J BIOL CHEM, V259, P5372; EVANS RM, 1982, CELL, V29, P43, DOI 10.1016/0092-8674(82)90088-5; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GOSS VL, 1994, J BIOL CHEM, V269, P19074; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Goto H, 2000, MICROSC RES TECHNIQ, V49, P173, DOI 10.1002/(SICI)1097-0029(20000415)49:2<173::AID-JEMT10>3.0.CO;2-A; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Kosako H, 1997, J BIOL CHEM, V272, P10333; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Passalacqua M, 1999, FEBS LETT, V453, P249, DOI 10.1016/S0014-5793(99)00729-2; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Sekimata M, 1996, J CELL BIOL, V132, P635, DOI 10.1083/jcb.132.4.635; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; TSUJIMURA K, 1994, J BIOL CHEM, V269, P31097; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249	43	76	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2868	2876		10.1038/sj.onc.1204407	http://dx.doi.org/10.1038/sj.onc.1204407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420699				2022-12-17	WOS:000168901800002
J	Graveel, CR; Jatkoe, T; Madore, SJ; Holt, AL; Farnham, PJ				Graveel, CR; Jatkoe, T; Madore, SJ; Holt, AL; Farnham, PJ			Expression profiling and identification of novel genes in hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; representational difference analysis; expression profiling; oligonucleotide microarrays	REPRESENTATIONAL DIFFERENCE ANALYSIS; C3H/HEJ MICE; OSTEOPONTIN; CANCER; RNA; HEPATOCARCINOGENESIS; C57BL/6J; DOMAINS; GROWTH; TUMORS	Liver cancer is the fifth most common cancer worldwide and unlike certain other cancers, such as colon cancer, a mutational model has not Set been developed. We have performed gene expression profiling of normal and neoplastic livers in C3H/HeJ mice treated with diethylnitrosamine. Using oligonucleotide microarrays, we compared gene expression in liver tumors to three different states of the normal liver: quiescent adult, regenerating adult, and newborn. Although each comparison revealed hundreds of differentially expressed genes, only 22 genes were found to be deregulated in the tumors in all three comparisons. Three of these genes were examined in human hepatocellular carcinomas and were found to be upregulated. As a second method of analysis, we used Representational Difference Analysis (RDA) to clone mRNA fragments differentially expressed in Ih er tumors versus regenerating livers. We cloned several novel mRNAs that are differentially regulated in murine liver tumors. Here we report the sequence of a novel cDNA whose expression is upregulated in both murine and human hepatocellular carcinomas. Our results suggest that DEN-treated mice provide an excellent model for human hepatocellular carcinomas.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; Pfizer Inc, Genom & Bioinformat, Ann Arbor, MI 48105 USA	University of Wisconsin System; University of Wisconsin Madison; Pfizer	Farnham, PJ (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA22484] Funding Source: Medline; NIGMS NIH HHS [GM08349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ariel I, 1998, J CLIN PATHOL-MOL PA, V51, P21, DOI 10.1136/mp.51.1.21; BENNETT LM, 1995, MOL CARCINOGEN, V14, P46, DOI 10.1002/mc.2940140109; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; FARBER E, 1976, LIVER CELL CANCER, P243; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Kojiro M, 1999, SEMIN LIVER DIS, V19, P287, DOI 10.1055/s-2007-1007118; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P1269, DOI 10.1164/ajrccm.160.4.9807094; Singhal H, 1997, CLIN CANCER RES, V3, P605; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Welford SM, 1998, NUCLEIC ACIDS RES, V26, P3059, DOI 10.1093/nar/26.12.3059; Yamada Y, 1999, LAB INVEST, V79, P1059; Ye XQ, 1997, BIOCHEM BIOPH RES CO, V239, P660, DOI 10.1006/bbrc.1997.7529; Yoong KF, 1999, HEPATOLOGY, V30, P100, DOI 10.1002/hep.510300147	24	76	83	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2704	2712		10.1038/sj.onc.1204391	http://dx.doi.org/10.1038/sj.onc.1204391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420682				2022-12-17	WOS:000168652600011
J	Kelley, ML; Winge, P; Heaney, JD; Stephens, RE; Farell, JH; Van Beneden, RJ; Reinisch, CL; Lesser, MP; Walker, CW				Kelley, ML; Winge, P; Heaney, JD; Stephens, RE; Farell, JH; Van Beneden, RJ; Reinisch, CL; Lesser, MP; Walker, CW			Expression of homologues for p53 and p73 in the softshell clam (Mya arenaria), a naturally-occurring model for human cancer	ONCOGENE			English	Article						p53; p73; Burkitt's lymphoma; cancer; Mya arenaria clam; nuclear exclusion	ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; P53-RELATED PROTEIN; NUCLEAR EXCLUSION; FUNCTIONAL DOMAIN; BREAST-CANCER; MUTANT P53; MDM2; LYMPHOMA	Homologues for human p53 (Hsp53) and p73 (Hsp73) genes were cloned and expression patterns for their corresponding proteins analysed in tissues from normal and leukemic softshell clams (Mya arenaria). These are the first structural and functional data for p53 and p73 cDNAs and gene products in a naturally occurring, nonmammalian disease model. Core sequence of the predicted clam p53 (Map53) and p73 (Map73) proteins is virtually identical and includes the following a highly conserved regions: the transcriptional activation domain (TAD), MDM2 binding site, ATM phosphorylation site, proline rich domain, DSA binding domains (DBDs) II-V, nuclear import and export signals and the tetramerization domain. The core sequence is a structural mosaic of the corresponding human proteins, with the TAD and DBDs resembling Hsp53 and Hsp73, respectively. This suggests that Map53 and Map73 proteins mag function similarly to human proteins. Clam proteins have either a short (Map53) or long (Map73) C-terminal extension, These features suggest that Map53 and Map73 mag be alternate splice variants of a p63/p73-like ancestral gene. Map73 is significantly upregulated in hemocytes and adductor muscle from leukemic clams. In leukemic hemocytes, both proteins are absent from the nucleus and sequestered in the cytoplasm, This observation suggests that a non-mutational p53/p73-dependent mechanism may be in col,ed in the clam disease. Further studies of these gene products in clams may reveal p53/p73-related molecular mechanisms that are held in common with Burkitt's lymphoma or other human cancers.	Univ New Hampshire, Dept Zool, Durham, NH 03824 USA; Univ New Hampshire, Marine Biomed Res Grp, Durham, NH 03824 USA; Univ Maine, Dept Biochem Microbiol & Mol Biol, Orono, ME 04469 USA; Univ Maine, Sch Marine Sci, Orono, ME 04469 USA; Univ Trondheim, Ctr Mol Biol, UNIGEN, N-7005 Trondheim, Norway; Marine Biol Lab, Woods Hole, MA 02543 USA; Boston Univ, Sch Med, Dept Physiol L720, Boston, MA 02118 USA	University System Of New Hampshire; University of New Hampshire; University System Of New Hampshire; University of New Hampshire; University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; Marine Biological Laboratory - Woods Hole; Boston University	Walker, CW (corresponding author), Univ New Hampshire, Dept Zool, Rudman Hall, Durham, NH 03824 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD028204] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA044307] Funding Source: NIH RePORTER; NCI NIH HHS [CA44307] Funding Source: Medline; NICHD NIH HHS [HD28204-01A1] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AUFFRET M, 1988, AM FISH SOC SPEC PUB, V18, P169; Avramis VI, 1998, ANTICANCER RES, V18, P2327; Bain BJ, 1999, LEUKEMIA DIAGNOSIS, P1; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barker CM, 1997, EXP CELL RES, V232, P240, DOI 10.1006/excr.1997.3513; Bhaskaran A, 2000, COMP BIOCHEM PHYS B, V126, P49, DOI 10.1016/S0305-0491(00)00174-7; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cheng T.C., 1981, INVERTEBRATE BLOOD C, P233; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Corn PG, 1999, CANCER RES, V59, P3352; DANG CV, 1989, J BIOL CHEM, V264, P18019; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; ELSTON RA, 1992, REV AQUAT SCI, V6, P405; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GROGAN TM, 1982, CANCER-AM CANCER SOC, V49, P1817, DOI 10.1002/1097-0142(19820501)49:9<1817::AID-CNCR2820490914>3.0.CO;2-F; Harlow E., 1999, USING ANTIBODIES LAB, P1; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Humason GL, 1979, ANIMAL TISSUE TECHNI, P1; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; MARIN MC, 2000, BIOCHIM BIOPHYS ACTA, V1470, P94; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIOSKY DL, 1989, J INVERTEBR PATHOL, V53, P32, DOI 10.1016/0022-2011(89)90071-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nagai J, 1998, LEUKEMIA LYMPHOMA, V28, P591, DOI 10.3109/10428199809058368; Nishimori H, 2000, J NEURO-ONCOL, V46, P17, DOI 10.1023/A:1006404110073; OConnor PM, 1997, CANCER RES, V57, P4285; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Peters UR, 1999, CANCER RES, V59, P4233; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; PROKOCIMER M, 1986, BLOOD, V68, P113; REINISCH CL, 1984, HAZARD WASTE HAZARD, V1, P73, DOI 10.1089/hzw.1984.1.73; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; SHAULSKY G, 1991, CANCER RES, V51, P5232; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Steller H, 2000, NAT CELL BIOL, V2, pE100, DOI 10.1038/35014093; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Van Beneden RJ, 1998, MAR ENVIRON RES, V46, P209, DOI 10.1016/S0141-1136(97)00093-7; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	70	76	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					748	758		10.1038/sj.onc.1204144	http://dx.doi.org/10.1038/sj.onc.1204144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314008				2022-12-17	WOS:000166806000010
J	Liu, JM; Yuan, Y; Huan, J; Shen, ZY				Liu, JM; Yuan, Y; Huan, J; Shen, ZY			Inhibition of breast and brain cancer cell growth by BCCIP alpha, an evolutionarily conserved nuclear protein that interacts with BRCA2	ONCOGENE			English	Article						BRCA2; calcium-binding protein; BCCIP	SUSCEPTIBILITY GENE BRCA2; TUMOR-SUPPRESSOR LOCI; LONG ARM; RADIATION HYPERSENSITIVITY; TERMINAL DELETION; HUMAN GLIOMAS; ALLELIC LOSS; RAD51; CHROMOSOME-10; 10Q	BRCA2 is a tumor suppressor gene involved in mammary tumorigenesis, Although important functions have been assigned to a few conserved domains of BRCA2, little is known about the longest internal conserved domain encoded by exons 14-24.,We identified a novel protein, designated BCCIP alpha, that interacts with part of the internal conserved region of human BRCA2, Human BCCIP represents a family of proteins that are evolutionarily conserved, and contain three distinct domains: an N-terminus acidic domain (NAD) of 30-60 amino acids, an internal conserved domain (ICD) of 180-220 amino acids, and a C-terminus variable domain (CVD) of 30-60 amino acids, The N-terminal half of the human BCCIP ICD shares moderate homology with regions of calmodulin and ill-calpain, suggesting that BCCIP may also bind Ca. Human cells express both a longer, BCCIP alpha, and a shorter, BCCIP beta, form of the protein, which differ in their CVD, BCCIP is a nuclear protein highly expressed in testis, Although BCCIP beta expression is relatively consistent in cancer cells, the expression of BCCIP alpha varies in cancer cell Lines. The BCCIP alpha gene is located at chromosome 10q25.3-26.2, a region frequently altered in brain and other cancers. Furthermore, expression of BCCIP alpha inhibits breast and brain cancer cell growth,but fails to inhibit HT1080 cells and a non-transformed human skin fibroblast, These results suggest that BCCIP alpha is an important cofactor for BRCA2 in tumor suppression.	Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ Illinois, Coll Med, Grad Program Mol Genet, Chicago, IL 60607 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Shen, ZY (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008353, R01ES008353] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES08353] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Gayther SA, 1998, DIS MARKERS, V14, P1; Ittmann M, 1996, CANCER RES, V56, P2143; Katagiri T, 1998, GENE CHROMOSOME CANC, V21, P217, DOI 10.1002/(SICI)1098-2264(199803)21:3<217::AID-GCC5>3.0.CO;2-2; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; Koul A, 1999, GENE CHROMOSOME CANC, V24, P207, DOI 10.1002/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nordling M, 1998, CANCER RES, V58, P1372; PEAR WS, 1997, GENE THERAPY PROTLCO, P41; PEIFFER SL, 1995, CANCER RES, V55, P1922; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; Pontremoli S, 1999, CALCIUM AS A CELLULAR REGULATOR, P371; RASHEED BKA, 1991, CANCER METAST REV, V10, P289; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Robertson GP, 1999, CANCER RES, V59, P3596; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shen ZY, 1996, MUTAT RES-DNA REPAIR, V364, P81, DOI 10.1016/0921-8777(96)00025-0; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanabe S, 1999, PEDIATR INT, V41, P565, DOI 10.1046/j.1442-200x.1999.01105.x; TAYSI K, 1982, ANN GENET-PARIS, V25, P141; VIDAL M, 1997, YEAST 2 HYBRID SYSTE, P109; Waggoner DJ, 1999, AM J MED GENET, V86, P1; WALKER GJ, 1995, GENE CHROMOSOME CANC, V12, P134, DOI 10.1002/gcc.2870120208; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Yano K, 2000, BIOCHEM BIOPH RES CO, V270, P171, DOI 10.1006/bbrc.2000.2392; YJANDRA N, 1999, CALCIUM CELL REGULAT, P152; Yuan SSF, 1999, CANCER RES, V59, P3547	37	76	80	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					336	345		10.1038/sj.onc.1204098	http://dx.doi.org/10.1038/sj.onc.1204098			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313963				2022-12-17	WOS:000166411000008
J	Adams, J; Elliott, PJ				Adams, J; Elliott, PJ			New agents in cancer clinical trials	ONCOGENE			English	Article						proteasome; tubulin; heat shock proteins; histone; antifolates; protein tyrosine kinase	TRANSFORMED-CELL DIFFERENTIATION; COMBRETASTATIN A-4 PHOSPHATE; ABL TYROSINE KINASE; NF-KAPPA-B; ANTITUMOR AGENTS; HISTONE DEACETYLASE; IN-VIVO; FORMYLTRANSFERASE INHIBITORS; PROTEASOME INHIBITORS; ANTINEOPLASTIC AGENTS		Millennium Pharmaceut Inc, Res & Dev, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Adams, J (corresponding author), Millennium Pharmaceut Inc, Res & Dev, 38 Sidney St, Cambridge, MA 02139 USA.							Adams J, 1999, CANCER RES, V59, P2615; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Akagi T, 1996, ONCOGENE, V13, P399; ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; BROGGINI M, 1989, NUCLEIC ACIDS RES, V17, P1051, DOI 10.1093/nar/17.3.1051; BROGGINI M, 1994, ANTI-CANCER DRUG DES, V9, P373; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; Buchdunger E, 1996, CANCER RES, V56, P100; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DINCALCI M, 1999, P 1999 AACR NCI EORT, V5, P144; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 1999, BLOOD, V94, p368A; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GarciaRocha M, 1996, BRIT J CANCER, V73, P875, DOI 10.1038/bjc.1996.176; GLICK RD, 1999, P AM ASS CANC RES, V40; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grosios K, 2000, ANTICANCER RES, V20, P229; Grosios K, 1999, BRIT J CANCER, V81, P1318, DOI 10.1038/sj.bjc.6692174; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Habeck Lillian L., 1994, Cancer Research, V54, P1021; Habeck LL, 1998, CANCER CHEMOTH PHARM, V41, P201; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; Hori K, 1999, JPN J CANCER RES, V90, P1026, DOI 10.1111/j.1349-7006.1999.tb00851.x; ITAZAKI H, 1990, J ANTIBIOT, V43, P1524, DOI 10.7164/antibiotics.43.1524; Jimeno Jose M., 1996, Drugs of the Future, V21, P1155; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Kamen B, 1997, SEMIN ONCOL, V24, P30; Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; KWON HJ, 1999, P AM ASS CANC RES, V40; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LIN CM, 1989, BIOCHEMISTRY-US, V28, P6984, DOI 10.1021/bi00443a031; Martinez EJ, 2000, ORG LETT, V2, P993, DOI 10.1021/ol0056729; Mendelsohn LG, 1996, INVEST NEW DRUG, V14, P287, DOI 10.1007/BF00194532; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Nguyen D., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P485; Nihei Y, 1999, JPN J CANCER RES, V90, P1016, DOI 10.1111/j.1349-7006.1999.tb00850.x; NOWELL PC, 1960, SCIENCE, V132, P1497; Ochel HJ, 1999, MOL GENET METAB, V66, P24, DOI 10.1006/mgme.1998.2774; Orlowski RZ, 1998, CANCER RES, V58, P4342; PETERS JM, 1998, UBIQUITIN BIOL CELL, pCH1; Pettit GR, 1998, ANTI-CANCER DRUG DES, V13, P183; PETTIT GR, 1989, EXPERIENTIA, V45, P209, DOI 10.1007/BF01954881; PIZZORNO G, 1993, J BIOL CHEM, V268, P1017; Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b; RAY MS, 1993, J NATL CANCER I, V85, P1154, DOI 10.1093/jnci/85.14.1154; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; RINEHART KL, 1990, J ORG CHEM, V55, P4512, DOI 10.1021/jo00302a007; Rosing H, 1998, J CHROMATOGR B, V710, P183, DOI 10.1016/S0378-4347(98)00143-1; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Taamma A, 1999, CLIN CANCER RES, V5, p3791S; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Takimoto C H, 1995, Oncology (Williston Park), V9, P649; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tozer GM, 1999, CANCER RES, V59, P1626; VAN AD, 1996, SCIENCE, V274, P787; VILLALONACALERO M, 1999, ASCO, V18, P180; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	75	76	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 27	2000	19	56					6687	6692		10.1038/sj.onc.1204088	http://dx.doi.org/10.1038/sj.onc.1204088			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415CY	11426656				2022-12-17	WOS:000167704000017
J	Rahman, KMW; Aranha, O; Glazyrin, A; Chinni, SR; Sarkar, FH				Rahman, KMW; Aranha, O; Glazyrin, A; Chinni, SR; Sarkar, FH			Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3-carbinol (I3C) treated breast cancer cells	ONCOGENE			English	Article						cell growth inhibition; I3C; Bax; mitochondria; apoptosis	CYTOCHROME-C; BCL-2; INDUCTION; INHIBITION; CYCLE; OVEREXPRESSION; CARCINOGENESIS; ACTIVATION; RELEASE; CYTOSOL	Epidemiological studies have suggested that the consumption of fruits and vegetables that provide several classes of compounds, including Indole3-carbinol (I3C), may have chemopreventive activity against breast cancer. Several in vitro and in vivo animal studies also provide convincing evidence for the anti-tumor activity of I3C, however, the molecular mechanism(s) by which I3C exerts its biological effects on breast cancer cells has not been fully elucidated. In this study, we investigated the effects of I3C in Her-2/neu over-expressing MDA-MB-435 breast cancer cells and compared these results with parental cells transfected with control vector, We focused our investigation in elucidating the molecular mechanism(s) by which I3C induces apoptosis in breast cancer cells. Our data show that I3C inhibits breast cancer cell growth in a dose dependent manner in Her-2/neu overexpressing and in normal Her-2/neu expressing cells. Induction of apoptosis was also observed in these cell lines when treated with I3C, as measured by poly (ADP-ribose) polymerase (PARP) and caspase-3 activation. In addition, we found that I3C up-regulates Bas, downregulates Bcl-2 and, thereby, increased the ratio of Bax to Bcl-2 favoring apoptosis, These results suggest that the alteration in the expression of these genes may play an important role in mediating the biological effects of I3C. Moreover, we also show the cellular localization of Bax by confocal microscopy, which showed diffuse distribution of Bax throughout the cytoplasmic compartment in breast cancer cells in control culture. However, in 13C treated cells, Bax showed a punctate pattern of distribution that was localized in the mitochondria, From these results, we conclude that the over-expression and translocation of Bax to mitochondria causes mitochondrial depolarization and activation of caspases, which may be one of the mechanism(s) by which I3C induces apoptotic processes in I3C treated breast cancer cells. Overall, our present data provide a novel molecular mechanism(s) by which 13C elicits its biological effects on both Her-2/neu over-expressing and with normal Her-2/neu expressing breast cancer cells, suggesting that 13C could be an effective agent in inducing apoptosis in breast cancer cells.	Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Sarkar, FH (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Karmanos Canc Inst, 9374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.				NCI NIH HHS [P30CA22453] Funding Source: Medline; NIEHS NIH HHS [P30ES06639, ES 06639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		*AIFCR, 1997, FOOD NUTR PREV CANC, P436; BAILEY G, 1987, ENVIRON HEALTH PERSP, V71, P147, DOI 10.2307/3430422; Birt DF, 1996, PROG CLIN BIOL RES, V395, P223; Bradbury MH, 1997, J CONTAM HYDROL, V28, P11, DOI 10.1016/S0169-7722(97)00002-8; BRADFIELD CA, 1991, ADV EXP MED BIOL, V289, P153; Broadbent TA, 1998, CURR MED CHEM, V5, P337; Byrd JC, 1998, BLOOD, V92, P3804, DOI 10.1182/blood.V92.10.3804; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Cover CM, 1999, CANCER RES, V59, P1244; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Flagg EW, 2000, EPIDEMIOLOGY, V11, P462, DOI 10.1097/00001648-200007000-00017; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huber WW, 1997, MUTAT RES-FUND MOL M, V376, P115, DOI 10.1016/S0027-5107(97)00033-X; Katdare M, 1998, ONCOL REP, V5, P311; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOJIMA T, 1994, CANCER RES, V54, P1446; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li YW, 1998, ONCOGENE, V17, P2915, DOI 10.1038/sj.onc.1202218; LOUB WD, 1975, J NATL CANCER I, V54, P985; MIYASHITA T, 1994, CANCER RES, V54, P3131; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIWA T, 1994, STEROIDS, V59, P523, DOI 10.1016/0039-128X(94)90070-1; Nomura M, 1999, CANCER RES, V59, P5542; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SALET C, 1995, INT J RADIAT BIOL, V67, P477, DOI 10.1080/09553009514550551; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; SEDLAK ML, 1995, P NATL ACAD SCI USA, V92, P7943; SHERTZER HG, 1984, CHEM-BIOL INTERACT, V48, P81, DOI 10.1016/0009-2797(84)90008-5; Tan M, 1997, CANCER RES, V57, P1199; TIWARI RK, 1994, J NATL CANCER I, V86, P126, DOI 10.1093/jnci/86.2.126; WATTENBERG LW, 1978, CANCER RES, V38, P1410; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yu DH, 1996, ONCOGENE, V13, P1359	43	76	76	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2000	19	50					5764	5771		10.1038/sj.onc.1203959	http://dx.doi.org/10.1038/sj.onc.1203959			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126363				2022-12-17	WOS:000165477700008
J	Kiguchi, K; Bol, D; Carbajal, S; Beltran, L; Moats, S; Chan, K; Jorcano, J; DiGiovanni, J				Kiguchi, K; Bol, D; Carbajal, S; Beltran, L; Moats, S; Chan, K; Jorcano, J; DiGiovanni, J			Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development	ONCOGENE			English	Article						erbB2; EGFr; erbB3; skin; carcinogenesis	GROWTH-FACTOR-RECEPTOR; TREATED MOUSE EPIDERMIS; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; ALTERED EXPRESSION; NEU-ONCOGENE; CELL-LINE; TGF-ALPHA; CANCER; OVEREXPRESSION	The erbB family of receptor tyrosine kinases, which consists of the epidermal growth factor receptor (EGFr/erbB1), erbB2 (neu), erbB3 and erbB4, has been shown to be important for both normal development as well as neoplasia. The expression of rat erbB2 was targeted to the basal layer of mouse epidermis with the bovine keratin 5 promoter. Overexpression of wild type rat erbB2 in the basal layer of epidermis led to alopecia, follicular hyperplasia and sebaceous gland enlargement as well as hyperplasia of the interfollicular epidermis. Spontaneous papillomas, some of which converted to squamous cell carcinomas, arose in homozygous erbB2 transgenic mice as early as 6 weeks of age with >90% incidence by 6 months. Analysis of several proliferationl differentiation markers indicated that erbB2 overexpression led to epidermal hyperproliferation and a possible delay in epidermal differentiation. Transgenic mice were also hypersensitive to the proliferative effects of the skin tumor promoter, 12-0-tetradecanoylphorbol-13-acetate (TPA) and were more sensitive to two-stage carcinogenesis. Elevations in EGFr and erbB2 protein as well as erbB2:EGFr and erbB2:erbB3 heterodimers were observed in skin of the erbB2 transgenic mice. Phosphotyrosine levels of the EGFr, erbB2 and erbB3 proteins were also elevated. These results indicate an important role for erbB2 signaling in epidermal growth, development and neoplasia.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Ciemat Inst, Dept Cell & Mol Biol, Madrid 28040, Spain	University of Texas System; UTMD Anderson Cancer Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas	DiGiovanni, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, R01CA076520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA76520] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALDAZ CM, 1989, SKIN TUMORS EXPT CLI, V11, P227; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.0.CO;2-R; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cohen BM, 1996, J BIOL CHEM, V271, P4813; DiGiovanni J, 2000, CANCER RES, V60, P1561; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ELDRIDGE SR, 1990, CARCINOGENESIS, V4, P281; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOGAN B, 1994, MANIPULATING MOUSE E; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.3.CO;2-B; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERSCH R, 1988, MOL CELL BIOL, V8, P486, DOI 10.1128/MCB.8.1.486; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; MOLLOY CJ, 1987, CANCER RES, V47, P4674; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NAITO M, 1987, CARCINOGENESIS, V8, P1807, DOI 10.1093/carcin/8.12.1807; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Riese DJ, 1996, ONCOGENE, V12, P345; SAMBROOK J, 1994, MOL CLONING LAB MAN; SCHLESSINGER J, 1992, NEURON, V9, P389; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TOFTGARD R, 1985, CANCER RES, V45, P5845; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WOOD DP, 1991, J UROLOGY, V146, P1398, DOI 10.1016/S0022-5347(17)38123-5; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; YOKOTA J, 1986, LANCET, V1, P765; YUSPA S, 1994, J INVEST DERMATOL, V103, P908; YUSPA SH, 1994, CANCER RES, V54, P1178; [No title captured]	60	76	76	2	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4243	4254		10.1038/sj.onc.1203778	http://dx.doi.org/10.1038/sj.onc.1203778			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980598				2022-12-17	WOS:000089032900007
J	Reiss, K; Wang, JY; Romano, G; Furnari, FB; Cavenee, WK; Morrione, A; Tu, X; Baserga, R				Reiss, K; Wang, JY; Romano, G; Furnari, FB; Cavenee, WK; Morrione, A; Tu, X; Baserga, R			IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation	ONCOGENE			English	Article						insulin-like growth factor; IGF-I receptor; prostate cancer; PTEN; IRS-I	GROWTH-FACTOR-I; DOMINANT-NEGATIVE MUTANT; FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; INSULIN-RECEPTOR; TUMOR-GROWTH; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; TYROSINE PHOSPHORYLATION; ALPHA-V-BETA-3 INTEGRIN; BINDING-PROTEINS	LNCaP prostatic cancer cells are characterized by having a PTEN mutation, low levels of type 1 insulin-like growth factor receptor (IGF-IR) and no IRS-1, one of the major substrates of the IGF-IR, The absence of IRS-1, an activator of PI3-kinase, is compensated in these cells by the mutation in PTEN, an inhibitor of PI3-kinase, However, IGF-IR signaling in the absence of IRS-1 can cause cell differentiation and growth arrest. We hypothesized that these three characteristics may not be unrelated, specifically that, together, they may favor the metastatic spread of prostatic cancer cells without decreasing their growth potential. In support of this hypothesis, we report here that: (1) IRS-1 expression increases cell adhesion and decreases cell motility; (2) over-expression of the IGF-IR, in the absence of IRS-1, causes growth arrest and (3) a combination of TGF-IR and IRS-1 restores the transformed phenotype of LNCaP cells. These findings suggest a mechanism by which prostatic cancer cells can achieve metastatic potential without interfering with their growth potential.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Jefferson University; Ludwig Institute for Cancer Research	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.			Furnari, Frank/0000-0003-1909-4361	NCI NIH HHS [CA 78890, CA 53484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053484, P01CA078890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; Baserga Renato, 1999, V17, P329; Bright RK, 1997, CANCER RES, V57, P995; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CARSON JP, 1999, CANCER RES, V59, P49; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Davies MA, 1999, CANCER RES, V59, P2551; Dunn SE, 1998, CANCER RES, V58, P3353; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; GLEAVE ME, 1992, CANCER RES, V52, P1598; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Huynh H, 1998, CANCER RES, V58, P215; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Soos G, 1997, ANTICANCER RES, V17, P4253; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; THALMANN GN, 1994, CANCER RES, V54, P2577; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 1998, RECENT PROG HORM RES, V53, P119; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	48	76	76	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2687	2694		10.1038/sj.onc.1203587	http://dx.doi.org/10.1038/sj.onc.1203587			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851068				2022-12-17	WOS:000087193000004
J	Veal, E; Groisman, R; Eisenstein, M; Gill, G				Veal, E; Groisman, R; Eisenstein, M; Gill, G			The secreted glycoprotein CREG enhances differentiation of NTERA-2 human embryonal carcinoma cells	ONCOGENE			English	Article						differentiation; mouse embryonic stem cell; NTERA-2 embryonal carcinoma cells; secreted glycoprotein	HEXAMETHYLENE BISACETAMIDE HMBA; RETINOIC ACID; MONOCLONAL-ANTIBODY; TGF-ALPHA; LINE; EXPRESSION; GROWTH; TERATOCARCINOMAS; ACTIVATION; INDUCTION	Differentiation of the human embryonal carcinoma cell Line NTERA-2 is characterized by changes in morphology, altered patterns of gene expression, reduced proliferative potential, and a loss of tumorigenicity. The cellular repressor of E1A-stimulated genes, CREG, was previously shown to antagonize transcriptional activation and cellular transformation by the Adenovirus EIA oncoprotein. These properties suggested that CREG may function to inhibit cell growth and/or promote differentiation, Here we show that CREG is a secreted glycoprotein which enhances differentiation of NTERA-2 cells. Northern blot analysis reveals that, although CREG mRNA is widely expressed in adult tissues, CREG mRNA is not significantly expressed in pluripotent mouse embryonic stem cells or NTERA-2 embryonal carcinoma cells. CREG mRNA is rapidly induced upon in vitro differentiation of both mouse embryonic stem cells and human NTERA-2 cells, We show that constitutive expression of CREG in NTERA-2 cells enhances neuronal differentiation upon treatment with retinoic acid. Media enriched in CREG was also found to promote NTERA-2 differentiation in the absence of an inducer such as retinoic acid. These studies suggest that secreted CREG protein participates in a signaling cascade important for differentiation of pluripotent stem cells such as those found in teratocarcinomas.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Gill, G (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Veal, Elizabeth/0000-0002-1152-5473; Groisman, Sonia/0000-0003-1153-3841; Groisman, Regina/0000-0003-3990-7622				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 1998, APMIS, V106, P158, DOI 10.1111/j.1699-0463.1998.tb01331.x; ANDREWS PW, 1986, DIFFERENTIATION, V31, P119, DOI 10.1111/j.1432-0436.1986.tb00392.x; ANDREWS PW, 1994, LAB INVEST, V71, P243; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KURIE JM, 1993, DIFFERENTIATION, V54, P115; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942	25	76	96	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2120	2128		10.1038/sj.onc.1203529	http://dx.doi.org/10.1038/sj.onc.1203529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815803				2022-12-17	WOS:000086728000005
J	Gazit, A; Yaniv, A; Bafico, A; Pramila, T; Igarashi, M; Kitajewski, J; Aaronson, SA				Gazit, A; Yaniv, A; Bafico, A; Pramila, T; Igarashi, M; Kitajewski, J; Aaronson, SA			Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response	ONCOGENE			English	Article						frizzled; Hfz; Wnt; TCF	BETA-CATENIN; SIGNALING PATHWAY; NEGATIVE REGULATOR; XENOPUS EMBRYOS; FAMILY; PROTEIN; WINGLESS; AXIN; EXPRESSION; HOMOLOG	The human homologue of fz1 (Hfz1) was cloned from a cDNA library. Hfz1 was shown to couple to Wnt signal transduction pathways by its ability to enhance Wnt induced TCF dependent transcription in both autocrine and paracrine modes. Enhanced TCF dependent signaling was dose dependent with respect to both Wnt-3A and Hfz1. Moreover, Hfz1 deletion mutants with truncated carboxy termini showed markedly reduced capacity to enhance Wnt signal transduction. Specificity was demonstrated with respect to signal transduction by different Wnts. While Wnt-3a, -3, -1 and to a lesser extent Wnt-2 cooperated with Hfz1 in the paracrine assay for TCF dependent signaling, neither Wnt-4, -5a, -5b, -6, -7a nor -7b did so, despite similar levels of expression. However, coimmunoprecipitation of Hfz1 with both Wnt-3a and Wnt-5a indicated that TCF dependent signaling in response to Wnts is not determined solely by their ability to bind the receptor. All of these findings provide strong evidence that Hfz1 is a functional partner for certain Wnts in inducing TCF dependent transcription.	CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Reprod Sci, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tel Aviv University; Sackler Faculty of Medicine; Columbia University; Columbia University	Aaronson, SA (corresponding author), CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.				NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA71672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Barnes MR, 1998, TRENDS PHARMACOL SCI, V19, P399, DOI 10.1016/S0165-6147(98)01246-2; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRADBURY JM, 1994, ONCOGENE, V9, P2597; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DU SJ, 1995, MOL CELL BIOL, V15, P2625; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JI TH, 1998, SCIENCE, V280, P1274; KENGAKU M, 1998, J BIOL CHEM, V273, P17299; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MIKI T, 1995, METHOD ENZYMOL, V254, P196; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zhang J, 1998, DEVELOPMENT, V125, P3075	38	76	97	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5959	5966		10.1038/sj.onc.1202985	http://dx.doi.org/10.1038/sj.onc.1202985			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557084				2022-12-17	WOS:000083359100001
J	Ashcroft, M; Stephens, RM; Hallberg, B; Downward, J; Kaplan, DR				Ashcroft, M; Stephens, RM; Hallberg, B; Downward, J; Kaplan, DR			The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth	ONCOGENE			English	Article						Trk; PC12; NGF; phosphatidylinositol 3-kinase; differentiation; survival	NERVE-GROWTH-FACTOR; TRK TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; NEURONAL DIFFERENTIATION; PHOSPHOINOSITIDE 3-KINASE; AKT PROTOONCOGENE; FACTOR RECEPTORS	The Trk/Nerve Growth Factor receptor mediates the rapid activation of a number of intracellular signaling proteins, including phosphatidylinositol 3-kinase (PI 3-kinase). Here, we describe a novel, NGF-inducible system that we used to specifically address the signaling potential of endogenous PI 3-kinase in NGF-mediated neuronal survival and differentiation processes. This system utilizes a Trk receptor mutant (Trk(def)) lacking sequences Y490, Y785 and KFG important for the activation of the major Trk targets; SHC, PLC-gamma I, Ras, PI 3-kinase and SNT. TrKdef was kinase active but defective for NGF-induced responses when stably expressed in PC12nnr5 cells (which lack detectable levels of TrkA and are non-responsive to NGF). The PI 3-kinase consensus binding site, YxxM (YYPM), was introduced into the insert region within the kinase domain of Trk(def). NGF-stimulated tyrosine phosphorylation of the Trk(def)+PI 3-kinase addback receptor, resulted in the direct association and selective activation ;of PI 3-kinase in vitro and the production of PI(3,4)P-2 and PI(3,4,5)P-3 in rivo (comparable to wild-type). PC12nnr5 cells stably expressing Trk(def)+PI 3-kinase, initiated neurite outgrowth but failed to stably extend and maintain these neurites in response to NGF as compared to PC12 parental cells, or PC12nnr5 cells overexpressing wild-type Trk. However, Trk(def)+PI 3-kinase was fully competent in mediating NGF-induced survival processes. We propose that while endogenous PI 3-kinase can contribute in part to neurite initiation professes, its selective activation and subsequent signaling to downstream effecters such as Akt, functions mainly to promote cell survival in the PC12 system.	NCI, ABL Basic Res Program, FCRDC, Frederick, MD 21702 USA; Imperial Canc Res Fund, London WC2A 3PX, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK	Ashcroft, M (corresponding author), NCI, ABL Basic Res Program, FCRDC, W 7th St, Frederick, MD 21702 USA.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Fanger GR, 1997, MOL CELL BIOL, V17, P89, DOI 10.1128/MCB.17.1.89; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKUDA M, 1995, ONCOGENE, V11, P239; Greene L. A., 1991, METHODOLOGIES CULTUR; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; INAGAKI N, 1995, EUR J NEUROSCI, V7, P1125, DOI 10.1111/j.1460-9568.1995.tb01102.x; Jackson TR, 1996, J CELL SCI, V109, P289; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOEB DM, 1993, J NEUROSCI, V13, P2919; MEAKIN SO, 1999, IN PRESS J BIOL CHEM; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller TM, 1997, J BIOL CHEM, V272, P9847; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Park EK, 1996, MOL CELLS, V6, P494; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Summers MD, 1987, MANUAL METHODS BACUL; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Teng KK, 1996, MOL CELL NEUROSCI, V8, P157, DOI 10.1006/mcne.1996.0054; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	63	76	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4586	4597		10.1038/sj.onc.1202814	http://dx.doi.org/10.1038/sj.onc.1202814			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467403				2022-12-17	WOS:000082018600008
J	Day, RM; Cioce, V; Breckenridge, D; Castagnino, P; Bottaro, DP				Day, RM; Cioce, V; Breckenridge, D; Castagnino, P; Bottaro, DP			Differential signaling by alternative HGF isoforms through c-Met: activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis	ONCOGENE			English	Article						HGF; c-met; MAPK; PI 3-kinase; motogenesis; mitogenesis	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; KIDNEY-CELLS REQUIRES; GRB2 BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; TRANSFORMATION; TRANSDUCTION; MOTILITY	HGF/NK2, a naturally occurring truncated HGF isoform, antagonizes the mitogenic and morphogenic activities of full length HGF, but stimulates cell scatter, or the motogenic response to HGF. We studied postreceptor signaling by these HGF isoforms in the human breast epithelial cell line 184B5, and in murine myeloid progenitor 32D cells transfected with c-Met, the human HGF receptor (32D/c-Met). HGF stimulated DNA synthesis in 184B5 and 32D/c-Met cells, while HGF/NK2 was mitogenically inactive, despite the ability of HGF/NK2 to stimulate c-Met autophosphorylation, mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3-kinase (PI3K) in both cell systems. In 184B5 cells, HGF stimulated sustained MAPK activation, while activation by HGF/NK2 declined rapidly. In contrast, both isoforms activated MAPK with rapidly attenuated kinetics in 32D/c-Met cells. In both cell systems the increased motility observed in response to either HGF or HGF/NK2 treatment was more potently blocked by the PI3 kinase inhibitor wortmannin, than by PD98059, an inhibitor of MAPK kinase (MEK1). These data suggest that (1) alternative HGF isoforms signaling through c-Met generate both common and distinct biological responses, (2) the extent and duration of ligand-stimulated c-Met and MAPK activities are dependent on the cellular context and are not predictive of mitogenic signaling, and (3) in at least some HGF target cells, the activation of both MAPK and PI3K signaling pathways is insufficient for mitogenesis elicited through c-Met.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bottaro, DP (corresponding author), NCI, Cellular & Mol Biol Lab, Div Basic Sci, Bldg 37,Room 1E24,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	DIVISION OF BASIC SCIENCES - NCI [Z01BC005626] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1989, ANN NY ACAD SCI, V567, P122, DOI 10.1111/j.1749-6632.1989.tb16464.x; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; FALCO JP, 1988, ONCOGENE, V2, P573; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; HUWILER A, 1995, BIOCHEM J, V305, P777, DOI 10.1042/bj3050777; Ishihara H, 1997, J BIOL CHEM, V272, P9581; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKUDA K, 1992, BLOOD, V79, P2880; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1997, J BIOL CHEM, V272, P9457; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHU H, 1994, J BIOL CHEM, V269, P29943; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	45	76	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3399	3406		10.1038/sj.onc.1202683	http://dx.doi.org/10.1038/sj.onc.1202683			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362361				2022-12-17	WOS:000080589300011
J	Lorentz, O; Cadoret, A; Duluc, I; Capeau, J; Gespach, C; Cherqui, G; Freund, JN				Lorentz, O; Cadoret, A; Duluc, I; Capeau, J; Gespach, C; Cherqui, G; Freund, JN			Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras	ONCOGENE			English	Article						caco-2; HT-29 cells; protein kinase c; MEK1-MAP kinase; AP-1; Jun/Fos	MIDDLE-T-ONCOGENES; PASSAGE RODENT CELLS; KINASE-C-ALPHA; EPITHELIAL-CELLS; CACO-2 CELLS; COLORECTAL CARCINOGENESIS; MALIGNANT TRANSFORMATION; INTESTINAL EPITHELIUM; NEGATIVE REGULATION; PROTEIN EXPRESSION	Constitutive activation of the ras proto-oncogene is a frequent and early event in colon cancers, but the downstream nuclear targets are not fully understood. The Cdx-1 and Cdx-2 homeobox genes play crucial roles in intestinal cell proliferation and differentiation, In addition, Cdx-2 is a colonic tumour-suppressor gene, whereas Cdx-1 has oncogenic potential. Here, we show that constitutive activation of ras alters Cdx-1 and Cdx-2 expression in human colonic Caco-2 and HT-29 cells that harbour a normal ras proto-oncogene. Oncogenic ras downregulates Cdx-2 through activation of the PKC pathway and a decline in activity of the Cdx-2 promoter AP-1 site, This decline results from a PKC-dependent decrease in the relative expression of c-Jun, an activator of Cdx-2 transcription, compared to c-Fos, an inhibitor of Cdx-2. Unlike Cdx-2, Cdx-1 is upregulated by oncogenic ras and this effect is mediated by activation of the MEK1 pathway. These results indicate that oncogenic ras activation has opposite effects on Cdx-1 and Cdx-2 expression through distinct signalling pathways and they provide the first evidence for a functional link between ras activation and the downregulation of the Cdx-2 tumour-suppressor gene in colon cancer cells.	INSERM, U381, F-67200 Strasbourg, France; INSERM, U402, F-75571 Paris, France; INSERM, U482, F-75571 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Freund, JN (corresponding author), INSERM, U381, 3 Ave Moliere, F-67200 Strasbourg, France.		Duluc, Isabelle/O-1972-2017; Cadoret, Axelle/L-2529-2017; Freund, Jean-Noel/R-4383-2016; DULUC, Isabelle/AAA-7062-2022	Duluc, Isabelle/0000-0001-8396-6385; Cadoret, Axelle/0000-0002-4283-6864; Freund, Jean-Noel/0000-0002-0971-3774; DULUC, Isabelle/0000-0001-8396-6385				BaronDelage S, 1996, AM J PHYSIOL-GASTR L, V270, pG314, DOI 10.1152/ajpgi.1996.270.2.G314; BARONDELAGE S, 1994, J BIOL CHEM, V269, P18686; Cadoret A, 1997, ONCOGENE, V14, P1589, DOI 10.1038/sj.onc.1200992; CHANTRET I, 1994, J CELL SCI, V107, P213; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; DAVIDSON LA, 1995, J NUTR, V125, P49; DELAGE S, 1993, CANCER RES, V53, P2762; Duluc I, 1997, J CELL SCI, V110, P1317; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EE HC, 1995, AM J PATHOL, V147, P586; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; FOSTER E, 1994, BIOTECHNIQUES, V16, P18; FREUND JN, 1992, FEBS LETT, V314, P163, DOI 10.1016/0014-5793(92)80965-J; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; HU YL, 1993, J BIOL CHEM, V268, P27214; Ilyas M, 1996, HISTOPATHOLOGY, V28, P389, DOI 10.1046/j.1365-2559.1996.339381.x; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; Peddanna N, 1995, ANTICANCER RES, V15, P2055; PINTO M, 1983, BIOL CELL, V47, P323; PINTO M, 1982, BIOL CELL, V44, P193; ROUSSET M, 1980, JNCI-J NATL CANCER I, V65, P885; Sambrook J, 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SPANDIDOS DA, 1986, J GEN VIROL, V67, P793, DOI 10.1099/0022-1317-67-4-793; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STOPERA SA, 1992, CARCINOGENESIS, V13, P573, DOI 10.1093/carcin/13.4.573; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Velazquez OC, 1996, JPEN-PARENTER ENTER, V20, P243, DOI 10.1177/0148607196020004243; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364	39	76	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					87	92		10.1038/sj.onc.1202280	http://dx.doi.org/10.1038/sj.onc.1202280			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926923				2022-12-17	WOS:000078166000010
J	Fahraeus, R; Lain, S; Ball, KL; Lane, DP				Fahraeus, R; Lain, S; Ball, KL; Lane, DP			Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule	ONCOGENE			English	Article						p16(INK4a); cyclin dependent kinases 4 and 6; cell cycle; peptide delivery; tumour suppressor	PROVIRUS INSERTIONAL MUTAGENESIS; RETINOBLASTOMA GENE-PRODUCT; REPLICATIVE SENESCENCE; TRANSCRIPTION FACTOR; PRB PHOSPHORYLATION; CDK INHIBITORS; HUMAN HEAD; WILD-TYPE; CELL; PROTEIN	We have previously shown that a 20 amino acid peptide derived from the third ankyrin-like repeat of the p16(CDKN2/INK4a) (p16) tumour suppressor protein (residues 84-103 of the human p16 protein) can bind to cdk4 and cdk6 and inhibit cdk4-cyclin D1 kinase activity in vitro as well as block cell cycle progression through G1. Substitution of two valine residues corresponding to amino acids 95 and 96 (V95A and V96A) of the p16 peptide reduces the binding to cdk4 and cdk6 and increases its IC0.5 for kinase inhibition approximately threefold when linked to the Antennapedia homeodomain carrier sequence. The same mutations increase the IC0.5 approximately fivefold in the p16 protein. Substitution of aspartic acid 92 by alanine instead increases the binding of the peptide to cdk4 and cdk6 and the kinase inhibitory activity. The p16 peptide blocks S-phase entry in nonsynchronized human HaCaT cells by approximately 90% at a 24 mu M concentration. The V95A and V96A double substitution minimizes the cell cycle inhibitory capacity of the peptide whereas the D92A substitution increases its capacity to block cell cycle progression. A deletion series of the p16 derived peptide shows that a 10 residue peptide still retains cdk4-cyclin D1 kinase and cell cycle inhibitory activity. The p16 peptide inhibited S-phase entry in five cell lines tested, varying between 47-75%, but had only a limited (11%) inhibitory effect in the pRb negative Saos-2 cells at a concentration of 24 mu M. Like the full length p16 protein, the p16 peptide does not inhibit cyclin E dependent cdk2 kinase activity in vitro. These data suggest that acute inhibition of CDK-cyclin D activity by a peptide derived from the INK4 family mill stop cells in late G1 in a pRb dependent fashion.	Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 4HN, Scotland	University of Dundee	Fahraeus, R (corresponding author), Univ Dundee, Dept Biochem, CRC, Cell Transformat Grp, Dundee DD1 4HN, Scotland.		Lane, David P/C-4920-2008; fahraeus, robin/K-8726-2014; Lain, Sonia/B-6980-2014	Lain, Sonia/0000-0001-9693-5246; Lane, David/0000-0003-0551-3545; , robin/0000-0003-0402-8492				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BALL K, 1997, CURR BIOL, V7, P81; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN F, 1995, MOL CELL BIOL, V15, P2681; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; EINHORN S, 1994, BLOOD, V84, P297; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNA Z, 1993, ONCOGENE, V8, P1661; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HERBERT J, 1994, BLOOD, V84, P4038; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Ichimura K, 1996, ONCOGENE, V13, P1065; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KATHIB ZA, 1993, CANCER RES, V53, P5535; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Loughran O, 1996, ONCOGENE, V13, P561; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, ONCOGENE, V11, P635; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Reifenberger G, 1996, CANCER RES, V56, P5141; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1973, CELL, V73, P1056; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; TREMBLAY PJ, 1992, J VIROL, V66, P1344, DOI 10.1128/JVI.66.3.1344-1353.1992; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	61	76	79	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					587	596		10.1038/sj.onc.1201580	http://dx.doi.org/10.1038/sj.onc.1201580			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482104				2022-12-17	WOS:000071816600003
J	Matsumoto, K; Asano, T; Endo, T				Matsumoto, K; Asano, T; Endo, T			Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton	ONCOGENE			English	Article						small GTPase; Ras family; Rho family; actin cytoskeleton; microspikes; stress fibers	NUCLEOTIDE EXCHANGE FACTORS; BINDING PROTEIN; SMOOTH-MUSCLE; CDC42 GTPASES; STRESS FIBERS; GENE-PRODUCT; RHO-PROTEIN; CELL-CYCLE; C-MYC; GROWTH	During an attempt to elucidate regulatory mechanisms of skeletal muscle cell differentiation, we cloned cDNAs encoding a novel smalt GTPase from cDNA libraries of the mouse skeletal muscle cell Line C2 and rat brain. It was designated as M-Ras due to the structural similarity to Ras family proteins. M-Ras contained conserved motifs for GDP/GTP-binding and GTPase activities, whereas it varied from the other Ras family proteins at several amino acids within the extended effector domain. From the C-terminal sequence, M-Ras is presumed to be anchored to the cell membrane with a geranylgeranyl group in combination with a polybasic region. Bacterially expressed recombinant M-Ras exerted the GTP-binding and GTPase activities. A mutant M-Ras(G22V) was unable to hydrolyze bound GTP, indicating that it serves as a constitutively active form. Epitope-tagging experiments showed that M-Ras was concentrated on certain plasma membrane-associated structures. Transfection of M-Ras cDNA and microinjection of the M-Ras(G22V) protein into fibroblasts induced formation of the peripheral microspikes. In addition, the actin stress fibers disappeared and instead numerous actin foci were formed in the injected cells. The transfected cells eventually exhibited dendritic appearances,vith microspikes. Consequently, M-Ras is likely to participate in reorganization of the actin cytoskeleton.	CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU,CHIBA 263,JAPAN	Chiba University								BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Dutartre H, 1996, J CELL SCI, V109, P367; Endo T, 1996, J BIOL CHEM, V271, P27855, DOI 10.1074/jbc.271.44.27855; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; ENDO T, 1984, J CELL BIOL, V99, P2322, DOI 10.1083/jcb.99.6.2322; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARRELL F, 1992, J LAB CLIN MED, V120, P533; Foster R, 1996, MOL CELL BIOL, V16, P2689; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8988; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nei M., 1987, MOL EVOLUTIONARY GEN; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; REY I, 1994, ONCOGENE, V9, P685; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SELF AJ, 1993, ONCOGENE, V8, P655; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANKRANEN HJ, 1994, CARCINOGENESIS, V15, P307, DOI 10.1093/carcin/15.2.307; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yaffe D, 1969, Curr Top Dev Biol, V4, P37, DOI 10.1016/S0070-2153(08)60480-9; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	60	76	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2409	2417		10.1038/sj.onc.1201416	http://dx.doi.org/10.1038/sj.onc.1201416			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395237				2022-12-17	WOS:A1997YE96300003
J	Palecek, E; Vlk, D; Stankova, V; Brazda, V; Vojtesek, B; Hupp, TR; Schaper, A; Jovin, TM				Palecek, E; Vlk, D; Stankova, V; Brazda, V; Vojtesek, B; Hupp, TR; Schaper, A; Jovin, TM			Tumor suppressor protein p53 binds preferentially to supercoiled DNA	ONCOGENE			English	Article						DNA-protein interaction; scanning force microscopy; SFM; p53 protein-DNA complexes; supercoiled DNA; wild type human and rat p53 proteins	C-TERMINAL DOMAIN; WILD-TYPE; COMPLEXES; DAMAGE; SITE	Wild type human tumor suppressor protein p53 (expressed in insect cells) binds strongly to negatively supercoiled (sc) plasmid DNA at a native superhelix density, as evidenced by electrophoretic retardation of scDNA in agarose gels and imaging by scanning force microscopy (SFM), The binding occurs both in the presence and absence of the p53 consensus sequence, At relatively low p53/DNA ratios, binding of p53 to scDNA results in the appearance of several retarded DNA bands on the gels, similar to a conventional topoisomer ladder generated enzymatically, :However, after removal of p53 by deproteination, the original mobility of the scDNA is recovered, indicating that the reduction of torsional stress accompanying p53 binding does not reflect changes in linking number, In DNA samples partially relaxed by topoisomerase I p53 binds preferentially to the scDNA molecules with the largest negative superhelix density, SFM imaging of the p53/scDNA complex reveals a partial or total relaxation of the compact scDNA, the degree of which increases with the number of bound p53 molecules, Competition assays with linear DNA reveal a preference of p53 for scDNA, In addition, scDNA induces dissociation of p53 from a preformed complex with a DNA fragment (474 bp) containing the consensus sequence, We conclude that the affinity of p53 for negatively supercoiled DNA is greater than that for the consensus sequence in linear fragments, However, thermally denatured linearized plasmid DNA is efficient in competing for the binding of p53 to scDNA, although the first retarded band (presumed to contain one bound p53 molecule) is retained in the case of the plasmid containing the consensus sequence, Thus, it appears that interactions involving both the core domain and the C-terminal domain regulate the binding of p53 to scDNA, The above results are not restricted to human p53; the wild type rat p53 protein also results in the retardation of scDNA on agarose gels, The biological implications of the novel DNA binding activities of p53 are discussed.	MASARYK MEM CANC INST, CR-65653 BRNO, CZECH REPUBLIC; UNIV DUNDEE, DEPT PATHOL, DUNDEE DD1 4HN, SCOTLAND; MAX PLANCK INST BIOPHYS CHEM, DEPT MOL BIOL, D-37070 GOTTINGEN, GERMANY	Masaryk Memorial Cancer Institute; University of Dundee; Max Planck Society	Palecek, E (corresponding author), ACAD SCI CZECH REPUBL, INST BIOPHYS, KRALOVOPOLSKA 135, CR-61265 BRNO, CZECH REPUBLIC.		Vlk, Daniel/A-1413-2014; Václav, Brázda/F-9582-2011; Brazda, Vaclav/ABH-9460-2020; Palecek, Emil/C-1075-2013	Václav, Brázda/0000-0003-2837-4226; Brazda, Vaclav/0000-0003-2837-4226; Palecek, Emil/0000-0003-2561-8336				ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; CHEN D, 1994, NUCL ACIDS MOL BIOL, V8, P147; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK DN, 1994, NUCL ACIDS MOL BIOL, V8, P133; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; HALL AR, 1995, ONCOGENE, V10, P561; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Muller BF, 1996, ONCOGENE, V12, P1941; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Pfannschmidt C, 1996, NUCLEIC ACIDS RES, V24, P1702, DOI 10.1093/nar/24.9.1702; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHAPER A, 1994, FEBS LETT, V355, P91, DOI 10.1016/0014-5793(94)01166-4; SCHAPER A, 1996, PROCEDURES SCANNING; SCHAPER A, 1997, UNPUB; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	34	76	76	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2201	2209		10.1038/sj.onc.1201398	http://dx.doi.org/10.1038/sj.onc.1201398			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393978				2022-12-17	WOS:A1997YD01900008
J	Takada, S; Kaneniwa, N; Tsuchida, N; Koike, K				Takada, S; Kaneniwa, N; Tsuchida, N; Koike, K			Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells	ONCOGENE			English	Article						hepatitis B virus; X gene transfection; X protein; p53 tumor suppressor gene; p53 protein; nuclear localization	HUMAN HEPATOCELLULAR-CARCINOMA; LONG TERMINAL REPEAT; WILD-TYPE; DNA-BINDING; TRANSACTIVATION FUNCTION; TRANSCRIPTIONAL ACTIVITY; CELLULAR PROTEINS; EXPRESSION SYSTEM; TRANS-ACTIVATION; VIRAL ENHANCERS	It has been suggested that hepatitis B virus (HBV) X gene activates X gene expression by disrupting the function of p53 tumor suppressor gene (Takada et al., 1996). To find out their connection, effect of X protein expression on the nuclear localization of p53 protein in human hepatoma cells was examined by the immunofluorescent double-staining technique. The location of transiently-expressed p53 protein was examined in X gene-transfected cells, where X protein was detected in the cytoplasm. The nuclear location of transiently-expressed p53 protein was changed to the cytoplasm by X protein co-expression. Endogenous p53 protein was also observed in the cytoplasm by X protein expression. The transcriptional activation domain of X protein and the carboxy-terminal region of p53 protein were found mutually responsible for the cytoplasmic retention of p53 in X gene-transfected cells. Therefore, the cytoplasmic retention of p53 protein may be closely correlated to the function of X protein expressed in transfected cells.	JAPANESE FDN CANC RES,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO 170,JAPAN; TOKYO MED & DENT UNIV,DEPT MOL & CELLULAR ONCOL,BUNKYO KU,TOKYO 113,JAPAN	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU)								ARII M, 1992, ONCOGENE, V7, P397; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAKTOR O, 1990, ONCOGENE, V5, P867; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KOBAYASHI M, 1984, GENE, V30, P227; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NATOLI G, 1994, ONCOGENE, V9, P2837; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SAKAI E, 1992, ONCOGENE, V7, P927; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1994, VIROLOGY, V205, P503, DOI 10.1006/viro.1994.1671; TAKADA S, 1994, ONCOGENE, V9, P341; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; Takada S, 1996, VIROLOGY, V216, P80, DOI 10.1006/viro.1996.0036; TAKADA S, 1994, VIRAL HEPATITIS LIVE, P753; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	52	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1895	1901		10.1038/sj.onc.1201369	http://dx.doi.org/10.1038/sj.onc.1201369			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365235				2022-12-17	WOS:A1997YA87200003
J	deJong, R; tenHoeve, J; Heisterkamp, N; Groffen, J				deJong, R; tenHoeve, J; Heisterkamp, N; Groffen, J			Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site	ONCOGENE			English	Article						SH2-SH3 adaptor protein; tyrosine-phosphorylation; BCR/ABL; leukemia; mutagenesis	CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; SH3 DOMAIN; C-CRK; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; KINASE-ACTIVITY; RAS ACTIVATION; ABL PROTEIN; FACTOR C3G	BCR/ABL has a causal role in Philadelphia (Ph)-chromosome positive leukemia. The SH2/SH3 adapter protein CRKL is a major substrate of the deregulated BCR/ABL tyrosine kinase and is aberrantly tyrosine-phosphorylated in Ph-positive leukemia cells. In this study, experiments were pursued to identify and analyse the CRKL phosphorylation site(s). In an in vitro kinase assay, CRKL phosphorylation by the abl kinase was limited to a small region between the two CRKL SH3 domains. Within this region, mutation of tyrosine residue 207 yielded a mutant CRKL which could not be phosphorylated by BCR/ABL. Stable overexpression of CRKL or CRKL-Y207F did not transform NIH3T3 cells, while the Y207F mutation eliminated tyrosine-phosphorylation of CRKL. These studies indicate that Y207 in CRKL represents the major in vivo phosphorylation site. Phosphorylation of Y207 provides a binding site for the CRKL SH2 domain and potentially for other SH2-containing proteins. The Y207F mutation in CRKL did not enhance or decrease association with various target signalling proteins, including SOS or C3G, which interact specifically with the CRKL N-SH3 domain. These findings suggest that complex formation with cellular targets is not modulated by CRKL tyrosine-phosphorylation.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, SECT MOL CARCINOGENESIS, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles			Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NCI NIH HHS [CA 47456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEJONG R, 1995, ONCOGENE, V11, P1469; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LUGO TG, 1990, SCIENCE, V237, P532; MALY FE, 1994, J BIOL CHEM, V269, P18743; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sattler M, 1996, ONCOGENE, V12, P839; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1993, LEUKEMIA ADV RES TRE; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	76	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					507	513		10.1038/sj.onc.1200885	http://dx.doi.org/10.1038/sj.onc.1200885			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053848				2022-12-17	WOS:A1997WF52400001
J	Hobert, O; Schilling, JW; Beckerle, MC; Ullrich, A; Jallal, B				Hobert, O; Schilling, JW; Beckerle, MC; Ullrich, A; Jallal, B			SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin	ONCOGENE			English	Article						vav; SH3; zyxin; focal adhesions	C-SRC ACTIVITY; TYROSINE; BINDING; KINASE; RAS; GTPASE; CELLS	Scr homology 3 (SH3) domain-mediated protein-protein interactions have been implicated in the localization of proteins to specific sites within the cell. We present evidence that the product of the vav proto-oncogene, p95(vav), interacts specifically with the focal adhesion protein zyxin both in vitro and in yeast two hybrid system. Solution binding and two-hybrid system experiments demonstrate that association of Vav with the LIM domain protein zyxin is mediated by the C-terminal SH3 domain of Vav and involves the proline-rich N-terminus of zyxin. The interaction appears to be selective, since no binding of the proline-rich N-terminus of zyxin with other SH3 domain-containing proteins such as GRB-2, phospholipase C gamma, GTPase-activating protein, or p85 was detected.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOLEC,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063; UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	Max Planck Society; Utah System of Higher Education; University of Utah				Hobert, Oliver/0000-0002-7634-2854				ADAMS JM, 1992, ONCOGENE, V7, P611; BAGSAGI D, 1993, CELL, V79, P83; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; EVANS GA, 1993, BIOCHEM J, V294, P399; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HALL A, 1993, PHILOS T ROY SOC B, V340, P267, DOI 10.1098/rstb.1993.0067; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOFFMAN R, 1989, BLOOD, V74, P1196; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MERILAINEN J, 1993, J CELL SCI, V105, P647; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSSACCHIO A, 1992, FEBS LETT, V307, P55; OKADA M, 1993, J BIOL CHEM, V268, P18070; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; POO WJ, 1988, NATURE, V332, P378, DOI 10.1038/332378a0; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	50	76	76	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1577	1581						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622875				2022-12-17	WOS:A1996UF07600023
J	Chan, AML; Takai, S; Yamada, K; Miki, T				Chan, AML; Takai, S; Yamada, K; Miki, T			Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning	ONCOGENE			English	Article						oncogene; expression cloning; neuroepithelioma; GEF; RAS; RHO	INSITU HYBRIDIZATION; GENE-PRODUCT; CDC24; BCR; PROTEINS; SYSTEM; CYCLE; VAV; RAS; DNA	We generated a cDNA expression library from a human neuroepithelioma cell line for detection of novel oncogenes by focus formation assay in NIH3T3 cells. A morphologically unique focus was identified upon transfection and the transforming plasmid was isolated. The transforming gene, designated NET1, encoded a predicted protein species of 54 kDa containing the Dbl-Homology (DH) motif. This motif is also present in other growth regulatory molecules including Bcr, Cdc24, Vav, Ras-Grf, Ect2, Ost, Tim and Tiam1, which have been implicated as regulators of small GTP-binding proteins. NIH3T3 cells transfected with NET1 expression plasmid showed altered growth properties in vitro and were tumorigenic when injected into nude mice. In addition, a 2.5 kb cDNA was isolated from a normal human cDNA library which represented the NET1 proto-oncogene contained a 5' extended open reading frame. The fact that the proto-oncogene failed to induce transformation in NIH3T3 cells suggested that the original NET1 oncogene was activated by 5'-truncation. The 3.0 and 2.4 kilobasepair (kb) transcripts of the NET1 gene was ubiquitously expressed in all tissues examined. Using fluorescence in situ hybridization, we localized the NET1 gene to the short arm of human chromosome 10 at band p15.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; INT MED CTR JAPAN, RES INST, DEPT GENET, SHINJUKU KU, TOKYO 162, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Center for Global Health & Medicine - Japan			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				ADAMS JM, 1992, ONCOGENE, V7, P611; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHAN AML, 1994, ONCOGENE, V9, P1057; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIU RG, 1995, NATURE, V374, P457; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RON D, 1991, NEW BIOL, V3, P372; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAI S, 1993, CYTOGENET CELL GENET, V63, P59, DOI 10.1159/000133503; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	35	76	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1259	1266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649828				2022-12-17	WOS:A1996UC06700011
J	PENG, ZY; CARTWRIGHT, CA				PENG, ZY; CARTWRIGHT, CA			REGULATION OF THE SRC TYROSINE KINASE AND SYP TYROSINE PHOSPHATASE BY THEIR CELLULAR-ASSOCIATION	ONCOGENE			English	Article						SRC; SYP; TYROSINE KINASE; TYROSINE PHOSPHATASE	HUMAN-COLON-CARCINOMA; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PP60C-SRC PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ACTIVATION; PHOSPHORYLATION; RECEPTOR; TRANSFORMATION; P60C-SRC; MITOSIS	The specific activity of the Src tyrosine kinase is elevated in human colon carcinoma cells. To identify Src-binding proteins that might upregulate Src activity in these cells, a human colon carcinoma lambda gt11 expression library was screened with purified, P-32-labeled Src. The SH-PTP2 (Syp) tyrosine phosphatase was isolated and shown to associate with Src. In vitro studies demonstrated that: (1) transforming F527 Src phosphorylates Syp, and (2) Syp dephosphorylates Src at Tyr 527. Both events are known to upregulate enzyme activity. Others have shown that overexpression of the receptor tyrosine phosphatase alpha in rat embryo fibroblasts results in Src activation by dephosphorylation of Tyr 527, cell transformation and tumorigenesis. Thus, transmembrane tyrosine phosphatases may be involved in cell transformation exerting at least some of their effects through activation of Src. To the best of our knowledge, this is the first identification of an intracellular tyrosine phosphatase which may activate Src by a similar mechanism.	STANFORD UNIV, SCH MED, DEPT MED, MED SCH LAB, STANFORD, CA 94305 USA	Stanford University					NIDDK NIH HHS [P30-DK38707, R29 DK43743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R29DK043743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DEMILIA JC, 1991, ONCOGENE, V6, P303; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; PARK J, 1995, MOL CELL BIOL, V15, P2374; PARK JS, 1993, ONCOGENE, V8, P2627; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STONE RL, 1994, J BIOL CHEM, V269, P31323; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	57	76	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					1955	1962						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478513				2022-12-17	WOS:A1995TF29700004
J	GANDARILLAS, A; WATT, FM				GANDARILLAS, A; WATT, FM			CHANGES IN EXPRESSION OF MEMBERS OF THE FOS AND JUN FAMILIES AND MYC NETWORK DURING TERMINAL DIFFERENTIATION OF HUMAN KERATINOCYTES	ONCOGENE			English	Note						AP-1; NDK; SQUAMOUS CELL CARCINOMA; SUSPENSION CULTURE	HUMAN INVOLUCRIN GENE; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; PROTEIN; GROWTH; MAX; PROLIFERATION; PROMOTER; CELL; PROTOONCOGENE	Normal human epidermal keratinocytes are induced to undergo terminal differentiation when disaggregated and placed in suspension: commitment occurs at about 5 h and overt differentiation by 24 h. In contrast, the squamous cell carcinoma line SCC12B2 does not initiate terminal differentiation until 75 h in suspension and the ndk strain of keratinocytes undergoes growth arrest but does not differentiate at all. In order to identify genes that may regulate terminal differentiation we have examined mRNA levels of members of the fos and jun gene families and myc gene network in suspension cultures of normal keratinocytes, SCC12B2 and ndk. The major changes observed were an up-regulation of c-Fos and Fra-1 and a decrease in c-Myc at the time of commitment, followed by an increase in Mad, Mxi1, Fra-2 and JunB expression at the onset of differentiation. The sequence of events shows a striking similarity to that which occurs during myeloid differentiation and suggests a role for AP-1 complexes and Myc and Mad complexes in regulating keratinocyte differentiation.	IMPERIAL CANC RES FUND,KERATINOCYTE LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; ADAMS JC, 1991, J CELL BIOL, V115, P8829; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GANDARILLAS A, 1995, IN PRESS MAMMALIAN G; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; HASHIRO M, 1991, BIOCHEM BIOPH RES CO, V174, P287, DOI 10.1016/0006-291X(91)90518-C; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LARSSON LG, 1994, ONCOGENE, V9, P1247; MATSUI M, 1990, ONCOGENE, V5, P249; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; READ J, 1988, J INVEST DERMATOL, V90, P739, DOI 10.1111/1523-1747.ep12560940; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P85; Sambrook J., 1989, MOL CLONING LAB MANU; SONOBE MH, 1995, ONCOGENE, V10, P689; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	41	76	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1403	1407						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478564				2022-12-17	WOS:A1995RY96700024
J	ROZAKISADCOCK, M; VANDERGEER, P; MBAMALU, G; PAWSON, T				ROZAKISADCOCK, M; VANDERGEER, P; MBAMALU, G; PAWSON, T			MAP KINASE PHOSPHORYLATION OF MSOS1 PROMOTES DISSOCIATION OF MSOS1-SHC AND MSOS1-EGF RECEPTOR COMPLEXES	ONCOGENE			English	Article						MAP KINASE PHOSPHORYLATION; EXCHANGE FACTORS; MSOS1; SHC; EGF RECEPTOR	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; RAS ACTIVATOR; GUANINE-NUCLEOTIDES; TYROSINE KINASES; ADAPTER PROTEIN; C-JUN; GRB2	The mouse protein mSos1 has a central Ras guanine nucleotide exchange domain, and a long proline-rich C-terminal tail which contains several potential binding sites for the SH3 domains of the adaptor protein, Grb2. In fibroblasts, growth factor stimulation results in the recruitment of Grb2-mSos1 into complexes with activated receptors and cytoplasmic phosphoproteins such as Shc, which are apparently involved in Ras activation, and subsequently to an increase in mSos1 phosphorylation on serine and threonine, The catalytic and C-terminal domains of mSos1 contain several potential sites for phosphorylation by mitogen-activated protein kinases. In vitro, purified p42/p44 MAP-kinase selectively phosphorylated the C-terminal tail of mSos1. Comparative tryptic phosphopeptide mapping of mSos1 phosphorylated in vitro by MAP kinase and of mSos1 immunoprecipitated from EGF-stimulated cells, revealed several phosphopeptides in common. These common phosphorylation sites have been mapped to a region encompassing the first three proline (pro)-rich motifs in the tail of mSos1. Furthermore, a region of mSos1 containing the first two pro-rich motifs could associate with MBP kinase activity in vitro. Phosphorylation of mSos1 did not affect binding of Grb2 to mSos1, but appeared to decrease binding of the mSos1-Grb2 complex to She and the EGF-receptor. These findings suggest a potential inhibitory role for MAP-kinase in attenuating nucleotide exchange on Ras, by uncoupling mSos1 from membrane-bound receptor complexes that lead to Ras activation.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON, 1995, CELL; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WANG W, 1995, IN PRESS NATURE GENE; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	41	76	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1417	1426						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478566				2022-12-17	WOS:A1995RY96700026
J	ELSON, A; DENG, CX; CAMPOSTORRES, J; DONEHOWER, LA; LEDER, P				ELSON, A; DENG, CX; CAMPOSTORRES, J; DONEHOWER, LA; LEDER, P			THE MMTV/C-MYC TRANSGENE AND P53 NULL ALLELES COLLABORATE TO INDUCE T-CELL LYMPHOMAS, BUT NOT MAMMARY CARCINOMAS IN TRANSGENIC MICE	ONCOGENE			English	Article						C-MYC; P53; COLLABORATION; T-CELL LYMPHOMA; MAMMARY CARCINOMA	C-MYC; P53-DEFICIENT MICE; BREAST-CANCER; GROWTH-FACTOR; N-MYC; TUMORS; GENE; ONCOGENE; MUTATION; CARCINOGENESIS	A number of properties of the cancer-related genes c-myc and p53 suggest that they might collaborate to induce tumorigenesis, To test this notion, we produced doubly heterozygotic mice bearing disrupted p53 alleles and a fusion transgene consisting of the mouse mammary tumor virus (MMTV) I;TR and the oncogene c-myc. Mice bearing both the MMTV/c-myc transgene and a single p53(-) allele develop very aggressive pre-T- and T-cell lymphomas with a significantly shorter latency than mice carrying either the p53- allele or the c-myc transgene alone, Moreover, every lymphoma occurring in these animals has lost or suffers an inactivation of its wild type p53 allele indicating that loss of p53 activity is necessary for this c-myc-accelerated lymphomagenesis. Nonetheless, p53 inactivation and expression of the MMTV/c-myc transgene are not sufficient for lymphoid transformation, Tumors that arise in homozygous p53(-) mice carrying the c-myc transgene are monoclonal, suggesting that at least one additional event is necessary for their transformation, Moreover, since mice bearing only the MMTV/c-myc transgene predominantly develop mammary carcinomas, it was surprising that the p53(-) allele failed to accelerate the incidence of mammary carcinomas, Further, in contrast to the lymphomas, only one in four mammary tumors that arose in the double heterozygotic mice had lost its wild type p53 allele, Apparently cell context influences the ability of c-myc and p53(-) to cooperate in inducing oncogenesis.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Baylor College of Medicine				Elson, Ari/0000-0001-9808-9135				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; EELES RA, 1993, CANCER SURV, V18, P57; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HARPER JW, 1993, CELL, V75, P805; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU B, 1995, ONCOGENE, V11, P175; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMAMURA J, 1993, CANCER RES, V53, P4053; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KREIPE H, 1993, CANCER RES, V53, P1956; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, BRIT J CANCER, V69, P409; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MOROY T, 1991, ONCOGENE, V6, P1941; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PURDIE CA, 1994, ONCOGENE, V9, P603; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLZENBERG MC, 1994, ONCOGENE, V9, P2799; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUBURA A, 1988, CANCER RES, V48, P6555; VARLEY JM, 1991, ONCOGENE, V6, P413; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	48	76	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					181	190						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624126				2022-12-17	WOS:A1995RJ29500021
J	MUNN, KE; WALKER, RA; VARLEY, JM				MUNN, KE; WALKER, RA; VARLEY, JM			FREQUENT ALTERATIONS OF CHROMOSOME-1 IN DUCTAL CARCINOMA IN-SITU OF THE BREAST	ONCOGENE			English	Note						DCIA; BREAST; CHROMOSOME 1; MICRODISSECTION	INTRADUCTAL CARCINOMA; FOLLOW-UP; CANCER; GENE; HETEROZYGOSITY; DISTINCT; DELETION; REGIONS; BIOPSY; INSITU	Ductal carcinoma in situ (DCIS) of the breast is commonly described as a premalignant lesion, Using PCR to amplify DNA from areas of tumour cells which have been microdissected from fixed material, we have studied the involvement of chromosome 1 in 19 cases of DCIS, A series of microsatellite repeat polymorphisms has been used to define regions of allelic imbalance and this has confirmed the involvement in DCIS of six of the regions previously implicated in studies of invasive breast tumours. This suggests that these regions may harbour tumour suppressor genes, the inactivation of which is important for the early stages of breast tumour development. Analysis of separate ducts from within the same tumour has revealed-that the same genetic alterations are not necessarily present throughout the lesion. In addition we have found that in three cases where frank invasive carcinoma is also present, similar alterations can be detected in the in situ and invasive component.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT CANC GENET,CRC,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV LEICESTER,DEPT PATHOL,LEICESTER LE2 7LX,LEICS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Leicester								BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; BIECHE I, 1993, CANCER RES, V53, P1990; BIECHE I, 1990, HUM GENET, V85, P101; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COXMATISE T, 1994, NAT GENET, V6, P384; CROPP CS, 1993, CANCER RES, V53, P5617; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FRYKBERG ER, 1994, ADV SURG, V26, P29; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; KLEIN KG, 1994, CANCER GENET CYTOGEN, V73, P109, DOI 10.1016/0165-4608(94)90194-5; KUGOH HM, 1990, ONCOGENE, V5, P1637; MERLO GR, 1989, CANCER RES, V49, P6966; MITCHELL ELD, 1990, GENE CHROMOSOME CANC, V2, P278, DOI 10.1002/gcc.2870020405; NIELSEN KV, 1989, ACTA ONCOL, V28, P919, DOI 10.3109/02841868909092332; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; Sambrook J., 1989, MOL CLONING; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; VERBEEK AL, 1984, LANCET, P1222; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	26	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1653	1657						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731721				2022-12-17	WOS:A1995QU68100023
J	MARIKOVSKY, M; LAVI, S; PINKASKRAMARSKI, R; KARUNAGARAN, D; LIU, N; WEN, DZ; YARDEN, Y				MARIKOVSKY, M; LAVI, S; PINKASKRAMARSKI, R; KARUNAGARAN, D; LIU, N; WEN, DZ; YARDEN, Y			ERBB-3 MEDIATES DIFFERENTIAL MITOGENIC EFFECTS OF NDF HEREGULIN ISOFORMS ON MOUSE KERATINOCYTES	ONCOGENE			English	Article						EGF FAMILY; TYROSINE KINASE; GROWTH FACTOR; SIGNAL TRANSDUCTION; ONCOGENE	FACTOR RECEPTOR FAMILY; GROWTH-FACTOR; HUMAN-BREAST; SIGNAL TRANSDUCTION; TYROSINE KINASE; MAMMARY-TUMORS; NERVOUS-SYSTEM; LIGAND; CELLS; EXPRESSION	The family of Neu differentiation factors (NDFs, or heregulins) includes a dozen secreted glycoproteins, whose receptor binding domain displays two variants, alpha and beta, and they bind to two receptor tyrosine kinases, ErbB3 and ErbB-4. Certain isoforms were reported to induce growth-arrest and differentiation of mammary tumor cells, while other breast cancer cell lines responded mitogenically, The present study addressed the biologic effects of various NDF isoforms on normal EGF-dependent epithelial cells, Balb/MK keratinocytes, that can undergo either proliferation or differentiation, We found that beta isoforms of NDF induced a mitogenic effect, that was significantly smaller than the maximal response to EGF, By contrast with NDF-beta, NDF-alpha isoforms exerted almost no mitogenic effect, but they were sufficient to maintain keratinocytes in culture, Consistent with their higher mitogenic potency, NDF-beta isoforms bound to Balb/MK cells with higher affinity (K-d=2.2 nM) than alpha isoforms, however both groups shared their receptor, that we identified as ErbB-3. No transcript of ErbB-4 was detectable in the keratinocytes, but these cells express multiple NDF mRNAs and also ErbB-2, We conclude that different isoforms of NDF induce distinct growth regulatory effects on cultured keratinocytes, through direct interaction with ErbB-3.	AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA; WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Amgen; Weizmann Institute of Science; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACUS SS, 1993, CANCER RES, V53, P5251; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; FALCO JP, 1988, ONCOGENE, V2, P573; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORRURTREGER A, 1992, P NATL ACAD SCI USA, P1746; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAFRAN A, 1990, ONCOGENE, V5, P635; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLOWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STANCOVSKI I, 1993, REGULATORY MECHANISM, P161; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNDERWOOD LE, 1986, CLIN ENDOCRINOL META, V1, P59; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	49	76	77	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1403	1411						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731691				2022-12-17	WOS:A1995QR65100018
J	VASIOUKHIN, V; SERFAS, MS; SIYANOVA, EY; POLONSKAIA, M; COSTIGAN, VJ; LIU, B; THOMASON, A; TYNER, AL				VASIOUKHIN, V; SERFAS, MS; SIYANOVA, EY; POLONSKAIA, M; COSTIGAN, VJ; LIU, B; THOMASON, A; TYNER, AL			A NOVEL INTRACELLULAR EPITHELIAL-CELL TYROSINE KINASE IS EXPRESSED IN THE SKIN AND GASTROINTESTINAL-TRACT	ONCOGENE			English	Article						INTESTINE; SKIN; TYROSINE KINASE; EPITHELIA	SH3 DOMAINS; TERMINAL DIFFERENTIATION; SIGNAL TRANSDUCTION; GENE-EXPRESSION; PROTEIN-KINASE; STEM-CELLS; MOUSE; FAMILY; RAS; DROSOPHILA	A portion of the catalytic domain of a novel tyrosine kinase was cloned from mouse intestinal crypt cells, in a screen designed to identify kinases that may play a role in the regeneration of the intestinal epithelium (E Siyanova, MS Serfas, IA Mazo and AL Tyner, Oncogene 9, 2053-2057). We have cloned a cDNA encoding this kinase, termed sik for src-related intestinal kinase. The sik cDNA encodes a 451 amino acid protein that shares 80% identity with the recently cloned human tyrosine kinase, brk. Sequences found in src family kinases, such as SH2 and SH3 domains and a putative regulatory tyrosine at the carboxy terminus are found in the sik kinase. In contrast, sik lacks a myristylation site. The protein encoded by the sik cDNA has tyrosine kinase activity when expressed in E. coli, We have determined that sik is expressed only in epithelial tissues, including the skin and lining of the alimentary canal, and using in situ hybridization we show that expression of sik mRNA is restricted to the cell layers immediately above the proliferative cell zone in these epithelia, The sik mRNA is first detected at day 15.5 of gestation in the mouse embryo, where it is expressed in the newly forming granular layer of the skin. The restricted expression of sik to differentiating cells of rapidly renewing epithelia suggests that sik may play a specialized role in these tissues.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA; AMGEN INC, AMGEN CTR, DEPT MOLEC BIOL, THOUSAND OAKS, CA 91320 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Amgen				Tyner, Angela/0000-0001-7448-8625; Vasioukhin, Valeri/0000-0002-6730-0281	NIDDK NIH HHS [R01 DK044525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FISHER C, 1987, CURR TOP DEV BIOL, V22, P209; GORDON JI, 1992, FASEB J, V6, P3039, DOI 10.1096/fasebj.6.12.1521737; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERMOS JA, 1971, J CELL BIOL, V50, P255, DOI 10.1083/jcb.50.1.255; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEE ST, 1993, ONCOGENE, V8, P3403; LINDBERG RA, 1988, ONCOGENE, V3, P629; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MESSIER B, 1960, AM J ANAT, V106, P247, DOI 10.1002/aja.1001060305; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OTTILIE S, 1992, ONCOGENE, V7, P1625; PAWSON T, 1994, CURR OPIN GENET DEV, V4, P1, DOI 10.1016/0959-437X(94)90084-1; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RUGH R, 1991, MOUSE ITS REPRODUCTI; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TYNER AL, 1990, J CELL BIOL, V110, P915, DOI 10.1083/jcb.110.4.915; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	76	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					349	357						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838533				2022-12-17	WOS:A1995QC62400014
J	RAMOSMORALES, F; DRUKER, BJ; FISCHER, S				RAMOSMORALES, F; DRUKER, BJ; FISCHER, S			VAV BINDS TO SEVERAL SH2/SH3 CONTAINING PROTEINS IN ACTIVATED LYMPHOCYTES	ONCOGENE			English	Article							T-CELL ACTIVATION; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL-3 KINASE; HEMATOPOIETIC-CELLS; PDGF RECEPTOR; BETA-SUBUNIT; EGF RECEPTOR; SH2 DOMAINS; SITE	In T lymphocytes, several proteins are rapidly phosphorylated on tyrosine after stimulation. In this study we examine the ability of tyrosine phosphorylated proteins from Jurkat T cells stimulated by CD2 or T cell receptor-CD3 to interact with the src homology 2 or src homology 3 domains from eight different proteins involved in signal transduction in lymphocytes: Vav, Shc, Nck, phosphatidylinositol-3-kinase, phospholipase C-gamma 1, Ras-GTPase activating protein, c-Crk and Grb2. Our data show that different SH2 domains have distinct pattern of binding to phosphotyrosine containing proteins. We show that Vav, a protein expressed only in hematopoietic cells that may have guanine nucleotide releasing factor activity, is able to interact with certain SH2-containing proteins depending on its tyrosine phosphorylation and with Grb2 in a manner independent of phosphorylation on tyrosine. Coimmunoprecipitation experiments support the idea of a trimolecular complex Shc-Grb2-Vav in vivo. These data suggest a central role played by Vav and provide insight in the complexity and specificity of protein-protein interactions in the signaling events in lymphocytes.	OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA	Oregon Health & Science University	RAMOSMORALES, F (corresponding author), HOP COCHIN, INSERM, U363, INST COCHIN GENET MOLEC, 27 RUE FAUBOURG ST JACQUES, F-75014 PARIS, FRANCE.		Ramos-Morales, Francisco/C-5734-2008	Ramos-Morales, Francisco/0000-0002-1151-4547; Druker, Brian/0000-0001-8331-8206				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HSI ED, 1989, J BIOL CHEM, V264, P10836; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOCH CA, 1991, SCIENCE, V252, P688; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SONGYANG Z, 1993, CELL, V72, P1; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	38	76	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1917	1923						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208538				2022-12-17	WOS:A1994NR68500015
J	QIAN, XL; DOUGALL, WC; HELLMAN, ME; GREENE, MI				QIAN, XL; DOUGALL, WC; HELLMAN, ME; GREENE, MI			KINASE-DEFICIENT NEU PROTEINS SUPPRESS EPIDERMAL GROWTH-FACTOR RECEPTOR FUNCTION AND ABOLISH CELL-TRANSFORMATION	ONCOGENE			English	Article							ATP-BINDING-SITE; NIH 3T3 CELLS; INSULIN-RECEPTOR; POINT MUTATION; HUMAN-BREAST; INTERMOLECULAR AUTOPHOSPHORYLATION; ONCOGENE; HETERODIMERIZATION; PHOSPHORYLATION; EXPRESSION	p185(c-neu) and epidermal growth factor receptor (EGFR) associate into an active heterodimer, and overexpression of these two receptors leads to a transformed phenotype. However, the association of EGFR and kinase-deficient Neu proteins (point mutant N757 or cytoplasmic domain deletion mutant N691stop) results in a defective or inactive heterodimeric complex. In this report we explore the biological consequences of heterodimerization between EGFR and wild-type (WT) or kinase-deficient mutant Neu proteins in living cells. We show that co-expression of EGFR and kinase-deficient Neu proteins abolished the synergistic transformation and tumorigenicity. Moreover, the normal responses of EGFR to ligand were significantly suppressed, e.g., loss of EGF-dependent transformation, reduced rate of receptor endocytosis and turnover, diminished DNA synthesis, and decreased EGF binding affinity. These results provide the first evidence that kinase-deficient Neu proteins suppress normal EGFR function and display a dominant negative mutant phenotype. Together with the stimulatory effects observed in cells forming active heterodimers, these studies provide a role for heterodimerization of EGFR and Neu/c-erbB2 in interreceptor activation and synergistic signaling which may be responsible for the transition from normal receptor function into oncogenesis.			QIAN, XL (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.			Dougall, William/0000-0001-9487-251X				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; DECKER SJ, 1989, J BIOL CHEM, V264, P9204; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KERN JA, 1990, CANCER RES, V50, P5184; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KORNILOVA ES, 1992, ONCOGENE, V7, P511; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MOOLENAAR BF, 1990, J CELL BIOL, V110, P491; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN X, 1994, IN PRESS P NATL ACAD; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	41	76	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1507	1514						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	7908733				2022-12-17	WOS:A1994NH40100026
J	YEUNG, RS; BELL, DW; TESTA, JR; MAYOL, X; BALDI, A; GRANA, X; KLINGALEVAN, K; KNUDSON, AG; GIORDANO, A				YEUNG, RS; BELL, DW; TESTA, JR; MAYOL, X; BALDI, A; GRANA, X; KLINGALEVAN, K; KNUDSON, AG; GIORDANO, A			THE RETINOBLASTOMA-RELATED GENE, RB2, MAPS TO HUMAN-CHROMOSOME-16Q12 AND RAT CHROMOSOME-19	ONCOGENE			English	Article							BREAST-CANCER; ALLELOTYPE; PROTEIN; PRODUCT	A retinoblastoma-related human gene, referred to as R B 2, has been cloned based on sequence homology of the E1A-binding domain of the retinoblastoma gene. Structural homology with the retinoblastoma gene suggests a possible function of R B 2 as a tumor suppressor gene. In this study, we have mapped this gene to human chromosome 16q12.2 and rat chromosome 19, using fluorescence in situ hybridization and somatic hybrid cell analysis, respectively. Based on known syntenic relationships among human, rat and mouse, the data suggest that the mouse homolog resides on chromosome 8. Deletions of chromosome 16q have been found in several human neoplasias (including breast, ovarian, hepatic, and prostatic cancers) which is in support of an involvement of R B 2 in human cancer as a tumor suppressor gene.	FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; UNIV GOTHENBURG,DEPT GENET,S-41390 GOTHENBURG,SWEDEN	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Gothenburg	YEUNG, RS (corresponding author), FOX CHASE CANC CTR,DIV MED SCI,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.		Giordano, Antonio/F-1927-2010; Mayol, Xavier/C-1391-2012; Baldi, Alfonso/ABG-2397-2021	Giordano, Antonio/0000-0002-5959-016X; Grana, Xavier/0000-0001-7134-0473; Baldi, Alfonso/0000-0002-8693-3842; Mayol, Xavier/0000-0001-7288-195X	NCI NIH HHS [CA-06927, CA-45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045745, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FUJIMORI M, 1991, CANCER RES, V51, P89; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAYOL X, 1993, ONCOGENE, V8, P261; NEVINS JR, 1992, SCIENCE, V258, P424; REEDERS ST, 1991, CYTOGENET CELL GENET, V58, P643, DOI 10.1159/000133176; SATO T, 1991, CANCER RES, V51, P5118; SATO T, 1990, CANCER RES, V50, P7184; SERIKAWA T, 1992, GENETICS, V131, P701; TAGUCHI T, 1993, CANCER RES, V53, P4349; YEUNG RS, 1993, CYTOGENET CELL GENET, V62, P149, DOI 10.1159/000133459; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	18	76	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3465	3468						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247552				2022-12-17	WOS:A1993MG78200034
J	SHORE, SK; NABISSA, PM; REDDY, EP				SHORE, SK; NABISSA, PM; REDDY, EP			RIBOZYME-MEDIATED CLEAVAGE OF THE BCRABL ONCOGENE TRANSCRIPT - IN-VITRO CLEAVAGE OF RNA AND IN-VIVO LOSS OF P210 PROTEIN-KINASE ACTIVITY	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CELL-LINE; PHILADELPHIA-CHROMOSOME; ANTISENSE TRANSCRIPTS; EXPRESSION; POINT; GENE; K562	The t(9,22) chromosomal translocation generating the Philadelphia chromosome and the BCRABL oncogene has been shown both cytogenetically and molecularly to be the etiologic event in chronic myelogenous leukemia (CML). We have designed a ribozyme to cleave the BCRABL mRNA by targeting a GUU triplet adjacent to the junction of the c-BCR and c-ABL fused genes. This ribozyme efficiently cleaved BCRABL RNA transcripts as demonstrted by in vitro cleavage reactions. To determine the effect of constitutive expression of the ribozyme on the elimination of the BCRABL gene product, the ribozyme cDNA sequence was inserted into different retroviral expression vectors. Introduction of the recombinant retroviruses into the CML blast crisis cell-line K562, resulted in the elimination of the P210 protein-kinase activity in several single cell clones infected with the ribozyme expression cassette. Therefore BCR-ABL specific ribozymes may provide a potential genetic therapy for CML.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	SHORE, SK (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST MOLEC BIOL & CANC RES,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA 47937-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047937] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARACCIOLO D, 1989, SCIENCE, V245, P1107, DOI 10.1126/science.2672339; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Kuzrock R, 1988, NEW ENGL J MED, V319, P990; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NOWELL PC, 1960, SCIENCE, V132, P1497; PERRIMAN R, 1992, GENE, V113, P157, DOI 10.1016/0378-1119(92)90391-2; ROWERY JD, 1973, NATURE, V243, P290; SCHTIVELMAN E, 1985, NATURE, V315, P550; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHORE SK, 1990, US PATENT TRADEMARK; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	28	76	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3183	3188						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414522				2022-12-17	WOS:A1993MC09300037
J	YOUNG, J; LEGGETT, B; WARD, M; THOMAS, L; BUTTENSHAW, R; SEARLE, J; CHENEVIXTRENCH, G				YOUNG, J; LEGGETT, B; WARD, M; THOMAS, L; BUTTENSHAW, R; SEARLE, J; CHENEVIXTRENCH, G			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-14 OCCURS IN ADVANCED COLORECTAL CARCINOMAS	ONCOGENE			English	Article							NEURO-BLASTOMA; DNA; GENE; IDENTIFICATION; DEFICIENCY; PATHOLOGY; LOCATION; CLONING	The current model for colorectal tumorigenesis defines four specific mutations (activation of a ras proto-oncogene and inactivation of the APC, p53 and DCC tumor-suppressor genes) that accumulate in a colonic epithelial cell as it progresses towards a carcinoma. However, further mutations must be needed for progression to malignancy because advanced adenomas have been observed with all four of these mutations. Loss of heterozygosity (LOH) for 11 loci spanning the distal portion of the long arm of chromosome 14 was studied in 89 sporadic colorectal adenocarcinomas and 25 adenomas. The overall rate of LOH in carcinomas was 53% (46/86 informative carcinomas). The smatlest region of overlap (SRO) of deletions includes the markers D14SI9 to D14S20. No LOH was seen in the 18 informative adenomas examined. There was a significant trend towards higher levels of LOH within the SRO in advanced Dukes' stages (P = 0.016). Since frequent loss of heterozygosity in a specific region of a chromosome may reflect the inactivation of a tumor-suppressor gene located there, these data suggest that a gene involved in the progression of colonic neoplasia may reside on the distal portion of the long arm of chromosome 14, and that its inactivation may be a critical event in this process.	UNIV QUEENSLAND,QUEENSLAND INST MED RES,BRISBANE,QLD 4000,AUSTRALIA; ROYAL BRISBANE HOSP FDN,BANCROFT CTR,GLAXO GASTROENTEROL RES LAB,BRISBANE,QLD,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland	YOUNG, J (corresponding author), UNIV QUEENSLAND,SCH MED,DEPT PATHOL,JOINT ONCOL PROGRAM,QUEENSLAND CANC FUND RES UNIT,HERSTON RD,BRISBANE,QLD 4006,AUSTRALIA.		Young, Joanne P/H-7774-2014; Leggett, Barbara A/D-3579-2011	Chenevix-Trench, Georgia/0000-0002-1878-2587; Leggett, Barbara/0000-0003-2062-7380				BAIRD M, 1986, AM J HUM GENET, V39, P489; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKHSHI A, 1983, NEW ENGL J MED, V309, P826, DOI 10.1056/NEJM198310063091404; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; COX DW, 1985, NATURE, V316, P79, DOI 10.1038/316079a0; COX DW, 1989, HUMAN GENOME MAPPING, V10; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEDMAN EA, 1985, CANCER INVEST, V3, P453, DOI 10.3109/07357908509039806; FUJIMOTO E, 1988, NUCLEIC ACIDS RES, V16, P380, DOI 10.1093/nar/16.1.380; HOFF M, 1988, NUCLEIC ACIDS RES, V16, P10400, DOI 10.1093/nar/16.21.10400; HOFKER MH, 1990, GENOMICS, V6, P33, DOI 10.1016/0888-7543(90)90445-Z; KELSEY GD, 1988, J MED GENET, V25, P361, DOI 10.1136/jmg.25.6.361; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KONSTANTINOVA LN, 1991, HUM GENET, V86, P491; MARTIN C, 1988, NUCLEIC ACIDS RES, V16, P5220, DOI 10.1093/nar/16.11.5220; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITELMAN F, 1991, CATALOG CHROMOSOME A; NAKAMURA Y, 1988, AM J HUM GENET, V43, P854; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P6257, DOI 10.1093/nar/16.13.6257; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3593, DOI 10.1093/nar/16.8.3593; NEWLAND RC, 1987, CANCER, V60, P852, DOI 10.1002/1097-0142(19870815)60:4<852::AID-CNCR2820600422>3.0.CO;2-5; RABIN M, 1986, SOMAT CELL MOLEC GEN, V12, P209, DOI 10.1007/BF01560668; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SASAKI M, 1989, CANCER RES, V49, P4402; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; SUZUKI T, 1989, CANCER RES, V49, P1095; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YOUNG J, 1992, CANCER RES, V52, P285; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x	33	76	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					671	675						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437850				2022-12-17	WOS:A1993KN00800018
J	CHEN, YM; CHEN, PL; ARNAIZ, N; GOODRICH, D; LEE, WH				CHEN, YM; CHEN, PL; ARNAIZ, N; GOODRICH, D; LEE, WH			EXPRESSION OF WILD-TYPE P53 IN HUMAN A673 CELLS SUPPRESSES TUMORIGENICITY BUT NOT GROWTH-RATE	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; HUMAN PROSTATE CARCINOMA; TUMOR-ANTIGEN; RB GENE; TRANSFORMATION; ONCOGENE; SARCOMAS; CANCER; IMMORTALIZATION; MECHANISMS	The p53 gene has been found to be mutated in many different kinds of human cancers. In a previous study, expression of exogenous wild-type p53 in human osteosarcoma cells by retrovirus-mediated gene transfer resulted in marked enlargement of cell size, reduced growth rate in culture and loss of tumorigenicity in nude mice. Here we examine the effects of expression of wild-type or mutated p53 on human peripheral neuroepithelioma (PNET) A673 cells; these cells contained apparently normal alleles of the p53 gene but did not express a detectable quantity of p53 protein. Various characteristics of the p53-expressing cells were examined including morphology, growth rate, soft-agar colony formation, and tumorigenicity in nude mice. In contrast to osteosarcoma Saos-2 cells, expression of wild-type or mutant p53 protein in A673 cells had no effect on morphology or growth characteristics. However, clones expressing wild-type p53 protein had reduced ability to form colonies in soft agar and tumors in nude mice. To substantiate the genotype of wild-type p53-expressing cells, the proviral p53-encoding DNA of one cell clone was amplified by the polymerase chain reaction and sequenced. We concluded that expression of a single allele of the wild-type p53 gene was sufficient to suppress PNET A673 tumorigenicity but had no detectable effect on growth rate in culture.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio	LEE, WH (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.				NATIONAL CANCER INSTITUTE [P01CA051495] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA51495] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DREYFUS F, 1990, LEUKEMIA, V4, P590; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	33	76	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1799	1805						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923505				2022-12-17	WOS:A1991GX11800012
J	MORELLO, D; LAVENU, A; BABINET, C				MORELLO, D; LAVENU, A; BABINET, C			DIFFERENTIAL REGULATION AND EXPRESSION OF JUN, C-FOS AND C-MYC PROTOONCOGENES DURING MOUSE-LIVER REGENERATION AND AFTER INHIBITION OF PROTEIN-SYNTHESIS	ONCOGENE			English	Article											MORELLO, D (corresponding author), UNITE GENET MAMMIFERES,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							ASSELIN C, 1989, ONCOGENE, V4, P549; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAUER SR, 1989, ONCOGENE, V4, P615; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONNIEU A, 1989, ONCOGENE, V4, P881; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CORRAL M, 1988, EXP CELL RES, V174, P107, DOI 10.1016/0014-4827(88)90146-2; CORRAL M, 1985, EXP CELL RES, V160, P427, DOI 10.1016/0014-4827(85)90190-9; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAUSTO N, 1987, S FUNDAM CANCER RES, V39, P69; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HORIKAWA S, 1987, BIOCHEM BIOPH RES CO, V144, P1049, DOI 10.1016/S0006-291X(87)80070-0; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MECHTA F, 1989, New Biologist, V1, P297; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1985, IMMUNOGENETICS, V22, P441, DOI 10.1007/BF00418090; MORELLO D, 1990, IN PRESS MOL CELL BI; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON NL, 1986, CANCER RES, V46, P3111; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEISINGER G, 1988, ONCOGENE, V3, P635; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	90	76	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1511	1519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2123531				2022-12-17	WOS:A1990EK50200010
J	MUNROE, DG; ROVINSKI, B; BERNSTEIN, A; BENCHIMOL, S				MUNROE, DG; ROVINSKI, B; BERNSTEIN, A; BENCHIMOL, S			LOSS OF A HIGHLY CONSERVED DOMAIN ON P53 AS A RESULT OF GENE DELETION DURING FRIEND VIRUS-INDUCED ERYTHROLEUKEMIA	ONCOGENE			English	Article									UNIV TORONTO,ONTARIO CANC INST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; MT SINAI HOSP,RES INST,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute				Benchimol, Samuel/0000-0003-3433-890X				BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	20	76	78	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					621	624						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290808				2022-12-17	WOS:A1988N841500015
J	REDMOND, SMS; REICHMANN, E; MULLER, RG; FRIIS, RR; GRONER, B; HYNES, NE				REDMOND, SMS; REICHMANN, E; MULLER, RG; FRIIS, RR; GRONER, B; HYNES, NE			THE TRANSFORMATION OF PRIMARY AND ESTABLISHED MOUSE MAMMARY EPITHELIAL-CELLS BY P21-RAS IS CONCENTRATION DEPENDENT	ONCOGENE			English	Article											REDMOND, SMS (corresponding author), INSELSPITAL,LUDWIG INST CANC RES,CH-3010 BERN,SWITZERLAND.							ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1984, MED BIOL, V62, P304; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BRAWERMAN G, 1972, BIOCHEMISTRY-US, V11, P637, DOI 10.1021/bi00754a027; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FOULDS L, 1969, NEOPLASTIC DEV, V1; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARCIA I, 1986, MOL CELL BIOL, V6, P1974, DOI 10.1128/MCB.6.6.1974; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; Peto R, 1977, ORIGINS HUMAN CANC C, P1403; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SONNENBERG A, 1986, J IMMUNOL, V137, P1264; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SONNENBERG A, 1986, CANCER RES, V46, P5913; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; VANDERHOORN FA, 1985, MOL CELL BIOL, V5, P2204, DOI 10.1128/MCB.5.9.2204; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	45	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					259	265						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3127778				2022-12-17	WOS:A1988M593100008
J	Khan, S; He, YH; Zhang, X; Yuan, YX; Pu, SY; Kong, QP; Zheng, GR; Zhou, DH				Khan, Sajid; He, Yonghan; Zhang, Xuan; Yuan, Yaxia; Pu, Shaoyan; Kong, Qingpeng; Zheng, Guangrong; Zhou, Daohong			PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics	ONCOGENE			English	Review							RENAL-CELL CARCINOMA; PROTEIN-DEGRADATION; MEDIATED DEGRADATION; SMALL MOLECULES; RECEPTOR; UBIQUITINATION; KNOCKDOWN; GENE; IAP; VHL	Using PROteolysis TArgeting Chimeras (PROTACs) to degrade proteins that are important for tumorigenesis has emerged as a potential therapeutic strategy for cancer. PROTACs are heterobifunctional molecules consisting of one ligand for binding to a protein of interest (POI) and another to an E3 ubiquitin (E3) ligase, connected via a linker. PROTACs recruit the E3 ligase to the POI and cause proximity-induced ubiquitination and degradation of the POI by the ubiquitin-proteasome system (UPS). PROTACs have been developed to degrade a variety of cancer targets with unprecedented efficacy against a multitude of tumor types. To date, most of the PROTACs developed have utilized ligands to recruit E3 ligases that are ubiquitously expressed in both tumor and normal tissues. These PROTACs can cause on-target toxicities if the POIs are not tumor-specific. Therefore, identifying and recruiting the E3 ligases that are enriched in tumors with minimal expression in normal tissues holds the potential to develop tumor-specific/selective PROTACs. In this review, we will discuss the potential of PROTACs to become anticancer therapeutics, chemical and bioinformatics approaches for PROTAC design, and safety concerns with a special focus on the development of tumor-specific/selective PROTACs. In addition, the identification of tumor types in terms of solid versus hematological malignancies that can be best targeted with PROTAC approach will be briefly discussed.	[Khan, Sajid; He, Yonghan; Yuan, Yaxia; Zhou, Daohong] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA; [Zhang, Xuan; Zheng, Guangrong] Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL USA; [Pu, Shaoyan; Kong, Qingpeng] Chinese Acad Sci, Kunming Inst Zool, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Chinese Academy of Sciences; Kunming Institute of Zoology	Zhou, DH (corresponding author), Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA.	zhoudaohong@cop.ufl.edu	khan, sajid/HGE-2406-2022; He, Yonghan/P-7271-2014; Khan, Sajid/AAR-8954-2020; ZHANG, XUAN/L-4393-2017	He, Yonghan/0000-0003-4409-4590; Khan, Sajid/0000-0003-1331-8846; ZHANG, XUAN/0000-0001-6062-6708	US National Institutes of Health (NIH) [R01CA211963, R01CA219836, R01CA242003, R21CA223371]	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors would like to thank the members of the Zheng and Zhou laboratories for thoughtful discussion and assistance. We greatly acknowledge help from Ms. Janet S. Wiegand for grammatical corrections. This study was supported by US National Institutes of Health (NIH) grants R01CA211963 (DZ), R01CA219836 (DZ), R01CA242003 (DZ and GZ) and R21CA223371 (GZ).	Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Bai L., 2019, CANCER CELL, V36; Bassi ZI, 2018, ACS CHEM BIOL, V13, P2862, DOI 10.1021/acschembio.8b00705; Bondeson DP, 2018, CELL CHEM BIOL, V25, P78, DOI 10.1016/j.chembiol.2017.09.010; Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]; Brand M, 2019, CELL CHEM BIOL, V26, P300, DOI 10.1016/j.chembiol.2018.11.006; Buckley DL, 2012, ANGEW CHEM INT EDIT, V51, P11463, DOI 10.1002/anie.201206231; Buckley DL, 2012, J AM CHEM SOC, V134, P4465, DOI 10.1021/ja209924v; Buhimschi AD, 2018, BIOCHEMISTRY-US, V57, P3564, DOI 10.1021/acs.biochem.8b00391; Burslem G. M., 2018, CELL CHEM BIOL, V25, pe63; Burslem GM, 2019, CANCER RES, V79, P4744, DOI 10.1158/0008-5472.CAN-19-1236; Burslem GM, 2018, J AM CHEM SOC, V140, P16428, DOI 10.1021/jacs.8b10320; Clifford SC, 1999, GENE CHROMOSOME CANC, V26, P20, DOI 10.1002/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.3.CO;2-Y; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Costales MG, 2020, J MED CHEM, V63, P8880, DOI 10.1021/acs.jmedchem.9b01927; Costales MG, 2020, P NATL ACAD SCI USA, V117, P2406, DOI 10.1073/pnas.1914286117; Crew AP, 2018, J MED CHEM, V61, P583, DOI 10.1021/acs.jmedchem.7b00635; Cromm PM, 2018, J AM CHEM SOC, V140, P17019, DOI 10.1021/jacs.8b08008; Daniels Danette L, 2019, Drug Discov Today Technol, V31, P61, DOI 10.1016/j.ddtec.2018.12.001; Demizu Y, 2016, BIOORG MED CHEM LETT, V26, P4865, DOI 10.1016/j.bmcl.2016.09.041; Dobrovolsky D, 2019, BLOOD, V133, P952, DOI 10.1182/blood-2018-07-862953; Donovan KA, 2018, ELIFE, V7, DOI 10.7554/eLife.38430; Eichhorn JM, 2014, EXP CELL RES, V322, P415, DOI 10.1016/j.yexcr.2014.02.010; Farnaby W, 2019, NAT CHEM BIOL, V15, P672, DOI 10.1038/s41589-019-0294-6; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/NCHEMBIO.2329, 10.1038/nchembio.2329]; Gechijian LN, 2018, NAT CHEM BIOL, V14, P405, DOI 10.1038/s41589-018-0010-y; Girardini M, 2019, BIOORGAN MED CHEM, V27, P2466, DOI 10.1016/j.bmc.2019.02.048; Gonzalez TL, 2020, BREAST CANCER RES TR, V180, P611, DOI 10.1007/s10549-020-05564-y; Han T, 2017, SCIENCE, V356, DOI 10.1126/science.aal3755; Han X, 2019, J MED CHEM, V62, P11218, DOI 10.1021/acs.jmedchem.9b01393; Han X, 2019, J MED CHEM, V62, P941, DOI 10.1021/acs.jmedchem.8b01631; Hines J, 2019, CANCER RES, V79, P251, DOI 10.1158/0008-5472.CAN-18-2918; Hines J, 2013, P NATL ACAD SCI USA, V110, P8942, DOI 10.1073/pnas.1217206110; Hsu JHR, 2020, CELL CHEM BIOL, V27, P41, DOI 10.1016/j.chembiol.2019.11.004; Ishoey M, 2018, ACS CHEM BIOL, V13, P553, DOI 10.1021/acschembio.7b00969; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Itoh Y, 2011, BIOORGAN MED CHEM, V19, P3229, DOI 10.1016/j.bmc.2011.03.057; Itoh Y, 2010, J AM CHEM SOC, V132, P5820, DOI 10.1021/ja100691p; Jaime-Figueroa S, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2019.126877; Jensen SM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02697; Jiang BS, 2019, ANGEW CHEM INT EDIT, V58, P6321, DOI 10.1002/anie.201901336; Kang CH, 2018, BIOCHEM BIOPH RES CO, V505, P542, DOI 10.1016/j.bbrc.2018.09.169; Khan S, 2019, NAT MED, V25, P1938, DOI 10.1038/s41591-019-0668-z; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Lai AC, 2016, ANGEW CHEM INT EDIT, V55, P807, DOI 10.1002/anie.201507634; Lebraud H, 2016, ACS CENTRAL SCI, V2, P927, DOI 10.1021/acscentsci.6b00280; Li YB, 2019, J MED CHEM, V62, P448, DOI 10.1021/acs.jmedchem.8b00909; Lindner S., 2019, JOVE-J VIS EXP, V147; Liu B, 2007, CANCER LETT, V250, P168, DOI 10.1016/j.canlet.2006.09.024; Liu B, 2017, DIABETES, V66, P689, DOI 10.2337/db16-1104; Liu BY, 2017, NAT IMMUNOL, V18, P214, DOI 10.1038/ni.3641; Liu J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5154; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Lu MC, 2018, EUR J MED CHEM, V146, P251, DOI 10.1016/j.ejmech.2018.01.063; Ma L, 2006, CELL DEATH DIFFER, V13, P2079, DOI 10.1038/sj.cdd.4401959; Ma XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0644-4; Maniaci C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00954-1; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; McCoull W, 2018, ACS CHEM BIOL, V13, P3131, DOI 10.1021/acschembio.8b00698; Mele M, 2015, SCIENCE, V348, P660, DOI 10.1126/science.aaa0355; Moreau K, 2020, BRIT J PHARMACOL, V177, P1709, DOI 10.1111/bph.15014; Moser SC, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01920; Nunes J, 2019, ACS MED CHEM LETT, V10, P1081, DOI 10.1021/acsmedchemlett.9b00219; Ohoka N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.471; Ohoka N, 2019, CHEM PHARM BULL, V67, P203, DOI 10.1248/cpb.c18-00567; Ohoka N, 2018, J BIOL CHEM, V293, P6776, DOI 10.1074/jbc.RA117.001091; Okuhira K, 2013, CANCER SCI, V104, P1492, DOI 10.1111/cas.12272; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Pfaff P, 2019, ACS CENTRAL SCI, V5, P1682, DOI 10.1021/acscentsci.9b00713; Powell CE, 2018, J MED CHEM, V61, P4249, DOI 10.1021/acs.jmedchem.7b01655; Reynders M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5064; Riching KM, 2018, ACS CHEM BIOL, V13, P2758, DOI 10.1021/acschembio.8b00692; Robb CM, 2017, CHEM COMMUN, V53, P7577, DOI 10.1039/c7cc03879h; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Schapira M, 2019, NAT REV DRUG DISCOV, V18, P949, DOI 10.1038/s41573-019-0047-y; Schiedel M, 2018, J MED CHEM, V61, P482, DOI 10.1021/acs.jmedchem.6b01872; Schmitt C, 2002, APOPTOSIS, V7, P277, DOI 10.1023/A:1015372322419; Schneekloth AR, 2008, BIOORG MED CHEM LETT, V18, P5904, DOI 10.1016/j.bmcl.2008.07.114; Schneekloth JS, 2004, J AM CHEM SOC, V126, P3748, DOI 10.1021/ja039025z; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; Shibata N, 2018, J MED CHEM, V61, P543, DOI 10.1021/acs.jmedchem.7b00168; Shibata N, 2017, CANCER SCI, V108, P1657, DOI 10.1111/cas.13284; Smith BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08027-7; Song H, 2016, GENES-BASEL, V7, DOI 10.3390/genes7060025; Spradlin JN, 2019, NAT CHEM BIOL, V15, P747, DOI 10.1038/s41589-019-0304-8; Steinebach C, 2018, ACS CHEM BIOL, V13, P2771, DOI 10.1021/acschembio.8b00693; Su S, 2019, J MED CHEM, V62, P7575, DOI 10.1021/acs.jmedchem.9b00871; Sun YH, 2019, LEUKEMIA, V33, P2105, DOI 10.1038/s41375-019-0440-x; Testa A, 2020, ANGEW CHEM INT EDIT, V59, P1727, DOI 10.1002/anie.201914396; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wang Y, 2020, ACTA PHARMACOL SIN B, V10, P207, DOI 10.1016/j.apsb.2019.08.001; Ward CC, 2019, ACS CHEM BIOL, V14, P2430, DOI 10.1021/acschembio.8b01083; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Xue G, 2019, J AM CHEM SOC, V141, P18370, DOI 10.1021/jacs.9b06422; Yaguchi H, 2012, J BIOL CHEM, V287, P12050, DOI 10.1074/jbc.M111.307678; Yang HY, 2019, CHEM COMMUN, V55, P14848, DOI 10.1039/c9cc08509b; Yang K, 2018, BIOORG MED CHEM LETT, V28, P2493, DOI 10.1016/j.bmcl.2018.05.057; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhang XY, 2019, NAT CHEM BIOL, V15, P737, DOI 10.1038/s41589-019-0279-5; Zhang X, 2020, EUR J MED CHEM, V192, DOI 10.1016/j.ejmech.2020.112186; Zhang X, 2019, CHEM COMMUN, V55, P14765, DOI 10.1039/c9cc07217a; Zhao QY, 2019, CHEM COMMUN, V55, P369, DOI 10.1039/c8cc07813k; Zhao QJ, 2019, J MED CHEM, V62, P9281, DOI 10.1021/acs.jmedchem.9b01264; Zhou HB, 2019, J MED CHEM, V62, P11280, DOI 10.1021/acs.jmedchem.9b01530; Zoppi V, 2019, J MED CHEM, V62, P699, DOI 10.1021/acs.jmedchem.8b01413; Zorba A, 2018, P NATL ACAD SCI USA, V115, pE7285, DOI 10.1073/pnas.1803662115	109	75	77	11	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4909	4924		10.1038/s41388-020-1336-y	http://dx.doi.org/10.1038/s41388-020-1336-y		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32475992	Green Accepted			2022-12-17	WOS:000536741100001
J	Liu, MX; Jin, L; Sun, SJ; Liu, P; Feng, X; Cheng, ZL; Liu, WR; Guan, KL; Shi, YH; Yuan, HX; Xiong, Y				Liu, Meng-Xi; Jin, Lei; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Liu, Wei-Ren; Guan, Kun-Liang; Shi, Ying-Hong; Yuan, Hai-Xin; Xiong, Yue			Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma	ONCOGENE			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; TUMOR-GROWTH; FATTY LIVER; MOUSE-LIVER; MICROENVIRONMENT; GLUCONEOGENESIS; CYCLE; ACID; GLUTATHIONE; WARBURG	Phosphoenolpyruvate carboxykinase (PEPCK or PCK) catalyzes the first rate-limiting step in hepatic gluconeogenesis pathway to maintain blood glucose levels. Mammalian cells express two PCK genes, encoding for a cytoplasmic (PCPEK-C or PCK1) and a mitochondrial (PEPCK-M or PCK2) isoforms, respectively. Increased expressions of both PCK genes are found in cancer of several organs, including colon, lung, and skin, and linked to increased anabolic metabolism and cell proliferation. Here, we report that the expressions of both PCK1 and PCK2 genes are downregulated in primary hepatocellular carcinoma (HCC) and low PCK expression was associated with poor prognosis in patients with HCC. Forced expression of either PCK1 or PCK2 in liver cancer cell lines results in severe apoptosis under the condition of glucose deprivation and suppressed liver tumorigenesis in mice. Mechanistically, we show that the pro-apoptotic effect of PCK1 requires its catalytic activity. We demonstrate that forced PCK1 expression in glucose-starved liver cancer cells induced TCA cataplerosis, leading to energy crisis and oxidative stress. Replenishing TCA intermediate a-ketoglutarate or inhibition of reactive oxygen species production blocked the cell death caused by PCK expression. Taken together, our data reveal that PCK1 is detrimental to malignant hepatocytes and suggest activating PCK1 expression as a potential treatment strategy for patients with HCC.	[Liu, Meng-Xi; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Mol & Cell Biol Res Lab, Shanghai, Peoples R China; [Liu, Meng-Xi; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Sch Basic Med Sci, Minist Educ, Key Lab Metab & Mol Med, Shanghai, Peoples R China; [Liu, Meng-Xi; Sun, Si-Jia; Liu, Peng; Feng, Xu; Cheng, Zhou-Li; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai, Peoples R China; [Liu, Meng-Xi; Guan, Kun-Liang; Yuan, Hai-Xin; Xiong, Yue] Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, State Key Lab Genet Engn, Shanghai, Peoples R China; [Jin, Lei; Liu, Wei-Ren; Shi, Ying-Hong] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg, Shanghai, Peoples R China; [Jin, Lei; Liu, Wei-Ren; Shi, Ying-Hong] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China; [Guan, Kun-Liang] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, Kun-Liang] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Yue] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; University of North Carolina; University of North Carolina Chapel Hill	Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Shanghai Med Coll, Inst Biomed Sci, Mol & Cell Biol Res Lab, Shanghai, Peoples R China.; Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Sch Basic Med Sci, Minist Educ, Key Lab Metab & Mol Med, Shanghai, Peoples R China.; Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Shanghai, Peoples R China.; Yuan, HX; Xiong, Y (corresponding author), Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, State Key Lab Genet Engn, Shanghai, Peoples R China.; Shi, YH (corresponding author), Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Liver Surg, Shanghai, Peoples R China.; Shi, YH (corresponding author), Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China.; Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	shi.yinghong@zs-hospital.sh.cn; yuanhaixin@fudan.edu.cn; yxiong@email.unc.edu	Liu, Mengxi/N-7308-2019; Guan, Kun-Liang/ADK-7088-2022		National Science and Technology Major Project of China [2017ZX10203207-002-004]; 973 Program [2015CB910401]; NSFC [31570784, 81773190]; NIH [CA163834, CA196878, GM51586]; NATIONAL CANCER INSTITUTE [P30CA016086, R01CA163834, R35CA196878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051586] Funding Source: NIH RePORTER	National Science and Technology Major Project of China; 973 Program(National Basic Research Program of China); NSFC(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Bin Zhao (Zhejiang University, Hangzhou, China) for providing plasmids used for inducing liver tumor in mice, including PB[CMV-myc-YAP-5SA] DS, PB[Act-RFP] DS, and Act-PB Transposase. We thank Xiaocan Guo for technical help on hydrodynamic injection. We also thank Dr Jiahuai Han (Xiamen University, Xiamen, China) for generously offering cDNAs for human PCK1 and PCK2 genes. This work was supported by the National Science and Technology Major Project of China (No. 2017ZX10203207-002-004 to HXY), the 973 Program (No. 2015CB910401 to YX), the NSFC grants (No. 31570784 and 81773190 to HXY), and NIH grants (CA163834 to YX; CA196878 and GM51586 to K-LG).	Balan MD, 2015, BIOCHEMISTRY-US, V54, P5878, DOI 10.1021/acs.biochem.5b00822; Beale EG, 2007, CELL BIOCHEM BIOPHYS, V48, P89, DOI 10.1007/s12013-007-0025-6; Burgess SC, 2004, J BIOL CHEM, V279, P48941, DOI 10.1074/jbc.M407120200; Burgess SC, 2007, CELL METAB, V5, P313, DOI 10.1016/j.cmet.2007.03.004; Dunten P, 2002, J MOL BIOL, V316, P257, DOI 10.1006/jmbi.2001.5364; Hakimi Parvin, 2005, Nutr Metab (Lond), V2, P33, DOI 10.1186/1743-7075-2-33; Haslene-Hox H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019217; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Leithner K, 2015, ONCOGENE, V34, P1044, DOI 10.1038/onc.2014.47; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Ma SH, 2015, ONCOTARGET, V6, P8606, DOI 10.18632/oncotarget.3330; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Mendez-Lucas A, 2013, J HEPATOL, V59, P105, DOI 10.1016/j.jhep.2013.02.020; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Satapati S, 2015, J CLIN INVEST, V125, P4447, DOI 10.1172/JCI82204; Shen SY, 2015, CELL RES, V25, P997, DOI 10.1038/cr.2015.98; Sullivan LB, 2013, MOL CELL, V51, P236, DOI 10.1016/j.molcel.2013.05.003; Sunny NE, 2011, CELL METAB, V14, P804, DOI 10.1016/j.cmet.2011.11.004; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Vincent EE, 2015, MOL CELL, V60, P195, DOI 10.1016/j.molcel.2015.08.013; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yang H, 2015, EMBO J, V34, P1110, DOI 10.15252/embj.201591041; Yang JQ, 2009, J BIOL CHEM, V284, P27025, DOI 10.1074/jbc.R109.040543; Zheng L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7001	32	75	81	9	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1637	1653		10.1038/s41388-017-0070-6	http://dx.doi.org/10.1038/s41388-017-0070-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29335519	Green Submitted, Green Accepted			2022-12-17	WOS:000428626700007
J	Gan, L; Meng, J; Xu, M; Liu, M; Qi, Y; Tan, C; Wang, Y; Zhang, P; Weng, W; Sheng, W; Huang, M; Wang, Z				Gan, L.; Meng, J.; Xu, M.; Liu, M.; Qi, Y.; Tan, C.; Wang, Y.; Zhang, P.; Weng, W.; Sheng, W.; Huang, M.; Wang, Z.			Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin beta 4/FAK/SOX2/HIF-1 alpha signaling pathway in gastric cancer	ONCOGENE			English	Article							STEM-CELLS; ECM1; OVEREXPRESSION; ACTIVATION; PHENOTYPE; MECHANISM; MIGRATION	Extracellular matrix protein 1 (ECM1) is related to strong invasiveness and poor prognosis in major malignancies, but the underlying mechanism remains unknown. Here we aimed to elucidate the function of ECM1 on cell metastasis and glucose metabolism in gastric cancer (GC). The level of ECM1 in sera and tissues of patient with GC were positively correlated with tumor invasion and recurrence. Genetic manipulation of ECM1 expression affected cell metastasis and glucose metabolism in GC cell lines. Enhanced ECM1 expression facilitated gene expression levels associated with epithelial-mesenchymal transition (EMT) and glucose metabolism. Interestingly, our results indicated that ECM1 directly interacted with integrin beta 4 (ITGB4) and activated ITGB4/focal adhesion kinase (FAK)/glycogen synthase kinase 3 beta signaling pathway, which further induced the expression of transcription factor SOX2. Aberrant expression of SOX2 altered gene expression of EMT factors and glucose metabolism enzymes. Furthermore, SOX2 enhanced hypoxia-inducible factor alpha (HIF-1 alpha) promoter activity to regulate glucose metabolism. The micro-positron emission tomography/computed tomography imaging of xenograft model showed that ECM1 substantially increased F-18-fluorodeoxyglucose uptake in xenograft tumors. Using in vivo mouse tail vein injection experiments, ECM1 was also found to increase in lung surface metastasis. These findings provide evidence that ECM1 regulates GC cell metastasis and glucose metabolism by inducing ITGB4/FAK/SOX2/HIF-1 alpha signal pathway and have important implications for the development of therapeutic target to prevent tumor metastasis and recurrence.	[Gan, L.; Meng, J.; Liu, M.; Zhang, P.; Wang, Z.] Fudan Univ, Canc Inst, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Gan, L.; Meng, J.; Qi, Y.; Huang, M.] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Gan, L.; Xu, M.; Qi, Y.; Tan, C.; Weng, W.; Sheng, W.; Huang, M.; Wang, Z.] Fudan Univ, Dept Oncol, Shanghai Med Coll, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Gan, L.] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China; [Xu, M.; Tan, C.; Weng, W.; Sheng, W.] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Wang, Y.] Nanchang Univ, Nanchang Med Coll, Nanchang, Jiangxi, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; Nanchang University	Wang, Z (corresponding author), Fudan Univ, Canc Inst, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China.; Huang, M; Wang, Z (corresponding author), Fudan Univ, Dept Oncol, Shanghai Med Coll, 270 Dongan Rd, Shanghai 200032, Peoples R China.	mingzhuhuang0718@163.com; huf_zlwang@126.com	xu, midie/AFS-3427-2022; Sheng, Weiqi/GXF-1216-2022	xu, midie/0000-0003-1775-6608; Sheng, Weiqi/0000-0002-8726-277X	National Nature Science Young Foundation of China [81502235, 81302096, 81602078]; Shanghai Natural Science Foundation [17ZR1406500]; Hospital Foundation of Fudan University Shanghai Cancer Center [YJ201504]; project of Shanghai Municipal Health Bureau [20114009]	National Nature Science Young Foundation of China; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); Hospital Foundation of Fudan University Shanghai Cancer Center; project of Shanghai Municipal Health Bureau	This work was supported by the National Nature Science Young Foundation of China (81502235, 81302096 and 81602078), Shanghai Natural Science Foundation (17ZR1406500), Hospital Foundation of Fudan University Shanghai Cancer Center (YJ201504) and by the project of Shanghai Municipal Health Bureau (20114009).	Basan M, 2015, NATURE, V528, P99, DOI 10.1038/nature15765; Beger RD, 2013, METABOLITES, V3, P552, DOI 10.3390/metabo3030552; Bergamaschi A, 2008, J PATHOL, V214, P357, DOI 10.1002/path.2278; Bianchini G, 2010, J CLIN ONCOL, V28, P4316, DOI 10.1200/JCO.2009.27.2419; Bugaj LJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7898; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Chamoto K, 2013, STEM CELL RES, V10, P267, DOI 10.1016/j.scr.2012.12.006; Chen H, 2011, MED ONCOL, V28, pS318, DOI 10.1007/s12032-010-9763-1; Chen HW, 2016, BOUND VALUE PROBL, DOI 10.1186/s13661-016-0524-8; Ci YQ, 2016, MOLECULES, V21, DOI 10.3390/molecules21121634; Desrochers LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11958; Duan J, 2011, INT J BIOCHEM CELL B, V43, P1218, DOI 10.1016/j.biocel.2011.04.015; Fujimoto N, 2006, EXP DERMATOL, V15, P300, DOI 10.1111/j.0906-6705.2006.00409.x; Gao F, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0533-9; Gomez-Contreras P, 2016, CLIN EXP METASTASIS; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Huang PH, 2017, ONCOGENE, V36, P2202, DOI 10.1038/onc.2016.378; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Khurana S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13500; Lal G, 2009, ANN SURG ONCOL, V16, P2280, DOI 10.1245/s10434-009-0533-2; Lauwers G, 2010, WHO CLASSIFICATION T, P48; Leask A, 2013, ADV WOUND CARE, V2, P160, DOI 10.1089/wound.2012.0365; Lee KM, 2015, ONCOGENE, V34, P6055, DOI 10.1038/onc.2015.54; Lee K, 2014, IEEE T MULTIMEDIA, V16, P1201, DOI 10.1109/TMM.2014.2311012; Lee KM, 2015, CELL SIGNAL, V27, P228, DOI 10.1016/j.cellsig.2014.11.004; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Massari F, 2016, CANCER TREAT REV, V45, P46, DOI 10.1016/j.ctrv.2016.03.005; MATHIEU E, 1994, J BONE MINER RES, V9, P903; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Nie W, 2015, LAB INVEST, V95, P56, DOI 10.1038/labinvest.2014.124; Qi P, 2015, INT J CANCER, V137, P1269, DOI 10.1002/ijc.29516; ROSZKOWSKI M, 1981, APPL RES MENT RETARD, V2, P359, DOI 10.1016/0270-3092(81)90030-8; Semenza G L, 2001, Novartis Found Symp, V240, P251; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Wang LP, 2003, CANCER LETT, V200, P57, DOI 10.1016/S0304-3835(03)00350-1; Wang ZL, 2015, ONCOTARGET, V6, P6670, DOI 10.18632/oncotarget.3118; Wang ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079117; Xiong GP, 2012, NEOPLASMA, V59, P409, DOI 10.4149/neo_2012_053; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Ye HQ, 2016, BIOMED PHARMACOTHER, V80, P109, DOI 10.1016/j.biopha.2016.02.019; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang W, 2016, ONCOTARGET, V7, P5800, DOI 10.18632/oncotarget.6807; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	47	75	77	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					744	755		10.1038/onc.2017.363	http://dx.doi.org/10.1038/onc.2017.363			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059156				2022-12-17	WOS:000424628100006
J	Ju, HQ; Lu, YX; Wu, QN; Liu, J; Zeng, ZL; Mo, HY; Chen, Y; Tian, T; Wang, Y; Kang, TB; Xie, D; Zeng, MS; Huang, P; Xu, RH				Ju, H-Q; Lu, Y-X; Wu, Q-N; Liu, J.; Zeng, Z-L; Mo, H-Y; Chen, Y.; Tian, T.; Wang, Y.; Kang, T-B; Xie, D.; Zeng, M-S; Huang, P.; Xu, R-H			Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer	ONCOGENE			English	Article							INHIBITS GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; CELLS; MECHANISMS; EXPRESSION; ACETYLATION; OXALIPLATIN; STATISTICS; RESISTANCE; APOPTOSIS; STRESS	Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme that generates NADPH to maintain reduced glutathione (GSH), which scavenges reactive oxygen species (ROS) to protect cancer cell from oxidative damage. In this study, we mainly investigate the potential roles of G6PD in colorectal cancer (CRC) development and chemoresistance. We discover that G6PD is overexpressed in CRC cells and patient specimens. High expression of G6PD predicts poor prognosis and correlated with poor outcome of oxaliplatin-based first-line chemotherapy in patients with CRC. Suppressing G6PD decreases NADPH production, lowers GSH levels, impairs the ability to scavenge ROS levels, and enhances oxaliplatin-induced apoptosis in CRC via ROS-mediated damage in vitro. In vivo experiments further shows that silencing G6PD with lentivirus or non-viral gene delivery vector enhances oxaliplatin anti-tumor effects in cell based xenografts and PDX models. In summary, our finding indicated that disrupting G6PD-mediated NADPH homeostasis enhances oxaliplatin-induced apoptosis in CRC through redox modulation. Thus, this study indicates that G6PD is a potential prognostic biomarker and a promising target for CRC therapy.	[Ju, H-Q; Lu, Y-X; Wu, Q-N; Zeng, Z-L; Mo, H-Y; Chen, Y.; Tian, T.; Wang, Y.; Kang, T-B; Xie, D.; Zeng, M-S; Huang, P.; Xu, R-H] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China; [Liu, J.; Chen, Y.] Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Huang, P; Xu, RH (corresponding author), Sun Yat Sen Univ, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	huangpeng@sysucc.org.cn; xurh@sysucc.org.cn	Xu, Rui-Hua/AAW-4766-2021; xu, rui/GRX-5734-2022	Xu, Rui-Hua/0000-0001-9771-8534; 	National Natural Science Foundation of China [81602137, 81372570, 81572392]; National High Technology Research and the Development Program of China [2015AA020103]; Science and the Technology Program of Guangdong [2015B020232008]; Science and Technology Program of Guangzhou [158100066, 15570006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and the Development Program of China(National High Technology Research and Development Program of China); Science and the Technology Program of Guangdong; Science and Technology Program of Guangzhou	This work was supported by grants from the National Natural Science Foundation of China (81602137, 81372570, 81572392); the National High Technology Research and the Development Program of China (2015AA020103); Science and the Technology Program of Guangdong (2015B020232008); the Science and Technology Program of Guangzhou (158100066, 15570006).	Ai GQ, 2016, MOL MED REP, V14, P1726, DOI 10.3892/mmr.2016.5449; Becouarn Y, 1998, J CLIN ONCOL, V16, P2739, DOI 10.1200/JCO.1998.16.8.2739; Biagiotti S, 2016, FEBS J, V283, P3962, DOI 10.1111/febs.13901; Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8; Choi YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22172; Fichtner I, 2004, EUR J CANCER, V40, P298, DOI 10.1016/j.ejca.2003.10.011; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graham J, 2004, NAT REV DRUG DISCOV, V3, P11, DOI 10.1038/nrd1287; Hu YM, 2010, BLOOD, V116, P2732, DOI 10.1182/blood-2009-11-256354; Ju HQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14437; Ju HQ, 2016, THERANOSTICS, V6, P1160, DOI 10.7150/thno.14848; Ju HQ, 2016, J PINEAL RES, V60, P27, DOI 10.1111/jpi.12285; Ju HQ, 2015, MOL CANCER THER, V14, P788, DOI 10.1158/1535-7163.MCT-14-0420; Kim SY, 2007, MOL CELL BIOCHEM, V302, P27, DOI 10.1007/s11010-007-9421-x; Li SD, 2006, GENE THER, V13, P1313, DOI 10.1038/sj.gt.3302838; Liu B, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.322; Margis R, 2008, FEBS J, V275, P3959, DOI 10.1111/j.1742-4658.2008.06542.x; Oronsky B, 2016, DISCOV MED, V21, P251; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Picco G, 2016, JNCI-J NATL CANCER I, V109, P1; Pilch DR, 2003, BIOCHEM CELL BIOL, V81, P123, DOI 10.1139/o03-042; Santoro V, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv394; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017; Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Wang JX, 2012, TUMOR BIOL, V33, P95, DOI 10.1007/s13277-011-0251-9; Wang X, 2015, EJSO-EUR J SURG ONC, V41, P1293, DOI 10.1016/j.ejso.2015.08.155; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Yang Z, 2014, NANOSCALE, V6, P10193, DOI 10.1039/c4nr02395a; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Zeng ZL, 2014, CLIN CANCER RES, V20, P1042, DOI 10.1158/1078-0432.CCR-13-0171; Zhang CH, 2014, ANTI-CANCER AGENT ME, V14, P280, DOI 10.2174/18715206113136660337; Zhou JB, 2012, NAT MATER, V11, P82, DOI [10.1038/nmat3187, 10.1038/NMAT3187]; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643; Zhou Q, 2015, CHIN J CANCER, V34, P1, DOI 10.1186/s40880-015-0026-6	38	75	80	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6282	6292		10.1038/onc.2017.227	http://dx.doi.org/10.1038/onc.2017.227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28692052	hybrid, Green Published			2022-12-17	WOS:000414774800007
J	Kim, J; Jin, H; Zhao, JC; Yang, YA; Li, Y; Yang, X; Dong, X; Yu, J				Kim, J.; Jin, H.; Zhao, J. C.; Yang, Y. A.; Li, Y.; Yang, X.; Dong, X.; Yu, J.			FOXA1 inhibits prostate cancer neuroendocrine differentiation	ONCOGENE			English	Article							ANDROGEN RECEPTOR; PROTEIN-KINASE; CELL-PROLIFERATION; EXPRESSION; INTERLEUKIN-8; TRANSCRIPTION; IDENTIFICATION; CHEMOTHERAPY; DEPRIVATION; METASTASIS	Neuroendocrine prostate cancer (NEPC) has increasingly become a clinical challenge. The mechanisms by which neuroendocrine (NE) cells arises from prostate adenocarcinoma cells are poorly understood. FOXA1 is a transcription factor of the forkhead family that is required for prostate epithelial differentiation. In this study, we demonstrated that FOXA1 loss drives NE differentiation, demarcated by phenotypical changes and NEPC marker expressions. Mechanistically, this is mediated by FOXA1 binding to the promoter of interleukin 8 (IL-8), a chemokine previously shown elevated in NEPC, to directly inhibit its expression. Further, IL-8 upregulation activates the MAPK/ERK pathway, leading to ERK phosphorylation and enolase 2 (ENO2) expression. IL-8 knockdown or ERK inhibition, on the other hand, abolished FOXA1 loss-induced NE differentiation. Analysis of xenograft mouse models confirmed FOXA1 loss in NEPC tumors relative to its adenocarcinoma counterparts. Importantly, FOXA1 is downregulated in human NEPC tumors compared to primary and castration-resistant prostate cancers, and its expression is negatively correlated with that of ENO2. These findings indicate that FOXA1 transcriptionally suppresses IL-8, the expression of which would otherwise stimulate the MAPK/ERK pathway to promote NE differentiation of prostate cancer cells. Our data strongly suggest that FOXA1 loss may play a significant role in enabling prostate cancer progression to NEPC, whereas IL-8 and MAPK/ERK pathways may be promising targets for therapeutic intervention.	[Kim, J.; Jin, H.; Zhao, J. C.; Yang, Y. A.; Yu, J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Li, Y.; Dong, X.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [Yang, X.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Yang, X.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; University of British Columbia; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	Dong, Xuesen/AGF-9228-2022	Jin, Hongjian/0000-0003-3833-7170; Kim, Jung/0000-0001-6274-2841; Yang, Angela/0000-0002-9868-7431	NIH [R01CA172384]; prostate cancer SPORE [P50CA180995]; National Institute of Diabetes and Digestive and Kidney Diseases [T32 DK007169]; NATIONAL CANCER INSTITUTE [R01CA172384, P50CA180995, R50CA211271, T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); prostate cancer SPORE; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by the NIH R01CA172384 (to JY), prostate cancer SPORE P50CA180995 (to JY), the Institutional Ruth L. Kirschstein National Research Service Award from the National Institute of Diabetes and Digestive and Kidney Diseases T32 DK007169 (to JK).	Akamatsu S, 2015, CELL REP, V12, P922, DOI 10.1016/j.celrep.2015.07.012; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2012, J CLIN ONCOL, V30, pE386, DOI 10.1200/JCO.2011.41.5166; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Bernardo GM, 2010, DEVELOPMENT, V137, P2045, DOI 10.1242/dev.043299; Besnard V, 2005, AM J PHYSIOL-LUNG C, V289, pL750, DOI 10.1152/ajplung.00151.2005; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chen HB, 2012, ENDOCR-RELAT CANCER, V19, P321, DOI 10.1530/ERC-11-0368; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Culine S, 2007, J UROLOGY, V178, P844, DOI 10.1016/j.juro.2007.05.044; DeGraff DJ, 2014, LAB INVEST, V94, P726, DOI 10.1038/labinvest.2014.64; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gao N, 2008, GENE DEV, V22, P3435, DOI 10.1101/gad.1752608; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Huang JT, 2005, AM J PATHOL, V166, P1807, DOI 10.1016/S0002-9440(10)62490-X; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Kim J, 2002, CANCER RES, V62, P1549; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028; Li Z, 2013, ASIAN J ANDROL, V15, P328, DOI 10.1038/aja.2013.7; Lin D, 2015, ONCOTARGET, V6, P1806, DOI 10.18632/oncotarget.2809; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Martin-Orozco RM, 2007, NEOPLASIA, V9, P614, DOI 10.1593/neo.07337; Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131; Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Murphy C, 2005, CLIN CANCER RES, V11, P4117, DOI 10.1158/1078-0432.CCR-04-1518; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Sagnak L, 2011, CLIN GENITOURIN CANC, V9, P73, DOI 10.1016/j.clgc.2011.07.003; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Santoni M, 2014, BBA-REV CANCER, V1846, P630, DOI 10.1016/j.bbcan.2014.10.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Sun YJ, 2009, PROSTATE, V69, P1119, DOI 10.1002/pros.20961; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wallace TA, 2008, CANCER RES, V68, P927, DOI 10.1158/0008-5472.CAN-07-2608; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wightman SC, 2015, BRIT J CANCER, V113, P327, DOI 10.1038/bjc.2015.193; Wilson C, 2008, J PHARMACOL EXP THER, V327, P746, DOI 10.1124/jpet.108.143826; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu Y, 2013, J CLIN ENDOCR METAB, V98, P2887, DOI 10.1210/jc.2012-4000; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zhang XT, 2015, CLIN CANCER RES, V21, P4698, DOI 10.1158/1078-0432.CCR-15-0157; Zhang XQ, 2003, ONCOGENE, V22, P6704, DOI 10.1038/sj.onc.1206764	58	75	77	1	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4072	4080		10.1038/onc.2017.50	http://dx.doi.org/10.1038/onc.2017.50			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28319070	Green Accepted			2022-12-17	WOS:000405379900012
J	Kwak, T; Drews-Elger, K; Ergonul, A; Miller, PC; Braley, A; Hwang, GH; Zhao, D; Besser, A; Yamamoto, Y; Yamamoto, H; El-Ashry, D; Slingerland, JM; Lippman, ME; Hudson, BI				Kwak, T.; Drews-Elger, K.; Ergonul, A.; Miller, P. C.; Braley, A.; Hwang, G. H.; Zhao, D.; Besser, A.; Yamamoto, Y.; Yamamoto, H.; El-Ashry, D.; Slingerland, J. M.; Lippman, M. E.; Hudson, B. I.			Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis	ONCOGENE			English	Article							GLYCATION END-PRODUCTS; TUMOR MICROENVIRONMENT; CYTOPLASMIC DOMAIN; NEURITE OUTGROWTH; DIABETES-MELLITUS; MOUSE MODEL; RECEPTOR; EXPRESSION; ACTIVATION; PROMOTES	The receptor for advanced glycation end products (RAGE) is highly expressed in various cancers and is correlated with poorer outcome in breast and other cancers. Here we tested the role of targeting RAGE by multiple approaches in the tumor and tumor microenvironment, to inhibit the metastatic process. We first tested how RAGE impacts tumor cell-intrinsic mechanisms using either RAGE overexpression or knockdown with short hairpin RNAs (shRNAs). RAGE ectopic overexpression in breast cancer cells increased MEK-EMT (MEK-epithelial-to-mesenchymal transition) signaling, transwell invasion and soft agar colony formation, and in vivo promoted lung metastasis independent of tumor growth. RAGE knockdown with multiple independent shRNAs in breast cancer cells led to decreased transwell invasion and soft agar colony formation, without affecting proliferation. In vivo, targeting RAGE shRNA knockdown in human and mouse breast cancer cells, decreased orthotopic tumor growth, reduced tumor angiogenesis and recruitment of inflammatory cells, and markedly decreased metastasis to the lung and liver in multiple xenograft and syngeneic mouse models. To test the non-tumor cell microenvironment role of RAGE, we performed syngeneic studies with orthotopically injected breast cancer cells in wild-type and RAGE-knockout C57BL6 mice. RAGE-knockout mice displayed striking impairment of tumor cell growth compared with wild-type mice, along with decreased mitogen-activated protein kinase signaling, tumor angiogenesis and inflammatory cell recruitment. To test the combined inhibition of RAGE in both tumor cell-intrinsic and nontumor cells of the microenvironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, two times per week). Compared with vehicle, FPS-ZM1 inhibited primary tumor growth, inhibited tumor angiogenesis and inflammatory cell recruitment and, most importantly, prevented metastasis to the lung and liver. These data demonstrate that RAGE drives tumor progression and metastasis through distinct tumor cell-intrinsic and -extrinsic mechanisms, and may represent a novel and therapeutically viable approach for treating metastatic cancers.	[Kwak, T.; Hudson, B. I.] Univ Miami, Leonard M Miller Sch Med, Dept Cell Biol, 1550 NW 10th Ave,PAP Bldg,Room 528, Miami, FL 33136 USA; [Drews-Elger, K.; Ergonul, A.; Miller, P. C.; El-Ashry, D.; Lippman, M. E.; Hudson, B. I.] Univ Miami, Leonard M Miller Sch Med, Dept Med, Miami, FL USA; [Braley, A.; Slingerland, J. M.] Univ Miami, Leonard M Miller Sch Med, Dept Biochem, Miami, FL USA; [Hwang, G. H.; Zhao, D.; Besser, A.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Yamamoto, Y.; Yamamoto, H.] Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa, Japan; [El-Ashry, D.; Slingerland, J. M.; Lippman, M. E.; Hudson, B. I.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Braman Family Breast Canc Inst, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami; Kanazawa University; University of Miami	Hudson, BI (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Cell Biol, 1550 NW 10th Ave,PAP Bldg,Room 528, Miami, FL 33136 USA.	bhudson@med.miami.edu	Ergonul, Ayse Burcu/AAF-4987-2022; Hudson, Barry/B-3122-2009; Ergonul, Ayse Burcu/AFJ-8120-2022	Hudson, Barry/0000-0001-7647-8121; Braley, Alexander/0000-0002-1443-1472; Drews-Elger, Katherine/0000-0001-9540-0610	Susan G Komen for the Cure [CCR15331076]; American Cancer Society Institutional Research [98-277-10]	Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); American Cancer Society Institutional Research(American Cancer Society)	This research was supported by a Career Catalyst Research from Susan G Komen for the Cure Grant No. CCR15331076 and by the American Cancer Society Institutional Research Grant No. 98-277-10.	Abe R, 2008, CURR PHARM DESIGN, V14, P940, DOI 10.2174/138161208784139765; Allmen EU, 2008, PROSTATE, V68, P748, DOI 10.1002/pros.20736; Arumugam T, 2012, CLIN CANCER RES, V18, P4356, DOI 10.1158/1078-0432.CCR-12-0221; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bjork P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063012; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Drews-Elger K, 2014, BREAST CANCER RES TR, V148, P41, DOI 10.1007/s10549-014-3122-4; Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hsieh HL, 2003, BIOCHEM BIOPH RES CO, V307, P375, DOI 10.1016/S0006-291X(03)01190-2; Huang JS, 2001, J CELL BIOCHEM, V81, P102, DOI 10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y; Hudson BI, 2008, J BIOL CHEM, V283, P34457, DOI 10.1074/jbc.M801465200; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Jackel A, 1999, HAUTARZT, V50, P250, DOI 10.1007/s001050050897; Jules J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078267; Kalea AZ, 2010, CANCER RES, V70, P5628, DOI 10.1158/0008-5472.CAN-10-0595; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koch M, 2010, STRUCTURE, V18, P1342, DOI 10.1016/j.str.2010.05.017; Kurozumi K, 2007, JNCI-J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Larsson SC, 2007, INT J CANCER, V121, P856, DOI 10.1002/ijc.22717; Leclerc E, 2007, J BIOL CHEM, V282, P31317, DOI 10.1074/jbc.M703951200; Liao SC, 2011, ASIAN PAC J CANCER P, V12, P1061; Logsdon CD, 2007, CURR MOL MED, V7, P777, DOI 10.2174/156652407783220697; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Myint KM, 2006, DIABETES, V55, P2510, DOI 10.2337/db06-0221; Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Pietzsch J, 2009, AMINO ACIDS, V36, P381, DOI 10.1007/s00726-008-0097-7; Radia AM, 2013, INT J MOL SCI, V14, P7959, DOI 10.3390/ijms14047959; Sharaf H, 2015, BBA-MOL BASIS DIS, V1852, P429, DOI 10.1016/j.bbadis.2014.12.009; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; SIROTNAK FM, 1984, CANCER CHEMOTH PHARM, V12, P26; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stewart TJ, 2007, J IMMUNOL, V179, P2851, DOI 10.4049/jimmunol.179.5.2851; Tafani M, 2011, CARCINOGENESIS, V32, P1167, DOI 10.1093/carcin/bgr101; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Vernon PJ, 2013, J IMMUNOL, V190, P1372, DOI 10.4049/jimmunol.1201151; Xiong F, 2011, J BIOL CHEM, V286, P35061, DOI 10.1074/jbc.M111.261073; Yamagishi S, 2006, METABOLISM, V55, P1227, DOI 10.1016/j.metabol.2006.05.007; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Yin CG, 2013, BREAST CANCER RES TR, V142, P297, DOI 10.1007/s10549-013-2737-1; Zen K, 2007, J IMMUNOL, V178, P2483, DOI 10.4049/jimmunol.178.4.2483; Zhou Z, 2006, J EXP MED, V203, P1067, DOI 10.1084/jem.20051947	56	75	81	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1559	1572		10.1038/onc.2016.324	http://dx.doi.org/10.1038/onc.2016.324			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27669433				2022-12-17	WOS:000397458100010
J	Gomez-Maldonado, L; Tiana, M; Roche, O; Prado-Cabrero, A; Jensen, L; Fernandez-Barral, A; Guijarro-Munoz, I; Favaro, E; Moreno-Bueno, G; Sanz, L; Aragones, J; Harris, A; Volpert, O; Jimenez, B; del Peso, L				Gomez-Maldonado, L.; Tiana, M.; Roche, O.; Prado-Cabrero, A.; Jensen, L.; Fernandez-Barral, A.; Guijarro-Munoz, I.; Favaro, E.; Moreno-Bueno, G.; Sanz, L.; Aragones, J.; Harris, A.; Volpert, O.; Jimenez, B.; del Peso, L.			EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination	ONCOGENE			English	Article							GENE-EXPRESSION; INDUCIBLE FACTORS; EPH RECEPTORS; MASTER REGULATORS; CELL-ADHESION; HIF-ALPHA; CANCER; IDENTIFICATION; MICRORNA-210; SIGNATURE	The presence of hypoxic regions in solid tumors is an adverse prognostic factor for patient outcome. Here, we show that hypoxia induces the expression of Ephrin-A3 through a novel hypoxia-inducible factor (HIF)-mediated mechanism. In response to hypoxia, the coding EFNA3 mRNA levels remained relatively stable, but HIFs drove the expression of previously unknown long noncoding (lnc) RNAs from EFNA3 locus and these lncRNA caused Ephrin-A3 protein accumulation. Ephrins are cell surface proteins that regulate diverse biological processes by modulating cellular adhesion and repulsion. Mounting evidence implicates deregulated ephrin function in multiple aspects of tumor biology. We demonstrate that sustained expression of both Ephrin-A3 and novel EFNA3 lncRNAs increased the metastatic potential of human breast cancer cells, possibly by increasing the ability of tumor cells to extravasate from the blood vessels into surrounding tissue. In agreement, we found a strong correlation between high EFNA3 expression and shorter metastasis-free survival in breast cancer patients. Taken together, our results suggest that hypoxia could contribute to metastatic spread of breast cancer via HIF-mediated induction of EFNA3 lncRNAs and subsequent Ephrin-A3 protein accumulation.	[Gomez-Maldonado, L.; Tiana, M.; Roche, O.; Prado-Cabrero, A.; Fernandez-Barral, A.; Moreno-Bueno, G.; Jimenez, B.; del Peso, L.] Univ Autonoma Madrid, Dept Bioquim, Madrid, Spain; [Gomez-Maldonado, L.; Tiana, M.; Roche, O.; Prado-Cabrero, A.; Fernandez-Barral, A.; Moreno-Bueno, G.; Jimenez, B.; del Peso, L.] Alberto Sols CSIC UAM, Inst Invest Biomed, Madrid 28029, Spain; [Roche, O.; del Peso, L.] Hosp Univ La Paz, Inst Invest Sanitaria, IdiPaz, Madrid, Spain; [Jensen, L.] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Jensen, L.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Guijarro-Munoz, I.; Sanz, L.] Hosp Univ Puerta Hierro Majadahonda, Mol Immunol Unit, Madrid, Spain; [Favaro, E.; Harris, A.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Oncol Labs, Oxford OX3 9DU, England; [Aragones, J.] Autonomous Univ Madrid, Res Inst Princesa, Hosp Univ Santa Cristina, Res Unit, E-28049 Madrid, Spain; [Volpert, O.] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Universitario La Paz; Linkoping University; Karolinska Institutet; Hospital Puerta de Hierro-Majadahonda; University of Oxford; Autonomous University of Madrid; Northwestern University; Feinberg School of Medicine	del Peso, L (corresponding author), Alberto Sols Univ Autonoma Madrid, Inst Invest Biomed, Fac Med, Dept Biochem,CSIC UAM, Arturo Duperier 4, Madrid 28029, Spain.	luis.peso@uam.es	Roche, UCLM/F-5697-2019; Harris, Adrian L/ABA-3343-2020; Prado-Cabrero, Alfonso/M-2504-2019; tiana, maria/G-4240-2016; Favaro, Elena/Q-4566-2016; Fernández-Barral, Asunión/O-8133-2015; del Peso, Luis/K-9391-2014; Prado-Cabrero, Alfonso/F-2823-2015; Tiana, María/AAA-1868-2020; Sanz, Laura/F-8542-2010; Moreno-Bueno, Gema/K-9354-2016; Cuenca, Benilde Jimenez/K-9959-2014	Roche, UCLM/0000-0003-1884-8256; Harris, Adrian L/0000-0003-1376-8409; Prado-Cabrero, Alfonso/0000-0001-8268-5362; tiana, maria/0000-0003-0678-1154; Favaro, Elena/0000-0001-5376-5515; Fernández-Barral, Asunión/0000-0002-1278-4645; del Peso, Luis/0000-0003-4014-5688; Prado-Cabrero, Alfonso/0000-0001-8268-5362; Tiana, María/0000-0003-0678-1154; Sanz, Laura/0000-0002-3119-3218; Moreno-Bueno, Gema/0000-0002-5030-6687; Jensen, Lasse/0000-0003-2338-357X; Jimenez Cuenca, Benilde/0000-0002-1806-6636	Ministerio de Ciencia e Innovacion (Spanish Ministry of Science and Innovation, MICINN) [SAF2008-03147, SAF2011_24225, SAF-2010-19256]; Comunidad Autonoma de Madrid [S2010/BMD-2542]; European Union (METOXIA project) [HEALTH-F2-2009-222741]; CSIC [JAE DOC 2010/FSE2007-2013]; Fondo de Investigacion Sanitaria/Instituto de Salud Carlos III [PI08/90856, PS09/00227]; Cancer Research UK [16466, 11359, 18974] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA172669] Funding Source: NIH RePORTER	Ministerio de Ciencia e Innovacion (Spanish Ministry of Science and Innovation, MICINN); Comunidad Autonoma de Madrid(Comunidad de Madrid); European Union (METOXIA project); CSIC; Fondo de Investigacion Sanitaria/Instituto de Salud Carlos III(Instituto de Salud Carlos III); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Amparo Acker-Palmer for expert advice on ephrin detection and Ignacio Palmero DGCR8 reagents. This work was supported by Ministerio de Ciencia e Innovacion (Spanish Ministry of Science and Innovation, MICINN) (grant numbers SAF2008-03147 and SAF2011_24225 to LdeIP and SAF-2010-19256 to BJ); by Comunidad Autonoma de Madrid (grant numbers S2010/BMD-2542 to LdeIP), by the 7th Research Framework Programme of the European Union (grant number METOXIA project ref. HEALTH-F2-2009-222741 to LdeIP); by CSIC (JAE DOC 2010/FSE2007-2013 to OR) and by Fondo de Investigacion Sanitaria/Instituto de Salud Carlos III (grants PI08/90856 and PS09/00227 to LS).	Barderas R, 2013, MOL CELL PROTEOMICS, V12, P1602, DOI 10.1074/mcp.M112.022848; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chen J, 2012, ADV CANCER RES, V114, P1, DOI 10.1016/B978-0-12-386503-8.00001-6; Cheng YM, 2006, BIOINFORMATICS, V22, P2320, DOI 10.1093/bioinformatics/btl394; Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345; Fukaya T, 2012, MOL CELL, V48, P825, DOI 10.1016/j.molcel.2012.09.024; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Miro-Murillo M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022589; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733; Nie L, 2012, AM J TRANSL RES, V4, P127; Nievergall E, 2012, CELL MOL LIFE SCI, V69, P1813, DOI 10.1007/s00018-011-0900-6; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Ortiz-Barahona A, 2010, NUCLEIC ACIDS RES, V38, P2332, DOI 10.1093/nar/gkp1205; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Rouhi P, 2010, NAT PROTOC, V5, P1911, DOI 10.1038/nprot.2010.150; Rouhi P, 2010, CELL CYCLE, V9, P913, DOI 10.4161/cc.9.5.10853; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sims D, 2010, BREAST CANCER RES TR, V124, P567, DOI 10.1007/s10549-010-0945-5; Surawska H, 2004, CYTOKINE GROWTH F R, V15, P419, DOI 10.1016/j.cytogfr.2004.09.002; TEAM RC, 2010, R LANG ENV STAT COMP; Tiana M, 2012, NUCLEIC ACIDS RES, V40, P1916, DOI 10.1093/nar/gkr842; Uniacke J, 2012, NATURE, V486, P126, DOI 10.1038/nature11055; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje; Villar D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045708; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; Yamashita T, 2008, J BIOL CHEM, V283, P18926, DOI 10.1074/jbc.M709133200; Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365	54	75	82	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2609	2620		10.1038/onc.2014.200	http://dx.doi.org/10.1038/onc.2014.200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023702	Green Accepted, Green Submitted			2022-12-17	WOS:000354541300007
J	Hardy, S; Uetani, N; Wong, N; Kostantin, E; Labbe, DP; Begin, LR; Mes-Masson, A; Miranda-Saavedra, D; Tremblay, ML				Hardy, S.; Uetani, N.; Wong, N.; Kostantin, E.; Labbe, D. P.; Begin, L. R.; Mes-Masson, A.; Miranda-Saavedra, D.; Tremblay, M. L.			The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis	ONCOGENE			English	Article							REGENERATING LIVER; CELL-MIGRATION; CANCER; MG2+; METASTASIS; IDENTIFICATION; PROLIFERATION; PURIFICATION; STIMULATION; MECHANISMS	The three PRL (phosphatases of regenerating liver) protein tyrosine phosphatases (PRL-1, -2 and -3) have been identified as key contributors to metastasis in several human cancers, yet the molecular basis of their pro-oncogenic property is unclear. Among the subfamily of PRL phosphatases, overexpression of PRL-2 in breast cancer cells has been shown to promote tumor growth by a mechanism that remains to be uncovered. Here we show that PRL-2 regulates intracellular magnesium levels by forming a functional heterodimer with the magnesium transporter CNNM3. We further reveal that CNNM3 is not a phosphorylated substrate of PRL-2, and that the interaction occurs through a loop unique to the CBS pair domains of CNNM3 that exists only in organisms having PRL orthologs. Supporting the role of PRL-2 in cellular magnesium transport is the observation that PRL-2 knockdown results in a substantial decrease of cellular magnesium influx. Furthermore, in PRL-2 knockout mice, serum magnesium levels were significantly elevated as compared with control animals, indicating a pivotal role for PRL-2 in regulating cellular magnesium homeostasis. Although the expression levels of CNNM3 remained unchanged after magnesium depletion of various cancer cell lines, the interaction between endogenous PRL-2 and CNNM3 was markedly increased. Importantly, xenograft tumor assays with CNNM3 and a mutant form that does not associate with PRL-2 confirm that CNNM3 is itself pro-oncogenic, and that the PRL-2/CNNM3 association is important for conferring transforming activities. This finding is further confirmed from data in human breast cancer tissues showing that CNNM3 levels correlate positively with both PRL-2 expression and the tumor proliferative index. In summary, we demonstrate that oncogenic PRL-2 controls tumor growth by modulating intracellular magnesium levels through binding with the CNNM3 magnesium transporter.	[Hardy, S.; Uetani, N.; Wong, N.; Kostantin, E.; Labbe, D. P.; Tremblay, M. L.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Wong, N.; Kostantin, E.; Tremblay, M. L.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A3, Canada; [Labbe, D. P.; Tremblay, M. L.] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada; [Begin, L. R.] Hop Sacre Coeur, Serv Anatomopathol, Montreal, PQ H4J 1C5, Canada; [Mes-Masson, A.] Univ Montreal, CR CHUM, Inst Canc Montreal, Montreal, PQ, Canada; [Mes-Masson, A.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Miranda-Saavedra, D.] Osaka Univ, World Premier Int Immunol Frontier Res Ctr, Osaka, Japan; [Miranda-Saavedra, D.] Newcastle Univ, Sch Med, Inst Cellular Med, Fibrosis Labs, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	McGill University; McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; Osaka University; Newcastle University - UK	Tremblay, ML (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Canc Res Bldg,1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	michel.tremblay@mcgill.ca	Labbé, David P./C-2702-2009	Labbé, David P./0000-0001-8864-8765; Mes-Masson, Anne-Marie/0000-0002-6498-266X	Canadian Institute of Health Research (CIHR); CIHR/Fonds de recherche du Quebec-Sante Training Grant in Cancer Research [FRN53888]; Quebec Breast Cancer Foundation; Canadian Breast Cancer Research Alliance	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR/Fonds de recherche du Quebec-Sante Training Grant in Cancer Research; Quebec Breast Cancer Foundation; Canadian Breast Cancer Research Alliance	We thank Dr Laurent Lessard (J. Wayne Cancer Institute) for his technical help. Dr Kalle Gehring, biochemistry department, McGill University for helpful discussion and colleagues at the Goodman Cancer Research Centre Drs Jose Teodoro and Jerry Pelletier for their constructive comments on the manuscript. MLT is a Jeanne and Jean-Louis Levesque chair in Cancer Research. DPL is a recipient of Canadian Institute of Health Research (CIHR) Frederick Banting and Charles Best Doctoral Research award and of CIHR/Fonds de recherche du Quebec-Sante Training Grant in Cancer Research FRN53888 the McGill Integrated Cancer Research Training Program. This research is supported by an operating grant from the Quebec Breast Cancer Foundation and the Canadian Breast Cancer Research Alliance to MLT.	Al-Aidaroos AQO, 2010, J CELL BIOCHEM, V111, P1087, DOI 10.1002/jcb.22913; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; Blanchetot C, 2005, METHODS, V35, P44, DOI 10.1016/j.ymeth.2004.07.007; Castiglioni S, 2011, MAGNESIUM RES, V24, pS92, DOI 10.1684/mrh.2011.0285; Chen GI, 2007, METHODS, V42, P298, DOI 10.1016/j.ymeth.2007.02.018; Chen SD, 2010, CHINESE MED J-PEKING, V123, P1447, DOI 10.3760/cma.j.issn.0366-6999.2010.11.018; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; Dai LJ, 1997, AM J PHYSIOL-RENAL, V272, pF249, DOI 10.1152/ajprenal.1997.272.2.F249; de Baaij JHF, 2012, J BIOL CHEM, V287, P13644, DOI 10.1074/jbc.M112.342204; Dong YS, 2012, J BIOL CHEM, V287, P32172, DOI 10.1074/jbc.M112.393462; Dumaual CM, 2006, J HISTOCHEM CYTOCHEM, V54, P1401, DOI 10.1369/jhc.6A7019.2006; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; Gomez-Garcia I, 2012, ACTA CRYSTALLOGR F, V68, P1198, DOI 10.1107/S1744309112035348; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hardy S, 2012, ANTI-CANCER AGENT ME, V12, P4, DOI 10.2174/187152012798764741; Hardy S, 2010, CANCER RES, V70, P8959, DOI 10.1158/0008-5472.CAN-10-2041; Hattori M, 2007, NATURE, V448, P1072, DOI 10.1038/nature06093; Ikari A, 2010, LIFE SCI, V86, P766, DOI 10.1016/j.lfs.2010.03.016; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kolisek M, 2012, AM J PHYSIOL-CELL PH, V302, pC318, DOI 10.1152/ajpcell.00289.2011; Kozlov G, 2004, J BIOL CHEM, V279, P11882, DOI 10.1074/jbc.M312905200; Krndija D, 2012, J CELL SCI, V125, P3883, DOI 10.1242/jcs.104885; Li FY, 2011, NATURE, V475, P471, DOI 10.1038/nature10246; Meyer TE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001045; Peng LR, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-110; Quamme GA, 2010, AM J PHYSIOL-CELL PH, V298, pC407, DOI 10.1152/ajpcell.00124.2009; Rios P, 2013, FEBS J, V280, P505, DOI 10.1111/j.1742-4658.2012.08565.x; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Skinner AL, 2009, BIOCHEMISTRY-US, V48, P4262, DOI 10.1021/bi900241k; Stephens B, 2008, MOL CANCER THER, V7, P202, DOI 10.1158/1535-7163.MCT-07-0542; Stuiver M, 2011, AM J HUM GENET, V88, P333, DOI 10.1016/j.ajhg.2011.02.005; Sun JP, 2005, BIOCHEMISTRY-US, V44, P12009, DOI 10.1021/bi0509191; Svotelis A, 2011, EMBO J, V30, P3947, DOI 10.1038/emboj.2011.284; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Touyz RM, 2008, AM J PHYSIOL-HEART C, V294, pH1103, DOI 10.1152/ajpheart.00903.2007; Wang CY, 2003, GENE, V306, P37, DOI 10.1016/S0378-1119(02)01210-6; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang JY, 2011, J BIOL CHEM, V286, P10177, DOI 10.1074/jbc.M110.163295; Wang Y, 2012, ONCOGENE, V31, P818, DOI 10.1038/onc.2011.281; Wolf FI, 2012, CLIN SCI, V123, P417, DOI 10.1042/CS20120086; Wolf FI, 2004, FRONT BIOSCI-LANDMRK, V9, P2056, DOI 10.2741/1389; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291	45	75	78	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					986	995		10.1038/onc.2014.33	http://dx.doi.org/10.1038/onc.2014.33			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632616				2022-12-17	WOS:000350121300005
J	Busch, S; Acar, A; Magnusson, Y; Gregersson, P; Ryden, L; Landberg, G				Busch, S.; Acar, A.; Magnusson, Y.; Gregersson, P.; Ryden, L.; Landberg, G.			TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer	ONCOGENE			English	Article						TGF-beta; tumour stroma; cancer-associated fibroblast; breast cancer; clonogenic survival	STROMAL FIBROBLASTS; CARCINOMA; MYOFIBROBLASTS; HETEROGENEITY; TAMOXIFEN	Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine with the capability to act as tumour suppressor or tumour promoter depending on the cellular context. TGF-beta receptor type-2 (TGFBR2) is the ligand-binding receptor for all members of the TGF-beta family. Data from mouse model experiments demonstrated that loss of Tgfbr2 expression in mammary fibroblasts was linked to tumour initiation and metastasis. Using a randomised tamoxifen trial cohort including in total 564 invasive breast carcinomas, we examined TGFBR2 expression (n = 252) and phosphorylation level of downstream target SMAD2 (pSMAD2) (n = 319) in cancer-associated fibroblasts (CAFs) and assessed links to clinicopathological markers, prognostic and treatment-predictive values. The study revealed that CAF-specific TGFBR2 expression correlated with improved recurrence-free survival. Multivariate analysis confirmed CAF-TGFBR2 to be an independent prognostic marker (multivariate Cox regression, hazard ratio: 0.534, 95% (Cl): 0.360-0.793, P = 0.002). CAF-specific pSMAD2 levels, however, did not associate with survival outcome. Experimentally, TGF-beta signalling in fibroblasts was modulated using a TGF-beta ligand and inhibitor or through lentiviral short hairpin RNA-mediated TGFBR2-specific knockdown. To determine the role of fibroblastic TGF-beta pathway on breast cancer cells, we used cell contact-dependent cell growth and clonogenicity assays, which showed that knockdown of TGFBR2 in CAFs resulted in increased cell growth, proliferation and clonogenic survival. Further, in a mouse model transfected CAFs were co-injected with MCF7 and tumour weight and proportion was monitored. We found that mouse xenograft tumours comprising TGFBR2 knockdown fibroblasts were slightly bigger and displayed increased tumour cell capacity. Overall, our data demonstrate that fibroblast-related biomarkers possess clinically relevant information and that fibroblasts confer effects on breast cancer cell growth and survival. Regulation of tumour-stromal cross-talk through fibroblastic TGF-beta pathway may depend on fibroblast phenotype, emphasising the importance to characterise tumour microenvironment subtypes.	[Busch, S.; Magnusson, Y.; Gregersson, P.; Landberg, G.] Gothenburg Univ, Sahlgrenska Canc Ctr, Dept Pathol, S-40530 Gothenburg, Sweden; [Acar, A.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester, Lancs, England; [Ryden, L.] Univ Lund Hosp, Inst Clin Sci, Dept Surg, S-22185 Lund, Sweden; [Landberg, G.] Univ Manchester, Paterson Inst Canc Res, Inst Canc Sci, Breakthrough Breast Canc Res Unit,Mol Pathol Grp, Manchester, Lancs, England	University of Gothenburg; University of Manchester; Lund University; Skane University Hospital; Paterson Institute for Cancer Research; University of Manchester	Landberg, G (corresponding author), Gothenburg Univ, Sahlgrenska Canc Ctr, Dept Pathol, Medicinaregatan 1F, S-40530 Gothenburg, Sweden.	Goran.landberg@gu.se	Acar, Ahmet/ABI-3298-2020	Acar, Ahmet/0000-0002-2478-8029	Swedish Cancer Society; Breakthrough Breast Cancer UK; BioCARE-a National Strategic Research Program at University of Gothenburg; Breast Cancer Now [MAN-Q1] Funding Source: researchfish	Swedish Cancer Society(Swedish Cancer Society); Breakthrough Breast Cancer UK; BioCARE-a National Strategic Research Program at University of Gothenburg; Breast Cancer Now	We thank Elise Nilsson for excellent technical assistance, the MCRC Biobank for providing us with patient material and Dr Akira Orimo for the kind gift of fibroblast model cell lines and lentiviral plasmids. We would further thank Eamon Hughes for his assistance with the animal work. This study was supported by the Swedish Cancer Society and Breakthrough Breast Cancer UK. The project was further supported by BioCARE-a National Strategic Research Program at University of Gothenburg.	Bacman D, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-156; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Busch S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045669; Casbas-Hernandez P, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/520987; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Cheng N, 2008, MOL CANCER RES, V6, P1521, DOI 10.1158/1541-7786.MCR-07-2203; Cheng N, 2007, CANCER RES, V67, P4869, DOI 10.1158/0008-5472.CAN-06-3381; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Polanska UM, 2011, JOVE-J VIS EXP, DOI 10.3791/3201; Ryden L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030; Samoszuk M, 2005, BREAST CANCER RES, V7, pR274, DOI 10.1186/bcr995; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stuelten CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009832; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282	29	75	78	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					27	38		10.1038/onc.2013.527	http://dx.doi.org/10.1038/onc.2013.527			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24336330				2022-12-17	WOS:000349740100003
J	Roy, SS; Gonugunta, VK; Bandyopadhyay, A; Rao, MK; Goodall, GJ; Sun, LZ; Tekmal, RR; Vadlamudi, RK				Roy, S. S.; Gonugunta, V. K.; Bandyopadhyay, A.; Rao, M. K.; Goodall, G. J.; Sun, L-Z; Tekmal, R. R.; Vadlamudi, R. K.			Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer	ONCOGENE			English	Article						ER coactivators; PELP1; breast cancer; metastasis; EMT; miR	EPITHELIAL-MESENCHYMAL TRANSITION; LEUCINE-RICH PROTEIN-1/MODULATOR; GLUTAMIC ACID-RICH; ESTROGEN-RECEPTOR; TUMOR-METASTASIS; MIR-200 FAMILY; PROLINE-RICH; PELP1; EXPRESSION; COREPRESSOR	Tumor metastasis is the leading cause of death among breast cancer patients. PELP1 (proline, glutamic acid and leucine rich protein 1) is a nuclear receptor coregulator that is upregulated during breast cancer progression to metastasis and is an independent prognostic predictor of shorter survival of breast cancer patients. Here, we show that PELP1 modulates expression of metastasis-influencing microRNAs (miRs) to promote cancer metastasis. Whole genome miR array analysis using PELP1-overexpressing and PELP1-underexpressing model cells revealed that miR-200 and miR-141 levels inversely correlated with PELP1 expression. Consistent with this, PELP1 knockdown resulted in lower expression of miR-200a target genes ZEB1 and ZEB2. PELP1 knockdown significantly reduced tumor growth and metastasis compared with parental cells in an orthotopic xenograft tumor model. Furthermore, re-introduction of miR-200a and miR-141 mimetics into PELP1-overexpressing cells reversed PELP1 target gene expression, decreased PELP1-driven migration/invasion in vitro and significantly reduced in vivo metastatic potential in a preclinical model of experimental metastasis. Our results demonstrated that PELP1 binds to miR-200a and miR-141 promoters and regulates their expression by recruiting chromatin modifier histone deacetylase 2 (HDAC2) as revealed by chromatin immunoprecipitation, small interfering RNA and HDAC inhibitor assays. Taken together, our results suggest that PELP1 regulates tumor metastasis by controlling the expression and functions of the tumor metastasis suppressors miR-200a and miR-141.	[Roy, S. S.; Gonugunta, V. K.; Tekmal, R. R.; Vadlamudi, R. K.] UT Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX USA; [Bandyopadhyay, A.; Rao, M. K.; Sun, L-Z] UT Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX USA; [Rao, M. K.; Sun, L-Z; Tekmal, R. R.; Vadlamudi, R. K.] UT Hlth Sci Ctr, Canc Therapy & Res Ctr, San Antonio, TX USA; [Goodall, G. J.] Univ Adelaide, Dept Med, Ctr Canc Biol, SA Pathol,Sch Mol & Biomed Sci, Adelaide, SA 5001, Australia	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Centre for Cancer Biology; SA Pathology; University of Adelaide	Vadlamudi, RK (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Div Reprod Res, San Antonio, TX 78229 USA.	vadlamudi@uthscsa.edu	, LuZhe/AAW-4095-2021	Goodall, Gregory/0000-0003-1294-0692	NIH/NCI [CA095681]; T32 training [CA148724]; William and Ella Owens foundation grant; Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio through the NCI Cancer Center [P30CA054174-17]; NATIONAL CANCER INSTITUTE [T32CA148724, R01CA095681, P30CA054174] Funding Source: NIH RePORTER; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); T32 training; William and Ella Owens foundation grant; Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio through the NCI Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Breast Cancer Foundation	This study was supported by the NIH/NCI Grant CA095681 (R.K.V.) T32 training grant CA148724 (SSR), William and Ella Owens foundation grant (MKR) and the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio through the NCI Cancer Center Support Grant P30CA054174-17.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chakravarty D, 2011, CLIN CANCER RES, V17, P2250, DOI 10.1158/1078-0432.CCR-10-2718; Chakravarty D, 2010, CANCER RES, V70, P4092, DOI 10.1158/0008-5472.CAN-09-3834; Chakravarty D, 2010, IUBMB LIFE, V62, P163, DOI 10.1002/iub.287; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Choi YB, 2004, J BIOL CHEM, V279, P50930, DOI 10.1074/jbc.M406831200; Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229; Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372; Goldshaid L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2579; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681; Mann M, 2012, Minerva Ginecol, V64, P75; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Nair BC, 2010, CANCER RES, V70, P7166, DOI 10.1158/0008-5472.CAN-10-0628; Nair SS, 2007, MOL ENDOCRINOL, V21, P613, DOI 10.1210/me.2006-0269; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; O'Malley BW, 2007, MOL ENDOCRINOL, V21, P1009, DOI 10.1210/me.2007-0012; O'Malley BW, 2006, SCIENCE, V313, P1749, DOI 10.1126/science.1132509; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Rajhans R, 2007, CANCER RES, V67, P5505, DOI 10.1158/0008-5472.CAN-06-3647; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Roy S, 2012, MOL CANCER RES, V10, P25, DOI 10.1158/1541-7786.MCR-11-0456; Saha RS, 2012, INT J BREAST CANC, V2012; Schiff R, 2005, CANC CHEMOTHER PH S1, V56; Shi M, 2010, CANCER METAST REV, V29, P785, DOI 10.1007/s10555-010-9265-9; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Vadlamudi Ratna K, 2007, Nucl Recept Signal, V5, pe004; Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579	42	75	79	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3707	3716		10.1038/onc.2013.332	http://dx.doi.org/10.1038/onc.2013.332			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23975430	Green Accepted			2022-12-17	WOS:000338942900010
J	Tang, W; Yu, F; Yao, H; Cui, X; Jiao, Y; Lin, L; Chen, J; Yin, D; Song, E; Liu, Q				Tang, W.; Yu, F.; Yao, H.; Cui, X.; Jiao, Y.; Lin, L.; Chen, J.; Yin, D.; Song, E.; Liu, Q.			miR-27a regulates endothelial differentiation of breast cancer stem like cells	ONCOGENE			English	Article						breast cancer; cancer stem cell; microRNA; miR-27a; angiogenesis; endothelial differentiation	TUMOR MICROVASCULATURE; MICROENVIRONMENT; ANGIOGENESIS; VASCULARIZATION; MICRORNAS; TARGETS	Recent studies suggested that cancer stem cells (CSCs) are capable of differentiating into endothelial cells and tumor endothelium may be derived from CSCs. But the mechanism remains unclear. We showed that vascular endothelial growth factor (VEGF) induced the expression of endothelial markers in breast cancer stem like cells (BCSLCs). In addition, the VEGF-treated BCSLCs formed capillary structure in matrigel and released vWF upon histamine treatment. The miR-27a expression was significantly increased in VEGF-treated BCSLCs. Antagonizing miR-27a by miR-27a anti-sense oligos (ASOs) in VEGF-treated BCSLCs led to decreased endothelial markers and function, while increasing miR-27a in BCSLCs resulted in enhanced endothelial properties. VEGF enhanced the transcription of miR-27a by increasing RUNX1 binding to miR-27a promoter. Increased miR-27a paralleled the reduced expression of ZBTB10, a known miR-27a target. Both expression of miR-27a and knockdown of ZBTB10 in BCSLCs promoted in vivo angiogenesis and tumor metastasis. Further, we demonstrated that VEGF-treated BCSLCs secreted more endogenous VEGF compared with undifferentiated BCSLCs. Thus, miR-27a promotes angiogenesis by mediating endothelial differentiation of BCSLCs and it may be a new target for anti-angiogenesis cancer therapy.	[Tang, W.; Yu, F.; Yao, H.; Lin, L.; Chen, J.; Song, E.; Liu, Q.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Guangdong, Peoples R China; [Cui, X.; Yin, D.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Key Lab Malignant Tumor Gene Regulat & Target The, Guangzhou 510120, Guangdong, Peoples R China; [Jiao, Y.] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Liu, Q (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.	songerwei02@yahoo.com.cn; victorlq@hotmail.com		Liu, Qiang/0000-0002-5451-4862; Yao, Herui/0000-0001-5520-6469; Lin, Ling/0000-0001-5603-0688	973 Projects from the Ministry of Science and Technology of China [2010CB912800, 2011CB504203]; Natural Science Foundation of China [81072178, 81272894, 81230060, 81261140373, 81071788]; Ministry of Education of China [20120171110075]; Ministry of Health of China [2011ZX09102-010-02]; Guangdong Natural Science Fundation for Distinguished Young Scholar [S20120011199]; Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD) [81000-3149001]	973 Projects from the Ministry of Science and Technology of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Ministry of Health of China; Guangdong Natural Science Fundation for Distinguished Young Scholar; Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD)(Foundation for the Author of National Excellent Doctoral Dissertation of China)	This work was supported by the 973 Projects (2010CB912800, 2011CB504203) from the Ministry of Science and Technology of China, and grants from the Natural Science Foundation of China (81072178, 81272894, 81230060, 81261140373, 81071788), Ministry of Education of China (20120171110075), a grant for Development of Important New Drugs from the Ministry of Health of China (2011ZX09102-010-02), grants from Guangdong Natural Science Fundation for Distinguished Young Scholar (S20120011199) and Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD, 81000-3149001).	Ben-Ami O, 2009, P NATL ACAD SCI USA, V106, P238, DOI 10.1073/pnas.0811466106; Bussolati B, 2009, J CELL MOL MED, V13, P309, DOI 10.1111/j.1582-4934.2008.00338.x; de Castro G, 2006, CRIT REV ONCOL HEMAT, V59, P40, DOI 10.1016/j.critrevonc.2006.02.007; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; Fang K, 2012, CURR MOL MED, V12, P536, DOI 10.2174/156652412800620002; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Fukumura D, 2007, J CELL BIOCHEM, V101, P937, DOI 10.1002/jcb.21187; Fukumura D, 2010, MICROCIRCULATION, V17, P206, DOI 10.1111/j.1549-8719.2010.00029.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; JAIN RK, 1988, CANCER RES, V48, P2641; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Leonardo TR, 2012, NAT CELL BIOL, V14, P1114, DOI 10.1038/ncb2613; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Shcherbata HR, 2006, CELL CYCLE, V5, P172, DOI 10.4161/cc.5.2.2343; Stratman AN, 2011, BLOOD, V117, P3709, DOI 10.1182/blood-2010-11-316752; Tang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051702; Wang H, 2005, CELL BIOL INT, V29, P654, DOI 10.1016/j.cellbi.2005.03.019; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Weigand Melanie, 2005, Angiogenesis, V8, P197, DOI 10.1007/s10456-005-9010-0; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108	25	75	78	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2629	2638		10.1038/onc.2013.214	http://dx.doi.org/10.1038/onc.2013.214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752185				2022-12-17	WOS:000336502700009
J	Bartolome, RA; Barderas, R; Torres, S; Fernandez-Acenero, MJ; Mendes, M; Garcia-Foncillas, J; Lopez-Lucendo, M; Casal, JI				Bartolome, R. A.; Barderas, R.; Torres, S.; Fernandez-Acenero, M. J.; Mendes, M.; Garcia-Foncillas, J.; Lopez-Lucendo, M.; Casal, J. I.			Cadherin-17 interacts with alpha 2 beta 1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis	ONCOGENE			English	Article						Cadherin-17; alpha 2 beta 1 integrin; adhesion; proliferation; liver metastasis; colorectal cancer	INTESTINE-CADHERIN; LI-CADHERIN; MATRIX-METALLOPROTEINASE; HEPATOCELLULAR-CARCINOMA; DIAGNOSTIC MARKER; LYMPH-NODE; EXPRESSION; COMPLEX; INVASION; DISEASE	Liver metastasis is the major cause of death associated to colorectal cancer. Cadherin-17 (CDH17) is a non-classical, seven domain, cadherin lacking the conserved cytoplasmic domain of classical cadherins. CDH17 was overexpressed in highly metastatic human KM12SM and present in many other colorectal cancer cells. Using tissue microarrays, we observed a significant association between high expression of CDH17 with liver metastasis and poor survival of the patients. On the basis of these findings, we decided to study cellular functions and signaling mechanisms mediated by CDH17 in cancer cells. In this report, loss-of-function experiments demonstrated that CDH17 caused a significant increase in KM12SM cell adhesion and proliferation. Coimmunoprecipitation experiments demonstrated an interaction between CDH17 and alpha 2 beta 1 integrin with a direct effect on beta 1 integrin activation and talin recruitment. The formation of this complex, together with other proteins, was confirmed by mass spectrometry analysis. CDH17 modulated integrin activation and signaling to induce specific focal adhesion kinase and Ras activation, which led to the activation of extracellular signal-regulated kinase and Jun N-terminal kinase and the increase in cyclin D1 and proliferation. In vivo experiments showed that CDH17 silencing in KM12 cells suppressed tumor growth and liver metastasis after subcutaneous or intrasplenic inoculation in nude mice. Collectively, our data reveal a new function for CDH17, which is to regulate alpha 2 beta 1 integrin signaling in cell adhesion and proliferation in colon cancer cells for liver metastasis.	[Bartolome, R. A.; Barderas, R.; Torres, S.; Mendes, M.; Casal, J. I.] CSIC, CIB, Dept Cellular & Mol Med, Madrid 28040, Spain; [Fernandez-Acenero, M. J.] Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain; [Garcia-Foncillas, J.] Fdn Jimenez Diaz, Dept Oncol, Madrid, Spain; [Lopez-Lucendo, M.] CSIC, CIB, Prote Core Facil, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Casal, JI (corresponding author), CSIC, CIB, Dept Cellular & Mol Med, Ramiro De Maeztu 9, Madrid 28040, Spain.	icasal@cib.csic.es	Barderas, Rodrigo/K-3560-2014; Casal, Ignacio/M-2312-2014; Mendes, Marta L/P-4062-2018; Mendes, Marta/AAM-9766-2021; Aceñero, M Jesús Fernández/ABC-5904-2020; Bartolome, Ruben A/M-1873-2014	Barderas, Rodrigo/0000-0003-3539-7469; Casal, Ignacio/0000-0003-1085-2840; Mendes, Marta L/0000-0002-3528-7123; Mendes, Marta/0000-0002-3528-7123; Aceñero, M Jesús Fernández/0000-0002-2439-3553; J, Garcia-Foncillas/0000-0002-7591-8006; Bartolome, Ruben A/0000-0002-3292-1491	Asociacion Espanola Contra el Cancer (AECC); JAE-DOC/FSE Contract (CSIC); Ramon y Cajal program; ProteoRed; Juan de la Cierva program; Spanish Ministry of Science and Innovation [BIO2009-08818]; Comunidad de Madrid [S2010/BMD-2344/ Colomics2]	Asociacion Espanola Contra el Cancer (AECC); JAE-DOC/FSE Contract (CSIC); Ramon y Cajal program(Spanish Government); ProteoRed; Juan de la Cierva program; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comunidad de Madrid(Comunidad de Madrid)	We thank Prof John M Luk (Hong Kong University) by the kind supply of CDH17 antibody. RA Bartolome was supported by a grant to established research groups of the Asociacion Espanola Contra el Cancer (AECC). R Barderas was a recipient of a JAE-DOC/FSE Contract (CSIC) and is currently a fellow of the Ramon y Cajal program. S Torres was a recipient of a ProteoRed contract and Juan de la Cierva program. This research was supported by grant BIO2009-08818 from the Spanish Ministry of Science and Innovation, grant to established research groups (AECC) and grant S2010/BMD-2344/ Colomics2 from Comunidad de Madrid.	Barderas R, 2012, CANCER RES, V72, P2780, DOI 10.1158/0008-5472.CAN-11-4090; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; Canonici A, 2008, INT J CANCER, V122, P572, DOI 10.1002/ijc.23164; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Elzagheid A, 2006, WORLD J GASTROENTERO, V12, P4304, DOI 10.3748/wjg.v12.i27.4304; Gessner R, 2000, ANN NY ACAD SCI, V915, P136; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Hintermann E, 2005, J BIOL CHEM, V280, P8004, DOI 10.1074/jbc.M406301200; Kreft B, 1997, J CELL BIOL, V136, P1109, DOI 10.1083/jcb.136.5.1109; Kwak JM, 2007, DIS COLON RECTUM, V50, P1873, DOI 10.1007/s10350-007-9034-1; Lawson C, 2012, J CELL BIOL, V196, P223, DOI 10.1083/jcb.201108078; Lee NP, 2010, BBA-REV CANCER, V1806, P138, DOI 10.1016/j.bbcan.2010.05.002; Liu LX, 2009, HEPATOLOGY, V50, P1453, DOI 10.1002/hep.23143; Luque-Garcia JL, 2010, PROTEOMICS, V10, P940, DOI 10.1002/pmic.200900441; Marchio S, 2012, EMBO MOL MED, V4, P1156, DOI 10.1002/emmm.201101164; MORIKAWA K, 1988, CANCER RES, V48, P1943; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Park JH, 2011, HISTOPATHOLOGY, V58, P316, DOI 10.1111/j.1365-2559.2011.03746.x; Paschos KA, 2009, CELL SIGNAL, V21, P665, DOI 10.1016/j.cellsig.2009.01.006; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Streuli CH, 2009, J CELL SCI, V122, P171, DOI 10.1242/jcs.018945; Su MC, 2008, MODERN PATHOL, V21, P1379, DOI 10.1038/modpathol.2008.107; Takamura M, 2004, CANCER LETT, V212, P253, DOI 10.1016/j.canlet.2004.03.016; Takamura M, 2003, CANCER SCI, V94, P425, DOI 10.1111/j.1349-7006.2003.tb01459.x; Weinberg RA, 2007, BIOL CANC; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wendeler MW, 2006, CELL MOL LIFE SCI, V63, P1564, DOI 10.1007/s00018-006-6014-x; Wendeler MW, 2007, J MOL BIOL, V370, P220, DOI 10.1016/j.jmb.2007.04.062; Wendeler MW, 2004, EXP CELL RES, V294, P345, DOI 10.1016/j.yexcr.2003.11.022; Wong BW, 2003, BIOCHEM BIOPH RES CO, V311, P618, DOI 10.1016/j.bbrc.2003.10.032; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; Yu QF, 2010, J CANCER RES CLIN, V136, P1641, DOI 10.1007/s00432-010-0822-y	41	75	79	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1658	1669		10.1038/onc.2013.117	http://dx.doi.org/10.1038/onc.2013.117			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604127				2022-12-17	WOS:000334344700006
J	Do, TV; Xiao, F; Bickel, LE; Klein-Szanto, AJ; Pathak, HB; Hua, X; Howe, C; O'Brien, SW; Maglaty, M; Ecsedy, JA; Litwin, S; Golemis, EA; Schilder, RJ; Godwin, AK; Connolly, DC				Do, T-V; Xiao, F.; Bickel, L. E.; Klein-Szanto, A. J.; Pathak, H. B.; Hua, X.; Howe, C.; O'Brien, S. W.; Maglaty, M.; Ecsedy, J. A.; Litwin, S.; Golemis, E. A.; Schilder, R. J.; Godwin, A. K.; Connolly, D. C.			Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion	ONCOGENE			English	Article						Aurora kinase A; SRC; ovarian cancer; migration; alisertib; adhesion	SMALL-MOLECULE INHIBITOR; SUPPRESSES TUMOR-GROWTH; A KINASE; ANTITUMOR-ACTIVITY; IN-VIVO; OVEREXPRESSION; CARCINOMA; METASTASIS; ACTIVATION; EXPRESSION	Aurora kinase A (AURKA) localizes to centrosomes and mitotic spindles where it mediates mitotic progression and chromosomal stability. Overexpression of AURKA is common in cancer, resulting in acquisition of alternate non-mitotic functions. In the current study, we identified a novel role for AURKA in regulating ovarian cancer cell dissemination and evaluated the efficacy of an AURKA-selective small molecule inhibitor, alisertib (MLN8237), as a single agent and combined with paclitaxel using an orthotopic xenograft model of epithelial ovarian cancer (EOC). Ovarian carcinoma cell lines were used to evaluate the effects of AURKA inhibition and overexpression on migration and adhesion. Pharmacological or RNA interference-mediated inhibition of AURKA significantly reduced ovarian carcinoma cell migration and adhesion and the activation-associated phosphorylation of the cytoskeletal regulatory protein SRC at tyrosine 416 (pSRC(Y416)). Conversely, enforced expression of AURKA resulted in increased migration, adhesion and activation of SRC in cultured cells. In vivo tumor growth and dissemination were inhibited by alisertib treatment as a single agent. Moreover, combination of alisertib with paclitaxel, an agent commonly used in treatment of EOC, resulted in more potent inhibition of tumor growth and dissemination compared with either drug alone. Taken together, these findings support a role for AURKA in EOC dissemination by regulating migration and adhesion. They also point to the potential utility of combining AURKA inhibitors with taxanes as a therapeutic strategy for the treatment of EOC patients.	[Do, T-V; Xiao, F.; Bickel, L. E.; Pathak, H. B.; Howe, C.; Schilder, R. J.; Godwin, A. K.; Connolly, D. C.] Fox Chase Canc Ctr, Womens Canc Program, Philadelphia, PA 19111 USA; [Do, T-V; Pathak, H. B.; Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Xiao, F.; O'Brien, S. W.; Maglaty, M.; Golemis, E. A.; Connolly, D. C.] Fox Chase Canc Ctr, Dev Therapeut Program, Philadelphia, PA 19111 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; [Hua, X.] Fox Chase Canc Ctr, Transgen Facil, Philadelphia, PA 19111 USA; [Ecsedy, J. A.] Millennium Pharmaceut Inc, Dept Translat Med, Cambridge, MA USA; [Litwin, S.] Fox Chase Canc Ctr, Biostat Facil, Philadelphia, PA 19111 USA; [Schilder, R. J.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; [Schilder, R. J.] Thomas Jefferson Univ, Dept Gynecol Med Oncol, Philadelphia, PA 19107 USA	Fox Chase Cancer Center; University of Kansas; University of Kansas Medical Center; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Fox Chase Cancer Center; Fox Chase Cancer Center; Jefferson University	Connolly, DC (corresponding author), Fox Chase Canc Ctr, Dev Therapeut Program, 333 Cottman Ave,W310, Philadelphia, PA 19111 USA.	Denise.Connolly@fccc.edu		Golemis, Erica/0000-0003-3618-3673	State of Pennsylvania; Fox Chase Cancer Center; Ovarian Cancer Research Fund Program of Excellence Award; Ovarian SPORE [P50 CA083638]; Fox Chase Cancer Center Core Grant [NCI P30 CA006927];  [R01 CA136596];  [R01 CA63366];  [R01 CA140323]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052027] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA063366, R01CA136596, P30CA006927, P30CA056036, P50CA083638, R01CA140323] Funding Source: NIH RePORTER	State of Pennsylvania; Fox Chase Cancer Center; Ovarian Cancer Research Fund Program of Excellence Award; Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fox Chase Cancer Center Core Grant; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Dr Maureen Murphy and Dr Timothy Yen for helpful discussions and critical review of this manuscript. We also thank Dr Maureen Murphy for providing access to the Guava EasyCyte system, and Dr Greg Enders for providing access to the Nikon Eclipse microscope. This work was supported by R01 CA136596, Tobacco Settlement funding from the State of Pennsylvania and Fox Chase Cancer Center via institutional support of the Keystone Program in Personalized Risk and Prevention (to DCC); Ovarian Cancer Research Fund Program of Excellence Award (to TVD); Ovarian SPORE P50 CA083638 (Project 4 to DCC, AKG and EAG and Pilot Award to TVD); R01 CA63366 (to EAG); R01 CA140323 (to AKG); and the Fox Chase Cancer Center Core Grant NCI P30 CA006927. The following Fox Chase Cancer Facilities were used: Laboratory Animal, Transgenic, Cell Culture, Biological Imaging, Histopathology, Biosample Repository and Biostatistics and Bioinformatics.	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chung CM, 2005, MOL CARCINOGEN, V43, P165, DOI 10.1002/mc.20098; Connolly DC, 2003, CANCER RES, V63, P1389; Connolly DC, 2009, CURR PROTOC PHARM, V45; Do TV, 2007, MOL CANCER RES, V5, P121, DOI 10.1158/1541-7786.MCR-06-0319; Feki A, 2009, CRIT REV ONCOL HEMAT, V72, P1, DOI 10.1016/j.critrevonc.2008.12.003; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Hsu LC, 2005, INT J CANCER, V113, P746, DOI 10.1002/ijc.20633; Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Komlodi-Pasztor E, 2012, CLIN CANCER RES, V18, P51, DOI 10.1158/1078-0432.CCR-11-0999; Landen CN, 2007, CLIN CANCER RES, V13, P4098, DOI 10.1158/1078-0432.CCR-07-0431; Lassmann S, 2007, CLIN CANCER RES, V13, P4083, DOI 10.1158/1078-0432.CCR-06-2775; Lassus H, 2011, GYNECOL ONCOL, V120, P11, DOI 10.1016/j.ygyno.2010.09.003; Lin YG, 2008, CLIN CANCER RES, V14, P5437, DOI 10.1158/1078-0432.CCR-07-4922; Luker KE, 2008, ANTIVIR RES, V78, P179, DOI 10.1016/j.antiviral.2008.01.158; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Matsuo K, 2010, ARCH GYNECOL OBSTET, V281, P325, DOI 10.1007/s00404-009-1121-1; Mazumdar A, 2009, HEAD NECK-J SCI SPEC, V31, P625, DOI 10.1002/hed.21007; Mortlock A, 2005, CURR TOP MED CHEM, V5, P199, DOI 10.2174/1568026053507651; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Payton M, 2010, CANCER RES, V70, P9846, DOI 10.1158/0008-5472.CAN-10-3001; Pugacheva EN, 2006, CELL CYCLE, V5, P384, DOI 10.4161/cc.5.4.2439; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Ratushny V, 2012, ONCOGENE, V31, P1217, DOI 10.1038/onc.2011.314; Reiter R, 2006, CLIN CANCER RES, V12, P5136, DOI 10.1158/1078-0432.CCR-05-1650; Shimomura T, 2010, MOL CANCER THER, V9, P157, DOI 10.1158/1535-7163.MCT-09-0609; Swift S., 2001, CURRENT PROTOCOLS IM; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tanaka E, 2007, CLIN CANCER RES, V13, P1331, DOI 10.1158/1078-0432.CCR-06-1192; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tatsuka M, 2005, ONCOGENE, V24, P1122, DOI 10.1038/sj.onc.1208293; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Wan XB, 2008, CARCINOGENESIS, V29, P1930, DOI 10.1093/carcin/bgn176; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Wysong DR, 2009, CELL CYCLE, V8, P876, DOI 10.4161/cc.8.6.7897; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang H, 2012, EUR ARCH OTO-RHINO-L, V269, P607, DOI 10.1007/s00405-011-1629-4	52	75	76	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					539	549		10.1038/onc.2012.632	http://dx.doi.org/10.1038/onc.2012.632			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334327	Green Accepted			2022-12-17	WOS:000331125100002
J	Li, N; Zoubeidi, A; Beraldi, E; Gleave, ME				Li, N.; Zoubeidi, A.; Beraldi, E.; Gleave, M. E.			GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer	ONCOGENE			English	Article						ER stress; GRP78; clusterin; cancer; retrotranslocation; apoptosis	UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; CELL-SURVIVAL; N-GLYCANASE; INDUCED APOPTOSIS; OXIDATIVE STRESS; CHAPERONE GRP78; EXPRESSION; GENE; SUPPRESSION	Expression of clusterin (CLU) closely correlates with the regulation of apoptosis in cancer. Although endoplasmic reticulum (ER) stress-induced upregulation and retrotranslocation of cytoplasmic CLU (presecretory (psCLU) and secreted (sCLU) forms) has been linked to its anti-apoptotic properties, mechanisms mediating these processes remain undefined. Here, we show using human prostate cancer cells that GRP78 (Bip) associates with CLU under ER stress conditions to facilitate its retrotranslocation and redistribution to the mitochondria. Many ER stress inducers, including thapsigargin, MG132 or paclitaxel, increased expression levels of GRP78 and CLU, as well as post-translationally modified hypoglycosylated CLU forms. ER stress increased association between GRP78 and CLU, which led to increased cytoplasmic CLU levels, while reducing sCLU levels secreted into the culture media. GRP78 stabilized CLU protein and its hypoglycosylated forms, in particular after paclitaxel treatment. Moreover, subcellular fractionation and confocal microscopy with CLUGFP indicated that GRP78 increased stress-induced CLU retrotranslocation from the ER with co-localized redistribution to the mitochondria, thereby reducing stress-induced apoptosis by cooperatively stabilizing mitochondrial membrane integrity. GRP78 silencing reduced CLU protein, but not mRNA levels, and enhanced paclitaxel-induced cell apoptosis. Taken together, these findings reveal novel dynamic interactions between GRP78 and CLU under ER stress conditions that govern CLU trafficking and redistribution to the mitochondria, elucidating how GRP78 and CLU cooperatively promote survival during treatment stress in prostate cancer. Oncogene (2013) 32, 1933-1942; doi:10.1038/onc.2012.212; published online 11 June 2012	[Li, N.; Zoubeidi, A.; Beraldi, E.; Gleave, M. E.] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC V5Z 3J5, Canada	University of British Columbia	Gleave, ME (corresponding author), Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, 2660 Oak St, Vancouver, BC V5Z 3J5, Canada.	m.gleave@ubc.ca		Gleave, Martin/0000-0003-4235-0167				Afshar N, 2005, MOL CELL BIOL, V25, P8844, DOI 10.1128/MCB.25.20.8844-8853.2005; Ammar H, 2008, J BIOL CHEM, V283, P12851, DOI 10.1074/jbc.M800403200; Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Blom D, 2004, EMBO J, V23, P650, DOI 10.1038/sj.emboj.7600090; Carver JA, 2003, IUBMB LIFE, V55, P661, DOI 10.1080/15216540310001640498; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Gleave M, 2005, WORLD J UROL, V23, P38, DOI 10.1007/s00345-004-0474-0; Graves TK, 2001, J CELL SCI, V114, P3685; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Hirsch C, 2003, EMBO J, V22, P1036, DOI 10.1093/emboj/cdg107; Kapron JT, 1997, PROTEIN SCI, V6, P2120; Katiyar S, 2005, MOL BIOL CELL, V16, P4584, DOI 10.1091/mbc.E05-04-0345; Kim N, 2012, J CELL PHYSIOL, V227, P1157, DOI 10.1002/jcp.22836; Lamoureux F, 2011, CANCER RES, V71, P5838, DOI 10.1158/0008-5472.CAN-11-0994; Lee DH, 2011, BIOCHEM BIOPH RES CO, V408, P541, DOI 10.1016/j.bbrc.2011.04.054; Leung SYL, 2000, PROSTATE, V44, P156, DOI 10.1002/1097-0045(20000701)44:2<156::AID-PROS8>3.0.CO;2-8; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Miyake H, 2000, CANCER RES, V60, P2547; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Nizard P, 2007, TRAFFIC, V8, P554, DOI 10.1111/j.1600-0854.2007.00549.x; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Shental-Bechor D, 2009, CURR OPIN STRUC BIOL, V19, P524, DOI 10.1016/j.sbi.2009.07.002; Shiota M, 2011, MOL CANCER RES, V9, P1755, DOI 10.1158/1541-7786.MCR-11-0379; Shu CV, 2008, J CELL PHYSIOL, V215, P627, DOI 10.1002/jcp.21340; Stanley P., 2009, ESSENTIALS GLYCOBIOL, V1; Sun FC, 2006, BIOCHEM J, V396, P31, DOI 10.1042/BJ20051916; Suzuki T, 2007, ARCH BIOCHEM BIOPHYS, V468, P1, DOI 10.1016/j.abb.2007.09.004; Trougakos IP, 2009, ADV CANCER RES, V104, P171, DOI 10.1016/S0065-230X(09)04009-3; Trougakos IP, 2009, CLIN CANCER RES, V15, P48, DOI 10.1158/1078-0432.CCR-08-1805; Trougakos IP, 2009, CANCER RES, V69, P403, DOI 10.1158/0008-5472.CAN-08-2912; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139; Wacker I, 1997, J CELL SCI, V110, P1453; Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yerbury JJ, 2005, BIOCHEMISTRY-US, V44, P10914, DOI 10.1021/bi050764x; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zoubeidi A, 2010, CLIN CANCER RES, V16, P1088, DOI 10.1158/1078-0432.CCR-09-2917; Zoubeidi A, 2010, MOL CANCER RES, V8, P119, DOI 10.1158/1541-7786.MCR-09-0277	49	75	77	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 11	2013	32	15					1933	1942		10.1038/onc.2012.212	http://dx.doi.org/10.1038/onc.2012.212			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22689054				2022-12-17	WOS:000317599900007
J	Fan, S; Niu, Y; Tan, N; Wu, Z; Wang, Y; You, H; Ke, R; Song, J; Shen, Q; Wang, W; Yao, G; Shu, H; Lin, H; Yao, M; Zhang, Z; Gu, J; Qin, W				Fan, S.; Niu, Y.; Tan, N.; Wu, Z.; Wang, Y.; You, H.; Ke, R.; Song, J.; Shen, Q.; Wang, W.; Yao, G.; Shu, H.; Lin, H.; Yao, M.; Zhang, Z.; Gu, J.; Qin, W.			LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump	ONCOGENE			English	Article						breast cancer; LASS2; V-ATPase; acidic tumor microenvironment; multidrug resistance	RESISTANT CELL-LINES; DRUG-RESISTANCE; ANTICANCER AGENTS; P-GLYCOPROTEIN; H+-ATPASES; KAPPA-B; EXPRESSION; LYSOSOMES; APOPTOSIS; THERAPY	A main obstacle to overcome during the treatment of tumors is drug resistance to chemotherapy; emerging studies indicate that a key factor contributing to this problem is the acidic tumor microenvironment. Here, we found that LASS2 expression was significantly lower in drug-resistant Michigan Cancer Foundation-7/adriamycin (MCF-7/ADR) human breast cancer cells than the drug-sensitive MCF-7 cells, and low expression of LASS2 was associated with poor prognosis in patients with breast cancer. Our results showed that the overexpression of LASS2 in MCF-7/ADR cells increased the chemosensitivity to multiple chemotherapeutic agents, including doxorubicin (Dox), whereas LASS2 knockdown in MCF-7 cells decreased the chemosensitivity. Cell-cycle analysis revealed a corresponding increase in apoptosis in the LASS2-overexpressing cells following Dox exposure, showing that the overexpression of LASS2 increased the susceptibility to Dox cytotoxicity. This effect was mediated by a significant increase in pH(e) (extracellular pH) and lysosomal pH, and more Dox entered the cells and stayed in the nuclei of cells. In nude mice, the combination of LASS2 overexpression and Dox significantly inhibited the growth of xenografts. Our findings suggest that LASS2 is involved in chemotherapeutic outcomes and low LASS2 expression may predict chemoresistance. Oncogene ( 2013) 32, 1682-1690; doi:10.1038/onc.2012.183; published online 14 May 2012	[Fan, S.; Niu, Y.; Wu, Z.; You, H.; Ke, R.; Song, J.; Shen, Q.; Wang, W.; Yao, G.; Shu, H.; Lin, H.; Zhang, Z.; Gu, J.; Qin, W.] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai 200032, Peoples R China; [Fan, S.] Jiangsu Normal Univ, Sch Life Sci, Dept Biotechnol, Xuzhou, Peoples R China; [Tan, N.] Guangdong Med Coll, Key Lab Med Mol Diag, Zhanjiang, Guangdong, Peoples R China; [Wang, Y.] Xuzhou Med Coll, Affiliated City Hosp, Dept Oncol, Xuzhou, Peoples R China; [Yao, M.] Shanghai Jiao Tong Univ, Sch Med, Dept Expt Pathol, Shanghai Canc Inst,Renji Hosp, Shanghai 200032, Peoples R China	Shanghai Jiao Tong University; Jiangsu Normal University; Guangdong Medical University; Xuzhou Medical University; Shanghai Jiao Tong University	Qin, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, 25-2200 Xietu Rd, Shanghai 200032, Peoples R China.	wxqin@sjtu.edu.cn	Ke, Rough/AAM-9687-2021; niu, yd/C-5030-2009	Niu, Yongdong/0000-0002-5392-3736; Fan, Shaohua/0000-0003-1878-5902; Zhang, Zhi-gang/0000-0001-8965-223X	National Key Basic Research Program of China [2009CB521803]; National Key Sci-Tech Special Project of China [2012ZX10002011-004]; National Natural Science Foundation of China [30973492, 81030038]	National Key Basic Research Program of China(National Basic Research Program of China); National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful to Shenglin Huang, Jun Li and Jie Chen for the kind suggestions and technical assistance. This work was supported by grants from the National Key Basic Research Program of China ( 2009CB521803), National Key Sci-Tech Special Project of China (2012ZX10002011-004) and National Natural Science Foundation of China (30973492 and 81030038).	Andreetta C, 2009, ANN ONCOL, V20, P265, DOI 10.1093/annonc/mdn592; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; COLEY HM, 1993, BRIT J CANCER, V67, P1316, DOI 10.1038/bjc.1993.244; Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802; Dai Y, 2009, AM J TRANSL RES, V1, P1; De Milito A, 2007, CANCER RES, V67, P5408, DOI 10.1158/0008-5472.CAN-06-4095; Ding J, 2010, NAT CELL BIOL, V12, P390, DOI 10.1038/ncb2039; Erez-Roman R, 2010, BIOCHEM BIOPH RES CO, V391, P219, DOI 10.1016/j.bbrc.2009.11.035; Fais S, 2007, CANCER RES, V67, P10627, DOI 10.1158/0008-5472.CAN-07-1805; Furu M, 2011, ONCOGENE, V30, P4015, DOI 10.1038/onc.2011.108; Generali D, 2006, ENDOCR-RELAT CANCER, V13, P921, DOI 10.1677/erc.1.01216; GERVASONI JE, 1991, CANCER RES, V51, P4955; Gerweck LE, 1996, CANCER RES, V56, P1194; Gong YP, 2003, J BIOL CHEM, V278, P50234, DOI 10.1074/jbc.M306606200; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Jiffar T, 2011, ONCOGENE, V30, P3163, DOI 10.1038/onc.2011.39; Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58; Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X; Lou PJ, 2006, INT J CANCER, V119, P2692, DOI 10.1002/ijc.22098; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; MA LD, 1992, BIOCHEM BIOPH RES CO, V182, P675, DOI 10.1016/0006-291X(92)91785-O; Mahoney BP, 2003, BIOCHEM PHARMACOL, V66, P1207, DOI 10.1016/S0006-2952(03)00467-2; National Comprehensive Cancer Network, 2011, NCCN CLIN PRACT GUID; Ottewell PD, 2008, JNCI-J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240; Ouar Z, 2003, BIOCHEM J, V370, P185, DOI 10.1042/BJ20021411; Pan H, 2001, GENOMICS, V77, P58, DOI 10.1006/geno.2001.6614; Petrangolini G, 2006, J PHARMACOL EXP THER, V318, P939, DOI 10.1124/jpet.106.103481; Raghunand N, 1999, BRIT J CANCER, V80, P1005, DOI 10.1038/sj.bjc.6690455; Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P1047, DOI 10.1016/S0006-2952(99)00021-0; Rojas JD, 2006, AM J PHYSIOL-HEART C, V291, pH1147, DOI 10.1152/ajpheart.00166.2006; Schiffmann S, 2009, CARCINOGENESIS, V30, P745, DOI 10.1093/carcin/bgp061; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Thussbas C, 2006, J CLIN ONCOL, V24, P3747, DOI 10.1200/JCO.2005.04.8587; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Wojtkowiak JW, 2011, MOL PHARMACEUT, V8, P2032, DOI 10.1021/mp200292c; Wulfing P, 2004, BRIT J CANCER, V91, P434, DOI 10.1038/sj.bjc.6601889; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; You HY, 2009, CANCER LETT, V280, P110, DOI 10.1016/j.canlet.2009.02.023; Zhao YJ, 2011, HEPATOLOGY, V53, P493, DOI 10.1002/hep.24079	45	75	78	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1682	1690		10.1038/onc.2012.183	http://dx.doi.org/10.1038/onc.2012.183			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22580606				2022-12-17	WOS:000316855800008
J	Gulzar, ZG; McKenney, JK; Brooks, JD				Gulzar, Z. G.; McKenney, J. K.; Brooks, J. D.			Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1	ONCOGENE			English	Article						prostate cancer; gene-expression profiling; NuSAP; E2F1; recurrence	GENE-EXPRESSION; PROGNOSTIC BIOMARKERS; BINDING PROTEIN-3; BREAST-CANCER; PROLIFERATION; SURVIVAL; REVEALS; OVEREXPRESSION; IDENTIFICATION; PROGRESSION	Increasing evidence suggests that prostate cancer is overdiagnosed and overtreated, and prognostic biomarkers would aid in treatment selection. To define prognostic biomarkers for aggressive prostate cancer, we carried out gene-expression profiling of 98 prostate tumors and 52 benign adjacent prostate tissue samples with detailed clinical annotation. We identified 28 transcripts significantly associated with recurrence after radical prostatectomy including NuSAP, a protein that binds DNA to the mitotic spindle. Elevated NuSAP transcript levels were associated with poor outcome in two independent prostate cancer gene-expression datasets. To characterize the role and regulation of NuSAP in prostate cancer, we studied the expression of NuSAP in the LNCaP and PC3 human prostate cancer cell lines. Posttranscriptional silencing of the NuSAP gene severely hampered the ability of PC3 to invade and proliferate in vitro. The promoter region of the NuSAP gene contains two CCAAT boxes and binding sites for E2F. Transient transfection of an E2F1 cDNA and 431 bp of the NuSAP promoter demonstrated E2F1 as an important regulator of expression. Deletion of the E2F-binding site at nucleotide -246 negated the effects of E2F1 on NuSAP expression. Electrophoretic mobility shift assays demonstrated that nuclear extracts of cells overexpressing E2F1 bound directly to the E2F-binding site in the NuSAP promoter region. Finally, immunohistochemistry showed a strong correlation between E2F1 and NuSAP expression in human prostate cancer samples. NuSAP is a novel biomarker for prostate cancer recurrence after surgery and its overexpression appears to be driven in part by E2F1 activation. Oncogene (2013) 32, 70-77; doi:10.1038/onc.2012.27; published online 20 February 2012	[Gulzar, Z. G.; Brooks, J. D.] Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA; [McKenney, J. K.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Brooks, JD (corresponding author), Stanford Univ, Dept Urol, Sch Med, Room S287,300 Pasteur Dr, Stanford, CA 94305 USA.	jdbrooks@stanford.edu			NIH [CA112016, CA111782, CA130472]; Department of Defense [W81XWH-11-1-0447]; NATIONAL CANCER INSTITUTE [F32CA130472, R01CA112016, R01CA111782] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was funded by the NIH (CA112016, CA111782 and CA130472 to JDB) and the Department of Defense (W81XWH-11-1-0447 to JDB).	Abraham JE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2629; Adamo B, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2852; Amemiya H, 2010, INVEST CLIN, V51, P369; Aune G, 2011, GYNECOL ONCOL, V121, P402, DOI 10.1016/j.ygyno.2010.12.355; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chotteau-Lelievre A, 2004, CLIN CANCER RES, V10, P7297, DOI 10.1158/1078-0432.CCR-04-0593; Davis JN, 2006, CANCER RES, V66, P11897, DOI 10.1158/0008-5472.CAN-06-2497; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Engers R, 2007, ENDOCR-RELAT CANCER, V14, P245, DOI 10.1677/ERC-06-0036; Freedland SJ, 2005, JAMA-J AM MED ASSOC, V294, P433, DOI 10.1001/jama.294.4.433; Fujiwara T, 2006, BRIT J HAEMATOL, V135, P583, DOI 10.1111/j.1365-2141.2006.06340.x; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Gorter A, 2010, MODERN PATHOL, V23, P1605, DOI 10.1038/modpathol.2010.154; Helfenstein A, 2004, AM J CLIN PATHOL, V122, P912, DOI 10.1309/G638TKNNG2CJUXWL; Hussain S, 2009, J CELL BIOL, V186, P27, DOI 10.1083/jcb.200810180; Iyer J, 2011, CELL SIGNAL, V23, P991, DOI 10.1016/j.cellsig.2010.11.006; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kim YH, 2009, METHODS MOL BIOL, V556, P21, DOI 10.1007/978-1-60327-192-9_3; Kosari F, 2008, CLIN CANCER RES, V14, P1734, DOI 10.1158/1078-0432.CCR-07-1494; Lammers L A, 2010, Br J Cancer, V103, P765, DOI 10.1038/sj.bjc.6605800; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; LaTulippe E, 2002, CANCER RES, V62, P4499; Luo J, 2001, CANCER RES, V61, P4683; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Malhotra S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020293; Miyata Y, 2004, UROLOGY, V63, P1184, DOI 10.1016/j.urology.2004.02.015; Monge M, 2009, CARCINOGENESIS, V30, P1288, DOI 10.1093/carcin/bgp119; Murphy AJ, 2007, CANCER RES, V67, P2893, DOI 10.1158/0008-5472.CAN-06-2962; Mustjoki S, 2009, HAEMATOL-HEMATOL J, V94, P1469, DOI 10.3324/haematol.2009.008094; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Rodriguez-Enriquez S, 2011, J CELL BIOCHEM, V112, P2703, DOI 10.1002/jcb.23224; Roobol MJ, 2009, EUR UROL, V56, P584, DOI 10.1016/j.eururo.2009.07.018; Schrader C, 2005, BRIT J CANCER, V93, P939, DOI 10.1038/sj.bjc.6602795; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Setoguchi T, 2011, CANCER SCI, V102, P883, DOI 10.1111/j.1349-7006.2011.01872.x; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Sherlock G, 2001, NUCLEIC ACIDS RES, V29, P152, DOI 10.1093/nar/29.1.152; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Vanden Bosch A, 2010, J CELL SCI, V123, P3244, DOI 10.1242/jcs.063875; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; von Euler H, 2011, VET COMP ONCOL, V9, P1, DOI 10.1111/j.1476-5829.2010.00238.x; Wadia PP, 2010, BLOOD, V115, P2077, DOI 10.1182/blood-2009-03-211375; Welsh JB, 2001, CANCER RES, V61, P5974; Wong N, 2009, INT J CANCER, V124, P644, DOI 10.1002/ijc.23968; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yuan RH, 2007, CLIN CANCER RES, V13, P5368, DOI 10.1158/1078-0432.CCR-07-1113	51	75	80	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					70	77		10.1038/onc.2012.27	http://dx.doi.org/10.1038/onc.2012.27			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22349817	Green Accepted			2022-12-17	WOS:000313029500007
J	Angus, L; Moleirinho, S; Herron, L; Sinha, A; Zhang, X; Niestrata, M; Dholakia, K; Prystowsky, MB; Harvey, KF; Reynolds, PA; Gunn-Moore, FJ				Angus, L.; Moleirinho, S.; Herron, L.; Sinha, A.; Zhang, X.; Niestrata, M.; Dholakia, K.; Prystowsky, M. B.; Harvey, K. F.; Reynolds, P. A.; Gunn-Moore, F. J.			Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP	ONCOGENE			English	Article						Willin/FRMD6; Expanded; Hippo pathway; ezrin; merlin	ORGAN SIZE CONTROL; CELL CONTACT INHIBITION; TUMOR-SUPPRESSOR; DROSOPHILA; GROWTH; PROLIFERATION; PROTEIN; APOPTOSIS; REGULATOR; UPSTREAM	The Salvador/Warts/Hippo (Hippo) signaling pathway defines a novel signaling cascade regulating cell contact inhibition, organ size control, cell growth, proliferation, apoptosis and cancer development in mammals. The Drosophila melanogaster protein Expanded acts in the Hippo signaling pathway to control organ size. Previously, willin/FRMD6 has been proposed as the human orthologue of Expanded. Willin lacks C-terminal sequences that are present in Expanded and, to date, little is known about the functional role of willin in mammalian cells. When willin is expressed in D. melanogaster epithelial tissues, it has the same subcellular localization as Expanded, but cannot rescue growth defects associated with expanded deficiency. However, we show that ectopic willin expression causes an increase in phosphorylation of the core Hippo signaling pathway components MST1/2, LATS1 and YAP, an effect that can be antagonized by ezrin. In MCF10A cells, loss of willin expression displays epithelial-to-mesenchymal transition features and willin overexpression antagonizes YAP activity via the N-terminal FERM domain of willin. Therefore, in mammalian cells willin influences Hippo signaling activity by activating the core Hippo pathway kinase cassette. Oncogene (2012) 31, 238-250; doi:10.1038/onc.2011.224; published online 13 June 2011	[Angus, L.; Moleirinho, S.; Herron, L.; Gunn-Moore, F. J.] Univ St Andrews, Sch Biol, St Andrews KY16 9TF, Fife, Scotland; [Moleirinho, S.; Niestrata, M.; Reynolds, P. A.] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland; [Sinha, A.; Zhang, X.; Harvey, K. F.] Peter MacCallum Canc Ctr, Cell Growth & Proliferat Lab, Melbourne, Vic, Australia; [Sinha, A.; Zhang, X.; Harvey, K. F.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Dholakia, K.] Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9TF, Fife, Scotland; [Prystowsky, M. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA	University of St Andrews; University of St Andrews; Peter Maccallum Cancer Center; University of Melbourne; University of St Andrews; Yeshiva University; Albert Einstein College of Medicine	Gunn-Moore, FJ (corresponding author), Univ St Andrews, Sch Biol, Med & Biol Sci Bldg, St Andrews KY16 9TF, Fife, Scotland.	fjg1@st-and.ac.uk	Herron, Lissa/C-7780-2013; Harvey, Kieran/AAD-5268-2022	Dholakia, Kishan/0000-0001-6534-9009; Reynolds, Paul/0000-0001-8738-1245; Harvey, Kieran/0000-0001-7845-369X; Herron, Lissa/0000-0001-9961-4421; Gunn-Moore, Francis James/0000-0003-3422-3387	BBSRC; EPSRC; Scottish University Life Science Alliance; International Human Frontier Science Program Organization; National Health and Medical Research Council of Australia; Melbourne International Research Scholarship; Fee Remission Scholarship	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Scottish University Life Science Alliance; International Human Frontier Science Program Organization(Human Frontier Science Program); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Melbourne International Research Scholarship; Fee Remission Scholarship	We thank P Burke for embryo injections and N Chang for technical assistance. We also thank the BBSRC and EPSRC for funding to LA; Scottish University Life Science Alliance for funding to SM. KFH holds Career Development Awards from the International Human Frontier Science Program Organization and the National Health and Medical Research Council of Australia and a Project Grant from the National Health and Medical Research Council of Australia. AS holds Melbourne International Research and Fee Remission Scholarships.	Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Bennett FC, 2006, CURR BIOL, V16, P2101, DOI 10.1016/j.cub.2006.09.045; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Gunn-Moore FJ, 2005, FEBS LETT, V579, P5089, DOI 10.1016/j.febslet.2005.07.097; Haase D, 2007, ONCOGENE, V26, P4464, DOI 10.1038/sj.onc.1210225; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Mao YP, 2011, DEVELOPMENT, V138, P947, DOI 10.1242/dev.057166; Milton CC, 2010, DEVELOPMENT, V137, P735, DOI 10.1242/dev.042309; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Silva E, 2006, CURR BIOL, V16, P2081, DOI 10.1016/j.cub.2006.09.004; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tyler DM, 2007, DEV BIOL, V305, P187, DOI 10.1016/j.ydbio.2007.02.004; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	35	75	77	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					238	250		10.1038/onc.2011.224	http://dx.doi.org/10.1038/onc.2011.224			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666719	Green Submitted			2022-12-17	WOS:000299307400009
J	Morris, LGT; Veeriah, S; Chan, TA				Morris, L. G. T.; Veeriah, S.; Chan, T. A.			Genetic determinants at the interface of cancer and neurodegenerative disease	ONCOGENE			English	Review						tumor suppressor; neurodegeneration; cancer; PARK2	AMYLOID-PRECURSOR-PROTEIN; TUMOR-SUPPRESSOR GENE; RECESSIVE JUVENILE PARKINSONISM; ACUTE LYMPHOBLASTIC-LEUKEMIA; DEPENDENT KINASE INHIBITORS; NERVOUS-SYSTEM DEVELOPMENT; MITOGEN-ACTIVATED PROTEIN; AGGREGATE-PRONE PROTEINS; DNA-DAMAGING AGENTS; ATAXIA-TELANGIECTASIA	It has been hypothesized that oncogenesis and neurodegeneration may share common mechanistic foundations. Recent evidence now reveals a number of genes in which alteration leads to either carcinogenesis or neurodegeneration, depending on cellular context. Pathways that have emerged as having critical roles in both cancer and neurodegenerative disease include those involving genes such as PARK2, ATM, PTEN, PTPRD, and mTOR. A number of mechanisms have been implicated, and commonly affected cellular processes include cell cycle regulation, DNA repair, and response to oxidative stress. For example, we have recently shown that the E3 ubiquitin ligase PARK2 is mutated or deleted in many different human malignancies and helps drive loss on chromosome 6q25.2-27, a genomic region frequently deleted in cancers. Mutation in PARK2 is also the most common cause of juvenile Parkinson's disease. Mutations in PARK2 result in an upregulation of its substrate cyclin E, resulting in dysregulated entry into the cell cycle. In neurons, this process results in cell death, but in cycling cells, the result is a growth advantage. Thus, depending on whether the cell affected is a dividing cell or a post-mitotic neuron, responses to these alterations may differ, ultimately leading to varying disease phenotypes. Here, we review the substantial data implicating specific genes in both cancer and neurodegenerative disease. Oncogene (2010) 29, 3453-3464; doi:10.1038/onc.2010.127; published online 26 April 2010	[Morris, L. G. T.; Veeriah, S.; Chan, T. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Morris, L. G. T.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA; [Chan, T. A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Chan, T. A.] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chan, TA (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave,Box 20, New York, NY 10065 USA.	chant@mskcc.org	Chan, Timothy A/ABD-5850-2021		Head and Neck Service, Department of Surgery at Memorial Sloan-Kettering Cancer Center; National Cancer Institute [T32 CA009685]; Doris Duke Charitable Foundation; Society of Memorial Sloan-Kettering Foundation; Flight Attendant Medical Research Institute; Louis Gerstner Foundation; Memorial Sloan-Kettering Brain Tumor Center; STARR Cancer Consortium; NATIONAL CANCER INSTITUTE [T32CA009685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS086875] Funding Source: NIH RePORTER	Head and Neck Service, Department of Surgery at Memorial Sloan-Kettering Cancer Center; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Society of Memorial Sloan-Kettering Foundation; Flight Attendant Medical Research Institute; Louis Gerstner Foundation; Memorial Sloan-Kettering Brain Tumor Center; STARR Cancer Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the Head and Neck Service, Department of Surgery at Memorial Sloan-Kettering Cancer Center for support (LGTM). LGTM is supported by National Cancer Institute T32 Grant CA009685. TAC is supported by the Doris Duke Charitable Foundation, the Society of Memorial Sloan-Kettering Foundation, the Flight Attendant Medical Research Institute, the Louis Gerstner Foundation, the Memorial Sloan-Kettering Brain Tumor Center, and the STARR Cancer Consortium.	Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Ackman JB, 2007, DEV NEUROSCI-BASEL, V29, P113, DOI 10.1159/000096216; Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Anandatheerthavarada HK, 2007, NEUROSCIENTIST, V13, P626, DOI 10.1177/1073858407303536; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Arvidsson Y, 2008, ENDOCR-RELAT CANCER, V15, P569, DOI 10.1677/ERC-07-0145; Auclair Y, 2008, P NATL ACAD SCI USA, V105, P17896, DOI 10.1073/pnas.0801585105; Baldus CD, 2004, P NATL ACAD SCI USA, V101, P3915, DOI 10.1073/pnas.0400272101; Ball LG, 2005, ACTA PHARMACOL SIN, V26, P897, DOI 10.1111/j.1745-7254.2005.00165.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Berger Z, 2006, HUM MOL GENET, V15, P433, DOI 10.1093/hmg/ddi458; Bixby JL, 2000, NEUROREPORT, V11, pR5, DOI 10.1097/00001756-200007140-00001; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 1996, J NEURAL TRANSM, V103, P455, DOI 10.1007/BF01276421; BRION JP, 1995, AM J PATHOL, V147, P1465; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Cairns P, 1997, CANCER RES, V57, P4997; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Chan TA, 2009, CELL CYCLE, V8, P3063, DOI 10.4161/cc.8.19.9455; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Cheng GJ, 2002, EXP NEUROL, V175, P407, DOI 10.1006/exnr.2002.7920; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Connor JR, 2003, NEUROLOGY, V61, P304, DOI 10.1212/01.WNL.0000078887.16593.12; Corti O, 2005, CR BIOL, V328, P131, DOI 10.1016/j.crvi.2004.10.009; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Den Hertog J, 1999, INT J DEV BIOL, V43, P723; Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FARINA L, 1994, J COMPUT ASSIST TOMO, V18, P724, DOI 10.1097/00004728-199409000-00008; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Fegan C, 1995, LEUKEMIA, V9, P2003; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Gakhar-Koppole N, 2008, EUR J NEUROSCI, V28, P871, DOI 10.1111/j.1460-9568.2008.06398.x; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gegg ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004756; Giardina SF, 2002, BRIT J PHARMACOL, V135, P1733, DOI 10.1038/sj.bjp.0704636; Gispert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005777; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x; Gronbaek K, 1998, BLOOD, V91, P4388; Gumy-Pause F, 2006, LEUKEMIA, V20, P526, DOI 10.1038/sj.leu.2404091; Hampe C, 2006, HUM MOL GENET, V15, P2059, DOI 10.1093/hmg/ddl131; Hansel DE, 2003, CANCER RES, V63, P7032; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Huynh DP, 2007, EXP NEUROL, V203, P531, DOI 10.1016/j.expneurol.2006.09.009; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Inglis KJ, 2009, J BIOL CHEM, V284, P2598, DOI 10.1074/jbc.C800206200; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; Inzelberg R, 2007, NEUROLOGY, V69, P1542, DOI 10.1212/01.wnl.0000277638.63767.b8; Ishiguro M, 1998, MOL BRAIN RES, V53, P24, DOI 10.1016/S0169-328X(97)00280-5; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Kerr F, 2006, FEBS LETT, V580, P3121, DOI 10.1016/j.febslet.2006.04.064; Kim RH, 2006, BRIT J CANCER, V94, P620, DOI 10.1038/sj.bjc.6602994; Kim RH, 2005, P NATL ACAD SCI USA, V102, P5215, DOI 10.1073/pnas.0501282102; Kim SK, 1998, ONCOGENE, V16, P89, DOI 10.1038/sj.onc.1201512; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Ko SY, 2004, INT J CANCER, V111, P727, DOI 10.1002/ijc.20328; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Krause K, 2008, J ENDOCRINOL, V198, P291, DOI 10.1677/JOE-08-0005; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Lewis KA, 2005, CANCER RES, V65, P7091, DOI 10.1158/0008-5472.CAN-05-1019; Liang YL, 2009, WORLD J SURG, V33, P661, DOI 10.1007/s00268-008-9840-1; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lovestone S, 1997, NEUROSCIENCE, V78, P309; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marino S, 2002, DEVELOPMENT, V129, P3513; Matrone C, 2008, J ALZHEIMERS DIS, V13, P81; Matsumoto T, 2009, P NATL ACAD SCI USA, V106, P14542, DOI 10.1073/pnas.0904229106; Mavrou A, 2008, ANTICANCER RES, V28, P401; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Milne RL, 2009, GENOME MED, V1, DOI 10.1186/gm12; MOLLER H, 1995, BRIT MED J, V310, P1500, DOI 10.1136/bmj.310.6993.1500; Moore DJ, 2008, J NEUROCHEM, V105, P1806, DOI 10.1111/j.1471-4159.2008.05261.x; MORRELL D, 1986, J NATL CANCER I, V77, P89; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Nishimura I, 2003, EXP CELL RES, V286, P241, DOI 10.1016/S0014-4827(03)00066-1; Nouspikel T, 2003, BIOESSAYS, V25, P168, DOI 10.1002/bies.10227; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; O'Driscoll M, 2006, CELL CYCLE, V5, P2339, DOI 10.4161/cc.5.20.3358; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Olsen JH, 2005, BRIT J CANCER, V92, P201, DOI 10.1038/sj.bjc.6602279; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1997, J NEUROSCI, V17, P8975; PARKER WD, 1991, ANN NY ACAD SCI, V640, P59; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Pridgeon JW, 2007, PLOS BIOL, V5, P1494, DOI 10.1371/journal.pbio.0050172; Prokopcova J, 2007, BREAST CANCER RES TR, V104, P121, DOI 10.1007/s10549-006-9406-6; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Rao KS, 2007, NAT CLIN PRACT NEURO, V3, P162, DOI 10.1038/ncpneuro0448; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Ravikumar Brinda, 2006, Molecular Aspects of Medicine, V27, P520, DOI 10.1016/j.mam.2006.08.008; Ravikumar Brinda, 2008, V445, P195, DOI 10.1007/978-1-59745-157-4_13; Rawal N, 2009, BIOCHEM BIOPH RES CO, V388, P473, DOI 10.1016/j.bbrc.2009.07.014; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Rickle A, 2006, NEUROCHEM INT, V48, P114, DOI 10.1016/j.neuint.2005.08.014; Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schmitz A, 2002, HISTOCHEM CELL BIOL, V117, P171, DOI 10.1007/s00418-001-0351-5; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shineman DW, 2009, BIOCHEMISTRY-US, V48, P3787, DOI 10.1021/bi802070j; Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272; Sriram SR, 2005, HUM MOL GENET, V14, P2571, DOI 10.1093/hmg/ddi292; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Staropoli JF, 2008, BIOESSAYS, V30, P719, DOI 10.1002/bies.20784; Stein TD, 2002, J NEUROSCI, V22, P7380; Stepanek L, 2005, J NEUROSCI, V25, P3813, DOI 10.1523/JNEUROSCI.4531-04.2005; SWIFT M, 1986, AM J HUM GENET, V39, P573; Tabira T, 2002, FRONT BIOSCI-LANDMRK, V7, pA44, DOI 10.2741/tabira; Tanaka K, 2001, J MOL MED, V79, P482, DOI 10.1007/s001090100242; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Toma MI, 2008, NEOPLASIA, V10, P634, DOI 10.1593/neo.08160; Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040; Uetani N, 2000, EMBO J, V19, P2775, DOI 10.1093/emboj/19.12.2775; Uetani N, 2006, J NEUROSCI, V26, P5872, DOI 10.1523/JNEUROSCI.0386-06.2006; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Wang T, 2009, J CELL BIOL, V186, P703, DOI 10.1083/jcb.200904090; Wei WL, 2002, J BIOL CHEM, V277, P17649, DOI 10.1074/jbc.M111704200; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; WONG KK, 2009, CURR OPIN GENET DEV; Xavier AC, 2009, J MOL DIAGN, V11, P371, DOI 10.2353/jmoldx.2009.080132; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang H, 2007, J NEUROIMMUNE PHARM, V2, P276, DOI 10.1007/s11481-007-9082-2; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhu Y, 2006, APOPTOSIS, V11, P197, DOI 10.1007/s10495-006-3714-5; Zighelboim I, 2009, J CLIN ONCOL, V27, P3091, DOI 10.1200/JCO.2008.19.9802	162	75	81	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2010	29	24					3453	3464		10.1038/onc.2010.127	http://dx.doi.org/10.1038/onc.2010.127			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20418918	Green Accepted			2022-12-17	WOS:000278835400001
J	Gao, Y; Yao, A; Zhang, W; Lu, S; Yu, Y; Deng, L; Yin, A; Xia, Y; Sun, B; Wang, X				Gao, Y.; Yao, A.; Zhang, W.; Lu, S.; Yu, Y.; Deng, L.; Yin, A.; Xia, Y.; Sun, B.; Wang, X.			Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice	ONCOGENE			English	Article						mesenchymal stem cells; PEDF; lentiviral vectors; hepatocellular carcinoma; angiogenesis	LUNG METASTASIS MODEL; GENE-THERAPY; TARGETED-DELIVERY; FACTOR EXPRESSION; PROSTATE-CANCER; INTERFERON-BETA; TUMOR STROMA; IN-VITRO; ANGIOGENESIS; GROWTH	The poor outcome of cancer gene therapy in clinical trials relates in part to insufficient gene delivery to tumor sites. Mesenchymal stem cells (MSCs) represent a new tool for the delivery of therapeutic agents to tumor cells. This study used an orthotopic nude mice model of hepatocellular carcinoma (HCC) to evaluate the potential of genetically modified human MSCs (hMSCs), to function as an effective delivery vehicle for therapeutic genes. hMSCs derived from the bone marrow were efficiently engineered to express human pigment epithelium-derived factor (PEDF) by lentiviral transduction, then tested in vitro for high-level expression and bioactivity of the transgenic protein. The preferential homing of hMSCs toward HCC was confirmed by in vitro and in vivo migration assays. in vivo efficacy experiments showed that intravenous (i.v.) injection of PEDF-expressing hMSCs significantly suppressed both the growth of primary liver tumors and the development of pulmonary metastases. Moreover, hMSCs-based PEDF gene delivery moderately increased the systemic levels of human PEDF. Immunohistochemistry of primary liver tumors demonstrated lower microvessel density in mice treated with hMSCs-PEDF than in control mice. This is the first study to show the potential of hMSCs as an effective delivery vehicle for therapeutic genes in the treatment of HCC. Oncogene (2010) 29, 2784-2794; doi: 10.1038/onc.2010.38; published online 1 March 2010	[Wang, X.] Nanjing Med Univ, Liver Transplantat Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; Nanjing Med Univ, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Wang, X (corresponding author), Nanjing Med Univ, Liver Transplantat Ctr, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.	sunbc@njmu.edu.cn; wangxh@njmu.edu.cn			Jiangsu Province's Outstanding Medical Academic Leader program [RC2007057]; Jiangsu Province's Key Medical Centre [2006-50]; Natural Science Foundation of China [30672367, 30772003]; Ministry of Health, China [Wkj2006-2-021]; New Century Excellent Talents in University; Ministry of Education	Jiangsu Province's Outstanding Medical Academic Leader program; Jiangsu Province's Key Medical Centre; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Health, China; New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Ministry of Education	This study was supported by grants from Jiangsu Province's Outstanding Medical Academic Leader program (RC2007057 to BS and YG), Jiangsu Province's Key Medical Centre (2006-50 to XW) and grants from the Natural Science Foundation of China (30672367 and 30772003 to BS), Ministry of Health, China (Wkj2006-2-021 to BS), New Century Excellent Talents in University, the Ministry of Education (To BS).	Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; Cai J, 2006, CLIN CANCER RES, V12, P3510, DOI 10.1158/1078-0432.CCR-06-0094; Chang CJ, 2007, HEPATOLOGY, V45, P746, DOI 10.1002/hep.21560; Chen QR, 2001, MOL GENET METAB, V74, P120, DOI 10.1006/mgme.2001.3223; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Ek ETH, 2007, CANCER GENE THER, V14, P616, DOI 10.1038/sj.cgt.7701044; Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744; Fritz V, 2008, CURR STEM CELL RES T, V3, P32, DOI 10.2174/157488808783489462; GAO Yun, 2009, Zhonghua Gan Zang Bing Za Zhi, V17, P363; Garcia M, 2004, CANCER RES, V64, P5632, DOI 10.1158/0008-5472.CAN-04-0230; Guan M, 2003, J CLIN PATHOL, V56, P277, DOI 10.1136/jcp.56.4.277; Halin S, 2004, CANCER RES, V64, P5664, DOI 10.1158/0008-5472.CAN-04-0835; HARALABOPOULOS GC, 1994, LAB INVEST, V71, P575; Hung SC, 2005, CLIN CANCER RES, V11, P7749, DOI 10.1158/1078-0432.CCR-05-0876; Kanehira M, 2007, CANCER GENE THER, V14, P894, DOI 10.1038/sj.cgt.7701079; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kikuchi E, 2004, CLIN CANCER RES, V10, P1835, DOI 10.1158/1078-0432.CCR-03-0099; Komarova S, 2006, MOL CANCER THER, V5, P755, DOI 10.1158/1535-7163.MCT-05-0334; Lau WY, 2008, HEPATOB PANCREAT DIS, V7, P237; Lee TK, 2005, CLIN CANCER RES, V11, P8458, DOI 10.1158/1078-0432.CCR-05-0447; Matsumoto K, 2004, HEPATOLOGY, V40, P252, DOI 10.1002/hep.20259; Mittler J, 2008, TRANSPLANTATION, V86, P895, DOI 10.1097/TP.0b013e318186ad7a; Mizuguchi H, 2005, BIOCHEM BIOPH RES CO, V332, P1101, DOI 10.1016/j.bbrc.2005.05.055; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Ou-Yang F, 2006, CANCER RES, V66, P378, DOI 10.1158/0008-5472.CAN-05-1578; Persano L, 2007, MOL ASPECTS MED, V28, P87, DOI 10.1016/j.mam.2006.12.005; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Ren C, 2008, GENE THER, V15, P1446, DOI 10.1038/gt.2008.101; Ren CC, 2008, STEM CELLS, V26, P2332, DOI 10.1634/stemcells.2008-0084; Sotiropoulou PA, 2006, STEM CELLS, V24, P462, DOI 10.1634/stemcells.2004-0331; Streck CJ, 2005, J PEDIATR SURG, V40, P236, DOI 10.1016/j.jpedsurg.2004.09.049; Studeny M, 2004, JNCI-J NATL CANCER I, V96, P1593, DOI 10.1093/jnci/djh299; Studeny M, 2002, CANCER RES, V62, P3603; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; Uehara H, 2004, CANCER RES, V64, P3533, DOI 10.1158/0008-5472.CAN-03-3725; Van Damme A, 2006, STEM CELLS, V24, P896, DOI 10.1634/stemcells.2003-0106; Yang ZF, 2008, ANAT REC, V291, P721, DOI 10.1002/ar.20668; Yoon SK, 2001, CANCER GENE THER, V8, P573, DOI 10.1038/sj.cgt.7700345	40	75	92	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2784	2794		10.1038/onc.2010.38	http://dx.doi.org/10.1038/onc.2010.38			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190814				2022-12-17	WOS:000277591900004
J	Zhang, P; Yang, Y; Nolo, R; Zweidler-McKay, PA; Hughes, DPM				Zhang, P.; Yang, Y.; Nolo, R.; Zweidler-McKay, P. A.; Hughes, D. P. M.			Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness	ONCOGENE			English	Article						NOTCH; HES1; Deltex1(DTX1); osteosarcoma; invasion	UBIQUITIN LIGASE; CELL; ACTIVATION; RECEPTOR; SUPPRESSOR; REPRESSION; PROMOTER; PATHWAY; DOMAIN	The highly conserved NOTCH signaling pathway has many essential functions in the development of diverse cells, tissues and organs from Drosophila to humans, and dysregulated NOTCH signaling contributes to several disorders, including vascular and bone defects, as well as several cancers. Here we describe a novel mechanism of NOTCH regulation by reciprocal inhibition of two NOTCH downstream effectors: Deltex1 and HES1. This mechanism appears to regulate invasion of osteosarcoma cells, as Deltex1 blocks osteosarcoma invasiveness by downregulating NOTCH/HES1 signaling. The inhibitory effect of endogenous Deltex1 on NOTCH signaling is mediated through binding with the intracellular domain of NOTCH and ubiquitination and degradation of NOTCH receptors. Conversely, we show that the NOTCH target gene HES1 causes transcriptional inhibition of Deltex1 by directly binding to the promoter of Deltex1. An HES1 binding site is identified 400 bp upstream of the transcription start site of Deltex1. HES1-mediated repression of Deltex1 requires the C-terminal H3/H4 and WRPW domains of HES1, which associate with the TLE/Groucho corepressors. Taken together, we define a molecular mechanism regulating NOTCH signaling by reciprocal inhibition of the NOTCH target genes HES1 and Deltex1 in mammalian cells. This mechanism may have important clinical implications for targeting NOTCH signaling in osteosarcoma and other cancers. Oncogene (2010) 29, 2916-2926; doi:10.1038/onc.2010.62; published online 8 March 2010	[Zhang, P.; Yang, Y.; Nolo, R.; Zweidler-McKay, P. A.; Hughes, D. P. M.] Univ Texas MD Anderson Canc Ctr, Dept Pediat Res, Childrens Canc Hosp, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hughes, DPM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pediat Res, Childrens Canc Hosp, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dphughes@mdanderson.org		Zweidler-McKay, Patrick/0000-0001-6621-523X	UT MD Anderson Cancer Center; NIH [K08CA118730-04]; Jori Zemel Children's Bone Cancer Foundation; Hope Street Kids Foundation; NATIONAL CANCER INSTITUTE [K08CA118730] Funding Source: NIH RePORTER	UT MD Anderson Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jori Zemel Children's Bone Cancer Foundation; Hope Street Kids Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Tetsuo Sudo, Dr Anders Strom and Dr Iannis Aifantis for providing reagents, and to Dr Shufang Jia and Dr Wendy Fang for technical assistance. This work was supported by Physician Scientist Awards from UT MD Anderson Cancer Center to Dr D Hughes and Dr P Zweidler-McKay and by NIH Grant K08CA118730-04 to Dr Dennis Hughes. Dr P Zhang was supported by the Jori Zemel Children's Bone Cancer Foundation (www.JoriZemel.com) and Hope Street Kids Foundation (www.hopestreetkids.org).	Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Axelson H, 2004, CANCER LETT, V204, P171, DOI 10.1016/S0304-3835(03)00453-1; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Cinnamon E, 2008, CURR OPIN GENET DEV, V18, P435, DOI 10.1016/j.gde.2008.07.010; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Hori K, 2004, DEVELOPMENT, V131, P5527, DOI 10.1242/dev.01448; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Liu WH, 2005, MOL CELL BIOL, V25, P1367, DOI 10.1128/MCB.25.4.1367-1378.2005; Matsuno K, 2002, DEVELOPMENT, V129, P1049; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Mukherjee A, 2005, NAT CELL BIOL, V7, P1191, DOI 10.1038/ncb1327; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilkin M, 2008, DEV CELL, V15, P762, DOI 10.1016/j.devcel.2008.09.002; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078-0432.CCR-07-1992; Zweidler-McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood-2005-01-0355; Zweidler-McKay PA, 2004, SEMIN CANCER BIOL, V14, P329, DOI 10.1016/j.semcancer.2004.04.012; Zweifel ME, 2005, STRUCTURE, V13, P1599, DOI 10.1016/j.str.2005.07.015	30	75	78	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2916	2926		10.1038/onc.2010.62	http://dx.doi.org/10.1038/onc.2010.62			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208568	Green Accepted			2022-12-17	WOS:000277890400003
J	Lenferink, AEG; Cantin, C; Nantel, A; Wang, E; Durocher, Y; Banville, M; Paul-Roc, B; Marcil, A; Wilson, MR; O'Connor-McCourt, MD				Lenferink, A. E. G.; Cantin, C.; Nantel, A.; Wang, E.; Durocher, Y.; Banville, M.; Paul-Roc, B.; Marcil, A.; Wilson, M. R.; O'Connor-McCourt, M. D.			Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies	ONCOGENE			English	Article						TGF-beta; clusterin; EMT; invasion; breast cancer	GROWTH-FACTOR-BETA; BREAST-CANCER METASTASIS; NECROSIS-FACTOR-ALPHA; RENAL-CELL CARCINOMA; MOUSE MAMMARY-TUMOR; RETE TESTIS FLUID; PROSTATE-CANCER; GENE-EXPRESSION; CLUSTERIN/APOLIPOPROTEIN-J; ANTISENSE OLIGONUCLEOTIDE	Transforming growth factor (TGF)-beta plays a dual role in tumorigenesis, switching from acting as a growth inhibitory tumor suppressor early in the process, to a tumor promoter in late-stage disease. Since TGF-beta's prometastatic role may be linked to its ability to induce tumor cell epithelial-to-mesenchymal transition (EMT), we explored TGF-beta's EMT-promoting pathways by analysing the transcriptome changes occurring in BRI-JM01 mammary tumor epithelial cells undergoing a TGF-beta-induced EMT. We found the clusterin gene to be the most highly upregulated throughout most of the TGF-beta time course, and showed that this results in an increase of the secreted form of clusterin. By monitoring several hallmark features of EMT, we demonstrated that antibodies targeting secreted clusterin inhibit the TGF-beta-induced EMT of BRI-JM01 cells, as well as the invasive phenotype of several other breast and prostate tumor cell lines (4T1, NMuMG, MDA-MB231LM2 and PC3), without affecting the proliferation of these cells. These results indicate that secreted clusterin is a functionally important EMT mediator that lies downstream within TGF-beta's EMT-promoting transcriptional cascade, but not within its growth-inhibitory pathways. To further investigate the role played by secreted clusterin in tumor metastasis, we assessed the effect of several anti-clusterin monoclonal antibodies in vivo using a 4T1 syngeneic mouse breast cancer model and found that these antibodies significantly reduce lung metastasis. Taken together, our results reveal a role for secreted clusterin as an important extracellular promoter of EMT, and suggest that antibodies targeting clusterin may inhibit tumor metastasis without reducing the beneficial growth inhibitory effects of TGF-beta. Oncogene (2010) 29, 831-844; doi:10.1038/onc.2009.399; published online 23 November 2009	[Lenferink, A. E. G.; Cantin, C.; Banville, M.; Paul-Roc, B.; O'Connor-McCourt, M. D.] Natl Res Council Canada, Receptor Signaling & Prote Grp, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; [Nantel, A.; Marcil, A.] Natl Res Council Canada, Biotechnol Res Inst, Genet Grp, Montreal, PQ H4P 2R2, Canada; [Wang, E.] Natl Res Council Canada, Biotechnol Res Inst, Computat Chem & Biol Grp, Montreal, PQ H4P 2R2, Canada; [Durocher, Y.] Natl Res Council Canada, Biotechnol Res Inst, Anim Cell Culture Technol Grp, Montreal, PQ H4P 2R2, Canada; [Wilson, M. R.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia	National Research Council Canada; National Research Council Canada; National Research Council Canada; National Research Council Canada; University of Wollongong	Lenferink, AEG (corresponding author), Natl Res Council Canada, Receptor Signaling & Prote Grp, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	anne.lenferink@cnrc-nrc.gc.ca	Wilson, Mark R/B-3254-2018; Wang, Edwin/Y-1553-2019; Durocher, Yves/K-8709-2019	Wilson, Mark R/0000-0002-9551-7445; Marcil, Anne/0000-0002-4111-1781				Al Moustafa AE, 1999, BIOTECHNIQUES, V27, P60; Ammar H, 2008, J BIOL CHEM, V283, P12851, DOI 10.1074/jbc.M800403200; Andersen CL, 2007, MOL CELL PROTEOMICS, V6, P1039, DOI 10.1074/mcp.M600261-MCP200; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Chi KN, 2005, J NATL CANCER I, V97, P1287, DOI 10.1093/jnci/dji252; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chou TY, 2009, CELL SIGNAL, V21, P704, DOI 10.1016/j.cellsig.2009.01.008; Cochrane DR, 2007, J BIOL CHEM, V282, P2278, DOI 10.1074/jbc.M608162200; DALAL BI, 1993, AM J PATHOL, V143, P381; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enjalbert B, 2003, MOL BIOL CELL, V14, P1460, DOI 10.1091/mbc.E02-08-0546; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; Gleave ME, 2001, UROLOGY, V58, P39, DOI 10.1016/S0090-4295(01)01241-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Hunakova L, 2009, NEOPLASMA, V56, P548, DOI 10.4149/neo_2009_06_548; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; Jo H, 2008, MOL CELL BIOL, V28, P4285, DOI 10.1128/MCB.01240-07; Jo M, 2009, J BIOL CHEM, V284, P22825, DOI 10.1074/jbc.M109.023960; Lakins JN, 2002, BIOCHEMISTRY-US, V41, P282, DOI 10.1021/bi0157666; Lau SH, 2006, ONCOGENE, V25, P1242, DOI 10.1038/sj.onc.1209141; Lee KB, 2008, BIOCHEM BIOPH RES CO, V366, P905, DOI 10.1016/j.bbrc.2007.12.033; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Lenferink AE, 2004, BREAST CANCER RES, V6, pR514, DOI 10.1186/bcr907; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Lou YM, 2008, DEV DYNAM, V237, P2755, DOI 10.1002/dvdy.21658; MATSUBARA M, 1991, INVEST OPHTH VIS SCI, V32, P3221; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miyake H, 2000, CANCER RES, V60, P2547; Miyake H, 2002, J UROLOGY, V167, P2203, DOI 10.1016/S0022-5347(05)65129-4; Miyake H, 2002, J UROLOGY, V167, P703, DOI 10.1016/S0022-5347(01)69130-4; Moretti RM, 2007, CANCER RES, V67, P10325, DOI 10.1158/0008-5472.CAN-07-0516; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nam JS, 2008, CANCER RES, V68, P3915, DOI 10.1158/0008-5472.CAN-08-0206; Nam JS, 2006, CANCER RES, V66, P6327, DOI 10.1158/0008-5472.CAN-06-0068; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Park DC, 2008, NEOPLASIA, V10, P964, DOI 10.1593/neo.08604; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Poon S, 2002, FEBS LETT, V513, P259, DOI 10.1016/S0014-5793(02)02326-8; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Santilli G, 2003, J BIOL CHEM, V278, P38214, DOI 10.1074/jbc.C300252200; Scaltriti M, 2004, BRIT J CANCER, V91, P1842, DOI 10.1038/sj.bjc.6602193; Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sintich SM, 1999, PROSTATE, V39, P87; So A, 2005, MOL CANCER THER, V4, P1837, DOI 10.1158/1535-7163.MCT-05-0178; So A, 2005, CURR OPIN UROL, V15, P320, DOI 10.1097/01.mou.0000175572.46986.2c; So A, 2005, WORLD J UROL, V23, P1, DOI 10.1007/s00345-004-0473-1; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOM R, 2007, METHODS EXPRESS EXPR, P203; Trougakos IP, 2009, CANCER RES, V69, P403, DOI 10.1158/0008-5472.CAN-08-2912; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Trougakos IP, 2005, FREE RADICAL BIO MED, V38, P436, DOI 10.1016/j.freeradbiomed.2004.10.038; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wegrowski Y, 1999, EXP CELL RES, V247, P475, DOI 10.1006/excr.1998.4378; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934	87	75	86	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	2010	29	6					831	844		10.1038/onc.2009.399	http://dx.doi.org/10.1038/onc.2009.399			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935703				2022-12-17	WOS:000274397800006
J	Sachdev, D; Zhang, X; Matise, I; Gaillard-Kelly, M; Yee, D				Sachdev, D.; Zhang, X.; Matise, I.; Gaillard-Kelly, M.; Yee, D.			The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival	ONCOGENE			English	Article						cancer metastasis; type I IGF receptor; antibodies against IGF1R; invasion; circulating tumor cells; survival	BREAST-CANCER; MONOCLONAL-ANTIBODY; CELLS; VIVO; EXPRESSION; INHIBITOR; COMBINATION; INVOLVEMENT; ACTIVATION; THERAPY	The type I insulin-like growth factor receptor (IGF1R) regulates multiple aspects of malignancy and is the target of several drugs currently in clinical trials. Although the function of IGF1R in proliferation and survival is well studied, the regulation of metastasis by IGF1R is not as clearly delineated. Previous work showed that disruption of IGF1R signaling by overexpression of a dominant-negative IGF1R inhibited metastasis. To establish a clinically applicable approach to inhibition of metastasis by targeting IGF1R, we examined the effect of an inhibitory antibody against IGF1R, EM164 and its humanized version, AVE1642, on metastasis of cancer cells. EM164 and AVE1642 did not affect primary tumor growth of MDA-435A/LCC6 cells but inhibited metastasis of these cells. Consistent with this inhibition in the formation of metastatic nodules, disruption of IGF1R also resulted in a decreased number of circulating tumor cells in blood of tumor-bearing mice. Disruption of IGF1R with a dominant-negative construct or antibody inhibited invasion across Matrigel in vitro. When tumor cells were directly injected into the circulation through the lateral tail vein of mice, IGF1R disruption also resulted in significant reduction of pulmonary nodules, suggesting that regulation of invasion is not the only function of IGF1R signaling. Further, disruption of IGF1R rendered cells more susceptible to anoikis. Thus, IGF1R regulated metastasis independently of tumor growth. The multiple phenotypes regulated by IGF1R must be considered during development of this therapeutic strategy as inhibition of metastasis independent of inhibition of tumor growth is not easily assessed in phase II clinical trials. Oncogene (2010) 29, 251-262; doi:10.1038/onc.2009.316; published online 19 October 2009	[Sachdev, D.; Zhang, X.; Matise, I.; Yee, D.] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA; [Sachdev, D.; Yee, D.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Matise, I.] Univ Minnesota, Dept Vet Clin Sci, St Paul, MN 55108 USA; [Gaillard-Kelly, M.] Sanofi Aventis, Antony, France	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Sanofi-Aventis	Sachdev, D (corresponding author), Univ Minnesota, Mason Canc Ctr, Mayo Mail Code 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	sachd003@umn.edu		Yee, Douglas/0000-0002-3387-4009	NIH [R01 CA074285, P30 CA077598PHS]; National Cancer Institute [P30 CA77398]; Prospect Creek Foundation; NATIONAL CANCER INSTITUTE [R01CA077398, P30CA077598, R01CA074285] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prospect Creek Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge ImmunoGen Inc. for providing us with EM164 and the isotype-matched control antibody (anti-CD20), sanofi-aventis for AVE1642 (the humanized version of EM164), and the National Cell Culture Center (NCCC), a division of Biovest International, Fridley, MN, USA, for producing supernatant containing scFv-Fc from NSO 3b1Fc 1F12 cells in spinner cultures. We thank Nicole Kirchoff and the staff of the Comparative Pathology Shared Resource of the Masonic Cancer Center, University of Minnesota. We thank Sarah Thuriot and Alissa Pelzer for assistance with the care of the mice. We also thank Michael Franklin for editorial assistance. This work was supported by NIH R01 CA074285 (D Yee), NIH P30 CA077598PHS Cancer Center Support Grant P30 CA77398 from the National Cancer Institute and the Prospect Creek Foundation.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Burtrum D, 2003, CANCER RES, V63, P8912; Byron SA, 2006, BRIT J CANCER, V95, P1220, DOI 10.1038/sj.bjc.6603354; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; Dearth RK, 2006, MOL CELL BIOL, V26, P9302, DOI 10.1128/MCB.00260-06; Dunn SE, 1998, CANCER RES, V58, P3353; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Gibson SL, 2007, CELL CYCLE, V6, P631, DOI 10.4161/cc.6.6.3987; Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haluska P, 2006, CANCER RES, V66, P362, DOI 10.1158/0008-5472.CAN-05-1107; Haluska P, 2007, CLIN CANCER RES, V13, P5834, DOI 10.1158/1078-0432.CCR-07-1118; Higano CS, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.08.8146; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karp DD, 2007, J CLIN ONCOL, V25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonessa F, 1996, BRIT J CANCER, V73, P154, DOI 10.1038/bjc.1996.29; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Maloney EK, 2003, CANCER RES, V63, P5073; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagle JA, 2004, MOL CELL BIOL, V24, P9726, DOI 10.1128/MCB.24.22.9726-9735.2004; Norton L, 2006, NAT MED, V12, P875, DOI 10.1038/nm0806-875; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Radisky ES, 2007, REV ENDOCR METAB DIS, V8, P279, DOI 10.1007/s11154-007-9037-1; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Rowinsky EK, 2007, CLIN CANCER RES, V13, p5549S, DOI 10.1158/1078-0432.CCR-07-1109; Sachdev D, 2006, CANCER RES, V66, P2391, DOI 10.1158/0008-5472.CAN-05-3126; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Sachdev D, 2003, CANCER RES, V63, P627; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Tolcher AW, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3582; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P279, DOI 10.1038/bjc.1987.190; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; van Golen CM, 2006, CANCER RES, V66, P6570, DOI 10.1158/0008-5472.CAN-05-1448; Wu JD, 2006, CLIN CANCER RES, V12, P6153, DOI 10.1158/1078-0432.CCR-06-0443; Wu YP, 2003, CANCER RES, V63, P4384; Wu YP, 2002, CANCER RES, V62, P1030; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Zhang XH, 2002, CANCER RES, V62, P4369	52	75	77	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					251	262		10.1038/onc.2009.316	http://dx.doi.org/10.1038/onc.2009.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19838209	Green Accepted			2022-12-17	WOS:000273650000008
J	Su, S; Li, Y; Luo, Y; Sheng, Y; Su, Y; Padia, RN; Pan, ZK; Dong, Z; Huang, S				Su, S.; Li, Y.; Luo, Y.; Sheng, Y.; Su, Y.; Padia, R. N.; Pan, Z. K.; Dong, Z.; Huang, S.			Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration	ONCOGENE			English	Article						PAR2; Src; JNK; paxillin; breast cancer; chemokinesis	N-TERMINAL KINASE; SIGNALING PATHWAY; TYROSINE PHOSPHORYLATION; MDA-MB-231 CELLS; COLON-CANCER; FACTOR VIIA; SRC KINASE; PAXILLIN; PROLIFERATION; GROWTH	Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is G(alpha i)-dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of G(alpha i) to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser(178) phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the G(alpha i)-c-Src-JNK-paxillin signaling pathway. Oncogene (2009) 28, 3047-3057; doi:10.1038/onc.2009.163; published online 22 June 2009	[Padia, R. N.; Huang, S.] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Su, S.; Li, Y.; Su, Y.] Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China; [Luo, Y.] Shuguang Hosp, Dept Surg, Shanghai, Peoples R China; [Sheng, Y.] Second Mil Med Univ, Dept Surg, Shanghai, Peoples R China; [Pan, Z. K.] Med Univ Ohio, Dept Med Microbiol & Immunol, Toledo, OH USA; [Dong, Z.] Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; Shanghai University of Traditional Chinese Medicine; Naval Medical University; University System of Georgia; Augusta University	Huang, S (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	shuang@mcg.edu			MOST of China [2006BAI08B0206]; Shanghai Municipal Science, Technology Commission [06DZ19728]; E-institutes of Shanghai Municipal Education Commission [E 03008]; NIH [CA093926, HL083335]; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524] Funding Source: NIH RePORTER	MOST of China(Ministry of Science and Technology, China); Shanghai Municipal Science, Technology Commission(Science & Technology Commission of Shanghai Municipality (STCSM)); E-institutes of Shanghai Municipal Education Commission; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by MOST of China (2006BAI08B0206) ( SS), Shanghai Municipal Science, Technology Commission (06DZ19728) (SS), E-institutes of Shanghai Municipal Education Commission (E 03008) (SS), NIH Grant CA093926 and HL083335 (SH).	Abdulrahman M, 2007, ONCOGENE, V26, P1661, DOI 10.1038/sj.onc.1209932; Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; Black PC, 2007, PROSTATE, V67, P743, DOI 10.1002/pros.20503; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Caruso R, 2006, AM J PATHOL, V169, P268, DOI 10.2353/ajpath.2006.050841; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Ciccarelli M, 2007, CELL SIGNAL, V19, P1949, DOI 10.1016/j.cellsig.2007.05.007; Cottrell GS, 2003, BIOCHEM SOC T, V31, P1191; D'Andrea MR, 2001, AM J PATHOL, V158, P2031, DOI 10.1016/S0002-9440(10)64675-5; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gallagher ED, 2004, J BIOL CHEM, V279, P1872, DOI 10.1074/jbc.M309525200; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang Z, 2008, CELL SIGNAL, V20, P2002, DOI 10.1016/j.cellsig.2008.07.014; Kimura K, 2008, INVEST OPHTH VIS SCI, V49, P125, DOI 10.1167/iovs.07-0725; Kozasa Tohru, 2003, V237, P153; Liu Y, 2006, BIOCHEM BIOPH RES CO, V344, P1263, DOI 10.1016/j.bbrc.2006.04.005; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Massi D, 2005, HUM PATHOL, V36, P676, DOI 10.1016/j.humpath.2005.04.008; Matej R, 2007, PHYSIOL RES, V56, P475, DOI 10.33549/physiolres.930959; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Nishibori M, 2005, J PHARMACOL SCI, V97, P25, DOI 10.1254/jphs.FMJ04005X5; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Ramachandran R, 2008, BRIT J PHARMACOL, V153, pS263, DOI 10.1038/sj.bjp.0707507; Ruf W, 2006, SEMIN THROMB HEMOST, V32, P61, DOI 10.1055/s-2006-939555; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Sanchez-Hernandez PE, 2008, GYNECOL ONCOL, V108, P19, DOI 10.1016/j.ygyno.2007.08.083; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Shi XL, 2004, MOL CANCER RES, V2, P395; Soreide K, 2006, J PATHOL, V209, P147, DOI 10.1002/path.1999; Su SB, 2001, CLIN CANCER RES, V7, P1320; Su SB, 2001, CLIN CANCER RES, V7, P309; Trejo J, 2003, J PHARMACOL EXP THER, V307, P437, DOI 10.1124/jpet.103.052100; Uusitalo-Jarvinen H, 2007, ARTERIOSCL THROM VAS, V27, P1456, DOI 10.1161/ATVBAHA.107.142539; Versteeg HH, 2008, BLOOD, V111, P190, DOI 10.1182/blood-2007-07-101048; Wang H, 2008, J BIOL CHEM, V283, P809, DOI 10.1074/jbc.M703021200; Wilson SR, 2004, PROSTATE, V60, P168, DOI 10.1002/pros.20047; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yada K, 2005, J SURG ONCOL, V89, P79, DOI 10.1002/jso.20197; Yamauchi J, 2002, FEBS LETT, V527, P284, DOI 10.1016/S0014-5793(02)03231-3	48	75	77	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2009	28	34					3047	3057		10.1038/onc.2009.163	http://dx.doi.org/10.1038/onc.2009.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487ZU	19543320	Green Accepted			2022-12-17	WOS:000269319000004
J	Kang, X; Chen, W; Kim, RH; Kang, MK; Park, NH				Kang, X.; Chen, W.; Kim, R. H.; Kang, M. K.; Park, N-H			Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells	ONCOGENE			English	Article						hTERT; telomerase; GRHL2; hnRNPs; MSH2; oral cancer	TELOMERASE-REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; GENE; EXPRESSION; BINDING; PROTEIN; CANCER; KERATINOCYTES; SP1; CARCINOGENESIS	Higher expression of human telomerase reverse transcriptase (hTERT) and subsequent activation of telomerase occur during cellular immortalization and are maintained in cancer cells. To understand the mode of hTERT expression in cancer cells, we identified cancer-specific trans-regulatory proteins that interact with the hTERT promoter, using the promoter magnetic precipitation assay coupled with mass spectrometry. The identified proteins include MutS homolog 2(MSH2), heterogeneous nuclear ribonucleoprotein (hnRNP) D, hnRNP K and grainyhead-like 2(GRHL2). We noticed a higher expression of these proteins in human oral squamous cell carcinoma (OSCC) cells than in normal cells, which do not exhibit telomerase activity. Knockdown of MSH2, hnRNP D and GRHL2 resulted in a notable reduction of the hTERT promoter activity in tested cancer cells. Silencing of the above genes resulted in a significant reduction of the telomerase activity in OSCC cells. Interestingly, among the four identified genes, silencing of GRHL2 was essential in reducing telomerase activity and viability of tested cancer cells. These results suggest a possible role of GRHL2 in telomerase activation during cellular immortalization.	[Kang, X.; Chen, W.; Kim, R. H.; Kang, M. K.; Park, N-H] Univ Calif Los Angeles, Sch Dent, Ctr Hlth Sci, Los Angeles, CA 90095 USA; [Kim, R. H.; Kang, M. K.; Park, N-H] Univ Calif Los Angeles, Dent Res Inst, Los Angeles, CA 90095 USA; [Kim, R. H.; Kang, M. K.; Park, N-H] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Park, N-H] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kang, MK (corresponding author), Univ Calif Los Angeles, Sch Dent, Ctr Hlth Sci, Room 43-009,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	mkang@dentistry.ucla.edu; nhpark@dentistry.ucla.edu			NIDCR [K22DE15316, R01DE18295, K02DE18959]; NIH; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K02DE018959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014147, R01DE018295, K22DE015316] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr JC Barrett (NIEHS/NIH) for providing the pGL3B-TRTP vector. This study was supported in part by the Grants (K22DE15316, R01DE18295, and K02DE18959 to MKK and R01DE14147 to N-HP) from NIDCR/NIH.	Cairney CJ, 2008, BIOCHIMIE, V90, P13, DOI 10.1016/j.biochi.2007.07.025; Campbell MR, 2006, ONCOGENE, V25, P2531, DOI 10.1038/sj.onc.1209277; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Deng WG, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M610579200; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Fujiki T, 2007, ONCOGENE, V26, P5258, DOI 10.1038/sj.onc.1210331; He C, 2006, EMBO J, V25, P3823, DOI 10.1038/sj.emboj.7601264; Isenmann S, 2007, J BONE MINER RES, V22, P897, DOI 10.1359/JBMR.070308; Kang MK, 2007, BRIT J CANCER, V96, P126, DOI 10.1038/sj.bjc.6603529; Kang MK, 2004, J CELL PHYSIOL, V199, P364, DOI 10.1002/jcp.10410; Kang MK, 1998, CELL GROWTH DIFFER, V9, P85; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim RH, 2007, EXP CELL RES, V313, P462, DOI 10.1016/j.yexcr.2006.10.025; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lebel R, 2007, BIOCHEMISTRY-US, V46, P10279, DOI 10.1021/bi700076m; Lou F, 2007, MOL CANCER RES, V5, P793, DOI 10.1158/1541-7786.MCR-07-0065; Lynch M, 2005, MOL CELL BIOL, V25, P6436, DOI 10.1128/MCB.25.15.6436-6453.2005; Moumen A, 2005, CELL, V123, P1065, DOI 10.1016/j.cell.2005.09.032; Ostareck-Lederer A, 2004, BIOL CELL, V96, P407, DOI 10.1016/j.biolcel.2004.03.010; Ostrowski J, 2004, J BIOL CHEM, V279, P54599, DOI 10.1074/jbc.M406753200; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Roychoudhury P, 2007, BRIT J CANCER, V97, P574, DOI 10.1038/sj.bjc.6603911; Shay JW, 2008, BRIT J CANCER, V98, P677, DOI 10.1038/sj.bjc.6604209; Stramer B, 2005, CURR BIOL, V15, pR425, DOI 10.1016/j.cub.2005.05.034; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilanowski T, 2002, MECH DEVELOP, V114, P37, DOI 10.1016/S0925-4773(02)00046-1; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Yan P, 2001, J PATHOL, V193, P21, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH728>3.0.CO;2-G; Zhu QJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001446	33	75	86	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					565	574		10.1038/onc.2008.404	http://dx.doi.org/10.1038/onc.2008.404			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19015635	Green Accepted			2022-12-17	WOS:000262866500010
J	Ndozangue-Touriguine, O; Sebbagh, M; Merino, D; Micheau, O; Bertoglio, J; Breard, J				Ndozangue-Touriguine, O.; Sebbagh, M.; Merino, D.; Micheau, O.; Bertoglio, J.; Breard, J.			A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma	ONCOGENE			English	Article						TRAIL; colon cancer; metastasis; resistance	CYTOCHROME-C RELEASE; PROTEASOME INHIBITOR BORTEZOMIB; BCL-2 FAMILY-MEMBERS; X-LINKED INHIBITOR; NF-KAPPA-B; CANCER CELLS; MEDIATED APOPTOSIS; TUMOR-METASTASIS; DEATH RECEPTORS; DECOY RECEPTORS	A pair of isogenic colon carcinoma cells, SW480 and 620, was used to investigate the mechanisms of acquired tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistance during tumour progression. Whereas primary tumour SW480 cells are sensitive to TRAIL-induced apoptosis, metastatic SW620 cells are resistant. The apoptotic signalling activated by TRAIL in SW480 cells is a type II pathway. We show that in SW620 cells, although caspase-8 is recruited and activated at the death-inducing-signalling complex and Bid is cleaved, this does not lead to caspase-9 activation. Comparison of Bcl-2, Bcl-xL and Mcl-1 levels in both cell lines showed no difference. In SW620 cells transfected with a tBid-GFP construct, tBid-GFP was correctly localized to the mitochondria. Thus, the resistance of SW620 cells is at the level of the mitochondria that can withstand large amounts of tBid. Although caspase-3 was directly cleaved by caspase-8 in SW620 cells to yield the p20 fragment, no further autocatalytic maturation into the p17 fragment was observed. We show that, in contrast to SW480 cells, the SW620 cell line expresses high amounts of X-linked inhibitor of apoptosis ( XIAP). Downregulation of XIAP with bortezomib or small-interfering RNA was sufficient to restore the sensitivity of SW620 cells to TRAIL-induced apoptosis in the absence of SMAC/Diablo or cytochrome c release from the mitochondria. Thus, SW620 cells have developed a dual resistance to TRAIL-induced apoptosis: a block at the level of the mitochondria and, after a conversion to a type I pathway, an increased expression of XIAP which inhibits this pathway.	[Ndozangue-Touriguine, O.; Bertoglio, J.; Breard, J.] Fac Pharm Chatenay Malabry, INSERM, U749, F-92290 Chatenay Malabry, Hauts Seine, France; [Sebbagh, M.] INSERM, UMR 891, Inst Paoli Calmettes, F-13258 Marseille, Bouches Rhone, France; [Merino, D.; Micheau, O.] INSERM, U866, Dijon, Cote Or, France; [Merino, D.; Micheau, O.] Univ Bourgogne, Dijon, Cote Or, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne	Breard, J (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U749, 5 Rue JB Clement, F-92290 Chatenay Malabry, Hauts Seine, France.	jacqueline.breard@u-psud.fr	Sebbagh, Michael/E-8502-2017; micheau, olivier/C-3574-2011; Merino, Delphine/L-9159-2017	Sebbagh, Michael/0000-0003-2468-7006; micheau, olivier/0000-0001-8499-7984; Merino, Delphine/0000-0002-8075-6275	INSERM; Ligue Nationale contre le Cancer; Olivia Ndozangue-Touriguine; ARC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Olivia Ndozangue-Touriguine; ARC(Australian Research Council)	We thank Valerie Nicolas for her assistance in confocal microscopy and G Ortiz-Ferron for providing FLBid-GFP vector. This work was supported by INSERM and the Ligue Nationale contre le Cancer (equipe labellisee). Olivia Ndozangue-Touriguine was a recipient of a fellowship from the Ministry of Research and Education and is a recipient of an ARC fellowship for her fourth year of PhD.	Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Ceballos-Cancino G, 2007, ONCOGENE, V26, P7569, DOI 10.1038/sj.onc.1210560; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Choi SY, 2007, CELL DEATH DIFFER, V14, P597, DOI 10.1038/sj.cdd.4402020; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; GAGOS S, 1995, ANTICANCER RES, V15, P369; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P659, DOI 10.1038/sj.cdd.4401585; Gonzalvez F, 2005, CELL DEATH DIFFER, V12, P614, DOI 10.1038/sj.cdd.4401571; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grosse-Wilde A, 2008, J CLIN INVEST, V118, P100, DOI 10.1172/JCI33061; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Hewitt RE, 2000, J PATHOL, V192, P446; Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508; Huerta S, 2007, J SURG RES, V142, P184, DOI 10.1016/j.jss.2006.12.551; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kashkar H, 2007, BLOOD, V109, P3982, DOI 10.1182/blood-2006-10-053959; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Koschny R, 2007, CLIN CANCER RES, V13, P6541, DOI 10.1158/1078-0432.CCR-07-1759; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kyritsis AP, 2007, CLIN CANCER RES, V13, P6540, DOI 10.1158/1078-0432.CCR-07-1447; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Liu XG, 2007, CANCER RES, V67, P4981, DOI 10.1158/0008-5472.CAN-06-4274; Lucken-Ardjomande S, 2008, CELL DEATH DIFFER, V15, P484, DOI 10.1038/sj.cdd.4402280; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Menoret E, 2006, BLOOD, V108, P1346, DOI 10.1182/blood-2005-12-007971; Nagy K, 2006, PATHOL ONCOL RES, V12, P133, DOI 10.1007/BF02893359; Nikrad M, 2005, MOL CANCER THER, V4, P443; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ortiz-Ferron G, 2006, CELL DEATH DIFFER, V13, P1857, DOI 10.1038/sj.cdd.4401875; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Ravi R, 2006, CANCER RES, V66, P1730, DOI 10.1158/0008-5472.CAN-05-3377; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Secchiero P, 2004, CELL MOL LIFE SCI, V61, P1965, DOI 10.1007/s00018-004-4197-6; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Sohn D, 2005, J BIOL CHEM, V280, P5267, DOI 10.1074/jbc.M408585200; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Tyurin VA, 2007, CELL DEATH DIFFER, V14, P872, DOI 10.1038/sj.cdd.4402068; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086; Voortman J, 2007, MOL CANCER THER, V6, P2103, DOI 10.1158/1535-7163.MCT-07-0167; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	58	75	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2008	27	46					6012	6022		10.1038/onc.2008.197	http://dx.doi.org/10.1038/onc.2008.197			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18560353				2022-12-17	WOS:000259891600004
J	Leng, X; Lin, H; Ding, T; Wang, Y; Wu, Y; Klumpp, S; Sun, T; Zhou, Y; Monaco, P; Belmont, J; Aderem, A; Akira, S; Strong, R; Arlinghaus, R				Leng, X.; Lin, H.; Ding, T.; Wang, Y.; Wu, Y.; Klumpp, S.; Sun, T.; Zhou, Y.; Monaco, P.; Belmont, J.; Aderem, A.; Akira, S.; Strong, R.; Arlinghaus, R.			Lipocalin 2 is required for BCR-ABL-induced tumorigenesis	ONCOGENE			English	Article						lipocalin 2; CML; tumorigenesis; BCR-ABL; apoptosis	GELATINASE-ASSOCIATED LIPOCALIN; CHRONIC MYELOGENOUS LEUKEMIA; NGAL; MICE; INDUCTION; CANCER; INFECTION; APOPTOSIS; COMPLEX; GROWTH	Our previous studies indicate that reduction of lipocalin 2 (mouse 24p3) expression by either anti-sense or siRNA approaches strongly reduces the overgrowth of BCR-ABL + mouse myeloid 32D in marrow and spleen of NOD/SCID mice. In this study, we used the mouse bone marrow transplant model to further explore the role of 24p3 in BCR-ABL-induced leukemia. Consistent with our previous findings, when using non-irradiated mice as recipient, donor marrow cells expressing BCR-ABL but lacking 24p3 did not cause leukemia or any disease after 75 days, whereas all mice receiving wild type BCR-ABL donor cells died with CML-like disease. An agar clone of the BCR-ABL + human CML cell line K562 (C5) that secretes relatively high levels of lipocalin 2 (human NGAL) induced suppression of hematopoiesis in spleen and marrow of mice, leading to early death in contrast to parental K562 or K562 clone (C6) expressing low amounts of NGAL. Compared with K562 cells, overexpressing NGAL in K562 led to a higher apoptosis rate and an atrophy phenotype in the spleen of the inoculated mice. Plasma from both leukemic mice and CML patients showed elevated lipocalin 2 levels compared with healthy individuals. Moreover, we found that a primary stable cell line from wild-type mouse marrow cells expressing BCR-ABL caused solid tumors in nude mice whereas a similar BCR-ABL + cell line from 24p3 null mice did not. These findings demonstrate that lipocalin 2 has at least two functions related to tumorigenesis, one involving apoptosis induction of normal hematopoietic cells and the other being tissue invasion by leukemia cells.	[Leng, X.; Lin, H.; Ding, T.; Wang, Y.; Sun, T.; Zhou, Y.; Arlinghaus, R.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; [Wu, Y.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Klumpp, S.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med, Houston, TX 77030 USA; [Monaco, P.; Belmont, J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Aderem, A.] Inst Syst Biol, Seattle, WA USA; [Akira, S.] Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Osaka, Japan; [Akira, S.] Japan Sci & Technol Corp, Exploratory Res Adv Technol ERAYO, Osaka, Japan; [Strong, R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Institute for Systems Biology (ISB); Osaka University; Japan Science & Technology Agency (JST); Fred Hutchinson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 7435 Fannin St,Unit 951, Houston, TX 77030 USA.	rarlingh@mdanderson.org	Belmont, John W/AAI-2494-2019; Akira, Shizuo/C-3134-2009; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NIH [PO1 CA49639]; NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We also want to thank Dr Bastinaella Perazzona for critically reading the paper. This research was supported in part by a grant from NIH (PO1 CA49639).	BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Berger T, 2006, P NATL ACAD SCI USA, V103, P1834, DOI 10.1073/pnas.0510847103; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Devireddy LR, 2005, CELL, V123, P1293, DOI 10.1016/j.cell.2005.10.027; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Flower DR, 1996, BIOCHEM J, V318, P1; Furutani M, 1998, CANCER LETT, V122, P209, DOI 10.1016/S0304-3835(97)00391-1; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Guo JQ, 2002, LEUKEMIA, V16, P2447, DOI 10.1038/sj.leu.2402730; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lim R, 2007, INT J CANCER, V120, P2426, DOI 10.1002/ijc.22352; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Lin H, 2005, ONCOGENE, V24, P3246, DOI 10.1038/sj.onc.1208500; Miharada K, 2005, FASEB J, V19, P1881, DOI 10.1096/fj.05-3809fje; Miharada K, 2008, J CELL PHYSIOL, V215, P526, DOI 10.1002/jcp.21334; Nieborowska-Skorska M, 2006, CANCER RES, V66, P4108, DOI 10.1158/0008-5472.CAN-05-1584; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Rudd PM, 1999, BIOCHEMISTRY-US, V38, P13937, DOI 10.1021/bi991162e; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4; Zhang HH, 2007, J CLIN PATHOL, V60, P555, DOI 10.1136/jcp.2006.039297	26	75	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2008	27	47					6110	6119		10.1038/onc.2008.209	http://dx.doi.org/10.1038/onc.2008.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18663364	Green Accepted			2022-12-17	WOS:000260083100004
J	Hernandez, JM; Floyd, DH; Weilbaecher, KN; Green, PL; Boris-Lawrie, K				Hernandez, J. M.; Floyd, D. H.; Weilbaecher, K. N.; Green, P. L.; Boris-Lawrie, K.			Multiple facets of junD gene expression are atypical among AP-1 family members	ONCOGENE			English	Review						JunD; AP-1; RNA helicase A and post-transcriptional control element; HTLV-1; cancer; heart failure	RNA HELICASE-A; LEUKEMIA-VIRUS TYPE-1; EXON JUNCTION COMPLEX; HUMAN OVARIAN-CANCER; C-JUN; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVITY; DNA-BINDING; TUMOR-SUPPRESSOR; ACTIVATED TRANSCRIPTION	JunD is a versatile AP-1 transcription factor that can activate or repress a diverse collection of target genes. Precise control of junD expression and JunD protein protein interactions modulate tumor angiogenesis, cellular differentiation, proliferation and apoptosis. Molecular and clinical knowledge of two decades has revealed that precise JunD activity is elaborated by interrelated layers of constitutive transcriptional control, complex post-transcriptional regulation and a collection of post-translational modi. cations and protein-protein interactions. The stakes are high, as inappropriate JunD activity contributes to neoplastic, metabolic and viral diseases. This article deconvolutes multiple layers of control that safeguard junD gene expression and functional activity. The activity of JunD in transcriptional activation and repression is integrated into a regulatory network by which JunD exerts a pivotal role in cellular growth control. Our discussion of the JunD regulatory network integrates important open issues and posits new therapeutic targets for the neoplastic, metabolic and viral diseases associated with JunD/AP-1 expression.	[Boris-Lawrie, K.] Ohio State Univ, Dept Vet Biosci, Goss Lab, Columbus, OH 43210 USA; [Floyd, D. H.; Weilbaecher, K. N.] Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; [Green, P. L.; Boris-Lawrie, K.] Ohio State Univ, Ctr Comprehens Canc, Dept Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; Washington University (WUSTL); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Boris-Lawrie, K (corresponding author), Ohio State Univ, Dept Vet Biosci, Goss Lab, 1925 Coffey Rd, Columbus, OH 43210 USA.	boris-lawrie.1@osu.edu	Boris-Lawrie, Kathleen/AAB-8953-2020	Boris-Lawrie, Kathleen/0000-0001-6366-6270	NATIONAL CANCER INSTITUTE [P01CA100730, P30CA016058, R01CA108882] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA100730-01, P30CA100730, P30 CA016058, R01 CA108882, P01CA16058, P01 CA100730-010005, R01CA108882, P01 CA100730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelhaleem M, 2003, ANTICANCER RES, V23, P485; ADLER V, 1994, J BIOL CHEM, V269, P11186; Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 2003, P NATL ACAD SCI USA, V100, P10770, DOI 10.1073/pnas.1834524100; Akhouayri O, 2007, CALCIFIED TISSUE INT, V80, P123, DOI 10.1007/s00223-006-0102-7; ALCIVAR AA, 1991, MOL REPROD DEV, V30, P187, DOI 10.1002/mrd.1080300304; Arguni E, 2006, INT IMMUNOL, V18, P1079, DOI 10.1093/intimm/dxl041; Arnold J, 2006, BLOOD, V107, P3976, DOI 10.1182/blood-2005-11-4551; Baird SD, 2006, RNA, V12, P1755, DOI 10.1261/rna.157806; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; BERGER I, 1991, ONCOGENE, V6, P561; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Bolinger C, 2007, NUCLEIC ACIDS RES, V35, P2629, DOI 10.1093/nar/gkm124; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; Butsch M, 1999, J VIROL, V73, P4847, DOI 10.1128/JVI.73.6.4847-4855.1999; Cavanagh MH, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-15; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; Dreijerink KMA, 2006, NAT CLIN PRACT ENDOC, V2, P562, DOI 10.1038/ncpendmet0292; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Finkel T, 2006, ANTIOXID REDOX SIGN, V8, P1857, DOI 10.1089/ars.2006.8.1857; Fries F, 2007, INT J CANCER, V120, P2135, DOI 10.1002/ijc.22447; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gobl AE, 1999, BBA-GENE STRUCT EXPR, V1447, P51, DOI 10.1016/S0167-4781(99)00132-3; Gudikote JP, 2005, NAT STRUCT MOL BIOL, V12, P801, DOI 10.1038/nsmb980; Gunthert AR, 2002, BIOCHEM BIOPH RES CO, V294, P11, DOI 10.1016/S0006-291X(02)00427-8; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Harper JW, 1999, NAT CELL BIOL, V1, pE5, DOI 10.1038/8952; Hartman TR, 2006, NAT STRUCT MOL BIOL, V13, P509, DOI 10.1038/nsmb1092; Hendy GN, 2005, HORM METAB RES, V37, P375, DOI 10.1055/s-2005-870152; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Hilfiker-Kleiner D, 2005, CIRCULATION, V112, P1470, DOI 10.1161/CIRCULATIONAHA.104.518472; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hivin P, 2006, NUCLEIC ACIDS RES, V34, P2761, DOI 10.1093/nar/gkl375; Ijiri K, 2005, J BIOL CHEM, V280, P38544, DOI 10.1074/jbc.M504202200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kameda T, 1997, CELL GROWTH DIFFER, V8, P495; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kim H, 2003, CANCER RES, V63, P6135; Kim H, 2005, EXP MOL MED, V37, P466, DOI 10.1038/emm.2005.57; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; Kuhlmann AS, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-92; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016/0006-291X(89)92322-X; Li L, 2002, GASTROENTEROLOGY, V123, P764, DOI 10.1053/gast.2002.35386; Li M, 2007, J VIROL METHODS, V142, P159, DOI 10.1016/j.jviromet.2007.01.023; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; LI Y, 1994, ONCOGENE, V9, P2261; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Meixner A, 2004, EMBO J, V23, P1325, DOI 10.1038/sj.emboj.7600133; Merrick WC., 1996, TRANSLATION CONTROL, P31; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; MORGAN IM, 1993, ONCOGENE, V8, P1135; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Myohanen S, 2001, J BIOL CHEM, V276, P1634, DOI 10.1074/jbc.M004481200; Naito J, 2005, J BIOL CHEM, V280, P4785, DOI 10.1074/jbc.M408143200; Neyns B, 1996, ONCOGENE, V12, P1247; Nott A, 2004, GENE DEV, V18, P210, DOI 10.1101/gad.1163204; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Persengiev SP, 2003, APOPTOSIS, V8, P225, DOI 10.1023/A:1023633704132; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pollack PS, 1997, J CELL BIOCHEM, V65, P245, DOI 10.1002/(SICI)1097-4644(199705)65:2<245::AID-JCB9>3.0.CO;2-U; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Punga T, 2006, J BIOL CHEM, V281, P25278, DOI 10.1074/jbc.M604983200; Robb GB, 2007, MOL CELL, V26, P523, DOI 10.1016/j.molcel.2007.04.016; Roberts TM, 2000, J VIROL, V74, P8111, DOI 10.1128/JVI.74.17.8111-8118.2000; Roberts TM, 2003, J VIROL, V77, P11973, DOI 10.1128/JVI.77.22.11973-11984.2003; Schwenger GTF, 2002, J BIOL CHEM, V277, P47022, DOI 10.1074/jbc.M207414200; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; Takeda Y, 1999, J IMMUNOL, V163, P6269; Tange TO, 2004, CURR OPIN CELL BIOL, V16, P279, DOI 10.1016/j.ceb.2004.03.012; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Thepot D, 2000, DEVELOPMENT, V127, P143; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Troen G, 2004, J MOL DIAGN, V6, P297, DOI 10.1016/S1525-1578(10)60525-9; Tsuji Y, 2005, ONCOGENE, V24, P7567, DOI 10.1038/sj.onc.1208901; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wiegand HL, 2003, P NATL ACAD SCI USA, V100, P11327, DOI 10.1073/pnas.1934877100; Willingham AT, 2006, CELL, V125, P1215, DOI 10.1016/j.cell.2006.06.009; Xiao L, 2007, BIOCHEM J, V403, P573, DOI 10.1042/BJ20061436; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Yazgan O, 2001, CANCER RES, V61, P916; Yilmaz A, 2006, CURR HIV RES, V4, P131, DOI 10.2174/157016206776055039; Zenz R, 2006, INT J BIOCHEM CELL B, V38, P1043, DOI 10.1016/j.biocel.2005.11.011; Zerbini LF, 2003, CANCER RES, V63, P2206; Zhang SS, 2004, ACTA BIOCH BIOPH SIN, V36, P177, DOI 10.1093/abbs/36.3.177; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou H, 2007, CELL PROLIFERAT, V40, P431, DOI 10.1111/j.1365-2184.2007.00444.x	100	75	76	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4757	4767		10.1038/onc.2008.120	http://dx.doi.org/10.1038/onc.2008.120			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18427548	Green Accepted			2022-12-17	WOS:000258445100001
J	Deshmukh, H; Yeh, TH; Yu, J; Sharma, MK; Perry, A; Leonard, JR; Watson, MA; Gutmann, DH; Nagarajan, R				Deshmukh, H.; Yeh, T. H.; Yu, J.; Sharma, M. K.; Perry, A.; Leonard, J. R.; Watson, M. A.; Gutmann, D. H.; Nagarajan, R.			High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas	ONCOGENE			English	Article						pilocytic astrocytomas; aCGH; HIPK2; amplification	HOMEODOMAIN-INTERACTING PROTEIN-KINASE-2; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; HUMAN GLIOMAS; TUMORS; TRANSCRIPTION; HETEROZYGOSITY; GLIOBLASTOMA; POLYMORPHISM; MUTATIONS	Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors. Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms. Although whole chromosomal gains and losses were not observed, a 1-Mb amplified region of 7q34 was detected in multiple patient samples using both array platforms. Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus. Furthermore, overexpression of wild-type HIPK2, but not a kinase-inactive mutant, in a glioma cell line conferred a growth advantage in vitro. Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth.	[Yeh, T. H.; Gutmann, D. H.] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; [Deshmukh, H.; Yu, J.; Sharma, M. K.; Perry, A.; Watson, M. A.; Nagarajan, R.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA; [Leonard, J. R.] Washington Univ, Dept Neurosurg, Sch Med, St Louis, MO 63110 USA; [Yeh, T. H.] Chang Gung Mem Hosp & Univ, Dept Neurol, Taipei, Taiwan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Chang Gung Memorial Hospital	Gutmann, DH (corresponding author), Washington Univ, Dept Neurol, Sch Med, 660 S Euclid Ave,306 Biotechnol Bldg,Campus Box 8, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu; rakesh@wustl.edu		Perry, Arie/0000-0002-8300-7261; Gutmann, David/0000-0002-3127-5045				AGAMANOLIS DP, 1995, CANCER GENET CYTOGEN, V81, P125, DOI 10.1016/0165-4608(94)00123-S; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Arjona D, 2006, CURR MOL MED, V6, P645, DOI 10.2174/156652406778195017; Calzado MA, 2007, CELL CYCLE, V6, P139, DOI 10.4161/cc.6.2.3788; Cheng Y, 2000, HISTOPATHOLOGY, V37, P437, DOI 10.1046/j.1365-2559.2000.01005.x; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Harada J, 2003, J BIOL CHEM, V278, P38998, DOI 10.1074/jbc.M307112200; Hayes VM, 1999, BRAIN PATHOL, V9, P463, DOI 10.1111/j.1750-3639.1999.tb00535.x; Ishii N, 1998, INT J CANCER, V76, P797, DOI 10.1002/(SICI)1097-0215(19980610)76:6<797::AID-IJC5>3.3.CO;2-1; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P253, DOI 10.1016/0165-4608(89)90192-1; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Konigshoff M, 2003, CLIN CHEM, V49, P219, DOI 10.1373/49.2.219; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Ohgaki H, 2005, NEUROPATHOLOGY, V25, P1, DOI 10.1111/j.1440-1789.2004.00600.x; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Pierantoni GM, 2002, BIOCHEM BIOPH RES CO, V290, P942, DOI 10.1006/bbrc.2001.6310; Sanoudou D, 2000, BRIT J CANCER, V82, P1218; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sharma MK, 2006, NEUROLOGY, V66, P127, DOI 10.1212/01.wnl.0000188667.66646.1c; Tada K, 2003, NEURO-ONCOLOGY, V5, P228, DOI 10.1215/S115285170300005X; THIEL G, 1992, CANCER GENET CYTOGEN, V58, P109, DOI 10.1016/0165-4608(92)90095-P; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Wemmert S, 2006, INT J ONCOL, V28, P353; WHITE FV, 1995, HUM PATHOL, V26, P979, DOI 10.1016/0046-8177(95)90087-X; Wiggins AK, 2004, J CELL BIOL, V167, P257, DOI 10.1083/jcb.200406131; Zattara-Cannoni H, 1998, CANCER GENET CYTOGEN, V104, P157, DOI 10.1016/S0165-4608(97)00455-X; Zhang JS, 2007, NAT NEUROSCI, V10, P77, DOI 10.1038/nn1816	33	75	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4745	4751		10.1038/onc.2008.110	http://dx.doi.org/10.1038/onc.2008.110			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408760				2022-12-17	WOS:000258236300012
J	Buytaert, E; Matroule, JY; Durinck, S; Close, P; Kocanova, S; Vandenheede, JR; Witte, PA; Piette, J; Agostinis, P				Buytaert, E.; Matroule, J. Y.; Durinck, S.; Close, P.; Kocanova, S.; Vandenheede, J. R.; de Witte, P. A.; Piette, J.; Agostinis, P.			Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells	ONCOGENE			English	Article						photodynamic therapy; microarrays; p38(MAPK)	ACTIVATED PROTEIN-KINASE; PHOTODYNAMIC THERAPY; P38 MAPK; SIGNALING PATHWAYS; UP-REGULATION; ER STRESS; EXPRESSION; GENE; TRANSCRIPTION; INHIBITION	Photodynamic therapy (PDT) is an anticancer approach utilizing a light-absorbing molecule and visible light irradiation to generate, in the presence of O-2, cytotoxic reactive oxygen species, which cause tumor ablation. Given that the photosensitizer hypericin is under consideration for PDT treatment of bladder cancer we used oligonucleotide microarrays in the T24 bladder cancer cell line to identify differentially expressed genes with therapeutic potential. This study reveals that the expression of several genes involved in various metabolic processes, stress-induced cell death, autophagy, proliferation, inflammation and carcinogenesis is strongly affected by PDT and pinpoints the coordinated induction of a cluster of genes involved in the unfolded protein response pathway after endoplasmic reticulum stress and in antioxidant response. Analysis of PDT-treated cells after p38(MAPK) inhibition or silencing unraveled that the induction of an important subset of differentially expressed genes regulating growth and invasion, as well as adaptive mechanisms against oxidative stress, is governed by this stress-activated kinase. Moreover, p38(MAPK) inhibition blocked autonomous regrowth and migration of cancer cells escaping PDT-induced cell death. This analysis identifies new molecular effectors of the cancer cell response to PDT opening attractive avenues to improve the therapeutic efficacy of hypericin-based PDT of bladder cancer.	[Buytaert, E.; Kocanova, S.; Vandenheede, J. R.; Agostinis, P.] Catholic Univ Louvain, Fac Med, Dept Mol & Cell Biol, Brabant, Belgium; [Matroule, J. Y.; Close, P.; Piette, J.] Univ Liege, Lab Virol & Immunol, Liege, Belgium; [Durinck, S.] Catholic Univ Louvain, Dept Elect Engn, ESAT SCD, Brabant, Belgium; [de Witte, P. A.] Catholic Univ Louvain, Fac Pharm, Lab Pharmaceut Biol & Phytopharmacol, Brabant, Belgium	Universite Catholique Louvain; University of Liege; Universite Catholique Louvain; Universite Catholique Louvain	Agostinis, P (corresponding author), KULeuven, Dept Mol & Cell Biol, Herestr 49,Campus Gasthuisberg, B-3000 Louvain, Brabant, Belgium.	patrizia.agostinis@med.kuleuven.be	Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020	Agostinis, Patrizia/0000-0003-1314-2115; de Witte, Peter/0000-0002-9989-9567; CLOSE, PIERRE/0000-0002-8844-9616				Agostinis P, 2004, PHOTOCH PHOTOBIO SCI, V3, P721, DOI 10.1039/b315237e; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birney E, 2006, NUCLEIC ACIDS RES, V34, pD556, DOI 10.1093/nar/gkj133; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Caristi S, 2005, J BIOL CHEM, V280, P14433, DOI 10.1074/jbc.M410725200; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; D'Hallewin MA, 2002, BJU INT, V89, P760, DOI 10.1046/j.1464-410X.2002.02690.x; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Elenitoba-Johnson KSJ, 2003, P NATL ACAD SCI USA, V100, P7259, DOI 10.1073/pnas.1137463100; Espel E, 2005, SEMIN CELL DEV BIOL, V16, P59, DOI 10.1016/j.semcdb.2004.11.008; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Hendrickx N, 2003, J BIOL CHEM, V278, P52231, DOI 10.1074/jbc.M307591200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hori O, 2006, MOL CELL BIOL, V26, P4257, DOI 10.1128/MCB.02055-05; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Imasato A, 2002, J BIOL CHEM, V277, P47444, DOI 10.1074/jbc.M208140200; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johansson N, 2000, J CELL SCI, V113, P227; Kamuhabwa A, 2004, PHOTOCH PHOTOBIO SCI, V3, P772, DOI 10.1039/b315586b; Kocanova S, 2007, APOPTOSIS, V12, P731, DOI 10.1007/s10495-006-0016-x; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; LIN Z, 2004, MOL CELL PROTEOMICS, V820; Liu RY, 2000, J BIOL CHEM, V275, P21086, DOI 10.1074/jbc.M001281200; Lou H, 2006, MOL PHARMACOL, V69, P1662, DOI 10.1124/mol.105.019794; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Makowski M, 2003, CLIN CANCER RES, V9, P5417; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Oh-Hashi K, 2001, FREE RADICAL BIO MED, V30, P213, DOI 10.1016/S0891-5849(00)00461-5; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Sengupta N, 2004, J R SOC PROMO HEALTH, V124, P228, DOI 10.1177/146642400412400520; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Van de Putte M, 2005, BRIT J CANCER, V92, P1406, DOI 10.1038/sj.bjc.6602512; Verwanger T, 2002, INT J ONCOL, V21, P1353; Volanti C, 2004, ONCOGENE, V23, P8649, DOI 10.1038/sj.onc.1207871; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Wong S, 2004, LASER SURG MED, V35, P336, DOI 10.1002/lsm.20110; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	55	75	76	0	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1916	1929		10.1038/sj.onc.1210825	http://dx.doi.org/10.1038/sj.onc.1210825			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17952126	Green Published			2022-12-17	WOS:000254150600011
J	Ceballos-Cancino, G; Espinosa, M; Maldonado, V; Melendez-Zajgla, J				Ceballos-Cancino, G.; Espinosa, M.; Maldonado, V.; Melendez-Zajgla, J.			Regulation of mitochondrial Smac/DIABLO-selective release by survivin	ONCOGENE			English	Article						antineoplastic drugs; cancer; DNA damage; inhibitor of apoptosis proteins; mitochondria	CYTOCHROME-C; INDUCED APOPTOSIS; IN-VITRO; SMAC; CELLS; ACTIVATION; EXPRESSION; PROTEIN; CANCER; BAX	The intrinsic apoptotic pathway is characterized by the release of several mitochondrial intermembrane proteins into the cytosol of dying cells. It is unclear whether the release of these proteins follows a common or specific pathway. In the present report we show that survivin and, to a lesser extent, the survivin splice variant survivin DeltaEx3 regulate the specific liberation of second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (Smac/DIABLO), an inhibitor of apoptosis proteins binding protein, during apoptosis induced by etoposide, a DNA damaging agent. This antineoplastic drug induced posttranscriptional upregulation of survivin and survivin DeltaEx3. In turn, mitochondrial survivin associated with Smac/DIABLO, delaying its release. In addition, cytosolic survivin also stabilized the cytosolic levels of released Smac/DIABLO. These results provide an explanation for the observed differences in the release of mitochondrial intermembrane proteins in various apoptotic models and present a new mechanism for the anti-apoptotic effects of survivin in cancer cells.	Inst Nacl Cancerol, Subdirecc Invest Basica, Mol Biol Lab, Mexico City 14080, DF, Mexico	Instituto Nacional de Cancerologia (INCAN)	Maldonado, V (corresponding author), Inst Nacl Cancerol, Subdirecc Invest Basica, Mol Biol Lab, Av San Fernando 22, Mexico City 14080, DF, Mexico.	vilmaml@gmail.com; jorgezajgla@salud.gob.mx	Melendez-Zajgla, Jorge/A-5708-2008					Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; Kandasamy K, 2003, CANCER RES, V63, P1712; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Lim MLR, 2006, EXP CELL RES, V312, P1174, DOI 10.1016/j.yexcr.2006.01.026; Ling X, 2004, J BIOL CHEM, V279, P15196, DOI 10.1074/jbc.M310947200; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martinez-Velazquez M, 2007, CELL SIGNAL, V19, P1212, DOI 10.1016/j.cellsig.2007.01.001; McNeish IA, 2005, EXP CELL RES, V302, P69, DOI 10.1016/j.yexcr.2004.08.029; Morizane Y, 2005, J BIOCHEM, V137, P125, DOI 10.1093/jb/mvi029; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Tirro E, 2006, CANCER RES, V66, P4263, DOI 10.1158/0008-5472.CAN-05-3248; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Wall NR, 2003, CANCER RES, V63, P230; Yamamoto S, 2002, J PHYS CHEM SOLIDS, V63, P1489, DOI 10.1016/S0022-3697(02)00032-X; Zhang WG, 2002, J EUR CERAM SOC, V22, P2869, DOI 10.1016/S0955-2219(02)00063-8; Zhou LL, 2005, APOPTOSIS, V10, P289, DOI 10.1007/s10495-005-0803-9	21	75	77	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7569	7575		10.1038/sj.onc.1210560	http://dx.doi.org/10.1038/sj.onc.1210560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546047	Bronze			2022-12-17	WOS:000251282100009
J	Covey, TM; Edes, K; Fitzpatrick, FA				Covey, T. M.; Edes, K.; Fitzpatrick, F. A.			Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor	ONCOGENE			English	Article						Akt; PTEN; cyclooxygenase-2; 5-lipoxygenase; tumor suppressor	SIGNALING PATHWAY; REDOX REGULATION; PHOSPHOINOSITIDE 3-KINASE; CANCER; KINASE; EXPRESSION; AKT/PKB; TARGETS; CELLS; SERUM	Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes are overexpressed during inflammation and multistage tumor progression in many neoplastic disorders including lung, breast and pancreatic cancers. Here we report that the tumor suppressor phosphatase and tensin homolog (PTEN) is oxidized and inactivated during arachidonic acid (AA) metabolism in pancreatic cancer cell lines expressing COX-2 or 5-LOX. Oxidation of PTEN decreases its phosphatase activity, favoring increased phosphatidylinositol 3,4,5-triphosphate production, activation of Akt and phosphorylation of downstream Akt targets including GSK-3 beta and S6K. These effects are recapitulated with pancreatic phospholipase A(2), which hydrolyses the release of membrane-bound AA. Interference with PTEN's physiological antagonism of signals from growth factors, insulin and oncogenes may confer risk for hypertrophic or neoplastic diseases associated with chronic inflammation or unwarranted oxidative metabolism of essential fatty acids.	Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Fitzpatrick, FA (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Med Chem & Oncol Sci, 200 Circle Hope, Salt Lake City, UT 84112 USA.	frank.fitzpatrick@hci.utah.edu			NCI NIH HHS [T32 CA093247, P01 CA73992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073992, T32CA093247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Bianchi M, 2005, BIOCHEM J, V391, P359, DOI 10.1042/BJ20050282; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding XZ, 2001, PANCREATOLOGY, V1, P291, DOI 10.1159/000055827; Gericke A, 2006, GENE, V374, P1, DOI 10.1016/j.gene.2006.02.024; Giardina C, 1998, BBA-MOL CELL RES, V1401, P277, DOI 10.1016/S0167-4889(97)00140-7; Goriely A, 2001, J NONLINEAR SCI, V11, P3, DOI 10.1007/s003320010009; Hii CST, 2001, J BIOL CHEM, V276, P27246, DOI 10.1074/jbc.M103250200; Hughes-Fulford M, 2006, CANCER RES, V66, P1427, DOI 10.1158/0008-5472.CAN-05-0914; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li F, 2005, AM J PHYSIOL-HEART C, V288, pH2306, DOI 10.1152/ajpheart.00571.2004; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b; NEVALAINEN TJ, 1985, CLIN CHEM, V31, P1116; Seo JH, 2005, MOL BIOL CELL, V16, P348, DOI 10.1091/mbc.E04-05-0369; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VINOKUROVA LV, 2001, ROSS GASTROENETEROL, V2, P72; Wagner TM, 2006, J BIOL CHEM, V281, P2598, DOI 10.1074/jbc.M509723200; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Wildroudt ML, 2006, BBA-MOL CELL BIOL L, V1761, P11, DOI 10.1016/j.bbalip.2005.11.009; Xiong HQ, 2004, CANCER CHEMOTH PHARM, V54, pS69, DOI 10.1007/s00280-004-0890-2; YAMASHITA S, 1994, CLIN CHIM ACTA, V228, P91, DOI 10.1016/0009-8981(94)90280-1; Yu CX, 2005, MOL PHARMACOL, V68, P847, DOI 10.1124/mol.104.010504	37	75	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5784	5792		10.1038/sj.onc.1210391	http://dx.doi.org/10.1038/sj.onc.1210391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369849				2022-12-17	WOS:000248885100010
J	Jiang, X; Ellison, SJ; Alarid, ET; Shapiro, DJ				Jiang, X.; Ellison, S. J.; Alarid, E. T.; Shapiro, D. J.			Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells	ONCOGENE			English	Article						estrogen; estrogen receptor; tamoxifen; proteinase inhibitor 9; natural killer cell; granzyme; breast cancer	INVASIVE BREAST-CANCER; B-MEDIATED APOPTOSIS; AROMATASE INHIBITORS; ALPHA CONCENTRATION; TARGET-CELLS; CYTOTOXICITY; PROTEASE; POSTMENOPAUSAL; EXPRESSION; MODULATORS	Estrogens promote cell proliferation and metastases in several human cancers. Here, we describe a different action of estrogens likely to contribute to tumor development-blocking immunosurveillance. In breast cancer cells, increasing concentrations of estrogen induce increasing levels of the granzyme B inhibitor, SerpinB9/proteinase inhibitor 9 (PI-9) and progressively block cell death induced by NK92 natural killer (NK) cells, but do not block killing by a second NK cell line, NKL cells. RNA interference knockdown of PI-9 abolishes estrogen's ability to block NK92 cell-induced cytotoxicity. Expressing elevated levels of estrogen receptor a (ER alpha) increases the induced level of PI-9, and makes tamoxifen (TAM), but not raloxifene or ICI 182,780, a potent inducer of PI-9. At elevated levels of ERa, induct ion of PI-9 by estradiol or TAM blocks killing by both NK92 and NKL cells. When the Erk pathway is activated with epidermal growth factor, the concentration of estrogen required to induce a protective level of PI-9 is reduced to 10 pM. Elevated concentrations of estrogen and ER may provide a dual selective advantage to breast cancer cells by controlling PI-9 levels and thereby blocking immunosurveillance. Expressing elevated levels of ERa reveals a potentially important difference in the effects of TAM, raloxifene and ICI 182,780 on immunosurveillance in breast cancer.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Wisconsin System; University of Wisconsin Madison	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, B-4 RAL,600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@uiuc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071909, R01DK064034] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16720] Funding Source: Medline; NIDDK NIH HHS [DK64034, DK071909] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Barrie MB, 2004, J IMMUNOL, V172, P6453, DOI 10.4049/jimmunol.172.10.6453; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Blomberg K, 1996, J IMMUNOL METHODS, V193, P199, DOI 10.1016/0022-1759(96)00063-4; Bots M, 2006, IMMUNOL CELL BIOL, V84, P79, DOI 10.1111/j.1440-1711.2005.01417.x; Bots M, 2005, BLOOD, V105, P1153, DOI 10.1182/blood-2004-03-0791; Bots M, 2006, BLOOD, V107, P4974, DOI 10.1182/blood-2006-01-0291; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Godal R, 2006, BLOOD, V107, P3205, DOI 10.1182/blood-2005-07-2880; Goping IS, 2003, IMMUNITY, V18, P355, DOI 10.1016/S1074-7613(03)00032-3; Gradishar WJ, 2006, JAMA-J AM MED ASSOC, V295, P2784, DOI 10.1001/jama.295.23.jed60037; Gritzapis AD, 2003, BREAST CANCER RES TR, V80, P1, DOI 10.1023/A:1024462416640; Hupperets PS, 1997, AM J CLIN ONCOL-CANC, V20, P546, DOI 10.1097/00000421-199712000-00002; Jiang XG, 2006, ENDOCRINOLOGY, V147, P1419, DOI 10.1210/en.2005-0996; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Kannan-Thulasiraman P, 2002, J BIOL CHEM, V277, P41230, DOI 10.1074/jbc.M200379200; Kataoka T, 1996, J IMMUNOL, V156, P3678; Kisanga ER, 2004, CLIN CANCER RES, V10, P2336, DOI 10.1158/1078-0432.CCR-03-0538; Krieg AJ, 2004, J BIOL CHEM, V279, P5025, DOI 10.1074/jbc.M307076200; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Lamboley C, 2000, CELL MOL BIOL, V46, P13; Levin ER, 2003, MOL ENDOCRINOL, V17, P309, DOI 10.1210/me.2002-0368; Lewis JS, 2005, MUTAT RES-FUND MOL M, V591, P247, DOI 10.1016/j.mrfmmm.2005.02.028; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lonning PE, 1997, J STEROID BIOCHEM, V61, P255; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Mahrus S, 2004, J BIOL CHEM, V279, P54275, DOI 10.1074/jbc.M411482200; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; MELDRUM DR, 1981, OBSTET GYNECOL, V57, P624; Phillips T, 2004, J IMMUNOL, V173, P3801, DOI 10.4049/jimmunol.173.6.3801; Riera J, 1999, AM J CLIN PATHOL, V111, P329; ROMAIN S, 1994, INT J CANCER, V59, P17, DOI 10.1002/ijc.2910590105; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SANCHOGARNIER H, 1995, EUR J CANCER, V31A, P1851, DOI 10.1016/0959-8049(95)00387-X; Sebbagh M, 2005, J EXP MED, V201, P465, DOI 10.1084/jem.20031877; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; ten Berge RL, 2003, J PATHOL, V200, P4, DOI 10.1002/path.1331; Thomas DA, 2000, IMMUNITY, V12, P621, DOI 10.1016/S1074-7613(00)80213-7; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; van Houdt IS, 2005, CLIN CANCER RES, V11, P6400, DOI 10.1158/1078-0432.CCR-05-0306; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Zhang ZH, 2006, MOL ECOL NOTES, V6, P24, DOI 10.1111/j.1471-8286.2005.01117.x	48	75	80	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4106	4114		10.1038/sj.onc.1210197	http://dx.doi.org/10.1038/sj.onc.1210197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17237823				2022-12-17	WOS:000247252700006
J	Ivanov, I; Lo, KC; Hawthorn, L; Cowell, JK; Ionov, Y				Ivanov, I.; Lo, K. C.; Hawthorn, L.; Cowell, J. K.; Ionov, Y.			Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells	ONCOGENE			English	Article						nonsense-mediated decay; mutations; caffeine; GINI	SHORT MONONUCLEOTIDE REPEATS; ESTROGEN-RECEPTOR-ALPHA; MICROSATELLITE INSTABILITY; FAMILIAL PREDISPOSITION; INTERNATIONAL CRITERIA; INSTITUTE WORKSHOP; ALTERED EXPRESSION; COLORECTAL-CANCER; MUTATIONS; PROTEIN	Inhibition of the nonsense-mediated decay (NMD) mechanism in cells results in stabilization of transcripts carrying premature translation termination codons. A strategy referred to as gene identification by NMD inhibition (GINI) has been proposed to identify genes carrying nonsense mutations. Genes containing frameshift mutations in colon cancer cell line have been identified using a modified version of GINI. To increase the efficiency of identifying mutant genes using GINI, we have now further improved the strategy. In this approach, inhibition of NMD with emetine is complemented with inhibiting NMD by blocking the phosphorylation of the hUpf1 protein with caffeine. In addition, to enhance the GINI strategy, comparing mRNA level alterations produced by inhibiting transcription alone or inhibiting transcription together with NMD following caffeine pretreatment were used for the efficient identification of false positives produced as a result of stress response to NMD inhibition. To demonstrate the improved efficiency of this approach, we analysed colon cancer cell lines showing microsatellite instability. Bi-allelic inactivating mutations were found in the FXR1, SEC31L1, NCOR1, BAT3, PHF14, ZNF294, C19ORF5 genes as well as genes coding for proteins with yet unknown functions.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Ionov, Y (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	Yurij.Ionov@RoswellPark.org	Martinez, Octavio/B-7375-2009; Ivanov, Igor/N-7609-2019	Ivanov, Igor/0000-0002-4942-1987; Hawthorn, Lesleyann/0000-0001-8179-0937; Cowell, John/0000-0002-2079-5950	NCI NIH HHS [1R01 CA109256-01, CA16056] Funding Source: Medline; NINDS NIH HHS [NS054543] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA109256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054543] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Boland CR, 1998, CANCER RES, V58, P5248; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; CHEN JS, 1995, CANCER RES, V55, P174; Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; El-Bchiri J, 2005, HUM MOL GENET, V14, P2435, DOI 10.1093/hmg/ddi245; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Garnon J, 2005, J BIOL CHEM, V280, P5750, DOI 10.1074/jbc.M401988200; Girault I, 2003, CLIN CANCER RES, V9, P1259; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P4191, DOI 10.1158/0008-5472.CAN-04-3865; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Liu LY, 2002, IN VITRO CELL DEV-AN, V38, P582; Maquat LE, 2005, J CELL SCI, V118, P1773, DOI 10.1242/jcs.01701; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Naef F, 2002, GENOME BIOL, V3; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Perucho M, 1999, CANCER RES, V59, P249; PERUCHO M, 1999, CANCER RES, V58, P5248; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rossi MR, 2005, CANCER GENET CYTOGEN, V161, P97, DOI 10.1016/j.cancergencyto.2005.02.006; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Suzuki K, 2002, CANCER RES, V62, P1961; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Usuki F, 2004, ANN NEUROL, V55, P740, DOI 10.1002/ana.20107; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weischenfeldt J, 2005, CURR BIOL, V15, pR559, DOI 10.1016/j.cub.2005.07.002; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; WU Z, 2004, 1 J HOPK U DEP BIOST; Zhang L, 2001, CANCER RES, V61, P3801; Zhang ZH, 2006, CANCER LETT, V237, P123, DOI 10.1016/j.canlet.2005.05.046	53	75	79	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2873	2884		10.1038/sj.onc.1210098	http://dx.doi.org/10.1038/sj.onc.1210098			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17086209				2022-12-17	WOS:000246210800007
J	Han, W; Wu, L; Chen, S; Bao, L; Zhang, L; Jiang, E; Zhao, Y; Xu, A; Hei, TK; Yu, Z				Han, W.; Wu, L.; Chen, S.; Bao, L.; Zhang, L.; Jiang, E.; Zhao, Y.; Xu, A.; Hei, T. K.; Yu, Z.			Constitutive nitric oxide acting as a possible intercellular signaling molecule in the initiation of radiation-induced DNA double strand breaks in non-irradiated bystander cells	ONCOGENE			English	Article						constitutive nitric oxide; radiation-induced bystander effects; DNA double strand breaks; initiation process	IONIZING-RADIATION; TYROSINE PHOSPHORYLATION; UNIRRADIATED CELLS; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; OPIATE RECEPTOR; HISTONE H2AX; SYNTHASE; PEROXYNITRITE; IRRADIATION	The initiation and propagation of the early processes of bystander signaling induced by low-dose alpha-particle irradiation are very important for understanding the underlying mechanism of the bystander process. Our previous investigation showed that the medium collected from cell culture exposed to low-dose alpha-particle rapidly induced phosphorylated form of H2AX protein foci formation among the non-irradiated medium receptor cells in a time-dependent manner. Using N-G-methyl-L-arginine, 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate and N-omega-nitro-L-arginine (L-NNA) treatment before exposure to 1 cGy alpha-particle, we showed in the present study that nitric oxide (NO center dot) produced in the irradiated cells was important and necessary for the DNA double strand break inducing activity (DIA) of conditioned medium and the generation of NO center dot in irradiated confluent AG1522 cells is in a time-dependent manner and that almost all NO center dot was generated within 15 min post-irradiation. Concurrently, the kinetics of NO center dot production in the medium of irradiated cells after irradiation was rapid and in a time-dependent manner as well, with a maximum yield observed at 10 min after irradiation with electron spin resonance analysis. Furthermore, our results that 7-Nitroindazole and L-NNA, but not aminoguanidine hemisulfate, treatment before exposure to 1 cGy alpha-particle significantly decrease the DIA of the conditioned medium suggested that constitutive NO center dot from the irradiated cells possibly acted as an intercellular signaling molecule to initiate and activate the early process ( <= 30 min) of bystander response after low-dose irradiation.	Chinese Acad Sci, Inst Plasma Phys, Key Lab Ion Beam Bioengn, Hefei 230031, Anhui, Peoples R China; Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Columbia University	Wu, L (corresponding author), Chinese Acad Sci, Inst Plasma Phys, Key Lab Ion Beam Bioengn, POB 1126,Shushanhu Rd 350, Hefei 230031, Anhui, Peoples R China.	ljw@ipp.ac.cn	Zhao, Ye/V-6986-2019; Zhao, Ye/H-9713-2013	Zhao, Ye/0000-0003-1384-6024; Zhao, Ye/0000-0003-1384-6024	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES012888] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES012888, ES09089] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Azzam EI, 2004, CURR CANCER DRUG TAR, V4, P53, DOI 10.2174/1568009043481641; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; AZZAM EI, 2003, BIOL EFF LOW LEVEL E, V11, P2; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Dahm-Daphi J, 2000, INT J RADIAT BIOL, V76, P67, DOI 10.1080/095530000139023; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; FAGAGNA FF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Femandes E, 2005, LIFE SCI, V77, P1983, DOI 10.1016/j.lfs.2005.02.018; HAN W, 2007, BR J RADIOL; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hu B, 2005, RADIAT RES, V164, P286, DOI 10.1667/RR3415.1; Hu BR, 2006, CARCINOGENESIS, V27, P245, DOI 10.1093/carcin/bgi224; Iyer R, 2000, CANCER RES, V60, P1290; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; JOURDHEUIL D, 1997, FRONT BIOSCI, V2, P189; Kiang JG, 2003, J CELL BIOCHEM, V89, P1030, DOI 10.1002/jcb.10564; Kojima H, 1998, NEUROREPORT, V9, P3345, DOI 10.1097/00001756-199810260-00001; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; Li NZ, 2003, J NEUROSCI, V23, P10302; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Liu SX, 2005, CANCER RES, V65, P3236, DOI 10.1158/0008-5472.CAN-05-0424; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Matsumoto H, 2000, INT J RADIAT BIOL, V76, P1649; Minetti M, 2002, FREE RADICAL BIO MED, V33, P744, DOI 10.1016/S0891-5849(02)00891-2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Murad F, 1998, RECENT PROG HORM RES, V53, P43; Nagar S, 2003, CANCER RES, V63, P324; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Qu XW, 2001, FASEB J, V15, P439, DOI 10.1096/fj.99-0343com; Rao CV, 2002, CANCER RES, V62, P165; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sedelnikova OA, 2004, INT J RADIAT BIOL, V80, P927, DOI 10.1080/09553000400017648; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2003, CANCER RES, V63, P8437; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, FASEB J, V17, P1422, DOI 10.1096/fj.02-1115com; Stefano GB, 1998, J NEUROIMMUNOL, V83, P70, DOI 10.1016/S0165-5728(97)00223-3; Stefano GB, 2000, PROG NEUROBIOL, V60, P513, DOI 10.1016/S0301-0082(99)00038-6; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vodovotz Y, 1999, CANCER RES, V59, P2142; Xiong QH, 2001, J INTERF CYTOK RES, V21, P529, DOI 10.1089/10799900152434411	57	75	80	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2330	2339		10.1038/sj.onc.1210024	http://dx.doi.org/10.1038/sj.onc.1210024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016433				2022-12-17	WOS:000245466000009
J	Yu, W; Imoto, I; Inoue, J; Onda, M; Emi, M; Inazawa, J				Yu, W.; Imoto, I.; Inoue, J.; Onda, M.; Emi, M.; Inazawa, J.			A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity	ONCOGENE			English	Article						DUSP26; ATC; amplification; p38; array-CGH	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; TUMOR-SUPPRESSOR; MICROARRAY ANALYSIS; PHOSPHATASE; EXPRESSION; APOPTOSIS; BREAST; PATHWAYS; IDENTIFICATION	Anaplastic thyroid cancer (ATC) is one of the most lethal of all human tumors, but cytogenetic information concerning ATC is extremely limited. Using our in-house array-based comparative genomic hybridization and 14 ATC cell lines with further fluorescence in situ hybridization analysis, we demonstrated ampli. cation of the DUSP26 gene, known by another report as MAP kinase phosphatase-8. DUSP26 was overexpressed in ATC cell lines and primary ATC tumor samples. When overexpressed, either exogenously or endogenously, DUSP26 promoted growth of the ATC cells. DUSP26 encodes a protein containing a dual-specificity phosphatase domain that can dephosphorylate itself. DUSP26 effectively dephosphorylates p38 and has a little effect on extracellular signal-regulated kinase in ATC cells. DUSP26 protein formed a physical complex with p38, and promoted survival of ATC cells by inhibiting p38-mediated apoptosis. Our findings suggest that DUSP26 may act as an oncogene in ATC, and might be a useful diagnostic marker and therapeutic target of this disease.	Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; 21st Century Ctr Excellence COE, Program Mol Destruct & Reconstruct Tooth & Bone, Tokyo, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan; Nippon Med Sch, Inst Gerontol, Dept Mol Biol, Kanagawa, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Nippon Medical School	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; yu, wei/B-5859-2011; Imoto, Issei/AAD-5799-2020					BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Hoornaert I, 2003, ONCOGENE, V22, P7728, DOI 10.1038/sj.onc.1207089; Hu YZ, 2006, MOL CELL BIOL, V26, P3282, DOI 10.1128/MCB.26.8.3282-3294.2006; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; McMullen ME, 2005, J BIOL CHEM, V280, P20995, DOI 10.1074/jbc.M407060200; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Onda M, 2004, ENDOCR-RELAT CANCER, V11, P843, DOI 10.1677/erc.1.00818; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Passler C, 1999, LANGENBECK ARCH SURG, V384, P284, DOI 10.1007/s004230050205; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Simon R, 2001, CANCER RES, V61, P4514; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Walentinsson A, 2001, CANCER RES, V61, P8263; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P662, DOI 10.1002/hed.10277; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Yu W, 2003, J HUM GENET, V48, P331, DOI 10.1007/s10038-003-0026-2	45	75	78	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1178	1187		10.1038/sj.onc.1209899	http://dx.doi.org/10.1038/sj.onc.1209899			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924234				2022-12-17	WOS:000244406400008
J	Ohashi, S; Sakashita, G; Ban, R; Nagasawa, M; Matsuzaki, H; Murata, Y; Taniguchi, H; Shima, H; Furukawa, K; Urano, T				Ohashi, S.; Sakashita, G.; Ban, R.; Nagasawa, M.; Matsuzaki, H.; Murata, Y.; Taniguchi, H.; Shima, H.; Furukawa, K.; Urano, T.			Phospho-regulation of human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal antibodies	ONCOGENE			English	Article						aurora-A; autophosphorylation; upstream kinase; phospho-specific antibody; monoclonal antibody; substrate specificity	CELL-CYCLE; SUSCEPTIBILITY GENE; CATALYTIC SUBUNIT; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CLEAVAGE FURROW; CENP-A; PHOSPHORYLATION; ACTIVATION	Mammalian Aurora- A is related to a serine/threonine protein kinase that was originally identified by its close homology with Saccharomyces cerevisiae IpI1p and Drosophila melanogaster aurora that are key regulators in the orchestration of mitotic events. The protein level of Aurora-A, its peak kinase activity during mitosis, and its activation have been attributed to phosphorylation. Here we show that this enzyme is an arginine-directed kinase and de. ne its substrate specificity. We also found that Thr288 within the activation loop is a critical residue for activating phosphorylation events in vitro and that it is spatiotemporally restricted to a brief window at mitosis on duplicated centrosomes and on spindle microtubules proximal to the poles in vivo. Immunodepletion assays indicated that an upstream kinase( s) of Aurora- A might exist in mammalian cells in addition to autophosphorylation. Furthermore, human activated Aurora- A forms complexes with the negative regulator protein serine/ threonine phosphatase type 1 ( PP1) that was negatively phosphorylated on Thr320. Interestingly, phospho- specific Aurora- A monoclonal antibodies restrain Aurora- A kinase activity in vitro, providing further therapeutic avenues to explore.	Nagoya Univ, Dept Biochem 2, Grad Sch Med, Showa Ku, 65 Tsurumai Machi, Nagoya, Aichi 4668550, Japan; RIKEN, Harima Inst, Spring 8, Synchrotron Radiat Res Network,Membrane Dynam Pro, Sayo, Hyogo, Japan; Miyagi Prefectural Canc Ctr, Inst Res, Div Canc Chemotherapy, Natori, Miyagi, Japan	Nagoya University; Japan Synchrotron Radiation Research Institute; RIKEN	Urano, T (corresponding author), Nagoya Univ, Dept Biochem 2, Grad Sch Med, Showa Ku, 65 Tsurumai Machi, Nagoya, Aichi 4668550, Japan.	turano@med.nagoya-u.ac.jp	Murata, Yasunobu/Y-5799-2019	Murata, Yasunobu/0000-0001-5757-2497; Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Ban R, 2004, J BIOL CHEM, V279, P16394, DOI 10.1074/jbc.M313257200; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Du J, 2004, P NATL ACAD SCI USA, V101, P8975, DOI 10.1073/pnas.0308484101; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Puntoni F, 1997, MOL CELL BIOCHEM, V171, P115, DOI 10.1023/A:1006892103306; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Sakai H, 2002, J BIOL CHEM, V277, P48714, DOI 10.1074/jbc.M208461200; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	79	75	79	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7691	7702		10.1038/sj.onc.1209754	http://dx.doi.org/10.1038/sj.onc.1209754			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785988				2022-12-17	WOS:000242830800004
J	Andrews, P; He, YJ; Xiong, Y				Andrews, P.; He, Y. J.; Xiong, Y.			Cytoplasmic localized ubiquitin ligase cullin 7 binds to p53 and promotes cell growth by antagonizing p53 function	ONCOGENE			English	Article						cullin 7; p53; ROC1; cytoplasmic localization	LARGE T-ANTIGEN; PROTEIN UBIQUITINATION; NUCLEAR EXPORT; RING FINGER; F-BOX; COMPLEX; FAMILY; DOMAIN; SCF; DEGRADATION	Cullins are a family of evolutionarily conserved proteins that bind to the small RING finger protein, ROC1, to constitute potentially a large number of distinct E3 ubiquitin ligases. CUL7 mediates an essential function for mouse embryo development and has been linked with cell transformation by its physical association with the SV40 large T antigen. We report here that, like its closely related homolog PARC, CUL7 is localized predominantly in the cytoplasm and binds directly to p53. In contrast to PARC, however, CUL7, even when overexpressed, did not sequester p53 in the cytoplasm. We have identified a sequence in the N-terminal region of CUL7 that is highly conserved in PARC and a sequence spanning the tetramerization domain in p53 that are required for CUL7-p53 binding. CUL7 and MDM2 did not form a detectable tertiary complex with p53. In vitro, CUL7 caused only mono- or di-ubiquitination of p53 under the conditions MDM2 polyubiquitinated p53. Co-expression of CUL7 reduced the transactivating activity of p53. Constitutive ectopic expression of CUL7 increased the rate of cell proliferation and delayed UV-induced G2 accumulation in U2OS cells expressing functional p53, but had no detectable effect in p53-deficient H1299 cells. Deletion of the N-terminal domain of CUL7 or a mutation disrupting p53 binding abolished the ability of CUL7 to increase the rate of U2OS cell proliferation. Our results suggest that CUL7 functions to promote cell growth through, in part, antagonizing the function of p53.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27514 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27514 USA.	yxiong@email.unc.edu		He, Yizhou/0000-0002-1396-7275	NCI NIH HHS [CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2004, J VIROL, V78, P2749, DOI 10.1128/JVI.78.6.2749-2757.2004; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Baptiste N, 2004, CELL, V116, P487, DOI 10.1016/S0092-8674(04)00164-3; Chipuk JE, 2004, CELL CYCLE, V3, P429; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Marin I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	43	75	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4534	4548		10.1038/sj.onc.1209490	http://dx.doi.org/10.1038/sj.onc.1209490			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547496				2022-12-17	WOS:000239457500004
J	He, YY; Pi, J; Huang, JL; Diwan, BA; Waalkes, MP; Chignell, CF				He, YY; Pi, J; Huang, JL; Diwan, BA; Waalkes, MP; Chignell, CF			Chronic UVA irradiation of human HaCaT keratinocytes induces malignant transformation associated with acquired apoptotic resistance	ONCOGENE			English	Article						UVA; transformation; carcinogenesis; AKT; keratinocyte; PTEN	SOLAR ULTRAVIOLET-RADIATION; SQUAMOUS-CELL-CARCINOMA; SKIN-CANCER; IV COLLAGENASE; SUN EXPOSURE; MOUSE SKIN; INDUCTION; PTEN; EXPRESSION; CARCINOGENESIS	Ultraviolet A ( UVA, 315 - 400 nm), constituting about 95% of ultraviolet irradiation in natural sunlight, represents a major environmental challenge to the skin and is clearly associated with human skin cancer. It has proven difficult to show direct actions of UVA as a carcinogen in human cells. Here, we demonstrate that chronic UVA exposures at environmentally relevant doses in vitro can induce malignant transformation of human keratinocytes associated with acquired apoptotic resistance. As evidence of carcinogenic transformation, UVA-long-treated ( 24 J/cm(2) once/week for 18 weeks) HaCaT ( ULTH) cells showed increased secretion of matrix metalloproteinase ( MMP-9), overexpression of keratin 13, altered morphology and anchorage-independent growth. Malignant transformation was established by the production of aggressive squamous cell carcinomas after inoculation of ULTH cells into nude mice ( NCr-nu). ULTH cells were resistant to apoptosis induced not only by UVA but also by UVB and arsenite, two other human skin carcinogens. ULTH cells also became resistant to apoptosis induced by etoposide, staurosporine and doxorubicin hydrochloride. Elevated phosphorylation of protein kinase B ( PKB, also called AKT) and reduced expression of phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) were detected in ULTH cells. The resistance of ULTH cells to UVA-induced apoptosis was reversed by either inhibition of phosphatidylinositol 3-kinase ( PI-3K) or adenovirus expression of PTEN or dominant negative AKT. These data indicate that UVA has carcinogenic potential in human keratinocytes and that the increased AKT signaling and decreased PTEN expression may contribute to this malignant transformation. Further comparisons between the transformed ULTH and control cells should lead to a better understanding of the mechanism of UVA carcinogenesis and may help identify biomarkers for UVA-induced skin malignancies.	NIEHS, Lab Comparat Carcinogenesis, Inorgan Carcinogenesis Sect, Res Triangle Pk, NC USA; Sci Applicat Int Corp, Basic Res Program, NCI, Frederick, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, 111 TW Alexander Dr,POB 12233,MD F0-06, Res Triangle Pk, NC 27709 USA.	he3@niehs.nih.gov	PI, JINGBO/GWC-2514-2022	PI, JINGBO/0000-0003-0227-8041	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050046] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanzar WE, 2001, CANCER RES, V61, P455; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Autier P, 1999, JNCI-J NATL CANCER I, V91, P1304, DOI 10.1093/jnci/91.15.1304; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; BERNHARD EJ, 1990, CANCER RES, V50, P3872; Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; Catani MV, 2001, BIOCHEM J, V356, P77, DOI 10.1042/0264-6021:3560077; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Cokkinides VE, 2001, PREV MED, V33, P141, DOI 10.1006/pmed.2001.0877; COX AD, 1994, METHOD ENZYMOL, V238, P277; Dahle J, 2003, CANCER RES, V63, P1464; Davies MA, 2002, CLIN CANCER RES, V8, P1904; DEGRUIJL FR, 1993, CANCER RES, V53, P53; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gasparro FP, 2000, ENVIRON HEALTH PERSP, V108, P71, DOI 10.2307/3454633; Geller AC, 2002, PEDIATRICS, V109, P1009, DOI 10.1542/peds.109.6.1009; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; JEANMOUGIN M, 1987, ANN DERMATOL VENER, V114, P671; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Minaguchi T, 1999, CANCER RES, V59, P6063; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Pi JB, 2005, INT J CANCER, V116, P20, DOI 10.1002/ijc.20990; Rossman TG, 2001, TOXICOL APPL PHARM, V176, P64, DOI 10.1006/taap.2001.9277; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Slaga T J, 1995, Prog Clin Biol Res, V391, P1; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suzuki A, 2003, CANCER RES, V63, P674; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WARREN BS, 1993, P SOC EXP BIOL MED, V202, P9; Wyllie A H, 1980, Int Rev Cytol, V68, P251	40	75	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2006	25	26					3680	3688		10.1038/sj.onc.1209384	http://dx.doi.org/10.1038/sj.onc.1209384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16682958				2022-12-17	WOS:000238448300007
J	Rubio, MF; Werbajh, S; Cafferata, EGA; Quaglino, A; Colo, GP; Nojek, IM; Kordon, EC; Nahmod, VE; Costas, MA				Rubio, MF; Werbajh, S; Cafferata, EGA; Quaglino, A; Colo, GP; Nojek, IM; Kordon, EC; Nahmod, VE; Costas, MA			TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B	ONCOGENE			English	Article						NF-kB; nuclear receptor coactivators; breast tumor; TNF-alpha; estrogen receptor	CYCLIN D1 EXPRESSION; CANCER CELLS; CROSS-TALK; RECEPTOR; ACTIVATION; GROWTH; AIB1; PROGRESSION; INDUCTION; MECHANISM	Breast tumors are usually classified according to their response to estrogens as hormone-dependent or -independent. In this work, we investigated the role of the proinflammatory cytokine TNF-alpha on the estrogen-receptor-positive T47D breast ductal tumor cells. We have found that TNF-alpha exerts a mitogenic effect, inducing cyclin D1 expression and activation of the transcription factor NF-kappa B. Importantly, activation of NF-kappa B was required for estrogen-induced proliferation and cyclin D1 expression. TNF-alpha enhanced the estrogen response by increasing the levels and availability of NF-kappa B. Chromatin immunoprecipitation analysis suggested that the action of estrogens is mediated by a protein complex that contains the activated estrogen receptor, the nuclear receptor coactivator RAC3 and a member of the NF-kappa B family. Finally, our results demonstrate that activation of this transcription factor could be one of the key signals for estrogen-mediated response.	Univ Buenos Aires, CONICET, IDIM, Dept Sustancias Vasoact,Fac Med,Lab Biol Mol & Ap, Buenos Aires, DF, Argentina; FIL, ANLIS, Ctr Genet Med, Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Div Med, Inst Invest Hematol, Acad Nacl Med, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Buenos Aires National Academy of Medicine; IIHEMA - Instituto de Investigaciones Hematologicas; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Costas, MA (corresponding author), Univ Buenos Aires, CONICET, IDIM, Dept Sustancias Vasoact,Fac Med,Lab Biol Mol & Ap, Combatients Malvinas 3150, Buenos Aires, DF, Argentina.	mcostas@lanari.fmed.uba.ar		Costas, Monica/0000-0002-4773-3389; Cafferata, Eduardo G/0000-0001-5089-3757				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chouchane L, 1997, CANCER, V80, P1489, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1489::AID-CNCR17>3.0.CO;2-1; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Costas M, 1996, J CLIN INVEST, V98, P1409, DOI 10.1172/JCI118928; Costas MA, 2000, BBA-MOL CELL RES, V1499, P122, DOI 10.1016/S0167-4889(00)00113-0; Evans MJ, 2001, CIRC RES, V89, P823, DOI 10.1161/hh2101.098543; Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamelers IHL, 2003, ENDOCR-RELAT CANCER, V10, P331, DOI 10.1677/erc.0.0100331; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu SM, 2000, BIOCHEM BIOPH RES CO, V279, P47, DOI 10.1006/bbrc.2000.3891; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MORA JF, 2000, MOL CELL BIOL, V20, P5041; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; PARTANEN R, 1995, OCCUP ENVIRON MED, V52, P316, DOI 10.1136/oem.52.5.316; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Speir E, 2000, CIRC RES, V87, P1006, DOI 10.1161/01.RES.87.11.1006; Tsai EM, 2001, CANCER RES, V61, P8390; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1; ZYAD A, 1994, CANCER RES, V54, P825	50	75	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1367	1377		10.1038/sj.onc.1209176	http://dx.doi.org/10.1038/sj.onc.1209176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16331275				2022-12-17	WOS:000235708200010
J	Inamura, K; Fujiwara, T; Hoshida, Y; Isagawa, T; Jones, MH; Virtanen, C; Shimane, M; Satoh, Y; Okumura, S; Nakagawa, K; Tsuchiya, E; Ishikawa, S; Aburatani, H; Nomura, H; Ishikawa, Y				Inamura, K; Fujiwara, T; Hoshida, Y; Isagawa, T; Jones, MH; Virtanen, C; Shimane, M; Satoh, Y; Okumura, S; Nakagawa, K; Tsuchiya, E; Ishikawa, S; Aburatani, H; Nomura, H; Ishikawa, Y			Two subclasses of lung squamous cell carcinoma with different gene expression profiles and prognosis identified by hierarchical clustering and non-negative matrix factorization	ONCOGENE			English	Article						lung; squamous cell carcinoma; cDNA microarray; hierarchical clustering; non-negative matrix factorization	PROTEIN-KINASE; POOR-PROGNOSIS; CANCER; ADENOCARCINOMA; OVEREXPRESSION; CDNA; HYPERMETHYLATION; CLASSIFICATION; MICROARRAYS; APOPTOSIS	Current clinical and histopathological criteria used to define lung squamous cell carcinomas (SCCs) are insufficient to predict clinical outcome. To make a clinically useful classification by gene expression profiling, we used a 40 386 element cDNA microarray to analyse 48 SCC, nine adenocarcinoma, and 30 normal lung samples. Initial analysis by hierarchical clustering (HC) allowed division of SCCs into two distinct subclasses. An additional independent round of HC induced a similar partition and consensus clustering with the non-negative matrix factorization approach indicated the robustness of this classification. Kaplan-Meier analysis with the log-rank test pointed to a nonsignificant difference in survival (P = 0.071), but the likelihood of survival to 6 years was significantly different between the two groups (40.5 vs 81.8%, P = 0.014, Z-test). Biological process categories characteristic for each subclass were identified statistically and upregulation of cell-proliferation-related genes was evident in the subclass with poor prognosis. In the subclass with better survival, genes involved in differentiated intracellular functions, such as the MAPKKK cascade, ceramide metabolism, or regulation of transcription, were upregulated. This work represents an important step toward the identification of clinically useful classification for lung SCC.	Japanese Fdn Canc Res, Dept Pathol, Inst Canc, Koto Ku, Tokyo 1358550, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo, Japan; Chugai Pharmaceut Co Ltd, Tokyo, Japan; Japanese Fdn Canc Res, Canc Inst Hosp, Dept Chest Surg, Tokyo 170, Japan; Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan	Japanese Foundation for Cancer Research; University of Tokyo; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Japanese Foundation for Cancer Research; Kanagawa Prefectural Cancer Center	Ishikawa, Y (corresponding author), Japanese Fdn Canc Res, Dept Pathol, Inst Canc, Koto Ku, 3-10-6 Ariake, Tokyo 1358550, Japan.	ishikawa@jfcr.or.jp	Hoshida, Yujin/R-7513-2019; Inamura, Kentaro/G-4229-2018	Inamura, Kentaro/0000-0001-6444-3861; Jones, Michael/0000-0002-2251-1990				Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Arboleda MJ, 2003, CANCER RES, V63, P196; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Esteller M, 2001, CANCER RES, V61, P3225; Fukumoto S, 2005, CLIN CANCER RES, V11, P1776, DOI 10.1158/1078-0432.CCR-04-1238; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Grille SJ, 2003, CANCER RES, V63, P2172; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miura K, 2002, CANCER RES, V62, P3244; Miyoshi T, 2003, AM J SURG PATHOL, V27, P101, DOI 10.1097/00000478-200301000-00011; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; Palackal NT, 2002, J BIOL CHEM, V277, P24799, DOI 10.1074/jbc.M112424200; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wikman H, 2004, J PATHOL, V203, P584, DOI 10.1002/path.1552; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yoo SH, 2003, LUNG CANCER, V42, P195, DOI 10.1016/S0169-5002(03)00287-3	33	75	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7105	7113		10.1038/sj.onc.1208858	http://dx.doi.org/10.1038/sj.onc.1208858			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007138				2022-12-17	WOS:000232833200012
J	Kienitz, A; Vogel, C; Morales, I; Muller, R; Bastians, H				Kienitz, A; Vogel, C; Morales, I; Muller, R; Bastians, H			Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol	ONCOGENE			English	Article						cell cycle; mitosis; mad2; apoptosis; genomic instability	ANAPHASE-PROMOTING COMPLEX; MITOTIC CHECKPOINT; KINETOCHORE LOCALIZATION; CHROMOSOME INSTABILITY; ASSEMBLY CHECKPOINT; AURORA-B; PROTEIN; BUBR1; CELLS; INHIBITION	The mitotic spindle assembly checkpoint ensures proper chromosome segregation during mitosis by inhibiting the onset of anaphase until all kinetochores are attached to the mitotic spindle and tension across the kinetochores is generated. Here, we report that the stable partial downregulation of the spindle checkpoint gene MAD1, which is observed in human cancer, leads to a functional inactivation of the spindle checkpoint resulting in gross aneuploidy. Interestingly, although Mad1 is thought to act as a kinetochore based activator of Mad2 during checkpoint activation, we show that normal levels of Mad2, but not of Mad1, are required for preventing premature sister chromatid separation and for maintaining the timing of an undisturbed mitosis, suggesting a Mad1 independent function of Mad2 that operates independent of its checkpoint function. Most significantly, a partial repression of either MAD1 or MAD2 confers resistance to nocodazole, a drug that inhibits microtubule attachment. In contrast, sensitivity to clinically relevant drugs like taxol or monastrol that inhibit the generation of tension across kinetochores is not modulated by partial downregulation of MAD1, suggesting a functional bifurcation of spindle checkpoint dependent apoptotic pathways.	Univ Marburg, Inst Mol Biol & Tumor Res, D-35037 Marburg, Germany	Philipps University Marburg	Bastians, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	bastians@imt.uni-marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Campbell MS, 2001, J CELL SCI, V114, P953; Canman JC, 2002, CELL MOTIL CYTOSKEL, V52, P61, DOI 10.1002/cm.10032; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Duesberg P, 2000, CANCER GENET CYTOGEN, V119, P83, DOI 10.1016/S0165-4608(99)00236-8; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Masuda A, 2003, AM J PATHOL, V163, P1109, DOI 10.1016/S0002-9440(10)63470-0; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Shichiri M, 2002, CANCER RES, V62, P13; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2004, CHROMOSOME RES, V12, P599, DOI 10.1023/B:CHRO.0000036610.78380.51; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Vogel C, 2005, J BIOL CHEM, V280, P4025, DOI 10.1074/jbc.C400545200; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Wang XH, 2002, CANCER RES, V62, P1662; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	61	75	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4301	4310		10.1038/sj.onc.1208589	http://dx.doi.org/10.1038/sj.onc.1208589			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782113				2022-12-17	WOS:000229815300013
J	Lin, JX; Liu, JL; Wang, Y; Zhu, JW; Zhou, K; Smith, N; Zhan, X				Lin, JX; Liu, JL; Wang, Y; Zhu, JW; Zhou, K; Smith, N; Zhan, X			Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein	ONCOGENE			English	Article						MIM; cortactin; N-WASP; actin; cell motility; PDGF	FILAMENT NETWORK FORMATION; ARP2/3 COMPLEX; ESCHERICHIA-COLI; ACTIVATION; CELLS; EXPRESSION; NUCLEATION; SUBSTRATE; INTERACTS; DYNAMICS	Missing in metastasis (MIM) gene encodes an actin binding protein that is expressed at low levels in a subset of malignant cell lines. MIM protein tagged by green fluorescent protein (GFP) colocalizes with cortactin, an Arp2/3 complex activator, and interacts directly with the SH3 domain of cortactin. Recombinant full-length MIM promotes markedly cortactin and Arp2/3 complex-mediated actin polymerization in an SH3 dependent manner. In contrast, MIM-CT, a short splicing variant of MIM, binds poorly to cortactin in vitro and is unable to enhance actin polymerization. Full-length MIM binds to G-actin with a similar affinity as N-WASP-VCA, a constitutively active form of N-WASP, and inhibits N-WASP-VCA-mediated actin polymerization as analysed in vitro. The significance of the association of MIM with cortactin and G-actin was evaluated in NIH3T3 cells expressing several MIM constructs. Overexpression of full-length wild-type MIM-GFP inhibited markedly the motility of NIH3T3 cells induced by PDGF and that of human vein umbilical endothelial cells induced by sphingosine 1 phosphate. However, an MIM mutant with deletion of the WH2 domain, which is responsible for G-actin binding, enhanced cell motility. The motility inhibition imposed by MIM was compromised in the cells overexpressing N-WASP. In contrast, deletion of an MIM proline-rich domain, which is required for an optimal binding to cortactin, substantiated the MIM-mediated inhibition of cell motility. These data imply that MIM regulates cell motility by modulating different Arp2/3 activators in a distinguished manner.	Amer Red Cross, Holland Lab, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Pathol, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	American Red Cross; University System of Maryland; University of Maryland Baltimore	Zhan, X (corresponding author), Amer Red Cross, Holland Lab, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	szhan001@umaryland.edu						Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Cheng L, 1997, GENE THER, V4, P1013, DOI 10.1038/sj.gt.3300507; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; Kim K, 2004, BIOCHEMISTRY-US, V43, P2422, DOI 10.1021/bi036173t; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Li YS, 2001, CANCER RES, V61, P6906; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; SAFER D, 1991, J BIOL CHEM, V266, P4029; Schafer DA, 2002, CURR BIOL, V12, P1852, DOI 10.1016/S0960-9822(02)01228-9; Uruno T, 2003, J BIOL CHEM, V278, P26086, DOI 10.1074/jbc.M301997200; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; WEISS S, 1992, GENE, V121, P203, DOI 10.1016/0378-1119(92)90123-7; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200; ZHAN X, 1993, J BIOL CHEM, V268, P24427	27	75	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2059	2066		10.1038/sj.onc.1208412	http://dx.doi.org/10.1038/sj.onc.1208412			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688017				2022-12-17	WOS:000227681900010
J	Rong, R; Jin, WX; Zhang, J; Sheikh, MS; Huang, Y				Rong, R; Jin, WX; Zhang, J; Sheikh, MS; Huang, Y			Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G(2)/M arrest	ONCOGENE			English	Article						RASSF1A; microtubules; apoptosis; cell cycle arrest	FREQUENT EPIGENETIC INACTIVATION; POLYPOSIS-COLI PROTEIN; CELL-CYCLE; CPG ISLAND; PROMOTER HYPERMETHYLATION; BREAST CANCERS; GENE-PRODUCT; LUNG-CANCER; ALLELE LOSS; SPINDLE	RASSF1A is a putative tumor suppressor gene that is inactivated in a variety of human tumors. Expression of exogenous RASSF1A has been shown to inhibit tumor growth in vitro and in animals. However, the molecular mechanisms by which RASSF1A mediates its tumor suppressive effects remain to be elucidated. Here, we report that RASSF1A is a microtubule-binding protein that interacts with and stabilizes microtubules. We have identified the RASSF1A region harboring a basic domain that appears to mediate the interactions between RASSF1A and microtubules. The basic domain-containing RASSF1C isoform also interacts with and stabilizes microtubules. We further show that in addition to G(1) arrest, RASSF1A promotes growth arrest in the G(2)/M phase of the cell cycle and endogenous RASSF1A also interacts with microtubules. Based on our results, we propose that RASSF1A may mediate its tumor suppressive effects by inducing growth arrest in the G(1) and G(2)/M phases. Together, these results provide important new insights into the molecular mechanisms by which this novel tumor suppressor mediates its biological effects.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NCI NIH HHS [CA86945] Funding Source: Medline; NIDDK NIH HHS [DK62136-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Alberts B., 2002, MOL BIOL CELL, P907; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bhalla KN, 2003, ONCOGENE, V22, P9075, DOI 10.1038/sj.onc.1207233; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bosc C, 1996, P NATL ACAD SCI USA, V93, P2125, DOI 10.1073/pnas.93.5.2125; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Cassimeris L, 1999, CURR OPIN CELL BIOL, V11, P134, DOI 10.1016/S0955-0674(99)80017-9; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; ERIMANN JDR, 2002, NATURE, V416, P850; Goedert M, 1996, J CELL SCI, V109, P2661; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Huang Y, 2001, CANCER RES, V61, P6918; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Lo KW, 2001, CANCER RES, V61, P3877; Lodish H, 2000, MOL CELL BIOL, P795; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Mimori-Kiyosue Y, 2001, J CELL BIOL, V154, P1105, DOI 10.1083/jcb.200106113; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Morrissey C, 2001, CANCER RES, V61, P7277; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nogales E, 2001, ANNU REV BIOPH BIOM, V30, P397, DOI 10.1146/annurev.biophys.30.1.397; Oliferenko S, 2002, NAT CELL BIOL, V4, P816, DOI 10.1038/ncb861; Reese EL, 2000, J CELL BIOL, V151, P155, DOI 10.1083/jcb.151.1.155; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Schuyler SC, 2001, J CELL SCI, V114, P247; Shimoda SL, 2002, CELL, V109, P9, DOI 10.1016/S0092-8674(02)00712-2; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; SMITH KJ, 1994, CANCER RES, V54, P3672; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; Tanaka TU, 2002, CURR OPIN CELL BIOL, V14, P365, DOI 10.1016/S0955-0674(02)00328-9; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Walenta JH, 2001, J CELL BIOL, V152, P923, DOI 10.1083/jcb.152.5.923; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wistuba II, 2000, CANCER RES, V60, P1949; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	55	75	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	2004	23	50					8216	8230		10.1038/sj.onc.1207901	http://dx.doi.org/10.1038/sj.onc.1207901			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378022				2022-12-17	WOS:000224749500004
J	Gururaj, A; Barnes, CJ; Vadlamudi, RK; Kumar, R				Gururaj, A; Barnes, CJ; Vadlamudi, RK; Kumar, R			Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase	ONCOGENE			English	Article						signaling; PGM; glycolysis; cancer metabolism	BREAST-CANCER CELLS; P21-ACTIVATED KINASES; SACCHAROMYCES-CEREVISIAE; ESTROGEN-RECEPTOR; REORGANIZATION; EXPRESSION; APOPTOSIS; TARGETS; COMPLEX; GROWTH	We have identified a novel mechanism of cross-talk between cell signaling and metabolic pathways, whereby the signaling kinase p21-activated kinase 1 (Pak1) binds to, phosphorylates and enhances the enzymatic activity of phosphoglucomutase 1 (PGM), an important regulatory enzyme in cellular glucose utilization and energy homeostasis. Pak1 and PGM were colocalized in model cell systems and showed functional interactions in a physiological setting. Strong direct interaction of PGM with Pak1 but not Pak2, Pak3, or Pak4 was observed. PGM binding was within 75-149 amino acids (aa) of Pak1, while Pak1 binding to PGM was in the N-terminal 96 aa. Pak1-mediated phosphorylation of PGM selectively on threonine 466 significantly increased PGM enzymatic activity and could be blocked by transfection with a dominant-negative Pak1 expression vector and by Pak1-specific small inhibitory RNA. Stable transfection of PGM into PGM-deficient K-562 leukemia cells further demonstrated the role of Pak1 in regulating PGM activity. The results presented here provide new evidence that the cell signaling kinase Pak1 is a novel regulator of glucose metabolism through its phosphorylation and regulation of PGM activity. These findings suggest a new mechanism whereby growth factor signaling may coordinately integrate metabolic regulation with established signaling functions of cell cycle regulation and cell growth.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Barnes, Christopher/B-1545-2015	Barnes, Christopher/0000-0001-9682-0748	NATIONAL CANCER INSTITUTE [R01CA090970] Funding Source: NIH RePORTER; NCI NIH HHS [CA90970, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Barnes CJ, 2002, CANCER RES, V62, P1251; BARNES CJ, 2003, NAT STRUCT BIOL, V3, P30; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Boros LG, 2002, PANCREAS, V24, P26, DOI 10.1097/00006676-200201000-00004; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DEY NB, 1994, J BIOL CHEM, V269, P27143; Gao H, 2004, ANAL BIOCHEM, V329, P269, DOI 10.1016/j.ab.2004.03.011; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Lindahl M, 2003, P NATL ACAD SCI USA, V100, P16107, DOI 10.1073/pnas.2534397100; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; PUTT W, 1993, BIOCHEM J, V296, P417, DOI 10.1042/bj2960417; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; Shanmuganathan A, 2004, FEBS LETT, V556, P253, DOI 10.1016/S0014-5793(03)01428-5; Takahashi N, 2001, HUM BIOL, V73, P755, DOI 10.1353/hub.2001.0076; Tomkins J, 1997, ANN HUM GENET, V61, P99; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Zhai WG, 1999, MOL CELL BIOL, V19, P2791	27	75	79	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8118	8127		10.1038/sj.onc.1207969	http://dx.doi.org/10.1038/sj.onc.1207969			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15378030				2022-12-17	WOS:000224692500009
J	Rippo, MR; Moretti, S; Vescovi, S; Tomasetti, M; Orecchia, S; Amici, G; Catalano, A; Procopio, A				Rippo, MR; Moretti, S; Vescovi, S; Tomasetti, M; Orecchia, S; Amici, G; Catalano, A; Procopio, A			FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells	ONCOGENE			English	Article						malignant mesothelioma; Fas; TRAIL; FLIP; caspase-8; apoptosis	LIGAND-INDUCED APOPTOSIS; TUMOR IMMUNE ESCAPE; PLEURAL MESOTHELIOMA; MEDIATED APOPTOSIS; FAS-LIGAND; EXPRESSION; TRAIL; PROTEIN; GROWTH; LINES	Tumors have developed several forms of resistance to receptor-induced cell death. Here, we show that malignant mesothelial (MM) cell lines as well as primary MM cells and normal mesothelial (NM) cells express Fas and TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5. We found that, although Fas expression levels are comparable, only MM cells are resistant to cell death. Furthermore, MM cells show resistance to TRAIL-induced apoptosis. Caspase-8 (FLICE) is not activated by death receptors triggering in malignant cells whereas it is well activated by nonreceptor stimuli, such as UV radiation. We found that FLIP (FLICE-Inhibitory Protein) is constitutively expressed in all MM cell lines and is more expressed in primary MM cells than in NM cells. Knockdown of FLIP expression in MM cell lines, by a FLIPsiRNA, re-established the normal response to apoptosis induced by Fas or DR4/DR5, which was blocked by pretreatment with the caspase-8 inhibitor z-IETD-fmk. These results indicate that MM cells develop an intrinsic resistance to apoptosis induced by death receptors upregulating the expression of the antiapoptotic protein c-FLIP.	Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60100 Ancona, Italy; Italian Natl Res Ctr Aging, Lab Cytol, I-860124 Ancona, Italy; S Antonio & Biagio Hosp, Dept Anat Pathol, I-15100 Alessandria, Italy; Pediat Hosp G Salesi, I-60100 Ancona, Italy	Marche Polytechnic University; IRCCS INRCA; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo	Rippo, MR (corresponding author), Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60100 Ancona, Italy.	m.r.rippo@univpm.it	Procopio, Antonio Domenico/AAB-2451-2021	Procopio, Antonio Domenico/0000-0001-6897-8724; RIPPO, Maria Rita/0000-0003-3024-3495				Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bradley M, 1998, BLOOD, V92, P4248, DOI 10.1182/blood.V92.11.4248.423k20_4248_4255; CARBONE M, 1994, ONCOGENE, V9, P1781; Catalan MP, 2003, KIDNEY INT, V64, P321, DOI 10.1046/j.1523-1755.2003.00062.x; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; French LE, 2002, SEMIN CANCER BIOL, V12, P51, DOI 10.1006/scbi.2001.0405; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frost P, 1997, CELL IMMUNOL, V180, P70, DOI 10.1006/cimm.1997.1169; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Jaklitsch MT, 2001, WORLD J SURG, V25, P210, DOI 10.1007/s002680020021; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; LEW F, 1986, J CLIN IMMUNOL, V6, P225, DOI 10.1007/BF00918702; Liu WH, 2001, AM J RESP CELL MOL, V25, P111, DOI 10.1165/ajrcmb.25.1.4472; MANNING LS, 1991, CLIN EXP IMMUNOL, V83, P85; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440-1843.2002.00404.x; Nagaraju K, 2000, J IMMUNOL, V164, P5459, DOI 10.4049/jimmunol.164.10.5459; Narasimhan SR, 1998, AM J PHYSIOL-LUNG C, V275, pL165, DOI 10.1152/ajplung.1998.275.1.L165; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Plasilova M, 2002, LEUKEMIA, V16, P67, DOI 10.1038/sj.leu.2402338; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Roth W, 2001, CANCER RES, V61, P2759; Screpanti V, 2001, J IMMUNOL, V167, P2068, DOI 10.4049/jimmunol.167.4.2068; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Stewart JH, 2002, J THORAC CARDIOV SUR, V123, P295, DOI 10.1067/mtc.2002.119882; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Tomasetti M, 2004, BRIT J CANCER, V90, P1644, DOI 10.1038/sj.bjc.6601707; Tomek S, 2003, BRIT J CANCER, V88, P167, DOI 10.1038/sj.bjc.6600673; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; Zang DY, 2001, BLOOD, V98, P3058, DOI 10.1182/blood.V98.10.3058	38	75	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	2004	23	47					7753	7760		10.1038/sj.onc.1208051	http://dx.doi.org/10.1038/sj.onc.1208051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334061				2022-12-17	WOS:000224331600001
J	Morelli, C; Garofalo, C; Sisci, D; del Rincon, S; Cascio, S; Tu, X; Vecchione, A; Sauter, ER; Miller, WH; Surmacz, E				Morelli, C; Garofalo, C; Sisci, D; del Rincon, S; Cascio, S; Tu, X; Vecchione, A; Sauter, ER; Miller, WH; Surmacz, E			Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters	ONCOGENE			English	Article						breast cancer; estrogen receptor alpha; nuclear insulin receptor substrate 1; insulin-like growth factor; estrogen-responsive elements	HUMAN BREAST-CANCER; FACTOR-I RECEPTOR; IRS-SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL-3-OH KINASE; CELL-LINE; T-ANTIGEN; IGF-I; GROWTH; EXPRESSION; TRANSLOCATION	Insulin receptor substrate 1 (IRS-1) is a major signaling molecule activated by the insulin and insulin-like growth factor I receptors. Recent data obtained in different cell models suggested that in addition to its conventional role as a cytoplasmic signal transducer, IRS-1 has a function in the nuclear compartment. However, the role of nuclear IRS-1 in breast cancer has never been addressed. Here we report that in estrogen receptor alpha (ERalpha)- positive MCF-7 cells, (1) a fraction of IRS-1 was translocated to the nucleus upon 17-beta-estradiol (E2) treatment; ( 2) E2-dependent nuclear translocation of IRS-1 was blocked with the antiestrogen ICI 182,780; ( 3) nuclear IRS-1 colocalized and co-precipitated with ERalpha; (4) the IRS-1: ERalpha complex was recruited to the E2-sensitive pS2 gene promoter. Notably, IRS-1 interaction with the pS2 promoter did not occur in ERalpha-negative MDA-MB-231 cells, but was observed in MDA-MB-231 cells retransfected with ERalpha. Transcription reporter assays with E2-sensitive promoters suggested that the presence of IRS-1 inhibits ERalpha activity at estrogen-responsive element-containing DNA. In summary, our data suggested that nuclear IRS-1 interacts with ERalpha and that this interaction might influence ERalpha transcriptional activity.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calabria, Postgrad Sch Clin Pathol, I-87036 Cosenza, Italy; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada; Univ Palermo, Dept Oncol, Sect Mol Oncol, Palermo, Italy; Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO 65212 USA	Jefferson University; University of Calabria; Lady Davis Institute; McGill University; University of Palermo; University of Missouri System; University of Missouri Columbia	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.	eva.surmacz@jefferson.edu	Garofalo, Cecilia/B-3834-2017; /AAD-9701-2019; Morelli, Catia/AAE-1886-2019	Garofalo, Cecilia/0000-0001-5334-8930; /0000-0001-6577-1541; Morelli, Catia/0000-0002-9407-0805; Cascio, Sandra/0000-0003-4234-0508; Vecchione, Andrea/0000-0002-5497-6856	NATIONAL CANCER INSTITUTE [R21CA087391] Funding Source: NIH RePORTER; NCI NIH HHS [CA87391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; Bartucci M, 2001, CANCER RES, V61, P6747; Boylan JM, 2002, ENDOCRINOLOGY, V143, P4178, DOI 10.1210/en.2002-220321; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chan TW, 2001, CLIN CANCER RES, V7, P2545; Guvakova MA, 1997, CANCER RES, V57, P2606; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Maggiolini M, 2001, MOL PHARMACOL, V60, P595; Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Salerno M, 1999, INT J CANCER, V81, P299; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Sciacca L, 2003, ENDOCRINOLOGY, V144, P2650, DOI 10.1210/en.2002-0136; Seol KC, 2003, BIOCHEM BIOPH RES CO, V306, P898, DOI 10.1016/S0006-291X(03)01046-5; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; Sun M, 2001, CANCER RES, V61, P5985; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Vladusic EA, 2000, ONCOL REP, V7, P157; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	34	75	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7517	7526		10.1038/sj.onc.1208014	http://dx.doi.org/10.1038/sj.onc.1208014			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15318176				2022-12-17	WOS:000224176500008
J	Bonner, AE; Lemon, WJ; Devereux, TR; Lubet, RA; You, M				Bonner, AE; Lemon, WJ; Devereux, TR; Lubet, RA; You, M			Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas	ONCOGENE			English	Article						lung cancer; expression profiling; mouse model; human; lung development	OLIGONUCLEOTIDE ARRAYS; EXPRESSION; TUMORIGENESIS	We have performed oligonucleotide array analysis on various murine lung tissues [normal lungs, lung adenomas, and lung adenocarcinomas (ACs)] using Affymetrix U74Av2 GeneChips to examine the complex genetic changes occurring during lung carcinogenesis. Analysis yielded 20 novel genes differentially expressed in both lung adenomas and ACs versus normal lungs, including the tumor suppressor APC2 and the oncogene Ros 1. In addition, 50 genes were found to be differentially expressed in lung adenomas versus lung ACs, including the differentiation factor Hox C6, the oncogene Ets 2, and the Ras nuclear transport factor, nuclear transport factor 2. To understand the potential relationship between genes expressed in murine lung tumors and its relationship to altered gene expression observed during embryogenesis and postnatal development, tissues from embryonic lungs and from lungs of mice up to 4 weeks following birth were examined using Affymetrix U74Av2 GeneChips. From this analysis, approximately 1300 genes were determined to exhibit differential expression in fetal lung versus postnatal lung. When we compared lung adenomas, lung ACs, and normal lung parenchyma, 24 developmentally regulated genes were found aberrantly expressed in lung tumors; these included the cell cycle control factor CDC5, the cellular differentiation factor TEA domain 4, and the proapoptotic factor BNIP 2. Finally, we compared the murine lung tumor gene expression data to the expression of genes in human lung cancer, in order to assess the relevance of murine lung cancer models in the study of human AC formation. When the 17 human lung ACs and six human lung large cell carcinomas were examined, it was found that 13 of the 17 human lung ACs clustered tightly together in a pattern that was different from the remaining four human lung ACs and six large cell carcinomas, which exhibited a different pattern. Interestingly, the mouse lung adenomas appeared similar to 13 clustered ACs, while mouse lung ACs appeared more similar in pattern to the group consisting of four ACs and six large-cell carcinomas (LCCs). Nevertheless, when compared with the combined human ACs, 39 genes with similar expression changes in murine lung tumors and human ACs/LCCs were identified, such as the oncogene-related BCL7B, the cell cycle regulator CDK4, and the proapoptotic Endophilin B1. Overall, we have determined, for the first time, the expression profiles during murine lung tumor progression and have established, at the molecular level, an association between murine lung tumorigenesis and lung development. We have also attempted to compare the expression profiles found in mouse lung cancers and those in human lung ACs.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; NCI, Chemoprevent Agent Dev Res Grp, Bethesda, MD 20892 USA	Washington University (WUSTL); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NCI NIH HHS [R01CA78797, R01CA58554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078797, R01CA058554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonner AE, 2003, J MED GENET, V40, P408, DOI 10.1136/jmg.40.6.408; Chen J, 2003, GENE, V302, P103, DOI 10.1016/S0378-1119(02)01095-8; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Miura K, 2002, CANCER RES, V62, P3244; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; Travis W. D., 1999, WHO INT HISTOLOGICAL; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wurzer G, 2001, J CELL BIOCHEM, P1; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2000, CANCER RES, V60, P901	16	75	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1166	1176		10.1038/sj.onc.1207234	http://dx.doi.org/10.1038/sj.onc.1207234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647414				2022-12-17	WOS:000188749900015
J	Meadows, KN; Bryant, P; Vincent, PA; Pumiglia, KM				Meadows, KN; Bryant, P; Vincent, PA; Pumiglia, KM			Activated Ras induces a proangiogenic phenotype in primary endothelial cells	ONCOGENE			English	Article						angiogenesis; VEGF; Erk; migration; PI3K; proliferation; Ras	THYROID EPITHELIAL-CELLS; WILD-TYPE P53; GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLE ARREST; TUMOR ANGIOGENESIS; COOPERATING ONCOGENES; ACTIN REORGANIZATION; NEURITE OUTGROWTH	Angiogenic factors alter endothelial cell phenotype to promote the formation of new blood vessels, a process critical for a number of normal and pathological conditions. Ras is required for the induction of the angiogenic phenotype in response to vascular endothelial growth factor (VEGF). However, VEGF generates many signals, several of which are not dependent upon Ras activation. Our current study investigates the sufficiency of Ras activation for driving angiogenic responses. An activated Ras(V12) mutant induces prominent membrane ruffling, branching morphogenesis on three-dimensional collagen, DNA synthesis, and cell migration in primary endothelial cells. An upregulation of PI3K/AKT, Erk, and Jnk signaling pathways accompany these phenotypic changes. The inhibition of Erk blocked cell proliferation, but only partially attenuated migration. Blocking PI3K had no effect on DNA synthesis, but caused a modest reduction in cell migration. Lastly, Jnk played a significant role in both the proliferation and migration response. These effects of Ras(V12) are not the result of increased autocrine secretion of VEGF. These data suggest that the acquisition of activating Ras mutations can lead to a proangiogenic conversion in the phenotype of primary endothelial cells. Furthermore, these data raise the possibility that chronic Ras activation in endothelial cells may be sufficient to promote angiogenesis and the development of vascular anomalies.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College; Albany Medical College	Pumiglia, KM (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	pumiglk@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [R01 CA081419, R01-CA-81419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FOX PL, 1994, ONCOGENE, V9, P3519; Fox SB, 1996, J PATHOL, V179, P232, DOI 10.1002/(SICI)1096-9896(199607)179:3<232::AID-PATH505>3.0.CO;2-A; Ghosh PK, 2002, NAT CELL BIOL, V4, P894, DOI 10.1038/ncb873; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Goi T, 1999, MOL CELL BIOL, V19, P1731; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MARION MJ, 1991, MOL CARCINOGEN, V4, P450, DOI 10.1002/mc.2940040607; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Pal S, 2001, CANCER RES, V61, P6952; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rak J, 2000, CANCER RES, V60, P490; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; Spyridopoulos I, 2002, BASIC RES CARDIOL, V97, P117, DOI 10.1007/s003950200001; Suzuki E, 2002, HYPERTENS RES, V25, P773; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zhang LL, 2000, CANCER RES, V60, P3655; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	64	75	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					192	200		10.1038/sj.onc.1206921	http://dx.doi.org/10.1038/sj.onc.1206921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712224				2022-12-17	WOS:000187895300020
J	Kumar, R; Angelini, S; Hemminki, K				Kumar, R; Angelini, S; Hemminki, K			Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9	ONCOGENE			English	Article						BRAF; N-ras; melanoma; mutation; FAL; SSCP	MALIGNANT-MELANOMA; TUMOR PROGRESSION; CDKN2A MUTATIONS; B-RAF; GENE; FREQUENCY; CANCER; HETEROZYGOSITY; PATHWAYS; COMMON	We searched and report mutations in the BRAF and N-ras genes in 22 out of 35 (63 percent) primary sporadic melanomas. In three melanomas, mutations were concomitantly present in both genes. In all, 10 out of 12 mutations in the BRAF gene involved the 'hot spot' codon 600 (In all communications on mutations in the BRAF gene, the nucleotide and codon numbers have been based on the NCBI gene bank nucleotide sequence NM_004333. However, according to NCBI gene bank sequence with accession number NT_007914, there is a discrepancy of one codon (three nucleotides) in exon 1 in the sequence with accession number NM_004333. The sequence analysis of exon 1 of the BRAF gene in our laboratory has shown that the sequence derived from NT_007914 is correct (Kumar et al., 2003). Due to the correctness of the latter, sequence numbering of codons and nucleotides after exon 1 are changed by +1 and +3, respectively.), one tandem CT1789-90TC base change represented a novel mutation and another mutation caused a G466R amino-acid change within the glycine-rich loop in the kinase domain. Mutations in the N-ras gene in 11 melanomas were at codon 61 whereas two melanomas carried mutations in codon 12 including a tandem mutation GG>AA. We observed an inverse association between BRAF/N-ras mutations and the frequency of loss of heterozygosity (LOH) on chromosome 9 at 10 different loci. Melanomas with BRAF/N-ras mutations showed a statistically significant decreased frequency of LOH on chromosome 9 compared with cases without mutations (mean fractional allelic loss (FAL) = 0.29 +/- 0.23 vs 0.72 +/- 0.33; t-test, P = 0.0001). Difference in the FAL value between tumours with and without BRAF/N-ras mutations on 33 loci on five other chromosomes was not statistically significant (mean FAL 0.17 +/- 0.19 vs 0.25 +/- 0.22; t-test, P = 0.24). Melanoma cases with BRAF/N-ras mutations were also associated with lower age at diagnosis than cases without mutations (mean age 80.38 +/- 7.24 vs 65.77 +/- 19.79 years; t-test, P = 0.02). Our data suggest that the occurrence of BRAF/N-ras mutations compensate the requirement for the allelic loss at chromosome 9, which is one of the key events in melanoma.	German Canc Res Ctr, Div Mol Genet Epidemiol, D-69210 Heidelberg, Germany; Karolinska Inst, Novum, Ctr Nutr & Toxicol, Dept Biosci, S-14157 Huddinge, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet	Kumar, R (corresponding author), German Canc Res Ctr, Div Mol Genet Epidemiol, Neuenheimer Feld 580 TP3, D-69210 Heidelberg, Germany.	kumar@cnt.ki.se	Kumar, Rajiv/H-6431-2019; angelini, Sabrina/AAB-5220-2022; ravegnini, gloria/K-1330-2016	Kumar, Rajiv/0000-0002-6093-0395; ravegnini, gloria/0000-0002-7774-402X; Angelini, Sabrina/0000-0002-1609-0421				Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Brose MS, 2002, CANCER RES, V62, P6997; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Eskandarpour M, 2003, J NATL CANCER I, V95, P790, DOI 10.1093/jnci/95.11.790; Funk JO, 1998, J CUTAN PATHOL, V25, P291, DOI 10.1111/j.1600-0560.1998.tb01748.x; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Hemminki K, 2001, MELANOMA RES, V11, P133, DOI 10.1097/00008390-200104000-00007; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kumar R, 1999, MELANOMA RES, V9, P138, DOI 10.1097/00008390-199904000-00005; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Kumar R, 1998, INT J CANCER, V75, P193, DOI 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.3.CO;2-5; Kumar R, 2001, INT J CANCER, V95, P388, DOI 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6; KUMAR R, 2003, IN PRESS CLIN CANC R; Laud K, 2003, CANCER RES, V63, P3061; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Naoki K, 2002, CANCER RES, V62, P7001; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Pollock PM, 2001, CANCER RES, V61, P1154; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Saida T, 2001, J DERMATOL SCI, V26, P1, DOI 10.1016/S0923-1811(01)00085-8; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smeds J, 2000, MUTAGENESIS, V15, P257, DOI 10.1093/mutage/15.3.257; vanElsas A, 1997, MELANOMA RES, V7, pS107; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; Yuen ST, 2002, CANCER RES, V62, P6451; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	42	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9217	9224		10.1038/sj.onc.1206909	http://dx.doi.org/10.1038/sj.onc.1206909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681681				2022-12-17	WOS:000187400400003
J	Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Ramos, MA; Nunez, MD; Campos, J; Lacal, JC				Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Ramos, MA; Nunez, MD; Campos, J; Lacal, JC			Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells	ONCOGENE			English	Article						choline kinase inhibitors; new therapies; signal transduction; specificity; apoptosis	NIH 3T3 FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTORS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPID-METABOLISM; ANTITUMOR STRATEGY; DRUG DISCOVERY; RAS ONCOGENE; ACTIVATION; STIMULATION	Cancer treatment is in the need of selective drugs that can interfere specifically with signalling pathways affected during the carcinogenic process. Identification of new potential molecular targets is the key event in the design of new anticancer strategies. Once identified, attempts for the generation of specific molecules to regulate their function can be achieved. The relevance of deregulation of choline kinase (ChoK, E.C. 2.7.1.32) in oncogene-driven cell transformation has been previously demonstrated. Here we provide strong evidence that MN58b, a selective inhibitor of ChoK, is rather specific to this enzyme, with no effect on a variety of oncogene-activated signalling pathways involved in the regulation of cell proliferation. MN58b does not affect MAPKs, PI3K, and other enzymes involved in the regulation of phospholipid metabolism such as phospholipases C, D, and A2, CTP:phosphocholine cytidylyltransferase, or diacylglycerol choline-phosphotransferase. Consistent with this specificity, ectopic expression of ChoK resulted in resistance to its inhibitor. Finally, nontransformed cells were able to resume cell proliferation after removal of the drug, while transformed cells were irreversibly affected. These results indicate that inhibition of ChoK is a rather specific strategy for the cytotoxic treatment of transformed cells.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, E-28029 Madrid, Spain; Fac Farm, Dept Quim Organ, E-18071 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Arturo Duperier 4, E-28029 Madrid, Spain.		Lacal, Juan Carlos/AAL-2235-2020; del Carmen Nuñez-Carretero, M/L-7150-2014; de Molina, Ana Ramirez/AAA-3848-2019; Rosa, Joaquín/L-8436-2014; Lacal, Juan Carlos/N-9064-2015	Rosa, Joaquín/0000-0002-9035-8123; Lacal, Juan Carlos/0000-0002-1908-2777				Aboagye EO, 1999, CANCER RES, V59, P80; ANSELL GB, 1974, J NEUROCHEM, V22, P1153, DOI 10.1111/j.1471-4159.1974.tb04352.x; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Bhakoo KK, 1996, CANCER RES, V56, P4630; CANNON JG, 1994, MED RES REV, V14, P505, DOI 10.1002/med.2610140503; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; Chung TW, 2000, CELL SIGNAL, V12, P279, DOI 10.1016/S0898-6568(00)00065-6; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; de Molina AR, 2001, BIOCHEM BIOPH RES CO, V285, P873, DOI 10.1006/bbrc.2001.5250; De molina AR, 2001, INT J ONCOL, V19, P5; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; Finney RE, 2000, CANCER RES, V60, P5204; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Friend SH, 1998, NEW ENGL J MED, V338, P125, DOI 10.1056/NEJM199801083380211; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; KO KWS, 1986, J BIOL CHEM, V261, P7846; Lacal J C, 2001, IDrugs, V4, P419; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; Momchilova A, 1999, CELL BIOL INT, V23, P603, DOI 10.1006/cbir.1999.0430; OIKAWA T, 1991, P NATL ACAD SCI USA, V88, P3057, DOI 10.1073/pnas.88.8.3057; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; RATMANT JC, 1995, ARCH BIOCHEM BIOPHYS, V323, P313; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; Ting YLT, 1996, ANTICANCER RES, V16, P1381; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; YANG W, 1990, J BIOL CHEM, V265, P13553; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	48	75	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8803	8812		10.1038/sj.onc.1207062	http://dx.doi.org/10.1038/sj.onc.1207062			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654777				2022-12-17	WOS:000186982200001
J	Prise, KM; Folkard, M; Michael, BD				Prise, KM; Folkard, M; Michael, BD			Bystander responses induced by low LET radiation	ONCOGENE			English	Article						bystander response; low LET; cell signalling; microbeam	CHARGED-PARTICLE MICROBEAM; INDUCED GENOMIC INSTABILITY; EARLY DNA-DAMAGE; IONIZING-RADIATION; HUMAN FIBROBLASTS; ALPHA-PARTICLES; IN-VIVO; X-RAY; UNIRRADIATED CELLS; INTERCELLULAR COMMUNICATION	Radiation-induced bystander responses are observed when cells respond to their neighbours being irradiated. Considerable evidence is now available regarding the importance of these responses in cell and tissue models. Most studies have utilized two approaches where either a media-transferable factor has been assessed or cells have been exposed to low fluences of charged particles, where only a few percent are exposed. The development of microbeams has allowed nontargeted responses such as bystander effects to be more carefully analysed. As well as charged particle microbeams, X-ray microprobes have been developed, and several groups are also developing electron microbeams. Using the Gray Cancer Institute soft X-ray microprobe, it has been possible to follow the response of individual cells to targeted low doses of carbon-characteristic soft X-rays. Studies in human fibroblasts have shown evidence of a significant radiation quality-dependent bystander effect, measured as chromosomal damage in the form of micronuclei which is radiation quality dependent. Other studies show that even under conditions when only a single cell is targeted with soft X-rays, significant bystander-mediated cell killing is observed. The observation of bystander responses with low LET radiation suggests that these may be important in understanding radiation risk from background levels of radiation, where cells observe only single electron track traversals. Also, the indirect evidence for these responses in vivo indicates that they may have a role to play in current radiotherapy approaches and future novel strategies involving modulating nontargeted responses.	Mt Vernon Hosp, Gray Canc Inst, Cell & Mol Biophys Grp, Northwood HA6 2RN, Middx, England	University of Oxford	Prise, KM (corresponding author), Mt Vernon Hosp, Gray Canc Inst, Cell & Mol Biophys Grp, POB 100, Northwood HA6 2RN, Middx, England.		Prise, Kevin/N-7872-2015; Michael, Barry D/C-7126-2008	Prise, Kevin/0000-0001-6134-7946; 				AUCLAIR C, 1990, ARCH BIOCHEM BIOPHYS, V278, P238, DOI 10.1016/0003-9861(90)90253-U; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Belyakov OV, 2002, RADIAT PROT DOSIM, V99, P249, DOI 10.1093/oxfordjournals.rpd.a006775; Belyakov OV, 1999, INT J RADIAT BIOL, V75, P985, DOI 10.1080/095530099139746; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; BISHAYEE A, 2000, RADIAT RES, V155, P1; BRABY LA, 1992, SCANNING MICROSCOPY, V6, P164; Brenner DJ, 2000, CANCER, V88, P398, DOI 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V; Camphausen K, 2003, CANCER RES, V63, P1990; Denning C, 1997, HUM GENE THER, V8, P1825, DOI 10.1089/hum.1997.8.15-1825; Emerit I, 1996, P NATL ACAD SCI USA, V93, P12799, DOI 10.1073/pnas.93.23.12799; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; EMERIT I, 1991, FREE RADICAL BIO MED, V10, P371, DOI 10.1016/0891-5849(91)90045-5; Engels H, 1999, STRAHLENTHER ONKOL, V175, P47, DOI 10.1007/BF03038888; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 2001, RADIAT RES, V156, P796, DOI 10.1667/0033-7587(2001)156[0796:AFUXRM]2.0.CO;2; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; HICKMAN AW, 1994, CANCER RES, V54, P5797; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; Iyer R, 2002, MUTAT RES-FUND MOL M, V503, P1, DOI 10.1016/S0027-5107(02)00068-4; Khan MA, 1998, INT J RADIAT ONCOL, V40, P467, DOI 10.1016/S0360-3016(97)00736-0; KORYSTOV YN, 1993, RADIAT RES, V134, P301, DOI 10.2307/3578189; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Miller JH, 2000, RADIAT ENVIRON BIOPH, V39, P173, DOI 10.1007/s004110000057; Miller RC, 1999, P NATL ACAD SCI USA, V96, P19, DOI 10.1073/pnas.96.1.19; Moiseenko VV, 2000, INT J RADIAT ONCOL, V48, P1539, DOI 10.1016/S0360-3016(00)00802-6; MORGAN GW, 1995, INT J RADIAT ONCOL, V31, P361, DOI 10.1016/0360-3016(94)00477-3; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagar S, 2003, CANCER RES, V63, P324; NAGASAWA H, 1992, CANCER RES, V52, P6394; Obedian E, 2000, J CLIN ONCOL, V18, P2406, DOI 10.1200/JCO.2000.18.12.2406; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Prise KM, 2000, ADV SPACE RES, V25, P2095, DOI 10.1016/S0273-1177(99)01060-1; PRISE KM, 2000, RADIAT RES, V2, P174; Ramesh R, 1996, EXP HEMATOL, V24, P829; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schettino G, 2002, RADIAT PROT DOSIM, V99, P287, DOI 10.1093/oxfordjournals.rpd.a006786; Schettino G, 2001, RADIAT RES, V156, P526, DOI 10.1667/0033-7587(2001)156[0526:LDHICH]2.0.CO;2; SCHETTINO G, UNPUB; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao CL, 2001, J RADIAT RES, V42, P305, DOI 10.1269/jrr.42.305; Watson GE, 2000, CANCER RES, V60, P5608; Wilson WE, 2001, RADIAT RES, V155, P89, DOI 10.1667/0033-7587(2001)155[0089:MOAKEM]2.0.CO;2; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699	55	75	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7043	7049		10.1038/sj.onc.1206991	http://dx.doi.org/10.1038/sj.onc.1206991			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557809				2022-12-17	WOS:000185903900009
J	Lui, VWY; Thomas, SM; Zhang, Q; Wentzel, AL; Siegfried, JM; Li, JY; Grandis, JR				Lui, VWY; Thomas, SM; Zhang, Q; Wentzel, AL; Siegfried, JM; Li, JY; Grandis, JR			Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor	ONCOGENE			English	Article						EGFR transactivation; GRPR; G-protein-coupled receptor; TGF-alpha; head and neck cancer	BOMBESIN ANTAGONIST RC-3095; LUNG-CARCINOMA CELLS; SMOOTH-MUSCLE-CELLS; PROSTATE-CANCER; MESSENGER-RNA; NEUROMEDIN-B; EGF RECEPTOR; AUTOCRINE GROWTH; EPITHELIAL-CELLS; PROTEIN-KINASE	Head and neck squamous cell carcinomas (HNSCC) are characterized by upregulation of the epidermal growth factor receptor ( EGFR), where EGFR serves as a potential therapeutic target. We previously reported that a gastrin-releasing peptide/gastrin-releasing peptide receptor (GRP/GRPR) autocrine growth pathway is activated early in HNSCC carcinogenesis. In the present study, we examined the mechanism of EGFR activation by GRP/GRPR in HNSCC proliferation. In HNSCC cells that express elevated levels of both GRPR and EGFR, we found that GRP induced rapid phosphorylation of EGFR as well as p44/42-MAPK activation. Using several EGFR-specific tyrosine kinase inhibitors and cells derived from EGFR knockout mice, we demonstrated that GRP-induced p44/42-MAPK activation was dependent upon EGFR activation. Further investigation demonstrated that cleavage of transforming growth factor-alpha (TGF-alpha) by matrix metalloproteinases mediated GRP-induced MAPK activation. In addition, HNSCC proliferation stimulated by GRP was eliminated upon specific inhibition of EGFR or MEK, and GRP failed to stimulate proliferation in EGFR- deficient cells. These results imply that the mitogenic effects of GRP in HNSCC are mediated by extracellular release of TGF-alpha and require the activation of an EGFR- dependent MEK/MAPK-dependent pathway.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Univ Pittsburgh, Sch Med, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.		Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022; Lui, Vivian W. Y./I-5458-2016; ZHANG, QING/AGY-7972-2022	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Lui, Vivian W. Y./0000-0001-6918-1573; ZHANG, QING/0000-0002-6595-8995	NATIONAL CANCER INSTITUTE [P50CA090440, R01CA079882, U01CA084968] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79882, P50CA90440, U01CA84968] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; ALEXANDER RW, 1988, CANCER RES, V48, P1439; ANASTASI A, 1971, EXPERIENTIA, V27, P166, DOI 10.1007/BF02145873; Boerner JL, 2001, J BIOL CHEM, V276, P3691, DOI 10.1074/jbc.M003801200; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CARNEY DN, 1987, CANCER RES, V47, P821; Carroll RE, 2000, CELL GROWTH DIFFER, V11, P385; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Charlesworth A, 1996, ONCOGENE, V12, P1337; Chaudhry A, 1999, CLIN CANCER RES, V5, P3385; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; FATHI Z, 1993, J BIOL CHEM, V268, P5979; Feldman RI, 1996, MOL PHARMACOL, V50, P1346; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1997, ONCOGENE, V15, P409, DOI 10.1038/sj.onc.1201188; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Halmos G, 1997, P NATL ACAD SCI USA, V94, P956, DOI 10.1073/pnas.94.3.956; HALMOS G, 1995, CANCER RES, V55, P280; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Kelley MJ, 1997, CHEST, V112, P256, DOI 10.1378/chest.112.1.256; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; Lango MN, 2002, J NATL CANCER I, V94, P375; LEBACQVERHEYDEN AM, 1990, HDB EXPT PHARM, V95, P71; LIEBOW C, 1994, P NATL ACAD SCI USA, V91, P3804, DOI 10.1073/pnas.91.9.3804; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Nagakawa O, 2001, INT J UROL, V8, P65, DOI 10.1046/j.1442-2042.2001.00250.x; Nagakawa O, 2000, CANCER LETT, V155, P173, DOI 10.1016/S0304-3835(00)00425-0; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; Pansky A, 2000, J AM SOC NEPHROL, V11, P1409, DOI 10.1681/ASN.V1181409; PINSKI J, 1994, BRIT J CANCER, V70, P886, DOI 10.1038/bjc.1994.415; Plonowski A, 2000, INT J CANCER, V88, P652, DOI 10.1002/1097-0215(20001115)88:4<652::AID-IJC21>3.3.CO;2-T; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Rounseville MP, 2000, J MOL ENDOCRINOL, V25, P121, DOI 10.1677/jme.0.0250121; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Santiskulvong C, 2001, AM J PHYSIOL-CELL PH, V281, pC886, DOI 10.1152/ajpcell.2001.281.3.C886; Sharif TR, 1997, MOL CELL ENDOCRINOL, V130, P119, DOI 10.1016/S0303-7207(97)00080-4; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Siegfried JM, 1999, PULM PHARMACOL THER, V12, P291, DOI 10.1006/pupt.1999.0210; SIEGFRIED JM, 1998, BIOL LUNG CANC, P317; SORENSON GD, 1982, REGUL PEPTIDES, V4, P59, DOI 10.1016/0167-0115(82)90095-7; Sun BD, 2000, REGUL PEPTIDES, V90, P77, DOI 10.1016/S0167-0115(00)00114-2; Sun BD, 2000, PROSTATE, V42, P295; Szepeshazi K, 1997, P NATL ACAD SCI USA, V94, P10913, DOI 10.1073/pnas.94.20.10913; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4	54	75	78	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6183	6193		10.1038/sj.onc.1206720	http://dx.doi.org/10.1038/sj.onc.1206720			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679857				2022-12-17	WOS:000185506200008
J	Soung, YH; Lee, JW; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Park, YG; Nam, SW; Jeong, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH				Soung, YH; Lee, JW; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Park, YG; Nam, SW; Jeong, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH			Inactivating mutations of CASPASE-7 gene in human cancers	ONCOGENE			English	Article						CASPASE-7; mutation; solid cancer; apoptosis; caspases	FAS APO-1/CD95 GENE; INDUCED APOPTOSIS; CELL-DEATH; MAMMALIAN HOMOLOG; CYSTEINE PROTEASE; CARCINOMA; DISTINCT; CLEAVES; CASCADE; CED-3	Caspase-7 is a caspase involved in the execution phase of apoptosis. To explore the possibility that the genetic alterations of CASPASE-7 might be involved in the development of human cancers, we analysed the entire coding region and all splice sites of human CASPASE-7 gene for the detection of somatic mutations in a series of human solid cancers, including carcinomas from stomach, colon, head/neck, esophagus, urinary bladder and lung. Overall, we detected CASPASE-7 mutations in two of 98 colon carcinomas (2.0%), one of 50 esophageal carcinomas (2.0%) and one of 33 head/neck carcinomas (3.0%). We expressed the tumor-derived caspase-7 mutants in 293 T cells and found that the apoptosis was reduced compared to the wild-type caspase-7. This is the first report on the CASPASE-7 gene, mutations in human malignancies, and our data suggest that the inactivating mutations of the CASPASE-7 gene might lead to the loss of its apoptotic function and contribute to the pathogenesis of some human solid cancers.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biostat, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.		kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022					Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kurokawa H, 1999, ONCOL REP, V6, P33; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Mollenhauer J, 2001, CANCER RES, V61, P8880; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; Palmerini F, 2001, HUM PATHOL, V32, P461, DOI 10.1053/hupa.2001.24328; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Schwartz S, 1999, CANCER RES, V59, P2995; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; ZORNIG M, 1995, ONCOGENE, V10, P2397	26	75	76	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					8048	8052		10.1038/sj.onc.1206727	http://dx.doi.org/10.1038/sj.onc.1206727			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970753				2022-12-17	WOS:000185388200020
